<SEC-DOCUMENT>0001144204-15-036361.txt : 20150610
<SEC-HEADER>0001144204-15-036361.hdr.sgml : 20150610
<ACCEPTANCE-DATETIME>20150609203856
ACCESSION NUMBER:		0001144204-15-036361
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20150331
FILED AS OF DATE:		20150610
DATE AS OF CHANGE:		20150609

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Ruthigen, Inc.
		CENTRAL INDEX KEY:			0001574235
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				461821392
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36199
		FILM NUMBER:		15922144

	BUSINESS ADDRESS:	
		STREET 1:		2455 BENNETT VALLEY RD. SUITE C116
		CITY:			SANTA ROSA
		STATE:			CA
		ZIP:			95404
		BUSINESS PHONE:		(707) 525-9900

	MAIL ADDRESS:	
		STREET 1:		2455 BENNETT VALLEY RD. SUITE C116
		CITY:			SANTA ROSA
		STATE:			CA
		ZIP:			95404
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>v412118_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 10-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Mark One)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings">x</FONT></TD><TD>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the fiscal year ended March
31, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>OR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings"><B>&uml;</B></FONT></TD><TD>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
the transition period from <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> to <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Commission
file number: 001-36199</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>RUTHIGEN, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>(Exact name of registrant as specified
in its charter)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 55%; text-align: center"><B>Delaware</B></TD>
    <TD STYLE="width: 45%; text-align: center"><B>46-1821392 </B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><I>(State or other jurisdiction</I></TD>
    <TD STYLE="text-align: center"><I>(I.R.S. Employer Identification No.)</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><I>of incorporation or organization)</I></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><B>2455 Bennett Valley Rd., Suite C116</B></TD>
    <TD STYLE="text-align: center"><B>95404<I> </I></B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><B>Santa Rosa, California </B></TD>
    <TD STYLE="text-align: center"><I>&nbsp;(Zip Code)</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><I>&nbsp;(Address of principal executive offices)</I></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; text-align: center">Registrant&rsquo;s
telephone number, including area code <B>(707) 525-9900</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; margin-left: -2.5in">Securities registered pursuant to Section
12(b) of the Exchange Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 42%">Title of each class</TD>
    <TD STYLE="width: 54%">Name of each exchange on which registered</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Common Stock, $0.0001 Par Value Per Share</TD>
    <TD>The NASDAQ Capital Market</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Securities registered pursuant to Section
12(g) of the Exchange Act: None</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark
if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. &nbsp;&nbsp;&nbsp;Yes&nbsp;<FONT STYLE="font-family: Wingdings"><B>&uml;</B></FONT>&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark
if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. &nbsp;&nbsp;&nbsp;
Yes <FONT STYLE="font-family: Wingdings"><B>&uml;</B></FONT>&nbsp;&nbsp; No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark
whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. &nbsp;&nbsp;&nbsp;Yes&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT>&nbsp;&nbsp;&nbsp;No&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark
whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required
to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that
the registrant was required to submit and post such files).&nbsp;&nbsp;&nbsp;Yes&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT>&nbsp;No&nbsp;<FONT STYLE="font-family: Wingdings"><B>&uml;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark
if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to
the best of registrant&rsquo;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of
this Form 10-K or any amendment to this Form 10-K.&nbsp;<FONT STYLE="font-family: Wingdings"><B>&uml;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark
whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.
See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo;
in Rule 12b-2 of the Exchange Act. (Check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%; text-align: justify">Large accelerated filer&nbsp;<FONT STYLE="font-family: Wingdings"><B>&uml;</B></FONT></TD>
    <TD STYLE="width: 42%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 27%; text-align: justify">Accelerated filer</TD>
    <TD STYLE="width: 6%; text-align: justify"><FONT STYLE="font-family: Wingdings"><B>&uml;</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Non-accelerated filer&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD STYLE="text-align: justify">[Do not check if a smaller reporting company]</TD>
    <TD>Smaller reporting company</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Wingdings">x</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark
whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings"><B>&uml;</B></FONT>&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The aggregate market
value of the registrant&rsquo;s voting and non-voting common stock held by non-affiliates of the registrant (without admitting
that any person whose shares are not included in such calculation is an affiliate) computed by reference to the price at which
the common stock was sold as of September 30, 2014, the last business day of its most recently completed second fiscal quarter,
was $13,572,764.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of June 5, 2015,
the registrant had 4,804,290 shares of common stock outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>DOCUMENTS INCORPORATED BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TABLE OF CONTENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 13%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 75%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 12%; text-decoration: none; text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom"><B><U STYLE="text-decoration: none">Page No.</U></B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-decoration: none; text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-align: justify"><A HREF="#a_002">Forward-Looking Statements</A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">3</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#a_001"><B>PART I</B></A></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Item 1.</TD>
    <TD STYLE="text-align: justify"><A HREF="#a_003">Business.</A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">3</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Item 1A.</TD>
    <TD STYLE="text-align: justify"><A HREF="#a_004">Risk Factors.</A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">24</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Item 1B.</TD>
    <TD STYLE="text-align: justify"><A HREF="#a_005">Unresolved Staff Comments.</A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">51</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Item 2.</TD>
    <TD STYLE="text-align: justify"><A HREF="#a_006">Properties.</A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">51</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Item 3.</TD>
    <TD STYLE="text-align: justify"><A HREF="#a_007">Legal Proceedings.</A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">51</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Item 4.</TD>
    <TD STYLE="text-align: justify"><A HREF="#a_008">Mine Safety Disclosures.</A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">51</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#a_009"><B>PART II</B></A></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Item 5.</TD>
    <TD STYLE="text-align: justify"><A HREF="#a_010">Market for Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">52</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Item 6.</TD>
    <TD STYLE="text-align: justify"><A HREF="#a_011">Selected Financial Data.</A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">52</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Item 7.</TD>
    <TD STYLE="text-align: justify"><A HREF="#a_012">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations.</A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">53</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Item 7A.</TD>
    <TD STYLE="text-align: justify"><A HREF="#a_013">Quantitative and Qualitative Disclosures About Market Risk.</A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">59</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Item 8.</TD>
    <TD STYLE="text-align: justify"><A HREF="#a_014">Financial Statements and Supplementary Data.</A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">59</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Item 9.</TD>
    <TD STYLE="text-align: justify"><A HREF="#a_015">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.</A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">59</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Item 9A.</TD>
    <TD STYLE="text-align: justify"><A HREF="#a_016">Controls and Procedures.</A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">60</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Item 9B.</TD>
    <TD STYLE="text-align: justify"><A HREF="#a_017">Other Information.</A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">60</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#a_018"><B>PART III</B></A></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Item 10.</TD>
    <TD><A HREF="#a_019">Directors, Executive Officers and Corporate Governance.</A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">61</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Item 11.</TD>
    <TD><A HREF="#a_020">Executive Compensation.</A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">64</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Item 12.</TD>
    <TD><A HREF="#a_021">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">71</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Item 13.</TD>
    <TD STYLE="text-align: justify"><A HREF="#a_022">Certain Relationships and Related Transactions, and Director Independence.</A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">73</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Item 14.</TD>
    <TD STYLE="text-align: justify"><A HREF="#a_023">Principal Accounting Fees and Services.</A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">74</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: -49.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#a_024"><B>PART IV</B></A></TD>
    <TD STYLE="text-align: justify; text-indent: -49.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: -49.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Item 15.</TD>
    <TD STYLE="text-align: justify"><A HREF="#a_025">Exhibits, Financial Statement Schedules.</A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">75</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#a_026"><B>Signatures</B></A></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">79<B>&nbsp;</B></P></TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_001"></A>PART I</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="a_002"></A><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Annual Report
contains forward-looking statements as that term is defined in the federal securities laws. The events described in forward-looking
statements contained in this Annual Report may not occur. Generally these statements relate to business plans or strategies, projected
or anticipated benefits or other consequences of our plans or strategies, projected or anticipated benefits from acquisitions to
be made by us, or projections involving anticipated revenues, earnings or other aspects of our operating results. The words &ldquo;may,&rdquo;
&ldquo;will,&rdquo; &ldquo;expect,&rdquo; &ldquo;believe,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;project,&rdquo; &ldquo;plan,&rdquo;
&ldquo;intend,&rdquo; &ldquo;estimate,&rdquo; and &ldquo;continue,&rdquo; and their opposites and similar expressions are intended
to identify forward-looking statements. We caution you that these statements are not guarantees of future performance or events
and are subject to a number of uncertainties, risks and other influences, many of which are beyond our control that may influence
the accuracy of the statements and the projections upon which the statements are based. Factors which may affect our results include,
but are not limited to, the risks and uncertainties discussed in Item 1A of this Annual Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any one or more of
these uncertainties, risks and other influences could materially affect our results of operations and whether forward-looking statements
made by us ultimately prove to be accurate. Our actual results, performance and achievements could differ materially from those
expressed or implied in these forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking
statements, whether from new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As used in this Annual
Report on Form 10-K, or this Annual Report, references to the &ldquo;Company&rdquo;, &ldquo;we&rdquo;, &ldquo;us&rdquo;, or &ldquo;our&rdquo;
refer to Ruthigen, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in; text-align: left"><B>Item 1.</B></TD><TD STYLE="text-align: justify"><B><A NAME="a_003"></A>BUSINESS.</B></TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were incorporated
in January 2013 as a wholly-owned subsidiary of Oculus Innovative Sciences, Inc. (&ldquo;Oculus&rdquo;) and operated as such until
the completion of our initial public offering in March 2014. We were reincorporated from Nevada to Delaware in September 2013.&nbsp;We
currently have no products approved for sale. We have been focusing on the commercialization of our lead drug candidate, RUT58-60,
which is a broad spectrum anti-infective drug for the prevention and treatment of infection in surgical and trauma procedures.
We have licensed the intellectual property rights underlying the RUT58-60 from Oculus pursuant to a License and Supply Agreement
with Oculus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Merger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 13, 2015,
we entered into an agreement and plan of merger (the &ldquo;Merger Agreement&rdquo;) with Ruthigen Merger Corp., our wholly owned
subsidiary (&ldquo;Merger Sub&rdquo;), and Pulmatrix Inc., a Delaware corporation (&ldquo;Pulmatrix&rdquo;), which provides for
the merger of Merger Sub with and into Pulmatrix, with Pulmatrix surviving as our wholly owned subsidiary, and Merger Sub will
cease to exist (the &ldquo;Merger&rdquo;). See our Current Report on Form 8-K dated March 13, 2015 for additional details related
to the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will issue shares
of our common stock to the Pulmatrix equity holders in connection with the Merger as merger consideration and shares of common
stock to certain lenders of Pulmatrix upon the conversion of bridge loans, such that the former Pulmatrix security holders will
hold approximately 83% of Ruthigen&rsquo;s post-merger shares. Although we are the legal acquirer and will issue shares of its
common stock to effect the merger with Pulmatrix, the business combination will be accounted for as a reverse acquisition of Ruthigen
by Pulmatrix under GAAP. In addition, at the effective time of the Merger, warrants to purchase shares of Pulmatrix common stock
will be converted into and exchangeable for warrants to purchase shares of our common stock pursuant to an exchange ratio described
in the Merger Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Merger is completed,
Hojabr Alimi, our Chief Executive Officer and Sameer Harish, our Chief Financial Officer will resign from their current positions
with the Company and continue to be employed by the combined company and have agreed to terminate equity grants previously made
to them and will receive cash and restricted stock units pursuant to the new employment agreements Pulmatrix and Ruthigen entered
into with each of Messrs. Alimi and Harish.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pending the consummation
of the Merger, the Merger Agreement permits us to scale down our operations as we deem necessary and requires us to scale back
patient enrollment in our clinical trial of RUT58-60, our primary drug candidate, and it is currently anticipated that the combined
company would focus its resources on the development of products within the scope of Pulmatrix&rsquo;s current business plan. As
a result, following the Merger, the combined company may seek to sell or assign its rights related to our current drug candidates,
including RUT58-60.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Sale of Common Stock by Oculus</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 8, 2015,
we consented to the proposed sale of 2,000,000 shares of common stock held by our former parent, Oculus, to certain accredited
investors (the &ldquo;Oculus Share Purchasers&rdquo;) at a purchase price of $2.75 per share subject to the occurrence of the closing
of the Merger pursuant to a securities purchase agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 13, 2015,
Oculus entered into a securities purchase follow-up agreement with the Oculus Share Purchasers pursuant to which it reduced the
number of shares of our common stock to be sold to 1,650,000 at a price of $2.75 per share, provided that 50,000 shares may be
sold to one or more investors prior to closing. If the Merger does not close by August 13, 2015 or as may be extended up to 60
calendar days at Oculus&rsquo;s discretion, there will be no obligation of the Oculus Share Purchasers to purchase the shares.
Oculus will retain the voting rights to the 50,000 shares until and through the date of closing of the Merger. In the event that
the closing of the Merger does not occur on or prior to September 30, 2015, the 50,000 shares of common stock will become fully
tradable and full voting rights will transfer to the buyer(s) of such shares. On March 13, 2015, Oculus entered into a securities
purchase agreement with several investors, pursuant to which the investors agreed to purchase the 350,000 shares of our common
stock at a price of $2.75 per share. On March 23, 2015, this sale closed. Oculus retained the voting rights to the 350,000 shares
until and through the date of closing of the Merger. In the event that the closing of the Merger does not occur on or prior to
September 30, 2015, the 350,000 shares of Ruthigen common stock will become fully tradable and full voting rights will transfer
to the purchasers of such shares. Voting restrictions applicable to shares of Ruthigen common stock held by Oculus are not affected
and remain in effect until the closing of the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a biopharmaceutical
company focused on pioneering new hypochlorous acid (&ldquo;HOCl&rdquo;), based therapies designed to improve patient outcomes
and reduce healthcare costs associated with infections related to surgical procedures. Our lead drug candidates, including RUT58-60,
are broad spectrum anti-infective products that we have been developing for the prevention and treatment of infection in surgical
and trauma procedures. We are focusing development of our drug candidates for use initially to prevent infections in abdominal
surgery due to the large addressable market, high rate of post-surgical infection associated with abdominal surgery, the high-impact
opportunity that abdominal surgery offers it in the clinical trial setting to expose multiple internal organs to RUT58-60 at one
time, and feedback from surgeons identifying post-surgical infection in abdominal surgery (relative to other surgeries) as a significant
unmet medical need. We submitted our Investigational New Drug Application (&ldquo;IND&rdquo;), for RUT58-60 to the U.S. Food and
Drug Administration (&ldquo;FDA&rdquo;), in early May 2014. In June 2014, our IND became effective thereby allowing us to begin
human clinical testing of RUT58-60. In July 2014, we began human clinical testing of RUT58-60 in a 21-day skin irritation trial.
In August 2014, we completed the skin irritation trial with 36 human subjects participating for 21 consecutive days. In October
2014, we initiated the Phase 1/2 clinical trial, and, in November 2014 we began patient enrollment in the Phase 1 portion of the
Phase 1/2 clinical trial to evaluate the safety, tolerability, and potential efficacy of our lead drug candidate, RUT58-60, for
use as an adjunct to systemic antibiotics in abdominal surgery and patient screening began at four clinical trial sites in the
United States. To date, we have not received any reports of any serious adverse events. Pursuant to the Merger Agreement we may
scale down our operations, including scaling back patient enrollment in our clinical trial to evaluate the safety of RUT58-60 within
the abdominal cavity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that our
drug candidates have the potential to significantly reduce the rate of post-surgical infections, reduce the use of systemic antibiotics
that have proven to be ineffective against certain common resistant strains of bacteria, including methicillin-resistant staphylococcus
aureus , or MRSA, and Vancomycin-resistant enterococcus, or VRE, reduce the negative side effects associated with the increasingly
widespread use of antibiotics, accelerate post-surgical healing which should lead to quicker patient discharge from the hospital,
and ultimately reduce hospital readmission rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that our
drug candidates will complement the paid for performance paradigm and they are designed to reduce the overall healthcare costs
associated with post-surgical infections and improve hospital economics. We believe the benefits of its drug candidates will be
significant as they:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">mimic the human body&rsquo;s own infection-fighting mechanism,</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">have not shown toxicity or serious side effects in its animal and other preclinical studies,</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">do not produce resistant bacteria in vitro, and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">demonstrate broad spectrum anti-microbial effectiveness in vitro.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that our
drug candidates have the potential to be used as a prophylactic therapy to prevent and treat infections, and may accelerate patient
discharge from the hospital and ultimately lead to an overall reduction in hospital readmission rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The benefits of HOCl
in preventing infection have been well-demonstrated in products with lower concentrations of HOCl than RUT58-60. To date, HOCl
based products have only been cleared for use as medical devices for topical applications in the United States, Europe and certain
other countries. Earlier formulations have not been able to achieve therapeutic indication status, primarily due to their lack
of stability, sterility and effectiveness and therefore have been limited for use as topical applications. Historically, the lack
of stability has posed a vexing problem to companies hoping to pursue HOCl products for therapeutic indications in invasive applications
and has prevented these companies from being able to conduct the clinical trials necessary to prove whether HOCl is safe and effective
for use as a therapeutic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">HOCl based products
have been used successfully to prevent infection in topical applications and have been sold commercially since at least 2005 by
other companies, generally as medical devices in the United States and Europe and for broader medical claims in certain other countries
where approval has been granted. Several of these HOCl based products have been commercialized as medical devices by Oculus, our
former parent company and the licensor of our technology. Through our license and supply agreement with Oculus, we have obtained
exclusive rights to the RUT58-60 technology, as well as a proprietary method of manufacturing and producing HOCl with pharmaceutical
potential by incorporating additional small molecules without sodium hypochlorite, the result of which increases the compound&rsquo;s
stability and biocompatibility, or the compound&rsquo;s ability to remain in direct contact with internal tissues and organs. We
believe our recent enhancements to the stability and biocompatibility of the compound will allow us to expand the use of HOCl so
that it may be used in direct contact with internal organs. With these enhancements, we believe our lead product candidate will
be able to meet the safety and efficacy standards that the FDA requires for the approval of a new drug. Obtaining approval of new
drug by the FDA is a lengthy, expensive and uncertain process, and we may not be successful in obtaining approval. The FDA review
processes can take years to complete and approval is never guaranteed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are approximately
30 million surgical and trauma procedures in the United States per year, approximately 7 million of which are abdominal surgeries,
based upon market research.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are successful
in receiving FDA approval for our drug candidates for the prevention of infection in abdominal surgery, we plan to pursue other
types of surgeries, including cardiac, pulmonary and spinal, among others. Based upon data from preclinical studies conducted by
us and data reported in third party publications, we believe that the safety and tolerability profile of our drug candidates, combined
with its broad-range antimicrobial potency without specificity, offer a practical and unique approach to stem the high rate of
hospital acquired infections and infections resulting from complications in surgeries and the increasing emergence of new antibiotic
resistant bacteria that pose a significant risk to public health. We believe that our technology represents a significant innovation
over existing uses of HOCl in topical applications and over systemic antibiotics for the prevention and treatment of infection
in surgical and other invasive applications, and has the potential to raise the clinical bar for anti-infective products generally
in the face of increasing headwinds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have focused much
of our research and development efforts for RUT58-60 and other formulations on pre-clinical development and optimization. Our research
and development team is working to further optimize the performance of our drug candidates by testing variations in the formulation
and chemical components of RUT58-60. We also seek to further optimize the proprietary chemical formulation and manufacturing process
that gives us reason to believe that RUT58-60 and other formulations may be able to be used in surgical applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under our license and
supply agreement with Oculus, we have exclusively licensed the HOCl technology relating to RUT58-60 and other formulations for
commercialization in the United States, Europe, Japan and Canada. According to IMS Health, an information technology firm, these
markets represented approximately 71% of the global medicines market in 2011. In parallel with our clinical development activities,
we have conducted discussions with various pharmaceutical companies for potential partnership and collaboration activities for
RUT58-60 in the United States, Canada, Europe and Japan. To date, we have not entered into any partnerships or collaborations for
RUT58-60 and we cannot guarantee that we will be successful entering into any such arrangements on favorable terms, or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were founded with
the goal of being the first company to market HOCl based drugs for the prevention and treatment of infection in surgical procedures.
We believe our technology may be able to reduce the number of post-surgical infections, reduce the increasingly widespread use
of systemic antibiotics and the negative side effects associated with them, accelerate post-surgical healing which should lead
to quicker patient discharge from the hospital, and reduce hospital readmission rates. We have agreed to scale back patient enrollment
in our clinical trial of RUT58-60 pending completion of our proposed merger with Pulmatrix. In order to move forward with our strategy,
the key elements to achieve our goals are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">Initiate and complete clinical trials for its drug candidates, for the first indication (abdominal
surgery) and obtain regulatory approval to market as a drug in the United States.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">Establish research and development and manufacturing facilities in compliance with the FDA&rsquo;s
Current Good Manufacturing Practices, or cGMP, requirements for manufacturing drugs.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">Commercialize our drug candidates in the United States either through a direct sales force or with
a partner.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">Engage strategic partners to develop, obtain regulatory approval for, and commercialize our drug
candidates for use in Europe and Japan.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><B>HOCl Technology</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that HOCl,
the active pharmaceutical ingredient in RUT58-60 and other drug candidates that we plan to develop in the future, has several potential
benefits over systemic antibiotics, which are the current standard of care for the prevention of infection associated with surgical
and trauma procedures, as described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify"><I>Broad Spectrum Activity Including Against Antibiotic Resistant Strains of Bacteria. </I> HOCl
has been shown in non-clinical studies to kill bacteria, viruses, spores, and fungi. We believe this can be achieved through common
mechanisms of action, including by denaturation, a process in which the structure of surface proteins on the microorganism is irreversibly
changed or damaged, which results in the destruction of pathogen. RUT58-60 has been shown in non-clinical studies to eradicate
MRSA, VRE, and other antibiotic resistant microorganisms. RUT58-60&rsquo;s biologic activity is localized and fast-acting, which
results in rapid bacterial destruction; in vitro studies have demonstrated potent 30-second kill times against several commonly
found, clinically relevant, aggressive treatment-resistant bacteria.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify"><I>Multi-targeted; Does Not Promote Emergence of Superbugs. </I>We believe that our technology
has the potential to be used broadly as a prophylactic agent to prevent infections in surgical patients. In pre-clinical studies,
our drug candidates have not been shown to promote resistance to bacteria and therefore do not increase the emergence of drug-resistant
pathogens. RUT58-60 does not target specific strains or receptor targets that the microorganism can then quickly mutate to induce
resistance. Further, exposure to HOCl causes irreversible destabilization of protein structures necessary for continued metabolism
for bacteria and other microbes.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify"><I>Pro-healing Potential. </I>HOCl products have demonstrated faster tissue healing in studies
published in peer-reviewed journals and other publications. Although the mechanism of action for incision site healing has not
been formally established in RUT58-60, we believe that incision sites will heal quicker, resulting in faster patient recovery and
discharge from the hospital.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify"><I>Mimics Body&rsquo;s Natural Microbe-Fighting Mechanism.</I> Human bodies have evolved over thousands
of years to produce HOCl naturally to kill infection-causing microbes quickly and without creating the opportunity for microbes
to mutate and become resistant. We believe that we have chemically engineered our drug candidates to mimic the body&rsquo;s natural
response to unfamiliar and unwanted organisms, without the undesirable side effects resulting from the proliferation and overuse
of antibiotics.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">&bull;</TD><TD STYLE="text-align: justify"><I>No Change to Surgeon Behavior Required.</I> Sterile
saline is currently the most commonly used irrigation solution to prevent infection during and following surgery when lavage is
used to wash the surgical site following surgical and trauma procedures, but it does not contain the antiseptic benefits traditionally
associated with antibiotics to prevent post-surgical infection. The use of a lavage wash &#9;in surgeries is not new and therefore,
we believe that the replacement of saline (or other currently used post-operative irrigation solutions) with our drug candidates
in surgical settings will be an easy and logical transition for surgeons and will not require additional training, time, education,
ramp up or behavior changes by surgeons.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD><I>Prepackaged, Sterilized, Ready to Use.</I> If approved by the FDA, we believe our drug candidates will be the only prepackaged,
sterilized, ready-to-use HOCl based drugs designed to prevent infection following surgery. We intend to package RUT58-60 in convenient,
sterile packaging that will not require mixing or solution preparation prior to use, thereby reducing the need for human intervention
and further minimizing opportunities to introduce other organisms that may cause infection and the risk of medical error.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify"><I>Stable Formulation.</I> Laboratory tests suggest that RUT58-60 may have a shelf life ranging
from one to two years depending on the size and type of packaging, and does not require special handling precautions or storage
requirements beyond those typically required for similar sterile products found in hospital and other indoor settings.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify"><I>Enhanced Biocompatibility for Internal Use.</I> We believe RUT58-60 is the first and only form
of HOCl based drug designed for internal use. We believe RUT58-60 represents an innovative way to improve the potential pharmaceutical
properties of HOCl by incorporating additional small molecules without sodium hypochlorite, the result of which enhances the biocompatibility
of the compound in a manner that allows the compound to remain in direct contact with internal tissues and organs.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify"><I>Hospital Cost Savings Potential.</I> We believe that our drug candidates has the potential to
improve surgical outcomes and lower hospital costs by preventing infection, decreasing the time to patient discharge and reducing
hospital readmission rates. Post-surgical infections are costly and, under new government regulations and payor policies, these
infections are increasingly not covered for reimbursement. High patient costs associated with the treatment of infections may be
related to longer hospitalizations and extended care, patient isolation due to the high rates of infection transmission, and the
use of expensive systemic antibiotics used to target infection. Post-surgical infection may also undermine the healing process,
prolong healing time and increase hospital readmissions after initial discharge.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Bacteria and Bacterial Resistance to Antibiotics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Bacteria are microscopic,
single cell organisms, or microorganisms, that can survive and reproduce in the human body; and in certain situations, may cause
infections. These bacterial infections may be caused by a number of types and variations of bacteria and may results in symptoms
that range from mild to serious and life threatening. Most bacteria can be categorized according to a single characteristic, the
cell wall. A Gram stain is often performed to differentiate bacteria into Gram-positive Bacteria, which have a permeable thick
cell wall, or Gram-negative Bacteria, which have a less permeable cell wall. The Gram stain is a violet or deep blue colored dye
that is absorbed into the cell wall of a Gram-positive bacteria, thus a Gram-positive bacterium can be seen with its violet or
deep blue hue stain when viewed under a microscope.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Common Gram-positive Bacteria include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">Staphylococcus, or &ldquo;Staph,&rdquo; including methicillin-resistant Staph aureus, or &ldquo;MRSA,&rdquo;
which was historically a common hospital acquired infection that is now and increasingly found outside of the hospital and in the
general community.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">Streptococcus, or &ldquo;Strep,&rdquo; including Streptococcus pneumoniae, or &ldquo;pneumonia,&rdquo;
which may cause infections in the lung, ear, throat, bloodstream, and/or meninges.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">Enterococcus, including vancomycin-resistant enterococcus, or &ldquo;VRE,&rdquo; which is a common
hospital acquired infection.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Common Gram-negative Bacteria include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">Escherichia coli, or &ldquo;E coli,&rdquo; which is commonly found in the human gastrointestinal
tract, and may cause infections in the gastrointestinal or urinary tracts in some patients, or in the bloodstream or skin.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">Acinetobacterbaumannii, which is an antibiotic resistant bacterial strain that has been linked
to hospital acquired infections.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">Pseudomonas aeruginosa, which is a naturally occurring antibiotic resistant bacterial strain that
produces a biofilm, or extracellular matrix, to adhere individual bacteria together and prevent antibiotic access to the cellular
targets.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">Klebsiellapneumoniae, or &ldquo;Klebsiella,&rdquo; including KPC, a strain of Klebsiella, which
is a bacterial strain that is resistant to the antibiotic drug carbapenem.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0.5in; text-align: justify">Bacteria
are thought to be among the earliest living organisms on Earth and have adapted to survive in many harsh and unique environments
that tend not to sustain other forms of life. In a similar fashion, bacteria have evolved and formed resistance to several types
of antibiotics, sterilizing agents, and environmental conditions. Therefore, in order to survive, bacteria have developed resistance
to many of these commonly used chemicals and conditions. Bacteria containing new genetic mutations, which strengthen them to resist
the impact of antibiotics that were designed to kill the bacteria, reproduce. This reproduction can lead to formation of new colonies
(populations) of bacteria with similar genetic traits. Additionally, many bacteria are capable of sharing genetic information
across bacterial species in ways that induce drug resistance from one organism to another and thus extend drug resistance to new
types of bacterial pathogens.</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0.5in; text-align: justify">There
are generally four primary mechanisms of bacterial activity found in microorganisms that cause resistance to antimicrobial drugs,
such as antibiotics:</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">Bacteria may develop capabilities to alter or inactivate the antimicrobial drug. The enzymatic
deactivation of penicillin G in some penicillin-resistant bacteria is an example of this type of bacterial resistance.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">Bacteria can alter the site being targeted by antibiotics. The alteration of the binding site of
penicillin and the creation of MRSA and other penicillin-resistant bacteria are examples of this type of mutation.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">Bacteria can alter their specific metabolic pathway to process chemicals in new ways. An example
of this type of bacterial resistance is how sulfonamide-resistant bacteria are now using preformed folic acid.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">Bacteria can reduce drug accumulation by decreasing permeability to the drug and/or increasing
active efflux (pumping out) of the drugs across the cell surface.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0.5in; text-align: justify">The
common practice of using antibiotics to treat patients with a wide range of infections that are known, or presumed to be attributable
to bacteria has resulted in the evolution and spread of drug-resistant bacteria in hospital and community settings and in the
global food supply. Over time, new antibiotic drugs have been developed by the medical community to address these drug-resistant
bacteria; however, the proliferation of new antibiotic drugs has resulted in the further evolution of &ldquo;Superbug&rdquo; bacteria
that have developed resistance to several commonly prescribed antibacterial drugs. In turn, physicians have modified their use
of broad-spectrum (treats a wide range of bacteria including Gram-positive and Gram-negative strains) and narrow-spectrum (treats
a select group of bacteria) antibiotics. Broad spectrum antibiotics are commonly used as first-line therapies to treat patients
with infections prior to the identification of the type or specific bacterial strain responsible for the infection, until such
a time as a more specific, narrow-spectrum antibiotic can be used or added.</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The widespread
increase in antibiotic-resistant bacteria has been widely recognized as a rapidly emerging threat to public health on a global
basis. Reports from several organizations have discussed the growing concern over the spread of antibiotic resistance and that
if significant efforts are not effectively made to decrease the proliferation of antibiotic resistant-related infections, infections
that were formerly treatable may become untreatable, thereby placing patients at risk for injury or death. The risk that a patient
contracts a life-threatening infection, simply while being treated for common medical conditions and procedures, such as surgery,
chemotherapy, care of the elderly and infants, and other patients with compromised immune systems, that causes a greater threat
to the patient&rsquo;s health than the common medical condition for which they are being treated, seems to invert the treatment
paradigm. The toll on patients and the healthcare system is becoming increasingly problematic. In the hospital setting, patients
that are infected with antibiotic-resistant bacteria tend to have longer and more expensive hospital stays, and are more likely
to experience significant negative health consequences, including death, as a result of these infections. Based on this data and
feedback from physicians and other healthcare professionals, we believe that innovative anti-infective drugs that are able to kill
antibiotic-resistant bacteria, which do not carry the negative side effects commonly associated with antibiotics, would meet this
significant unmet medical need.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Limitations of Current Anti-Infective
Products</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In post-surgical
and trauma applications, common methods of controlling infection, include the use of systemic and topical antibiotics and mechanical
washes, such as saline, which have proven to be only moderately effective in preventing infections. In addition, certain topical
and systemic antibiotics have negative side effects and antibiotics and antiseptic agents also tend to inhibit the healing process
due to their toxicity and may require specialized preparation or handling. Antibiotics, both topical and systemic, can lead to
the emergence of drug-resistant bacteria, such as MRSA and VRE. As a result, no single treatment is used universally for post-surgical
applications; and, we believe that our candidates have the potential to fill that void by preventing or treating infection in surgical
and other invasive applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Commonly used antiseptics,
mechanical washes, such as saline or Ringer&rsquo;s solution, and systemic antibiotics have limitations and negative side effects
that may constrain their usage. For example:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">Antibiotics and antiseptics can kill bacteria and cure infection but may promote antibiotic resistance
in select microbial strains;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">Many antiseptics, including Betadine, hydrogen peroxide and Dakin&rsquo;s solution, can be toxic
when exposed to the body&rsquo;s internal organs. Dilute forms of these antiseptics may not be as effective in eradicating pathogens;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">Advanced care products, such as silver based products, are not cleared by the FDA for internal
use; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">The increase in antibiotic-resistant bacterial strains, such as MRSA, VRE, and C. diff, has compromised
the effectiveness of some antibiotics, such as Daptomycin and Bacitracin.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><B>Drug Formulation,
RUT58-60</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have developed our
investigational drug, RUT58-60, for the prevention of infection in surgical and other invasive applications. The initial indication
that we have been pursuing is for use in abdominal surgery. The active pharmaceutical ingredient in RUT58-60 is HOCl. It is manufactured
without any sodium hypochlorite, and it incorporates additional small molecules, the result of which increases the stability and
biocompatibility of the compound so that it may be used in direct contact with internal organs. We believe that we are the first
company to have produced a shelf stable and tissue biocompatible form of HOCl for use in abdominal surgery. To date, despite attempts
by several commercial enterprises, we are not aware of any company that has been successful in developing HOCl as a drug for invasive
use in the United States. Our plan for RUT58-60 has been to conduct the clinical trials that will be necessary to prove its safety
and efficacy for use during surgery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We submitted an IND
for a Phase 1/2 clinical trial of RUT58-60 in the United States in early May 2014. The IND package also included, among other items,
pre-clinical data derived from studies using HOCl based products, as well as a several independent publications and reports using
topical formulations of HOCl from various manufacturers. Several topical HOCl based products have been cleared by the FDA as medical
devices and marketed in the United States, Europe and certain other countries by various companies and have accumulated an extensive
clinical data bank demonstrating the safety and efficacy of HOCl as a topical product used to moisten, debride and clean, and in
some instances, be used as an anti-infective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2014,
our IND became effective thereby allowing it to begin human clinical testing of RUT58-60. In July 2014, we began human clinical
testing of RUT58-60 in a 21-day skin irritation trial. In August 2014, we completed the skin irritation trial with 36 human subjects
participating for 21 consecutive days. In October 2014, we initiated the Phase 1/2 clinical trial, and, in November 2014 we began
patient enrollment in the Phase 1 portion of its Phase 1/2 clinical trial to evaluate the safety, tolerability, and potential efficacy
of our lead drug candidate, RUT58-60, for use as an adjunct to systemic antibiotics in abdominal surgery and patient screening
began at four clinical trial sites in the United States. Pursuant to the Merger Agreement, we may scale down our operations, including
scaling back patient enrollment in our Phase 1/2 clinical trial to evaluate the safety of RUT58-60 within the abdominal cavity.
To date, we have not received any reports of any serious adverse events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><B>Improvements in
RUT58-60 Over Existing HOCl Formulations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With most classes of
anti-infective products containing HOCl, chemists have generally not been able to synthesize a formulation containing HOCl that
meets the FDA&rsquo;s requirements applicable to a drug for invasive use, such as sufficient tolerability, biocompatibility, efficacy,
stability and sterility; and, only been able to achieve tolerability and efficacy sufficient for use as a topical agent. We believe
the proprietary chemical formulation and manufacturing process that formed the basis for RUT58-60 will further optimize the earlier
formulations of hypochlorous acid in a manner that will result in tolerability, biocompatibility, efficacy, stability and sterility
to potentially allow for it to be used as a drug in surgical and other invasive procedures where it will be in direct contact with
human internal organs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that the
absence of hypochlorite (ClO) in RUT58-60 and the incorporation of additional small molecules increase the stability and biocompatibility
of the compound so that it may be used in direct contact with internal organs. We believe these chemical attributes are substantial
improvements over existing HOCl formulations. Furthermore, the final packaged RUT58-60 has been subject to a standard sterilization
process as required for internal use. This final critical step in the manufacturing of RUT58-60 is designed to prevent the potential
for introduction of infectious agents related to the packaging material when the drug is used in sterile surgical suites. In preclinical
studies for RUT58-60, we have demonstrated that RUT58-60&rsquo;s stability withstands the temperature treatment associated with
the sterilization processes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Select Pathogen Activity of RUT58-60</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2013, we tested
the pathogen activity of RUT58-60 in preclinical studies. Below are the average kill times using RUT58-60 on certain common bacteria
that cause infection. The results demonstrate that RUT58-60 is effective in reducing the organism populations by &gt; 7 logs at
all intervals shown. Notably, RUT58-60 completely eradicated the bacteria within the first 30 seconds after application of the
drug solution onto the cell cultures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="14" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Contact Times (Log Reductions*)</B></FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>% Bacterial</B></FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Incubation***</B></FONT></TD>
    <TD NOWRAP STYLE="vertical-align: top; border-bottom: black 1pt solid; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD NOWRAP STYLE="vertical-align: bottom; border-bottom: black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Bacteria Challenge Populations</B></FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>30 Sec</B></FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>1 Min</B></FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>2 Min</B></FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>5 Min</B></FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>10 Min</B></FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Reduction**</B></FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Times (hrs)</B></FONT></TD>
    <TD NOWRAP STYLE="vertical-align: top; border-bottom: black 1pt solid; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; padding-left: 10pt; text-indent: -10pt; width: 42%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>MRSA (Methicillin-resistant S. aureus)</I></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right; width: 6%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8.5</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right; width: 6%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8.5</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right; width: 6%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8.5</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right; width: 6%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8.5</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right; width: 6%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8.5</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right; width: 6%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">99.9999997</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left; width: 1%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">%</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 6%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">24.5</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>E. coli</I></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8.4</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8.4</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8.4</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8.4</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8.4</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">99.9999996</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">%</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">24</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>P. aeruginosa</I></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8.2</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8.2</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8.2</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8.2</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8.2</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">99.9999993</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">%</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">25</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>VRE (E. faecalis)</I></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">99.9999993</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">%</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">24</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>P. mirabilis&rsquo;</I></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8.3</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8.3</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8.3</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8.3</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8.3</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">99.9999995</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">%</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">57</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>S. marcescens</I></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8.8</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8.8</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8.8</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8.8</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8.8</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">99.9999999</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">%</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">24.5</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>C. albicans</I></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">99.9999929</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">%</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">22.5</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify">Log Reduction is a mathematical term used to demonstrate
a Log, or 10-fold, reduction in live bacteria.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">**</TD><TD STYLE="text-align: justify">Calculations show no detectable surviving bacterial presence
in the samples tests. Test methods did not use serial dilutions (a series of dilution that reduces the concentration of bacteria
by a defined amount per stage).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">***</TD><TD STYLE="text-align: justify">Incubated on Tryptic Soy Agar (TSA) at 30&nbsp;&ndash;&nbsp;35&deg;C.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Proven Utility of HOCl</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While we do not have
the requisite regulatory approval to market RUT58-60 as a drug with an antimicrobial or healing indication in the United States,
Europe, or Japan, we believe several factors including clinical results, laboratory testing, scientific papers authored on and
physician-led clinical studies based on other HOCl containing solutions and formulations, suggest that HOCl, the active pharmaceutical
ingredient in RUT58-60, may significantly reduce a wide range of infections in surgical and traumatic injuries and potentially
accelerate patient discharge. Further, a number of physician-led clinical studies suggest that HOCl is safe, easy to use and may
shorten hospital stays, lower aggregate patient care costs and, in certain cases, reduce the need for antibiotics. In one such
clinical presentation at the 11 th Scientific Conference 2008 in Kota Bharu, Malaysia, Dr. M.G. Khairulasri, et al., reported results
from a prospective, randomized clinical trial of 178 patients who underwent elective coronary artery bypass graft, or CABG, surgery.
Oculus provided product at no cost for purposes of this study. Results of this study were also published in the Heart Surgery Forum,
a cardiothoracic multimedia journal, in August 2010. Patients received either Dermacyn (Group A), a HOCl based formulation manufactured
by Oculus, or a 10% povidone-iodine solution (Group B) as an adjunct therapy to the use of systemic antibiotics. All patients also
received intravenous prophylaxis (antibiotics) in addition to the lavage solution. After their surgeries, the patients&rsquo; sternums
were closed and in both groups, the wounds were soaked for 15 minutes. Patients were evaluated several times prior to discharge
and again following discharge at weeks 2, 4, and 6 for the presence of wound infection and side-effects. The primary outcome was
the presence of sternotomy wound infection, which was defined and graded according to the United States Centers for Disease Control
and Prevention, or CDC, in their National Nosocomial Infections System (Horan 1992). On average, 5.7% of the patients in Group
A and 15.6% of the patients in Group B showed an incidence of sternal wound infection (p=0.033). 100% of the patients in Group
A who showed signs of infection exhibited superficial infections. 71% of the patients in Group B who showed signs of infection
exhibited superficial infections and 29% exhibited deep (non-superficial) infections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As demonstrated by
Malle E in 2003, the over production and storage of enzymes required by our body to produce HOCl, and its subsequent byproducts
can cause potential harm to internal arteries and organs including kidney. By contrast, we believe that RUT58-60 provides the clinical
benefits of HOCl without the toxicity resulting from other precursors and byproducts. HOCl is generally understood to be unstable
because it carries a weak chlorine bond leading to diffusion of chlorine gas with the passage of time. We believe that RUT58-60
contains HOCl without the presence of toxic precursors, byproducts or sodium hypochlorite. Upon reaction with proteins, amino acids,
nucleic acids (deoxyribonucleic acid, or DNA, and ribonucleic acid, or RNA), and lipids, including those associated with bacteria,
RUT58-60 loses its chlorine thus forms an aqueous solution and is rendered neutral. Our in vivo toxicity tests have shown animals
are capable of tolerating higher doses of RUT58-60 with long-term exposures. Based on our initial research, we believe that RUT58-60
may have a shelf life ranging from one to two years depending on the size and type of packaging.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mechanism of Action of RUT58-60&rsquo;s
Active Pharmaceutical Ingredient, HOCl</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">HOCl is extremely unstable
as it is produced in the body or under laboratory conditions. The short shelf life of HOCl is attributable to its weak chlorine
bond that readily reacts with biomolecular sites including general surface proteins on bacterial membranes. Through reactions with
biomolecules, the chlorine ion is rapidly lost as it binds to nearby available biomolecules including surface bacterial proteins.
After reaction, water remains as the final residue. We believe the tissue absorbs the water. Initial cell surface reactions to
HOCl have been reported to occur in as little as 100 milliseconds, as reported by Albrich and Hurst (FEBS Letters, 1982).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">HOCl has been described
in peer reviewed literature as the most potent antibacterial agent when compared to other anti-infectives. Winter in 2008 reported
that HOCl, on the other hand, reacts with free cysteines about seven orders of magnitudes faster than hydrogen peroxide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">HOCl has demonstrated
to be potent and fast acting through targeting non-specific biomolecules on bacterial cell membrane. It is widely documented that
HOCl readily reacts with a wide range of biomolecules including DNA strands, RNA strands, fatty acid groups, cholesterol and proteins
amongst others. It is a highly reactive compound and upon reaction it is completely rendered neutral. Unlike antibiotics, the potency
of HOCl and damage is delivered with no specificity as reported by McKenna in 1988. We believe this mechanism of action induced
by HOCl drastically reduces the potential for emergence of new superbugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Bonvillain RW et al
in 2011 demonstrated that HOCl can damage the integrity of the bacterial cell membrane through increasing its permeability, showing
the rapid drop in bacterial viability followed by immediate cell membrane integrity damage at concentrations of approximately 0.05mM
to 0.1mM of HOCl. By contrast, RUT58-60 contains 2.0mM of HOCl, which represents a 40-fold increase in the minimal concentration
of HOCl needed to initiate bacterial cell membrane damage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to Bonvillain
RW in 2011 and Barrette WC Jr. in 1989, HOCl targets and disrupts the energy cycle within bacteria (adenosine triphosphate &mdash;
ATP). ATP is the central function for production of energy for bacteria. Therefore, HOCl first, induces irreversible damage to
bacterial cell membrane proteins thus interrupting the proteins&rsquo; functionality, then it targets the bacterial cell membrane
and finally shuts down the center for production of energy for bacteria. As a direct result of protein damage by HOCl according
to Barrette WC Jr., in 1989, cellular metabolism is disrupted causing a principally decreased production of Adenosine-5&rdquo;-triphosphate,
energy production (ATP), a universal, biological energy storage and transfer molecule. Studies show protein instability induced
by HOCl is non-reversible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other sources for production
of HOCl includes white blood cells. Neutrophils are specific type of white blood cells that are responsible for production of HOCl
to fight infection. Our body&rsquo;s immune system has evolved to incorporate the use of HOCl to fight pathogens. The production
of HOCl by immune cells requires the involvement of additional biomolecules and transient chemicals. Myeloperoxidase has been reported
as the key enzyme to convert hydrogen peroxide into HOCl in our body (Anitra Carr in 1996). Therefore, higher concentrations of
myeloperoxidase are required by our body to produce the potent concentrations of HOCl found in RUT58-60. However, the higher presence
of myeloperoxidase and its oxidative ability is associated with toxicity and damage found in patients suffering from late stage
kidney disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The science of HOCl
is not well understood in the industry. For example, it has been demonstrated that HOCl reacts with unsaturated bonds in lipids
which comprise the bacterial cell membrane, whereas bleach (OCl-) does not participate in this reaction. While topical disinfectants
such as bleach may induce necrosis in certain open wounds, Ruthigen has demonstrated that exposure to HOCl both in vivo and in
vitro induces no harm. In contrast to hypochlorite, HOCl is highly tolerated by mammalian cells as demonstrated by Gonzales in
2006. Additionally, as reported by Allison Kutner in 2013 as well as Diana Gonzales-Espinosa in 2007, mammalian cells contain cellular
amino acids and pumps that assist in neutralizing HOCl and keeping mammalian cells safe. Mammalian cells contain amino acids such
as Taurine that help protect the cells from the oxidation process caused by HOCl.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">HOCl has also been
studied for purposes of evaluating, and has been shown to demonstrate, pro-healing capabilities. Landsman, et al (2011), a clinical
trial sponsored by Oculus which used Oculus&rsquo; HOCl based product (not RUT58-60), showed a statistically significant improvement
in clinical success, as determined by the complete resolution of signs and symptoms of disease, in diabetic foot ulcer patients.
The HOCl group outperformed a control group of patients that used saline with levofloxacin, an antibiotic commonly used with these
patients. The HOCl group showed a 93% success rate at 14 days vs. a 56% success rate in the control group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Market Opportunity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under our license and
supply agreement with Oculus, we have exclusively licensed certain HOCl technology relating to RUT58-60 for commercialization in
the United States, Europe, Japan and Canada. According to a report from IMS Health from July 2012, these markets represented approximately
71% of the global medicines market in 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2005, $4.7 billion
was spent for the treatment of surgical and trauma wounds according to Kalorama Information, a life sciences market research firm.
Based on 46 million surgical and trauma procedures annually in the United States and more than 230 million procedures worldwide
according to Medtech Insight, we estimate our ultimate addressable market to be in excess of $4 billion in the United States alone.
We have focused the clinical and regulatory development for RUT58-60 on the prevention of infection in the abdominal surgery market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The medical community
is facing an increased rate of infection and the traditional use of antibiotics, antiseptics and antimicrobials not only cannot
meet the medical need, but also, the ever-increasing overuse of these agents carries side effects, including the emergence of new
superbugs, that have created other medical needs. The burden of infection following surgical and trauma procedures imposes significant
economic consequences that impact both patients and hospitals. The hospital direct cost of treating healthcare-associated infections
ranged from approximately $36 billion to $45 billion in 2007, according to the 2009 CDC report titled &ldquo;The Direct Medical
Cost of Healthcare-Associated Infections in U.S. Hospitals and the benefits of Prevention.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In a 2008 study funded
by the World Health Organization and published in The Lancet, it was estimated that 234 million major surgical procedures are undertaken
on an annual basis worldwide. This estimate included 64 million procedures in the United States, 43 million in Europe and 16 million
in Japan. For this estimate, major surgery was defined as any intervention occurring in a hospital operating theatre involving
the incision, excision, manipulation, or suturing of tissue, and usually requiring regional or general anesthesia or profound sedation
to control pain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The CDC estimates there
were 48 million in-patient procedures in the United States in 2009. Further, the CDC estimates there were approximately 53 million
ambulatory procedures in 2006. Based on an analysis of data from a variety of industry sources and input from our physician consultants,
we estimate that the number of patients undergoing advanced surgical interventions and that may benefit from its drug candidates
is 30 million. We believe this represents an addressable market in the United States of approximately $3.0 billion to $4.5 billion
based upon its market research. Our clinical development focus for RUT58-60 has been on the prevention of infections associated
with abdominal surgery in the United States, which, based upon input from its physician consultants, we estimate is approximately
a $700 million market opportunity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><B>Clinical Development</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The overarching goal
of our clinical development program has been to develop drugs, which use HOCl as the active pharmaceutical ingredient, without
sodium hypochlorite, and incorporate additional small molecules for the prevention and treatment of infection in surgical and other
invasive applications. We believe the potential of our enhanced HOCl formulations will be increased stability and improved biocompatibility
for use in direct contact with internal organs. We have designed RUT58-60 to prevent infections associated with surgical and trauma
procedures, initially in abdominal surgery. We have conducted pre-clinical testing to support our IND for RUT58-60, and we have
received feedback from the FDA to our proposed Phase 1/2 clinical trial protocol. We submitted our IND for RUT58-60 to the FDA,
in early May 2014. In June 2014, our IND became effective thereby allowing us to begin human clinical testing of RUT58-60. In July
2014, we began human clinical testing of RUT58-60 in a 21-day skin irritation trial. In August 2014, we completed the skin irritation
trial with 36 human subjects participating for 21 consecutive days. In October 2014, we initiated the Phase 1/2 clinical trial,
and, in November 2014 we began patient enrollment in the Phase 1 portion of our Phase 1/2 clinical trial to evaluate the safety,
tolerability, and potential efficacy of our lead drug candidate, RUT58-60, for use as an adjunct to systemic antibiotics in abdominal
surgery and patient screening began at four clinical trial sites in the United States. We may scale down our operations, including
scaling back patient enrollment in our clinical trial to evaluate the safety of RUT58-60 within the abdominal cavity. To date,
we have not received any reports of any serious adverse events. Initiation and completion of clinical trials for our lead drug
candidate, for the first indication (abdominal surgery) as a drug in the United States, will be dependent on authorization by our
board of directors after the proposed Merger is consummated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our clinical trial
protocol includes two arms, test (RUT58-60) and control (saline). All patients receive the same pre-surgical systemic antibiotic,
which is the current standard of care to prevent infections associated with abdominal surgery. Following the surgery, patients
in both arms of the trial receive a total of two lavage washes in the abdominal cavity and a single rinse above the fascia, a layer
of connective tissue that surrounds the abdominal cavity. The first and second lavages consist of either RUT58-60 for patients
in the test arm or saline for patients in the control arm. Saline is the most commonly used irrigation solution when lavage is
used to wash the surgical site following abdominal surgery. Each lavage consists of a total of 400 ml of RUT58-60 or saline, as
applicable. The surgical site during the first lavage are rinsed with RUT58-60 or saline. The surgical site during the second lavage
are exposed to RUT58-60 or saline for approximately three minutes. Finally, after the abdominal cavity is closed, patients are
rinsed once more (no extended exposure time) with 100 ml of RUT58-60 or saline, as applicable. Incisions will be closed after this
final rinse.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, in both
arms of the trial, prior to each lavage and after the last lavage, a microbiological sample from each patient&rsquo;s peritoneal
surface (parietal and visceral) are obtained with a swab. The swab samples are evaluated to identify the potential types and population
of microorganisms present in the abdominal cavity prior to final closure of the surgical site. The data we obtain from the swabs
are for informational purposes only and are not clinical endpoints of the trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><B>Development History
of RUT58-60</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2011, Hojabr
Alimi, Oculus&rsquo; then-chief executive officer and currently our Chief Executive Officer, authorized and directed Oculus to
engage an external drug development consultant to assist an internal working group formed to focus on pursuing new strategies.
In February 2012, the Oculus research and development group prepared a series of alternative formulations to Oculus&rsquo; existing
HOCl based formulations, some of which formed the understanding and basis of the potential drug candidate, RUT58-60. In July 2012,
a potential conceptual formulation, called RD-4, among three other formulations designed for invasive applications including surgical,
was also identified. In November 2012, the Oculus board concluded that the interest in pursuing invasive surgical applications
for the then-to-be-formed subsidiary, was the most attractive, because it would best leverage the body of knowledge and intellectual
property for HOCl based applications that Oculus had accumulated to date. The Oculus board further concluded that the focus on
invasive surgical applications would involve significant future research and development and clinical and commercial expenditures,
as well as a longer term plan that would require a separate cost center and additional financing, separate and apart from Oculus&rsquo;
existing HOCl business. In December 2012, Oculus disclosed new HOCl based formulations to its intellectual property counsel, which
formulations formed the basis for the current RUT58-60 formulation. The formulation, discovery and development activities directed
by an Oculus internal working group resulted in the technology for a new class of products, the first of which was ultimately conceived
as RUT58-60 in January 2013, at which time the operations of the internal working group were formally separated into our company.
Through the license and supply agreement we entered into with Oculus, we have obtained exclusive rights to the technology that
resulted from the efforts of the internal working group, including the RUT58-60 technology, as well as a proprietary method of
manufacturing and producing HOCl with pharmaceutical potential by incorporating additional small molecules without sodium hypochlorite,
the result of which increases the compound&rsquo;s stability and biocompatibility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><B>Collaboration with
Oculus</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have licensed the
intellectual property rights underlying the newly discovered RUT58-60 from Oculus pursuant to a license and supply agreement with
Oculus, the terms of which are described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>License and Supply Agreement </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 23, 2013, we
entered into license and supply agreement with Oculus pursuant to which Oculus agreed to license certain of its proprietary technology
to us to enable our research, development and commercialization of RUT58-60 and any improvements to it and any sterile prescription
drug product (the &ldquo;Product&rdquo;) in the United States, Canada, the European Union and Japan (collectively, the &ldquo;Territory&rdquo;)
for use in the surgical irrigation drug product indications set forth in the development and commercialization plan set forth in
Schedule 3 of the License and Supply Agreement (the &ldquo;Field&rdquo;). Oculus will be prohibited from using the licensed proprietary
technology to sell products that compete with our products within the Territory, and we may not sell any device or product that
competes with Oculus products being sold or developed as of the effective date of the license and supply agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the license and
supply agreement, our right to commercialize the Product in the Field in the Territory is exclusive and shall be performed in accordance
with the development and commercialization plan set forth in the agreement and Oculus shall manufacture and supply to us, at a
purchase price equal to 20% over the cost of goods to Oculus, the Product as and when we request. Under the license and supply
agreement, we are required to make a total of $8 million of milestone payments over the next several years to Oculus for our first
Product only, as follows: $1.5 million upon completion of last patient enrollment in our Phase 1/2 clinical trial; $1.5 million
upon completion of last patient enrollment in our first pivotal clinical trial; $3 million upon completion of our first meeting
with the FDA following completion of our first pivotal clinical trial; and $2 million upon first patient enrollment in our second
pivotal clinical trial. In addition, we will be required to make royalty payments to Oculus based on our annual net sales of the
Product from the date of the first commercial sale which percentage royalty rate will vary between 3% and 20% and will increase
based on various net sales thresholds and will differ depending on the country in which the sales are made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The license and supply
agreement contains representations and warranties of the parties regarding its enforceability, no conflict with agreements to which
the parties are bound, and no violations of law, and representations of Oculus that it has not granted any other license with respect
to the Product for use in the Field in the Territory. We have agreed to indemnify Oculus with respect to third party claims arising
from its development, commercialization or manufacture of the Product in the Field in the Territory with certain exceptions, and
each party has agreed to indemnify the other with respect to third party claims arising from its inaccuracies and/or breach of
representations and warranties or negligence or willful misconduct. Either party may terminate the agreement for an uncured material
breach, but only after undergoing a dispute resolution process. In addition, either party may terminate the agreement if the other
party ceases to do business, makes an assignment for the benefit of creditors or voluntarily files, fails to contest an involuntary
filing or is adjudicated bankrupt or insolvent under bankruptcy, insolvency, receivership or similar law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Terminated Shared Services Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our shared services
agreement with Oculus was terminated effective April 6, 2015 pursuant to written notice from Oculus received on March 5, 2015.
We have constructed our own manufacturing apparatus and have secured a third party contract manufacturing organization to fulfill
our manufacturing needs. We do not anticipate the need to produce any additional clinical trial materials through Oculus at this
time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the shared
services agreement, Oculus provided us with general accounting, human resources, consulting and technical services at fixed rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, Oculus
provided us with certain standard activities which included the transfer of protocols, procedures related to methods of manufacturing,
for building manufacturing equipment and employee training for test methods, manufacturing and manufacturing transfer. As of the
termination of the shared services agreement, our employees will not be permitted access to Oculus facilities without prior consent
from Oculus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, Oculus
had made available to us their laboratories and laboratory personnel for product development testing. We have has secured a third
party contract research organization to fulfill our analytical testing requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Separation Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 2, 2013,
we entered into a separation agreement with Oculus that contained provisions relating to our ongoing relationship with Oculus.
On January 31, 2014, we amended the separation agreement with Oculus. The separation agreement became effective upon the closing
of our initial public offering in March 2014 and has a term of 8.5 years, unless earlier terminated by agreement of the parties</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Voting.</I> So long
as Oculus and its affiliates own 19.9% of our common stock, Oculus will vote all of its shares in the same manner as the majority
of the minority holders of our common stock (non-Oculus holders).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Expense Allocation
and Reimbursement. </I> The separation agreement sets forth the methodology for the allocation of the operational and initial public
offering related expenses incurred prior to and in connection with our initial public offering for which it is required to reimburse
Oculus. We will also reimburse Oculus for expenses such as salaries and benefits advanced or paid on our behalf or for our benefit
during a transition period which began upon the closing of its initial public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Marketing and Transfer
Restrictions.</I> In order for the parties to control the flow of shares held by Oculus into the market to attempt to minimize
price volatility and instability in the trading market, the separation agreement contains a series of restrictions on Oculus&rsquo;
ability to transfer the shares of common stock owned by Oculus. As a general matter, transfers of shares are primarily expected
to be conducted through private marketing efforts in private placement transactions, except in the cases prescribed in the separation
agreement. For example, Oculus is restricted from engaging in marketing efforts related to the transfer of shares and is required
to refer indications of interest from third parties regarding the transfer of shares it owns to us, except during certain prescribed
periods set forth in the separation agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Lockup.</I> Oculus
and its affiliates are restricted from transferring, pledging, or encumbering shares for twelve months from the closing of the
initial public offering (the &ldquo;Oculus Lock Up Period&rdquo;) without the consent of our board of directors and the managing
underwriter in our initial public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the Oculus
Lock Up Period, transfers by Oculus of the shares of our common stock shares that it owns must be conducted with the consent of
our board of directors or within the prescribed requirements for such transfers set forth in the separation agreement. These prescribed
requirements include that the transfers must be in private placement transactions, that the purchase price discount may not exceed
15% or 20% of the prevailing market price depending on the type of transferee, the amount of shares transferred in a given transfer
(or series of transfers comprising a single transaction) may not exceed the greater of 5% of our outstanding shares or $1,500,000
in net proceeds to Oculus, as well as certain other requirements set forth in the separation agreement. In addition to the prescribed
manner for Oculus to conduct transfers described above, if, after 41.5 months following the closing of its initial public offering,
Oculus has not consummated transfers of shares it owns resulting in at least $3.8 million in net proceeds to Oculus, then Oculus
has a one-time transfer and registration right to transfer shares it owns in an amount equal to the difference between $3.8 million
and the net proceeds received by Oculus resulting from transfers of the shares as of the time Oculus elects to exercise its one-time
right. Transfers conducted using this one-time right must be conducted with the consent of our board of directors or within the
prescribed requirements for such transfers set forth in the separation agreement, including, for example, that the purchase price
discount may not exceed 30% of the prevailing market price, the amount of shares transferred may not exceed $3,800,000 in net proceeds
to Oculus, as well as certain other requirements set forth in the separation agreement. The separation agreement also provides
for certain cooling off periods between marketing attempts and/or successful transfers, the length of which are dependent upon
whether and how many shares Oculus transfers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Distribution. </I>We
believe that a distribution of our shares by Oculus to Oculus stockholders would be advantageous to the market for our shares by
increasing liquidity, would accelerate our ability to become independent from Oculus by decreasing Oculus&rsquo; ownership of our
common stock and would be beneficial for Oculus&rsquo; stockholders who would have a direct opportunity to participate in our value
proposition. The decision to conduct any such distribution is at the sole discretion of Oculus&rsquo; board of directors and would
be subject to the expiration of the Oculus Lock Up Period and other agreements we have or may have with Oculus. There is no assurance
that a distribution will ever occur. However, pursuant to the separation agreement, Oculus has agreed, from time to time, to retain
investment bankers and tax advisors to re-evaluate the advisability of conducting a plan of distribution of our shares to Oculus
stockholders and we have agreed to register any shares that Oculus may distribute in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Registration Rights.</I>
If after the Lock-Up Period, Oculus and its affiliates own greater than 19.9% of our common stock, and we register shares in connection
with a public offering for cash, Oculus has &ldquo;piggy back&rdquo; registration rights of up to 30% of the value of the securities
we register. The agreement also provides for certain demand registration rights. In addition, as described under &ldquo; Marketing
and Transfer Restrictions &rdquo; above, if, following a minimum of 41.5 months following the closing of the initial public offering,
Oculus has not consummated transfers of shares resulting in at least $3.8 million in net proceeds to Oculus, then Oculus has a
one-time transfer and registration right that requires us, subject to certain conditions and limitations, to register the difference
between $3.8 million and the shares transferred by Oculus pursuant to the separation agreement as of the time Oculus elects to
exercise its one-time right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Standstill</I>.
If Oculus and its affiliates own greater than 19.9% of our common stock, Oculus shall not, and shall not act in concert with any
person to, make or participate in a solicitation of proxies or powers of attorney or similar rights to vote any shares Oculus owns
or deposit any shares in a voting trust.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Restrictions Relating
to Debt</I>. Oculus has agreed that, if it its affiliates own greater than 19.9% of our common stock, Oculus shall disclose in
writing to any creditor holding shares as collateral that such shares are subject to certain transfer restrictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Equity Plan, Oculus
Equity and Corporate Governance</I>. The parties agreed on the terms of our equity incentive plan, including the formula for the
number of shares reserved under the plan, the vesting schedule of awards under the plan, timing, size and award type of the initial
grants which we made following the closing of its initial public offering, and the formula for an annual evergreen refresh provision
which shall provide for the reservation of additional shares, and other share caps on certain types of awards and future equity
plans. The separation agreement also provides that options for common stock of Oculus held by our employees and directors shall
continue to vest as long as such persons continue to be employed by or serve as a director of our company. In addition, the separation
agreement provides that our restated certificate of incorporation and bylaws shall contain provisions for a staggered board of
directors and plurality voting for the election of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Indemnification.</I>
The separation agreement provides that each party will indemnify the other party and its affiliates for third party claims asserted
against the other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Directors&rsquo;
and Officers&rsquo; Insurance</I>. The separation agreement provides that so long as Oculus shall maintain a directors&rsquo; and
officers&rsquo; insurance program covering the past and present officers and directors of Oculus, the program shall be standard
in Oculus&rsquo; industry and such coverage shall include our directors and officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Oculus Side Letter Agreement </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
the proposed Merger, on March 13, 2015, Pulmatrix entered into a side letter agreement with Oculus pursuant to which, among other
things, Oculus agreed, from the effective date of the Merger, to (i) waive our obligations to use commercially reasonable efforts
to develop and commercialize products licensed from Oculus under the License and Supply Agreement until the earlier of one year
from the closing of the Merger or August 31, 2016; (ii) provide a general release from claims and liabilities arising under the
License and Supply Agreement, the separation agreement and the shared services agreement in favor of us; and (iii) permit us to
run a sale process for our pre-merger business, including any products licensed from Oculus, and to assign all of our surviving
rights under the License and Supply Agreement, the separation agreement and the shared services agreement, subject to certain consent
rights of Oculus with respect to the identity of the proposed purchaser. In the event of a sale of our pre-merger business with
a minimum aggregate purchase price of $1 million, Oculus will have a right of first refusal to acquire such business on exactly
the same terms, and in the event that Oculus does not exercise its right of first refusal and the aggregate purchase price exceeds
$10 million, Oculus will receive 10% of the gross consideration from such sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The proprietary nature
of, and protection for, our drug candidates and our discovery programs, processes and know-how are important to our business. Oculus
has sought patent protection in the United States and internationally for its topical HOCl based inventions and we intend to do
the same for our discovery programs, and any other inventions we make, where available and when appropriate. Our policy is to pursue,
maintain and defend patent rights, whether developed internally or licensed from third parties, and to protect the technology,
inventions and improvements that are commercially important to our business. We also rely on trade secrets to protect our proprietary
discoveries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial success
will depend in part on our ability and Oculus&rsquo; ability to obtain and maintain patent protection and trade secret protection
of our current and future drug candidates and the innovative methods used to develop and manufacture them, as well as to successfully
defend these patent and trade secret rights against potential competitors. Our ability to stop third parties from making, using,
selling, offering to sell or importing its products depends on the extent to which we have rights under valid and enforceable patents
or trade secrets that cover these activities. We cannot be sure that patents will be granted with respect to any of Oculus&rsquo;
pending patent applications or with respect to any patent applications filed by us, Oculus or other licensors in the future, nor
can we be sure that any of Oculus&rsquo; existing patents or any patents that may be granted to us, Oculus or other licensors in
the future will be commercially useful in protecting our product candidates, discovery programs and processes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The intellectual property
rights upon which we rely to operate our business derive from our collaboration with Oculus. Through our license and supply agreement
with Oculus, we have exclusive rights to certain of Oculus&rsquo; patents and pending applications (both U.S. and foreign) that
cover composition of matter, proprietary manufacturing processes for HOCl based products, know-how to develop and market specified
products within the territory and field described in the agreement. Oculus&rsquo; patent portfolio generally relates to oxidative
reductive potential water including, for example, formulations, apparatuses, methods of use and processes for producing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 31, 2015,
the patent portfolio owned or licensed by Oculus includes 5 issued U.S. patents, 36 issued foreign patents, 16 pending U.S. patent
applications and 77 pending foreign patent applications. In general, the issued U.S. and foreign patents expire in 2020 &ndash;
2027. The expiration dates of pending U.S. and foreign patent application will be from 2020 &ndash; 2027 in the event that such
applications issue. Several of these patents relate to the innovative HOCl formulation and manufacturing process that formed the
basis for RUT58-60, which we licensed from Oculus. These patents and pending applications (if issued) will expire in 2027 &ndash;
2034.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Manufacturing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since our inception,
RUT58-60 has been manufactured at Oculus in its Petaluma, California manufacturing facility. We have a third party contract manufacturing
organization, or CMO, that complies with the FDA&rsquo;s cGMP requirements for manufacturing sterile drugs. Our ability to transfer
our manufacturing to a CMO is dependent on our ability to assist the CMO to pass regulatory inspections and gain necessary certifications
and clearances, and continue to work with the CMO to maintain a compliant manufacturing facility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">RUT58-60 is manufactured
using a proprietary process in which the creation of HOCl is controlled through uniquely developed chemical processing apparatuses
that yield HOCl in a stable form. The resulting formulation can be further sterilized including its final packaging to make it
suitable for use in the surgical suite. To date, we are not aware of any sterile forms of HOCl approved for invasive use in the
surgical suite in the United States or elsewhere. RUT58-60 has been manufactured under cGMP conditions and has been subject to
the standard sterilization processes required by FDA. This final critical step in the manufacturing of RUT58-60 is designed to
prevent the potential for the introduction of infectious agents related to the packaging material when the drug is used in sterile
surgical suites. In laboratory studies for RUT58-60, we have demonstrated that RUT58-60&rsquo;s stability withstands the conditions
associated with the sterilization processes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Sales and Marketing/Commercialization</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not currently
have a commercialization organization capable of marketing, selling and distributing our drug candidates. We have conducted discussions
with pharmaceutical, biotechnology and other organizations that we believe have existing experience and resources to bring our
initial, and potentially future, product candidates to market. To date, we have not entered into any partnerships or collaborations
for RUT58-60 and we cannot guarantee that we will be successful entering into any such arrangements on favorable terms, or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><B>Competition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe the principal
competitive factors in our target market include improved patient outcomes, such as time in the hospital, healing time, adverse
events, and safety of products; ease of use; stability; eliminating the emergence of resistant pathogens; and, cost effectiveness.
The anti-infective pharmaceutical and biotechnology industries are highly competitive. We compete with a number of large well-established
and well-funded companies that sell a broad range of products, including topical anti-infective products and antibiotics; prescription
products for the prevention and treatment of infections; advanced technologies, such as skin substitutes, growth factors and sophisticated
delayed release silver based dressings; and other anti-infective products used in the hospital settings. We potentially may compete
with academic, government and other private and public research institutes and organizations in the discovery and development of
innovative anti-infective compounds and solutions. Our competitors may discover, develop, or license technologies that are more
effective, have an improved safety or tolerability profile, or a more cost effective than RUT58-60 or any future product candidate
we may discover, develop or license. These competitive product candidates may render our product candidates obsolete or non-competitive.
Currently, we believe no single anti-infective product dominates the surgical or traumatic injury markets because many of the products:
have limitations to product stability and ease of use; are not broad spectrum covering all gram negative and gram positive bacteria;
induce resistance in pathogens, specifically bacteria; have known systemic side effects; rely principally on the treatment of already
infected patients or may not be cost effective for hospitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While many companies
are able to produce HOCl based products, we believe these products are not and may not ever be designed to meet the same rigorous
product stability targets for RUT58-60, have not made the scientific enhancement and advances to produce formulations to withstand
sterilization and are not formulated for use with internal organs and tissue exposure during surgery. The following three companies
in the United States and/or Europe produce HOCl products intended for medical applications:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">Oculus, our licensor with which we have a non-competition provision as part of our licensing agreement
designed to protect both companies&rsquo; ability to develop and commercialize products in their respective fields and territories;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">PuriCore, a company whose core revenue is focused on developing and selling a form of HOCl for
topical use and the other major uses of their products include sterilization of endoscopes; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">NovaBay, a company which is developing HOCl products for ophthalmology and wound care.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notable societies,
including IDSA and WHO, have issued public statements expressing concern over the limited number of new antibiotic approvals and
drugs under development, specifically in regards to the management of drug-resistant pathogens. Amidst these calls-to-action and
additional physician interest in innovative and novel antibiotic therapies, We expect the field of biotechnology and pharmaceutical
companies that market or are developing antibiotic therapies to grow. Notably, in July 2012, the Food and Drug Administration Safety
and Innovation Act, or FDASIA, was passed, which included the Generating Antibiotics Incentives Now Act, or GAIN Act. The GAIN
Act is intended to provide incentives for the development of new, qualified infectious disease products. These incentives may result
in more competition in the market for new antibiotics, and may cause pharmaceutical and biotechnology companies to shift their
efforts towards the development of products that could be competitive with RUT58-60 and any of our future potential product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Protocols for the prevention
of infection prior to surgery vary from hospital to hospital and to a lesser degree from surgeon to surgeon. Several common techniques
described in medical literature include the prophylactic use of systemic broad-spectrum antibiotics, which historically has been
considered a standard of care by many physicians, antiseptics used to sterilize an incision site, saline or saline plus active
lavage of the surgical site, diagnostic testing to identify bacterial colonization and to assess an individual&rsquo;s risk of
infection, and general improvements to protocols used by personnel within the surgical suite. Despite these efforts, post-surgical
infections remain a significant unmet medical need and many companies have commercialized or are developing antibiotics to address
this growing concern. Principal companies include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cubist Pharmaceuticals,
Forest Laboratories, Astra Zeneca, and Tetraphase Pharmaceuticals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other notable companies
developing antibiotic therapies include: Achaogen, Basilea, Cempra, Durata Therapeutics, GlaxoSmithKline, Merck, Paratek, Rempex,
Rib-X, and Trius. Select major broad spectrum antibiotic drugs include: Levaquin (JNJ/Generic), Zosyn (generic), Meerem (Astra
Zeneca/generic), Primaxin (Merck/generic), Tygacil (Pfizer), Augmentin (generic), Metronidazole in combinations (Forest Laboratories,
Astra Seneca, Cubist), Cephalosporin (generic), Doribax (JNJ), Avelox (Bayer), and Invanz (Merck).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Some of our competitors
producing antibiotics enjoy several competitive advantages over us, including: significantly greater name recognition; established
relationships with healthcare professionals, patients and third party payors; established distribution networks; additional product
lines and the ability to offer rebates or bundle products to offer discounts or incentives; greater experience in conducting research
and development, manufacturing, obtaining regulatory approval for products and marketing; and greater financial and human resources
for product development, sales and marketing and patient support.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><B>Government Regulation
and Product Approval</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Governmental authorities
in the United States, at the federal, state and local level, and in other countries extensively regulate, among other things, the
research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion,
advertising, distribution, marketing and export and import of products such as those we are developing. Our product candidates
must be approved by the FDA through the NDA process before they may be legally marketed in the United States and by the European
Medicines Agency, or EMA, through the Marketing Authorization Application, or MAA, process before they may be legally marketed
in Europe. Our product candidates will be subject to similar requirements in other countries prior to marketing in those countries.
The process of obtaining regulatory approvals in the United States and in foreign countries, along with subsequent compliance with
applicable statutes and regulations, require the expenditure of substantial time and financial resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>United States Drug Development Process</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States,
the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and implementing regulations. Failure to comply
with the applicable U.S. requirements at any time during the product development process or approval process, or after approval,
may subject an applicant to administrative or judicial sanctions, any of which could have a material adverse effect on us. These
sanctions could include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">refusal to approve pending applications;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">withdrawal of an approval;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">imposition of a clinical hold;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">warning letters;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">product seizures;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">total or partial suspension of production or distribution; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">injunctions, fines, disgorgement, or civil or criminal penalties.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The process required
by the FDA before a drug may be marketed in the United States generally involves the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">completion of preclinical laboratory tests, animal studies and formulation studies according to
Good Laboratory Practices, or GLP, or other applicable regulations;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">submission to the FDA of an IND which must become effective before human clinical trials may begin;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">performance of adequate and controlled human clinical trials according to Good Clinical Practices,
or GCP, and other applicable requirements to establish the safety and efficacy of the proposed drug for its intended use;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">submission to the FDA of a new drug application (&ldquo; NDA&rdquo;);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which
the drug is produced to assess compliance with cGMP to assure that the facilities, methods and controls are adequate to preserve
the drug&rsquo;s identity, strength, quality and purity; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">FDA review and approval of the NDA.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of the IND,
an IND sponsor must submit to the FDA the results of preclinical tests, which may include laboratory evaluations and animal studies,
together with manufacturing information and analytical data, and the proposed clinical protocol for the first Phase of the clinical
trial of the drug. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day
time period, places the clinical trial on a &ldquo;clinical hold&rdquo; because of safety concerns or perceived procedural deficiencies.
In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials may begin. A clinical
hold may be imposed by the FDA at any time during the life of an IND, and may affect one or more specific studies or all studies
conducted under the IND.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All clinical trials
must be conducted under the supervision of one or more qualified investigators in accordance with GCP. They must be conducted under
protocols detailing the objectives of the trial, dosing procedures, research subject selection and exclusion criteria and the safety
and effectiveness criteria to be evaluated. Each protocol must be submitted to the FDA as part of the IND, and progress reports
detailing the status of the clinical trials must be submitted to the FDA annually. Sponsors also must timely report to FDA serious
and unexpected adverse reactions, any clinically important increase in the rate of a serious suspected adverse reaction over that
listed in the protocol or investigation brochure, or any findings from other studies or animal or in vitro testing that suggest
a significant risk in humans exposed to the drug. An institutional review board, or IRB, must also review and approve each new
clinical protocol and patient informed consent form prior to commencement of the corresponding clinical trial at each institution
where a trial is to be performed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Human clinical trials
are typically conducted in three sequential Phases that may overlap or be combined:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify"><I>Phase 1:</I> The drug is initially introduced into healthy human subjects and tested for safety,
dosage tolerance, absorption, metabolism, distribution and excretion. In the case of some products for severe or life-threatening
diseases, such as cancer, especially when the product may be inherently too toxic to ethically administer to healthy volunteers,
the initial human testing is often conducted in patients.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify"><I>Phase 2:</I> Clinical trials are performed on a limited patient population intended to identify
possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases
and to determine dosage tolerance and optimal dosage.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify"><I>Phase 3:</I> Clinical trials are undertaken to further evaluate dosage, clinical efficacy and
safety in an expanded patient population at geographically dispersed clinical study sites. These studies are intended to establish
the overall risk-benefit ratio of the product and provide, if appropriate, an adequate basis for product labeling.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Human clinical trials
are inherently uncertain and Phase 1, Phase 2 and Phase 3 testing may not be successfully completed. The FDA or the sponsor may
suspend a clinical trial at any time for a variety of reasons, including a finding that the research subjects or patients are being
exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution
if the clinical trial is not being conducted in accordance with the IRB&rsquo;s requirements or if the drug has been associated
with unexpected serious harm to patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the development
of a new drug, sponsors are given an opportunity to meet with the FDA at certain points. These points may be prior to submission
of an IND, at the end of Phase 2, and before an NDA is submitted. These meetings can provide an opportunity for the sponsor to
share information about the data gathered to date and for the FDA to provide advice on the next phase of development. Sponsors
typically use the end-of-Phase 2 meeting to discuss their Phase 2 clinical results and present their plans for the pivotal Phase
3 clinical trial that they believe will support approval of the new drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Concurrent with clinical
trials, sponsors usually complete additional animal safety studies and also develop additional information about the chemistry
and physical characteristics of the drug and finalize a process for manufacturing commercial quantities of the product in accordance
with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug and the
manufacturer must develop methods for testing the quality, purity and potency of the drug. Additionally, appropriate packaging
must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable
deterioration over its proposed shelf-life.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a drug is intended
to treat a serious or life threatening condition for which there is an unmet medical need, a company may request that the FDA consider
the drug for a fast track development program at the time of submitting its IND or at any time prior to receiving marketing approval.
The fast track program is designed to facilitate the development and expedite the review of a new drug for the treatment of specific
conditions. If the FDA agrees that the drug meets the criteria for fast track development for treatment of one or more conditions,
it will grant fast track status.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>United States Drug Review and Approval
Processes</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The results of product
development, preclinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted
on the chemistry of the drug, proposed labeling, and other relevant information are submitted to the FDA as part of an NDA requesting
approval to market the product. The FDA reviews all NDAs submitted to ensure that they are sufficiently complete for substantive
review before it accepts them for filing. It may request additional information rather than accept an NDA for filing. In this event,
the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA
accepts it for filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Once the submission
is accepted for filing, the FDA begins an in-depth and substantive review. The FDA reviews an NDA to determine, among other things,
whether a product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant. The FDA may seek
advice and a recommendation from an external advisory committee as to whether the application should be approved and under what
conditions. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations.
Before approving an NDA, the FDA will inspect the facility or facilities where the product is manufactured and tested. The FDA
may refuse to approve an NDA if the applicable regulatory criteria are not satisfied or may require submission of additional clinical
or other data and information which, upon agency review and interpretation, may or may not be deemed by the FDA to satisfy the
criteria for approval. The FDA may also issue a &ldquo;complete response&rdquo; letter, which may require additional clinical or
other data or impose other conditions that must be met in order to secure final approval of the NDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NDAs receive either
standard or priority review. A drug representing a significant improvement in treatment, prevention or diagnosis of disease may
receive priority review. In addition, products studied for their safety and effectiveness in treating serious or life-threatening
illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval and may be
approved on the basis of adequate and well-controlled clinical trials establishing that the drug candidate has an effect on a surrogate
endpoint that is reasonably likely to predict clinical benefit or on the basis of an effect on a clinical endpoint other than survival
or irreversible morbidity. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval
perform adequate and well-controlled post-marketing clinical trials. Priority review and accelerated approval do not change the
standards for approval, but may expedite the approval process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the recently enacted
FDASIA, Congress encouraged the FDA to utilize innovative and flexible approaches to the assessment of products under accelerated
approval. The law requires the FDA to issue related draft guidance within a year after the law&rsquo;s enactment and also promulgate
confirming regulatory changes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If approved by the
FDA, a product&rsquo;s use may be limited to specific diseases, dosages or indications. In addition, the FDA may require us to
conduct additional testing post-approval, which may involve further nonclinical studies or clinical trials designed to further
assess the drug&rsquo;s safety and effectiveness and may require additional testing and surveillance programs to monitor the safety
of the drug in the marketplace.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Patent Term Restoration and Marketing
Exclusivity</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Depending upon the
timing, duration and specifics of FDA approval of its product candidates, a U.S. patent we own or license from Oculus may be eligible
for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the
Hatch-Waxman Act. The Hatch-Waxman Act permits a patent restoration term of up to five years as compensation for patent term lost
during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining
term of a patent beyond a total of 14 years from the product&rsquo;s approval date. The patent term restoration period is generally
one-half the time between the effective date of an IND, and the submission date of NDA, plus the time between the submission date
of a NDA and the approval of that application. Only one patent applicable to an approved drug is eligible for the extension and
the application for extension must be made prior to expiration of the patent. The United States Patent and Trademark Office, in
consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we
intend to apply for restorations of patent term for some of its currently owned or licensed patents to add patent life beyond their
current expiration date, depending on the expected length of clinical trials and other factors involved in the submission of the
relevant NDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Market exclusivity
provisions under the FDCA also can delay the submission or the approval of certain applications. The FDCA provides a five-year
period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a new
chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same
active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the
FDA may not accept for review an Abbreviated New Drug Application, or ANDA, or a 505(b)(2) NDA submitted by another company for
another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval.
However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement.
The FDCA also provides three years of marketing exclusivity for an NDA, 505(b)(2) NDA or supplement to an approved NDA if new clinical
investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to
be essential to the approval of the application, for example, for new indications, dosages or strengths of an existing drug. This
three-year exclusivity covers only the conditions associated with the new clinical investigations and does not prohibit the FDA
from approving ANDAs for drugs containing the original active pharmaceutical ingredient. Five-year and three-year exclusivity will
not delay the submission or approval of a full NDA; however, an applicant submitting a full NDA would be required to conduct or
obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate
safety and effectiveness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Pediatric Exclusivity and Pediatric
Use</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Best Pharmaceuticals
for Children Act, or BPCA, certain drugs may obtain an additional six months of exclusivity, if the sponsor submits information
requested in writing by the FDA, or a Written Request, relating to the use of the active moiety of the drug in children. The FDA
may not issue a Written Request for studies on unapproved or approved indications or where it determines that information relating
to the use of a drug in a pediatric population, or part of the pediatric population, may not produce health benefits in that population.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To receive the six-month
pediatric market exclusivity, we would have to receive a Written Request from the FDA, conduct the requested studies in accordance
with a written agreement with the FDA or, if there is no written agreement, in accordance with commonly accepted scientific principles,
and submit reports of the studies. A Written Request may include studies for indications that are not currently in the labeling
if the FDA determines that such information will benefit the public health. The FDA will accept the reports upon its determination
that the studies were conducted in accordance with and are responsive to the original Written Request or commonly accepted scientific
principles, as appropriate, and that the reports comply with the FDA&rsquo;s filing requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the Pediatric
Research Equity Act, or PREA, requires a sponsor to conduct pediatric studies for most drugs and biologicals, for a new active
ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original NDAs, Biologics
License Applications, or BLA, and supplements thereto, must contain a pediatric assessment unless the sponsor has received a deferral
or waiver. The required assessment must assess the safety and effectiveness of the product for the claimed indications in all relevant
pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is safe and
effective. The sponsor or FDA may request a deferral of pediatric studies for some or all of the pediatric subpopulations. A deferral
may be granted for several reasons, including a finding that the drug or biologic is ready for approval for use in adults before
pediatric studies are complete or that additional safety or effectiveness data needs to be collected before the pediatric studies
begin. After April 2013, the FDA must send a non-compliance letter to any sponsor that fails to submit the required assessment,
keep a deferral current or fails to submit a request for approval of a pediatric formulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of the FDASIA,
Congress made a few revisions to BPCA and PREA, which were slated to expire on September 30, 2012, and made both laws permanent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Post-Approval Requirements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Once an approval is
granted, the FDA may withdraw the approval if compliance with regulatory requirements is not maintained or if problems occur after
the product reaches the market. Later discovery of previously unknown problems with a product may result in restrictions on the
product or even complete withdrawal of the product from the market. After approval, some types of changes to the approved product,
such as adding new indications, manufacturing changes and additional labeling claims, are subject to further FDA review and approval.
In addition, the FDA may require testing and surveillance programs to monitor the effect of approved products that have been commercialized,
and the FDA has the power to prevent or limit further marketing of a product based on the results of these post-marketing programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any drug products manufactured
or distributed by us pursuant to FDA approvals are subject to continuing regulation by the FDA, including, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">record-keeping requirements;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">reporting of adverse experiences with the drug;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">providing the FDA with updated safety and efficacy information;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">drug sampling and distribution requirements;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">notifying the FDA and obtaining its approval of specified manufacturing or labeling changes; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">complying with FDA promotion and advertising requirements.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Drug manufacturers
and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments
with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and some state agencies
for compliance with cGMP and other laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We rely, and expect
to continue to rely, on third parties for the production of clinical and commercial quantities of its products. Future FDA and
state inspections may identify compliance issues at the facilities of its contract manufacturers that may disrupt production or
distribution, or require substantial resources to correct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time,
legislation is drafted, introduced and passed in Congress that could significantly change the statutory provisions governing the
approval, manufacturing and marketing of products regulated by the FDA. In addition, FDA regulations and guidance are often revised
or reinterpreted by the agency in ways that may significantly affect our business and products. It is impossible to predict whether
legislative changes will be enacted, or FDA regulations, guidance or interpretations changed or what the impact of such changes,
if any, may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Foreign Regulation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to regulations
in the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and
distribution of its products. Whether or not we obtain FDA approval for a product, we must obtain approval by the comparable regulatory
authorities of foreign countries before it can commence clinical trials or marketing of the product in those countries. The approval
process varies from country to country and the time may be longer or shorter than that required for FDA approval. The requirements
governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under European Union
regulatory systems, a company may submit marketing authorization applications either under a centralized or decentralized procedure.
The centralized procedure, which is compulsory for medicines produced by biotechnology or those medicines intended to treat AIDS,
cancer, neurodegenerative disorders or diabetes and optional for those medicines which are highly innovative, provides for the
grant of a single marketing authorization that is valid for all European Union member states. The decentralized procedure provides
for mutual recognition of national approval decisions. Under this procedure, the holder of a national marketing authorization may
submit an application to the remaining member states. Within 90 days of receiving the applications and assessments report, each
member state must decide whether to recognize approval. If a member state does not recognize the marketing authorization, the disputed
points are eventually referred to the European Commission, whose decision is binding on all member states.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Reimbursement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sales of our product
candidates, if approved, will depend, in part, on the extent to which surgeons believe that the use of our products will lead to
fewer post-surgical infections and hospitals and other institutions at which surgical procedures are performed believe that the
use of our products will result in cost savings to them. The costs of most drugs used during surgical procedures are typically
included in the cost of the procedure and are not reimbursed as separate expenses by third-party payors, such as government health
programs such as Medicare and Medicaid, commercial health insurers and managed care organizations. The containment of healthcare
costs has become a priority for federal and state governments, and decreasing infections following surgery, accelerating patient
discharge from hospitals following surgery and reducing hospital readmissions have been primary targets in this effort.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that there
will continue to be a number of federal and state proposals to limit the growth of healthcare costs, including the cost of surgical
procedures and hospital stays. The adoption of other legislative or regulatory proposals could have a material adverse effect on
its business, financial condition and profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, in some
foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing
drug pricing vary widely from country to country. For example, the European Union provides options for its member states to restrict
the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices
of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt
a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There
can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow
favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union
do not follow price structures of the United States and generally tend to be significantly lower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Other United States Regulations</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pharmaceutical companies
also are subject to various federal and state laws pertaining to healthcare &ldquo;fraud and abuse,&rdquo; including anti-kickback
laws and false claims laws, and the reporting of payments to physicians and teaching hospitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Anti-Kickback Laws</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">U.S. federal laws prohibit
fraud and abuse involving state and federal healthcare programs, such as Medicare and Medicaid. These laws are interpreted broadly
and enforced aggressively by various state and federal agencies, including the Centers for Medicare &amp; Medicaid Services, or
CMS, the Department of Justice, the Office of Inspector General for the Department of Health and Human Services and various state
agencies. These anti-kickback laws prohibit, among other things, knowingly and willfully offering, paying, soliciting, receiving
or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing,
arranging for or recommending of an item or service that is reimbursable, in whole or in part, by a federal healthcare program.
Remuneration is broadly defined to include anything of value, such as, cash payments, gifts or gift certificates, discounts, or
the furnishing of services, supplies or equipment. The anti-kickback laws are broad and prohibit many arrangements and practices
that are lawful in businesses outside of the healthcare industry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The penalties for violating
the anti-kickback laws can be severe. The sanctions include criminal and civil penalties, and possible exclusion from the federal
healthcare programs. Many states have adopted laws similar to the federal anti-kickback laws, and some apply to items and services
reimbursable by any payor, including third-party payors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>State and Federal Prohibitions on False
Claims</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The federal False Claims
Act imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false
or fraudulent claim for payment to the federal government. Under the False Claims Act, a person acts knowingly if he has actual
knowledge of the information or acts in deliberate ignorance or in reckless disregard of the truth or falsity of the information.
Specific intent to defraud is not required. Provisions of the False Claims Act allow a private individual to bring an action on
behalf of the federal government and to share in any amounts paid by the defendant to the government in connection with the action.
The number of filings under these provisions has increased significantly in recent years. When an entity is determined to have
violated the False Claims Act, it may be required to pay up to three times the actual damages sustained by the government, plus
civil penalties for each false claim. Conduct that violates the False Claims Act may also lead to exclusion from the federal healthcare
programs. Given the number of claims likely to be at issue, potential damages under the False Claims Act for even a single inappropriate
arrangement could be significant. In addition, various states have enacted similar laws modeled after the False Claims Act that
apply to items and services reimbursed under Medicaid and other state healthcare programs, and, in several states, such laws apply
to claims submitted to all payors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Federal Prohibitions on Healthcare Fraud
and False Statements Related to Healthcare Matters</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the administrative
simplification provisions of the Health Insurance Portability and Accountability Act of 1996, or HIPAA, and state laws there are
numerous regulations for protecting the privacy and security of protected health information. Additional administrative simplification
provisions created the following new federal crimes: healthcare fraud, false statements relating to healthcare matters, theft or
embezzlement in connection with a health benefit program and obstruction of criminal investigation of healthcare offenses. The
healthcare fraud statute prohibits knowingly and willfully executing a scheme to defraud any healthcare benefit program, including
a private insurer. The false statements statute prohibits knowingly and willfully falsifying, concealing, or covering up a material
fact or making any materially false, fictitious, or fraudulent statement in connection with the delivery of or payment for healthcare
benefits, items, or services. The theft or embezzlement statute prohibits knowingly and willfully embezzling, stealing or otherwise
converting or misapplying the money or property of a healthcare benefit program. The obstruction of criminal investigations of
healthcare offenses statute prohibits willfully preventing, obstructing, misleading or delaying the communication of information
and records relating to a violation of a federal healthcare offense to a criminal investigator. A violation of any of these laws
is a felony and may result in fines, or exclusion from the federal healthcare programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>The Physician Payment Sunshine Act</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Physician Payment
Sunshine Act, or the Sunshine Act, which was enacted as part of the Patient Protection and Affordable Care Act, or ACA, requires
applicable manufacturers of drugs, devices, biologicals, or medical supplies covered under Medicare, Medicaid or the Children&rsquo;s
Health Insurance Program, to report annually to the Secretary of the Department of Health and Human Services payments or other
transfers of value made by that entity, or by a third party as directed by that entity, to physicians and teaching hospitals, or
to third parties on behalf of physicians or teaching hospitals, during the course of the preceding calendar year. The Final Rule
implementing the Sunshine Act, published on February 8, 2013, requires data collection on payments to begin on August 1, 2013.
The first annual report, comprised of data collected from August 1, 2013 to December 31, 2013, is due March 31, 2014. Failure to
comply with the reporting requirements can result in significant civil monetary penalties ranging from $1,000 to $10,000 for each
payment or other transfer of value that is not reported (up to a maximum per annual report of $150,000) and from $10,000 to $100,000
for each knowing failure to report (up to a maximum per annual report of $1 million). We will be required to collect data on and
report these payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Employees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of June 5, 2015, we employed a total
of five full-time employees and several part-time consultants and CROs, all of whom are based in the United States. We are not
a party to any collective bargaining agreements. We believe our relations with our employees are good.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in; text-align: left">Item 1A.</TD><TD STYLE="text-align: justify"><A NAME="a_004"></A>RISK FACTORS.</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>You should consider carefully the following
risk factors, together with all of the other information included or incorporated in this report. If any of the following risks,
either alone or taken together, or other risks not presently known to us or that we currently believe to not be significant, develop
into actual events, then our business, financial condition, results of operations or prospects could be materially adversely affected.
If that happens, the market price of our common stock could decline, and stockholders may lose all or part of their investment<FONT STYLE="font-weight: normal">.</FONT></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Risks Related to Our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We are a development stage company with no commercial
products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are developing RUT58-60,
our lead drug candidate, initially for the prevention of infection associated with abdominal surgery. We currently have no products
approved for sale. We submitted our IND, for RUT58-60 to the FDA in early May 2014. In June 2014, Our IND became effective thereby
allowing us to begin human clinical testing of RUT58-60. In July 2014, we began human clinical testing of RUT58-60 in a 21-day
skin irritation trial. In August 2014, we completed the skin irritation trial with 36 human subjects participating for 21 consecutive
days. In October 2014, we initiated the Phase 1/2 clinical trial, and, in November 2014, we began patient enrollment in the Phase
1 portion of the Phase 1/2 clinical trial to evaluate the safety, tolerability, and potential efficacy of our lead drug candidate,
RUT58-60, for use as an adjunct to systemic antibiotics in abdominal surgery and patient screening began at four clinical trial
sites in the United States. Pursuant to the Merger Agreement, we may scale down our operations, including scaling back patient
enrollment in our clinical trial to evaluate the safety of RUT58-60 within the abdominal cavity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We are heavily dependent on the success of our drug candidates
and we cannot provide any assurance that our lead drug candidate, RUT58-60, or other product candidates will be commercialized.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future success
depends heavily on our ability to successfully develop, obtain regulatory approval for, and commercialize our drug candidates,
which may never occur. We currently generate no revenues and incur substantial losses and we may never be able to develop or commercialize
a marketable drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before we generate
any revenues from product sales, we must complete preclinical studies and clinical trials, establish manufacturing capabilities
that comply with the FDA&rsquo;s cGMP requirements for manufacturing sterile drugs, receive approval from the FDA in the United
States and other regulatory agencies in foreign jurisdictions, build a commercial organization, make substantial investments and
undertake significant marketing efforts alone or in partnership with others. We will not be permitted to market or promote RUT58-60
or other product candidates, before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and
we may never receive such regulatory approval for any of its product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not previously
submitted a BLA or a NDA to the FDA, or similar drug approval filings to comparable foreign authorities, for any product candidate.
We cannot be certain that our lead drug candidate or any other product candidate will be successful in clinical trials or receive
regulatory approval. Further, our lead drug candidate or any other product candidate may not receive regulatory approval even if
our clinical trials are successful. If we do not receive regulatory approvals for our drug candidates, we may not be able to continue
our operations. Even if we successfully obtain regulatory approvals to market our lead drug candidate or any other product candidate,
our revenues will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval
and have commercial rights. If the markets for patient subsets that we are targeting are not as significant as we estimate, we
may not generate significant revenues from sales of such products, if approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have has licensed
RUT58-60 for development and commercialization in the United States, Canada, Europe and Japan. While the scope of regulatory approval
is similar in other countries, to obtain separate regulatory approval in many other countries we must comply with numerous and
varying regulatory requirements of such countries regarding safety and efficacy, clinical trials and commercial sales, pricing
and distribution of our lead drug candidate or any other product candidate, and we cannot predict success in these jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Clinical trials involve a lengthy and expensive process
with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Drug candidates that
we pursue will be subject to extensive regulation by the FDA in the United States and other regulatory agencies in foreign jurisdictions,
including activities related to preclinical studies, human clinical trials, manufacturing, labeling, packaging and sterilization,
storage, recordkeeping, advertising, promotion, export, import, marketing and distribution and other possible activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our lead drug candidate,
RUT58-60, is a proprietary formulation of HOCl, and we believe it has unique features and properties that will differentiate it
from other HOCl formulations that are marketed as topical products and regulated by the FDA as medical devices under 510(k) clearances.
We expect to pursue FDA drug approval for RUT58-60 as a new chemical entity. There may be other HOCl drug candidates in development
by other companies and these candidates may gain FDA drug approval prior to RUT58-60. We have has conducted a number of pre-clinical
tests using RUT58-60 in support of the IND for RUT58-60, which was submitted to the FDA in early May 2014. In June 2014, our IND
became effective thereby allowing us to begin human clinical testing of RUT58-60. In July 2014, we began human clinical testing
of RUT58-60 in a 21-day skin irritation trial. In August 2014, we completed the skin irritation trial with 36 human subjects participating
for 21 consecutive days. In October 2014, we initiated the Phase 1/2 clinical trial, and, in November 2014, we began patient enrollment
in the Phase 1 portion of the Phase 1/2 clinical trial to evaluate the safety, tolerability, and potential efficacy of our lead
drug candidate, RUT58-60, for use as an adjunct to systemic antibiotics in abdominal surgery and patient screening began at our
clinical trial sites in the United States. If and when, we move through the regulatory process, the FDA may make other suggestions
that may impact our ability to complete our clinical trials within the timeframe or budget that we anticipate, which could impact
investors&rsquo; interest in our business and our stock price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The results of preclinical
studies and clinical trials of previously published HOCl based products may not necessarily be indicative of the results of its
future clinical trials. The design of our clinical trials is based on many assumptions about the expected effects of HOCl used
historically in the industry and if those assumptions are incorrect, the trials may not produce statistically significant results.
Preliminary results may not be confirmed upon full analysis of the detailed results of an early clinical trial. Product candidates
in later stages of clinical trials may fail to show safety and efficacy sufficient to support intended use claims despite having
progressed through initial clinical trials. The data collected from clinical trials of our product candidates may not be sufficient
to obtain regulatory approval in the United States or elsewhere. Because of the uncertainties associated with drug development
and regulatory approval, we cannot determine if, or when, we may have an approved product for commercialization or whether we will
ever achieve sales or profits of RUT58-60 or other product candidates we may pursue in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may be subject to extensive regulations and may not
obtain marketing approvals for products in Europe and other jurisdictions.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to regulations
in the United States, should we or our collaborators pursue marketing approvals for RUT58-60 or its other drug candidates internationally,
we and our collaborators will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical
trials and any commercial sales and distribution of its products. Whether or not we, or our collaborators, obtain FDA approval
for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement
of clinical trials or marketing of the product in those countries. The requirements and process governing the conduct of clinical
trials, product licensing, pricing and reimbursement vary from country to country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to pursue
marketing approvals for RUT58-60 in Europe and other jurisdictions outside the United States with collaborative partners. The time
and process required to obtain regulatory approvals and reimbursement in Europe and other jurisdictions may be different from those
in the United States regulatory and approval in one jurisdiction does not ensure approvals in any other jurisdiction; however,
negative regulatory decisions in any jurisdiction may have a negative impact on the regulatory process in other jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we, or our collaborators,
fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or
withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We have limited knowledge and experience with NDA studies
and product applications and we may not be successful in obtaining FDA approvals for our drug candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Currently, we have
no products approved for sale. We have not submitted an application or obtained any FDA approval for any product through the NDA
process. This lack of previous experience with NDA processes and requirements may impede our ability to obtain FDA approval in
a timeframe consistent with our expectations and plans, or at all, for its drug candidates. Failure to comply with FDA and other
applicable regulatory requirements, either before or after product approval, may subject us to sanctions, including: warning letters,
deficiency notifications, application denials, approval denials, requirements for additional pre-clinical and/or clinical studies,
civil and/or criminal penalties, injunctions or suspensions of production, black box warnings and other product label requirements,
loss of product approvals, product seizures, or recalls.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If our products do not gain market
acceptance, our business will suffer because we may not be able to fund future operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A number of factors
may affect the market acceptance of our products or any other products we develop or acquire, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">the price of our products relative to other products for the same or similar treatments;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">the perception by patients, physicians and other members of the health care community of the effectiveness
and safety of our products for their indicated applications and treatments;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">our ability to fund our sales and marketing efforts; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">the effectiveness of our sales and marketing efforts.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our products do
not gain market acceptance, we may not be able to fund future operations, including developing, testing and obtaining regulatory
approval for new product candidates and expanding our sales and marketing efforts for any approved products, which would cause
our business to suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our research and development program
for drug candidates other than RUT58-60 is at an early stage, and we cannot be certain our development activities will result in
the commercialization of any drug.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except for our development
program for RUT58-60, our research and development program targeting non-infectious open surgery indications is at an early stage.
Any product candidates we develop will require significant additional research and development efforts prior to commercial sale,
including extensive pre-clinical and clinical testing and regulatory approval. This may require increases in spending on internal
projects, the acquisition of third party technologies or products, and other types of investments. We cannot be sure that our approach
to drug discovery, acting independently or with partners, will be effective or will result in the development of any drug. We cannot
expect that any drug candidates that do result from our research and development efforts will be commercially available for many
years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have limited experience
in conducting pre-clinical testing and clinical trials. Even if we receive initially positive clinical trial results, those results
will not mean that similar results will be obtained in the later stages of drug development. Our drug candidates are prone to the
risks of failure inherent in pharmaceutical product development, including the possibility that none of our drug candidates will
be:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">safe, non-toxic and effective;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">approved by regulatory authorities;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">developed into a commercially viable drug;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">manufactured or produced economically;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">successfully marketed; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">accepted widely by customers.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are dependent on a third party
manufacturing organization to fulfill our manufacturing needs, our development of RUT58-60, and our commercialization of RUT58-60,
if and when RUT58-60 receives regulatory approval, could be stopped or delayed or made less profitable if third party manufacturers
fail to provide us with sufficient quantities at acceptable prices.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The manufacture of
biotechnology and pharmaceutical products is complex and requires significant expertise, capital investment, process controls and
know-how. Common difficulties in biotechnology and pharmaceutical manufacturing may include: sourcing and producing raw materials,
transferring technology from chemistry and development activities to production activities, validating initial production designs,
scaling manufacturing techniques, improving costs and yields, establishing and maintaining quality controls and stability requirements,
eliminating contaminations and operator errors, and maintaining compliance with regulatory requirements. We currently rely on a
third party organization to manufacture RUT58-60 and we have no independent experience in manufacturing and cannot assure you that
any clinical-grade product will ever be produced or that we, or our other third party manufacturers on which we may rely in the
future will maintain operations necessary to continue to produce clinical-grade product for us. We lack the facilities and personnel
to manufacture products in accordance with cGMP prescribed by the FDA or to produce an adequate supply of compounds to meet future
requirements for clinical trials and commercialization of RUT58-60. Drug manufacturing facilities are subject to inspection before
the FDA will issue an approval to market a new drug product, and all of the manufacturers that we intend to use must adhere to
the cGMP regulations prescribed by the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our shared services
agreement with Oculus, which covered our manufacturing arrangement with Oculus, was terminated effective April 6, 2015. We previously
relied on Oculus to manufacture, and prepare for shipment, RUT58-60, out of its Petaluma, California, facility for its preclinical
studies and Phase 1/2 clinical trial. We did not control the manufacturing processes of Oculus and have been dependent on Oculus
for the production of RUT58-60 in accordance with cGMP, which include, among other things, quality control, quality assurance and
the maintenance of records and documentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may choose, or be forced, to terminate
our manufacturing arrangement with the third party manufacturing organization if it:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD>does not perform as agreed;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD>is not capable of producing or processing sufficient quantities of our drug candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD>is not able to manufacture materials that conform to our specifications;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD>is not able to hire or retain the necessary employees; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD>is unable to comply with cGMP requirements and with FDA, state and foreign regulatory requirements, and does not pass regulatory
inspections.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Manufacturers are periodically
subject to inspections by various regulatory agencies, some of which may be unannounced. The FDA and other regulatory agencies
have the ability to issue warning letters and sanctions against manufacturers based upon deficiencies noted during inspections
of facilities or based upon material defects in the product label, design, production, or distribution. In addition, we have no
control over the ability or willingness of our third party manufacturer to comply with regulatory requirements, maintain adequate
quality controls and processes, or maintain qualified personnel. Loss of our third party manufacturer may adversely affect our
ability to meet our requirements to conduct clinical trials, secure and maintain regulatory approvals, and meet commercialization
targets that we may establish in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have secured manufacturing
capabilities through a third party contract manufacturing organization, or CMO, that complies with the FDA&rsquo;s cGMP requirements
for manufacturing sterile drugs. Our ability to transfer our manufacturing to a CMO is dependent on our ability to transfer technology
and know-how, assist the CMO to pass regulatory inspections and gain necessary certifications and clearances, and continue to work
with the CMO to maintain a compliant manufacturing facility. In the future, we may establish an independent manufacturing facility
to conduct our Phase 3 clinical trial and, if the drug is approved, for our initial commercial supplies; however, we can give no
assurances that we will be able to do so or to maintain a self-directed manufacturing facility. In order to establish an in-house
manufacturing facility, we would be required to transfer manufacturing processes, acquire manufacturing equipment, and transfer
know-how as required to satisfy various regulatory requirements. We can offer no assurances that we would be able to enter into
any definitive agreements on acceptable terms for the expanded development and commercial scale manufacturing of RUT58-60 with
any other third party manufacturers or establish an independent manufacturing facility. Any supply disruptions may cause significant
delays in clinical trials and negatively impact commercial efforts, which may have an adverse effect on the value of our stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We and/or our third
party manufacturers may be adversely affected by developments outside of our control, and these developments may delay or prevent
further manufacturing of our products. Adverse developments may include labor disputes, resource constraints, shipment delays,
inventory shortages, lot failures, unexpected sources of contamination, laws related to our manufacturing techniques, equipment
used during manufacturing, or composition of matter, unstable political environments, acts of terrorism, war, natural disasters,
and other natural and man-made disasters. If we or our third party manufacturers encounters any of the above difficulties, or otherwise
fail to comply with contractual obligations, our ability to provide any product for clinical trial or commercial purposes would
be jeopardized. This may increase the costs associated with completing our clinical trials and commercial production. Further,
production disruptions may cause us to terminate ongoing clinical trials and/or commence new clinical trials at additional expense.
We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications
or pass safety inspections. If production difficulties cannot be solved with acceptable costs, expenses, and timeframes, we may
be forced to abandon our clinical development and commercialization plans, which could have a material adverse effect on our business,
prospects, financial condition, and the value of our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be unable to obtain sufficient
clinical trial liability insurance.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our inability to obtain
and retain sufficient clinical trial liability insurance at an acceptable cost to protect against potential liability claims could
prevent or inhibit our ability to conduct clinical trials for product candidates we develop. We expect to obtain clinical trial
liability insurance; however, any claim that may be brought against us could result in a judgment or settlement in an amount that
is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. We expects
we will supplement our clinical trial coverage with product liability coverage in connection with the commercial launch of RUT58-60
or other product candidates we develop in the future; however, we may be unable to obtain such increased coverage on acceptable
terms or at all. If we are found liable in a clinical trial lawsuit or a product liability lawsuit in the future, we will have
to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered
by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may need to increase the size
of our organization and the scope of our outside vendor relationships, and we may experience difficulties in managing growth.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of June 5, 2015,
we employed a total of five full-time employees. Our current internal departments include finance, research and development and
administration. We are led by a team that includes two executives, a Director of Regulatory and Quality Assurance and two operations
specialists.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may expand our management
team to include an operation ramp up of additional technical staff required to achieve our business objectives. We may need to
expand our managerial, operational, technical and scientific, financial and other resources in order to manage our operations and
clinical trials, establish independent manufacturing, continue our research and development activities, and commercialize our product
candidate. Our management and scientific personnel, systems and facilities currently in place may not be adequate to support our
future growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our need to effectively
manage our operations, growth and various projects requires that we:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">manage our clinical trials effectively, including our planned Phase 1/2 clinical trial of RUT58-60;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">manage our internal development efforts effectively while carrying out our contractual obligations
to licensors, contractors and other third parties;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">continue to improve our operational, financial and management controls and reporting systems and
procedures; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">attract and retain sufficient numbers of talented employees.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may utilize the
services of third party vendors to perform tasks including pre-clinical and clinical trial management, statistics and analysis,
regulatory affairs, medical advisory, market research, formulation development, Chemistry, Manufacturing and Controls, or CMC,
activities, other drug development functions, legal, auditing, financial advisory, and investor relations. Our growth strategy
may also entail expanding our group of contractors or consultants to implement these and other tasks going forward. Because we
rely on numerous consultants to outsource many key functions of our business, we will need to be able to effectively manage these
consultants to ensure that they successfully carry out their contractual obligations and meet expected deadlines. However, if we
are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants
is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory
approval for our product candidate or otherwise advance our business. There can be no assurance that we will be able to manage
our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all.
If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors,
we may be unable to successfully implement the tasks necessary to further develop and commercialize our product candidate and,
accordingly, may not achieve our research, development and commercialization goals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we are unable to develop satisfactory
sales and marketing capabilities, it may not succeed in commercializing RUT58-60 or any other product candidate.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have no experience
in marketing and selling drug products. We have not entered into any sales and marketing arrangements for our drug candidates.
We are developing our drug candidates for large patient populations served by surgeons. These patient populations may number in
the millions. Typically, pharmaceutical companies would employ groups of sales representatives and associated sales and marketing
staff numbering in the hundreds to thousands of individuals to call on this large number of physicians and hospitals. We may seek
to collaborate with a third party to market our drugs or may seek to market and sell our drugs by ourselves. If we seeks to collaborate
with a third party, we cannot be sure that a collaborative agreement can be reached on terms acceptable to it. If we seek to market
and sell our drugs directly, we will need to hire additional personnel skilled in marketing and sales. We cannot be sure that we
will be able to acquire, or establish third party relationships to provide, any or all of these marketing and sales capabilities.
The establishment of a direct sales force or a contract sales force or a combination direct and contract sales force to market
our products will be expensive and time-consuming and could delay any product launch. Further, we can give no assurances that it
may be able to maintain a direct and/or contract sales force for any period of time or that our sales efforts will be sufficient
to grow our revenues or that our sales efforts will ever lead to profits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Even if we obtain regulatory approvals
to commercialize RUT58-60 or any other drug, its drug candidates may not be accepted by physicians or the medical community in
general.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There can be no assurance
that RUT58-60 or any other product candidate successfully developed by us, independently or with partners, will be accepted by
physicians, hospitals and other health care facilities. RUT58-60 and any future product candidates we develop will compete with
a number of anti-infective drugs and antiseptic and cleansing products manufactured and marketed by major pharmaceutical and medical
technology companies. The degree of market acceptance of any drug candidates we develop depends on a number of factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD>our demonstration of the clinical efficacy and safety of such drugs;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD>timing of market approval and commercial launch of such drugs;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD>the clinical indication(s) for which such drugs are approved;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD>product label and package insert requirements;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD>advantages and disadvantages of our product candidates compared to existing therapies;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD>continued interest in and growth of the market for anti-infective drugs;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD>strength of sales, marketing, and distribution support;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD>product pricing in absolute terms and relative to alternative treatments;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD>future changes in health care laws, regulations, and medical policies; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">availability of reimbursement codes and coverage in select jurisdictions, and future changes to
reimbursement policies of government and third party payors.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Significant uncertainty
exists as to the coverage and reimbursement status of any product candidate for which we obtain regulatory approval. In the United
States and markets in other countries, sales of any products for which we receive regulatory approval for commercial sale will
depend in part on the availability of reimbursement from third-party payors. Third-party payors include government health administrative
authorities, managed care providers, private health insurers and other organizations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our failure to successfully acquire,
develop and market additional drug candidates or approved drug products could impair our ability to grow.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of our growth
strategy, we may evaluate, acquire, license, develop and/or market additional product candidates and technologies. However, our
internal research capabilities are limited, and we may be dependent upon pharmaceutical and biotechnology companies, academic scientists
and other researchers to sell or license products or technology to us. The success of this strategy depends partly upon our ability
to identify, select and acquire promising pharmaceutical product candidates and products. The process of proposing, negotiating
and implementing a license or acquisition of a product candidate or approved product is lengthy and complex. Other companies, including
some with substantially greater financial, marketing and sales resources, may compete with us for the license or acquisition of
product candidates and approved products. We have limited resources to identify and execute the acquisition or in-licensing of
third party products, businesses and technologies and integrate them into our current infrastructure. Moreover, we may devote resources
to potential acquisitions or in-licensing opportunities that are never completed, or we may fail to realize the anticipated benefits
of such efforts. We may not be able to acquire the rights to additional product candidates on terms that we find acceptable, or
at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, future
acquisitions may entail numerous operational and financial risks, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD>exposure to unknown liabilities;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">disruption of our business and diversion of our management&rsquo;s and technical personnel&rsquo;s
time and attention to develop acquired products or technologies;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD>incurrence of substantial debt or dilutive issuances of securities to pay for acquisitions;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD>higher than expected acquisition and integration costs;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">increased amortization expenses;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">difficulty and cost in combining the operations and personnel of any acquired businesses with our
operations and personnel;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">impairment of relationships with key suppliers or customers of any acquired businesses due to changes
in management and ownership; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">inability to retain key employees of any acquired businesses.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any product candidate
that we acquire may require additional development efforts prior to commercial sale, including extensive clinical testing and approval
by the FDA and applicable foreign regulatory authorities. All product candidates are prone to risks of failure typical of pharmaceutical
product development, including the possibility that a product candidate will not be shown to be sufficiently safe and effective
for approval by regulatory authorities. In addition, we cannot provide assurance that any products that we develop or approved
products that we acquire will be manufactured profitably or achieve market acceptance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not be able to attract, retain,
or manage highly qualified personnel, which could adversely impact our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future success
and ability to compete in the biopharmaceutical industry is substantially dependent on our ability to identify, attract, and retain
highly qualified key managerial, scientific, medical, and operations personnel. The market for key employees in the pharmaceutical
and biotechnology industries can be competitive. The loss of the services of any of our key employees without an adequate replacement
or our inability to hire new employees as needed could delay our product development efforts, harm our ability to sell our products
or otherwise negatively impact our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The scientific, research
and development personnel upon which we rely to operate our business have expertise in certain aspects of drug discovery, clinical
development and regulatory affairs, and it may be difficult to retain or replace these individuals. We currently conduct our operations
at our facilities in Santa Rosa, California, within the greater San Francisco Bay Area, and this region is headquarters to many
other biotechnology, pharmaceutical, and medical technology companies, as well as many academic and research institutions, and,
therefore, we face increased competition for technical and managerial personnel in this region.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we have
scientific, medical and clinical advisors who assist us in designing and formulating our products and with development and clinical
strategies. These advisors are not our employees and may have commitments to, or consulting or advisory contracts with, other entities
that may limit their availability to us, or may have arrangements with other companies to assist in the development of products
that may compete with our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Despite our efforts
to retain valuable employees, members of our management and scientific and development teams may terminate their employment with
us on short notice. Although we have written employment agreements with our executive officers, these employment agreements provide
for at-will employment, which means that our executive officers can leave our employment at any time, with or without notice. The
loss of the services of any of our executive officers or our other key employees, and our inability to find suitable replacements
could potentially harm our business, financial condition and prospects. We do not maintain &ldquo;key man&rdquo; insurance policies
on the lives of these individuals or the lives of any of our other employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our employees may engage in misconduct
or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are exposed to the
risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with any regulations
applicable to us, to provide accurate information to regulatory authorities, to comply with manufacturing standards we may have
established, to comply with federal and state healthcare fraud and abuse laws and regulations, or to report financial information
or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the
healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing
and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing
and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve
the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious
harm to our reputation. We have adopted a Code of Business Conduct, but it is not always possible to identify and deter employee
misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged
risk.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Business interruptions could adversely
affect our future operations, revenues, and financial conditions, and may increase our costs and expenses.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our operations, and
those of our directors, advisors, contractors, consultants, CROs, and collaborators, could be adversely affected by earthquakes,
floods, hurricanes, typhoons, extreme weather conditions, fires, water shortages, power failures, business systems failures, medical
epidemics and other natural and man-made disaster or business interruptions. Our telephones, electronic devices and computer systems
and those of our directors, advisors, contractors, consultants, CROs, and collaborators are vulnerable to damages, theft and accidental
loss, negligence, unauthorized access, terrorism, war, electronic and telecommunications failures, and other natural and man-made
disasters. Our headquarters are in Santa Rosa, California and may be subject to risks particularly those that are characteristic
of the region such as earthquakes, wildfires, shipping and port delays and closures, flooding, fog, and other natural and man-made
events that may adversely affect our results of operations and financial condition. Operating as a virtual company, our employees
conduct business outside of our headquarters and leased or owned facilities. These locations may be subject to additional security
and other risk factors due to the limited control of our employees. If such an event as described above were to occur in the future,
it may cause interruptions in our operations, delay research and development programs, clinical trials, regulatory activities,
manufacturing and quality assurance activities, sales and marketing activities, hiring, training of employees and persons within
associated third parties, and other business activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Likewise, we relies
on third parties to manufacture RUT58-60 and conduct clinical trials, and similar events as those described in the prior paragraph
relating to their business systems, equipment and facilities could also have a material adverse effect on our business. To the
extent that any disruption or security breach results in a loss of, or damage to, our data or applications, or inappropriate disclosure
of confidential or proprietary information, we could incur liability and the further development and commercialization of our product
candidate could be delayed or altogether terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If the Merger is consummated, the
business operations, strategies and focus of Ruthigen will fundamentally change, and these changes may not result in an improvement
in the value of its common stock. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pending the consummation
of the Merger, the Merger Agreement permits us to scale down our operations as we deem necessary and requires us to scale back
patient enrollment in our clinical trial of RUT58-60, our primary drug candidate, and it is currently anticipated that the combined
company would focus its resources on the development of products within the scope of Pulmatrix&rsquo;s current business plan. As
a result, following the Merger, the combined company may seek to sell or assign its rights related to our current drug candidates,
including RUT58-60. If completed, any such sale or assignment may be at a substantial discount, the consideration received may
not accurately represent the value of the assets sold or assigned and stockholders may not participate in the future prospects
of such drug candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the Merger,
it is expected that the combined company&rsquo;s primary products will be PUR1900, Pulmatrix&rsquo;s lead anti-infective product
candidate, PUR0200, Pulmatrix&rsquo;s bronchodilator therapy candidate and Pulmatrix&rsquo;s other iSPERSE-based product candidates.
Consequently, if the Merger is consummated, an investment in Ruthigen&rsquo;s common stock will primarily represent an investment
in the business operations, strategies and focus of Pulmatrix. All of Pulmatrix&rsquo;s product candidates are still under development
and may never be approved for sale or successfully commercialized. The failure to successfully commercialize one or more of Pulmatrix&rsquo;s
current product candidates will significantly diminish the anticipated benefits of the Merger and have a material adverse effect
on the business of the combined company. We cannot assure you that Ruthigen&rsquo;s business operations, strategies or focus will
be successful following the Merger, and the Merger could depress the value of Ruthigen&rsquo;s common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Risks Related to Development and Regulatory
Approval of RUT58-60 and Our Product Candidates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We cannot be certain that RUT58-60
or any of our future product candidates will</I></B><I> <B>receive regulatory approval, and without regulatory approval we will
not be able to market our product candidates.</B></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business currently
depends on the successful development and commercialization of RUT58-60. Our ability to generate revenue related to product sales,
if ever, will depend on the successful development and regulatory approval of RUT58-60 for the prevention of infection associated
with abdominal surgery and other indications and our future product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently have no
products approved for sale and we cannot guarantee that we will ever have marketable products. The development of a product candidate
and issues relating to our approval and marketing are subject to extensive regulation by the FDA in the United States and regulatory
authorities in other countries, with regulations differing from country to country. We are not permitted to market our product
candidates in the United States until we receive approval of an NDA from the FDA. We have not submitted any marketing applications
for any of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NDA&rsquo;s must include
extensive preclinical and clinical data and supporting information to establish the product candidate&rsquo;s safety and effectiveness
for each desired indication. NDA&rsquo;s must also include significant information regarding the CMC for the product. Obtaining
approval of an NDA is a lengthy, expensive and uncertain process, and we may not be successful in obtaining approval. The FDA review
processes can take years to complete and approval is never guaranteed. If we submit an NDA to the FDA, the FDA must decide whether
to accept or reject the submission for filing. We cannot be certain that any submissions will be accepted for filing and review
by the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Regulators of other
jurisdictions have their own procedures for approval of product candidates. Even if a product is approved, the FDA may limit the
indications for which the product may be marketed, require extensive warnings on the product labeling or require expensive and
time-consuming clinical trials or reporting as conditions of approval. Regulatory authorities in countries outside of the United
States also have requirements for approval of drug candidates with which we must comply prior to marketing in those countries.
Obtaining regulatory approval for marketing of a product candidate in one country does not ensure that we will be able to obtain
regulatory approval in any other country. In addition, delays in approvals or rejections of marketing applications in the United
States or other countries may be based upon many factors, including regulatory requests for additional analyses, reports, data,
preclinical studies and clinical trials, regulatory questions regarding different interpretations of data and results, changes
in regulatory policy during the period of product development and the emergence of new information regarding our product candidates
or other products. Also, regulatory approval for any of our product candidates may be withdrawn.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot predict whether
our future trials and studies will be successful or whether regulators will agree with our conclusions regarding the preclinical
studies and clinical trials it has conducted to date. If we are unable to obtain approval from the FDA or other regulatory agencies
for RUT58-60 and our other product candidates, or if, subsequent to approval, we are unable to successfully commercialize RUT58-60
or our other product candidates, we will not be able to generate sufficient revenue to become profitable or to continue our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Clinical trials for our product candidates
are expensive, time-consuming, uncertain and susceptible to change, delay or termination.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical trials are
very expensive, time-consuming and difficult to design and implement. Even if the results of our clinical trials are favorable,
clinical trials usually continue for several years and may take significantly longer to complete. In addition, we, the FDA, an
Institutional Review Board, or other regulatory authorities, including state and local, may suspend, delay or terminate our clinical
trials at any time for various reasons, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">lack of effectiveness of our lead drug candidate or any other product candidate during clinical
trials;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">discovery of serious or unexpected toxicities or side effects experienced by study participants
or other safety issues;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">slower than expected rates of subject recruitment and enrollment rates in clinical trials;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">delays or inability in manufacturing or obtaining sufficient quantities of materials for use in
clinical trials due to regulatory and manufacturing constraints;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">inadequacy of or changes in our manufacturing process or product formulation;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">delays in obtaining regulatory authorization to commence a study, including &ldquo;clinical holds&rdquo;
or delays requiring suspension or termination of a study by a regulatory agency, such as the FDA, before or after a study is commenced;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">changes in applicable regulatory policies and regulations;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">delay or failure in reaching agreement on acceptable terms in clinical trial contracts or protocols
with prospective clinical trial sites;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">delay or failure to supply product for use in clinical trials which conforms to regulatory specification;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">unfavorable results from ongoing clinical trials and pre-clinical studies;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">failure of our contract research organizations, or CROs, or other third-party contractors to comply
with all contractual requirements or to perform their services in a timely or acceptable manner;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">failure by us, our employees, our CROs or their employees to comply with all applicable FDA or
other regulatory requirements relating to the conduct of clinical trials or the handling, storage, security and recordkeeping for
controlled substances;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">scheduling conflicts with participating clinicians and clinical institutions; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">failure to design appropriate clinical trial protocols.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of the foregoing
could have a material adverse effect on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>There is a high rate of failure for
drug candidates proceeding through clinical trials.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Generally, there is
a high rate of failure for drug candidates proceeding through clinical trials. We may suffer significant setbacks in our clinical
trials similar to the experience of a number of other companies in the pharmaceutical and biotechnology industries, even after
receiving promising results in earlier trials. Further, even if we view the results of a clinical trial to be positive, the FDA
or other regulatory authorities may disagree with our interpretation of the data. In the event that we obtain negative results
from our current of future clinical trials or receive poor clinical results for other product candidates, or the FDA chooses to
block progress of the trials due to potential CMC issues or other hurdles or does not approve our NDA for RUT58-60, we may not
be able to generate sufficient revenue or obtain financing to continue our operations, our ability to execute on our current business
plan will be materially impaired, our reputation in the industry would likely be significantly damaged and the price of our stock
would likely decrease significantly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Serious adverse events or other safety
risks could require us to abandon development and preclude, delay or limit approval of our product candidates, or limit the scope
of any approved label or market acceptance.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If RUT58-60 or any
of our product candidates, prior to or after any approval for commercial sale, cause serious or unexpected side effects, a number
of potentially significant negative consequences could result, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">regulatory authorities may interrupt, delay or halt clinical trials;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">regulatory authorities may deny regulatory approval of our product candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">regulatory authorities may withdraw their approval of the product or impose restrictions on our
distribution in the form of a risk evaluation and mitigation strategy, or REMS;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">regulatory authorities may require the addition of labeling statements, such as warnings or contraindications
or limitations on the indications for use;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">we may be required to change the way the product is administered or conduct additional clinical
trials;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">we could be sued and held liable for harm caused to patients; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">our reputation may suffer.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may voluntarily
suspend or terminate our planned clinical trials if at any time we believe that they present an unacceptable risk to participants
or if preliminary data demonstrate that our product candidates are unlikely to receive regulatory approval or unlikely to be successfully
commercialized. In addition, regulatory agencies, institutional review boards or data safety monitoring boards may at any time
order the temporary or permanent discontinuation of our clinical trials or request that we cease using investigators in the clinical
trials if they believe that the clinical trials are not being conducted in accordance with applicable regulatory requirements,
or that they present an unacceptable safety risk to participants. If we elect or are forced to suspend or terminate any planned
clinical trial of RUT58-60 or any other of our product candidates, the commercial prospects for that product will be harmed and
our ability to generate product revenue from that product may be delayed or eliminated. Furthermore, any of these events could
prevent us from achieving or maintaining market acceptance of the affected product and could substantially increase the costs of
commercializing our product candidates and impair our ability to generate revenue from the commercialization of these products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Any failure by us to comply with
existing regulations could harm our reputation and operating results.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will be subject
to extensive regulation by U.S. federal and state and foreign governments in each of the markets where we intend to sell RUT58-60,
or any other drug candidate, if and after it is approved. For example, we will have to adhere to all regulatory requirements including
the FDA&rsquo;s current GCP, GLP and cGMP requirements. If we fail to comply with applicable regulations, including FDA pre-or
post-approval cGMP requirements, then the FDA or other foreign regulatory authorities could sanction us. Even if a drug is FDA-approved,
regulatory authorities may impose significant restrictions on a product&rsquo;s indicated uses or marketing or impose ongoing requirements
for potentially costly post-marketing studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If RUT58-60, or any
other drug candidate, is approved in the United States, it will be subject to ongoing regulatory requirements for labeling, packaging,
storage, advertising, promotion, sampling, record-keeping and submission of safety and other post-market information, including
both federal and state requirements in the United States. In addition, manufacturers and manufacturers&rsquo; facilities are required
to comply with extensive FDA requirements, including ensuring that quality control and manufacturing procedures conform to cGMP.
As such, we and our contract manufacturers are subject to continual review and periodic inspections to assess compliance with cGMP.
Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance,
including manufacturing, production and quality control. We will also be required to report certain adverse reactions and production
problems, if any, to the FDA, and to comply with requirements concerning advertising and promotion for our products. Promotional
communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent
with the information in the product&rsquo;s approved label. As such, we may not promote our products for indications or uses for
which they do not have FDA approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a regulatory agency
discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems
with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of the product, a regulatory
agency may impose restrictions on that product or on us, including requiring withdrawal of the product from the market. If we fail
to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">issue warning letters;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">impose civil or criminal penalties;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">suspend regulatory approval;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">suspend any of our ongoing clinical trials;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">refuse to approve pending applications or supplements to approved applications submitted by us;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">impose restrictions on our operations, including closing our contract manufacturers&rsquo; facilities;
or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">seize or detain products or require a product recall.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any government investigation
of alleged violations of law could require us to expend significant time and resources in response, and could generate negative
publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize
and generate revenue from RUT58-60 and our product candidates. If regulatory sanctions are applied or if regulatory approval is
withdrawn, the value of our company and our operating results will be adversely affected. Additionally, if we are unable to generate
revenue from sales of RUT58-60, or any other drug candidate, our potential for achieving profitability will be diminished and the
capital necessary to fund our operations will be increased.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any action against
us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses,
divert our management&rsquo;s attention from the operation of our business and damage our reputation. We expend significant resources
on compliance efforts and such expenses are unpredictable and might adversely affect our results. Changing laws, regulations and
standards might also create uncertainty, higher expenses and increase insurance costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we are found in violation of federal
or state &ldquo;fraud and abuse&rdquo; laws, we may be required to pay a penalty and/or be suspended from participation in federal
or state health care programs, which may adversely affect our business, financial condition and results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States,
we will be subject to various federal and state health care &ldquo;fraud and abuse&rdquo; laws, including anti-kickback laws, false
claims laws and other laws intended to reduce fraud and abuse in federal and state health care programs, which could affect it,
particularly upon successful commercialization of our products in the United States. The federal Anti-Kickback Statute makes it
illegal for any person, including a prescription drug manufacturer (or a party acting on our behalf), to knowingly and willfully
solicit, receive, offer or pay any remuneration that is intended to induce the referral of business, including the purchase, order
or prescription of a particular drug for which payment may be made under a federal health care program, such as Medicare or Medicaid.
Under federal government regulations, some arrangements, known as safe harbors, are deemed not to violate the federal Anti-Kickback<B>
</B>Statute. Although we seek to structure our business arrangements in compliance with all applicable requirements, these laws
are broadly written, and it is often difficult to determine precisely how the law will be applied in specific circumstances. Accordingly,
it is possible that our practices may be challenged under the federal Anti-Kickback Statute. False claims laws prohibit anyone
from knowingly and willfully presenting or causing to be presented for payment to third-party payers, including government payers,
claims for reimbursed drugs or services that are false or fraudulent, claims for items or services that were not provided as claimed,
or claims for medically unnecessary items or services. Cases have been brought under false claims laws alleging that off-label
promotion of pharmaceutical products or the provision of kickbacks has resulted in the submission of false claims to governmental
health care programs. Under the Health Insurance Portability and Accountability Act of 1996, we are prohibited from knowingly and
willfully executing a scheme to defraud any health care benefit program, including private payers, or knowingly and willfully falsifying,
concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with
the delivery of or payment for health care benefits, items or services. Violations of fraud and abuse laws may be punishable by
criminal and/or civil sanctions, including fines and/or exclusion or suspension from federal and state health care programs such
as Medicare and Medicaid and debarment from contracting with the U.S. government. In addition, private individuals have the ability
to bring actions on behalf of the government under the federal False Claims Act as well as under the false claims laws of several
states.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many states have adopted
laws similar to the federal anti-kickback statute, some of which apply to the referral of patients for health care services reimbursed
by any source, not just governmental payers. Neither the government nor the courts have provided definitive guidance on the application
of fraud and abuse laws to our business. Law enforcement authorities are increasingly focused on enforcing these laws, and if we
are found in violation of one of these laws, we could be required to pay a penalty and could be suspended or excluded from participation
in federal or state health care programs, and our business, results of operations and financial condition may be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We expect to face competition, often
from companies with greater resources and experience.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The pharmaceutical
industry is highly competitive and subject to rapid change. The industry continues to expand and evolve as an increasing number
of competitors and potential competitors enter the market. Many of these competitors and potential competitors have substantially
greater financial, technological, managerial and research and development resources and experience than us. Some of these competitors
and potential competitors have more experience than we do in the development of pharmaceutical products, including validation procedures
and regulatory matters. We are aware of three companies in the United States and/or Europe that produce HOCl based products intended
for medical applications, including Novabay, Oculus and Puricore, which we consider our potential competitors in this regard. In
addition, many other companies have commercialized or are developing antibiotics that aim to address the increasingly growing concern
of post-surgical infections, including Achaogen, Basilea, Cempra, Cubist Pharmaceuticals, Durata Therapeutics, Forest Laboratories
&amp; Astra Zeneca, GlaxoSmithKline, Merck, Paratek, Rempex, Rib-X, Tetraphase Pharmaceuticals, and Trius. If we are unable to
compete successfully with these and other potential future competitors, we may be unable to grow and sustain revenues, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Risks Relating to Our Financial Position
and Need for Additional Capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our limited operating history makes
evaluating our business and future prospects difficult and may increase the risk of any investment in our securities.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were incorporated
in Nevada in January 2013 as a wholly owned subsidiary of Oculus. We reincorporated in Delaware on September 25, 2013. We have
a limited operating history on which to evaluate our business. We have incurred net losses since we began operations in October
2011. Through March 31, 2015, we had an accumulated deficit of $10,360,000. These losses have resulted principally from costs incurred
in connection with our research and development activities, pre-clinical tests and other regulatory activities, preparations for
our initial public offering, other general and administrative costs associated with our operations, and carve-out financial information
from Oculus prior to our incorporation on January 18, 2013. We face considerable risks and difficulties as a company with limited
operating history. If we do not successfully address these risks, our business, prospects, operating results and financial condition
may be materially and adversely harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to incur
significant additional operating losses over the next several years as we expand our research and development efforts, pre-clinical
testing and clinical trials, and implement manufacturing, marketing and sales programs. In addition, as our development testing
activities continue, our operating losses may increase. Further, this may result in negative cash flow in future periods as we
fund operating losses and capital expenditures, and, therefore, will result in decreases in our working capital, total assets and
stockholders&rsquo; equity, which may not be offset by future financings. Our limited operating history makes it particularly difficult
for us to predict our future operating results and appropriately budget for our expenses. In the event that actual results differ
from our estimates or it adjusts our estimates in future periods, our operating results and financial position could be materially
affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, we do not
have a product approved for commercial sale. We have limited experience as a newly formed research and development stage entity
in the biopharmaceutical field, and our prospects must be considered in light of the fact that we have not yet demonstrated an
ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving
fields, particularly in the pharmaceutical or biotechnology areas. These risks include, but are not limited to, unforeseen capital
requirements, delays in obtaining regulatory approvals, failure to gain market acceptance and competition from foreseen and unforeseen
sources. Accordingly, you should consider our prospects in light of the costs, uncertainties, delays and difficulties encountered
by companies in the early stage of development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our operating results for the foreseeable
future will depend significantly on our ability to fund our research and development programs for, obtain regulatory approval of,
and to successfully commercialize our drug candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">RUT58-60 is currently
our only drug candidate in a clinical trial. We may not receive revenues or royalties from commercial sales of RUT58-60 or any
other drug in the foreseeable future, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our development of
drug candidates involves a high degree of risk. Many important factors affect its ability to successfully develop and commercialize
RUT58-60, and our other drug candidates including our ability to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">demonstrate safety and efficacy at each stage of the clinical trial process;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">meet applicable regulatory standards and receive required regulatory approvals;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">obtain and maintain necessary patents and/or licenses;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">produce drugs in commercial quantities at reasonable costs;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">obtain reimbursement coverage;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">compete successfully against other products; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">market RUT58-60, or our other drug candidates, successfully.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot assure you
that we will successfully develop and commercialize RUT58-60, or our other drug candidates, or that we will obtain required regulatory
approvals for our commercialization. As a result, we may never generate revenues from RUT58-60 sales or sales of our other drug
candidates. To date, we have not generated any revenue from RUT58-60 or any other product and we do not know when, or if, we will
generate any revenue in the future. We may never be able to successfully develop or commercialize RUT58-60 or any other product.
Even if we do commercialize RUT58-60 or other product candidates in the future, we may incur significant sales, marketing, manufacturing
and other general and administrative expenses, as well as continued research and development expenses. As a result, we cannot predict
when we will become profitable, if at all, and if we do, we may not remain profitable for any substantial period of time. If we
fail to achieve profitability within the timeframe expected by investors, the market price of the common stock may decline, and,
therefore, may negatively impact our ability to raise capital, invest in or expand our business, acquire additional products or
licenses, commercialize our products, or continue our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will need additional funding to
advance our clinical trial programs, launch and commercialize our lead drug candidate or any other product candidate.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pharmaceutical product
development, which includes research and development, pre-clinical and clinical studies and human clinical trials, is a time-consuming
and expensive process that takes years to complete. We expect that our expenses will increase substantially if and when we advance
RUT58-60 into future clinical trials, seek regulatory approval for RUT58-60 for the abdominal surgery indication, seek regulatory
approval for RUT58-60 in additional surgical and traumatic injury indications, pursues development of additional innovative HOCl
based pharmaceutical formulations and/or pursues development of HOCl based pharmaceuticals in additional indications. If we obtain
marketing approval for RUT58-60 or any other product candidate that we develop, license, or acquire, we expect to incur significant
commercialization expenses related to pre-launch activities, regulatory compliance requirements, sales and marketing, manufacturing
and distribution. Additionally, we may incur expenses directly related to license and product acquisitions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that our
existing cash, which includes the proceeds from our initial public offering, will be sufficient to fund our current operations
into the quarter ending June 30, 2016. These funds will not be sufficient to enable us to conduct future clinical trials, seek
marketing approval for RUT58-60 or commercially launch RUT58-60, or any other drug candidate, in the United States or any other
country or geographic area.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our inability to raise
capital on acceptable terms in the future may cause us to delay, diminish, or curtail our operations, and such inability would
have a material adverse effect on its business and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect capital outlays
and operating expenditures to increase over the next several years as we work to conduct clinical trials, establish independent
manufacturing operations, commercialize our products and expand our infrastructure. We may need to raise additional capital to,
among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">fund any planned clinical trials for our drug candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">sustain commercialization of any other product candidate;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">develop our manufacturing capabilities;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">increase our sales and marketing efforts;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">acquire, license or in-license other product candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">finance capital expenditures and our general and administrative expenses;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">develop new products;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">maintain, expand and protect our intellectual property;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">add operational, financial and management information systems; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">hire additional clinical, quality control, scientific, and general and administrative personnel.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">Our present and future funding requirements will depend on many factors, including but not limited
to:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">the progress and timing of our clinical trials;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">the level of research and development investment required to maintain and improve our technology
position;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">the cost of filing, prosecuting, defending and enforcing patent claims and other intellectual property
rights;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">our efforts to acquire or license complementary technologies or acquire complementary businesses;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">changes in product development plans;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">competing technological and market developments;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">changes in regulatory policies or laws that may affect our operations; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">changes in physician acceptance or medical society recommendations that may affect commercial efforts.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Failure to secure any
necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial
performance, and share price and could require us to delay or abandon development or commercialization plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Market and economic conditions may
negatively impact our business, financial condition and share price.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Concerns over inflation,
energy costs, geopolitical issues, the U.S. mortgage market and a declining real estate market, unstable global credit markets
and financial conditions, and volatile oil prices have led to periods of significant economic instability, diminished liquidity
and credit availability, declines in consumer confidence and discretionary spending, diminished expectations for the global economy
and expectations of slower global economic growth going forward, increased unemployment rates, and increased credit defaults in
recent years. Our general business strategy may be adversely affected by any such economic downturns, volatile business environments
and continued unstable or unpredictable economic and market conditions. If these conditions continue to deteriorate or do not improve,
it may make any necessary debt or equity financing more difficult to complete, more costly, and more dilutive. In addition, there
is a risk that one or more of our current and future service providers, manufacturers, suppliers, hospitals and other medical facilities,
our third party payors, and other partners could be negatively affected by difficult economic times, which could adversely affect
our ability to attain our operating goals on schedule and on budget or meet our business and financial objectives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Risks Related to Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we and Oculus do not obtain protection
for our respective intellectual property rights, our competitors may be able to take advantage of our research and development
efforts to develop competing drugs.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success, competitive
position and future revenues will depend in part on our ability and the ability of Oculus, the licensor of intellectual property
rights relating to RUT58-60, to obtain and maintain patent protection for our products, methods, processes and other technologies,
to preserve our trade secrets, to prevent third parties from infringing on our proprietary rights and to operate without infringing
the proprietary rights of third parties. Under our license and supply agreement with Oculus, we hold certain exclusive patent rights
for a specified field and territory, including licensed rights under U.S. patents and U.S. patent applications as well as licensed
rights under foreign patents and patent applications owned by Oculus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may file additional
patent applications both in the United States and in other countries, as appropriate. However, the patent process is subject to
numerous risks and uncertainties, and there can be no assurance that we will be successful in protecting our products by obtaining
and defending patents. These risks and uncertainties include but are not limited to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">Patents may not be granted from patent applications submitted by us or our licensor, Oculus, to
the U.S. Patent and Trademark Office or foreign patent applications.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">Patents that have issued or will issue, where our own or in-licensed patents and patent applications
from Oculus or another entity, may be challenged, invalidated, or circumvented, or otherwise may not provide any competitive advantage.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">Countries other than the United States may have less restrictive patent laws than those upheld
by United States courts, allowing foreign competitors the ability to exploit these laws to create, develop, and market competing
products.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">Our, many of which have substantially greater resources than us and many of which have made significant
investments in competing technologies, may seek, or may already have obtained, patents that will limit, interfere with, or eliminate
its ability to make, use, and sell our potential products either in the United States or in international markets.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">There may be significant pressure on the United States government and other international governmental
bodies to limit the scope of patent protection both inside and outside the United States for treatments that prove successful as
a matter of public policy regarding worldwide health concerns.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the U.S.
Patent and Trademark Office and patent offices in other jurisdictions have often required that patent applications concerning pharmaceutical
and/or biotechnology-related inventions be limited or narrowed substantially to cover only the specific innovations exemplified
in the patent application, thereby limiting the scope of protection against competitive challenges. Thus, even if we or Oculus
are able to obtain patents, the patents may be substantially narrower than anticipated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to patents,
we also rely on trade secrets and proprietary know-how. Although we take measures to protect this information by entering into
confidentiality and inventions agreements with our employees, scientific advisors, consultants, and collaborators, we cannot provide
any assurances that these agreements will not be breached, that we will be able to protect ourselves from the harmful effects of
disclosure if they are breached, or that our trade secrets will not otherwise become known or be independently discovered by competitors.
If any of these events occurs, or we otherwise lose protection for our trade secrets or proprietary know-how, the value of this
information may be greatly reduced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Patent protection and other intellectual
property protection are important to the success of our business and prospects, and there is a substantial risk that such protections
will prove inadequate.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our intellectual property
may not be sufficient to protect our products from competition and may negatively affect our business as well as limit our partnership
or acquisition appeal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be subject to
competition despite the existence of intellectual property that we may license or own. We can give no assurances that our intellectual
property protection will be sufficient to prevent third parties from designing around patents it owns or licenses and developing
and commercializing competitive products. The existence of competitive products that avoid our intellectual property could materially
adversely affect our operating results and financial condition. Furthermore, limitations, or perceived limitations, in our intellectual
property may limit the interest of third parties to partner, collaborate or otherwise transact with us, if third parties perceive
a higher than acceptable risk to commercialization of our products or future products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may elect to sue
a third party, or otherwise make a claim, alleging infringement or other violation of patents, trademarks, trade dress, copyrights,
trade secrets, domain names or other intellectual property rights that we either owns or licenses. If we dos not prevail in enforcing
its intellectual property rights in this type of litigation, we may be subject to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">paying monetary damages related to the legal expenses of the third party;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">facing additional competition that may have a significant adverse effect on our product pricing,
market share, business operations, financial condition, and the commercial viability of our products; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">restructuring our company or delaying or terminating select business opportunities, including,
but not limited to, research and development, clinical trial, and commercialization activities, due to a potential deterioration
of its financial condition or market competitiveness.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A third party
may also challenge the validity, enforceability or scope of the intellectual property rights that we license or own; and, the result
of these challenges may narrow the scope or claims of or invalidate patents that are integral to RUT58-60 or other drug candidates
in the future. There can be no assurance that we will be able to successfully defend patents we own or license in an action against
third parties due to the unpredictability of litigation and the high costs associated with intellectual property litigation, amongst
other factors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Intellectual property
rights and enforcement may be less extensive in jurisdictions outside of the United States; thus, we may not be able to protect
our intellectual property and third parties may be able to market competitive products that may use some or all of our intellectual
property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Changes to patent law
may substantially change the regulations and procedures surrounding patent applications, issuance of patents, and prosecution of
patents. We can give no assurances that its patents and those of any licensor can be defended or will protect us against future
intellectual property challenges, particularly as they pertain to changes in patent law and future patent law interpretations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The actual or purported intellectual
property rights of third parties may negatively affect our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A third party may sue
us or our licensor or otherwise make a claim, alleging infringement or other violation of the third party&rsquo;s intellectual
property rights. If we do not prevail in successfully defending this type of litigation, we may be required to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">pay monetary damages;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">obtain a license in order to continue manufacturing or marketing the affected products, which may
not be available on commercially reasonable terms, or at all; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">stop commercial activities relating to the affected products, which could include a recall of the
affected products and/or a cessation of sales.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The costs of defending
an intellectual property claim could be substantial and could materially adversely affect our operating results and financial condition,
even if we successfully defend such claims. We cannot offer assurances that we will be able to defend ourselves against claims
by third parties due to the high costs associated with intellectual property litigation, amongst other factors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Intellectual property
rights in the field of surgical medicine frequently involve complex legal and factual questions. We are not guaranteed the right
to practice our patented technology or develop, manufacture or commercialize its patented products even if we own or license patent
rights relating to its products. We cannot be certain that a competitor or other third party does not have or will not obtain rights
to intellectual property that may prevent it from manufacturing, developing or marketing certain of its products, regardless of
whether we believe such intellectual property rights are valid and enforceable or we believe we would be otherwise able to develop
a more commercially successful product, which may harm our operating results and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, any intellectual
property litigation could be perceived negatively by securities analysts or investors which could have a material adverse effect
on the value of its securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we materially breach or default
under our license and supply agreement with Oculus, Oculus will have the right to terminate the agreement and we could lose critical
license rights, which would materially harm our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not currently
own any patents, trademarks, or copyrights; however, our business is substantially dependent upon certain intellectual property
rights that we license from Oculus. Therefore, our commercial success will depend to a large extent on our ability to maintain
and comply with our obligations under our license and supply agreement with Oculus. Our license and supply agreement with Oculus
provides Oculus with the right to terminate the agreement for an uncured breach by us, or if we are insolvent or the subject of
a bankruptcy proceeding, or potentially other reasons. In addition, under the license and supply agreement, we are required to
use commercially reasonable efforts to satisfy certain development milestones and other obligations with regard to the development
and commercialization of RUT58-60 in order for us to maintain the license. We expect that other technology in-licenses that we
may enter into in the future will contain similar provisions and impose similar obligations on us. If we fail to comply with any
such obligations to Oculus or future licensors, such licensor will likely terminate their out-licenses to us, in which case we
would not be able to market products covered by these licenses, including the RUT58-60 technology. The loss of our license with
Oculus with respect to the RUT58-60 technology, and potentially other licenses that we enter into in the future, would have a material
adverse effect on our business. In addition, our failure to comply with obligations under our material in-licenses may cause us
to become subject to litigation or other potential disputes under any such license agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our license
and supply agreement with Oculus requires us to make certain payments, including license fees, milestone payments royalties, and
other such terms typically required under licensing agreements and these types of technology in-licenses could make it less profitable
for us to develop product candidates utilizing these existing product candidates and technologies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be subject to claims that
our employees, independent consultants or agencies have wrongfully used or inadvertently disclosed confidential information of
third parties.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We employ individuals
and contract with independent consultants and agencies that may have previously worked at or conducted business with third parties;
and, we may be subject to claims that we or our employees, consultants or agencies have inadvertently or otherwise used or disclosed
confidential information of our employees&rsquo; former employers or other third parties. We may also be subject to claims that
former employers or other third parties have an ownership interest in our patents. Litigation may be necessary to defend against
these claims. There is no guarantee of success in defending these claims, and if we are successful, litigation could result in
substantial cost and be a distraction to our management and other employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Risks Related to its Relationship with
Oculus</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Approval of commercial terms between
us and Oculus does not preclude the possibility of stockholder litigation, including but not limited to derivative litigation nominally
against Oculus and against its directors and officers and also against us and our directors and officers.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The commercial terms
of the license and supply agreement, shared services agreement and separation agreement that we entered into with Oculus have been
negotiated on behalf of Oculus by a Special Transaction Committee consisting solely of disinterested Oculus directors. We believe
such negotiations have been at arms&rsquo; length. We have no basis for believing that the terms of these agreements will not be
in the best interests of both Oculus and its stockholders and also us and our stockholders. Nonetheless, no assurance can be given
that any stockholder of Oculus will not claim in a lawsuit that such terms in fact are not in the best interests of Oculus and
its stockholders, that the directors and officers of Oculus breached their fiduciary duties in connection with such agreements
and that any disclosures by Oculus to its stockholders regarding these agreements and the relationship between Oculus and us did
not satisfy applicable requirements. In any such instance, we and our directors and officers may also be named as defendants and
we would have to defend ourselves and our directors and officers. While we will seek indemnification from Oculus under the terms
of these agreements against any damages or other costs, which could be substantial, no such indemnification has yet been agreed
to or may be agreed to and be in effect. Further, any such litigation would be time-consuming and would divert focus and resources
from the development of our product candidates and our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Your investment in our securities
may be adversely affected due to Oculus&rsquo; ownership of our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The liquidity of the
market for our common stock may be constrained for as long as Oculus continues to hold a significant position in its common stock.
As of June 5, 2015, Oculus holds approximately 34% of our outstanding common stock and approximately 42% of the voting power of
our common stock. Additionally, without a distribution or other liquidity event of our shares of common stock held by Oculus, there
will be limited liquidity in the market for our common stock, which will impact our stockholders and stock price. A lack of liquidity
in the market for our common stock may adversely affect our stock price and therefore, our ability to raise additional funds in
the public markets, which may have a material adverse effect on our ability to grow our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The ownership by our executive officers
and our directors of shares of Oculus common stock and rights to purchase Oculus common stock may create, or may create the appearance
of, conflicts of interest.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ownership by our
executive officers and our directors of shares of Oculus common stock, options to purchase shares of Oculus common stock, or other
equity awards of Oculus may create, or may create the appearance of, conflicts of interest. Our chief executive officer and chairman
of the board served as the chief executive officer of Oculus until February 2013 and chairman of the board of Oculus until February
2014. Our chief financial officer since February 2013 has been granted options in Oculus. Two of our three directors formerly served
on the board of directors of Oculus. Because of the current and former positions of our executive officers and our directors with
Oculus, they own shares of Oculus common stock, options to purchase shares of Oculus common stock or other equity awards of Oculus.
Ownership by our executive officers and directors of common stock or options to purchase common stock of Oculus, or any other equity
awards, may create the appearance of conflicts of interest when these individuals are faced with decisions that could have different
implications for Oculus than the decisions have for us. Any perceived conflicts of interest resulting from investors questioning
the independence of our management or the integrity of corporate governance procedures may materially affect our stock price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Any disputes that arise between us
and Oculus with respect to our past and ongoing relationships could harm our business operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Disputes may arise
between us and Oculus in a number of areas relating to our past and ongoing relationships, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">intellectual property, technology and business matters, including failure to make required technology
transfers and failure to comply with non-compete provisions applicable to Oculus and us;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">labor, tax, employee benefit, indemnification and other matters arising from our separation from
Oculus;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">distribution and supply obligations;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">employee retention and recruiting;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">business combinations involving us;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">sales or distributions by Oculus of all or any portion of our ownership interest in us;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">the nature, quality and pricing of services Oculus has agreed to provide us; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">business opportunities that may be attractive to both Oculus and us.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a party to a
the separation agreement with Oculus related to the separation of our business operations from those of Oculus that contains certain
limitations on Oculus&rsquo; ability to control various aspects of our business and operations, notwithstanding Oculus&rsquo; substantial
ownership position in our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We and our stockholders may not achieve
some or all of the expected benefits of our separation from Oculus.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are focused on developing
HOCl based drugs to prevent and treat infection in invasive applications. Drug development is an expensive and time-consuming process,
but we believe the knowledge we have gained while operating as a subsidiary of Oculus has helped expedite this process. However,
in order to realize the value proposition of us as a drug development company, we intend to target early stage healthcare and pharmaceutical
focused investors, who are interested in investing in drug development companies and who appreciate the risks, rewards and typically
longer investment timelines associated with such investments. In order to successfully attract this type of new investment, we
believe it is critical that we separate from Oculus, because we believe that doing so will provide it with some or all of the following
benefits:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">improving strategic and operational flexibility, increasing management focus and streamlining decision-making
by providing the flexibility to implement our strategic plan and to respond more effectively to different customer needs and the
changing economic environment;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">allowing us to adopt the capital structure, investment policy and dividend policy best suited to
our financial profile and business needs, without competing for capital with Oculus&rsquo; other businesses;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">creating an independent equity structure that will facilitate our ability to affect future acquisitions
utilizing our common stock; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">facilitating incentive compensation arrangements for employees more directly tied to the performance
of our business, and enhancing employee hiring and retention by, among other things, improving the alignment of management and
employee incentives with performance and growth objectives of our business.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Risks Related to Our Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The trading market in our common
stock has been extremely limited.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since our initial listing
on the NASDAQ Capital Market on March 21, 2014, the trading market in our common stock has been extremely limited. The quotation
of our common stock on the NASDAQ Capital Market does not assure that a meaningful, consistent and liquid trading market currently
exists. We cannot predict whether a more active market for our common stock will develop in the future. An absence of an active
trading market could adversely affect our stockholders&rsquo; ability to sell our common stock at current market prices in short
time periods, or possibly at all. Additionally, market visibility for our common stock may be limited and such lack of visibility
may have a depressive effect on the market price for our common stock. As of March 31, 2015, approximately 50% of our outstanding
shares of common stock were controlled by our officers, directors, beneficial owners of 5% or more of our securities and their
respective affiliates, which adversely affects the liquidity of the trading market for our common stock, in as much as federal
securities laws restrict sales of our shares by these stockholders. If our affiliates continue to hold their shares of common stock,
there will be limited trading volume in our common stock, which may make it more difficult for investors to sell their shares or
increase the volatility of our stock price. In addition, as of March 31, 2015, 2,000,000 shares of common stock, or 42% of our
outstanding shares, were restricted from resale under securities laws or as a result of lock-up agreements, further limiting the
liquidity of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The price of our common stock may
fluctuate substantially.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market price of
our common stock may fluctuate, as a result of, among other factors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">the sale of our common stock by Oculus, our former parent and largest stockholder at potentially
significant discounts to the prevailing market price, subject to certain contractual conditions;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">the sale of our common stock by our stockholders, executives, and directors;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">the limitations in trading volumes of our shares of common stock;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">our ability to obtain financing when needed to fund our operations;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">our ability to secure resources and the necessary personnel to conduct clinical trials on our desired
schedule;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">commencement, enrollment or results of our clinical trials of RUT58-60 or any future clinical trials
we may conduct;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">changes in the development status of RUT58-60;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">any delays or adverse developments or perceived adverse developments with respect to the FDA&rsquo;s
review of our planned pre-clinical and clinical trials;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">any delay in our submission for studies or product approvals or adverse regulatory decisions, including
failure to receive regulatory approval for RUT58-60;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">new products or services, enhancements, significant contracts, acquisitions or strategic investments;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">unanticipated safety concerns related to the use of RUT58-60;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">failures to meet external expectations or management guidance;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">changes in our capital structure or dividend policy, future issuances of securities, sales or distributions
of large blocks of common stock by our stockholders, including Oculus;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">our cash position;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">announcements and events surrounding financing efforts;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">our inability to enter into new markets or develop new products;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">reputational issues;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">competition from existing technologies and products or new technologies and products that may emerge;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">announcements related to acquisitions, partnerships, collaborations, joint ventures, new products,
capital commitments, or other events by us or our competitors;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">changes in general economic, political and market conditions in or any of the regions in which
we conduct our business;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">changes in industry conditions or perceptions;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">changes in valuations of similar companies;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">analyst research reports, recommendations and changes in recommendations, price targets, and withdrawals
of coverage;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">departures and additions of key personnel;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">disputes and litigation related to intellectual property, proprietary rights, and contractual obligations;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">changes in applicable laws;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">announcements or actions taken by Oculus as our principal stockholder;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">open-market transactions that may occur prior to or immediately after any distribution of shares
by Oculus; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">other events or factors, many of which may be out of our control.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, if the
market for stocks in our industry or industries related to our industry, or the stock market in general, experiences a loss of
investor confidence, the trading price of our common stock could fluctuate or decline for reasons unrelated to our business, financial
condition and results of operations. If any of the foregoing occurs, it could cause our stock price to fall and may expose us to
lawsuits that, even if unsuccessful, could be costly to defend and a distraction to management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Raising additional capital may cause
dilution to existing stockholders, restrict our operations or require us to relinquish rights.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may seek the additional
capital necessary to fund our operations through public or private equity offerings, debt financings, and collaborative and licensing
arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, existing
stockholders ownership interests will be diluted and the terms may include liquidation or other preferences that adversely affect
their rights as a stockholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting
our ability to take specific actions such as incurring additional debt, making capital expenditures, or declaring dividends. If
we raise additional funds through collaboration and licensing arrangements with third parties, we may have to relinquish valuable
rights to our technologies or grant licenses on terms that are not favorable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Due to the speculative nature of
warrants, there is no guarantee that it will ever be profitable for holders of the warrants to exercise the warrants.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Series A warrants
that we issued in our initial public offering do not confer any rights of common stock ownership on our holders, such as voting
rights or the right to receive dividends, but rather merely represent the right to acquire shares of common stock at a formulaic
price that is subject to adjustment for a limited period of time. The holders of our Series A warrants may exercise their right
to acquire additional shares of our common stock and Series B warrants to purchase additional shares of our common stock. In order
to do so, they must pay an exercise price of $7.25 per Series A warrant within the two years following the date of issuance, after
which date any unexercised Series A warrants will expire and have no further value. There can be no assurance that the market price
of our common stock will equal or exceed the exercise price of the Series A warrants, and consequently, whether it will ever be
profitable for holders of the Series A warrants to exercise the Series A warrants. This same analysis applies with equal effect
to our Series B warrants that are issuable upon exercise of the Series A warrants, however the exercise of the Series B warrants
is $9.0625 per share and the expiration date is five years following the date of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>There is no public market for our
warrants, and we do not expect one to develop.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We sold units in our
initial public offering, each of which contained one share of common stock and one Series A warrant. The Series A warrants are
exercisable for additional shares of common stock and Series B warrants. The Series B warrants are issuable for additional shares
of common stock. There is no public trading market for our Series A warrants or our Series B warrants that are issuable upon exercise
of the Series A warrants, and we do not expect a market to develop. In addition, we do not intend to apply for listing of the warrants
on any securities exchange. Without an active market, the liquidity of our warrants will be limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The exercise of outstanding options
and warrants to acquire shares of our common stock will cause additional dilution, which could cause the price of our common stock
to fall.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In our initial public
offering, we issued an aggregate of 3,047,500 Series A warrants, all of which are outstanding as of March 31, 2015. Each of our
Series A warrants is exercisable for one share of common stock and one Series B Warrant to purchase one share of common stock.
Accordingly, we have reserved 6,095,000 shares of our common stock for issuance upon exercise of our Series A warrants and Series
B warrants. If the holders of our Series A warrants exercise their warrants, you will experience dilution at the time they exercise
their Series A warrants. Similarly, if those who exercised their Series A warrants also exercise the Series B warrants they receive
upon exercise of the Series A warrants, you will experience further dilution at the time they exercise their Series B warrants.
The Series A warrants and Series B warrants contains price adjustment provisions, which may cause the exercise prices to be reduced
relative to the initial exercise prices of 100% and 125% of the initial public offering price per unit, respectively, if we complete
future equity sales at discounts to the then-market price and below the initial exercise price of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, as of
April 1, 2015, we have reserved 1,230,855 shares of our common stock under our 2013 Employee, Director and Consultant Equity Incentive
Plan (the &ldquo;2013 Plan&rdquo;), and a majority of these shares are subject to outstanding stock options and restricted stock
units. Furthermore, we may issue additional options, warrants and other types of equity in the future as part of stock-based compensation,
capital raising transactions, technology licenses, financings, strategic licenses or other strategic transactions. To the extent
these options are exercised, existing stockholders would experience additional dilution. In addition, subject to the approval of
the Company&rsquo;s stockholders, the pool of available stock available for grant under our 2013 Plan will increase at the beginning
of each fiscal year by the lower of: (i) 2,551,500 shares; (ii) 5% of the number of shares of outstanding common stock; and (iii)
an amount determined by our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 12, 2015,
in connection with the Merger Agreement, our compensation committee and board of directors unanimously approved the Ruthigen,
Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan (the &ldquo;New 2013 Plan&rdquo;), subject
to the approval of our stockholders. The New 2013 Plan will allow for the issuance of up to 6,853,319 shares of our common stock,
up from 1,230,855 shares, pursuant to awards to be granted under the New 2013 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&ldquo;Penny stock&rdquo; rules may
make buying or selling our securities difficult which may make our stock less liquid and make it harder for investors to buy and
sell our securities.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our shares of common
stock are delisted by NASDAQ and begin to trade on an over-the-counter market such as the Over-the-Counter Bulletin Board or any
quotation system maintained by OTC Markets, Inc., trading in our securities will be subject to the SEC&rsquo;s &ldquo;penny stock&rdquo;
rules and it is anticipated that trading in our securities will continue to be subject to the penny stock rules for the foreseeable
future. The SEC has adopted regulations that generally define a penny stock to be any equity security that has a market price of
less than $5.00 per share, subject to certain exceptions. These rules require that any broker-dealer who recommends our securities
to persons other than prior customers and accredited investors must, prior to the sale, make a special written suitability determination
for the purchaser and receive the purchaser&rsquo;s written agreement to execute the transaction. Unless an exception is available,
the regulations require the delivery, prior to any transaction involving a penny stock, of a disclosure schedule explaining the
penny stock market and the risks associated with trading in the penny stock market. In addition, broker-dealers must disclose commissions
payable to both the broker-dealer and the registered representative and current quotations for the securities they offer. The additional
burdens imposed upon broker-dealers by these requirements may discourage broker-dealers from recommending transactions in our securities,
which could severely limit the liquidity of our securities and consequently adversely affect the market price for our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Financial reporting obligations of
being a public company in the United States are expensive and time-consuming, and our management may be required to devote substantial
time to compliance matters.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a publicly traded
company, we incur significant additional legal, accounting and other expenses that we did not incur as a privately held, wholly
owned subsidiary of Oculus. The obligations of being a public reporting company require significant expenditures, including costs
resulting from public company reporting obligations under the Securities Exchange Act of 1934, as amended, or the Exchange Act,
and the rules and regulations regarding corporate governance practices, including those under the Sarbanes-Oxley Act of 2002, or
the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, and the listing requirements
of the stock exchange on which our securities are listed. These rules require the establishment and maintenance of effective disclosure
and financial controls and procedures, internal control over financial reporting and changes in corporate governance practices,
among many other complex rules that are often difficult to implement, monitor and maintain compliance with. Moreover, despite recent
reforms made possible by the JOBS Act, the reporting requirements, rules, and regulations will make some activities more time-consuming
and costly, particularly after we are no longer an &ldquo;emerging growth company.&rdquo; In addition, these rules and regulations
make it more difficult and more expensive for us to obtain director and officer liability insurance. Compliance with such requirements
also places demands on management&rsquo;s time and attention.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We do not intend to pay cash dividends
on our shares of common stock so any returns will be limited to the value of our shares.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently anticipate
that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring
or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the increase,
if any, of our share price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are an &ldquo;emerging growth
company&rdquo; and our election to delay adoption of new or revised accounting standards applicable to public companies may result
in our financial statements not being comparable to those of other public companies. As a result of this and other reduced disclosure
requirements applicable to emerging growth companies, our securities may be less attractive to investors.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an &ldquo;emerging
growth company,&rdquo; as defined in the JOBS Act, and we intend to take advantage of certain exemptions from various reporting
requirements that are applicable to other public companies that are not &ldquo;emerging growth companies&rdquo; including, but
not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act,
reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from
the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute
payments not previously approved. In addition, Section 107 of the JOBS Act also provides that an &ldquo;emerging growth company&rdquo;
can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act, for complying with new
or revised accounting standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In other words, an
&ldquo;emerging growth company&rdquo; can delay the adoption of certain accounting standards until those standards would otherwise
apply to private companies. We are electing to delay such adoption of new or revised accounting standards, and as a result, we
may not comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for
non-emerging growth companies. As a result of such election, our financial statements may not be comparable to the financial statements
of other public companies. We cannot predict whether investors will find our securities less attractive because we will rely on
these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market
for our common stock and our stock price may be more volatile. We may take advantage of these reporting exemptions until we are
no longer an &ldquo;emerging growth company.&rdquo; We could remain an &ldquo;emerging growth company&rdquo; until the earliest
to occur of earliest of (i) the last day of the fiscal year in which it has total annual gross revenues of $1 billion or more;
(ii) March 31, 2019; (iii) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three
years; or (iv) the date on which we are deemed to be a large accelerated filer under the rules of the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be at risk of securities class
action litigation.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be at risk of
securities class action litigation. This risk is especially relevant due to our dependence on positive clinical trial outcomes
and regulatory approvals of RUT58-60. In the past, biotechnology and pharmaceutical companies have experienced significant stock
price volatility, particularly when associated with binary events such as clinical trials and product approvals. If we face such
litigation, it could result in substantial costs and a diversion of management&rsquo;s attention and resources, which could harm
our business and results in a decline in the market price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we fail to comply with listing
requirements, NASDAQ may delist our common stock from our exchange, which could limit investors&rsquo; ability to make transactions
in our common stock and subject it to additional trading restrictions.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we fail to satisfy
the continued listing requirements of the NASDAQ Capital Market (&ldquo;NASDAQ&rdquo;), such as the corporate governance requirements
or the minimum closing bid price requirement, the NASDAQ may take steps to delist our common stock. Such a delisting would likely
have a negative effect on the price of our common stock and would impair our ability to sell or purchase our common stock when
you wish to do so. In the event of a delisting, we would take actions to restore our compliance with NASDAQ&rsquo;s listing requirements,
but we can provide no assurance that any such action taken by us would allow our common stock to become listed again, stabilize
the market price or improve the liquidity of our common stock, prevent our common stock from dropping below the NASDAQ minimum
bid price requirement or prevent future non-compliance with NASDAQ&rsquo;s listing requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the NASDAQ Capital
Market does not maintain the listing of our securities for trading on our exchange, we could face significant material adverse
consequences, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">a limited availability of market quotations for our securities;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">reduced liquidity with respect to our securities;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">a determination that our shares of common stock are &ldquo;penny stock,&rdquo; which will require
brokers trading in our shares of common stock to adhere to more stringent rules, possibly resulting in a reduced level of trading
activity in the secondary trading market for our shares of common stock;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">a limited amount of news and analyst coverage; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">decreased ability to issue additional securities or obtain additional financing in the future.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Risks Related to the Proposed Merger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The issuance of our shares of common
stock to Pulmatrix stockholders in the Merger will substantially dilute the voting power of current stockholders. Having a minority
share position may reduce the influence that current stockholders have on our management. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the terms
of the Merger Agreement, at the effective time of the Merger, we will issue approximately 27,848,269 shares of our common stock
to Pulmatrix equity holders as merger consideration, and immediately following the Merger, we will issue 1,636,364 shares of common
stock upon conversion of Pulmatrix bridge loans. Upon completion of the Merger, current stockholders will hold 5,653,618 shares,
or approximately 16.1% of the issued and outstanding equity and former Pulmatrix stockholders will own 29,484,633 shares or approximately
83.9% of our issued and outstanding equity, in each case, excluding options and restricted stock units. Accordingly, the issuance
of shares of our common stock to Pulmatrix equity holders in the Merger will significantly reduce the ownership stake and relative
voting power of each share of common stock held by current stockholders. Consequently, following the Merger, the ability of our
current stockholders to influence the management of Ruthigen will be substantially reduced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>There is no assurance when or if
the Merger will be completed. Any delay in completing the Merger may substantially reduce the benefits that we expect to obtain
from the Merger. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Completion of the
Merger is subject to the satisfaction or waiver of a number of conditions as set forth in the Merger Agreement. There can be no
assurance that we and Pulmatrix will be able to satisfy the closing conditions or that closing conditions beyond their control
will be satisfied or waived. If the Merger and the integration of the companies&rsquo; respective businesses are not completed
within the expected timeframe, such delay may materially and adversely affect the synergies and other benefits that we and Pulmatrix
expect to achieve as a result of the Merger and could result in additional transaction costs, loss of revenue or other effects
associated with uncertainty about the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Because the lack of a public market
for Pulmatrix&rsquo;s outstanding shares makes it difficult to evaluate the fairness of the Merger, Pulmatrix stockholders may
receive consideration in the Merger that is greater than or less than the fair market value of the Pulmatrix shares. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The outstanding capital
stock of Pulmatrix is privately held and is not traded in any public market. The lack of a public market makes it extremely difficult
to determine the fair market value of Pulmatrix shares. Since the percentage of our common stock to be issued to Pulmatrix equity
holders was determined based on negotiations between the parties, it is possible that the value of our common stock to be issued
in connection with the Merger will be greater than the fair market value of Pulmatrix shares. Alternatively, it is possible that
the value of our shares common stock to be issued in connection with the Merger will be less than the fair market value of Pulmatrix
shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our directors and officers may have
interests in the Merger that are different from, or in addition to, those of our stockholders generally that may influence them
to support or approve the Merger. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our officers and directors
may have interests in the Merger that are different from, or are in addition to, those of our stockholders. Effective upon the
closing of the Merger, Messrs. Alimi and Harish will be employed by the combined company and receive compensation and other consideration
These interests may have influenced our directors and executive officers of Ruthigen and Pulmatrix to support or recommend the
proposals presented to our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The announcement and pendency of
the Merger could have an adverse effect on our business, financial condition, results of operations or business prospects. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The announcement and
pendency of the Merger could disrupt our business in the following ways, among others:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">our employees may experience
                                         uncertainty regarding their future roles in the combined company, which might adversely
                                         affect our ability to retain, recruit and motivate key personnel;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">the attention of our management
                                         may be directed towards the completion of the Merger and other transaction-related considerations
                                         and may be diverted from the day-to-day business operations and matters related to the
                                         Merger may require commitments of time and resources that could otherwise have been devoted
                                         to other opportunities that might have been beneficial to us; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">suppliers and other third parties
                                         with business relationships with us may decide not to renew or may decide to seek to
                                         terminate, change or renegotiate their relationships with us as a result of the Merger,
                                         whether pursuant to the terms of their existing agreements with us or otherwise.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">Should they occur, any of these matters
could adversely affect our business, financial condition, results of operations or business prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Covenants in the Merger Agreement
place certain restrictions on our conduct of business prior to the closing of the Merger, including entering into a business combination
with another party. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Merger Agreement
restricts us from taking certain specified actions with respect to the conduct of our business without Pulmatrix&rsquo;s consent,
including prohibition on soliciting, initiating, encouraging discussions or negotiations with or providing non-public information
to any person concerning a merger, reorganization, consolidation, share exchange, business combination, recapitalization, liquidation,
dissolution or similar transaction. These restrictions may prevent us from pursuing otherwise attractive business opportunities
or other capital structure alternatives and making other changes to our business or executing certain of its business strategies
prior to the completion of the Merger, which could be favorable to our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 48; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The issuance of our common stock
in connection with the Merger could decrease the market price of our common stock. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
the Merger and as part of the merger consideration, we will issue shares of common stock to Pulmatrix equity holders. The issuance
of our common stock in the Merger may result in fluctuations in the market price of our common stock, including a stock price
decrease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We expect to incur substantial expenses
related to the Merger and the integration of Pulmatrix. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to incur
substantial expenses in connection with the Merger and integration of Pulmatrix. We may incur additional costs to maintain employee
morale and to retain key employees and will incur significant fees and expenses relating to legal, accounting, financial advisory
and other transaction fees and costs associated with the Merger. Specifically, based on estimates as of March 31, 2015, we expect
to incur approximately $3.6 million of transaction costs related to the Merger, including $2.4 million payable in cash and $1.2
million payable in stock. Additionally, there are a large number of processes, policies, procedures, operations, technologies
and systems that must be integrated, including purchasing, accounting and finance, sales, billing, payroll, manufacturing, marketing
and employee benefits, and we may incur after-tax integration and restructuring costs and other costs incurred to execute the
transaction following completion of the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Risks Related to the Combined Company
Following the Merger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Although we expect that the Merger
will result in benefits to the combined company, the combined company may not realize those benefits because of various challenges.
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not be able
to fully realize the anticipated benefits of the Merger. The integration of a new company is a complex, costly and time-consuming
process. This process may disrupt the business of either or both of the companies, and may not result in the full benefits expected
by us. Delays in the integration process could adversely affect the combined company&rsquo;s business, financial results, financial
condition, and stock price following the Merger. There can be no assurance that the combination will result in the realization
of the anticipated benefits from the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The market price of the combined
company&rsquo;s common stock after the Merger may be subject to significant fluctuations and volatility, and stockholders may
be unable to resell their shares at a profit and incur losses. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There has not been
a public market for the combined company&rsquo;s common stock. The market price of the combined company&rsquo;s common stock could
be subject to significant fluctuation following the Merger. Our business differs from that of Pulmatrix in important respects
and, accordingly, the results of operations of the combined company and the market price of the combined company common stock
following the Merger may be affected by factors different from those currently affecting the independent results of operations
of our company. Market prices for securities of early-stage pharmaceutical, medical device, biotechnology and other life science
companies have historically been particularly volatile. Some of the factors that may cause the market price of the combined company&rsquo;s
common stock to fluctuate include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">the announcement of new products,
                                         new developments, services or technological innovations by the combined company or the
                                         combined company&rsquo;s competitors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">actual or anticipated quarterly
                                         increases or decreases in revenue, gross margin or earnings, and changes in the combined
                                         company&rsquo;s business, operations or prospects;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">announcements relating to strategic
                                         relationships, mergers, acquisitions, partnerships, collaborations, joint ventures, capital
                                         commitments, or other events by the combined company or the combined company&rsquo;s
                                         competitors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">conditions or trends in the
                                         biotechnology and pharmaceutical industries;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">changes in the economic performance
                                         or market valuations of other biotechnology and pharmaceutical companies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 49; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">general market conditions or
                                         domestic or international macroeconomic and geopolitical factors unrelated to the combined
                                         company&rsquo;s performance or financial condition;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">sale of the combined company&rsquo;s
                                         common stock by stockholders, including executives and directors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">volatility and limitations in
                                         trading volumes of the combined company&rsquo;s common stock;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">the combined company&rsquo;s
                                         ability to obtain financings to conduct and complete research and development activities
                                         including, but not limited to, its human clinical trials, and other business activities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">ability to secure resources
                                         and the necessary personnel to conduct clinical trials on the combined company&rsquo;s
                                         desired schedule;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">failures to meet external expectations
                                         or management guidance;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">changes in the combined company&rsquo;s
                                         capital structure or dividend policy, future issuances of securities, sales or distributions
                                         of large blocks of common stock by stockholders;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">the combined company&rsquo;s
                                         cash position;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">announcements and events surrounding
                                         financing efforts, including debt and equity securities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">analyst research reports, recommendation
                                         and changes in recommendations, price targets, and withdrawals of coverage;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">departures and additions of
                                         key personnel;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">disputes and litigations related
                                         to intellectual properties, proprietary rights, and contractual obligations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">changes in applicable laws,
                                         rules, regulations, or accounting practices and other dynamics; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">other events or factors, many
                                         of which may be out of the combined company&rsquo;s control.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If the Merger is consummated, our
business operations, strategies and focus will fundamentally change, and these changes may not result in an improvement in the
value of our common stock. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pending the consummation
of the Merger, the Merger Agreement permits us to scale down our operations as we deem necessary and requires us to scale back
patient enrollment in our clinical trial of RUT58-60, our primary drug candidate, and it is currently anticipated that the combined
company would focus its resources on the development of products within the scope of Pulmatrix&rsquo;s current business plan.
As a result, following the Merger, the combined company may seek to sell or assign its rights related to our current drug candidates,
including RUT58-60. If completed, any such sale or assignment may be at a substantial discount, the consideration received may
not accurately represent the value of the assets sold or assigned and our stockholders may not participate in the future prospects
of such drug candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the Merger,
it is expected that the combined company&rsquo;s primary products will be PUR1900, Pulmatrix&rsquo;s lead anti-infective product
candidate, PUR0200, Pulmatrix&rsquo;s bronchodilator therapy candidate and Pulmatrix&rsquo;s other iSPERSE-based product candidates.
Consequently, if the Merger is consummated, an investment in Ruthigen&rsquo;s common stock will primarily represent an investment
in the business operations, strategies and focus of Pulmatrix. All of Pulmatrix&rsquo;s product candidates are still under development
and may never be approved for sale or successfully commercialized. The failure to successfully commercialize one or more of Pulmatrix&rsquo;s
current product candidates will significantly diminish the anticipated benefits of the Merger and have a material adverse effect
on the business of the combined company. We cannot assure you that Ruthigen&rsquo;s business operations, strategies or focus will
be successful following the Merger, and the Merger could depress the value of Ruthigen&rsquo;s common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may issue additional equity securities
in the future, which may result in dilution to existing investors. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent we raise
additional capital by issuing equity securities, including in a debt financing where we issue convertible notes or notes with
warrants our stockholders may experience substantial dilution. We may, from time to time, sell additional equity securities in
one or more transactions at prices and in a manner we determine. If we sell additional equity securities, existing stockholders
may be materially diluted. In addition, new investors could gain rights superior to existing stockholders, such as liquidation
and other preferences. In addition, the number of shares available for future grant under our equity compensation plans may be
increased in the future. In addition, the exercise or conversion of outstanding options or warrants to purchase shares of capital
stock may result in dilution to our stockholders upon any such exercise or conversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 50; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of our outstanding
shares of common stock are, and any shares of common stock that are issued in the Merger will be, freely tradable without restrictions
or further registration under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;) except for the restricted
stock units that will be issued to certain employees and consultants, shares of common stock issued to certain advisors, and any
shares held by affiliates, as defined in Rule 144 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The concentration of the capital
stock ownership with insiders of the combined company after the Merger will likely limit the ability of the stockholders of the
combined company to influence corporate matters. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the Merger,
the executive officers, directors, 5% percent or greater stockholders, and their respective affiliated entities of the combined
company will in the aggregate beneficially own approximately 57% of the combined company&rsquo;s outstanding common stock. As
a result, these stockholders, acting together, have control over matters that require approval by the combined company&rsquo;s
stockholders, including the election of directors and approval of significant corporate transactions. Corporate actions might
be taken even if other stockholders oppose them. This concentration of ownership might also have the effect of delaying or preventing
a corporate transaction that other stockholders may view as beneficial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>In the event that the combined company
fails to satisfy any of the listing requirements of The NASDAQ Capital Market, its common stock may be delisted, which could affect
its market price and liquidity. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the Merger,
the combined company&rsquo;s common stock is expected to be listed on The NASDAQ Capital Market. For continued listing on The
NASDAQ Capital Market, the combined company will be required to comply with the continued listing requirements, including the
minimum market capitalization standard, the corporate governance requirements and the minimum closing bid price requirement, among
other requirements. In the event that the combined company fails to satisfy any of the listing requirements of The NASDAQ Capital
Market, its common stock may be delisted. If the combined company is unable to list on The NASDAQ Stock Market, it would likely
be more difficult to trade in or obtain accurate quotations as to the market price of the combined company&rsquo;s common stock.
If the combined company&rsquo;s securities are delisted from trading on The NASDAQ Stock Market, and the combined company is not
able to list its securities on another exchange or to have them quoted on NASDAQ, the combined company&rsquo;s securities could
be quoted on the OTC Bulletin Board or on the &ldquo;pink sheets.&rdquo; As a result, the combined company could face significant
adverse consequences including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">a limited availability of market
                                         quotations for its securities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">a determination that its common
                                         stock is a &ldquo;penny stock&rdquo; which will require brokers trading in its common
                                         stock to adhere to more stringent rules and possibly result in a reduced level of trading
                                         activity in the secondary trading market for its securities;</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; font-size: 10pt"><FONT STYLE="font-size: 10pt">Item 1B.</FONT></td>
    <TD STYLE="font-weight: bold; font-size: 10pt"><A NAME="a_005"></A><FONT STYLE="font-size: 10pt">UNRESOLVED STAFF COMMENTS.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">None.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; font-size: 10pt"><FONT STYLE="font-size: 10pt">Item 2.</FONT></td>
    <TD STYLE="font-weight: bold; font-size: 10pt"><A NAME="a_006"></A><FONT STYLE="font-size: 10pt">PROPERTIES.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our corporate headquarters
are located in Santa Rosa, California, where we lease and occupy approximately 995 square feet of executive office space. The
term of our lease expires in June 2015 and our monthly rent is approximately $1,700. We also maintain an office located in Walnut
Creek, California, where we lease and occupy approximately 400 square feet of executive office space under a lease which expires
in September 2015 and has a monthly rent of approximately $700.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; font-size: 10pt"><FONT STYLE="font-size: 10pt">Item 3.</FONT></td>
    <TD STYLE="font-weight: bold; font-size: 10pt"><A NAME="a_007"></A><FONT STYLE="font-size: 10pt">LEGAL PROCEEDINGS.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There are no pending legal proceedings
to which we are a party. Our property is not the subject of any pending legal proceedings.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; font-size: 10pt"><FONT STYLE="font-size: 10pt">Item 4.</FONT></td>
    <TD STYLE="font-weight: bold; font-size: 10pt"><A NAME="a_008"></A><FONT STYLE="font-size: 10pt">MINE SAFETY DISCLOSURES.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 51; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_009"></A>PART II</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; font-size: 10pt"><FONT STYLE="font-size: 10pt">Item 5.</FONT></td>
    <TD STYLE="font-weight: bold; font-size: 10pt"><A NAME="a_010"></A><FONT STYLE="font-size: 10pt">MARKET FOR REGISTRANT&rsquo;S COMMON EQUITY,
    RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Market Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock began
trading on The NASDAQ Capital Market on March 21, 2014 under the symbol &ldquo;RTGN.&rdquo; The following table sets forth the
high and low sales prices per share of our common stock as reported on The NASDAQ Capital Market for the periods shown:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
sets forth the high and low trading prices per share of Ruthigen common stock as reported on The NASDAQ Capital Market for the
periods shown:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 41.9pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 41.9pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Common Stock</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">High</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Low</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Year Ended March 31, 2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 66%; text-align: left">First Quarter</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">7.15</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">5.75</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Second Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.49</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.05</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Third Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5.70</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.31</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Fourth Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.64</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.25</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">High</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Low</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Year Ended March 31, 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 66%">Fourth Quarter (beginning March 21, 2014)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">8.47</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">6.65</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 41.9pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 41.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Stockholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of June 5, 2015,
there were 9 stockholders of record of the 4,804,290 outstanding shares of Common Stock, one of which represents stock held by
multiple investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Dividends</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has not
paid dividends to its stockholders since its inception and does not plan to pay cash dividends in the foreseeable future. The
Company currently intends to retain earnings, if any, to finance the growth of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Unregistered Sales of Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Issuer Purchases of Equity Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Use of Proceeds from the Sale of Registered
Securities </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As March 31, 2015,
approximately $6.7 million of the $17.0 million of net proceeds from our IPO had been used. There has been no material change
in our expected use of the net proceeds from our IPO as described in our final prospectus dated March 21, 2014, filed with the
SEC pursuant to Rule 424(b)(4) under the Securities Act on March 21, 2014. We have broad discretion in the use of the net proceeds
from our IPO. We may find it necessary or advisable to use the net proceeds from our IPO for other purposes than those described
in our final prospectus.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; font-size: 10pt"><FONT STYLE="font-size: 10pt">Item 6.</FONT></td>
    <TD STYLE="font-weight: bold; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A NAME="a_011"></A>SELECTED FINANCIAL DATA.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not required for smaller reporting companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 52; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Item 7.</FONT></td>
    <TD STYLE="font-weight: bold; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><A NAME="a_012"></A>MANAGEMENT&rsquo;S DISCUSSION
    AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>You should read
the following discussion and analysis of our financial condition and results of operations together with our consolidated financial
statements and related notes appearing elsewhere in this Annual Report on Form 10-K. In addition to historical information, this
discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results
may differ materially from those anticipated in these forward-looking statements as a result of certain factors. We discuss factors
that we believe could cause or contribute to these differences below and elsewhere in this report, including those set forth under
Item 1A. &ldquo;Risk Factors&rdquo; and under &ldquo;Forward-Looking Statements&rdquo; in this Annual Report on Form 10-K.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a biopharmaceutical
company focused on pioneering new hypochlorus acid, or HOCl, based therapies designed to improve patient outcomes and reduce healthcare
costs associated with infections related to post-operative invasive procedures. Our lead drug candidate, RUT58-60, is a broad
spectrum anti-infective that we are developing for the prevention and treatment of infection in surgical and trauma procedures.
We are focusing RUT58-60 for use initially to prevent infections in abdominal surgery due to the large addressable market, high
rate of post-surgical infection associated with abdominal surgery, the high-impact opportunity that abdominal surgery offers us
in the clinical trial setting to expose multiple internal organs to RUT58-60 at one time, and feedback from surgeons identifying
post-surgical infection in abdominal surgery (relative to other surgeries) as a significant unmet medical need. We were incorporated
in January 2013 as a wholly-owned subsidiary of Oculus Innovative Sciences, Inc., or Oculus or the Former Parent, and we were
operated as a wholly-owned subsidiary of Oculus until the completion of our initial public offering, or IPO, in March 2014. We
currently have no products approved for sale. We submitted our Investigational New Drug Application, or IND, for RUT58-60 to the
United States Food and Drug Administration, or FDA, in early May 2014. In June 2014, our IND became effective thereby allowing
us to begin human clinical testing of RUT58-60. In July 2014, we began human clinical testing of RUT58-60 in a 21-day skin irritation
trial. In August 2014, we completed the skin irritation trial with 36 human subjects participating for 21 consecutive days. In
October 2014, we initiated the Phase 1/2 clinical trial, and, in November 2014 we began patient enrollment in the Phase 1/2 clinical
trial to evaluate the safety, tolerability, and potential efficacy of our lead drug candidate, RUT58-60, for use as an adjunct
to systemic antibiotics in abdominal surgery and patient screening began at four clinical trial sites in the United States. We
are in the process of enrolling the first 20 patients in the Phase 1 part of our exploratory Phase 1/2 clinical trial to evaluate
the safety of RUT58-60 within the abdominal cavity. To date, the company has not received any reports of any serious adverse events.
The study is being conducted at seven clinical sites in the U.S. The company has identified a number of additional clinical sites
for the potential Phase 2 part of our Phase 1/2 clinical trial for RUT58-60. Following a review of the safety run-in data, we
plan to pursue our Phase 2 and Phase 3 clinical trial strategy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that our
drug candidates have the potential to significantly reduce the rate of post-surgical infections, reduce the use of systemic antibiotics
that have proven to be ineffective against certain common resistant strains of bacteria, including methicillin-resistant staphylococcus
aureus , or MRSA, and Vancomycin-resistant enterococcus, or VRE, reduce the negative side effects associated with the increasingly
widespread use of antibiotics, accelerate post-surgical healing which should lead to quicker patient discharge from the hospital,
and ultimately reduce hospital readmission rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that our
drug candidates will complement the paid for performance paradigm and they are designed to reduce the overall healthcare costs
associated with post-surgical infections and improve hospital economics. We believe the benefits of its drug candidates will be
significant as they:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">mimic the human body&rsquo;s
                                         own infection-fighting mechanism,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">have not shown toxicity or serious
                                         side effects in its animal and other preclinical studies,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">do not produce resistant bacteria
                                         in vitro, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">demonstrate broad spectrum anti-microbial
                                         effectiveness in vitro.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that our
drug candidates have the potential to be used as a prophylactic therapy to prevent and treat infections, and may accelerate patient
discharge from the hospital and ultimately lead to an overall reduction in hospital readmission rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The benefits of HOCl
in preventing infection have been well-demonstrated in products with lower concentrations of HOCl than RUT58-60. To date, HOCl
based products have only been cleared for use as medical devices for topical applications in the United States, Europe and certain
other countries. Earlier formulations have not been able to achieve therapeutic indication status, primarily due to their lack
of stability and therefore have been limited for use as topical applications. Historically, the lack of stability has posed a
vexing problem to companies hoping to pursue HOCl products for therapeutic indications in invasive applications and has prevented
these companies from being able to conduct the clinical trials necessary to prove whether HOCl is safe and effective for use as
a therapeutic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 53; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">HOCl based products
have been used successfully to prevent infection in topical applications and have been sold commercially since at least 2005 by
other companies, generally as medical devices or for the disinfection of medical devices. Several of these HOCl based products
have been commercialized as medical devices by Oculus, our former parent company and the licensor of our technology. Through our
license and supply agreement with Oculus, we have obtained exclusive rights to the RUT58-60 technology, as well as a proprietary
method of manufacturing and producing HOCl with pharmaceutical potential by incorporating additional small molecules without sodium
hypochlorite, the result of which increases the compound&rsquo;s stability and biocompatibility, or the compound&rsquo;s ability
to remain in direct contact with internal tissues and organs. We believe our recent enhancements to the stability and biocompatibility
of the compound will allow us to expand the use of HOCl so that it may be used in direct contact with internal organs and thus,
for invasive applications, including surgical and trauma procedures, as well as additional clinical indications. With these enhancements,
we believe our lead product candidate will be able to meet the safety and efficacy standards that the FDA requires for the approval
of a new drug. Obtaining approval of new drug by the FDA is a lengthy, expensive and uncertain process, and we may not be successful
in obtaining approval. The FDA review processes can take years to complete and approval is never guaranteed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are approximately
30 million surgical and trauma procedures in the United States per year, approximately 7 million of which are abdominal surgeries,
based upon its market research.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are successful
in receiving FDA approval for our drug candidates for the prevention of infection in abdominal surgery, we plan to pursue other
types of surgeries, including cardiac, pulmonary and spinal, among others. Based upon data from preclinical studies conducted
by us and data reported in third party publications, we believe that the safety and tolerability profile of our drug candidates,
combined with its broad-range antimicrobial potency without specificity, offer a practical and unique approach to stem the high
rate of hospital acquired infections and infections resulting from complications in surgeries and the increasing emergence of
new antibiotic resistant bacteria that pose a significant risk to public health. We believe that our technology represents a significant
innovation over existing uses of HOCl in topical applications and over systemic antibiotics for the prevention and treatment of
infection in surgical and other invasive applications, and has the potential to raise the clinical bar for anti-infective products
generally in the face of increasing headwinds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have focused much
of our research and development efforts for RUT58-60 and other formulations on pre-clinical development and optimization. Our
research and development team is working to further optimize the performance of our drug candidates by testing variations in the
formulation and chemical components of RUT58-60. We also seek to further optimize the proprietary chemical formulation and manufacturing
process that gives us reason to believe that RUT58-60 and other formulations may be able to be used in surgical applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under our license and supply agreement
with Oculus, we have exclusively licensed the HOCl technology relating to RUT58-60 and other formulations for commercialization
in the United States, Europe, Japan and Canada. According to IMS Health, an information technology firm, these markets represented
approximately 71% of the global medicines market in 2011. In parallel with our clinical development activities, we have conducted
discussions with various pharmaceutical companies for potential partnership and collaboration activities for RUT58-60 in the United
States, Canada, Europe and Japan. To date, we have not entered into any partnerships or collaborations for RUT58-60 and we cannot
guarantee that we will be successful entering into any such arrangements on favorable terms, or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Merger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 13, 2015,
we entered into the Merger Agreement with Merger Sub and Pulmatrix which provides for the merger of Merger Sub with and into Pulmatrix,
with Pulmatrix surviving as our wholly owned subsidiary, and Merger Sub will cease to exist. See our Current Report on Form 8-K
dated March 13, 2015 for additional details related to the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Merger is consummated,
we will issue shares of our common stock to the Pulmatrix equity holders in connection with the Merger as merger consideration
and shares of common stock to certain lenders of Pulmatrix upon the conversion of bridge loans, such that the former Pulmatrix
security holders will hold approximately 83% of Ruthigen&rsquo;s post-merger shares. Although we are the legal acquirer and will
issue shares of its common stock to effect the merger with Pulmatrix, the business combination will be accounted for as a reverse
acquisition of Ruthigen by Pulmatrix under GAAP. In addition, at the effective time of the Merger, warrants to purchase shares
of Pulmatrix common stock will be converted into and exchangeable for warrants to purchase shares of our common stock pursuant
to an exchange ratio described in the Merger Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Merger is completed,
Hojabr Alimi, our Chief Executive Officer and Sameer Harish, our Chief Financial Officer will step down in their current roles
and continue to be employed by the combined company and have agreed to terminate equity grants previously made to them and will
receive cash and restricted stock units pursuant to the new employment agreements Pulmatrix and Ruthigen entered into with each
of Messrs. Alimi and Harish.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 54; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pending the consummation
of the merger, the Merger Agreement permits us to scale down our operations as we deem necessary and requires us to scale back
patient enrollment in our clinical trial of RUT58-60, our primary drug candidate, and it is currently anticipated that the combined
company would focus its resources on the development of products within the scope of Pulmatrix&rsquo;s current business plan.
As a result, following the Merger, the combined company may seek to sell or assign its rights related to our current drug candidates,
including RUT58-60.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Results of Operations </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Year Ended March 31, 2015 Compared with Year Ended March
31, 2014</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table presents selected items
in our statements of operations for the years ended March 31, 2015 and 2014, respectively:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">For The Years Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Revenues</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Operating Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 66%; text-align: left; padding-left: 9pt">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">2,178,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">1,382,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Selling, general and administrative</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,530,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,736,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total Operating Expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,708,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,118,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Loss From Operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(6,708,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,118,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Other Income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Interest income</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">17,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total Other Income</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">17,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net Loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(6,691,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,118,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Revenue</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We did not recognize
product sales for the years ended March 31, 2015 or 2014. Our ability to generate product revenues in the future will depend almost
entirely on our ability to successfully develop, obtain regulatory approval for and then successfully commercialize RUT58-60 in
the United States. In the event we choose to pursue a partnering arrangement to commercialize RUT58-60 or other products outside
the United States, we would expect to initiate additional research and development and clinical trial activities in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Research and Development Expense</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development
expense was $2,178,000 and $1,382,000 for the years ended March 31, 2015 and 2014, respectively, representing an increase of $796,000,
or 58%. The increase in research and development expense is primarily a result of the increases in activity directly related to
RUT58-60 and the Company&rsquo;s preparations and initiation of clinical trial activities. Research and development expense consists
of costs related to the research and development of RUT58-60 and our manufacturing process; the development and testing of new
drug formulations; preclinical studies; consulting fees; personnel related costs, including salaries, and benefits; and clinical
trials, which are designed to obtain FDA drug approvals for RUT58-60. Research and development expense is charged as incurred.
The expansion of our research and development staff was due to our increased focus on medical education, preclinical studies,
clinical trials and the management of regulatory trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 55; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that research
and development expense will continue to increase substantially in future years as we pursue regulatory approvals for RUT58-60
Based on the anticipated timelines and the resources we have allocated, we expect the total operating expense to bring RUT58-60
through our goal of FDA approval will be approximately $50 million. In addition, we expect to expand the scope of our new product
development, which may also result in substantial increases in research and development expense. If the Merger is consummated,
it is currently anticipated that the combined company would focus its resources on the development of products within the scope
of Pulmatrix&rsquo;s current business plan. As a result, following the Merger, the combined company may seek to sell or assign
its rights related to our current drug candidates, including RUT58-60</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Selling, General and Administrative
Expense</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Selling, general and
administrative expense was $4,530,000 and $1,736,000 for the years ended March 31, 2015 and 2014, respectively, representing an
increase of $2,794,000, or 161%. The increase in selling, general and administrative expense is primarily a result of higher legal,
accounting, and insurance expenses associated with being a public company of $1,154,000, the Company&rsquo;s preparations for its
initiation of clinical trials and the inclusion of non-cash stock compensation expenses of $1,079,000, which were not incurred
for the fiscal year ended March 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Liquidity and Capital
Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We measure our liquidity in a number of
ways, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 62%; padding-bottom: 2.5pt">Cash</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="width: 16%; text-align: right; border-bottom: Black 2.5pt double">10,357,000</TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="width: 16%; text-align: right; border-bottom: Black 2.5pt double">15,571,000</TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Working capital</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">9,888,000</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">14,627,000</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We reported net losses
of $6,691,000 and $3,118,000 for the years ended March 31, 2015 and 2014, respectively. At March 31, 2015 and 2014, our accumulated
deficit was $10,360,000 and $3,669,000, respectively. We have not yet achieved profitability. We expect that our research and
development and general and administrative expenses will continue to increase and, as a result, we will eventually need to generate
significant product revenues to achieve profitability. We may never achieve profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended
March 31, 2015, we received an additional $865,000 of net proceeds from the underwriter&rsquo;s exercise of the IPO over-allotment
option. At March 31, 2015, we had a cash balance of $10,357,000. We believe that our existing cash, which includes the proceeds
from our IPO, will be sufficient to fund our current business operations through the quarter ending June 30, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Future Capital Requirements and
Availability of Funds</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to continue
to incur substantial operating losses in the future and to make capital expenditures to support the expansion of our research
and development programs, establishment of a research and development and manufacturing facility and to initiate commercial operations.
We anticipate using a portion of the net proceeds from the IPO to finance these activities. It may take several years to obtain
the necessary regulatory approvals to commercialize RUT58-60 as a drug in the United States. There is no assurance that such approvals
will be obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future funding
requirements will depend on many factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>the scope, rate of progress and cost of our clinical trials
                                         and other research and development activities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>future clinical trial results;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>the terms and timing of any collaborative, licensing and
                                         other arrangements that we may establish;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>the cost and timing of regulatory approvals;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 56; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>the cost and delays in product development as a result
                                         of any changes in regulatory oversight applicable to our products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>the cost and timing of establishing sales, marketing and
                                         distribution capabilities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>the effect of competing technological and market developments;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>the cost of filing, prosecuting, defending and enforcing
                                         any patent claims and other intellectual property rights; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>the extent to which we acquire or invest in businesses,
                                         products and technologies.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may seek to raise
additional funds through public or private equity offerings, debt financings, capital lease transactions, corporate collaborations
or other means. We may seek to raise additional capital due to favorable market conditions or strategic considerations even if
we have sufficient funds for planned operations. The sale of additional equity or convertible debt securities could result in
dilution to our stockholders. Debt financing could require us to pledge certain assets and enter into covenants that could restrict
certain business activities or our ability to incur further indebtedness, and may contain other terms that are not favorable to
our stockholders or us. To the extent that we raise additional funds through collaborative arrangements, it may be necessary to
relinquish some rights to our technologies or grant licenses on terms that are not favorable to us. We do not know whether additional
funding will be available on acceptable terms, or at all. A failure to secure additional funding when needed may require us to
curtail certain operational activities, including regulatory trials, sales and marketing, and international operations and would
have a material adverse effect on our future business and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The obligation of
Pulmatrix to complete the Merger is subject to the Company having unrestricted cash on hand, net of outstanding liabilities, at
closing of at least (a) $9,000,000, if the Merger closing date is no later than July 31, 2015, or (b) $8,850,000, if the Merger
closing date is after July 31, 2015 but no later than August 13, 2015. Accordingly, the Merger Agreement permits us to scale down
our pre-merger operations as we deem necessary and requires us to scale back patient enrollment in our clinical trial of RUT58-60,
our primary drug candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to comply
with the applicable required amount of unrestricted cash at hand at the closing of the merger, we may enter into a binding stock
purchase agreement obligating one or more investors to purchase up to 948,555 shares of our common stock at a price not less than
$2.75 per share, prior to the closing. There can be no assurance that we will be successful in raising the funds needed to meet
such cash requirement. If we are unable to meet this cash requirement, Pulmatrix may not complete the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Cash Flows During the Years Ended March 31, 2015 and
2014</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">During the years ended March 31, 2015 and
2014, our sources and uses of cash were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Net Cash Used in Operating Activities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in operating
activities was $5,386,000 and $2,969,000 for the years ended March 31, 2015 and 2014, respectively. The net cash used in operating
activities for the year ended March 31, 2015 was primarily due to cash used to fund a net loss of $6,691,000, adjusted for non-cash
expenses of $1,080,000, partially offset by $225,000 of cash provided by changes in the levels of operating assets and liabilities,
primarily as a result of increases in accounts payable and accrued expenses, due to an expansion of operating activities. The
net cash used in operating activities for the year ended March 31, 2014 was primarily due to cash used to fund a net loss of $3,118,000,
adjusted for non-cash expenses of $2,000, partially offset by $147,000 of cash provided by changes in the levels of operating
assets and liabilities, primarily as a result of increases in accounts payable and accrued expenses, due to an expansion of operating
activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Net Cash Used in Investing Activities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in investing
activities was $156,000 and $0 for the years ended March 31, 2015 and 2014, respectively. The net cash used during the year ended
March 31, 2015 was related to purchases of property and equipment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Net Cash Provided by Financing Activities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash provided
by financing activities for the years ended March 31, 2015 and 2014 was $328,000 and $18,444,000, respectively. The net cash provided
by financing activities during the year ended March 31, 2015 was attributable to $865,000 of net proceeds from the underwriter&rsquo;s
exercise of the IPO over-allotment option (gross proceeds of $1,117,000 less $252,000 of offering costs paid during the year ended
March 31, 2015), partially offset by $537,000 of cash used in the repayment of advances to Oculus, our former parent. The net
cash provided by financing activities during the year ended March 31, 2014 was primarily attributable to $16,228,000 of net proceeds
from our IPO (gross proceeds of $19,216,000 less $2,988,000 of offering costs paid during the year ended March 31, 2014), $1,679,000
of investment from Oculus and $537,000 of net proceeds from advances from Oculus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 57; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Off-Balance Sheet Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have no off-balance
sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in
financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is
material to investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Critical Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of
our consolidated financial statements in conformity with accounting principles generally accepted in the United States of America,
or GAAP, requires management to exercise its judgment. We exercise considerable judgment with respect to establishing sound accounting
policies and in making estimates and assumptions that affect the reported amounts of our assets and liabilities, our recognition
of revenues and expenses, and disclosure of commitments and contingencies at the date of the consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On an ongoing basis,
we evaluate our estimates and judgments. We base our estimates and judgments on a variety of factors including our historical
experience, knowledge of our business and industry, current and expected economic conditions, the attributes of our products,
the regulatory environment, and in certain cases, the results of outside appraisals. We periodically re-evaluate our estimates
and assumptions with respect to these judgments and modify our approach when circumstances indicate that modifications are necessary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While we believe that
the factors we evaluate provide us with a meaningful basis for establishing and applying sound accounting policies, we cannot
guarantee that the results will always be accurate. Since the determination of these estimates requires the exercise of judgment,
actual results could differ from such estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A description of significant
accounting policies that require us to make estimates and assumptions in the preparation of our financial statements is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Use of Estimates</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of
consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosures of contingent liabilities at the dates of the consolidated financial
statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these
estimates. Significant estimates and assumptions include stock-based compensation, the valuation allowance related to our deferred
tax assets and the expense allocations relating to our operations prior to our deconsolidation from Oculus on March 26, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Stock-Based Compensation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We account for share-based
awards exchanged for employee and director services at the estimated grant date fair value of the award. We estimate the fair
value of stock options using the Black-Scholes option pricing model. We estimate the fair value of restricted stock and restricted
stock units (&ldquo;RSUs&rdquo;) based upon the closing market price of our common stock on the date the award is granted. We
amortize the fair value of employee awards on a straight-line basis over the requisite service period of the awards. Stock-based
compensation expense includes the impact of an estimate for forfeitures for all stock awards. We recognize stock-based compensation
expense for awards with performance conditions if and when we conclude that it is probable that the performance condition will
be achieved. We reassess the probability of vesting at each reporting period for awards with performance conditions and adjust
stock-based compensation expense based on our probability assessment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We account for equity
instruments issued to non-employees at their fair value on the measurement date. The measurement of stock-based compensation is
subject to periodic adjustment as the underlying equity instrument vests or becomes non-forfeitable. Non-employee stock-based
compensation charges are amortized over the requisite service period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Income Taxes</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We account for income
taxes under Accounting Standards Codification, or ASC, 740 Income Taxes, or ASC 740. Under ASC 740, deferred tax assets and liabilities
are determined based on the differences between the financial reporting and tax bases of assets and liabilities and net operating
loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to impact taxable
income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 58; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ASC 740 also clarifies
the accounting for uncertainty in income taxes recognized in an enterprise&rsquo;s financial statements and prescribes a recognition
threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be
taken in a tax return.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Tax benefits claimed
or expected to be claimed on a tax return are recorded in our financial statements. A tax benefit from an uncertain tax position
is only recognized if it is more likely than not that the tax position will be sustained on examination by the taxing authorities,
based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are
measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution.
Uncertain tax positions have had no impact our financial condition, results of operations or cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Research and Development</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development
expense is charged to operations as incurred and consists primarily of personnel expenses, clinical and regulatory services and
supplies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Recent Accounting Pronouncements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2014, the
Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, No. 2014-12, &quot;Compensation - Stock
Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could
be Achieved after the Requisite Service Period,&quot; (&quot;ASU 2014-12&quot;). The amendments in ASU 2014-12 require that a
performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance
condition. A reporting entity should apply existing guidance in Accounting Standards Codification Topic No. 718, &quot;Compensation
- Stock Compensation&quot; as it relates to awards with performance conditions that affect vesting to account for such awards.
The amendments in ASU 2014-12 are effective for annual periods and interim periods within those annual periods beginning after
December 15, 2015. Early adoption is permitted. Entities may apply the amendments in ASU 2014-12 either: (a) prospectively to
all awards granted or modified after the effective date; or (b) retrospectively to all awards with performance targets that are
outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified
awards thereafter. We do not anticipate that the adoption of this standard will have a material impact on our consolidated financial
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2014, the
FASB issued ASU No. 2014-15, &ldquo;Presentation of Financial Statements &ndash; Going Concern (Subtopic 205-40): Disclosure of
Uncertainties about an Entity&rsquo;s Ability to Continue as a Going Concern.&rdquo; The guidance, which is effective for annual
reporting periods ending after December 15, 2016, extends the responsibility for performing the going-concern assessment to management
and contains guidance on how to perform a going-concern assessment and when going-concern disclosures would be required under
U.S. GAAP. We do not believe adoption of this ASU will have a material effect on our consolidated financial statements.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; font-size: 10pt"><FONT STYLE="font-size: 10pt">Item 7A.</FONT></td>
    <TD STYLE="font-weight: bold; font-size: 10pt"><A NAME="a_013"></A><FONT STYLE="font-size: 10pt">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT
    MARKET RISK.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not required for smaller reporting companies.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; font-size: 10pt"><FONT STYLE="font-size: 10pt">Item 8.</FONT></td>
    <TD STYLE="font-weight: bold; font-size: 10pt"><A NAME="a_014"></A><FONT STYLE="font-size: 10pt">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.5pt">The information required by this Item
8 is included at the end of this Annual Report on Form 10-K beginning on page F-1.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; font-size: 10pt"><FONT STYLE="font-size: 10pt">Item 9.</FONT></td>
    <TD STYLE="font-weight: bold; font-size: 10pt"><A NAME="a_015"></A><FONT STYLE="font-size: 10pt">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS
    ON ACCOUNTING AND FINANCIAL DISCLOSURE.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.5pt">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 59; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; font-size: 10pt"><FONT STYLE="font-size: 10pt">Item 9A.</FONT></td>
    <TD STYLE="font-weight: bold; font-size: 10pt"><A NAME="a_016"></A><FONT STYLE="font-size: 10pt">CONTROLS AND PROCEDURES.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Disclosure Controls and Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our principal executive
officer and principal financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined
in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this Form 10-K, have concluded that, based
on such evaluation, our disclosure controls and procedures were effective to ensure that information required to be disclosed
by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the
time periods specified in the SEC&rsquo;s rules and forms, and is accumulated and communicated to our management, including our
principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely
decisions regarding required disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Internal Control over Financial Reporting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Management&rsquo;s Annual Report on
Internal Control over Financial Reporting</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management is
responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule&nbsp;13a-15(f)
under the Exchange Act. Internal control over financial reporting is a process designed by, or under the supervision of, our Principal
Executive and Financial Officer, and effected by the Board of Directors, management and other personnel, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with GAAP including those policies and procedures that: (i)&nbsp;pertain to the maintenance of records that, in reasonable
detail, accurately and fairly reflect our transactions and the disposition of our assets, (ii)&nbsp;provide reasonable assurance
that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with GAAP
and that receipts and expenditures are being made only in accordance with authorizations of our management and Board of Directors,
and (iii)&nbsp;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition
of our assets that could have a material effect on the consolidated financial statements. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;Because of its
inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of
any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes
in conditions, or that the degree of compliance with policies and procedures may deteriorate. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;Management conducted
an evaluation of the effectiveness of our internal control over financial reporting based on the 1992 framework in&nbsp;<I>Internal
Control &ndash; Integrated Framework</I>&nbsp;issued by the Committee of Sponsoring Organizations of the Treadway Commission.
Based on this evaluation, management concluded that our internal control over financial reporting was effective as of March 31,
2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Changes in Internal Controls</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-weight: normal">There
were no changes in our internal control over financial reporting that occurred during our last fiscal quarter ended March 31,
2015 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; font-size: 10pt"><FONT STYLE="font-size: 10pt">Item 9B.</FONT></td>
    <TD STYLE="font-weight: bold; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A NAME="a_017"></A>OTHER INFORMATION.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 60; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_018"></A>PART III</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left">Item 10.</TD><TD STYLE="text-align: justify"><A NAME="a_019"></A>DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Executive Officers and Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Set forth below is certain information with
respect to our directors and executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 28%; border-bottom: black 1pt solid"><B>Name</B></TD>
    <TD NOWRAP STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 7%; border-bottom: black 1pt solid; text-align: center"><B>Age</B></TD>
    <TD NOWRAP STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 61%; border-bottom: black 1pt solid; text-align: center"><B>Position(s)</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 10.1pt; text-indent: -10.1pt">Hojabr Alimi </TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">53</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Executive Officer, Chief Science Officer and</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chairman of the Board of Directors</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 10.1pt; text-indent: -10.1pt">Sameer Harish</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">39</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>Chief Financial Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 10.1pt; text-indent: -10.1pt">Richard Conley (1)(2)(3)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">64</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.1pt; text-indent: -10.1pt">Gregory French (1)(2)(3)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.1pt; text-indent: -10.1pt">Akihisa Akao (1)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.1pt; text-indent: -10.1pt">&nbsp;</P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">54</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">61</P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Director</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Director</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1) Member of our audit committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(2) Member of our compensation committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(3) Member of our nominating and governance committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Executive Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Hojabr Alimi
</I></B>has served as our Chief Executive Officer and Chief Science Officer since February 4, 2013. Mr. Alimi was also appointed
Chairman of our board of directors on that same date. From 1999 to February 2013, Mr. Alimi held the position of President and
Chief Executive Officer at our former parent company, Oculus, a public company which he co-founded with his spouse. Mr. Alimi
served as Chairman of the Board of Oculus, from 1999 until February 2014. Upon completion of our initial public offering, Mr.
Alimi resigned from Oculus&rsquo; board of directors. Prior to founding Oculus, Mr. Alimi was a corporate microbiologist for Arterial
Vascular Engineering. Mr. Alimi received a B.A. in biology from Sonoma State University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors
has determined that Mr. Alimi possesses specific attributes that qualify him to serve as a member of our board of directors, including
his depth of scientific, operating, strategic, transactional, and senior management experience in our industry, his longevity in
the industry, and his intimate knowledge of our company, as he is the founder of Ruthigen and Oculus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Sameer Harish
</I></B>has served as our Chief Financial Officer since February 1, 2013. Prior thereto, from December 2011, Mr. Harish served
as the principal of Harish Life Science Advisors, an independent consulting firm, which he founded that provided financial, strategic,
and market research advisory services to life science companies. From 2005 to 2011, Mr. Harish held the position of senior equity
research analyst covering the medical devices and diagnostics sectors at ThinkEquity LLC and Needham &amp; Co. From 2002 to 2005,
Mr. Harish was a research analyst at Symmetry Capital, a health care focused hedge fund, where he guided investments in medical
device, biotech, and diagnostic companies. Mr. Harish also held research and laboratory positions at Guidant (now part of Abbott
Laboratories) and Synteni (acquired by Incyte Corporation). He received a B.A. from the University of California, Berkeley, where
he studied molecular and cell biology with an emphasis in immunology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Non-Employee Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Richard Conley
</I></B>has served as a director since February 2013. From 1999 until March 2014, Mr. Conley served as a member of the board of
directors of Oculus. Upon completion of our IPO, Mr. Conley resigned from Oculus&rsquo; board of directors. Since 2012, Mr. Conley
has served as a volunteer member of the Finance Committee and Citizens Bond Oversight Committee of the Sonoma Valley Health Care
District. Mr. Conley held the position of Chief Operating Officer at Kautz Family Vineyards, a wine production and marketing and
hospitality company, from 2009 to 2011. From 2001 to 2009, Mr. Conley served as Executive Vice President and Chief Operating Officer
at Don Sebastiani &amp; Sons International Wine Negociants, a branded wine marketing company. From 1994 to 2001, he served as
Vice President and Chief Operating Officer at Sebastiani Vineyards, a California wine producer, where he was originally hired
as Chief Financial Officer in 1994. Mr. Conley received a B.S. in finance and accounting from Western Carolina University and
an M.B.A. from St. Mary&rsquo;s College of California.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&nbsp;</P>


<!-- Field: Page; Sequence: 61; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors
has determined that Mr. Conley possesses specific attributes that qualify him to serve as a member of our board of directors, including
the depth of his financial, accounting, operating and transactional experience.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Gregory
French</I></B> has served as a director since February 2013. Mr. French is the co-owner of G&amp;C Enterprises LLC, a real estate
and investment company, which he founded in 1999. Mr. French has held various engineering and senior management positions at several
medical device companies, including Advanced Cardiovascular Systems, Peripheral Systems Group and Arterial Vascular Engineering.
He received a B.S.I.E. from the California Polytechnic State University, San Luis Obispo. Mr. French was a director of Oculus from
2000 until his resignation effective as of February 21, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors
has determined that Mr. French possesses specific attributes that qualify him to serve as a member of our board of directors, including
extensive experience in the healthcare industry and a depth of operating and senior management experience.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Akihisa Akao
</I></B>has served as a director since February 27, 2015. Mr. Akao has been the Chief Executive Officer of White Moon Medical,
Inc. since he founded such company in 1999. The company provides consulting services as well as capital to early-stage healthcare
companies which are expanding into Asian markets. Mr. Akao served as a director of Oculus from April 1999 until May 2008. Mr.
Akao has 38 years of experience in the healthcare industry and development therapies in areas of pulmonology, wound care, general
surgery, cardiovascular and anesthesiology. Mr. Akao has served on the board of directors at MedTech Heart K.K., a medical technology
company, since August 2011. Mr. Akao has served as the general manager in Japan at Power Medical Interventions Inc., a medical
device company, from January 2001 to September 2005 and as President from December 2006 to December 2009 until its merger with
Covidien. Mr. Akao received a B.A. in electronic engineering from Doshisha University, Kyoto Japan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors
has determined that Mr. Akao possesses specific attributes that qualify him to serve as a member of our board of directors, including
extensive experience in the healthcare industry and of his financial, operating and transactional experience.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Merger is completed
all of our current officers and directors will resign immediately prior to the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Other Involvement in Certain Legal Proceedings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no legal
proceedings that have occurred within the past ten years concerning our directors, or control persons which involved a criminal
conviction, a criminal proceeding, an administrative or civil proceeding limiting one's participation in the securities or banking
industries, or a finding of securities or commodities law violations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Board Composition and Election of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors
currently consists of four directors. Our board of directors is divided into three classes, class I, class II and class III, with
members of each class serving staggered terms where the term of each class of directors expires at each successive annual meeting
of the stockholders. The members of the classes are divided as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify">the class I director is Hojabr Alimi, and his term will expire at the 2018 annual meeting of stockholders</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify">the class II directors are Richard Conley and Akihisa Akao, and their terms will expire at the
2016 annual meeting of stockholders; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">the class III director is Gregory French, and his term will expire at the 2017 annual meeting of
stockholders.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the expiration of the term of a
class of directors, directors in that class will be eligible to be elected for a new term at the annual meeting of stockholders
in that year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Board Committees and Independence</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors
has established an audit committee, a compensation committee, and a nominating and corporate governance committee, each of which
operates under a charter that has been approved by our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&nbsp;</P>


<!-- Field: Page; Sequence: 62; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors
has determined that all of the members of the audit committee, the compensation committee and the nominating and corporate governance
committee are independent, as defined under The NASDAQ Marketplace Rules, including, in the case of all of the members of our audit
committee, the independence requirements contemplated by Rule 10A-3 under the Securities Exchange Act of 1934. In making such determination,
the board of directors considered the relationships that each director has with our company and all other facts and circumstances
that the board of directors deemed relevant in determining director independence, including the beneficial ownership of our capital
stock by each director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no family relationships among
any of our directors or executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None of our directors or officers is
a director in any other reporting companies. None of our directors or officers has been affiliated with any company that has filed
for bankruptcy within the last ten years. The Company is not aware of any proceedings to which any of the Company&rsquo;s officers
or directors, or any associate of any such officer or director, is a party adverse to the Company or has a material interest adverse
to it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Audit Committee.
</I>&nbsp;&nbsp;Our audit committee is comprised of Richard Conley, Gregory French and Akihisa Akao. Our board of directors has
determined that Richard Conley is an audit committee financial expert, as defined by the rules of the Securities and Exchange
Commission, and satisfies the financial sophistication requirements of applicable NASDAQ rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the applicable
NASDAQ rules, we are permitted to phase in our compliance with the independent audit committee requirements set forth in NASDAQ
Marketplace Rule 5605(c)(2)(A)(ii) on the same schedule as we are permitted to phase in our compliance with the independent audit
committee requirement pursuant to Rule 10A-3(b)(1)(iv)(A) under the Exchange Act, which require (1) one independent member at the
time of listing; (2) a majority of independent members within 90 days of listing; and (3) all independent members within one year
of listing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors
has determined that each of Messrs. Conley, French and Akao is an independent director under the NASDAQ Marketplace Rules and Rule
10A-3 of the Exchange Act. Mr. Alimi resigned from our audit committee on February 27, 2015 and was replaced with Mr. Akao on such
date who is independent under NASDAQ Marketplace Rule 5605(c)(2)(A)(ii) and Rule 10A-3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audit committee
is authorized to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.2pt; text-align: justify; text-indent: -15.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">review the proposed scope and results of the audit;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -15.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>review and pre-approve audit and non-audit fees and services;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -15.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>review accounting and financial controls with the independent auditors and our financial and accounting staff;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -15.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>review and approve transactions between us and our directors, officers and affiliates;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -15.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>recognize and prevent prohibited non-audit services;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -15.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>establish procedures for complaints received by us regarding accounting matters;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -15.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>oversee internal audit functions, if any; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -15.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">prepare the report of the audit committee that the
rules of the Securities and Exchange Commission require to be included in our annual meeting proxy statement .</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Compensation Committee.</I> &nbsp;&nbsp;Our
compensation committee is comprised of Gregory French and Richard Conley.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our compensation committee is authorized
to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.2pt; text-indent: -15.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">review and recommend the compensation arrangements
for management, including the compensation for our president and chief executive officer;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66.2pt; text-indent: -15.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">establish and review general compensation policies
with the objective to attract and retain superior talent, to reward individual performance and to achieve our financial goals;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66.2pt; text-indent: -15.1pt">&nbsp;</P>


<!-- Field: Page; Sequence: 63; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>administer our stock incentive plans;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66.2pt; text-indent: -15.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">prepare the report of the compensation committee that
the rules of the Securities and Exchange Commission require to be included in our annual meeting proxy statement; and</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66.2pt; text-indent: -15.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">have the sole authority to retain or obtain the advice
of any compensation consultant, independent legal counsel or other adviser after taking into account certain factors which address
the independence of that consultant, counsel or adviser.</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Nominating and Governance Committee.</I>
&nbsp;&nbsp;Our nominating and governance committee is comprised of Richard Conley and Gregory French.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our nominating and governance committee
is authorized to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.2pt; text-indent: -15.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>identify and nominate members of the board of directors;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66.2pt; text-indent: -15.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">develop and recommend to the board of directors a set
of corporate governance principles applicable to our company; and</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66.2pt; text-indent: -15.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>oversee the evaluation of our board of directors.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.2pt; text-indent: -30.2pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.2pt; text-indent: -30.2pt"><B>Section&nbsp;16(a) Beneficial
Ownership Reporting Compliance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.2pt; text-indent: -30.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;16(a)
of the Securities Exchange Act of 1934, as amended, requires our directors and executive officers, and persons who own more than
ten percent of a registered class of our equity securities, to file with the Securities and Exchange Commission initial reports
of ownership and reports of changes in ownership of our common stock and other of our equity securities. Officers, directors and
greater than ten percent stockholders are required by regulations of the Securities and Exchange Commission to furnish us with
copies of all Section&nbsp;16(a) forms they file.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our records reflect
that all reports required to be filed pursuant to Section&nbsp;16(a) of the Securities Exchange Act of 1934, as amended, by our
executive officers and directors have been filed on a timely basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Code of Conduct and Ethics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors
has adopted a written Corporate Code of Conduct and Ethics and Whistleblower Policy (the<BR>
&ldquo;Corporate Code&rdquo;) applicable to our employees, officers and directors, including those officers responsible for financial
reporting. The Corporate Code is available on our website at www.ruthigen.com. We expect that any amendments to the code, or any
waivers of its requirements, will be disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left">Item 11.</TD><TD STYLE="text-align: justify"><A NAME="a_020"></A>EXECUTIVE COMPENSATION.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Summary Compensation Table</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table sets forth the compensation
paid to, accrued or earned during the fiscal years ended March 31, 2015 and March 31, 2014 by our chief executive officer and our
only other executive officer as of March 31, 2015 and March 31, 2014. We refer to these officers as our named executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Stock</B></FONT></TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Option</B></FONT></TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>All Other</B></FONT></TD><TD NOWRAP STYLE="text-align: center"><SUP>&nbsp;</SUP></TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Awards ($)</B></FONT></TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Awards ($)</B></FONT></TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Compensation</B></FONT></TD><TD NOWRAP STYLE="text-align: center"><SUP>&nbsp;</SUP></TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Name and Principal Position</B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Year</B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Salary ($)</B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Bonus ($)</B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><SUP>(1)</SUP></B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><SUP>(1)</SUP></B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>($)</B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center"><SUP>&nbsp;</SUP></TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Total ($)</B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 30%; text-align: left">Hojabr Alimi</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 7%; text-align: center">2015</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">375,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">939,047</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">764,005</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">50,856</TD><TD STYLE="width: 1%; text-align: left"><SUP>(3)</SUP></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">2,128,908</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Chief Executive Officer and Chief Science Officer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2014</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">375,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">158,000</FONT></TD><TD STYLE="text-align: left"><SUP>(2)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">51,856</TD><TD STYLE="text-align: left"><SUP>(4)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">584,856</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Sameer Harish</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2015</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">225,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">563,850</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">95,800</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7,961</TD><TD STYLE="text-align: left"><SUP>(5)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">892,611</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Chief Financial Officer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2014</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">225,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left"><SUP>&nbsp;</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">225,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>The amounts reported in these columns represent the grant date fair value of the stock and option awards granted during the
fiscal year ended March 31, 2015 as calculated in accordance with FASB ASC Topic 718. For a detailed discussion of the assumptions
used in estimating fair values, see Note 7. Stockholders&rsquo; Equity in the notes that accompany our consolidated financial statements.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 64; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>Represents a one-time cash bonus of $158,000 related to the preparation and filing of our registration statement on Form S-1
for our initial public offering.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(3)</TD><TD>Includes Company matching 401(k) contributions in the amount of $8,654 and Company paid vacation of $42,202.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(4)</TD><TD>Includes the reimbursement of tax preparation services of $25,884, the reimbursement of legal fees of $18,744, Company matching
401(k) contributions of $3,750, personal use of our company car in the amount of $3,462, and payment by the Company of life insurance
premiums in the amount of $16.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(5)</TD><TD>Represents Company matching 401(k) contributions in the amount of $7,961.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Narrative to Summary Compensation Table</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Employment Agreements with Our Named Executive Officers</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Hojabr Alimi</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 21, 2013,
we entered into an employment agreement with an effective date of February 4, 2013 (the &ldquo;Alimi Employment Agreement&rdquo;)
with Hojabr Alimi to reflect his role and responsibilities as President and Chief Executive Officer. The Alimi Employment Agreement
provided for an annual base salary of $375,000, subject to increase (but not decrease), as determined by our board of directors.
Mr. Alimi may also receive stock options and/or other stock-based awards as determined by us in our sole discretion. Additionally,
Mr. Alimi is eligible to participate in our bonus plans and incentive plans as established from time to time by us. The Alimi Employment
Agreement also provides for payments to Mr. Alimi in the event of termination without cause or resignation by Mr. Alimi for Good
Reason, as such terms are defined in the Alimi Employment Agreement. In the event Mr. Alimi is terminated without cause or resigns
for Good Reason, he is entitled to (i) a lump severance payment equal to 24 times the average monthly base salary paid to Mr. Alimi
over the preceding 12 months (or for the term of Mr. Alimi&rsquo;s employment with us if less than 12 months); (ii) automatic vesting
of all unvested options and other equity awards; (iii) the extension of exercisability of all options and other equity awards to
at least 12 months following the date Mr. Alimi terminates employment or, if earlier, until the option expires; (iv) up to one
year (the lesser of one year following the date of termination or until Mr. Alimi becomes eligible for medical insurance coverage
provided by another employer) reimbursement for health care premiums under COBRA; and (v) a full gross up of any excise taxes payable
by Mr. Alimi under Section 4999 of the Internal Revenue Code because of the foregoing payments and acceleration (including the
reimbursement of any additional federal, state and local taxes payable as a result of the gross up), subject to the restrictions
of Section 409A of the Internal Revenue Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Alimi Employment
Agreement, &ldquo;Good Reason&rdquo; is defined as the occurrence of one or more of the following without Mr. Alimi&rsquo;s consent:
(i) the assignment of Mr. Alimi to duties materially inconsistent with Mr. Alimi&rsquo;s authorities, responsibilities, and status
(including titles and reporting requirements) as Chief Executive Officer, or a material reduction or alteration in the nature or
status of Mr. Alimi&rsquo;s authorities, duties or responsibilities, other than an insubstantial and inadvertent act that is remedied
by the company promptly after receipt of notice thereof given by Mr. Alimi; (ii) a reduction by us in Mr. Alimi&rsquo;s base salary
as in effect on the effective date or as the same shall be increased from time to time, or we otherwise fail to satisfy our compensation
obligations to Mr. Alimi under the Alimi Employment Agreement, after notice by Mr. Alimi and a reasonable opportunity to cure;
or (iii) the failure by us to obtain a satisfactory agreement from any successor of our company to assume and agree to perform
the Alimi Employment Agreement. Mr. Alimi may terminate his employment for any reason upon at least 60 days prior written notice
to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Receipt of the termination
benefits described above is contingent on Mr. Alimi&rsquo;s execution of a general release of claims against us, our subsidiaries,
and our affiliates; his resignation from any and all directorships and every other position held by him with us and each of our
affiliates, including but not limited to the board of directors of Oculus; and his return to us and our affiliates (the &ldquo;Company
Group&rdquo;) of all property belonging to the Company Group, received from or on account of us, any other entity in the Company
Group, or any of the Company Group&rsquo;s respective affiliates by Mr. Alimi. In addition, Mr. Alimi is not entitled to such benefits
if he does not comply with the non-competition and invention assignment provisions of the Alimi Employment Agreement during the
term of his employment, or the confidentiality provisions of the Alimi Employment Agreement, whether during or after the term of
his employment. Furthermore, we are under no obligation to pay the above-mentioned benefits if Mr. Alimi does not comply with the
non-solicitation provisions of the Alimi Employment Agreement, which prohibit Mr. Alimi from interfering with our business relations
or those of any other entity in the Company Group, and from soliciting employees of any entity in the Company Group, which provisions
apply during the term of employment and for two years following termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>


<!-- Field: Page; Sequence: 65; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, on
August 12, 2013, the Compensation Committee of Oculus approved the grant of a one-time cash bonus of $158,000 to Mr. Alimi in order
to recognize his efforts related to the filing of our registration statement for our IPO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 31, 2014,
in connection with our entry into various amendments to our commercial agreements with Oculus, Oculus guaranteed the payment of
Mr. Alimi&rsquo;s severance in an amount not to exceed $385,000, under certain circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 28, 2014,
the compensation committee of the board of directors approved an amended and restated employment agreement for Mr. Alimi which
supersedes the employment agreement previously in effect between us and Mr. Alimi. The prior employment agreement went into effect
when we were a wholly-owned subsidiary of Oculus and Mr. Alimi was the Chairman of the board of directors of Oculus. The amended
and restated employment agreement primarily removes all references to Oculus and other legacy references related to us being a
subsidiary of Oculus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amended and restated
employment agreement continues to provide for an annual base salary of $375,000, subject to increase, as determined by our board
of directors. The amended and restated employment agreement further provides for payments to Mr. Alimi in the event of termination
without cause or resignation by Mr. Alimi for good reason, as such terms are defined in the amended and restated employment agreement.
In the event that Mr. Alimi is terminated without cause or resigns for good reason, he is entitled to: (i) a lump severance payment
equal to 24 times the average monthly base salary paid to Mr. Alimi over the preceding 12 months; (ii) up to one year (the lesser
of one year following the date of termination or until Mr. Alimi becomes eligible for medical insurance coverage provided by another
employer) reimbursement for health care premiums under COBRA; and (iii) automatic vesting of all unvested options and other equity
awards. In addition, if we consummate a change of control all equity awards granted by us that are then-outstanding and unvested
shall become fully vested and exercisable immediately prior to and subject to the consummation of the change of control. In addition,
we will reimburse Mr. Alimi for any excise taxes owed by him under Section 280G and Section 4999 of the Internal Revenue Code
because of any acceleration of the equity awards (including a gross up of any additional federal, state and local taxes payable
as a result of the reimbursement of the tax payments). Furthermore, we will reimburse Mr. Alimi for relocation expenses if our
principal executive offices are moved or he is required to relocate, subject to certain conditions. Mr. Alimi may terminate his
employment for any reason upon at least 60 days prior written notice to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Receipt of the
termination benefits described above is contingent on Mr. Alimi&rsquo;s execution of a general release of claims against us, our
subsidiaries and our affiliates; his resignation from any and all directorships and every other position held by him with us and
each of our subsidiaries; and his return to us and our affiliates or the Company Group (as such term is defined in the employment
agreement), of all property belonging to the Company Group, received from or on account of the Company Group, or any other entity
of the Company Group, or any of the Company Group&rsquo;s respective affiliates by Mr. Alimi. In addition, Mr. Alimi is not entitled
to such benefits if he does not comply with the non-competition and invention assignment provisions of the employment agreement
during the term of his employment, or the confidentiality provisions of the employment agreement, whether during or after the
term of his employment. Furthermore, we are under no obligation to pay the above-mentioned benefits if Mr. Alimi does not comply
with the non-solicitation provisions of the employment agreement, which prohibit Mr. Alimi from interfering with our business
relations or those of any other entity in the Company Group, and from soliciting employees of any entity in the Company Group,
which provisions apply during the term of employment and for two years following termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Sameer Harish</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 1, 2013,
and as amended on May 23, 2013, Oculus entered into an employment letter with Sameer Harish to reflect his roles and responsibilities
as Chief Financial Officer of our company (the &ldquo;Harish Employment Letter&rdquo;). Mr. Harish&rsquo;s employment was contingent
upon, in addition to proof of identity, his signing of a Proprietary Information and Inventions Agreement and a Confidentiality
Agreement with Oculus. Pursuant to the terms of the Harish Employment Letter, Mr. Harish was entitled to receive an annual base
salary of $225,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 24, 2014,
our compensation committee approved an employment agreement for Mr. Harish (the &ldquo;Harish Employment Agreement&rdquo;), which
replaced the offer letter previously in effect between us and Mr. Harish. The Harish Employment Agreement continues to provide
for an annual base salary of $225,000, subject to increase, as determined by our board of directors. Mr. Harish may also receive
stock options and/or other stock-based awards as determined by us in our sole discretion. In addition, Mr. Harish is eligible to
participate in our bonus plans and incentive plans that we establish from time to time, as well as all employee pension and welfare
benefit plans and programs made available by us to our senior-level employees generally. The Harish Employment Agreement further
provides for payments to Mr. Harish in the event of termination without cause or resignation by Mr. Harish for good reason, as
such terms are defined in the Harish Employment Agreement. In the event that Mr. Harish is terminated without cause or resigns
for good reason, he is entitled to: (i) a lump severance payment equal to 18 times the average monthly base salary paid to Mr.
Harish over the preceding 12 months; (ii) up to one year (the lesser of one year following the date of termination or until Mr.
Harish becomes eligible for medical insurance coverage provided by another employer) reimbursement for health care premiums under
COBRA; and (iii) automatic vesting of all unvested options and other equity awards; provided that in the event Mr. Harish resigns
for good reason prior to a change of control, only the vesting of the restricted stock units granted by us on May 12, 2014 shall
be accelerated. In addition, if we consummate a change of control all equity awards granted by us that are then-outstanding and
unvested shall become fully vested and exercisable immediately prior to and subject to the consummation of the change of control.
In addition, we will reimburse Mr. Harish for any excise taxes owed by him under Section 280G and Section 4999 of the Internal
Revenue Code because of any acceleration of the equity awards (including a gross up of any additional federal, state and local
taxes payable as a result of the reimbursement of the tax payments). Mr. Harish may terminate his employment for any reason upon
at least 60 days prior written notice to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>


<!-- Field: Page; Sequence: 66; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Receipt of the termination
benefits described above is contingent on Mr. Harish&rsquo;s execution of a general release of claims against us, our subsidiaries
and our affiliates; his resignation from any and all directorships and every other position held by him with us and each of our
subsidiaries; and his return to us and our affiliates (the &ldquo;Company Group&rdquo;) of all property belonging to the Company
Group, received from or on account of the Company Group, or any other entity of the Company Group, or any of the Company Group&rsquo;s
respective affiliates by Mr. Harish. In addition, Mr. Harish is not entitled to such benefits if he does not comply with the non-competition
and invention assignment provisions of the Harish Employment Agreement during the term of his employment, or the confidentiality
provisions of the Harish Employment Agreement, whether during or after the term of his employment. Furthermore, we are under no
obligation to pay the above-mentioned benefits if Mr. Harish does not comply with the non-solicitation provisions of the Harish
Employment Agreement, which prohibit Mr. Harish from interfering with our business relations or those of any other entity in the
Company Group, and from soliciting employees of any entity in the Company Group, which provisions apply during the term of employment
and for two years following termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Merger is completed,
Messrs. Alimi and Harish will be employed by the combined company and have agreed to terminate equity grants previously made to
them and will receive cash and restricted stock units pursuant to new employment agreements Pulmatrix and Ruthigen entered into
with each of Messrs. Alimi and Harish, effective upon the closing of the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Outstanding Equity Awards</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The table below
reflects all outstanding equity awards made to any named executive officer that were outstanding at March&nbsp;31, 2015.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 20.15pt"><B>OUTSTANDING EQUITY
AWARDS AT FISCAL YEAR-END</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 20.15pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="16" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Option
    Awards</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="14" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Stock
    Awards</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Equity</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>incentive</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Plan</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>awards :</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Equity</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Market or</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Equity</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>incentive</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>payout</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>incentive plan</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>plan awards:</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>value of</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>awards:</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Number of</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>unearned</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Number of</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Number of</B> &nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Number of</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Number of</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Market</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>unearned</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>shares,</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>securities</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>securities</B>
    &nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>securities</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>shares or</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>value of</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>shares,</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>units or</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>underlying</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>underlying</B>
    &nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>underlying</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>units of</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>shares of</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>units or</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>other</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>unexercised</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>unexercised</B>
    &nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>unexercised</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Option</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Option</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>stock that</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>units that</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>other rights</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>rights that</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>options</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>options</B> &nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>unearned</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>exercise</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>expiration</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>have not</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>have not</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>that have not</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>have not</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Name</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>exercisable</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>unexercisable
    </B>&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>options</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>price</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>date</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>vested</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>vested</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>vested</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>vested</B></FONT></TD><TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 37%; text-align: left"><FONT STYLE="font-size: 8pt">Hojabr Alimi</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-size: 8pt">39,906</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;119,594</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt"><SUP>(1)</SUP></FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$&nbsp;</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-size: 8pt">6.37</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">5/12/2024</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">93,725</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">322,414</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">24,055</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"><SUP>(2)</SUP>&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">82,749</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Sameer Harish</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">26,271</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;78,729</FONT></TD><TD STYLE="text-align: left"><SUP>(3)<FONT STYLE="font-size: 8pt">&nbsp;</FONT></SUP></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">6.37</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">5/12/2024</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">55,937</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">192,423</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">14,900</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">51,256</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">14,900</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"><SUP>(2)</SUP></FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">51,256</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 20.15pt"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 20.15pt"><B></B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 67; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>Option is exercisable to the extent of 13,302 shares quarterly
                                         between May 12, 2015 to February 12, 2016, and 13,178 shares on May 12, 2016.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>Represents restricted stock units that vest based upon the
                                         completion of certain performance conditions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(3)</TD><TD>Option is exercisable to the extent of 8,757 shares quarterly
                                         between May 12, 2015 to February 12, 2016, and 8,673 shares on May 12, 2016.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 68; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Director Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table summarizes the compensation
awarded during the fiscal year ended March 31, 2015 to our directors who are not named executive officers in the Summary Compensation
Table above:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Fees Earned</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP><SUP>&nbsp;</SUP></TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">or Paid in</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Stock</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Option</TD><TD NOWRAP STYLE="font-weight: bold"><SUP>&nbsp;</SUP></TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Name</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Cash ($)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: Black 1pt solid; text-align: center"><B>Awards ($) </B><SUP>(1)</SUP></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: Black 1pt solid; text-align: center"><B>Awards ($) </B><SUP>(1)</SUP></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><SUP>&nbsp;</SUP></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total ($)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: left">Gregory French</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">38,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">441,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">$ 47,900 </TD><TD STYLE="width: 1%; text-align: left"><SUP>(2)</SUP></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">526,900</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Richard Conley</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">43,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">441,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">$ 47,900</TD><TD STYLE="text-align: left"><SUP>(2)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">531,900</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Akihisa Akao <FONT STYLE="font-size: 10pt"><SUP>(3)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,712</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left"><SUP>&nbsp;</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,712</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>The amounts reported in this column represent the grant date fair value of the stock and option awards granted during the year
ended March 31, 2015, calculated in accordance with FASB ASC Topic 718. For a detailed discussion of the assumptions used in estimating
fair values, see Note 10 &ndash; Stockholders&rsquo; Deficiency in the notes that accompany our consolidated financial statements.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>Represents options to purchase 10,000 shares of common stock at an exercise price of $6.37 per share. The shares vest ratably
over three years on a quarterly basis.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(3)</TD><TD>Mr. Akao was appointed as a director effective February 27,
                                         2015.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 30,
2013, our board of directors approved a director compensation policy that took effect upon the completion of our IPO that provides
cash compensation of $40,000 per year to our chairman, if such person is not an employee, $25,000 per year to each non-employee,
non-chairman director, plus $10,000 per year to the chairman of our audit committee, $5,000 per year to each other member of our
audit committee, $5,000 per year to the chairman of our compensation committee and our nominating and governance committee and
$3,000 per year to each other member of our compensation committee and our nominating and governance committee. Members of our
board of directors who are also our employees, such as Mr. Alimi, do not receive any fees for their service on our board of directors,
as a chairman or committee member. The policy also provides that directors may elect, in lieu of annual cash payments, to receive,
in part or in full, fully-vested stock options or fully-vested shares of common stock, or a combination thereof, equal to the
dollar-value of the non-cash portion of their annual compensation, calculated in accordance with FASB Accounting Standards Codification
ASC 718, &ldquo;Share-Based Payment&rdquo; on the payment date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the policy, upon
initial election or appointment to the board of directors, new non-employee directors receive a non-qualified stock option to purchase
5,000 shares of our common stock at an exercise price equal to the fair market value on the date of grant that vests one year from
the date of grant. Each year of a non-employee director&rsquo;s tenure, the director will receive a non-qualified stock option
to purchase 5,000 shares of our common stock at an exercise price equal to the fair market value on the date of grant that vests
three years from the date of grant. The options become fully vested and exercisable upon a change of control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, equity
awards may be granted under the 2013 Plan to our non-employee directors from time to time as may be determined by our compensation
committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All directors are eligible
to receive reimbursement for reasonable out-of-pocket expenses incurred in connection with attendance at meetings of our board
of directors, and our non-employee directors are also eligible to receive reimbursement, upon approval of the board of directors
or a committee thereof, for reasonable out-of-pocket expenses incurred in connection with attendance at various conferences or
meetings with our management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&nbsp;</P>


<!-- Field: Page; Sequence: 69; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Equity Compensation Plan Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.9pt; text-indent: 15pt">The following table provides information
as of March 31, 2015:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Number of securities</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Number of securities</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">to be issued upon</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted-average</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">remaining available for</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">exercise of</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">exercise price of</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">future issuance under</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">outstanding options,</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">outstanding options,</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">equity compensation plans</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">warrants and rights</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">warrants and rights</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">(excluding securities</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(a)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(b)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">reflected in column (a))</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: left">Equity compensation plans approved by security holders [1]</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">895,691</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">6.37</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">102,664</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Equity compensation plans not approved by security holders</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">895,691</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6.37</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">102,664</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[1] &ndash; Shares represent grants under the 2013 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>2013 Employee, Director and Consultant Equity Incentive Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our 2013 Plan became
effective on the closing of our initial public offering in March 2014 and will expire on September 30, 2023. Under the 2013 Plan,
we may grant incentive stock options, non-qualified stock options, restricted and unrestricted stock awards and other stock-based
awards. When the 2013 Plan took effect in March 2014, 998,355 shares of our common stock were authorized for issuance thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the 2013
Plan contains an &ldquo;evergreen&rdquo; provision, which allows for an annual increase in the number of shares of our common stock
available for issuance under the plan on the first day of each fiscal year equal to the lowest of: (i) 232,500 shares of our common
stock; (ii) 5% of the number of shares of our common stock outstanding as of such date; and (iii) an amount determined by our board
of directors or compensation committee. As of April 1, 2015, there were 1,230,855 shares of common stock authorized for issuance
under the 2013 Plan and there were 335,164 shares available for issuance under the 2013 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The board of directors has authorized
our compensation committee to administer the 2013 Plan. In accordance with the provisions of the plan, the compensation committee
will determine the terms of options and other awards. The compensation committee or the independent members of our board of directors
will determine:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.2pt; text-indent: -15.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">which employees, directors and consultants shall be granted
options and other awards;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.2pt; text-indent: -15.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>the number of shares of our common stock subject to options and other awards;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.2pt; text-indent: -15.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>the exercise price of each option, which generally shall not be less than fair market value on the date of grant;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.2pt; text-indent: -15.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>the schedule upon which options become exercisable;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.2pt; text-indent: -15.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>the termination or cancellation provisions applicable to options;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.2pt; text-indent: -15.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">the terms and conditions of other awards, including
conditions for repurchase, termination or cancellation, issue price and repurchase price; and</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.2pt; text-indent: -15.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>all other terms and conditions upon which each award may be granted in accordance with the 2013 Plan.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Upon a merger, consolidation or sale of
all or substantially all of our assets, the administrator of the 2013 Plan, or the board of directors of any corporation assuming
our obligations, may, in its sole discretion, take any one or more of the following actions pursuant to our plan, as to some or
all outstanding awards:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.2pt; text-indent: -15.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">provide that outstanding options will be substituted
for shares of the successor corporation or consideration payable with respect to our outstanding stock in connection with the
corporate transaction;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.2pt; text-indent: -15.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">provide that the outstanding options must be exercised
within a certain number of days, either to the extent the options are then exercisable, or at our board of directors&rsquo; discretion,
any such options being made partially or fully exercisable;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.2pt; text-indent: -15.1pt">&nbsp;</P>


<!-- Field: Page; Sequence: 70; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">terminate outstanding options in exchange for payment
of an amount equal to the difference between (a) the consideration payable upon consummation of the corporate transaction to a
holder of the number of shares into which such option would have been exercisable to the extent then exercisable (or, in our board
of directors&rsquo; discretion, any such options being made partially or fully exercisable) and (b) the aggregate exercise price
of those options;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.2pt; text-indent: -15.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">provide that outstanding stock grants will be substituted
for shares of the successor corporation or consideration payable with respect to our outstanding stock in connection with the
corporate transaction;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.2pt; text-indent: -15.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">the terms and conditions of other awards, including
conditions for repurchase, termination or cancellation, issue price and repurchase price; and</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.2pt; text-indent: -15.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">terminate outstanding stock grants in exchange for payment
        of any amount equal to the consideration payable upon consummation of the corporate transaction to a holder of the
        same number of shares comprising the stock grant, to the extent the stock grant is no longer subject to any forfeiture or
        repurchase rights (or, at our board of directors&rsquo; discretion, all forfeiture and repurchase rights being waived upon
        the corporate transaction).</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in; text-align: left">Item 12.</TD><TD STYLE="text-align: left"><A NAME="a_021"></A>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
AND RELATED STOCKHOLDER MATTERS.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
lists, as of June 5, 2015, the number of shares of common stock of our Company that are beneficially owned by (i) each person or
entity known to our Company to be the beneficial owner of more than 5% of the outstanding common stock; (ii) each executive officer
and director of our Company; and (iii) all officers and directors as a group. Information relating to beneficial ownership of common
stock by our principal shareholders and management is based upon information furnished by each person using &ldquo;beneficial ownership&rdquo;
concepts under the rules of the Securities and Exchange Commission. Under these rules, a person is deemed to be a beneficial owner
of a security if that person has or shares voting power, which includes the power to vote or direct the voting of the security,
or investment power, which includes the power to vote or direct the voting of the security. The person is also deemed to be a beneficial
owner of any security of which that person has a right to acquire beneficial ownership within 60 days. Under the Securities and
Exchange Commission rules, more than one person may be deemed to be a beneficial owner of the same securities, and a person may
be deemed to be a beneficial owner of securities as to which he or she may not have any pecuniary beneficial interest. Except as
noted below, each person has sole voting and investment power.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The percentages below are calculated based
on 4,804,290 shares of our common stock issued and outstanding as of June 5, 2015. Unless otherwise indicated, the address of each
person listed is c/o Ruthigen, Inc., 2455 Bennett Valley Rd., Suite C116, Santa Rosa, California 95404.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 71; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Percentage of</TD><TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Number of Shares</TD><TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Common Stock</TD><TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Beneficially</TD><TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Beneficially</TD><TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: left">Beneficial Owner</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center">Owned</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center">Owned</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Directors and Executive Officers</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left">Hojabr Alimi</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">53,208</TD><TD STYLE="width: 1%; text-align: left">(1)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1.10</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Sameer Harish</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,028</TD><TD STYLE="text-align: left">(1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Richard Conley</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,336</TD><TD STYLE="text-align: left">(1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Gregory French</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,336</TD><TD STYLE="text-align: left">(1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Akihisa Akao</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,000</TD><TD STYLE="text-align: left">(1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">All current executive officers and directors as a group (5 persons)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">109,908</TD><TD STYLE="text-align: left">(1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.24</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">5% Stockholders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Oculus Inovative Sciences, Inc.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">1129 N. McDowell Blvd.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Petaluma, CA 94954</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,000,000</TD><TD STYLE="text-align: left">(2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">41.63</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Marlin Capital Investments LLC</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">555 South Federal Highway #450</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Boca Raton, FL 33432</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">369,773 </TD><TD STYLE="text-align: left">(3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.70</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Barry Honig</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">555 South Federal Highway #450</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Boca Raton, FL 33432</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">384,052</TD><TD STYLE="text-align: left">(4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.99</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify">Represents beneficial ownership of less than 1%.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15.1pt; text-indent: -15.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>Represents shares issuable upon the exercise of stock options.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>Based on a Schedule 13D filed on March 23, 2015 and includes (i) 350,000 shares of common stock that Oculus sold on March 23,
2015 and for which Oculus retained voting power but has no dispositive power and (ii) 1,650,000 shares of common stock that Oculus
has agreed to sell upon the closing of the Merger and for which Oculus has retained voting power but has no dispositive power.
Jim Schutz, chief executive officer of Oculus, may be deemed to beneficially own the shares held by Oculus.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(3)</TD><TD STYLE="text-align: justify">Based on a Schedule 13G filed on February 13, 2015. Barry Honig, the manager of Marlin Capital
Investments LLC (&ldquo;Marlin Capital&rdquo;), has voting and dispositive power over such securities held by Marlin Capital. Does
not include 14,279 shares held by Mr. Honig in his own name. Excludes Series A warrants to purchase an aggregate of 383,793 shares
of our common stock exercisable at an initial exercise price of $7.25 per share, and (ii) Series B warrants to purchase one share
of our common stock at an initial exercise price of $9.0625 per share. The Series A warrant and the Series B warrant are governed
by certain beneficial ownership blockers preventing the holder from exercising such securities to the extent such conversion or
exercise would cause the holder to beneficially hold in excess of 4.99% of our issued and outstanding common stock, which may be
waived upon 61 days&rsquo; prior notice. Mr. Honig&rsquo;s and Marlin Capital&rsquo;s beneficial ownership has been limited accordingly.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(4)</TD><TD>Includes (i) 14,279 shares of common stock and (ii) 369,773 shares of common stock which are held by Marlin Capital and are
also reported on this table as being beneficially owned by Marlin Capital. Barry Honig, manager of Marlin Capital holds voting
and dispositive power over such securities. Excludes Series A warrants to purchase an aggregate of 383,793 shares of our common
stock exercisable at an initial exercise price of $7.25 per share and (ii) Series B warrants to purchase one share of our common
stock at an initial exercise price of $9.0625 per share. The Series A warrant and the Series B warrant are governed by certain
beneficial ownership blockers preventing the holder from exercising such securities to the extent such conversion or exercise would
cause the holder to beneficially hold in excess of 4.99% of Ruthigen&rsquo;s issued and outstanding common stock, which may be
waived upon 61 days&rsquo; prior notice. Mr. Honig&rsquo;s and Marlin Capital&rsquo;s beneficial ownership has been limited accordingly.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 72; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 10%; text-align: left">Item 13.&nbsp; </TD><TD STYLE="text-align: justify; width: 90%"><A NAME="a_022"></A>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS,
AND DIRECTOR INDEPENDENCE.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Certain Relationships and Related Person Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Relationship with Oculus</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have a license and
supply agreement, a shared services agreement and a separation agreement with Oculus, the holder of 2,000,000 shares or approximately
42% of our outstanding shares of common stock. These agreements, which took effect upon the completion of our initial public offering
in March 2014, govern our relationship with Oculus. In addition, we entered into a funding agreement with Oculus that governed
certain aspects of our operations, financing and governance until the completion of our initial public offering. The license and
supply agreement covers our exclusive rights to the license, development and manufacturing of our lead drug candidate, RUT58-60.
The shared services agreement covers certain transitional services to be provided by Oculus following the completion of our offering.
We entered into the separation agreement with Oculus in order to maximize our ability to operate as independently as possible from
Oculus in order to unlock the value proposition of RUT58-60, notwithstanding Oculus&rsquo; substantial ownership of us, and therefore
the separation agreement contains certain limitations on Oculus&rsquo; ability to control various aspects of our business and operations.
In addition, the members of our Board of Directors who were also members of Oculus&rsquo; board of directors stepped down from
Oculus&rsquo; board and continued their service on our Board following our initial public offering. The shared services agreement
was terminated on April 6, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the terms of the separation
agreement with Oculus, so long as Oculus and its affiliates own 19.9% of our common stock, Oculus shall vote all of its shares
in the same manner as the majority of the minority holders of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Equity Awards and Compensation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Following the closing of our initial public
offering and during the year ended March 31, 2015, we granted Hojabr Alimi, our Chief Executive Officer, Chief Science Officer
and Chairman of the Board of Directors, 159,500 stock options, 125,000 restricted stock units and 24,055 performance-based restricted
stock units. At that same time, we also granted Sameer Harish, our Chief Financial Officer, 105,000 stock options, 74,600 restricted
stock units and 14,900 performance-based restricted stock units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">During the fiscal year ended March 31, 2014,
our non-employee directors did not receive any compensation for their service on our Board, other than Gregory French for whom
we reimbursed certain legal expenses of $51,975 incurred in connection with our separation from Oculus. During the fiscal year
ended March 31, 2015, we granted our non-employee directors restricted stock units for 140,000 shares of our common stock under
our 2013 Plan and options to purchase 20,000 shares of our common stock under our 2013 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Directors and Officers</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to February 21,
2014, all of our then directors also served as directors of Oculus. Gregory French resigned from the board of directors of Oculus
effective as of February 21, 2014, and he continues to serve on our Board of Directors. Hojabr Alimi, our Chief Executive Officer,
Chief Science Officer and Chairman of our Board of Directors, previously served as the Chairman of the board of directors of Oculus.
Richard Conley previously served as a director of Oculus. Upon completion of our initial public offering in March 2014, Messrs.
Alimi and Conley stepped down from Oculus&rsquo; board and continue their service on our Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Indemnification Agreements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#9;We have entered into indemnification
agreements with each of our directors and officers. The indemnification agreements and our restated certificate of incorporation
and restated by-laws require us to indemnify our directors and officers to the fullest extent permitted by Delaware law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>


<!-- Field: Page; Sequence: 73; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><I>Director Independence</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors
has determined that Richard Conley, Gregory French and Akihisa Akao qualify as independent directors under the definition promulgated
by The NASDAQ Stock Market LLC.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 10%; text-align: left">Item 14.&nbsp;&nbsp;</TD><TD STYLE="text-align: justify; width: 90%"><A NAME="a_023"></A>PRINCIPAL
ACCOUNTING FEES AND SERVICES.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
presents fees for professional audit services rendered by Marcum LLP for the audit of the Company&rsquo;s annual consolidated financial
statements for the years ended March 31, 2015 and 2014, and fees billed for other services rendered by Marcum LLP during those
periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center">For the Years Ended</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left">Audit fees <SUP>(1)</SUP></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">143,639</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">276,762</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Audit related fees <SUP>(2)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Tax Fees <SUP>(3)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,790</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">All other fees <SUP>(4)</SUP></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">158,429</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">276,762</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>(1)</SUP> Audit fees consisted of
fees for professional services rendered by Marcum LLP for the audit of the Company&rsquo;s annual financial statements and reviews
of interim financial statements and services that are normally provided by Marcum LLP in connection with statutory and regulatory
filings or engagement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>(2)</SUP> No audit related fees were
incurred by the Company in fiscal 2014 or 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>(3)</SUP> Tax fees consisted of fees
for professional services rendered by Marcum LLP for the preparation of the Company&rsquo;s tax return.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>(4)</SUP> No other fees were incurred by the Company in
fiscal 2014 or 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Policy on Audit Committee Pre-Approval of Audit and Permissible
Non-audit Services of Independent Public Accountant</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Consistent with SEC
policies regarding auditor independence, the Audit Committee has responsibility for appointing, setting compensation and overseeing
the work of our independent registered public accounting firm. In recognition of this responsibility, the Audit Committee has established
a policy to pre-approve all audit and permissible non-audit services provided by our independent registered public accounting firm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to engagement
of an independent registered public accounting firm for the next year&rsquo;s audit, management will submit an aggregate of services
expected to be rendered during that year for each of four categories of services to the Audit Committee for approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1&#9;<B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Audit</I></B> services include
audit work performed in the preparation of financial statements, as well as work that generally only an independent registered
public accounting firm can reasonably be expected to provide, including comfort letters, statutory audits, and attest services
and consultation regarding financial accounting and/or reporting standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Audit-Related</I></B>
services are for assurance and related services that are traditionally performed by an independent registered public accounting
firm, including due diligence related to mergers and acquisitions, employee benefit plan audits, and special procedures required
to meet certain regulatory requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Tax</I></B>
services include all services performed by an independent registered public accounting firm&rsquo;s tax personnel except those
services specifically related to the audit of the financial statements, and includes fees in the areas of tax compliance, tax planning,
and tax advice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Other
Fees</I></B> are those associated with services not captured in the other categories. The Company generally does not request such
services from our independent registered public accounting firm.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 74; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_024"></A>PART IV</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left">Item 15.</TD><TD STYLE="text-align: justify"><A NAME="a_025"></A>EXHIBITS, FINANCIAL STATEMENT SCHEDULES.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><B>Item 15(a).</B></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal">The
                                         following documents are filed as part of this annual report on Form 10-K.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><B>Item 15(a)(1)<BR> and (2)</B></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal">See
                                         &ldquo;Index to Consolidated Financial Statements and Financial Statement Schedules&rdquo;
                                         at Item 8 to this Annual Report on Form 10-K. Other financial statement schedules have
                                         not been included because they are not applicable or the information is included in the
                                         financial statements or notes thereto.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><B>&nbsp;&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><B>Item 15(a)(3)</B></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal"><U>Exhibits</U></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"></TD><TD STYLE="text-align: justify">The following is a list of exhibits filed as part of this Annual Report on Form
                                                                         10-K:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="width: 8%; border-bottom: black 1pt solid; padding-left: 6pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit</B></FONT><BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Number</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 45%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit Description</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 8%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Included</B></FONT><BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>with this</B></FONT><BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Report</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 14%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Incorporated by</B></FONT><BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Reference</B></FONT><BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>herein from</B></FONT><BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Form or</B></FONT><BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Schedule</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 7%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Filing <BR>
Date</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 13%; border-bottom: black 1pt solid; padding-right: 6pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SEC <BR>
File/Reg.</B></FONT><BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Number</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.1</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Agreement and Plan of Merger dated March 13, 2015, by and among the Company, Pulmatrix and Ruthigen Merger Corp.</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 8-K</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exhibit 2.1)</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3/13/15</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">001-36199</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;3.1</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Restated Certificate of Incorporation</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 8-K</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exhibit 3.1)</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">03/31/14</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">001-36199</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.2</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Restated Bylaws</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 8-K</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exhibit 3.2)</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">03/31/14</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">001-36199</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.1</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Specimen certificate evidencing shares of common stock.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form S-1</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exhibit 4.1)</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10/16/13</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">333-190476</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.2</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Representative&rsquo;s Warrant Agreement.</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form S-1</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exhibit 4.2)</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">02/24/14</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">333-190476</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.3</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Series A Warrant.</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form S-1</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exhibit 4.3)</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">02/24/14</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">333-190476</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.4</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Series B Warrant.</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form S-1</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exhibit 4.4)</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">02/24/14</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">333-190476</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.5</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Form of Warrant Agreement between the Company and VStock Transfer,
        LLC</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form S-1</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exhibit 4.5)</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">02/24/14</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">333-190476</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Agreements with Executive Officers and Directors</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.1.1*</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Offer of Employment Letter between Oculus Innovative Sciences,
        Inc. and Sameer Harish, dated January 31, 2013; Amendment to the Offer of Employment as Chief Financial Officer, dated May 23,
        2013.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form S-1</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exhibit 10.1)</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">08/08/13</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">333-190476</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.1.2*</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Employment Agreement by and between the Company and Sameer Harish, dated June 24, 2014</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 10-K</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exhibit 10.1.2)</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6/30/14</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">001-36199</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.2*</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Employment Agreement by and between the Company and Hojabr Alimi,
        dated March 21, 2013.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 51pt">&nbsp;</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form S-1</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exhibit 10.2)</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">08/08/13</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">333-190476</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.3*</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Letter Agreement dated January 31, 2014 to Employment Agreement
        by and between Oculus Innovative Sciences, Inc. and Hojabr Alimi.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form S-1</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exhibit 10.2.1)</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">02/24/14</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">333-190476</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.4*</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Non-Employee Director Compensation Policy</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form S-1</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exhibit 10.7)</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10/16/13</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">333-190476</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 75; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.5*</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 45%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Indemnification Agreement by and between the Company and its directors and officers.</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 14%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form S-1 <BR>
(Exhibit 10.8)</FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10/16/13</FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 13%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">333-190476</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 6pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.5.1*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amended and Restated Employment Agreement dated November 29, 2014 between the Company and Hojabr Alimi</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form 8-K<BR>
 (Exhibit 10.1)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">11/28/14</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">001&mdash;36199</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 6pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.5.2*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Employment Agreement dated March 13, 2015, between the Company, Pulmatrix and Hojabr Alimi</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form S-4 <BR>
(Exhibit 10.4.1)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4/15/15</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">333-203417</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 6pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.5.3*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Employment Agreement dated March 13, 2015, between the Company, Pulmatrix and Sameer Harish</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form S-4 <BR>
(Exhibit 10.3.1)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4/15//15</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">333-203417</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 6pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.15</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Cancellation Agreement dated March 13, 2015 between the Company and Sameer Harish</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form S-4 <BR>
(Exhibit 10.3.2)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4/15/15</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">333-203417</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 6pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.16</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Lock-Up Agreement dated March 13, 2015 between the Company and Sameer Harish</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form S-4 <BR>
(Exhibit 10.3.3)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4/15/15</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">333-203417</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 6pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.17</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Cancellation Agreement dated March 13, 2015 between the Company and Hojabr Alimi</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form S-4 <BR>
(Exhibit 10.4.2)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4/15/15</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">333-203417</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 6pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.18</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Lock-Up Agreement dated March 13, 2015 between the Company and Hojabr Alimi</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form S-4 &nbsp;<BR>
(Exhibit 10.4.3)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4/15/15</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">333-203417</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Lease Agreements</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.6.1</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Assignment and Assumption of Lease Agreement by and between
        Gladiator Capital Funds, LLC, the Company., SR Office Properties LLC, and Hojabr Alimi, dated March 5, 2013; Office Lease by and
        between CA-Waterfall Towers Limited Partnership and Gladiator Capital Funds LLC, dated June 29, 2010; First Amendment to Office
        Lease by and between CA-Waterfall Towers Limited Partnership and Gladiator Capital Funds LLC, dated August 18, 2011; Second Amendment
        to Office Lease by and between CA-Waterfall Towers Limited Partnership and Gladiator Capital Funds LLC, dated September 1, 2012.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form S-1</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exhibit 10.3)</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">08/08/13</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">333-190476</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">10.6.2</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Third Amendment to Office Lease by and between the Company and
        SR Office Properties LLC, dated October 3, 2013.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form S-1</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exhibit 10.3.1)</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10/16/13</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">333-190476</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Agreements with Respect to Collaborations, Licenses, Research
        and Development</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.7.1**</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">License and Supply Agreement by and between the Company and
        Oculus Innovative Sciences, Inc., dated May 23, 2013.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form S-1</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exhibit 10.4)</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10/16/13</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">333-190476</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.7.2</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amendment No. 1 to License and Supply Agreement by and between
        the Company and Oculus Innovative Sciences, Inc., dated October 9, 2013.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form S-1</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exhibit 10.4.1)</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10/16/13</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">333-190476</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.7.3</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amendment No. 2 to License and Supply Agreement by and between
        We, Inc. and Oculus Innovative Sciences, Inc., dated November 6, 2013.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form S-1</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exhibit 10.4.2)</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">11/07/13</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">333-190476</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.7.4</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment No. 3 to License and Supply Agreement by and between the Company and Oculus Innovative Sciences, Inc., dated January 31, 2014.</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form S-1</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exhibit 10.4.3)</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">02/24/14</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">333-190476</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 76; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 8%; padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.8.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 45%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shared Services Agreement by and between the Company and Oculus
        Innovative Sciences, Inc., dated May 23, 2013.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 8%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 14%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form S-1</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exhibit 10.5)</P></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 7%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">08/08/13</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 13%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">333-190476</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.8.2</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amendment No. 1 to Shared Services Agreement by and between
        the Company and Oculus Innovative Sciences, Inc., dated January 31, 2014.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form S-1</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exhibit 10.5.1)</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">02/24/14</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">333-190476</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.9</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amended Separation Agreement by and between the Company and
        Oculus Innovative Sciences, Inc., dated January 31, 2014.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form S-1</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exhibit 10.9)</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">02/24/14</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">333-190476</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Equity Compensation Plans</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.11</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2013 Employee, Director and Consultant Equity Incentive Plan</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 10-K</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exhibit 10.11)</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6/30/14</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">001-36199</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.12</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of option agreement under the 2013 Incentive Plan.</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 10-K</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exhibit 10.12)</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6/30/14</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">001-36199</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.13</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of restricted stock unit agreement under the 2013 Incentive Plan.</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 10-K</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exhibit 10.13)</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6/30/14</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">001-36199</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.14</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of performance-based restricted stock unit agreement for grants made under the 2013 Incentive Plan on May 11, 2014 to the executive officers and directors</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form 10-K</FONT><BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Exhibit 10.14)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6/30/14</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">001-36199</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 6pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.19</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form S-4/A</FONT><BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Exhibit 10.14)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5/1/15</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">333-203417</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Other Exhibits</B></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.20</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Securities Purchase Agreement dated January 8, 2015 between Michael Brauser, Barry Honig, Oculus and the Company</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form 8-K</FONT><BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Exhibit 10.1)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1/13/15</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">001-36199</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.21</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Securities Purchase Follow-Up Agreement dated March 12, 2015 between Michael Brauser, Barry Honig, Oculus, the Company and Dawson James Securities, Inc.</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form 8-K</FONT><BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Exhibit 10.1)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3/13/15</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">001-36199</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.22</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Securities Purchase Agreement dated March 12, 2015 between, Oculus, the Company, Dawson James Securities, Inc. and the listed investors</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form 8-K</FONT><BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Exhibit 10.2)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3/13/15</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">001-36199</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.23</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Consulting Agreement dated March 3, 2015 between Dawson James Securities, Inc. and the Company</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">X</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.24</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Consulting Agreement dated March 10, 2015 between Robert B. Prag and the Company</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">X</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.25</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Engagement Letter dated May 7, 2015 between the Company and Dawson James Securities, Inc.</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">X</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.26</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment No. 1 to Securities Purchase Follow-Up Agreement, dated March 12, 2015 between Michael Brauser, Barry Honig, Oculus, the Company and Dawson James Securities, Inc.</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">X</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 77; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 8%; padding-left: 6pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">21</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 45%">Subsidiaries</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 8%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">X</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 14%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 7%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 13%; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt">23.1</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Consent of Marcum LLP, independent registered public accounting firm.</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">X</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">31.1</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certification of the Chief Executive Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">X</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt">31.2</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certification of the Chief Financial Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">X</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt">32***</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">X</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 6pt">101</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">The following materials from the Registrant&rsquo;s Annual Report on Form 10-K for the year ended March 31, 2015, formatted in XBRL (eXtensible Business Reporting Language): (i) Consolidated Balance Sheets as of March 31, 2015 and 2014, (ii) Consolidated Statements of Operations for the years ended March 31, 2015 and 2014, (iii) Consolidated Statements of Changes in Stockholders&rsquo; Equity for the years ended March 31, 2015 and 2014, (iv) Consolidated Statements of Cash Flows for the years ended March 31, 2015 and 2014, and (v) Notes to Consolidated Financial Statements.</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">X</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 15%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 31.5pt">*</TD><TD>Management contract or compensatory plan or arrangement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 31.5pt; text-align: left">**</TD><TD STYLE="text-align: justify">Confidential treatment has been granted with respect to
certain portions of this Exhibit, which portions have been omitted and filed separately with the SEC as part of an application
for confidential treatment pursuant to the Securities Act of 1933, as amended.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 31.5pt; text-align: left">***</TD><TD STYLE="text-align: justify">Furnished herewith.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 78; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_026"></A>SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of Section
13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized<B>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>RUTHIGEN, INC.</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%">Date: June 9, 2015</TD>
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid">&nbsp;/s/ Hojabr Alimi</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Hojabr Alimi</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Executive Officer, Chief Science Officer and</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Chairman of the Board of Directors</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant
and in the capacities indicated below and on the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%; border-bottom: black 1pt solid"><B>Signature</B></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 45%; border-bottom: black 1pt solid; text-align: center"><B>Title</B></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 16%; border-bottom: black 1pt solid; text-align: center"><B>Date</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Hojabr Alimi</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>Chief Executive Officer, Chief Science</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">June 9, 2015</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Hojabr Alimi</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>Officer and Chairman of the Board of Directors (Principal Executive Officer)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Sameer Harish</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>Chief Financial Officer (Principal Financial</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">June 9, 2015</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Sameer Harish</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>Officer and Principal Accounting Officer)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Richard Conley</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>Director</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">June 9, 2015</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Richard Conley</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Gregory French</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>Director</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">June 9, 2015</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Gregory French</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%; border-bottom: Black 1pt solid">/s/ Akihisa Akao</TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 45%">Director</TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 16%; text-align: center">June 9, 2015</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Akihisa Akao</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 79; Options: NewSection; Value: 79 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RUTHIGEN, INC. &amp; SUBSIDIARY</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD NOWRAP STYLE="width: 90%">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; width: 10%; border-bottom: Black 1pt solid; text-align: center"><B>Page</B></TD></TR>
<TR>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP><A HREF="#fin_001">Report of Independent Registered Public Accounting Firm</A></TD>
    <TD NOWRAP STYLE="text-align: center">F-1</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP><A HREF="#fin_002">Consolidated Balance Sheets as of March 31, 2015 and 2014</A></TD>
    <TD NOWRAP STYLE="text-align: center">F-2</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP><A HREF="#fin_003">Consolidated Statements of Operations for the Years Ended March 31, 2015 and 2014</A></TD>
    <TD NOWRAP STYLE="text-align: center">F-3</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="text-indent: 30pt">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP><A HREF="#fin_004">Consolidated Statements of Changes in Stockholders' Equity for the Years Ended March 31, 2015 and 2014</A></TD>
    <TD NOWRAP STYLE="text-align: center">F-4</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP><A HREF="#fin_005">Consolidated Statements of Cash Flows for the Years Ended March 31, 2015 and 2014</A></TD>
    <TD NOWRAP STYLE="text-align: center">F-5</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="text-indent: 30pt">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP><A HREF="#fin_006">Notes to Consolidated Financial Statements</A></TD>
    <TD NOWRAP STYLE="text-align: center">F-6</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 80; Value: 79 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="fin_001"></A><B><U>REPORT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the Audit Committee of the Board of Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">and Stockholders of Ruthigen, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have audited the accompanying consolidated balance
sheets of Ruthigen, Inc. and Subsidiary (the &ldquo;Company&rdquo;) as of March 31, 2015 and 2014, and the related
consolidated statements of operations, changes in stockholders&rsquo; equity, and cash flows for the years then ended. These
consolidated financial statements are the responsibility of the Company&rsquo;s management. Our responsibility is to express
an opinion on these consolidated financial statements based on our audits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We conducted our audits in accordance with the standards
of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits
to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement. The
Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.
Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that
are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the
Company&rsquo;s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes
examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial
statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the
overall consolidated financial statement presentation. We believe that our audits provide a reasonable basis for our
opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In our opinion, the consolidated financial statements
referred to above present fairly, in all material respects, the consolidated financial position of Ruthigen, Inc. and
Subsidiary as of March 31, 2015 and 2014, and the consolidated results of its operations and its cash flows for the years
then ended in conformity with accounting principles generally accepted in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">/s/ Marcum LLP</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Marcum LLP</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">New York, NY</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: justify">June 9, 2015</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 81; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="fin_002"></A>RUTHIGEN, INC. &amp; SUBSIDIARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED BALANCE SHEETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Current Assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; padding-left: 9pt">Cash</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">10,357,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">15,571,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Prepaid expenses and other current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">166,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Total Current Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,523,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,574,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Property and equipment, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">157,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Total Assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">10,680,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">15,576,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Liabilities and Stockholders' Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Current Liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Accounts payable and accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">635,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">410,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Payable to Former Parent</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">537,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total Current Liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">635,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">947,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Commitments and contingencies</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Stockholders' Equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in; text-indent: -0.125in">Preferred stock, $0.0001 par value; 500,000 shares authorized; no shares issued and outstanding at March 31, 2015 and 2014, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in; text-indent: -0.125in">Common stock, $0.0001 par value; 100,000,000 shares authorized; 4,804,290 and 4,650,000 shares issued and outstanding at March 31, 2015 and 2014, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">480</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">465</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,404,520</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,297,535</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(10,360,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,669,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total Stockholders' Equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,045,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">14,629,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Total Liabilities and Stockholders' Equity</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">10,680,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">15,576,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying footnotes are an integral part of these consolidated
financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="fin_003"></A>RUTHIGEN, INC. &amp; SUBSIDIARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED STATEMENTS OF OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center">For The Years Ended</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Revenues</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Operating Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; text-align: left; padding-left: 9pt">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">2,178,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">1,382,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Selling, general and administrative</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,530,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,736,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total Operating Expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,708,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,118,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Loss From Operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(6,708,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,118,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Other Income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Interest income</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">17,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total Other Income</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">17,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net Loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(6,691,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,118,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Net Loss Per Share </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in">- Basic and Diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">(1.39</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">(1.53</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Weighted Average Number of Common Shares Outstanding </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">- Basic and Diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,823,907</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,036,301</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying footnotes are an integral part of these consolidated
financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="fin_004"></A>RUTHIGEN, INC. &amp; SUBSIDIARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED STATEMENTS OF CHANGES IN
STOCKHOLDERS' EQUITY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE YEARS ENDED MARCH 31, 2015 AND
2014</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Additional</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Common Stock</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">Paid-In</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">Accumulated</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Capital</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Deficit</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; font-weight: bold">Balance - March 31, 2013</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">200</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">597,800</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(551,000</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">47,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Investment from Former Parent</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,679,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,679,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Shares and warrants issued&nbsp;&nbsp;for cash in connection with initial public offering</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,650,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">265</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,020,735</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,021,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,118,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,118,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Balance - March 31, 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,650,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">465</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,297,535</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,669,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,629,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Shares issued for cash in connection with underwriter's exercise of overallotment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">154,290</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,027,985</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,028,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,079,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,079,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(6,691,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(6,691,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Balance - March 31, 2015</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,804,290</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">480</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">20,404,520</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(10,360,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">10,045,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying footnotes are an integral part of these consolidated
financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="fin_005"></A>RUTHIGEN, INC. &amp; SUBSIDIARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED STATEMENTS OF CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center">For The Years Ended</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Cash Flows From Operating Activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; text-align: left; padding-left: 9pt">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(6,691,000</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(3,118,000</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in">Depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,079,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Prepaid expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(163,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Accounts payable and accrued expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">388,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">146,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Net Cash Used in Operating Activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,386,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,969,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Cash Flows From Investing Activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Purchases of property and equipment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(156,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Net Cash Used in Investing Activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(156,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Cash Flows From Financing Activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Advances from Former Parent</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,453,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Repayment of Former Parent advances</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(537,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(916,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt">Proceeds from issuance of common stock and warrants less issuance costs [1]</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">865,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,228,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Investment from Former Parent</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,679,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Net Cash Provided by Financing Activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">328,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">18,444,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0.25in">Net (Decrease) Increase In Cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,214,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,475,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Cash - Beginning</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">15,571,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">96,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Cash - Ending</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">10,357,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">15,571,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">[1]</TD><TD STYLE="text-align: justify">During the year ended March 31, 2015, gross proceeds
from the initial public offering of $1,117,000 less $252,000 of offering costs, of which $89,000 was withheld from the proceeds
and $163,000 was paid in cash that was previously accrued at March 31, 2014. During the year ended March 31, 2014, gross proceeds
from the initial public offering of $19,216,000 less $3,195,000 of offering costs, of which $2,826,000 was withheld from the proceeds,
$206,000 was paid in cash (including $44,000 paid during the fiscal year ended March 31, 2013) and $163,000 was accrued as of
March 31, 2014.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying footnotes are an integral part of these consolidated
financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="fin_006"></A>RUTHIGEN, INC. &amp; SUBSIDIARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Note 1. Organization and Plan of Merger</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Organization</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Ruthigen, Inc. (the &ldquo;Company&rdquo;
or &ldquo;Ruthigen&rdquo;) was incorporated under the laws of the State of Nevada on January 18, 2013. The Company was reincorporated
from Nevada to Delaware on September 25, 2013. The Company&rsquo;s principal office is located in Santa Rosa, California. Ruthigen
is a biopharmaceutical company focused on pioneering new hypochlorus acid, or HOCl, based therapies designed to improve patient
outcomes and reduce healthcare costs associated with infections related to post-operative invasive procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company closed its initial public offering
(&ldquo;IPO&rdquo;) on March 26, 2014, pursuant to which an aggregate of 2,650,000 units were sold at a price of $7.25 per unit.
Prior to the IPO, the Company was a wholly-owned subsidiary of Oculus Innovative Sciences, Inc. (&ldquo;Oculus&rdquo; or &ldquo;Former
Parent&rdquo;). See Note 7 &ndash; Stockholders&rsquo; Equity &ndash; Initial Public Offering for additional details.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Agreement and Plan of Merger</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On March 13, 2015, the Company entered into
an Agreement and Plan of Merger (the &ldquo;Merger Agreement&rdquo;) with Pulmatrix Inc. (&ldquo;Pulmatrix&rdquo;), a privately
held biopharmaceutical company focused on the discovery, development, and commercialization of inhalable therapeutics and enabling
technologies that treat and control respiratory infectious diseases. The Merger Agreement provides for the merger of Pulmatrix
with and into Ruthigen Merger Corp., with Pulmatrix continuing after the merger as the surviving corporation and a wholly owned
subsidiary of Ruthigen (the &ldquo;Merger&rdquo;). See Note 6 &ndash; Commitments and Contingencies &ndash; Agreement and Plan
of Merger for additional details.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Note 2. Summary of Significant Accounting Policies</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Liquidity and Financial Condition </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company incurred net losses of $6,691,000
and $3,118,000 for the years ended March 31, 2015 and 2014, respectively. At March 31, 2015, the Company&rsquo;s working capital
and accumulated deficit were $9,888,000 and $10,360,000, respectively. The Company has not yet achieved profitability and it is
expected that its research and development and general and administrative expenses will continue to increase and, as a result,
the Company will eventually need to generate significant product revenues to achieve profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company believes that its existing cash,
which includes the proceeds from its IPO, will be sufficient to fund its stand-alone operations through the quarter ending June
30, 2016. However, in order for the Company to execute its research and development strategy and to obtain the necessary regulatory
approvals to commercialize RUT58-60 as a drug in the United States, the Company will need to raise additional funds through public
or private equity offerings, debt financings, corporate collaborations or other means. The Company has not secured any commitment
for new financing at this time, nor can it provide any assurance that new financing will be available on commercially acceptable
terms, if at all. If the Company is unable to secure additional capital, it may be required to curtail its research and development
initiatives and take additional measures to reduce costs in order to conserve its cash. See Note 6 &ndash; Commitments and Contingencies
&ndash; Agreement and Plan of Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Principles of Consolidation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The consolidated financial statements of
the Company include the accounts of its wholly-owned subsidiary, Ruthigen Merger Corp., which was incorporated in the state of
Delaware on March 2, 2015. All significant intercompany transactions have been eliminated in the consolidation. See Note 6 &ndash;
Commitments and Contingencies &ndash; Agreement and Plan of Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Use of Estimates</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The preparation of financial statements in conformity with accounting
principles generally accepted in the United States of America (&ldquo;U. S. GAAP&rdquo;) requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the dates
of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual
results could differ from these estimates. Significant estimates and assumptions include stock-based compensation, the valuation
allowance related to the Company&rsquo;s deferred tax assets and the expense allocations relating to the Company&rsquo;s operations
prior to its deconsolidation from its Former Parent on March 26, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RUTHIGEN, INC. &amp; SUBSIDIARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 2. Summary of Significant Accounting Policies - Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Concentration of Credit Risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Financial instruments that potentially subject
the Company to concentrations of credit risk include amounts held as cash. Cash is maintained in financial institutions located
in the United States. The Company is exposed to credit risk in the event of default by these financial institutions for amounts
in excess of the Federal Deposit Insurance Corporation insured limits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Fair Value of Financial Assets and Liabilities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Financial instruments, including cash, accounts
payable and accrued expenses are carried at cost, which management believes approximates fair value due to the short-term nature
of these instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company measures the fair value of financial
assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (an exit
price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants
on the measurement date. The Company maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring
fair value. The Company uses three levels of inputs that may be used to measure fair value:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Level 1&nbsp;&mdash;&nbsp;quoted prices
in active markets for identical assets or liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Level 2&nbsp;&mdash;&nbsp;quoted prices
for similar assets and liabilities in active markets or inputs that are observable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Level 3&nbsp;&mdash;&nbsp;inputs that are
unobservable (for example cash flow modeling inputs based on assumptions).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Property and Equipment</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Property and equipment are stated at cost,
net of accumulated depreciation and amortization which is recorded commencing at the in-service date. Depreciation of property
and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Depreciation
of leasehold improvements is computed using the straight-line method over the lesser of the estimated useful life of the improvement
or the remaining term of the lease. Estimated useful asset life by classification is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="width: 80%; font-size: 10pt">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 20%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Years</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-size: 10pt">Office equipment</TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: center">3</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-size: 10pt">Medical equipment</TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: center">5</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-size: 10pt">Furniture and fixtures</TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: center">7</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Upon retirement or sale, the cost and related
accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance
and repairs are charged to operations as incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Impairment of Long-Lived Assets</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 30.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 30.2pt">The Company periodically reviews the carrying
values of its long-lived assets when events or changes in circumstances would indicate that it is more likely than not that their
carrying values may exceed their realizable values, and records impairment charges when considered necessary. Specific potential
indicators of impairment include, but are not necessarily limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>a significant decrease in the fair value of an asset;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>a significant change in the extent or manner in which an asset is used or a significant physical change in an asset;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>a significant adverse change in legal factors or in the business climate that affects the value of an asset;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>an adverse action or assessment by the U.S. Food and Drug Administration or another regulator;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>an accumulation of costs significantly in excess of the amount originally expected to acquire or construct an asset; and operating
or cash flow losses combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing
losses associated with an income-producing asset.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RUTHIGEN, INC. &amp; SUBSIDIARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 2. Summary of Significant Accounting Policies - Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Impairment of Long-Lived Assets &ndash; Continued </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">When circumstances indicate that an impairment
may have occurred, the Company tests such assets for recoverability by comparing the estimated undiscounted future cash flows expected
to result from the use of such assets and their eventual disposition to their carrying amounts. In estimating these future cash
flows, assets and liabilities are grouped at the lowest level for which there are identifiable cash flows that are largely independent
of the cash flows generated by other such groups. If the undiscounted future cash flows are less than the carrying amount of the
asset, an impairment loss, measured as the excess of the carrying value of the asset over its estimated fair value, will be recognized.
The cash flow estimates used in such calculations are based on estimates and assumptions, using all available information that
management believes is reasonable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Stock-Based Compensation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company accounts for share-based awards
exchanged for employee and director services at the estimated grant date fair value of the award. The Company estimates the fair
value of stock options using the Black-Scholes option pricing model. The Company estimates the fair value of restricted stock and
restricted stock units (&ldquo;RSUs&rdquo;) based upon the closing market price of the Company&rsquo;s common stock on the date
the award is granted. The Company amortizes the fair value of employee awards on the straight-line basis over the requisite service
period of the awards. Stock-based compensation expense includes the impact of an estimate for forfeitures for all stock awards.
The Company recognizes stock-based compensation expense for awards with performance conditions if and when the Company concludes
that it is probable that the performance condition will be achieved. The Company reassesses the probability of vesting at each
reporting period for awards with performance conditions and adjusts stock-based compensation expense based on its probability assessment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company accounts for equity instruments
issued to non-employees at their fair value on the measurement date. The measurement of stock-based compensation is subject to
periodic adjustment as the underlying equity instrument vests or becomes non-forfeitable. Non-employee stock-based compensation
charges are amortized over the requisite service period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Research and Development</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Research and development expense is charged
to operations as incurred and consists primarily of personnel expenses, clinical and regulatory services and supplies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Net Loss per Share</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company computes basic net loss per
share by dividing net loss per share available to common stockholders by the weighted average number of common shares outstanding
for the period and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would
include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock
using the &ldquo;treasury stock&rdquo; and/or &ldquo;if converted&rdquo; methods, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following securities are excluded from
the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 66%">Options</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">315,836</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,145,650</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,140,250</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Restricted stock units</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">324,047</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,785,533</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,140,250</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RUTHIGEN, INC. &amp; SUBSIDIARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 2. Summary of Significant Accounting Policies - Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Income Taxes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company accounts for income taxes under
Accounting Standards Codification (&ldquo;ASC&rdquo;) 740 Income Taxes (&ldquo;ASC 740&rdquo;). Under ASC 740, deferred tax assets
and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities
and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected
to impact taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected
to be realized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">ASC 740 also clarifies the accounting for
uncertainty in income taxes recognized in an enterprise&rsquo;s financial statements and prescribes a recognition threshold and
measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax
return.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Tax benefits claimed or expected to be claimed
on a tax return are recorded in the Company&rsquo;s consolidated financial statements. A tax benefit from an uncertain tax position
is only recognized if it is more likely than not that the tax position will be sustained on examination by the taxing authorities,
based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such a
position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate
resolution. Uncertain tax positions have had no impact on the Company&rsquo;s consolidated financial condition, results of operations
or cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Recent Accounting Pronouncements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In June 2014, the Financial Accounting Standards
Board (&ldquo;FASB&rdquo;) issued Accounting Standards Update (&ldquo;ASU&rdquo;) No. 2014-12, &quot;Compensation - Stock Compensation
(Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could be Achieved
after the Requisite Service Period,&quot; (&quot;ASU 2014-12&quot;). The amendments in ASU 2014-12 require that a performance target
that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting
entity should apply existing guidance in Accounting Standards Codification Topic No. 718, &quot;Compensation - Stock Compensation&quot;
as it relates to awards with performance conditions that affect vesting to account for such awards. The amendments in ASU 2014-12
are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption
is permitted. Entities may apply the amendments in ASU 2014-12 either: (a) prospectively to all awards granted or modified after
the effective date; or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the
earliest annual period presented in the financial statements and to all new or modified awards thereafter. The Company does not
anticipate that the adoption of this standard will have a material impact on its consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In August 2014, the FASB issued ASU No.
2014-15, &ldquo;Presentation of Financial Statements &ndash; Going Concern (Subtopic 205-40): Disclosure of Uncertainties about
an Entity&rsquo;s Ability to Continue as a Going Concern.&rdquo; The guidance, which is effective for annual reporting periods
ending after December 15, 2016, extends the responsibility for performing the going-concern assessment to management and contains
guidance on how to perform a going-concern assessment and when going-concern disclosures would be required under U.S. GAAP. The
Company does not believe adoption of this ASU will have a material effect on its consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Subsequent Events</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Management has evaluated subsequent events
or transactions occurring through the date these consolidated financial statements were issued. See Note 10 &ndash; Subsequent
Events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RUTHIGEN, INC. &amp; SUBSIDIARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Note 3. Prepaid Expenses and Other Current Assets</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Prepaid expenses and other current assets
consists of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 66%; text-align: left">Prepaid insurance</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">12,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Clinical testing and other deposits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">114,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Prepaid rent</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Other prepaid expenses and current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">38,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">166,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Note 4. Property and Equipment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Property and equipment consists of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 66%; text-align: left">Office equipment</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">4,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">4,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Medical equipment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">156,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">160,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less: accumulated depreciation and amortization</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Property and equipment, net</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">157,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Depreciation expense amounted to $1,000
and $2,000 for the years ended March 31, 2015 and 2014, respectively. Depreciation expense is reflected in selling, general and
administrative expenses in the consolidated statements of operations. As of March 31, 2015, the Company&rsquo;s medical equipment
had not been placed into service and, as a result, the Company had not begun depreciating the assets.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Note 5. Accounts Payable and Accrued Expenses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Accounts payable and accrued expenses consist
of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 66%; text-align: left">Accrued employee compensation</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">92,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">109,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accrued director compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accrued legal fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">144,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">183,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accrued other professional fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accrued research and development fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">128,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accrued franchise taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">146,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Other accrued expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">32,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">14,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">635,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">410,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RUTHIGEN, INC. &amp; SUBSIDIARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Note 6. Commitments and Contingencies</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Agreement and Plan of Merger</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On March 13, 2015, the Company entered into
the Merger Agreement with Pulmatrix, a privately held biopharmaceutical company focused on the discovery, development, and commercialization
of inhalable therapeutics and enabling technologies that treat and control respiratory infectious diseases, which provides for
the merger of Pulmatrix with and into Ruthigen Merger Corp., with Pulmatrix continuing after the merger as the surviving corporation
and a wholly owned subsidiary of Ruthigen (the &ldquo;Merger&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Subject to the terms and conditions of the
Merger Agreement, on a pro forma basis, based upon the number of shares of Ruthigen common stock to be issued in the Merger, following
the closing of the Merger, current Pulmatrix stockholders and their designees will own approximately 83% of the combined company
and current Ruthigen stockholders and their designees will own approximately 17% of the combined company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company&rsquo;s and Pulmatrix&rsquo;s
obligations to consummate the Merger are subject to the satisfaction or waiver of customary closing conditions, including, among
others, obtaining the requisite approvals of the stockholders of Ruthigen and Pulmatrix, including the approval of the issuance
of the shares of common stock of Ruthigen to be issued in connection with the Merger and the charter amendments by the stockholders
of Ruthigen, and the effectiveness of a registration statement on Form S-4 relating to the shares of Ruthigen common stock to be
issued to Pulmatrix stockholders pursuant to the Merger Agreement. Ruthigen is required to have unrestricted cash on hand, net
of outstanding liabilities, at closing of at least (a) $9,000,000, if the Merger closing date is no later than July 31, 2015 or
(b) $8,850,000, if the Merger closing date is after July 31, 2015 but no later than August 13, 2015. In order to meet the cash
minimum requirements, the Company engaged a placement agent in anticipation of an offering prior to the closing of the Merger,
although no assurance can be provided that an offering will be completed. See Note 6 &ndash; Commitments and Contingencies &ndash;
New Consulting Agreements. On May 4, 2015, the registration statement on Form S-4 became effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Although Ruthigen is the legal acquirer
and will issue shares of its common stock to effect the merger with Pulmatrix, the business combination will be accounted for as
a reverse acquisition of Ruthigen by Pulmatrix under GAAP. Under the &ldquo;acquisition&rdquo; method of accounting, the assets
and liabilities of Ruthigen will be recorded, as of the completion of the merger, at their respective fair values in the financial
statements of Pulmatrix. The financial statements of Pulmatrix issued after the completion of the merger will reflect these values,
but will not be restated retroactively to reflect the historical financial position or results of operations of Ruthigen.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As a result of the Merger, certain RSUs
and stock options will become fully-vested as a result of change of control provisions in the original award agreements. In addition,
pursuant to the Merger Agreement, the Company will issue an aggregate of 90,000 shares of common stock to an employee and a director
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following other merger-related agreements
have been disclosed in: (i) Note 6 &ndash; Commitments and Contingencies &ndash; New Employment Agreements, (ii) Note 6 &ndash;
Commitments and Contingencies &ndash; New Consulting Agreements, (iii) Note 6 &ndash; Commitments and Contingencies &ndash; Oculus
Side Letter Agreement, (iv) Note 7 &ndash; Stockholders&rsquo; Equity &ndash; New 2013 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Employment Agreements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On August 12, 2013, the compensation committee
of Oculus approved the grant of a one-time cash bonus of $158,000 to the Company&rsquo;s Chief Executive Officer (&ldquo;CEO&rdquo;)
in order to recognize the CEO&rsquo;s efforts related to the preparation and filing of the Company&rsquo;s registration statement
on Form S-1 for its IPO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RUTHIGEN, INC. &amp; SUBSIDIARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 6. Commitments and Contingencies - Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Employment Agreements &ndash; Continued </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On June 24, 2014, the compensation committee
of the Company&rsquo;s board of directors approved an employment agreement for its Chief Financial Officer (&ldquo;CFO&rdquo;),
which replaced the offer letter previously in effect between the Company and the CFO. The employment agreement continues to provide
for an annual base salary of $225,000, subject to increase, as determined by the Company&rsquo;s board of directors. The employment
agreement further provides for payments to the CFO in the event of termination without cause or resignation by the CFO for good
reason, as such terms are defined in the employment agreement. In the event that the CFO is terminated without cause or resigns
for good reason, the CFO is entitled to: (i) a lump severance payment equal to 18 times the average monthly base salary paid to
the CFO over the preceding 12 months; (ii) up to one year (the lesser of one year following the date of termination or until the
CFO becomes eligible for medical insurance coverage provided by another employer) reimbursement for health care premiums under
COBRA; and (iii) automatic vesting of all unvested options and other equity awards; provided that in the event the CFO resigns
for good reason prior to a change of control, only the vesting of the restricted stock units granted by the Company on May 12,
2014 shall be accelerated. In addition, if the Company consummates a change of control, all equity awards granted by the Company
that are then-outstanding and unvested shall become fully vested and exercisable immediately prior to and subject to the consummation
of the change of control. In addition, the Company will reimburse the CFO for any excise taxes owed by the CFO under Section 280G
and Section 4999 of the Internal Revenue Code because of any acceleration of the equity awards (including a gross up of any additional
federal, state and local taxes payable as a result of the reimbursement of the tax payments).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On November 28, 2014, the compensation committee
of the Company&rsquo;s board of directors approved an amended and restated employment agreement for its CEO, which supersedes the
employment agreement previously in effect between the Company and the CEO. The prior employment agreement went into effect when
the Company was a wholly-owned subsidiary of Oculus, and the CEO was the Chairman of the board of directors of Oculus. The employment
agreement primarily removes all references to Oculus and other legacy references related to Ruthigen being a subsidiary of Oculus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The employment agreement continues to provide
for an annual base salary of $375,000 to the CEO, subject to increase, as determined by the Company&rsquo;s board of directors.
The employment agreement further provides for payments to the CEO in the event of termination without cause or resignation by the
CEO for good reason, as such terms are defined in the employment agreement. In the event that the CEO is terminated without cause
or resigns for good reason, the CEO is entitled to: (i) a lump severance payment equal to 24 times the average monthly base salary
paid to the CEO over the preceding 12 months; (ii) up to one year (the lesser of one year following the date of termination or
until the CEO becomes eligible for medical insurance coverage provided by another employer) reimbursement for health care premiums
under COBRA; and (iii) automatic vesting of all unvested options and other equity awards. In addition, if the Company consummates
a change of control, all equity awards granted by the Company that are then-outstanding and unvested shall become fully vested
and exercisable immediately prior to and subject to the consummation of the change of control. In addition, the Company will reimburse
the CEO for any excise taxes owed by the CEO under Section 280G and Section 4999 of the Internal Revenue Code because of any acceleration
of the equity awards (including a gross up of any additional federal, state and local taxes payable as a result of the reimbursement
of the tax payments). Furthermore, the Company will reimburse the CEO for relocation expenses if the Company&rsquo;s principal
executive offices are moved or the CEO is required to relocate, subject to certain conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Receipt of the termination benefits described
above is contingent on the CEO&rsquo;s execution of a general release of claims against the Company, its subsidiaries and its affiliates;
the CEO&rsquo;s resignation from any and all directorships and every other position held by the CEO with the Company and each of
its subsidiaries; and the CEO&rsquo;s return to the Company and its affiliates or the Company Group (as such term is defined in
the employment agreement), of all property belonging to the Company Group, received from or on account of the Company Group, or
any other entity of the Company Group, or any of the Company Group&rsquo;s respective affiliates by the CEO. In addition, the CEO
is not entitled to such benefits if the CEO does not comply with the non-competition, invention assignment, confidentiality, non-solicitation
provisions of the employment agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of March 31, 2015, the potential cash
severance payment related to the Company&rsquo;s employment agreements currently in effect with its CEO and CFO amounted to $1,144,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RUTHIGEN, INC. &amp; SUBSIDIARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 6. Commitments and Contingencies - Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>New Employment Agreements </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On March 12, 2015, in connection with the
Merger Agreement, the Ruthigen board of directors approved that, as of the effective time of the merger, each of the CEO and the
CFO will receive cash and restricted stock units, further discussed below, from Ruthigen as consideration for the termination of
outstanding stock options and restricted stock units held by them and for their continued provision of services after the merger
and for the one-year non-competition provisions in their new employment agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the Merger is approved by the respective
stockholders, the CEO and CFO will terminate their current employment agreements with Ruthigen dated November 28, 2014 and June
24, 2014, respectively. At such time, the New Employment Agreement with the CEO and the New Employment Agreement with the CFO will
each become effective. Additionally, lock-up agreements and cancellation agreements between Ruthigen and the CEO and CFO with respect
to the cancellation of outstanding stock options and restricted stock units immediately prior to the merger will become effective.
If the Merger is not approved by the respective stockholders, the current employment agreements with each of the CEO and CFO will
remain in effect and the lock-up agreements and cancellation agreements will not become effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">At the effective time of the merger, any
and all outstanding stock options and restricted stock units previously granted to the CEO will be terminated in exchange for (i)
a lump-sum payment in the amount of $547,600, less taxes and other withholdings and (ii) a lump-sum equivalent to the CEO&rsquo;s
premiums under COBRA for one year, in the same amounts for the same medical coverage as in effect as of the effective time of the
merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The CEO shall also receive a grant of restricted
stock units, pursuant to Ruthigen&rsquo;s 2013 Employee, Director and Consultant Equity Incentive Plan, equal to the lesser of
(i) 930,000 and (ii) the quotient of $3,125,000 divided by the fair market value of the common stock of the combined company as
of the effective time of the merger, with such restricted stock units vesting as follows: (i) a number of restricted stock units
equal to the lesser of (a) 930,000 and (b) such number of restricted stock units with an aggregate value equal to $1,400,000 shall
be fully vested at the effective time of the merger and (ii) an amount equal to 25% of the restricted stock units unvested as of
the effective time of the merger will vest on a quarterly basis over the following twelve months. The shares of Ruthigen common
stock underlying the vested restricted stock units at the effective time of the merger will be delivered to the CEO on the first
trading day following the first anniversary of the effective time of the merger, and the shares of Ruthigen common stock underlying
the restricted stock units that will vest on a quarterly basis thereafter will be delivered on the first trading day following
the 15, 18, 21 and 24 month anniversary of the effective time of the merger, respectively. The shares are subject to lock-up and
leak out provisions that limit sales of these shares during the six month period following the delivery of any shares associated
with vested restricted stock units, except to the extent necessary to cover tax liabilities associated with receipt of these shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">At the effective time of the merger, any
and all outstanding stock options and restricted stock units previously granted to the CFO will be terminated in exchange for (i)
a lump-sum payment in the amount of $337,500, less taxes and other withholdings and (ii) a lump-sum equivalent to the CFO&rsquo;s
premiums under COBRA for one year, in the same amounts for the same medical coverage as in effect as of the effective time of the
merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The CFO shall also receive a grant of restricted
stock units, pursuant to Ruthigen&rsquo;s 2013 Employee, Director and Consultant Equity Incentive Plan, equal to the lesser of
(i) 355,000 and (ii) the quotient of $1,037,500 divided by the fair market value of the common stock of the combined company as
of the effective time, with such restricted stock units vesting as follows: (i) a number of restricted stock units equal to the
lesser of (a) 355,000 and (b) such number of restricted stock units with an aggregate value equal to $250,000 shall be fully vested
at the effective time of the merger and (ii) an amount equal to 25% of the restricted stock units unvested as of the effective
time of the merger will vest on a quarterly basis over the following twelve months. The shares of Ruthigen common stock underlying
the vested restricted stock units at the effective time of the merger will be delivered to the CFO on the first trading day following
the first anniversary of the effective time of the merger, and the shares of Ruthigen common stock underlying the restricted stock
units that will vest on a quarterly basis thereafter will be delivered on the first trading day following the 15, 18, 21 and 24
month anniversary of the effective time of the merger, respectively. The shares are subject to lock-up and leak out provisions
that limit sales of these shares during the six month period following the delivery of any shares associated with vested restricted
stock units, except to the extent necessary to cover tax liabilities associated with receipt of these shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RUTHIGEN, INC. &amp; SUBSIDIARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 6. Commitments and Contingencies - Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>New Consulting Agreements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On March 3, 2015, the Company executed an
agreement with an investment banking firm to provide pre-merger strategic services, in exchange for the issuance of 340,000 shares
of common stock upon effectiveness of the merger, as a success fee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On March 10, 2015, the Company executed
an agreement with an individual to provide post-merger investor relations services for one year, in exchange for the issuance of
250,000 shares of common stock upon effectiveness of the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company will account for the common
stock upon issuance of the shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>License and Supply Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company entered into a license and supply
agreement with Oculus which was effective upon the completion of the<B><I> </I></B>IPO, pursuant to which Oculus has agreed to
exclusively license certain of its proprietary technology to the Company to enable the Company&rsquo;s research, development and
commercialization of newly discovered RUT58-60 and any improvements to it (the &ldquo;Product&rdquo;) in the United States, Canada,
the European Union and Japan (collectively, the &ldquo;Territory&rdquo;) in certain invasive uses in humans (the &ldquo;Field&rdquo;)
which do not include dermatologic uses or uses for ophthalmic, sinusitis or otic indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In order to pay for the costs of development
of the Product, Ruthigen obtained financing from Oculus until the IPO was completed. Under the agreement, the Company&rsquo;s right
to commercialize the Product in the Field in the Territory is exclusive and shall be performed in accordance with the development
and commercialization plan set forth in the agreement (which may be modified by the Company&rsquo;s discretion), and Oculus shall
manufacture and supply, at a purchase price equal to 20% over the cost of goods to Oculus, the Product as and when the Company
requests. In addition, the Company has the right to purchase certain manufacturing equipment from Oculus at a purchase price equal
to a fixed percentage over the cost of the equipment to Oculus, so that the Company may manufacture the Product independently.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the license and supply agreement,
the Company will be required to make a total of $8 million of milestone payments to Oculus over the next several years for the
first Product only, as follows: $1.5 million upon the completion of last patient enrollment in the Phase 1/2 clinical trial, $1.5
million upon the completion of last patient enrollment of the Company&rsquo;s first pivotal trial, $3 million upon completion of
the first meeting with the FDA following completion of the Company&rsquo;s first pivotal clinical trial, and $2 million upon first
patient enrollment in the second pivotal clinical trial. In addition, as further consideration under the agreement, the Company
will be required to make royalty payments to Oculus based on its annual net sales of the Product from the date of first commercial
sale to the date that the Company ceases to commercialize the Product, which percentage royalty rate will vary between 3% and 20%
and will increase based on various net sales thresholds and will differ depending on the country in which the sales are made. The
Company will accrue for the milestone payment liability if and when the Company determines that the achievement of such conditions
is probable. As of March 31, 2015, the Company has not accrued for any portion of the milestone payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The agreement contains representations and
warranties of the parties regarding its enforceability, no conflict with agreements to which the parties are bound, and no violations
of law, and representations of Oculus that it has not granted any other license with respect to the Product for use in the Field
in the Territory. The Company has agreed to indemnify Oculus with respect to third party claims arising from the Company&rsquo;s
development, commercialization or manufacture of the Product in the Field in the Territory with certain exceptions, and the Company
and Oculus have each agreed to indemnify the other with respect to third party claims arising from their respective inaccuracy
and/or breach of representations and warranties or negligence or willful misconduct. Either party may terminate the agreement for
an uncured material breach, but only after undergoing a dispute resolution process. In addition, either party may terminate the
agreement if the other party ceases to do business, makes an assignment for the benefit of creditors or voluntarily files, fails
to contest an involuntary filing or is adjudicated bankrupt or insolvent under bankruptcy, insolvency, receivership or similar
law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">See Note 6 &ndash; Commitments and Contingencies
&ndash; Oculus Side Letter Agreement for additional details.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>





<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RUTHIGEN, INC. &amp; SUBSIDIARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 6. Commitments and Contingencies - Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Shared Services Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company entered into a shared services
agreement with Oculus which was effective upon the completion of the IPO, pursuant to which Oculus will provide Ruthigen with general
services, including general accounting and human resources, until the termination of agreement. Additionally, Oculus will permit
the Company to access its Petaluma, California and Seattle, Washington facilities during normal business hours (subject to certain
exceptions) and for the purposes described in the shared services agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Oculus shall also provide the Company with
consulting and technical services. Such services shall be billable at the hourly or fixed monthly rate as set forth in the shared
services agreement, which is subject to change based upon mutual written agreement between Oculus and Ruthigen. After the completion
of the IPO, the Company agreed to pay invoices generated by Oculus within thirty days of receipt thereof. The costs incurred by
the Company in connection with the shared services agreement were not material.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On March 5, 2015, the Company received a
written notice from Oculus of termination of the shared services agreement, effective on April 6, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">See Note 6 &ndash; Commitments and Contingencies
&ndash; Oculus Side Letter Agreement for additional details.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Separation Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company has entered into a separation
agreement with Oculus that contains key provisions relating to the ongoing relationship with Oculus following the completion of
the IPO. The separation agreement became effective upon the completion of the IPO and terminates on the earlier of 8.5 years following
the closing of the IPO or when the parties mutually agree to terminate it. The separation agreement also contains a series of restrictions
on Oculus&rsquo; ability to transfer the Ruthigen shares that Oculus owns. Oculus is restricted from transferring any of the Ruthigen
shares it owns during the first year (the &ldquo;Lock-Up Period&rdquo;) immediately following the IPO unless it receives consent
to do so from the Company&rsquo;s Board of Directors and the lead underwriter in the Company&rsquo;s IPO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Following the Lock-Up Period, transfers
by Oculus of the Ruthigen shares it owns must be conducted with the consent of the board of directors or within the prescribed
requirements for such transfers set forth in the separation agreement. These prescribed requirements include that the transfers
must be in private placement transactions, the purchase price discount may not exceed certain percentages depending on the transferee,
the amount of shares transferred in a given transfer (or series of transfers comprising a single transaction) may not exceed the
greater of 5% of the Company&rsquo;s outstanding shares or $1,500,000 in net proceeds to Oculus, as well as certain other requirements
set forth in the separation agreement. In addition to the manner described above, if, following a minimum of 41.5 months following
the closing of the IPO have lapsed and Oculus has not consummated transfers of the Ruthigen shares it owns resulting in at least
$3.8 million in net proceeds to Oculus, then Oculus has a one-time transfer and registration right to transfer the Ruthigen shares
it owns in an amount equal to the difference between $3.8 million and the proceeds received by Oculus from prior transfers as of
the time Oculus elects to exercise its one-time right. Transfers conducted using this one-time right must be conducted with the
consent of the Company&rsquo;s board of directors or within the prescribed requirements for such transfers set forth in the separation
agreement, including, for example, that the purchase price discount may not exceed certain percentages, the amount of shares transferred
may not exceed $3,800,000 in net proceeds to Oculus, as well as certain other requirements set forth in the separation agreement.
The separation agreement provides Oculus with certain &ldquo;piggy back&rdquo; registration rights of up to 30% of the value of
the securities the Company registers after the lock-up period, if the Company proposes to register any of its common stock following
the completion of the IPO, subject to certain conditions and limitations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The separation agreement also provides for
certain cooling off periods between market attempts and/or successful transfers, the length of which are dependent upon whether
and the quantity of the Ruthigen shares that Oculus transfers. The majority of the material restrictions and obligations contained
in the separation agreement lapse if and when Oculus own less than 19.9% of the outstanding shares of the Company&rsquo;s common
stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RUTHIGEN, INC. &amp; SUBSIDIARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 6. Commitments and Contingencies - Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Separation Agreement &ndash; Continued </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The separation agreement also defined the
methodology for the allocation of the operational and IPO related expenses incurred prior to and in connection with the IPO for
which the Company was required to reimburse Oculus. The Company will also reimburse Oculus for expenses such as salaries and benefits
advanced or paid on the Company&rsquo;s behalf or for the Company&rsquo;s benefit during a transition period following the closing
of the IPO. During the year ended March 31, 2014, the Company incurred $1,450,000 of IPO and other costs which were reimbursed
to Oculus at the closing of the IPO or shortly thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The separation agreement provides that each
party will indemnify, defend and hold harmless the other party and its affiliates for third party claims asserted against the other
party. The separation agreement also provides that, so long as Oculus maintains a directors&rsquo; and officers&rsquo; insurance
program covering the past and present officers and directors of Oculus, the program shall be standard in Oculus&rsquo; industry
and Oculus shall not exclude any former Oculus director from any insurance policy coverage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">See Note 6 &ndash; Commitments and Contingencies
&ndash; Oculus Side Letter Agreement for additional details.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Funding Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On January 31, 2014, the Company entered
into a funding agreement with Oculus, pursuant to which Oculus agreed to fund the Company in the additional amount of up to $760,000
to pay certain accounts payables outstanding at December 31, 2013 and to fund certain future expenditures through the closing of
the IPO. Through the closing of the IPO, Oculus funded the Company in the additional amount of $534,000, which was repaid to Oculus
on April 1, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Oculus Side Letter Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In connection with the Merger, on March
13, 2015, Pulmatrix entered into an agreement (the &ldquo;Oculus Side Letter Agreement&rdquo;), pursuant to which, among other
things, Oculus agreed, from the effective date of the merger, to (i) waive Ruthigen&rsquo;s obligations to use commercially reasonable
efforts to develop and commercialize products licensed from Oculus under the outstanding License and Supply Agreement between Oculus
and Ruthigen, for a period lasting until the earlier of one year from the closing of the merger or August 31, 2016; (ii) provide
a general release from claims and liabilities arising under the License and Supply Agreement, the separation agreement and the
shared services agreement, each between Oculus and Ruthigen, in favor of Ruthigen; and (iii) to run a sale process for the pre-merger
Ruthigen business, including any products licensed from Oculus, and to assign or delegate all of Ruthigen&rsquo;s surviving rights
under the License and Supply Agreement, the separation agreement and the shared services agreement, subject to Oculus&rsquo;s consent
with respect to the identity of the proposed purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Ruthigen is under no obligation to achieve
any milestone event during the waiver period, and no payments will accrue or become due and payable by Ruthigen to Oculus under
the License and Supply Agreement, the separation agreement and the shared services agreement, other than the liabilities not exceeding
$5,000 due and payable on the effective date of the merger. After the expiration of the waiver period, Ruthigen may unilaterally
terminate the License and Supply Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the right of first refusal that
was granted to Oculus, prior to a sale of the pre-merger business of Ruthigen with a minimum aggregate purchase price of $1.0 million,
Ruthigen must first notify Oculus of the pending transaction and Oculus will have five (5) business days after receipt of such
notice to notify Ruthigen whether it intends to acquire the pre-merger business of Ruthigen on exactly the same terms, including
the amount and kind of consideration, unless securities of the proposed acquirer will be offered as consideration, in which case
Oculus will instead pay cash equal to the fair market value of such securities. If Oculus does not exercise its right of first
refusal, Ruthigen may consummate the transaction pursuant to the agreed upon terms. Additionally, if such a transaction is consummated
and the transaction generates aggregate proceeds in excess of $10.0 million, Ruthigen will be obligated to pay ten percent (10%)
of the aggregate gross proceeds to Oculus within ten (10) calendar days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, the Oculus Side Letter Agreement
provides that, as of the effective date of the merger, certain provisions in the separation agreement regarding marketing and stock
transfer restrictions, lock-up, registration rights, voting, management, compensation and equity incentive plan, will be terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Oculus Side Letter Agreement is conditioned
upon the receipt of payment by Oculus for Oculus&rsquo;s shares of Ruthigen common stock sold in certain specified transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RUTHIGEN, INC. &amp; SUBSIDIARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 6. Commitments and Contingencies - Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Operating Lease</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company leases a facility in Santa Rosa,
California under a non-cancelable operating lease for approximately 995 square feet of executive office space. On February 11,
2015, the Company and the landlord agreed to amend the lease such that the lease now expires on June 30, 2015 and the monthly base
rent is approximately $1,700. The aggregate base rent payable over the lease term is being recognized on a straight-line basis.
Rent expense related to the lease amounted to approximately $20,000 and $20,000 for the years ended March 31, 2015 and 2014, respectively.
Rent expense is reflected in selling, general and administrative expenses in the consolidated statements of operations. Future
minimum rentals through the lease expiration date of June 30, 2015 are $5,075.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Note 7. Stockholders&rsquo; Equity</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Reverse Stock Split</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On September 25, 2013, the board of directors
and the stockholders of the Company approved a 1-for-2.5 reverse stock split of the Company&rsquo;s outstanding common stock, $0.0001
par value, which was effected on September 25, 2013. In connection with the reverse stock split, every 2.5 shares of common stock
were reclassified and combined into one share of common stock. The reverse stock split reduced the number of shares of common stock
outstanding from 5,000,000 to 2,000,000. The total number of authorized common stock that the Company shall have the authority
to issue as set forth in the Company&rsquo;s Restated Certificate of Incorporation, as amended, was not proportionally decreased
in connection with the reverse stock split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All common shares and per share amounts
contained in the Company&rsquo;s accompanying financial statements have been retroactively adjusted to reflect a 1-for-2.5 reverse
stock split, effective as of September 25, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Authorized Capital</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company is authorized to issue up to
100,000,000 shares of common stock with a par value of $0.0001 per share and 500,000 shares of preferred stock with a par value
of $0.0001 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Description of Common Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Each share of common stock has the right
to one vote. The holders of common stock are entitled to dividends when funds are legally available and when declared by the board
of directors.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>2013 Plan</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In September and October 2013, respectively,
the Company&rsquo;s board of directors and stockholders approved the 2013 Employee, Director and Consultant Equity Incentive Plan
(the &ldquo;2013 Plan&rdquo;), which became effective upon the closing of the IPO. The 2013 Plan will expire on September 30, 2023.
Under the 2013 Plan, the Company may grant incentive stock options, non-qualified stock options, restricted and unrestricted stock
awards and other stock-based awards. There are 998,355 shares of the Company&rsquo;s common stock authorized for issuance under
the 2013 Plan. The Company intends to issue new shares of common stock to satisfy 2013 Plan obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, the 2013 Plan contains an &ldquo;evergreen&rdquo;
provision, which allows for an annual increase in the number of shares of the Company&rsquo;s common stock available for issuance
under the 2013 Plan on the first day of each calendar year beginning with calendar year 2015. The annual increase in the number
of shares shall be equal to the lowest of: (a) 232,500 shares of the Company&rsquo;s common stock; (b) 5% of the number of shares
of the Company&rsquo;s common stock outstanding as of such date; and (c) an amount determined by the Company&rsquo;s board of directors
or compensation committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RUTHIGEN, INC. &amp; SUBSIDIARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 7. Stockholders&rsquo; Equity - Continued </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>New 2013 Plan</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On March 12, 2015, in connection with the
Merger Agreement, Ruthigen&rsquo;s compensation committee and Ruthigen&rsquo;s board of directors unanimously approved the Ruthigen,
Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan (the &ldquo;New 2013 Plan&rdquo;), subject
to the approval of Ruthigen&rsquo;s stockholders. The New 2013 Plan will allow for the issuance of up to 6,853,319 shares of Ruthigen&rsquo;s
common stock, up from 1,230,855 shares, pursuant to awards to be granted under the New 2013 Plan. In addition, the New 2013 Plan
contains an &ldquo;evergreen&rdquo; provision, which allows for an annual increase in the number of shares of Ruthigen&rsquo;s
common stock available for issuance under the plan on the first day of each fiscal year beginning in calendar year 2016. The annual
increase in the number of shares shall be equal to the lowest of: (i) 2,551,500 shares of Ruthigen&rsquo;s common stock; (ii) five
percent (5%) of the number of shares of Ruthigen&rsquo;s common stock outstanding as of such date; and (iii) an amount determined
by Ruthigen&rsquo;s board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Initial Public Offering</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On March 21, 2014, the Company announced
that it had priced its IPO of 2,650,000 units (the &ldquo;IPO&rdquo;), with each unit consisting of (i) one share of common stock
and (ii) one Series A warrant (the &ldquo;Series A Warrant&rdquo;), at an IPO price of $7.25 per unit (each a &ldquo;Unit&rdquo;),
less underwriting discounts and commissions and IPO expenses. In addition, the Company granted to the underwriters a 45-day option
(the &ldquo;Over-Allotment Option&rdquo;) to purchase up to (i) 397,500 additional shares of common stock at price of $6.6608 per
share, which price reflects underwriting discounts and commissions, and/or (ii) 397,500 additional Series A Warrants at a price
of $0.0092 per Series A Warrant, which price reflects underwriting discounts and commissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On March 26, 2014, the Company closed on
the sale of 2,650,000 Units and the underwriters exercised a portion of the Over-Allotment Option by purchasing Series A Warrants
from the Company to purchase 397,500 shares of common stock for nominal value, all of which resulted in $16,021,000 of aggregate
net proceeds to the Company ($19,216,000 of gross proceeds less $3,195,000 of issuance costs). As a result, an aggregate of 2,650,000
shares of common stock and Series A Warrants to purchase an aggregate of 3,047,500 shares of common stock were issued in the IPO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Series A Warrant is exercisable at a
price of $7.25 per warrant for (x) one share of common stock and (y) one Series B warrant (the &ldquo;Series B Warrant&rdquo;)
to purchase one share of common stock at an exercise price of $9.0625 per share. The Series A Warrants are exercisable on the date
of issuance and terminate on the second anniversary of the date of issuance. The exercise price and the number of shares for which
each Series A Warrant may be exercised is subject to adjustment in the event of stock dividends, stock splits, reorganizations
or similar events affecting the Company&rsquo;s common stock. In addition, subject to certain exceptions, the exercise price of
the Series&nbsp;A Warrants is subject to a weighted average reduction if the Company issues shares of common stock (or securities
convertible into common stock) in the future at a price below both (a) the current exercise price of the Series A Warrant; and
(b) the current market price of the Company&rsquo;s common stock. The Series A Warrants may be called by the Company, for consideration
equal to $0.0001 per Series A Warrant, on not less than 10 business days&rsquo; notice if the closing price of the common stock
is above 150% of the $7.25 IPO price per unit for any period of 20 consecutive business days ending not more than three business
days prior to the call notice date. The Series B Warrants will be exercisable on the date that the warrants are issued and will
terminate on the fifth anniversary of the date the warrants are first exercisable. The Company agrees that, during the period the
Series A Warrants are outstanding, it will maintain the effectiveness of the registration statement such that the holder may exercise
the Series A Warrants to receive registered shares of common stock and registered Series B Warrants (and the shares of common stock
underlying the Series B Warrants). The Company determined that the Series A and Series B Warrants are equity instruments because
the warrants are (a) freestanding financial instruments; (b) indexed to the Company&rsquo;s own stock; (c) not permitted to be
settled for cash; and (d) exercisable into common stock for which the Company has sufficient authorized and unissued shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company issued to the representative
of the underwriters warrants to purchase 92,750 shares of the Company&rsquo;s common stock at an exercise price of $9.0625 per
share (the &ldquo;Representative&rsquo;s Warrants&rdquo;). The Representative&rsquo;s Warrants are exercisable commencing on March
21, 2015 and expiring on March 21, 2019. The Representative&rsquo;s Warrants and the shares of common stock underlying the warrants
have been deemed compensation by Financial Industry Regulatory Authority, Inc. (&ldquo;FINRA&rdquo;) and are, therefore, subject
to a 180-day lock-up pursuant to Rule 5110(g)(1) of FINRA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RUTHIGEN, INC. &amp; SUBSIDIARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 7. Stockholders&rsquo; Equity - Continued </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Initial Public Offering &ndash; Continued </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company, its officers and directors
and its Former Parent have entered into lock-up agreements with the underwriters. Under these agreements, the Company and the other
parties have agreed, subject to specified exceptions, not to sell or transfer any common stock or securities convertible into,
or exchangeable or exercisable for, common stock, during a period ending 180 days after the date of its prospectus (one year for
the shares of common stock owned by the Company&rsquo;s Former Parent), without first obtaining the written consent of representative
of the underwriters. The lock up period for the Company, its officers and directors is subject to extension for up to an additional
18 days upon the occurrence of certain specified events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Underwriter&rsquo;s Exercise of IPO Over-Allotment Option
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Following the closing of the IPO, during
the year ended March 31, 2015 and in connection with its IPO, the underwriters exercised a portion of the over-allotment option
pursuant to which the Company sold an additional 154,290 shares of common stock at $6.6608 per share, which resulted in approximately
$1,028,000 of aggregate net proceeds to the Company. In connection with the underwriters&rsquo; partial exercise of the over-allotment
option, the Company issued to the representative of the underwriters a five-year warrant to purchase an additional 5,400 shares
of the Company&rsquo;s common stock at an exercise price of $9.0625 per share. The warrant is exercisable commencing one year from
the date of issuance. The warrant and the shares of common stock underlying the warrant have been deemed compensation by FINRA
and are, therefore, subject to a 180-day lock-up pursuant to Rule 5110(g)(1) of FINRA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Investment from Former Parent</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">During the year ended March 31, 2014, the
Company&rsquo;s Former Parent made capital contributions to the Company in the amount of $1,679,000, which were recorded as additional
paid-in capital in the consolidated statement of changes in stockholders&rsquo; equity. See Note 9 &ndash; Related Party Transactions
for details associated with the Former Parent&rsquo;s ownership interest in the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Stock Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A summary of the warrant activity during
the years ended March 31, 2015 is presented below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Average</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Average</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Remaining</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Number of</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Exercise</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Life</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Intrinsic</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Warrants</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In Years</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Value</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%">Outstanding, March 31, 2014</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">3,140,250</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">7.30</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,400</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.06</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Forfeited</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Outstanding, March 31, 2015</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,145,650</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7.31</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1.1</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Exercisable, March 31, 2015</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,140,250</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7.30</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1.1</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RUTHIGEN, INC. &amp; SUBSIDIARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 7. Stockholders&rsquo; Equity - Continued </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Stock Warrants &ndash; Continued </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table presents information
related to stock warrants at March 31, 2015:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Warrants Outstanding</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Warrants Exercisable</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Outstanding</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Average</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Exercisable</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Exercise</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Number of</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Remaining Life</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Number of</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Warrants</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In Years</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Warrants</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 23%; text-align: right">7.2500</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 22%; text-align: right">3,047,500</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 22%; text-align: right">1.0</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 22%; text-align: right">3,047,500</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; text-align: right">9.0625</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">98,150</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">4.0</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">92,750</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,145,650</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">1.1</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,140,250</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Stock Options</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has computed
the fair value of options granted using the Black-Scholes option pricing model. Option forfeitures are estimated at the time of
valuation and reduce expense ratably over the vesting period. This estimate will be adjusted periodically based on the extent to
which actual option forfeitures differ, or are expected to differ, from the previous estimate, when it is material. The Company
estimated forfeitures related to option grants at an annual rate of 0% for options unvested during the year ended March 31, 2015.
The expected term used for options issued to non-employees is the contractual life and the expected term used for options issued
to employees and directors is the estimated period of time that options granted are expected to be outstanding. The Company utilizes
the &ldquo;simplified&rdquo; method to develop an estimate of the expected term of &ldquo;plain vanilla&rdquo; employee option
grants. Since the Company&rsquo;s stock has not been publicly traded for a sufficiently long period of time, the Company is utilizing
an expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected
life of the instrument being valued, of similarly positioned public companies within its industry. The risk-free interest rate
was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected
term of the instrument being valued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In applying the Black-Scholes
option pricing model to stock options granted, the Company used the following weighted average assumptions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="5" NOWRAP STYLE="font-weight: bold; text-align: center">For the Year Ended</TD>
    <TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="5" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,</TD>
    <TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD>
    <TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 75%; text-align: left">Risk free interest rate</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1.67</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center">n/a</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected term (years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.61</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">n/a</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Expected volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">95</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">n/a</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected dividends</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.00</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">n/a</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The weighted average
estimated fair value of the options granted during the year ended March 31, 2015 was $4.79 per share. There were no options granted
during the year ended March 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 12, 2014, the
Company granted options to employees and directors to purchase an aggregate of 332,500 shares of common stock at an exercise price
of $6.37 per share, pursuant to the 2013 Plan. The shares vest ratably over three years on a quarterly basis. The aggregate grant
date value of $1,593,000 will be recognized proportionate to the vesting period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company recorded stock&ndash;based compensation
expense related to stock options of $452,000 and $0 during the years ended March 31, 2015 and 2014, respectively. As of March 31,
2015, there was $1,060,000 of unrecognized stock-based compensation expense related to stock options that will be amortized over
a weighted average period of 2.1 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RUTHIGEN, INC. &amp; SUBSIDIARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 7. Stockholders&rsquo; Equity - Continued </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Stock Options - Continued</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A summary of the stock option activity during
the year ended March 31, 2015 is presented below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Average</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Average</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Remaining</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Number of</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Exercise</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Life</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Intrinsic</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In Years</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Value</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Outstanding, March 31, 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%">Granted</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">332,500</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">6.37</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Forfeited</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(16,664</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6.37</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Outstanding, March 31, 2015</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">315,836</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6.37</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">9.0</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Exercisable, March 31, 2015</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">81,522</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6.37</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8.7</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table presents information
related to stock options at March 31, 2015:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options Outstanding</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options Exercisable</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Outstanding</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Average</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Exercisable</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Exercise</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Number of</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Remaining Life</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Number of</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In Years</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">$</TD><TD STYLE="width: 23%; padding-bottom: 1pt; text-align: right">6.37</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 22%; border-bottom: Black 1pt solid; text-align: right">315,836</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 22%; padding-bottom: 1pt; text-align: right">8.7</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 22%; border-bottom: Black 1pt solid; text-align: right">81,522</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">315,836</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">8.7</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">81,522</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Restricted Stock Units</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On May 11, 2014, the Company granted RSUs
issuable for an aggregate of 409,355 shares to employees and directors, pursuant to the 2013 Plan. RSUs for 341,000 shares of
common stock vest ratably over three years on a quarterly basis and had an aggregate grant date value of $2,148,000. RSUs for
68,355 shares had an aggregate grant date value of $431,000 and vest in equal installments based on achievement of the following:
(1) enrollment of the first patient in the first pivotal clinical trial for RUT58-60 on or prior to May 11, 2017; (2) enrollment
of the first patient in the second pivotal clinical trial for RUT58-60 on or prior to May 11, 2018; and (3) completion of the
clinical study report containing the results of the second pivotal clinical trial for RUT58-60 on or prior to May 11, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company recorded stock&ndash;based compensation
expense related to RSUs of $627,000 and $0 during the years ended March 31, 2015 and 2014, respectively. As of March 31, 2015,
there was $1,522,000 of unrecognized stock-based compensation expense related to RSUs that will be amortized over a weighted average
period of 2.1 years. The Company recognizes stock-based compensation expense for RSUs with performance conditions if and when the
Company concludes that it is probable that the performance condition will be achieved. As of March 31, 2015, the Company has not
recognized any expense related to RSUs with performance conditions. As of March 31, 2015, there was $431,000 of unrecognized stock-based
compensation expense related to RSUs with performance conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RUTHIGEN, INC. &amp; SUBSIDIARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 7. Stockholders&rsquo; Equity - Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Restricted Stock Units - Continued</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A summary of RSU activity for the years
ended March 31, 2015 and 2014 is presented below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Average</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Total</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Number of</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Grant Date</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Grant Date</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Units</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fair Value</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fair Value</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Non-vested, March 31, 2013</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Vested</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Forfeited</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Non-vested, March 31, 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 61%">Granted</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">409,355</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">6.30</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2,579,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Vested</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(85,308</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.30</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(537,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Forfeited</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Non-vested, March 31, 2015</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">324,047</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6.30</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,042,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Note 8. Income Taxes</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company is included in the U.S.
federal and state (California) tax returns with its Former Parent through the March 26, 2014 closing date of the IPO.
Post-IPO, the Company  filed separate, stand-alone tax returns. During the year ended March 31, 2015, following the
deconsolidation, the Company adjusted its net operating loss (&ldquo;NOL&rdquo;) carry forward to reflect the value of the
NOL available to the Company in future periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following summarizes the income tax
provision (benefit):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center">For The Years Ended</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Federal</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">Current</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; padding-left: 9pt">Deferred</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(1,754,000</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(1,031,000</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">State and local</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">Current</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt">Deferred</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(309,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(182,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,063,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,213,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Change in valuation allowance</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,063,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,213,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Income tax provision (benefit)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RUTHIGEN, INC. &amp; SUBSIDIARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 8. Income Taxes - Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company has the following net deferred
tax assets:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left">Net operating loss carryforwards</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3,224,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1,427,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">262,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Charitable donation carryforwards</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Gross deferred tax assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,490,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,427,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Valuation allowance</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,490,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,427,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;Net deferred tax assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A reconciliation of the statutory federal
income tax rate to the Company&rsquo;s effective tax rate is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center">For The Years Ended</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">Expected federal statutory rate</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(34.0</TD><TD STYLE="width: 1%; text-align: left">)%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(34.0</TD><TD STYLE="width: 1%; text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">State tax rate, net of federal benefit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6.0</TD><TD STYLE="text-align: left">)%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6.0</TD><TD STYLE="text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Change in effective state tax rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.0</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.3</TD><TD STYLE="text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Permanent items - stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.5</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.0</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Permanent items - non-deductible merger expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.4</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.0</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Permanent items - other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.1</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Adjustment of NOL due to deconsolidation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.2</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.0</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Change in valuation allowance</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">30.8</TD><TD STYLE="padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">39.0</TD><TD STYLE="padding-bottom: 1pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Income tax provision (benefit)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.0</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.0</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For the years ended March 31, 2015 and 2014,
the Company had approximately $8,059,000 and $2,539,000 of federal and state net operating loss carryovers (&ldquo;NOLs&rdquo;),
respectively, which begin to expire in 2033. These net operating loss carryovers are  subject to annual limitations under Internal
Revenue Code Section 382 because there has  been a greater than 50% ownership change following the March 26, 2014 closing of
the IPO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company, after considering all available
evidence, fully reserved its deferred tax assets since it is more likely than not that such benefits will not be realized in future
periods. The Company has incurred losses for both financial reporting and income tax purposes for the years ended March 31, 2015
and 2014. The Company will continue to evaluate its deferred tax assets to determine whether any changes in circumstances could
affect the realization of their future benefit. If it is determined in future periods that portions of the Company&rsquo;s deferred
tax assets satisfy the realization standards, the valuation allowance will be reduced accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company does not have any tax positions
for which it is reasonably possible that the total amount of gross unrecognized tax benefits will increase or decrease within 12
months of March 31, 2015. The unrecognized tax benefits may increase or change during the next year for items that arise in the
ordinary course of business. The Company has elected to reflect interest and penalties attributable to income taxes, to the extent
they arise, as a component of its income tax provision or benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RUTHIGEN, INC. &amp; SUBSIDIARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Note 9. Related Party Transactions</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Beginning in March 2013, the Company employed
an immediate family member of the Chief Executive Officer as an operations technician at an annual salary of approximately $36,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Upon completion of the IPO, on March 26,
2014, Oculus owned 2,000,000 shares of the Company&rsquo;s common stock or approximately 43% of the then outstanding common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On March 13, 2015, Oculus entered into a
securities purchase agreement with several investors, pursuant to which the investors agreed to purchase 350,000 shares of the
Company&rsquo;s common stock at a price of $2.75 per share. On March 23, 2015, this sale closed. Oculus retained the voting rights
to the 350,000 shares until and through the date of closing of the Merger. In the event that the closing of the Merger does not
occur on or prior to September 30, 2015, the 350,000 shares of the Company&rsquo;s common stock will become fully tradable and
full voting rights will transfer to the purchasers of such shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On March 13, 2015, Oculus entered into a
securities purchase follow-up agreement with several investors pursuant to which Oculus agreed to sell 1,650,000 shares of the
Company&rsquo;s common stock at a price of $2.75 per share to the investors upon completion of the Merger, provided that 50,000
shares may be sold to one or more investors prior to closing. If the Merger does not close by August 13, 2015 or as may be extended
up to 60 calendar days at Oculus&rsquo;s discretion, there will be no obligation of the investors to purchase the shares. Oculus
will retain the voting rights to the 50,000 shares until and through the date of closing of the Merger. In the event that the closing
of the Merger does not occur on or prior to September 30, 2015, the 50,000 shares of common stock will become fully tradable and
full voting rights will transfer to the investors.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Note 10. Subsequent Events</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Stock-Based Compensation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On April 30, 2015, the Company granted to
its directors fully-vested, ten-year options to purchase an aggregate of 15,000 shares of common stock at an exercise price of
$3.35 per share, pursuant to the 2013 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 104; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.23
<SEQUENCE>2
<FILENAME>v412118_ex10-23.htm
<DESCRIPTION>EXHIBIT 10.23
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 10.23</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">March 3, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Strictly Private and Confidential</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Hojabr Alimi</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ruthigen, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2455 Bennett Valley Rd., Suite C116</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Santa Rosa, California 95404</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Hojabr:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This letter agreement (the &ldquo;<U>Agreement</U>&rdquo;)
documents an oral understanding discussed by the parties in February, 2015, is binding upon each of the parties and shall include
all arrangements and agreements pursuant to which Dawson James Securities, Inc. (&ldquo;<U>Dawson</U>&rdquo;) is or has been engaged
by Ruthigen, Inc. (together with its subsidiaries and affiliates, the &ldquo;<U>Company</U>&rdquo;) on a non-exclusive basis to
introduce the Company to potential Transaction Parties (as defined below) in connection with a potential Transaction (as defined
below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of this Agreement, &ldquo;<U>Transaction</U>&rdquo;
shall be defined as the Company&rsquo;s proposed merger with Pulmatrix, Inc (&ldquo;Pulmatrix&rdquo;) and as described in the agreements,
(collectively the &ldquo;Merger Agreements&rdquo;) by and between Ruthigen and Pulmatrix and related parties. The parties to this
Agreement understand and agree that Dawson has or will receive separate consideration from other persons or entities for the introduction
of Oculus Innovative Sciences, Inc. to investors in connection with transactions not involving the Company, and that the consideration
paid or payable to Dawson in connection therewith shall not serve to reduce the Fees payable to Dawson under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The terms of this engagement
are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify"><B>Introductory Services.</B> In connection with a proposed Transaction, Dawson has and will provide
the Company with strategic advice and assistance (the &ldquo;Services&rdquo;), including, the introduction of the Company to Transaction
Parties. The scope of Dawson&rsquo;s engagement shall be limited to those matters expressly set forth in this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify"><B>Compensation &amp; Expense Reimbursement.</B> As compensation for the services provided hereunder,
the Company agrees to pay Dawson the following fees and expenses:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><U>Upfront Fee</U>: There shall be no fee payable by the Company upon signing of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><U>Success Fee</U>: A fee payable upon completion of a Transaction (the &ldquo;<U>Success Fee</U>&rdquo;)
equal to 340,000 shares of the Company&rsquo;s Common Stock, free and clear of any lien or encumbrance created by company. The
parties acknowledge and agree that the Success Fee has been earned and is payable only upon closing of the Transaction. The Company
covenants that the Transaction will not be closed unless contemporaneous with such closing the Success Fee is paid to Dawson. The
shares of Company Common Stock comprising the Success Fee will be subject to restrictions on resale set forth in a Lock-Up And
Leak-Out Agreement, the form of which is annexed hereto as Schedule B.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ruthigen, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">March 3, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Page 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Under no circumstances is the
Company obligated to consider, review or engage in discussions in connection with any proposed Transaction, nor is Company obligated
to enter into any agreement or consummate any Transaction. Anything to the contrary herein notwithstanding it is understood and
agreed that Dawson will receive the Success Fee only connection with a consummated Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">All amounts owing to Dawson hereunder
shall be the joint and several liability of the Company and each of its subsidiaries. No amounts paid or payable to Dawson or any
of its affiliates under this Agreement shall be credited against any other amounts paid or payable to Dawson except as otherwise
expressly stated in this Agreement. The Company&rsquo;s obligation to pay any fee set forth in this Agreement shall be absolute
and unconditional and shall not be subject to reduction by way of setoff, recoupment or counterclaim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">Representations. Dawson represents that it is acquiring the Success Fee for investment for its
own account and not with a view towards, or for resale in connection with any distribution thereof. Dawson understands that the
Success Fee has not been registered under applicable state or federal securities laws, and is receiving the Success Fee pursuant
to an exemption from the registration requirements of the Securities Act.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify"><B>Other Matters.</B> Dawson has and will treat confidentially non-public information concerning
the Company, its business and any Transaction that the Company discloses to Dawson in connection with this engagement for a period
from the date of this Agreement to the date which is eighteen (18) months from the date of termination or expiration of this Agreement
and, except as otherwise required by law, rule, regulation (including, but not limited to, regulations or rules of any governmental
agency or self-regulatory agency with appropriate jurisdiction) or legal process, Dawson will not disclose such information to
a third party without the Company&rsquo;s consent, which consent shall not be unreasonably withheld.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company agrees that any press
release it may issue announcing a Transaction will, at Dawson&rsquo;s request, contain a reference to Dawson&rsquo;s role in connection
with any Transaction in form and substance satisfactory to Dawson. The Company agrees that, after the public announcement of a
Transaction which, if consummated, would give rise to a Success Fee under this Agreement, Dawson may, at its option, publish a
notice or other form of advertising referring to such Transaction and Dawson in such form, in such media and at such times as Dawson
reasonably deems appropriate, consistent with its customary practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company recognizes that Dawson
has been retained only by the Company and that its engagement is not deemed to be on behalf of, and is not intended to confer or
bestow the status of third-party beneficiary rights upon, any security holder, director, officer or employee or creditor of the
Company, or any person or entity not a party hereto as against Dawson or any of its affiliates, their respective partners, directors,
officers, agents and employees, their respective affiliates or each other person or entity, if any, controlling Dawson or any of
its affiliates. Unless otherwise expressly stated in writing by Dawson, no advice rendered to the Company during the course of
the engagement hereunder shall constitute a recommendation to any other party. No one other than the Company is authorized to rely
upon the engagement of Dawson or any statements or any conduct by Dawson. Moreover, it is acknowledged that the relationship of
Dawson to the Company is that of an independent contractor, that the obligations and responsibilities of Dawson are solely to the
Company, that the obligations and responsibilities of Dawson to the Company are limited to those specifically set forth in this
Agreement, and that Dawson, by entering into this Agreement and satisfying its obligations hereunder, does not assume any fiduciary
duties with respect to the Company, or the Company&rsquo;s Board of Directors, officers, management, employees, security holders
or creditors. All decisions made with respect to any Transactions undertaken by the Company, whether or not consistent with advice
rendered by Dawson, shall be those of the Company. Notwithstanding anything herein to the contrary, it is understood that Dawson
is not undertaking to provide any legal, regulatory, accounting or tax advice in connection with its engagement hereunder, and
the Company shall rely solely upon its own experts for such matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ruthigen, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">March 3, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Page 3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As further consideration under
this Agreement, the Company shall indemnify and hold harmless the Indemnified Persons (as defined in <U>Schedule A</U>) in accordance
with <U>Schedule A</U> attached hereto. The terms and provisions of <U>Schedule A</U> are incorporated herein by reference, constitute
an integral part of this Agreement and shall survive any termination or expiration of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company acknowledges that
Dawson and its subsidiaries and affiliates (collectively, the &ldquo;<U>Dawson Group</U>&rdquo;) are a full service financial institution
and involved in a wide range of investment banking and other activities from which conflicting interests, or duties, may arise.
The Dawson Group has implemented procedures designed to prevent (when appropriate to prevent) the dissemination of non-public information
between departments, and these procedures have been implemented to permit continuation of the routine activities of these departments
regardless of the activities, or knowledge, of the other departments. Accordingly, knowledge of the confidential information by
personnel of one department will not be imputed to personnel of other departments not in actual possession of such confidential
information. Information that is held elsewhere within the Dawson Group, but of which none of the individuals in the Dawson Group&rsquo;s
investment banking department providing the services contemplated by this Agreement actually has knowledge, will not for any purpose
be taken into account in determining the Dawson Group&rsquo;s responsibilities to the Company under this Agreement. The Dawson
Group will not have any duty to disclose to the Company or any other party, or utilize for the Company&rsquo;s benefit, any non-public
information acquired in the course of providing services to any other person or entity engaging in any transaction (on its own
account or otherwise) or otherwise. In addition, in the ordinary course of business, the Dawson Group may trade the securities
of the Company and of potential participants in any Transaction for its own account and for the accounts of customers, and may
at any time hold a long or short position in such securities. The Company acknowledges that from time to time the Dawson Group&rsquo;s
research department may publish research reports or other materials, the substance and/or timing of which may conflict with the
views or advice of the members of the Dawson Group&rsquo;s investment banking department, which reports or materials may have an
adverse effect on the Company&rsquo;s interests in connection with any Transaction or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">By signing
this Agreement, the Company expressly acknowledges that Dawson does not guarantee, warrant or otherwise provide assurance that
the Company will be able to implement or consummate any Transaction contemplated herein, or achieve any other result.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ruthigen, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">March 3, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Page 4</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Dawson&rsquo;s engagement under
this Agreement will run from the date hereof until the earlier of (i) nine months following the date hereof, (ii) the consummation
of a Transaction or (iii) until terminated in accordance with the following sentence. Either Dawson or the Company may terminate
this Agreement and the engagement contemplated hereby, with or without cause, at any time upon 30 days advance written notice to
the other party. Upon termination, this Agreement shall have no further force or effect except that: (i) any fee earned (or deemed
to have been earned) or payable pursuant to Section 2 as of the effective date of termination shall be paid in accordance with
the terms of this Agreement; (ii) if the Company terminates this Agreement and if either (A) the Company shall consummate (or terminate,
as applicable) a Transaction within six (6) months following such termination, and/or (B) the Company shall enter into a definitive
agreement with respect to a Transaction within six (6) months following such termination, and in case of either (A) or (B) with
a party introduced to the Company by Dawson during the term of this Agreement, and with whom the Company or its subsidiaries and
affiliates has not previously engaged or was otherwise known to the Company or its subsidiaries and affiliates, then the Company
shall pay Dawson the Success Fee upon consummation of such Transaction; (iii) the indemnity, contribution and other provisions
as contained in <U>Schedule A</U> shall continue in full force and effect and shall survive any termination of this Agreement;
and (v) the representations, warranties and covenants contained in this Agreement shall survive any completion or termination of
this engagement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Any right to trial by jury
with respect to any claim or action arising out of this Agreement or conduct in connection with the engagement is hereby waived
by the parties hereto and their affiliates.</B> This Agreement, including <U>Schedule A</U> attached hereto, shall be deemed made
in Florida. This Agreement, together with <U>Schedule A</U> attached hereto, and any controversies arising from or related to performance
under this Agreement and <U>Schedule A</U> attached hereto shall be governed by the laws of the State of Florida, without regard
to such State&rsquo;s rules concerning conflicts of laws. All controversies arising from or related to performance under this Agreement
and <U>Schedule A</U> attached hereto shall be adjudicated in State or Federal court within Palm Beach County.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Dawson may not assign its rights
and obligations under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Each of the parties hereto represents
that it has all requisite power and authority to enter into this Agreement including <U>Schedule A</U> and that this Agreement
including <U>Schedule A</U> has been duly and validly authorized by all necessary action on its part, has been duly executed and
delivered by such party and constitutes a legal, valid and binding agreement of such party, enforceable in accordance with its
terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">If any term, provision, covenant
or restriction contained in this Agreement, including in <U>Schedule A</U>, is held by a court of competent jurisdiction or other
authority to be invalid, void, unenforceable or against its regulatory policy, the remainder of the terms, provisions, covenants
and restrictions contained in this Agreement, including in <U>Schedule A</U>, shall remain in full force and effect and shall in
no way be affected, impaired or invalidated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ruthigen, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">March 3, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Page 5</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">All notices, demands, requests,
consents, approvals, and other communications required or permitted hereunder shall be in writing and, unless otherwise specified
herein, shall be (i) personally served, (ii) deposited in the mail, registered or certified, return receipt requested, postage
prepaid, (iii) delivered by reputable air courier service with charges prepaid, or (iv) transmitted by hand delivery, telegram,
or facsimile, addressed as set forth below or to such other address as such party shall have specified most recently by written
notice. Any notice or other communication required or permitted to be given hereunder shall be deemed effective (a) upon hand delivery
or delivery by facsimile, with accurate confirmation generated by the transmitting facsimile machine, at the address or number
designated below (if delivered on a business day during normal business hours where such notice is to be received), or the first
business day following such delivery (if delivered other than on a business day during normal business hours where such notice
is to be received) or (b) on the second business day following the date of mailing by express courier service, fully prepaid, addressed
to such address, or upon actual receipt of such mailing, whichever shall first occur. The addresses for such communications shall
be:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><U>To the Company</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="background-color: white">Ruthigen,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="background-color: white">2455
Bennett Valley Rd.; #C116</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="background-color: white">Santa
Rosa, CA 95404</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="background-color: white">Attn:
Hojabr Alimi</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">halimi@ruthigen.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><U>To Dawson</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="background-color: white">Dawson
James Securities, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="background-color: white">[ADDRESS]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="background-color: white">[ADDRESS]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="background-color: white">[Email
or Fax Number]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">It is understood that either
party may change the address to which notices for it shall be addressed by providing notice of such change to the other party in
the manner set forth in this paragraph.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">This Agreement, including <U>Schedule
A</U> attached hereto, embodies the entire agreement and understanding of the parties hereto regarding the matters provided for
herein, and supersedes any and all prior agreements, arrangements and understandings relating to such matters. No alteration, waiver,
amendment, change or addition hereto shall be binding or effective unless the same is set forth in writing and signed by a duly
authorized representative of each party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">This Agreement may be executed
in any number of counterparts, each of which shall be an original, but all of which shall constitute one instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ruthigen, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">March 3, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Page 6</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dawson is pleased to accept this engagement and looks forward
to working with the Company on this important matter. Please confirm that you agree to be bound by this Agreement by signing and
returning to Dawson the enclosed duplicate of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt; text-transform: uppercase">DAWSON JAMES SECURITIES, Inc</FONT><FONT STYLE="font-size: 10pt">.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 38%">&nbsp;</TD>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 38%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Robert Keyser</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Accepted and Agreed to:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">RUTHIGEN, INC.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Hojabr Alimi</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Reference is hereby made to the engagement
letter to which this <U>Schedule A</U> is annexed (the &ldquo;<U>Agreement</U>&rdquo;) among Dawson and the Company. Unless otherwise
defined herein, all capitalized terms used in this <U>Schedule A</U> shall have the meanings ascribed to them in the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company agrees to indemnify and hold
harmless Dawson and its affiliates, and each of their respective owners, security holders, directors, officers, managers, members,
parents, partners, counsel, agents and employees, and each other person or entity, if any, controlling Dawson or any of its affiliates
(collectively, &ldquo;<U>Indemnified Persons</U>&rdquo;) from and against any losses, claims, damages, liabilities (joint or several)
and expenses (collectively, &ldquo;<U>Losses</U>&rdquo;) related to or arising out of or in connection with the Agreement, Dawson&rsquo;s
services under the Agreement, any Transaction, occurrence or obligation contemplated by the Agreement, or any Indemnified Person&rsquo;s
role in connection therewith arising out of or in connection with materially false statements or materially false information provided
by the Company to Indemnified Persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company further agrees that no Indemnified
Person shall have any liability (whether direct or indirect, in contract, tort or otherwise) to the Company or the Company&rsquo;s
owners, security holders, creditors, directors, officers, managers, members, parents, partners, counsel, agents, employees, subsidiaries
or affiliates related to or arising out of or in connection with the Agreement, Dawson&rsquo;s services under the Agreement, any
Transaction, occurrence or obligation contemplated by the Agreement, or any Indemnified Person&rsquo;s role in connection therewith,
except to the extent that such liability is found by a court of competent jurisdiction in a final non-appealable judgment to have
resulted solely from the gross negligence or willful misconduct of such Indemnified Person (other than an action or failure to
act undertaken at the request or with the consent of the Company).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company further agrees to reimburse
each Indemnified Person for all expenses (including, but not limited to, fees and disbursements of in-house or outside counsel,
and expenses incurred in connection with responding to third party subpoenas) as they are incurred by such Indemnified Person in
connection with investigating, preparing for, defending or settling any action, claim, suit, investigation, inquiry, arbitration
or other proceeding relating to, or enforcing the terms of, this <U>Schedule A</U> or the Agreement (each, an &ldquo;<U>Action</U>&rdquo;),
whether or not pending or threatened and whether or not any Indemnified Person is a party to any such Action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding the foregoing, the Company
shall not be liable to an Indemnified Person for any Losses to the extent that a court of competent jurisdiction shall have determined
by final non-appealable judgment that such Losses resulted solely from the gross negligence or willful misconduct of such Indemnified
Person (other than an action or failure to act undertaken at the request or with the consent of the Company).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any indemnification or reimbursement
sought pursuant to this <U>Schedule A</U> were for any reason (by judicial determination or otherwise) not to be available to any
Indemnified Person or insufficient to satisfy all Losses of such Indemnified Person, in each case, as and to the extent contemplated
by this <U>Schedule A</U>, then the Company, in lieu of indemnifying or reimbursing such Indemnified Person, shall contribute to
the amount paid or payable by such Indemnified Person with respect to such Losses (including, but not limited to, expenses relating
thereto) (i) in such proportion as is appropriate to reflect the relative benefits received (or anticipated to be received) by
Dawson, on the one hand, and the Company, on the other hand, of the engagement under the Agreement, or (ii) if the allocation provided
by clause (i) above is not available, in such proportion as is appropriate to reflect not only the relative benefits referred to
in such clause (i), but also the relative fault of each of Dawson and the Company, as well as any other relevant equitable considerations;
<U>provided</U> that in no event shall Dawson&rsquo;s aggregate contribution to the amount paid or payable exceed the aggregate
amount of fees actually received by Dawson under the Agreement (and in no event shall it include amounts received by Dawson as
reimbursement of expenses). For the purposes of this <U>Schedule A</U>, the relative benefits to Dawson and the Company of the
Agreement shall be deemed to be in the same proportion as (a) the total value paid or contemplated to be paid or received or contemplated
to be received by the Company or its security holders, as the case may be, in the Transactions that are contemplated by the Agreement,
whether or not any such Transaction is consummated, bears to (b) the fees paid or to be paid to Dawson under the Agreement. For
the purposes of this <U>Schedule A</U>, the relative fault of Dawson and the Company will be determined by reference to such party&rsquo;s
or person&rsquo;s or entity&rsquo;s knowledge, access to information and opportunity to prevent or correct any misstatement, omission,
misconduct or breach of duty. Dawson and the Company agree that it would not be just and equitable if contribution were determined
by any other method of allocation which does not take account of the equitable considerations referred to above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event an Indemnified Person appears
as a witness, gives deposition or other testimony, or responds to discovery in any action brought against the Company in which
an Indemnified Person is not named as a defendant, the Company agrees to reimburse such Indemnified Person for all expenses incurred
by such Indemnified Person and time expended by it in connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The obligations of the Company hereunder
shall be in addition to any liability which the Company may otherwise have to any Indemnified Person (whether in common law or
otherwise) and shall be binding upon and inure to the benefit of any successors, assigns, heirs and personal representatives of
the Company or any Indemnified Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company shall not settle or compromise,
or consent to the entry of any judgment in, or otherwise seek to terminate, any pending or threatened Action in which any Indemnified
Person is or may be a party unless (i) such Indemnified Person has given its prior written consent; or (ii) such settlement, compromise,
consent or termination includes an express unconditional release of such Indemnified Person from all Losses arising out of such
Action and does not include a statement as to or an admission of fault, culpability or a failure to act, by or on behalf of any
Indemnified Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Solely for the purpose of enforcing this
<U>Schedule A</U>, the Company hereby consents to personal jurisdiction and to service and venue in any court in which any Action
or claim which is subject to this <U>Schedule A</U> is brought by or against any Indemnified Person. <B>Dawson hereby agrees, and
the Company hereby agrees on its own behalf and, to the extent permitted by applicable law, on behalf of its security holders and
creditors, to waive any right to trial by jury with respect to any claim, counter-claim or action related to or arising out of
or in connection with the Agreement, Dawson&rsquo;s services under the Agreement, any Transaction, occurrence or obligation contemplated
by the Agreement, or any Indemnified Person&rsquo;s role in connection therewith.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The provisions of this <U>Schedule A</U>
shall apply to the Agreement (including, but not limited to, any related activities prior to the date hereof) and any modification
or amendment thereof, and shall remain in full force and effect regardless of (i) whether or not any Transactions or services contemplated
by the Agreement are initiated or consummated; (ii) any termination, completion or expiration of the Agreement; and (iii) whether
or not Dawson is called upon to render any particular services or advice in the course of its engagement under the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.24
<SEQUENCE>3
<FILENAME>v412118_ex10-24.htm
<DESCRIPTION>EXHIBIT 10.24
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"><B>EXHIBIT 10.24</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Consulting Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Consulting Agreement (&ldquo;Agreement&rdquo;),
effective as of March 10, 2015 (&ldquo;Effective Date&rdquo;) is entered into by and between Ruthigen, Inc.<B>,</B> a Delaware
corporation (herein referred to as the &ldquo;Company&rdquo;) and Robert B. Prag (herein referred to as the &ldquo;Consultant&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>RECITALS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, Company
desires to engage Consultant to assist in business development, strategic relationships and strategic planning, and assisting with
writing corporate collateral material and press releases;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW THEREFORE</B>,
in consideration of the promises and the mutual covenants and agreements hereinafter set forth, as well as previous services rendered,
the parties hereto covenant and agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Term.</U>
Company hereby agrees to retain Consultant for a period commencing on the effective date of the merger pursuant to which Pulmatrix,
Inc. (&ldquo;Pulmatrix&rdquo;), a Delaware corporation, becomes a wholly-owned subsidiary of the Company pursuant to a Merger Agreement
to which the Company and Pulmatrix are or will be parties (the &ldquo;Commencement Date&rdquo;) and ending on August 31, 2016 (such
period, the &ldquo;Term&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Duties
of Consultant</U>. From the commencement of this Agreement up and until termination, Consultant agrees that he will generally provide
the following specified duties:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">Assist the Company&rsquo;s management team in developing and implementing business development
strategies and initiatives;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Introduce the Company&rsquo;s management to prospective customers, resellers, and strategic relationships
with respect to the Company&rsquo;s products and services;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">Assist the Company&rsquo;s management in negotiating business development and strategic relationships
with prospective customers, resellers, and strategic relationships;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">Assist the Company&rsquo;s management with respect to presenting the Company&rsquo;s products and
its business offerings to prospective customers, resellers, and strategic relationships;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(e)</TD><TD STYLE="text-align: justify">Upon and with the Company management's direction, conduct meetings, in person or by telephone,
with prospective customers, resellers, and strategic relationships;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(f)</TD><TD STYLE="text-align: justify">Review business plans, strategies, budgets, proposed transactions and other plans for the purpose
of assisting the Company&rsquo;s management on matters concerning prospective customers, resellers, and strategic relationships;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(g)</TD><TD STYLE="text-align: justify">Assist in creating collateral material for the Company including sales presentation, powerpoints
and press releases.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(h)</TD><TD STYLE="text-align: justify">Assist management with respect to corporate symbols, logos, names, the presentation of such symbols,
logos and names, and other matters relating to corporate image;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD STYLE="text-align: justify">Perform the functions generally assigned to internal stockholder relations departments in public
corporations, including responding to telephone and written inquiries, preparing press releases for the Company with the Company
managements&rsquo; involvement and approval of press releases, reports and other communications with or to shareholders, assisting
with respect to the timing, form, distribution and other matters related to such releases, reports and communications;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Allocation
of Time and Non-exclusive Relationship</U>. Consultant hereby promises to perform and discharge faithfully the responsibilities
which may be assigned to Consultant from time to time by the Company&rsquo;s management in connection with this Consulting Agreement.
It is understood that are no specific number of days per week or hours per day are required by this Agreement, but rather during
the Term, Consultant will perform the duties set forth herein above in a diligent and professional manner. The parties acknowledge
and agree that this Agreement does not contemplate any exclusive relationship between the parties and that Consultant currently
has consulting engagements with other companies and that during the Term, Consultant will enter into additional consulting engagements
with other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Remuneration</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
entering into this Agreement to provide services after the Commencement Date, and for other good and valuable consideration, the
Company agrees to pay to Consultant a &ldquo;Commencement Bonus&rdquo; in the form the form of 250,000 restricted shares of the
Company's common stock (hereinafter the &quot;Restricted Shares&quot;). The Restricted Shares shall be issued to Consultant within
15 days of the Commencement Date. The Company understands and agrees that Consultant has foregone significant opportunities to
enter into this Agreement and that the Company derives substantial benefit from the execution of this Agreement and the ability
to announce its engagement of Consultant. Therefore, the payment of the Commencement Bonus after the Commencement Date is a non-refundable
payment for future services. Consultant acknowledges that Consultant will not be entitled to any remuneration unless and until
there is a Commencement Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company warrants that the Restricted Shares issuable to Consultant under this Agreement by the Company shall be or have been validly
issued, fully paid and non-assessable and that the Company&rsquo;s board of directors has or shall have duly authorized the issuance
and any transfer to Consultant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company has the right to terminate this Agreement at any time during the Term of this Agreement, upon providing Consultant thirty
(30) days written notice of Company&rsquo;s intention to terminate. If the Company decides to terminate this Agreement for any
reason whatsoever, it is agreed and understood that Consultant will not return any portion of the Restricted Shares issuable to
Consultant. Further, if and in the event the Company is acquired during the term of this Agreement, it is agreed and understood
that Consultant will not be requested or demanded by the Company to return any of the Restricted Shares payable to him hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.4 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consultant
agrees that during the Term he will not sell or transfer any of the Restricted Shares issued to him by the Company hereunder, except
to the Company; nor will he pledge or assign such Shares as collateral or as security for the performance of any obligation, or
for any other purpose, without the prior written consent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consultant
acknowledges that the Restricted Shares to be issued pursuant to this Agreement have not been registered under the Securities Act
of 1933, as amended (the &ldquo;Securities Act&rdquo;) and accordingly are &ldquo;restricted securities&rdquo; within the meaning
of Rule 144 of the Act. As such, the Restricted Shares may not be resold or transferred unless the Company has received an opinion
of counsel and in form reasonably satisfactory to the Company and its counsel that such resale or transfer is exempt from the registration
requirements of that Securities Act. The Company agrees that in the event Consultant wishes to effect a transfer in compliance
with Rule 144, Consultant will provide a Rule 144 opinion of counsel to the Company to Consultant within 5 business days of Consultant&rsquo;s
request of such opinion, provided that Consultant provides such information and additional documentation as may reasonably be requested
by Company and its counsel to confirm that such transfer will be made in compliance with Rule 144 and any applicable state securities
laws. Company agrees to bear all costs and expenses associated with any such Rule 144 legal opinions and any related transfer agents&rsquo;
fees. Consultant shall otherwise be responsible for all other costs, expenses and compliance requirements under federal and state
securities laws, including any other opinions of counsel reasonably required by the Company or its transfer agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with the acquisition of the Restricted Shares, Consultant represents and warrants to Company as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(a)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consultant has been afforded
the opportunity to ask questions of and receive answers from duly authorized officers or other representatives of the Company concerning
an investment in the Restricted Shares, and any additional information that Consultant has requested.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consultant has had an
opportunity to review or has had access to the EDGAR Website of the Securities and Exchange Commission (the &ldquo;Commission&rdquo;)
to the Company filings made with the Commission available at the EDGAR website.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(c)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consultant&rsquo;s investment
in restricted securities is reasonable in relation to Consultant&rsquo;s net worth, which is in excess of ten (10) times Consultant&rsquo;s
cost basis in the Restricted Shares. Consultant has experience in investments in restricted and publicly traded securities, and
Consultant has experience in investments in speculative securities and other investments that involve the risk of loss of investment.
Consultant acknowledges that an investment in the Restricted Shares is speculative and involves the risk of loss. Consultant has
the requisite knowledge to assess the relative merits and risks of this investment without the necessity of relying upon other
advisors, and Consultant can afford the risk of loss of his entire investment in the Restricted Shares. Consultant is an accredited
investor, as that term is defined in Regulation D promulgated under the Securities Act, and has provided a form of questionnaire
regarding such status annexed hereto as Exhibit A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(d)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consultant is acquiring
the Restricted Shares for Consultant&rsquo;s own account for long-term investment and not with a view toward resale or distribution
thereof except in accordance with applicable securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(e)&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Consultant </U>is not
subject to any of the &quot;Bad Actor&quot; disqualifications described in Rule 506(d)(1)(i) to (viii) under the Securities Act
(a &quot;Disqualification Event&quot;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Non-Assignability
of Services</U>. Consultant&rsquo;s services under this Agreement are offered to Company only and may not be assigned by Company
except to any entity with which Company merges with or which acquires the Company or substantially all of its assets. In the event
of such merger or acquisition, all compensation to Consultant herein under the schedules set forth herein shall remain due and
payable. Consultant shall not assign his rights or delegate his duties hereunder without the prior written consent of Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Independent
Contractor</U>. Consultant is an independent contractor and is not an employee, partner, or co-venturer of, or in any other service
relationship with the Company. The manner in which Consultant&rsquo;s services are rendered shall be within Consultant&rsquo;s
sole control and discretion. Consultant is not authorized to speak for, represent, or obligate the Company in any manner without
the prior express written authorization from an officer of the Company. Consultant shall be responsible for all taxes arising from
compensation and other amounts paid under this Agreement. Neither federal, nor state, nor local income tax, nor payroll tax of
any kind, shall be withheld or paid by the Company on behalf of Consultant. Consultant understands that he is responsible to pay,
according to law, Consultant&rsquo;s taxes and Consultant shall, when requested by the Company, properly document to the Company
that any and all federal and state taxes have been paid. Consultant will not be eligible for and shall not participate in any employee
pension, health, welfare, or other fringe benefit plan, of the Company. No workers' compensation insurance shall be obtained by
Company covering Consultant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Expenses</U>.
Consultant will be reimbursed for extraordinary expenses he incurs (like travel required by/or specifically requested by the Company),
as long as such expenses have been approved by the Company in writing prior to its incurring an obligation for reimbursement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification</U>.
The Company warrants and represents that all oral communications, written documents or materials furnished to Consultant or the
public by the Company with respect to its products and services are accurate in all material respects and Consultant may rely upon
the accuracy thereof without independent investigation. The Company will protect, indemnify and hold harmless Consultant against
any claims or litigation including any damages, liability, cost and reasonable attorney's fees as incurred with respect thereto
resulting from Consultant's communication or dissemination of any said information, documents or materials unless resulting from
Consultant's communication or dissemination of information not provided by the Company or in a manner not authorized by the Company.
Consultant will indemnify and hold Company harmless against any claims or litigation, including any damages, liability, cost and
reasonable attorney&rsquo;s fees as incurred with respect thereto resulting from (i) Consultant&rsquo;s communication or dissemination
of any false or inaccurate information, unless resulting from Consultant's communication or dissemination of information provided
by the Company or in a manner authorized by the Company, and (ii) any breach of Consultant&rsquo;s representations, warrants and
covenants under this Agreement. Notwithstanding anything to the contrary set forth in this Agreement, the Company shall not be
obligated to indemnify Consultant for any such losses, claims, damages, liabilities or expenses incurred by Consultant which have
resulted solely from Consultant&rsquo;s bad faith, gross negligence or willful misconduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations</U>.
Consultant represents that he is not required to maintain any licenses and registrations under federal or any state regulations
necessary to perform the services set forth herein. Consultant acknowledges that, to the best of his knowledge, the performance
of the services set forth under this Agreement will not violate any rule or provision of any regulatory agency having jurisdiction
over Consultant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Legal
Representation</U>. Each of Company and Consultant represents that they have consulted with independent legal counsel and/or tax,
financial and business advisors, to the extent that they deemed necessary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Attorney's
Fee</U>. If any legal action or any arbitration or other proceeding is brought for the enforcement or interpretation of this Agreement,
or because of an alleged dispute, breach, default or misrepresentation in connection with or related to this Agreement, the successful
or prevailing party shall be entitled to recover reasonable attorneys' fees and other costs in connection with that action or proceeding,
in addition to any other relief to which it or they may be entitled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Waiver</U>.
The waiver by either party of a breach of any provision of this Agreement by the other party shall not operate or be construed
as a waiver of any subsequent breach by such other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.
All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing
and, unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered or certified, return
receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid, or (iv) transmitted
by hand delivery, telegram, or facsimile, addressed as set forth below or to such other address as such party shall have specified
most recently by written notice. Any notice or other communication required or permitted to be given hereunder shall be deemed
effective (a) upon hand delivery or delivery by facsimile, with accurate confirmation generated by the transmitting facsimile machine,
at the address or number designated below (if delivered on a business day during normal business hours where such notice is to
be received), or the first business day following such delivery (if delivered other than on a business day during normal business
hours where such notice is to be received) or (b) on the second business day following the date of mailing by express courier service,
fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first occur. The addresses for
such communications shall be:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><U>To the Company</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="background-color: white">Hojabr
Alimi</FONT>, CEO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="background-color: white">Ruthigen,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="background-color: white">2455
Bennett Valley Rd.; #C116</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="background-color: white">Santa
Rosa, CA 95404 </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">halimi@ruthigen.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><U>To Consultant</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">Robert B. Prag, President</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">The Del Mar Consulting Group,
Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">2455 El Amigo Road</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">Del Mar, CA 92014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">bprag@delmarconsulting.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is understood that either party may
change the address to which notices for it shall be addressed by providing notice of such change to the other party in the manner
set forth in this paragraph.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">14. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="background-color: white"><U>Choice of Law and Severability</U>.&nbsp; This Agreement shall be interpreted in accordance
with the laws of the State of Delaware without giving effect to provisions governing the choice of law.&nbsp; If any provision
of this Agreement becomes or is deemed invalid, illegal or unenforceable in any applicable jurisdiction by reason of the scope,
extent or duration of its coverage, then such provision shall be deemed amended to the minimum extent necessary to conform to applicable
law so as to be valid and enforceable or, if such provision cannot be so amended without materially altering the intention of the
parties, then such provision shall be stricken and the remainder of this Agreement shall continue in full force and effect.&nbsp;
If any provision of this Agreement is rendered illegal by any present or future statute, law, ordinance or regulation (collectively,
the &quot;Law&quot;) then that provision shall be curtailed or limited only to the minimum extent necessary to bring the provision
into compliance with the Law.&nbsp; All the other terms and provisions of this Agreement shall continue in full force and effect
without impairment or limitation.</FONT><U> </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>Survival.</U>&nbsp;Any
provision of this Agreement which imposes an obligation after termination or expiration of this Agreement shall survive the termination
or expiration of this Agreement.</FONT><U> </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Complete
Agreement</U>. This Agreement contains the entire agreement of the parties relating to the subject matter hereof. This Agreement
and its terms may not be changed orally but only by an agreement in writing signed by the party against whom enforcement of any
waiver, change, modification, extension or discharge is sought. This Agreement may be executed in one or more counterparts, each
of which shall be deemed to be an original and all of which shall constitute one agreement. A telefacsimile or email of this Agreement
may be relied upon as full and sufficient evidence as an original.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IN WITNESS WHEREOF, the parties have executed this Agreement
as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">AGREED TO:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Company:&nbsp;&nbsp;Ruthigen, Inc.</FONT></TD></TR>
<TR>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 96%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Name: </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Hojabr Alimi</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">CEO and its Duly Authorized Agent</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Consultant:</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Robert B. Prag</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ACCREDITED INVESTOR QUESTIONNAIRE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><U>INSTRUCTIONS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">PLEASE ANSWER ALL QUESTIONS.
If the appropriate answer is &ldquo;None&rdquo; or &ldquo;Not Applicable&rdquo;, so state. Please print or type your answers to
all questions. Attach additional sheets if necessary to complete your answers to any item.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Your answers will be
kept strictly confidential at all times. However, the Company may present this Questionnaire to such parties as it deems appropriate
in order to assure itself that the offer and sale of securities of the Company will not result in a violation of the registration
provisions of the Securities Act of 1933, as amended, or a violation of the securities laws of any state.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please
provide the following information:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">Name:</TD>
    <TD STYLE="width: 95%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 26%">Name of additional purchaser:</TD>
    <TD STYLE="width: 74%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Please complete information in Question 5)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date of birth, or if other than an individual, year of organization
or incorporation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Residence
address, or if other than an individual, principal office address:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 13%">Telephone&nbsp;number:</TD>
    <TD STYLE="width: 87%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 18%">Social&nbsp;Security&nbsp;Number:</TD>
    <TD STYLE="width: 82%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%">Taxpayer&nbsp;Identification&nbsp;Number:</TD>
    <TD STYLE="width: 75%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 21%">3.&nbsp;&nbsp;Business&nbsp;address:</TD>
    <TD STYLE="width: 79%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 23%">Business&nbsp;telephone&nbsp;number:</TD>
    <TD STYLE="width: 77%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 29%">4.&nbsp;&nbsp;Send mail to:</TD>
    <TD STYLE="width: 29%">Residence &#9744;</TD>
    <TD STYLE="width: 42%">Business &#9744;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
respect to tenants in common, joint tenants and tenants by the entirety, complete only if information differs from that above:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 14%">Residence&nbsp;address:</TD>
    <TD STYLE="width: 86%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 14%">Telephone&nbsp;number:</TD>
    <TD STYLE="width: 86%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 19%">Social&nbsp;Security&nbsp;Number:</TD>
    <TD STYLE="width: 81%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 28%">Taxpayer&nbsp;Identification&nbsp;Number:</TD>
    <TD STYLE="width: 72%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%">Business&nbsp;address:</TD>
    <TD STYLE="width: 85%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 21%">Business&nbsp;telephone&nbsp;number:</TD>
    <TD STYLE="width: 79%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 22%; text-align: justify">Send Mail to:</TD>
    <TD STYLE="width: 28%; text-align: justify">Residence &#9744;</TD>
    <TD STYLE="width: 50%; text-align: justify">Business &#9744;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please
describe your present or most recent business or occupation and indicate such information as the nature of your employment, how
long you have been employed there, the principal business of your employer, the principal activities under your management or supervision
and the scope (e.g. dollar volume, industry rank, etc.) of such activities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please
state whether you (i) are associated with or affiliated with a member of the Financial Industry Regulatory Association, Inc. (&ldquo;FINRA&rdquo;),
(ii) are an owner of stock or other securities of FINRA member (other than stock or other securities purchased on the open market),
or (iii) have made a subordinated loan to any FINRA member:&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 21%; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 28%; text-indent: 0in"></TD>
    <TD STYLE="width: 51%; text-indent: 0in"></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in">Yes &#9744;</TD>
    <TD STYLE="text-indent: 0in">No &#9744;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">If you answered yes to any of (i) &ndash;
(iii) above, please indicate the applicable answer and briefly describe the facts below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Applicable
to Individuals ONLY. Please answer the following questions concerning your financial condition as an &ldquo;accredited investor&rdquo;
(within the meaning of Rule 501 of Regulation D). If the purchaser is more than one individual, each individual must initial an
answer where the question indicates a &ldquo;yes&rdquo; or &ldquo;no&rdquo; response and must answer any other question fully,
indicating to which individual such answer applies. If the purchaser is purchasing jointly with his or her spouse, one answer may
be indicated for the couple as a whole:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">8.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Does
your net worth* (or joint net worth with your spouse) exceed $1,000,000?&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 21%; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 28%; text-indent: 0in"></TD>
    <TD STYLE="width: 51%; text-indent: 0in"></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in">Yes &#9744;</TD>
    <TD STYLE="text-indent: 0in">No &#9744;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Did
you have an individual income** in excess of $200,000 or joint income together with your spouse in excess of $300,000 in each
of the two most recent years and do you reasonably expect to reach the same income level in the current year?&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 21%; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 28%; text-indent: 0in"></TD>
    <TD STYLE="width: 51%; text-indent: 0in"></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in">Yes</TD>
    <TD STYLE="text-indent: 0in">No &#9744;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">8.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Are
you an executive officer of the Company?&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 21%; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 28%; text-indent: 0in"></TD>
    <TD STYLE="width: 51%; text-indent: 0in"></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in">Yes &#9744;</TD>
    <TD STYLE="text-indent: 0in">No &#9744;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">* For purposes hereof, net worth shall
be deemed to include ALL of your assets, liquid or illiquid MINUS any liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">** For purposes hereof, the term &ldquo;income&rdquo;
is not limited to &ldquo;adjusted gross income&rdquo; as that term is defined for federal income tax purposes, but rather includes
certain items of income which are deducted in computing &ldquo;adjusted gross income&rdquo;. For investors who are salaried employees,
the gross salary of such investor, minus any significant expenses personally incurred by such investor in connection with earning
the salary, plus any income from any other source including unearned income, is a fair measure of &ldquo;income&rdquo; for purposes
hereof. For investors who are self-employed, &ldquo;income&rdquo; is generally construed to mean total revenues received during
the calendar year minus significant expenses incurred in connection with earning such revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">8.B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Applicable
to Corporations, Partnerships, Trusts, Limited Liability Companies and other Entities ONLY:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The purchaser is an accredited investor
because the purchaser falls within at least one of the following categories (Check all appropriate lines):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">&#9744;</TD><TD STYLE="text-align: justify">(i) a bank as defined in Section 3(a)(2) of the Act or a savings and loan association or other
institution as defined in Section 3(a)(5)(A) of the Act whether acting in its individual or fiduciary capacity;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">&#9744;</TD><TD STYLE="text-align: justify">(ii) a broker-dealer registered pursuant to Section 15 of the Securities Exchange Act of 1934,
as amended;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">&#9744;</TD><TD STYLE="text-align: justify">(iii) an insurance company as defined in Section 2(13) of the Act;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">&#9744;</TD><TD STYLE="text-align: justify">(iv) an investment company registered under the Investment Company Act of 1940, as amended (the
&ldquo;Investment Act&rdquo;) or a business development company as defined in Section 2(a)(48) of the Investment Act;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">&#9744;</TD><TD STYLE="text-align: justify">(v) a Small Business Investment Company licensed by the U.S. Small Business Administration under
Section 301(c) or (d) of the Small Business Investment Act of 1958, as amended;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">&#9744;</TD><TD STYLE="text-align: justify">(vi) a plan established and maintained by a state, its political subdivisions, or any agency or
instrumentality of a state or its political subdivisions, for the benefit of its employees, where such plan has total assets in
excess of $5,000,000;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">&#9744;</TD><TD STYLE="text-align: justify">(vii) an employee benefit plan within the meaning of Title 1 of the Employee Retirement Income
Security Act of 1974, as amended (the &ldquo;Employee Act&rdquo;), where the investment decision is made by a plan fiduciary, as
defined in Section 3(21) of the Employee Act, which is either a bank, savings and loan association, insurance company, or registered
investment adviser, or an employee benefit plan that has total assets in excess of $5,000,000, or a self-directed plan the investment
decisions of which are made solely by persons that are accredited investors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">&#9744;</TD><TD STYLE="text-align: justify">(viii) a private business development company, as defined in Section 202(a)(22) of the Investment
Advisers Act of 1940, as amended;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">&#9744;</TD><TD STYLE="text-align: justify">(ix) an organization described in Section 501(c)(3) of the Internal Revenue Code, a corporation,
a Massachusetts or similar business trust, or a partnership, not formed for the specific purpose of acquiring the securities offered,
with total assets in excess of $5,000,000;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">&#9744;</TD><TD STYLE="text-align: justify">(x) a trust, with total assets in excess of $5,000,000, not formed for the specific purpose of
acquiring the securities offered, whose purchase is directed by a &ldquo;sophisticated&rdquo; person, as described in Rule 506(b)(2)(ii)
promulgated under the Act, who has such knowledge and experience in financial and business matters that he or she is capable of
evaluating the merits and risks of the prospective investment;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">&#9744;</TD><TD STYLE="text-align: justify">(xi) an entity in which all of the equity investors are persons or entities described above (&ldquo;accredited
investors&rdquo;). ALL EQUITY OWNERS MUST COMPLETE &ldquo;EXHIBIT A&rdquo; ATTACHED HERETO.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">9.A&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Do
you have sufficient knowledge and experience in financial and business matters so as to be capable of evaluating the merits and
risks associated with investing in the Company?&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 21%; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 28%; text-indent: 0in"></TD>
    <TD STYLE="width: 51%; text-indent: 0in"></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in">Yes &#9744;</TD>
    <TD STYLE="text-indent: 0in">No &#9744;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ANSWER QUESTION 9B ONLY IF THE ANSWER TO QUESTION 9A WAS &ldquo;NO.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">9.B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the answer to Question 9A was &ldquo;NO,&rdquo; do you have a financial or investment adviser (a) that is acting in the capacity
as a purchaser representative and (b) who has sufficient knowledge and experience in financial and business matters so as to be
capable of evaluating the merits and risks associated with investing in the Company?&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 21%; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 28%; text-indent: 0in"></TD>
    <TD STYLE="width: 51%; text-indent: 0in"></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in">Yes &#9744;</TD>
    <TD STYLE="text-indent: 0in">No &#9744;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If you have a financial or investment adviser(s),
please identify each such person and indicate his or her business address and telephone number in the space below. (Each such person
must complete, and you must review and acknowledge, a separate Purchaser Representative Questionnaire which will be supplied at
your request).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
have the right, will be afforded an opportunity, and are encouraged to investigate the Company and review relevant factors and
documents pertaining to the officers of the Company, and the Company and its business and to ask questions of a qualified representative
of the Company regarding this investment and the properties, operations, and methods of doing business of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Have you or has your purchaser representative,
if any, conducted any such investigation, sought such documents or asked questions of a qualified representative of the Company
regarding this investment and the properties, operations, and methods of doing business of the Company?&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 21%; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 28%; text-indent: 0in"></TD>
    <TD STYLE="width: 51%; text-indent: 0in"></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in">Yes &#9744;</TD>
    <TD STYLE="text-indent: 0in">No &#9744;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 10%">If so, briefly describe:</TD>
    <TD STYLE="width: 90%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 93%; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 7%; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If so, have you completed your investigation
and/or received satisfactory answers to your questions?&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 21%; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 28%; text-indent: 0in"></TD>
    <TD STYLE="width: 51%; text-indent: 0in"></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in">Yes &#9744;</TD>
    <TD STYLE="text-indent: 0in">No &#9744;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Do
you understand the nature of an investment in the Company and the risks associated with such an investment?&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 21%; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 28%; text-indent: 0in"></TD>
    <TD STYLE="width: 51%; text-indent: 0in"></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in">Yes &#9744;</TD>
    <TD STYLE="text-indent: 0in">No &#9744;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Do
you understand that there is no guarantee of any financial return on this investment and that you will be exposed to the risk
of losing your entire investment?&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 21%; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 28%; text-indent: 0in"></TD>
    <TD STYLE="width: 51%; text-indent: 0in"></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in">Yes &#9744;</TD>
    <TD STYLE="text-indent: 0in">No &#9744;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Do
you understand that this investment is not liquid?&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 21%; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 28%; text-indent: 0in"></TD>
    <TD STYLE="width: 51%; text-indent: 0in"></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in">Yes &#9744;</TD>
    <TD STYLE="text-indent: 0in">No &#9744;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Do
you have adequate means of providing for your current needs and personal contingencies in view of the fact that this is not a
liquid investment?&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 21%; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 28%; text-indent: 0in"></TD>
    <TD STYLE="width: 51%; text-indent: 0in"></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in">Yes &#9744;</TD>
    <TD STYLE="text-indent: 0in">No &#9744;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Are
you aware of the Company&rsquo;s business affairs and financial condition, and have you acquired all such information about the
Company as you deem necessary and appropriate to enable you to reach an informed and knowledgeable decision to acquire the Interests?&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 21%; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 28%; text-indent: 0in"></TD>
    <TD STYLE="width: 51%; text-indent: 0in"></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in">Yes &#9744;</TD>
    <TD STYLE="text-indent: 0in">No &#9744;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Do
you have a &ldquo;pre-existing relationship&rdquo; with the Company or any of the officers of the Company?&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 21%; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 28%; text-indent: 0in"></TD>
    <TD STYLE="width: 51%; text-indent: 0in"></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in">Yes &#9744;</TD>
    <TD STYLE="text-indent: 0in">No &#9744;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(For purposes hereof, &ldquo;pre-existing
relationship&rdquo; means any relationship consisting of personal or business contacts of a nature and duration such as would enable
a reasonably prudent investor to be aware of the character, business acumen, and general business and financial circumstances of
the person with whom such relationship exists.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If so, please name the individual or other
person with whom you have a pre-existing relationship and describe the relationship:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exceptions
to the representations and warranties made in Section 3.2 of the Securities Purchase Agreement (if no exceptions, write &ldquo;none&rdquo;
&ndash; if left blank, the response will be deemed to be &ldquo;none&rdquo;): ___________________________________________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: _______________, 20___</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If purchaser is one or more individuals (all individuals must
sign):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(Type or print name of prospective purchaser)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Signature of prospective purchaser</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Social Security Number</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(Type or print name of additional purchaser)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Signature of spouse, joint tenant, tenant in common or other signature, if required</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Social Security Number</TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Annex A</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Definition of Accredited Investor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The securities will
only be sold to investors who represent in writing in the Securities Purchase Agreement that they are accredited investors, as
defined in Regulation D, Rule 501 under the Act which definition is set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
natural person whose net worth, or joint net worth with spouse, at the time of purchase exceeds $1 million (excluding home); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
natural person whose individual gross income exceeded $200,000 or whose joint income with that person&rsquo;s spouse exceeded $300,000
in each of the last two years, and who reasonably expects to exceed such income level in the current year; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
trust with total assets in excess of $5 million, not formed for the specific purpose of acquiring the securities offered, whose
purchase is directed by a sophisticated person described in Regulation D; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
director or executive officer of the Company; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
investor is an entity, all of the owners of which are accredited investors; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)
bank as defined in Section 3(a)(2) of the Act, or any savings and loan association or other institution as defined in Section 3(a)(5)(A)
of the Act, (b) any broker or dealer registered pursuant to Section 15 of the Securities Exchange Act of 1934, (c) an insurance
Company as defined in Section 2(13) of the Act, (d) an investment Company registered under the Investment Company Act of 1940 or
a business development Company as defined in Section 2(a)(48) of such Act, (e) a Small Business Investment Company licensed by
the United States Small Business Administration under Section 301(c) or (d) of the Small Business Investment Act of 1958, (f) an
employee benefit plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a
state or its political subdivisions, if such plan has total assets in excess of $5 million, (g) an employee benefit plan within
the meaning of Title I of the Employee Retirement Income Securities Act of 1974, and the employee benefit plan has assets in excess
of $5 million, or the investment decision is made by a plan fiduciary, as defined in Section 3(21) of such act, that is either
a bank, savings and loan institution, insurance Company, or registered investment advisor, or, if a self-directed plan, with an
investment decisions made solely by persons that are accredited investors, (h) a private business development company as defined
in Section 202(a)(22) of the Investment Advisers Act of 1940, or (i) an organization described in Section 501(c)(3) of the Internal
Revenue code, corporation, Massachusetts or similar business trust, or partnership, not formed for the specific purpose of acquiring
the securities offered, with assets in excess of $5 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT &ldquo;A&rdquo; TO ACCREDITED INVESTOR
QUESTIONNAIRE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ACCREDITED CORPORATIONS, PARTNERSHIPS,
LIMITED LIABILITY COMPANIES, TRUSTS OR OTHER ENTITIES INITIALING QUESTION 8B(xi) MUST PROVIDE THE FOLLOWING INFORMATION.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I hereby certify that set forth below is
a complete list of all equity owners in __________________ [NAME OF ENTITY], a <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
[TYPE OF ENTITY] formed pursuant to the laws of the State of<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U>. I also certify that <U>EACH SUCH OWNER HAS INITIALED THE SPACE OPPOSITE HIS OR HER NAME</U> and that each such owner understands
that by initialing that space he or she is representing that he or she is an accredited individual investor satisfying the test
for accredited individual investors indicated under &ldquo;Type of Accredited Investor.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="RIGHT" STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>signature of authorized corporate officer, general partner or trustee</TD></TR>
</TABLE><BR STYLE="clear: both">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 48%; border-bottom: Black 1pt solid; text-align: center">Name of Equity Owner</TD>
    <TD NOWRAP STYLE="width: 4%; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 48%; border-bottom: Black 1pt solid; text-align: center">Type of Accredited Investor<SUP>1</SUP></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="width: 97%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">6.</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">7.</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">8.</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">9.</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">10.</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>1</SUP>&#9;<FONT STYLE="font-size: 10pt">Indicate which
Subparagraph of 8.1 - 8.3 the equity owner satisfies.</FONT></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 15; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.25
<SEQUENCE>4
<FILENAME>v412118_ex10-25.htm
<DESCRIPTION>EXHIBIT 10.25
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 10.25</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="ex10-25logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">May 7, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CONFIDENTIAL</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Hojabr Alimi</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ruthigen, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2455 Bennett Valley Rd., Suite C116</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Santa Rosa, California 95404</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Re:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>PIPE Offering</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Hojabr:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The purpose of this engagement
letter is to outline our agreement pursuant to which Dawson James Securities, Inc. <B>(</B>&ldquo;<B><U>Dawson</U>&rdquo;) </B>will
act as the lead or managing placement agent on a best efforts, agency basis in connection with the proposed PIPE (Private Placement
Into Public Equity) offering (the <B>&ldquo;<U>Offering</U>&rdquo;) </B>pursuant to Rule 506 of Regulation D primulgated under
the Securities Act of 1933 (the <B>&ldquo;<U>Securities Act</U>&rdquo;) </B>and limited to &ldquo;accredited investors&rdquo; (as
that term is defined under Rule 501 of Regulation D by Ruthigen, Inc. (collectively, with its subsidiaries and affiliates, the
&ldquo;<B><U>Company</U>&rdquo;) </B>of<B> </B>its equity or equity-linked securities<B>. </B>This engagement letter (this <B>&ldquo;<U>Agreement</U>&rdquo;</B>)
sets forth certain conditions and assumptions upon which the Offering is premised. However, except as expressly provided herein,
this engagement letter is not intended to be a binding legal document, as the agreement between the parties hereto on the matters
relating to the Offering will be embodied in the Placement Agency Agreement (as defined below). The terms of the Offering and the
Securities (as defined below) shall be mutually agreed upon by the Company and the investors and nothing herein implies that Dawson
would have the power or authority to bind the Company or an obligation for the Company to issue any Securities or complete the
Offering. The Company expressly acknowledges and agrees that the execution of this Agreement does not constitute a commitment by
Dawson to purchase the Securities and does not ensure the successful placement of the Securities or any portion thereof or the
success of Dawson with respect to securing any other financing on behalf of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The terms of our agreement in principle are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B><U>Engagement</U></B>.
The Company hereby engages Dawson, for the period beginning on the date hereof and ending five business days before the closing
of the merger described in the Company&rsquo;s S-4 Registration Statement filed with the Securities and Exchange Commission on
April 15, 2015 (the &ldquo;<B><U>S-4</U></B>&rdquo;) (&ldquo;<B><U>Merger</U></B>&rdquo;), unless sooner terminated pursuant to
the terms of this engagement letter (the &ldquo;<B><U>Engagement Period</U>&rdquo;), </B>to act as the Company&rsquo;s exclusive
financial advisor, lead or managing placement agent and/or book runner and investment banker in connection with the proposed Offering
or any other financing. During the Engagement Period or until the consummation of the Offering, and as long as Dawson is proceeding
in good faith with preparations for the Offering, the Company agrees not to solicit, negotiate with or enter into any agreement
with any other source of financing (whether equity, debt or otherwise; whether private or public), any underwriter, potential underwriter,
placement agent, financial advisor, investment banking firm or any other person or entity in connection with an offering of the
Company&rsquo;s debt or equity securities or any other financing by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 100%; border-top: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">1 North Federal Highway <FONT STYLE="color: navy"><B>&bull; </B></FONT>Suite
                                                         500 <FONT STYLE="color: navy"><B>&bull; </B></FONT>Boca Raton, FL 33432 &bull; Toll Free 866.928.0928 &bull; Main
                                                         561.391.5555 &bull; Fax 561.391.5757 &bull;&nbsp;www.dawsonjames.com <FONT STYLE="font-family: Times New Roman, Times, Serif; color: navy"> </FONT>Member
                                                         FINRA/SIPC</P>
                            <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B><U>The
Offering</U></B>. The Offering, the closing of which is not contingent on the closing of the Merger, will consist of the
offer for sale of up to 948,555 shares of common stock at not less than $2.75 pre share (the
&ldquo;<B><U>Securities</U>&rdquo;)</B>. The purpose of the Offering is to enable the Company to satisfy its net cash
requirements as described in a certain Merger Agreement filed as an exhibit to the S-4. It is understood that the net
proceeds to the Company after deduction and payment of all offering and related expenses must be not less than $2,100,000.
The Offering proceeds will be held in escrow and will be released contemporaneously with the closing of the Merger (as
described in the Merger Agreement). Dawson will act as the lead or managing placement agent for the Offering, subject to,
among other matters referred to herein and additional customary conditions, completion of Dawson&rsquo;s due diligence
examination of the Company and its affiliates, and the execution of a Placement Agency Agreement between the Company and
Dawson in connection with the Offering (the &ldquo;<B><U>Placement Agency Agreement</U>&rdquo;). </B>Dawson may: (i) with the
Company&rsquo;s approval (not to be unreasonably withheld, conditioned or delayed), create selling group for the
Offering comprised of broker-dealers who are members of the Financial Industry Regulatory Authority (&ldquo;<B>FINRA&rdquo;), </B>(ii)
rely on soliciting dealers who are FINRA members to participate in placing a portion of the Offering, and/or (iii) offer
Securities in foreign jurisdictions. The actual size of the Offering, the precise number of Securities to be offered by the
Company and the offering price will be the subject of continuing negotiations between the Company and Dawson and will depend
upon, among other factors: (i) the capitalization of the Company at the time of the Offering, (ii) market and general
economic conditions and changes in the prospects and/or forecasts of the Company, (iii) the preparation and Dawson&rsquo;s
review of the Company&rsquo;s financial statements, (iv) Dawson&rsquo;s determination of the Company&rsquo;s pre-money
valuation (based upon the information provided to Dawson by the Company) and (v) other factors determined by Dawson. The
Company shall be responsible for any and all compliance with the securities laws applicable to it, including Regulation D and
the Securities Act, and Rule 506 promulgated thereunder, and unless otherwise agreed in writing, all state securities
(&ldquo;blue sky&rdquo;) laws. Dawson agrees to cooperate with counsel to the Company in that regard.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B><U>Placement
Agent Compensation</U></B>. The Company will pay to Dawson a placement agent fee of 8% of the gross proceeds received in the Offering.
Dawson will also be entitled to a non-accountable expense allowance equal to 1% of the gross proceeds received in the Offering.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B><U>Private
Placement Memorandum</U>. </B>The Company will, as soon as practicable following the date of this Agreement, prepare a private
placement memorandum (the &ldquo;<B><U>Private Placement Memorandum</U></B>&rdquo;) covering the private offer and sale of the
Securities to be offered and sold in the Offering. The Private Placement Memorandum, and all amendments and supplements thereto,
will be in form reasonably satisfactory to Dawson and counsel to Dawson and will contain: (i) all audited financial statements
of the Company and such interim and other financial statements and schedules as may be required by the Securities Act and rules
and regulations promulgated thereunder, including without limitation Regulation D, and (ii) a description of the business of the
Company and such other disclosures regarding the Company and its officers and directors as may be required by the Securities Act
and rules and regulations of the Securities and Exchange Commission (the &ldquo;<B><U>Commission</U>&rdquo;) </B>thereunder. The
Company will be solely responsible for the contents of its Private Placement Memorandum and any and all other written or oral communications
provided by or on behalf of the Company to any actual or prospective investor of the Securities, and the Company represents and
warrants that such materials and such other communications will not, as of the date of the offer or sale of the Securities, contain
any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to
make the statements therein, in light of the circumstances under which they were made, not misleading. If at any time prior to
the completion of the offer and sale of the Securities an event occurs which would cause the Private Placement Memorandum (as supplemented
or amended) to contain an untrue statement of a material fact or to omit to state a material fact necessary in order to make the
statements therein, in light of the circumstances under which they were made, not misleading, the Company will notify Dawson immediately
of such event and Dawson will suspend solicitations of the prospective purchasers of the Securities until such time as the Company
shall prepare a supplement or amendment to the Private Placement Memorandum which corrects such statement or omission. The Private
Placement Memorandum will include a description of the Placement Agency Agreement. The Placement Agency Agreement will be in form
satisfactory to Dawson and will include indemnification provisions and other terms and conditions customarily found in placement
agency agreements for PIPE offerings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B><U>Left
Blank Intentionally</U></B> </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B><U>Left
Blank Intentionally</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B><U>Expenses</U></B>.
The Company will be responsible for and will pay all expenses relating to the Offering, including, without limitation, (a) all
filing fees and expenses relating to the registration of the Securities with the Commission; (b) all fees and expenses relating
to the listing of the Company&rsquo;s common stock on the Nasdaq Stock Market or the NYSE MKT or on such other stock exchanges
as the Company and Dawson together determine; (c) all fees, expenses and disbursements relating to background checks of the Company&rsquo;s
officers and directors; (d) all fees, expenses and disbursements required under the &ldquo;blue sky&rdquo; securities laws of such
states and other jurisdictions as Dawson may reasonably designate; (e) all fees, expenses and disbursements relating to the registration,
qualification or exemption of the Securities under the securities laws of such foreign jurisdictions as Dawson may reasonably designate;
(f) the costs of all mailing and printing of the Offering documents; (g) the costs associated with bound volumes of the offering
materials as well as commemorative mementos and lucite tombstones, each of which the Company or its designee will provide within
a reasonable time after the Closing in such quantities as Dawson may reasonably request; (h) the fees and expenses of the Company&rsquo;s
accountants; (i) the fees and expenses of the Company&rsquo;s legal counsel and other agents and representatives; and (j) up to
$25,000 of Dawson&rsquo;s legal and additional diligence expenses not covered by the provisions and terms of this Section 6 herein.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B><U>Left
Blank Intentionally</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B><U>Left
Blank Intentionally</U></B> </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B><U>Survival</U>.
</B>Except as provided in Paragraphs 1, 9, 10, 11, 13, 14, 15, and 16 hereof (which Paragraphs are intended to be legally binding
and enforceable on and against the Company and Dawson), this engagement letter is not intended to be a binding legal document nor
a legal commitment on the part of Dawson to provide any financing to the Company, as the agreement between the parties hereto on
these matters will be embodied in the Placement Agency Agreement. Until the Placement Agency Agreement has been finally negotiated
and signed, the Company or Dawson may at any time terminate their further participation in the proposed transactions contemplated
hereby and the engagement by the Company of Dawson, and the party so terminating will have no liability to the other on account
of any matters provided for herein, except as provided for in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B><U>Termination</U>.
</B>Regardless of which party elects to terminate their further participation in the proposed transactions contemplated hereby
and the engagement by the Company of Dawson, upon such termination, the Company will reimburse Dawson for, or otherwise pay and
bear, the expenses and fees to be paid and borne by the Company as provided for in Paragraph 6 above and to reimburse Dawson for
the full amount of its actual accountable expenses incurred to such date for all such expenses (which expenses will include, but
will not be limited to, all reasonable fees and disbursements of Dawson&rsquo;s counsel, travel, lodging and other &ldquo;road
show&rdquo; expenses, mailing, printing and reproduction expenses, and any expenses incurred by Dawson in conducting its due diligence,
including background checks of the Company&rsquo;s officers and directors), less amounts, if any, previously paid to Dawson in
reimbursement for such expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B><U>No
Other Agreements</U>. </B>The Company represents and warrants to Dawson that the entry into this engagement letter or any other
action of the Company in connection with the proposed Offering will not violate any agreement between the Company and any other
broker-dealer, underwriter or financial advisor.</FONT><FONT STYLE="font: 9pt Sans-Serif; color: Red"><B></B></FONT><FONT STYLE="font-size: 10pt">
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B><U>Publicity</U></B>.
The Company agrees that it will not issue press releases or engage in any other publicity, without Dawson&rsquo;s prior written
consent (which shall not be unreasonably withheld), commencing on the date hereof and continuing for a period of thirty (30) days
from final Closing of the Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B><U>Information</U></B>.
During the Engagement Period or until the final Closing, the Company agrees to cooperate with Dawson and to furnish, or
cause to be furnished, to Dawson, any and all information and data concerning the Company, and the Offering that Dawson deems
appropriate (the &ldquo;<B><U>Information</U>&rdquo;). </B>The Company will provide Dawson reasonable access during normal
business hours from and after the date of execution of this engagement letter until the date of the Closing to all of the
Company&rsquo;s assets, properties, books, contracts, commitments and records and to the Company&rsquo;s officers, directors,
employees, appraisers, independent accountants, legal counsel and other consultants and advisors. Except as contemplated by
the terms hereof or as required by applicable law, Dawson will keep strictly confidential all non-public Information
concerning the Company provided to Dawson. No obligation of confidentiality will apply to Information that: (a) is in the
public domain as of the date hereof or hereafter enters the public domain without a breach by Dawson, (b) was known or became
known by Dawson prior to the Company&rsquo;s disclosure thereof to Dawson as demonstrated by the existence of its written
records, (c) becomes known to Dawson from a source other than the Company, and other than by the breach of an obligation of
confidentiality owed to the Company, (d) is disclosed by the Company to a third party without restrictions on its disclosure
or (e) is independently developed by Dawson.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B><U>No
Third Party Beneficiaries; No Fiduciary Obligations</U></B>. This engagement letter does not create, and shall not be construed
as creating rights enforceable by any person or entity not a party hereto, except those entitled hereto by virtue of the indemnification
provisions hereof. The Company acknowledges and agrees that: (i) Dawson is not and shall not be construed as a fiduciary of the
Company and shall have no duties or liabilities to the equity holders or the creditors of the Company or any other person by virtue
of this engagement letter or the retention of Dawson hereunder, all of which are hereby expressly waived; and (ii) Dawson is a
full service securities firm engaged in a wide range of businesses and from time to time, in the ordinary course of its business,
Dawson or its affiliates may hold long or short positions and trade or otherwise effect transactions for its own account or the
account of its customers in debt or equity securities or loans of the companies which may be the subject of the transactions contemplated
by this Agreement. During the course of Dawson engagement with the Company, Dawson may have in its possession material, non-public
information regarding other companies that could potentially be relevant to the Company or the transactions contemplated herein
but which cannot be shared due to an obligation of confidence to such other companies. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B><U>Indemnification,
Advancement &amp; Contribution</U>. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) &#9;<U>Indemnification</U>.
The Company agrees to indemnify and hold harmless Dawson, its affiliates and each person controlling Dawson (within the meaning
of Section 15 of the Securities Act), and the directors, officers, agents and employees of Dawson, its affiliates and each such
controlling person (Dawson, and each such entity or person hereafter is referred to as an &ldquo;<B><U>Indemnified Person</U></B>&rdquo;)
from and against any losses, claims, damages, judgments, assessments, costs and other liabilities (collectively, the &ldquo;<B><U>Liabilities</U></B>&rdquo;),
and shall reimburse each Indemnified Person for all fees and expenses (including the reasonable fees and expenses of counsel for
the Indemnified Persons) (collectively, the &ldquo;<B><U>Expenses</U></B>&rdquo;) and agrees to advance payment of such Expenses
as they are incurred by an Indemnified Person in investigating, preparing, pursuing or defending any actions, whether or not any
Indemnified Person is a party thereto, arising out of the Offering or based upon or arising out of alleged any untrue statement
or alleged untrue statement of a material fact contained in (i) the Private Placement Memorandum, or any other offering documents
(as from time to time each may be amended and supplemented); (ii) any materials or information provided to investors by, or with
the approval of, the Company in connection with the marketing of the Offering, including any &ldquo;road show&rdquo; or investor
presentations made to investors by the Company (whether in person or electronically); or (iii) any application or other document
or written communication (collectively called &ldquo;application&rdquo;) executed by the Company or based upon written information
furnished by the Company in any jurisdiction in order to qualify the Securities under the securities laws thereof or to file for
an exemption from such requirement or filed with the Commission, any state securities commission or agency, any national securities
exchange; or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the
statements therein, in the light of the circumstances under which they were made, not misleading, unless such statement or omission
was made in reliance upon, and in conformity with, information provided to the Company by Dawson in writing specifically for use
in the Private Placement Memorandum, or any other offering documents. The Company also agrees to advance and to reimburse each
Indemnified Person for all Expenses as they are incurred in connection with such Indemnified Person&rsquo;s enforcement of his
or its rights under this Section 15.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Procedure</U>.
Upon receipt by an Indemnified Person of actual notice of an action against such Indemnified Person with respect to which indemnity
may reasonably be expected to be sought under this Section 15, such Indemnified Person shall promptly notify the Company in writing;
provided that failure by any Indemnified Person so to notify the Company shall not relieve the Company from any obligation or liability
which the Company may have on account of this Section 15 or otherwise to such Indemnified Person. The Company shall, if requested
by Dawson, assume the defense of any such action (including the employment of counsel designated by Dawson and reasonably satisfactory
to the Company). Any Indemnified Person shall have the right to employ separate counsel in any such action and participate in the
defense thereof, but the fees and expenses of such counsel shall be at the expense of such Indemnified Person unless: (i) the Company
has failed promptly to assume the defense and employ separate counsel designated by Dawson for the benefit of Dawson and the other
Indemnified Persons or (ii) such Indemnified Person shall have been advised that in the opinion of counsel that there is an actual
or potential conflict of interest that prevents (or makes it imprudent for) the counsel designated by Dawson and engaged by the
Company for the purpose of representing the Indemnified Person, to represent both such Indemnified Person and any other person
represented or proposed to be represented by such counsel. The Company shall not be liable for any settlement of any action effected
without its written consent (which shall not be unreasonably withheld). In addition, the Company shall not, without the prior written
consent of Dawson, settle, compromise or consent to the entry of any judgment in or otherwise seek to terminate any pending or
threatened action in respect of which advancement, reimbursement, indemnification or contribution may be sought hereunder (whether
or not such Indemnified Person is a party thereto) unless such settlement, compromise, consent or termination (i) includes an unconditional
release of each Indemnified Person, acceptable to such Indemnified Party, from all Liabilities arising out of such action for which
indemnification or contribution may be sought hereunder and (ii) does not include a statement as to or an admission of fault, culpability
or a failure to act, by or on behalf of any Indemnified Person. The advancement, reimbursement, indemnification and contribution
obligations of the Company required hereby shall be made by periodic payments of the amount thereof during the course of the investigation
or defense, as every Liability and Expense is incurred and is due and payable, and in such amounts as fully satisfy each and every
Liability and Expense as it is incurred (and in no event later than 30 days following the date of any invoice therefore).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Contribution</U>.
In the event that a court of competent jurisdiction makes a finding that indemnity is unavailable to an Indemnified Person, the
Company shall contribute to the Liabilities and Expenses paid or payable by such Indemnified Person in such proportion as is appropriate
to reflect (i) the relative benefits to the Company, on the one hand, and to Dawson and any other Indemnified Person, on the other
hand, of the matters contemplated by this Section 15 or (ii) if the allocation provided by the immediately preceding clause is
not permitted by applicable law, not only such relative benefits but also the relative fault of the Company, on the one hand, and
Dawson and any other Indemnified Person, on the other hand, in connection with the matters as to which such Liabilities or Expenses
relate, as well as any other relevant equitable considerations; provided that in no event shall the Company contribute less than
the amount necessary to ensure that all Indemnified Persons, in the aggregate, are not liable for any Liabilities and Expenses
in excess of the amount of commissions actually received by Dawson in the Offering. The relative fault shall be determined by reference
to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to
state a material fact relates to information supplied by the Company on the one hand or Dawson on the other and the parties&rsquo;
relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The Company
and Dawson agree that it would not be just and equitable if contributions pursuant to this subsection (c) were determined by pro
rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to above
in this subsection (c). For purposes of this paragraph, the relative benefits to the Company, on the one hand, and to Dawson on
the other hand, of the matters contemplated by this Section 15 shall be deemed to be in the same proportion as: (a) the total value
received by the Company in the Offering, whether or not such Offering is consummated, bears to (b) the commissions paid to Dawson
under this Agreement. Notwithstanding the above, no person guilty of fraudulent misrepresentation within the meaning of Section
11(f) of the Securities Act shall be entitled to contribution from a party who was not guilty of fraudulent misrepresentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Limitation</U>.
The Company also agrees that no Indemnified Person shall have any liability (whether direct or indirect, in contract or tort or
otherwise) to the Company for or in connection with advice or services rendered or to be rendered by any Indemnified Person pursuant
to this engagement letter, the transactions contemplated thereby or any Indemnified Person&rsquo;s actions or inactions in connection
with any such advice, services or transactions, except to the extent that a court of competent jurisdiction has made a finding
that Liabilities (and related Expenses) of the Company have resulted exclusively from such Indemnified Person&rsquo;s gross negligence
or willful misconduct in connection with any such advice, actions, inactions or services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B><U>Governing
Law; Venue</U></B>. This engagement letter will be deemed to have been made and delivered in the State of Florida and both
the binding provisions of this Agreement and the transactions contemplated hereby and by the Underwriting Agreement will be
governed as to validity, interpretation, construction, effect and in all other respects by the internal laws of the State of
Florida, without regard to the conflict of laws principles thereof. Each of Dawson and the Company: (i) agrees that any legal
suit, action or proceeding arising out of or relating to this engagement letter and/or the transactions contemplated hereby
will be instituted exclusively in the courts located in the county of Palm Beach, Florida (ii) waives any objection which it
may have or hereafter to the venue of any such suit, action or proceeding, and (iii) irrevocably consents to the jurisdiction
of the courts located in the county of Palm Beach, Florida, in any such suit, action or proceeding. Each of Dawson and the
Company further agrees to accept and acknowledge service of any and all process which may be served in any such suit, action
or proceeding in such courts and agrees that service of process upon the Company mailed by certified mail to the
Company&rsquo;s address will be deemed in every respect effective service of process upon the Company, in any such suit,
action or proceeding, and service of process upon Dawson mailed by certified mail to Dawson&rsquo;s address will be deemed in
every respect effective service process upon Dawson, in any such suit, action or proceeding. Notwithstanding any provision of
this engagement letter to the contrary, the Company agrees that neither Dawson nor its affiliates, and the respective
officers, directors, employees, agents and representatives of Dawson, its affiliates and each other person, if any,
controlling Dawson or any of its affiliates, will have any liability (whether direct or indirect, in contract or tort or
otherwise) to the Company for or in connection with the engagement and transaction described herein except for any such
liability for losses, claims, damages or liabilities incurred by the Company that are finally judicially determined to have
resulted from the bad faith or gross negligence of such individuals or entities. Dawson will act under this engagement letter
as an independent contractor with duties to the Company. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">If you are in agreement
with the foregoing, please sign and return to us one copy of this engagement letter together with a payment to Dawson James Securities,
Inc. in the amount of the Advance. This engagement letter may be executed in counterparts (including facsimile or .pdf counterparts),
each of which shall be deemed an original but all of which together shall constitute one and the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</td>
    <TD STYLE="width: 50%; text-align: justify"><font style="font-size: 10pt">Very truly yours,</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">DAWSON JAMES SECURITIES, INC.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</td>
    <TD STYLE="width: 4%; text-align: justify"><font style="font-size: 10pt">By </font></td>
    <TD STYLE="width: 46%; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">Name:</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">Title:</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify"><font style="font-size: 10pt">Accepted and agreed as of</font></td>
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">the date first written above:</font></td>
    <TD STYLE="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">RUTHIGEN<font style="text-transform: uppercase">, Inc.</font></font></td>
    <TD STYLE="text-align: justify">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 4%; text-align: justify"><font style="font-size: 10pt">By </font></td>
    <TD STYLE="width: 46%; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</td>
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">Name:</font></td>
    <TD STYLE="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">Title:</font></td>
    <TD STYLE="text-align: justify">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.26
<SEQUENCE>5
<FILENAME>v412118_ex10-26.htm
<DESCRIPTION>EXHIBIT 10.26
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>EXHIBIT 10.26</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMENDMENT NO. 1 to</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES PURCHASE <FONT STYLE="text-transform: uppercase">Follow-Up</FONT>
AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This AMENDMENT NO. 1, dated as of June
__, 2015 (the &ldquo;<B>Amendment</B>&rdquo;), to the SECURITIES PURCHASE FOLLOW-UP AGREEMENT (the &ldquo;<B>Follow-Up</B> <B>Agreement</B>&rdquo;),
dated as of March 12, 2015, by and among Oculus Innovative Sciences, Inc., a Delaware corporation, with its principal place of
business at 1129 N. McDowell Blvd., Petaluma, CA 94954 (the &ldquo;<B>Seller</B>&rdquo;), Michael Brauser and Barry Honig or their
respective assignee(s) (collectively, the &ldquo;<B>Buyer</B>&rdquo;), Ruthigen, Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;)
and Dawson James Securities, Inc. (the &ldquo;<B>Underwriter</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WHEREAS, reference is made to that certain
Securities Purchase Agreement between the Parties hereto, dated January 8, 2015 (the &ldquo;Securities Purchase Agreement&rdquo;)
which expired according to its terms;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WHEREAS, reference is made to that certain
Securities Purchase Follow-Up Agreement between the Parties hereto, dated March 12, 2015 (the &ldquo;Follow-Up Agreement&rdquo;)
which incorporated all terms of the Securities Purchase Agreement, as if it had not expired, and amended the Securities Purchase
Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WHEREAS, on March 12, 2015 the Company,
Ruthigen Merger Corp., a wholly owned subsidiary of the Company (&ldquo;Merger Sub&rdquo;), and Pulmatrix Inc. (&ldquo;Pulmatrix&rdquo;)
entered into an agreement and plan of merger (the &ldquo;Merger Agreement&rdquo;) which provides for, among other things, the merger
of Pulmatrix with and into Merger Sub, with Pulmatrix continuing as the surviving corporation and a wholly owned subsidiary of
the Company, on the terms and conditions set forth in the Merger Agreement, such merger defined as Event and such Merger Agreement
defined as Event Definitive Agreement in the Securities Purchase Agreement. The boards of directors of each of the Company and
Pulmatrix have unanimously approved the Merger Agreement and the transactions contemplated by the Merger Agreement, including the
merger;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WHEREAS, on June 12, 2015, the Company
will hold a special shareholders&rsquo; meeting to consider and approve the merger and the Merger Agreement, among others, following
which the Merger Agreement is expected to close, subject to certain closing conditions, as further described in the Joint Proxy
and Consent Solicitation Statement/Prospectus on Form 424(b)(3) filed with the SEC on May 4, 2015, such closing defined as Event
Closing in the Securities Purchase Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WHEREAS, the Parties wish to amend the
Follow-Up Agreement as follows;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WHEREAS, Section 9(b) of the Securities
Purchase Agreement, as incorporated, provides that it may be amended only with the written consent of Seller and Buyer, and with
respect to Sections 4 and 9 of the Securities Purchase Agreement only with written consent of the Company and the Underwriter;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WHEREAS, Section 10 of the Follow-Up Agreement
provides that it may be amended only with written consent of all parties;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NOW, THEREFORE, for and in consideration
of the premises, the mutual agreements and covenants herein contained, and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="text-transform: uppercase">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase">AMENDMENT TO
SECTION 5.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following section
is added to Section 5:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Section 5(e): In the event that
the Buyer pre-pays the Purchase Price prior to Closing (the &ldquo;Prepaid Purchase Price&rdquo;), the Seller shall hold the Prepaid
Purchase Price, without any obligation to pay interest, subject to the Event Closing upon which the Prepaid Purchase Price shall
be retained by the Company and be treated as the Purchase Price, provided that it is received in full. However, Seller shall not
be obligated to deliver the Shares prior to the Closing Date. In case the Seller did not receive the entire Purchase Price prior
to Closing, Buyer shall be obligated to pay the difference between the Prepaid Purchase Price and the Purchase Price on the Closing
Date as set forth in Section 5(b) of the Securities Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">If the Event Closing is not consummated
within seven (7) Business Days of June 12, 2015, the Company shall return the Prepaid Purchase Price free of interest to the Buyer,
only upon written request and instructions from the Buyer within three (3) calendar days of receipt of such written request in
immediately available funds. Buyer is responsible for all bank fees related to any transfers of funds and Seller may deduct reasonable
and actual fees from funds returned to Buyer. In no event, shall the return of any part of the Prepaid Purchase Price relieve the
Buyer from its obligations under the Securities Purchase Agreement and the Follow-Up Agreement as amended. Seller reserves the
right to sell the Shares to Buyer until the Expiration Date, as may be extended by Seller at its sole discretion pursuant to Section
5(d). For purposes of clarity, whether or not funds are prepaid or prepaid funds are returned, the Buyer(s) remain obligated to
purchase the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase">CONSENT TO SALE OF THE SHARES PURSUANT TO SEPARATION AGREEMENT.
</FONT>Pursuant to Section 2.1 of that certain Amended Separation Agreement between the Seller and the Company, dated January 31,
2014, the consent of the Underwriter and the board of directors of the Company is required for the sale of the Shares in accordance
with the terms of this Amendment. Now, therefore, subject to and contingent upon an Event Closing, the Underwriter and the Company
hereby consent to the Purchase (the &ldquo;<B>Consent</B>&rdquo;), which Consent shall become effective only upon the occurrence
of an Event Closing, if at all. The Company and Underwriter further warrant that all necessary corporate actions and approvals
by their respective boards of directors have been obtained in order to provide the Consent.<FONT STYLE="text-transform: uppercase">
</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase">Effect of this AMENDMENT</FONT>. Except as specifically
amended as set forth herein, each term and condition of the Securities Purchase Agreement and Follow-Up Agreement shall continue
in full force and effect.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase">Governing Law. </FONT>This Amendment shall be governed
by and construed in accordance with the laws in force in the State of California, without giving effect to the choice of laws provisions
thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase">5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase">Counterparts; Facsimile Signatures. </FONT>This Amendment
may be executed or consented to in counterparts, each of which shall be deemed an original and all of which taken together shall
constitute one and the same instrument. This Amendment may be executed and delivered by facsimile or electronically and, upon such
delivery, the facsimile or electronically transmitted signature will be deemed to have the same effect as if the original signature
had been delivered to the other party.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase">6.</FONT></TD><TD STYLE="text-align: justify">MUTUAL AGREEMENT TO AMEND. This Amendment can only be amended by written consent of all parties.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page Follows.]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IN WITNESS WHEREOF, this Amendment No.
1 to the Securities Purchase Follow-Up Agreement has been executed by each of the parties hereto on the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">OCULUS INNOVATIVE SCIENCES, INC.</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</TD></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify; width: 50%">&nbsp;</td>
    <TD STYLE="width: 5%">&nbsp;</td>
    <TD STYLE="width: 35%">&nbsp;</td>
    <TD STYLE="width: 5%">&nbsp;</td>
    <TD STYLE="width: 5%">&nbsp;</TD></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD><font style="font-family: Times New Roman, Times, Serif">By:</font></td>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</td>
    <TD>&nbsp;</TD></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</TD></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD><font style="font-family: Times New Roman, Times, Serif">Name:</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif">Jim Schutz</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</TD></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</TD></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD><font style="font-family: Times New Roman, Times, Serif">Title:</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif">Chief Executive Officer</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</TD></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</TD></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">MICHAEL BRAUSER</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</TD></tr>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</TD></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</TD></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">BARRY HONIG</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</TD></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</TD></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</TD></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</TD></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">DAWSON JAMES SECURITIES, INC.</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</TD></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</TD></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD><font style="font-family: Times New Roman, Times, Serif">By:</font></td>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</td>
    <TD>&nbsp;</TD></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</TD></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD><font style="font-family: Times New Roman, Times, Serif">Name:</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif">Robert D. Keyser, Jr.</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</TD></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</TD></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD><font style="font-family: Times New Roman, Times, Serif">Title:</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif">Chief Executive Officer</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</TD></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</TD></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">RUTHIGEN, INC.</FONT></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</TD></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</TD></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD><font style="font-family: Times New Roman, Times, Serif">By:</font></td>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</td>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</td>
    <TD>&nbsp;</TD></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</TD></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD><font style="font-family: Times New Roman, Times, Serif">Name:</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif">Hoji Alimi</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</TD></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</TD></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</td>
    <TD><font style="font-family: Times New Roman, Times, Serif">Title:</font></td>
    <TD><font style="font-family: Times New Roman, Times, Serif">Chief Executive Officer</font></td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</TD></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>6
<FILENAME>v412118_ex21.htm
<DESCRIPTION>EXHIBIT 21
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><B><U>Exhibit 21</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>SUBSIDIARY LIST</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; text-decoration: none">
    <TD NOWRAP STYLE="width: 25%; text-decoration: none; border-bottom: Black 1pt solid"><B>Name of Subsidiary</B></TD>
    <TD NOWRAP STYLE="width: 1%; text-decoration: none; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 74%; text-decoration: none; border-bottom: Black 1pt solid"><B>Jurisdiction of Incorporation/Organization</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Ruthigen Merger Corp.</TD>
    <TD>&nbsp;</TD>
    <TD>Delaware</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>7
<FILENAME>v412118_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><U>Exhibit 23.1</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><U>Independent
Registered Public Accounting Firm&rsquo;s Consent</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We consent to the incorporation
by reference in the Registration Statement of Ruthigen, Inc. on Form S-8<B> </B>(File No. 333-195737)<B> </B>of our report
dated June 9, 2015 with respect to our audits of the consolidated financial statements of Ruthigen, Inc. and Subsidiary as of
March 31, 2015 and 2014 and for the years then ended, which report is included in this Annual Report on Form 10-K of
Ruthigen, Inc. for the year ended March 31, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Marcum <FONT STYLE="font-variant: small-caps">llp</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Marcum <FONT STYLE="font-variant: small-caps">llp</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">June 9, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>8
<FILENAME>v412118_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><U>Exhibit 31.1</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATIONS UNDER SECTION 302</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Hojabr Alimi, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">1.</TD><TD>I have reviewed this Annual Report on Form 10-K of Ruthigen, Inc.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">2.</TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">3.</TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">4.</TD><TD>The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">a)</TD><TD>designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">b)</TD><TD>designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">c)</TD><TD>evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">d)</TD><TD>disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the
registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">5.</TD><TD>The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
(or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">a)</TD><TD>all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
information; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">b)</TD><TD>any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: June 9, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Hojabr Alimi</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Hojabr Alimi</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Chief Executive Officer, Chief Science Officer and Chairman of the Board of Directors</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>(Principal Executive Officer)</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>9
<FILENAME>v412118_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><U>Exhibit 31.2</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATIONS UNDER SECTION 302</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Sameer Harish, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">1.</TD><TD>I have reviewed this Annual Report on Form 10-K of Ruthigen, Inc.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">2.</TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">3.</TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">4.</TD><TD>The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -18.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.8pt"></TD><TD STYLE="width: 18.2pt">a)</TD><TD>designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -18.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.8pt"></TD><TD STYLE="width: 18.2pt">b)</TD><TD>designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -18.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.8pt"></TD><TD STYLE="width: 18.2pt">c)</TD><TD>evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -18.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.8pt"></TD><TD STYLE="width: 18.2pt">d)</TD><TD>disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the
registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">5.</TD><TD>The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
(or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -18.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.8pt"></TD><TD STYLE="width: 18.2pt">a)</TD><TD>all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
information; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -18.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.8pt"></TD><TD STYLE="width: 18.2pt">b)</TD><TD>any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: June 9, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Sameer Harish</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Sameer Harish</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Financial Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal Financial and Accounting Officer)</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>10
<FILENAME>v412118_ex32.htm
<DESCRIPTION>EXHIBIT 32
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><U>Exhibit 32</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>CERTIFICATIONS UNDER
SECTION 906</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to section 906 of the Sarbanes-Oxley
Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers
of Ruthigen, Inc., a Delaware corporation (the &ldquo;Company&rdquo;), does hereby certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Annual Report of the Company for the
year ended March 31, 2015 (the &ldquo;Form 10-K&rdquo;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange Act of 1934, and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition
and results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 93%; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dated: June 9, 2015</FONT></TD>
    <TD STYLE="width: 60%; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Hojabr Alimi</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Hojabr Alimi</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Chief Executive Officer, Chief Science Officer and</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Chairman of the Board of Directors</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal Executive Officer)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dated: June 9, 2015</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Sameer Harish</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Sameer Harish</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Financial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal Financial Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ex10-25logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-25logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`6@%S`P$1``(1`0,1`?_$`-0``0`"`@(#`0$`````
M```````("08*!0<"`P0!"P$!``$%`0$!``````````````<!`@0%!@,("1``
M``8"`@$#`@,#"`0'$0```0(#!`4&!P@`$1(A$PDQ%$$B%5&!"F%QD3(C)!87
M\+9W&+'!,S2W.'C10E)R=)2T);4V=I8G9QDI.1$``0($!`,$!@0*!0D)`0``
M`0(#`!$$!2$Q$@9!40=A<2(3@9&A,A05L5(C"/#!T4)RLC-T%C9B@I)#).&B
M4[-4M#4F%_'"TG.#D\,T)0G_V@`,`P$``A$#$0`_`-_CB$.(1^#Z!RBM4O#+
M5VPCP\^Q\0#L0^O^@=\L\Q)P205\0#%2E0$Q*4=6WG.>',9BH7(.5L:TE1,I
MA,C;;S6Z\N`E#Z"A)R""_7?H/1!ZYFL4%SJDA=+2U#B.:4%0]8G&%47*W4@_
MQ#[2%=J@/QQ$"P[TUR6>&98CS-HO.N1,8&[6W;.NHERZ]1]LO410)-!%0WXA
MYJ%*/XCS?T^VJY("[A2W%"%#`H8*N^<RF-(=U6<DH;JJ76#@%.2G[(Q"3VWW
MDJT>I80T:I6=JBGT8TYK'M'5[F],CZF%1K7;?2Z@]D513#LJ:"IS&'T`?IS,
M38=NNJ\E5P<HZG"8JV"V)<]22N0[Y1>U>:UXSIV&JAKZS+R5I'8<)ZN,I'".
M$QQ\QVI=DM!,>9>2R3JQDH%BMG-/V(I,C2`1<B<$O`+`G^H0A$?<'H%5U6Z8
M_7OH0$<ZOZ8;I98-99S272W@`^;2.^:G21/(`*"DY*!&![XQ$;WL86&ZM984
M5%,U@A.H9B9`X\92BT6%L$/8HEC/0$M%3D+)HD<QTO#2+63BW[94/)-PRD&2
MB[1VB<![`R9S%']O(\>#E,[Y%4A33Q,@E8(5/DH$81U#3Z*AL.TRDNM\2@S'
MH/&.9*/90']H`/\`2'*XC!7O1[`@B8R,?O$5AQ"'$(<0AQ"'$(<0AQ"'$(<0
MAQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'
M$(<0AQ"'$(<0AQ"/$YO`AC=@'B43=C]`Z#OUZ]>4,Y89PDI6"?>.45_;V?)#
MKQH/36\ME*9//WZP-5EJ-B&KK-E[M:S)]D!ZHDLI[%=K22X>*TF\\42CV5(%
ME`]OG6;.V7?-[5@I;<@-L`R6XY@A([^9X#'T"-+=[Y1V=!\\@N@>Z./Y(U(,
MT?*W\A6^EW/CW$[FW42"L#@[>"PSKNTG%K&_9*#XE+8K5%H_XMFC^`?VZA5&
M+`H]C[12\^IK1THV)L*C35[D\IYX)F77%#RTJP(TI$I$RP))/.<1+<=S7Z\E
M3-O"T-E6&D'+UGG'>6&O@9WCRN5"RY3?T7$)9("NUSY"L3VYWA0%NS&4>1==
M+*E3<B'U(YD$U`'^L`>O,"MZ\;,L*O@+*RM]*"<&D(2D=LR)D=P],8"NFNY[
MT`Y7OI0V3/QZICT#$&)P17\..[39D_5]JFA7WB`'3C\1"LQ*(!Z@4[R[(KG#
MU^HE#^;FJ'WIZA*PANTE;(S!<0GZ6\?1&KNGW?A7-25<0T](R.A2L^4E"7MG
M'$D^$W=K7V5"XZM[8PZ<O'F%=LR92%NQ<^>J$\A(1<C5S8JW(>8#T*3LGL#]
M!YN6_O`]-MRMFAWMMU!:5+Q`-N:1*6J82E04)F4IRSB([M]VWJW9*H7?I]N1
M0JVQ/3J<;!(,Y:2HI.$L3W1F$YGN^(1C'`GS-:IM+-3GR@0L!L9&UE!1S!N%
M0%!*1&QU/S9"HGW[AG,0[:/`[$RC18.P#`I^G]DN3B[_`/=]O:DU[2=:[:ZX
M-;W%7D@@$G#%+DYXR4,HK2=9MW[4>3MK[QUC<%I<.A-V;9*FVR<!YR4"0`X+
M3(\2"!&"7/#6TOQ?LV^R6C.5GF?M+9GV;%-4J2>&M4-#5YV8%0=3L?''!%2&
M$A_;+88@K5RU-Z/$NBB)L>TUVR^JE0O:6_Z5%IZ@(5Y8>T^65.C"2]4Q,832
M93E,&.\OK^Y]@VEO?73FK^:[#4CS-"%>:GRSF4Z983GS(R,7?Z,[^8BWAQ\>
M>I:Q:S?J^T;?X\QA+.T5IVM+JE*4L@R6(*9)ZKNU1Z;OD2@'8>"I4U/R\A;J
M3TNW+TQNPM]W"7J%Q1+-2V/LGD\$@SP<`]X$YX@2B5^D_6/;G5JT*K;0H,W5
MD2>IG,'&E<5D3Q;)RECP)G$\0'L`']H`/(YB7AESC]XBL.(0XA#B$.(0XA#B
M$.(0XA#B$.(0XA#B$.(0XA#B$.(0XA#B$.(0XA#B$.(0XA#B$.(0XA#B$.(0
MXA#B$.(0XA#B$.(0XA#B$5Z?)5OU2?CVUOG,N3Z+2>O4\JI4L.T)5<$5KG?G
MC159J5R`""Z5<@&Y!>RBQ0[(W3!,H@JLD`]7L?:5PWK?!:J4$4[?B=7R;'O2
M[3D.V9X1H[_>Z>Q4*JIX^,I.@<U<(TN--=0=K?F6V4NV5\B7"63KJT\B^S-G
M6;:*.8^%*K_;,:#CZ)5$C%>6;QI2I1\6@)&<8T\57'0"4%?JK<NY]M](K`U:
M[<EIZO+?A;3B0>;AQ)EF2>/;$7V:V7+=58JNJR13J,YD<(WHM4=+=>--*&UH
MV#*`PKOD@D6PVYZ5.1O=R>ID*"DC:;0HF#Z045.7R*@04VB'?BDD0OISY&O^
MZKWNRM5775]:DSF$":4#N0,,.$\>V)<H+70VI`:HT)`EB3B3ZY^R)7`4`^G?
MH'7U_9S0%M),Q@KF,#&QG./P2%'ZAW^\>"VA7O8]\4'AGIPG'X*91`2CWT/U
M]1Y5*$(P2`!RX1843$IJ[YX^N.`LU0K%S@Y.LVV`B;-79EL=I*P<ZQ;2D3(-
ME2^!TG;%XFJW5*(#^)>P'U#H>95'5U=NJ6ZRVNN4]8TH*0XTHH6DCDI,CW\Q
M@8Q+G;+?>:)RVW9AJIH'D%#C;B0I*TG@H$$'L.8X17?#8(=:2626DL6%D;%J
M+='RW^9.%I$R\\;#B\J!D'=ZQZD[%TX>T4XKB$]#'\Q1:F%PCY`D<O)1NNZF
M.I-&S27HM4W4.G3JIJM*0W\:$8EA_3(!T#%#TIJ,DDXB/GJW[&JNBEU>J]J-
MNU/2>M5IK+?,N+H2O#XBF2LF=.5$EUO\T%2@#+"E/>/5RX_&]L+2MQ=3':D'
MBJW6`BS9A&J*.(&FV"5_OLA1I$B1C(/\;7UB"AF22@F(D;R2*("1N;GTATBW
MA;>M&TWNE6_-/SE*`AE:P$K`3X0M!$B'$D8J&*IS.<?*W7;9-YZ![NI.LO3=
M2Q8'WBX^E"E+;.LZBA05,%M0,D@X`2EE&R1JELK4MK,*U7+U0$C4)9$6%DKY
MEB+/:I;(\"HSE?>"'B)Q;./SH*"``LV434#T-T'R%U`V==>G>ZJK:]U25*IU
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MN9-M:5JHVEIG]4`'Q*C;?U:RW\;.JF$Z1@;$&S^LT74L=1H,W"JN9\;H34S.
MJ)@>=M-G,,\BLYL%@>F,X<G4#L!.!"])D(4/F2[6W?&X[@Y?:N@N#A==)F&#
MY8Y`$3DD<)8]F<291W#;EMI4T2*AI"P.)E,C.<Y1W<I\B&A2"@HJ[GZN)*%$
M0$A\Z8V*8!`>A`0&Q]@/?,/^$]VGQ?+*O_VU_P#AC(%_L8P%8Q_:'Y8R^K[I
M:@W=RFSI^TNO-G>*F*1)I"9EQY(.53G-XD(D@WL)U53F,/0`4!$1YB5=AW+0
MM^=56^J0R#(J4A:0/24@1ZM7NSO*"$5;!4<O&G\L21:.V[Y!-TT62<M5B%40
M<H*IKMUTS^I5$%T3J)*D$/H)1$.:W2I)(6%!7(\(V:2E20M*DJ2<B(]BRA42
M*+*'!-)),RBAS"`%(0@"8QC"/H`%*'8CWZ`'+3@H*)/*7.!.E)5P$15_W[-+
M"O'$8MMEKLUDFAC%=,'V8Z"Q>MQ*)BC[S5W.H+IE\BB'8EZ$0']G-HBP7ZM`
M-%25"T''4E"B#W2!C7KO-K:7H??:0YR*@#WXRC-\;;(:XYPF9*NXDS9B;*LS
M&LE7\M$4.^5JXN6<>15%HLY>-X.1?^TU*LZ(F<3@!?)0`'Z\\*VV7"W+`KF'
M&G#(>(%*AQXR(]$H,5EMN.IMAQ#LC.0,QE+AF.8Q'9'IS-K_`$C-.$;K@J>8
M((U2UUY["-$_'S"!<AYKP4E&%'U15K\F5)=L!1#VP2`@?E].;+;6X[CMS<=+
MN2E617TK^LB?OI!R5+@1@8YK>.Q[1N[9U;LZM2CY=5M%*,)AIPC!2>12<0/1
M&N;\2^3[-K3ME>-6<@.C,F%VGIFDO8]03`W891I2KQ*)?MDC=E3)/QK99KY>
MGN@=#OL0#GW)]X[;5#U$Z86WJ?8FP3;R'%+3FFG>DG0H\4I69XXC&/S(^Z;O
M2X=+NN5SZ-;B);M]P4ME`,PE553J/E.`?6?1.<C(R$A&UCS\_H_6V'*&<L,X
M12Y\T6XVTOQ]ZXEVAP1/8NG(AG?Z;19G'&1\?2DN04;4C*(%G(RTP5U@':3E
MO),DO)!9LJF9-0>C`)?S2'TSVM;=Z7Q5GN!?0VBF<>*FBG5]GI\,E@ID9X\>
M4<9O:]7';UL%PH=*E%Q*-*AA-4\9\Q+(X8QV91X/Y6+SC2E7QEM#IQ'RMQI]
M;MA(1UJMDE>*8&L4*RF4XT\FCL(1\N1L#P$A7!$@FZ\@3#OQY@/O[(IJYZC7
M1W%2&W5("@ZW/"8F?!+#EZ)QG,)W-4T3+Z7:9+JVDJ((,ID`RR]<HB)G?Y(/
MD6^.Y9C;-[-4\99BUI5D6D;.;(:;3UH(O2?O%DD$7MUQCD(SM]&)*J*@4AA>
MH-%%.DR.14,4@[^P;$VYO.H-#M6O?9OI!*6JTH#:\"9(4@`3!SG//"-%<-R[
MFV[]M>:-IRWD_M&R<!S5/*<YC+(Q=1KWL%B3:3$E1SA@ZY1U[QM=F(/82=CQ
M.0Y54A]F0BI5@N5-[#SD.](=N[9N"$706()3%^@C'ETM-RL=Q>M-V;+=<PLI
M4.!E^<F1,TG@9F<=M07"CNE(BMHEA;*Q/N/(]HY1UKO-LJPU#U-SWL2]]M5U
MC/'DQ*UEBL3W23%XD"$A:+"%;@(*.S2UMD6:(ID[,8AC<R-MV=_<.XZ2S-^%
M#S@!5V'/U`'TQB7NY"T6JIN)Q+200.W\.<8!\<&W`;R:3X.V'!Q'M[A<:@6-
MR*UC$B@Q@LHUA16O7ADBR$QA;M?U]DHY;HF,/359,.^A[YF[RL#NT=S5-B>\
M;;+DDJY@@*2?49=X,8VWKVC<-H:N#0T+4G$=H)!_+%7F[N_&^VFN^FHNM4S=
M<#RFO^V]M@:Y#9B?X;L#:XTUZXL["KV.!>QZ&325E_(L'$W'+MG(D33.B\_.
MEVD;R[3:6S+%N;:5VO?F/(NEJ8\PM`@AP8R,\P,#'-W_`'!?+-?*2B`:5;JQ
M00E9&*%3$Y\)X\8V)HU!^V8MT9)Z61?)-D$W+Y-L5D1XY31*1PZ*S(=4C0'"
MH"<$P.8"=]`(]=\B<RQX#Z(D092.<5BV7Y*:;7OE1Q[\<*B$8=S;L#35^D;(
M9RH5_&9-^Y_7ZM13)^?VI22N.HB0?F`P>Z*IVY2CT80'LZ395P>V`[O11DEN
MM#03GJ:QFYZ#('A,QRSNY:5O=*+!/Q*:G_6S'L]L6@/?>%HX!NK["YDC%16]
MHJ_LJG#Q(J*)C%*J"9A[$HB`&ZZ[#G%+U:24^\,>^6,O3E'5!)49)(![<HIG
MU3V1W6S]NYN/AQ[D'#QM:-0;Q5L>K9`C,1R;6]Y#R!-0$=9IVDBJKD-W6X=*
MF,EU4I%\@V5/[IT"E23$3B'?[@L^V[/MBTW)M50N_7-"EJ9_,92DZ9SD22K`
MB9EGCA')6FY76NO=6APM?*:9<L)3,N'$]IQCWX.V*VT^1=SE;(^M>7*/J_JY
M0,I7/#^.+@^Q3'YDRSFR<QX_"%MMY69V>P0U.HM$_6RJ(1K8K9](.RI&4551
M`0)SSN-KLFRT,TU^8=K+J\PEXH\TM)0A9P&H)4I1ER``PYQYT=RN6X"X];GD
M4M$AXH"E("RJ6<A.0X8_Y8D/JD_WDK&;LV8DVPR)C;,=(K]-Q[=<+Y7H6,'.
M+Y>P-K%,W&'M4'>85*>G:^WGJ\M7VXE38F!-1!R17O\`/X$U6X7]KOT-/7;=
M9=IWUZDNM+=\T`C3I4@Z4F2ID8SRX2C.LWSHU[]+<WFWF$A);6A&B8,]6KA,
M891C^P>^-EC\_,],-/\`'<9G?:U2O-;=?PLDVYKN%M<*0^.0D?;\X6F*:R,O
M]_+^X48RO1J)Y20`2F$4$S%.-;?MV=L_B&_.&ELX5I3+%;JI3D@'EQ4<(\J_
M<*6J[Y/:D*J+F1,_40)RFHX2[NZ/O/@SY(I2.4DG_P`@6-:Q:%D_=""JFGE5
M?8\8.NNQ9)FM61Y&\23`I^B@L:006,7L?$!]`MIKQM(22;:ZZR/SU5*FUJ'/
M0$2'9P,7/TFY4I*A74Z7)>[Y.H#T@@^R(73/R@;%:(9QHN#_`)2Z!C^.QEE:
M5"#Q/O!@4DZTQ'*2PF*3](RE0;&O*S&/Y=N"I#NC(O7"**0BN0BC8JBR?5TN
MR+=NNRU%ZV=4#XNE$WJ-Q04Z)G`,JD/,&GC*9.&!C2?Q/7V:O:M^YD8/'[)]
MH$-J_P#,!/AD<QRGA+&+4-O\N63#^H.P^;\<R$6O:,=8+R!D:ER#E)&9A%Y:
M`J+^<@WJR)#@WE8Q19!,XE*H!%DQ]#``]\X:QT*+C?*2VU04V'7DH6DX$34$
MD'D4Y'MCJ;K7N4-JJ;@U):FVM0EB)RG,=G$=D1-^*?Y1<7_)5@Q"U1@LZIG*
MELXJ/S9B0793O*U-N$@2)9:X"QBN92@V1=(ZC)ST)FY_)LL(*I]FW^_=CW'8
M]Y^'=)=M:YEMR6"AR_2&1'I&$:S:NZZ3<UO#[8"*X8*;GB.WN,6JJ=^!NA$!
M\1Z$/J`]?S#SBCJEX):^$\HZL9Q2]F[8S=G'/R0ZJ:;U_)N&W.+]F:+EK(#F
MY2V&I0]\IB.)&9Y&4K\>DVR2A7I<99%XS30=K-R"CY*F.DIT7OO[19+!7;/N
M%]?+XN=$6PE`,VUZUI3-2I33+4<.)`YQR%;<;O3;CI;9J;-%4!1F!B-*5&6/
M:/5$S-XLHYGP%KK>\X8PL%//)XR@H^4DJY;JDYF(VS)J3,=&/E2/8ZP0SV'<
M%0?"HF4OO)@8GB/?EV'`C#42)@G#NY1W-L::JJIJF>,@I0!,95I;D;)^9=><
M:YBRI*UIU/9.JT;;4H:J5QQ`Q%<:R!G!F\>DJ]FII[)J&;>V9150R?1^P*4`
MY4RX0KF&Z>L<9:,VTJD(Y#<G/(:TZVY4S"@9L:<K5<60I[-T3WD9*[3:J4-5
M&1VW8&=I#,O4E%4RCV9%,_X`/$6T=.JKJDTR1XE1S.J.<&.QVO&*,S-#H?<7
M6IQ[N=;-Q+[<=:691C;3'`0HC[16D^S<%(4?4$_'\!`>4BVIIUTKZF%^\DQ(
M(XCZ=#T(B'_#^_E1E&(LD$`<X@/J#N*UV#RCM3B.7<,$K7@?,EI@81!JF1`T
MUC(LFI%0$O[8"(K.HR5CW+1VH'U,9$P]"?C"-G74AIVFGA[JT3],3[Y2,"(<
M[X;.H:D:T7W+B!V2MM1;)5['D8_`%&\K>9T3MX=-9OY%,Y:1J9%7S@@"'D@U
M.`B'?*QF45*JLJ`TD>&4SW1(RDS[FXXZJ=F0=II.[72X"?;O2H$512<3L"SD
M".BMA,1-1)-9UY@GY``@'CV`<K*,5XI:>4VK($CU&*JW6SFY+K?2T:65RW8,
M*TBL?(9&B+_8\7VI=TO&KQ<<_+%2,/$9$8-S/BK/A3%9)0B8E3\O`!'Q"G9&
MT%'2BU-UZU*U%9!E*<N!Y1*NOJ;T5_,N,8S(MHP5;\/V%Q:F]O>X\Q]<JY:8
M9U'563E(`%U)ZVV2.1BI&4:D1,L404!42I]='[!*,1PT)8)8\SS?Z4I2]$>S
M/6PU^B\U8PU8P>WK09=R76I^_P`W<+JV>R56QAC2NN`8O+&O`QCI@\L]AEI(
M1;1S#[ELB*A1.LIX!T*%/2CX5=4^3H3[2>$8U<8+>/%\S0+/&9\I&8J4ZR%1
M:_DBISF$XRHS;*IV:SQ<#+SU3EJM/KF%Q$)2'O"DZ(H4J)3'$YO'H:G"+$NT
MJT'P2)R,S%@?0_M_'O\`=^SEL8LC[8ZSS#>"XTQ'E+(IA#QH..;O=#"<?RC_
M`(6K,I._F\O3K^X^O\G,BW(36W5JWJPUNH2>Y2@G\<8]8Y\)1+=4<4H49^@F
M-1;^%GP$-YG-G]W;LU+)V"0E"XJJDE((_<&&5M:H9!RE*H*K%'R=.Q>Q;8YP
M`!]LZI!'U,'/H_[P5X51M4&T*!12RPT%+D9`A.")CC+'3/*6$15TSH_.%;>'
MI*+KDA/'/E/U1#W^*%Q;0J]O_KC,PE4@8=WD[#$&-U4BHMG''L;V+RA+0J4C
M*"S11^\D/T=V#85S=JBDF0HFZ(4`ZWH!<JES8EWU.$KIZHZ"LE00/)5@)SD)
MXX<<8Y/JK3,M[FIFT)2AI:43D``?'+&6>7&-PBM_&O\`'W$5J(B&6E>L(,4(
MMF@5-;"]#=N!*+5(IA6>/89=\X6.(=F444,<P^HB(B(\^8G=\;P4\X57:L!\
MPY/.`9]BL.X8=D34WMS;P8210TRR4)_ND3RSRB.&;?@H^+7.$4[9R>J=*QU+
MNBG^VMV&3/<96",7'R,F[;%KZY(%RJF?H?%VQ<I"(>I1#L.;6V=4M\VIX._'
M*J$#)#Q\U*NPA<Y^N-;7;(VO5ME"J3R=69;\.GMPP]D:XVUFJGR6?`O,(9\T
M]V.R%EG3U.;9)3<%;3NK)"4L'3HJ+.#R]CE=9>`+!/S*`U0L<*6/.14Y2G!H
M<R?N3CM>]=/.KZQ9=U4C5NW"L>%QI*4:U2(FD@#+BDSS[)Q&UZMV[=ARN%HJ
M555C09D$DE(F,%CC/AP]<;*OQ3_*;C'Y,L.2%@CHU&C9LH*D=&YAQ.=^+X(5
MU()'*PM57<N/%S*T.PK-U0;*G+[S58AVZ_YRE.I!O43I_=.GUV515`UT!F67
M"/>0#^M$G;2W71[KH0[[M4D24D?3ZXI6_BTL;4E##^IF36M6@&MT)E.[4YU9
M&L0P;S#ZOOJ828+%2$@B@1T\8-G\055%)0QBI*',8@`)C=R[]VZNJEW*YLZE
M+IQ0I4$J)*4J\U()2DX`D8$@3E$?]9*-A-!2U+:$IJ%/%)4``H@2D"1B0,<(
MO=^'S']3H/QHZ8,ZQ7X6%&5P)1[++KQD<T9KRL[:(Q.=FY:07;HIJ/'\C(/3
MJ*JJ"8YAZ]>@#J'.H=5456]+D:A:E2K'``22`$JD``<@!@`(D79U(Q3[?I5-
MH0EPM3)"0"9DYD"9],66@4OI^4/V_0/K]>_Z><5(:M7YV4^R.H*4Y2$IS]//
MOC4Y^3>`5P1\AD'EJM`$>-G9X\RTT.U`4.Y^L2Q(B;/Y%`H>Z\-74SJ"'J/N
MB(_UN?HU]W5W^->A=XVE<IK12(=0H'$*2M*E(!YA)((Y$`C$1^,_WP:973K[
MREJWI;U%"*IR@K1I.F7EJT*E*4IZ23WGG&U/7Y5*=BHJ;;'$6LQ'1TJV`#"8
MOV\DT1>(]?M#VEP_GY^=%6CX>J<I5?M&'2V>T@R,_3'["VJN1=+?3W1K]E5T
MC#R1R"TA6'H,9#RR-I&N]_$_`'_XLK$'0=?Y[8;_`/:$MR9^@24JZBL-J`+:
MJ9\$'(C1D1D1WQ'75#';29_[4U_WHO!P"!?\C,+%\2]%Q'C?H.@Z`/\`!T*`
M=!^'0!R);F`FZU)2)3J',NQ9`CMK>E*K?3:@#_AT9_HB,SN]+JF0JI8J-=X"
M*L].M\))UNSUR9:)O(J<@IAJ=E(QCYLJ`D5;NFRIBB'78?4.A`!#%9K*BA=3
M441*:QLA:98'PG@?3[>4>[[#-0V:>H2%4[B2@I(!!GE@<.'*-5'X,FUATY^2
MOY'?C+)-24CBFH/W66L8,WSA57],3CIJNLFCA,#'$B3J=H%YAR/!+_RZT<4X
MAV`CR?.K#3.XM@6+?+:4HKUH++ND2FI)4K&7<1CSE$4[#<5:=R7#:JB2VT2I
M/+&6('<1%L.[#XFP.\>B^DZ`)R%5K,S.;Q;`QYTRNF:E)PH/Z#ARO3*!A,DH
MRM68YQ%P**I1*L6('L!`.1KM[5:=L7/=+Q"'9HI6"#)0<=,R4G,*"4X$8XQU
ME\=;K[Y0;>5[LC4N#@M#>&E0R4"3B#,=D0#^(F76TL^1;Y"_BYGUE&52>7%Q
MM/K2U=*&307I]N(S=S\5$E,/MG!.!EHT3%+Z>Y&.C#Z@/.UZE,_Q'LRT[_9`
M-5H33UDI2\Q!*0H]I2F9.<SC&DV>KY/?J_;+Q(0MTO-'(!!DH)`X``X`>K$Q
MV=_$H8,EKMH;!;"5!%4M^U!R[3,P1$DT[^[85Z2DFM=LBB1R!YE39R3J+?&'
MT``8^0]==\Q>B-TIV-YNV"L5_@KK3E@B>!^K,9'`$8\3'MU(MIJ+"U<:,S71
M5'G#N),_:1%Q>#MD*=E35+&VTCV6:,*5;<(0>7YZ4,J!&4/'C3TK%:16.`@"
M9(51%T13Z"441Y&=UM%31;AJ;`$GS45);2/Z^@#TB7KCLZ"Z,5%F3=`9I\K5
MWR3,^T$1J-;?8DR'4=6\`_.@RB7C78%;=8FU]O:F0<%EH_6?)<Q$U+#=$>^0
M>X2&KE"JL$F*0_E)^ONA$/S&Y]#;4N;-TOE7T@!2:1=I734QPQ?8'G5"Y?6]
M\3SP`B(K];E4]"QOUC7\>:I*G,<D3]T<LI'AC&X),;"X]BM:I3:?]617Q>QP
MNZSJG*>^G[3BGI4T]W0.54#>'N+1H%*!>^_,?'Z\^<F[0^N\_(%S^*^+#./U
MBO0/\[*)@=NC+=L-U5+R!3>9ZAJ_R1"?X@,03E#T?I-YR$T51RKM58KOMCED
M'!!3>FL>P$PO;V#!T<>EO*%I;N-9%*;H4_9$`ZYU&_J\5>YG*9L@,6Y"*1(3
ME-B049#":E:B><XT^TK<FDM*7%&;CZE5![0],I2>8`E('***=9]M;Q\#&UN2
MM&MQ:_,+:4Y:RC;,H:]9]C8QV]:U)C<Y7[AR]<%:@K^K5X@G11L#%'SD(:02
M.Z(FLW7$1EJ^;>INK6W6-W[:5JW914J6*AB>;:!X5#MGEP(C@+=?:W8=X=LM
M[3_^34OEQ#@R2%88<A@.XQM;W/.%)@=?[EL369B$N5$K^*+/EB'GJ](MI2#L
M\%`U>0L[5U&2C)15N]:2+=B`$4(80_-^'7/G=BUU3UU;MM2"FL*PVI)$M*E+
M2!@<CG$M/5S7RYRO85JIFV5.)(,Y@`D^B*/?X;2.?9#U6SUM_?'!IS-&UVTN
M2+9D*T/.EI!XTK8,&,'"@X.!E"1D0ZD7PMT0'VTR*@4H=``!+O7%#-JW.QM9
MM(324%`PV$#W=12%%4LM1!3,YGC'#=.E+K[=47HGQU-6I4^(2$I$I\ISPC8T
M`I1#^J`^H_4`^O\`1R',1APB1P-&`PBL'YC]=*QLO\<>TE+FHUHZEJEC6P9;
MI+Q9`BB\/<L71SFW1KUD?KR25>-(YPQ5ZZ\VSM0@^AN==T\NILV\J&L;,DKJ
MD-J'/49>DX^R.8WG0BX[<J0??0@D'C,=O=.*I](<[6?/7\-;F]_;W[J5GL8:
MV[0X6&5>+K.';R(HM4F@J?OKJF,=4\?595DT`W_@MP`?4.2+OJS4MGZY>53?
MWMPIW".`+BDJ6`.U1)/..5VU5U-?TV.K%;=)4(QQGY<PDX]@PY1T-L!H=FG!
M&)M2OEY^---2'SS4=;<+V#8S#D&R54A<UTPF,*J>SV`E98&2+-/G$:U_]?QR
M9?>?I)E?-O%^W\EMEM_=]JNU;7]-]ZG79*JH<%.^L!3C3@40VE*U3*4SD.`E
M@9@X:BLL5?;[=2;PVVG37AI)=;3@E20)J,A@<,Q&P'\<GR)X;^1K`D9EK&3D
ML5;(TK2(RWB]Z]36L>,;BHW]Q>.?$[(H\@)+VSK14@4@)/&P>OBJ15,D.;TV
MA=MDW5=OKP32D'RUXR6,9$'GS$\#V1(FV]P46XK:*MDRJY>-'U3W<HC1M*R*
M/S3_`!8/S$`1_P`D-W&I3?L,6HU%;\!]1`#C]?3Z\Z+:RB.F-]$S(JH9]OVA
M/TB??+E&NO(_YRM?Z+O^K7$L?E``/]P;9KT#_P!PF_\`K-`\CJ)%M(!N3,P/
M?$9+\>(]:.ZN#_\`9RI?O$6?X\N`CRNJ@BM>/],QUWGE5KF_<?7?755(DE4,
M4P5BV=RU'JE*Y8N%VJ3FB8D@I1,P"F;[F?F'TA[1^_(K,@]?3E.Z+J<*IJ(U
MX)2X"$@Y'F9&(N?&++N]?\^;;Z$6%RJ1OCR]/LJ8B(Y-[8O*%:%6IG2#,AP`
M54TF3Z,<]$[`#K+#UZ#QV1L+LDOTC5S&(4G2KOQ,R><78*K)H(K+JF`J:!#J
MJ',(`4I$R>9S"(^@%*4!$?Y..,HT:4S('$QJ98Z>S6J$QK=\D4;^H*4;-N8<
MXT389LF=91N:O6?*UI_0Y@X>0IE(,0R]](/H#F+3Z]5![\5$@SX3CJWEHKFE
MV^0UMI$OP_#.-LB/?,I-@QDHYTB^CY!FV?,'K90JK=XR=HD7:ND%2B)5$7""
MA3E,`]"40'GH,HY0I*#H.!&'JB@_Y(XISM1&;6/D3JO,7Z28K>,(<J1SBQGM
MC;,>&F;.Z`2B!7?^6N/`*S,7\WMO)-0!]0Y4^Z>XQO;4Y\(ZC#QN&7HD?I,6
MF:+6<;EIQK183G!51WARCM%C=@;^WAX=O#."=^O8IK1YBC_-RC9.@=T:JX)'
MQS@($M1BJ^XY1Q_B#YM;7;\E6B.J%9)K=#QII>3^X%J5\]@XP6K7IJ@Y5!18
MJ!Q#\O7Y>7'.-PEM3FWFD-)FKS5>R+7<<[EZT9?R`TQAB[*,+>KL[B)6>-$0
M+665,PAH8&P/9"3=.8]LV8M_?>HII^1Q,HHH`%`?40=\:=VFJ&VRMT$(BNOY
M+8'-F`\VX>^0S",(:WM<55B0QSF2HE(LJ5>@OY)S(??ODVQ57"4(J$@LBX=)
MD,+!<C9P8!(4_3*-C;%L5E*N@=,BK%/?%ANJ6X&&MP,?H7?%LP`OV1&R-NI,
MF=!*V4F563`18R[(AS>\T5'R%L]1\FKI,.R&\O(A6,:VHHW:-?E.B0X=W9$J
MN4C'B,>YT.]L&H.U4#'E.9_,ZY9KC&1"`;R.Z>XUL;=`A0+ZB8ZB@`'7,ZQD
M)O\`0*/N^>B?+WTYQJ+TA;EIK$(!*BTJ0&)/A.0XQ4[_``TU8:5_XI\922*9
M"N;GDK+=HD%"E`!6<!:5*X@)^@[\DH^O(D]?4`+R3NOU1YW4BJ9'NMT].)\/
M=2?7CE'-=.FD-[5:E+5,CU`8=XQ[HI'_`(J#_KQ:6_[&4?\`ID<\E_[O_P#(
MM\_>5?[NJ(]ZN?S+0=R?US&])%_\Q8_^1-/_`$=+GR$KW_ZZOIB>V?V*?T$_
M1')<NB^,/OU&J>2J;9\?WJ#CK-3+G`2U9M-=EFI'D;-P,TS48R<<\;J=E.DX
M:K&#O^L4W1@$!`!YZT]2_1U+=92J**EI86E7(I,\X\7V&ZEA=,X)MN)*#W*P
M,?SM==DK/\/7SN1N(FTO)?Y=$S-'X9EE'9U0"U8&SBO&C17LHEY`1V\@23\8
M\]PW8`]CSB4?40'[6ORZ+JET?-V*2+U3T_G&0G-UO!03SFD8@<#./FNVD[(W
MTBVIF6//T@\TK&?MSYQ=1_%J=?[KFJP!^&?;*']&.)8/^+D9_=K)_B2O_<!_
MKD1W75],J"B/.K4?6TJ+VOBQ_P#YOZ0_]F?$G^J,=R'-]_SG=/WY[]<QWNT/
MY7H/W5O]6)\<Y..CC6@^<UFW+E77][V3[EQC^[-%2AUY?;MK''+(]_CT)W*G
M7[^??GW)2I5+?!B1K;'>9'#O[,X_)/\`_I2PD7C;50F6OX>K!Y@>8C23V'&7
M`\(V`,%J++X6PVNY#Q<*XQQ^=<O[%35.*$Y1]1]0'GP_NW2-YW0)EI%=5#N(
M?5AW]D?ICTV=4]T[VZM8(5\GHYSSQI$1V_S1QW<:[O\`%`#_`/JQL8@(>F=L
M-#]0]!"0EA_;]0#UY,_0-24]16%D@(%,_,G(#RSF>$1YU.(3MF9P_P`2U])B
M[[7DX*8%PBJ)@'W,08S/WV'0^5*@S=@/T$![Y$MU*?F]4`0?\0[[5F.VM>-K
MI0/]G1^J([>4$H^GD7L`$?J'7[Q[].N:]901Y:B!JP'?R':8S5!0$Y9$1K+_
M`!45K_>&^67Y4?D"@R%7Q`G9$=9L9VI,#?I=MD*N>LM;E+1#L0]EVP8,Z"P.
M=4HB3^_$]?J')EZ@O_*^G%CVDH*^,>3\0XG'4C65(`4G-//$#`1&FUF&ZO=]
MTO9(TM+\L'AD#B>[C&::;X5N>_>?=S?D-@]DL\8&@;[E^1ULP8MA]:@-B6;`
M6NJ@5I"7=*7FBW418V'(@RCY'[0S<AE/,3@H(@)<+=%R9VY9;3M"IHZ)]QIG
MXE3B@LKU5'CT**%)]T2`!RPC*L=,[>KE57YJH6TA:RTD#$:6S+WO5EGZ(AG\
MKF",A_&WLEI#\I4?G'-6P(8^RO%8BS=,954I2DNRQK.)22C6*;K42FTQNK%2
ML'(3S0P.DEC@Z5;`50`$"AV/32X6_>E@N_3QZE9:=>IEU5.4DI`<0,AK)S($
MA.9QC1[KH7K!=Z'=`6MU84&E$C&1)D3R$IC'E&T%F;'U+VIUKR'C)5RRF:/G
MO#\Y7F,FGTNS=0]]JJQ(.<;&]0,1,'Z#M$_KT)2CR![?6UEAO--<2DHJZ:H&
MH2]TI5B#RQ!!B2*RG8NUN?HI@MO,88C'4G`CGP,:F.BF;;CD_P",&L_%*O)N
MX_/5@W3L>BEI:IG53FZI@%M+O\LYKLX)D/\`<(1T1CN.G88BH@!2JNDB%]1#
MD_[ZM=)0;]5OE(G9GJ/XUO*2GE(T!"3D5:B%$`S'&(NV[<GWMO)VR9?-DU'P
MI(X-!6HJ[I32#D3QG&UML+K12,Z:K93U8<QK*.I5ZQ!+XKAV2:()M*^@6`_3
M*BY:D*'BF%;?M&:Z'0!XF;EZ^G("LEXJK/N-G<A5-33Z'#CR5-4^/B$P>^)2
MN5MIZ^SNV8"27&E('9,2'JPC5+U*SS<,\?%YCCXI[*]<M\_+;KP^A&18DYSF
MFXO`E4GWV6\ASRQ!-[Y(N*QI496`%00\.DR$[_-T$_;NL;5%OE_?0`-M>M8N
M`/YI<=3Y*4`Y%06L*TC'C+C$4V:ZKKMNM[;=U&X*K`R4RQ2A"@Y-0S2GPRF<
M(W,VR,-5(-NW1*SA*[7HI)LB"ATF<=$PT0S*DD!U%#$1:LF+%N'8B(%(0G8^
M@<^<-3M4\'!,J4588S*B>69G$S)0BG202`@!(Q.&`E$?-K]3<!;M8<E\,9]I
MT==*9-HF>1CU/VT;%59@S8Y6%LI-@2*9W`S[#W0.DX1$2*E[35*HD<Q#;K;^
MY+SM6Z(O%D?4R^TJ2P)D+'U%`<)R,O3&LO%IM]^I#;*X`I<&!XC#,?A(QKF?
M%-BG,.$LN_)_\*61KLZON+JCB:6L^&+1)`IXPE8S+$J5THMDBJ*)Q36>CKBP
M>N6*1A0;RC5V=$`!4W<Q=0KK9Z^W63J=2,!BX.5:14`$>-2%`@E/"12H3X@B
M([VHQ74U5<]EK5JHVV%!LS^L",>^8P[(S'^&(RTK3L2[-:#Y$1&NYJUISI:)
M]_4Y(1;2JM=GSLJY/N&[-7I95"!NM<6(L8H>)2/VYOHJ41\?O!6]-9>:#>-M
MQMU=3MJ*_P`TK`,QJR]TCCP/*,KI=4%B@=L53A5L/+D,C+#@<<XVG4SD\?0Q
M?J/T$/\`3OD%R,S*><2EXE3GB9\(KY^53--:P+\>.WV0;$_:M$_\D+S3X=-=
M<B:DA:,A0KBD5R-:)B8#N'3J6G4O$A>S"4##]`$0Z79%L5=]WT-O;!4M-2AX
MR_-2@S*CR`"3B<(Y[=-0FBL%05&2W$$)'$DX2'$G.*HM4];+)J]_#@Y;I5WC
MW,-=KQJEL5F&SPSU(6SR(<9,J4[*PL:\1.!3HO6E5)'E63,`'35[((=@/)*W
M3N%&Y>N":VG(6TU<:9I*D^)*@TH)P(P.(.4<C:;<Y;^FZVEA0<71U"R""""Y
M-0!'`R(E%R'QTO\`]2T(TP?>8&%SJ_A`_GZ#WUCJ`)]!]!Z\>15O'^;KJ>'S
M-P]@\4=IML?\O405EY(^B*&/D+T=SC\9^PK[Y7OC1A%E:U[CF1V\U@B$'(5B
MR5-VZ&0M5HB*_'D-Y5A\?R=R+=NF*\$^`))H`(_<)DE_96Z+;OVU#I]OI>E2
M$J31O*(3H<D=`4LX2X3.8P..<?[AV]7[:KE;FVOA,ZJA&<T#%4AV\A$BJ)N'
MA3?7?/XAMC<(S`.H26QIO'#V6MO%6PV6@7)MC2CNI>E6IJ@<XMY&..KY)+`'
MLO6QB+HB)%`YHU;<N&T]H7ZTWEI2'M="6<#)2-9\:21B"DY\#A&R:O-#?MP6
MRIMZAYB$N>:.*3Y:AI/];Z8M`^4#_J#;-?\`P&W_`-9H#D0Q+-H_XDS^F(YW
MX^7*#71?6!PY73;MT,+U==9=4Y2))((L#*K*J',(%*FFD01$1]``.5SBRY8W
M%U`Q*G"(B#JGB>U;1V+/6YK3-N7<2I9KR=+U;'[;'ZM/00DL,XE76I](=NS6
MBI61<0?/F[]T0$#HIC[HB)3";L*B7",A]X4R4TJFTK*!C/@3GQ$1QW-Q[9=%
M-J=6-V%,F9$RC"2-I#$^89^]&KBDJVK+]JHV;-3*5>NUMBHR4@'C]1,%D5%`
M<,4_S]>(`,HSJ)Y-=2.4.A*`/$`.?/CCA%YF7;:UK^%,G7=!T@HRAL8W*S-7
MJ2@';KMV=5D9-HX24#\ITERD*)1`>A`0Z'E.,<ZRD_$)1+'7^.*[M<];H//7
MQ*8IP99$4T!OV%$I6/D%D@,>(MDQ(R%OKE@*(E,8%&4VZ15.(="=(3%[Z,/`
MRC9U-4JDNY=3P4/H$1^TOW?G,8Z59@QYDUHX<;$:@R1L.P],>G$TW;YF;DUJ
MMB"&005$7#U0;./Z4<2E$`;-2*"/B<!XG'M7T7GUZ*D?LG`%$\!,3,SPB:XZ
M[+8Q^/#*N))A<)B\V'"N6+5DVP*`*BUFRO=*[,V>Z3BJH^1G!SV%R9)N(]B5
MN@D7_O>#SC!2_JN:%#W?,3+N!$8W\/MH"S?']A$HJ>1ZV-RJRG8]B3]*N4X=
M`@]^H=-728@'X`/&>4>MXE\Q64RD3$<8KVU/G8MA#%*H!=8&?F4Q0,4/*"A?
MRB!@$/SD,/[N(S%JEMUJ68=,7&KT"I.;G!7\T4S1M-<B)^#CI-NV:-UPB[(I
M$K2C-RLF@5=P@=:%0.0@G\2G*(]"(\1HM:B)&<O3&2K&CI4DA'"=B_(CY,95
M@8R#LA2NVI3G9R+4WF0`<LW`&%-4O1TS@/0@(<"7&/-96E.IO.->/;+79+X\
M]G\&[?ZTF6JM%R/E:#QOE/%K$YTZZ<;>]`7C2)9)F\4Z_8&A7)R,A*)8^213
M4;^)3`0C'T1T]#4+NE`JCJ""I`F#Z_:(V*?=+^P?V_0?IUU^SZ_R<KI,<Y(3
MEAG+TYQ\TK&LIF-D(B21*YCY1B\C7S<X`)%V;YNHU=(F`0$!*J@J8H_R#PAQ
M3*P\G!2"".\8Q:1,2.44Z_"?27>#-;,R:JS':4_J[MWG_&*S90/%52LRUB:Y
M"H,P1/H/[E/4ZY-7"!@]#D'L.=[U-JTWB^,7ILZFJRVL.J4,O,"0%)[TE,B.
M<<?M&D-#0.4"Q)UJI?)2<PDDE)[CPC7B_BH/^O%I;_L91_Z9'/)]^[__`"+?
M/WE7^[JB,NKG\RT'<G]<QO218?W%C_*R:]?^;I<^05>__75],3VS^Q3^@GZ(
MY+ET7QZU/P]/P$/Z>N6K(T*"L$Z3%"H@@#(J$?S^OX@"O!)?-G@^,JZ0#9+1
M6]44%2MO^<+6!?)4K%1IC`7\P+D8-VH`/U`A2C].?8W11X_]**YQPR88-4HJ
M.24J82`3V%4Q'SWU#:5_U!HEI!D2W],6<?Q:H=:N:K?[?;+_`-',OSA_NS@I
MW%7@Y_`__,F.GZP?\.H/WD_ZI47L_%C_`/S?TA_[,^)/]48[D/[[_G.Z?OSW
MZYCN]G_RO0?NK?ZL3XYR<='&KE\R,M_C_<3$.+(8PNY2'H,#!J-$O(QPF<AV
MUT=JWZ)V(*"S(W/T'J)5`Y^AWW1:=&W^F=[W34?9@UKCB%*P"D,,DK4.Q),B
M?1'Y!_?YJ3N7J_8=FT7VM4FB8:4VC%074/\`@21]90(($;,=3@PK=>KM=3*/
ML0$'#PZ1@`/'PBHQM'D$O0_02H]\_/6M?56U[]>L'S*FJ>>5WK42)]\X_66R
M6_Y5:*6U@>"D89:3W-LI1AW2C*1^G/(F0G&V(GA%*'S<Z=[/[_:SQVL6O=;H
M#=L^R'4[_9K[D*_*UF/;M:LVGBHUV+AXRO3\F^?NWT@@H9=3V$")D$`$QO0)
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MDTU9M.PE-72EVX79M25-^:V&V$$9E0F5+))&D$`8&<>=91[ANS9I:C316Q0/
MF>4X5NKY!)E)(E/5SG&99=URRY@+3"1T^^-3$./:J1QC.7H=.N-WR&:KP]#>
MV9)Y'S]QERMX"P6FYW==%ZM(`Y,!`7D50.JJ`$$@XM!>Z6[[N:W1NY;K[8J@
MX\TD&2D`#[-&0",!(=\953:ZZCLR[58&VT*4W(+5[QG@2KFL\2>$=Q_')@RW
M:NZ:X%UTNE.A*A/X?HT74)H:[9D+7"V6=13._L=QCY,C"*=D1LMB>N70I.FZ
M;@AE1`W?0&-A;LNM->-PU=TI=0HG7B6P<TM_F(X^ZF0]$XV%AHEV^ULTCJ$H
M?2GQ!,I:B9DX<S'N^1;5Q/<[2_8#7)!A&O;#D*E.4Z,K*NRQK&,R##N6LU29
MEQ)BU?'8-HZQ1Z!UU")*'%O[A0*/EURW:.X7=M;CIK^C46V'0%)^N@^\/2"1
MWQY[AMOS>SOVT$><XDZ3]4\_1CZXCQ\6>.=[=<==\=:U;?4W&\X&*(E2K4S+
MV.LJ*63[ND1I##5H*SUJ9K,'*_JD$V$L>BY;*K)JM$D14*0Y3";;=0;EM.[;
MEJ+]MQ;K3-29K:=$@'EF9`E,`%1\,\8UVTZ._6RU(MES#3BFD!*'9@C0!(3X
MG".JM6_BW#"'RK[G[V2#:)+3<L0L$OA>/1=)+O(FWY#:LGV=Y=U%D`/TM<96
M"30;*F`#+H22_C^7OFUW!U`5>>GUHVBI)%52+65K_HB>D3[OHC&M>U$6_=U9
M?U?_`%7422GFHRF9<L_7QB[8Y@,F;P.'8@(%'Z]#^'IR-%N-(_:XI(G+F([=
MLA1"ABF*2,#_`!7DQ/\`,'LEOX9**+CC(6.8Q]CB*1=D,^CLS7U,D1F*66B@
M`!9)EBJ^4Z#@?^6&><%+_4/R3[GU!77]-Z'9#R9U],^I:W?K-?W:!V)/T1PU
M!M+X/>-5N$*DVXC`<RH8^K&+8L\4B9R7A'+N-ZU)MH:PW_&5\I,%,/16^SB9
MBU566@HV3>"V35<`V8O7Y%5!3*8X%*/B`CZ<CNA?8IZZGK'PI333Z%R3F=)R
M]4XZVM;=?HWF*<I%0IM03JRG+"*SL&9<^6K'.-*SB_,6BV,<L9%J$!'U4F::
M'M72:MCJ[C#,D8UE:IVN62M*WBNKOR-RK/4FS-T8RAC"DF4!`@='=[;LJMN:
MWZ&L=8MU0L*<;*%^8G*83*07+@=2<)`DQH:&HW'3,(I:FG0[5(;'V@("3C*1
M[9?ECN32/3:[X<R%L+M)L19JU<ML-JIBO/<@OJ*U?M\>8WHU-8FC*'A['2LR
M4DU)0=78]&=R3M-)>3>#[HIIE*4.6[FW&S=;?2;;M[>C;]`%^6%@!YPK(UK<
ME/&8&D3D`3*,FS65ZAK7[O6%'QE01,)X`3P[<_9$9-WOB=LN1-B:YOCHKF%M
MJ[NW6$$D9N=DHI66Q5FV,2;I,%8C*$&P*+@CF0BT"-'3M-%RF\;II@N@*J22
MZ>[VWU#9I;-_#&ZZ==QVPHG0E,RXR3Q03E(XRF`.["-/>]H^?<OGMD>-->)8
MXR0L3)\0YG*.XJ'L)\JD1$(0F6/CEQG;K>U(5NYN^)=O:'"X\G%R%*0\HC!7
MNODN5?:KG_.*!B/%"!Z%$WTYJ'[/LLO>;;[JXFG4H_9N4[BEH!X:DS2H_P!D
M1ELU.YRW*JH65O@2U)>"09<92.??&/O](<Y[F9/QYD[Y#YC'C3%N);*SO.+]
M+,.OIFR8S&]1QC&A[OGG(UACH-_EJ<K_`&(L8IK&1\(V.83&*X\C`;V&YZ7;
M=`[;]H(5\TJ3H=K'4Z%^2<VV4">@$9DJF>P17Y-47.I;J[U)*&C-+(.H)/:K
MCS],L(DW\@&.\W9FU0S9@G!M*K=BM^:,97/&C>8MEQ0J%;J1+7$*0IYN2$D1
M-2,HDW:O%#IMVK<3&43*4PE*;R#3;8>MUOW'17>XK=31T;R7-")ZUR(,N`"B
M1F3A,F-C?J2HK;15T-")+=:DGAC]&6$<3\=N/=A<(ZL83U_V`H=4@[1A+&54
MQS_BRDWI&W5BWH55J6&CGS%HO"P4W#K&B&J!EDW")B`MY`0Y@Z'E^[*BT73<
M%7=[?YOPE6YJ\L@S1C/'@3.<R#*44L%'54%JI:&LQ6TB2C,9XR_#&)ZN$4G"
M"S=9--9%=)1%9%4A%4E4E2B11-1-0IB*)G(80,4P"`@/0AS0E2T#6W[XR[^$
M;HI2H%*Q-!P([(H2QG\,-:UH^5;'V[^MJ\75L(3,#EXF5,,J**LFE+O-TJ+N
M+86/&S1,AFAJ[8)!QXNHX?;&-4#R;B+<WM(RS6=4:B^;`7M"^M%V]-EO158G
M6V%I5Y9)^KI/X\<X_IMCMVG="+Y;EA-*HK*T3XJ21ZID2Y=N<3;^62P,X#X_
M]ACN52IGEH.N0#0HB`"J[E[G74$T2_M.=(#B`?R<BB)5LO\`Q%M9]Q)F3R'X
M&.OXW'.S@_'7BO`V$:O6H^^6772I5-]=;A;PKS.F%LM<2)/>S$L8>6E7DTUC
M7ITDN@22364\A,(I^)K5`RPBU3E/\T<?<(TH=*AQGC$UM6,>RV),`8KQ9,UA
MA4WV.Z7`5!>/BYI&>C7;J'CD$9"99R"35BH=&9DA6<>*J2:P"<?,.QY1(($H
MQ*ITOU2WCCJ,XP+>K7AUM)K+DS#L6RCG%EG(UA(4ES+/!CX^.N4-)(/H=\[>
ME:O5&S1/P4(N)$CG.@H<@!V;ET>M!5?!U0J#BG(CLB*]?Q-O.?12RZJW:H8U
MELD+XUD<35S)K3*+@T$O6'S$\*Q?V-FYJI9DDQ"P*GV_]@18CHR9#"*8B?E9
MQ[NOTJJ[XIGPHF#*7&6/MQB;6J50O6-L#XOQ=?ZS%5Z;QK1ZO25E82PI6*(F
M1KT.UC32L<X*PC7+9NY.W$WM+HE4*)NNS`'D-(PZEP/5"W1B%&<15LWQY5J=
M^0*M[?)+M&]7;5P)FTTOQ6($WF*O`G%TVUG;I%^R<-&L4L9RJ*@^99!FBH4!
M%0Y@K&5\P<3;%4H]Z>`[/P]D6*V^(/8*G9X$B:2RDW79J((BNH***IY*-<LR
MIK+`FJ*21S+=&,!#>(#WT/TY:H3!`C"96$.H6H>$*!/H,5D_''K[M%I[C&1P
MCDVJ8_M=54NTE:*]:J5?%C/(9">29A+,).%G*Y&F=H)/&@K(G06\_P"U,42>
M@#RK8DF1SC.N3]-6U(>:&A/*.IK%K/O$P^0">W8H=$PP\B'U5;4!OCNUY0E&
M$H]JZ%>80ZCES,15.D6,;+*/F7W*?@#A,A1`AO+L1Y7MC*9K*#Y.FVNA0<UD
ME0&0X?DB7"DGO3D.VX_KUEPWB;%&-T+M7Y[(MHA,TR5UM#FNUQZ6:&`K\2C3
M*VFFI.2#)!NNHJJ8OVIU"^/YN^)QKRBA:25-*6MR4I$&7TQ\%@0W,Q)L3E6Z
M8\Q;3,Z8,RK_`(-ED*VGD5AC[(%&LU>J4;5I59N:RLC0$I%S1(M)0R0*@<HD
M`P&*(G`S#**I^&=82@G0ZDG,'&<?#8\*9PVMR5B:R;"4^M8CPQA:X-<DPF(X
MRV-<@W#(.1(I%1*MREWGXU@QK,)6:RHL=9)@S,\6=+&_M52E#Q!A%R7T4C:A
M3JU.*$IY2]<6)>(=_0?ZWE^'U\>N^N(UVE,YRQG/TY1[.4SP.471&^(Q(>D;
M&7++-:;%+#YNJ%<B\FL4O'I*[XT(Z9TNYE#O\YY6GR:T0^,`>0_I\?\`4`,(
M9+M6MVV)IW9AQE4D#/P*.(GPEF!VF,(4WE52ZAO)8Q_+ZL(TU?XJ)9,F\>F@
M&'U;X4154#]A1S&\$H]_R^V/]'/K+[OQ!V-?$C,U*O\`=U1!G5M05N6A`S`3
M[5F-ZF*,!XV.$/Q8-#!_XIFZ0ASY#4DAP\PI4XGME0\I*?Z"?HCD>"91ZQ\K
MITV;)G4<K)H)$345565,":2221?-1954P@1)-,@"(F,(```(]^G/-Y0"-!!)
M60D``F95AD/;RXP,@G6J00G$DX?3&D9K14S?*[_$'Y1VHA4#S.M>J-LB91C:
M2)&4A)HV)X\:=B.-9.!`6RRMKNC!U/II_P!88]J8XAT<!'ZHOE>CIUT5I]M@
M^7?KDDJ=1^<&UXF9&4AA+@8@JA85NSJ*Y<<5V^D=D#+`Z1,9\SRB57\6F/>K
MFJWX=Y^LOU$1$?\`Z;RP]_O#FI^[0C1N*O3,G_`#VO(C:=8%*%NI%+$DIJU#
MT>4J47M_%B`A\<&D(#Z"&L^)>_\`Y2CN0]OO^<[I^_/?KF._VBDIVQ0!6?PK
M?ZHB<LK,QD''OY:7>HQ\9%LW<C(OG)O;;,V+!!1T\=+JB'B1%NW1,<P_@4.<
MJVA;SS=.T"IYU6E(&9.4HW-55TU%3/5E6L(I6&];BCDE($R>W#@)F-7'3MD]
MWM^3.\[#.VJKC'=#L[J_I*K$%9`D;!'_`,.8DA?[8OC[KC[%%Z)/3T;JFZ^G
M7W[U%K$](?N]TFQ:<AN^5U(W2D`S45.J\ZK>PX`$-:C@H$2G'Y-=([8_]X#[
MU]?U&K4*7MJTUJZL*.*0EG[*B:`.))(#A2)E,C.4;4//@"/UNCQ/_5'_`$_'
ME"9"+5`E,AG%:V[NUF8L4Y=U6U>U^:XPBLN[8SN1VL)DC-WZTMC2B06+*VRL
M4\4D#7GL1+W6]V`)-%O$12;UJ50P**',)2>(])MRR4590U-XN7GN45*4A262
MGS-2YR)U`@-C2=2B)`D1H+U=WZ6M8ME'I34O'!2O='9/*9B5&OC38V,IKQAL
M_9<0VZ_(SS_],G\+UBV4ZN/JF*+,8M27K]OG+"_C[(5T9P5P5%THV%,J8DZ,
M)@YI[BJU/54[0FI%.!(EU:%>*>20B4L.,L8V].NN;&FK*%JF!X<@3VY16S5-
MB?DCV)V'W1Q[KY-Z;TC'^KF<V>'8@^7<?YBLMML`/,>U>[!+/7E.O\/%%!,]
MA%$2$;IB($`?3\>N>LVV+5:Z&LO(KG*JMIO.1Y*D)2E.HH\6M))F4G(B4NV.
M;I;C>+G7UC%"MI%/3/>7XA,DB9/#AAGG.+(,K9P@M:==+MG;/DQ'-HS$F.%;
MEDJ3JL>\"/=R4/$HFE6]4BGRZ[\WZU._W>,;+JF6,9=),YQ-V;G(6RW+OMX1
M:;27%O/O$-A2DD@"1Q4,$@`S,Y<3E'05=6JV6]5?6K"@VC&0^@=YB"N.+7\N
MN=Z[6<S1;73C7&G7!&,LU8P5DFKY2R;DAI2)84'T8EDF]5FV5B#@KJ\@ERJ+
M,XV/<HL7!_:4.H8I@#I*BFV7;U+HE&O?K$"2G6U-H;*^(2A22N23@5%0U'$8
M1IZ=[<=<A%6V6F&%XZ58JT\%3`.*APX1WS\BFS]_U"UF_P`XJ##UB<M">7L"
M8^4C[6A(+PHQ64<NU'']@=%2BG\<[!\TBK`LJT'W?`JY""H4Y0,4<#:]F:OM
MV^6N*4EHLNK!,BJ;:%KD?[(CUW%<ZFV6Y-0T`MWXA""<II41,Q]'R%;-WG4[
M!E8R9CV'K4[.36P>O>)W+.UH/W$8G`99RK7*+/ODB1CZ-<!*L8N845:&%04B
MKE*)R'+V4?3:&W*3<MT=H*E90@4CKH,IDN,H*TC$<0,XR;Y=Q9J,/H3J47$(
M`[5Y?B[(Y+Y%]C[QJ)IEG#8C&\/69^ZXWAJ^ZK\5<DI)>M.GD]=:U51-+H0[
MV.DUF[9"=.J!$5DS&.0H=]=\QMK6FEONY:6VURU(I%:IZ<_""3*>`)`D)X3,
MX\[]7O6BUKJZ?%:2!,_FZC(&7&4YX1&.$V?W.P)LQJW@_;)#7?)='V^D[M4J
M'?L"5^_4.TT*_P!-H[C(/V-LI]TL-M:V"G2T*Q61+(LW+=5HX`OO)B4P=[5^
MT[<NMIK*VS.5[-50O";;NE25MSE[Z0!/F)2/YISEKV[E=Z-^FHKJMM]=5[BF
M\)#BHC,`3G$AMNMG;Y@',>B6/ZC$5B2AMH-F%<,7IS/H2*TC#UI/&=SN82%8
M.Q?M&Z$T,G7$DQ,Y(X1]@YP\/+HP:RR66GN5)=+BZI0=HZ9*TC@?M$(D?[4_
M1&RN5P<H:RCID8M5#I03RD)CUQFVTX[GM8Z(F-4K)K=`LX6'LLE?D,^U/(UF
M7D#,VS9W"DJAZ#9J\1@!4D'177W8+>0G3\.O$W>/8_DRWT,W<5!9<7I'DE(4
M)F4YJ!&'+VQ?=/F>DJMGD>:E./FZM,Y3PTB<_9$3/C7SMO[M=C'#FS&:)+4Z
M,P;EBBS5A1I.-*;E6.RI&2I9!]$0I%I^RW29JBC%)[&J'=%*V\SIG*!#%$!$
M=_O:U;>V[<7[+:/CEUE.1J4^ILI)4D*`3H$^.9/#*-5MBMO%RIF[C7?"&D<G
MI\H+"L%%)F%"4ICAC'?K#9N^O/D?L.GYX>LEQW$:<P.P[>=(C(!;5+=)Y<>X
M_<1*S@7XQ7^'R134%2D*U!Q]P(B*@E_+S45%C(V2G<B%'XHW$4P3A(D(UK]4
MP)Y&,U%P=5N15K7[@;"_1W_BCIS;'8_;F&W1U]U$U:-K]#.\KX,RYF*>MF=:
MQ?[0T9&QG9:C")Q$6UHMIKBZ0R*5H\A,M[@`*?H(=]#LK/:;&_8*J^73XORZ
M>H;:`86VGWPHB:%S4<4GQ`2'&,:[UMU5>&K=;!2:5LZSYP63@2,-/"0]<3CP
M.TV'8T<4-F9O$$]DG]:D3E?X2K]NK-)_P\<&X1"'Z;=YNPSGZPD8%1<J_<>R
M<#$\"EZ'OF[BY0&K#=L#PI2/[TI*\,\4@)ERPG&ZM[=8VRKX_P`KX@?Z,$([
M,\9\XK3Q%LYOCN+><W6O6Z9U1QCAK!FQ=WP":C9=J^1KGEFY*XNFFT-<;):9
M.IVF!CL:$L!A65@F@,'RAT`356.)3]<ZFZ6G;FW;?3KN:;@NLJJ=+Y*%(#02
MLD)T:@292\6(D9X"-!;[E>KI5/I86RFD8<T8D%<P`<4YXSPBYY(1%),1'L1(
M41'KKL1*'8]=CU_3SC``!(3EVF9])X]\=8`H`!6*I8\,>Z/9Q%8<0CQ/Y>(^
M/7EZ==_3ZA_Q<0D#@<HAIF/`4KM!<ZK#Y48A%X#QC;V5R3I!W#9S(YFNT&!Q
M@'UI^T440B<<UU=0RR+`3&>2;H0,N""*92*5C);>#*26S]H1+N$3*3(5,I2D
M*!"D(4A2E`"E*4H=`4I2@`%*4/0`#T`.)QBYJ*CF8\^4BL.(0XA#B$.(0XA#
MB$.(0XA#B$.(0XA#B$?'(/&<<Q>R4@X19L8]HY>O7CA0J3=JT:HG7<N5U#"!
M$T4$4S&,8?0H`(\H4J4-*`5+.``S)Y1:L@())``&9R$?SR_XC3,<-M'N]0)G
M7Y">RK3\08-@:S(7>DUJQ3U3/;'5OLMJ>L&,]'QBL>^)&M73,%U45#$35.8G
MEY%$.?:'0*C1;-GW%N[*;9-34%20I:`=/EEO$%4Q-1$L,L>4?./5)\U=_9JJ
M(%3324S5(Z1)4^`GV8#.-E'6G^(1^.J]XWIO^<&3;%KOD9E6H5G;ZGEF@79@
MW9S[6.;MI48VSP\!+U^4C3O4CF05]Y%4R9@$Z28]E"`KUT>WI05SKU/3HJ*5
M2R4K:=;4D@DRS4#EGAZ8E2W=1-N/TZ$/NK:6$">MM<I@<P#GPCO*U_.]\6<!
M'F<PNS\=DJ2$.FM7Q/1<C7^SR*I@'VVS2,A:FH7WEC!T7W5$B]_40YJ6>EF^
M:X%"*13(&:EN-(`$_P"DOZ!.,US?.VTR4R^75#\U"%3_`,X)'MB`^:\W_)?\
MM\6]P7J1@K(&BVH=U(>)R5M)L=&JT_*5YI3L3)2D/CK'B*P3T8RFF(F3/[)C
M*N4S"FH\:)F4*;J;);-G=.Z@73<56W<[ZP%%MAF3C:7!D75JTC`XX3&&6`GH
MKE7;CW9*BMS#E+:7/>6Z-*R/Z,M7>>^+IM%M&<(:`X#@,"X3ASDC6*_ZQ;+A
M*^RK:\B7%PW12DK=:'B*21#NEP2*DW;)A]LQ:D302#Q*(C&VYMRW;>%T5=KR
MJ:EB24#W4IG,)`X#GVQVMELM)8*(4E$/%FI1S4J4IF-=O^+CF4FN`]/X,QRE
M6D,O9(ER%_$$8:@L6BA_V]`:9*')T^[.E2MSW!)D`*#/A+SD9GG+&(QZR+2F
MU4K9Q<75$R_],H^E0C8A^.2!<U70/3&"?D,B[8ZS87!=(Y1(=-5U08-X9,Q#
M="4Y/N.A`?4!#D*;UJ&WMWW1U!\!KGI'F/,5E$E;9;6C;]&VH26BF0#Z$@'Z
M(KV^7K;V59L(G1[!/WEIS9FQQ'Q-QBZUVZE(*G3*I2-:R`(F\F\[>._$Q1,7
M[>+(JLIXD4(;DX_=ZZ?4U17O]4=WI#6SK4DE+C@DA;R1@!/WM)Q(&9D(^3?O
M5]2ZM-N1T?V.I3^];P-*VVL5-MJ^L0?#J]<HGAH!J!&Z?8&AZ.Z^R>Y"L2J-
MGR;/,Q\R/;,Y;D(2(9+B0#'AJRT*5HV_`XD45Z`5!Y&O5_J)6]3]W.WITJ3;
M6T>13MG#2PDS"B!,!:LSCE(3PB6?N_\`1^CZ/]/Z6QJ2VK<+ROB*UU))"GU)
M`*$J*4J*$#`3`QF>,3KY&<3I'B<.RB'\W_"'&/"+5A)3)645N?(9+_'1/5VE
M8;^0&SXUJ\;;G<G;,:R>09N4HSN'GJH#1NZL5&R?&J1BU(MD;^J)>RHC(M'*
MQ!,!2J$*<`W6W'MQ4;E16;9+A=6@A:0)A2,-06G'P&0U&1E&EOALOEAN[J+;
M>87R(RD>9CI7X@[Q>;;4-F8%ODW(N=M8,>Y\>5+3W.F5SOW]TO\`BI.K0CN?
M:?XKE64?*9!J].N:[J-BIY=,QWR*1@!0Y2%ZW^^VZ$/T%6RRS37-ZD0JH99,
MT)7/WY?FE6:DS,O3&KVBY4H8>8"E.VX/S:<5.:DS,\\<!EWQ5U7V_P`;`[P_
M*,;>3,SC%MR/MI$GI;`,_P"9<-!*5(N&:`5>13B\;6ZLQLR5.7]Y(7:Z:RY/
M#VP.!0`O.PK[EN`[;LK=D8;?:1;O+=/DI=*5!UQ4B5`E$PL$8B>/*.?H:6UL
M7NXKNCKC3AK"M$B0"E7.0QE+_MBYG?W"\AM]\9F8,;ZY23"WO+WB"IVG"ZJ4
MHL]C;RG47U:OM.B@E9!4RS]M<65>1;$7<'`53.2G5-ZF'D?;-N:;#O:FN-UD
M&4..>9I2$E/F)T9<=)))QP`CL+[3)N>WUL4*@I>D%/;+A^'&,<PA\P&B5HQM
M55,CYNK&!,K,&$-7,@8(S"5_1,KT6_((MHN7J3JE3#-"9DC-I<ADV[ADDX;N
M41(<ANAZ#TNNTKW353KK+*GZ$J*DO-^)M25&8.K($<092/9*/*U[AMSE&TT^
MHM5*$A!0H$&:<#E/`G(\LX^GYDL?W/).@&25\>5N7N<W0+MA'-9JI7V:S^PV
M*NX?R]3,AVAC!1R)#K/Y4:U!.E442`)U13\2@)A`!]=AU=/0;F:55J"&U(=;
MGP!<:4A,^R9$X\]UL.U-F*F`5Z'DN$#,I3G+MB'6\6X6O&_^/]7]<=0\D1.<
M,J9:VDUJR2^K5(([E)+%.-L5Y#ALEWZX9=;I(`..D*]&0!FIV\J+9RH^5*D0
MAC=];_9MLK-L7&MNM["6**FHJA)4HB2RXT6T!OZ^I1F",-./9&EOERI=P4[-
M%:U:ZM;[+A1*10$2*@O@%#*4SB,XEO\`.`477Q:[8-DRN!.ZKE"2+]L"GW`>
M[EO'P"9`4P,H18A!$Q3`'Y!#O\.<QTZ=2=YV]9TIF'%#7@GW%$!1Y'+TQN]X
MMJ=L#K2`2IPI`EWB(N!@R,TG^2?1J_.[UE?-E'V>I64=>6LSL;=YO,=EP;D^
M.J3;(-3=8HMUA$SJEL,H1<6^B91J7L'@HI>)P`/`=RF["^;6N-*`Q1U%-5)<
M*&AI#R9R*3,DJ"<QE*>7&-.W;%6G<-#7)\UQIZG\LZC/2<,1RSQB0WR6$.;9
MSXA!*FH<$]]')E!(0QP3+_D)E,/,XE`0(7L>NQZ#OTYKMJ.MILU]2I0"U4:0
M`<R?.:P'HQ[HV]_2HW"V2!(353/=IE^.+3;V8!HMS/T8`&IV,0`0_-Z0KWL.
M@[]><?;R/C&$G#2\`?7/U81T%1X6G',P4$X9X)/MQBN7X5?(GQ:Z:)*)J)J%
MQ>\`2*$,0P=7.T&]2FZ,4>A_$.=5U%JFJO>]<[3^)#I001R"$@SCG]FM.,[=
MIV'!)Q)6#/M<4KZ(Q"'*<OSFW504U/;'XOZBG[O@?VO<_P!Y>6-[?N"`)B?Q
M'OQ`>P#U^G,JHK*=/2M#!4/.1?RZ1QT+9`!'<4X_C@EAP;T55']D:?3Z<#ZH
MA_\`)\CJTI\G>F1MP[RMCG#0:G;'@I9R9'ON*"DM9KSC@(&.&WX[FJ_.E.[1
M,Y$&@N00<>'YR'\"@&[VC47RDV7<FK(RA^J77TYD6D.@!/F*)\4U3Q&`01G,
MCCJ[^Q0_Q-3KN#BFV13$3$QCJ41CWR$6UZ.S.IC["8P^FV0TLG8CKULG(Y6;
M+D>YY37:6E\+68EXQY;<@3,Y9%UB$D4E"H'<F2034*5,"E].<'?E7%ZOUWEO
MR:X@>%*`V`.!T@`"8[,8ZNU?!>06J!:G&!,E1,\3F)Q2'\@&3=""/<G;(:+;
M`C0/D^C;<SJU9HNO\[9&]YS]E:"L[*MCC?-6`2-/TR_0DJ+=9J[EG\:7V6A?
MN`>F3(7RD#:HO+SS%HW.RE[:ZF%R4Z,$,:5*!;<S$ES\(PGA+.7'7E%G+BG;
M,ZIJ_I="B&\5*.`(6G++\,8V;ZJO-NJQ7'-E9-XZQN(&'7L$>T-YM6$VM'MU
M)5DV/Y'\V[5^90A!['LI0]1Y%[R6DNJ2P9LA1"?T9X>R.]IU.KIT+?GYY0DJ
MG@=1`G,<YQSW/./:'$(?7B$.O^YQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ
M"'$(<0CQ,4#E,40`0,42B`@`@("'7J`^@ARA$Q*!`(DH33Q$?,5J0@`4A4BD
MZZ\2I$*'77TZ*4`ZYYE"I89_I+_+'D66LD(;2.82)_DC@)*DU.9.8\O5ZS*B
M8!`PR4#%/C&[Z[\C.FBHF^G,D//)D4N.`@9:C*+33,D24$G^JG\D>B+H-,@E
MRNH&H5.$=`/?W,37(>.<=>(E]%F;-%0!Z']OTYYON5+P`4HJD9^)2OQ$104M
M,E0/EMJ[TC#ND,XRSVNQ[-T;L`#U`.PZ]0Z_?RW2E2?&/%QE'N`4KU)/A/#E
MW1^&.")1$?7\>N^OY/Q_;URI*4R"L$Y#\D4Q*R$XJ./<(T[_`)HL?6;Y/_E/
MU1^/[$":TS"X+J;BY[&V9@F+N'Q?#9"F85_8EYYXF(M6TJVHM>:)LVYQ*JL^
ME$42@(B;Q^C^F-QI]A=/[KO"Z#2]5A3-.D$:W))4D%(.8UJU83P3W1#>]6%[
MHW+36>BF6Z4I4XJ7A$YD@D9$"4XN@V:WK2QK^G:B:-T\<Y[.-X5C5(6NU4B<
MQ2L+1,<T1B6,OD2:25)$,G,0Q1)XLE5R$(8GDY,F3HBG!;/V+\S;_BW>SGR_
M;`^T"GIH=JQ.:@PVH!1),QJD1R)X>^_=\55`P=K;%9<K=S/)"$EN1;ISI`!=
M5DD#/NCE]`?CD)KI(S.>\\V8F8=M\AG>RUNOL@=61CZBYFP$\I%519T4BJ[Y
MP4P).Y$2)"HD4$4")-R^)]GU*ZKU&ZZ)K:FVD+H-BT8`8IY@>84B0=>"0)E6
M93C(G.<<STCZ)M;+KWMY;L6W<.H5<2I]\@GR0O%33)43[I.G6)`@8"46N@7H
M`#\0Z[_<'(;!/'./H1(TB4>7$5ARAF1(0C@YVM5^S-`86&"A9YD"I%P9S<4Q
MEFH+$_J*@W?H.$05*'T-X]A^WE[:W6L6%K;/-)D2.7<8\7F6WDR<0A?8H3$<
M@U8MF2"#5FW;M&K9)-!NV:H)MVZ""0>*2***)2))))E]"E*`%`/H'+`5E16X
M=3AXG.7;'HVA#:=*`$IED,`.X1PCNF5.0<K/']7K;UVX-YN'3N"C'+E<_0%\
MUUUVJBJIO$H!V81'H.7AZK&"'G$('!)D/3_DE'DJDI534IM"EGB4@_BG'.H-
M$&J23=JBBV;(ID11;H)$11113*!2(I))%*FFD0@=`4```#EBTA>*IE?/C'LA
M+:!)*0,)88#U1CSVD5&2F$[!(U2KOYU#VP;33VOQ3J70!+T3!*27:*/4_;`/
MR]'#K\.>H?JTI\IM]Y+'U`?#WRCP52TZCYA;:+\_>*1.7#'.,E!+HH%[#H.N
M@Z]`Z]0_>`\\9**]1.,>ZL1@`"<^4<%%5*M0;N0?PM=K\.^E5!5DGL3#1T<[
MD5/(Q_<?N6;9%9XIYF$>U#&'L>_KR]URI>2$/.K<;&849C3R'+E&.U2LMK*T
MMMH6>*4@'TF.6>Q[20;G:/FC1ZU4Z!5L];).FZ@`)3%]Q%8ITS^)B@(=@/J`
M?LY8-:#K;.EP8)(X"/=2&W$Z7!J';C],>I:*9.3M3NFC-R+%<KIF+AJBN9HY
M)Z)N&@JE,+9=,@B!3DZ,`#Z#R[Q`J*3(*&/:><%H2MQ*U`>%,O3S'*/8XCF3
MM9JNZ9M'*K);[AHJY;)+JM%_`R8+M3J%,9NMX'$OF00-XB(=]<L"5(6IQLD%
M20#R,N<%-M+D7$@J&6&4?6=,IRB4Q2F*("!BF*!BB40$#`(#Z"`@/7*I3I,_
M3Z8JH$B0_`1\S1@T8()M&+5JR9HD\$6K-NDV;HD$PF\$D42D23+Y"(]``!V/
M*267/-69N9$]G"*(2&\$`!'``<8\/TUG]X,A]HT^_%`K47OVR7WAFI5!5!L9
MT!07%N54?(">7B!O7KOEGE:FO(<)+,R9<)SP]4"VWJ#DOM!QCXY2N04VHDI,
M0D-+'0(9-$\G%LGYT2',!CD2,[06%,IC``B`=`(\]4J>1[BO:1[`8M<98>,W
M6T+/:`3[8^B,AHF&;F:Q,7&QC8ZHK';QS!JQ0.J8"E%4Z+5)),R@E(`"80[$
M`#EREK6=3AFOTGZ8N0VTT-+*4H1R``'LCC4Z?5T9Q2S)5NNIV)4HD//DA(PD
MV9,Q`(<AI8C4K\Y#$#H0%00$/3EY?J2SY2G%E/`$G2!RERCQ-,P'?.0VVEWB
MH)&H^F,E#T#KGD``)#(1D0Y6$.(0XA#B$.(0XA#B$.(0XA#B$.(0XA#B$.(0
MXA#B$.(0XA#B$.(0XA#B$.(1'394=D7%&-#:NM,=,\C6!;])->LGR4@G7,=1
M*Z2P.[6TK<5$2KNZV-B(A]A'*F:,C+B!W"PI%,DIG6WY?\8DW3S#2#$I0!,D
M<B<I_1E&MN9KTL$V\`/'#5R'=QBO_!?Q:RN/ZM::M/YYM%?99/GW=OSG.8E(
MO#9DV"N$B9525G<Q;#3XO;S)-W9EU$T8R`:5R-8-C^PW3*7L3=A6;UIWGD*9
MI&ZAJG&EE-1-;3,I2+;`(0E8(!UDJ*C(D81I:;;;C=/Y)?4AMPE3@"1J7JQ,
MUG'V818WA37+#&NE9)4,+4"O4&$%05WP1#+N4FW1NQ._L,ZZ4<34_(J'$3&7
M>+K*"81]><O>[_?=R5)J[]5O5;Q_TAF$@``);`D&P```$CA&VMMBM5J3IH64
MMD<4X*5SUG->/UN&'".[BE\2@'??0`'?[>@ZYJ$C2`D3D.>)]<;33SS]7LCR
MY6+H<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(
M<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(]9_W
M?0?Y^7"+TQ^I_P!7]X\HK.*+SCSY2+8<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"
M'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<
,0AQ"'$(<0AQ"/__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>12
<FILENAME>rtgn-20150331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.8 on 09-Jun-2015 [02:22:47] {PM} EST - www.datatracks.com -->
<!-- Based on XBRL 2.1 -->
<xbrli:xbrl xmlns:rtgn="http://www.ruthigen.com/20150331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr">
  <link:schemaRef xlink:type="simple" xlink:href="rtgn-20150331.xsd" />

<!--Context Section-->
  <xbrli:context id="P02_01_2015To02_11_2015">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-02-01</xbrli:startDate>

      <xbrli:endDate>2015-02-11</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2014To03_26_2014">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-03-01</xbrli:startDate>

      <xbrli:endDate>2014-03-26</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_13_2015">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-03-13</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2014">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2015">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2012To03_31_2013">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-04-01</xbrli:startDate>

      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2013To03_31_2014">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-04-01</xbrli:startDate>

      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2014To03_31_2015">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_05_2015">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-06-05</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P09_01_2013To09_25_2013">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-09-01</xbrli:startDate>

      <xbrli:endDate>2013-09-25</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_25_2013">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-09-25</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2014">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2013">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

<!--Dimension Section-->
  <xbrli:context id="P04_01_2013To03_31_2014_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-04-01</xbrli:startDate>

      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2013To03_31_2014_WarrantMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-04-01</xbrli:startDate>

      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2013To03_31_2014_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-04-01</xbrli:startDate>

      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2014To03_31_2015_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2014To03_31_2015_WarrantMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2014To03_31_2015_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P06_01_2014To06_24_2014_ChiefFinancialOfficerMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_EmployeeAgreementMemberrtgnLicenseAgreementAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="rtgn:LicenseAgreementAxis">rtgn:EmployeeAgreementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ChiefFinancialOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-06-01</xbrli:startDate>

      <xbrli:endDate>2014-06-24</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P11_01_2014To11_28_2014_ChiefExecutiveOfficerMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_EmployeeAgreementMemberrtgnLicenseAgreementAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="rtgn:LicenseAgreementAxis">rtgn:EmployeeAgreementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-11-01</xbrli:startDate>

      <xbrli:endDate>2014-11-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2014To03_31_2015_TwoExecutivesMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rtgn:TwoExecutivesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2014To03_31_2015_ChiefExecutiveOfficerMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_EmployeeAgreementMemberrtgnLicenseAgreementAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="rtgn:LicenseAgreementAxis">rtgn:EmployeeAgreementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2014To03_31_2015_ChiefFinancialOfficerMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_EmployeeAgreementMemberrtgnLicenseAgreementAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="rtgn:LicenseAgreementAxis">rtgn:EmployeeAgreementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ChiefFinancialOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2015_LicenseAndSupplyAgreementMemberrtgnLicenseAgreementAxis_OculusMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="rtgn:LicenseAgreementAxis">rtgn:LicenseAndSupplyAgreementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rtgn:OculusMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2014_WarrantMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2015_WarrantMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2015_ExercisePriceRangeOneMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">rtgn:ExercisePriceRangeOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2015_ExercisePriceRangeTwoMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">rtgn:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2014To03_31_2015_ExercisePriceRangeOneMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">rtgn:ExercisePriceRangeOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2014To03_31_2015_ExercisePriceRangeTwoMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">rtgn:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2015_ExercisePriceMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">rtgn:ExercisePriceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2014To03_31_2015_ExercisePriceMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">rtgn:ExercisePriceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2013_RestrictedStockMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2013To03_31_2014_RestrictedStockMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-04-01</xbrli:startDate>

      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2014To03_31_2015_RestrictedStockMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2014_RestrictedStockMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2015_RestrictedStockMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2014To03_21_2014_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-03-01</xbrli:startDate>

      <xbrli:endDate>2014-03-21</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_21_2014_IPOMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-03-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2014To03_31_2015_PerformanceSharesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2015_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P05_01_2014To05_12_2014_TwoThousandThirteenPlanMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rtgn:TwoThousandThirteenPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-05-01</xbrli:startDate>

      <xbrli:endDate>2014-05-12</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P05_01_2014To05_11_2014_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-05-01</xbrli:startDate>

      <xbrli:endDate>2014-05-11</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2014To03_21_2014_IPOMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-03-01</xbrli:startDate>

      <xbrli:endDate>2014-03-21</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2014To03_26_2014_IPOMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-03-01</xbrli:startDate>

      <xbrli:endDate>2014-03-26</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_21_2014_TwoThousandThirteenPlanMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rtgn:TwoThousandThirteenPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-03-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_26_2014_IPOMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-03-26</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_26_2014_UnderwritersMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rtgn:UnderwritersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-03-26</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2013_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2013_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2013_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2014To03_31_2015_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2014To03_31_2015_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2014To03_31_2015_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2013To03_31_2014_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-04-01</xbrli:startDate>

      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2013To03_31_2014_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-04-01</xbrli:startDate>

      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2013To03_31_2014_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-04-01</xbrli:startDate>

      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2014_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2014_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2014_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2015_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2015_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2015_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2014To03_31_2015_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2014To03_31_2015_ManufacturingFacilityMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2014To03_31_2015_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2014_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2014_MedicalEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rtgn:MedicalEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2015_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2015_MedicalEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rtgn:MedicalEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2014To03_31_2015_OculusMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rtgn:OculusMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2014To03_31_2015_LicenseAndSupplyAgreementMemberrtgnLicenseAgreementAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="rtgn:LicenseAgreementAxis">rtgn:LicenseAndSupplyAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2012To03_31_2013_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-04-01</xbrli:startDate>

      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2014To03_26_2014_OculusMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rtgn:OculusMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-03-01</xbrli:startDate>

      <xbrli:endDate>2014-03-26</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_26_2014_OculusMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rtgn:OculusMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-03-26</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2015To03_13_2015_OculusMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rtgn:OculusMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-03-01</xbrli:startDate>

      <xbrli:endDate>2015-03-13</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2015To03_13_2015_MergerMemberusgaapRestructuringPlanAxis_OculusMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rtgn:OculusMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">rtgn:MergerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-03-01</xbrli:startDate>

      <xbrli:endDate>2015-03-13</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_13_2015_OculusMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rtgn:OculusMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-03-13</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_13_2015_MergerMemberusgaapRestructuringPlanAxis_OculusMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rtgn:OculusMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">rtgn:MergerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-03-13</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2015To03_31_2015_OculusMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rtgn:OculusMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-03-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2015To03_31_2015_MergerMemberusgaapRestructuringPlanAxis_OculusMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rtgn:OculusMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">rtgn:MergerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-03-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2015To04_30_2015_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-04-01</xbrli:startDate>

      <xbrli:endDate>2015-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2014_IPOMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn10_31_2013_TwoThousandThirteenPlanMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rtgn:TwoThousandThirteenPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2015To03_12_2015_NewTwoThousandThirteenPlanMemberusgaapPlanNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rtgn:NewTwoThousandThirteenPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-03-01</xbrli:startDate>

      <xbrli:endDate>2015-03-12</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2014To03_31_2015_TwoThousandThirteenPlanMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rtgn:TwoThousandThirteenPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2014To03_26_2014_UnderwritersMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rtgn:UnderwritersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-03-01</xbrli:startDate>

      <xbrli:endDate>2014-03-26</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2014To03_31_2015_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2015_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2014To03_31_2015_RepresentativeOfUnderwritersMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rtgn:RepresentativeOfUnderwritersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2015_RepresentativeOfUnderwritersMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rtgn:RepresentativeOfUnderwritersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_13_2015_PulmatrixIncMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rtgn:PulmatrixIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-03-13</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn07_31_2015_MergerClosingDateIsNoLaterThanJuly312015MemberrtgnDateOfMergerAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="rtgn:DateOfMergerAxis">rtgn:MergerClosingDateIsNoLaterThanJuly312015Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn08_13_2015_MergerClosingDateIsAfterJuly312015ButNoLaterThanAugust132015MemberrtgnDateOfMergerAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="rtgn:DateOfMergerAxis">rtgn:MergerClosingDateIsAfterJuly312015ButNoLaterThanAugust132015Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-08-13</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2015To03_13_2015_EmployeeAndDirectorMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">rtgn:EmployeeAndDirectorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-03-01</xbrli:startDate>

      <xbrli:endDate>2015-03-13</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2015To03_12_2015_ChiefExecutiveOfficerMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-03-01</xbrli:startDate>

      <xbrli:endDate>2015-03-12</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2015To03_12_2015_ChiefFinancialOfficerMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ChiefFinancialOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-03-01</xbrli:startDate>

      <xbrli:endDate>2015-03-12</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2015To03_12_2015_ChiefExecutiveOfficerMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_EmployeeDirectorAndConsultantEquityIncentivePlanMemberusgaapPlanNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rtgn:EmployeeDirectorAndConsultantEquityIncentivePlanMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-03-01</xbrli:startDate>

      <xbrli:endDate>2015-03-12</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2015To03_03_2015_NewConsultingAgreementsMemberrtgnAgreementTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="rtgn:AgreementTypeAxis">rtgn:NewConsultingAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-03-01</xbrli:startDate>

      <xbrli:endDate>2015-03-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2015To03_10_2015_NewConsultingAgreementsMemberrtgnAgreementTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="rtgn:AgreementTypeAxis">rtgn:NewConsultingAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-03-01</xbrli:startDate>

      <xbrli:endDate>2015-03-10</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2015To03_13_2015_OculusSideLetterAgreementMemberrtgnAgreementTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="rtgn:AgreementTypeAxis">rtgn:OculusSideLetterAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-03-01</xbrli:startDate>

      <xbrli:endDate>2015-03-13</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2015To03_13_2015_MinimumMemberusgaapRangeAxis_OculusMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rtgn:OculusMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-03-01</xbrli:startDate>

      <xbrli:endDate>2015-03-13</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2014To03_31_2015_MaximumMemberusgaapRangeAxis_OculusMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rtgn:OculusMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2014To03_31_2015_LicenseAndSupplyAgreementMemberrtgnLicenseAgreementAxis_MinimumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="rtgn:LicenseAgreementAxis">rtgn:LicenseAndSupplyAgreementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2014To03_31_2015_LicenseAndSupplyAgreementMemberrtgnLicenseAgreementAxis_MaximumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="rtgn:LicenseAgreementAxis">rtgn:LicenseAndSupplyAgreementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2014To03_31_2015_FirstPhaseMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_LicenseAndSupplyAgreementMemberrtgnLicenseAgreementAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">rtgn:FirstPhaseMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="rtgn:LicenseAgreementAxis">rtgn:LicenseAndSupplyAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2014To03_31_2015_LicenseAndSupplyAgreementMemberrtgnLicenseAgreementAxis_SecondPhaseMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">rtgn:SecondPhaseMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="rtgn:LicenseAgreementAxis">rtgn:LicenseAndSupplyAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2014To03_31_2015_LicenseAndSupplyAgreementMemberrtgnLicenseAgreementAxis_ThirdPhaseMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="rtgn:LicenseAgreementAxis">rtgn:LicenseAndSupplyAgreementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">rtgn:ThirdPhaseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2014To03_31_2015_FourthPhaseMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_LicenseAndSupplyAgreementMemberrtgnLicenseAgreementAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="rtgn:LicenseAgreementAxis">rtgn:LicenseAndSupplyAgreementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">rtgn:FourthPhaseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>

      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn01_31_2014_OculusMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rtgn:OculusMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn04_02_2014_OculusMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rtgn:OculusMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-04-02</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2013To03_31_2014_OculusMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rtgn:OculusMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-04-01</xbrli:startDate>

      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P08_01_2013To08_12_2013_ChiefExecutiveOfficerMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-08-01</xbrli:startDate>

      <xbrli:endDate>2013-08-12</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2015_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001574235</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:unit id="shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>

  <xbrli:unit id="USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>

  <xbrli:unit id="USD_per_Share">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>

      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>

  <xbrli:unit id="sqft">
    <xbrli:measure>utr:sqft</xbrli:measure>
  </xbrli:unit>

  <xbrli:unit id="pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>

<!--Element Section-->
  <rtgn:DisclosureOfPrepaidExpensesAndOtherCurrentAssetsTextBlock contextRef="P04_01_2014To03_31_2015" id="Factid_1">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt;Note 3. Prepaid Expenses and Other Current Assets&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;Prepaid expenses and other current assets consists of the following:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div&gt;March&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"&gt; &lt;div&gt;Prepaid insurance&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;12,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"&gt; &lt;div&gt;Clinical testing and other deposits&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;114,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"&gt; &lt;div&gt;Prepaid rent&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"&gt; &lt;div&gt;Other prepaid expenses and current assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;38,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"&gt; &lt;div&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;166,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</rtgn:DisclosureOfPrepaidExpensesAndOtherCurrentAssetsTextBlock>

  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="P04_01_2014To03_31_2015" id="Factid_2">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; Note 5. Accounts Payable and Accrued Expenses&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Accounts payable and accrued expenses consist of the following:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div&gt;March&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Accrued employee compensation&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;92,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;109,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Accrued director compensation&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;43,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;50,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Accrued legal fees&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;144,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;183,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Accrued other professional fees&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;50,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;45,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Accrued research and development fees&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;128,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;9,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Accrued franchise taxes&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;146,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Other accrued expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;32,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;14,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;635,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;410,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>

  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P04_01_2014To03_31_2015" id="Factid_3">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;b&gt;Note 6. Commitments and Contingencies&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;b&gt;&lt;i&gt;Agreement and Plan of Merger&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;On March 13, 2015, the Company entered into the Merger Agreement with Pulmatrix, a privately held biopharmaceutical company focused on the discovery, development, and commercialization of inhalable therapeutics and enabling technologies that treat and control respiratory infectious diseases, which provides for the merger of Pulmatrix with and into Ruthigen Merger Corp., with Pulmatrix continuing after the merger as the surviving corporation and a wholly owned subsidiary of Ruthigen (the &amp;#8220;Merger&amp;#8221;).&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;Subject to the terms and conditions of the Merger Agreement, on a pro forma basis, based upon the number of shares of Ruthigen common stock to be issued in the Merger, following the closing of the Merger, current Pulmatrix stockholders and their designees will own approximately &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;83&lt;/font&gt;% of the combined company and current Ruthigen stockholders and their designees will own approximately &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;17&lt;/font&gt;% of the combined company.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;The Company&amp;#8217;s and Pulmatrix&amp;#8217;s obligations to consummate the Merger are subject to the satisfaction or waiver of customary closing conditions, including, among others, obtaining the requisite approvals of the stockholders of Ruthigen and Pulmatrix, including the approval of the issuance of the shares of common stock of Ruthigen to be issued in connection with the Merger and the charter amendments by the stockholders of Ruthigen, and the effectiveness of a registration statement on Form S-4 relating to the shares of Ruthigen common stock to be issued to Pulmatrix stockholders pursuant to the Merger Agreement. Ruthigen is required to have unrestricted cash on hand, net of outstanding liabilities, at closing of at least (a) $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;9,000,000&lt;/font&gt;, if the Merger closing date is no later than July 31, 2015 or (b) $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;8,850,000&lt;/font&gt;, if the Merger closing date is after July 31, 2015 but no later than August 13, 2015. In order to meet the cash minimum requirements, the Company engaged a placement agent in anticipation of an offering prior to the closing of the Merger, although no assurance can be provided that an offering will be completed. See Note 6 &amp;#150; Commitments and Contingencies &amp;#150; New Consulting Agreements. On May 4, 2015, the registration statement on Form S-4 became effective.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;Although Ruthigen is the legal acquirer and will issue shares of its common stock to effect the merger with Pulmatrix, the business combination will be accounted for as&amp;#160;a reverse&amp;#160;acquisition of Ruthigen by Pulmatrix under GAAP. Under the &amp;#8220;acquisition&amp;#8221; method of accounting, the assets and liabilities of Ruthigen will be recorded, as of the completion of the merger, at their respective fair values in the financial statements of Pulmatrix. The financial statements of Pulmatrix issued after the completion of the merger will reflect these values, but will not be restated retroactively to reflect the historical financial position or results of operations of Ruthigen.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;As a result of the Merger, certain RSUs and stock options will become fully-vested as a result of change of control provisions in the original award agreements. In addition, pursuant to the Merger Agreement, the Company will issue an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;90,000&lt;/font&gt; shares of common stock to an employee and a director of the Company.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;The following other merger-related agreements have been disclosed in: (i) Note 6 &amp;#150; Commitments and Contingencies &amp;#150; New Employment Agreements, (ii) Note 6 &amp;#150; Commitments and Contingencies &amp;#150; New Consulting Agreements, (iii) Note 6 &amp;#150; Commitments and Contingencies &amp;#150; Oculus Side Letter Agreement, (iv) Note 7 &amp;#150; Stockholders&amp;#8217; Equity &amp;#150; New 2013 Plan.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Employment Agreements&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;On August 12, 2013, the compensation committee of Oculus approved the grant of a one-time cash bonus of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;158,000&lt;/font&gt; to the Company&amp;#8217;s Chief Executive Officer (&amp;#8220;CEO&amp;#8221;) in order to recognize the CEO&amp;#8217;s efforts related to the preparation and filing of the Company&amp;#8217;s registration statement on Form S-1 for its IPO.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;On June 24, 2014, the compensation committee of the Company&amp;#8217;s board of directors approved an employment agreement for its Chief Financial Officer (&amp;#8220;CFO&amp;#8221;), which replaced the offer letter previously in effect between the Company and the CFO. The employment agreement continues to provide for an annual base salary of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;225,000&lt;/font&gt;, subject to increase, as determined by the Company&amp;#8217;s board of directors. The employment agreement further provides for payments to the CFO in the event of termination without cause or resignation by the CFO for good reason, as such terms are defined in the employment agreement. In the event that the CFO is terminated without cause or resigns for good reason, the CFO is entitled to: &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;(i) a lump severance payment equal to 18 times the average monthly base salary paid to the CFO over the preceding 12 months; (ii) up to one year (the lesser of one year following the date of termination or until the CFO becomes eligible for medical insurance coverage provided by another employer) reimbursement for health care premiums under COBRA; and (iii) automatic vesting of all unvested options and other equity awards; provided that in the event the CFO resigns for good reason prior to a change of control, only the vesting of the restricted stock units granted by the Company on May 12, 2014 shall be accelerated.&lt;/font&gt; In addition, if the Company consummates a change of control, all equity awards granted by the Company that are then-outstanding and unvested shall become fully vested and exercisable immediately prior to and subject to the consummation of the change of control. In addition, the Company will reimburse the CFO for any excise taxes owed by the CFO under Section 280G and Section 4999 of the Internal Revenue Code because of any acceleration of the equity awards (including a gross up of any additional federal, state and local taxes payable as a result of the reimbursement of the tax payments).&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;On November 28, 2014, the compensation committee of the Company&amp;#8217;s board of directors approved an amended and restated employment agreement for its CEO, which supersedes the employment agreement previously in effect between the Company and the CEO. The prior employment agreement went into effect when the Company was a wholly-owned subsidiary of Oculus, and the CEO was the Chairman of the board of directors of Oculus. The employment agreement primarily removes all references to Oculus and other legacy references related to Ruthigen being a subsidiary of Oculus.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;The employment agreement continues to provide for an annual base salary of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;375,000&lt;/font&gt; to the CEO, subject to increase, as determined by the Company&amp;#8217;s board of directors. The employment agreement further provides for payments to the CEO in the event of termination without cause or resignation by the CEO for good reason, as such terms are defined in the employment agreement. In the event that the CEO is terminated without cause or resigns for good reason, the CEO is entitled to: &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;(i) a lump severance payment equal to 24 times the average monthly base salary paid to the CEO over the preceding 12 months; (ii) up to one year (the lesser of one year following the date of termination or until the CEO becomes eligible for medical insurance coverage provided by another employer) reimbursement for health care premiums under COBRA; and (iii) automatic vesting of all unvested options and other equity awards&lt;/font&gt;. In addition, if the Company consummates a change of control, all equity awards granted by the Company that are then-outstanding and unvested shall become fully vested and exercisable immediately prior to and subject to the consummation of the change of control. In addition, the Company will reimburse the CEO for any excise taxes owed by the CEO under Section 280G and Section 4999 of the Internal Revenue Code because of any acceleration of the equity awards (including a gross up of any additional federal, state and local taxes payable as a result of the reimbursement of the tax payments). Furthermore, the Company will reimburse the CEO for relocation expenses if the Company&amp;#8217;s principal executive offices are moved or the CEO is required to relocate, subject to certain conditions.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;Receipt of the termination benefits described above is contingent on the CEO&amp;#8217;s execution of a general release of claims against the Company, its subsidiaries and its affiliates; the CEO&amp;#8217;s resignation from any and all directorships and every other position held by the CEO with the Company and each of its subsidiaries; and the CEO&amp;#8217;s return to the Company and its affiliates or the Company Group (as such term is defined in the employment agreement), of all property belonging to the Company Group, received from or on account of the Company Group, or any other entity of the Company Group, or any of the Company Group&amp;#8217;s respective affiliates by the CEO. In addition, the CEO is not entitled to such benefits if the CEO does not comply with the non-competition, invention assignment, confidentiality, non-solicitation provisions of the employment agreement.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;As of March 31, 2015, the potential cash severance payment related to the Company&amp;#8217;s employment agreements currently in effect with its CEO and CFO amounted to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,144,000&lt;/font&gt;.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;New Employment Agreements&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;On March 12, 2015, in connection with the Merger Agreement, the Ruthigen board of directors approved that, as of the effective time of the merger, each of the CEO and the CFO will receive cash and restricted stock units, further discussed below, from Ruthigen as consideration for the termination of outstanding stock options and restricted stock units held by them and for their continued provision of services after the merger and for the one-year non-competition provisions in their new employment agreement.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;If the Merger is approved by the respective stockholders, the CEO and CFO will terminate their current employment agreements with Ruthigen dated November 28, 2014 and June 24, 2014, respectively. At such time, the New Employment Agreement with the CEO and the New Employment Agreement with the CFO will each become effective. Additionally, lock-up agreements and cancellation agreements between Ruthigen and the CEO and CFO with respect to the cancellation of outstanding stock options and restricted stock units immediately prior to the merger will become effective. If the Merger is not approved by the respective stockholders, the current employment agreements with each of the CEO and CFO will remain in effect and the lock-up agreements and cancellation agreements will not become effective.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;At the effective time of the merger, any and all outstanding stock options and restricted stock units previously granted to the CEO will be terminated in exchange for (i) a lump-sum payment in the amount of $547,600, less taxes and other withholdings and (ii) a lump-sum equivalent to the CEO&amp;#8217;s premiums under COBRA for one year, in the same amounts for the same medical coverage as in effect as of the effective time of the merger.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;The CEO shall also receive a grant of restricted stock units, pursuant to Ruthigen&amp;#8217;s 2013 Employee, Director and Consultant Equity Incentive Plan, &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;equal to the lesser of (i) 930,000 and (ii) the quotient of $3,125,000 divided by the fair market value of the common stock of the combined company as of the effective time of the merger, with such restricted stock units vesting as follows: (i) a number of restricted stock units equal to the lesser of (a) 930,000 and (b) such number of restricted stock units with an aggregate value equal to $1,400,000 shall be fully vested at the effective time of the merger and (ii) an amount equal to 25% of the restricted stock units unvested as of the effective time of the merger will vest on a quarterly basis over the following twelve months.&lt;/font&gt; The shares of Ruthigen common stock underlying the vested restricted stock units at the effective time of the merger will be delivered to the CEO on the first trading day following the first anniversary of the effective time of the merger, and the shares of Ruthigen common stock underlying the restricted stock units that will vest on a quarterly basis thereafter will be delivered on the first trading day following the 15, 18, 21 and 24 month anniversary of the effective time of the merger, respectively. The shares are subject to lock-up and leak out provisions that limit sales of these shares during the six month period following the delivery of any shares associated with vested restricted stock units, except to the extent necessary to cover tax liabilities associated with receipt of these shares.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;At the effective time of the merger, any and all outstanding stock options and restricted stock units previously granted to the CFO will be terminated in exchange for (i) a lump-sum payment in the amount of $337,500, less taxes and other withholdings and (ii) a lump-sum equivalent to the CFO&amp;#8217;s premiums under COBRA for one year, in the same amounts for the same medical coverage as in effect as of the effective time of the merger.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;The CFO shall also receive a grant of restricted stock units, pursuant to Ruthigen&amp;#8217;s 2013 Employee, Director and Consultant Equity Incentive Plan, &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;equal to the lesser of (i) 355,000 and (ii) the quotient of $1,037,500 divided by the fair market value of the common stock of the combined company as of the effective time, with such restricted stock units vesting as follows: (i) a number of restricted stock units equal to the lesser of (a) 355,000 and (b) such number of restricted stock units with an aggregate value equal to $250,000 shall be fully vested at the effective time of the merger and (ii) an amount equal to 25% of the restricted stock units unvested as of the effective time of the merger will vest on a quarterly basis over the following twelve months.&lt;/font&gt; The shares of Ruthigen common stock underlying the vested restricted stock units at the effective time of the merger will be delivered to the CFO on the first trading day following the first anniversary of the effective time of the merger, and the shares of Ruthigen common stock underlying the restricted stock units that will vest on a quarterly basis thereafter will be delivered on the first trading day following the 15, 18, 21 and 24 month anniversary of the effective time of the merger, respectively. The shares are subject to lock-up and leak out provisions that limit sales of these shares during the six month period following the delivery of any shares associated with vested restricted stock units, except to the extent necessary to cover tax liabilities associated with receipt of these shares.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;New Consulting Agreements&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;On March 3, 2015, the Company executed an agreement with an investment banking firm to provide pre-merger strategic services, in exchange for the issuance of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;340,000&lt;/font&gt; shares of common stock upon effectiveness of the merger, as a success fee.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;On March 10, 2015, the Company executed an agreement with an individual to provide post-merger investor relations services for one year, in exchange for the issuance of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;250,000&lt;/font&gt; shares of common stock upon effectiveness of the Merger.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;The Company will account for the common stock upon issuance of the shares.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;License and Supply Agreement&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;The Company entered into a license and supply agreement with Oculus which was effective upon the completion of the&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;IPO, pursuant to which Oculus has agreed to exclusively license certain of its proprietary technology to the Company to enable the Company&amp;#8217;s research, development and commercialization of newly discovered RUT58-60 and any improvements to it (the &amp;#8220;Product&amp;#8221;) in the United States, Canada, the European Union and Japan (collectively, the &amp;#8220;Territory&amp;#8221;) in certain invasive uses in humans (the &amp;#8220;Field&amp;#8221;) which do not include dermatologic uses or uses for ophthalmic, sinusitis or otic indications.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;In order to pay for the costs of development of the Product, Ruthigen obtained financing from Oculus until the IPO was completed. Under the agreement, the Company&amp;#8217;s right to commercialize the Product in the Field in the Territory is exclusive and shall be performed in accordance with the development and commercialization plan set forth in the agreement (which may be modified by the Company&amp;#8217;s discretion), and &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;Oculus shall manufacture and supply, at a purchase price equal to 20% over the cost of goods to Oculus&lt;/font&gt;, the Product as and when the Company requests. In addition, the Company has the right to purchase certain manufacturing equipment from Oculus at a purchase price equal to a fixed percentage over the cost of the equipment to Oculus, so that the Company may manufacture the Product independently.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;Under the license and supply agreement, the Company will be required to make a total of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;8&lt;/font&gt; million of milestone payments to Oculus over the next several years for the first Product only, as follows: $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.5&lt;/font&gt; million upon the completion of last patient enrollment in the Phase 1/2 clinical trial, $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.5&lt;/font&gt; million upon the completion of last patient enrollment of the Company&amp;#8217;s first pivotal trial, $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3&lt;/font&gt; million upon completion of the first meeting with the FDA following completion of the Company&amp;#8217;s first pivotal clinical trial, and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2&lt;/font&gt; million upon first patient enrollment in the second pivotal clinical trial. In addition, as further consideration under the agreement, the Company will be required to make royalty payments to Oculus based on its annual net sales of the Product from the date of first commercial sale to the date that the Company ceases to commercialize the Product, which percentage royalty rate will vary between &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3&lt;/font&gt;% and &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;20&lt;/font&gt;% and will increase based on various net sales thresholds and will differ depending on the country in which the sales are made. The Company will accrue for the milestone payment liability if and when the Company determines that the achievement of such conditions is probable. As of March 31, 2015, the Company has not accrued for any portion of the milestone payments.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;The agreement contains representations and warranties of the parties regarding its enforceability, no conflict with agreements to which the parties are bound, and no violations of law, and representations of Oculus that it has not granted any other license with respect to the Product for use in the Field in the Territory. The Company has agreed to indemnify Oculus with respect to third party claims arising from the Company&amp;#8217;s development, commercialization or manufacture of the Product in the Field in the Territory with certain exceptions, and the Company and Oculus have each agreed to indemnify the other with respect to third party claims arising from their respective inaccuracy and/or breach of representations and warranties or negligence or willful misconduct. Either party may terminate the agreement for an uncured material breach, but only after undergoing a dispute resolution process. In addition, either party may terminate the agreement if the other party ceases to do business, makes an assignment for the benefit of creditors or voluntarily files, fails to contest an involuntary filing or is adjudicated bankrupt or insolvent under bankruptcy, insolvency, receivership or similar law.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;See Note 6 &amp;#150; Commitments and Contingencies &amp;#150; Oculus Side Letter Agreement for additional details.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Shared Services Agreement&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;The Company entered into a shared services agreement with Oculus which was effective upon the completion of the IPO, pursuant to which Oculus will provide Ruthigen with general services, including general accounting and human resources, until the termination of agreement. Additionally, Oculus will permit the Company to access its Petaluma, California and Seattle, Washington facilities during normal business hours (subject to certain exceptions) and for the purposes described in the shared services agreement.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;Oculus shall also provide the Company with consulting and technical services. Such services shall be billable at the hourly or fixed monthly rate as set forth in the shared services agreement, which is subject to change based upon mutual written agreement between Oculus and Ruthigen. After the completion of the IPO, the Company agreed to pay invoices generated by Oculus within thirty days of receipt thereof. The costs incurred by the Company in connection with the shared services agreement were not material.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;On March 5, 2015, the Company received a written notice from Oculus of termination of the shared services agreement, effective on April 6, 2015.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;See Note 6 &amp;#150; Commitments and Contingencies &amp;#150; Oculus Side Letter Agreement for additional details.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Separation Agreement&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;The Company has entered into a separation agreement with Oculus that contains key provisions relating to the ongoing relationship with Oculus following the completion of the IPO. The &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;separation agreement became effective upon the completion of the IPO and terminates on the earlier of 8.5 years following the closing of the IPO or when the parties mutually agree to terminate it.&lt;/font&gt; The separation agreement also contains a series of restrictions on Oculus&amp;#8217; ability to transfer the Ruthigen shares that Oculus owns. Oculus is restricted from transferring any of the Ruthigen shares it owns during the first year (the &amp;#8220;Lock-Up Period&amp;#8221;) immediately following the IPO unless it receives consent to do so from the Company&amp;#8217;s Board of Directors and the lead underwriter in the Company&amp;#8217;s IPO.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;Following the Lock-Up Period, transfers by Oculus of the Ruthigen shares it owns must be conducted with the consent of the board of directors or within the prescribed requirements for such transfers set forth in the separation agreement. These prescribed requirements include that the transfers must be in private placement transactions, the purchase price discount may not exceed certain percentages depending on the transferee, the amount of shares transferred in a given transfer (or series of transfers comprising a single transaction) may not exceed the greater of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5&lt;/font&gt;% of the Company&amp;#8217;s outstanding shares or $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,500,000&lt;/font&gt; in net proceeds to Oculus, as well as certain other requirements set forth in the separation agreement. In addition to the manner described above, if, following a minimum of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;41.5&lt;/font&gt; months following the closing of the IPO have lapsed and Oculus has not consummated transfers of the Ruthigen shares it owns resulting in at least $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3.8&lt;/font&gt; million in net proceeds to Oculus, then Oculus has a one-time transfer and registration right to transfer the Ruthigen shares it owns in an amount equal to the difference between $3.8 million and the proceeds received by Oculus from prior transfers as of the time Oculus elects to exercise its one-time right. &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;Transfers conducted using this one-time right must be conducted with the consent of the Company&amp;#8217;s board of directors or within the prescribed requirements for such transfers set forth in the separation agreement, including, for example, that the purchase price discount may not exceed certain percentages, the amount of shares transferred may not exceed $3,800,000 in net proceeds to Oculus, as well as certain other requirements set forth in the separation agreement. The separation agreement provides Oculus with certain &amp;#8220;piggy back&amp;#8221; registration rights of up to 30%&lt;/font&gt; of the value of the securities the Company registers after the lock-up period, if the Company proposes to register any of its common stock following the completion of the IPO, subject to certain conditions and limitations.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;The separation agreement also provides for certain cooling off periods between market attempts and/or successful transfers, the length of which are dependent upon whether and the quantity of the Ruthigen shares that Oculus transfers. The majority of the material restrictions and obligations contained in the separation agreement lapse if and when Oculus own less than &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 19.9&lt;/font&gt;% of the outstanding shares of the Company&amp;#8217;s common stock.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;The separation agreement also defined the methodology for the allocation of the operational and IPO related expenses incurred prior to and in connection with the IPO for which the Company was required to reimburse Oculus. The Company will also reimburse Oculus for expenses such as salaries and benefits advanced or paid on the Company&amp;#8217;s behalf or for the Company&amp;#8217;s benefit during a transition period following the closing of the IPO. During the year ended March 31, 2014, the Company incurred $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,450,000&lt;/font&gt; of IPO and other costs which were reimbursed to Oculus at the closing of the IPO or shortly thereafter.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;The separation agreement provides that each party will indemnify, defend and hold harmless the other party and its affiliates for third party claims asserted against the other party. The separation agreement also provides that, so long as Oculus maintains a directors&amp;#8217; and officers&amp;#8217; insurance program covering the past and present officers and directors of Oculus, the program shall be standard in Oculus&amp;#8217; industry and Oculus shall not exclude any former Oculus director from any insurance policy coverage.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;See Note 6 &amp;#150; Commitments and Contingencies &amp;#150; Oculus Side Letter Agreement for additional details.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Funding Agreement&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;On January 31, 2014, the Company entered into a funding agreement with Oculus, pursuant to which Oculus agreed to fund the Company in the additional amount of up to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;760,000&lt;/font&gt; to pay certain accounts payables outstanding at December 31, 2013 and to fund certain future expenditures through the closing of the IPO. Through the closing of the IPO, Oculus funded the Company in the additional amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;534,000&lt;/font&gt;, which was repaid to Oculus on April 1, 2014.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Oculus Side Letter Agreement&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;In connection with the Merger, on March 13, 2015, Pulmatrix entered into an agreement (the &amp;#8220;Oculus Side Letter Agreement&amp;#8221;), pursuant to which, among other things, Oculus agreed, from the effective date of the merger, to (i) waive Ruthigen&amp;#8217;s obligations to use commercially reasonable efforts to develop and commercialize products licensed from Oculus under the outstanding License and Supply Agreement between Oculus and Ruthigen, for a period lasting until the earlier of one year from the closing of the merger or August 31, 2016; (ii) provide a general release from claims and liabilities arising under the License and Supply Agreement, the separation agreement and the shared services agreement, each between Oculus and Ruthigen, in favor of Ruthigen; and (iii) to run a sale process for the pre-merger Ruthigen business, including any products licensed from Oculus, and to assign or delegate all of Ruthigen&amp;#8217;s surviving rights under the License and Supply Agreement, the separation agreement and the shared services agreement, subject to Oculus&amp;#8217;s consent with respect to the identity of the proposed purchaser.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;Ruthigen is under no obligation to achieve any milestone event during the waiver period, and no payments will accrue or become due and payable by Ruthigen to Oculus under the License and Supply Agreement, the separation agreement and the shared services agreement, other than the liabilities not exceeding $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5,000&lt;/font&gt; due and payable on the effective date of the merger. After the expiration of the waiver period, Ruthigen may unilaterally terminate the License and Supply Agreement.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;Pursuant to the right of first refusal that was granted to Oculus, prior to a sale of the pre-merger business of Ruthigen with a minimum aggregate purchase price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.0&lt;/font&gt; million, Ruthigen must first notify Oculus of the pending transaction and Oculus will have five (5) business days after receipt of such notice to notify Ruthigen whether it intends to acquire the pre-merger business of Ruthigen on exactly the same terms, including the amount and kind of consideration, unless securities of the proposed acquirer will be offered as consideration, in which case Oculus will instead pay cash equal to the fair market value of such securities. If Oculus does not exercise its right of first refusal, Ruthigen may consummate the transaction pursuant to the agreed upon terms. Additionally, if such a transaction is consummated and the transaction generates aggregate proceeds in excess of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;10.0&lt;/font&gt; million, Ruthigen will be obligated to pay ten percent (&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;10&lt;/font&gt;%) of the aggregate gross proceeds to Oculus within ten (10) calendar days.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;In addition, the Oculus Side Letter Agreement provides that, as of the effective date of the merger, certain provisions in the separation agreement regarding marketing and stock transfer restrictions, lock-up, registration rights, voting, management, compensation and equity incentive plan, will be terminated.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;The Oculus Side Letter Agreement is conditioned upon the receipt of payment by Oculus for Oculus&amp;#8217;s shares of Ruthigen common stock sold in certain specified transactions.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Operating Lease&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;The Company leases a facility in Santa Rosa, California under a non-cancelable operating lease for approximately &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 995&lt;/font&gt; square feet of executive office space. On February 11, 2015, the Company and the landlord agreed to amend the lease such that the lease now expires on June 30, 2015 and the monthly base rent is approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,700&lt;/font&gt;. The aggregate base rent payable over the lease term is being recognized on a straight-line basis. Rent expense related to the lease amounted to approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;20,000&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;20,000&lt;/font&gt; for the years ended March 31, 2015 and 2014, respectively. Rent expense is reflected in selling, general and administrative expenses in the consolidated statements of operations. Future minimum rentals through the lease expiration date of June 30, 2015 are $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5,075&lt;/font&gt;.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>

  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P04_01_2014To03_31_2015" id="Factid_4">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; Note 7. Stockholders&amp;#8217; Equity&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;Reverse Stock Split&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; On September 25, 2013, the board of directors and the stockholders of the Company approved a 1-for-2.5 reverse stock split of the Company&amp;#8217;s outstanding common stock, $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.0001&lt;/font&gt; par value, which was effected on September 25, 2013. In connection with the reverse stock split, every 2.5 shares of common stock were reclassified and combined into one share of common stock. The reverse stock split reduced the number of shares of common stock outstanding from &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 5,000,000&lt;/font&gt; to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 2,000,000&lt;/font&gt;. The total number of authorized common stock that the Company shall have the authority to issue as set forth in the Company&amp;#8217;s Restated Certificate of Incorporation, as amended, was not proportionally decreased in connection with the reverse stock split.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; All common shares and per share amounts contained in the Company&amp;#8217;s accompanying financial statements have been retroactively adjusted to reflect a 1-for-2.5 reverse stock split, effective as of September 25, 2013.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;Authorized Capital&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company is authorized to issue up to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 100,000,000&lt;/font&gt; shares of common stock with a par value of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.0001&lt;/font&gt; per share and &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 500,000&lt;/font&gt; shares of preferred stock with a par value of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.0001&lt;/font&gt; per share.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;Description of Common Stock&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; Each share of common stock has the right to one vote. The holders of common stock are entitled to dividends when funds are legally available and when declared by the board of directors.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;2013 Plan&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; In September and October 2013, respectively, the Company&amp;#8217;s board of directors and stockholders approved the 2013 Employee, Director and Consultant Equity Incentive Plan (the &amp;#8220;2013 Plan&amp;#8221;), which became effective upon the closing of the IPO. The 2013 Plan will expire on September 30, 2023. Under the 2013 Plan, the Company may grant incentive stock options, non-qualified stock options, restricted and unrestricted stock awards and other stock-based awards. There are &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 998,355&lt;/font&gt; shares of the Company&amp;#8217;s common stock authorized for issuance under the 2013 Plan. The Company intends to issue new shares of common stock to satisfy 2013 Plan obligations.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; In addition, the 2013 Plan contains an &amp;#8220;evergreen&amp;#8221; provision, which allows for an annual increase in the number of shares of the Company&amp;#8217;s common stock available for issuance under the 2013 Plan on the first day of each calendar year beginning with calendar year 2015. The annual increase in the number of shares shall be equal to the lowest of: (a) 232,500 shares of the Company&amp;#8217;s common stock; (b) 5% of the number of shares of the Company&amp;#8217;s common stock outstanding as of such date; and (c) an amount determined by the Company&amp;#8217;s board of directors or compensation committee.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;New 2013 Plan&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; On March 12, 2015, in connection with the Merger Agreement, Ruthigen&amp;#8217;s compensation committee and Ruthigen&amp;#8217;s board of directors unanimously approved the Ruthigen, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan (the &amp;#8220;New 2013 Plan&amp;#8221;), subject to the approval of Ruthigen&amp;#8217;s stockholders. The New 2013 Plan will allow for the issuance of up to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 6,853,319&lt;/font&gt; shares of Ruthigen&amp;#8217;s common stock, up from &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1,230,855&lt;/font&gt; shares, pursuant to awards to be granted under the New 2013 Plan. In addition, the New 2013 Plan contains an &amp;#8220;evergreen&amp;#8221; provision, which allows for an annual increase in the number of shares of Ruthigen&amp;#8217;s common stock available for issuance under the plan on the first day of each fiscal year beginning in calendar year 2016. The annual increase in the number of shares shall be equal to the lowest of: (i) 2,551,500 shares of Ruthigen&amp;#8217;s common stock; (ii) five percent (5%) of the number of shares of Ruthigen&amp;#8217;s common stock outstanding as of such date; and (iii) an amount determined by Ruthigen&amp;#8217;s board of directors.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;Initial Public Offering&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; On March 21, 2014, the Company announced that it had priced its IPO of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 2,650,000&lt;/font&gt; units (the &amp;#8220;IPO&amp;#8221;), with each unit consisting of (i) one share of common stock and (ii) one Series A warrant (the &amp;#8220;Series A Warrant&amp;#8221;), at an IPO price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;7.25&lt;/font&gt; per unit (each a &amp;#8220;Unit&amp;#8221;), less underwriting discounts and commissions and IPO expenses. In addition, the Company granted to the underwriters a 45-day option (the &amp;#8220;Over-Allotment Option&amp;#8221;) to purchase up to (i) &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 397,500&lt;/font&gt; additional shares of common stock at price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;6.6608&lt;/font&gt; per share, which price reflects underwriting discounts and commissions, and/or (ii) &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 397,500&lt;/font&gt; additional Series A Warrants at a price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.0092&lt;/font&gt; per Series A Warrant, which price reflects underwriting discounts and commissions.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; On March 26, 2014, the Company closed on the sale of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 2,650,000&lt;/font&gt; Units and the underwriters exercised a portion of the Over-Allotment Option by purchasing Series A Warrants from the Company to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 397,500&lt;/font&gt; shares of common stock for nominal value, all of which resulted in $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;16,021,000&lt;/font&gt; of aggregate net proceeds to the Company ($&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;19,216,000&lt;/font&gt; of gross proceeds less $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3,195,000&lt;/font&gt; of issuance costs). As a result, an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 2,650,000&lt;/font&gt; shares of common stock and Series A Warrants to purchase an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 3,047,500&lt;/font&gt; shares of common stock were issued in the IPO.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The Series A Warrant is exercisable at a price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;7.25&lt;/font&gt; per warrant for (x) one share of common stock and (y) one Series B warrant (the &amp;#8220;Series B Warrant&amp;#8221;) to purchase one share of common stock at an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;9.0625&lt;/font&gt; per share. The Series A Warrants are exercisable on the date of issuance and terminate on the second anniversary of the date of issuance. The exercise price and the number of shares for which each Series A Warrant may be exercised is subject to adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting the Company&amp;#8217;s common stock. In addition, subject to certain exceptions, the exercise price of the Series&amp;#160;A Warrants is subject to a weighted average reduction if the Company issues shares of common stock (or securities convertible into common stock) in the future at a price below both (a) the current exercise price of the Series A Warrant; and (b) the current market price of the Company&amp;#8217;s common stock. The Series A Warrants may be called by the Company, for consideration equal to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.0001&lt;/font&gt; per Series A Warrant, on not less than 10 business days&amp;#8217; notice if the closing price of the common stock is above &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 150&lt;/font&gt;% of the $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;7.25&lt;/font&gt; IPO price per unit for any period of 20 consecutive business days ending not more than three business days prior to the call notice date. The Series B Warrants will be exercisable on the date that the warrants are issued and will terminate on the fifth anniversary of the date the warrants are first exercisable. The Company agrees that, during the period the Series A Warrants are outstanding, it will maintain the effectiveness of the registration statement such that the holder may exercise the Series A Warrants to receive registered shares of common stock and registered Series B Warrants (and the shares of common stock underlying the Series B Warrants). The Company determined that the Series A and Series B Warrants are equity instruments because the warrants are (a) freestanding financial instruments; (b) indexed to the Company&amp;#8217;s own stock; (c) not permitted to be settled for cash; and (d) exercisable into common stock for which the Company has sufficient authorized and unissued shares.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company issued to the representative of the underwriters warrants to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 92,750&lt;/font&gt; shares of the Company&amp;#8217;s common stock at an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;9.0625&lt;/font&gt; per share (the &amp;#8220;Representative&amp;#8217;s Warrants&amp;#8221;). The Representative&amp;#8217;s Warrants are exercisable commencing on March 21, 2015 and expiring on March 21, 2019. The Representative&amp;#8217;s Warrants and the shares of common stock underlying the warrants have been deemed compensation by Financial Industry Regulatory Authority, Inc. (&amp;#8220;FINRA&amp;#8221;) and are, therefore, subject to a 180-day lock-up pursuant to Rule 5110(g)(1) of FINRA.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company, its officers and directors and its Former Parent have entered into lock-up agreements with the underwriters. Under these agreements, the Company and the other parties have agreed, subject to specified exceptions, not to sell or transfer any common stock or securities convertible into, or exchangeable or exercisable for, common stock, during a period ending 180 days after the date of its prospectus (one year for the shares of common stock owned by the Company&amp;#8217;s Former Parent), without first obtaining the written consent of representative of the underwriters. The lock up period for the Company, its officers and directors is subject to extension for up to an additional 18 days upon the occurrence of certain specified events.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;Underwriter&amp;#8217;s Exercise of IPO Over-Allotment Option&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; Following the closing of the IPO, during the year ended March 31, 2015 and in connection with its IPO, the underwriters exercised a portion of the over-allotment option pursuant to which the Company sold an additional &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 154,290&lt;/font&gt; shares of common stock at $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;6.6608&lt;/font&gt; per share, which resulted in approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,028,000&lt;/font&gt; of aggregate net proceeds to the Company. In connection with the underwriters&amp;#8217; partial exercise of the over-allotment option, the Company issued to the representative of the underwriters a five-year warrant to purchase an additional &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 5,400&lt;/font&gt; shares of the Company&amp;#8217;s common stock at an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;9.0625&lt;/font&gt; per share. The warrant is exercisable commencing one year from the date of issuance. The warrant and the shares of common stock underlying the warrant have been deemed compensation by FINRA and are, therefore, subject to a 180-day lock-up pursuant to Rule 5110(g)(1) of FINRA.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;Investment from Former Parent&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; During the year ended March 31, 2014, the Company&amp;#8217;s Former Parent made capital contributions to the Company in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,679,000&lt;/font&gt;, which were recorded as additional paid-in capital in the consolidated statement of changes in stockholders&amp;#8217; equity. See Note 9 &amp;#150; Related Party Transactions for details associated with the Former Parent&amp;#8217;s ownership interest in the Company.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;Stock Warrants&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;A summary of the warrant activity during the years ended March 31, 2015 is presented below:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Remaining&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Number&amp;#160;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Exercise&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Life&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Intrinsic&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;In&amp;#160;Years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Value&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Outstanding, March 31, 2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,140,250&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;7.30&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5,400&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;9.06&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Exercised&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Outstanding, March 31, 2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,145,650&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;7.31&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.1&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Exercisable, March 31, 2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,140,250&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;7.30&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.1&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The following table presents information related to stock warrants at March 31, 2015:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%" colspan="5"&gt; &lt;div&gt;Warrants&amp;#160;Outstanding&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="33%" colspan="5"&gt; &lt;div&gt;Warrants&amp;#160;Exercisable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="17%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="17%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Outstanding&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Exercisable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="18%" colspan="2"&gt; &lt;div&gt;Exercise&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Number&amp;#160;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Remaining&amp;#160;Life&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Number&amp;#160;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="18%" colspan="2"&gt; &lt;div&gt;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;In&amp;#160;Years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="17%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"&gt; &lt;div&gt;7.2500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;3,047,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;1.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;3,047,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"&gt; &lt;div&gt;9.0625&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;98,150&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;4.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;92,750&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;3,145,650&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;1.1&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;3,140,250&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;Stock Options&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The Company has computed the fair value of options granted using the Black-Scholes option pricing model. Option forfeitures are estimated at the time of valuation and reduce expense ratably over the vesting period. This estimate will be adjusted periodically based on the extent to which actual option forfeitures differ, or are expected to differ, from the previous estimate, when it is material. The Company estimated forfeitures related to option grants at an annual rate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0&lt;/font&gt;% for options unvested during the year ended March 31, 2015. The expected term used for options issued to non-employees is the contractual life and the expected term used for options issued to employees and directors is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the &amp;#8220;simplified&amp;#8221; method to develop an estimate of the expected term of &amp;#8220;plain vanilla&amp;#8221; employee option grants. Since the Company&amp;#8217;s stock has not been publicly traded for a sufficiently long period of time, the Company is utilizing an expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected life of the instrument being valued, of similarly positioned public companies within its industry. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;&amp;#160;&lt;/div&gt;&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;In applying the Black-Scholes option pricing model to stock options granted, the Company used the following weighted average assumptions:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 50%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="25%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div&gt;For&amp;#160;the&amp;#160;Year&amp;#160;Ended&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="25%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div&gt;March&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="25%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="25%"&gt; &lt;div&gt;Risk free interest rate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.67&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;n/a&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="25%"&gt; &lt;div&gt;Expected term (years)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5.61&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;n/a&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="25%"&gt; &lt;div&gt;Expected volatility&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;95&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;n/a&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="25%"&gt; &lt;div&gt;Expected dividends&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;n/a&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The weighted average estimated fair value of the options granted during the year ended March 31, 2015 was $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;4.79&lt;/font&gt; per share. There were no options granted during the year ended March 31, 2014.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;strong&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;On May 12, 2014, the Company granted options to employees and directors to purchase an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 332,500&lt;/font&gt; shares of common stock at an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;6.37&lt;/font&gt; per share, pursuant to the 2013 Plan. The shares vest ratably over three years on a quarterly basis. The aggregate grant date value of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,593,000&lt;/font&gt; will be recognized proportionate to the vesting period.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company recorded stock&amp;#150;based compensation expense related to stock options of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;452,000&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0&lt;/font&gt; during the years ended March 31, 2015 and 2014, respectively. As of March 31, 2015, there was $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,060,000&lt;/font&gt; of unrecognized stock-based compensation expense related to stock options that will be amortized over a weighted average period of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 2.1&lt;/font&gt; years.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;A summary of the stock option activity during the year ended March 31, 2015 is presented below:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Remaining&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Number&amp;#160;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Exercise&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Life&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Intrinsic&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Options&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;In&amp;#160;Years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Value&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Outstanding,&amp;#160;March&amp;#160;31,&amp;#160;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;332,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;6.37&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Exercised&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(16,664)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;6.37&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Outstanding, March 31, 2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;315,836&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;6.37&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;9.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Exercisable, March 31, 2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;81,522&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;6.37&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;8.7&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The following table presents information related to stock options at March 31, 2015:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%" colspan="5"&gt; &lt;div&gt;Options&amp;#160;Outstanding&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="32%" colspan="4"&gt; &lt;div&gt;Options&amp;#160;Exercisable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="17%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="17%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Outstanding&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Exercisable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="18%" colspan="2"&gt; &lt;div&gt;Exercise&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Number&amp;#160;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Remaining&amp;#160;Life&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Number&amp;#160;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="18%" colspan="2"&gt; &lt;div&gt;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Options&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;In&amp;#160;Years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Options&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="17%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"&gt; &lt;div&gt;6.37&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;315,836&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;8.7&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;81,522&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;315,836&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;8.7&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;81,522&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;Restricted Stock Units&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;font style="FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; On May 11, 2014, the Company granted RSUs issuable for an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 409,355&lt;/font&gt; shares to employees and directors, pursuant to the 2013 Plan. RSUs for 341,000 shares of common stock vest ratably over three years on a quarterly basis and had an aggregate grant date value of $2,148,000. RSUs for 68,355 shares had an aggregate grant date value of $431,000 and vest in equal installments based on achievement of the following: (1) enrollment of the first patient in the first pivotal clinical trial for RUT58-60 on or prior to May 11, 2017; (2) enrollment of the first patient in the second pivotal clinical trial for RUT58-60 on or prior to May 11, 2018; and (3) completion of the clinical study report containing the results of the second pivotal clinical trial for RUT58-60 on or prior to May 11, 2019.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company recorded stock&amp;#150;based compensation expense related to RSUs of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;627,000&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0&lt;/font&gt; during the years ended March 31, 2015 and 2014, respectively. As of March 31, 2015, there was $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,522,000&lt;/font&gt; of unrecognized stock-based compensation expense related to RSUs that will be amortized over a weighted average period of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 2.1&lt;/font&gt; years. The Company recognizes stock-based compensation expense for RSUs with performance conditions if and when the Company concludes that it is probable that the performance condition will be achieved. As of March 31, 2015, the Company has not recognized any expense related to RSUs with performance conditions. As of March 31, 2015, there was $431,000 of unrecognized stock-based compensation expense related to RSUs with performance conditions.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;A summary of RSU activity for the years ended March 31, 2015 and 2014 is presented below:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="33%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="33%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="33%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Number&amp;#160;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Grant&amp;#160;Date&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Grant&amp;#160;Date&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="33%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Units&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Fair&amp;#160;Value&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Fair&amp;#160;Value&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="33%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"&gt; &lt;div&gt;Non-vested, March 31, 2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"&gt; &lt;div&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"&gt; &lt;div&gt;Vested&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"&gt; &lt;div&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"&gt; &lt;div&gt;Non-vested, March 31, 2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"&gt; &lt;div&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;409,355&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;6.30&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,579,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"&gt; &lt;div&gt;Vested&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(85,308)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;6.30&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(537,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"&gt; &lt;div&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"&gt; &lt;div&gt;Non-vested, March 31, 2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;324,047&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;6.30&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,042,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>

  <us-gaap:LiquidityDisclosureTextBlock contextRef="P04_01_2014To03_31_2015" id="Factid_5">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px 0pt -0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;Liquidity and Financial Condition&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company incurred net losses of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;6,691,000&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3,118,000&lt;/font&gt; for the years ended March 31, 2015 and 2014, respectively. At March 31, 2015, the Company&amp;#8217;s working capital and accumulated deficit were $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;9,888,000&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;10,360,000&lt;/font&gt;, respectively. The Company has not yet achieved profitability and it is expected that its research and development and general and administrative expenses will continue to increase and, as a result, the Company will eventually need to generate significant product revenues to achieve profitability.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company believes that its existing cash, which includes the proceeds from its IPO, will be sufficient to fund its stand-alone operations through the quarter ending June 30, 2016. However, in order for the Company to execute its research and development strategy and to obtain the necessary regulatory approvals to commercialize RUT58-60 as a drug in the United States, the Company will need to raise additional funds through public or private equity offerings, debt financings, corporate collaborations or other means. The Company has not secured any commitment for new financing at this time, nor can it provide any assurance that new financing will be available on commercially acceptable terms, if at all. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash. See Note 6 &amp;#150; Commitments and Contingencies &amp;#150; Agreement and Plan of Merger.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LiquidityDisclosureTextBlock>

  <us-gaap:UseOfEstimates contextRef="P04_01_2014To03_31_2015" id="Factid_6">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (&amp;#8220;U. S. GAAP&amp;#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include stock-based compensation, the valuation allowance related to the Company&amp;#8217;s deferred tax assets and the expense allocations relating to the Company&amp;#8217;s operations prior to its deconsolidation from its Former Parent on March 26, 2014.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:UseOfEstimates>

  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="P04_01_2014To03_31_2015" id="Factid_7">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company accounts for share-based awards exchanged for employee and director services at the estimated grant date fair value of the award. The Company estimates the fair value of stock options using the Black-Scholes option pricing model. The Company estimates the fair value of restricted stock and restricted stock units (&amp;#8220;RSUs&amp;#8221;) based upon the closing market price of the Company&amp;#8217;s common stock on the date the award is granted. The Company amortizes the fair value of employee awards on&amp;#160;the straight-line basis over the requisite service period of the awards. Stock-based compensation expense includes the impact of an estimate for forfeitures for all stock awards. The Company recognizes stock-based compensation expense for awards with performance conditions if and when the Company concludes that it is probable that the performance condition will be achieved. The Company reassesses the probability of vesting at each reporting period for awards with performance conditions and adjusts stock-based compensation expense based on its probability assessment.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company accounts for equity instruments issued to non-employees at their fair value on the measurement date. The measurement of stock-based compensation is subject to periodic adjustment as the underlying equity instrument vests or becomes non-forfeitable. Non-employee stock-based compensation charges are amortized over the requisite service period.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>

  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="P04_01_2014To03_31_2015" id="Factid_8">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;Net Loss per Share&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company computes basic net loss per share by dividing net loss per share available to common stockholders by the weighted average number of common shares outstanding for the period and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the &amp;#8220;treasury stock&amp;#8221; and/or &amp;#8220;if converted&amp;#8221; methods, as applicable.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;March&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Options&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;315,836&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3,145,650&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3,140,250&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Restricted stock units&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;324,047&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3,785,533&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3,140,250&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>

  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P04_01_2014To03_31_2015" id="Factid_9">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; In June 2014, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No. 2014-12, "Compensation - Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could be Achieved after the Requisite Service Period," ("ASU 2014-12"). The amendments in ASU 2014-12 require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Accounting Standards Codification Topic No. 718, "Compensation - Stock Compensation" as it relates to awards with performance conditions that affect vesting to account for such awards. The amendments in ASU 2014-12 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in ASU 2014-12 either: (a) prospectively to all awards granted or modified after the effective date; or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The Company does not anticipate that the adoption of this standard will have a material impact on its consolidated financial statements.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; In August 2014, the FASB issued ASU No. 2014-15, &amp;#8220;Presentation of Financial Statements &amp;#150; Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&amp;#8217;s Ability to Continue as a Going Concern.&amp;#8221; The guidance, which is effective for annual reporting periods ending after December 15, 2016, extends the responsibility for performing the going-concern assessment to management and contains guidance on how to perform a going-concern assessment and when going-concern disclosures would be required under U.S. GAAP. The Company does not believe adoption of this ASU will have a material effect on its consolidated financial statements.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>

  <us-gaap:SubsequentEventsPolicyPolicyTextBlock contextRef="P04_01_2014To03_31_2015" id="Factid_10">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;Subsequent Events&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; Management has evaluated subsequent events or transactions occurring through the date these consolidated financial statements were issued. See Note 10 &amp;#150; Subsequent Events.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>

  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="P04_01_2014To03_31_2015" id="Factid_11">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;March&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Options&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;315,836&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3,145,650&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3,140,250&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Restricted stock units&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;324,047&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3,785,533&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3,140,250&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>

  <rtgn:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock contextRef="P04_01_2014To03_31_2015" id="Factid_12">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; Prepaid expenses and other current assets consists of the following:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div&gt;March&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"&gt; &lt;div&gt;Prepaid insurance&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;12,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"&gt; &lt;div&gt;Clinical testing and other deposits&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;114,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"&gt; &lt;div&gt;Prepaid rent&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"&gt; &lt;div&gt;Other prepaid expenses and current assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;38,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"&gt; &lt;div&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;166,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</rtgn:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock>

  <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="P04_01_2014To03_31_2015" id="Factid_13">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; Accounts payable and accrued expenses consist of the following:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div&gt;March&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Accrued employee compensation&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;92,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;109,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Accrued director compensation&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;43,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;50,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Accrued legal fees&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;144,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;183,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Accrued other professional fees&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;50,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;45,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Accrued research and development fees&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;128,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;9,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Accrued franchise taxes&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;146,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Other accrued expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;32,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;14,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;635,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;410,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>

  <rtgn:ScheduleOfSharebasedCompensationWarrantActivityTableTextBlock contextRef="P04_01_2014To03_31_2015" id="Factid_14">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; A summary of the warrant activity during the years ended March 31, 2015 is presented below:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Remaining&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Number&amp;#160;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Exercise&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Life&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Intrinsic&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;In&amp;#160;Years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Value&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Outstanding, March 31, 2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,140,250&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;7.30&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5,400&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;9.06&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Exercised&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Outstanding, March 31, 2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,145,650&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;7.31&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.1&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Exercisable, March 31, 2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,140,250&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;7.30&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.1&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</rtgn:ScheduleOfSharebasedCompensationWarrantActivityTableTextBlock>

  <rtgn:ScheduleOfShareBasedCompensationWarrantsByExercisePriceRangeTableTextBlock contextRef="P04_01_2014To03_31_2015" id="Factid_15">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The following table presents information related to stock warrants at March 31, 2015:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%" colspan="5"&gt; &lt;div&gt;Warrants&amp;#160;Outstanding&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="33%" colspan="5"&gt; &lt;div&gt;Warrants&amp;#160;Exercisable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="17%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="17%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Outstanding&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Exercisable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="18%" colspan="2"&gt; &lt;div&gt;Exercise&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Number&amp;#160;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Remaining&amp;#160;Life&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Number&amp;#160;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="18%" colspan="2"&gt; &lt;div&gt;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;In&amp;#160;Years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="17%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"&gt; &lt;div&gt;7.2500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;3,047,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;1.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;3,047,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"&gt; &lt;div&gt;9.0625&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;98,150&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;4.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;92,750&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;3,145,650&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;1.1&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;3,140,250&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</rtgn:ScheduleOfShareBasedCompensationWarrantsByExercisePriceRangeTableTextBlock>

  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="P04_01_2014To03_31_2015" id="Factid_16">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;In applying the Black-Scholes option pricing model to stock options granted, the Company used the following weighted average assumptions:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 50%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="25%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div&gt;For&amp;#160;the&amp;#160;Year&amp;#160;Ended&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="25%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div&gt;March&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="25%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="25%"&gt; &lt;div&gt;Risk free interest rate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1.67&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;n/a&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="25%"&gt; &lt;div&gt;Expected term (years)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5.61&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;n/a&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="25%"&gt; &lt;div&gt;Expected volatility&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;95&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;n/a&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="25%"&gt; &lt;div&gt;Expected dividends&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;n/a&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>

  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P04_01_2014To03_31_2015" id="Factid_17">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; A summary of the stock option activity during the year ended March 31, 2015 is presented below:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Remaining&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Number&amp;#160;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Exercise&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Life&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Intrinsic&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Options&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;In&amp;#160;Years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Value&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Outstanding,&amp;#160;March&amp;#160;31,&amp;#160;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;332,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;6.37&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Exercised&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(16,664)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;6.37&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Outstanding, March 31, 2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;315,836&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;6.37&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;9.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Exercisable, March 31, 2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;81,522&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;6.37&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;8.7&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>

  <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="P04_01_2014To03_31_2015" id="Factid_18">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The following table presents information related to stock options at March 31, 2015:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%" colspan="5"&gt; &lt;div&gt;Options&amp;#160;Outstanding&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="32%" colspan="4"&gt; &lt;div&gt;Options&amp;#160;Exercisable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="17%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="17%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Outstanding&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Exercisable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="18%" colspan="2"&gt; &lt;div&gt;Exercise&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Number&amp;#160;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Remaining&amp;#160;Life&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Number&amp;#160;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="18%" colspan="2"&gt; &lt;div&gt;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Options&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;In&amp;#160;Years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Options&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="17%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"&gt; &lt;div&gt;6.37&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;315,836&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;8.7&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;81,522&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;315,836&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;8.7&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;81,522&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>

  <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="P04_01_2014To03_31_2015" id="Factid_19">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; A summary of RSU activity for the years ended March 31, 2015 and 2014 is presented below:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="33%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="33%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="33%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Number&amp;#160;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Grant&amp;#160;Date&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Grant&amp;#160;Date&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="33%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Units&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Fair&amp;#160;Value&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Fair&amp;#160;Value&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="33%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"&gt; &lt;div&gt;Non-vested, March 31, 2013&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"&gt; &lt;div&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"&gt; &lt;div&gt;Vested&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"&gt; &lt;div&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"&gt; &lt;div&gt;Non-vested, March 31, 2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"&gt; &lt;div&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;409,355&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;6.30&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,579,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"&gt; &lt;div&gt;Vested&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(85,308)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;6.30&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(537,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"&gt; &lt;div&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"&gt; &lt;div&gt;Non-vested, March 31, 2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;324,047&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;6.30&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,042,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>

  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P04_01_2013To03_31_2014" id="Factid_20" unitRef="shares" decimals="INF">3140250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P04_01_2013To03_31_2014_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis" id="Factid_21" unitRef="shares" decimals="INF">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P04_01_2013To03_31_2014_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_22" unitRef="shares" decimals="INF">3140250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P04_01_2013To03_31_2014_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" id="Factid_23" unitRef="shares" decimals="INF">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P04_01_2014To03_31_2015" id="Factid_24" unitRef="shares" decimals="INF">3785533</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P04_01_2014To03_31_2015_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityEquityAxis" id="Factid_25" unitRef="shares" decimals="INF">315836</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P04_01_2014To03_31_2015_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_26" unitRef="shares" decimals="INF">3145650</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P04_01_2014To03_31_2015_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" id="Factid_27" unitRef="shares" decimals="INF">324047</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

  <us-gaap:Cash contextRef="PAsOn03_31_2014" id="Factid_28" unitRef="USD" decimals="0">15571000</us-gaap:Cash>

  <us-gaap:Cash contextRef="PAsOn03_31_2015" id="Factid_29" unitRef="USD" decimals="0">10357000</us-gaap:Cash>

  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="PAsOn03_31_2014" id="Factid_30" unitRef="USD" decimals="0">3000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>

  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="PAsOn03_31_2015" id="Factid_31" unitRef="USD" decimals="0">166000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>

  <us-gaap:AssetsCurrent contextRef="PAsOn03_31_2014" id="Factid_32" unitRef="USD" decimals="0">15574000</us-gaap:AssetsCurrent>

  <us-gaap:AssetsCurrent contextRef="PAsOn03_31_2015" id="Factid_33" unitRef="USD" decimals="0">10523000</us-gaap:AssetsCurrent>

  <us-gaap:PropertyPlantAndEquipmentNet contextRef="PAsOn03_31_2014" id="Factid_34" unitRef="USD" decimals="0">2000</us-gaap:PropertyPlantAndEquipmentNet>

  <us-gaap:PropertyPlantAndEquipmentNet contextRef="PAsOn03_31_2015" id="Factid_35" unitRef="USD" decimals="0">157000</us-gaap:PropertyPlantAndEquipmentNet>

  <us-gaap:Assets contextRef="PAsOn03_31_2014" id="Factid_36" unitRef="USD" decimals="0">15576000</us-gaap:Assets>

  <us-gaap:Assets contextRef="PAsOn03_31_2015" id="Factid_37" unitRef="USD" decimals="0">10680000</us-gaap:Assets>

  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="PAsOn03_31_2014" id="Factid_38" unitRef="USD" decimals="0">410000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>

  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="PAsOn03_31_2015" id="Factid_39" unitRef="USD" decimals="0">635000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>

  <us-gaap:DueToRelatedPartiesCurrent contextRef="PAsOn03_31_2014" id="Factid_40" unitRef="USD" decimals="0">537000</us-gaap:DueToRelatedPartiesCurrent>

  <us-gaap:DueToRelatedPartiesCurrent contextRef="PAsOn03_31_2015" id="Factid_41" unitRef="USD" decimals="0">0</us-gaap:DueToRelatedPartiesCurrent>

  <us-gaap:LiabilitiesCurrent contextRef="PAsOn03_31_2014" id="Factid_42" unitRef="USD" decimals="0">947000</us-gaap:LiabilitiesCurrent>

  <us-gaap:LiabilitiesCurrent contextRef="PAsOn03_31_2015" id="Factid_43" unitRef="USD" decimals="0">635000</us-gaap:LiabilitiesCurrent>

  <us-gaap:CommitmentsAndContingencies contextRef="PAsOn03_31_2014" id="Factid_44" unitRef="USD" xsi:nil="true" />

  <us-gaap:CommitmentsAndContingencies contextRef="PAsOn03_31_2015" id="Factid_45" unitRef="USD" xsi:nil="true" />

  <us-gaap:PreferredStockValue contextRef="PAsOn03_31_2014" id="Factid_46" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>

  <us-gaap:PreferredStockValue contextRef="PAsOn03_31_2015" id="Factid_47" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>

  <us-gaap:CommonStockValue contextRef="PAsOn03_31_2014" id="Factid_48" unitRef="USD" decimals="0">465</us-gaap:CommonStockValue>

  <us-gaap:CommonStockValue contextRef="PAsOn03_31_2015" id="Factid_49" unitRef="USD" decimals="0">480</us-gaap:CommonStockValue>

  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="PAsOn03_31_2014" id="Factid_50" unitRef="USD" decimals="0">18297535</us-gaap:AdditionalPaidInCapitalCommonStock>

  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="PAsOn03_31_2015" id="Factid_51" unitRef="USD" decimals="0">20404520</us-gaap:AdditionalPaidInCapitalCommonStock>

  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="PAsOn03_31_2014" id="Factid_52" unitRef="USD" decimals="0">-3669000</us-gaap:RetainedEarningsAccumulatedDeficit>

  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="PAsOn03_31_2015" id="Factid_53" unitRef="USD" decimals="0">-10360000</us-gaap:RetainedEarningsAccumulatedDeficit>

  <us-gaap:StockholdersEquity contextRef="PAsOn03_31_2014" id="Factid_54" unitRef="USD" decimals="0">14629000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn03_31_2015" id="Factid_55" unitRef="USD" decimals="0">10045000</us-gaap:StockholdersEquity>

  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="PAsOn03_31_2014" id="Factid_56" unitRef="USD" decimals="0">15576000</us-gaap:LiabilitiesAndStockholdersEquity>

  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="PAsOn03_31_2015" id="Factid_57" unitRef="USD" decimals="0">10680000</us-gaap:LiabilitiesAndStockholdersEquity>

  <rtgn:WorkingCapital contextRef="PAsOn03_31_2015" id="Factid_58" unitRef="USD" decimals="0">9888000</rtgn:WorkingCapital>

  <us-gaap:PrepaidInsurance contextRef="PAsOn03_31_2014" id="Factid_59" unitRef="USD" decimals="0">0</us-gaap:PrepaidInsurance>

  <us-gaap:PrepaidInsurance contextRef="PAsOn03_31_2015" id="Factid_60" unitRef="USD" decimals="0">12000</us-gaap:PrepaidInsurance>

  <us-gaap:OtherAssetsCurrent contextRef="PAsOn03_31_2014" id="Factid_61" unitRef="USD" decimals="0">1000</us-gaap:OtherAssetsCurrent>

  <us-gaap:OtherAssetsCurrent contextRef="PAsOn03_31_2015" id="Factid_62" unitRef="USD" decimals="0">114000</us-gaap:OtherAssetsCurrent>

  <us-gaap:PrepaidRent contextRef="PAsOn03_31_2014" id="Factid_63" unitRef="USD" decimals="0">2000</us-gaap:PrepaidRent>

  <us-gaap:PrepaidRent contextRef="PAsOn03_31_2015" id="Factid_64" unitRef="USD" decimals="0">2000</us-gaap:PrepaidRent>

  <rtgn:OtherPrepaidExpensesAndCurrentAssets contextRef="PAsOn03_31_2014" id="Factid_65" unitRef="USD" decimals="0">0</rtgn:OtherPrepaidExpensesAndCurrentAssets>

  <rtgn:OtherPrepaidExpensesAndCurrentAssets contextRef="PAsOn03_31_2015" id="Factid_66" unitRef="USD" decimals="0">38000</rtgn:OtherPrepaidExpensesAndCurrentAssets>

  <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="PAsOn03_31_2014" id="Factid_67" unitRef="USD" decimals="0">109000</us-gaap:AccruedEmployeeBenefitsCurrent>

  <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="PAsOn03_31_2015" id="Factid_68" unitRef="USD" decimals="0">92000</us-gaap:AccruedEmployeeBenefitsCurrent>

  <rtgn:AccruedDirectorCompensation contextRef="PAsOn03_31_2014" id="Factid_69" unitRef="USD" decimals="0">50000</rtgn:AccruedDirectorCompensation>

  <rtgn:AccruedDirectorCompensation contextRef="PAsOn03_31_2015" id="Factid_70" unitRef="USD" decimals="0">43000</rtgn:AccruedDirectorCompensation>

  <rtgn:AccruedLegalFees contextRef="PAsOn03_31_2014" id="Factid_71" unitRef="USD" decimals="0">183000</rtgn:AccruedLegalFees>

  <rtgn:AccruedLegalFees contextRef="PAsOn03_31_2015" id="Factid_72" unitRef="USD" decimals="0">144000</rtgn:AccruedLegalFees>

  <us-gaap:AccruedProfessionalFeesCurrent contextRef="PAsOn03_31_2014" id="Factid_73" unitRef="USD" decimals="0">45000</us-gaap:AccruedProfessionalFeesCurrent>

  <us-gaap:AccruedProfessionalFeesCurrent contextRef="PAsOn03_31_2015" id="Factid_74" unitRef="USD" decimals="0">50000</us-gaap:AccruedProfessionalFeesCurrent>

  <rtgn:AccruedResearchAndDevelopmentCurrent contextRef="PAsOn03_31_2014" id="Factid_75" unitRef="USD" decimals="0">9000</rtgn:AccruedResearchAndDevelopmentCurrent>

  <rtgn:AccruedResearchAndDevelopmentCurrent contextRef="PAsOn03_31_2015" id="Factid_76" unitRef="USD" decimals="0">128000</rtgn:AccruedResearchAndDevelopmentCurrent>

  <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="PAsOn03_31_2014" id="Factid_77" unitRef="USD" decimals="0">14000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>

  <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="PAsOn03_31_2015" id="Factid_78" unitRef="USD" decimals="0">32000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>

  <us-gaap:OfficersCompensation contextRef="P06_01_2014To06_24_2014_ChiefFinancialOfficerMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_EmployeeAgreementMemberrtgnLicenseAgreementAxis" id="Factid_79" unitRef="USD" decimals="0">225000</us-gaap:OfficersCompensation>

  <us-gaap:OfficersCompensation contextRef="P11_01_2014To11_28_2014_ChiefExecutiveOfficerMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_EmployeeAgreementMemberrtgnLicenseAgreementAxis" id="Factid_80" unitRef="USD" decimals="0">375000</us-gaap:OfficersCompensation>

  <us-gaap:SeveranceCosts1 contextRef="P04_01_2014To03_31_2015_TwoExecutivesMemberusgaapTitleOfIndividualAxis" id="Factid_81" unitRef="USD" decimals="0">1144000</us-gaap:SeveranceCosts1>

  <us-gaap:DeferredCompensationArrangementWithIndividualDescription contextRef="P04_01_2014To03_31_2015_ChiefExecutiveOfficerMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_EmployeeAgreementMemberrtgnLicenseAgreementAxis" id="Factid_82">(i) a lump severance payment equal to 24 times the average monthly base salary paid to the CEO over the preceding 12 months; (ii) up to one year (the lesser of one year following the date of termination or until the CEO becomes eligible for medical insurance coverage provided by another employer) reimbursement for health care premiums under COBRA; and (iii) automatic vesting of all unvested options and other equity awards</us-gaap:DeferredCompensationArrangementWithIndividualDescription>

  <us-gaap:DeferredCompensationArrangementWithIndividualDescription contextRef="P04_01_2014To03_31_2015_ChiefFinancialOfficerMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_EmployeeAgreementMemberrtgnLicenseAgreementAxis" id="Factid_83">(i) a lump severance payment equal to 18 times the average monthly base salary paid to the CFO over the preceding 12 months; (ii) up to one year (the lesser of one year following the date of termination or until the CFO becomes eligible for medical insurance coverage provided by another employer) reimbursement for health care premiums under COBRA; and (iii) automatic vesting of all unvested options and other equity awards; provided that in the event the CFO resigns for good reason prior to a change of control, only the vesting of the restricted stock units granted by the Company on May 12, 2014 shall be accelerated.</us-gaap:DeferredCompensationArrangementWithIndividualDescription>

  <us-gaap:SignificantSupplyCommitmentRemainingMinimumAmountCommitted contextRef="PAsOn03_31_2015_LicenseAndSupplyAgreementMemberrtgnLicenseAgreementAxis_OculusMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_84" unitRef="USD" decimals="-6">8000000</us-gaap:SignificantSupplyCommitmentRemainingMinimumAmountCommitted>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="PAsOn03_31_2014_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_85" unitRef="shares" decimals="INF">3140250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="P04_01_2014To03_31_2015_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_86" unitRef="shares" decimals="INF">5400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="P04_01_2014To03_31_2015_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_87" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures contextRef="P04_01_2014To03_31_2015_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_88" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="PAsOn03_31_2015_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_89" unitRef="shares" decimals="INF">3145650</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>

  <rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber contextRef="PAsOn03_31_2015_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_90" unitRef="shares" decimals="INF">3140250</rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber>

  <rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice contextRef="PAsOn03_31_2014_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_91" unitRef="USD_per_Share" decimals="2">7.30</rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice>

  <rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsGrantedWeightedAverageExercisePrice contextRef="P04_01_2014To03_31_2015_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_92" unitRef="USD_per_Share" decimals="2">9.06</rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsGrantedWeightedAverageExercisePrice>

  <rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisedWeightedAverageExercisePrice contextRef="P04_01_2014To03_31_2015_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_93" unitRef="USD_per_Share" decimals="0">0</rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisedWeightedAverageExercisePrice>

  <rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice contextRef="P04_01_2014To03_31_2015_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_94" unitRef="USD_per_Share" decimals="0">0</rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice>

  <rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice contextRef="PAsOn03_31_2015_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_95" unitRef="USD_per_Share" decimals="2">7.31</rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice>

  <rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice contextRef="PAsOn03_31_2015_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_96" unitRef="USD_per_Share" decimals="2">7.30</rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="P04_01_2014To03_31_2015_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_97">P1Y1M6D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>

  <rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms contextRef="P04_01_2014To03_31_2015_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_98">P1Y1M6D</rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="PAsOn03_31_2015_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_99" unitRef="USD" decimals="0">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>

  <rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable contextRef="PAsOn03_31_2015_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_100" unitRef="USD" decimals="0">0</rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn03_31_2015_ExercisePriceRangeOneMemberusgaapRangeAxis" id="Factid_101" unitRef="USD_per_Share" decimals="4">7.2500</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn03_31_2015_ExercisePriceRangeTwoMemberusgaapRangeAxis" id="Factid_102" unitRef="USD_per_Share" decimals="4">9.0625</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="PAsOn03_31_2015" id="Factid_103" unitRef="shares" decimals="INF">3145650</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="PAsOn03_31_2015_ExercisePriceRangeOneMemberusgaapRangeAxis" id="Factid_104" unitRef="shares" decimals="INF">3047500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="PAsOn03_31_2015_ExercisePriceRangeTwoMemberusgaapRangeAxis" id="Factid_105" unitRef="shares" decimals="INF">98150</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>

  <rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms contextRef="P04_01_2014To03_31_2015" id="Factid_106">P1Y1M6D</rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms>

  <rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms contextRef="P04_01_2014To03_31_2015_ExercisePriceRangeOneMemberusgaapRangeAxis" id="Factid_107">P1Y</rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms>

  <rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms contextRef="P04_01_2014To03_31_2015_ExercisePriceRangeTwoMemberusgaapRangeAxis" id="Factid_108">P4Y</rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms>

  <rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber contextRef="PAsOn03_31_2015" id="Factid_109" unitRef="shares" decimals="INF">3140250</rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber>

  <rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber contextRef="PAsOn03_31_2015_ExercisePriceRangeOneMemberusgaapRangeAxis" id="Factid_110" unitRef="shares" decimals="INF">3047500</rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber>

  <rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber contextRef="PAsOn03_31_2015_ExercisePriceRangeTwoMemberusgaapRangeAxis" id="Factid_111" unitRef="shares" decimals="INF">92750</rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="P04_01_2013To03_31_2014" id="Factid_112" unitRef="pure" xsi:nil="true" />

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="P04_01_2014To03_31_2015" id="Factid_113" unitRef="pure" decimals="4">0.0167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P04_01_2014To03_31_2015" id="Factid_114">P5Y7M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="P04_01_2013To03_31_2014" id="Factid_115" unitRef="pure" xsi:nil="true" />

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="P04_01_2014To03_31_2015" id="Factid_116" unitRef="pure" decimals="2">0.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="P04_01_2013To03_31_2014" id="Factid_117" unitRef="pure" xsi:nil="true" />

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="P04_01_2014To03_31_2015" id="Factid_118" unitRef="pure" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn03_31_2014" id="Factid_119" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P04_01_2014To03_31_2015" id="Factid_120" unitRef="shares" decimals="INF">332500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="P04_01_2014To03_31_2015" id="Factid_121" unitRef="shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="P04_01_2014To03_31_2015" id="Factid_122" unitRef="shares" decimals="INF">16664</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn03_31_2015" id="Factid_123" unitRef="shares" decimals="INF">315836</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="PAsOn03_31_2015" id="Factid_124" unitRef="shares" decimals="INF">81522</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="PAsOn03_31_2014" id="Factid_125" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="P04_01_2014To03_31_2015" id="Factid_126" unitRef="USD_per_Share" decimals="2">6.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="P04_01_2014To03_31_2015" id="Factid_127" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="P04_01_2014To03_31_2015" id="Factid_128" unitRef="USD_per_Share" decimals="2">6.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="PAsOn03_31_2015" id="Factid_129" unitRef="USD_per_Share" decimals="2">6.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="PAsOn03_31_2015" id="Factid_130" unitRef="USD_per_Share" decimals="2">6.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P04_01_2014To03_31_2015" id="Factid_131">P9Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="P04_01_2014To03_31_2015" id="Factid_132">P8Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="PAsOn03_31_2015" id="Factid_133" unitRef="USD" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="PAsOn03_31_2015" id="Factid_134" unitRef="USD" decimals="0">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="PAsOn03_31_2015_ExercisePriceMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_135" unitRef="USD_per_Share" decimals="2">6.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn03_31_2015_ExercisePriceMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_136" unitRef="shares" decimals="INF">315836</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="P04_01_2014To03_31_2015_ExercisePriceMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_137">P8Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="PAsOn03_31_2015_ExercisePriceMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_138" unitRef="shares" decimals="INF">81522</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="PAsOn03_31_2013_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_139" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="P04_01_2013To03_31_2014_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_140" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="P04_01_2014To03_31_2015_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_141" unitRef="shares" decimals="INF">409355</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="P04_01_2013To03_31_2014_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_142" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="P04_01_2014To03_31_2015_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_143" unitRef="shares" decimals="INF">85308</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="P04_01_2013To03_31_2014_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_144" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="P04_01_2014To03_31_2015_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_145" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="PAsOn03_31_2014_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_146" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="PAsOn03_31_2015_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_147" unitRef="shares" decimals="INF">324047</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="PAsOn03_31_2013_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_148" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="P04_01_2013To03_31_2014_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_149" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="P04_01_2014To03_31_2015_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_150" unitRef="USD_per_Share" decimals="2">6.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="P04_01_2013To03_31_2014_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_151" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="P04_01_2014To03_31_2015_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_152" unitRef="USD_per_Share" decimals="2">6.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="P04_01_2013To03_31_2014_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_153" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="P04_01_2014To03_31_2015_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_154" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="PAsOn03_31_2014_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_155" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="PAsOn03_31_2015_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_156" unitRef="USD_per_Share" decimals="2">6.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>

  <rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedGrantDateFairValue contextRef="PAsOn03_31_2013_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_157" unitRef="USD" decimals="0">0</rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedGrantDateFairValue>

  <rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue contextRef="P04_01_2013To03_31_2014_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_158" unitRef="USD" decimals="0">0</rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue>

  <rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue contextRef="P04_01_2014To03_31_2015_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_159" unitRef="USD" decimals="0">2579000</rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue>

  <rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodGrantDateFairValue contextRef="P04_01_2013To03_31_2014_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_160" unitRef="USD" decimals="0">0</rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodGrantDateFairValue>

  <rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodGrantDateFairValue contextRef="P04_01_2014To03_31_2015_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_161" unitRef="USD" decimals="0">537000</rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodGrantDateFairValue>

  <rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodGrantDateFairValue contextRef="P04_01_2013To03_31_2014_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_162" unitRef="USD" decimals="0">0</rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodGrantDateFairValue>

  <rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodGrantDateFairValue contextRef="P04_01_2014To03_31_2015_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_163" unitRef="USD" decimals="0">0</rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodGrantDateFairValue>

  <rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedGrantDateFairValue contextRef="PAsOn03_31_2014_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_164" unitRef="USD" decimals="0">0</rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedGrantDateFairValue>

  <rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedGrantDateFairValue contextRef="PAsOn03_31_2015_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_165" unitRef="USD" decimals="0">2042000</rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedGrantDateFairValue>

  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="PAsOn03_31_2014" id="Factid_166" unitRef="USD_per_Share" decimals="4">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>

  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="PAsOn03_31_2015" id="Factid_167" unitRef="USD_per_Share" decimals="4">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>

  <us-gaap:PreferredStockSharesAuthorized contextRef="PAsOn03_31_2014" id="Factid_168" unitRef="shares" decimals="INF">500000</us-gaap:PreferredStockSharesAuthorized>

  <us-gaap:PreferredStockSharesAuthorized contextRef="PAsOn03_31_2015" id="Factid_169" unitRef="shares" decimals="INF">500000</us-gaap:PreferredStockSharesAuthorized>

  <us-gaap:PreferredStockSharesIssued contextRef="PAsOn03_31_2014" id="Factid_170" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>

  <us-gaap:PreferredStockSharesIssued contextRef="PAsOn03_31_2015" id="Factid_171" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>

  <us-gaap:PreferredStockSharesOutstanding contextRef="PAsOn03_31_2014" id="Factid_172" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>

  <us-gaap:PreferredStockSharesOutstanding contextRef="PAsOn03_31_2015" id="Factid_173" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>

  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="PAsOn03_31_2014" id="Factid_174" unitRef="USD_per_Share" decimals="4">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>

  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="PAsOn03_31_2015" id="Factid_175" unitRef="USD_per_Share" decimals="4">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>

  <us-gaap:CommonStockSharesAuthorized contextRef="PAsOn03_31_2014" id="Factid_176" unitRef="shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>

  <us-gaap:CommonStockSharesAuthorized contextRef="PAsOn03_31_2015" id="Factid_177" unitRef="shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>

  <us-gaap:CommonStockSharesIssued contextRef="PAsOn03_31_2014" id="Factid_178" unitRef="shares" decimals="INF">4804290</us-gaap:CommonStockSharesIssued>

  <us-gaap:CommonStockSharesIssued contextRef="PAsOn03_31_2015" id="Factid_179" unitRef="shares" decimals="INF">4804290</us-gaap:CommonStockSharesIssued>

  <us-gaap:CommonStockSharesOutstanding contextRef="PAsOn03_31_2014" id="Factid_180" unitRef="shares" decimals="INF">4650000</us-gaap:CommonStockSharesOutstanding>

  <us-gaap:CommonStockSharesOutstanding contextRef="PAsOn03_31_2015" id="Factid_181" unitRef="shares" decimals="INF">4650000</us-gaap:CommonStockSharesOutstanding>

  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="P03_01_2014To03_21_2014_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_182" unitRef="shares" decimals="INF">397500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>

  <us-gaap:SharePrice contextRef="PAsOn03_21_2014_IPOMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_183" unitRef="USD_per_Share" decimals="4">6.6608</us-gaap:SharePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="P04_01_2013To03_31_2014" id="Factid_184" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="P04_01_2014To03_31_2015" id="Factid_185" unitRef="USD_per_Share" decimals="2">4.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="P04_01_2014To03_31_2015" id="Factid_186" unitRef="USD" decimals="0">1593000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>

  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="P04_01_2013To03_31_2014" id="Factid_187" unitRef="USD" decimals="0">0</us-gaap:AllocatedShareBasedCompensationExpense>

  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="P04_01_2013To03_31_2014_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" id="Factid_188" unitRef="USD" decimals="0">0</us-gaap:AllocatedShareBasedCompensationExpense>

  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="P04_01_2014To03_31_2015" id="Factid_189" unitRef="USD" decimals="0">452000</us-gaap:AllocatedShareBasedCompensationExpense>

  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="P04_01_2014To03_31_2015_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" id="Factid_190" unitRef="USD" decimals="0">627000</us-gaap:AllocatedShareBasedCompensationExpense>

  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="P04_01_2014To03_31_2015_PerformanceSharesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" id="Factid_191" unitRef="USD" decimals="0">431000</us-gaap:AllocatedShareBasedCompensationExpense>

  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="PAsOn03_31_2015" id="Factid_192" unitRef="USD" decimals="0">1060000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>

  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="PAsOn03_31_2015_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" id="Factid_193" unitRef="USD" decimals="0">1522000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>

  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P04_01_2014To03_31_2015" id="Factid_194">P2Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>

  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P04_01_2014To03_31_2015_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" id="Factid_195">P2Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights contextRef="P04_01_2014To03_31_2015_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" id="Factid_196">RSUs for 341,000 shares of common stock vest ratably over three years on a quarterly basis and had an aggregate grant date value of $2,148,000. RSUs for 68,355 shares had an aggregate grant date value of $431,000 and vest in equal installments based on achievement of the following: (1) enrollment of the first patient in the first pivotal clinical trial for RUT58-60 on or prior to May 11, 2017; (2) enrollment of the first patient in the second pivotal clinical trial for RUT58-60 on or prior to May 11, 2018; and (3) completion of the clinical study report containing the results of the second pivotal clinical trial for RUT58-60 on or prior to May 11, 2019.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P05_01_2014To05_12_2014_TwoThousandThirteenPlanMemberusgaapAwardTypeAxis" id="Factid_197" unitRef="shares" decimals="INF">332500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="P05_01_2014To05_11_2014_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" id="Factid_198" unitRef="shares" decimals="INF">409355</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="P05_01_2014To05_12_2014_TwoThousandThirteenPlanMemberusgaapAwardTypeAxis" id="Factid_199" unitRef="USD_per_Share" decimals="2">6.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>

  <rtgn:WarrantsToPurchaseOfCommonStock contextRef="P03_01_2014To03_21_2014_IPOMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_200" unitRef="shares" decimals="INF">397500</rtgn:WarrantsToPurchaseOfCommonStock>

  <rtgn:WarrantsToPurchaseOfCommonStock contextRef="P03_01_2014To03_26_2014_IPOMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_201" unitRef="shares" decimals="INF">397500</rtgn:WarrantsToPurchaseOfCommonStock>

  <rtgn:InitialPublicOfferingPricePerUnit contextRef="PAsOn03_21_2014_IPOMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_202" unitRef="USD_per_Share" decimals="2">7.25</rtgn:InitialPublicOfferingPricePerUnit>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn03_21_2014_TwoThousandThirteenPlanMemberusgaapAwardTypeAxis" id="Factid_203" unitRef="USD_per_Share" decimals="4">0.0092</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn03_26_2014_IPOMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_204" unitRef="USD_per_Share" decimals="4">9.0625</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn03_26_2014_UnderwritersMemberusgaapAwardTypeAxis" id="Factid_205" unitRef="USD_per_Share" decimals="4">9.0625</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

  <rtgn:InitialPublicOfferingUnits contextRef="P03_01_2014To03_21_2014_IPOMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_206" unitRef="shares" decimals="INF">2650000</rtgn:InitialPublicOfferingUnits>

  <rtgn:InitialPublicOfferingUnits contextRef="P03_01_2014To03_26_2014_IPOMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_207" unitRef="shares" decimals="INF">2650000</rtgn:InitialPublicOfferingUnits>

  <us-gaap:Revenues contextRef="P04_01_2013To03_31_2014" id="Factid_208" unitRef="USD" decimals="0">0</us-gaap:Revenues>

  <us-gaap:Revenues contextRef="P04_01_2014To03_31_2015" id="Factid_209" unitRef="USD" decimals="0">0</us-gaap:Revenues>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P04_01_2013To03_31_2014" id="Factid_210" unitRef="USD" decimals="0">1382000</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P04_01_2014To03_31_2015" id="Factid_211" unitRef="USD" decimals="0">2178000</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="P04_01_2013To03_31_2014" id="Factid_212" unitRef="USD" decimals="0">1736000</us-gaap:SellingGeneralAndAdministrativeExpense>

  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="P04_01_2014To03_31_2015" id="Factid_213" unitRef="USD" decimals="0">4530000</us-gaap:SellingGeneralAndAdministrativeExpense>

  <us-gaap:OperatingExpenses contextRef="P04_01_2013To03_31_2014" id="Factid_214" unitRef="USD" decimals="0">3118000</us-gaap:OperatingExpenses>

  <us-gaap:OperatingExpenses contextRef="P04_01_2014To03_31_2015" id="Factid_215" unitRef="USD" decimals="0">6708000</us-gaap:OperatingExpenses>

  <us-gaap:OperatingIncomeLoss contextRef="P04_01_2013To03_31_2014" id="Factid_216" unitRef="USD" decimals="0">-3118000</us-gaap:OperatingIncomeLoss>

  <us-gaap:OperatingIncomeLoss contextRef="P04_01_2014To03_31_2015" id="Factid_217" unitRef="USD" decimals="0">-6708000</us-gaap:OperatingIncomeLoss>

  <us-gaap:InvestmentIncomeNonoperating contextRef="P04_01_2013To03_31_2014" id="Factid_218" unitRef="USD" decimals="0">0</us-gaap:InvestmentIncomeNonoperating>

  <us-gaap:InvestmentIncomeNonoperating contextRef="P04_01_2014To03_31_2015" id="Factid_219" unitRef="USD" decimals="0">17000</us-gaap:InvestmentIncomeNonoperating>

  <us-gaap:NonoperatingIncomeExpense contextRef="P04_01_2013To03_31_2014" id="Factid_220" unitRef="USD" decimals="0">0</us-gaap:NonoperatingIncomeExpense>

  <us-gaap:NonoperatingIncomeExpense contextRef="P04_01_2014To03_31_2015" id="Factid_221" unitRef="USD" decimals="0">17000</us-gaap:NonoperatingIncomeExpense>

  <us-gaap:NetIncomeLoss contextRef="P04_01_2013To03_31_2014" id="Factid_222" unitRef="USD" decimals="0">-3118000</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P04_01_2014To03_31_2015" id="Factid_223" unitRef="USD" decimals="0">-6691000</us-gaap:NetIncomeLoss>

  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="P04_01_2013To03_31_2014" id="Factid_224" unitRef="USD_per_Share" decimals="2">-1.53</us-gaap:EarningsPerShareBasicAndDiluted>

  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="P04_01_2014To03_31_2015" id="Factid_225" unitRef="USD_per_Share" decimals="2">-1.39</us-gaap:EarningsPerShareBasicAndDiluted>

  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P04_01_2013To03_31_2014" id="Factid_226" unitRef="shares" decimals="INF">2036301</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>

  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P04_01_2014To03_31_2015" id="Factid_227" unitRef="shares" decimals="INF">4823907</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>

  <us-gaap:StockholdersEquity contextRef="PAsOn03_31_2013" id="Factid_228" unitRef="USD" decimals="0">47000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn03_31_2013_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_229" unitRef="USD" decimals="0">200</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn03_31_2013_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_230" unitRef="USD" decimals="0">597800</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn03_31_2013_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_231" unitRef="USD" decimals="0">-551000</us-gaap:StockholdersEquity>

  <us-gaap:SharesOutstanding contextRef="PAsOn03_31_2013_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_232" unitRef="shares" decimals="INF">2000000</us-gaap:SharesOutstanding>

  <us-gaap:StockIssuedDuringPeriodValueIssuedForCash contextRef="P04_01_2014To03_31_2015" id="Factid_233" unitRef="USD" decimals="0">1028000</us-gaap:StockIssuedDuringPeriodValueIssuedForCash>

  <us-gaap:StockIssuedDuringPeriodValueIssuedForCash contextRef="P04_01_2014To03_31_2015_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_234" unitRef="USD" decimals="0">15</us-gaap:StockIssuedDuringPeriodValueIssuedForCash>

  <us-gaap:StockIssuedDuringPeriodValueIssuedForCash contextRef="P04_01_2014To03_31_2015_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_235" unitRef="USD" decimals="0">1027985</us-gaap:StockIssuedDuringPeriodValueIssuedForCash>

  <us-gaap:StockIssuedDuringPeriodValueIssuedForCash contextRef="P04_01_2014To03_31_2015_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_236" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueIssuedForCash>

  <us-gaap:StockIssuedDuringPeriodSharesIssuedForCash contextRef="P04_01_2014To03_31_2015_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_237" unitRef="shares" decimals="INF">154290</us-gaap:StockIssuedDuringPeriodSharesIssuedForCash>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P04_01_2014To03_31_2015" id="Factid_238" unitRef="USD" decimals="0">1079000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P04_01_2014To03_31_2015_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_239" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P04_01_2014To03_31_2015_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_240" unitRef="USD" decimals="0">1079000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P04_01_2014To03_31_2015_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_241" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:NetIncomeLoss contextRef="P04_01_2013To03_31_2014_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_242" unitRef="USD" decimals="0">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P04_01_2013To03_31_2014_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_243" unitRef="USD" decimals="0">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P04_01_2013To03_31_2014_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_244" unitRef="USD" decimals="0">-3118000</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P04_01_2014To03_31_2015_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_245" unitRef="USD" decimals="0">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P04_01_2014To03_31_2015_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_246" unitRef="USD" decimals="0">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P04_01_2014To03_31_2015_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_247" unitRef="USD" decimals="0">-6691000</us-gaap:NetIncomeLoss>

  <us-gaap:StockholdersEquity contextRef="PAsOn03_31_2014_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_248" unitRef="USD" decimals="0">465</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn03_31_2014_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_249" unitRef="USD" decimals="0">18297535</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn03_31_2014_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_250" unitRef="USD" decimals="0">-3669000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn03_31_2015_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_251" unitRef="USD" decimals="0">480</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn03_31_2015_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_252" unitRef="USD" decimals="0">20404520</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn03_31_2015_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_253" unitRef="USD" decimals="0">-10360000</us-gaap:StockholdersEquity>

  <us-gaap:SharesOutstanding contextRef="PAsOn03_31_2014_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_254" unitRef="shares" decimals="INF">4650000</us-gaap:SharesOutstanding>

  <us-gaap:SharesOutstanding contextRef="PAsOn03_31_2015_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_255" unitRef="shares" decimals="INF">4804290</us-gaap:SharesOutstanding>

  <us-gaap:Depreciation contextRef="P04_01_2013To03_31_2014" id="Factid_256" unitRef="USD" decimals="0">2000</us-gaap:Depreciation>

  <us-gaap:Depreciation contextRef="P04_01_2014To03_31_2015" id="Factid_257" unitRef="USD" decimals="0">1000</us-gaap:Depreciation>

  <us-gaap:ShareBasedCompensation contextRef="P04_01_2013To03_31_2014" id="Factid_258" unitRef="USD" decimals="0">0</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P04_01_2014To03_31_2015" id="Factid_259" unitRef="USD" decimals="0">1079000</us-gaap:ShareBasedCompensation>

  <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="P04_01_2013To03_31_2014" id="Factid_260" unitRef="USD" decimals="0">-1000</us-gaap:IncreaseDecreaseInPrepaidExpense>

  <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="P04_01_2014To03_31_2015" id="Factid_261" unitRef="USD" decimals="0">163000</us-gaap:IncreaseDecreaseInPrepaidExpense>

  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="P04_01_2013To03_31_2014" id="Factid_262" unitRef="USD" decimals="0">146000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>

  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="P04_01_2014To03_31_2015" id="Factid_263" unitRef="USD" decimals="0">388000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>

  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="P04_01_2013To03_31_2014" id="Factid_264" unitRef="USD" decimals="0">-2969000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>

  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="P04_01_2014To03_31_2015" id="Factid_265" unitRef="USD" decimals="0">-5386000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>

  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="P04_01_2013To03_31_2014" id="Factid_266" unitRef="USD" decimals="0">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>

  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="P04_01_2014To03_31_2015" id="Factid_267" unitRef="USD" decimals="0">156000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>

  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="P04_01_2013To03_31_2014" id="Factid_268" unitRef="USD" decimals="0">0</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>

  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="P04_01_2014To03_31_2015" id="Factid_269" unitRef="USD" decimals="0">-156000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>

  <us-gaap:ProceedsFromRelatedPartyDebt contextRef="P04_01_2013To03_31_2014" id="Factid_270" unitRef="USD" decimals="0">1453000</us-gaap:ProceedsFromRelatedPartyDebt>

  <us-gaap:ProceedsFromRelatedPartyDebt contextRef="P04_01_2014To03_31_2015" id="Factid_271" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromRelatedPartyDebt>

  <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="P04_01_2013To03_31_2014" id="Factid_272" unitRef="USD" decimals="0">916000</us-gaap:RepaymentsOfRelatedPartyDebt>

  <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="P04_01_2014To03_31_2015" id="Factid_273" unitRef="USD" decimals="0">537000</us-gaap:RepaymentsOfRelatedPartyDebt>

  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="P04_01_2013To03_31_2014" id="Factid_274" unitRef="USD" decimals="0">16228000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>

  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="P04_01_2014To03_31_2015" id="Factid_275" unitRef="USD" decimals="0">865000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>

  <rtgn:InvestmentFromRelatedParty contextRef="P04_01_2013To03_31_2014" id="Factid_276" unitRef="USD" decimals="0">1679000</rtgn:InvestmentFromRelatedParty>

  <rtgn:InvestmentFromRelatedParty contextRef="P04_01_2014To03_31_2015" id="Factid_277" unitRef="USD" decimals="0">0</rtgn:InvestmentFromRelatedParty>

  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="P04_01_2013To03_31_2014" id="Factid_278" unitRef="USD" decimals="0">18444000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>

  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="P04_01_2014To03_31_2015" id="Factid_279" unitRef="USD" decimals="0">328000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>

  <us-gaap:CashPeriodIncreaseDecrease contextRef="P04_01_2013To03_31_2014" id="Factid_280" unitRef="USD" decimals="0">15475000</us-gaap:CashPeriodIncreaseDecrease>

  <us-gaap:CashPeriodIncreaseDecrease contextRef="P04_01_2014To03_31_2015" id="Factid_281" unitRef="USD" decimals="0">-5214000</us-gaap:CashPeriodIncreaseDecrease>

  <us-gaap:Cash contextRef="PAsOn03_31_2013" id="Factid_282" unitRef="USD" decimals="0">96000</us-gaap:Cash>

  <rtgn:GrossProceedsFromIssuanceOfCommonStockAndWarrants contextRef="P04_01_2013To03_31_2014" id="Factid_283" unitRef="USD" decimals="0">19216000</rtgn:GrossProceedsFromIssuanceOfCommonStockAndWarrants>

  <rtgn:GrossProceedsFromIssuanceOfCommonStockAndWarrants contextRef="P04_01_2014To03_31_2015" id="Factid_284" unitRef="USD" decimals="0">1117000</rtgn:GrossProceedsFromIssuanceOfCommonStockAndWarrants>

  <rtgn:OfferingCost contextRef="P04_01_2013To03_31_2014" id="Factid_285" unitRef="USD" decimals="0">3195000</rtgn:OfferingCost>

  <rtgn:OfferingCost contextRef="P04_01_2014To03_31_2015" id="Factid_286" unitRef="USD" decimals="0">252000</rtgn:OfferingCost>

  <rtgn:OfferingCostWithheldFromProceeds contextRef="P04_01_2013To03_31_2014" id="Factid_287" unitRef="USD" decimals="0">2826000</rtgn:OfferingCostWithheldFromProceeds>

  <rtgn:OfferingCostWithheldFromProceeds contextRef="P04_01_2014To03_31_2015" id="Factid_288" unitRef="USD" decimals="0">89000</rtgn:OfferingCostWithheldFromProceeds>

  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="P04_01_2012To03_31_2013" id="Factid_289" unitRef="USD" decimals="0">44000</us-gaap:PaymentsOfStockIssuanceCosts>

  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="P04_01_2013To03_31_2014" id="Factid_290" unitRef="USD" decimals="0">206000</us-gaap:PaymentsOfStockIssuanceCosts>

  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="P04_01_2014To03_31_2015" id="Factid_291" unitRef="USD" decimals="0">163000</us-gaap:PaymentsOfStockIssuanceCosts>

  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="P04_01_2014To03_31_2015" id="Factid_292">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt;Note 1. Organization and Plan of Merger&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;b&gt;&lt;i&gt;Organization&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;Ruthigen, Inc. (the &amp;#8220;Company&amp;#8221; or &amp;#8220;Ruthigen&amp;#8221;) was incorporated under the laws of the State of Nevada on January 18, 2013. The Company was reincorporated from Nevada to Delaware on September 25, 2013. The Company&amp;#8217;s principal office is located in Santa Rosa, California. Ruthigen is a biopharmaceutical company focused on pioneering new hypochlorus acid, or HOCl, based therapies designed to improve patient outcomes and reduce healthcare costs associated with infections related to post-operative invasive procedures.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;The Company closed its initial public offering (&amp;#8220;IPO&amp;#8221;) on March 26, 2014, pursuant to which an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2,650,000&lt;/font&gt; units were sold at a price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;7.25&lt;/font&gt; per unit. Prior to the IPO, the Company was a wholly-owned subsidiary of Oculus Innovative Sciences, Inc. (&amp;#8220;Oculus&amp;#8221; or &amp;#8220;Former Parent&amp;#8221;). See Note 7 &amp;#150; Stockholders&amp;#8217; Equity &amp;#150; Initial Public Offering for additional details.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Agreement and Plan of Merger&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;On March 13, 2015, the Company entered into an Agreement and Plan of Merger (the &amp;#8220;Merger Agreement&amp;#8221;) with Pulmatrix Inc. (&amp;#8220;Pulmatrix&amp;#8221;), a privately held biopharmaceutical company focused on the discovery, development, and commercialization of inhalable therapeutics and enabling technologies that treat and control respiratory infectious diseases. The Merger Agreement provides for the merger of Pulmatrix with and into Ruthigen Merger Corp., with Pulmatrix continuing after the merger as the surviving corporation and a wholly owned subsidiary of Ruthigen (the &amp;#8220;Merger&amp;#8221;). See Note 6 &amp;#150; Commitments and Contingencies &amp;#150; Agreement and Plan of Merger for additional details.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>

  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P04_01_2014To03_31_2015" id="Factid_293">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; Note 2. Summary of Significant Accounting Policies&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px 0pt -0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Liquidity and Financial Condition&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company incurred net losses of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;6,691,000&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3,118,000&lt;/font&gt; for the years ended March 31, 2015 and 2014, respectively. At March 31, 2015, the Company&amp;#8217;s working capital and accumulated deficit were $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;9,888,000&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;10,360,000&lt;/font&gt;, respectively. The Company has not yet achieved profitability and it is expected that its research and development and general and administrative expenses will continue to increase and, as a result, the Company will eventually need to generate significant product revenues to achieve profitability.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company believes that its existing cash, which includes the proceeds from its IPO, will be sufficient to fund its stand-alone operations through the quarter ending June 30, 2016. However, in order for the Company to execute its research and development strategy and to obtain the necessary regulatory approvals to commercialize RUT58-60 as a drug in the United States, the Company will need to raise additional funds through public or private equity offerings, debt financings, corporate collaborations or other means. The Company has not secured any commitment for new financing at this time, nor can it provide any assurance that new financing will be available on commercially acceptable terms, if at all. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash. See Note 6 &amp;#150; Commitments and Contingencies &amp;#150; Agreement and Plan of Merger.&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Principles of Consolidation&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The consolidated financial statements of the Company include the accounts of its wholly-owned subsidiary, Ruthigen Merger Corp., which was incorporated in the state of Delaware on March 2, 2015. All significant intercompany transactions have been eliminated in the consolidation. See Note 6 &amp;#150; Commitments and Contingencies &amp;#150; Agreement and Plan of Merger.&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Use of Estimates&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (&amp;#8220;U. S. GAAP&amp;#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include stock-based compensation, the valuation allowance related to the Company&amp;#8217;s deferred tax assets and the expense allocations relating to the Company&amp;#8217;s operations prior to its deconsolidation from its Former Parent on March 26, 2014.&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Concentration of Credit Risk&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; Financial instruments that potentially subject the Company to concentrations of credit risk include amounts held as cash. Cash is maintained in financial institutions located in the United States. The Company is exposed to credit risk in the event of default by these financial institutions for amounts in excess of the Federal Deposit Insurance Corporation insured limits.&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Fair Value of Financial Assets and Liabilities&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; Financial instruments, including cash, accounts payable and accrued expenses are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company measures the fair value of financial assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. The Company uses three levels of inputs that may be used to measure fair value:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; Level 1&amp;#160;&amp;#151;&amp;#160;quoted prices in active markets for identical assets or liabilities.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; Level 2&amp;#160;&amp;#151;&amp;#160;quoted prices for similar assets and liabilities in active markets or inputs that are observable.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; Level 3&amp;#160;&amp;#151;&amp;#160;inputs that are unobservable (for example cash flow modeling inputs based on assumptions).&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Property and Equipment&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; Property and equipment are stated at cost, net of accumulated depreciation and amortization which is recorded commencing at the in-service date. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Depreciation of leasehold improvements is computed using the straight-line method over the lesser of the estimated useful life of the improvement or the remaining term of the lease. &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Estimated useful asset life by classification is as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;table style="WIDTH: 50%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Years&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 80%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Office equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; WIDTH: 19%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 3&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Medical equipment&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 5&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Furniture and fixtures&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 7&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred.&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Impairment of Long-Lived Assets&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.2pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.2pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company periodically reviews the carrying values of its long-lived assets when events or changes in circumstances would indicate that it is more likely than not that their carrying values may exceed their realizable values, and records impairment charges when considered necessary. Specific potential indicators of impairment include, but are not necessarily limited to:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#8226;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;a significant decrease in the fair value of an asset;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#8226;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;a significant change in the extent or manner in which an asset is used or a significant physical change in an asset;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#8226;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;a significant adverse change in legal factors or in the business climate that affects the value of an asset;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#8226;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;an adverse action or assessment by the U.S. Food and Drug Administration or another regulator;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#8226;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;an accumulation of costs significantly in excess of the amount originally expected to acquire or construct an asset; and operating or cash flow losses combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with an income-producing asset.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; When circumstances indicate that an impairment may have occurred, the Company tests such assets for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of such assets and their eventual disposition to their carrying amounts. In estimating these future cash flows, assets and liabilities are grouped at the lowest level for which there are identifiable cash flows that are largely independent of the cash flows generated by other such groups. If the undiscounted future cash flows are less than the carrying amount of the asset, an impairment loss, measured as the excess of the carrying value of the asset over its estimated fair value, will be recognized. The cash flow estimates used in such calculations are based on estimates and assumptions, using all available information that management believes is reasonable.&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Stock-Based Compensation&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company accounts for share-based awards exchanged for employee and director services at the estimated grant date fair value of the award. The Company estimates the fair value of stock options using the Black-Scholes option pricing model. The Company estimates the fair value of restricted stock and restricted stock units (&amp;#8220;RSUs&amp;#8221;) based upon the closing market price of the Company&amp;#8217;s common stock on the date the award is granted. The Company amortizes the fair value of employee awards on&amp;#160;the straight-line basis over the requisite service period of the awards. Stock-based compensation expense includes the impact of an estimate for forfeitures for all stock awards. The Company recognizes stock-based compensation expense for awards with performance conditions if and when the Company concludes that it is probable that the performance condition will be achieved. The Company reassesses the probability of vesting at each reporting period for awards with performance conditions and adjusts stock-based compensation expense based on its probability assessment.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company accounts for equity instruments issued to non-employees at their fair value on the measurement date. The measurement of stock-based compensation is subject to periodic adjustment as the underlying equity instrument vests or becomes non-forfeitable. Non-employee stock-based compensation charges are amortized over the requisite service period.&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Research and Development&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; Research and development expense is charged to operations as incurred and consists primarily of personnel expenses, clinical and regulatory services and supplies.&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Net Loss per Share&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company computes basic net loss per share by dividing net loss per share available to common stockholders by the weighted average number of common shares outstanding for the period and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the &amp;#8220;treasury stock&amp;#8221; and/or &amp;#8220;if converted&amp;#8221; methods, as applicable.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;March&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Options&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;315,836&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3,145,650&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3,140,250&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Restricted stock units&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;324,047&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3,785,533&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3,140,250&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Income Taxes&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company accounts for income taxes under Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) 740 Income Taxes (&amp;#8220;ASC 740&amp;#8221;). Under ASC 740, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&amp;#8217;s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; Tax benefits claimed or expected to be claimed on a tax return are recorded in the Company&amp;#8217;s consolidated financial statements. A tax benefit from an uncertain tax position is only recognized if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. Uncertain tax positions have had no impact on the Company&amp;#8217;s consolidated financial condition, results of operations or cash flows.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; In June 2014, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No. 2014-12, "Compensation - Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could be Achieved after the Requisite Service Period," ("ASU 2014-12"). The amendments in ASU 2014-12 require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Accounting Standards Codification Topic No. 718, "Compensation - Stock Compensation" as it relates to awards with performance conditions that affect vesting to account for such awards. The amendments in ASU 2014-12 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in ASU 2014-12 either: (a) prospectively to all awards granted or modified after the effective date; or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The Company does not anticipate that the adoption of this standard will have a material impact on its consolidated financial statements.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; In August 2014, the FASB issued ASU No. 2014-15, &amp;#8220;Presentation of Financial Statements &amp;#150; Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&amp;#8217;s Ability to Continue as a Going Concern.&amp;#8221; The guidance, which is effective for annual reporting periods ending after December 15, 2016, extends the responsibility for performing the going-concern assessment to management and contains guidance on how to perform a going-concern assessment and when going-concern disclosures would be required under U.S. GAAP. The Company does not believe adoption of this ASU will have a material effect on its consolidated financial statements.&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Subsequent Events&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; Management has evaluated subsequent events or transactions occurring through the date these consolidated financial statements were issued. See Note 10 &amp;#150; Subsequent Events.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>

  <dei:DocumentType contextRef="P04_01_2014To03_31_2015" id="Factid_294">10-K</dei:DocumentType>

  <dei:AmendmentFlag contextRef="P04_01_2014To03_31_2015" id="Factid_295">false</dei:AmendmentFlag>

  <dei:DocumentPeriodEndDate contextRef="P04_01_2014To03_31_2015" id="Factid_296">2015-03-31</dei:DocumentPeriodEndDate>

  <dei:DocumentFiscalYearFocus contextRef="P04_01_2014To03_31_2015" id="Factid_297">2015</dei:DocumentFiscalYearFocus>

  <dei:DocumentFiscalPeriodFocus contextRef="P04_01_2014To03_31_2015" id="Factid_298">FY</dei:DocumentFiscalPeriodFocus>

  <dei:EntityRegistrantName contextRef="P04_01_2014To03_31_2015" id="Factid_299">Ruthigen, Inc.</dei:EntityRegistrantName>

  <dei:EntityCentralIndexKey contextRef="P04_01_2014To03_31_2015" id="Factid_300">0001574235</dei:EntityCentralIndexKey>

  <dei:CurrentFiscalYearEndDate contextRef="P04_01_2014To03_31_2015" id="Factid_301">--03-31</dei:CurrentFiscalYearEndDate>

  <dei:EntityWellKnownSeasonedIssuer contextRef="P04_01_2014To03_31_2015" id="Factid_302">No</dei:EntityWellKnownSeasonedIssuer>

  <dei:EntityVoluntaryFilers contextRef="P04_01_2014To03_31_2015" id="Factid_303">No</dei:EntityVoluntaryFilers>

  <dei:EntityCurrentReportingStatus contextRef="P04_01_2014To03_31_2015" id="Factid_304">Yes</dei:EntityCurrentReportingStatus>

  <dei:EntityFilerCategory contextRef="P04_01_2014To03_31_2015" id="Factid_305">Smaller Reporting Company</dei:EntityFilerCategory>

  <dei:EntityPublicFloat contextRef="PAsOn09_30_2014" id="Factid_306" unitRef="USD" decimals="0">13572764</dei:EntityPublicFloat>

  <dei:TradingSymbol contextRef="P04_01_2014To03_31_2015" id="Factid_307">RTGN</dei:TradingSymbol>

  <dei:EntityCommonStockSharesOutstanding contextRef="PAsOn06_05_2015" id="Factid_308" unitRef="shares" decimals="INF">4804290</dei:EntityCommonStockSharesOutstanding>

  <rtgn:InvestmentFromFormerParent contextRef="P04_01_2013To03_31_2014" id="Factid_309" unitRef="USD" decimals="0">1679000</rtgn:InvestmentFromFormerParent>

  <rtgn:InvestmentFromFormerParent contextRef="P04_01_2013To03_31_2014_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_310" unitRef="USD" decimals="0">0</rtgn:InvestmentFromFormerParent>

  <rtgn:InvestmentFromFormerParent contextRef="P04_01_2013To03_31_2014_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_311" unitRef="USD" decimals="0">1679000</rtgn:InvestmentFromFormerParent>

  <rtgn:InvestmentFromFormerParent contextRef="P04_01_2013To03_31_2014_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_312" unitRef="USD" decimals="0">0</rtgn:InvestmentFromFormerParent>

  <rtgn:AccruedOfferingCosts contextRef="P04_01_2013To03_31_2014" id="Factid_313" unitRef="USD" decimals="0">163000</rtgn:AccruedOfferingCosts>

  <rtgn:InitialPublicOfferingPricePerUnit contextRef="PAsOn03_26_2014_IPOMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_314" unitRef="USD_per_Share" decimals="2">7.25</rtgn:InitialPublicOfferingPricePerUnit>

  <us-gaap:ConsolidationPolicyTextBlock contextRef="P04_01_2014To03_31_2015" id="Factid_315">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;Principles of Consolidation&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The consolidated financial statements of the Company include the accounts of its wholly-owned subsidiary, Ruthigen Merger Corp., which was incorporated in the state of Delaware on March 2, 2015. All significant intercompany transactions have been eliminated in the consolidation. See Note 6 &amp;#150; Commitments and Contingencies &amp;#150; Agreement and Plan of Merger.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ConsolidationPolicyTextBlock>

  <us-gaap:ConcentrationRiskCreditRisk contextRef="P04_01_2014To03_31_2015" id="Factid_316">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;Concentration of Credit Risk&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; Financial instruments that potentially subject the Company to concentrations of credit risk include amounts held as cash. Cash is maintained in financial institutions located in the United States. The Company is exposed to credit risk in the event of default by these financial institutions for amounts in excess of the Federal Deposit Insurance Corporation insured limits.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ConcentrationRiskCreditRisk>

  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="P04_01_2014To03_31_2015" id="Factid_317">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;Fair Value of Financial Assets and Liabilities&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; Financial instruments, including cash, accounts payable and accrued expenses are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company measures the fair value of financial assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. The Company uses three levels of inputs that may be used to measure fair value:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; Level 1&amp;#160;&amp;#151;&amp;#160;quoted prices in active markets for identical assets or liabilities.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; Level 2&amp;#160;&amp;#151;&amp;#160;quoted prices for similar assets and liabilities in active markets or inputs that are observable.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; Level 3&amp;#160;&amp;#151;&amp;#160;inputs that are unobservable (for example cash flow modeling inputs based on assumptions).&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>

  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="P04_01_2014To03_31_2015" id="Factid_318">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; Property and equipment are stated at cost, net of accumulated depreciation and amortization which is recorded commencing at the in-service date. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Depreciation of leasehold improvements is computed using the straight-line method over the lesser of the estimated useful life of the improvement or the remaining term of the lease. &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Estimated useful asset life by classification is as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;table style="WIDTH: 50%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Years&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 80%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Office equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; WIDTH: 19%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 3&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Medical equipment&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 5&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Furniture and fixtures&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 7&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>

  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="P04_01_2014To03_31_2015" id="Factid_319">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;Impairment of Long-Lived Assets&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.2pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.2pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company periodically reviews the carrying values of its long-lived assets when events or changes in circumstances would indicate that it is more likely than not that their carrying values may exceed their realizable values, and records impairment charges when considered necessary. Specific potential indicators of impairment include, but are not necessarily limited to:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#8226;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;a significant decrease in the fair value of an asset;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#8226;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;a significant change in the extent or manner in which an asset is used or a significant physical change in an asset;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#8226;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;a significant adverse change in legal factors or in the business climate that affects the value of an asset;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#8226;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;an adverse action or assessment by the U.S. Food and Drug Administration or another regulator;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#8226;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;an accumulation of costs significantly in excess of the amount originally expected to acquire or construct an asset; and operating or cash flow losses combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with an income-producing asset.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; When circumstances indicate that an impairment may have occurred, the Company tests such assets for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of such assets and their eventual disposition to their carrying amounts. In estimating these future cash flows, assets and liabilities are grouped at the lowest level for which there are identifiable cash flows that are largely independent of the cash flows generated by other such groups. If the undiscounted future cash flows are less than the carrying amount of the asset, an impairment loss, measured as the excess of the carrying value of the asset over its estimated fair value, will be recognized. The cash flow estimates used in such calculations are based on estimates and assumptions, using all available information that management believes is reasonable.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>

  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="P04_01_2014To03_31_2015" id="Factid_320">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;Research and Development&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; Research and development expense is charged to operations as incurred and consists primarily of personnel expenses, clinical and regulatory services and supplies.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>

  <us-gaap:IncomeTaxPolicyTextBlock contextRef="P04_01_2014To03_31_2015" id="Factid_321">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Income Taxes&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company accounts for income taxes under Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) 740 Income Taxes (&amp;#8220;ASC 740&amp;#8221;). Under ASC 740, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&amp;#8217;s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; Tax benefits claimed or expected to be claimed on a tax return are recorded in the Company&amp;#8217;s consolidated financial statements. A tax benefit from an uncertain tax position is only recognized if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. Uncertain tax positions have had no impact on the Company&amp;#8217;s consolidated financial condition, results of operations or cash flows.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:IncomeTaxPolicyTextBlock>

  <rtgn:PropertyPlanTandEquipmentUsefulLife1TableTextBlock contextRef="P04_01_2014To03_31_2015" id="Factid_322">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; Estimated useful asset life by classification is as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;table style="WIDTH: 50%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Years&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 80%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Office equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; WIDTH: 19%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 3&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Medical equipment&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 5&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Furniture and fixtures&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 7&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</rtgn:PropertyPlanTandEquipmentUsefulLife1TableTextBlock>

  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P04_01_2014To03_31_2015_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_323">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>

  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P04_01_2014To03_31_2015_ManufacturingFacilityMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_324">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>

  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P04_01_2014To03_31_2015_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_325">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>

  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="P04_01_2014To03_31_2015" id="Factid_326">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; Note 4. Property and Equipment&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Property and equipment consists of the following:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div&gt;March&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Office equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Medical equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;156,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;160,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Less: accumulated depreciation and amortization&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(3,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(2,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Property and equipment, net&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;157,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; Depreciation expense amounted to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,000&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2,000&lt;/font&gt; for the years ended March 31, 2015 and 2014, respectively. Depreciation expense is reflected in selling, general and administrative expenses in the consolidated statements of operations. As of March 31, 2015, the Company&amp;#8217;s medical equipment had not been placed into service and, as a result, the Company had not begun depreciating the assets.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>

  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="P04_01_2014To03_31_2015" id="Factid_327">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; Property and equipment consists of the following:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"&gt; &lt;div&gt;March&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Office equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Medical equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;156,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;160,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Less: accumulated depreciation and amortization&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(3,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(2,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Property and equipment, net&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;157,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn03_31_2014" id="Factid_328" unitRef="USD" decimals="0">4000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn03_31_2014_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_329" unitRef="USD" decimals="0">4000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn03_31_2014_MedicalEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_330" unitRef="USD" decimals="0">0</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn03_31_2015" id="Factid_331" unitRef="USD" decimals="0">160000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn03_31_2015_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_332" unitRef="USD" decimals="0">4000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn03_31_2015_MedicalEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_333" unitRef="USD" decimals="0">156000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="PAsOn03_31_2014" id="Factid_334" unitRef="USD" decimals="0">2000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>

  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="PAsOn03_31_2015" id="Factid_335" unitRef="USD" decimals="0">3000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>

  <rtgn:AccruedFranchisesTaxes contextRef="PAsOn03_31_2014" id="Factid_336" unitRef="USD" decimals="0">0</rtgn:AccruedFranchisesTaxes>

  <rtgn:AccruedFranchisesTaxes contextRef="PAsOn03_31_2015" id="Factid_337" unitRef="USD" decimals="0">146000</rtgn:AccruedFranchisesTaxes>

  <us-gaap:SubsequentEventsTextBlock contextRef="P04_01_2014To03_31_2015" id="Factid_338">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; Note 10. Subsequent Events&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; On April 30, 2015, the Company granted to its directors fully-vested, ten-year options to purchase an aggregate of 15,000 shares of common stock at an exercise price of $3.35 per share, pursuant to the 2013 Plan.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SubsequentEventsTextBlock>

  <rtgn:DescriptionOfSeparationAgreement contextRef="P04_01_2014To03_31_2015_OculusMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_339">separation agreement became effective upon the completion of the IPO and terminates on the earlier of 8.5 years following the closing of the IPO or when the parties mutually agree to terminate it.</rtgn:DescriptionOfSeparationAgreement>

  <us-gaap:SignificantPurchaseCommitmentDescription contextRef="P04_01_2014To03_31_2015_LicenseAndSupplyAgreementMemberrtgnLicenseAgreementAxis" id="Factid_340">Oculus shall manufacture and supply, at a purchase price equal to 20% over the cost of goods to Oculus</us-gaap:SignificantPurchaseCommitmentDescription>

  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P04_01_2014To03_31_2015" id="Factid_341">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; Note 9. Related Party Transactions&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; Beginning in March 2013, the Company employed an immediate family member of the Chief Executive Officer as an operations technician at an annual salary of approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;36,000&lt;/font&gt;.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; Upon completion of the IPO, on March 26, 2014, Oculus owned &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 2,000,000&lt;/font&gt; shares of the Company&amp;#8217;s common stock or approximately &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 43&lt;/font&gt;% of the then outstanding common stock.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; On March 13, 2015, Oculus entered into a securities purchase agreement with several investors, pursuant to which the investors agreed to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 350,000&lt;/font&gt; shares of the Company&amp;#8217;s common stock at a price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2.75&lt;/font&gt; per share. On March 23, 2015, this sale closed. Oculus retained the voting rights to the 350,000 shares until and through the date of closing of the Merger. In the event that the closing of the Merger does not occur on or prior to September 30, 2015, the 350,000 shares of the Company&amp;#8217;s common stock will become fully tradable and full voting rights will transfer to the purchasers of such shares.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;font style="FONT-WEIGHT: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal"&gt;On March 13, 2015, Oculus entered into a securities purchase follow-up agreement with&lt;/font&gt; &lt;font style="FONT-WEIGHT: normal"&gt;several investors &lt;font style="FONT-SIZE: 10pt"&gt;pursuant to which Oculus agreed to sell &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1,650,000&lt;/font&gt; shares of the Company&amp;#8217;s common stock at a price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2.75&lt;/font&gt; per share to the investors upon completion of the Merger, provided that &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 50,000&lt;/font&gt; shares may be sold to one or more investors prior to closing. If the Merger does not close by August 13, 2015 or as may be extended up to 60 calendar days at Oculus&amp;#8217;s discretion, there will be no obligation of the investors to purchase the shares. Oculus will retain the voting rights to the 50,000 shares until and through the date of closing of the Merger. In the event that the closing of the Merger does not occur on or prior to September 30, 2015, the 50,000 shares of common stock will become fully tradable and full voting rights will transfer to the investors.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>

  <us-gaap:SalariesWagesAndOfficersCompensation contextRef="P04_01_2012To03_31_2013_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_342" unitRef="USD" decimals="0">36000</us-gaap:SalariesWagesAndOfficersCompensation>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P03_01_2014To03_26_2014_OculusMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_343" unitRef="shares" decimals="INF">2000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="PAsOn03_26_2014_OculusMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_344" unitRef="pure" decimals="2">0.43</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>

  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="P03_01_2015To03_13_2015_OculusMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_345" unitRef="shares" decimals="INF">350000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>

  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="P03_01_2015To03_13_2015_MergerMemberusgaapRestructuringPlanAxis_OculusMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_346" unitRef="shares" decimals="INF">1650000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>

  <us-gaap:SaleOfStockPricePerShare contextRef="PAsOn03_13_2015_OculusMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_347" unitRef="USD_per_Share" decimals="2">2.75</us-gaap:SaleOfStockPricePerShare>

  <us-gaap:SaleOfStockPricePerShare contextRef="PAsOn03_13_2015_MergerMemberusgaapRestructuringPlanAxis_OculusMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_348" unitRef="USD_per_Share" decimals="2">2.75</us-gaap:SaleOfStockPricePerShare>

  <rtgn:SaleOfStockNumberOfSharesIssuedInTransactionOmneOrMoreInvestorsPriorToClosing contextRef="P03_01_2015To03_13_2015_MergerMemberusgaapRestructuringPlanAxis_OculusMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_349" unitRef="shares" decimals="INF">50000</rtgn:SaleOfStockNumberOfSharesIssuedInTransactionOmneOrMoreInvestorsPriorToClosing>

  <us-gaap:SaleOfStockDescriptionOfTransaction contextRef="P03_01_2015To03_31_2015_OculusMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_350">In the event that the closing of the Merger does not occur on or prior to September 30, 2015, the 350,000 shares of the Company&amp;#8217;s common stock will become fully tradable and full voting rights will transfer to the purchasers of such shares.</us-gaap:SaleOfStockDescriptionOfTransaction>

  <us-gaap:SaleOfStockDescriptionOfTransaction contextRef="P03_01_2015To03_31_2015_MergerMemberusgaapRestructuringPlanAxis_OculusMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_351">If the Merger does not close by August 13, 2015 or as may be extended up to 60 calendar days at Oculus&amp;#8217;s discretion, there will be no obligation of the investors to purchase the shares. Oculus will retain the voting rights to the 50,000 shares until and through the date of closing of the Merger. In the event that the closing of the Merger does not occur on or prior to September 30, 2015, the 50,000 shares of common stock will become fully tradable and full voting rights will transfer to the investors.</us-gaap:SaleOfStockDescriptionOfTransaction>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P04_01_2015To04_30_2015_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_352" unitRef="shares" decimals="INF">15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="P04_01_2015To04_30_2015_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_353" unitRef="USD_per_Share" decimals="2">3.35</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>

  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P04_01_2014To03_31_2015" id="Factid_354">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt; Note 8. Income Taxes&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company is included in the U.S. federal and state (California) tax returns with its Former Parent through the March 26, 2014 closing date of the IPO. Post-IPO, the Company filed separate, stand-alone tax returns. During the year ended March 31, 2015, following the deconsolidation, the Company adjusted its net operating loss (&amp;#8220;NOL&amp;#8221;) carry forward to reflect the value of the NOL available to the Company in future periods.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The following summarizes the income tax provision (benefit):&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;table style="WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="white-space:nowrap;"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; FONT-WEIGHT: bold"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"&gt; &lt;div&gt;For The Years Ended&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; FONT-WEIGHT: bold"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="white-space:nowrap;"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"&gt; &lt;div&gt;March 31,&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="white-space:nowrap;"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; &lt;div&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; &lt;div&gt;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td&gt; &lt;div&gt;Federal&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-LEFT: 9pt"&gt; &lt;div&gt;Current&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-LEFT: 9pt; WIDTH: 74%"&gt; &lt;div&gt;Deferred&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt; &lt;div&gt;(1,754,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt; &lt;div&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt; &lt;div&gt;(1,031,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt; &lt;div&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;State and local&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-LEFT: 9pt"&gt; &lt;div&gt;Current&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 1pt; PADDING-LEFT: 9pt"&gt; &lt;div&gt;Deferred&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; &lt;div&gt;(309,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; &lt;div&gt;(182,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;(2,063,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;(1,213,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;Change in valuation allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; &lt;div&gt;2,063,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; &lt;div&gt;1,213,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt; &lt;div&gt;Income tax provision (benefit)&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company has the following net deferred tax assets:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;table style="WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="white-space:nowrap;"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"&gt; &lt;div&gt;March 31,&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="white-space:nowrap;"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; &lt;div&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; &lt;div&gt;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 74%"&gt; &lt;div&gt;Net operating loss carryforwards&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt; &lt;div&gt;3,224,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt; &lt;div&gt;1,427,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td&gt; &lt;div&gt;Stock-based compensation&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;262,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;Charitable donation carryforwards&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; &lt;div&gt;4,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt"&gt; &lt;div&gt;Gross deferred tax assets&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;3,490,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;1,427,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;Valuation allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; &lt;div&gt;(3,490,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; &lt;div&gt;(1,427,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt; &lt;div&gt;&amp;#160;Net deferred tax assets&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; A reconciliation of the statutory federal income tax rate to the Company&amp;#8217;s effective tax rate is as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;table style="WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="white-space:nowrap;"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; FONT-WEIGHT: bold"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"&gt; &lt;div&gt;For The Years Ended&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; FONT-WEIGHT: bold"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="white-space:nowrap;"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"&gt; &lt;div&gt;March 31,&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="white-space:nowrap;"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; &lt;div&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; &lt;div&gt;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 74%"&gt; &lt;div&gt;Expected federal statutory rate&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt; &lt;div&gt;(34.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt; &lt;div&gt;)%&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt; &lt;div&gt;(34.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt; &lt;div&gt;)%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;State tax rate, net of federal benefit&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;(6.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;)%&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;(6.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;)%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;Change in effective state tax rate&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;0.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;(0.3&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;)%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;Permanent items - stock-based compensation&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;2.5&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;0.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;Permanent items - non-deductible merger expenses&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;0.4&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;0.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;Permanent items - other&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;0.1&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;1.3&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;Adjustment of NOL due to deconsolidation&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;6.2&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;0.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;Change in valuation allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; &lt;div&gt;30.8&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; &lt;div&gt;39.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt; &lt;div&gt;Income tax provision (benefit)&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; &lt;div&gt;0.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; &lt;div&gt;0.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; For the years ended March 31, 2015 and 2014, the Company had approximately $8,059,000 and $2,539,000 of federal and state net operating loss carryovers (&amp;#8220;NOLs&amp;#8221;), respectively, which begin to expire in 2033. These net operating loss carryovers are subject to annual limitations under Internal Revenue Code Section 382 because there has been a greater than 50% ownership change following the March 26, 2014 closing of the IPO.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company, after considering all available evidence, fully reserved its deferred tax assets since it is more likely than not that such benefits will not be realized in future periods. The Company has incurred losses for both financial reporting and income tax purposes for the years ended March 31, 2015 and 2014. The Company will continue to evaluate its deferred tax assets to determine whether any changes in circumstances could affect the realization of their future benefit. If it is determined in future periods that portions of the Company&amp;#8217;s deferred tax assets satisfy the realization standards, the valuation allowance will be reduced accordingly.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company does not have any tax positions for which it is reasonably possible that the total amount of gross unrecognized tax benefits will increase or decrease within 12 months of March 31, 2015. The unrecognized tax benefits may increase or change during the next year for items that arise in the ordinary course of business. The Company has elected to reflect interest and penalties attributable to income taxes, to the extent they arise, as a component of its income tax provision or benefit.&amp;#160;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:IncomeTaxDisclosureTextBlock>

  <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="P04_01_2014To03_31_2015" id="Factid_355">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The following summarizes the income tax provision (benefit):&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;table style="WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="white-space:nowrap;"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; FONT-WEIGHT: bold"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"&gt; &lt;div&gt;For The Years Ended&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; FONT-WEIGHT: bold"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="white-space:nowrap;"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"&gt; &lt;div&gt;March 31,&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="white-space:nowrap;"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; &lt;div&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; &lt;div&gt;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td&gt; &lt;div&gt;Federal&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-LEFT: 9pt"&gt; &lt;div&gt;Current&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-LEFT: 9pt; WIDTH: 74%"&gt; &lt;div&gt;Deferred&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt; &lt;div&gt;(1,754,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt; &lt;div&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt; &lt;div&gt;(1,031,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt; &lt;div&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;State and local&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-LEFT: 9pt"&gt; &lt;div&gt;Current&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 1pt; PADDING-LEFT: 9pt"&gt; &lt;div&gt;Deferred&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; &lt;div&gt;(309,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; &lt;div&gt;(182,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;(2,063,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;(1,213,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;Change in valuation allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; &lt;div&gt;2,063,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; &lt;div&gt;1,213,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt; &lt;div&gt;Income tax provision (benefit)&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>

  <rtgn:ScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateTableTextBlock contextRef="P04_01_2014To03_31_2015" id="Factid_356">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company has the following net deferred tax assets:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;table style="WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="white-space:nowrap;"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"&gt; &lt;div&gt;March 31,&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="white-space:nowrap;"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; &lt;div&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; &lt;div&gt;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 74%"&gt; &lt;div&gt;Net operating loss carryforwards&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt; &lt;div&gt;3,224,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt; &lt;div&gt;1,427,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td&gt; &lt;div&gt;Stock-based compensation&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;262,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;Charitable donation carryforwards&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; &lt;div&gt;4,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt"&gt; &lt;div&gt;Gross deferred tax assets&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;3,490,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;1,427,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;Valuation allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; &lt;div&gt;(3,490,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; &lt;div&gt;(1,427,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt; &lt;div&gt;&amp;#160;Net deferred tax assets&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</rtgn:ScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateTableTextBlock>

  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="P04_01_2014To03_31_2015" id="Factid_357">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; A reconciliation of the statutory federal income tax rate to the Company&amp;#8217;s effective tax rate is as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;table style="WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="white-space:nowrap;"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; FONT-WEIGHT: bold"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"&gt; &lt;div&gt;For The Years Ended&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; FONT-WEIGHT: bold"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="white-space:nowrap;"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"&gt; &lt;div&gt;March 31,&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="white-space:nowrap;"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; &lt;div&gt;2015&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; &lt;div&gt;2014&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 74%"&gt; &lt;div&gt;Expected federal statutory rate&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt; &lt;div&gt;(34.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt; &lt;div&gt;)%&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt; &lt;div&gt;(34.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt; &lt;div&gt;)%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;State tax rate, net of federal benefit&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;(6.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;)%&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;(6.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;)%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;Change in effective state tax rate&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;0.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;(0.3&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;)%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;Permanent items - stock-based compensation&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;2.5&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;0.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;Permanent items - non-deductible merger expenses&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;0.4&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;0.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;Permanent items - other&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;0.1&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;1.3&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;Adjustment of NOL due to deconsolidation&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;6.2&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;0.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;Change in valuation allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; &lt;div&gt;30.8&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; &lt;div&gt;39.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt; &lt;div&gt;Income tax provision (benefit)&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; &lt;div&gt;0.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; &lt;div&gt;0.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>

  <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="P04_01_2013To03_31_2014" id="Factid_358" unitRef="USD" decimals="0">0</us-gaap:CurrentFederalTaxExpenseBenefit>

  <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="P04_01_2014To03_31_2015" id="Factid_359" unitRef="USD" decimals="0">0</us-gaap:CurrentFederalTaxExpenseBenefit>

  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="P04_01_2013To03_31_2014" id="Factid_360" unitRef="USD" decimals="0">-1031000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>

  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="P04_01_2014To03_31_2015" id="Factid_361" unitRef="USD" decimals="0">-1754000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>

  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="P04_01_2013To03_31_2014" id="Factid_362" unitRef="USD" decimals="0">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>

  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="P04_01_2014To03_31_2015" id="Factid_363" unitRef="USD" decimals="0">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>

  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="P04_01_2013To03_31_2014" id="Factid_364" unitRef="USD" decimals="0">-182000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>

  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="P04_01_2014To03_31_2015" id="Factid_365" unitRef="USD" decimals="0">-309000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>

  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="P04_01_2013To03_31_2014" id="Factid_366" unitRef="USD" decimals="0">1213000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>

  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="P04_01_2014To03_31_2015" id="Factid_367" unitRef="USD" decimals="0">2063000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>

  <us-gaap:IncomeTaxExpenseBenefit contextRef="P04_01_2013To03_31_2014" id="Factid_368" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxExpenseBenefit>

  <us-gaap:IncomeTaxExpenseBenefit contextRef="P04_01_2014To03_31_2015" id="Factid_369" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxExpenseBenefit>

  <us-gaap:OperatingLossCarryforwards contextRef="PAsOn03_31_2014" id="Factid_370" unitRef="USD" decimals="0">1427000</us-gaap:OperatingLossCarryforwards>

  <us-gaap:OperatingLossCarryforwards contextRef="PAsOn03_31_2015" id="Factid_371" unitRef="USD" decimals="0">3224000</us-gaap:OperatingLossCarryforwards>

  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation contextRef="PAsOn03_31_2014" id="Factid_372" unitRef="USD" decimals="0">0</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>

  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation contextRef="PAsOn03_31_2015" id="Factid_373" unitRef="USD" decimals="0">262000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>

  <us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards contextRef="PAsOn03_31_2014" id="Factid_374" unitRef="USD" decimals="0">0</us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards>

  <us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards contextRef="PAsOn03_31_2015" id="Factid_375" unitRef="USD" decimals="0">4000</us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards>

  <us-gaap:DeferredTaxAssetsGross contextRef="PAsOn03_31_2014" id="Factid_376" unitRef="USD" decimals="0">1427000</us-gaap:DeferredTaxAssetsGross>

  <us-gaap:DeferredTaxAssetsGross contextRef="PAsOn03_31_2015" id="Factid_377" unitRef="USD" decimals="0">3490000</us-gaap:DeferredTaxAssetsGross>

  <us-gaap:OperatingLossCarryforwardsValuationAllowance contextRef="PAsOn03_31_2014" id="Factid_378" unitRef="USD" decimals="0">1427000</us-gaap:OperatingLossCarryforwardsValuationAllowance>

  <us-gaap:OperatingLossCarryforwardsValuationAllowance contextRef="PAsOn03_31_2015" id="Factid_379" unitRef="USD" decimals="0">3490000</us-gaap:OperatingLossCarryforwardsValuationAllowance>

  <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="PAsOn03_31_2014" id="Factid_380" unitRef="USD" decimals="0">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>

  <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="PAsOn03_31_2015" id="Factid_381" unitRef="USD" decimals="0">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>

  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="P04_01_2013To03_31_2014" id="Factid_382" unitRef="pure" decimals="3">-0.340</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>

  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="P04_01_2014To03_31_2015" id="Factid_383" unitRef="pure" decimals="3">-0.340</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>

  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="P04_01_2013To03_31_2014" id="Factid_384" unitRef="pure" decimals="3">-0.060</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>

  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="P04_01_2014To03_31_2015" id="Factid_385" unitRef="pure" decimals="3">-0.060</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>

  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="P04_01_2013To03_31_2014" id="Factid_386" unitRef="pure" decimals="3">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>

  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="P04_01_2014To03_31_2015" id="Factid_387" unitRef="pure" decimals="1">0.0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>

  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther contextRef="P04_01_2013To03_31_2014" id="Factid_388" unitRef="pure" decimals="3">0.013</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther>

  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther contextRef="P04_01_2014To03_31_2015" id="Factid_389" unitRef="pure" decimals="3">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther>

  <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="P04_01_2013To03_31_2014" id="Factid_390" unitRef="pure" decimals="1">0.0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>

  <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="P04_01_2014To03_31_2015" id="Factid_391" unitRef="pure" decimals="3">0.025</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>

  <rtgn:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensesPercent contextRef="P04_01_2013To03_31_2014" id="Factid_392" unitRef="pure" decimals="1">0.0</rtgn:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensesPercent>

  <rtgn:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensesPercent contextRef="P04_01_2014To03_31_2015" id="Factid_393" unitRef="pure" decimals="3">0.004</rtgn:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensesPercent>

  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="P04_01_2013To03_31_2014" id="Factid_394" unitRef="pure" decimals="3">0.390</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>

  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="P04_01_2014To03_31_2015" id="Factid_395" unitRef="pure" decimals="3">0.308</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>

  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="P04_01_2013To03_31_2014" id="Factid_396" unitRef="pure" decimals="1">0.0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>

  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="P04_01_2014To03_31_2015" id="Factid_397" unitRef="pure" decimals="1">0.0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>

  <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="P04_01_2013To03_31_2014" id="Factid_398" unitRef="USD" decimals="0">-1213000</us-gaap:CurrentIncomeTaxExpenseBenefit>

  <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="P04_01_2014To03_31_2015" id="Factid_399" unitRef="USD" decimals="0">-2063000</us-gaap:CurrentIncomeTaxExpenseBenefit>

  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="PAsOn03_31_2014" id="Factid_400" unitRef="USD" decimals="0">2539000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>

  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="PAsOn03_31_2015" id="Factid_401" unitRef="USD" decimals="0">8059000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>

  <rtgn:OperatingLossCarryforwardsExpirationPeriod contextRef="P04_01_2014To03_31_2015" id="Factid_402">2033</rtgn:OperatingLossCarryforwardsExpirationPeriod>

  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="PAsOn03_31_2014_IPOMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_403" unitRef="pure" decimals="1">0.5</us-gaap:EquityMethodInvestmentOwnershipPercentage>

  <us-gaap:StockholdersEquityReverseStockSplit contextRef="P09_01_2013To09_25_2013" id="Factid_404">1-for-2.5</us-gaap:StockholdersEquityReverseStockSplit>

  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="PAsOn09_25_2013" id="Factid_405" unitRef="USD_per_Share" decimals="4">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>

  <us-gaap:CommonStockSharesOutstanding contextRef="PAsOn09_25_2013" id="Factid_406" unitRef="shares" decimals="INF">5000000</us-gaap:CommonStockSharesOutstanding>

  <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits contextRef="P09_01_2013To09_25_2013" id="Factid_407" unitRef="shares" decimals="INF">2000000</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>

  <us-gaap:CommonStockSharesAuthorized contextRef="PAsOn10_31_2013_TwoThousandThirteenPlanMemberusgaapAwardTypeAxis" id="Factid_408" unitRef="shares" decimals="INF">998355</us-gaap:CommonStockSharesAuthorized>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="P03_01_2015To03_12_2015_NewTwoThousandThirteenPlanMemberusgaapPlanNameAxis" id="Factid_409">The annual increase in the number of shares shall be equal to the lowest of: (i) 2,551,500 shares of Ruthigen&amp;#8217;s common stock; (ii) five percent (5%) of the number of shares of Ruthigen&amp;#8217;s common stock outstanding as of such date; and (iii) an amount determined by Ruthigen&amp;#8217;s board of directors.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="P04_01_2014To03_31_2015_TwoThousandThirteenPlanMemberusgaapAwardTypeAxis" id="Factid_410">The annual increase in the number of shares shall be equal to the lowest of: (a) 232,500 shares of the Company&amp;#8217;s common stock; (b) 5% of the number of shares of the Company&amp;#8217;s common stock outstanding as of such date; and (c) an amount determined by the Company&amp;#8217;s board of directors or compensation committee.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P03_01_2015To03_12_2015_NewTwoThousandThirteenPlanMemberusgaapPlanNameAxis" id="Factid_411" unitRef="shares" decimals="INF">6853319</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease contextRef="P03_01_2015To03_12_2015_NewTwoThousandThirteenPlanMemberusgaapPlanNameAxis" id="Factid_412" unitRef="shares" decimals="INF">1230855</us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease>

  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="P03_01_2014To03_26_2014_IPOMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_413" unitRef="USD" decimals="0">16021000</us-gaap:ProceedsFromIssuanceOfCommonStock>

  <rtgn:GrossProceedsFromIssuanceOfCommonStockAndWarrants contextRef="P03_01_2014To03_26_2014_IPOMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_414" unitRef="USD" decimals="0">19216000</rtgn:GrossProceedsFromIssuanceOfCommonStockAndWarrants>

  <rtgn:OfferingCost contextRef="P03_01_2014To03_26_2014_IPOMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_415" unitRef="USD" decimals="0">3195000</rtgn:OfferingCost>

  <us-gaap:CommonStockSharesIssued contextRef="PAsOn03_26_2014_IPOMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_416" unitRef="shares" decimals="INF">2650000</us-gaap:CommonStockSharesIssued>

  <rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber contextRef="PAsOn03_26_2014_IPOMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_417" unitRef="shares" decimals="INF">3047500</rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber>

  <invest:InvestmentWarrantsExercisePrice contextRef="P03_01_2014To03_26_2014" id="Factid_418" unitRef="USD_per_Share" decimals="4">0.0001</invest:InvestmentWarrantsExercisePrice>

  <rtgn:ClosingPriceOfCommonStockPercentage contextRef="P03_01_2014To03_26_2014" id="Factid_419" unitRef="pure" decimals="1">1.5</rtgn:ClosingPriceOfCommonStockPercentage>

  <rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice contextRef="PAsOn03_26_2014_IPOMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_420" unitRef="USD_per_Share" decimals="2">7.25</rtgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="PAsOn03_26_2014_UnderwritersMemberusgaapAwardTypeAxis" id="Factid_421" unitRef="shares" decimals="INF">92750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>

  <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable contextRef="P03_01_2014To03_26_2014_UnderwritersMemberusgaapAwardTypeAxis" id="Factid_422">2015-03-21</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>

  <rtgn:ClassOfWarrantOrRightsExpiringDateWarrantsOrRightsExercisable contextRef="P03_01_2014To03_26_2014_UnderwritersMemberusgaapAwardTypeAxis" id="Factid_423">2019-03-21</rtgn:ClassOfWarrantOrRightsExpiringDateWarrantsOrRightsExercisable>

  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="P04_01_2014To03_31_2015_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_424" unitRef="shares" decimals="INF">154290</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>

  <us-gaap:SaleOfStockPricePerShare contextRef="PAsOn03_31_2015_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_425" unitRef="USD_per_Share" decimals="4">6.6608</us-gaap:SaleOfStockPricePerShare>

  <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="P04_01_2014To03_31_2015_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_426" unitRef="USD" decimals="0">1028000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>

  <rtgn:TermOfWarrant contextRef="P04_01_2014To03_31_2015_RepresentativeOfUnderwritersMemberusgaapTitleOfIndividualAxis" id="Factid_427">P5Y</rtgn:TermOfWarrant>

  <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="P04_01_2014To03_31_2015_RepresentativeOfUnderwritersMemberusgaapTitleOfIndividualAxis" id="Factid_428" unitRef="shares" decimals="INF">5400</us-gaap:StockIssuedDuringPeriodSharesOther>

  <us-gaap:SharesIssuedPricePerShare contextRef="PAsOn03_31_2015_RepresentativeOfUnderwritersMemberusgaapTitleOfIndividualAxis" id="Factid_429" unitRef="USD_per_Share" decimals="4">9.0625</us-gaap:SharesIssuedPricePerShare>

  <rtgn:ClassOfWarrantOrRightDurationFromWhichWarrantsOrRightsExercisable contextRef="P04_01_2014To03_31_2015" id="Factid_430">P1Y</rtgn:ClassOfWarrantOrRightDurationFromWhichWarrantsOrRightsExercisable>

  <rtgn:PercentageOfOptionsUnvested contextRef="P04_01_2014To03_31_2015" id="Factid_431" unitRef="pure" decimals="0">0</rtgn:PercentageOfOptionsUnvested>

  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="PAsOn03_13_2015" id="Factid_432" unitRef="pure" decimals="2">0.17</us-gaap:EquityMethodInvestmentOwnershipPercentage>

  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="PAsOn03_13_2015_PulmatrixIncMemberdeiLegalEntityAxis" id="Factid_433" unitRef="pure" decimals="2">0.83</us-gaap:EquityMethodInvestmentOwnershipPercentage>

  <us-gaap:Cash contextRef="PAsOn07_31_2015_MergerClosingDateIsNoLaterThanJuly312015MemberrtgnDateOfMergerAxis" id="Factid_434" unitRef="USD" decimals="0">9000000</us-gaap:Cash>

  <us-gaap:Cash contextRef="PAsOn08_13_2015_MergerClosingDateIsAfterJuly312015ButNoLaterThanAugust132015MemberrtgnDateOfMergerAxis" id="Factid_435" unitRef="USD" decimals="0">8850000</us-gaap:Cash>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P03_01_2015To03_13_2015_EmployeeAndDirectorMemberusgaapTitleOfIndividualAxis" id="Factid_436" unitRef="shares" decimals="INF">90000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <rtgn:OutstandingStockOptionsAndRestrictedStockUnitsTerminationDescription contextRef="P03_01_2015To03_12_2015_ChiefExecutiveOfficerMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_437">a lump-sum payment in the amount of $547,600, less taxes and other withholdings and (ii) a lump-sum equivalent to the CEO&amp;#8217;s premiums under COBRA for one year, in the same amounts for the same medical coverage as in effect as of the effective time of the merger.</rtgn:OutstandingStockOptionsAndRestrictedStockUnitsTerminationDescription>

  <rtgn:OutstandingStockOptionsAndRestrictedStockUnitsTerminationDescription contextRef="P03_01_2015To03_12_2015_ChiefFinancialOfficerMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_438">a lump-sum payment in the amount of $337,500, less taxes and other withholdings and (ii) a lump-sum equivalent to the CFO&amp;#8217;s premiums under COBRA for one year, in the same amounts for the same medical coverage as in effect as of the effective time of the merger.</rtgn:OutstandingStockOptionsAndRestrictedStockUnitsTerminationDescription>

  <rtgn:RestrictedStockUnitsGrantsDescription contextRef="P03_01_2015To03_12_2015_ChiefExecutiveOfficerMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_EmployeeDirectorAndConsultantEquityIncentivePlanMemberusgaapPlanNameAxis" id="Factid_439">equal to the lesser of (i) 930,000 and (ii) the quotient of $3,125,000 divided by the fair market value of the common stock of the combined company as of the effective time of the merger, with such restricted stock units vesting as follows: (i) a number of restricted stock units equal to the lesser of (a) 930,000 and (b) such number of restricted stock units with an aggregate value equal to $1,400,000 shall be fully vested at the effective time of the merger and (ii) an amount equal to 25% of the restricted stock units unvested as of the effective time of the merger will vest on a quarterly basis over the following twelve months.</rtgn:RestrictedStockUnitsGrantsDescription>

  <rtgn:RestrictedStockUnitsGrantsDescription contextRef="P03_01_2015To03_12_2015_ChiefFinancialOfficerMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_440">equal to the lesser of (i) 355,000 and (ii) the quotient of $1,037,500 divided by the fair market value of the common stock of the combined company as of the effective time, with such restricted stock units vesting as follows: (i) a number of restricted stock units equal to the lesser of (a) 355,000 and (b) such number of restricted stock units with an aggregate value equal to $250,000 shall be fully vested at the effective time of the merger and (ii) an amount equal to 25% of the restricted stock units unvested as of the effective time of the merger will vest on a quarterly basis over the following twelve months.</rtgn:RestrictedStockUnitsGrantsDescription>

  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="P03_01_2015To03_03_2015_NewConsultingAgreementsMemberrtgnAgreementTypeAxis" id="Factid_441" unitRef="shares" decimals="INF">340000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>

  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="P03_01_2015To03_10_2015_NewConsultingAgreementsMemberrtgnAgreementTypeAxis" id="Factid_442" unitRef="shares" decimals="INF">250000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>

  <rtgn:PercentageOfGrossProceedsPayable contextRef="P03_01_2015To03_13_2015_OculusMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_443" unitRef="pure" decimals="1">0.1</rtgn:PercentageOfGrossProceedsPayable>

  <us-gaap:LiabilitiesAssumed1 contextRef="P03_01_2015To03_13_2015_OculusSideLetterAgreementMemberrtgnAgreementTypeAxis" id="Factid_444" unitRef="USD" decimals="0">5000</us-gaap:LiabilitiesAssumed1>

  <us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets contextRef="P03_01_2015To03_13_2015_MinimumMemberusgaapRangeAxis_OculusMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_445" unitRef="USD" decimals="-5">1000000</us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets>

  <us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets contextRef="P03_01_2015To03_13_2015_OculusMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_446" unitRef="USD" decimals="-5">10000000</us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets>

  <rtgn:ConsiderationForSharesTransferByParent contextRef="P04_01_2014To03_31_2015_MaximumMemberusgaapRangeAxis_OculusMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_447" unitRef="USD" decimals="0">1500000</rtgn:ConsiderationForSharesTransferByParent>

  <rtgn:RoyaltyGuaranteesCommitmentsPercentage contextRef="P04_01_2014To03_31_2015_LicenseAndSupplyAgreementMemberrtgnLicenseAgreementAxis_MinimumMemberusgaapRangeAxis" id="Factid_448" unitRef="pure" decimals="2">0.03</rtgn:RoyaltyGuaranteesCommitmentsPercentage>

  <rtgn:RoyaltyGuaranteesCommitmentsPercentage contextRef="P04_01_2014To03_31_2015_LicenseAndSupplyAgreementMemberrtgnLicenseAgreementAxis_MaximumMemberusgaapRangeAxis" id="Factid_449" unitRef="pure" decimals="1">0.2</rtgn:RoyaltyGuaranteesCommitmentsPercentage>

  <us-gaap:CostOfServicesLicensesAndServices contextRef="P04_01_2014To03_31_2015_FirstPhaseMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_LicenseAndSupplyAgreementMemberrtgnLicenseAgreementAxis" id="Factid_450" unitRef="USD" decimals="-5">1500000</us-gaap:CostOfServicesLicensesAndServices>

  <us-gaap:CostOfServicesLicensesAndServices contextRef="P04_01_2014To03_31_2015_LicenseAndSupplyAgreementMemberrtgnLicenseAgreementAxis_SecondPhaseMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis" id="Factid_451" unitRef="USD" decimals="-5">1500000</us-gaap:CostOfServicesLicensesAndServices>

  <us-gaap:CostOfServicesLicensesAndServices contextRef="P04_01_2014To03_31_2015_LicenseAndSupplyAgreementMemberrtgnLicenseAgreementAxis_ThirdPhaseMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis" id="Factid_452" unitRef="USD" decimals="-6">3000000</us-gaap:CostOfServicesLicensesAndServices>

  <us-gaap:CostOfServicesLicensesAndServices contextRef="P04_01_2014To03_31_2015_FourthPhaseMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_LicenseAndSupplyAgreementMemberrtgnLicenseAgreementAxis" id="Factid_453" unitRef="USD" decimals="-6">2000000</us-gaap:CostOfServicesLicensesAndServices>

  <rtgn:FundToPayCertainAccountPayablesOutstanding contextRef="PAsOn01_31_2014_OculusMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_454" unitRef="USD" decimals="0">760000</rtgn:FundToPayCertainAccountPayablesOutstanding>

  <rtgn:FundToPayCertainAccountPayablesOutstanding contextRef="PAsOn04_02_2014_OculusMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_455" unitRef="USD" decimals="0">534000</rtgn:FundToPayCertainAccountPayablesOutstanding>

  <rtgn:PercentageOfSharesTransferByFormerParent contextRef="P04_01_2014To03_31_2015_MaximumMemberusgaapRangeAxis_OculusMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_456" unitRef="pure" decimals="2">0.05</rtgn:PercentageOfSharesTransferByFormerParent>

  <rtgn:MinimumDurationForSharesTransfer contextRef="P04_01_2014To03_31_2015_OculusMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_457">P41M15D</rtgn:MinimumDurationForSharesTransfer>

  <rtgn:ProceedsFromTransferAtleastForNotConsummated contextRef="P04_01_2014To03_31_2015" id="Factid_458" unitRef="USD" decimals="-5">3800000</rtgn:ProceedsFromTransferAtleastForNotConsummated>

  <rtgn:ShareTransferAgreementTerms contextRef="P04_01_2014To03_31_2015_OculusMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_459">Transfers conducted using this one-time right must be conducted with the consent of the Companys board of directors or within the prescribed requirements for such transfers set forth in the separation agreement, including, for example, that the purchase price discount may not exceed certain percentages, the amount of shares transferred may not exceed $3,800,000 in net proceeds to Oculus, as well as certain other requirements set forth in the separation agreement. The separation agreement provides Oculus with certain piggy back registration rights of up to 30%</rtgn:ShareTransferAgreementTerms>

  <rtgn:PercentageOfOutstandingSharesForLapsOfTransfer contextRef="P04_01_2014To03_31_2015_OculusMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_460" unitRef="pure" decimals="3">0.199</rtgn:PercentageOfOutstandingSharesForLapsOfTransfer>

  <rtgn:ReimbursementOfExpensesRelatedToTransfer contextRef="P04_01_2013To03_31_2014_OculusMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_461" unitRef="USD" decimals="0">1450000</rtgn:ReimbursementOfExpensesRelatedToTransfer>

  <rtgn:CashBonus contextRef="P08_01_2013To08_12_2013_ChiefExecutiveOfficerMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_462" unitRef="USD" decimals="0">158000</rtgn:CashBonus>

  <us-gaap:LandSubjectToGroundLeases contextRef="PAsOn03_31_2015" id="Factid_463" unitRef="sqft" decimals="0">995</us-gaap:LandSubjectToGroundLeases>

  <us-gaap:LeaseAndRentalExpense contextRef="P02_01_2015To02_11_2015" id="Factid_464" unitRef="USD" decimals="0">1700</us-gaap:LeaseAndRentalExpense>

  <us-gaap:LeaseAndRentalExpense contextRef="P04_01_2013To03_31_2014" id="Factid_465" unitRef="USD" decimals="0">20000</us-gaap:LeaseAndRentalExpense>

  <us-gaap:LeaseAndRentalExpense contextRef="P04_01_2014To03_31_2015" id="Factid_466" unitRef="USD" decimals="0">20000</us-gaap:LeaseAndRentalExpense>

  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="PAsOn06_30_2015_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_467" unitRef="USD" decimals="0">5075</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>

  <rtgn:InitialPublicOfferinfgValueOfUnits contextRef="P04_01_2013To03_31_2014" id="Factid_468" unitRef="USD" decimals="0">16021000</rtgn:InitialPublicOfferinfgValueOfUnits>

  <rtgn:InitialPublicOfferinfgValueOfUnits contextRef="P04_01_2013To03_31_2014_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_469" unitRef="USD" decimals="0">265</rtgn:InitialPublicOfferinfgValueOfUnits>

  <rtgn:InitialPublicOfferinfgValueOfUnits contextRef="P04_01_2013To03_31_2014_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_470" unitRef="USD" decimals="0">16020735</rtgn:InitialPublicOfferinfgValueOfUnits>

  <rtgn:InitialPublicOfferinfgValueOfUnits contextRef="P04_01_2013To03_31_2014_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_471" unitRef="USD" decimals="0">0</rtgn:InitialPublicOfferinfgValueOfUnits>

  <rtgn:InitialPublicOfferingUnits1 contextRef="P04_01_2013To03_31_2014_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_472" unitRef="shares" decimals="INF">2650000</rtgn:InitialPublicOfferingUnits1>

  <rtgn:ChangeInAvailableNolDueToDeconsolidation contextRef="P04_01_2013To03_31_2014" id="Factid_473" unitRef="pure" decimals="1">0.0</rtgn:ChangeInAvailableNolDueToDeconsolidation>

  <rtgn:ChangeInAvailableNolDueToDeconsolidation contextRef="P04_01_2014To03_31_2015" id="Factid_474" unitRef="pure" decimals="3">0.062</rtgn:ChangeInAvailableNolDueToDeconsolidation>

<!--FootNote Section Ref-->

  <link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="#Factid_274" xlink:type="locator" xlink:label="loc_1" />

    <link:footnote xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:type="resource" xlink:label="FN_1">During the year ended March 31, 2015, gross proceeds from the initial public offering of $1,117,000 less $252,000 of offering costs, of which $89,000 was withheld from the proceeds and $163,000 was paid in cash that was previously accrued at March 31, 2014. During the year ended March 31, 2014, gross proceeds from the initial public offering of $19,216,000 less $3,195,000 of offering costs, of which $2,826,000 was withheld from the proceeds, $206,000 was paid in cash (including $44,000 paid during the fiscal year ended March 31, 2013) and $163,000 was accrued as of March 31, 2014.</link:footnote>

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_275" xlink:type="locator" xlink:label="loc_3" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
  </link:footnoteLink>
</xbrli:xbrl>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>rtgn-20150331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.8 on 09-Jun-2015 [02:22:47] {PM} EST - www.datatracks.com -->
<schema targetNamespace="http://www.ruthigen.com/20150331" elementFormDefault="qualified" xmlns:rtgn="http://www.ruthigen.com/20150331" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2014-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.ruthigen.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>101 - Document - Document And Entity Information</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
        <link:definition>102 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
        <link:definition>103 - Statement - CONSOLIDATED BALANCE SHEETS [Parenthetical]</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/ConsolidatedStatementsOfOperations" id="ConsolidatedStatementsOfOperations">
        <link:definition>104 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" id="ConsolidatedStatementsOfChangesInStockholdersEquity">
        <link:definition>105 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#39; EQUITY</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
        <link:definition>106 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/ConsolidatedStatementsOfCashFlowsParenthetical" id="ConsolidatedStatementsOfCashFlowsParenthetical">
        <link:definition>107 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS [Parenthetical]</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/OrganizationAndPlanOfMerger" id="OrganizationAndPlanOfMerger">
        <link:definition>108 - Disclosure - Organization and Plan of Merger</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>109 - Disclosure - Summary of Significant Accounting Policies</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/PrepaidExpensesAndOtherCurrentAssets" id="PrepaidExpensesAndOtherCurrentAssets">
        <link:definition>110 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
        <link:definition>111 - Disclosure - Property and Equipment</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/AccountsPayableAndAccruedExpenses" id="AccountsPayableAndAccruedExpenses">
        <link:definition>112 - Disclosure - Accounts Payable and Accrued Expenses</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>113 - Disclosure - Commitments and Contingencies</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/StockholdersEquity" id="StockholdersEquity">
        <link:definition>114 - Disclosure - Stockholders&#39; Equity</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>115 - Disclosure - Income Taxes</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
        <link:definition>116 - Disclosure - Related Party Transactions</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>117 - Disclosure - Subsequent Events</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>118 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>119 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" id="PrepaidExpensesAndOtherCurrentAssetsTables">
        <link:definition>120 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
        <link:definition>121 - Disclosure - Property and Equipment (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/AccountsPayableAndAccruedExpensesTables" id="AccountsPayableAndAccruedExpensesTables">
        <link:definition>122 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
        <link:definition>123 - Disclosure - Stockholders&#39; Equity (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
        <link:definition>124 - Disclosure - Income Taxes (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/OrganizationAndPlanOfMergerDetailsTextual" id="OrganizationAndPlanOfMergerDetailsTextual">
        <link:definition>125 - Disclosure - Organization and Plan of Merger (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/SummaryOfSignificantAccountingPoliciesDetails" id="SummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>126 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/SummaryOfSignificantAccountingPoliciesDetails1" id="SummaryOfSignificantAccountingPoliciesDetails1">
        <link:definition>127 - Disclosure - Summary of Significant Accounting Policies (Details 1)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" id="SummaryOfSignificantAccountingPoliciesDetailsTextual">
        <link:definition>128 - Disclosure - Summary of Significant Accounting Policies (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" id="PrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>129 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/PropertyAndEquipmentDetails" id="PropertyAndEquipmentDetails">
        <link:definition>130 - Disclosure - Property and Equipment (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/PropertyAndEquipmentDetailsTextual" id="PropertyAndEquipmentDetailsTextual">
        <link:definition>131 - Disclosure - Property and Equipment (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/AccountsPayableAndAccruedExpensesDetails" id="AccountsPayableAndAccruedExpensesDetails">
        <link:definition>132 - Disclosure - Accounts Payable and Accrued Expenses (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/CommitmentsAndContingenciesDetailsTextual" id="CommitmentsAndContingenciesDetailsTextual">
        <link:definition>133 - Disclosure - Commitments and Contingencies (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/StockholdersEquityDetails" id="StockholdersEquityDetails">
        <link:definition>134 - Disclosure - Stockholders&#39; Equity (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/StockholdersEquityDetails1" id="StockholdersEquityDetails1">
        <link:definition>135 - Disclosure - Stockholders&#39; Equity (Details 1)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/StockholdersEquityDetails2" id="StockholdersEquityDetails2">
        <link:definition>136 - Disclosure - Stockholders&#39; Equity (Details 2)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/StockholdersEquityDetails3" id="StockholdersEquityDetails3">
        <link:definition>137 - Disclosure - Stockholders&#39; Equity (Details 3)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/StockholdersEquityDetails4" id="StockholdersEquityDetails4">
        <link:definition>138 - Disclosure - Stockholders&#39; Equity (Details 4)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/StockholdersEquityDetails5" id="StockholdersEquityDetails5">
        <link:definition>139 - Disclosure - Stockholders&#39; Equity (Details 5)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/StockholdersEquityDetailsTextual" id="StockholdersEquityDetailsTextual">
        <link:definition>140 - Disclosure - Stockholders&#39; Equity (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
        <link:definition>141 - Disclosure - Income Taxes (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/IncomeTaxesDetails1" id="IncomeTaxesDetails1">
        <link:definition>142 - Disclosure - Income Taxes (Details 1)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/IncomeTaxesDetails2" id="IncomeTaxesDetails2">
        <link:definition>143 - Disclosure - Income Taxes (Details 2)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/IncomeTaxesDetailsTextual" id="IncomeTaxesDetailsTextual">
        <link:definition>144 - Disclosure - Income Taxes (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/RelatedPartyTransactionsDetailsTextual" id="RelatedPartyTransactionsDetailsTextual">
        <link:definition>145 - Disclosure - Related Party Transactions (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.ruthigen.com/role/SubsequentEventsDetailsTextual" id="SubsequentEventsDetailsTextual">
        <link:definition>146 - Disclosure - Subsequent Events (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:linkbaseRef xlink:type="simple" xlink:href="rtgn-20150331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />

      <link:linkbaseRef xlink:type="simple" xlink:href="rtgn-20150331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />

      <link:linkbaseRef xlink:type="simple" xlink:href="rtgn-20150331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />

      <link:linkbaseRef xlink:type="simple" xlink:href="rtgn-20150331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>

  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />

  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />

  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />

  <import namespace="http://fasb.org/us-gaap/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/currency/2014-01-31" schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/exch/2014-01-31" schemaLocation="http://xbrl.sec.gov/exch/2014/exch-2014-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />

  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />

  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />

  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />

  <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />

  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />

  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />

  <import namespace="http://fasb.org/us-types/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-types-2014-01-31.xsd" />

  <element name="DisclosureOfPrepaidExpensesAndOtherCurrentAssetsTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsTextBlock" />

  <element name="PropertyPlanTandEquipmentUsefulLife1TableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_PropertyPlanTandEquipmentUsefulLife1TableTextBlock" />

  <element name="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" />

  <element name="ScheduleOfSharebasedCompensationWarrantActivityTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_ScheduleOfSharebasedCompensationWarrantActivityTableTextBlock" />

  <element name="ScheduleOfShareBasedCompensationWarrantsByExercisePriceRangeTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_ScheduleOfShareBasedCompensationWarrantsByExercisePriceRangeTableTextBlock" />

  <element name="ScheduleOfSummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="rtgn_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" />

  <element name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_SummaryOfSignificantAccountingPoliciesLineItems" />

  <element name="WorkingCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="rtgn_WorkingCapital" />

  <element name="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="rtgn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTable" />

  <element name="PrepaidExpensesAndOtherCurrentAssetsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_PrepaidExpensesAndOtherCurrentAssetsLineItems" />

  <element name="OtherPrepaidExpensesAndCurrentAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="rtgn_OtherPrepaidExpensesAndCurrentAssets" />

  <element name="ScheduleOfAccountsPayableAndAccuredExpensesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="rtgn_ScheduleOfAccountsPayableAndAccuredExpensesTable" />

  <element name="AccountsPayableAndAccruedExpensesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_AccountsPayableAndAccruedExpensesLineItems" />

  <element name="AccruedDirectorCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="rtgn_AccruedDirectorCompensation" />

  <element name="AccruedLegalFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="rtgn_AccruedLegalFees" />

  <element name="AccruedResearchAndDevelopmentCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="rtgn_AccruedResearchAndDevelopmentCurrent" />

  <element name="AccruedFranchisesTaxes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="rtgn_AccruedFranchisesTaxes" />

  <element name="ScheduleOfCommitmentsAndContingenciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="rtgn_ScheduleOfCommitmentsAndContingenciesTable" />

  <element name="LicenseAgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="rtgn_LicenseAgreementAxis" />

  <element name="LicenseAgreementDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_LicenseAgreementDomain" />

  <element name="EmployeeAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_EmployeeAgreementMember" />

  <element name="LicenseAndSupplyAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_LicenseAndSupplyAgreementMember" />

  <element name="TwoExecutivesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_TwoExecutivesMember" />

  <element name="OculusMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_OculusMember" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsGrantedWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsGrantedWeightedAverageExercisePrice" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisedWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisedWeightedAverageExercisePrice" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable" />

  <element name="ExercisePriceRangeOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_ExercisePriceRangeOneMember" />

  <element name="ExercisePriceRangeTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_ExercisePriceRangeTwoMember" />

  <element name="ExercisePriceMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_ExercisePriceMember" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedGrantDateFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedGrantDateFairValue" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodGrantDateFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodGrantDateFairValue" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodGrantDateFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodGrantDateFairValue" />

  <element name="TwoThousandThirteenPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_TwoThousandThirteenPlanMember" />

  <element name="WarrantsToPurchaseOfCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_WarrantsToPurchaseOfCommonStock" />

  <element name="InitialPublicOfferingPricePerUnit" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="rtgn_InitialPublicOfferingPricePerUnit" />

  <element name="InitialPublicOfferingUnits" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_InitialPublicOfferingUnits" />

  <element name="InvestmentFromFormerParent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="rtgn_InvestmentFromFormerParent" />

  <element name="InitialPublicOfferinfgValueOfUnits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="rtgn_InitialPublicOfferinfgValueOfUnits" />

  <element name="InitialPublicOfferingUnits1" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_InitialPublicOfferingUnits1" />

  <element name="InvestmentFromRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="rtgn_InvestmentFromRelatedParty" />

  <element name="GrossProceedsFromIssuanceOfCommonStockAndWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="rtgn_GrossProceedsFromIssuanceOfCommonStockAndWarrants" />

  <element name="OfferingCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="rtgn_OfferingCost" />

  <element name="OfferingCostWithheldFromProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="rtgn_OfferingCostWithheldFromProceeds" />

  <element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_DocumentAndEntityInformationAbstract" />

  <element name="AccruedOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="rtgn_AccruedOfferingCosts" />

  <element name="DescriptionOfSeparationAgreement" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_DescriptionOfSeparationAgreement" />

  <element name="MedicalEquipmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_MedicalEquipmentMember" />

  <element name="MergerMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_MergerMember" />

  <element name="SaleOfStockNumberOfSharesIssuedInTransactionOmneOrMoreInvestorsPriorToClosing" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_SaleOfStockNumberOfSharesIssuedInTransactionOmneOrMoreInvestorsPriorToClosing" />

  <element name="ScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_ScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateTableTextBlock" />

  <element name="ScheduleOfComponentsOfIncomeTaxExpenseBenefitTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="rtgn_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTable" />

  <element name="ComponentsOfIncomeTaxExpenseBenefitLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_ComponentsOfIncomeTaxExpenseBenefitLineItems" />

  <element name="ScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="rtgn_ScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateTable" />

  <element name="ReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_ReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateLineItems" />

  <element name="ScheduleOfEffectiveIncomeTaxRateReconciliationTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="rtgn_ScheduleOfEffectiveIncomeTaxRateReconciliationTable" />

  <element name="EffectiveIncomeTaxRateReconciliationLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_EffectiveIncomeTaxRateReconciliationLineItems" />

  <element name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensesPercent" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensesPercent" />

  <element name="ChangeInAvailableNolDueToDeconsolidation" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_ChangeInAvailableNolDueToDeconsolidation" />

  <element name="OperatingLossCarryforwardsExpirationPeriod" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_OperatingLossCarryforwardsExpirationPeriod" />

  <element name="FormerParrentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_FormerParrentMember" />

  <element name="NewTwoThousandThirteenPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_NewTwoThousandThirteenPlanMember" />

  <element name="ClosingPriceOfCommonStockPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_ClosingPriceOfCommonStockPercentage" />

  <element name="UnderwritersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_UnderwritersMember" />

  <element name="ClassOfWarrantOrRightsExpiringDateWarrantsOrRightsExercisable" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_ClassOfWarrantOrRightsExpiringDateWarrantsOrRightsExercisable" />

  <element name="TermOfWarrant" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_TermOfWarrant" />

  <element name="ClassOfWarrantOrRightDurationFromWhichWarrantsOrRightsExercisable" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_ClassOfWarrantOrRightDurationFromWhichWarrantsOrRightsExercisable" />

  <element name="RepresentativeOfUnderwritersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_RepresentativeOfUnderwritersMember" />

  <element name="PercentageOfOptionsUnvested" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_PercentageOfOptionsUnvested" />

  <element name="DateOfMergerAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="rtgn_DateOfMergerAxis" />

  <element name="PulmatrixIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_PulmatrixIncMember" />

  <element name="DateOfMergerDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_DateOfMergerDomain" />

  <element name="MergerClosingDateIsNoLaterThanJuly312015Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_MergerClosingDateIsNoLaterThanJuly312015Member" />

  <element name="MergerClosingDateIsAfterJuly312015ButNoLaterThanAugust132015Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_MergerClosingDateIsAfterJuly312015ButNoLaterThanAugust132015Member" />

  <element name="EmployeeAndDirectorMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_EmployeeAndDirectorMember" />

  <element name="OutstandingStockOptionsAndRestrictedStockUnitsTerminationDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_OutstandingStockOptionsAndRestrictedStockUnitsTerminationDescription" />

  <element name="AgreementTypeAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="rtgn_AgreementTypeAxis" />

  <element name="EmployeeDirectorAndConsultantEquityIncentivePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_EmployeeDirectorAndConsultantEquityIncentivePlanMember" />

  <element name="AgreementTypeDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_AgreementTypeDomain" />

  <element name="NewConsultingAgreementsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_NewConsultingAgreementsMember" />

  <element name="OculusSideLetterAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_OculusSideLetterAgreementMember" />

  <element name="OculusInnovativeSciencesIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_OculusInnovativeSciencesIncMember" />

  <element name="RestrictedStockUnitsGrantsDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_RestrictedStockUnitsGrantsDescription" />

  <element name="PercentageOfGrossProceedsPayable" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_PercentageOfGrossProceedsPayable" />

  <element name="ConsiderationForSharesTransferByParent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="rtgn_ConsiderationForSharesTransferByParent" />

  <element name="FirstPhaseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_FirstPhaseMember" />

  <element name="SecondPhaseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_SecondPhaseMember" />

  <element name="ThirdPhaseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_ThirdPhaseMember" />

  <element name="FourthPhaseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_FourthPhaseMember" />

  <element name="RoyaltyGuaranteesCommitmentsPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_RoyaltyGuaranteesCommitmentsPercentage" />

  <element name="FundToPayCertainAccountPayablesOutstanding" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="rtgn_FundToPayCertainAccountPayablesOutstanding" />

  <element name="PercentageOfSharesTransferByFormerParent" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_PercentageOfSharesTransferByFormerParent" />

  <element name="MinimumDurationForSharesTransfer" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_MinimumDurationForSharesTransfer" />

  <element name="ProceedsFromTransferAtleastForNotConsummated" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="rtgn_ProceedsFromTransferAtleastForNotConsummated" />

  <element name="ShareTransferAgreementTerms" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_ShareTransferAgreementTerms" />

  <element name="PercentageOfOutstandingSharesForLapsOfTransfer" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_PercentageOfOutstandingSharesForLapsOfTransfer" />

  <element name="ReimbursementOfExpensesRelatedToTransfer" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="rtgn_ReimbursementOfExpensesRelatedToTransfer" />

  <element name="CashBonus" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="rtgn_CashBonus" />

  <element name="CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="rtgn_CommitmentsAndContingenciesLineItems" />
</schema>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>14
<FILENAME>rtgn-20150331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.8 on 09-Jun-2015 [02:22:47] {PM} EST - www.datatracks.com -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#PrepaidExpensesAndOtherCurrentAssets" roleURI="http://www.ruthigen.com/role/PrepaidExpensesAndOtherCurrentAssets" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#AccountsPayableAndAccruedExpenses" roleURI="http://www.ruthigen.com/role/AccountsPayableAndAccruedExpenses" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#StockholdersEquity" roleURI="http://www.ruthigen.com/role/StockholdersEquity" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#ConsolidatedBalanceSheets" roleURI="http://www.ruthigen.com/role/ConsolidatedBalanceSheets" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#PrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://www.ruthigen.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#AccountsPayableAndAccruedExpensesDetails" roleURI="http://www.ruthigen.com/role/AccountsPayableAndAccruedExpensesDetails" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#ConsolidatedStatementsOfOperations" roleURI="http://www.ruthigen.com/role/ConsolidatedStatementsOfOperations" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.ruthigen.com/role/ConsolidatedStatementsOfCashFlows" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#PropertyAndEquipment" roleURI="http://www.ruthigen.com/role/PropertyAndEquipment" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#PropertyAndEquipmentDetails" roleURI="http://www.ruthigen.com/role/PropertyAndEquipmentDetails" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#IncomeTaxes" roleURI="http://www.ruthigen.com/role/IncomeTaxes" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#IncomeTaxesDetails" roleURI="http://www.ruthigen.com/role/IncomeTaxesDetails" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#IncomeTaxesDetails1" roleURI="http://www.ruthigen.com/role/IncomeTaxesDetails1" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#IncomeTaxesDetails2" roleURI="http://www.ruthigen.com/role/IncomeTaxesDetails2" />

  <calculationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/ConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_Cash" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="20" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/ConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="40" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaap_PrepaidInsurance" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaap_PrepaidInsurance" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaap_OtherAssetsCurrent" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidRent" xlink:label="loc_us-gaap_PrepaidRent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaap_PrepaidRent" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_OtherPrepaidExpensesAndCurrentAssets" xlink:label="loc_rtgn_OtherPrepaidExpensesAndCurrentAssets" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_rtgn_OtherPrepaidExpensesAndCurrentAssets" use="optional" order="40" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/ConsolidatedStatementsOfOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" use="optional" order="10" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_Revenues" use="optional" order="10" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InvestmentIncomeNonoperating" use="optional" order="10" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/ConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashPeriodIncreaseDecrease" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_Depreciation" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" use="optional" order="40" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" order="50" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="10" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt" use="optional" order="20" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_InvestmentFromRelatedParty" xlink:label="loc_rtgn_InvestmentFromRelatedParty" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_rtgn_InvestmentFromRelatedParty" use="optional" order="40" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/PropertyAndEquipmentDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" use="optional" order="20" weight="-1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/AccountsPayableAndAccruedExpensesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_AccruedDirectorCompensation" xlink:label="loc_rtgn_AccruedDirectorCompensation" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_rtgn_AccruedDirectorCompensation" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_AccruedLegalFees" xlink:label="loc_rtgn_AccruedLegalFees" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_rtgn_AccruedLegalFees" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_AccruedResearchAndDevelopmentCurrent" xlink:label="loc_rtgn_AccruedResearchAndDevelopmentCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_rtgn_AccruedResearchAndDevelopmentCurrent" use="optional" order="50" weight="1" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_AccruedFranchisesTaxes" xlink:label="loc_rtgn_AccruedFranchisesTaxes" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_rtgn_AccruedFranchisesTaxes" use="optional" order="60" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" use="optional" order="70" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/IncomeTaxesDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxAssetsGross" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_OperatingLossCarryforwards" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance" use="optional" order="20" weight="-1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/IncomeTaxesDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensesPercent" xlink:label="loc_rtgn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensesPercent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_rtgn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensesPercent" use="optional" order="50" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" use="optional" order="60" weight="1" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ChangeInAvailableNolDueToDeconsolidation" xlink:label="loc_rtgn_ChangeInAvailableNolDueToDeconsolidation" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_rtgn_ChangeInAvailableNolDueToDeconsolidation" use="optional" order="70" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" use="optional" order="80" weight="1" />
  </calculationLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>15
<FILENAME>rtgn-20150331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.8 on 09-Jun-2015 [02:22:47] {PM} EST - www.datatracks.com -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#SummaryOfSignificantAccountingPoliciesDetails1" roleURI="http://www.ruthigen.com/role/SummaryOfSignificantAccountingPoliciesDetails1" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#ConsolidatedBalanceSheets" roleURI="http://www.ruthigen.com/role/ConsolidatedBalanceSheets" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#SummaryOfSignificantAccountingPoliciesDetailsTextual" roleURI="http://www.ruthigen.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#PrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://www.ruthigen.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#AccountsPayableAndAccruedExpensesDetails" roleURI="http://www.ruthigen.com/role/AccountsPayableAndAccruedExpensesDetails" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#CommitmentsAndContingenciesDetailsTextual" roleURI="http://www.ruthigen.com/role/CommitmentsAndContingenciesDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#StockholdersEquityDetails" roleURI="http://www.ruthigen.com/role/StockholdersEquityDetails" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#StockholdersEquityDetails1" roleURI="http://www.ruthigen.com/role/StockholdersEquityDetails1" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#StockholdersEquityDetails2" roleURI="http://www.ruthigen.com/role/StockholdersEquityDetails2" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#StockholdersEquityDetails3" roleURI="http://www.ruthigen.com/role/StockholdersEquityDetails3" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#StockholdersEquityDetails4" roleURI="http://www.ruthigen.com/role/StockholdersEquityDetails4" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#StockholdersEquityDetails5" roleURI="http://www.ruthigen.com/role/StockholdersEquityDetails5" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.ruthigen.com/role/ConsolidatedBalanceSheetsParenthetical" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#StockholdersEquityDetailsTextual" roleURI="http://www.ruthigen.com/role/StockholdersEquityDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#ConsolidatedStatementsOfOperations" roleURI="http://www.ruthigen.com/role/ConsolidatedStatementsOfOperations" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#ConsolidatedStatementsOfChangesInStockholdersEquity" roleURI="http://www.ruthigen.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.ruthigen.com/role/ConsolidatedStatementsOfCashFlows" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#ConsolidatedStatementsOfCashFlowsParenthetical" roleURI="http://www.ruthigen.com/role/ConsolidatedStatementsOfCashFlowsParenthetical" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#DocumentAndEntityInformation" roleURI="http://www.ruthigen.com/role/DocumentAndEntityInformation" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#OrganizationAndPlanOfMergerDetailsTextual" roleURI="http://www.ruthigen.com/role/OrganizationAndPlanOfMergerDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.ruthigen.com/role/SummaryOfSignificantAccountingPoliciesDetails" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#PropertyAndEquipmentDetails" roleURI="http://www.ruthigen.com/role/PropertyAndEquipmentDetails" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#PropertyAndEquipmentDetailsTextual" roleURI="http://www.ruthigen.com/role/PropertyAndEquipmentDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#SubsequentEventsDetailsTextual" roleURI="http://www.ruthigen.com/role/SubsequentEventsDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#RelatedPartyTransactionsDetailsTextual" roleURI="http://www.ruthigen.com/role/RelatedPartyTransactionsDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#IncomeTaxesDetails" roleURI="http://www.ruthigen.com/role/IncomeTaxesDetails" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#IncomeTaxesDetails1" roleURI="http://www.ruthigen.com/role/IncomeTaxesDetails1" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#IncomeTaxesDetails2" roleURI="http://www.ruthigen.com/role/IncomeTaxesDetails2" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#IncomeTaxesDetailsTextual" roleURI="http://www.ruthigen.com/role/IncomeTaxesDetailsTextual" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />

  <definitionLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/SummaryOfSignificantAccountingPoliciesDetails1">
    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_rtgn_SummaryOfSignificantAccountingPoliciesLineItems_67" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_rtgn_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_57" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_rtgn_SummaryOfSignificantAccountingPoliciesLineItems_67" xlink:to="loc_rtgn_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_57" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_58" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rtgn_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_57" xlink:to="loc_us-gaap_AwardTypeAxis_58" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_59" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_59" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_59_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_59_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_60" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_59" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_60" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_61" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rtgn_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_57" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_61" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_62" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_61" xlink:to="loc_us-gaap_EquityComponentDomain_62" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_62_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_61" xlink:to="loc_us-gaap_EquityComponentDomain_62_default" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_63" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_62" xlink:to="loc_us-gaap_WarrantMember_63" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_64" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rtgn_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_57" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_64" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_65" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_64" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_65" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_65_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_64" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_65_default" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_66" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_65" xlink:to="loc_us-gaap_EmployeeStockOptionMember_66" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_68" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_SummaryOfSignificantAccountingPoliciesLineItems_67" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_68" use="optional" order="14" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/ConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_74" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_71" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_74" xlink:to="loc_us-gaap_StatementTable_71" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_72" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_71" xlink:to="loc_us-gaap_StatementClassOfStockAxis_72" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_73" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_72" xlink:to="loc_us-gaap_ClassOfStockDomain_73" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_73_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_72" xlink:to="loc_us-gaap_ClassOfStockDomain_73_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_75" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_74" xlink:to="loc_us-gaap_AssetsAbstract_75" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_76" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_75" xlink:to="loc_us-gaap_AssetsCurrentAbstract_76" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_77" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_76" xlink:to="loc_us-gaap_Cash_77" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_78" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_76" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_78" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_79" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_76" xlink:to="loc_us-gaap_AssetsCurrent_79" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_80" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_76" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_80" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_81" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_76" xlink:to="loc_us-gaap_Assets_81" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_82" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_74" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_82" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_83" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_82" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_83" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_84" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_84" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_85" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_85" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_86" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83" xlink:to="loc_us-gaap_LiabilitiesCurrent_86" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_87" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83" xlink:to="loc_us-gaap_CommitmentsAndContingencies_87" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_88" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_82" xlink:to="loc_us-gaap_StockholdersEquityAbstract_88" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_89" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_88" xlink:to="loc_us-gaap_PreferredStockValue_89" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_90" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_88" xlink:to="loc_us-gaap_CommonStockValue_90" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_91" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_88" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_91" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_92" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_88" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_92" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_93" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_88" xlink:to="loc_us-gaap_StockholdersEquity_93" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_94" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_88" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_94" use="optional" order="24" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual">
    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_rtgn_SummaryOfSignificantAccountingPoliciesLineItems_100" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_rtgn_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_97" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_rtgn_SummaryOfSignificantAccountingPoliciesLineItems_100" xlink:to="loc_rtgn_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_97" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_98" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rtgn_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_97" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_98" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_99" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_98" xlink:to="loc_us-gaap_EquityComponentDomain_99" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_99_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_98" xlink:to="loc_us-gaap_EquityComponentDomain_99_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_101" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_SummaryOfSignificantAccountingPoliciesLineItems_100" xlink:to="loc_us-gaap_NetIncomeLoss_101" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_WorkingCapital" xlink:label="loc_rtgn_WorkingCapital_102" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_SummaryOfSignificantAccountingPoliciesLineItems_100" xlink:to="loc_rtgn_WorkingCapital_102" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_103" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_SummaryOfSignificantAccountingPoliciesLineItems_100" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_103" use="optional" order="7" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails">
    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_PrepaidExpensesAndOtherCurrentAssetsLineItems" xlink:label="loc_rtgn_PrepaidExpensesAndOtherCurrentAssetsLineItems_109" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTable" xlink:label="loc_rtgn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTable_106" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_rtgn_PrepaidExpensesAndOtherCurrentAssetsLineItems_109" xlink:to="loc_rtgn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTable_106" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_107" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rtgn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTable_106" xlink:to="loc_us-gaap_StatementClassOfStockAxis_107" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_108" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_107" xlink:to="loc_us-gaap_ClassOfStockDomain_108" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_108_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_107" xlink:to="loc_us-gaap_ClassOfStockDomain_108_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaap_PrepaidInsurance_110" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_PrepaidExpensesAndOtherCurrentAssetsLineItems_109" xlink:to="loc_us-gaap_PrepaidInsurance_110" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_111" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_PrepaidExpensesAndOtherCurrentAssetsLineItems_109" xlink:to="loc_us-gaap_OtherAssetsCurrent_111" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidRent" xlink:label="loc_us-gaap_PrepaidRent_112" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_PrepaidExpensesAndOtherCurrentAssetsLineItems_109" xlink:to="loc_us-gaap_PrepaidRent_112" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_OtherPrepaidExpensesAndCurrentAssets" xlink:label="loc_rtgn_OtherPrepaidExpensesAndCurrentAssets_113" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_PrepaidExpensesAndOtherCurrentAssetsLineItems_109" xlink:to="loc_rtgn_OtherPrepaidExpensesAndCurrentAssets_113" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_114" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_PrepaidExpensesAndOtherCurrentAssetsLineItems_109" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_114" use="optional" order="9" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/AccountsPayableAndAccruedExpensesDetails">
    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_AccountsPayableAndAccruedExpensesLineItems" xlink:label="loc_rtgn_AccountsPayableAndAccruedExpensesLineItems_120" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ScheduleOfAccountsPayableAndAccuredExpensesTable" xlink:label="loc_rtgn_ScheduleOfAccountsPayableAndAccuredExpensesTable_117" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_rtgn_AccountsPayableAndAccruedExpensesLineItems_120" xlink:to="loc_rtgn_ScheduleOfAccountsPayableAndAccuredExpensesTable_117" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_118" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rtgn_ScheduleOfAccountsPayableAndAccuredExpensesTable_117" xlink:to="loc_dei_LegalEntityAxis_118" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_119" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_118" xlink:to="loc_dei_EntityDomain_119" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_119_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_118" xlink:to="loc_dei_EntityDomain_119_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_121" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_AccountsPayableAndAccruedExpensesLineItems_120" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_121" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_AccruedDirectorCompensation" xlink:label="loc_rtgn_AccruedDirectorCompensation_122" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_AccountsPayableAndAccruedExpensesLineItems_120" xlink:to="loc_rtgn_AccruedDirectorCompensation_122" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_AccruedLegalFees" xlink:label="loc_rtgn_AccruedLegalFees_123" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_AccountsPayableAndAccruedExpensesLineItems_120" xlink:to="loc_rtgn_AccruedLegalFees_123" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_124" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_AccountsPayableAndAccruedExpensesLineItems_120" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_124" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_AccruedResearchAndDevelopmentCurrent" xlink:label="loc_rtgn_AccruedResearchAndDevelopmentCurrent_125" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_AccountsPayableAndAccruedExpensesLineItems_120" xlink:to="loc_rtgn_AccruedResearchAndDevelopmentCurrent_125" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_AccruedFranchisesTaxes" xlink:label="loc_rtgn_AccruedFranchisesTaxes_466" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_AccountsPayableAndAccruedExpensesLineItems_120" xlink:to="loc_rtgn_AccruedFranchisesTaxes_466" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_126" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_AccountsPayableAndAccruedExpensesLineItems_120" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_126" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_127" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_AccountsPayableAndAccruedExpensesLineItems_120" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_127" use="optional" order="12" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/CommitmentsAndContingenciesDetailsTextual">
    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_CommitmentsAndContingenciesLineItems" xlink:label="loc_rtgn_CommitmentsAndContingenciesLineItems_675" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ScheduleOfCommitmentsAndContingenciesTable" xlink:label="loc_rtgn_ScheduleOfCommitmentsAndContingenciesTable_130" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_rtgn_ScheduleOfCommitmentsAndContingenciesTable_130" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_LicenseAgreementAxis" xlink:label="loc_rtgn_LicenseAgreementAxis_131" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rtgn_ScheduleOfCommitmentsAndContingenciesTable_130" xlink:to="loc_rtgn_LicenseAgreementAxis_131" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_LicenseAgreementDomain" xlink:label="loc_rtgn_LicenseAgreementDomain_132" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_rtgn_LicenseAgreementAxis_131" xlink:to="loc_rtgn_LicenseAgreementDomain_132" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_LicenseAgreementDomain" xlink:label="loc_rtgn_LicenseAgreementDomain_132_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_rtgn_LicenseAgreementAxis_131" xlink:to="loc_rtgn_LicenseAgreementDomain_132_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_EmployeeAgreementMember" xlink:label="loc_rtgn_EmployeeAgreementMember_133" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_LicenseAgreementDomain_132" xlink:to="loc_rtgn_EmployeeAgreementMember_133" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_LicenseAndSupplyAgreementMember" xlink:label="loc_rtgn_LicenseAndSupplyAgreementMember_134" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_LicenseAgreementDomain_132" xlink:to="loc_rtgn_LicenseAndSupplyAgreementMember_134" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_135" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rtgn_ScheduleOfCommitmentsAndContingenciesTable_130" xlink:to="loc_us-gaap_TitleOfIndividualAxis_135" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_136" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_135" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_136" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_136_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_135" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_136_default" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_TwoExecutivesMember" xlink:label="loc_rtgn_TwoExecutivesMember_137" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_136" xlink:to="loc_rtgn_TwoExecutivesMember_137" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_EmployeeAndDirectorMember" xlink:label="loc_rtgn_EmployeeAndDirectorMember_636" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_136" xlink:to="loc_rtgn_EmployeeAndDirectorMember_636" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_138" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rtgn_ScheduleOfCommitmentsAndContingenciesTable_130" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_138" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_139" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_138" xlink:to="loc_us-gaap_RelatedPartyDomain_139" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_139_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_138" xlink:to="loc_us-gaap_RelatedPartyDomain_139_default" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_OculusMember" xlink:label="loc_rtgn_OculusMember_140" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_139" xlink:to="loc_rtgn_OculusMember_140" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaap_ChiefExecutiveOfficerMember_141" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_139" xlink:to="loc_us-gaap_ChiefExecutiveOfficerMember_141" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ChiefFinancialOfficerMember" xlink:label="loc_us-gaap_ChiefFinancialOfficerMember_142" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_139" xlink:to="loc_us-gaap_ChiefFinancialOfficerMember_142" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_OculusInnovativeSciencesIncMember" xlink:label="loc_rtgn_OculusInnovativeSciencesIncMember_647" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_139" xlink:to="loc_rtgn_OculusInnovativeSciencesIncMember_647" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_143" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rtgn_ScheduleOfCommitmentsAndContingenciesTable_130" xlink:to="loc_us-gaap_RangeAxis_143" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_144" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_143" xlink:to="loc_us-gaap_RangeMember_144" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_144_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_143" xlink:to="loc_us-gaap_RangeMember_144_default" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_145" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_144" xlink:to="loc_us-gaap_MinimumMember_145" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_146" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_144" xlink:to="loc_us-gaap_MaximumMember_146" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_147" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rtgn_ScheduleOfCommitmentsAndContingenciesTable_130" xlink:to="loc_dei_LegalEntityAxis_147" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_629" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_147" xlink:to="loc_dei_EntityDomain_629" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_629_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_147" xlink:to="loc_dei_EntityDomain_629_default" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_PulmatrixIncMember" xlink:label="loc_rtgn_PulmatrixIncMember_630" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_629" xlink:to="loc_rtgn_PulmatrixIncMember_630" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_DateOfMergerAxis" xlink:label="loc_rtgn_DateOfMergerAxis_628" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rtgn_ScheduleOfCommitmentsAndContingenciesTable_130" xlink:to="loc_rtgn_DateOfMergerAxis_628" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_DateOfMergerDomain" xlink:label="loc_rtgn_DateOfMergerDomain_633" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_rtgn_DateOfMergerAxis_628" xlink:to="loc_rtgn_DateOfMergerDomain_633" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_DateOfMergerDomain" xlink:label="loc_rtgn_DateOfMergerDomain_633_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_rtgn_DateOfMergerAxis_628" xlink:to="loc_rtgn_DateOfMergerDomain_633_default" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_MergerClosingDateIsNoLaterThanJuly312015Member" xlink:label="loc_rtgn_MergerClosingDateIsNoLaterThanJuly312015Member_634" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_DateOfMergerDomain_633" xlink:to="loc_rtgn_MergerClosingDateIsNoLaterThanJuly312015Member_634" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_MergerClosingDateIsAfterJuly312015ButNoLaterThanAugust132015Member" xlink:label="loc_rtgn_MergerClosingDateIsAfterJuly312015ButNoLaterThanAugust132015Member_635" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_DateOfMergerDomain_633" xlink:to="loc_rtgn_MergerClosingDateIsAfterJuly312015ButNoLaterThanAugust132015Member_635" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_632" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rtgn_ScheduleOfCommitmentsAndContingenciesTable_130" xlink:to="loc_us-gaap_PlanNameAxis_632" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_641" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_632" xlink:to="loc_us-gaap_PlanNameDomain_641" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_641_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_632" xlink:to="loc_us-gaap_PlanNameDomain_641_default" use="optional" order="35" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_EmployeeDirectorAndConsultantEquityIncentivePlanMember" xlink:label="loc_rtgn_EmployeeDirectorAndConsultantEquityIncentivePlanMember_642" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_641" xlink:to="loc_rtgn_EmployeeDirectorAndConsultantEquityIncentivePlanMember_642" use="optional" order="36" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_AgreementTypeAxis" xlink:label="loc_rtgn_AgreementTypeAxis_640" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rtgn_ScheduleOfCommitmentsAndContingenciesTable_130" xlink:to="loc_rtgn_AgreementTypeAxis_640" use="optional" order="37" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_AgreementTypeDomain" xlink:label="loc_rtgn_AgreementTypeDomain_644" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_rtgn_AgreementTypeAxis_640" xlink:to="loc_rtgn_AgreementTypeDomain_644" use="optional" order="38" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_AgreementTypeDomain" xlink:label="loc_rtgn_AgreementTypeDomain_644_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_rtgn_AgreementTypeAxis_640" xlink:to="loc_rtgn_AgreementTypeDomain_644_default" use="optional" order="39" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_NewConsultingAgreementsMember" xlink:label="loc_rtgn_NewConsultingAgreementsMember_645" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_AgreementTypeDomain_644" xlink:to="loc_rtgn_NewConsultingAgreementsMember_645" use="optional" order="40" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_OculusSideLetterAgreementMember" xlink:label="loc_rtgn_OculusSideLetterAgreementMember_646" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_AgreementTypeDomain_644" xlink:to="loc_rtgn_OculusSideLetterAgreementMember_646" use="optional" order="41" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_643" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rtgn_ScheduleOfCommitmentsAndContingenciesTable_130" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_643" use="optional" order="42" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_655" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_643" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_655" use="optional" order="43" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_655_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_643" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_655_default" use="optional" order="44" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_FirstPhaseMember" xlink:label="loc_rtgn_FirstPhaseMember_656" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_655" xlink:to="loc_rtgn_FirstPhaseMember_656" use="optional" order="45" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_SecondPhaseMember" xlink:label="loc_rtgn_SecondPhaseMember_657" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_655" xlink:to="loc_rtgn_SecondPhaseMember_657" use="optional" order="46" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ThirdPhaseMember" xlink:label="loc_rtgn_ThirdPhaseMember_658" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_655" xlink:to="loc_rtgn_ThirdPhaseMember_658" use="optional" order="47" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_FourthPhaseMember" xlink:label="loc_rtgn_FourthPhaseMember_659" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_655" xlink:to="loc_rtgn_FourthPhaseMember_659" use="optional" order="48" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_654" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rtgn_ScheduleOfCommitmentsAndContingenciesTable_130" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_654" use="optional" order="49" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_676" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_654" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_676" use="optional" order="50" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_676_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_654" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_676_default" use="optional" order="51" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_677" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_676" xlink:to="loc_us-gaap_SubsequentEventMember_677" use="optional" order="52" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_148" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_us-gaap_OfficersCompensation_148" use="optional" order="53" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_149" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_us-gaap_SeveranceCosts1_149" use="optional" order="54" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualDescription" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualDescription_150" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualDescription_150" use="optional" order="55" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:label="loc_us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted_151" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted_151" use="optional" order="56" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_DescriptionOfSeparationAgreement" xlink:label="loc_rtgn_DescriptionOfSeparationAgreement_478" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_rtgn_DescriptionOfSeparationAgreement_478" use="optional" order="57" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SignificantPurchaseCommitmentDescription" xlink:label="loc_us-gaap_SignificantPurchaseCommitmentDescription_479" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_us-gaap_SignificantPurchaseCommitmentDescription_479" use="optional" order="58" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_631" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_631" use="optional" order="59" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_637" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_us-gaap_Cash_637" use="optional" order="60" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_638" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_638" use="optional" order="61" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_OutstandingStockOptionsAndRestrictedStockUnitsTerminationDescription" xlink:label="loc_rtgn_OutstandingStockOptionsAndRestrictedStockUnitsTerminationDescription_639" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_rtgn_OutstandingStockOptionsAndRestrictedStockUnitsTerminationDescription_639" use="optional" order="62" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_RestrictedStockUnitsGrantsDescription" xlink:label="loc_rtgn_RestrictedStockUnitsGrantsDescription_648" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_rtgn_RestrictedStockUnitsGrantsDescription_648" use="optional" order="63" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_649" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_649" use="optional" order="64" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_PercentageOfGrossProceedsPayable" xlink:label="loc_rtgn_PercentageOfGrossProceedsPayable_650" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_rtgn_PercentageOfGrossProceedsPayable_650" use="optional" order="65" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaap_LiabilitiesAssumed1_651" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_us-gaap_LiabilitiesAssumed1_651" use="optional" order="66" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:label="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_652" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_652" use="optional" order="67" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ConsiderationForSharesTransferByParent" xlink:label="loc_rtgn_ConsiderationForSharesTransferByParent_653" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_rtgn_ConsiderationForSharesTransferByParent_653" use="optional" order="68" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_RoyaltyGuaranteesCommitmentsPercentage" xlink:label="loc_rtgn_RoyaltyGuaranteesCommitmentsPercentage_660" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_rtgn_RoyaltyGuaranteesCommitmentsPercentage_660" use="optional" order="69" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfServicesLicensesAndServices" xlink:label="loc_us-gaap_CostOfServicesLicensesAndServices_661" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_us-gaap_CostOfServicesLicensesAndServices_661" use="optional" order="70" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_FundToPayCertainAccountPayablesOutstanding" xlink:label="loc_rtgn_FundToPayCertainAccountPayablesOutstanding_662" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_rtgn_FundToPayCertainAccountPayablesOutstanding_662" use="optional" order="71" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_PercentageOfSharesTransferByFormerParent" xlink:label="loc_rtgn_PercentageOfSharesTransferByFormerParent_663" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_rtgn_PercentageOfSharesTransferByFormerParent_663" use="optional" order="72" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_MinimumDurationForSharesTransfer" xlink:label="loc_rtgn_MinimumDurationForSharesTransfer_664" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_rtgn_MinimumDurationForSharesTransfer_664" use="optional" order="73" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ProceedsFromTransferAtleastForNotConsummated" xlink:label="loc_rtgn_ProceedsFromTransferAtleastForNotConsummated_665" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_rtgn_ProceedsFromTransferAtleastForNotConsummated_665" use="optional" order="74" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareTransferAgreementTerms" xlink:label="loc_rtgn_ShareTransferAgreementTerms_666" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_rtgn_ShareTransferAgreementTerms_666" use="optional" order="75" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_PercentageOfOutstandingSharesForLapsOfTransfer" xlink:label="loc_rtgn_PercentageOfOutstandingSharesForLapsOfTransfer_667" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_rtgn_PercentageOfOutstandingSharesForLapsOfTransfer_667" use="optional" order="76" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ReimbursementOfExpensesRelatedToTransfer" xlink:label="loc_rtgn_ReimbursementOfExpensesRelatedToTransfer_668" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_rtgn_ReimbursementOfExpensesRelatedToTransfer_668" use="optional" order="77" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_CashBonus" xlink:label="loc_rtgn_CashBonus_669" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_rtgn_CashBonus_669" use="optional" order="78" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LandSubjectToGroundLeases" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_670" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_670" use="optional" order="79" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_671" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_us-gaap_LeaseAndRentalExpense_671" use="optional" order="80" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_672" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_672" use="optional" order="81" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/StockholdersEquityDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_158" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_154" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_158" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_154" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_155" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_154" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_155" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_156" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_155" xlink:to="loc_us-gaap_EquityComponentDomain_156" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_156_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_155" xlink:to="loc_us-gaap_EquityComponentDomain_156_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_157" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_156" xlink:to="loc_us-gaap_WarrantMember_157" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_159" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_158" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_159" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_160" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_158" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_160" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_161" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_158" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_161" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_162" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_158" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_162" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber_164" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_158" xlink:to="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber_164" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_165" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_158" xlink:to="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_165" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsGrantedWeightedAverageExercisePrice" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsGrantedWeightedAverageExercisePrice_166" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_158" xlink:to="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsGrantedWeightedAverageExercisePrice_166" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisedWeightedAverageExercisePrice" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisedWeightedAverageExercisePrice_167" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_158" xlink:to="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisedWeightedAverageExercisePrice_167" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice_168" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_158" xlink:to="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice_168" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_170" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_158" xlink:to="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_170" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_171" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_158" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_171" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_172" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_158" xlink:to="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_172" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_173" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_158" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_173" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable_174" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_158" xlink:to="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable_174" use="optional" order="19" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/StockholdersEquityDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_182" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_177" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_182" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_177" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_178" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_177" xlink:to="loc_us-gaap_RangeAxis_178" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_179" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_178" xlink:to="loc_us-gaap_RangeMember_179" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_179_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_178" xlink:to="loc_us-gaap_RangeMember_179_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ExercisePriceRangeOneMember" xlink:label="loc_rtgn_ExercisePriceRangeOneMember_180" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_179" xlink:to="loc_rtgn_ExercisePriceRangeOneMember_180" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ExercisePriceRangeTwoMember" xlink:label="loc_rtgn_ExercisePriceRangeTwoMember_181" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_179" xlink:to="loc_rtgn_ExercisePriceRangeTwoMember_181" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_183" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_182" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_183" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_184" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_182" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_184" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_185" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_182" xlink:to="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_185" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber_186" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_182" xlink:to="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber_186" use="optional" order="10" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/StockholdersEquityDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_192" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_189" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_192" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_189" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_190" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_189" xlink:to="loc_us-gaap_StatementClassOfStockAxis_190" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_191" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_190" xlink:to="loc_us-gaap_ClassOfStockDomain_191" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_191_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_190" xlink:to="loc_us-gaap_ClassOfStockDomain_191_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_193" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_192" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_193" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_194" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_192" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_194" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_195" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_192" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_195" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_196" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_192" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_196" use="optional" order="8" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/StockholdersEquityDetails3">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_202" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_199" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_202" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_199" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_200" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_199" xlink:to="loc_dei_LegalEntityAxis_200" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_201" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_200" xlink:to="loc_dei_EntityDomain_201" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_201_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_200" xlink:to="loc_dei_EntityDomain_201_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_203" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_202" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_203" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_204" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_202" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_204" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_205" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_202" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_205" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_206" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_202" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_206" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_208" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_202" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_208" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_209" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_202" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_209" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_210" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_202" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_210" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_211" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_202" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_211" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_212" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_202" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_212" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_214" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_202" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_214" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_215" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_202" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_215" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_216" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_202" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_216" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_217" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_202" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_217" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_218" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_202" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_218" use="optional" order="18" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/StockholdersEquityDetails4">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_225" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_221" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_225" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_221" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_222" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_221" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_222" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_223" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_222" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_223" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_223_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_222" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_223_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ExercisePriceMember" xlink:label="loc_rtgn_ExercisePriceMember_224" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_223" xlink:to="loc_rtgn_ExercisePriceMember_224" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_226" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_225" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_226" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_227" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_225" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_227" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_228" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_225" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_228" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_229" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_225" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_229" use="optional" order="9" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/StockholdersEquityDetails5">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_236" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_232" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_236" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_232" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_233" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_232" xlink:to="loc_us-gaap_AwardTypeAxis_233" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_234" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_233" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_234" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_234_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_233" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_234_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_235" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_234" xlink:to="loc_us-gaap_RestrictedStockMember_235" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_237" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_236" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_237" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_238" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_236" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_238" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_239" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_236" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_239" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_240" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_236" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_240" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_242" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_236" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_242" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_243" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_236" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_243" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_244" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_236" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_244" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_245" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_236" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_245" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedGrantDateFairValue" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedGrantDateFairValue_247" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_236" xlink:to="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedGrantDateFairValue_247" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_248" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_236" xlink:to="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_248" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodGrantDateFairValue" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodGrantDateFairValue_249" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_236" xlink:to="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodGrantDateFairValue_249" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodGrantDateFairValue" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodGrantDateFairValue_250" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_236" xlink:to="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodGrantDateFairValue_250" use="optional" order="17" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/ConsolidatedBalanceSheetsParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_257" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_254" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_257" xlink:to="loc_us-gaap_StatementTable_254" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_255" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_254" xlink:to="loc_us-gaap_StatementClassOfStockAxis_255" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_256" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_255" xlink:to="loc_us-gaap_ClassOfStockDomain_256" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_256_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_255" xlink:to="loc_us-gaap_ClassOfStockDomain_256_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_258" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_257" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_258" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_259" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_257" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_259" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_260" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_257" xlink:to="loc_us-gaap_PreferredStockSharesIssued_260" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_261" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_257" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_261" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_262" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_257" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_262" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_263" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_257" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_263" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_264" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_257" xlink:to="loc_us-gaap_CommonStockSharesIssued_264" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_265" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_257" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_265" use="optional" order="12" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/StockholdersEquityDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_268" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_268" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_269" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_268" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_269" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_270" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_269" xlink:to="loc_us-gaap_EquityComponentDomain_270" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_270_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_269" xlink:to="loc_us-gaap_EquityComponentDomain_270_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_271" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_270" xlink:to="loc_us-gaap_CommonStockMember_271" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_272" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_268" xlink:to="loc_us-gaap_AwardTypeAxis_272" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_273" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_272" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_273" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_273_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_272" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_273_default" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_274" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_273" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_274" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_TwoThousandThirteenPlanMember" xlink:label="loc_rtgn_TwoThousandThirteenPlanMember_275" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_273" xlink:to="loc_rtgn_TwoThousandThirteenPlanMember_275" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_UnderwritersMember" xlink:label="loc_rtgn_UnderwritersMember_612" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_273" xlink:to="loc_rtgn_UnderwritersMember_612" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_276" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_268" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_276" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_277" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_276" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_277" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_277_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_276" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_277_default" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_278" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_277" xlink:to="loc_us-gaap_IPOMember_278" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_622" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_277" xlink:to="loc_us-gaap_OverAllotmentOptionMember_622" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_279" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_268" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_279" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_280" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_279" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_280" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_280_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_279" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_280_default" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_281" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_280" xlink:to="loc_us-gaap_PerformanceSharesMember_281" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_282" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_268" xlink:to="loc_us-gaap_PlanNameAxis_282" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_599" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_282" xlink:to="loc_us-gaap_PlanNameDomain_599" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_599_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_282" xlink:to="loc_us-gaap_PlanNameDomain_599_default" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_NewTwoThousandThirteenPlanMember" xlink:label="loc_rtgn_NewTwoThousandThirteenPlanMember_600" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_599" xlink:to="loc_rtgn_NewTwoThousandThirteenPlanMember_600" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_598" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_268" xlink:to="loc_us-gaap_TitleOfIndividualAxis_598" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_624" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_598" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_624" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_624_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_598" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_624_default" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_RepresentativeOfUnderwritersMember" xlink:label="loc_rtgn_RepresentativeOfUnderwritersMember_625" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_624" xlink:to="loc_rtgn_RepresentativeOfUnderwritersMember_625" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_283" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_283" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_284" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_SharePrice_284" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_287" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_287" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_288" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_288" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_289" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_289" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_290" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_290" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_291" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_291" use="optional" order="35" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_292" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_292" use="optional" order="36" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_293" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_293" use="optional" order="37" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_294" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_294" use="optional" order="38" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_295" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_295" use="optional" order="39" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_WarrantsToPurchaseOfCommonStock" xlink:label="loc_rtgn_WarrantsToPurchaseOfCommonStock_296" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_rtgn_WarrantsToPurchaseOfCommonStock_296" use="optional" order="40" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_InitialPublicOfferingPricePerUnit" xlink:label="loc_rtgn_InitialPublicOfferingPricePerUnit_297" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_rtgn_InitialPublicOfferingPricePerUnit_297" use="optional" order="41" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_298" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_298" use="optional" order="42" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_InitialPublicOfferingUnits" xlink:label="loc_rtgn_InitialPublicOfferingUnits_299" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_rtgn_InitialPublicOfferingUnits_299" use="optional" order="43" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_590" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_590" use="optional" order="44" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_591" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_591" use="optional" order="45" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_592" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_592" use="optional" order="46" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_593" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_593" use="optional" order="47" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_594" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_594" use="optional" order="48" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_595" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_595" use="optional" order="49" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_596" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_596" use="optional" order="50" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_597" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_597" use="optional" order="51" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_601" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_601" use="optional" order="52" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_602" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_602" use="optional" order="53" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_603" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_603" use="optional" order="54" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_GrossProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="loc_rtgn_GrossProceedsFromIssuanceOfCommonStockAndWarrants_604" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_rtgn_GrossProceedsFromIssuanceOfCommonStockAndWarrants_604" use="optional" order="55" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_OfferingCost" xlink:label="loc_rtgn_OfferingCost_605" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_rtgn_OfferingCost_605" use="optional" order="56" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_606" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_CommonStockSharesIssued_606" use="optional" order="57" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber_607" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber_607" use="optional" order="58" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExercisePrice" xlink:label="loc_invest_InvestmentWarrantsExercisePrice_608" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_invest_InvestmentWarrantsExercisePrice_608" use="optional" order="59" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ClosingPriceOfCommonStockPercentage" xlink:label="loc_rtgn_ClosingPriceOfCommonStockPercentage_609" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_rtgn_ClosingPriceOfCommonStockPercentage_609" use="optional" order="60" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_610" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_610" use="optional" order="61" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_611" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_611" use="optional" order="62" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_613" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_613" use="optional" order="63" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ClassOfWarrantOrRightsExpiringDateWarrantsOrRightsExercisable" xlink:label="loc_rtgn_ClassOfWarrantOrRightsExpiringDateWarrantsOrRightsExercisable_614" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_rtgn_ClassOfWarrantOrRightsExpiringDateWarrantsOrRightsExercisable_614" use="optional" order="64" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_615" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_615" use="optional" order="65" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_616" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_616" use="optional" order="66" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_617" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_617" use="optional" order="67" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_TermOfWarrant" xlink:label="loc_rtgn_TermOfWarrant_618" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_rtgn_TermOfWarrant_618" use="optional" order="68" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_619" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_619" use="optional" order="69" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_620" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_620" use="optional" order="70" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ClassOfWarrantOrRightDurationFromWhichWarrantsOrRightsExercisable" xlink:label="loc_rtgn_ClassOfWarrantOrRightDurationFromWhichWarrantsOrRightsExercisable_621" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_rtgn_ClassOfWarrantOrRightDurationFromWhichWarrantsOrRightsExercisable_621" use="optional" order="71" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_InvestmentFromFormerParent" xlink:label="loc_rtgn_InvestmentFromFormerParent_626" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_rtgn_InvestmentFromFormerParent_626" use="optional" order="72" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_PercentageOfOptionsUnvested" xlink:label="loc_rtgn_PercentageOfOptionsUnvested_627" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_rtgn_PercentageOfOptionsUnvested_627" use="optional" order="73" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/ConsolidatedStatementsOfOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_305" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_302" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_305" xlink:to="loc_us-gaap_StatementTable_302" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_303" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_302" xlink:to="loc_dei_LegalEntityAxis_303" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_304" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_303" xlink:to="loc_dei_EntityDomain_304" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_304_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_303" xlink:to="loc_dei_EntityDomain_304_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_306" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_305" xlink:to="loc_us-gaap_Revenues_306" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_307" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_305" xlink:to="loc_us-gaap_OperatingExpensesAbstract_307" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_308" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_307" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_308" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_309" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_307" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_309" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_310" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_307" xlink:to="loc_us-gaap_OperatingExpenses_310" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_311" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_307" xlink:to="loc_us-gaap_OperatingIncomeLoss_311" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_312" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_305" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_312" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating_313" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_312" xlink:to="loc_us-gaap_InvestmentIncomeNonoperating_313" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_314" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_312" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_314" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_315" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_312" xlink:to="loc_us-gaap_NetIncomeLoss_315" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_316" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_305" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_316" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_317" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_316" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_317" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_318" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_305" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_318" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_319" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_318" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_319" use="optional" order="18" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_328" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_322" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_328" xlink:to="loc_us-gaap_StatementTable_322" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_323" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_322" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_323" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_324" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_323" xlink:to="loc_us-gaap_EquityComponentDomain_324" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_324_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_323" xlink:to="loc_us-gaap_EquityComponentDomain_324_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_325" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_324" xlink:to="loc_us-gaap_CommonStockMember_325" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_326" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_324" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_326" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_327" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_324" xlink:to="loc_us-gaap_RetainedEarningsMember_327" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_329" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_328" xlink:to="loc_us-gaap_StockholdersEquity_329" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_330" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_328" xlink:to="loc_us-gaap_SharesOutstanding_330" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_InvestmentFromFormerParent" xlink:label="loc_rtgn_InvestmentFromFormerParent_402" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_328" xlink:to="loc_rtgn_InvestmentFromFormerParent_402" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_InitialPublicOfferinfgValueOfUnits" xlink:label="loc_rtgn_InitialPublicOfferinfgValueOfUnits_673" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_328" xlink:to="loc_rtgn_InitialPublicOfferinfgValueOfUnits_673" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_InitialPublicOfferingUnits1" xlink:label="loc_rtgn_InitialPublicOfferingUnits1_674" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_328" xlink:to="loc_rtgn_InitialPublicOfferingUnits1_674" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForCash" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForCash_331" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_328" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForCash_331" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForCash" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForCash_332" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_328" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForCash_332" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_333" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_328" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_333" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_334" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_328" xlink:to="loc_us-gaap_NetIncomeLoss_334" use="optional" order="16" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/ConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_342" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_339" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_342" xlink:to="loc_us-gaap_StatementTable_339" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_340" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_339" xlink:to="loc_dei_LegalEntityAxis_340" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_341" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_340" xlink:to="loc_dei_EntityDomain_341" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_341_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_340" xlink:to="loc_dei_EntityDomain_341_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_343" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_342" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_343" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_344" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_343" xlink:to="loc_us-gaap_NetIncomeLoss_344" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_345" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_343" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_345" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_346" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_345" xlink:to="loc_us-gaap_Depreciation_346" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_347" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_345" xlink:to="loc_us-gaap_ShareBasedCompensation_347" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_348" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_345" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_348" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_349" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_348" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_349" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_350" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_348" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_350" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_351" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_343" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_351" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_352" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_342" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_352" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_353" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_352" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_353" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_354" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_352" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_354" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_355" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_342" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_355" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_356" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_355" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_356" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_357" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_355" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_357" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_359" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_355" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_359" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_InvestmentFromRelatedParty" xlink:label="loc_rtgn_InvestmentFromRelatedParty_360" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_355" xlink:to="loc_rtgn_InvestmentFromRelatedParty_360" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_361" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_355" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_361" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashPeriodIncreaseDecrease_362" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_342" xlink:to="loc_us-gaap_CashPeriodIncreaseDecrease_362" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_363" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_342" xlink:to="loc_us-gaap_Cash_363" use="optional" order="24" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/ConsolidatedStatementsOfCashFlowsParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_370" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_367" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_370" xlink:to="loc_us-gaap_StatementTable_367" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_368" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_367" xlink:to="loc_dei_LegalEntityAxis_368" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_369" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_368" xlink:to="loc_dei_EntityDomain_369" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_369_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_368" xlink:to="loc_dei_EntityDomain_369_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_GrossProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="loc_rtgn_GrossProceedsFromIssuanceOfCommonStockAndWarrants_371" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_370" xlink:to="loc_rtgn_GrossProceedsFromIssuanceOfCommonStockAndWarrants_371" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_OfferingCost" xlink:label="loc_rtgn_OfferingCost_372" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_370" xlink:to="loc_rtgn_OfferingCost_372" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_OfferingCostWithheldFromProceeds" xlink:label="loc_rtgn_OfferingCostWithheldFromProceeds_373" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_370" xlink:to="loc_rtgn_OfferingCostWithheldFromProceeds_373" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_374" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_370" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_374" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_AccruedOfferingCosts" xlink:label="loc_rtgn_AccruedOfferingCosts_403" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_370" xlink:to="loc_rtgn_AccruedOfferingCosts_403" use="optional" order="9" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_384" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_383" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_384" xlink:to="loc_dei_DocumentInformationTable_383" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_400" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_383" xlink:to="loc_us-gaap_StatementClassOfStockAxis_400" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_401" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_400" xlink:to="loc_us-gaap_ClassOfStockDomain_401" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_401_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_400" xlink:to="loc_us-gaap_ClassOfStockDomain_401_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_385" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_384" xlink:to="loc_dei_DocumentType_385" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_386" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_384" xlink:to="loc_dei_AmendmentFlag_386" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_387" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_384" xlink:to="loc_dei_DocumentPeriodEndDate_387" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_388" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_384" xlink:to="loc_dei_DocumentFiscalYearFocus_388" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_389" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_384" xlink:to="loc_dei_DocumentFiscalPeriodFocus_389" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_390" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_384" xlink:to="loc_dei_EntityRegistrantName_390" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_391" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_384" xlink:to="loc_dei_EntityCentralIndexKey_391" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_392" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_384" xlink:to="loc_dei_CurrentFiscalYearEndDate_392" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_393" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_384" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_393" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_394" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_384" xlink:to="loc_dei_EntityVoluntaryFilers_394" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_395" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_384" xlink:to="loc_dei_EntityCurrentReportingStatus_395" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_396" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_384" xlink:to="loc_dei_EntityFilerCategory_396" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_397" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_384" xlink:to="loc_dei_EntityPublicFloat_397" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_398" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_384" xlink:to="loc_dei_TradingSymbol_398" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_399" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_384" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_399" use="optional" order="19" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/OrganizationAndPlanOfMergerDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_412" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_406" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_412" xlink:to="loc_us-gaap_StatementTable_406" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_407" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_406" xlink:to="loc_us-gaap_StatementClassOfStockAxis_407" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_408" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_407" xlink:to="loc_us-gaap_ClassOfStockDomain_408" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_408_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_407" xlink:to="loc_us-gaap_ClassOfStockDomain_408_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_409" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_406" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_409" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_413" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_409" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_413" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_413_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_409" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_413_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_414" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_413" xlink:to="loc_us-gaap_IPOMember_414" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_InitialPublicOfferingUnits" xlink:label="loc_rtgn_InitialPublicOfferingUnits_410" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_412" xlink:to="loc_rtgn_InitialPublicOfferingUnits_410" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_InitialPublicOfferingPricePerUnit" xlink:label="loc_rtgn_InitialPublicOfferingPricePerUnit_411" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_412" xlink:to="loc_rtgn_InitialPublicOfferingPricePerUnit_411" use="optional" order="10" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/SummaryOfSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_431" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_425" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_431" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_425" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_426" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_425" xlink:to="loc_us-gaap_StatementClassOfStockAxis_426" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_427" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_426" xlink:to="loc_us-gaap_ClassOfStockDomain_427" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_427_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_426" xlink:to="loc_us-gaap_ClassOfStockDomain_427_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_428" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_425" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_428" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_432" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_428" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_432" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_432_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_428" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_432_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_434" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_432" xlink:to="loc_us-gaap_OfficeEquipmentMember_434" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ManufacturingFacilityMember" xlink:label="loc_us-gaap_ManufacturingFacilityMember_435" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_432" xlink:to="loc_us-gaap_ManufacturingFacilityMember_435" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_436" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_432" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_436" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_433" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_431" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_433" use="optional" order="11" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/PropertyAndEquipmentDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_454" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_445" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_454" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_445" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_446" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_445" xlink:to="loc_us-gaap_StatementClassOfStockAxis_446" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_447" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_446" xlink:to="loc_us-gaap_ClassOfStockDomain_447" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_447_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_446" xlink:to="loc_us-gaap_ClassOfStockDomain_447_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_448" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_445" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_448" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_455" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_448" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_455" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_455_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_448" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_455_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_457" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_455" xlink:to="loc_us-gaap_OfficeEquipmentMember_457" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_MedicalEquipmentMember" xlink:label="loc_rtgn_MedicalEquipmentMember_491" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_455" xlink:to="loc_rtgn_MedicalEquipmentMember_491" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_451" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_454" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_451" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_452" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_454" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_452" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_453" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_454" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_453" use="optional" order="12" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/PropertyAndEquipmentDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_463" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_460" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_463" xlink:to="loc_us-gaap_StatementTable_460" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_461" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_460" xlink:to="loc_us-gaap_StatementClassOfStockAxis_461" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_462" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_461" xlink:to="loc_us-gaap_ClassOfStockDomain_462" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_462_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_461" xlink:to="loc_us-gaap_ClassOfStockDomain_462_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_464" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_463" xlink:to="loc_us-gaap_Depreciation_464" use="optional" order="5" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/SubsequentEventsDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_475" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_472" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_475" xlink:to="loc_us-gaap_SubsequentEventTable_472" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_473" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_472" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_473" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_474" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_473" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_474" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_474_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_473" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_474_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_505" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_474" xlink:to="loc_us-gaap_SubsequentEventMember_505" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_503" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_475" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_503" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_504" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_475" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_504" use="optional" order="7" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/RelatedPartyTransactionsDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_498" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_483" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_498" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_483" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_484" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_483" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_484" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_485" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_484" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_485" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_485_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_484" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_485_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_486" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_483" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_486" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_489" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_486" xlink:to="loc_us-gaap_RelatedPartyDomain_489" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_489_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_486" xlink:to="loc_us-gaap_RelatedPartyDomain_489_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" xlink:label="loc_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_490" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_489" xlink:to="loc_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_490" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_OculusMember" xlink:label="loc_rtgn_OculusMember_494" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_489" xlink:to="loc_rtgn_OculusMember_494" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaap_RestructuringPlanAxis_488" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_483" xlink:to="loc_us-gaap_RestructuringPlanAxis_488" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_499" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_488" xlink:to="loc_us-gaap_RestructuringPlanDomain_499" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_499_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_488" xlink:to="loc_us-gaap_RestructuringPlanDomain_499_default" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_MergerMember" xlink:label="loc_rtgn_MergerMember_500" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_499" xlink:to="loc_rtgn_MergerMember_500" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaap_SalariesWagesAndOfficersCompensation_487" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_498" xlink:to="loc_us-gaap_SalariesWagesAndOfficersCompensation_487" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_492" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_498" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_492" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_495" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_498" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_495" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_496" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_498" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_496" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_497" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_498" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_497" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_SaleOfStockNumberOfSharesIssuedInTransactionOmneOrMoreInvestorsPriorToClosing" xlink:label="loc_rtgn_SaleOfStockNumberOfSharesIssuedInTransactionOmneOrMoreInvestorsPriorToClosing_501" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_498" xlink:to="loc_rtgn_SaleOfStockNumberOfSharesIssuedInTransactionOmneOrMoreInvestorsPriorToClosing_501" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaap_SaleOfStockDescriptionOfTransaction_502" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_498" xlink:to="loc_us-gaap_SaleOfStockDescriptionOfTransaction_502" use="optional" order="20" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ComponentsOfIncomeTaxExpenseBenefitLineItems" xlink:label="loc_rtgn_ComponentsOfIncomeTaxExpenseBenefitLineItems_523" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTable" xlink:label="loc_rtgn_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTable_520" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_rtgn_ComponentsOfIncomeTaxExpenseBenefitLineItems_523" xlink:to="loc_rtgn_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTable_520" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_521" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rtgn_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTable_520" xlink:to="loc_us-gaap_StatementClassOfStockAxis_521" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_522" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_521" xlink:to="loc_us-gaap_ClassOfStockDomain_522" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_522_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_521" xlink:to="loc_us-gaap_ClassOfStockDomain_522_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_530" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_ComponentsOfIncomeTaxExpenseBenefitLineItems_523" xlink:to="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_530" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_531" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_530" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_531" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_532" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_530" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_532" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_533" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_ComponentsOfIncomeTaxExpenseBenefitLineItems_523" xlink:to="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_533" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_534" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_533" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_534" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_535" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_533" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_535" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_573" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_ComponentsOfIncomeTaxExpenseBenefitLineItems_523" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_573" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_537" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_ComponentsOfIncomeTaxExpenseBenefitLineItems_523" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_537" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_538" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_ComponentsOfIncomeTaxExpenseBenefitLineItems_523" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_538" use="optional" order="13" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/IncomeTaxesDetails1">
    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateLineItems" xlink:label="loc_rtgn_ReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateLineItems_543" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateTable" xlink:label="loc_rtgn_ScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateTable_540" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_rtgn_ReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateLineItems_543" xlink:to="loc_rtgn_ScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateTable_540" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_541" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rtgn_ScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateTable_540" xlink:to="loc_us-gaap_StatementClassOfStockAxis_541" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_542" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_541" xlink:to="loc_us-gaap_ClassOfStockDomain_542" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_542_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_541" xlink:to="loc_us-gaap_ClassOfStockDomain_542_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_549" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_ReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateLineItems_543" xlink:to="loc_us-gaap_OperatingLossCarryforwards_549" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_550" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_ReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateLineItems_543" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_550" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_551" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_ReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateLineItems_543" xlink:to="loc_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_551" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_552" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_ReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateLineItems_543" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_552" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_553" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_ReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateLineItems_543" xlink:to="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_553" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_554" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_ReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateLineItems_543" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_554" use="optional" order="10" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/IncomeTaxesDetails2">
    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_rtgn_EffectiveIncomeTaxRateReconciliationLineItems_561" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ScheduleOfEffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_rtgn_ScheduleOfEffectiveIncomeTaxRateReconciliationTable_558" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_rtgn_EffectiveIncomeTaxRateReconciliationLineItems_561" xlink:to="loc_rtgn_ScheduleOfEffectiveIncomeTaxRateReconciliationTable_558" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_559" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rtgn_ScheduleOfEffectiveIncomeTaxRateReconciliationTable_558" xlink:to="loc_us-gaap_StatementClassOfStockAxis_559" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_560" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_559" xlink:to="loc_us-gaap_ClassOfStockDomain_560" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_560_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_559" xlink:to="loc_us-gaap_ClassOfStockDomain_560_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_565" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_EffectiveIncomeTaxRateReconciliationLineItems_561" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_565" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_566" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_EffectiveIncomeTaxRateReconciliationLineItems_561" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_566" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_567" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_EffectiveIncomeTaxRateReconciliationLineItems_561" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_567" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_569" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_EffectiveIncomeTaxRateReconciliationLineItems_561" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_569" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensesPercent" xlink:label="loc_rtgn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensesPercent_570" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_EffectiveIncomeTaxRateReconciliationLineItems_561" xlink:to="loc_rtgn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensesPercent_570" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_568" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_EffectiveIncomeTaxRateReconciliationLineItems_561" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_568" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ChangeInAvailableNolDueToDeconsolidation" xlink:label="loc_rtgn_ChangeInAvailableNolDueToDeconsolidation_678" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_EffectiveIncomeTaxRateReconciliationLineItems_561" xlink:to="loc_rtgn_ChangeInAvailableNolDueToDeconsolidation_678" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_571" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_EffectiveIncomeTaxRateReconciliationLineItems_561" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_571" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_572" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rtgn_EffectiveIncomeTaxRateReconciliationLineItems_561" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_572" use="optional" order="13" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/IncomeTaxesDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_587" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_575" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_587" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_575" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_576" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_575" xlink:to="loc_us-gaap_StatementClassOfStockAxis_576" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_577" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_576" xlink:to="loc_us-gaap_ClassOfStockDomain_577" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_577_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_576" xlink:to="loc_us-gaap_ClassOfStockDomain_577_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_578" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_575" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_578" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_585" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_578" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_585" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_585_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_578" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_585_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_586" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_585" xlink:to="loc_us-gaap_IPOMember_586" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_584" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_575" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_584" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_588" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_584" xlink:to="loc_us-gaap_RelatedPartyDomain_588" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_588_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_584" xlink:to="loc_us-gaap_RelatedPartyDomain_588_default" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_FormerParrentMember" xlink:label="loc_rtgn_FormerParrentMember_589" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_588" xlink:to="loc_rtgn_FormerParrentMember_589" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_581" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_587" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_581" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_OperatingLossCarryforwardsExpirationPeriod" xlink:label="loc_rtgn_OperatingLossCarryforwardsExpirationPeriod_582" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_587" xlink:to="loc_rtgn_OperatingLossCarryforwardsExpirationPeriod_582" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_583" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_587" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_583" use="optional" order="15" />
  </definitionLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>16
<FILENAME>rtgn-20150331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.8 on 09-Jun-2015 [02:22:47] {PM} EST - www.datatracks.com -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />

  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xml:lang="en-US">Prepaid Expense and Other Assets, Current [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="loc_rtgn_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsTextBlock" xml:lang="en-US">Disclosure Of Prepaid Expenses And Other Current Assets [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsTextBlock" xml:lang="en-US">Entire disclosure of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="lab_rtgn_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xml:lang="en-US">Payables and Accruals [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders&#39; Equity Note [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders&#39; Equity Note Disclosure [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiquidityDisclosureTextBlock" xlink:label="loc_us-gaap_LiquidityDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiquidityDisclosureTextBlock" xml:lang="en-US">Liquidity Disclosure [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiquidityDisclosureTextBlock" xlink:to="lab_us-gaap_LiquidityDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_PropertyPlanTandEquipmentUsefulLife1TableTextBlock" xlink:label="loc_rtgn_PropertyPlanTandEquipmentUsefulLife1TableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_PropertyPlanTandEquipmentUsefulLife1TableTextBlock" xml:lang="en-US">Property Plan tAnd Equipment Useful Life1 [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_rtgn_PropertyPlanTandEquipmentUsefulLife1TableTextBlock" xml:lang="en-US">Property Plant And Equipment Useful Life1 [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_PropertyPlanTandEquipmentUsefulLife1TableTextBlock" xml:lang="en-US">Tabular disclosure for property plant and equipment useful life.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_PropertyPlanTandEquipmentUsefulLife1TableTextBlock" xlink:to="lab_rtgn_PropertyPlanTandEquipmentUsefulLife1TableTextBlock" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:label="loc_rtgn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xml:lang="en-US">Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xml:lang="en-US">Tabular disclosure of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="lab_rtgn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ScheduleOfSharebasedCompensationWarrantActivityTableTextBlock" xlink:label="loc_rtgn_ScheduleOfSharebasedCompensationWarrantActivityTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_ScheduleOfSharebasedCompensationWarrantActivityTableTextBlock" xml:lang="en-US">Schedule Of Share-Based Compensation, Warrant, Activity [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_ScheduleOfSharebasedCompensationWarrantActivityTableTextBlock" xml:lang="en-US">Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share warrants that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share warrants that were granted, exercised or converted, forfeited, and expired during the year.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_ScheduleOfSharebasedCompensationWarrantActivityTableTextBlock" xlink:to="lab_rtgn_ScheduleOfSharebasedCompensationWarrantActivityTableTextBlock" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ScheduleOfShareBasedCompensationWarrantsByExercisePriceRangeTableTextBlock" xlink:label="loc_rtgn_ScheduleOfShareBasedCompensationWarrantsByExercisePriceRangeTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_ScheduleOfShareBasedCompensationWarrantsByExercisePriceRangeTableTextBlock" xml:lang="en-US">Schedule Of Share Based Compensation, Warrants, By Exercise Price Range [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_ScheduleOfShareBasedCompensationWarrantsByExercisePriceRangeTableTextBlock" xml:lang="en-US">Tabular disclosure of warrant exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under warrants, weighted average exercise price and remaining contractual warrant terms.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_ScheduleOfShareBasedCompensationWarrantsByExercisePriceRangeTableTextBlock" xlink:to="lab_rtgn_ScheduleOfShareBasedCompensationWarrantsByExercisePriceRangeTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xml:lang="en-US">Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_rtgn_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Schedule Of Summary Of Significant Accounting Policies [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_rtgn_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Equity Award [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WarrantMember" xml:lang="en-US">Warrants [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xml:lang="en-US">Option Indexed to Issuer&#39;s Equity [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xml:lang="en-US">Option Indexed to Issuer&#39;s Equity, Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee Stock Option [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_rtgn_SummaryOfSignificantAccountingPoliciesLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_SummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_rtgn_SummaryOfSignificantAccountingPoliciesLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current Assets:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash - Beginning</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash - Ending</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid expenses and other current assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Total</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total Current Assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total Assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Stockholders&#39; Equity</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current Liabilities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts payable and accrued expenses</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Total</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xml:lang="en-US">Due to Related Parties, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xml:lang="en-US">Payable to Former Parent</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total Current Liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders&#39; Equity Attributable to Parent [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders&#39; Equity:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock, $0.0001 par value; 500,000 shares authorized; no shares issued and outstanding at March 31, 2015 and 2014, respectively</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.0001 par value; 100,000,000 shares authorized; 4,804,290 and 4,650,000 shares issued and outstanding at March 31, 2015 and 2014, respectively</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional paid-in capital</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders&#39; Equity Attributable to Parent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total Stockholders&#39; Equity</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total Liabilities and Stockholders&#39; Equity</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Loss</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_WorkingCapital" xlink:label="loc_rtgn_WorkingCapital" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_WorkingCapital" xml:lang="en-US">Working Capital</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_WorkingCapital" xml:lang="en-US">Amount of working capital as of the balance sheet date.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_WorkingCapital" xlink:to="lab_rtgn_WorkingCapital" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTable" xlink:label="loc_rtgn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTable" xml:lang="en-US">Schedule Of Prepaid Expenses And Other Current Assets [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTable" xlink:to="lab_rtgn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTable" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_PrepaidExpensesAndOtherCurrentAssetsLineItems" xlink:label="loc_rtgn_PrepaidExpensesAndOtherCurrentAssetsLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_PrepaidExpensesAndOtherCurrentAssetsLineItems" xml:lang="en-US">Prepaid Expenses And Other Current Assets [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_PrepaidExpensesAndOtherCurrentAssetsLineItems" xlink:to="lab_rtgn_PrepaidExpensesAndOtherCurrentAssetsLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaap_PrepaidInsurance" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidInsurance" xml:lang="en-US">Prepaid Insurance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PrepaidInsurance" xml:lang="en-US">Prepaid insurance</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other Assets, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Clinical testing and other deposits</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidRent" xlink:label="loc_us-gaap_PrepaidRent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidRent" xml:lang="en-US">Prepaid Rent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PrepaidRent" xml:lang="en-US">Prepaid rent</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidRent" xlink:to="lab_us-gaap_PrepaidRent" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_OtherPrepaidExpensesAndCurrentAssets" xlink:label="loc_rtgn_OtherPrepaidExpensesAndCurrentAssets" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_OtherPrepaidExpensesAndCurrentAssets" xml:lang="en-US">Other Prepaid Expenses And Current Assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_rtgn_OtherPrepaidExpensesAndCurrentAssets" xml:lang="en-US">Other prepaid expenses and current assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_OtherPrepaidExpensesAndCurrentAssets" xml:lang="en-US">Amount of other prepaid expenses and current assets as of the balance sheet date.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_OtherPrepaidExpensesAndCurrentAssets" xlink:to="lab_rtgn_OtherPrepaidExpensesAndCurrentAssets" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ScheduleOfAccountsPayableAndAccuredExpensesTable" xlink:label="loc_rtgn_ScheduleOfAccountsPayableAndAccuredExpensesTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_ScheduleOfAccountsPayableAndAccuredExpensesTable" xml:lang="en-US">Schedule Of Accounts Payable And Accured Expenses [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_ScheduleOfAccountsPayableAndAccuredExpensesTable" xlink:to="lab_rtgn_ScheduleOfAccountsPayableAndAccuredExpensesTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_AccountsPayableAndAccruedExpensesLineItems" xlink:label="loc_rtgn_AccountsPayableAndAccruedExpensesLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_AccountsPayableAndAccruedExpensesLineItems" xml:lang="en-US">Accounts Payable And Accrued Expenses [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_AccountsPayableAndAccruedExpensesLineItems" xlink:to="lab_rtgn_AccountsPayableAndAccruedExpensesLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xml:lang="en-US">Accrued Employee Benefits, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xml:lang="en-US">Accrued employee compensation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_AccruedDirectorCompensation" xlink:label="loc_rtgn_AccruedDirectorCompensation" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_AccruedDirectorCompensation" xml:lang="en-US">Accrued Director Compensation</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_rtgn_AccruedDirectorCompensation" xml:lang="en-US">Accrued director compensation</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_AccruedDirectorCompensation" xml:lang="en-US">Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to directors pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_AccruedDirectorCompensation" xlink:to="lab_rtgn_AccruedDirectorCompensation" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_AccruedLegalFees" xlink:label="loc_rtgn_AccruedLegalFees" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_AccruedLegalFees" xml:lang="en-US">Accrued Legal Fees</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_rtgn_AccruedLegalFees" xml:lang="en-US">Accrued legal fees</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_AccruedLegalFees" xml:lang="en-US">Carrying value balance sheet date provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_AccruedLegalFees" xlink:to="lab_rtgn_AccruedLegalFees" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Accrued Professional Fees, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Accrued other professional fees</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_AccruedResearchAndDevelopmentCurrent" xlink:label="loc_rtgn_AccruedResearchAndDevelopmentCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_AccruedResearchAndDevelopmentCurrent" xml:lang="en-US">Accrued Research And Development, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_rtgn_AccruedResearchAndDevelopmentCurrent" xml:lang="en-US">Accrued research and development fees</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_AccruedResearchAndDevelopmentCurrent" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_AccruedResearchAndDevelopmentCurrent" xlink:to="lab_rtgn_AccruedResearchAndDevelopmentCurrent" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_AccruedFranchisesTaxes" xlink:label="loc_rtgn_AccruedFranchisesTaxes" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_AccruedFranchisesTaxes" xml:lang="en-US">Accrued Franchises Taxes</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_rtgn_AccruedFranchisesTaxes" xml:lang="en-US">Accrued franchise taxes</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_AccruedFranchisesTaxes" xml:lang="en-US">Its represents accrued franchise taxes.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_AccruedFranchisesTaxes" xlink:to="lab_rtgn_AccruedFranchisesTaxes" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other accrued expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ScheduleOfCommitmentsAndContingenciesTable" xlink:label="loc_rtgn_ScheduleOfCommitmentsAndContingenciesTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_ScheduleOfCommitmentsAndContingenciesTable" xml:lang="en-US">Schedule of Commitments And Contingencies [Table]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_ScheduleOfCommitmentsAndContingenciesTable" xml:lang="en-US">Disclosure of information commitments and contingencies.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_ScheduleOfCommitmentsAndContingenciesTable" xlink:to="lab_rtgn_ScheduleOfCommitmentsAndContingenciesTable" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_LicenseAgreementAxis" xlink:label="loc_rtgn_LicenseAgreementAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_LicenseAgreementAxis" xml:lang="en-US">License Agreement [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_LicenseAgreementAxis" xlink:to="lab_rtgn_LicenseAgreementAxis" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_LicenseAgreementDomain" xlink:label="loc_rtgn_LicenseAgreementDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_LicenseAgreementDomain" xml:lang="en-US">License Agreement [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_LicenseAgreementDomain" xlink:to="lab_rtgn_LicenseAgreementDomain" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_EmployeeAgreementMember" xlink:label="loc_rtgn_EmployeeAgreementMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_EmployeeAgreementMember" xml:lang="en-US">Employee Agreement [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_EmployeeAgreementMember" xlink:to="lab_rtgn_EmployeeAgreementMember" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_LicenseAndSupplyAgreementMember" xlink:label="loc_rtgn_LicenseAndSupplyAgreementMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_LicenseAndSupplyAgreementMember" xml:lang="en-US">License And Supply Agreement [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_LicenseAndSupplyAgreementMember" xlink:to="lab_rtgn_LicenseAndSupplyAgreementMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualAxis" xlink:to="lab_us-gaap_TitleOfIndividualAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Relationship to Entity [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_TwoExecutivesMember" xlink:label="loc_rtgn_TwoExecutivesMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_TwoExecutivesMember" xml:lang="en-US">Two Executives [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_TwoExecutivesMember" xlink:to="lab_rtgn_TwoExecutivesMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_OculusMember" xlink:label="loc_rtgn_OculusMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_OculusMember" xml:lang="en-US">Oculus [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_OculusMember" xlink:to="lab_rtgn_OculusMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaap_ChiefExecutiveOfficerMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ChiefExecutiveOfficerMember" xml:lang="en-US">Chief Executive Officer [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChiefExecutiveOfficerMember" xlink:to="lab_us-gaap_ChiefExecutiveOfficerMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ChiefFinancialOfficerMember" xlink:label="loc_us-gaap_ChiefFinancialOfficerMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ChiefFinancialOfficerMember" xml:lang="en-US">Chief Financial Officer [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChiefFinancialOfficerMember" xlink:to="lab_us-gaap_ChiefFinancialOfficerMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RangeAxis" xml:lang="en-US">Range [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis" xlink:to="lab_us-gaap_RangeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RangeMember" xml:lang="en-US">Range [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember" xlink:to="lab_us-gaap_RangeMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinimumMember" xml:lang="en-US">Minimum [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember" xlink:to="lab_us-gaap_MinimumMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MaximumMember" xml:lang="en-US">Maximum [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember" xlink:to="lab_us-gaap_MaximumMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OfficersCompensation" xml:lang="en-US">Officers&#39; Compensation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficersCompensation" xlink:to="lab_us-gaap_OfficersCompensation" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeveranceCosts1" xml:lang="en-US">Severance Costs</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualDescription" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualDescription" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualDescription" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Description</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualDescription" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualDescription" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:label="loc_us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xml:lang="en-US">Supply Commitment, Remaining Minimum Amount Committed</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:to="lab_us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xml:lang="en-US">Number of Warrants Outstanding, March 31, 2014</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xml:lang="en-US">Number of Warrants Outstanding, March 31, 2015</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xml:lang="en-US">Warrants Outstanding Number of Warrants</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xml:lang="en-US">Number of Warrants Granted</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/negativeLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xml:lang="en-US">Number of Warrants Exercised</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xml:lang="en-US">Number of Warrants Forfeited</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instrument Other Than Options Equity Instruments Exercisable Number</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber" xml:lang="en-US">Number of Warrants Exercisable, March 31, 2015</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber" xml:lang="en-US">Warrants Exercisable Number of Warrants</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber" xml:lang="en-US">Represented the value of Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber" xlink:to="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instrument Other Than Options Equity Instruments Outstanding Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price Outstanding, March 31, 2014</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price Outstanding, March 31, 2015</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price of other than options outstanding, including both vested and non-vested instruments.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsGrantedWeightedAverageExercisePrice" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsGrantedWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsGrantedWeightedAverageExercisePrice" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instrument Other Than Options Equity Instruments Granted Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsGrantedWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price Granted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsGrantedWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price of other than options granted, including both vested and non-vested instruments.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsGrantedWeightedAverageExercisePrice" xlink:to="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsGrantedWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisedWeightedAverageExercisePrice" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisedWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisedWeightedAverageExercisePrice" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instrument Other Than Options Equity Instruments Exercised Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisedWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Exercised</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisedWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price of other than options exercised, including both vested and non-vested instruments.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisedWeightedAverageExercisePrice" xlink:to="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisedWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instrument Other Than Options Equity Instruments Forfeited Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price Forfeited</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price of other than options forfeited, including both vested and non-vested instruments.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice" xlink:to="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instrument Other Than Options Equity Instruments Exercisable Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price Exercisable, March 31, 2015</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price of other than options exercisable, including both vested and non-vested instruments.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice" xlink:to="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xml:lang="en-US">Weighted Average Remaining Life Outstanding, March 31, 2015</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable Weighted Average Remaining Contractual Terms</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" xml:lang="en-US">Warrants Exercisable Weighted Average Remaining Life</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" xml:lang="en-US">Weighted average remaining contractual term of exercisable other than options, in &#39;PnYnMnDTnHnMnS&#39; format, for example, &#39;P1Y5M13D&#39; represents the reported fact of one year, five months, and thirteen days.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" xlink:to="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xml:lang="en-US">Intrinsic Value Outstanding, March 31, 2015</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable" xml:lang="en-US">Share based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Exercisable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable" xml:lang="en-US">Intrinsic Value Exercisable, March 31, 2015</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable" xml:lang="en-US">Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of other than options outstanding and currently exercisable.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable" xlink:to="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ExercisePriceRangeOneMember" xlink:label="loc_rtgn_ExercisePriceRangeOneMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_ExercisePriceRangeOneMember" xml:lang="en-US">Exercise Price Range One [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_ExercisePriceRangeOneMember" xlink:to="lab_rtgn_ExercisePriceRangeOneMember" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ExercisePriceRangeTwoMember" xlink:label="loc_rtgn_ExercisePriceRangeTwoMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_ExercisePriceRangeTwoMember" xml:lang="en-US">Exercise Price Range Two [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_ExercisePriceRangeTwoMember" xlink:to="lab_rtgn_ExercisePriceRangeTwoMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Warrants Outstanding Exercise Price</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk free interest rate</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected term (years)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected volatility</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividends</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of Options Outstanding, March 31, 2014</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of Options Outstanding, March 31, 2015</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Options Outstanding Number of Options</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Number of Options Granted</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Number of Options Exercised</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Number of Options Forfeited</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Number of Options Exercisable, March 31, 2015</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Options Exercisable Number of Options</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price Outstanding, March 31, 2015</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price Outstanding, March 31, 2015</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Options Outstanding Exercise Price</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price Granted</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price Exercised</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price Forfeited</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price Exercisable, March 31, 2015</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Weighted Average Remaining Life Outstanding, March 31, 2015</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Weighted Average Remaining Life Exercisable, March 31, 2015</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Options Exercisable Weighted Average Remaining Life</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Intrinsic Value Outstanding, March 31, 2015</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Intrinsic Value Exercisable, March 31, 2015</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xml:lang="en-US">Exercise Price Range [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ExercisePriceMember" xlink:label="loc_rtgn_ExercisePriceMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_ExercisePriceMember" xml:lang="en-US">Exercise Price [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_ExercisePriceMember" xlink:to="lab_rtgn_ExercisePriceMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Stock [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Number of Units Non-vested</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Number of Units Non-vested</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Number of Units Granted</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Number of Units Vested</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Number of Units Forfeited</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value Non-vested</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value Non-vested</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value Granted</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value Vested</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value Forfeited</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedGrantDateFairValue" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedGrantDateFairValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedGrantDateFairValue" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other than Options Nonvested Grant Date Fair Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedGrantDateFairValue" xml:lang="en-US">Total Grant Date Fair Value Non-vested</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedGrantDateFairValue" xml:lang="en-US">Total Grant Date Fair Value Non-vested</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedGrantDateFairValue" xml:lang="en-US">Value of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedGrantDateFairValue" xlink:to="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedGrantDateFairValue" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Grant Date Fair Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xml:lang="en-US">Total Grant Date Fair Value Granted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xml:lang="en-US">Value of grants made during the period on other than stock (or unit) option plans.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:to="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodGrantDateFairValue" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodGrantDateFairValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodGrantDateFairValue" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other than Options Vested In Period Grant Date Fair Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodGrantDateFairValue" xml:lang="en-US">Total Grant Date Fair Value Vested</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodGrantDateFairValue" xml:lang="en-US">Value of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodGrantDateFairValue" xlink:to="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodGrantDateFairValue" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodGrantDateFairValue" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodGrantDateFairValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodGrantDateFairValue" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other than Options Forfeited In Period Grant Date Fair Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodGrantDateFairValue" xml:lang="en-US">Total Grant Date Fair Value Forfeited</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodGrantDateFairValue" xml:lang="en-US">Value of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodGrantDateFairValue" xlink:to="lab_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodGrantDateFairValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value (in dollars per share)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value (in dollars per share)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_TwoThousandThirteenPlanMember" xlink:label="loc_rtgn_TwoThousandThirteenPlanMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_TwoThousandThirteenPlanMember" xml:lang="en-US">Two Thousand Thirteen Plan [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_rtgn_TwoThousandThirteenPlanMember" xml:lang="en-US">2013 Plan [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_TwoThousandThirteenPlanMember" xlink:to="lab_rtgn_TwoThousandThirteenPlanMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IPOMember" xml:lang="en-US">IPO [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PerformanceSharesMember" xml:lang="en-US">Performance Shares [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Share Price</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Allocated Share-based Compensation Expense</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_WarrantsToPurchaseOfCommonStock" xlink:label="loc_rtgn_WarrantsToPurchaseOfCommonStock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_WarrantsToPurchaseOfCommonStock" xml:lang="en-US">Warrants to Purchase of Common Stock</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_WarrantsToPurchaseOfCommonStock" xml:lang="en-US">This element represent warrants to purchase of common stock.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_WarrantsToPurchaseOfCommonStock" xlink:to="lab_rtgn_WarrantsToPurchaseOfCommonStock" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_InitialPublicOfferingPricePerUnit" xlink:label="loc_rtgn_InitialPublicOfferingPricePerUnit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_InitialPublicOfferingPricePerUnit" xml:lang="en-US">Initial Public Offering Price Per Unit</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_InitialPublicOfferingPricePerUnit" xml:lang="en-US">Exercise price per share or per unit of public offering outstanding.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_InitialPublicOfferingPricePerUnit" xlink:to="lab_rtgn_InitialPublicOfferingPricePerUnit" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_InitialPublicOfferingUnits" xlink:label="loc_rtgn_InitialPublicOfferingUnits" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_InitialPublicOfferingUnits" xml:lang="en-US">Initial Public Offering Units</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_InitialPublicOfferingUnits" xml:lang="en-US">This element represent initial public offering units</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_InitialPublicOfferingUnits" xlink:to="lab_rtgn_InitialPublicOfferingUnits" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Revenues</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Revenues</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xml:lang="en-US">Selling, General and Administrative Expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xml:lang="en-US">Selling, general and administrative</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total Operating Expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss From Operations</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other Income</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeNonoperating" xml:lang="en-US">Investment Income, Nonoperating</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InvestmentIncomeNonoperating" xml:lang="en-US">Interest income</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNonoperating" xlink:to="lab_us-gaap_InvestmentIncomeNonoperating" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total Other Income</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xml:lang="en-US">Net Loss Per Share</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Basic and Diluted (in dollars per share)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US">Weighted Average Number of Common Shares Outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Basic and Diluted (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders&#39; Equity [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated Deficit [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in shares)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_InvestmentFromFormerParent" xlink:label="loc_rtgn_InvestmentFromFormerParent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_InvestmentFromFormerParent" xml:lang="en-US">Investment From Former Parent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_rtgn_InvestmentFromFormerParent" xml:lang="en-US">Investment From Former Parent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_InvestmentFromFormerParent" xml:lang="en-US">Equity impact of the value due to investment from the former parent during the period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_InvestmentFromFormerParent" xlink:to="lab_rtgn_InvestmentFromFormerParent" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_InitialPublicOfferinfgValueOfUnits" xlink:label="loc_rtgn_InitialPublicOfferinfgValueOfUnits" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_InitialPublicOfferinfgValueOfUnits" xml:lang="en-US">Initial Public Offerinfg Value Of Units</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_rtgn_InitialPublicOfferinfgValueOfUnits" xml:lang="en-US">Shares and warrants issued for cash in connection with initial public offering</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_InitialPublicOfferinfgValueOfUnits" xml:lang="en-US">Represents the total value of Initial public offering units during the period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_InitialPublicOfferinfgValueOfUnits" xlink:to="lab_rtgn_InitialPublicOfferinfgValueOfUnits" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_InitialPublicOfferingUnits1" xlink:label="loc_rtgn_InitialPublicOfferingUnits1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_InitialPublicOfferingUnits1" xml:lang="en-US">Initial Public Offering Units1</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_rtgn_InitialPublicOfferingUnits1" xml:lang="en-US">Shares and warrants issued for cash in connection with initial public offering (in shares)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_InitialPublicOfferingUnits1" xml:lang="en-US">This element represent initial public offering units</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_InitialPublicOfferingUnits1" xlink:to="lab_rtgn_InitialPublicOfferingUnits1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForCash" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForCash" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForCash" xml:lang="en-US">Development Stage Entities, Stock Issued, Value, Issued for Cash</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForCash" xml:lang="en-US">Shares issued for cash in connection with underwriter&#39;s exercise of overallotment, net</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForCash" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForCash" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForCash" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForCash" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForCash" xml:lang="en-US">Development Stage Entities, Stock Issued, Shares, Issued for Cash</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForCash" xml:lang="en-US">Shares issued for cash in connection with underwriter&#39;s exercise of overallotment, net (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForCash" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForCash" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Stock-based compensation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Cash Flows From Operating Activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">Prepaid expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Accounts payable and accrued expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Used in Operating Activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Cash Flows From Investing Activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchases of property and equipment</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Used in Investing Activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Cash Flows From Financing Activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt" xml:lang="en-US">Proceeds from Related Party Debt</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt" xml:lang="en-US">Advances from Former Parent</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="lab_us-gaap_ProceedsFromRelatedPartyDebt" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfRelatedPartyDebt" xml:lang="en-US">Repayments of Related Party Debt</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfRelatedPartyDebt" xml:lang="en-US">Repayment of Former Parent advances</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="lab_us-gaap_RepaymentsOfRelatedPartyDebt" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xml:lang="en-US">Proceeds from issuance of common stock and warrants less issuance costs</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_InvestmentFromRelatedParty" xlink:label="loc_rtgn_InvestmentFromRelatedParty" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_InvestmentFromRelatedParty" xml:lang="en-US">Investment From Related Party</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_rtgn_InvestmentFromRelatedParty" xml:lang="en-US">Investment from Former Parent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_InvestmentFromRelatedParty" xml:lang="en-US">The value represents the investments from related parties (Former Parent).</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_InvestmentFromRelatedParty" xlink:to="lab_rtgn_InvestmentFromRelatedParty" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by Financing Activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashPeriodIncreaseDecrease" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashPeriodIncreaseDecrease" xml:lang="en-US">Cash, Period Increase (Decrease)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashPeriodIncreaseDecrease" xml:lang="en-US">Net (Decrease) Increase In Cash</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashPeriodIncreaseDecrease" xlink:to="lab_us-gaap_CashPeriodIncreaseDecrease" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_GrossProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="loc_rtgn_GrossProceedsFromIssuanceOfCommonStockAndWarrants" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_GrossProceedsFromIssuanceOfCommonStockAndWarrants" xml:lang="en-US">Gross Proceeds From Issuance Of Common Stock And Warrants</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_GrossProceedsFromIssuanceOfCommonStockAndWarrants" xml:lang="en-US">Gross proceeds from the issuance of common stock and warrants.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_GrossProceedsFromIssuanceOfCommonStockAndWarrants" xlink:to="lab_rtgn_GrossProceedsFromIssuanceOfCommonStockAndWarrants" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_OfferingCost" xlink:label="loc_rtgn_OfferingCost" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_OfferingCost" xml:lang="en-US">Offering Cost</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_OfferingCost" xml:lang="en-US">Total Offering cost for issuance of common stock and warrants.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_OfferingCost" xlink:to="lab_rtgn_OfferingCost" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_OfferingCostWithheldFromProceeds" xlink:label="loc_rtgn_OfferingCostWithheldFromProceeds" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_OfferingCostWithheldFromProceeds" xml:lang="en-US">Offering Cost Withheld From The Proceeds</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_OfferingCostWithheldFromProceeds" xml:lang="en-US">Value of offering cost withheld from the proceeds.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_OfferingCostWithheldFromProceeds" xlink:to="lab_rtgn_OfferingCostWithheldFromProceeds" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments of Stock Issuance Costs</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_DocumentAndEntityInformationAbstract" xlink:label="loc_rtgn_DocumentAndEntityInformationAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document And Entity Information [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_DocumentAndEntityInformationAbstract" xlink:to="lab_rtgn_DocumentAndEntityInformationAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationTable" xml:lang="en-US">Document Information [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityVoluntaryFilers" xml:lang="en-US">Entity Voluntary Filers</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityPublicFloat" xml:lang="en-US">Entity Public Float</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationLineItems" xml:lang="en-US">Document Information [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_AccruedOfferingCosts" xlink:label="loc_rtgn_AccruedOfferingCosts" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_AccruedOfferingCosts" xml:lang="en-US">Accrued Offering Costs</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_AccruedOfferingCosts" xml:lang="en-US">The amount of accrued offering costs during the period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_AccruedOfferingCosts" xlink:to="lab_rtgn_AccruedOfferingCosts" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xml:lang="en-US">Subsequent Events, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OfficeEquipmentMember" xml:lang="en-US">Office Equipment [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OfficeEquipmentMember" xml:lang="en-US">Office equipment [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ManufacturingFacilityMember" xlink:label="loc_us-gaap_ManufacturingFacilityMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ManufacturingFacilityMember" xml:lang="en-US">Manufacturing Facility [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ManufacturingFacilityMember" xml:lang="en-US">Medical equipment [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ManufacturingFacilityMember" xlink:to="lab_us-gaap_ManufacturingFacilityMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and Fixtures [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and fixtures [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property Plant And Equipment Gross</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Less: accumulated depreciation and amortization</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_DescriptionOfSeparationAgreement" xlink:label="loc_rtgn_DescriptionOfSeparationAgreement" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_DescriptionOfSeparationAgreement" xml:lang="en-US">Description Of Separation Agreement</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_DescriptionOfSeparationAgreement" xml:lang="en-US">This description about separation agreement</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_DescriptionOfSeparationAgreement" xlink:to="lab_rtgn_DescriptionOfSeparationAgreement" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SignificantPurchaseCommitmentDescription" xlink:label="loc_us-gaap_SignificantPurchaseCommitmentDescription" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantPurchaseCommitmentDescription" xml:lang="en-US">Purchase Commitment, Description</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantPurchaseCommitmentDescription" xlink:to="lab_us-gaap_SignificantPurchaseCommitmentDescription" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xml:lang="en-US">Related Party Transaction [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xml:lang="en-US">Related Party Transaction [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaap_SalariesWagesAndOfficersCompensation" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SalariesWagesAndOfficersCompensation" xml:lang="en-US">Salaries, Wages and Officers&#39; Compensation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalariesWagesAndOfficersCompensation" xlink:to="lab_us-gaap_SalariesWagesAndOfficersCompensation" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaap_RestructuringPlanAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringPlanAxis" xml:lang="en-US">Restructuring Plan [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" xlink:label="loc_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" xml:lang="en-US">Immediate Family Member of Management or Principal Owner [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" xlink:to="lab_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_MedicalEquipmentMember" xlink:label="loc_rtgn_MedicalEquipmentMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_MedicalEquipmentMember" xml:lang="en-US">Medical Equipment [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_MedicalEquipmentMember" xlink:to="lab_rtgn_MedicalEquipmentMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of Stock, Price Per Share</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringPlanDomain" xml:lang="en-US">Restructuring Plan [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_MergerMember" xlink:label="loc_rtgn_MergerMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_MergerMember" xml:lang="en-US">Merger [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_MergerMember" xlink:to="lab_rtgn_MergerMember" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_SaleOfStockNumberOfSharesIssuedInTransactionOmneOrMoreInvestorsPriorToClosing" xlink:label="loc_rtgn_SaleOfStockNumberOfSharesIssuedInTransactionOmneOrMoreInvestorsPriorToClosing" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_SaleOfStockNumberOfSharesIssuedInTransactionOmneOrMoreInvestorsPriorToClosing" xml:lang="en-US">Sale Of Stock Number Of Shares Issued In Transaction Omne Or More Investors Prior To Closing</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_rtgn_SaleOfStockNumberOfSharesIssuedInTransactionOmneOrMoreInvestorsPriorToClosing" xml:lang="en-US">Sale Of Stock Number Of Shares Issued In Transaction One Or More Investors Prior To Closing</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_SaleOfStockNumberOfSharesIssuedInTransactionOmneOrMoreInvestorsPriorToClosing" xml:lang="en-US">Its represents the number of shares sold to one or more investors prior to closing.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_SaleOfStockNumberOfSharesIssuedInTransactionOmneOrMoreInvestorsPriorToClosing" xlink:to="lab_rtgn_SaleOfStockNumberOfSharesIssuedInTransactionOmneOrMoreInvestorsPriorToClosing" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaap_SaleOfStockDescriptionOfTransaction" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockDescriptionOfTransaction" xml:lang="en-US">Sale of Stock, Description of Transaction</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockDescriptionOfTransaction" xlink:to="lab_us-gaap_SaleOfStockDescriptionOfTransaction" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateTableTextBlock" xlink:label="loc_rtgn_ScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_ScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateTableTextBlock" xml:lang="en-US">Schedule Of Reconciliation Of The Statutory Federal Income Tax Rate To The Company&#8217;s effective Tax Rate [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_ScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateTableTextBlock" xml:lang="en-US">Tabular Disclosure of Of Reconciliation Of The Statutory Federal Income Tax Rate To The Company&#8217;s effective Tax Rate.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_ScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateTableTextBlock" xlink:to="lab_rtgn_ScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTable" xlink:label="loc_rtgn_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTable" xml:lang="en-US">Schedule Of Components Of Income Tax Expense Benefit [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTable" xlink:to="lab_rtgn_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTable" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ComponentsOfIncomeTaxExpenseBenefitLineItems" xlink:label="loc_rtgn_ComponentsOfIncomeTaxExpenseBenefitLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_ComponentsOfIncomeTaxExpenseBenefitLineItems" xml:lang="en-US">Components Of Income Tax Expense Benefit [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_ComponentsOfIncomeTaxExpenseBenefitLineItems" xlink:to="lab_rtgn_ComponentsOfIncomeTaxExpenseBenefitLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Federal Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xml:lang="en-US">Current Federal Tax Expense (Benefit)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xml:lang="en-US">Current</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">State and Local Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xml:lang="en-US">Current</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xml:lang="en-US">Current Income Tax Expense (Benefit)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xml:lang="en-US">Current Income Tax Expense (Benefit)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US">Change in valuation allowance</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateTable" xlink:label="loc_rtgn_ScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_ScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateTable" xml:lang="en-US">Schedule Of Reconciliation Of The Statutory Federal Income Tax Rate To The Company&#8217;s effective Tax Rate [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_ScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateTable" xlink:to="lab_rtgn_ScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateTable" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateLineItems" xlink:label="loc_rtgn_ReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_ReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateLineItems" xml:lang="en-US">Reconciliation Of The Statutory Federal Income Tax Rate To The Company&#8217;s effective Tax Rate [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_ReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateLineItems" xlink:to="lab_rtgn_ReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating Loss Carryforwards</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Net operating loss carryforwards</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xml:lang="en-US">Stock-based compensation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xml:lang="en-US">Deferred Tax Assets, Charitable Contribution Carryforwards</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xml:lang="en-US">Charitable donation carryforwards</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Deferred Tax Assets, Gross</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Gross deferred tax assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance" xml:lang="en-US">Operating Loss Carryforwards, Valuation Allowance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance" xml:lang="en-US">Valuation allowance</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:to="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Deferred Tax Assets, Net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Net deferred tax assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ScheduleOfEffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_rtgn_ScheduleOfEffectiveIncomeTaxRateReconciliationTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_ScheduleOfEffectiveIncomeTaxRateReconciliationTable" xml:lang="en-US">Schedule Of Effective Income Tax Rate Reconciliation [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_ScheduleOfEffectiveIncomeTaxRateReconciliationTable" xlink:to="lab_rtgn_ScheduleOfEffectiveIncomeTaxRateReconciliationTable" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_rtgn_EffectiveIncomeTaxRateReconciliationLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_EffectiveIncomeTaxRateReconciliationLineItems" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="lab_rtgn_EffectiveIncomeTaxRateReconciliationLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Expected federal statutory rate</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">State tax rate, net of federal benefit</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Change in effective state tax rate</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Percent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xml:lang="en-US">Permanent items - stock-based compensation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensesPercent" xlink:label="loc_rtgn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensesPercent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensesPercent" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Merger Expenses, Percent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_rtgn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensesPercent" xml:lang="en-US">Permanent items - non-deductible merger expenses</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensesPercent" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to merger expenses.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensesPercent" xlink:to="lab_rtgn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensesPercent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xml:lang="en-US">Permanent items - other</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ChangeInAvailableNolDueToDeconsolidation" xlink:label="loc_rtgn_ChangeInAvailableNolDueToDeconsolidation" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_ChangeInAvailableNolDueToDeconsolidation" xml:lang="en-US">Change In Available NOL Due To Deconsolidation</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_rtgn_ChangeInAvailableNolDueToDeconsolidation" xml:lang="en-US">Adjustment of NOL due to deconsolidation</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_ChangeInAvailableNolDueToDeconsolidation" xml:lang="en-US">It represents percentage of change in available NOL due to deconsolidation during the period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_ChangeInAvailableNolDueToDeconsolidation" xlink:to="lab_rtgn_ChangeInAvailableNolDueToDeconsolidation" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Change in valuation allowance</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax provision (benefit)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xml:lang="en-US">Operating Loss Carryforwards [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_OperatingLossCarryforwardsExpirationPeriod" xlink:label="loc_rtgn_OperatingLossCarryforwardsExpirationPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_OperatingLossCarryforwardsExpirationPeriod" xml:lang="en-US">Operating Loss Carryforwards, Expiration Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_OperatingLossCarryforwardsExpirationPeriod" xml:lang="en-US">Expiration period of each operating loss carryforward included in operating loss carryforward.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_OperatingLossCarryforwardsExpirationPeriod" xlink:to="lab_rtgn_OperatingLossCarryforwardsExpirationPeriod" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_FormerParrentMember" xlink:label="loc_rtgn_FormerParrentMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_FormerParrentMember" xml:lang="en-US">Former Parrent [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_FormerParrentMember" xlink:to="lab_rtgn_FormerParrentMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityReverseStockSplit" xml:lang="en-US">Stockholders&#39; Equity, Reverse Stock Split</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityReverseStockSplit" xlink:to="lab_us-gaap_StockholdersEquityReverseStockSplit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Stock Splits</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Description</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_NewTwoThousandThirteenPlanMember" xlink:label="loc_rtgn_NewTwoThousandThirteenPlanMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_NewTwoThousandThirteenPlanMember" xml:lang="en-US">New Two Thousand Thirteen Plan [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_rtgn_NewTwoThousandThirteenPlanMember" xml:lang="en-US">New 2013 Plan [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_NewTwoThousandThirteenPlanMember" xlink:to="lab_rtgn_NewTwoThousandThirteenPlanMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xml:lang="en-US">Stock Issued During Period, Shares, Period Increase (Decrease)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExercisePrice" xlink:label="loc_invest_InvestmentWarrantsExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_invest_InvestmentWarrantsExercisePrice" xml:lang="en-US">Investment Warrants, Exercise Price</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_invest_InvestmentWarrantsExercisePrice" xlink:to="lab_invest_InvestmentWarrantsExercisePrice" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ClosingPriceOfCommonStockPercentage" xlink:label="loc_rtgn_ClosingPriceOfCommonStockPercentage" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_ClosingPriceOfCommonStockPercentage" xml:lang="en-US">Closing Price Of Common Stock Percentage</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_ClosingPriceOfCommonStockPercentage" xml:lang="en-US">Represents the percentage of Closing Price of common stock.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_ClosingPriceOfCommonStockPercentage" xlink:to="lab_rtgn_ClosingPriceOfCommonStockPercentage" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_UnderwritersMember" xlink:label="loc_rtgn_UnderwritersMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_UnderwritersMember" xml:lang="en-US">Underwriters [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_UnderwritersMember" xlink:to="lab_rtgn_UnderwritersMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xml:lang="en-US">Class of Warrant or Right, Date from which Warrants or Rights Exercisable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="lab_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ClassOfWarrantOrRightsExpiringDateWarrantsOrRightsExercisable" xlink:label="loc_rtgn_ClassOfWarrantOrRightsExpiringDateWarrantsOrRightsExercisable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_ClassOfWarrantOrRightsExpiringDateWarrantsOrRightsExercisable" xml:lang="en-US">Class Of Warrant Or Rights Expiring Date Warrants Or Rights Exercisable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_ClassOfWarrantOrRightsExpiringDateWarrantsOrRightsExercisable" xml:lang="en-US">Date the warrants or rights are expiration , in CCYY-MM-DD format.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_ClassOfWarrantOrRightsExpiringDateWarrantsOrRightsExercisable" xlink:to="lab_rtgn_ClassOfWarrantOrRightsExpiringDateWarrantsOrRightsExercisable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_TermOfWarrant" xlink:label="loc_rtgn_TermOfWarrant" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_TermOfWarrant" xml:lang="en-US">Term Of Warrant</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_TermOfWarrant" xml:lang="en-US">Period of time between issuance and maturity of Warrant.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_TermOfWarrant" xlink:to="lab_rtgn_TermOfWarrant" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesOther" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares Issued, Price Per Share</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ClassOfWarrantOrRightDurationFromWhichWarrantsOrRightsExercisable" xlink:label="loc_rtgn_ClassOfWarrantOrRightDurationFromWhichWarrantsOrRightsExercisable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_ClassOfWarrantOrRightDurationFromWhichWarrantsOrRightsExercisable" xml:lang="en-US">Class Of Warrant Or Right Duration From Which Warrants Or Rights Exercisable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_ClassOfWarrantOrRightDurationFromWhichWarrantsOrRightsExercisable" xml:lang="en-US">It represents the period from which the warrants are exercisable.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_ClassOfWarrantOrRightDurationFromWhichWarrantsOrRightsExercisable" xlink:to="lab_rtgn_ClassOfWarrantOrRightDurationFromWhichWarrantsOrRightsExercisable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xml:lang="en-US">Over-Allotment Option [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_RepresentativeOfUnderwritersMember" xlink:label="loc_rtgn_RepresentativeOfUnderwritersMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_RepresentativeOfUnderwritersMember" xml:lang="en-US">Representative Of Underwriters [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_RepresentativeOfUnderwritersMember" xlink:to="lab_rtgn_RepresentativeOfUnderwritersMember" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_PercentageOfOptionsUnvested" xlink:label="loc_rtgn_PercentageOfOptionsUnvested" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_PercentageOfOptionsUnvested" xml:lang="en-US">Percentage Of Options Unvested</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_PercentageOfOptionsUnvested" xml:lang="en-US">It represents the percentage of options unvested during the period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_PercentageOfOptionsUnvested" xlink:to="lab_rtgn_PercentageOfOptionsUnvested" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_DateOfMergerAxis" xlink:label="loc_rtgn_DateOfMergerAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_DateOfMergerAxis" xml:lang="en-US">Date Of Merger [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_DateOfMergerAxis" xlink:to="lab_rtgn_DateOfMergerAxis" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_PulmatrixIncMember" xlink:label="loc_rtgn_PulmatrixIncMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_PulmatrixIncMember" xml:lang="en-US">Pulmatrix Inc [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_PulmatrixIncMember" xlink:to="lab_rtgn_PulmatrixIncMember" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_DateOfMergerDomain" xlink:label="loc_rtgn_DateOfMergerDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_DateOfMergerDomain" xml:lang="en-US">Date Of Merger [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_DateOfMergerDomain" xlink:to="lab_rtgn_DateOfMergerDomain" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_MergerClosingDateIsNoLaterThanJuly312015Member" xlink:label="loc_rtgn_MergerClosingDateIsNoLaterThanJuly312015Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_MergerClosingDateIsNoLaterThanJuly312015Member" xml:lang="en-US">Merger Closing Date Is No Later Than July 31, 2015 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_MergerClosingDateIsNoLaterThanJuly312015Member" xlink:to="lab_rtgn_MergerClosingDateIsNoLaterThanJuly312015Member" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_MergerClosingDateIsAfterJuly312015ButNoLaterThanAugust132015Member" xlink:label="loc_rtgn_MergerClosingDateIsAfterJuly312015ButNoLaterThanAugust132015Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_MergerClosingDateIsAfterJuly312015ButNoLaterThanAugust132015Member" xml:lang="en-US">Merger Closing Date Is After July 31, 2015 But No Later Than August 13, 2015 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_MergerClosingDateIsAfterJuly312015ButNoLaterThanAugust132015Member" xlink:to="lab_rtgn_MergerClosingDateIsAfterJuly312015ButNoLaterThanAugust132015Member" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_EmployeeAndDirectorMember" xlink:label="loc_rtgn_EmployeeAndDirectorMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_EmployeeAndDirectorMember" xml:lang="en-US">Employee And Director [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_EmployeeAndDirectorMember" xlink:to="lab_rtgn_EmployeeAndDirectorMember" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_OutstandingStockOptionsAndRestrictedStockUnitsTerminationDescription" xlink:label="loc_rtgn_OutstandingStockOptionsAndRestrictedStockUnitsTerminationDescription" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_OutstandingStockOptionsAndRestrictedStockUnitsTerminationDescription" xml:lang="en-US">Outstanding Stock Options And Restricted Stock Units Termination Description</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_OutstandingStockOptionsAndRestrictedStockUnitsTerminationDescription" xml:lang="en-US">It represents the outstanding stock options and restricted stock units termination description during the period</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_OutstandingStockOptionsAndRestrictedStockUnitsTerminationDescription" xlink:to="lab_rtgn_OutstandingStockOptionsAndRestrictedStockUnitsTerminationDescription" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_AgreementTypeAxis" xlink:label="loc_rtgn_AgreementTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_AgreementTypeAxis" xml:lang="en-US">Agreement Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_AgreementTypeAxis" xlink:to="lab_rtgn_AgreementTypeAxis" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_EmployeeDirectorAndConsultantEquityIncentivePlanMember" xlink:label="loc_rtgn_EmployeeDirectorAndConsultantEquityIncentivePlanMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_EmployeeDirectorAndConsultantEquityIncentivePlanMember" xml:lang="en-US">Employee, Director And Consultant Equity Incentive Plan [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_rtgn_EmployeeDirectorAndConsultantEquityIncentivePlanMember" xml:lang="en-US">2013 Employee, Director And Consultant Equity Incentive Plan [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_EmployeeDirectorAndConsultantEquityIncentivePlanMember" xlink:to="lab_rtgn_EmployeeDirectorAndConsultantEquityIncentivePlanMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_AgreementTypeDomain" xlink:label="loc_rtgn_AgreementTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_AgreementTypeDomain" xml:lang="en-US">Agreement Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_AgreementTypeDomain" xlink:to="lab_rtgn_AgreementTypeDomain" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_NewConsultingAgreementsMember" xlink:label="loc_rtgn_NewConsultingAgreementsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_NewConsultingAgreementsMember" xml:lang="en-US">New Consulting Agreements [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_NewConsultingAgreementsMember" xlink:to="lab_rtgn_NewConsultingAgreementsMember" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_OculusSideLetterAgreementMember" xlink:label="loc_rtgn_OculusSideLetterAgreementMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_OculusSideLetterAgreementMember" xml:lang="en-US">Oculus Side Letter Agreement [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_OculusSideLetterAgreementMember" xlink:to="lab_rtgn_OculusSideLetterAgreementMember" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_OculusInnovativeSciencesIncMember" xlink:label="loc_rtgn_OculusInnovativeSciencesIncMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_OculusInnovativeSciencesIncMember" xml:lang="en-US">Oculus Innovative Sciences, Inc [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_OculusInnovativeSciencesIncMember" xlink:to="lab_rtgn_OculusInnovativeSciencesIncMember" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_RestrictedStockUnitsGrantsDescription" xlink:label="loc_rtgn_RestrictedStockUnitsGrantsDescription" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_RestrictedStockUnitsGrantsDescription" xml:lang="en-US">Restricted Stock units Grants Description</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_RestrictedStockUnitsGrantsDescription" xml:lang="en-US">It represents the number of restricted stock units grants description during the period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_RestrictedStockUnitsGrantsDescription" xlink:to="lab_rtgn_RestrictedStockUnitsGrantsDescription" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_PercentageOfGrossProceedsPayable" xlink:label="loc_rtgn_PercentageOfGrossProceedsPayable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_PercentageOfGrossProceedsPayable" xml:lang="en-US">Percentage Of Gross proceeds Payable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_PercentageOfGrossProceedsPayable" xml:lang="en-US">It represents Percentage Of Gross proceeds Payable.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_PercentageOfGrossProceedsPayable" xlink:to="lab_rtgn_PercentageOfGrossProceedsPayable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaap_LiabilitiesAssumed1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAssumed1" xml:lang="en-US">Liabilities Assumed</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAssumed1" xlink:to="lab_us-gaap_LiabilitiesAssumed1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:label="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xml:lang="en-US">Proceeds from Sales of Business, Affiliate and Productive Assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ConsiderationForSharesTransferByParent" xlink:label="loc_rtgn_ConsiderationForSharesTransferByParent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_ConsiderationForSharesTransferByParent" xml:lang="en-US">Consideration For Shares Transfer By Parent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_ConsiderationForSharesTransferByParent" xml:lang="en-US">The maximum amount of net proceeds for shares transfer.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_ConsiderationForSharesTransferByParent" xlink:to="lab_rtgn_ConsiderationForSharesTransferByParent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_FirstPhaseMember" xlink:label="loc_rtgn_FirstPhaseMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_FirstPhaseMember" xml:lang="en-US">First Phase [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_FirstPhaseMember" xlink:to="lab_rtgn_FirstPhaseMember" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_SecondPhaseMember" xlink:label="loc_rtgn_SecondPhaseMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_SecondPhaseMember" xml:lang="en-US">Second Phase [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_SecondPhaseMember" xlink:to="lab_rtgn_SecondPhaseMember" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ThirdPhaseMember" xlink:label="loc_rtgn_ThirdPhaseMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_ThirdPhaseMember" xml:lang="en-US">Third Phase [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_ThirdPhaseMember" xlink:to="lab_rtgn_ThirdPhaseMember" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_FourthPhaseMember" xlink:label="loc_rtgn_FourthPhaseMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_FourthPhaseMember" xml:lang="en-US">Fourth Phase [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_FourthPhaseMember" xlink:to="lab_rtgn_FourthPhaseMember" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_RoyaltyGuaranteesCommitmentsPercentage" xlink:label="loc_rtgn_RoyaltyGuaranteesCommitmentsPercentage" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_RoyaltyGuaranteesCommitmentsPercentage" xml:lang="en-US">Royalty Guarantees Commitments Percentage</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_RoyaltyGuaranteesCommitmentsPercentage" xml:lang="en-US">The percentage the entity has committed to make for future royalty guarantees.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_RoyaltyGuaranteesCommitmentsPercentage" xlink:to="lab_rtgn_RoyaltyGuaranteesCommitmentsPercentage" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfServicesLicensesAndServices" xlink:label="loc_us-gaap_CostOfServicesLicensesAndServices" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfServicesLicensesAndServices" xml:lang="en-US">Cost of Services, Licenses and Services</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfServicesLicensesAndServices" xlink:to="lab_us-gaap_CostOfServicesLicensesAndServices" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_FundToPayCertainAccountPayablesOutstanding" xlink:label="loc_rtgn_FundToPayCertainAccountPayablesOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_FundToPayCertainAccountPayablesOutstanding" xml:lang="en-US">Fund To Pay Certain Account Payables Outstanding</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_FundToPayCertainAccountPayablesOutstanding" xml:lang="en-US">The amount related to fund agreement to pay certain account payables outstanding.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_FundToPayCertainAccountPayablesOutstanding" xlink:to="lab_rtgn_FundToPayCertainAccountPayablesOutstanding" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_PercentageOfSharesTransferByFormerParent" xlink:label="loc_rtgn_PercentageOfSharesTransferByFormerParent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_PercentageOfSharesTransferByFormerParent" xml:lang="en-US">Percentage Of Shares Transfer By Former Parent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_PercentageOfSharesTransferByFormerParent" xml:lang="en-US">The maximum percentage of shares transfer by former parent.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_PercentageOfSharesTransferByFormerParent" xlink:to="lab_rtgn_PercentageOfSharesTransferByFormerParent" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_MinimumDurationForSharesTransfer" xlink:label="loc_rtgn_MinimumDurationForSharesTransfer" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_MinimumDurationForSharesTransfer" xml:lang="en-US">Minimum Duration For Shares Transfer</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_MinimumDurationForSharesTransfer" xml:lang="en-US">The fact represents minimum duration for shares transfer.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_MinimumDurationForSharesTransfer" xlink:to="lab_rtgn_MinimumDurationForSharesTransfer" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ProceedsFromTransferAtleastForNotConsummated" xlink:label="loc_rtgn_ProceedsFromTransferAtleastForNotConsummated" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_ProceedsFromTransferAtleastForNotConsummated" xml:lang="en-US">Proceeds From Transfer Atleast For Not Consummated</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_ProceedsFromTransferAtleastForNotConsummated" xml:lang="en-US">The amount proceeds atleast for non consummated transfers.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_ProceedsFromTransferAtleastForNotConsummated" xlink:to="lab_rtgn_ProceedsFromTransferAtleastForNotConsummated" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareTransferAgreementTerms" xlink:label="loc_rtgn_ShareTransferAgreementTerms" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_ShareTransferAgreementTerms" xml:lang="en-US">Share Transfer Agreement Terms</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_ShareTransferAgreementTerms" xml:lang="en-US">Represents terms related to share transfers.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_ShareTransferAgreementTerms" xlink:to="lab_rtgn_ShareTransferAgreementTerms" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_PercentageOfOutstandingSharesForLapsOfTransfer" xlink:label="loc_rtgn_PercentageOfOutstandingSharesForLapsOfTransfer" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_PercentageOfOutstandingSharesForLapsOfTransfer" xml:lang="en-US">Percentage Of Outstanding Shares For Laps Of Transfer</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_PercentageOfOutstandingSharesForLapsOfTransfer" xml:lang="en-US">Represents percentage of outstanding shares for laps of transfer.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_PercentageOfOutstandingSharesForLapsOfTransfer" xlink:to="lab_rtgn_PercentageOfOutstandingSharesForLapsOfTransfer" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ReimbursementOfExpensesRelatedToTransfer" xlink:label="loc_rtgn_ReimbursementOfExpensesRelatedToTransfer" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_ReimbursementOfExpensesRelatedToTransfer" xml:lang="en-US">Reimbursement Of Expenses Related To Transfer</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_ReimbursementOfExpensesRelatedToTransfer" xml:lang="en-US">The amount reimbursement of expenses related to transfer.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_ReimbursementOfExpensesRelatedToTransfer" xlink:to="lab_rtgn_ReimbursementOfExpensesRelatedToTransfer" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_CashBonus" xlink:label="loc_rtgn_CashBonus" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_CashBonus" xml:lang="en-US">Cash Bonus</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_CashBonus" xml:lang="en-US">The amount of bonus price which is settled in cash.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_CashBonus" xlink:to="lab_rtgn_CashBonus" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LandSubjectToGroundLeases" xlink:label="loc_us-gaap_LandSubjectToGroundLeases" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xml:lang="en-US">Land Subject to Ground Leases</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandSubjectToGroundLeases" xlink:to="lab_us-gaap_LandSubjectToGroundLeases" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xml:lang="en-US">Operating Leases, Rent Expense</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense" xlink:to="lab_us-gaap_LeaseAndRentalExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_CommitmentsAndContingenciesLineItems" xlink:label="loc_rtgn_CommitmentsAndContingenciesLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_rtgn_CommitmentsAndContingenciesLineItems" xml:lang="en-US">Commitments And Contingencies [Line Items]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_rtgn_CommitmentsAndContingenciesLineItems" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems" xlink:to="lab_rtgn_CommitmentsAndContingenciesLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Income tax provision (benefit)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
  </labelLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>17
<FILENAME>rtgn-20150331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.8 on 09-Jun-2015 [02:22:47] {PM} EST - www.datatracks.com -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#DocumentAndEntityInformation" roleURI="http://www.ruthigen.com/role/DocumentAndEntityInformation" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#PrepaidExpensesAndOtherCurrentAssets" roleURI="http://www.ruthigen.com/role/PrepaidExpensesAndOtherCurrentAssets" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#PropertyAndEquipment" roleURI="http://www.ruthigen.com/role/PropertyAndEquipment" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#AccountsPayableAndAccruedExpenses" roleURI="http://www.ruthigen.com/role/AccountsPayableAndAccruedExpenses" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#CommitmentsAndContingencies" roleURI="http://www.ruthigen.com/role/CommitmentsAndContingencies" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#StockholdersEquity" roleURI="http://www.ruthigen.com/role/StockholdersEquity" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#IncomeTaxes" roleURI="http://www.ruthigen.com/role/IncomeTaxes" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#RelatedPartyTransactions" roleURI="http://www.ruthigen.com/role/RelatedPartyTransactions" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#SubsequentEvents" roleURI="http://www.ruthigen.com/role/SubsequentEvents" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.ruthigen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#ConsolidatedBalanceSheets" roleURI="http://www.ruthigen.com/role/ConsolidatedBalanceSheets" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.ruthigen.com/role/SummaryOfSignificantAccountingPoliciesTables" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" roleURI="http://www.ruthigen.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#PropertyAndEquipmentTables" roleURI="http://www.ruthigen.com/role/PropertyAndEquipmentTables" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#AccountsPayableAndAccruedExpensesTables" roleURI="http://www.ruthigen.com/role/AccountsPayableAndAccruedExpensesTables" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#StockholdersEquityTables" roleURI="http://www.ruthigen.com/role/StockholdersEquityTables" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#IncomeTaxesTables" roleURI="http://www.ruthigen.com/role/IncomeTaxesTables" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#OrganizationAndPlanOfMergerDetailsTextual" roleURI="http://www.ruthigen.com/role/OrganizationAndPlanOfMergerDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.ruthigen.com/role/SummaryOfSignificantAccountingPoliciesDetails" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#SummaryOfSignificantAccountingPoliciesDetails1" roleURI="http://www.ruthigen.com/role/SummaryOfSignificantAccountingPoliciesDetails1" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#SummaryOfSignificantAccountingPoliciesDetailsTextual" roleURI="http://www.ruthigen.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.ruthigen.com/role/ConsolidatedBalanceSheetsParenthetical" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#PrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://www.ruthigen.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#PropertyAndEquipmentDetails" roleURI="http://www.ruthigen.com/role/PropertyAndEquipmentDetails" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#PropertyAndEquipmentDetailsTextual" roleURI="http://www.ruthigen.com/role/PropertyAndEquipmentDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#AccountsPayableAndAccruedExpensesDetails" roleURI="http://www.ruthigen.com/role/AccountsPayableAndAccruedExpensesDetails" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#CommitmentsAndContingenciesDetailsTextual" roleURI="http://www.ruthigen.com/role/CommitmentsAndContingenciesDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#StockholdersEquityDetails" roleURI="http://www.ruthigen.com/role/StockholdersEquityDetails" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#StockholdersEquityDetails1" roleURI="http://www.ruthigen.com/role/StockholdersEquityDetails1" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#StockholdersEquityDetails2" roleURI="http://www.ruthigen.com/role/StockholdersEquityDetails2" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#StockholdersEquityDetails3" roleURI="http://www.ruthigen.com/role/StockholdersEquityDetails3" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#StockholdersEquityDetails4" roleURI="http://www.ruthigen.com/role/StockholdersEquityDetails4" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#ConsolidatedStatementsOfOperations" roleURI="http://www.ruthigen.com/role/ConsolidatedStatementsOfOperations" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#StockholdersEquityDetails5" roleURI="http://www.ruthigen.com/role/StockholdersEquityDetails5" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#StockholdersEquityDetailsTextual" roleURI="http://www.ruthigen.com/role/StockholdersEquityDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#IncomeTaxesDetails" roleURI="http://www.ruthigen.com/role/IncomeTaxesDetails" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#IncomeTaxesDetails1" roleURI="http://www.ruthigen.com/role/IncomeTaxesDetails1" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#IncomeTaxesDetails2" roleURI="http://www.ruthigen.com/role/IncomeTaxesDetails2" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#IncomeTaxesDetailsTextual" roleURI="http://www.ruthigen.com/role/IncomeTaxesDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#RelatedPartyTransactionsDetailsTextual" roleURI="http://www.ruthigen.com/role/RelatedPartyTransactionsDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#SubsequentEventsDetailsTextual" roleURI="http://www.ruthigen.com/role/SubsequentEventsDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#ConsolidatedStatementsOfChangesInStockholdersEquity" roleURI="http://www.ruthigen.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.ruthigen.com/role/ConsolidatedStatementsOfCashFlows" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#ConsolidatedStatementsOfCashFlowsParenthetical" roleURI="http://www.ruthigen.com/role/ConsolidatedStatementsOfCashFlowsParenthetical" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#OrganizationAndPlanOfMerger" roleURI="http://www.ruthigen.com/role/OrganizationAndPlanOfMerger" />

  <roleRef xlink:type="simple" xlink:href="rtgn-20150331.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.ruthigen.com/role/SummaryOfSignificantAccountingPolicies" />

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_DocumentAndEntityInformationAbstract" xlink:label="loc_rtgn_DocumentAndEntityInformationAbstract_382" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_383" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_DocumentAndEntityInformationAbstract_382" xlink:to="loc_dei_DocumentInformationTable_383" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_400" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_383" xlink:to="loc_us-gaap_StatementClassOfStockAxis_400" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_401" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_400" xlink:to="loc_us-gaap_ClassOfStockDomain_401" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_384" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_383" xlink:to="loc_dei_DocumentInformationLineItems_384" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_385" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_384" xlink:to="loc_dei_DocumentType_385" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_386" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_384" xlink:to="loc_dei_AmendmentFlag_386" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_387" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_384" xlink:to="loc_dei_DocumentPeriodEndDate_387" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_388" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_384" xlink:to="loc_dei_DocumentFiscalYearFocus_388" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_389" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_384" xlink:to="loc_dei_DocumentFiscalPeriodFocus_389" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_390" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_384" xlink:to="loc_dei_EntityRegistrantName_390" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_391" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_384" xlink:to="loc_dei_EntityCentralIndexKey_391" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_392" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_384" xlink:to="loc_dei_CurrentFiscalYearEndDate_392" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_393" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_384" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_393" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_394" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_384" xlink:to="loc_dei_EntityVoluntaryFilers_394" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_395" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_384" xlink:to="loc_dei_EntityCurrentReportingStatus_395" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_396" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_384" xlink:to="loc_dei_EntityFilerCategory_396" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_397" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_384" xlink:to="loc_dei_EntityPublicFloat_397" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_398" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_384" xlink:to="loc_dei_TradingSymbol_398" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_399" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_384" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_399" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/PrepaidExpensesAndOtherCurrentAssets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_19" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="loc_rtgn_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsTextBlock_20" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_19" xlink:to="loc_rtgn_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsTextBlock_20" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/PropertyAndEquipment">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_438" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_439" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_438" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_439" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/AccountsPayableAndAccruedExpenses">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_23" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_22" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_23" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/CommitmentsAndContingencies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_26" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_25" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_26" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/StockholdersEquity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_29" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_28" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_29" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_508" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_509" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_508" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_509" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_477" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_480" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_477" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_480" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_468" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_469" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_468" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_469" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_31" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiquidityDisclosureTextBlock" xlink:label="loc_us-gaap_LiquidityDisclosureTextBlock_32" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_31" xlink:to="loc_us-gaap_LiquidityDisclosureTextBlock_32" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_415" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_31" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_415" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_33" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_31" xlink:to="loc_us-gaap_UseOfEstimates_33" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_416" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_31" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_416" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_417" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_31" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_417" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_418" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_31" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_418" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_419" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_31" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_419" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_34" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_31" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_34" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_420" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_31" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_420" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_35" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_31" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_35" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_421" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_31" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_421" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_36" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_31" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_36" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_37" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_31" xlink:to="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_37" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/ConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_70" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_71" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_70" xlink:to="loc_us-gaap_StatementTable_71" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_72" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_71" xlink:to="loc_us-gaap_StatementClassOfStockAxis_72" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_73" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_72" xlink:to="loc_us-gaap_ClassOfStockDomain_73" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_74" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_71" xlink:to="loc_us-gaap_StatementLineItems_74" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_75" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_74" xlink:to="loc_us-gaap_AssetsAbstract_75" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_76" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_75" xlink:to="loc_us-gaap_AssetsCurrentAbstract_76" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_77" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_76" xlink:to="loc_us-gaap_Cash_77" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_78" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_76" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_78" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_79" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_76" xlink:to="loc_us-gaap_AssetsCurrent_79" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_80" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_76" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_80" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_81" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_76" xlink:to="loc_us-gaap_Assets_81" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_82" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_74" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_82" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_83" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_82" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_83" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_84" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_84" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_85" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_85" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_86" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83" xlink:to="loc_us-gaap_LiabilitiesCurrent_86" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_87" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83" xlink:to="loc_us-gaap_CommitmentsAndContingencies_87" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_88" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_82" xlink:to="loc_us-gaap_StockholdersEquityAbstract_88" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_89" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_88" xlink:to="loc_us-gaap_PreferredStockValue_89" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_90" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_88" xlink:to="loc_us-gaap_CommonStockValue_90" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_91" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_88" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_91" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_92" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_88" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_92" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_93" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_88" xlink:to="loc_us-gaap_StockholdersEquity_93" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_94" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_88" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_94" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/SummaryOfSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_39" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_PropertyPlanTandEquipmentUsefulLife1TableTextBlock" xlink:label="loc_rtgn_PropertyPlanTandEquipmentUsefulLife1TableTextBlock_422" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_39" xlink:to="loc_rtgn_PropertyPlanTandEquipmentUsefulLife1TableTextBlock_422" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_40" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_39" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_40" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/PrepaidExpensesAndOtherCurrentAssetsTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_42" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:label="loc_rtgn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_43" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_42" xlink:to="loc_rtgn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_43" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/PropertyAndEquipmentTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_441" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_442" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_441" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_442" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/AccountsPayableAndAccruedExpensesTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_45" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_46" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_45" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_46" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/StockholdersEquityTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_48" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ScheduleOfSharebasedCompensationWarrantActivityTableTextBlock" xlink:label="loc_rtgn_ScheduleOfSharebasedCompensationWarrantActivityTableTextBlock_49" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_48" xlink:to="loc_rtgn_ScheduleOfSharebasedCompensationWarrantActivityTableTextBlock_49" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ScheduleOfShareBasedCompensationWarrantsByExercisePriceRangeTableTextBlock" xlink:label="loc_rtgn_ScheduleOfShareBasedCompensationWarrantsByExercisePriceRangeTableTextBlock_50" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_48" xlink:to="loc_rtgn_ScheduleOfShareBasedCompensationWarrantsByExercisePriceRangeTableTextBlock_50" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_51" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_48" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_51" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_52" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_48" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_52" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_53" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_48" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_53" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_54" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_48" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_54" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_511" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_512" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_511" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_512" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateTableTextBlock" xlink:label="loc_rtgn_ScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateTableTextBlock_513" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_511" xlink:to="loc_rtgn_ScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateTableTextBlock_513" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_514" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_511" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_514" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/OrganizationAndPlanOfMergerDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_405" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_406" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_405" xlink:to="loc_us-gaap_StatementTable_406" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_407" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_406" xlink:to="loc_us-gaap_StatementClassOfStockAxis_407" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_408" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_407" xlink:to="loc_us-gaap_ClassOfStockDomain_408" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_409" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_406" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_409" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_413" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_409" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_413" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_414" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_413" xlink:to="loc_us-gaap_IPOMember_414" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_412" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_406" xlink:to="loc_us-gaap_StatementLineItems_412" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_InitialPublicOfferingUnits" xlink:label="loc_rtgn_InitialPublicOfferingUnits_410" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_412" xlink:to="loc_rtgn_InitialPublicOfferingUnits_410" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_InitialPublicOfferingPricePerUnit" xlink:label="loc_rtgn_InitialPublicOfferingPricePerUnit_411" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_412" xlink:to="loc_rtgn_InitialPublicOfferingPricePerUnit_411" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/SummaryOfSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_424" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_425" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_424" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_425" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_426" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_425" xlink:to="loc_us-gaap_StatementClassOfStockAxis_426" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_427" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_426" xlink:to="loc_us-gaap_ClassOfStockDomain_427" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_428" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_425" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_428" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_432" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_428" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_432" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_434" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_432" xlink:to="loc_us-gaap_OfficeEquipmentMember_434" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ManufacturingFacilityMember" xlink:label="loc_us-gaap_ManufacturingFacilityMember_435" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_432" xlink:to="loc_us-gaap_ManufacturingFacilityMember_435" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_436" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_432" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_436" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_431" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_425" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_431" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_433" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_431" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_433" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/SummaryOfSignificantAccountingPoliciesDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_56" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_rtgn_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_57" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_56" xlink:to="loc_rtgn_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_57" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_58" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_57" xlink:to="loc_us-gaap_AwardTypeAxis_58" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_59" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_59" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_60" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_59" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_60" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_61" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_57" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_61" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_62" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_61" xlink:to="loc_us-gaap_EquityComponentDomain_62" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_63" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_62" xlink:to="loc_us-gaap_WarrantMember_63" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_64" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_57" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_64" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_65" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_64" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_65" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_66" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_65" xlink:to="loc_us-gaap_EmployeeStockOptionMember_66" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_rtgn_SummaryOfSignificantAccountingPoliciesLineItems_67" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_57" xlink:to="loc_rtgn_SummaryOfSignificantAccountingPoliciesLineItems_67" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_68" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_SummaryOfSignificantAccountingPoliciesLineItems_67" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_68" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_96" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ScheduleOfSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_rtgn_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_97" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_96" xlink:to="loc_rtgn_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_97" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_98" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_97" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_98" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_99" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_98" xlink:to="loc_us-gaap_EquityComponentDomain_99" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_rtgn_SummaryOfSignificantAccountingPoliciesLineItems_100" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_ScheduleOfSummaryOfSignificantAccountingPoliciesTable_97" xlink:to="loc_rtgn_SummaryOfSignificantAccountingPoliciesLineItems_100" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_101" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_SummaryOfSignificantAccountingPoliciesLineItems_100" xlink:to="loc_us-gaap_NetIncomeLoss_101" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_WorkingCapital" xlink:label="loc_rtgn_WorkingCapital_102" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_SummaryOfSignificantAccountingPoliciesLineItems_100" xlink:to="loc_rtgn_WorkingCapital_102" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_103" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_SummaryOfSignificantAccountingPoliciesLineItems_100" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_103" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/ConsolidatedBalanceSheetsParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_253" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_254" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_253" xlink:to="loc_us-gaap_StatementTable_254" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_255" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_254" xlink:to="loc_us-gaap_StatementClassOfStockAxis_255" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_256" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_255" xlink:to="loc_us-gaap_ClassOfStockDomain_256" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_257" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_254" xlink:to="loc_us-gaap_StatementLineItems_257" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_258" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_257" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_258" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_259" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_257" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_259" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_260" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_257" xlink:to="loc_us-gaap_PreferredStockSharesIssued_260" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_261" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_257" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_261" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_262" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_257" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_262" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_263" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_257" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_263" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_264" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_257" xlink:to="loc_us-gaap_CommonStockSharesIssued_264" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_265" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_257" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_265" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_105" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTable" xlink:label="loc_rtgn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTable_106" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_105" xlink:to="loc_rtgn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTable_106" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_107" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTable_106" xlink:to="loc_us-gaap_StatementClassOfStockAxis_107" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_108" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_107" xlink:to="loc_us-gaap_ClassOfStockDomain_108" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_PrepaidExpensesAndOtherCurrentAssetsLineItems" xlink:label="loc_rtgn_PrepaidExpensesAndOtherCurrentAssetsLineItems_109" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTable_106" xlink:to="loc_rtgn_PrepaidExpensesAndOtherCurrentAssetsLineItems_109" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaap_PrepaidInsurance_110" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_PrepaidExpensesAndOtherCurrentAssetsLineItems_109" xlink:to="loc_us-gaap_PrepaidInsurance_110" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_111" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_PrepaidExpensesAndOtherCurrentAssetsLineItems_109" xlink:to="loc_us-gaap_OtherAssetsCurrent_111" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidRent" xlink:label="loc_us-gaap_PrepaidRent_112" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_PrepaidExpensesAndOtherCurrentAssetsLineItems_109" xlink:to="loc_us-gaap_PrepaidRent_112" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_OtherPrepaidExpensesAndCurrentAssets" xlink:label="loc_rtgn_OtherPrepaidExpensesAndCurrentAssets_113" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_PrepaidExpensesAndOtherCurrentAssetsLineItems_109" xlink:to="loc_rtgn_OtherPrepaidExpensesAndCurrentAssets_113" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_114" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_PrepaidExpensesAndOtherCurrentAssetsLineItems_109" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_114" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/PropertyAndEquipmentDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_444" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_445" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_444" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_445" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_446" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_445" xlink:to="loc_us-gaap_StatementClassOfStockAxis_446" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_447" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_446" xlink:to="loc_us-gaap_ClassOfStockDomain_447" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_448" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_445" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_448" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_455" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_448" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_455" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_457" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_455" xlink:to="loc_us-gaap_OfficeEquipmentMember_457" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_MedicalEquipmentMember" xlink:label="loc_rtgn_MedicalEquipmentMember_491" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_455" xlink:to="loc_rtgn_MedicalEquipmentMember_491" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_454" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_445" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_454" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_451" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_454" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_451" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_452" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_454" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_452" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_453" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_454" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_453" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/PropertyAndEquipmentDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_459" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_460" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_459" xlink:to="loc_us-gaap_StatementTable_460" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_461" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_460" xlink:to="loc_us-gaap_StatementClassOfStockAxis_461" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_462" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_461" xlink:to="loc_us-gaap_ClassOfStockDomain_462" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_463" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_460" xlink:to="loc_us-gaap_StatementLineItems_463" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_464" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_463" xlink:to="loc_us-gaap_Depreciation_464" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/AccountsPayableAndAccruedExpensesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_116" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ScheduleOfAccountsPayableAndAccuredExpensesTable" xlink:label="loc_rtgn_ScheduleOfAccountsPayableAndAccuredExpensesTable_117" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_116" xlink:to="loc_rtgn_ScheduleOfAccountsPayableAndAccuredExpensesTable_117" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_118" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_ScheduleOfAccountsPayableAndAccuredExpensesTable_117" xlink:to="loc_dei_LegalEntityAxis_118" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_119" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_118" xlink:to="loc_dei_EntityDomain_119" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_AccountsPayableAndAccruedExpensesLineItems" xlink:label="loc_rtgn_AccountsPayableAndAccruedExpensesLineItems_120" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_ScheduleOfAccountsPayableAndAccuredExpensesTable_117" xlink:to="loc_rtgn_AccountsPayableAndAccruedExpensesLineItems_120" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_121" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_AccountsPayableAndAccruedExpensesLineItems_120" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_121" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_AccruedDirectorCompensation" xlink:label="loc_rtgn_AccruedDirectorCompensation_122" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_AccountsPayableAndAccruedExpensesLineItems_120" xlink:to="loc_rtgn_AccruedDirectorCompensation_122" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_AccruedLegalFees" xlink:label="loc_rtgn_AccruedLegalFees_123" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_AccountsPayableAndAccruedExpensesLineItems_120" xlink:to="loc_rtgn_AccruedLegalFees_123" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_124" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_AccountsPayableAndAccruedExpensesLineItems_120" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_124" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_AccruedResearchAndDevelopmentCurrent" xlink:label="loc_rtgn_AccruedResearchAndDevelopmentCurrent_125" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_AccountsPayableAndAccruedExpensesLineItems_120" xlink:to="loc_rtgn_AccruedResearchAndDevelopmentCurrent_125" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_AccruedFranchisesTaxes" xlink:label="loc_rtgn_AccruedFranchisesTaxes_466" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_AccountsPayableAndAccruedExpensesLineItems_120" xlink:to="loc_rtgn_AccruedFranchisesTaxes_466" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_126" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_AccountsPayableAndAccruedExpensesLineItems_120" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_126" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_127" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_AccountsPayableAndAccruedExpensesLineItems_120" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_127" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/CommitmentsAndContingenciesDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_129" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ScheduleOfCommitmentsAndContingenciesTable" xlink:label="loc_rtgn_ScheduleOfCommitmentsAndContingenciesTable_130" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_129" xlink:to="loc_rtgn_ScheduleOfCommitmentsAndContingenciesTable_130" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_LicenseAgreementAxis" xlink:label="loc_rtgn_LicenseAgreementAxis_131" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_ScheduleOfCommitmentsAndContingenciesTable_130" xlink:to="loc_rtgn_LicenseAgreementAxis_131" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_LicenseAgreementDomain" xlink:label="loc_rtgn_LicenseAgreementDomain_132" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_LicenseAgreementAxis_131" xlink:to="loc_rtgn_LicenseAgreementDomain_132" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_EmployeeAgreementMember" xlink:label="loc_rtgn_EmployeeAgreementMember_133" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_LicenseAgreementDomain_132" xlink:to="loc_rtgn_EmployeeAgreementMember_133" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_LicenseAndSupplyAgreementMember" xlink:label="loc_rtgn_LicenseAndSupplyAgreementMember_134" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_LicenseAgreementDomain_132" xlink:to="loc_rtgn_LicenseAndSupplyAgreementMember_134" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_135" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_ScheduleOfCommitmentsAndContingenciesTable_130" xlink:to="loc_us-gaap_TitleOfIndividualAxis_135" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_136" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_135" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_136" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_TwoExecutivesMember" xlink:label="loc_rtgn_TwoExecutivesMember_137" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_136" xlink:to="loc_rtgn_TwoExecutivesMember_137" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_EmployeeAndDirectorMember" xlink:label="loc_rtgn_EmployeeAndDirectorMember_636" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_136" xlink:to="loc_rtgn_EmployeeAndDirectorMember_636" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_138" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_ScheduleOfCommitmentsAndContingenciesTable_130" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_138" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_139" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_138" xlink:to="loc_us-gaap_RelatedPartyDomain_139" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_OculusMember" xlink:label="loc_rtgn_OculusMember_140" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_139" xlink:to="loc_rtgn_OculusMember_140" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaap_ChiefExecutiveOfficerMember_141" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_139" xlink:to="loc_us-gaap_ChiefExecutiveOfficerMember_141" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ChiefFinancialOfficerMember" xlink:label="loc_us-gaap_ChiefFinancialOfficerMember_142" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_139" xlink:to="loc_us-gaap_ChiefFinancialOfficerMember_142" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_OculusInnovativeSciencesIncMember" xlink:label="loc_rtgn_OculusInnovativeSciencesIncMember_647" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_139" xlink:to="loc_rtgn_OculusInnovativeSciencesIncMember_647" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_143" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_ScheduleOfCommitmentsAndContingenciesTable_130" xlink:to="loc_us-gaap_RangeAxis_143" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_144" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_143" xlink:to="loc_us-gaap_RangeMember_144" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_145" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_144" xlink:to="loc_us-gaap_MinimumMember_145" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_146" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_144" xlink:to="loc_us-gaap_MaximumMember_146" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_147" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_ScheduleOfCommitmentsAndContingenciesTable_130" xlink:to="loc_dei_LegalEntityAxis_147" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_629" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_147" xlink:to="loc_dei_EntityDomain_629" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_PulmatrixIncMember" xlink:label="loc_rtgn_PulmatrixIncMember_630" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_629" xlink:to="loc_rtgn_PulmatrixIncMember_630" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_DateOfMergerAxis" xlink:label="loc_rtgn_DateOfMergerAxis_628" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_ScheduleOfCommitmentsAndContingenciesTable_130" xlink:to="loc_rtgn_DateOfMergerAxis_628" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_DateOfMergerDomain" xlink:label="loc_rtgn_DateOfMergerDomain_633" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_DateOfMergerAxis_628" xlink:to="loc_rtgn_DateOfMergerDomain_633" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_MergerClosingDateIsNoLaterThanJuly312015Member" xlink:label="loc_rtgn_MergerClosingDateIsNoLaterThanJuly312015Member_634" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_DateOfMergerDomain_633" xlink:to="loc_rtgn_MergerClosingDateIsNoLaterThanJuly312015Member_634" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_MergerClosingDateIsAfterJuly312015ButNoLaterThanAugust132015Member" xlink:label="loc_rtgn_MergerClosingDateIsAfterJuly312015ButNoLaterThanAugust132015Member_635" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_DateOfMergerDomain_633" xlink:to="loc_rtgn_MergerClosingDateIsAfterJuly312015ButNoLaterThanAugust132015Member_635" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_632" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_ScheduleOfCommitmentsAndContingenciesTable_130" xlink:to="loc_us-gaap_PlanNameAxis_632" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_641" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_632" xlink:to="loc_us-gaap_PlanNameDomain_641" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_EmployeeDirectorAndConsultantEquityIncentivePlanMember" xlink:label="loc_rtgn_EmployeeDirectorAndConsultantEquityIncentivePlanMember_642" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_641" xlink:to="loc_rtgn_EmployeeDirectorAndConsultantEquityIncentivePlanMember_642" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_AgreementTypeAxis" xlink:label="loc_rtgn_AgreementTypeAxis_640" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_ScheduleOfCommitmentsAndContingenciesTable_130" xlink:to="loc_rtgn_AgreementTypeAxis_640" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_AgreementTypeDomain" xlink:label="loc_rtgn_AgreementTypeDomain_644" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_AgreementTypeAxis_640" xlink:to="loc_rtgn_AgreementTypeDomain_644" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_NewConsultingAgreementsMember" xlink:label="loc_rtgn_NewConsultingAgreementsMember_645" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_AgreementTypeDomain_644" xlink:to="loc_rtgn_NewConsultingAgreementsMember_645" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_OculusSideLetterAgreementMember" xlink:label="loc_rtgn_OculusSideLetterAgreementMember_646" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_AgreementTypeDomain_644" xlink:to="loc_rtgn_OculusSideLetterAgreementMember_646" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_643" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_ScheduleOfCommitmentsAndContingenciesTable_130" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_643" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_655" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_643" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_655" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_FirstPhaseMember" xlink:label="loc_rtgn_FirstPhaseMember_656" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_655" xlink:to="loc_rtgn_FirstPhaseMember_656" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_SecondPhaseMember" xlink:label="loc_rtgn_SecondPhaseMember_657" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_655" xlink:to="loc_rtgn_SecondPhaseMember_657" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ThirdPhaseMember" xlink:label="loc_rtgn_ThirdPhaseMember_658" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_655" xlink:to="loc_rtgn_ThirdPhaseMember_658" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_FourthPhaseMember" xlink:label="loc_rtgn_FourthPhaseMember_659" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_655" xlink:to="loc_rtgn_FourthPhaseMember_659" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_654" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_ScheduleOfCommitmentsAndContingenciesTable_130" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_654" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_676" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_654" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_676" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_677" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_676" xlink:to="loc_us-gaap_SubsequentEventMember_677" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_CommitmentsAndContingenciesLineItems" xlink:label="loc_rtgn_CommitmentsAndContingenciesLineItems_675" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_ScheduleOfCommitmentsAndContingenciesTable_130" xlink:to="loc_rtgn_CommitmentsAndContingenciesLineItems_675" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_148" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_us-gaap_OfficersCompensation_148" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_149" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_us-gaap_SeveranceCosts1_149" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualDescription" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualDescription_150" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualDescription_150" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:label="loc_us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted_151" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted_151" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_DescriptionOfSeparationAgreement" xlink:label="loc_rtgn_DescriptionOfSeparationAgreement_478" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_rtgn_DescriptionOfSeparationAgreement_478" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SignificantPurchaseCommitmentDescription" xlink:label="loc_us-gaap_SignificantPurchaseCommitmentDescription_479" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_us-gaap_SignificantPurchaseCommitmentDescription_479" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_631" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_631" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_637" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_us-gaap_Cash_637" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_638" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_638" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_OutstandingStockOptionsAndRestrictedStockUnitsTerminationDescription" xlink:label="loc_rtgn_OutstandingStockOptionsAndRestrictedStockUnitsTerminationDescription_639" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_rtgn_OutstandingStockOptionsAndRestrictedStockUnitsTerminationDescription_639" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_RestrictedStockUnitsGrantsDescription" xlink:label="loc_rtgn_RestrictedStockUnitsGrantsDescription_648" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_rtgn_RestrictedStockUnitsGrantsDescription_648" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_649" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_649" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_PercentageOfGrossProceedsPayable" xlink:label="loc_rtgn_PercentageOfGrossProceedsPayable_650" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_rtgn_PercentageOfGrossProceedsPayable_650" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaap_LiabilitiesAssumed1_651" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_us-gaap_LiabilitiesAssumed1_651" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:label="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_652" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_652" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ConsiderationForSharesTransferByParent" xlink:label="loc_rtgn_ConsiderationForSharesTransferByParent_653" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_rtgn_ConsiderationForSharesTransferByParent_653" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_RoyaltyGuaranteesCommitmentsPercentage" xlink:label="loc_rtgn_RoyaltyGuaranteesCommitmentsPercentage_660" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_rtgn_RoyaltyGuaranteesCommitmentsPercentage_660" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfServicesLicensesAndServices" xlink:label="loc_us-gaap_CostOfServicesLicensesAndServices_661" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_us-gaap_CostOfServicesLicensesAndServices_661" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_FundToPayCertainAccountPayablesOutstanding" xlink:label="loc_rtgn_FundToPayCertainAccountPayablesOutstanding_662" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_rtgn_FundToPayCertainAccountPayablesOutstanding_662" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_PercentageOfSharesTransferByFormerParent" xlink:label="loc_rtgn_PercentageOfSharesTransferByFormerParent_663" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_rtgn_PercentageOfSharesTransferByFormerParent_663" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_MinimumDurationForSharesTransfer" xlink:label="loc_rtgn_MinimumDurationForSharesTransfer_664" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_rtgn_MinimumDurationForSharesTransfer_664" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ProceedsFromTransferAtleastForNotConsummated" xlink:label="loc_rtgn_ProceedsFromTransferAtleastForNotConsummated_665" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_rtgn_ProceedsFromTransferAtleastForNotConsummated_665" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareTransferAgreementTerms" xlink:label="loc_rtgn_ShareTransferAgreementTerms_666" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_rtgn_ShareTransferAgreementTerms_666" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_PercentageOfOutstandingSharesForLapsOfTransfer" xlink:label="loc_rtgn_PercentageOfOutstandingSharesForLapsOfTransfer_667" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_rtgn_PercentageOfOutstandingSharesForLapsOfTransfer_667" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ReimbursementOfExpensesRelatedToTransfer" xlink:label="loc_rtgn_ReimbursementOfExpensesRelatedToTransfer_668" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_rtgn_ReimbursementOfExpensesRelatedToTransfer_668" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_CashBonus" xlink:label="loc_rtgn_CashBonus_669" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_rtgn_CashBonus_669" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LandSubjectToGroundLeases" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_670" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_670" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_671" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_us-gaap_LeaseAndRentalExpense_671" use="optional" order="71" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_672" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_CommitmentsAndContingenciesLineItems_675" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_672" use="optional" order="72" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/StockholdersEquityDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_153" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_154" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_153" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_154" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_155" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_154" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_155" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_156" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_155" xlink:to="loc_us-gaap_EquityComponentDomain_156" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_157" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_156" xlink:to="loc_us-gaap_WarrantMember_157" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_158" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_154" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_158" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_159" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_158" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_159" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_160" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_158" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_160" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_161" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_158" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_161" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/negativeLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_162" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_158" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_162" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_163" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_158" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_163" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber_164" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_158" xlink:to="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber_164" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_165" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_158" xlink:to="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_165" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsGrantedWeightedAverageExercisePrice" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsGrantedWeightedAverageExercisePrice_166" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_158" xlink:to="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsGrantedWeightedAverageExercisePrice_166" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisedWeightedAverageExercisePrice" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisedWeightedAverageExercisePrice_167" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_158" xlink:to="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisedWeightedAverageExercisePrice_167" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice_168" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_158" xlink:to="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice_168" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_169" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_158" xlink:to="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_169" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_170" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_158" xlink:to="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_170" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_171" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_158" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_171" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_172" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_158" xlink:to="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_172" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_173" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_158" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_173" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable_174" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_158" xlink:to="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable_174" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/StockholdersEquityDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_176" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_177" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_176" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_177" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_178" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_177" xlink:to="loc_us-gaap_RangeAxis_178" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_179" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_178" xlink:to="loc_us-gaap_RangeMember_179" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ExercisePriceRangeOneMember" xlink:label="loc_rtgn_ExercisePriceRangeOneMember_180" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_179" xlink:to="loc_rtgn_ExercisePriceRangeOneMember_180" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ExercisePriceRangeTwoMember" xlink:label="loc_rtgn_ExercisePriceRangeTwoMember_181" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_179" xlink:to="loc_rtgn_ExercisePriceRangeTwoMember_181" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_182" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_177" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_182" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_183" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_182" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_183" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_184" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_182" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_184" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_185" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_182" xlink:to="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_185" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber_186" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_182" xlink:to="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber_186" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/StockholdersEquityDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_188" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_189" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_188" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_189" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_190" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_189" xlink:to="loc_us-gaap_StatementClassOfStockAxis_190" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_191" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_190" xlink:to="loc_us-gaap_ClassOfStockDomain_191" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_192" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_189" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_192" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_193" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_192" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_193" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_194" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_192" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_194" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_195" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_192" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_195" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_196" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_192" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_196" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/StockholdersEquityDetails3">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_198" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_199" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_198" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_199" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_200" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_199" xlink:to="loc_dei_LegalEntityAxis_200" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_201" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_200" xlink:to="loc_dei_EntityDomain_201" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_202" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_199" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_202" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_203" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_202" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_203" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_204" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_202" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_204" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_205" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_202" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_205" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_206" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_202" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_206" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_207" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_202" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_207" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_208" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_202" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_208" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_209" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_202" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_209" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_210" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_202" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_210" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_211" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_202" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_211" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_212" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_202" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_212" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_213" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_202" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_213" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_214" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_202" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_214" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_215" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_202" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_215" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_216" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_202" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_216" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_217" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_202" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_217" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_218" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_202" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_218" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/StockholdersEquityDetails4">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_220" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_221" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_220" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_221" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_222" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_221" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_222" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_223" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_222" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_223" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ExercisePriceMember" xlink:label="loc_rtgn_ExercisePriceMember_224" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_223" xlink:to="loc_rtgn_ExercisePriceMember_224" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_225" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_221" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_225" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_226" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_225" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_226" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_227" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_225" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_227" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_228" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_225" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_228" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_229" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_225" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_229" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/ConsolidatedStatementsOfOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_301" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_302" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_301" xlink:to="loc_us-gaap_StatementTable_302" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_303" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_302" xlink:to="loc_dei_LegalEntityAxis_303" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_304" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_303" xlink:to="loc_dei_EntityDomain_304" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_305" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_302" xlink:to="loc_us-gaap_StatementLineItems_305" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_306" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_305" xlink:to="loc_us-gaap_Revenues_306" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_307" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_305" xlink:to="loc_us-gaap_OperatingExpensesAbstract_307" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_308" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_307" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_308" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_309" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_307" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_309" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_310" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_307" xlink:to="loc_us-gaap_OperatingExpenses_310" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_311" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_307" xlink:to="loc_us-gaap_OperatingIncomeLoss_311" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_312" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_305" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_312" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating_313" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_312" xlink:to="loc_us-gaap_InvestmentIncomeNonoperating_313" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_314" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_312" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_314" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_315" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_312" xlink:to="loc_us-gaap_NetIncomeLoss_315" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_316" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_305" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_316" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_317" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_316" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_317" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_318" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_305" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_318" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_319" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_318" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_319" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/StockholdersEquityDetails5">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_231" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_232" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_231" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_232" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_233" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_232" xlink:to="loc_us-gaap_AwardTypeAxis_233" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_234" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_233" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_234" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_235" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_234" xlink:to="loc_us-gaap_RestrictedStockMember_235" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_236" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_232" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_236" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_237" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_236" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_237" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_238" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_236" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_238" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_239" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_236" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_239" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_240" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_236" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_240" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_241" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_236" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_241" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_242" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_236" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_242" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_243" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_236" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_243" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_244" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_236" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_244" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_245" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_236" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_245" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_246" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_236" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_246" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedGrantDateFairValue" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedGrantDateFairValue_247" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_236" xlink:to="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedGrantDateFairValue_247" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_248" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_236" xlink:to="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_248" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodGrantDateFairValue" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodGrantDateFairValue_249" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_236" xlink:to="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodGrantDateFairValue_249" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodGrantDateFairValue" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodGrantDateFairValue_250" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_236" xlink:to="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodGrantDateFairValue_250" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedGrantDateFairValue" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedGrantDateFairValue_251" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_236" xlink:to="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedGrantDateFairValue_251" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/StockholdersEquityDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_267" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_268" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_267" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_268" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_269" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_268" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_269" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_270" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_269" xlink:to="loc_us-gaap_EquityComponentDomain_270" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_271" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_270" xlink:to="loc_us-gaap_CommonStockMember_271" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_272" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_268" xlink:to="loc_us-gaap_AwardTypeAxis_272" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_273" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_272" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_273" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_274" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_273" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_274" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_TwoThousandThirteenPlanMember" xlink:label="loc_rtgn_TwoThousandThirteenPlanMember_275" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_273" xlink:to="loc_rtgn_TwoThousandThirteenPlanMember_275" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_UnderwritersMember" xlink:label="loc_rtgn_UnderwritersMember_612" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_273" xlink:to="loc_rtgn_UnderwritersMember_612" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_276" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_268" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_276" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_277" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_276" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_277" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_278" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_277" xlink:to="loc_us-gaap_IPOMember_278" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_622" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_277" xlink:to="loc_us-gaap_OverAllotmentOptionMember_622" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_279" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_268" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_279" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_280" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_279" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_280" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_281" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_280" xlink:to="loc_us-gaap_PerformanceSharesMember_281" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_282" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_268" xlink:to="loc_us-gaap_PlanNameAxis_282" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_599" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_282" xlink:to="loc_us-gaap_PlanNameDomain_599" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_NewTwoThousandThirteenPlanMember" xlink:label="loc_rtgn_NewTwoThousandThirteenPlanMember_600" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_599" xlink:to="loc_rtgn_NewTwoThousandThirteenPlanMember_600" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_598" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_268" xlink:to="loc_us-gaap_TitleOfIndividualAxis_598" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_624" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_598" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_624" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_RepresentativeOfUnderwritersMember" xlink:label="loc_rtgn_RepresentativeOfUnderwritersMember_625" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_624" xlink:to="loc_rtgn_RepresentativeOfUnderwritersMember_625" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_268" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_283" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_283" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_284" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_SharePrice_284" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_287" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_287" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_288" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_288" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_289" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_289" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_290" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_290" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_291" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_291" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_292" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_292" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_293" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_293" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_294" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_294" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_295" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_295" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_WarrantsToPurchaseOfCommonStock" xlink:label="loc_rtgn_WarrantsToPurchaseOfCommonStock_296" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_rtgn_WarrantsToPurchaseOfCommonStock_296" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_InitialPublicOfferingPricePerUnit" xlink:label="loc_rtgn_InitialPublicOfferingPricePerUnit_297" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_rtgn_InitialPublicOfferingPricePerUnit_297" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_298" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_298" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_InitialPublicOfferingUnits" xlink:label="loc_rtgn_InitialPublicOfferingUnits_299" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_rtgn_InitialPublicOfferingUnits_299" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_590" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_590" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_591" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_591" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_592" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_592" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_593" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_593" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_594" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_594" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_595" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_595" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_596" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_596" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_597" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_597" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_601" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_601" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_602" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_602" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_603" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_603" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_GrossProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="loc_rtgn_GrossProceedsFromIssuanceOfCommonStockAndWarrants_604" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_rtgn_GrossProceedsFromIssuanceOfCommonStockAndWarrants_604" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_OfferingCost" xlink:label="loc_rtgn_OfferingCost_605" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_rtgn_OfferingCost_605" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_606" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_CommonStockSharesIssued_606" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber_607" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber_607" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExercisePrice" xlink:label="loc_invest_InvestmentWarrantsExercisePrice_608" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_invest_InvestmentWarrantsExercisePrice_608" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ClosingPriceOfCommonStockPercentage" xlink:label="loc_rtgn_ClosingPriceOfCommonStockPercentage_609" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_rtgn_ClosingPriceOfCommonStockPercentage_609" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice" xlink:label="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_610" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_610" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_611" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_611" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_613" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_613" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ClassOfWarrantOrRightsExpiringDateWarrantsOrRightsExercisable" xlink:label="loc_rtgn_ClassOfWarrantOrRightsExpiringDateWarrantsOrRightsExercisable_614" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_rtgn_ClassOfWarrantOrRightsExpiringDateWarrantsOrRightsExercisable_614" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_615" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_615" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_616" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_616" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_617" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_617" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_TermOfWarrant" xlink:label="loc_rtgn_TermOfWarrant_618" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_rtgn_TermOfWarrant_618" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_619" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_619" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_620" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_620" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ClassOfWarrantOrRightDurationFromWhichWarrantsOrRightsExercisable" xlink:label="loc_rtgn_ClassOfWarrantOrRightDurationFromWhichWarrantsOrRightsExercisable_621" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_rtgn_ClassOfWarrantOrRightDurationFromWhichWarrantsOrRightsExercisable_621" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_InvestmentFromFormerParent" xlink:label="loc_rtgn_InvestmentFromFormerParent_626" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_rtgn_InvestmentFromFormerParent_626" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_PercentageOfOptionsUnvested" xlink:label="loc_rtgn_PercentageOfOptionsUnvested_627" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_623" xlink:to="loc_rtgn_PercentageOfOptionsUnvested_627" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_519" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTable" xlink:label="loc_rtgn_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTable_520" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_519" xlink:to="loc_rtgn_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTable_520" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_521" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTable_520" xlink:to="loc_us-gaap_StatementClassOfStockAxis_521" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_522" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_521" xlink:to="loc_us-gaap_ClassOfStockDomain_522" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ComponentsOfIncomeTaxExpenseBenefitLineItems" xlink:label="loc_rtgn_ComponentsOfIncomeTaxExpenseBenefitLineItems_523" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTable_520" xlink:to="loc_rtgn_ComponentsOfIncomeTaxExpenseBenefitLineItems_523" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_530" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_ComponentsOfIncomeTaxExpenseBenefitLineItems_523" xlink:to="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_530" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_531" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_530" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_531" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_532" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_530" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_532" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_533" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_ComponentsOfIncomeTaxExpenseBenefitLineItems_523" xlink:to="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_533" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_534" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_533" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_534" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_535" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_533" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_535" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_573" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_ComponentsOfIncomeTaxExpenseBenefitLineItems_523" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_573" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_537" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_ComponentsOfIncomeTaxExpenseBenefitLineItems_523" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_537" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_538" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_ComponentsOfIncomeTaxExpenseBenefitLineItems_523" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_538" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/IncomeTaxesDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_539" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateTable" xlink:label="loc_rtgn_ScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateTable_540" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_539" xlink:to="loc_rtgn_ScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateTable_540" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_541" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_ScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateTable_540" xlink:to="loc_us-gaap_StatementClassOfStockAxis_541" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_542" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_541" xlink:to="loc_us-gaap_ClassOfStockDomain_542" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateLineItems" xlink:label="loc_rtgn_ReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateLineItems_543" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_ScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateTable_540" xlink:to="loc_rtgn_ReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateLineItems_543" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_549" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_ReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateLineItems_543" xlink:to="loc_us-gaap_OperatingLossCarryforwards_549" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_550" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_ReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateLineItems_543" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_550" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_551" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_ReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateLineItems_543" xlink:to="loc_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_551" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_552" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_ReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateLineItems_543" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_552" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_553" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_ReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateLineItems_543" xlink:to="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_553" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_554" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_ReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateLineItems_543" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_554" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/IncomeTaxesDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_557" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ScheduleOfEffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_rtgn_ScheduleOfEffectiveIncomeTaxRateReconciliationTable_558" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_557" xlink:to="loc_rtgn_ScheduleOfEffectiveIncomeTaxRateReconciliationTable_558" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_559" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_ScheduleOfEffectiveIncomeTaxRateReconciliationTable_558" xlink:to="loc_us-gaap_StatementClassOfStockAxis_559" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_560" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_559" xlink:to="loc_us-gaap_ClassOfStockDomain_560" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_rtgn_EffectiveIncomeTaxRateReconciliationLineItems_561" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_ScheduleOfEffectiveIncomeTaxRateReconciliationTable_558" xlink:to="loc_rtgn_EffectiveIncomeTaxRateReconciliationLineItems_561" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_565" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_EffectiveIncomeTaxRateReconciliationLineItems_561" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_565" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_566" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_EffectiveIncomeTaxRateReconciliationLineItems_561" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_566" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_567" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_EffectiveIncomeTaxRateReconciliationLineItems_561" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_567" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_569" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_EffectiveIncomeTaxRateReconciliationLineItems_561" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_569" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensesPercent" xlink:label="loc_rtgn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensesPercent_570" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_EffectiveIncomeTaxRateReconciliationLineItems_561" xlink:to="loc_rtgn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensesPercent_570" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_568" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_EffectiveIncomeTaxRateReconciliationLineItems_561" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_568" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_ChangeInAvailableNolDueToDeconsolidation" xlink:label="loc_rtgn_ChangeInAvailableNolDueToDeconsolidation_678" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_EffectiveIncomeTaxRateReconciliationLineItems_561" xlink:to="loc_rtgn_ChangeInAvailableNolDueToDeconsolidation_678" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_571" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_EffectiveIncomeTaxRateReconciliationLineItems_561" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_571" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_572" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rtgn_EffectiveIncomeTaxRateReconciliationLineItems_561" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_572" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/IncomeTaxesDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_574" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_575" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_574" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_575" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_576" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_575" xlink:to="loc_us-gaap_StatementClassOfStockAxis_576" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_577" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_576" xlink:to="loc_us-gaap_ClassOfStockDomain_577" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_578" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_575" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_578" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_585" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_578" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_585" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_586" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_585" xlink:to="loc_us-gaap_IPOMember_586" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_584" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_575" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_584" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_588" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_584" xlink:to="loc_us-gaap_RelatedPartyDomain_588" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_FormerParrentMember" xlink:label="loc_rtgn_FormerParrentMember_589" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_588" xlink:to="loc_rtgn_FormerParrentMember_589" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_587" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_575" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_587" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_581" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_587" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_581" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_OperatingLossCarryforwardsExpirationPeriod" xlink:label="loc_rtgn_OperatingLossCarryforwardsExpirationPeriod_582" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_587" xlink:to="loc_rtgn_OperatingLossCarryforwardsExpirationPeriod_582" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_583" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_587" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_583" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/RelatedPartyTransactionsDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_482" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_483" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_482" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_483" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_484" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_483" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_484" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_485" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_484" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_485" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_486" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_483" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_486" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_489" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_486" xlink:to="loc_us-gaap_RelatedPartyDomain_489" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" xlink:label="loc_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_490" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_489" xlink:to="loc_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_490" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_OculusMember" xlink:label="loc_rtgn_OculusMember_494" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_489" xlink:to="loc_rtgn_OculusMember_494" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaap_RestructuringPlanAxis_488" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_483" xlink:to="loc_us-gaap_RestructuringPlanAxis_488" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_499" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_488" xlink:to="loc_us-gaap_RestructuringPlanDomain_499" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_MergerMember" xlink:label="loc_rtgn_MergerMember_500" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_499" xlink:to="loc_rtgn_MergerMember_500" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_498" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_483" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_498" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaap_SalariesWagesAndOfficersCompensation_487" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_498" xlink:to="loc_us-gaap_SalariesWagesAndOfficersCompensation_487" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_492" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_498" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_492" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_495" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_498" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_495" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_496" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_498" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_496" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_497" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_498" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_497" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_SaleOfStockNumberOfSharesIssuedInTransactionOmneOrMoreInvestorsPriorToClosing" xlink:label="loc_rtgn_SaleOfStockNumberOfSharesIssuedInTransactionOmneOrMoreInvestorsPriorToClosing_501" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_498" xlink:to="loc_rtgn_SaleOfStockNumberOfSharesIssuedInTransactionOmneOrMoreInvestorsPriorToClosing_501" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaap_SaleOfStockDescriptionOfTransaction_502" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_498" xlink:to="loc_us-gaap_SaleOfStockDescriptionOfTransaction_502" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/SubsequentEventsDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_471" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_472" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_471" xlink:to="loc_us-gaap_SubsequentEventTable_472" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_473" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_472" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_473" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_474" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_473" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_474" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_505" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_474" xlink:to="loc_us-gaap_SubsequentEventMember_505" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_475" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_472" xlink:to="loc_us-gaap_SubsequentEventLineItems_475" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_503" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_475" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_503" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_504" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_475" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_504" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_321" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_322" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_321" xlink:to="loc_us-gaap_StatementTable_322" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_323" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_322" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_323" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_324" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_323" xlink:to="loc_us-gaap_EquityComponentDomain_324" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_325" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_324" xlink:to="loc_us-gaap_CommonStockMember_325" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_326" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_324" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_326" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_327" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_324" xlink:to="loc_us-gaap_RetainedEarningsMember_327" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_328" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_322" xlink:to="loc_us-gaap_StatementLineItems_328" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_329" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_328" xlink:to="loc_us-gaap_StockholdersEquity_329" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_330" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_328" xlink:to="loc_us-gaap_SharesOutstanding_330" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_InvestmentFromFormerParent" xlink:label="loc_rtgn_InvestmentFromFormerParent_402" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_328" xlink:to="loc_rtgn_InvestmentFromFormerParent_402" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_InitialPublicOfferinfgValueOfUnits" xlink:label="loc_rtgn_InitialPublicOfferinfgValueOfUnits_673" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_328" xlink:to="loc_rtgn_InitialPublicOfferinfgValueOfUnits_673" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_InitialPublicOfferingUnits1" xlink:label="loc_rtgn_InitialPublicOfferingUnits1_674" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_328" xlink:to="loc_rtgn_InitialPublicOfferingUnits1_674" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForCash" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForCash_331" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_328" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForCash_331" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForCash" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForCash_332" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_328" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForCash_332" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_333" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_328" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_333" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_334" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_328" xlink:to="loc_us-gaap_NetIncomeLoss_334" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_335" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_328" xlink:to="loc_us-gaap_StockholdersEquity_335" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_336" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_328" xlink:to="loc_us-gaap_SharesOutstanding_336" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/ConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_338" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_339" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_338" xlink:to="loc_us-gaap_StatementTable_339" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_340" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_339" xlink:to="loc_dei_LegalEntityAxis_340" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_341" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_340" xlink:to="loc_dei_EntityDomain_341" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_342" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_339" xlink:to="loc_us-gaap_StatementLineItems_342" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_343" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_342" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_343" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_344" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_343" xlink:to="loc_us-gaap_NetIncomeLoss_344" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_345" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_343" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_345" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_346" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_345" xlink:to="loc_us-gaap_Depreciation_346" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_347" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_345" xlink:to="loc_us-gaap_ShareBasedCompensation_347" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_348" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_345" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_348" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_349" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_348" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_349" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_350" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_348" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_350" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_351" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_343" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_351" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_352" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_342" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_352" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_353" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_352" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_353" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_354" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_352" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_354" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_355" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_342" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_355" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_356" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_355" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_356" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_357" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_355" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_357" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_359" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_355" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_359" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_InvestmentFromRelatedParty" xlink:label="loc_rtgn_InvestmentFromRelatedParty_360" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_355" xlink:to="loc_rtgn_InvestmentFromRelatedParty_360" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_361" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_355" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_361" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashPeriodIncreaseDecrease_362" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_342" xlink:to="loc_us-gaap_CashPeriodIncreaseDecrease_362" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_363" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_342" xlink:to="loc_us-gaap_Cash_363" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_364" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_342" xlink:to="loc_us-gaap_Cash_364" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/ConsolidatedStatementsOfCashFlowsParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_366" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_367" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_366" xlink:to="loc_us-gaap_StatementTable_367" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_368" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_367" xlink:to="loc_dei_LegalEntityAxis_368" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_369" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_368" xlink:to="loc_dei_EntityDomain_369" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_370" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_367" xlink:to="loc_us-gaap_StatementLineItems_370" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_GrossProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="loc_rtgn_GrossProceedsFromIssuanceOfCommonStockAndWarrants_371" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_370" xlink:to="loc_rtgn_GrossProceedsFromIssuanceOfCommonStockAndWarrants_371" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_OfferingCost" xlink:label="loc_rtgn_OfferingCost_372" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_370" xlink:to="loc_rtgn_OfferingCost_372" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_OfferingCostWithheldFromProceeds" xlink:label="loc_rtgn_OfferingCostWithheldFromProceeds_373" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_370" xlink:to="loc_rtgn_OfferingCostWithheldFromProceeds_373" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_374" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_370" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_374" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="rtgn-20150331.xsd#rtgn_AccruedOfferingCosts" xlink:label="loc_rtgn_AccruedOfferingCosts_403" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_370" xlink:to="loc_rtgn_AccruedOfferingCosts_403" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/OrganizationAndPlanOfMerger">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_376" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_377" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_376" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_377" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.ruthigen.com/role/SummaryOfSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_379" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_380" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_379" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_380" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2XAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity (Details 5) (Restricted Stock [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">Restricted Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Units Non-vested</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Units Granted</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">409,355</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Units Vested</a></td>
        <td class="num"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">(85,308)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Units Forfeited</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Units Non-vested</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">324,047</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Non-vested</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Granted</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">$ 6.30</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Vested</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">$ 6.30</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Forfeited</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Non-vested</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">$ 6.30</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedGrantDateFairValue', window );">Total Grant Date Fair Value Non-vested</a></td>
        <td class="nump"><a title="rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedGrantDateFairValue[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedGrantDateFairValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
        <td class="nump"><a title="rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedGrantDateFairValue[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedGrantDateFairValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue', window );">Total Grant Date Fair Value Granted</a></td>
        <td class="nump"><a title="rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">2,579,000</a><span style="display:none;white-space:normal;text-align:left;">rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
        <td class="nump"><a title="rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodGrantDateFairValue', window );">Total Grant Date Fair Value Vested</a></td>
        <td class="num"><a title="rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodGrantDateFairValue[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">(537,000)</a><span style="display:none;white-space:normal;text-align:left;">rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodGrantDateFairValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
        <td class="nump"><a title="rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodGrantDateFairValue[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodGrantDateFairValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodGrantDateFairValue', window );">Total Grant Date Fair Value Forfeited</a></td>
        <td class="nump"><a title="rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodGrantDateFairValue[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodGrantDateFairValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
        <td class="nump"><a title="rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodGrantDateFairValue[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodGrantDateFairValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedGrantDateFairValue', window );">Total Grant Date Fair Value Non-vested</a></td>
        <td class="nump"><a title="rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedGrantDateFairValue[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">$ 2,042,000</a><span style="display:none;white-space:normal;text-align:left;">rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedGrantDateFairValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
        <td class="nump"><a title="rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedGrantDateFairValue[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedGrantDateFairValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodGrantDateFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of grants made during the period on other than stock (or unit) option plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedGrantDateFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodGrantDateFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>19
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0!(WZ?U$0(``!T=```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,F=%NVC`8A>\G[1TBWT[$
MV,[:;B+THNTNMTIK'\!+?DA$8ENVV\';SPDMJBH&0D/:N2&"V/_YL)3O(F=V
MO>Z[[)E\:*TIF<BG+"-3V;HURY(]/GR;7+$L1&UJW5E#)=M08-?SCQ]F#QM'
M(4N[32A9$Z/[RGFH&NIUR*TCD^XLK.]U3%_]DCM=K?22N)Q.+WAE3203)W&8
MP>:S6UKHIRYF=^OT\Y;$4Q=8=K-=.&253#O7M96.B90_F_I=RN0E(4\[QS6A
M:5WXE#`8WYLPW/E[P,N^'^EH?%M3=J]]_*[[A,'7'?]M_>J7M:O\\)`]E':Q
M:"NJ;?74IQ/(@_.DZ]`0Q;[+QVO>Z]:\<A_('Q<'/E[$F4&&_S<./I%#@G`H
M$(X"A.,S",<%",<E",<5",<7$`XQ10%!,:I`4:I`<:I`D:I`L:I`T:I`\:I`
M$:M`,:M$,:M$,:M$,:M$,:M$,:M$,:M$,:M$,:M$,:M$,:M",:M",:M",:M"
M,:M",:M",:M",:M",:M",:M",6N!8M8"Q:P%BED+%+,6*&8M4,Q:_"^SQE3^
M$!\___UY&<<<:1]"W'04SOS&<#OT6'*C/=4_HT\UV=D!WLX^PE'IKKII4E]T
MYD/8S3V4GTJL>V]=2'6>I],!7ONZ8??$I4'D8TN[QFY?\[5+3%7@Z8'OJC<:
MRL::ZCW9?"PWYW\```#__P,`4$L#!!0`!@`(````(0"U53`C]0```$P"```+
M``@"7W)E;',O+G)E;',@H@0"**```@``````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````C)+/3L,P
M#,;O2+Q#Y/OJ;D@(H:6[3$B[(50>P"3N'[6-HR1`]_:$`X)*8]O1]N?//UO>
M[N9I5!\<8B].P[HH0;$S8GO7:GBMGU8/H&(B9VD4QQJ.'&%7W=YL7WBDE)MB
MU_NHLHN+&KJ4_"-B-!U/%`OQ['*ED3!1RF%HT9,9J&7<E.4]AK\>4"T\U<%J
M"`=[!ZH^^CSYLK<T36]X+^9]8I=.C$">$SO+=N5#9@NIS]NHFD++28,5\YS3
M$<G[(F,#GB;:7$_T_[8X<2)+B=!(X/,\WXIS0.OK@2Z?:*GXO<X\XJ>$X4UD
M^&'!Q0]47P```/__`P!02P,$%``&``@````A`&[?[9\]`@``5AP``!H`"`%X
M;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<R"B!`$HH``!````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````+R936O;0!"&[X7^!['W>CTS:R<ID7-H*>3:
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M<0QQ;N;$2=E`(2_XTN2G0WOZA+=HE?TW7WM7OJT^U;[ISB#3*;05L^[$Y+<S
MQ'3J17DW"$:[2F"1D+;O"/J.M7W'T'>D[3N"S<3:OF/H.]&N9(&E+-I=+K#-
MW:SFFPSSNG3<$EG'K>84\34X*X2C30-A2)N&(`YK)W2&"9VU$SK#A"[:$TO@
MQ'*S3JQ8^S%LOZ4Q/R[&<ZM?G$9M1=K2(2@=FG5SKI`.P7$NVN-<X#AWVN/<
MP7&N3H,*6;MP8-V0]M80O%&LG;L8YB[6SET,<Y=H*U"@`D4[6PC,%DX[6SB8
M+=RLV2*F8YM?ITXO*?X>(\W,>ODKYA-.-LH)'=X9TI8,0<F0MF0(2H:UNYIA
M5XMV5PNL'=%N*X%]Y;2?&!Q\8F#M`<5P0#GM4.Q@*-:F@3#:A3/5C;WX-W#S
M!P``__\#`%!+`P04``8`"````"$`P-,3-/4#``!F#@``#P```'AL+W=O<FMB
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MGK4NJ#+_4O(4[MYX8\\>W3=%KI65L`TM4QU!>6_JX)?KN^ZT^F5EQ0_.]L5Y
M415:AY]<)')?_12L/3:1!PGLZUL_>:)W<'\\'C?7'AG?[O3;19`?(?W:07A.
M_6F)NKPW1\A<)"00FNLC68J3^US"%E:N+Z$RQ[;4+8<O:IDX5>)89;%Z"E??
ME@_S*'@@7^;?YD^+@(2/01"%2,)%$NX`";*F2,5#*K77[R821I#/]^`I"LGJ
M*UFM`Z3B(Q6_-Y>VRN)QCE3`]\:4R1"5.?9EBE1J)JZL:#$/85>:'?J(9#YV
MDUFI+17\3\T[@:XDZY0*(C?D.U-;AE1\+/.I*Q.664;5L5H8\JW@T%14:#*/
M8UD*C66@_1MK;KHR:\5RR@&X`W1[P8HZHY7>,446I<(R-TC&&9LZ,"X4(%M5
M%/PJ>5YU-UH_@=YITG`,;E_S+H"P(WU.6:T#%U7)0`_KM/`WX959QG7U[%,I
M"PF=)+8P$#F,O?,637`+.`:]H9;QRTZF"0RANAQ]Q(LQ^8X![1*F;\9(1`_M
M1V+2'0/2?ZL9",6N:65CI*@H:%P/1?QDS+EC(!J6SP7[54+U)/A=>8"78K@=
M`\M^GC#=$\RE,Q!,L+UIDPDFTQF(9BLCS"8,Z<Y,7*M+;,+^`&?8H2E&U!V(
M*,YGBAEU#48OP'4A&0RH:P"*&;NP&`/J&H#VCR!<B8MY@Z#C;#\TD$2SUW#$
MGMO_=-[BV=HO!(US%L+TN0,QAFK.0I@^U\"X?S!BC-T6?1<PODC?`].4IQ@_
M#^,'0<?K=RA^U<&;YF'\(.@(]8]:7)F'&82@([3HF[4$63W%D\\S6+[4#Q?L
M:8D83/>(D)8YF&CX"]>IJ4^F90WFV3,'L7E^D->2"&X+#],,P8!L<%-XF&4(
M!LC@EO`PR1`,D(D8VF\?DPQ!1Z<UN\R-]C&^$%RQNK7#/J86@FO6XZWU\?"$
MX)KU$3OHDL(+2C->?(PK!!V5]T_[BA.L@WGU35Z[)WZ#6942UL'`^C6PHSI9
M>`V):1K#^U'U4;]@^)/IZ?@;O;TBWO\/``#__P,`4$L#!!0`!@`(````(0`8
MT%0-N0,``*(,```8````>&PO=V]R:W-H965T<R]S:&5E=#0N>&ULE)=1CZ)(
M$,??+[GO0'A7:%!0(TY&)W,[R6VRN=SN/2.T2@9H0K?CS+??*@J1;CV#+S/2
M_/GWKZK+HEP^?1:Y]<%KF8DRLMG8M2U>)B+-RGUD__SW=32S+:GB,HUS4?+(
M_N+2?EK]^<?R).IW>>!<6>!0RL@^*%4M'$<F!U[$<BPJ7L*=G:B+6,%EO7=D
M5?,X;1XJ<L=SW<`IXJRTR6%1#_$0NUV6\!>1'`M>*C*I>1XKX)>'K))GMR(9
M8E?$]?NQ&B6BJ,!BF^69^FI,;:M(%F_[4M3Q-H>X/]DD3L[>S<65?9$EM9!B
MI\9@YQ#H=<QS9^Z`TVJ99A`!IMVJ^2ZRG]EBPP+;62V;!/W*^$GV/EOR($Y_
MU5GZ=U9RR#:<$Y[`5HAWE+ZEN`0/.U=/OS8G\*.V4KZ+C[GZ1YR^\6Q_4'#<
M4X@(`UND7R]<)I!1L!E[4W1*1`X`\-<J,BP-R$C\V?P_9:DZ1+8?C*>AZS.0
M6ULNU6N&EK:5'*42Q7\D8JT5F7BMB0_T[7UOJ(E#0$U\+[&*5\M:G"PH&MA2
M5C&6(%N`\3DPPNA"_;]((40T>4:7R(9JAR`D',_':CI;.A^0T:25K*\E3%=L
MS@H\"*#K$"'N/N+MG)])4(PD>`:(MJ8%\.[0/&/?&XIY)]%(($'#25`<V6#>
M;3R]V!(;28(F86ZW97-O<_N>AC-Y!`?%4'8]G,#8<DV229>[36]!VQAJ=G@>
M4*SG(3!.?DV2L,F#Q\*9ZQIHF[Z"^3-H?Q>%AA8\@H9B`\THCC5)"&TR]6'?
MR\9T4'T%"_V@K]#0PD?04&R@^7J%K$E":$'HWLA:7^$SIBDT-'Q/];K`_:\8
MB@VTB8%&$D(;W6;3)'?AYH_`H=@H\ZD!1Y)>F?<6M*PP>$\,3TNC-O(2&%NW
M&DH,"_NE0L74"B9&2]"QL%$./BU&;;7?AX+0Q"+-'2P2W,?"/CH<B[JNAG7U
MRB`-]<=1$,S9C81IFKMUQ+"E#@>D!JPU3+-_-XZ1W2NE_HI^:`\U:T:=MY^=
MT.@[ZU8S;TIEQ,:^0;<Q!=-+`]'1C':.,X`/I7^_"^#X8WS30K.OMYI^?NBI
M9D6'>*AQPZQG]J#0[-RMAHIZ,O/\N6O4/8Z,:$,2S_4#W[V$0'@T$M+(5/!Z
MSS<\SZ65B"..>QXDOUOM1M%G#U^AQOH:1U1<=[H;,"%6\9Y_C^M]5DHKYSNP
M=,<AY*BF&9,NE*B:06TK%,R&S<<#_!;@,-ZX8Q#OA%#G"]R@^W6Q^@T``/__
M`P!02P,$%``&``@````A`):6I?O6`@``Q0<``!D```!X;"]W;W)K<VAE971S
M+W-H965T,S8N>&ULE%5=;YLP%'V?M/]@^;U\)80F"JF:=-TF;=(T[>/9,0:L
M8HQLIVG__:YQ8$#:*GW!V#X^/O?<RV5]\R0J],B4YK).<>@%&+&:RHS718I_
M_[J_NL9(&U)GI)(U2_$ST_AF\_'#^BC5@RX9,P@8:IWBTIAFY?N:EDP0[<F&
MU;"32R6(@:DJ?-TH1K+VD*C\*`@6OB"\QHYAI2[AD'G.*;N3]"!8;1R)8A4Q
MH%^7O-$=FZ"7T`FB'@[-%96B`8H]K[AY;DDQ$G3UM:BE(OL*XGX*YX1VW.WD
MC%YPJJ26N?&`SG="SV->^DL?F#;KC$,$UG:D6)[BVW"U2["_6;?^_.'LJ`?O
M2)?R^%GQ[!NO&9@-:;()V$OY8*%?,[L$A_VST_=M`GXHE+&<'"KS4QZ_,%Z4
M!K(=0T`VKE7V?,<T!4.!QHMBRT1E!0+@B02WE0&&D*=V//+,E"F>+;PX"68A
MP-&>:7//+25&]*"-%'\=*#Q1.9+H1`+CB22:77P8D*T"&$^'P^A2!;Z+IC7G
MCABR62MY1%!PH%<WQ)9ON`+BSA470^_3:S:!/Y;DUK*D&+X4<$!#:A\W<9*L
M_4?(!SUAMN>8<(S8=0B;1I#7:P2WAAI?SE@GQ8*M%)M!JVWK%H"[UQ9-[GT!
ML>PA(R7@T%")=6O^:@UUBNPAJ):!@#@.>GXGTF'FO>K=8&&D8#Y6\+87%IQB
M"*\/?19-;W:89-EF+?06R:>KJ3\.`L^>9OX_=2-UX,70G[?56?!4W6SBB\,,
MKXZ3ZS%FUV&F9;-XCQ@+GHJ9CR_:.LS)JL!;QN/]G=L?BGW-I^0]TBQX*FUR
M]=9A.FD376[S35VN;;K.()@JV(Y5E494'FQ+C*`X^M6^6]]&MEPGZUOHXFW/
M\_L-Z*(-*=AWH@I>:U2Q'"@#+X&\*=>'W<3(INU'>VF@?[:O)?PN&7S$@0?@
M7$K336RN^Q_PYA\```#__P,`4$L#!!0`!@`(````(0"2299PB`,``*(,```9
M````>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;)Q7VVZ;0!!]K]1_0+S'>,'@
MBVQ'2:.TD5JIJGIY7L/:7@58M+N.D[_O[`X&#,27O-@&SLR9.3,[C.>WKUGJ
MO#"IN,@7+AD,78?EL4AXOEFX?WX_WDQ<1VF:)S05.5NX;TRYM\O/G^9[(9_5
MEC'M@(=<+=RMUL7,\U2\91E5`U&P')ZLA<RHADNY\50A&4VL499Z_G`8>1GE
MN8L>9O(2'V*]YC%[$/$N8[E&)Y*E5$/\:LL+=?"6Q9>XRZA\WA4WL<@*<+'B
M*==OUJGK9/'L:9,+25<IY/U*1C0^^+87'?<9CZ508JT'X,[#0+LY3[VI!YZ6
M\X1#!D9V1[+UPKTCLWLR=;WEW`KTE[.]:OQVU%;LOTJ>?.<Y`[6A3J8"*R&>
M#?0I,;?`V.M8/]H*_)1.PM9TE^I?8O^-\<U60[E#R,@D-DO>'IB*05%P,_!#
MXRD6*00`GT[&36N`(O35?N]YHK<+-X@&X7@8$(`[*Z;T(S<N72?>*2VR?P@B
MI2MTXI=.X+MTX@?GC#T,Q.;U0#5=SJ78.]`L0*4*:EJ/S,!A?R*0@<'>&?#"
MA6:&&!6H_[(,Q].Y]P**Q27F'C'P66%(A?"`M&(&MLN9#=@P&TE-*/=XHTGC
M]].`-$T:4['1NQ4[)&J,H#:-),)P6/G'"!`SLOW2S&O4)0R@T4XK:XP6+B15
MJ19.VH2(&5G=ZV='FD)BS61/<QIPF[.N%2:)F+'E#`(_'+Y#'%U#;,!MXKIZ
M2(R8D\F.K^$TX#9GT*HH8C#9&Q)%T:@"'*ELIGGCS)B6.E]A8]0.H/:/22.F
M5)N$DR#J#V#ZD0",43N`L/*/`2`&`YB0T*^K<B0`@7Z^7@%KU8J@(3%&4(*B
M4UU.S(RYN@#6JDW?[O<2-+7TT2`85P(="]`:7I>U`,&A=7S*ZQ*7`B#HM``]
M0^U\!Q*<6$?T4?L,E*"S`GQHRI&>,=?M``2=C:`UZRXL0<_0B]JGP+S1X:B<
MC:`U]"Z,H&?Z19TF.(R_YOO@O5YLS<$+P^@;B).JV\M>1!`4I/%:JE_XQT?B
M0U.1](S%J$ZT#`-!IX_$AV8B[(J=H1AU5$!0/SVNBKA294QNV!>6ILJ)Q<ZL
M@03F2'6W6E'O?+LT5`]@0RSHAOV@<L-SY:1L#:;#P1C:4.*.B1=:%'9A6PD-
MNZ']N87_`@SVH>$`P&LA].'";+'5OXOE?P```/__`P!02P,$%``&``@````A
M`":?/451`P``V0H``!D```!X;"]W;W)K<VAE971S+W-H965T,S@N>&ULG%9=
M;YLP%'V?M/^`_%X($)(0A51-JFZ5-FF:]O'L@`E6`2/;:=I_OVN;4'#:E/4E
M!/O<XW//]35>73]5I?-(N*"L3I#O3I!#ZI1EM-XGZ/>ONZL%<H3$=89+5I,$
M/1.!KM>?/ZV.C#^(@A#I`$,M$E1(V2P]3Z0%J;!P64-JF,D9K["$5[[W1,,)
MSG1057K!9#+S*DQK9!B6?`P'RW.:DEN6'BI22T/"28DEZ!<%;<2)K4K'T%68
M/QR:JY15#5#L:$GELR9%3I4N[_<UXWA70MY/_A2G)V[]<D9?T90SP7+I`IUG
MA)[G''NQ!TSK548A`V6[PTF>H!M_N?5#Y*U7VJ`_E!Q%[[\C"G;\PFGVC=8$
MW(8ZJ0KL&'M0T/M,#4&P=Q9]IROP@SL9R?&AE#_9\2NA^T)"N2/(2"6VS)YO
MB4C!4:!Q@T@QI:P$`?#K5%1M#7`$/^GGD6:R2%`X<Z/Y)/0![NR(D'=442(G
M/0C)JK\&Y+=4AB1H2>#9D@3AZ&!`:@7P;(/]8*P"SV2CS;G%$J]7G!T=V'&@
M5S18[5]_"<2ONP$V*.R-`B<(.@(2%5#"QW443U;>(]B>MIB-P<!OA_&'B.T)
MH:H%*CHI8,IX*0JLI*A"*6T;,]!?-[#6?041=Y"!$C"BKT1ME>F;6^5DC@J"
M3=%+/(IL<PQFVJG>]@8&"J9#!9?+HL`)@O0ZRZ/8,GUC,+$NVLP-YUWBVKVM
MF9[IZ1?1`TE@@&U*"%UX69H*LJ59==D8S%RO'?K1(IQ9X@Q@>DG<["/B5)`M
M+ARNO3$8L.?%V\7+KC'FG3#VAIY_1)0*LD5-+5$&8QQ;^%%@.;HU\WJ;#4JH
MOF6CFUV!;2&1)<1@>ONY-S!8.1ZN/*ZC5-!['64P/06]@8$"'_;J^.0UVL[>
M[JD6]&93M?/G=?#5$=@KA++C_5[24;8FJ_2;%G2AFUK$*ZK4`?G_JLRQ.CQ]
M["[R#>AR&W4@NX_@6O`18>9L'0JS.TE3)^CM5FH!/;?,#<-\1"O"]V1+RE(X
M*3NHVX,/IU0WVMUL;@)UY'O=!%PL&KPGWS'?TUHX)<DA=.+.X:3CYFIB7B1K
M]"=ZQR1<*?3?`JZ0!#YX$Q?`.6/R]*(6Z"ZEZW\```#__P,`4$L#!!0`!@`(
M````(0#4ZDMK[@,``(P.```9````>&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM
M;)2776^K.!"&[U?:_X"X;_@F)4IR5*BZ>Z0]TFJU']<$G`05,,).T_[[G6$(
MBQV2#3=ML%_&C\?C%WO][;,JC0_6BH+7&]-9V*;!ZHSG17W8F'_]^?;T;!I"
MIG6>EKQF&_.+"?/;]N>?UF?>OHLC8]*`"+78F$<IFY5EB>S(JE0L>,-JZ-GS
MMDHE/+8'2S0M2_/NI:JT7-L.K2HM:I,BK-I'8O#]OLC8*\].%:LE!6E9F4K@
M%\>B$9=H5?9(N"IMWT_-4\:K!D+LBK*07UU0TZBRU?=#S=MT5\*\/QT_S2ZQ
MNX>K\%61M5SPO5Q`.(M`K^<<69$%D;;KO(`98-J-ENTWYHNS2IS(M+;K+D%_
M%^PL1K\-<>3G7]HB_ZVH&60;U@E78,?Y.TJ_Y]@$+UM7;[]U*_![:^1LGYY*
M^0<__\J*PU'"<@<P(YS8*O]Z92*#C$*8A1M@I(R7``!_C:K`TH",I)_=_W.1
MR^/&],)%L+0]!^3&C@GY5F!(T\A.0O+J'Q(Y?2@*XO9!/*#O^]U'@U@$U,WO
M-97I=MWRLP%%`T.*)L42=%80^#(QPABF>FNF,$4,\H)1-B94.TQ"P/)\;(,H
M7%L?D-*LU\37&D=5)!<%K@3@#8PP\3'C=-(O*"A&%%P$9(NI`6(/;*XV[H0B
M&B0*"63H<1(4;TP(/@P<1,LA+L&1QA]HDU&#,K*OCHSKY-\LP$LN\"4HM3%!
M8&L$I!D1C!H4`ACM\;FC6)_[LS8R:?RN7#2J9+I/X0GG\*!8Y_EOC6DM2+/L
M>'P[\H)`!4Y(H`,K4,LY4"A6H4);2T1,&H)Z>@X\6\MB0H*[4/@5&NWQ^_L'
MQ3J4ME%CTNAC=EE,ION4)$5S>%"L\@21EH.8-)0DS_5M7]MF"0ET8`7*@8_"
M.$NXPSQHNY^M[BT5+[0U?XE[43A9Z3<Z539TQM$*/LA&?CHVH-#VU)J.'1)%
M'5NXT+J3OEM'5^G0/^?3D>NJ=+Y.1Z*;=-1]GPX==3X=^;!*I_E![)!('Y[V
MP8U.-7,3KOY`S9%#JVQ7-4>BFYFC;AU=I9OE^'@<TC9J:%^=`4BD#]MG;+I3
M99KE^LZU[8>VY@UQ+R+W<(-E9.LFG/22^_XQR_J=*>_7;:T7]>8?>,L)L@?L
MWYGE_YU:=S3]4]F+](3TZ_C`)P`.Z\JN_!^7O?X(3-06B:BV7-N'*Y+V,<4K
M`M:H7GY4873XI\-QQ=H#2UA9"B/C)SS8NV"00^MPZ7AQ\>2FM<=X&<%V:^B`
MNT"3'MB/M#T4M3!*MH>0]F()%=_2;8(>)&^Z(_F.2[@%=#^/<.MC<(ZU%R#>
M<RXO#SC`<(_<_@L``/__`P!02P,$%``&``@````A`+^7`Y&+`P``!PP``!D`
M``!X;"]W;W)K<VAE971S+W-H965T,S4N>&ULG%9=;Z,X%'T?:?\#XGT`)Q":
M*&34;M7=D6:DU6H^GAUP$JN`D>TT[;_?>VU"P"1-MB])(,?G?AT.=_GEM2J]
M%R85%W7FDR#R/5;GHN#U-O-__GCZ?.=[2M.ZH*6H6>:_,>5_6?WQ:7D0\EGM
M&-,>,-0J\W=:-XLP5/F.550%HF$U_+,1LJ(:+N4V5(UDM#"'JC*<1-$LK"BO
M?<NPD+=PB,V&Y^Q1Y/N*U=J22%92#?FK'6_4D:W*;Z&KJ'S>-Y]S435`L>8E
MUV^&U/>J?/%U6PM)UR74_4IBFA^YS<6(ON*Y%$IL=`!TH4UT7/,\G(?`M%H6
M'"K`MGN2;3+_GBP>R)T?KI:F0;\X.ZC>;T_MQ.$OR8MOO&;0;9@33F`MQ#-"
MOQ9X"PZ'H]-/9@+_2*]@&[HO];_B\#?CVYV&<2=0$1:V*-X>F<JAHT`33!)D
MRD4)"<"G5W&4!G2$OIKO`R_T+O.GLR!)HRD!N+=F2C]QI/2]?*^TJ'Y;$&FI
M+,FD)8'OEF02!22.9M<Y0IN/*>^1:KI:2G'P0#,04344%4@6P'N^'B@$L?<(
MSGS0-*2J8`@OJV0V7X8OT+B\Q3Q8#'QV&-(A0@C:189HMT=&,$;&SF(J#_9&
M/\SD?)CI,`P.+KXXN&.A>`A&U"LB2:*.WV9@,;&13;^N>!QP"GI[O[-X*/.A
MJ*YK(`XGH,6DIN]3$B>S7DJ#SD)Y_<YBR=<SP$-.!LG4R<!B((]3EDG<808Y
MS#Z2`QYR<DA/ZK%MMYBN"]'D4A?280;O]Q_!;N23H&QDBQD/'#V^]PC=IC`\
M=$UA%C,..!\&?+\R!+N5N7.UF-@H*P4#.S]2`BIV"[VN*W/*3<"5=@MJIQK%
M:1*=(`-=$?07I]LW)&%=:?!\C=1MJ,$=^O).+\B;H/_\_S2L:PW2&`G<4&?^
M+;UPO.U](1!K6,/@IU%;C;>@L>8(NH]3\'4?-:>NR;P%G8GI&-F5^LXX6.HJ
M'=_9\#A8J<\#?'5>$/N'#(R<<["3DML>]RUL?D<N&1AQ'.PV'S>GG.=M+/6C
ME_6</)U=Z,09?[OAB;/F-52;Z^6PL>$TK-3G$WCJG13L/F87EHK)+?N3E:7R
M<K''78N`875WNSWP?F)>R=T?L(8U=,N^4[GEM?)*MH&C49""$J1=Y.R%%HU9
MA]9"PP)F?NY@X6:P;40!@#="Z.,%KHK="K_Z#P``__\#`%!+`P04``8`"```
M`"$``&UHQ.\#```:#P``&0```'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6R<
M5UV/HE@0?9]D_P/AO?D2<#3JI'L[O=O)3#+9[,P^(UR5-'`)]]IV__NMNH5\
M7%")+RIZJD[5J>+@77W[R#/CG54BY<7:="W'-%@1\R0M]FOSU[\O#U]-0\BH
M2**,%VQM?C)A?MO\\65UXM6;.#`F#<A0B+5YD+)<VK:(#RR/A,5+5L`O.U[E
MD83+:F^+LF)1HH+RS/8<)[3S*"U,RK"LIN3@NUT:LV<>'W-62$I2L2R24+\X
MI*4X9\OC*>GRJ'H[E@\QSTM(L4VS5'ZJI*:1Q\O7?<&K:)M!WQ^N'\7GW.IB
MD#Y/XXH+OI,6I+.IT&'/"WMA0Z;-*DFA`Y3=J-AN;3ZZRR?/-^W-2@GT.V4G
MT?ELB`,__56ER?>T8*`VS`DGL.7\#:&O"7X%P?8@^D5-X&=E)&P7'3/Y#S_]
MS=+]0<*X`^@(&ULFG\],Q*`HI+&\`#/%/(,"X-7(4UP-4"3Z4.^G-)&'M3D+
MK6#NS%R`&ULFY$N**4TC/@K)\_\(Y-:I*(E7)X'W.HGG6*[OA+=SV%2/:N\Y
MDM%F5?&3`3L#C**,<`/=)>0=[P<:0>PC@M<F[#24*F`([YO`7ZSL=Q`NKC%/
MA('7!N,V"!M(&V9@F\Z,8&1&9;&4)_JB2^.-T\SZ-#@X_^+@SHUB$(RHTT00
M.$U^JH`P:N=Z??E#PAGLVW5E,6AM0E.-:D'0ZD:$A)DKW6>N'X2=DGH50'M=
M9;'EVQ5@D%Y!*RE50)BF`L>[5$%X3P48I%<PTT0G#"C1T<EO,#T5YOT:KNN/
M8)T[:/)2]X09#AP]OG,+3=LP#+JU8809$BZ&A+?GBT%ZAZ'6(6$FS->%A>[V
M?%U<A=:YYQIW#2+RP'?:VZTW51?]I:/V#69RH_Y]]55G)I"O;JQ+M.@WTVG)
MG?JT`Z,DT'7:$?>Z/6J7K*E/K[M)#6J&?=E.W+L<347I0]<-I08U15QV%'S8
M=@<PS=14E%9$V(Z8[NL:1(.86ZWE]!?O+D]S1TPM'(SB[&KX1%U83GM;]BO0
M'&VB!"/6%@[F</8VK*#5IT\_XG,3=I%,K+>+82MQ/8&STUVCO\OUW!';"]L'
M1DU/H&8!VOGT!/`TTYNFOXK25U!_M-2@IH+&H?H%:-XWL8`1#PS;%2,)O+,'
M3GBP>FA<'2^<6`;976\1`GT15&KX@S;E^>[=Y8TJ2A^'_BRJ05>M&4X;]ZB`
M43J]_D!2J5&%L=N!CBCT'SYGU9[]R;),&#$_XO'#A9CFV^9H].BIPTWS`YQ,
MRFC/?D35/BV$D;$=A#K6'#RVHK,-74A>JA/"EDLXDZB/!SB#,O@#[E@`WG$N
MSQ=X>FI.M9O_`0``__\#`%!+`P04``8`"````"$`FH*-B]$6``#CH```&0``
M`'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6RDW5MSV[B2P/'WK=KOX/+[B:V;
M):N2G!J)!`C>R=K+L\=1$M?$5LKV3.9\^T,*E`CTGVO)VGE(G%\:L,060723
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M</^\?=E^??W03'=E7RC?\^W5[54ST^>/7QZ:=]`>]HOGS==/E[^-EO7M]/+J
M\\?=`?J?A\VO%^?KBY?OVU_Z^>%+^O"T:8YVDZ<V`[]OMW^TH>9+2\W@*XQ6
MNPR4SQ=?-E_O_OSQ6F]_19N';]]?FW3/FG?4OK'EEW\%FY?[YH@VTWP8S]J9
M[K<_FA?0_'KQ^-!^-)HC<O?W[O=?#U]>OW^ZG-Q\F,VO)Z,F_.+WS<NK>FBG
MO+RX__/E=?OXOS9HU$UE)QEWDS2_=Y.,9A^FX]E\\9Y9)MTLS>_GOY1I-\G\
M,,EH_.[WTYP<NX/2_/[_>#^WW2S-[^>_GU'SB;`):C\:W<$?O__@C@Z);K[H
MYWEOID?[5+=?'*8Y^8,RVN>X_>(P_-WY&>VSW'YQF.;T5]%\LNTQ;;[8#Q^=
M<4QO]O,T7^SG.2<WS8?5OA[O4SN:7M^\XR0<[3^U[1?[5S/ZL)C-IC>+^=&3
M^<HN#+MU)KA[O?O\\7G[ZZ)9O)O/R\O/N_92,%JV4^]7&+L>'-:<_VO):=::
M=I;?VFD^73;CF]7DI5DG__H\G5]_O/JK6=ONNYB5C6E^=6)&?LR:\XB(8!_1
M+G;MMP[W\,:T:A^S'Z0E1!::7_L7-[GQ7YS9#W)BYN+EQ?N8_7=*]N`,DA.G
M^YC]H,R"78;;-YE+*"24$BH)M0-73?8/'X'F7/<^`L,7EWVFV^@VT_O7NMJ#
M\P;G8__(K6U,\P(.1U=$!)QE?.M/$C)D.I_Z,6HH9N;'Z*$8D>IH(&:R\.<Q
M`S'SN1\3#\6(>9*A&/'>TX&8A3B_,L:,1A/_]>2,F2[$1[@8BA'I*H=BQ/>J
MAF)$ONJAF#Y?WL>TN::\XV/:1GL?4PEK"^YG<CH7;R&0@T()2H*6$$DP$F()
MB8140B8AEU!(*"54$FH'O"/?7(:](]]>(R;-AN7MA:(=U<0YY_QT(4ZSE8W9
M;:!WB_E:0B`AE*`D:`F1!",AEI!(2"5D$G()A8120B6A=L#+0'-]/R,#[:A/
ME\TI=EAUIPNQ0*ULC),!"8&$4(*2H"W,;W<;@>L/(_%-(SG`2(@E)!)2"9F$
M7$(AH9102:@=\!+2;`F]A+Q]*K31?B(F8M%=V1`G#Q9N=H=P=#UIMO+78L$/
MO)#9;#Y"2"BG51*TA$B"D1!+2"2D$C(+]MW<WN!UYG)`(:&44$FH'?!RU6R[
MO5R=MGRUH_R<31?BRKVR,4[2+,QW29LLFK>)G,DAH00E04N()!@)L81$0BHA
MDY!+*"24$BH)M0->2II"P4O)VZ=/&RU3(39(*QOCI&(/;2UR>]OO*7;7F6#_
MM_M=;"A!2=`2(@E&0BPAD9!*R"3D$@H)I81*0NV`EX:F=_&.-+31(@VW8DE:
MV1A[`HR:)<O??J[=OVY:B?+O@R-_']J_[[.L)&@)D00C(9:02$@E9!)R"86$
M4D(EH7;`RU+;)'I'FG;A,D_R<M,%]4=R#0D@(41!-"2"&$@,22`I)(/DD`)2
M0BI([8J?C+:*E@V3XYOAMD'7G#QO[X:[(#<I=E@O`6)"B()H2`0QD!B20%)(
M!LDA!:2$5)#:%3\I;1EY1E)L]>EMD&]%I;MJ6Z%-YOH4K"$!)(0HB(9$$`.)
M(0DDA620O!.[5,^NY^(*66!$":D@M2M^BMKBTDW1VY?\MH.,BXVHSE==D)L:
M.ZR7`#$A1$$T)((82`Q)("DD@^20`E)"*DCMBI^,MLYTDW':EKCMQQ]?Q)P:
MUM;TW3`W*3(F1(R":$@$,9`8DD!22`;)(06DA%20VA4_*6VM>492;(GJ+V*B
MS;9J[QF*14Q*@)BPDZZ<F7*_IKR(\8P1&K-&$`.)(0DDA620'%)`2D@%J5WQ
MD]86G6<DS=:J?M+$"KP:.05M=R9)"1`30A1$0R*(@<20!))",D@.*2`EI(+4
MKOA):<O.,Y)BJ]4C>S2GI.V2(B4820DA"J(A$<1`8D@"22$9)(<4D!)206I7
M_*2T1:B;E",;`%NS^F>(;!^W-RS%LB8E0$P(41#=R7YW)`O5"",,)(8DD!22
M07)(`2DA%:1VQ4]-6WFZJ3EQ.V`+5C]%HM6[&CE5;7>^2`D0$T(41$,BB('$
MD`220C)(#BD@):2"U*YX21G+JO^TI.R&'2LTNZ!^1[:&!)`0HB`:$D$,)(8D
MD!2207)(`2DA%:1VQ4^*K/[?7L3&MGQWSQ`T_KL8-Q<H^A$30A1$0R*(@<20
M!))",D@.*3JQ:^IMNU>4RVJ)016D=L5/3G.<L8Q-FWWND22UPV2_3';ZQS;(
MS9*4`#$A1$$T)((82`Q)("DD@^20`E)"*DCMBI\46?>?N(S90O[MO=C8!KE)
MD1(@)H0HB(9$$`.)(0DDA620'%)`2D@%J5WQDR+K_R-GB"W7FP_\X48RES%9
MTJ_'4@)("%$0#8D@!A)#$D@*R2`YI("4G=B%;;$8*(,K#*I=\9/35N;N;NQ(
M<FPA[R9G>BOOCK4/&OH;94@`"2$*HB$1Q$!B2`))(1DDAQ20$E)!:E?\9)Q7
MWX]MH7YD^9+5_+H;UB]H`22$*(B&1!`#B2$))(5DD!Q20$I(!:E=\9/2UM?N
M&7+B-<66Y=Z9@N=AQK)V7T,"2`A1$-W)X:F8A6AG1QAB(#$D@:20#))#"D@)
MJ2"U*WZ.WE?NCUGN-\NH?_=XU07UI\<:$D!"B()H2`0QD!B20%)(!LDA!:2$
M5)#:%3\9YQ7X8UNI'UG%9#F_[H;U:0H@(41!-"2"&$@,22`I)(/DD`)20BI(
M[8J7E/:F,5:QVZ./5>Z&^>7*[%K>WN^"^A2L#]+OX6;7XEYG<`@Z/!8#41`-
MB2`&$D,22`K)(#FD@)20"E*[XN=)UORG76TFK/UGUV+)7W5!;IY0_",FA"B(
MAD2=V%WJ[N$;N<`:#(HA"22%9)`<4D!*2`6I7?&SU);C[I[@[5WSI`V79Y&\
M:]8%N=FQPWH)$!-"%$1W<M@+B/,WP@@#B2$))(5DD!Q20$I(!:E=\5/3%N5N
M:DX\@6PM[V[79M?R'MG$!O4)64,"2`A1$-V)/5W:)VO;__P-2811!A)#$D@*
MR2`YI("4D`I2N^*G238%3DP3FP.S:WFC9B)[`6M(``DA"J(A$<1`8D@"22$9
M)(<4D!)2=6(_6K-)>V/=_V#57L2\?5ZZC_"3]KYFP83-@N;1'_^;K[H@]YS:
MMP_<S8-HD088%D(41$,BB('$D`220C)(#BD@):2"U*[X^1GJ'XQGS?$\<GVR
MO0%_\9-=G0D:"`=Q$C7J/SJ[&W#!(:C?Y<F)%&(T)((82`Q)("DD@^20`E)"
M*DCMBI^H\WH*$_849B-Q-5]U0>X)98?UU__;[GY(>Z8W_XD9`LP00A1$0R*(
M@<20!))",D@.*2`EI(+4KO@IDRV&$R]8`ZV&D:B$5A,;Y*9,2M#%=#N$Z4#;
M-\0T"J(A$<1`8D@"22$9)(<4D!)206I7_"R=UWN8V+:"MP#*?\VZZH+<+,EN
M1("8$*(@&A)!#"2&))`4DD%R2`$I(16D=L5+RG2H]]!6P&]?E7;#CCU<T`4Y
M28$$D!"B(!H200PDAB20%))!<D@!*2$5I';%3\IYC8;I4*-!UDE=D)L4-!H0
M$T(41'?BU4G^AC+"(`.)(0DDA620'%)`2D@%J5WQL]2V`-Y?S4[;8:+A,)(-
MAR[(S9(=UDN`F!"B(!H200PDAB20%))!<D@!*2$5I';%3\IY+8:I[1XTOQYN
M;`_\&W6T&+IA;E)D3(@8!=&0"&(@,22!I)`,DD,*2`FI(+4K?E+.:RA,!QH*
M(ZQG:"ATP[IU:+<9DX5/%]+G+80HB(9$$`.)(0DDA620'%)`2D@%J5WQLR0[
M"*?MHMOGJK">R;9/%]0?\'4GA\)'-O0"#`DA"J(A$<1`8D@"22$9)(<4D!)2
M06I7_!S)+L*1;=I`\T#^#(;55-;\:T@`"2$*HB$1Q$!B2`))(1DDAQ20$E)!
M:E?\9)S7*9C:DO_(M<8&N2>,E*";J(\)(0JB(1'$0&)(`DDA&22'%)`24D%J
M5_RD#/4"1NUSO$=.E:%F@.ALKJ:R]%]#`D@(41`-B2#F(/TF9382K<#X$+3O
MZ260%))!<D@!*2$5I';%3Y1L!QS)ST`;8"RNZZNI+/K7D``20A1$0R*(@<2=
M[+<B[<\!\2NB!&-22`;)(06DA%20VA4O.;.AML#-T9-H-TS4-F/1PEQU0?VR
MM88$D!"B(!H200PDAB20%))!<D@!*2$5I';%3\IY;8&9K>_?OMYT06Y2T!9`
M3`A1$`V)(`820Q)("LD@.:2`E)`*4KOB)V6H"S">'S]5!MH`8]E\GLFB?PT)
M("%$030D@IB#.->;L7AP)3X$':XWD!2207)(`2DA%:1VQ4]46YF[[9JWKS<S
M6\@W"3AT!&9CV:;I@MRSQ@[K)4!,"%$0#8D@!A)#$D@*R2`YI("4D`I2N^(G
MX[R.P,P6^T>6,G0$NF%N4F1,B!@%T9`(8B`Q)(&DD`R20PI(":D@M2M^4H8:
M`"=LG=N;V.@`R*US%]3G8`T)("%$030D@IB#N&>S:"7%AZ!^*;/OK'_1*6(R
M2`XI("6D@M2N^(F278"V4W/"LP2S@78`KSEH!W3#^J,00$*(@FA(!#$'<1,E
MNDGQ(:A/E'S1*6(R2`XI("6D@M2N^(F2'8(CUQQ;XOO7'/E0SDSV`=:0`!)"
M%$1#(HB!Q)`$DD(R2`XI("6D@M2N^,D8Z@P<O]4YLS7_D6L.&@/=,/>DD3$A
M8A1$0R*(@<20!))",D@.*2`EI(+4KOA)>5\78#;4!<"E!EV`;EA7AX^F?-`N
MZ$+Z?(40!=&0"&(@,22!I)`,DD,*2`FI(+4K7G;:BO\=>^9=N"S_18-JU07U
M!WH-"2`A1$$T)((82`Q)("DD@^20`E)"*DCMBI^,\\K_FU/*_R[(30K*?\2$
M$`71D`AB(#$D@:20#))#"D@)J2"U*WY2V@K=K2I/NVEV8PM[[TJ/?Q/2!;E)
ML<-Z"1`30A1$=V+7P]T#AWY;,L(0`XDA"22%9)`<4D!*2`6I7?%SU-;D9^3(
MEO)>CB:B?[NZL4%]1M:0`!)"%$1#(HB!Q)`$DD(R2`XI("6D@M2N^$DYKP-P
M<TH'H`MRDR+K_0`Q(41!-"2"&$@,22`I)(/DD`)20BI([8J?%-D!>+M>N1DH
M_/'S(+H@-QFRJ@X0$T(41$,BB('$D*03NQI.YNT3(_YRF&),!LDA!:2$5)#:
M%3\Y0U7_Z+8YF$>R-%#U3V2G^486T.N#.)7X1'1_@T/0OA(/(0JB(1'$0&)(
M`DDA&22'%)`24D%J5_Q$R:K_Q#W!0/4_D1WG&U3_D``20A1$0R*(@<20!))"
M,D@.*2`EI(+4KOA).:_ZOSFE^N^"W"5.UOH!8D*(@FA(!#&0&))`4D@&R2$%
MI(14D-H5/RGOJ_YO!JI_7F]0_7?#^O0$D!"B(!H200PDAB20M!-[!1KO?GRN
M?P7*,":'%)`24D%J5[SDM/<PL6T^X<[F;ISH`N!ZTP7U.5D?Q+W>B!9]<`@Z
M7&\@"J(A$<1`8D@"22$9)(<4D!)206I7_$2=UQB8VPK?KV]$JWW5!;EY0F,`
M,2%$030D@AA(#$D@*22#Y)`"4D(J2.V*GY2V5']_T3FW%?[;W>8NR$V*'=9+
M@)@0HB`:$D$,)(8DD!2207)(`2DA%:1VQ4_*4">@?=CV[1WT?*@3(._+=$%]
M"M8'<5<TT:P.#D']BB9;"@HQ&A)!#"2&))`4DD%R2`$I(16D=L7/TWG-@;FM
M\OT53?:?NR`W3V@.(":$*(B&1!`#B2$))(5DD!Q20$I(!:E=\9/2ENUGK&BV
MVC^RHMD@-RE2@O;_;=P\9M#'A!`%T9`(8B`Q)(&DD`R20PI(":D@M2M^4F13
MX,A*-M`+F(INQVJ.7D`GW?VSP7]2@T$A1$$T)((82`Q)("DD@^20`E)"*DCM
MBI^=\SH!\X%.P%0^1ML%]:?#&A)`0HB":$@$,9`8DD!22`;)(06DA%20VA4_
M*>=U`N:G=`*Z(#<IZ`0@)H0HB(9$$`.)(0DDA620'%)`2D@%J5WQD_*^3D#S
MS\;PR!G7,70"NF%OKF-R4-@-ZG.J(!H200PDAB20%))!<D@!*2$5I';%R\YB
MJ!5P_-&9W3#1"9C*SG,7U!_>-22`A!`%T9`(8B`Q)(&DD`R20PI(":D@M2M^
M4LXK^Q>V?G][/]8%N4E!V8^8$*(@&A)!#"2&))`4DD%R2`$I(16D=L5/BBS[
MW]Z/+6S=[E4L6,>Z(#<9=EAWQZK].4'REE6`02%$030D@AA(#$D@*22#Y)`"
M4D(J2.V*GYVVM'Y_";.P%;F?)7$K;-4%N5FRPWH)$!-"%$1#(HB!Q)`$DD(R
M2`XI("6D@M2N^$DYK]A?V*K]R#HF2_MU-\Q-BHP)$:,@&A)!#"2&))`4DD%R
M2`$I(16D=L5/2EMLNV?*D77,UN;^&2+KRH4LX->==/<]AM<Q.2C$-`JB(1'$
M0&)(`DDA&22'%)`24D%J5_SLR*K_M#O,BZ'J7]YA[H+Z$V0-"2`A1$$T)((8
M2`Q)("DD@^20`E)"*DCMBI^4\XK]A2WVCZQC-LA-BI2@FZB/"2$*HB$1Q$!B
M2`))(1DDAQ20$E)!:E?\I)Q7["]LU>ZO9^)FY*H+Z@_XNI.FCOK\\:_/UQ_D
M(YT!AH00!=&0"&(@,22!I)`,DD,*2`FI(+4K?HYD[7_B:C;4`Y#W+Q>RG%]#
M`D@(41`-B2`&$D,22`K)(#FD@)20"E*[XB6E_?\/>!N`TY*R&W;L!P-V0<Z)
M`PD@(41!-"2"&$@,22`I)(/DD`)20BI([8J?E/-*_EM;N[^]FG5!;E+LL,-J
M)CHW`4:$$`71D`AB(#$D@:20#))#"D@)J2"U*WZ*FJ-\SGG3#I.M,GF+^=8&
MN2F2$B`FA"B(AD00`XDA"22%9)`<4D!*2`6I7?&3TE;B;C5SXF)F"_BWMV:W
M-LA-BI0`,2%$030D@AA(#$D@*22#Y)`"4D(J2.V*GY3SZOY;6ZXW'_S^!S-,
MQ5,5JR[(38H==K/;F;4_B*?YSW_&+L"@$*(@&A)!#"2&))`4DD%R2`$I(16D
M=L5FZ>KE^V;S&MR]WGW^^+AY_K99;W[\>+FXW_[YU/YK\U%S(`]\\;SY^NDR
M'R_SR67S'(OP8KPLAKP<+\LAK\;+:LCK\;(>\FB\C(;<C)=FR./Q,A[R9+Q,
MACP=+],AS\;+;,A_&RU_&_+U:!F,!HY/.%KJ(3>C93SDR6B9#OEJO%P-?=]@
MO`R&/!POPR%7XZ4:<CU>ZIU?'1+\\OGCS[MOF^SN^=O#T\O%C\W7YK-Q_:%]
M7.'YX5N[RMH_O&Y_?KILMA._;U]?MX^[+[]O[KYLGMN`)OCK=ONZ_T/S`;KZ
MM7W^8_?Y^_QO`0```/__`P!02P,$%``&``@````A`(GO+>G^`@``'`D``!D`
M``!X;"]W;W)K<VAE971S+W-H965T,S(N>&ULE);;;]HP%,;?)^U_B/S>7$@(
M%P%5H>I6:9.F:9=GDSC$:A)'MBGM?[]C'RYQ8!6\M`1__OP[GT]L9O=O=>6]
M,JFX:.8D\D/BL283.6\V<_+[U]/=F'A*TR:GE6C8G+PS1>X7GS_-=D*^J)(Q
M[8%#H^:DU+J=!H'*2E93Y8N6-3!2"%E3#8]R$ZA6,IK;2745#,(P#6K*&X(.
M4WF-AR@*GK%'D6UKUF@TD:RB&OA5R5MU<*NS:^QJ*E^V[5TFZA8LUKSB^MV:
M$J_.IL^;1DBZKJ#NMRBAV<';/IS9USR30HE"^V`7(.AYS9-@$H#38I9SJ,#$
M[DE6S,E#-%U%(0D6,QO0'\YVJO/94Z78?9$\_\8;!FG#/ID=6`OQ8J3/N?D*
M)@=GLY_L#OR07LX*NJWT3['[ROBFU+#=0ZC(%#;-WQ^9RB!1L/$'0^.4B0H`
MX*]7<],:D`A]L_]W/-?EG,2I/QR%<01R;\V4?N+&DGC95FE1_T51M+="D\'>
M)`;Z_?C@6I,`@6Q]CU33Q4R*G0=-`TNJEIH6C*9@;`J+(9[+A4%%9LZ#F62G
M@EK!;KPNDG0\"UXAP6RO69YK!JYB=4$Q.4H"X#M"0N6W0YI)4`SQ.I`G?UO(
M$C6)C=E4MNI\X1"`39?@XWB,>$[`ZKCR($R/E>'*J$EM>!-XFT-W?-4=C\))
M5^"`);>`&7$?;.0NO$3-"'<U[JYKP5?=\2$,G\`=+FCKZP,SXCY7OY]0@UQ1
MDG071C!',';(';+T%C(C[I/UFP@U2.8F@F#=\<0(CHD[7".7Z[HWT4SJ\44G
M?VPUU.R3&XR[``C8%?R_T\Q=UCDI/GX%C+C/%1WK1B[4''8T/>="06);\524
M$]KD%B@C[D/U#J4E:A`JOO!>=L<CIPL=+KB,;DC+JEVR4=)+:Z_!$R.-G3["
M;704201Y]D/#^PW/_Y9NV'<J-[Q17L4*.*I"?P3OD,3;#1^T:.TYOQ8:;B7[
ML81?(0R.RM`'<2&$/CR8^_/XNV;Q#P``__\#`%!+`P04``8`"````"$``D57
MH%L"```]!0``&0```'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6R,E%]OFS`4
MQ=\G[3M8?B\&DJ8+"JG21MTJ;=(T[<^S8RY@!6-D.R']]KO&"6N:3LI+@NW#
MCW/O/;"X/ZB&[,%8J=N<)E%,";1"%[*M<OKKY]/-)TJLXVW!&]U"3E_`TOOE
MQP^+7INMK0$<04)K<UH[UV6,65&#XC;2';1X4FJCN,.EJ9CM#/!BN$DU+(WC
M&5-<MC00,G,-0Y>E%+#68J>@=0%BH.$._=M:=O9$4^(:G.)FN^MNA%8=(C:R
MD>YE@%*B1/9<M=KP38-U'Y(I%R?VL+C`*RF,MKIT$>)8,'I9\YS-&9*6BT)B
M!;[MQ$"9TU62/4XH6RZ&_OR6T-M7U\36NO]L9/%5MH#-QC'Y`6RTWGKI<^&W
M\&9V<??3,(#OAA10\EWC?NC^"\BJ=CCM6RS(UY45+VNP`AN*F"B]]22A&S2`
MOT1)GPQL"#\,_[TL7)W3R2RZO8LG"<K)!JQ[DAY)B=A9I]6?($J.J`!)CY`)
MNC^>I]="6#`TU+?FCB\71O<$,X./M!WW"4PR!)\*"S;&4O]7*9;H(2M/R2F&
M'8NP.)W]<CJ[6[`]ME0<-0^7FN1<\7A2^$F@O=$C%O[:X_M-/UGQ8F_%#\%[
M>P@;R!Z]I6^>^XYB/DK.G&"'KG?BQ3E%^/C@^73$!F]!,ALZEL1Q?'Z,B?:$
M<(PO_+_C8"K$-8Q3@:G@$9K&$J%W/HHI4L?=\2U9I;XS;_8?\.T9LL;&`TQO
MQROXQDTE6TL:*!$91W<85Q/R'Q9.=T.(-MIA;H?+&C]3@)V/(Q276KO3PL]U
M_/`M_P(``/__`P!02P,$%``&``@````A`-/B;Q[X`@``20D``!D```!X;"]W
M;W)K<VAE971S+W-H965T,S`N>&ULE%9=;]HP%'V?M/]@^;WY("$,1*A:JFZ5
M-FF:]O%L$H=83>+(-J7]][NV*=BA'RD/$-OG'I][KN/+\O*Q;=`#%9+Q+L=Q
M$&%$NX*7K-OF^,_OVXLO&$E%NI(TO*,Y?J(27ZX^?UKNN;B7-:4*`4,G<UPK
MU2_"4!8U;8D,>$\[6*FX:(F"H=B&LA>4E":H;<))%&5A2UB'+<-"C.'@5<4*
M>L.+74L[94D$;8@"_;)FO7QF:XLQ="T1][O^HN!M#Q0;UC#U9$@Q:HO%W;;C
M@FP:R/LQ3DGQS&T&9_0M*P27O%(!T(56Z'G.\W`>`M-J63+(0-N.!*UR?!4O
MUG&,P]72&/27T;UTGI&L^?ZK8.5WUE%P&^JD*[#A_%Y#[TH]!<'A6?2MJ<!/
M@4I:D5VC?O']-\JVM8)R3R$CG=BB?+JAL@!'@2:83#53P1L0`-^H9?IH@"/D
MT?SN6:GJ'"=9,)U%20QPM*%2W3)-B5&QDXJW_RS(9'0DF1Q($E!_6)^,)0FM
M()/?#5%DM11\C^#0P):R)_H(Q@L@UHDE8,_+B4%&.N9*!YE00$NHQL,JS9)E
M^``.%@?,]3EFXB/6+R#F1T@(^HXB(?./B]1!D`Q&)Y%I>N0WB5Q;3&HJIC-;
M.Q.>`J!Q%;QMCP;G&*A..V?#G2TF,^;%600?7]K:!:3NLJ<K]76-*Y\.\O7%
M\Y/SUAF+F1E]%XF[OUE?>^MP&YWD>_K@=(_W38-]7<G0-@NQLF)X@9Q]K2X7
M\+JL[".R--B7E693OUK7%N,<)&?",V3F[SRN8#KHO:-L,8X"9\)3H'N2\\:_
M?90U>)C[L"868VOBG51;D5>7/57SCZC2X*&J;%`1BW'\<":\G6.X[EQ#QI7$
M1+U7DP/($>'.^"H&%_';98%>=^[`L"X'T.&.F>I+QO=(MTQ-8Q&G12O,-D/;
M+'JRI3^(V+).HH96<*]%P0Q>-6%;H1THWINFL.$*6IAYK.$O"X5[-0H`7'&N
MG@>ZV1[_!*W^`P``__\#`%!+`P04``8`"````"$`&`$;^!`0``#K7@``&0``
M`'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6R<G-M/(SD:Q=]7VO\!\3Z0N@90
MTZM)^:Y=:;7:RW,:0A,-$)2DIV?^^[5C5^KS=PHJT`_0_'+LQ*=\.>6JU)>_
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M4W65&]&AIBU8NP5JRKP6.:*XSB4*)?5\GFOTB*9B&A,U5[-#?ZF+^9SU&`L"
MUAR'[](60X.R`^`GM.P`A(Y>OSE%]P<BE/*3,?&]:=BG7$1-?3Q8'0>"`\F!
MXD!S8#BP'#@"LI;[2?@3+0^E;L^]P<<>UQ95?I`744-:SH'H09@1F&^R?ZWO
MY(H#S8'AP'+@",A,\$<:3)A/'OY0BIM0,Q.BAIC`@8C@.G;SBSD;3C*^W!Y>
M9AXI7I?FP'!@.7`$9);X)1$L:?T2\/[4%$IQ2QIF2=002S@0$<0V%\UU-9NQ
MEDM>1'&@.3`<6`X<`9D5?F$'*ZI)*T(I;@5;T!910ZS@0$0PC[VC\<&=.]&7
M&!E#JG^M'T.:`\.!Y<`1D)D23DYX-)B>,4,I;@J;^!=10TSA0$0032EFK3>%
MN\*+*`XT!X8#RX$C(+/"1S:P8GJHA%+<"K9H+Z*&6,&!Z`&=B/D4TFOZ;J`X
MT!P8#BP'CH#,C!`3P8WICG$HQNPHV5%=)!'Q`XA()':.JBH;Z!M01@'10`P0
M"\11DIL2@A\?+=,+3!'S8K;,EBSE+)*(FA*+#40D35QDV@N>M234H8!H(`:(
M!>(HR2T)Z8Q;,CVK%C'4Y98,H>YP6K!(HL&`[DC(."E98!%'43]0)!`%1`,Q
M0"P01TGN2PAJG_`EYKO<%QY&"A("#TYUB<2.4<A?6`DQ\;J<>%W!.VH@!H@%
MXBC)[0J1CMKU?CXI8@*D-C5\_4D:VGMBJ3BG^`D%%QR1"J6%NCV(\MPCIR4*
MWEH#,4`L$$=);E>(>]2N<*)SPJB+*9':YC=\\O8MPI:67]&H;Y%$4T)V\?_R
M0@(*22`*B`9B@%@@CI+<E9#\J"L3G2@&1>I&`V:0,)F&&B>BB"3:4T1[N$'R
M%)%*HL%Z#<0`L4`<);E#(09^P*&8&C.'8-TBR3(YQ(DH(J$#+^\_<E*ADH)Z
MP]_'@,8"<93DWH1<2+TY<4S%.$D]:DM^@E"0S)E,XD0DS5MSN)QX7<%[:"`&
MB`7B*,D-"EGQ$P;%B$D-*@JV0"T*DD.309R(I$GCK"CF,`W)7')=%N&D(N]J
M"MY*`S%`+!!'2>93R:/S^]/009Y'YJ+@\U`2#;V_`R(22=/TV$EFIJB*Z["\
M,7>@6@W$`+%`'"6Y.SQ#3[B#V;GAHZOD0;D#(A*)YM17L[J\9DV7TQ(%]6H@
M!H@%XBC)W?'#!,;8]!E&&8KE?:@M>2!*(MJ'8K&!B*2)-E5%/?,G7GD/D5"-
M`J*!&"`6B*,D=X6'Z8D^,Q:B^3EY&45O3;==>IUZPV.W!(T"HH$8(!:(HR2W
M@@?ETU:I$@-S6[(-AD42S9,G%VP2ZM+KU))8[4`D:!00#<0`L4`<);DE8V%X
M>N,F7.GD8Z9BG7V11$,#.R`BD>.8:?QI`Q\S/%,KJ$8#,4`L$$=)[DI(I7RU
MGM[`*6.8I:MU6_',ET34%4C%1\UPJM[,V;(OCZ+^5%T!T4`,$`O$49+[$E(C
M]65B+HDAD_IQQ8[NHN1!M`,B@,A$8K<IVOGUR&+,*]90C0%B@3A*<C-XYITP
M8R3K5GS7IN3)M@,B$DDS#?-3@EX!T4`,$`O$49(;\;EL6V*V;2NV'[5((CI:
M(-N"1@)10#00`\0"<91D)H0-A&QHG'CY-!2;O'X:1<2$P[O1?08!1`)10#00
M`\0"<93D)GPLGU:83]N*37.+)**-YY%5'#7#?%G7++3(H^@X7P+10`P0"\11
MDOL1,B*=+T\+'%6,EG3>;"L6*!9)1'V)Q08BDB9.DTW-3U@DU*&`:"`&B`7B
M*,DM^5@<K4;B*+\/99%$0\,[("*1&,^N+V:P=R>AC`*B@1@@%HBC)#>#!]+W
MEY!J)(CRZQB+)*)F\*`I0".!*"`:B`%B@3A*\L:/1<_ID%7%..C[Q?&^BY$[
M3GAF[%*QP18!1`)10#00`\0"<93D)HPES2)L`$QTA;&HR6:\1<6#90=$`)%`
MU)$,EK<5.P'21U$_O1H@%HBC)#>&1\T3ITZ,G,V,AXJ*1\,.B``B@:A$XO3:
M7C65WQ;*3UXT%#)`+!!'2>X*SYPGNC*2/6N6'!<59$\@`H@$HA))V;RL9E?\
MRH"&0@:(!>(HR5WA`71B[&#PK'EW7E0\9G9`!!`)1`'10`P0"\11DC6^_ESP
M/!2;"IY)-$R:'1`!1`)10#00`\0"<93D)GPL>-8CP;/F)^I)1!L/P1,T$H@"
MHA.)6:2]:-O9E3]_[?^QSV&@O`7B*,F-X0GT_:%1CR3/FI^D)E$<X-7U'&XO
MZ9)BL$X`D4`4$)W(V^]DH(P%XBC)S?E8%JTQB];8:Z(H'MNY_S)#OB!TJ1)J
M32PQ$`D:!40G\M;[&"AA@3A*<F-X+CUMF:E'\FG-%]\D>CN(=TDQ&"*`2"`*
MB`9B@%@@CI+<%)Y7)X92C*#T)*Z&-3?$77_Z'SMX.7;+1)<DU`T>;B5H%!`]
M_58&"ED@CI+<GK$D&W8*)FP:";(UWP.HHRA%BG96ACL%^,#B85>D4H-S$H@"
MHH$8(!:(HR2WY7,YML8<BQ=^DRC9,GK%MDN:P00!1`)10#00`\0"<93DMO`@
M.]%+,,#B==XZBM)J,7:%MDL2Z@9/O1(T"H@&8H!8((Z2W(V/!=@:`RQ<UTV:
M=V<6'G%%*C38(X$H(!J(`6*!.$HR,YJQ0#M]&?=0;.HR;A*E+C*K1[)+D@P>
M""`2B`*B@1@@%HBC)'>%)]RP))_@REC299EDT4316UFB2Z]32W@2EJ!10#00
M`\0"<93DEGPLVS9CV9;?#I%$0U,[(`*(!**`:"`&B`7B*,D;S[-KZ`]A<7Y_
M(FUBV/0_W]D]2R)J`L^H`C02B`*B@1@@%HBC)#?A<SFU&<NI_(Z/)*(FQ&(#
M$4F3%N!FY+X8J$4!T4`,$`O$49*;$N(AO>@PT2-BFJ0YM>773A8-CYP=$)%(
MG$6FSFHEE%=`-!`#Q`)QE.3&?"ZA-F,)E>WS+9)HZ!L=$)%(ZBVS,ISTYR%6
M0B$%1`,Q0"P01TGN"@^H$]T%@VD-X:.)(NH&)P(T$H@"HH$8(!:(HR1O/(^A
M)\ZB,31.S*(\678-)P*(!**`:"`&B`7B*,E-X.GSM+/]!E-H6\!ZRC-FEXH-
M?4,D$L>%O_5N9%CTM8Q]PP\JU$`,$`O$49+Y$VZ'RB;4TSK)H1@+I`5?99)H
M<*,#(A+I5YERY!N04$@!T4`,$`O$49*[,A9(@_K]^:,=":0%OW"51-05'CC%
M43,DF99??I%'47]12@'10`P0"\11DOO"4VGH+;Y33QHS$D_YO7"+-HJH,9R(
MHX88T[!-97D4#<;PBC1H#!`+Q%&2&Q,R),TEP9@3.DR,GO[3'1-KV_`MZ9;G
MTPZ(`"*!*"`:B$DD#L=Z=EWQRUL6RCA*<E,^EV#;D03;\)W6)**=!1(L:"00
M!40#,4`L$$=);@)/K"=.L#&4OK\*MY!<@0@@$H@"HH$8(!:(HR0WX7/IM!U)
MI[`*)Q'M";'80$32I&Y=X0ZKA%H4$`W$`+%`'"6Y*1\+IRV&T[;AF\E)-#2]
M`R*`2"`*B`9B@%@@CI*\\9\+I^TIX32)J`D03D$C@2@@&H@!8H$X2G(3QL+I
M]#Y'.Q).X;OT241-Z(-FORP*T$@@"H@&8H#81.*`&_N6OJ-E,E-"FH"E='HS
M\%",)5+X+GT2$5.`""`2B`*B@1@@-I%^$X'?W>9HB=R2L3@Z??EI/A)'X9)E
M$E%+((Z"1@)10'0B_<70XCK[=R5_86NZ@2HL$$=)[E&(>#2!O1_5YS$1TN3%
MH\XB::@UL=1`!&@D$`5$`S%`+!"72!Q4U]=7-)SE7HRET2+<IS=ARD@<Y0\:
M6\PAC@(11T)S+=N9ET=1/Q\I(!J(`6*!.$IR8W@BG?!C+(GR78`YSYT=$`%$
M`E%`-!`#Q`)QE.2-_UP2#5/OY%W\230,C`Z(`"*!*"`:B`%B@3A*<A,^ET3G
M(TD4I](HZB<\O`V[2]4,-@D@$H@"HH$8(!:(HR0WA2?1T\Y>YR.)%+XHET1I
MTBK]1<E\6[A+`NI)K'<@$C0*B`9B@%@@CI+<D[&`>L*:&Y,F75=:>`+)/(J:
M^-2O<G;%8GR7!(,#`H@$HH!H(`:(!>(HR3T9RZLG>#*25QN^+>:_\A6FF>1)
MU=1LN>B2@'K"`ZT$C0*B@1@@%HBC)//$/\#R([GC(,]CZIRU=)$T0TL[(`*(
M!**`:"`&B`7B*,G;/I9+I\]?KF+`?']O(XFH"9!+02.!*"`:B`%B@3A*<A-"
M)J3!\[0-GJL8);.)`AZQF434A%AL(`(T$H@"HA-))V@C][D:*&.!.$IR4W@"
M?3]H^:=SA\%/S8`OTR;-T/(.B``B$QE_OB;(-1`#Q`()#Q</'__PT:(-\5GA
M\5G+SZOM]U6W>GK:G=UM?H3G@-=^XC_2XS/*?RW#0V097Q0WW>%!WXR+XD:.
M<5/<^,<2^WHNCP7\H\9?E]]7_UANOZ]?=F=/JP?_$687(2)MX\/*XQ_[S>OA
MB=#?-GO_D/'#?Q_]0^57_D',LPLO?MAL]OT?X0V.CZG_^G\!````__\#`%!+
M`P04``8`"````"$`D@A/)R\#``#9"0``&0```'AL+W=O<FMS:&5E=',O<VAE
M970T,2YX;6R4EEUOVC`4AN\G[3]$OB_Y@E`0H2I4W2IMTC3MX]HD#K&:Q)%M
M2OOO=TX,:6PH8C=`[->OGW..G</B[K6NO!<F%1=-2L)10#S69"+GS38EOW\]
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MOBTUE'L"$6%@\_SM@:D,,@HVHVB"3IFH```^O9KCT8",T-?N>\]S7:8D3D:3
M:1"'(/<V3.E'CI;$RW9*B_JO$741]2;1P20&^L-\=*V);X"Z^!ZHILN%%'L/
M#@ULJ5J*1S"<@_$Q,(/1A_I1I!`BFMRC2TK@M$,0"LKSLDPFLX7_`BG-#IK5
MJ2:T%>NC`BL!>#TC!#YD/)_T(PJ*$06+@&PK,P#>/5OD['M&\0YOD4"&AB28
MK1@.TV4B7`2Z`4"2!#;"RFC&/?5Z,&`1C&V"RSNC."407A]Z/(F=G8TFZ8KF
M4*W/SUD\<'R'&;G,@V*79^SP&,VTX[D)IY-Q$+A8M@0NT5!BT24V'=9K#*LO
M4^(BMU[.45T9S:!>@P&+8&H37-X9Q6Y^W'H9S?ALO<[/63S8D0;W_3(/BET>
MMUY&<ZA7',R&M>@NX-I2A+?0NMX+:K'-_H<-Q39;DC@7>V4T![8H2.+AU@;.
MDH11:$DLNA`N^O6IZ]0V7YRXM3R(#.!Y/DMRF0]?GU>7%KJEF[\X<6M[$)U_
M.7PP:7)F.JGI-#636[9F5:6\3.RP2T9P>OO1OH/?1_CZ<\97V-EQW.\GH+&V
M=,N^4[GEC?(J5H!E,)K"Q9:F-9L'+=JNOVV$AI;:_2SA+Q2#IA",0%P(H8\/
MN$'_IVSY#P``__\#`%!+`P04``8`"````"$`3WZPX;H"``#3!P``&0```'AL
M+W=O<FMS:&5E=',O<VAE970T,BYX;6R4E5UOVC`4AN\G[3]8OB??A`\1JI:J
M6Z5-FJ9]7!O'(19)'-FFM/]^QS;0)#!$;R".7[]YSFOG9''W6E?HA4G%19/A
MT`LP8@T5.6\V&?[]ZVDTQ4AITN2D$@W+\!M3^&[Y^=-B+^16E8QI!`Z-RG"I
M=3OW?45+5A/EB98U,%,(61,-0[GQ52L9R>VBNO*C($C]FO`&.X>YO,5#%`6G
M[%'07<T:[4PDJX@&?E7R5AW=:GJ+74WD=M>.J*A;L%CSBNLW:XI13>?/FT9(
MLJZ@[M<P(?3H;0=G]C6G4BA1:`_L?`=Z7O/,G_G@M%SD'"HPL2/)B@S?A_/5
M%/O+A<WG#V=[U;E&JA3[+Y+GWWC#(&S8)K,!:R&V1OJ<FUNPV#];_60WX(=$
M.2O(KM(_Q?XKXYM2PVZ/H2!3USQ_>V2*0J!@XT5CXT1%!0#PBVIN3@8$0E[M
M_Y[GNLQPG'KC21"'($=KIO03-Y88T9W2HO[K1.'!RIE$!Y,8Z`_ST:TFO@.R
M]3T2398+*?8(S@P\4K7$G,!P#L:7"X)*C/;>B.T28%6P"2_+-(T7_@LD1P^:
MAW--U%>L+BAF)XD/7"<XJ+@+9U)/_IOZ$=(L@GPQZD`F)W];R(/3)#9>4]FJ
M<Z-'`#9=@NOQ&'&&P>KTY#A-!T]VFM2&%T=1$@1!7['J*L(DFG05/;;D(VQ&
MW&>;3OL/?G"2B46+4F@P0S(G2*S@?:['!+MS>UY&W&>*T\D`RFD<U(6PW/15
MI/0C2$8\1!KFY#0.*4YFD--[&/9XK;J*JULX^0B;$0_9WE\<=["=QK&-+L/U
M)%?IS,?KYMY@Q'VZ-!T/-M-IW.$?9G9YSATNUY==WVK)AGTG<L,;A2I6P*L6
M>!,X!M)U93?0HK5]:BTT=%-[6<+'D\&K'G@@+H30QX'I^Z?/\?(?````__\#
M`%!+`P04``8`"````"$`^$B$Q_(#``"&#@``&````'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;)Q776^;/!B]G[3_@+AOP&#(AY),:ZIND_9*KZ9]7!-P$JN`
M$7:;]M_OL4V";;*,["8M<'R>X_/8![/\\%J5W@MI.67URD>3T/=(G;."UON5
M_^/[X]W,][C(ZB(K64U6_AOA_H?U^W?+(VN?^($0X0%#S5?^08AF$00\/Y`J
MXQ/6D!J>[%A;90(NVWW`FY9DA1I4E4$4AFE09;3V-<.B'</!=CN:DP>6/U>D
M%IJD)64F0#\_T(:?V*I\#%V5M4_/S5W.J@8HMK2DXDV1^EZ5+[[L:]9FVQ+F
M_8IPEI^XU<6`OJ)YRSC;B0G0!5KH<,[S8!X`TWI94)B!M-UKR6[E?T2+#9K[
MP7JI#/I)R9$;_WO\P(Z?6EI\I34!MZ%/L@-;QIXD]$LA;\'@8##Z477@_]8K
MR"Y[+L4W=OQ,Z/X@H-T)S$A.;%&\/1">@Z-`,XD2R92S$@3`KU=1N33`D>Q5
M_3W20AQ6?IQ.DFD8(X![6\+%(Y64OI<_<\&J7QJ$.BI-$G4D,:COGD=C20(M
M2,WO(1/9>MFRHP>+!DKR)I-+$"V`6$XL!GLN3PQF),=\E(/44$!SZ,;+.IHM
M@Q<P,.\@]Q<@-F)S`3$_0P*0=]8($S<U7M<FP3`'WSMKB\,SK9)_KR%8F2OG
MLS%N6(6!97QA"5[Y0-471DYA#4F58RB,80&$CK:-!4F2*3(AECALBQO7.3G(
M$1DY(C5DJD6FJ5E?V;<Q`;'YV)('ZWJ\=Q+LR(H=61K2R0J3R*JLA5D0\`[_
M45QZBS@)=L1A1YR&=.(NM=4$0';W7;<\F]XB2X(=68DC2T-.GJ4S*-Q7UIY9
M$/#,ZK<E3K[+C*2XO@LEV-F%J2-.0XQ=:-RP"L_MPN,6NASDN#-U!&B(=B>-
MDZ$W)@#+C=B;9PE$$)CCK5%H1]H@/27CRL=J$_95=<LZ`BT\B:T0L74YX7Z]
M94@'LA5@?2"KTO<=YHIG%F*.KXB3H3MZ/2$=T:8X[/ARWV$@GLX)C)T$WES'
MV.[=E/Y(!S?\]L7=9.TPQI(W[]C%9<@:[LA%G_[]O:RCV7+)S5&D,7]86I<?
MVM*<9)?2IG#O+ZM+A[,ES4U1>:(ZKWH\<_J[L1^G?=C9\F[*=C0,=]P3=XO>
M#F\<XB0::#,Q:!;-ITG<\]@";TIY-(QY["9IA]&[\@X.%C+$!PK-I+^+TW1N
M8FR%-T4]TKEM==:-V@ZC%4*2X@MI:V-P&ET1^$^O!/A`<-\)>!"\&G,ZHEU\
M978\'>;R.U-_2>B3=I/MR7]9NZ<U]TJR@^T23N2&:?5WA+X0K%$GZBT3</Y7
M_Q[@>X_`\32<`'C'F#A=R"^5\Q?D^C<```#__P,`4$L#!!0`!@`(````(0"M
M'MLPOP(``)$(```8````>&PO=V]R:W-H965T<R]S:&5E=#,N>&ULE)9=;]HP
M%(;O)^T_6+XG'Q"@082JT'6KU$G3M(]KXSC$:A)'MBGMO]^Q3;O:4`1<A!B_
MY\USCD]LYM?/;8.>F%1<=`5.HP0CUE%1\FY3X-^_[@97&"E-NI(THF,%?F$*
M7R\^?YKOA'Q4-6,:@4.G"EQKW<_B6-&:M41%HF<=S%1"MD3#4&YBU4M&2AO4
M-O$P229Q2WB'G<-,GN,AJHI3=BOHMF6==B:2-40#OZIYKU[=6GJ.74ODX[8?
M4-'V8+'F#=<OUA2CEL[N-YV09-U`WL]I1NBKMQT<V+><2J%$I2.PBQWH8<YY
MG,?@M)B7'#(P94>2506^26>K',>+N:W/'\YVZMT]4K78?96\?.`=@V+#,ID%
M6`OQ:*3WI?D)@N.#Z#N[`#\D*EE%MHW^*7;?&-_4&E9[#`F9O&;ERRU3%`H*
M-M%P;)RH:```KJCEIC.@(.39?N]XJ>L"CR;1>)J,4I"C-5/ZCAM+C.A6:='^
M=:)T;^5,AGN3$=#OYX?GFL0.R.9W2S19S*78(>@9>*3JB>G`=`;&)K$1E.=X
M8I"1B;DQ0384U`H6XVF1Y?/X"0I(]Y+EH63H*U9'%/]-8L![8X3$+V<T006&
MZQOC./$)EDZ2VP32+X/,GUY]..W!0='>PYTNG!$'4*G_U*633"W4.#$?7[`Z
M(?#`LDO`C#@`"]9KZ229!0N9CL]Y.-#GY]?)B`.<D5^&I9,<QSD^Y^%,?)SS
M^MX$!5A!TRR=Y,.>^G#:@YOZ<*=[RH@#J'%0*R=Q/97:GCILJ],:#\\<:N_V
MC--X1AS@30(\)W%XV562#?.POTXI/+3\$C0C#M"F`9J3[-$F]GWT%7#J&)/C
M"H?F3A6WZ_9DP[X3N>&=0@VK8&]*HBFTJW1GBAMHT=O==2TTG`7VMH:CG\'6
MFT0@KH30KP-S:KW]F5C\`P``__\#`%!+`P04``8`"````"$`^<UY615R``#_
MA0$`%````'AL+W-H87)E9%-T<FEN9W,N>&UL[)W;;AQ7EJ;O!YAW"`AJM`20
MM$@=+)==;M"49+-*%C4BU4;!Z(M@9I",5C(S*R-3$ONJWF'FIH`9P)A'\:/4
MD\SWK[7WCAT1F23E<G<U>NJBNJUDQ#ZLX[\.>\=7__3Q<E*\KQ9-/9O^]L[N
MSH,[134=S<;U]/RW=]Z>O-A^>J=HEN5T7$YFT^JW=ZZJYLX_??W?_]M73;,L
M>'?:_/;.Q7(Y_\UGGS6CB^JR;'9F\VK*7\YFB\MRR3\7YY\U\T55CIN+JEI>
M3C[;>_#@R6>793V]4XQFJ^F2>1\_>7BG6$WK/ZZJ`__IR=/'=[[^JJF__FKY
M];/9:'5939?%_G1</)\NZ^55<3CU"5AW<>_M\;/B[OVO/EM^_=5G>L5?V]TK
MOI]-EQ<-[XRK<?_/WY>+G>+A[E:Q]V#W<?^/OUM-=XH'C]?_\;B:\^8#^^.C
M_IMIL?D*?WQ93ZOB<%E=-O^R\863JWG5_^/N@^W?]W_;AQ9CH\>+27G>_VN:
M_W6UJ&>BU[AX5BX'(Z?G7M3-J)P4?ZC*1?$"2C<;1PQ/AH'7/OOB#_VW`[_>
M5.=ULUR4</%5>3E8S9O5\J(^KZ9;,':TLV&,`V1@P5(/8>?'XO?55?^Y@]5B
M(3G)M[1I_V%=/U23R?:[Z>S#M#BNR@8A'Q>'3;.J%OW!7\WZOX0A_GDV64V7
MY>**>2>HTH;'XN+>5//98HF"%<?+<CDD]Q^J32/8\,4!S#R?+0:;/[XL)TQ?
MM.,?S"[GY73P8%CVZ]7II!X5+R:S<ME?\LFBE`DHCJ\N3V>3_E_?G'S[JO];
M&)0I+]'(X^5L]&ZK.+XH%U53'*V69D,8L?_:P=&KXZ.7A\_V3YX_*[[9?[G_
MZN!Y<?S=\^<GQYO4.M?;@?9%(N\W3;5L?C.8KFPN^K^]7E3SLAX7U4<,5\-R
ML7;%;'D!*4=!GDH;K?_BR6R),'9G[#_S>H$Y7&"O-&CUQU4]E^)N%=-J2',;
MSA?>'R9.\K(N3^M)O:RKX=[V1V9-FV)>7I6GD\JF+$>CQ0J1CIOK#_PZ/+N<
MH?N+2_;\&I9--RQNS3+Z`TH`ZJ4VZ80<88'A.TZ%-?<?_OFGGW_J_V:B<S&;
MC-&D?RR>0[+EU8"/\.RL0M?'.">3M+L/=AX\>+#+WA?%^W*RJKXL'C]XL,5O
M1>-"6&)A9HOZWZKQE\5T%G^MI>IC9WDKI46Y+!"ST47R#_8$CN+15H%$SZO1
MLGY?30:J%<1_\Z)V?5&;%O9HZ^F#1UM[7SRP^1YM/7G<V<.OO-K]\1A1FDV1
M8FG`=CTM1N6\1JK[3$&V5I>K"99G7(RKLWI4;Y"0==SK#^9ZDXFR;?8V;UYG
M+7YTP;VHEC7N[%\V68^!Y"2)*>ZQ__%L,BD7Z!":8()SO[_Z=@!;<3)R^TF^
M;ON&N9GQ;9^^SHBZT0U2]ZD;6FNR-^]FW>-X;=.C_E[6/WO=3G)W<'R"5_C^
M^2M<P=&+XNCU\S?[)X<\L(FU;ZKWU70UM#)',+,TA_L\F/C^.M]4#>@'=9>5
M'C/,9&9VNO_<,6`!8[958,\8<V+/E^/+>FK81C:A_XH+^\U+>#EKFN+%8G99
MA&=GTX&Y/#*G!$":#0'4X71989F61;WVSV$9UPSPJEH66D1_`_'W`MCG#KW_
MQ#=E`XX0Z9[5DY5,Q.TTZ8>J/K_0X_L$(.5Y5;Q:79XRR>RLB()S(WY8/[>;
M_('J=LQ'5[H.OMM_]>WSX^+P57%\<G3P^^^.7CY[_N88!_0_WAZ>_&&3R!E9
M^_2(BY=G*G[\OM*F!J@_L[VO@^T]<-N[^97,"#]S([SQV6_*23D=@0',D:4X
MYV%_K?$Y<2Q0[<9W#J?O$30/0"2PUP*'X^!]D8X/Y4+XORF"&R.`P]\T%X@L
M@>!T*J<*=OQ0+_43GDE^R4'J[`QWOP8^_KJCF]QND!VIP62->D0"]@C]Z!<0
M>O!.V-TMR+4B(EI\6-38@']L`'O58E0WE31I)MV:3&;&K[6X\]]GENMH:8YS
M^[1LT'ULF6`W]GDVW42S'FT?;WKN&B$>O'.=+=@__JYX\?+HAXV>YD!22^#T
MH6NR"9CV!0P-G_<7N3_^UY5K35.`MA<5(C\B7E0H8)*E7_7?IA(KT0:]4/3@
MOJM,(P_0\+-JSG#U6AH>7)2@;W2N,Y;%,V:R)]=$%$"=3F34WY)TPDCQ-JRV
M=7.;Z="GG5L3=/L:VKU>X9P1ET82/5\;4MVXMMO,TU_;BWJ*%;U^;?OC][*T
M37%VHRTD,B^OS&ZRC8[5+,HP2G\;Q(^CJAJ'T64)S*SS/HJC2-M`GW$RF==)
M!91(CXYFS7+@U'_<'3BDS*K?O)/$>=;WOB:Y5IPJ^W$SM?3BO6?5B'Q@4]U7
MLL?^B_\P2>IOWQBR77Q#\F@Z76/_P]_)\:SYX[.57$8!YBFNE-RJE`7LQ75`
MN860%T*5T5FO;/!`DL"[NUN[NY];#&>TOKOW>,_^Q=^BIX(_T'U+CW^XJ(&6
M=Y]^8<]\*!MS<1?59.PRH]G2_()1=W>?/$S/F@;*0\KF+"^PA1H!A7]?SU;-
MA,Q""/'=2C)3R&D^VBEN00$"VE]$@2^V]G:?9"1XN+7[Q>.;B;"W]73/7[N>
M#EO%W;T'[8,=(F#F1Y.5Y:?N/GID<]K?QRV_SSRGN8GM#^^;QG3HG,AH1J83
M_3\:)"1OYSUN&9+F":T!0/O6Q#.9`8L0#J,9.&J1LH'-?83GAX"R^JIT%"`4
MV+H9!.^=/Q8_@,!,/&VV$\0SSM\?E/21IWH0<_/J%@B:B=(T`[M#'L'249WY
M!D\=+<[+:?UOYL^,4:\!L]*D[ZO%^3`QFS^^Q?:FS6Q2C[.WB8O(1_D/C!+L
M%.A2"=C*-_#C_JG2TZ/EP##^*L,_0R"!CZM%5?QX4GU<%M],B`X&<[V:+:MB
M=Z?(Y_Q$"O19U,VL%_=D;?[RI_]-D#(G-_R7/_V?`AC.#_$Y?KEO)D:!Y()4
MM25]#&":*9V4H!ZHJ'&,?OK'J^I].2X+_-'ORNE*J?#=IU8>>;A32'[";#;N
MHNJ,;,XFO`\">E8Q`2E(C46=!?8H)-SS2DQWM+_\Z<\RA(Q6SV$FEK<FXJD;
MT-3(%HW5/";@*(LWLZ9$,LI)3<PQK<N=(NY6CY?%:3V;$Z=<EJ-J9>DC@Z60
MISA3002OP6KF(-3*HA!@VH?BXFH^&UU,9HL5(XSJ,:9^47QW=##9*AS90J`%
M$1W(8%PU];D*"^ROOL34O\?@(XX(93%;+?'D/"3#3T)SQ18NJG*RO!B)"N9%
M"O+/,^$[A@C1T9D'2PVO>%:.H>=HW'8`C,Q03]\3F&LJ^3:,8]4,[%C.&\DG
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M"&G^Z`9\'3WI?F(BC'9U*CDXUK:28T]<*TJWE/3CU>5ET-)CC&2-#9<%`2BH
M#T`;?(TW7U<\6O-(L=F+WS#XS5YY#_7_Q6M]26<#YBC4`5L``DV]!-/WVB?P
M.)HW')SJD..4*4#D9".?;#WY8M?@K_A^%P2.TU7%*\JCX"_9H#5ACTG*L)RU
M4^SW"U\=8V(>]\-L\<X$+Z0K3>BRU&2H#[EMO_O%UM.GOBI;Y.Z#K8=/K*;5
M+:1U80*Q/C6Z)6$;>CJZJ,G(CZ5N9]2FK/[I]=1Z*?>MTN9(KM&46UY%>&]=
M.M]VO3EUGXJDZ.-D@F))_E;8%KQVC%/9!/9(F(%)5I-EASS^GJH0RQ4YMRL8
MIF7-0KD`OR$<$$6<_>#MEPSD90L]&#;;W>NU7ONTFH@\P;1I]]5'BA'.H.8"
MVV+1)QL@9++'LF#3L)?>,9=JNSZ5;1&2,G3"DLZ`?@8*K(2_;7U`,2T%U(;J
MB]GJ7*%I5?P1Z"=[A<AI`3315+%/YLE.\=WL`RM=;$%-L-*8YZ*@1DEG.G*7
M(VH(-N-&/@JITP3A4L!+LU/<Z-260!:9](<L"JA#%4O9]'(N6UU.6.VLXTFJ
MXLW;D\=/MY]0<!53QXO5N9:GS;S%A<,^P[C@!/T4UVF4BLQ=E$JU9DY=%&OI
M$C/8"YA:RRU:&P"6`+QJ:)*QQ]7ILCB+Z1-^B$9=`)""Y*E0.`8>O<>]L)(%
MOJ:<!L<45Q6UIH&",A?"KZ-DQ(W8`JYI'F$NNFY8:GU9D1IF;&POE)?XR;/9
M"&#/%6E[<)GI5W>$*#+E>V",.6*\D.9T5^W9"5"\^^AJ<<G>ZC,#>Y/)3G'H
M843<`$M9R6V;RODN<KJ&VC0C+(O+\JI`5!=JJ=!>Q=?50F#J>LEQ9"L(Z#!A
M6;[K\`ZRLEWIB5*TAL8=@B>9-0FB3V0AB(WJ*"^3(<-?PW<.%![XJR"'9),,
M/TZCC7#7.0XL5W@`R@1VEQ/U\<5HEU%R>0[6P7XC#R+/:S-I?QM@]58;0O6P
MC-D;97<8M0T@@U+9&K2)/,X+<82C5WP0QC<WE"`GQ,GCU0+-IUI@E:*FN"AA
MPFE530NL(%58]B>@9?MHB8#B_'LSB`2X-O4<PPLZ'I:@3S`><V7378_U[%J^
ML';6C5D$>5T%[-@B(0Q(%(/@Q9*"M?ONF"U-1+L@855I4/TMA-@IOMW??VV(
M/JA/@SI-*<!::AKYOI124.+SO9C7E!6XG+L-,CM08KUP7I(B]D5#&RLH+Y/D
M\#S]5_9J5F&P?POE>RK$9(S]REOA,XO.DSXV:1P7>DW4LG237`MC;%I2\K-Z
M*/9#%5G2T/<AQT71A=9)S"ME##PY.Y2O1]=G*^*9<2W+G7*WL#[1"O)F'C[]
M/"!A5#C+WJ^IA+F[42.39ZU4P?M@1CB+][718#H-F`&\O"=J67Y4RB`R0,^%
M_18:B.2(^1(;2MN%Y?VQ0AI!+@>I4WP#"(("8Y6M6NOC1-`?7N3=8TJ7=),#
M`Y-V0/4+GK?Z<("YQ;"_J9MW?9OVPCTCC*BGN'[K!9:#Q7_-B<:1'T-;Q/S_
M&F4RNA2WUNU,+G(^U8*I9*0$C)+L6L2*\7*S;O4%W)*ZE04Q7,U:U=5ZZB4Y
M(Q$J2SN)G!U%[.);1ZV6;M$".\LQ5AB&E/+"TQ+14WF%,1&U#7,+247UPXA4
M'X6"-(!6\J(";$$]ZH2S!AH?3J-+5_P9L(5H:[!!EI2^[0$3RGI1_+-:ZS1L
MRY+]5M"REJ[!V^M8B"=/F7S1&V0=G<]U/8R%)<9(<]>R.11,R7M%G)L9LH2,
M#?U]#,;L3-N08I%N<&PO"C6T!BZW<3.7!4X$,@320?!,Y`8T.>'5*&DM<N#'
M;!:(U?(LT\K<V'G"$*716N"=U6RE>*.`NCZ8X3'`,ZH`+[AU,9R(7]07*K0*
MB!19_E'FJ4SF]*JXQY.$!0)V#'F?/=E,P9\@&0QP"16]#+G$%5!:0N@7[QA<
M,VE=::JX<N5*M`;#\GBBS#7CE)<?Y)?#&#@^\JJD:0U8^.R!8.9T9.:[*G)9
MPC&Z-:7G54$.5AR9G0IW&4*LIW/Z-<VPJOUJ\.AJ.GSXPX569`A/9J]E4G=J
M)M.L9."*"8I(U,#483XS.@%\\IP!S["1;+Q!A?ZEQBEV?_[I+W_Z7S__],<5
M5DL!+<RPRKSP#$C&B>7Y).`W=DV-^4%FX$(D/)FL@2CZ#'MK9Q`'&TA$9V,<
M33XP&\XXV5T$[^1[MI1\(O^&Z1^&Z?LO=IAQ3\NI/I:7X%FO:I[AW)"_,2`.
MMH27DTZP_P@][@_F?9TW`ZA9>&W?7N>IU(5M=L0`:69&U($!NS%$6<,KT"VT
M5YC`86@1YU"?"O&UL@[`W3%\!:HBU-8V8!&6;,BV!%?J[)*>=VQH.@(N,$>_
M35S9#09#T!EUU9BK1AD4_:IS;AMR*>E(7S,%BO?HO)F/@-OT1G6VFL!F!3M,
MHK^"9$+S<I`$BL19]X@>FRCGJ:QVK%5X@>R7K$75<985YHYP*%O9632T^5RR
M1KY6N5W;M0QS&,66MY.@=AK,S1,5'B("XMX)_[9,BWRS57FD5X)1P\YY'7T9
M%B&]G)2DI>_1O@>N2#TW/O!B1:G)?(F4[:S^J/\>3/-VSO(6-"TO''Y+5<L)
MX;@H(,]F$A=1WV:QQ&4Q`E+`5&I$T>NGH0G0#E[9.$$$0!0BZSGD%;'5UR82
MT50_\52:?O?.(X#-#EA.,9BZ.Y034)T*=T-JT1PQA;-S9L7WM*\@7`@]$3G0
M9J"SAU0>:\X:J/IU1L_I]'S[I?FT?8,2?4*?L)/H9!V8B^[X&[5`5!0CC5+`
M@2OMR5R[6VS<`X?6SE$34<7D0^&LHD6EZ'B(A$?;'C6J%^@\]D!UH<(];DTB
M2[5$YD"5<:!0">7',=3O5-_@YZEE*NWO+`1P0=VNLQ1Y"^$QT<@>H/R@(H;R
M'+Y:KW"X_8!N+7E8';0-BQ;PQBM`4?**@G<DN8@W4&?)>8N$(;PM>@:#H&\V
M7,"Z%"A7B!6[F))CC6/5;,>@G_%RX,'^\J?_VV=,V8G2B0R\E2>`B]:[:A60
MR1CPY?6#!.03AJ!.;D("."EI#Y5#"NG,.)SX86X85G:7,[^XHBL9_6R'C"_=
ML`9:L3AZ@O(Y"F/."?7+">Y]1#+1I":L[U0V63A[!.&2E'AD[&+I0//:_4.8
M,*%G-225(E73F(8X\"_>[ASO$&-AZ*5_SY2FW,_ZSK$A>@U^*C>8,I_#G3);
M]&RRBZS,TUM9O@4Y8'_=",)#"^:H:<0RY6NS[LI:6Q;.]`DA)4(C,Y"H;2L.
MI@$%E=*IE<F<OBP/\HV3.[7@RJK;94%2TO*V+._Z%XWM.$_%?;8?RRE73+!T
ME1UC$[4B2R.@0=@]JZN%B2%TI[#.HE$2ZO';#$KV3Q;%Y'9@Q'Z0'>F:C*ZQ
MT%"M)LL(6+9J!OEE%;L)99(<V*-F1?>63><84!8!68PE#[DU9<'(`GE76^90
M4?G&\G9H[]G*O$ZB<EXB4593N8S62:`^$H-\;HF8FRHSE,J`,+S%CB*RHHRN
MI0N1)PE=!,?Q1U@C@P^6HP)*2D[D(%0FB6:TU9Q-!.2$OV9`Q^$6B3C<DICC
MBOB?X^0SNEAS-"GM8P0]`.@]EZF&.Q6=QH+5VB\CM'+8I`J--3*Z%AE%;#E-
MRE23V;^.SC:?#(+Y!9\B.(.H03ZS$4!F/Y<1R>16B$]$`3<A747L.I>X$1O.
M(:!R,:U<M$9816;RJJ>"":,952@.PGG8D^0DO1=L*E;`:(`5I7\B)(VTQ03-
MXT0>A[&*"-2W`ES%5!1M;8#2NAT*-R$2?]9%ZX9#=!!7'!VHG369;7\#0AT;
M*-C4.GZ2@8:45+`X2.<10L9-C49C:8>;>C0'>U(1E\RNB/VD!6-@F:Q^$>`[
M&Y5A:3-^8P16]6K!^BP`3(S1#-WHLJ69QFD99$IH77RSD&=M$?\WDW+T;OMX
M!"H7E+>_6_@H+;/`Z?9SH/^T;UC!%"/+"14'=+T?U7;36,KXS?';QI+%SO65
M\*I)-N)JTWN6P),50;$"7+.L)":K[5,.[QJU-(AQ0$[<J!@E,KRNA);B++8\
M)%7+)F?B;/KS3WI*MKX-CE@S@Z?8R/+=9,!X+(1C#B@[[$+;7<I\PS*Y4<H0
M%?VW`KJLG"HSC\-C[^AS9*_)$O)T5ED,X`9=ZA"(;JON<BTI)IY`G%F3%TX+
MD*0&\36?R3[X"7T:*6K`2GE*4K4VQ-A`KZ@3*<LC:0-(M`-;7-ZIF=$(9I4'
M'XZ:#$FLS/=W(6MD;ETS^J`ZLVR=6#HY)*EATHKW,49S\9A?`B=NN3'MJK03
M%;<@EC,2V9-,YPORE0IG#0S-24:MC@%1O,=>LK0@\FN'B/&+T]ET.TIFM!6$
M!+F67Y?\RE-B\LF;I`"93LEN^OZL6J$C>.F(270>^*MJ,;'`:+!NKOT0Z$"0
M3O$(:D'4ZJ&_1-:,+[UN[78VKP;K:5&*7$-4V2PAL4GI!B1_4V5M&\^4,5M_
M"K/S7'9:,RD'Y/$U`6,V1:6F%Z@!]L&$`@"_4`@$V:$G[F=*PBY6B2C(DVNQ
M<,*M9>HL:/T"`MFLYG.Z,8;).9UZ>&G'#$#GQ_)`_3`H%S=9'%(^C?PL7%5&
M2M!`Z_(S>DIPC.G^&DMOUORY];ALG]&2_0V]BJ&:0(=..(!)&=4.8$[3`<SX
MEM:*C&1'XZ6@IM@F=49&'&C;7%)989!W9'JNVK`4VHYU/%2)3JOMVRDITD_A
MS"@Y&.5ZLFU2'E!F#*D@^0!@CB&Y%VRT!A_0G`H&Q?]N`+M(;JH]"T?<,>/D
MHEUU8ZO#&.?EHS6K0\M[%,S2</3"JI.0HLF5ZP9>4N3X#`+Q-];N\[%V_<7S
M=``\<!T5"7K:U@(<"8+GJ<3<EE"&90.ALQ1/ALVTIP%'TZ:Z#$7C2P%_B(AY
M,F^F&X`""=NR.M"FWHYC#'("WZO)ZN>?.&_2%^<CAS#]G[?[/_RPX;`"*MX%
M*89'^F\?6JA6G)0?AWDUT?%`T1(RV+'?'M\5U$@1;+./>;/AL=UU)%1XP"5(
M:D:TN%*-S_O'!X:#/G_T@#@'>E8^LZ$D_ECP!SVP0^4/JUN$G]3=<[:V+ML/
M?6@&)L]I<7#R6"[EJC=;NW*JJ^CWMJS4>E&9)Y5_-8#KX(90B^<LU8U188N(
MFID8O1[*D19IH.P.KQR+D@+T3CMF\)!:F0+O!(AVP<[<\',*U-#2=OWR$7GJ
M(&`GEFS(PYFS8W5&ISR0R2O?:(W>)3]'7R\9S8!J8OJ*7%SJV%E'</XJFH5(
MM;.&4\5$2LFMR54&)E(W;S"EQ)+(!(2UH=K&#.U]!?12`]+4P(%T2A+B8I:0
M'3EU*YG)HBV`S$UE&+GEI)4C/.$N7LCZC1;U*5.JX]`"-Q-(E:<H6JIQGL=R
MW`"^&2D$U9K6C-L9I?^N;+:)3QOKTPIBN:6<:1!,?5/*E83G26"3[1YX]!-)
M(E<ET+>I)%E)GQG`0-6?V+(Y4T2:_M(=SABN35M5A;E$]:#3(;2(K0@,NV:O
M(/E]UP9?@R<]`.F)5]W-*E28XJ=R=I%`O3GKVQTF!MK-"FZ:.F-95?!2@Y*L
M;,CI(1M2O'`QC>[TB4='S*-!9+6N&^I0"X^PFF</(G<<>#-,2^1\Z2%.`^/X
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MY5GIL`X$,:V#R]JT#O]+P*LI,L6>VA^\V0OS%./<[##&IIA&ULR.EZ!KIA'Y
MK$GL9)9:EXTL*:#$FJNY3-!0]:+0PWW.L0$+ZC%_:YG?@2G.13$?3MZ&\7>T
M2@R<UQ?Q:R3SW>%?EU7(Z&9!I'19;[I"F.=Q<V)#W<0G<^O&!(4&DCB*/<HY
M0SMUX9F'4_UQ45^FW[0\\P@T4?6?/XVGQ0/#.&[NIPAWPWV.5(]+HF+BY9!*
MP_`S&6U/8'7^*(;(RRMI[_R0I'-KX09)(UXF'_T;VFSN*[T0*^S,(*HH!>HT
M#4DN>4"2=D(2\#L=\'$<)1I(G;_44_=.[\,:CBAM''+`)A=M(12LLDB;QVXP
M.[B0ED;A!\(OA:Z\DQ._#;_DZT6%=6[6.!2VJO[PSOY\ZR)097OM9HO&,^@\
MI0RI2$,-0K'6:A2/_+$U*ND1T+FGH"Q,*>&21`-YB7DXS_.@;=?[O0%:P4[O
MK\YQVKFEQ@#'_(Z,2VM8D26"@M<X*Q38_3K+;"T[YCQV6^NLX+<S:<F!NAX7
MW%AZO#I=FLG=>_!X^]$#K.ZSU!8K'B6_9X+(`8"52!0N/S7PLQ\.PD!W1@7"
MT\UF)J<STP[NP.QD-"2Q40YJM@*7*5UKEZ+Z(?4&4TQ0^[K$V4^KTJ*FXAC4
M(#_<U&%M&C=80+,1/'$N.FS#'*-#FX"3JF3E``M$V!;XB>1P-((@D`M:A7@T
MC"K,L6E`#6&)S^X3*N`0ZZQ8:@AWL=G!5]!,8J&;55N_I4MZ@["&UL+6@$0!
ME8@8_.O+9@B2V(!!X4^63>2EP9\)=SRWYH5^+/Q]V\$M+,9Y;/4.8V!(%,8W
MV[:'K%4/DV`E26=0>Y;',`4\Q;[>J$I^ULLQ"MESBB>O["#[`U2$8[+M"GSM
M`\U#BZQ_\7FXG\T,BM]V=J!JJ="6Q;']7?=>S-[SYSGT'=[??#(P4[PC3F[V
ME[*/&*U;RLTG!A_JW/)?N3%%2M=>2FK,L1RFR6"6/!JD:^)BK-%7H*)/S;O]
M'PYBUE/U:3,"$,.KHQ13%2H,P&Z<1$SK#^=DG`>:=+8V"FR205@WJ,#YDG/!
MN@E"EI![C4%W<VN1V,Q:H.@U[V6,O_%.AD?BI0_6G;V_Q\Y30J"^1JG0[;CT
MDN#]-\)2M^L_[,_?Z>8+)`Y9#XP!EI/+:W1&5"2\Z[?6R$K+>/^"XZ)K9\.U
M=#K)FIMO3;2,@,EY@!D=DX/;CZX4(6_C-'"T`1K+0\9K;_#+VDR>)R#K8%%T
MRPZ/'!7#DL684UV%-I;K;4+0`7D\4\M6AN<\V]?/5]P9FAHHA8.9VX5X8.4"
M?F^X8K>]H)<?[4:4:/KZ_`S/.@JVAW6,<;/(7SO)R_:RKQQOW"C]CZ&T@_M/
M6WQZZ=IV_J`;$9JF[/?`@-GVX52LL&'[VL"V3[CX<"KAW^;AT.E5#?/)<3BW
M?J#\,_24%`6X\^R:QP4/UQY%ONZE,YVWI`<JI`_[.W,S6@;!B6:T_Q0*L/GX
M_B<]W!&5C=?D7#M?9XB;[K_AJ/"U@_47?Q0/&]WB`@RI9SBOV-Y>8$%4NGX!
MO2?LL:.Z1'#_-6ZPB*@?N?VO=&5%7Q)`FGX"S)/]Q(7DIN3I,#&Q)2+`I+X0
M<'V/LL\02"F(2^X$4NM(3,BF<F);(6U":?2L/0B+A4FE5KE:`HN0MPM>S2?=
M8@95-6)(I'!$_]U9&27G`(F28'J5,=9PM2VDF?+=N%+W)D;(0P]]RB`[\H0,
M/WWX#W%PENB=EOS'W&ICHDZ8*=T.8HT'OV"BW<\W3C3PAB<])ZW]I*U:A#NC
MT,/%01A92TS)3>@"#LL0)"U6BH,0)V=[PSN-NG65QP;;?"A)JM@I!.YR6LXH
M].M\@-.\%8SL,!H6`#["$.B[0`;\>H'(KC;W9U0FT$I9E0[=8&<B:&=SV4P.
M%^922QQ)$`#)C.7\PK];2>L(6#Y^7]C8%H4Q(X`9M\SL!;FQ#@D4)$]KA;K$
MIEU`%I>Y-G-@W<\L1,4I_[Z'S9D`FY3J!>I4'&\_XI$)G!%&<O5L]Y7HU-E@
M9U/\(TE'5Q'R6Z>R?2;SOM.RP9"I984-"EN0OIKBHV.QV;+^K)G6;_"?%4@!
MG%GW0U:SA1S+)$>B@=I4U7BL-"#WGH"R[7_J8LC6%27/XFL61`$#LL2BR>]6
MZ&O\*$U,`=Y]NO74/P1@+1'7#.;9Q.X@IZ2.NI.$+%=TE]:VZQ=R0.5+/M)C
MZS5:V-FZU26\,[)99;(#L(MJ>LYYP;%LIW"T163\0)2&T4M9/5-%=80@Y!2S
M)07X6`4>+@N1*D'DHZ'4/6AVNP@;`%6O!(S4MTL-S5K+Y,QD!I7KS(:.%3@9
MN0E5=9*Z*2EQVPL:7I'(/)#)\;,R29P:;N<3X+@J'N77;=U"_D]INJ`DG-)N
M`Y.X'W>;]`'Y$+<=EH8V>^7'R6RIF]>\2[BW6];#<TM=)Q0R3QKFTN^GZL,=
M_:D]RF`.PO.9D8Q`31WLA](*%<OFYY^D[]C4IN(_U?P?BH8L(2T=8](JK*?5
M/*/VUE)LFI3\:?:V,I7Q,!N2XG,B*"YN'E/9UC,=U*;3C'&YJH&J9(R")LL<
M)"&(84L,4V+^B1O%#,2C<6V_GE65]/C:O#>SISUZJO#&QR(B://^FY;F+`Z1
MM,2`>$!9/2L3H].VW2FI<\M?FLG5R2RJ!7)]=,^%E@@[TV5BY,<J+!1NUYDJ
MOK#68UTC6AMEYS0>BJS*OOZ:GA.EHNZ2X%7ZME`#L?'-_$KH7@Y8!950EP3'
M%+FY3Q4X&9+ND",_AL/@.#6[K<U`K&*OQ)QX+B7T$Y?Q]CQT]1`C%.[;ZUY0
MV"ZUO>:N:]DR%<.X=.XQ_*+S619;6U?K>"%%J5)7KA:*K>2!3`<.P`84/9&P
M)7SHX:8K[G8Z!9CVE]V`$O+:$+">4HJJ[WL.]E/,W7-K?3<+WIJ[+<;Z)8.M
MM9TVV*>.%FYO/,;6%R\K:G3T5D4*:,#W8:LW7LHHDTX1_J%E$0>$7[O[?H2!
MZ8_>D\JZ!G.9D1*G:CK_L%JB':P)JW>L:,Y*AUR4Q400=&5JM:W[E[SAX'0V
M79GZW=U][+>F!?\8I,5P\0$7HG'7C%V4I7(AETMRLIAJ(?;TX+G?SHG>)8\N
M>V@'/DP][8D_6_6'SFNEZ@0_#`]))>;*SH9;.22X9[1NM[%)OHP;/=ZNN0OY
M)*X7&Y`;2GI7A+M1_J^FWTQ'_36?_M2:)*!A5"S,A@%IF9"H?0&-Q,LTY;ZT
M'J=@6ZOK4/"%43!&S)##TX.:W[`+WMAD$$K%*[BA=G"SI^'>@VRU9OOLWR^.
MW$FX9>BM3=9-13R+=4*<[OY6,,H*XFK#T>G@<%_BW3VNQ17*S`,@^LXHM#8<
M(,:.YAV%.JQZ$P6O6=[9:L'[E//R#`)I/>W"EAQV&.O$5FLREV`]C1%0",Z!
MFJWYU!T.H:O_,40?!R^.;-OG:A725F93VXMU%(2(GIB/'C]KK8+TFGD=2<WX
MVQ]5,>,Q4&):)6L."T->A(C6K,N;Z#H+R=YGS'HY,<UQ>\N-&ZO+.3V[("/#
MJ8$\.B).=(<F[SXMI.L.ZF+3-:'F\@)GG7,WW>8AED&0=((%H2-7+8WDZY;V
M9O.E&^C57#-@3ORR>[O@LSU_GWYO78NV8D&('%+&)-@"V.,BM;A7=])8#,+Q
M6L?LI$8QIYZ*2:BN]LUG?(*(T#9&^P0`16+C_*D6ZF>H+T]70$>3?PWEUQTC
M%+"5_5W6G,(.A=B#HV_>[']I&H07PG'0+$<`3ZM`:CR1%04*K^RC-'`CGIZ2
M\0IS`U!IL/$FC"_;Y9E`1/D)(N+D!M`@E@/V\VH(6<IX.IC9`RQ1`DF0"ZK&
M5B(1EG\R6HPO'0+YX:K8#1+E/B1DB#X57*AQ2PUC0O=L#XP'(J[XOJ.,=0_6
MA``S6$<M*"1*A*0&^`EM8D#%<XDH\?A5[$R,(Z4F$K8QW<[C8%$WD3PN$>,=
ML)R1P`RQKMK298"-]_=R,P:W,MO=P"TQ&:N7PDE;R`#[8",]*HC4<>$&W9*D
M)4FV\(6&</KH4W:=>W)9:&0"NN:QRG%(G^P]??"MR5_\X=$77WP1H>ZANI)4
M`G@C<T<#!MU8Q%*AN5Z2Z=WGSK=L+UWJ9Q\T4`^ESGJ@S?'U]K;H,[_'"7NO
M@IBM2G=.H:G6S)Z*+%T`[2*8*UV02S6.1@L^O%D%__P*C?;KU_TR]U_;1UM'
M59`2*8GAD'66/`$)P$MTS!RV40!*\M/8N_8UK,DGNNCGP46[<*X=](.<B14+
M@\\?G*[3Y8?Q&N9K[B-'$9%\$]OG1W8UOOWWA2['`,$$+JW!.?S%4>4U_IH-
MA!--?BT(*T+K[;.9%3D4<]D1FB9+J3S#2/W/I&C\J0P=ICC;FW>Y;F'-'>L#
MF'>"5JXEH\SF)^*=AY_[%T8B)I8P9(;C;PM]8&''EXA]F5?=`#&ZT(<Q9*(Z
MB`-9^A6ACU;YUT`??_\70)^]1[\$^C#=WP[Z,/E_*>C3\Y=_1PV*+,SD!NBU
M#C4@!#>C!A[Z_Q0U%-QR!0D7NA3IUL3$J81+2+.^'\?*`<!9G@,7%C[MXI>"
M*]=!!&Z7YBE6\-NNL)?&0WB`94N-G$N=!O,;.3M.(F8E<3^A(CQP66\(L>JY
MY6<T<F[%PYD7^Z2+G<LBUW"*A=+4[M"L\@&&#VNRC83E\RM.`83':21=Q\GZ
M%*GK1SL!A8O6C5Q4D.QE%THJ/L37R=6J+5VH03]RT1#)&4`3(6`^G4<O[EGL
M+K!8YQ4"2-F2BWKN0RE<Y=PS(Q#=Q^,_WO80<@:0-E41(\+6(NP$/ZOOK]`#
MMNZ2=#XL%GOR,;H;4<4KVWS!UZ]`PO=R'RA2WR+XYT,D(C8[)ARU)D",N:X#
M4^R,<`QFT5F@>+>F+E!C)3`LE"$TUIHW>$:T#6&F\@%V@/R:)]<,8R("SV+Q
MH65KBDJ$2@_S1+;-X!*O"D#FCQTL)#F-1IYG4ZO]",DB4DTLU;%__<8E=*K>
MJCRM:%CA"E47`F%%ZKJ3?GKFM^UP:DN]F'I/+?8CK@NPIRWP]\1\H-<ZY#?0
MMWW+>*YKXIO'VWT].SK,K*!"%C1T&>I*UR:SVWI`;'5@^X"UB-_U71O)(=&%
M*9<R+GY0E."$H?6]/__0W&#M2BD_;V=*>>E!7^Q1:E+RP)XV158`33?5Z=-0
M;E9;]'U-WE/QNB7+(OG3L1I+,8=?O9I`X[XNX(B"';9N@L7V@RLTA7#B2^'7
M9S+H9PG)0=4@5G3P$D^C:Q_X@S0I+1TU9L-VB5VP3D'=<Q/+@O)$0[=HM'D1
MH5'++-:E<5%NF^U0V7/+O&)924*U[]#K*4/*`DR_0X54TX37+4%O9YI[:M*.
M%<M0S*33+[>2^4,W!%XKDTE+N>N0B<@,0MZ/$7QL)JC&J4A`O)7O.'3TK%N+
M2F\(?.**<H#C8:QO-.QEZ-M%3;AZ<'\9(A-2FKZN3=K0VIJH8I*S6SP=)=%$
MU<%X5C_G"CSWX9AY[!'>_MTV[B)3=S&2;@$29]@),VBQ<,3M&B%5GPBAATW^
M.]2%5&';T6UT!OREXEJORX1I]B""QM;AC@=R(_/_2;(3F[VN$8UUAD$V,1@%
MW<J:F<](MD\DOPVFU0\V^=5GRZ^_^JRIO_Y*_UM^C9R),&ZM!0+7&;,<X_PB
M^S%O<T4Q,XOIC_(0V)'`(!HC!Q*OZI:Q4,G52P#;I%]C9DV/:1#W)S([=Q\_
M^GSKB<HV2L^'W)V(Z#!"RJG6.W"*XS,KOV8#*W=('P`^.0ID+.FQA4'RW.Q8
MS/Z;S]%J&C6BQ+L0HJ6S'V->/V7S,=K:J7F2K*'B.FX,O.0)4TKS/5%L=RD$
ML"4X'(NAF[Q+WN`5E=5<O-5RW?M66*!GL<(N8AYXZX[JK,\]U7V(&0#5(#^O
M.42"^XM5&1&DK92(C5\\]/J^!C+RZQ'=VNV?;(2'?&S+BV\`:F]""G;;6D?(
MO.GF=.O6B!X6A-4VAR(&&I+?>MV8J6'E.OJ2`I4%M[30>J*E$@3<\XH/9TI<
M0-L.U@VO;J(+76T=NG`VU59PXX"VV$X'A1,F302^>N3-<FVUPUI"4AGA9@M@
M[LI5!=AJ'R)I.;SW^!\B&S9L.M4R(%A@SG4<<%.H.H\%"?'#5U[%PYNGI%56
M;OM039`]K]EYXA9U8#F:+XJU)**5$LLI^.U=DI;0'[-A!Z&X>?.J*27IIG6B
M/HQ89N*`^YKEC(N=(?>BM"KCF%)4MH?T=RK2&D%W$-^&7FVJ^Q/WO&&S5I@R
MF[R9!VPF'#EV;G7V?<O-ZL2X?<EVU^2+)*;QCW]\XO;91XCOA)Q.H&,@A!(9
M60X[.5$L#]F!=\+".=*TC=LUS79->!16]06X,(U7UEPI3C9\I-.72_S+2?H>
M(X,0&/_D/>.">E?B7BMU.OT[XOM>48["C<V=2WG,D]CU'7GC'I%EY^9=\P<I
MZ9+V,W`E?W,P$'$0XI10]U\!!AX^_'SK\:\*!M2_\F?=<_B?&0Q`1>2-[,Q_
M?C#P\+%7G3:#`4Y4.A?_8\#`W\S]=RCQ*[K_/6]N#Q*!8OW=^;_S@L)_C/-'
M&6_I#QT<?++WD^J81_HTP/-WY_]WY]_)!"AC%`([I?%3BG1SMO5A?D;C(-3Y
MO!X#^K6@)#:'QC!%V>]F:=UII^74/G6,V/-%%6X=\>9'^=;MD*?1?=-\BI:&
MM)A.M""[DQF0Z.>'NAX^NK9]W`X;)AP?CUAI$)_3,KQJOZ`A3!?]5<-KTMML
M,VD&PF1@K-Z_+0$LI@T]BVG/?(LF;MI)1,[#\N_DU:A0^<%Y[YGKY!NN)45F
M^M%VA1+="&B.85I+"L^<#N#A2;9+BP]B`2<F.8;#YYP1D1P'#T9^2=U15W_+
MEAWKHM^K5O[Z&:M\%>0<+-*RCB%]E*T=QNX+IC$QYB0]K`]=.7Y_IEJ)TO[;
M6VW9Q9PV9&4T/5JU#SCGB1)_/8QEM_-I%@OX8,B$^SSMA$A<3BR+,IHJ(3"=
MZFNU5'AGMQ#.)C,^MQRCQ:!'_),;0=41F@E7+&?9L7==?IKN<3;2B?[^<>#X
M`2VF)&T..54]4.#,*MNO,D-M!2?<[83N^?UZ6@9WEL5/V+_V[VC[-7D>PW8^
MO<@=,-R-,RY=!9ZO5`Y$\7D&ZHF;OROG_/O>B$,7:OH37?Q9^NE/*CXSJ&^1
MQ.$CH5`!#@@3T*]TT2H9LHL535M<F2]2\.*+NIKHWM_[X2+4L2X'5]^8WUX\
MIF3.MZFA*I;#AD";[/]+4&?S"P*]R64]HG9-DY2.5Z$<_$&=K^$[(U*[@90>
M9GW_]/99]D\K\J^\0.J<'RXZNMA$'R+/ONCK!U[A0S@FA*VU2DX0IQ5IM(GQ
M'+&SQK4@C^I,;8]W);GN&!^7#UT\+3[FXN!B%%8CDFKA1L?XC\0-54R2&!L3
M/9H`.Q+K0D+2F'I)VK_P"_3,O&O$G`)B?[Z$4,<D/XA!6XIZ*@V&#&Y2TWNN
M7+H>C@G356XA`WC@VF'[E$AS)`M648_69(&"OEH$9J5SRJN%FQ6W!SQ(2K]`
MF4?HK5JB,1E9+NL!N2RTQ*AC'PB#C>H8RUKZG."1DI@033UH4U2O!)ZN65=;
M#AHNPR&:\=T?YU=:5=2#=@_RR(P8+KS)Y>7:_90(V4>X!=^4GU4#^6![6D([
M-&+C9$0YE*$/F:]`=[NUKUU57ZBXK*7B`.)T21ZF;[9;T8UF473K6^F.-*?4
M4MYX8M]/YB+=V9(N#[AS]VG!QQ<GP5KSGU!=+C(VWTH1@F"DK4])I2"#,)HQ
M_&:>Z,(<A$?NJNO<$$'*\][=W7F<)DPW%R#FF<N8Z*`RM^U90KN:+K!]AGB"
MK+\VR=O];(_.E'#Q/2WLY62+6O@O'SS8FUQ!?"_S^KW1*L[QL+O\[M(E#/Z:
MCBI+ZI)JOWBVGR6YAJ]MGKF_33'^+B<L`MN,BF&M&XG&9>TT%15Q,]TA>TJ&
M7L6B.2]E)7'+^9K.K3>?FP5N,;OBN#0W[F:'<H)4I?M[K=O&#Q/I<#MGB1QT
MB:91H$QS]8,*PQ)?WS?4#([;7I/,IH<&.CA28Y,9I/8U[M>V-\(\L8\[T_NX
M`R%JW^=[`9!8J.46"[%E#P-H]LQ.0(?C3NT5Q;Q2Z^NU[?[27=G!#NJ]\`UO
MMP:2(;"`MF,'G9D3/6@O,'<R6<M9.>Y]IS:"3"YQ2LYVH.&@OO@1+QIR;/'Z
M?)@F#"*)5P(FZO)W&=Q@T<+%LZ:8\,&J+1(Q:],!=!A.LT^VW.(F++NB61`$
MGV@W3LF<"%K-]0&6!"0E\CWS-+"3)ZP[22<D"]<T<E0.#"\;KO$"L?V"?[6M
M!>WG=*'=:<GQ06X+%NDEE)4^#874^,61ZBW2N&?881UTQ@FG^4RJ6M[$X<0=
M;LFT:[L0$MZG\]^+_C;UI*0=193OKY)E!2TQN@,LY?1$J%@&%I&\-AO=@JTH
MI/2C(B3U<2`74<-Z_.(E@,A[36C[,WBN#Y5=3NNSJ[BNX6PUURQKX_:=TUIW
MW'"5O$B9=#<,[2"DA>#JXHIJG/`WA[DR(!+8%+<3',+Z;3AK(A0`D%$*$.N=
MTKEXB_*!S';KAK48K-NS7FH+X7#+ZB9.Y!NWW3W%SR7;NME2)QJ87I_E.*4@
MY#U/?2DPG<QD5:T\YYQWTRD(`6^I.5E)M(,892JXS#W!R*5Z)HT1`H.NP3)>
MVD626+,+(,J5/H@*TDD7UOIRN&.(-(\='O-&)',!=FDI,!`$J8_!B!#A4G0%
M9PK\>Q[%+R&^Q6I"2Z`3.4A1,M=C;BTBW%#2@4_1<<F_U#AK`TPV+G082JO]
M@Q'ATYCO6246P+ZE0WNJ+BN@),X5.?@+60ILBT8D?`H/$J.$(\:<S64VOF&D
MV_K4DZ3TRV*EHI"^4<+^[9">>\CXMQ'@)_Y-_QWZ"A8-_:UZ+W[W&OT?V+%/
MOA,D2/#:D^C.Y=20)(.N?0\G50Z4%$+,E^S'L**/1D\R[X!1S9,(EJ(`F<8Q
M6E$S6Q&6Z4;RMAD$'=+NWI#@[\?!Y#61/#4[M.5JFR[V,\?EB"&*<F60XM]"
M&D8_2=4L6#:9)LJ1C"`S(:2,2A1<4MH:+BX15XBWLRZY3N+)C&*(&W,J/R;W
M\AIF<#B7',`!S:NXFFE=VD*.^6`!AWBWBA_X)BFK`Y<CKR-]KTP^*U13I[H1
MC$.803.XA)@#K,6]K&X[M($T`['1B-F)F^BMUHCA@QX6GFK!&WDYD)RP8X\=
MK6X6^9%OW%B"IL6+:[2*]D,2D4=<B*./C<9_MJ47'/#$4CH!@VBKY&;0)`_3
MK*#,#X;1\%N#,'GC?B+@0\ESPOGU'HY0#69?\OE2B/V!O`N?_\W,:,2!@0[:
M6.R;0#A2#R<>+@MT1!J3[)Q&)E3F;)4CD2VR0P4NK&9Y.L[7?&`M=TL[A*&)
M6*UFT$4U.W-W[CD69%_-E^V1TA!*,PA<&73[;B27WZDL'!+]Q5`@8D\QZ=UA
MDC=80O)GB9:,IEQ"'IO+W1OP]-1'\/X;5T7!/_44HRK[)"<F!9>`:_K!^H[;
MJR1N9>6$@_J6KATB60)''4$*#+3)L>CD1/&N`L_*2'D7NJ>GL3DA6*']WZYA
M3VEK.8G<9'9;7=9*4NC>6+>NT]X%3]?D:R639B`B\060/2+PF_CMOKJGQ-HQ
M]K_FQD"-)8P28PHY=5DOUR24U4AG1`BLIAX!@#F1^5FW$3,NB:B4&N@?T0+/
M9++M++L!?!;L7`!F<@Y&1M-SQ'3T-6<A1155-.35/;H)S..J0F!,^`=V(8Z.
M]CB2#0-92XO!<.^;ZX^)[==0T5Q+U3UHM<;MF))]J?[@MW-]D81N&$_H`H;C
M>?0N[T73U13\(@<2487WKR.BHN5XIO336L3M'W"!7+$E42@*>\.Z:.H)M\S+
MP/T_]LYLMZXD.].O<BZ4,`50,D=)["XT0$T%&<JD0#&KT"@8!L5!29=$TAR4
M*:/?HJ_ZH@$]BYZLOW^M%<..V/N<PTQ5VG`78*-2ASNF%6N>`AB%@ETK[*S=
MT=)+/#2E9>3P*'BD`E!D-6?.%:0\!:N/MVAB[V3QFCH+R(T0M$=^DAF7++:Q
M"F1IQ/$"AS5MP,W)*U6RKO``DGG"<`\%F=%:MM>+BQ'\,\PTSV<6EH-YDQ,]
M&\IE_G0JH`IK^B1=O+2EL\^\+R0JATZ:W9GN9+4(Q"TGES8OUBN3AE,EZ5Y\
M%1+D<B1*H0FZ39M0*JKF+AF_QDW1@!,V,R/[(_.5^`$TGZAE1>IJIK3TLW".
MX(?;=Y`B*RK@HD%^E/OM;K4X2B5G-R92<A]K'!OD2$=8_DJ5+DI&4H-P=B@7
MBAD;)T/G,FR:9,8/R@9.D'%K8G!+2U[U*R`1BEUBTYBC5,A5JI+5V*%6GM:M
M4WGY`]?D1U*MP?0M<TLB!GX2VM6DTG06%%V;!?KA\%*%*J++8$#)[A?Z>Z-1
M2#83U@)R@G5%IT!=;6H%>6_S8?']SH$H5Y9XJ;D?JKY0:0>VTT'/I>R4SY_H
MYJ?H7=OB_YK,6(TH[_-E5]M@WXEU953(FD5A-L8&P5)0..T&GF<B0TM8QGZ`
MF:K'(Y@#'#0Z@T@82?I%(RP[%BP@0[YP*.G?:K&.J!A^CJA;EIO51/"[<[;*
M-!(JZR6\0VFKXABA</]ZEK0$VVGX&FGL3WYG<C\`&T9UCK!EKA,UNAT3/00)
MJ%Z>O2<"_8Z'T)'<R)FJW:QAC.$:U3_@U:9"9*XI#%+PJ]=4A92!"3$7R<Q5
M(5C*PX7CZ_&QU,,U#6&S;LZQFF\%?A4*BI#YJ$[C;OC1N'E2FT1Q:.%]N'I%
M@I;UZZ[53CN8A&IM)KI`3AS[Z(+234FO4WOQV%[:2A96U"]@&E,EQ'%87NZS
MR#B1'RP3N2,=U2CO<=("='<:R!N;(VVN!J.=`G1!R14AJB^P^5$8)QBK$42P
MC+R:ZZP?#_^5CH]E:#*0N(I*.]5"=0MIP"DCP86O[G\4#4TLZ+HUW#3JV(/:
M:ILZR,;.9^L[#W<RDHW)4D>_FMG4.'''"TSUSMJUMTCU?(SD72"1-A74!S1S
M^TXL:9U$8L^L'HZ?7@Q`Q(>I&HP;EPF?(B@`56>H:@:M5USOB1CD8:K#GZ7O
MDH/.+RU_+4=29/U&4Z)$\LX04:OD*#'%D9D)ON!-Y`?M+=<U'QY_4ED?-RP'
M[!G_.PBGF-_[W0DY%%23XKK@_P6[^CJ2`S-</(1K)7",WA2+[O/E>T6"QZMO
M<[:]F1IHA.QI4,J\Y122CI]AKJ*7R'OES@1='=#U*/<DA/\.#P/@#5!!.SE6
M'`*CWY>.S'."5\2X=>RH@E@>YS(K-AHTE[G[B2W8E>,3_K(QF];&[2U:],B/
M02/)B^\##:_$2'++@KB3WJ5/^?"57#!U+X3*5^W(-$JZ0UZGO5N"@(K^I8H$
M':MZT9T%I2?KM1FP`K^WTK1_XT\@>"#_/_`@%O01LB`<[QH(/RJ"KG-=PG7<
M6K(VG(ZHN<V"V)NO['B0YL(F@`ZPOVA[=7ZL=S.A._]0FP'(:#0$(K5"[-R'
MA%FB!]?YHV7X$)=-WZ1UW2[5WZMCJ%:?D)%.09I%AP\O\:SK=).^FCU:=A(I
M4DPV6I0WR`T8:C?U:4PXZKF9XVNV[PW3-4--N0*2"#E9#.)NKM$"9A?^]QX_
M<@,&0I%W+\F[\$`3,_77=]`7JK[NT%)^VB[.MFFP9Q;;1)KF%.\D!&D\%.G,
M?Z/*_E2>3>NI41@[[^_9E:UU0/R*4<T][KWMS2UO_QF,PMAPZAP9.`-;=!_=
MNOGHMKI+C^]&0QI_:`IQ7XU+!D_%5/_#X'RIL3S/==U^0#A?48@T1`T,D13V
MR!ES\W8B9\T(PJSJ]J7#B,L!.+`7PSXF<BR*'@0":O%<ILP&_0KQO#^Y@C@O
MK$#2'HO(1I3)D5J)X"NR]$R_\RQ&N<*M2:DYS5G"FNKR6:29&1(=54%78R<*
M(%ZG7-!P=L6VA00NK6K\?%VEC;;9I]EJ2P>'9I(5Z%8&V60NT93V(Q+'QQ'A
MELK;F+)VBT^K068'E:1+]$`.2GD4+4A#;LBST;2X,?,P-;EA>RD?PN1Z^#;*
MP><=UKGH./\/7C'/>:WP;])R1\$%@SD]_,0182@)B'4#4F[VZA;T]2083FPQ
MIJ1@(`L>!)32X!PUJFP_8]R,G48#,%NG02.S#BR".?5ZI$S@T)+@J'9G.(JH
M^D0A,E<;QM#O`<W*9G%8VE90'DT>F@$'>U3=HTXB8O/^,45S!P:RHQ"BD>UX
MU3&H#$>,?C\4N1V%)`U&1W3$)A57XJZDK_`+GKQ0[[1XO`.33#H!F*ERNE2=
MR0.X<>:KG>DQ>3WZ,J2&_*MY1QRJ(]J_'>XF)H?UH=/4)%1<E<*`>UZOUNX\
M-.1Y7+`.HR'AS@CR11AV!'X9#'(JT-+V@QR.X&:;!S$/(MUMOR&P*L,P(8S[
MN,!V]^?3F?(6@P``(+!E=Z0<G7P52`GW0D$Z3J,,UNXKTLQQW(J*W/M=?(JE
MW7]"34V,,L@8<B#7A&C*Z*RRILT'Y?OD0JH$GK2#$]>OS-!PWZVA5N"0X9^Y
M)D^55[ZR?3^S#H\[>G:(.=^\4-9,)"W%M@!`+)KO)5G<Q"]0>5G<G&[QBLA2
M,`%E<%`=A1T!."$(+ODC0M9]\$(W`3>4,!$*!3/2HV5#EK1&!?C-,*A<,`DJ
MB07DYTT,$&C&UFU=EH"'7>`=CH]:/,Q0WJBA__W1+?4,7"!\$6WW1A$6T_P(
MZ9>\:6USM#F#0;'LB[2:I+&7EED#3^4X3M:((+4S.Y$-0/6=@U`#'`]UUS-U
M!5W(<)#J@#?"K6&W40-UX(=E$3?"=,9ZI130QB9YC[YETL-$EASZ`%'A#0)<
MAM)KHSB=[\+?XI)ZZFJU0O-PTB/QV)7UM>_N:Q9#A;R2=S+.ZV42S:$CIF#H
M?3KTX#_"!C(T[U@"6F=2]UWXQWV/JJP0:;QPY_8?N!/[FL?W2(L+GYL-'[PM
M,JIJ"):>O.BN,M&!D-^[5=D5*/Y9^Z-R?R+E*'7.R]49&=#,HJ2K<XPS!=`L
M64_>$.?"FE_1-:0GQ,??Q24(;L&"TBV)-LEZPWSNH'@`:LP%G*.3.QRYYIPW
M7O&;$)55C%%ZC\_J6LB"^DY2N-R_%-"6;G!V>B:LDO/%$;M/F=H#T8`!,'ZM
M1+4_-&:)CI;<*]91$71/23R"U>PM`N5PMG]Q/<S_<6WB$+Y)_SMK$F4Z?+C.
M6,TF,T>%=5CZA8[*UKE\9V=[=HW_$CN0XKL;85BT>.1&W(4PN[[D,2QBV[Q_
M=O+NRFSF=;?!2-80G:0=ZUKU;R[R^`/%*FX9&9U9?VS_H\[M3,!$GPVPW\YY
M#]U$-78H[-H:=M&]QA(R#"7U:4K:L2<&KD2RW/;P3+BC'J^MN7>E,(LR(.D_
MN4#!@2.,TV3>$QI<\9=&D`"F(W.MJAQY@*>9]%R]J,AK;%H_?)"0@M0&.VTY
MDTL3_[79Y49IS',O_COIWIXH`2-AX,`#MVUP($,%;T7HHY".^G`,ML(IXK$E
M)@!K_H;/%K]T)T**7^I&<%YQT\5/X."ME+!DLS8W#`Y*WWL\DGUS0[Y#/.+X
M#]$$J26=MR/?^+M!TR\,3X]Y3G(L[RK*/[+P2>''9*!5B\,^)K:HUOKT>?>O
M9V\O23)I3P&1O27S.'K5>S+4IE/92(0O$9SQZO3(90B)3)27$@3@P>%L_0$(
M]F"#3!P:A-E.;"`$SDZ2<(EQQ@1KL_VHB@-1.X.,75M;1SFY\MY0*25.FJS+
M)Y:$<OK36+(OXKYSRX]LBAPM-OIYICU'Z@''J[?BN650ZP>9E\:`!14^>1<!
M$H2UW`$V7(>L1SN3&%D8"&'1<@21<FD+-;&'&D[F'S"SQ7(/6-V>)M<_?#6O
MI2IS\@X(#FY*2KQ^#YCYK63N^"S2[E@<M=#4:NTJQB%#6<.?SP/V7:I"C+;[
MW">H9#SJ&5(+8"DW62!Y=4YMX>5%TDF9)MXSX%;Y!]JXE!$^D`UE=M'QB;_-
MXS)PN<OL!/DNQTFWX>)65X>$C,MRYFFZX3#<59])SE![_U5"-8H\,:OLH)Z[
M8Q"SY]&O!D_**3_;GFD#?L$N%Q%)G3,(8`#="'ZW-+U;+OC9X24=9C^T7QQP
MG7$F$V=E0+Y:]PBO>XC;,&L"%\U7@9<L$:8VF:FU@!9`I_28,M&E/9>@C$]'
MP:7FZJ[UN:4Z6?F$%N=@"&UG>NW!7\B)9>OK2RY27_K:2F$1FKN)`AQ$Q&B6
M4;14<;O!,&DR4BCC.2,R0I3F+8/1(J!R3(/=?&0/42JA\!.Y[9XF#$SL(Y";
M0!U0P$.B+?2<MSLS(MG?8FM/B,I?4$3HO7=T<_&.>]"(H1`?*%-&K_W"135/
M`,@=,[53V\:O;".8O=?Y+.ZJ=I?\N^F$T.&;SX3_G,_E:5RG=\UN*!)<N]O8
MK$NM\[`!."PQS-LK%HO!$25>2?(FSFJ$Z%*@^6.R7[A5W<+@J5S_U!]5LK^Z
M?\I^?N#IW/Y'.QBX(_S9V7FR2A>A2BSI`H**[?:&>%EH6EI>[M3@FGN^._5S
M=/#%3*AOV=_A3)X.`]6B@T6@$G\Q&HF9$+)R,/;F2&>0EF%(Z(@MGJL)@.2P
MXASG2EG)IF62^LB$BY\]*0.?'CEO2GOGHA1/P%7J;KXB\@K'F0^S3)J+0":T
MTE3NLE*G/]B)17NS06Y![7>8J_2[0U)X3DZRUNV/G'W;8;_L`3@'(NR=571S
M8,"O30`*Y"P[H$\EG28W-C>4B5C=V;Q#$W^@'55)=+PST&I=Q$64.5RD<X?S
M_^@^-Y3\7+E8,W.[&H5'&!#("\X56UX(J/*&/@BK%C<9GUJ^N)<C;'=O(I[<
M@HG*1C9C9#SX;N0HM^>'9%U282LQD-1D74X:N"K-"!<6>H1,,3&.K$+9R7XK
MJQV`R-EM%8G05GQ?(!<(G;9EYS;N%$+`L78PF3-=H\N<,Y*9#G.Y/O&(U[@W
M5S?7=RKL'*Q2LQ<\GY<>4%M?W8!U/\G<;QC/#$8*-4`9R:M=^-Q@FTWEGTX\
M^#NX]GNPH<DS5^K!!`^2VVJ:_9QB1W)Y#?.!(0[Y$LCTZ%NS'IK_PGBV+0UZ
MF>N-R*=Y[+,[=+MX0\<XT33<%K,A?P1Q@A$-)NY)M]._7IV3[@2@W]SBW3W2
M.[*6WC+)=38BB6"H9,#WJ;MVLX^H#$;Q3W+`*UB"H7-CK[^*$#=6'T6^D[]_
MF,HRT'U"9U*=M\D??2`DQE]D;C]&JWGQI$5J3,::_^J3MYP";]@N9M@5;L72
M*2C_X<_^!U^6/8.,2L`J`9['#S>VS::RG:S8I@XET7]D9S[,PAE&H"KDD'1,
MU0.HRO`\8_%8UYS"_JT%PNMU/4+`S\)>3:0?8C$O@.<!.VMK^X'):;<3$@3W
M4#,>8!=>>->R/?NK=FG.^HBL!O,2'#=WK.=H=JN#`D6YJ)F7$MD+4!X]?/1H
M[4DQ-9,>XU^$,1A!VH4PL0"WDDKMVD9VU%X6Q^>BJNW(F;*S8=MIO_U-.^O(
M)$O=#2]T:Y*>Y/("TT.9ND8[&F*[4,910(QZ<*$IK(24;-LPC-ZI;*L(1PKA
MVF.C2^J]#2V3T`DTRO'+!.2)NQ:K/K]0_.!#\DY)48/VW)C!&*#"031]3@3T
MT>H:[$"%(GQ0',9MR4B]EY5[ZSNK&QKIHYKXD!&4&JOO>/R:>;/LM83(^R@5
M(@+?B!"H6IBO"X.9.*'(LH=9#:)VRLW5M2VGE8DI?R;?S?U(!A<=5[9<RT(/
M^+U=64Z+0(!4<%NC=V9!B8OI?E9^6<@%/_L7L=K3*2;XE(IGXXX=GYC#98U3
M)J2M2''GX=JC8)@&)Y?*[8&Y.X!5'SEH)KFV\W7KHG(L*U.6M]=!W."]'W0>
M;\?[\LT^;4ZNH9/(@JMCN+'Y=M=F1,M:^44)7Z)T[JW2-]TA)J=9,MFP^O@'
M".DF<G:FD(TJC[=[CJ_EQKBX>H\R_>^>U*\<G]2MP*8`7EYK"ZE7=)04^.SU
M::1)M;>CB+/5G3DT4SI+N4+]ZB?_^F4WH8:UF*FFHY#X1.$<8)`>KS:/KR6)
M1%N)Q'C,[`90.2(XD"M>ZD;V.9(348VHYTIO['%IZY-8?WP_P352+RLQ\$ZO
M#.%I0F^0T:A#,*<%N.8=$=4@D#^,.XS'>FR4/V3)I[_%N4:`?Y!!5^:E]A9S
M&JQ!8]43X>$3BTD\*<_TFY334/(4:K=CBXN68WF.8SF2K&%7ZVO#+!$V:(D@
M1[`E#\BG)+[!<6H`"Z']%;OU[;7OA+@Z\#UC0$4MDH?9M"'1BS*M^$%)\F*\
M:Z:LG1S=6DPZI]=8M?R))[UHUWHDD+G9M5HRX2),_13L0_;'S*'W"&[I'"+O
M`4?)O"N2/@IU>@#7W1K&%7(\(+BH\R!#3I`8-F.A\X[7G)Z=JN?0!*L1>`;S
MN0<E4$Y[\.W&=7M$5XY99:17"6D!04W7WK3OL[('2'HAXTDI+BF!W6XI9S74
M;6('^079I]^$C]T*-CS-M#*^$Z[$D@`(;OO,R#R<W>.4+9A67\6YJAM;28QX
M8@)3D$K?ZVX"M(`#`)9@6[EB\EUG8&JI;@*70BF1@B3[6X]XR%FKW-[N=L5:
M3L%7R]0?!DR4;A3CW0>EX@AU,PPTCET:UU`!D0D`OL2;)((``<P-9-^#Q<2A
MS`4O$B.UZ:=@3\?W$\<V_.XXI/DJ7(1I\PDT"@9<WZJBP;K\52$SP05:OK[6
MFVA^#Z,J2YHIOHQ#U;V3+.'!0#90;#-U,"3KGSL;JX^WEW7IF;:O#"67ND52
MW6N5C>R"WZ_ZCWTZ,9@'FZ>>X_\&WLSYJ%-/CO#2T0!*5XZFXCD%80-[3H&Y
MY\?^O.-(.G<Q[D"WM1P99("6N-SQ"5E"9F<65QYRYB4*/'M&B7^5:DCV3][?
M?J#;[!4MB]VCKN<;S4NWHE:UKW[8WS4U4'B!CF;V/?:<O>DZD/_K3];,`,WE
MD;<EE6W_%LMG>WU];>7]_95UM-#3F<T\#[/$U101'*V<T6[TYY=JYWHU>\/.
MT*L,`/R',2$CA;297%(@L0#[%G1KK*P")I!Y^;IU9_B]>#CC,EIIV*JIHJ`"
M2<E@JG4LT3:8KPP2:74Y'TQB4T@%-KDJR!]+YF&G!B'N52%\9"UR7+3IWT81
M]D]NR#NZI0FS>,&2</$<XI>+JY-(!9JL-0-B8A.6ITT:Y8KT?W.]B0O-P5#X
M&>@WU&R,Z`;W1=F&+@-)%G$&[RTLHM'<J<N/E*'0FA>S%R<N7;N<&G'0M-O@
M67,Q:ZC!VZ,U<M08'W4?KPS!G(/)$T`.O)P4=Z'&<J`C6A9H?M2EL[G^WF'^
MCZKM\+X?!JD7B;LQB32M4:/_#TVZV[`32-+NF$'P9):,`_JW720XP$V-Y$3)
MI=JD(83#SFFBIIZ$>,S4.2M(E;EZ@,86#B@/+HKQYSS77CI9+F`#YNVMU8V=
M6D(,B`7%_]Z4#ZIV3C0I8W@I-IXDG\-2G@HSJ%K`")HU/+A`Y0N8`S5+J;B%
M47@,V<R=1:KZ)'\Z>6`7&M)@X-X;@G);+ZI5LD6[#\HPS&L!R^A\B&PH=*+6
M"2^MWO@O-&66EHF%)']49C;H'$JU',XD3J\=WDD6NB2P%)4I42C!9EK^WUZH
M/<>6#9XV17-#OV'/*M'%J>D\\FP7$2:%<^\PJ>1!'NJ3R2*.M'NPCO3-1X]W
MA.7)]VF>*?1V4DI%LA@4A9^I2/"!Q5,NE5F3IA,3ID94=Z5D%O['W!I,[R+(
M<L9-<$4(333@*<D/T;.)0I%I,MO!3_Z_9_N1V(G4)MGJH$KO-2X;W1%5WC1X
M!DQ8,)`?!B:)&N_HJ,`^M)Y]+8'3':=]:YZ6I/ZU+'07O?@C5OYG<6\MF5!:
M&<B?E&%=66FZ3O4E&^&A4,`ENY$V@B24,^*_M4O].3PF[>^[L$SRO-N?]T]D
MWH%)[1]^N/U(`LS7+Q>G[5^2$&E_?WUVVDW_2CA%6.6H_?B-PC7MCZ_.OW[Y
MGSI]^X<_T4RQ^WJOE-.N#H7-5CO^CPK+G!RW/Z>3='\`(T[I;]J/F%YS>V)R
MZ4W-]KI/#\"(JFF'J5IQSR(!-`T2P:4O5-G+KL\%'D%L-T,0;/>(X>[7ZZ]?
MJD.TFTX(_/5+P$9[:3^:,W[.J(QI7[^,88H3D(>2NOL7@(+RX,+RWWU4DUIG
MXE9DD_NN1*)1"6E'"Y^3V=,/]')Y\/8(7J+<=0]I2?:(C_*HPLD'TN?]5R"N
M^[^%UF:P\AD,P'+QX6LHVFPFO0BL94NUA#DGY>V4@83SXO`&\$'SD)Z-TCL_
M6LPU2(DDB;28VYTM&.4YX]$_(_]3-6Z>X00.:/EX]A`F[7H.;$2Y/'&F>O?>
M:\D4>SL(6SLRP%$P?*;X:U6O#,K1PQJ5/&U)K)V:&1Q![#,U/7%)FFXC?6J=
M1S/,*CR-/5F8T=!4>H.G'@$?4V?7OC,6[5\JGA=/0#8\<90E^FX$<3^6R@-P
MJMAV`A[R*IOC`7"I]((6,Q\N/N->T:D$39-\`4+RTKB!4`^6GK9,J:&I)T)>
MH``I;`=)`1XQ9W7P*9T[16+;>P(E+@JK&X(?:?V!I&0_!Z8U_GS2Q)5@C7T=
MK5LDRTMQ>+[<)(J&AV1G3$.Z!-*:CB?X_PXU4SI@0C&_3H2P\OP,B($0)CZ=
M-Z7V9J8Q75K('SS&-CV.ZZ%>,GN+^(OUS1@"J%5A9WY>T9`ID''KGZSQNG6#
M/#U[#]46:E'T[M,9.4XA>*$X_!*B*=)4/T"ZC"(B`(&(2+,5&Q=$)C%^.XA<
MIF*H1!E>ABHQ;?'+(9:U/>-'QTQ+5.:,TLU#-;6E])C5L'=)5_`4"#$RH,P%
MRF@%YC*'4B\.OVJJU?_Z0.Y`?@]=Q`CG9_A@Y8S,D5C#`%;XK`>!(D+[X\.W
M3*8\OUMTD'\_N;IXP,,#EW"3=_1\"O>%0!7*@`7#1!=*B-#9LW\CGYZM6",\
M$=#$Z3LEZ16DKX>L!""-6\R1!73'IH9*AIAA%*\9BQ3M(D=H?K<TEY)VV\E&
MY/W7+XQW]0/A)^6K%7O[7(3Y98<7T7[V7?O#^3\>MC^]&/"K%=/X[D]^E!'U
M\^0G.>;7?G$`4#I0%'XTE)V"8`/G5C$=9<*HL]>S>UL/'^](M+E59<@+)9I9
MH`IZ!WV6RTLP]Y'F(?**?IZM>S;BT+[),Z>50)W$MA`\`[[,G[*76/(HEY!"
MKIM=)BA$6CQH,&QC/9V;^-'#S<?E^,-D.P$V)UDZ68?I*5'7*@JB=3<"(-##
M]JUO'UZV;*S8G6M9"5);S1UR"3#)4ZFF++/WQ'[%>TJ5"`(XV%JCFXSA49+Y
MV<@SRL3X<MU$O"P7CXI/F`Y4ZNV&=`RD[VUM6]6-7<X]_(5#DW;"!M)-`DLN
M'^U,`B!JZW:MTF/H=#(N(204?N*7B4X]K*W4\@P0VUGDD-_M%";`$XBQCG'/
M",(A3#K"*])MX^&ZWW'')#M;L88;/>;'#<9QNES"7JR4^=6O7PQ\7[_09^7K
M%P%Y#`T*CY5Z:XT.9)%*;LVQ5!)5+C94]IQ3S+53\C=S#0YOSL=]O#7KW!*C
MVA/M!4L9335,*MG^VQ^ES.%*TH$YI7A`(4'P:6MMIRXTF.8]<QF#K:/I-[<\
MUVG"075WKF$TICS)P<9'><?&ZOJ6^2^I5]6YM9]'@S**Y>;9`HO$@42PMF'4
M&]0I<__@[/$'P*CD/8QLMN;U(?',C&HDZ1/AJ=X-`^3VP=D5_/,2/4Y:"@M4
M/\8;7\-GL>PT^;5'^"N'RXD`)EL<$1X3--U8>D5B*NA1$R]Q+;ODDXB^;M*@
M`%8Z>&ZS/(MV?7-[K!90E_`:LUS<?6,'AR&2,6=\4'#X)KO:Z1C4`5/_1E%@
M>"4)\&CC<<:1WT,";&^XQ/DM$L`V_PT8_R"M($LC0NAB5O.DD0C2-F%:.3*%
M'^CB@"$F+#0+`VY5=105,J0;XQ.]E6(F([S8;7LT`GO6"RSB-WT^.FM6)H)4
M>7US4NKF!9,9F$\H'O2Y.$F*@K#H3'-62S(^\9S??+]S0-L1Q$!B<X@BI'53
M@N8<EVY29^2,N%S@V_VCW)A?OSS';]**L5'9]O+P#+OF3V/.TQ]PA(@IGV"C
M#G2FS7;F/]E7[:^3XSN58?++S@U*@H`Z8!T<_L([!J6R?_<=<AR]YY_;/4Q\
M?Z"7+)\J6MN-^$'Q@B<*MZ653N;Z&KD3'!PBE^,D7,R4/CTAKHH@T^59W&*V
M\BR_\T-N'R>@BOGVBD"*(5*?55"W7G#XIV1O6#UN`BSD%,(2`BG'=_9&+V);
MP+4F:#UZQ2[\60-<S98U1'!48?5J(TOUCJ6501:YAK@4V>88#9;ST.K.CDH=
M3XG852>3"]K\*-?CA[W7ENEQA/?9>H?BL<9M6VJY=91LM^@?C*CJ><(Z2=P+
M"1]9F:Y*]\62!TQ1SN!AE^PAXS*%80)+KHZDE(_F@:=G-_?'W`+&I"TF,1MU
M"F3::9'SI:-(^_,S3Q=M?WY^@BL6]W'[^PI=4@A2HT:U?^G<!7RZYAI7^^E;
M1=8,5R&*OJY]91/==62%E?4G)BS;Z5;X]9$9E]U?*#FC7GIDKF>64B(:TEV'
MQUSEJ!);[31!G1.WU'ZM"T_H(5DC'"H((+2DF[4!U^X=-]#)3>\!^J%'7T-9
M.+@PMN,2'(A<8C,'CNFV8-&9N0/^2,:+'';=5MKSB%TO`-#*YNK6CC6F:0>#
M!%NN4K5_^?I%1UQB_5U8EY0$/*.^C5"UQ>=N+:<K<;^*FLPC.:15\P3G=%%G
M1<)#>"JWY#?4WT/VC*5%RK):HSW5RN;6PYXTOFL_<PHP;L@D%*'KMNGQ%VP\
M&$`[:N51/W=!Y'(T;3%X[=@6UQYV,O4-SM/#<S-9B'E?SQY,*GWMGOJ1"FD@
MGVYQ#,@XC6Z@X7_I\+8?;WEG[3*[UG4C1>/%DM7=D0MN!$([[N7R"L]0EIA)
M>0E3SDVO[F&#;AMC,M9UCS+)3?]G=7-%`-N5(A3`660G(I0HH62.7#%9%%E>
MYM!QE-(7WJGH7"<$<CPH)%:UL;:Y:=XV8GGSIU?(IDK2B_A6]8""9_*@=^`V
M5[W3OA*V@.@SPHYD,G!WF**;3S:('N2D8.84/[/P"1UN\=XS&/:&!6]I\SE'
MX<B9:V%Z8H$32D40L_2)]NXJ1DJMDSUO)^&O-H@"J1+D2QL.@BHT[#B"EGB=
M@="&-->K3U*3T`5&N(S>$<)`B5"B\O(_G/V5GEA^GG/E+\KTL"KX($?I3JRI
MO[U3)C@*EGQKO0HP,*0$,I:2F*7M+VB`I2,UW(HV2N<9-Z#M7.AP%2?#+^PO
M;=Q!=W>7;!)"MFL@!R(ZS9RXS-/IQV%C=,7E4@N'KS*_6T'NIMVL#C0[.KLZ
MNOT(JP&,"H#?TMG.RW5,XCEX:H;-V[2A*@4\47NI<+L1`Z[B1ATX_2+D7E"H
M),7-XG#&U$>OEZ6O>4)8J%?O11M6MWDB;/K3B/3/1J5'SSD5O8*LUR$=T^;@
M:&F6Z;FRV)2F,42,S6_=P^-^:+9UC:A61)X;OC9NF>U=[_=4\IN\5G#@)=;L
M0]0$;30I01-U2X[_EL(/4-=YS!T<X'DH2"YKB?)<;SNZ3,^M4IYZZJ#ORCU^
M+A-'1J6A-HDJR!`[BMYE-MXE8!L4E70$MJBC&1M)%3!#C!7-V"M)D`RXF-HL
MY7BCN"SN?%Y[5Z225UHL3\R4'SXOQ*,X*C]H[92A\!,/)-JF8"D,92L?"3M*
M\K$;T4,97:GDHE=7RA]^_=+BP'2FU_)?SJ;;S4U//[!*%UF99.1/S]1N]&GN
M>`+F!.>VSD,"9>(K$<PR%^Y9>D>0OI-$EVE#[<WH@KT_HS_UZ0S?>%1(46E/
MNA5>:P7"DIDFZKXY.?KIG`P8>85O]+<07==Z!,6RU9KDUDVKINWH\D?%DG6W
M0Z^E&:O\92B,<L=\S^@V(\.\@->YQ*<ZM[$<IBXA.+!CN*NMS>\2GV(@!RSI
M$MI4'MEM>R]MK;P@$#U+P="2\$^B`I",VL$2.%2G'5.1S,:_1J3+)\#KKGA,
M>)UZZ.DO"<GY`R\),)++DVY&RX(E0:%+@V[4D)FKO[?Q\+&W$;#AU@TT0+]9
M7FR%_W.].`NMCIR/O)TQ#@M<R>(`XM/6''86O=V#IIN]W5I/?_&&VIF1O!;)
MBQ$8^;V]>F")SIK?\M6=9>F?HQ\7!F_9[RJ)X>:SL[XT[$KM1UW$-+M,%`%N
MXG;LD2F"=Z`)9J.I,LI0,=ZFH^FG!AHV@H_BR5'G=^D"T359T5L\&S9_6YQS
M'>\!-0.YG,0]3!WVC63#QT5[58D8M=6+D,C[#7$N\?^"Y)9FTK,&1PAHQ/LG
M"XE`YN%.HJ;5,O?9KCQ:8(!5=9;Y,T($$IF:(Z3R%0H6&;ZK?B0>DT@TKSEA
MC+&8"2[Y^[PNXQ&EIJG_E%6-LLFJ`;%:<$`XR36&6AOXA-I:]?1*W*GLFN,D
ME#&"<WK/Q&BS.$7:GT?I<0BL_Z3D.-PDM%$SY`2MWTI]&:X=M;V]?7=-T%$*
MQPN5R5_/D?PCWRZ2\NNT"^V&M=(=*>-OX@P9U3-G23EO!90P`P'K\TCRP]E1
M]M*3A^7%&"F27J.0)'>=Q++N+2V*%!E`W47]22H&*O)C\^%F)3^&`DPD57)8
MVC.^+?GM;\_(,U';4F"^BRXOQ,1^?*/7H*0_KJ3_ZER8K\_(MB.`]7F@:=GG
MI/1/N_6?#7W4,>`OBP?^Z%KQBVM/[T5D+S^61=4470X')).2PU9GS[!A,#;\
M'\M/I3C-3'X_,2WEZ)E:<9?-O"&EAZ(PJBS5FU":W+&U-[Z4?G*7B5XA)L\H
M?Y2"?J5KP%1"J8%N7_/PT8/7)-L<$_23#_4NT[Z5+(R8IO`^Y0FA"EJVAVWX
ME0&4%>P0UW>XBWV\#X=7="G5N9^C7'RXL).C`FLIO!3+7\:+PRO50[`\"K/M
M^RZC.4/$L.XR2MW4:E*YNO`65[J'N\&Y97=WV<5=:/A`&M)U1\$)#P,-=VLT
MG$%MJ%,S9?^OT[#;=*PY5)VH$E'L`\UUC]^(#&VD>.HE37MD$>!\MS)9_[A(
M47I!Y%WXT?'9!U*)P31\;TFQ?_%+1/HLE598>HMC5W,SJ,>*)4[P!B^3WHH,
M+)3Q16M9&.G5[)G'@8*49BL3\,S[WCN==;,)NJ.S+89MOB?MZ`5<U\EE:AOI
M<["I9R]+`")P&YKRM_`,$/QXI7X`&3I3JV<@Z/)<H(S/]/KL\%TD="^Q*4L*
MB\*RU*]^J8MP9O;4\I:&S"S*9U;99J3I+;Z*?#JNV&:>S9D99O#TLPQ[:PT$
M2LCRVS\\?Z\.^(L(*J\$'&N&S*48P]]5I&LUDN4BPV[5Y)*3`6P_95#_AM6&
M$+-+""'`X7X-W)K3-/.[2Z'J[FTUM8-#NKA9%5/YQI`=[@4IA>?,ZE3\V"*^
M[D?+Y+@+((K(D7*UB)$`+>W*?'!FJY;AB1)G*T\C(GZ7:P9]]X>!0WXY0&E4
M\,T#AR\CWE8MN:_0V<%%[<)_]R^_\&C!SK_@D_1V5+#I`WRO]NG=L/Q%GJ!=
MLMGJXFGWJM99QK[$"249PLQ<>2[_"8]J2**1Y'A_MH+W:_:7[\TQ]\^KLQ_?
M/I_=ZP3F^NQ[]Q)/91<\G*4NF*W*C6>'/T:+P/:/]=K=W\;;<,Y&<X@F>G8&
MZY&.I&'M$G=1)0)P'6C<:6D5."Z=$BS;Q19(I]>*JKR2C[S+!YH[DBLK"DN[
MYJ;G=+4_?X_^C[]@B4UOCT_PDJ0A*SPT'#L]`Y<(K64T:M=[/#[+KP#_;+V[
M@#0+=+S(IOO+'"!_(WT+X6`O[[8@>!'E?$.6/H4K(:&G(3K!CU>4G'A_\AX2
MJ.`'BT`UPBC&68/R-8)MK;PF8'5_MMM$7JAUQT!H`?+GBRO>Q'L_FWC&8C_Y
M>;-*NX)2=?M1'7O0QIZ3"G5$,E0[:Z=]3NNRB:!G*^,'ZZ::5F3GH%6B72.4
M2H5=O+J;RJ,FBF7IM$</1E36F$*N1/V+OURP^4J(C(-PKAI<%.I%L.BFT4WP
MXU`OGT?<Z!)T%#,[U2X"KXB\/>K+(6TD-K#P/&MSQ2`OFCV<I=?,VMNY_K?3
MC@1,-*YM>LRC'6!_7(\GR\;_.'=DM,)O1^)59I/^QR[AYX>+3\CJ)_XF=CN2
M%[;X(P5-8Q4W]L?D..Q'4K,>CR)WZ;2^H8FCX)!\.%N+.KIN6CUO$=-NM7^L
M;USH,KSQ>;@BLL"W]_T)[9F.86V*DPES<`+E7!84"GG51CI50#)')WI'\J5Z
MO!RD^,LN#>P.J0%1YM$/I(K(%RA?)+RLW?EKL2R\M?^*?U5Q"H@=8V#V6B'\
M+E%J#W\:9@]\U/_.<YOL*ZG([=2M#WA24/33QMMLW].%X^/M1UG(3DW/^XX7
M<A/9^0C$L['=%("<EF9N9[SR^O?G7E\'B.FCB9UGIA%]V?RORG>A=^$G+,H>
M&!XB''\!<XH;UM:XF8[]C83N_(Q(I`[TG%MC.]SC[#7_>855@([]3[?$MQ.2
M3P)V8JI=RV,:3O'T]J99HHT(31VI/"^/8)[<2L39IB:I7UZ2:N69V_(SY0MM
MT2NRN_6-1>_,7%>J&$'+8B19I$UN^B,,O"X0;^S9DXR`+:9?M)*@,OT,4*.Y
M/.']-J]4&*:2-=%9F1;@BK6&T&J7T;+N(X\,6JL*VZ(%`BVE29=Z=M-'9JPF
M;SYJ"N'MBPXC"Y_@&8&9)]=>)@X17J86BIF#F(/O+6$],X"?1E=8%$S2))3U
MZLG2?&Y9E9B?[O!NYWLI[H'MRG*S9]&2+21J<G1=SZKZRG9\(GGHTATLXF%.
ME9F_M6.VUE-:T?JV]8AK/W`74F&/B4?,#KB,#HSI.VN)K-,J\&FT2!*3<.3D
M@36J\/>][,%I<O&.*#/R;RWSP5$N]]/3/^5B(-Q.]N*%\OU!KM(40[CC.5*&
M/9@W1^03L?#5"0+"8Q^>O65A="(L%FDG:P&%&"Y%IT6R9#1VC"SHPV<5&_`3
M;WO,@]*B!B4'$/>R)6\)%<#S(W%",5P%J2P"?(X(46=%MD/"C#(B5`H5(NG:
M,PQ*EMBU>Y?2%I5RJ#!R-0G]Y9_X<W#:M+)(,Y8B@9Q36&K4SR?*K^0>8E5O
M!SD`R5+G]\RN,<BD4#LXZ>S<+B^M=WGV_KVZS-#CT-OI!DY&"@@WZ`'QS;4N
MNWI(BQ7")V067K\^O&1A/$)QG2W>[I^<?7RG-#7C;7R8M=B41B4OT<3@AN/.
M_M<LT=84$QX9<4CJ,0)X:H0$+SFOTZ0JS^RX138$4$/A&@:`/L*#QT=/)7--
M;71P`<9DPY=+Y&/2WRCNH)><)6(J`=7>TN'L`R[@!VA8L'WW&@<M%J*XM[WU
M>/61&L-YU_##7^"S4KT<I85U\KI#H/ZS/<A132PN0)ZHM"U(Q+C)"UYL^3]6
M'_?QC"38R*9^MO>4=GMP!,L,D>02\3MGD&3T+3DK,7:A'VEA:QZ:(R6&HV:*
MYACD4E3_`-/U<1&KJ=>3?N66WI]<=;+LV2$OOS^].+_M&.RBRP-5+:B>O!BK
MQ%P]_F^W%=J>0KJA/:-X`)D4))W$ULZ-<6NO@E@%X?6\&P;ZAQ\2X'6!KAOH
M&9<=S)!4T&V7)HC\VRVI8KHKX*;'-#8\\^#87G3,[5I/%>'^>'CU5QB@<H`M
M$*?AJ"HY/2^!GM_\65CI,:H57>Y6O/&KYUXA5)*K_=I(P(\OBT.*)A.F`A1[
MZ(<WN:W=G78P,70*+O3J'L"%UOXFMA9.:-QWD+?A@,D+T;""GIHI,1+I@.3U
M##4=`U$3XFP>IAK=.8&A.IK_+&KP(:V-\H#=Q*%S*Z[E;L#3>;0[:9==YY+2
M"*W2+Y%[*%C@`*G2/5U9'FOI,)WR6*=87\5%IMG3YJ:]L/(-V=/+_^3L*:.4
M*&Y(TSR.N8"F55;H3]+\+C3]'T;%`TA\0RK>*!EP_U_2\,'/%PJK>B;Z'$^%
MI4\CW+`=KF\Z.9KDHTG%+"*G^$#Y.IL_Z5,$[B*9W"H]P76N_\',FI2ZU'Z%
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M?6)!`C",,3E96@:[U-$0%B^MP]0;\Q<E&=+.)8FE)=^&^WR5'$<#G!NXZ>=V
MV+);($=1W:7F[V'9R>@YC$/NV\SUDKI"&.VWF6R1QV;_XC-L_?/LC[>'R`>>
MLKZ6.,[!Q^)C^;5@_GZ!`VA9"#>NI78[04=E[XHLI;ZK"0B[;JKY1U!F-XF,
MVBYW<5&XUSQ/(UG8`RT%OE%_AW/;/'*6'#B;%][SCO&B@YQD4;FBFC9#7;1R
M9'0DXRFM<='HO&(U9I9:X<^B]WT%9^4@MS#UAHRS<+#/'HVZUV.A2>8W<HQI
M('2QU9'1YK'I$6#DRY2[V"'+R+<X',<;W'<P2[-&PM<=#K-HJHF3+1BV*F/"
M'\9L+W#!2'E9O_6A.S1>M(<*/Q?B='K[<AQ]Z\C2HJGR,PQ193)]B]V!VJ%W
M.(`%GZ>8%/EF4_E!F9BK;<YZ).ZN/QXX2`ABZ="+AR5T&B13[V'V3$G[T>T-
M9VFWYJRE_74X)M*X92Y/K;PUD>TW3QC,-KI4KA3E?9Q#B?Y65[N_^?='F\J)
M_*X"\Q1XJ"ZR0=4Y+#`-GN`3_2H)GG,88)ISDA7TLT[OO:.5?G!L:2D1UI)[
M.DX@9OIG=[J=<:SH.%'1,B3]:BII[J0[UY-("WB2$69C5#C.1YBM281)MU*!
M.FV/6C#5.+2H.3:B@_[4H.I2[JHCI'7K*1:NFVXN+G**NN=#;QOH[9>HAGV<
M&<54=OGD@!8TY0R6!$YZ3&H/N>C+A=3I$_[)0A:+)ILDRPZ9;5E/&*JJ)Z>W
MO>0$$Z=9<O3X(9<</'GV@PL]F777`\\;-7'*>4/&CS9OQ.1YYN-Y*9\8SWPE
M78IDR6U+EMQL\6GOZ"8G+G9_K*T:#*MQ'^T\ZR<5JY(&DDC:8L>8GB34M7OY
MELO9A55KK?9\:Q0__I9[<HR0H\O/OSHKA-BNNTNK1^HT<>%.0B72/=J1V9,?
M3I3)"5;%LSYY8-1L56YI<,OFI/F!])[/Q*#W<:GX:PB_^X+44!J^6.)"[$-I
M%^U&-D+HSK=')^%9!QZ61.H>RT;3X9=9DL2O.6Z$BI#Z-3MVF6AM7!,8XR;R
MJ.#9QG'I8O(M;R+=M/!=?W!Z<?5@XV&G[<CI@K?4AG)9--DBIJ`B-M#W3Y:[
MP`4Z'K9S^G+S<QI'MM8%$=[0@LN#2;]J%\I*&ZDB';AYGL;]Q'=#-\\+CW"\
MRJ^-1YVQY>-F':C]Z#JQQ<KR:B%4LKZSEZAPT_$;3MG!7NRZ9_6+^8)$3)&=
MURZU#)XN0%/I$W[<DGY#8LFM96B#Q:7/%.S',DC:33S[0-6Z\MZ2XVCOBO80
M[W^ZF96L3^6S__FG,]H7%-,ROAJ`M)V['%T+I&OY,;A@^_7^X+5RC?BQO`X\
M'9=58EBU_W;693#>:M2[@9XZZ;0"F5DE\R1A*1$X-Q_):N_HG+_%OSDW3G%`
MS"7:HY%BZHW_(LQSGK.'KOU8_(]'5W*,0K$8^AU;;LPISUD0WZ6CZ38/]0S>
MS=WGO?0SRF>Z1E41E=6;O"DC=;:R_9T]>ZZYNRU<4(\[-=F@0YKG]EC2DL*W
M@^AH3AHZ/O&0KD=A!Q/W*;Y='&D9+.'NT:)4\>:@I7;(_ZOS7QAAC_.*3$#$
M?7(<"DC4/+W%&B=1/DHD"KLW$FT9T\"UG3X:X=U1IV)9YL)OBV8OV(2?J:_\
M_WUY]AUE[QY"]H%T.ROC2:U<)NU;<CHM2B9W5>*7]D/-"J106IHO0<`1K4A9
M^]4D"]A&\_4PA1?=ZP1J.E:NVKP5M;O?QE1V?U82O!1F)5H8;G5HH_I24PG_
M_O2/Q:US7LG?G_[Y0&G8$2Z`__BG?XQ+_39:Z%1+M"/D5S2V#B5FU=T=E<7;
M,NW.L^5NII5AF3;Q>\0*>KX_CV/;GU9U%BL8WU8%('5X8Q,E8*``2);+;AUK
M5HD.0&)BR=H=D_GSQB\A]H](.YL0^NW,O=R7H714>U;X!P%Z8O6=1K"4[CE'
M,C]'4^$Q3C1G;ZR:!7^6R[4QTF+/I%8N?9OV[V+3MD*>=F\9A1S=)9I_D9R0
M:I\GO=XCW5#""5(:L,B'H8+J6^TH:D?5MW>Z?;$9JI8Z\UJ/?:0.`FJ@\@UF
M3VVKRDG[65M@EV\KJ,P)_\DG4CT_L7?Z-^@B,Z>O@-HNC'0X7^Y4?;#MQ=(M
M:.;L:1R$BURE5:VQGD-XIN<0X(521L"@.<OE5%9AC=<^RF6C)#'AH9I1#&>C
MF+B451L%6251"[/Y4Y1QX2%KAZ="L#<4G-(/DBR@:U<2"['-%L'D56Z<_=(;
M9WM_'JF4WQ^>4P]DR2XP$31+D/`2"K+B]$F;<W)3<R&,8GIX18<$'+FL&8WA
MO$GW@C1C7!*0AS(#40O>0][892B6W,](#;W<&\T`_ZP%;:,H5XG)@DP%ZG;@
MJZ@BCCS'*$EI*H:C-OOX@I.>XX']K]7/V8LID]6#RA''3;^T(#-8P]7<*':W
MD3PLH9V$]Q#`5F"?*2$!&?2]7LYP'YHZQ(*DH.K!Q2Q\9.U2//@@J=W"7]=C
M/13;NG<FPQOP]T[(N53X6R)RJ0.!8$56THZP/:^M0.T;]2&_2R?DI*$L9)J[
M:A8RU8.D;WTQ*EG^\?KZYG_\/P$```#__P,`4$L#!!0`!@`(````(0#//N/2
M20P``"9X```-````>&PO<W1Y;&5S+GAM;.1=_V_BR!7_O5+_!\O;5G=2LX`Q
M`7(AIX6-VY6VV]-MJE;J594!D_CB+]28W>1._=_[WOC;&\#V&`],HAZZ#3:>
M]S[OZ[P9C\?7WS_YGO;%B39N&$STWMNNKCG!(ERZP?U$_]N==3'2M4UL!TO;
M"P-GHC\[&_W[F]_^YGH3/WO.YP?'B34@$6PF^D,<KZ\ZG<WBP?'MS=MP[03P
MRRJ,?#N&P^B^LUE'CKW<8"/?ZQC=[F7'M]U`3RA<^0L1(KX=/6[7%XO07]NQ
M.W<]-WYFM'3-7UQ]N`_"R)Y[`/6I9]J+C#8[V"/ONXLHW(2K^"V0ZX2KE;MP
M]E&..^,.4+JY#K:^Y<<;;1%N@WBB&_DI+?GEPW*B7^I:(O(L7`*(/_QG&\;?
M_2[Y\^:/;]YT__WM=__\T5G^ZZ=O]G_[Z5N]D[$A-,$&U33?=BO)PL\)Y4XJ
MP<WU*@R((`:H";5U]1B$7P,+?P-G`/'PLIOKS2_:%]N#,SV$MPB],-)BL#+(
MQ\X$MN\D5\QLSYU'+EZVLGW7>TY.&WB".49ZG>^"F?!D)^%P7CYS1)/)-$(8
MG$Q]/$-E\D$D&T]6RV3_?$`FCM>@GE<;_7&\F!35<DGCM>\7>SILPRNW%>$3
MW<\GNF5!#NEUNZA6:K`3,1O/NL#O;,PN!V>3K&_UK:%4R3A?W+<;,NQ;,E59
MP]!Z-WQ_-G7*9U8F79J&SQ4!&'!RM>A"Z%;$]]#"SSG\Y,P=FE2+00$7O_/<
M^R#I;C?;-51TB\A=QZBY0^H]J;1,-J[K80F@R-!WKN]LM$_.5^W'T+<#!$F[
M5G8U5QEP[G\:\IPCRF3!!-F`A*[GY;5C?X#5%9RYN88R-G:BP((#+?U^][R&
MVBJ`BAM5TTFNJ[GZ/K*?>P:K,,0:;$+/72**^QFKZ-(>=79Y:\UN&5^"3!1%
M"5'+F@U/0/1V.I[)1SH;CV43-2SX2";Z;H`?R40M^&\F3:=IEC%E@<SI:;&+
M([#NV^%X/![U+D>CT=CL]TR3*7F>>K0;+)TG!P=ETM2TCV``",;]T?C2`"!=
M<\18G15!'P`,!X/1H#<V3/B?I<_3(Y"MTX&NVJH$@2*K$@2*K,H&`1T)F3^-
M%)@/41RK!($BJQ($BJPZE)R!A\JM2A`HLBI!H,BJ;.I*8JS"/*/B6"4(%%F5
M(%!D56G%9YJ!Q\JM2A`HLBI!<&ZKIL,J+*PM-I&Q7YE)JX^S(=SL]K8Y+S9J
MA''J/(R6,'V0W>7H7<(8,3EW<^TYJQA&I)%[_X!_XW`-_\[#.(;;)S?72]>^
M#P/;@Z^=K$7VMZ(EW&"">TD3/7YP%X_`C)LY2'23L#@5ASSKF3B:,(=F=V@.
MC,MDP":)M>\LW:V_+UW.^Z!?@AI1M_6"$QT&.9/4'8HYM`Y:(36?8`MF:F9I
MP0;@$YE+"+:0(6,QGRPJ(VDA)B-I("@C:2$J(X3.H>#*-+D,MW!O<]?`EC7J
M=I-),U$^U00)\`,><Q@$:;.OS]HF!S1:VZ:IK)!?]F)C:N"'5<<')*UIL2]G
M38,#4M:T$)61]YO,NASQ?.H"T_,!)#OZYBX_#@8P2AIF>':28)J?\)9"<E-!
M.-T=%K>6_`&I:]L<)[JPQ`02"-6L!SV&2=9FQ]JR35%+OHW<>WY5RZW*B&FI
M`I7/PO&\SUB+_&.5ES\PHWAS_;0BJS%@B0PN5\#%'O@5INW3KTFIDQP`Q+)&
ML-BBI)%FK]?>\Z>M/W<BBZV;82S860OX%$=35J,5Q^SFC^^P.5$](?-#%,;.
M(F;K>MCMC#(\_1(\O920")XV_,T2_J`G87VTX0]S;@?M`7I1RA^<2YB_3'_`
M%4RI4X,)J%-7X9&)`&96,@1@!!4(<,55J@-P3Q4(8,2:(0`'+1``G`JO:!,'
M/9+-P`<*EL#_5"PAQV12<BQ/*&59^@7^%5):7/IMI6:2;\'1"S7#006`5BS+
M4JRJ%$/,#I%6J``.*E1@0:\KI\OKE>5\90HA21<P%!J!-%"E$7E>27(N\"P`
M5&MD*K$.(4Z!J4@U!("C!`(Q1$]1_]NC&!3UP-0;%'7!%`+7!Y\Q)J@EN!Y2
M$0;`HR0JBCJAQ_489U0#@:`J0Q)O,%2E2(I!58XL3&&H2I$$@JH,22VA*D52
M#*IR)#&%JA1)((!&E&1(:@E5*9)B4)4C"U/T5:5(`D%5AB26Z)\X17;HM&DR
MB4KF3T?X&%G9U",8*!O^[]KJ:54[D0IWIFN;)Z.G9.0(MF!C*3*41G`V+IS'
MN5/M(8S<7V"0B<^Z+>"$$^GX;&3L+NB9KY&]OG.>8"B:W')[6K42L`93P1]F
MS'6M"7/I^FF!1<#2-8JHE9P-ZFLGYK7,L1)V_.1VK8?4@D"75(T!)YA48T![
MIQBDNZ&D,(5.,H,H[)VRW86J"?&D<\YPFJLA>)^U0+&8?-H&#&$NK(#2W%D;
M&5*YM<A$.'!2IN<>5$7-F%?<2&Q.3*+'&.!_S221R;RQ#2O46.H0.`M9%7G3
M=/*S-A(/):PF\4(-W=\=;58AM-C\<"-\N`JF89E!?/H4Z%ZJIK(*\5A\X%WM
MD[RD1'@*N[7U>AJ7/#Z<%Q=W>S5ANCLA(XZWM(NE"FT9IF=!5_BF<*B0TI5+
M>M5X#U=E?)ET1"IDR_M:Y,)JT,KAG:4CD>@#U7A?@P_4%12\CQZ5MY*\(%'K
MG!/O"]!<[4>))344]Z6HBD4E>#E?[\&1>/=Q%%[I;E,CP,MUFXJJHV8X("%Z
MA?M)'/^DTRL5@*'P/['?M`4LI09N4H`K';;2DN;LDDMG7EV.:KCY`LY3)=L$
M5$V24V0[A?[I0TZPD(9\E@5<$[@O-\\UD>+%=8]\47*N[K$VSY0Y20W<5^(D
MO!2G'X*WC,P:N*]$Z5P=U2@;"DTCO+:Z6M`G0%$"V?K%Y(TRN+P+GQYN6V_@
MG+4'Z$]<?4KUAM/#;:M>WAU@M=7+4"]8_6"PU<!])0FX1HJ74!J5CP#E=QC'
M#/B4EII)CCAB0NRE)&49`I1[R*N[E7(&P'+S].D+Y=8QR>6XEY$S.(_]/\=W
MA#]RZN/*,OGF??4)ZK0"R%=X%N_M.K5R%SG#_1$Y(G"%Q0F21.V$3UF-<):(
MH^CRV=;Z)<FG5IK@M'!#H)Q&<:7ORQC["#G`&>"V[")`C#E;S);N9%*E7*%Y
MI32^8=5=IVKFG^8@#D-="CKJ)F=K4#7WTZ2#0BUD0VO\*K0Z^/"XNM1J-(L<
M-!==5B^^E/LP"GZT7(J)II!F/05[%@6>/B%[^?`[^>3/JFCX-@)XAU/W]]J%
M]FZ!;'+S8HJ<;UT/-D/%@,#GB!;;#>S#-TU.ID]^5-'*JWX#,Q>A!=U44UI`
M(0E(`Y\M([1@Q7A36L`^H=4':0DMV.:H,:T\"\/+##A:\!!$4US0),7%ZWX@
MJ'OSD!TQO1`946017)1684>L+XCN0>2FM`H[XO-YA!:(W)1684=`2&B9P*0I
MK<*.8`5*"]RM*:W<CB:O^X&@[B\/VI'W57R@3007I578D??5OJ"O4EJ%'7E?
M19&;XBKL"%2I[N&'IK0*._)YPA3,$U3&PHZ\[@>"NM_-J+S'&X(>GU`I;`??
MB(YPK8"(CA(JA=5X+^\+>GE"I;`7[]^FH'\G5`I+`3TBD0D_B$N4VZC/:]<4
MU.[47F99EW<8[&=$8,#;_A9;#]["&.(['-D#F_"*0"H0/IXO1.G!63QJ,]A_
M+R?$QP-VHR*$;I_6GAW8<1@]:_B09DZ.-_I`D-R?PC#7$4_!@$,10'^&-U["
MRS0UT$O:B7,*PHJJ"9D\%GCUX(XM3<A`ZP0-[W^XMT83,M`Z(<,G5:R?1,A\
M"-;;W$)\+L6N6X3$1S=X=):\Y_!9P@"0(I0^.=LXLG/_XT/*$%3,)]RU,:?!
MIXCDG5+9%I-I_?D)-FG,E(B5-DD&6/V+`/_K-B9JQ%:$"*YW$R%RY\:PKW`6
MQ!P)A"5$(H0'IW,2.QE%D,;?[2C`:.%"=\='2R0J'D.'ZG_Y5.S@R?0>XSMA
MV=Z>^7@`%+5T5O;6B^_R'R=Z\?TO;,=N<*;TJA_<+V',2$STXOM'W`H=HAC&
M3I!N/FY@>VWXJVTC=Z+_>CL=CM_?6L;%J#L=79A]9W`Q'DS?7PS,V?3]>VO<
M-;JS_X+*\`6Z5_`&UA8OJ&4OTH4'T7OFU<:#U]A&J;`I^,_%N8E.#A+X;/]C
M@`W#]4R(SB9_P>_-_P```/__`P!02P,$%``&``@````A`/MBI6V4!@``IQL`
M`!,```!X;"]T:&5M92]T:&5M93$N>&UL[%E/;]LV%+\/V'<@=&]M)[8;!W6*
MV+&;K4T;Q&Z''FF9EEA3HD#227T;VN.``<.Z89<!N^TP;"O0`KMTGR9;AZT#
M^A7V2$JR&,M+T@8;UM6'1")_?/_?XR-U]=J#B*%#(B3E<=NK7:YZB,0^'],X
M:'MWAOU+&QZ2"L=CS'A,VMZ<2._:UOOO7<6;*B010;`^EINX[85*)9N5BO1A
M&,O+/"$QS$VXB+""5Q%4Q@(?`=V(5=:JU68EPC3V4(PC('M[,J$^04--TMO*
MB/<8O,9*Z@&?B8$F39P5!CN>UC1"SF67"72(6=L#/F-^-"0/E(<8E@HFVE[5
M_+S*UM4*WDP7,;5B;6%=W_S2=>F"\73-\!3!*&=:Z]=;5W9R^@;`U#*NU^MU
M>[6<G@%@WP=-K2Q%FO7^1JV3T2R`[.,R[6ZU4:V[^`+]]2696YU.I]%*9;%$
M#<@^UI?P&]5F?7O-P1N0Q3>6\/7.=K?;=/`&9/'-)7S_2JM9=_$&%#(:3Y?0
MVJ']?DH]ATPXVRV%;P!\HYK"%RB(ACRZ-(L)C]6J6(OP?2[Z`-!`AA6-D9HG
M9()]B.(NCD:"8LT`;Q)<F+%#OEP:TKR0]`5-5-O[,,&0$0MZKYY__^KY4_3J
M^9/CA\^.'_YT_.C1\<,?+2UGX2Z.@^+"E]]^]N?7'Z,_GG[S\O$7Y7A9Q/_Z
MPR>__/QY.1`R:"'1BR^?_/;LR8NO/OW]N\<E\&V!1T7XD$9$HEOD"!WP"'0S
MAG$E)R-QOA7#$%-G!0Z!=@GIG@H=X*TY9F6X#G&-=U=`\2@#7I_==V0=A&*F
M:`GG&V'D`/<X9QTN2@UP0_,J6'@XBX-RYF)6Q!U@?%C&NXMCQ[6]60)5,PM*
MQ_;=D#AB[C,<*QR0F"BDY_B4D!+M[E'JV'6/^H)+/E'H'D4=3$M-,J0C)Y`6
MBW9I!'Z9E^D,KG9LLW<7=3@KTWJ''+I(2`C,2H0?$N:8\3J>*1R5D1SBB!4-
M?A.KL$S(P5SX15Q/*O!T0!A'O3&1LFS-;0'Z%IQ^`T.]*G7['IM'+E(H.BVC
M>1-S7D3N\&DWQ%%2AAW0."QB/Y!3"%&,]KDJ@^]Q-T/T._@!QRO=?9<2Q]VG
M%X([-'!$6@2(GIF)$E]>)]R)W\&<33`Q509*NE.I(QK_7=EF%.JVY?"N;+>]
M;=C$RI)G]T2Q7H7[#Y;H'3R+]PEDQ?(6]:Y"OZO0WEM?H5?E\L77Y44IABJM
M&Q+;:YO..UK9>$\H8P,U9^2F-+VWA`UHW(=!O<X<.DE^$$M">-29#`P<7""P
M68,$5Q]1%0Y"G$#?7O,TD4"FI`.)$B[AO&B&2VEK//3^RIXV&_H<8BN'Q&J/
MC^WPNA[.CALY&2-58,ZT&:-U3>"LS-:OI$1!M]=A5M-"G9E;S8AFBJ+#+5=9
MF]B<R\'DN6HPF%L3.AL$_1!8N0G'?LT:SCN8D;&VN_51YA;CA8MTD0SQF*0^
MTGHO^ZAFG)3%RI(B6@\;#/KL>(K5"MQ:FNP;<#N+DXKLZBO89=Y[$R]E$;SP
M$E`[F8XL+B8GB]%1VVLUUAH>\G'2]B9P5(;'*`&O2]U,8A;`?9.OA`W[4Y/9
M9/G"FZU,,3<):G#[8>V^I+!3!Q(AU0Z6H0T-,Y6&`(LU)RO_6@/,>E$*E%2C
MLTFQO@'!\*])`79T74LF$^*KHK,+(]IV]C4MI7RFB!B$XR,T8C-Q@,'].E1!
MGS&5<.-A*H)^@>LY;6TSY1;G-.F*EV(&9\<Q2T*<EEN=HEDF6[@I2+D,YJT@
M'NA6*KM1[ORJF)2_(%6*8?P_4T7O)W`%L3[6'O#A=EA@I#.E[7&A0@Y5*`FI
MWQ?0.)C:`=$"5[PP#4$%=]3FOR"'^K_-.4O#I#6<)-4!#9"@L!^I4!"R#V7)
M1-\IQ&KIWF5)LI20B:B"N#*Q8H_((6%#70.;>F_W4`BA;JI)6@8,[F3\N>]I
M!HT"W>04\\VI9/G>:W/@G^Y\;#*#4FX=-@U-9O]<Q+P]6.RJ=KU9GNV]147T
MQ*+-JF=9`<P*6T$K3?O7%.&<6ZVM6$L:KS4RX<"+RQK#8-X0)7"1A/0?V/^H
M\)G]X*$WU"$_@-J*X/N%)@9A`U%]R38>2!=(.SB"QLD.VF#2I*QIT]9)6RW;
MK"^XT\WYGC"VENPL_CZGL?/FS&7GY.)%&CNUL&-K.[;2U.#9DRD*0Y/L(&,<
M8[Z4%3]F\=%]</0.?#:8,25-,,&G*H&AAQZ8/(#DMQS-TJV_````__\#`%!+
M`P04``8`"````"$`;7O;(0`#``"<"```&0```'AL+W=O<FMS:&5E=',O<VAE
M970T-BYX;6R45MENHS`4?1]I_@'YO>PABT*J-E5G*DVET6B69P=,L`H8V4[3
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M+HY?)$^_\8J!V=`F;,!.B">$/J0X!).=R>S[I@'?I96RC!X*_4,<OS*^SS5T
M>P8%85VK]/6.J00,!1K;GR%3(@H0`$>KY)@,,(2^-.<C3W4>DR"R9W,W\`!N
M[9C2]QPIB94<E!;E'P/R3E2&Q#^1P/E$XD5VZ,_FBX^P!"<6.+<LLXM9'%-7
M8],=U72SEN)H0?1`N:HI!ME;`7/KCZFF<^P]P\`I)+E!EIC`.P->*&CR\R9:
M^&OG&3J3G#"W!@/'#N,-$=LI(@RB#N.`XDXV6-F7_78[6W4(1G787I1[:P;Z
M4D9BMU-$M`C>E@*N72X%P9"AG@G1(NQXC3J#"3NYV][`P(1PN#+V+GPWVZT9
M."DF4%_7ALAW1PH,9MXT,@C\F3L";`V@D3A0!*OWO4!%\[.*<-)8T2@:MP:S
M--&R@_E0\-8\GNJ)AGK^'Q,$#W6$R[$.@^GUIC<P<&+^D941?"X5!M-;N3<P
M6!EWKM$;?3X5.&E8^S05!M-38`9,3#P(R;^4#`0MIX+.AP(GC06-FV$P/4%F
MP*0DL(-9EQ*CQ^P2YO-7,KEG6U84RDK$`7<`#\+5C7:;TXV/[Z'3/8#-H:9[
M]DCEGE?**E@&4UT;"Y)F>S$W6M3-QW4G-&P+S64.?P$,/C^N#>!,"-W>X`+=
M?\7F+P```/__`P!02P,$%``&``@````A`'[+3?27!```[!```!D```!X;"]W
M;W)K<VAE971S+W-H965T-#4N>&ULG%A;CZ)(%'[?9/\#X7WD(H(:==("O3O)
M;++9[.49L5320!D*V^Y_O^?40:PJ>M2>?FCD\]3'=VYU*!=?WZK2>F6-*'B]
MM+V1:UNLSOFVJ/=+^Y^_G[],;4NT6;W-2EZSI?W.A/UU]>LOBS-O7L2!L=8"
MAEHL[4/;'N>.(_(#JS(QXD=6PS<[WE19"[?-WA''AF5;N:@J'=]U0Z?*BMHF
MAGGS"`??[8J<)3P_5:QNB:1A9=:"?G$HCN+"5N6/T%59\W(Z?LEY=02*35$6
M[;LDM:TJGW_;U[S)-B7X_>8%67[AEC<#^JK(&R[XKAT!G4-"AS[/G)D#3*O%
MM@`/,.Q6PW9+^\F;I][4=E8+&:!_"W86RF=+'/CYMZ;8?B]J!M&&/&$&-IR_
MH.FW+4*PV!FL?I89^+.QMFR7G<KV+W[^G17[0POIGH!'Z-A\^YXPD4-$@6;D
M3Y`IYR4(@/]656!I0$2R-WD]%]OVL+3'X6@2N6,/S*T-$^US@92VE9]$RZO_
MR,CKJ(C$[TC@VI%XX2CP)]'T,RSCC@6N%Y;)YUF"C@6N/^\0N"ZC`M>+%/_1
MJ#@489FP)&NSU:+A9PNZ`&(HCAGVE#<'XDNF**Y][GZ4.L@9DCPAR]*&]H6L
M"*BWUU48^0OG%6HD[VS69`/_>QM/MXB'%D%DV"3#)P7C4.=)+S98HN!F[RM4
M@NKKQ]5X<0F-T26L3O1Q38"FWQOK3XZ'-D%DJ$N&-D:DTJ%%,)[V3])<@K)4
M7<+T!9#&VZ[AHJ4-3^DS$4:&)VNR"7KW8Q-(3"!5`$TC%+VJ\;8V-(9VU[0%
MO>^4";)1M)E`8@*I`FC:(%:J-HS?&+:[VQIQD1F_B:&1;$+9"^/0=5W]^YB^
MO_J0F$"J`)KD4)=\6RH:ZU(GII0UV5REQ":0F$"J`)JVZ#/:T/A>JLE&T68"
MB0FD"J!IPY<+8Z>[GVI<9,;/;!6R432:0&("*0&1K`YX-\&_OCXTT;.?$8V+
M=-&AN0NMR481;0*)":0$1#.IVAT%USAHDCWHG\\'6JXR1`=1'Q1J_,Y(4=TA
M%,DQU+822+DF&:Q)5417CH-#*9';K>71F-&VT>"Z37>*R4A53`A%T1]%QL:1
M=+37%:F*Z'IQ4"AZY?!V8=^X(YSFBR8\&H2:C*XR8L]$DAY1!XD1@;0W,J>Q
MA_-"47]'-$T77?3,K`]E!,GXQ_(A,!/[.98,D%1%]/CBU'A<(<V8VZ/+4P91
MI]!$DH%-JB*Z0AP2BL+'YA>^BIL;Q+#7E/G3*26$>LT+/VPV<U':/4LF0)>.
M,T21?B?]-'&T]`^;31E+G61"?MQLYHK44Q!=+\X51>]CKUH>32--]_2ZUTN5
MZ\[H6J1QAU"H/PRT,N4D2:J2Z,)QV!C"?=P#[T2<9I2F?+A+F),MAF,EUM;5
MEZ1'E%UB:KS6XVFT7T;JZ7!)9Y6*-7L6L[(45LY/>'#T80CU:'^H??*QSPT\
MP<,NXD[_!9PUC]F>_9$U^Z(65LEV0.G"7FQ;#9U6Z:;E1WE"VO`63IGRXP%^
M56!P''!'8+SCO+W<X`/ZWRE6_P,``/__`P!02P,$%``&``@````A`,0<PED8
M`P``/`D``!D```!X;"]W;W)K<VAE971S+W-H965T-#0N>&ULG)9=;YLP%(;O
M)^T_(-^7[T`2A51-4+=*JS1-^[AVP(!5P,AVFO;?[Q@GQ)"I2WN3A,-[WCSG
M^&"SNGUI:NN9<$%9FR#/=I%%VHSEM"T3].OG_<T<64+B-L<U:TF"7HE`M^O/
MGU8'QI]$18BTP*$5":JD[):.([**-%C8K",MW"D8;["$2UXZHN,$YWU24SN^
MZT9.@VF+M,.27^/!BH)F)&79OB&MU":<U%@"OZAH)TYN37:-78/YT[Z[R5C3
M@<6.UE2^]J;(:K+E0]DRCG<UU/WBA3@[>?<7%_8-S3@3K)`VV#D:]++FA;-P
MP&F]RBE4H-IN<5(DZ,Y;I@ODK%=]?WY3<A#&;TM4[/"%T_P;;0DT&Y9)+<".
ML2<E?<A5")*=B^S[?@&^<RLG!=[7\@<[?"6TK"2L]@P*4G4M\]>4B`P:"C:V
M/U-.&:L!`#ZMAJK)@(;@E_[[0'-9)2B([%GL!A[(K1T1\IXJ2V1E>R%9\T>+
MO*.5-O&/)O!]-/$B._1G\?P]+L'1)3R[^->B.+JLODLIEGB]XNQ@P>0!N.BP
MFF-O"<;_;@OT0VGOE#A!\&1`Q0*6\GD=1?.5\PS]SXZ:C=;`YZ#QQHKM2:&:
MK6Q3(^``UL`&[;J>38D5V\EUHP,FB#\!N52$<336I)<:?S%(1K2P/":M&K0`
MQO7MCJHDT!G=BJ*S?]^>C=:$0V7;:2`U`B,D6-#W(ZFD!$'=PP)&L3N4K)&T
M)NI'8.[.%JX[46RUX@R=FBG^+!BEC*#AL7H_M$J:0D_F;J,U80_MNT$PKFE[
MNGT:H-0(C`"CCP"JI#%@.(_'!!NM.?=LJP/QHD=V;6^2D!H)(\)X3/CV""KQ
MA"R8CJ#6&&330&H$1BCJ&#7VE^N>"I7TOZ=":PRD:2`U`B.DQ4>05-*D2Q?K
MIS4&TC0`!YUR&19T-@R`!M2GF-Z?&\)+LB5U+:R,[=4)Y<$8#-'A\+SSU<;@
M##?@\.IP21XQ+VDKK)H4D.K:,4PSU\>?OI"LZW?_'9-P;/4_*WA+(;`ANS:(
M"\;DZ4+]P?#>L_X+``#__P,`4$L#!!0`!@`(````(0`=)<_X9@,``.$*```9
M````>&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;)266V^;,!3'WR?M.R#>PS4E
M%X54#6VW2ILT3;L\.V""5<#(=IKVV^\8$X*=AJ5Y2`+^^^_?.<>WU>UK55HO
MF'%"Z]CV'<^V<)W2C-2[V/[]ZW$RMRTN4)VADM8XMM\PMV_7GS^M#I0]\P)C
M88%#S6.[$*)9NBY/"UPA[M`&U]"24U8A`8]LY_*&892UG:K2#3PO<BM$:ELY
M+-DU'C3/28KO:;JO<"V4"<,E$L#/"]+PHUN57F-7(?:\;R8IK1JPV)*2B+?6
MU+:J=/FTJRE#VQ+B?O6G*#UZMP]G]A5)&>4T%P[8N0KT/.:%NW#!:;W*"$0@
MTVXQG,?VG;],_,!VUZLV07\(/O#!?XL7]/"%D>P;J3%D&^HD*["E]%E*GS+Y
M"CJ[9[T?VPK\8%:&<[0OQ4]Z^(K)KA!0[AN(2`:VS-[N,4\AHV#C!#?2*:4E
M`,"W51$Y-2`CZ+7]/9!,%+$=1L[-S`M]D%M;S,4CD9:VE>ZYH-5?)?([*V42
M="8AT'?MP;4FK@)JX[M'`JU7C!XLF#0P)&^0G(+^$HR/@2F,/M1+D4*(TN1.
MNL0VS'8(@D-Y7M91%*W<%TAIVFDVYQI?5R1'A:P$X/6,$/B0\?VD'U&D6*+(
M(DBVC7H!WCU;8(S[CF+12S02R-"01&8KA,DT3B0[@6X`$$6SWE]!*LVTITX&
M+S2"J4XP/K(4QS:$UX<>SJ;&R$HS6[15FWA.:`B2$8%&!A-YF)MQ,BDVR<R<
M*,V)S#-F5#(BT,BBCY!)L4EVF@VJ6DK3D7EZ0A.M<1(ZGO[Q'R9AWT/#G.F8
MUTTNV<G`G1OK:J,T'2YL&6=`YH+0.ISBTVCET69L'/]?"K*326L,OE&:CG8Z
MFKZV&HG6X0+M0J<=GYQ2;%*>:J:F@-)TE%I-%93>[@0+_?,P.86MI=6'[>3C
M>6U[F<C&0MYTHHXY<H(AA*+6)1=RZ<M]>E#Z\62V:@,M,K/9B3HTV(2\>;]&
M.C)U.)P4IS6IYT]NYM?#J:U?VR&CL[PIT7%H$^Q"JZ)2-PIUXE:8[7""RY);
M*=W+VT(`FV[_MK_)W+47&>/]1MYPY/'@]@UPP6C0#G]';$=J;I4X!TO/F<&V
MR-0513T(VK3G_)8*N%JT?PNX2F(X'#T'Q#FEXO@@!^@OI^M_````__\#`%!+
M`P04``8`"````"$`<V!DMEH$``!4#P``&````'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;)2778^K-A"&[ROU/R#N$S#YCI(<+43;'JF5JGY>$V(2M(!3[&QV
M_WUG,#:V.3TB-R$,K\</,^,QWGWYJ$KOG3:\8/7>)]/0]VB=L7-17_;^7W^^
M3M:^QT5:G].2U73O?U+N?SG\^,/NP9HW?J54>."AYGO_*L1M&P0\N](JY5-V
MHS4\R5E3I0)NFTO`;PU-S^V@J@RB,%P&55K4OO2P;<;X8'E>9/3(LGM%:R&=
M-+1,!?#S:W'CREN5C7%7I<W;_3;)6'4#%Z>B+,1GZ]3WJFS[]5*S)CV5\-X?
M9)YFRG=[,W!?%5G#.,O%%-P%$G3XSIM@$X"GP^Y<P!M@V+V&YGO_A6R/9.T'
MAUT;H+\+^N#&?X]?V>.GICC_4M04H@UY$NGI#UK23-`S9,[W,",GQMYPZ%<P
MA3`);P4X"?]73?,2X2R!GL;\KZ9\;=/V6^.=:9[>2_$[>_Q,B\M5P$P+"`-&
M8WO^/%*>01I@KFFT0*\9*\$%_'I5@?4$84P_)%UQ%M>]/UM.%ZMP1D#NG2@7
MKP6Z]+WLS@6K_I$BTKF23J+."5P?\GFTG))YN'S"QZSS`=?.!P%W(P'FW6"X
MZL'3:+T@BQ$(@0Q)&^UC*M+#KF$/#VH=7IK?4EPY9`N>56AE('2P_R_6$&1T
M\H)>]CXL4@@CAX2_'\)=\`XIS3I%+!7PJQ7$5B1*@?E#IT?#$`"M1H:0F<C?
MK@)%AF(D4UYC:3!!(@=DJ)C9BN-0,=<*"Q42/1X5Q5":1H@6VFL;D5@JYOIE
M$M=P-`P6"*1V/`B*]SZ\I,[5T@&1"OC5BI6M2)1"Q?UH&"PR6('CR5!LDZWM
M>6.ID&2G;U5BHA2:S#!89,MGR%!LDVT<,JE8M$SS*-ST)=,F-Y'/^^0>#8/%
MM7J&"\4V%W&7II3,6[`H)$[1)>JQCI=AL+APCS9:R??7)8H=+J<AQ%)B%AEQ
MEZJ2:#;#8+%MGF%#L</F=(!82BPV-Y]*HMD,@\5&8!<='[A6[=`Y*8L[C4PI
M6:SFT<R1)%JB\4R+S8>->'1BB6S;9O<@;OOH-,B7'R:3V60&N<]QVYA$SH).
MM+8'E3.T*\4&Q;X\'E1V<0O4Z6(Q;L]0"E:>!X!*TP,:%AL0V_-X0-G,+4"W
MJ1#5\/M.3`:`2M,#&A8;$-[T"4!4VZ48N<V%2(T9P<A9Z(G6](!J%%AL0&S6
MXR,H6[L9P<AI(3%^2#HICIS5GFA-#ZA&#0"Q:X\'E#W>`G3Z2$R,?4#N%`/+
ML;,LVQY.9HM5M%KV?NP(8OL>#RB;O07HM)*8J`VAK\'(6?&)UO015*,&$<0>
M;@#B)^D,6N3W]Q,XM`QJ<;":C=VABZ2TK.2FO`[GT<8I8#P-R?K0G/+,(K^B
M*]I<:$++DGL9N^,9A(`O;=6'JNZTHQ_`\>267NBO:7,I:NZ5-(>AX70%9=7(
M`XZ\$>S6?J.?F("#2?OW"J=7"M_'X13$.6-"W2"@/@\?_@,``/__`P!02P,$
M%``&``@````A`*(11[2:`@``0P<``!D```!X;"]W;W)K<VAE971S+W-H965T
M,CDN>&ULE%5=;Z,P$'P_Z?Z#Y?=B")0T44C5INI=I3OI=+J/9\>88!5C9#M-
M^^]O;2<Y(&V5OB28G1UF9Y=E<?TL&_3$M1&J+7`2Q1CQEJE2M)L"__YU?W&%
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MFI<O=]PP,!1HHLFE8V*J`0'PBZ1PDP&&T&?_OQ.EK0N<YM'E-$X3@*,U-_9>
M.$J,V-98)?\&4+*G"B23/4D*ZO?QR;DD)`CR]=U12Y<+K78(9@8>:3KJ)C"9
M`[$K+`5[7B\,*G(Y-R[)IP+:0#.>EEF>+,@3.,CVF-M3S&2(6+V"F!TA!/0=
M14+E'Q?IDJ`8C'HB1Q)N`R;S-KO*5KT;`P5`TU?POCT.7&"@.CXYF<7'RKR%
MMP&3>_,2>)E'\54__C\VT)1]1),#CS6-W0B8:="49*>B!H!^>*`+)OI\KQQX
MK"L=>14P0=<K5KT9'JC*AZK.&W27-%:7C=0%3%"77O5=\9U>A7CF77VCD].A
MMO>GRX&'FJ9C20&R'ZX\/]74!Z3]<+`L[,&P)SJZX=^IWHC6H(97,-)Q-`7+
M==B"X6!5Y_?!6EG87OZRAH\5AU<JC@!<*64/![=GCY^_Y3\```#__P,`4$L#
M!!0`!@`(````(0`(:75N70,``+$*```9````>&PO=V]R:W-H965T<R]S:&5E
M=#(W+GAM;(Q676^;,!1]G[3_@'AO^$Z:**1J4G6;M$G3M(]G!TRP"AC93M/^
M^]V+`1G2)+RTX7)\?.XYMO'ZX:TLK%<J).-5;'LSU[9HE?"458?8_O/[^>[>
MMJ0B54H*7M'8?J?2?MA\_K0^<?$B<TJ5!0R5C.U<J7KE.#+):4GDC->T@C<9
M%R51\"@.CJP%)6DSJ"P<WW7G3DE896N&E9C"P;.,)?2))\>25DJ3"%H0!?IE
MSFK9L97)%+J2B)=C?9?PL@:*/2N8>F](;:M,5M\.%1=D7T#?;UY(DHZ[>3BC
M+UDBN.29F@&=HX6>][QTE@XP;=8I@P[0=DO0++8?O=7."VQGLVX,^LOH21J_
M+9GSTQ?!TN^LHN`VY(0)[#E_0>BW%$LPV#D;_=PD\%-8*<W(L5"_^.DK98=<
M0=P1=(2-K=+W)RH3<!1H9GZ$3`DO0`#\M4J&2P,<(6_-_Q-+51[;P7P6+=S`
M`[BUIU(],Z2TK>0H%2__:9#74FD2OR4)0'W[WI]*XFA!37]/1)'-6O"3!8L&
MII0UP27HK8"X:TS+Z%N]U"FTB"2/R!+;L-JA"0GQO&["R%L[KV!ITF*VYY@1
M8M<A,`F0UVN$QDV-'YO>24$P2L$04-M6%X"[U^8/E>T^0"Q[R$`).&0J0;<"
M6$S7%>$@P!D"PF@D8:LQ8:]Z9Q0&"L)S!>'%A=AY@H-B&]KL+0BCH.]0VZ0Q
MBR:\8'$?1<$(L1L@O-#U([?G&&@$/:9+U]U!\%A;V/-J;1ICN&,4!C//AS-/
MRP<'W<I'8PP%1F&@8'&NX'8^.&CLP<C]K<:T^7C1?3`?FK33@+`)\$(P^#DR
M-OOU8!`\%A4-Y]QJC&&+41C8LAS./"T8''0K&(TQ%!B%@0(/]JG9/$JXG4PS
M:NS".)H6U&431G-C9S0K>#>&7-X\'IZ"DT-JT&-]HY6Q;4&&269EZ!*>A<;L
MTX+R]`EZ_8AK0:8*/:RI#%7@Z3=2,2$K?69>/^;@EH"+JLW*#]UP,5S3>(]`
MQ,<;2=\0]!>TI.)`=[0HI)7P(W[]?=A\?;6_F3SZ>*R/ZEN\L6#=Z5_`A:$F
M!_J#B`.KI%70#"C=V0(..Z&O'/I!\;KY;N^Y@JM"\S.'JR&%CYT[`W#&N>H>
M<(+^LKGY#P``__\#`%!+`P04``8`"````"$`/W=>EA4&``".%P``&0```'AL
M+W=O<FMS:&5E=',O<VAE970Q,2YX;6RLF%MOHT84Q]\K]3L@WF/,S1=D>Q5S
ME[9256W;9X*QC6*,!239_?8]P\S`S!PV<=J^A/CG<_Z><YD+L_GRO;IHKT73
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M[_`C*-H<,@HR,\LE2GE]@0'`7ZTJ26M`1K+O6]V"'RX/W7FKVXN9NYS;)IAK
M3T7;1261U+7\I>WJZF]J9#(I*F(S$7@R$<N962O7=!=$Y1U/AWG"DWDZLY7K
M.HO5\GU'^+8?-SR9H[F<.9:[7/4#?^<G%\P3GI\<[))YPO-S@X7)U@\6GGRP
MSGV#73-/>-XW6(/6MV^7(.NRW::IWS28@U#!]I:1&6UZH,;[A"9JZ)R?-0YT
M#!%Y)"I;'>*`GFBAVU]WIK/<&*_0H3FSV4_8R!8^MR#M2&0#%80JB%00JR!1
M02H``Y(P9`):_7_(!%$AF>`Q[#D84V,I87,+[A*H(%1!I()8!8D*4@%(8</D
M5,.V8;F97BAXO8D3+`EBO=>N'-:>VIAT22#E]!$)$`D1B1")$4D0244BQ0M+
MBACO^W$28Y@9D+NQL=<+)5!J9$O=OU:ZWQ^,ABHC$B(2(1(CDB"2BD2*'5;%
M^V,GQGWL?,1[2IQ^Y^DGJ(](@$B(2(1(C$B"2"H2*2I8L>^/BAC+45$"48DU
M7LDU]@<CGHP`D1"1")$8D0215"12H+#!W!\H,98#I40L'R(!(B$B$2(Q(@DB
MJ4BDJ&#>B%'1'6A&]OGN7.;/^YJ>,R8FJ@T[#=U_B(8<+"66/2S$/B(!)3;D
M>YS=2U.N?#@8\<I'B,2()(BDE-`!2?'#KON?XR<:<OR4B/$C$E!B+_L-VYJ;
MR@H>#M\/H3,-9\AJ/-B031\T'#E]R?`]UTB91E\9*1$F3$$Q$Q,5AV,C+WEO
M+<?,D!@T1@%'8Q`A1A%'8P/%'(V."48I1Q/QD9.'<-;Z(#YZ3H&]AV=N#WLI
M*3,Y.X\-Z\[EC/O<:C$X!AQ)CFNUT[D5[0=G/E>4(VXP*L<<O:N<<*N?*:?<
MH%>6FX*<6X2D_:OE@6S@ROS@"+I1R*62$I]966LAEU3+&>L2,BN'K$=P\G47
M$ZFC7H)0S+U&H80CV,#'02UMN<"I-"@Y6>34(R3K@PYC9Z1Q`'N3(N@PWG0^
M1V/1`X:<Y6`5<K2B*2`90-W#M$>AF'N-0@E'5`@W8<H,K(E6(><>(7K2*A9L
M._=O(R8].4&">?A[CJ0^6:_EDOC,2BAOP)#4)U2>]<F#/9$C:B'HQ%@GX8CV
MVP-<K2BY3J7QR"T",U5-DNE^<KLE-PGJ?*)(6IML93/PF1^M'7O%HWX./,:6
MQTL3LUJP&;9$(4=8.V;H?>V$6U'MJ62RT"8ZCAS5E(X3D_FMOL$.]='+E$D/
M?%+7403O%+P1?68EH`"C$*,(HQBC!*-40G(3D<.<$K>](C=)[%+G_HL#>BR4
M8A].BF-'0%74&3=8\0P%)D(A1A%&,48)1JF$Y'20LYV0C@^677H2E$*FJ#]8
M4&5ZL4=O:JJB.15^<;FT6EZ_D$L[F-Z[S8#IC>)^X<&;`R1#Y4L/SMX3W`0'
M*/'4-^`"T>)O@I4')]L)OO;@L(AYO/;@`(@YW'X^]FNL.E9R*SIAO[<\N+_`
M.GO;@Q=]S!\=[Y'>KJH_X'CP=HP=]JX'[Y?`C<$!;D-OV:GX+6M.Y;75+L41
M$C_O%\J&WJ?2#QV;XT]U!_>@_70_P[UW`1<>\QE,B&-==_P#^8'A)GWW#P``
M`/__`P!02P,$%``&``@````A`.D9)Q8E!@``8!@``!D```!X;"]W;W)K<VAE
M971S+W-H965T,3(N>&ULK)E;C^(V%,??*_4[1'E?@DFX1<!J(%>IE:IJVSYG
M0H!H"$9)YO;M>QS;B>U#9YG=OFR6'\=_?"ZV3SRKKV_5V7HIZJ:DE[5-1F/;
M*BXYW9>7X]K^ZUOT96%;39M=]MF97HJU_5XT]M?-K[^L7FG]U)R*HK5`X=*L
M[5/;7GW':?)3467-B%Z+"WQSH'65M?"Q/CK-M2ZR?3>H.CN3\7CF5%EYL;F"
M7]^C00^',B\"FC]7Q:7E(G5QSEJ8?W,JKXU4J_)[Y*JL?GJ^?LEI=06)Q_)<
MMN^=J&U5N9\>+[3.'L_@]QOQLEQJ=Q^0?%7F-6WHH1V!G,,GBGU>.DL'E#:K
M?0D>L+!;=7%8VP_$3\G2=C:K+D!_E\5KH_S?:D[T-:[+_6_EI8!H0YY8!AXI
M?6*FZ9XA&.R@T5&7@3]J:U\<LN=S^R=]38KR>&HAW5/PB#GF[]^#HLDAHB`S
MFDR94D[/,`'XUZI*5AH0D>RM>[Z6^_:TMMW9:#H?NP3,K<>B::.22=I6_MRT
MM/J'&Q$AQ44F0@2>4F0RFBRF9#K[A(HG5.`I5,AH,9UZL\7\_JF`9><//(7(
MY]V9"PUX_OA$8(%U$X'G9R?B\!QU*0^R-MNL:OIJP3J"+#37C*U*XB]M2^::
M9Z;/_G\E'[+.1!Z8RMJ&>4%>&ZC8E\UD3%;."U19+FRVV,:PV$D+5E),-C!!
M:(+(!+$)$A.D"G`@"'TDH-+^AT@P%18)Z<-6`B4T>F!VTD(."4P0FB`R06R"
MQ`2I`C2W7=WMVXM<YID9PW+6\CS1W=ER&\*7,TOC#I$`D1"1")$8D0215"6:
MG[`%J.G]V$]F#"L"8J84M&LXRHU<O>H]W6C7&_79121$)$(D1B1!)%6)YCOL
M7/?[SHP[W^6,MYQXW:G1+<P=(@$B(2(1(C$B"2*I2C2O9I_QBAGK7G$"7JDY
MGAKIZXUD,`)$0D0B1&)$$D12E6B.PJ%Q?_J8L>XH)VKZ$`D0"1&)$(D121!)
M5:)Y!>M&]8J?/"-V+K>G,G_:4MXCW%BH+IPP_-QA&KJSG$S<?@/>(1)PXD*\
M^]5-YL9A%/9&,O,1(C$B"2(I)WQ"FO]PVOZT_TQ#]Y\3U7]$`D[<N3RHC:(/
M^^][UX6&UT<U[FW$86_L>TG_O=1(A4:7&2T0!):@&HD;&8>63Z:\L]9]%DAU
M&J-`HL&)$*-(HJ&`8HF&@0E&J40W_&,=A])C?<<_WI_`V2,CMX6SE*69];U]
MP4[&,V.KDE:S?F`@D3J0+,U*EU:\'I;PMC76I2-I,4C'$GTHG4@K+DW&2Z2=
M2I-.6Z\+UK+<'S?>X&AQ$P@J3XG;7'=NQTYY%MWNC4KTG?U`F8-06+GC;M%X
M+G(DPCJQ0/QEK9-.=)TIR!C!3C4=/2"LN;D_(*(54@N)(Z.0%F9`A-60[8#T
M`X>`""12ZWG(DTB.&H1BB?A[(^L.$XF$T`*'-I4F-VJ$]3SWAX1W2!!AZ<:6
M"*37R-(,";?2:J0?*+5"H25JY$9N(V&AZ,3#!*1.HNMX3$B?3ZKIZ#4""_(3
M`6'6QF;*D5XCQ)C`CMT'L$4SI#:0:$AM*)%([62!/(FDR2`42S0()1)QH5N[
MB#H?/2"LK;J_0G@3IE6(0%J%$&,3W1%NI60V$$A9_:%`HD*(-[L1$"048Z%$
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MY[UAOYWX<)N#=;:N#]<?F#]X_@/?A,P?\'RX,\`#ME,?WKJ!._T`N-^]9L?B
M]ZP^EI?&.A<'".*X>UNK^0TQ_]"*!#[2%FYVNUR>X":_@(-^/((]^D!I*S^P
M'^C_-K#Y%P``__\#`%!+`P04``8`"````"$`:@1E;6`(``#;,```&0```'AL
M+W=O<FMS:&5E=',O<VAE970Q,RYX;6R<FUN/VS80A=\+]#\8?H\MZFHMUAML
M&J0-T`)%T<NSUI;70FS+D+39Y-]W.**TXI!CD7E)N\SA'!U2_#SR*O?OOYU/
MBZ]ETU;U9;L4JV"Y*"^[>E]=GK?+?_[^]&ZS7+1=<=D7I_I2;I??RW;Y_N'G
MG^Y?Z^9+>RS+;@$5+NUV>>RZZ]UZW>Z.Y;EH5_6UO,#?'.KF7'3P8_.\;J]-
M6>QQTOFT#H,@79^+ZK+L*]PU+C7JPZ':E1_KW<NYO'1]D:8\%1U<?WNLKNU0
M[;QS*7<NFB\OUW>[^GR%$D_5J>J^8]'EXKR[^_Q\J9OBZ02YOXFXV`VU\0>C
M_+G:-75;'[H5E%OW%VIFSM?Y&BH]W.\K2""7?=&4A^WR4=Q]$$(LUP_WN$+_
M5N5K._G_17NL7W]MJOWOU:6$Y8:-DEOP5-=?I/3S7@[!Y+4Q^Q-NP9_-8E\>
MBI=3]U?]^EM9/1\[V.\$(LED=_OO'\MV!TL*959A(BOMZA-<`/RY.%?RWH`E
M*;YMER$85_ONN%U&Z2K)@DB`?/%4MMVG2I9<+G8O;5>?_^M%F&C=U\)+^UAT
MQ<-]4[\N8,-!W5X+>?N(.RALOQ:X"*E]E.+M$FY(L&EA!;\^A"*Z7W^%T#NE
M^=!KX,]1(T;%&DQ'9W!S=Y9BZ2Q715[*AWY@:A/:;2+=1BYZ!%MW.ZB<!+I)
MB%#$8_W^"GI-C%L^S17KAK>-I!B6'M*,RQ6*A#@ID7XYZ2C25A7N!/=5E6)T
M'Y=5C:1&JM2GKA3K==4(_&?,*4(F0N9C)<6ZE1K!$Z0MC03IY%;OCU^TRB#S
M[4V2$W4/-0(SQSBAR.P[DNNVMZVD6+=2(V8<`7>QD2>&$W';`:?I%L.0'F=C
MCP.$U&QGW*2:N*DA2R*"!#RKFTC2<"Z4PD'X!@AYIJ2S'BIG0LG#/+DW9D+U
M1Q\<QG,CU)`E%.&!#!4&L<-M)T8XO-FH(2U4&#"A0.412JK)3JDA2RB"`SQ+
M0>@2RF2#4$-Z*.930WC1`=4D%,L'80.$2%9P73/W@PD(K$7OOI#YB!)>B$`U
MR:0@86([))"X'035>NEA:$KN,'S[T-<(&WJQ`=7$C65#:&&#<+KC<":QL;$A
M?/N`UT-YL2$TV3`,F<<HM+`A#O(5+/;,1IEHP%H04S]%;ZV$GDF>;&?>2?X2
M-`Q#EDSR-$]*(QIR6/"91`H"$Z:&:DA/Q#0-H1<74$WN"98+H84+;KMD<@%K
M&;O$=`ZA%Q=033*QS8-L@>DNA>EFGG4X47<9AO1]8MJ'R`L1J"9N+"(B"R+2
MV"&2HL'DUL-2QC8QS4/D!0A4DTB*&2:^(P*(VV<(U:2T`@4<I;=.-6(:ALB+
M"J@F;@H4)A4B&Q52>'R=XP).)"XV+D1,OQ!Y<0'5Q(WE0F3A0AC#7L[LDDD%
MK`2VV@F*F&XA\J("JDDBE@JQA0HBW#@TX#A3MQF&]%!,YR"?6Z8\NKV$J"9N
M+!9B"Q:<\(T3B8M"A9Z):1SDK>"124%@0B$L`!=@'J>8<`$_9-TVRNP<L!C:
M3!G!=`XQ1/<()=5D"=60)92%$6X;I8`P73HK(YC>(?9B!*I))L4($^`Q8<3,
M?6VB`0N`&^29`)QI&&(O-*":!&'1D%C0D&4.9,")NLLPI)\BIF%(O,B`:N+&
MDB&QD,$MD]DQ8"TPUC,Q'4/B1094DTP*%N8A2BQD"%.7?3+!@+5HIIAI'A)Y
MKB=]_^T['=4DDP*#>8@2`H:9TB8-L`"X:8<H9CJ&Q(L&J"9!V(XA(31P?#;"
M:<1#D4*[W6*F8TB\L(!JXL9B(;5@(4P2AR^"<*9N,PSIH9B.(?7B`JJ)&\N%
MU,*%R.E[2)Q);&PM0\RT#*D7&%!-W%@PI!8P1%DPWX'C1.*B6*%O%-,QI/)<
M.X,!U<1-%H`A$W8I`8,\3[+AO0T(G$4L%#/T0$R[D'H!`M7$C6T74@*(F2!F
MNX`%P$TG'=,NI%Y<0#4)PG(ALW!!N#SOX43=91C2-X=I%S(O+*":N+%8R"Q8
M<,MDM@M8"XSU3$R[D'E1`=4D$TN%S$*%1#C@&R<2%QL5$J9=D+]U<Z<"JHF;
M+(`K"+\=T;[<S'Z("CB+6/A0(?.B`JJ)&TN%S(L*J":E%2@T*B1,_Y-Y40'5
MQ(VEPL9"!8=O3'":[C$,:><G8?J?C1<34$W<6"9L+$QP>F;%B<3%UBDD3/NS
M\6("JHD;RX2-A0EB_A?+.(UX6(G`]#X;+R*@FKBQ1-A8B"#F?R>!TXB'#0D)
MT_ELO)"`:N*FD&!V/AN"!'R22)Q>9C";!BP&SOIA8KJ?C1<>4$U"L7C(+7B8
M;^=PEFXQ#&F!8B90[D4'5!,W10?SP57>8NX?<J@FI142='`S[5SNA014$S<6
M"?F/(0&G$0\K$IAF+O="`JJ)FT*"96L($FYWVKDZ]I-O&(<A?6N8#B[W(@&J
M21"6!+F%!)'\EG8FD8D!K`2VVJE)F?XM]\(`JDDB%@,BL'!`.,&MGZH;C6-Z
M+J;[$8$7#GHY-63;!7AC02<"/K&*?/XIO)])C6P=0\IT02+PXD,OIX8L(41@
M0X33"QK]5.IDXT3*-$,BD.?<^3N&7DX-90D8,S]K14!8(3?-Y1?+_43JHU"B
MWXU,3R0"+W#T<FJHT!$9[W2*@+#C-C)Z.:VN.*)A,&4:(A%X4:.74T.>&[8W
M(AT>+\3P_N.$[N.8ODU,"R%?&_>Y_U!.<JFQR?O$_8OD_=O:Y[)Y+G\I3Z=V
ML:M?Y$OB(;Q_/8Z.;[`_8@8Z'M\]JC?;U^-?P9OEU^*Y_*-HGJM+NSB5!R@:
MX)-_T[^;WO_0U5>X4GB_O.[@G7+\WR/\(X(27L+&+P\/==T-/\@G\?&?)3S\
M#P``__\#`%!+`P04``8`"````"$`4*"K<\0"```"!P``&0```'AL+W=O<FMS
M:&5E=',O<VAE970R."YX;6R<55UOFS`4?9^T_V#YO>$K(1\*J9I4W2IMTC3M
MX]DQ!JQBC&RG:?_]KNV$`>FJ:"\)-L>'<\Z]7-:W+Z)&STQI+IL,1Y,0(]90
MF?.FS/#/'P\W"XRT(4U.:MFP#+\RC6\W'S^LCU(]Z8HQ@X"AT1FNC&E70:!I
MQ031$]FR!NX44@EB8*G*0+>*D=P=$G40AV$:",(;[!E6ZAH.612<LGM)#X(U
MQI,H5A,#^G7%6WUF$_0:.D'4TZ&]H5*T0+'G-3>OCA0C05>/92,5V=?@^R6:
M$GKF=HL+>L&IDEH69@)T@1=ZZ7D9+`-@VJQS#@YL[$BQ(L-WT6J7XF"S=OG\
MXNRH>]=(5_+X2?'\"V\8A`UEL@782_EDH8^YW8+#P<7I!U>`;PKEK""'VGR7
MQ\^,EY6!:L_`D/6URE_OF:80*-!,XIEEHK(&`?"+!+>=`8&0%_=_Y+FI,IRD
MD]D\3"*`HSW3YH%;2HSH01LI?GM0=*+R)/&))`'UI_OQM22!%^3\W1-#-FLE
MCPAZ!AZI6V([,%H!\=F8E]%9_9=3L&A)[BQ+AJ'9P82&ZCQOIK/Y.GB&2.D)
ML[W$1$/$[HRPE0!YG48PWM?X=NAG*19LI=@B6&U;OP'<G;9X]-PW$,L.,E`"
M"?65V+02:*;W%=E#@.L)F,Y&$K8>,^U4[WH;`P73_U%@#V48;'813&>+SJ&/
MR6-25[R;-%U&81@.(;L!)(FB11\R4`E-W<_I_7PL>*SN;_Y>G<?,G;KE8C%X
MLD/L/,(E.)"2#J5<5S)[:"0I':6Q]9A38%&8I)#&"`,CR?*<,`FDVH=XF7[F
M^'=2,%6R':MKC:@\V'D2@^-NMQMU=[%ME-'^%D:@&QA!=P-&4$M*]I6HDC<:
MU:P`RG`RAZR4'V)^863K)L%>&A@^[K*";PV#UR><`+B0TIP7]N7LOEZ;/P``
M`/__`P!02P,$%``&``@````A`/3AEH:`!0``,!4``!D```!X;"]W;W)K<VAE
M971S+W-H965T,3`N>&ULK)A;CZ,V%,??*_4[(-XWA$!N*,EJ$J[25JJJ;?O,
M$"=!$W`$S&6_?8^Q#=B'G<WL]F68_'+\C\_%^-B;SV_%U7@A59W3<FO:DZEI
MD#*CQ[P\;\V_OX:?5J91-VEY3*^T)%OS&ZG-S[O??]N\TNJIOA#2&*!0UEOS
MTC0WS[+J[$**M)[0&RGAFQ.MBK2!C]79JF\528_MH.)JS:;3A56D>6ER!:^Z
M1X.>3GE&?)H]%Z1LN$A%KFD#\Z\O^:V6:D5VCUR15D_/MT\9+6X@\9A?\^9;
M*VH:1>8EYY)6Z>,5_'ZSW323VNT')%_D645K>FHF(&?QB6*?U];:`J7=YIB#
M!RSL1D5.6_/!]A)[85J[31N@?W+R6@_^-^H+?8VJ_/@E+PE$&_+$,O!(Z1,S
M38X,P6`+C0[;#/Q9&4=R2I^OS5_T-2;Y^=)`NN?@$7/,.W[S29U!1$%F,ILS
MI8Q>80+PURAR5AH0D?2M?;[FQ^:R-9W%9+Z<.C:8&X^D;L*<29I&]EPWM/B7
M&]E"BHO,A`@\I8@[L=WIX@,:KM"`I]"P)ZOYW%VLEO=/!"Q;;^`I1#[NS%)H
MP//G)P++JYT(/(6(>[<W%D]1FW$_;=+=IJ*O!BPC2$)]2]FBM+VU:<A4\\1T
MR?]>[B'I3.2!J6Q-F!BDM8:"?=G9J_G&>H$BRX3-?L1&M3A("U913-;70:"#
M4`>1#F(=)`-@01"Z2$"A_0^18"HL$M*'O01]:&::V])"#O%U$.@@U$&D@U@'
MR0`H;CO8;0?>&.-K7>:;#8)5K>1[H;JUYS8V7]4LG0=$?$0"1$)$(D1B1)(A
M4?R%=\$PS>_[R8QA94#L!H6]U!SE1HY:_2O5Z-`9=5E&)$`D1"1")$8D&1+%
M=WB%W>\[,VY]ES/><^*VFT>[0`^(^(@$B(2(1(C$B"1#HGBU^(A7S%CUBA/P
M:ICCM9:^SD@&PT<D0"1$)$(D1B09$L51V#WN3Q\S5AWE9)@^1'Q$`D1"1")$
M8D22(5&\@G4S](KO0!.V03>7/'O:4]XJC"Q4!W8:OO\P#=593F9.]R(^(.)S
MXD"\^]6]M-7,!YV1S'R(2(1(C$C""9^0XC_LNK_L/]-0_>=DZ#\B/B?.LMVP
M9U-;V[&#[OO.=:'A=E&-.ANVZ8.&JX8O[KZ7&HG0:#.C!,*&)3B,Q$C&H?>3
M*6^M59\%&CJ-D2]1[T2`42A17T"11/W`&*-$HA'_6.<QZ+5^X!_O4V#OD9';
MPU[*TLP:X+Y@UU,UX@=IU1X01!\U.E"O=#F0UX,-ARY-.I06O70DD3HG33J6
M5K`(^IDO'77FB;1JY=728-W+_:'CO8X2.H&@^/H)K/5.C&WT+,#K+N:^0':/
M`H&@2VH;73B3X$`AH0@+Q9H0DDF$`9^/&A#6W]P?$-$-#6N)(ZV6M(P<;&'5
M)]R7B!_\6%\72"1?)#@<2":28WJ96*+OR2328*0^6,LS",=/;2(V[YL@Z/V*
M$T@M&^T==Q`#E;+A`]U>*Q!6+MNU7G;."J4[Q#J1'-3KQ!+!+_2EC-<2G\!8
MZ;!&ZI=CQ42TMR]'2D4M4:B$T;"@.'+AT?NSUMX@`;M_@!]T%WS1+18CX4/:
MD1SUKG8LK;BV@Y0383`;*3S6K+T3S*_T!E'ZT7$*+G-0-$47R&J1KWQ^7<,/
M[P6ISN1`KM?:R.@SNXJ!JMUM.LSOB?8+#YI)$-#YTH-V#'-_Y4'C,L+7'O0"
MF$=K#_9WS.%^ZJ$M6/UWV;W5B/U^YL'Q%.OL'0_.<9@_N-X#O__2?\#UX/"#
M!^SG'AP?@%O=`+BONJ5G\D=:G?.R-J[D!$&<MFUGQ6^\^(=&)/"1-G!3U>;R
M`C>3!-Y[TPF4U8G21GY@/]#==>[^`P``__\#`%!+`P04``8`"````"$`$EFF
M>7(2```/;0``&````'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;*R=VVXC-Q*&
M[Q?8=S!\'UNMLXSQ!./F$=@%%HOL[K7&EL=";,N0-)GD[;?8))LL_HRL-G(3
M9SX6*585V?R;3;4^_?S[R_/%;YO]8;M[O;ULKD:7%YO7^]W#]O7;[>5_?E$_
M+2\O#L?UZ\/Z>?>ZN;W\8W.X_/GSW__VZ<=N_^OA:;,Y7E`+KX?;RZ?C\>WF
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MGX__WOTPF^VWIR/E>T8N.<]N'OX0F\,]A92:N1K/7$OWNV?J`/WWXF7KQ@:%
M9/U[]_?']N'X='LYF5_-%J-)0^877S>'H]JZ)B\O[K\?CKN7_WFC)C3E&QF'
M1NAO;&1ZM6A&J\F"&CE1<1(JTM]8\:3]--C3WV@_O+?4I<YE^AL::697X^6L
MF<V=SR>Z.P\U%ZGFXBP_:;IU'TE_!W[D*M2DO['FR8^\]OGMAHM8']>?/^UW
M/RYH$E(&#V]K-Z6;&VHLCA/O;3]R_FS@T(AQC7QQK=Q>DALT)@XTW'_[W(R7
MGZY_HQ%Z'VSN*C;<HHT6;CBZ9D4)9`E4"70)3`EL!JXI"'TD:)3^!9%PK;A(
M1!_N(DBA&1=N1XM8191`ED"50)?`E,!F@+E-<RQWNWZ!B'EVQG0I8'E><7?N
MO$WC+P4NC2T0`40"44`T$`/$YH3Y2=>&\_UTQC0C*&9I0$]&A:/>:,)&_:3A
M1FUOU&<7B`2B@&@@!HC-"?.=+E_G^^Z,.]]CC^\\F:SZ0=T"$4`D$`5$`S%`
M;$Z85W39/=\K9\R]\H2\RG-<SLW>*`9#`)%`%!`-Q`"Q.6&.TKIROJ/.F#OJ
MR;03#-UUM04B@$@@"H@&8H#8G#"O:-[D7KF59[)T:B0LM6<O/JXA[K$GY'&>
MVDDQ,WNC/K5`)!`%1`,Q0&Q.6!!H].5!.'WU=<;<44_RU`(10"00!40#,4!L
M3IA7#44^=\OE=CZY2JKO[-QV+7&?`RJR.RVRFZSZ]"*2B!0BC<@@(CW?I<<G
M@X?#28Y,9)W.,JV<99H#RJ_`B`0BB4@ATH@,(LL0]\]IB_/]\TJ$%M>8F3NW
MT-+(+J[%LS*EO56L*%+%B"0BA4@C,H@L0]QEIS/.=SFHDMQEC_*IVP`2B"0B
MA4@C,H@L0]P_IR4R_]P,'L^NAE^<&R]**)(Q0W<!%1-X7F;;5\P")%+%V)9$
MI!!I1`:198A'PVF0+!KO3&"O6)C+'K$)#$BX&W0_#9)_@!1::40&D66(^^>D
MQ_G^>:'"_.NU2[[B+LJ4]E;1/]$`DH@4(HW((+(,<9>=+CG?9:]BF,NYL/&R
MJ@$D$$E$"I%&9!!9AKA_3G)D_KD)/*.59>B-O5<NS/%>S.2Y+N[VVZ:W2KD&
M)-%*(=*(#"++$(^%$RI9+-Z9OE[6,)<]HEN]Z$S;`!*()"*%2",RB"Q#S+]Q
M(;=.^]=9<TD54+'^%C?V;;**41"()"*%2",RB"Q#W.5!DFJ,DBJ@;'EI$0E$
M$I%"I!$91)8A[E\AJ3Z\_HY1;07$U]]IL;O1)JN4;=]6%C.)5@J11F00689X
M-`:IK3&JK8#R]1>10"01*40:D4%D&>+^%6KKG0F,DFKL$9_`TW(O*EFEE/85
M(Y)HI1!I1`:198B[[(3-V==DMRM0W/H&E`W&%I%`)!$I1!J10609XOXY87.^
M?UX&Y6O.V*-BEI;[4\DJYD\@DH@4(HW((+(,<9<'2:HQ2JJ`6$I14J&51*00
M:40&D66(^^?T2Y92=TW^V([5V"LAENY>'&6J:EKN686*680$(HE((=*(#"++
M$`_'(%4U1E454.9,BT@@DH@4(HW((+(,,?\F@U159\U554#%#"XWJI)5/X,1
M240*D49D$%F&N,N#5-4$555`>4H1"402D4*D$1E$EB'N7Z&J3J^S$Y1.`14I
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M\:X.DCQ3E#P14?C3I\W*W91@11M:<:B)B)KNO%12^KQ[@Q3+%!5+1+Q[Y<Y`
ML&+=\VW1%I4[SI4D#N_>('4Q1741$>]>>9<;K%CW?%NA>^G:SKLW2!Q,41P$
M1",JIJU%)!!)1`J11F0068:X?X42^/`NX11%0D!N,F7C.@U3_\@C6<4`"402
MD4*D$1E$EB$>C4&Z88JZ(2"ZKD5G6D0"D42D$&E$!I%EB/LW2"1,420$Y*[;
M64K+&])D%:,@$$E$"I%&9!!9AKC+A6ZH+!BT!=>O&*@-IK#$MX@$(HE((=*(
M#"++$/>/4E$NE!]ZS#YU#16+I4?%!$X7\C"!>ZN4;4`R-)]=!Q4BC<@@L@RQ
M:,P*V7`ZVYTU=SD@6EFC,RTB@4@B4H@T(H/(,L3]*[1&NER_XRFJ#O<HE_)-
MCTR2ISW*9W=Q(RM2Q=SJ3];/V2#UT5D7"?$B@B4$D`@5,RN)2"'2B`PBRQ!/
M2"%?LAW==S*"2F86!$F>D1[EL8:,5*W2[0OO\2!%,T-%$U`6ZQ:10"01*40:
MD4%D&>+^511-V&-_)R.H8&8>L3G2HY,9J5K]R0W$;)#JZ*R+.>*%",L((!$J
M9E82D4*D$1E$EB&>D4)UG#]'4(#,/&(9Z=')C-2LYNDFB_=XD&B8H6@(*(MU
MBT@@DH@4(HW((+(,<?_<^EP\AVI&=%E]9X;X93U_Z#3SB.6C1R?S4;.:I[M*
MUM_YH&6]L^8S)*!,?;2(!"*)2"'2B`PBRQ#WK[*L?^RT\QP7^H"XBIN7-\C)
M*LH!@4@B4H@T(H/(,L3#,4@TS+T<R$=E0/EM&"*!2")2B#0B@\@RQ/USZW4V
M_4[/NKE?W9E_'O';L'EY9QTJ9E$0B"0BA4@C,H@L0]SE0:ICCJHC(#:#O56&
M!%I)1`J11F0068:X?V[!SU+JUK@%?8-T\'')N5<.+-L>%1.XO.D.%5DT^HIQ
M3DNT4H@T(H/(,L2C,4C1S+U682X'^9+MF@4KYA]82;12B#0B@\@RQ/US8J+(
M]H=NNN=>E3#7/2JR7=YTAXHL&GW%E&U`"BMJ1`:198A'8Y!:FJ-:"BB[4+6(
M!"*)2"'2B`PBRQ#WSTF5+-OO7*Z]L&$I]:BX7!=W<>V\MXKY$X@D(H5((S*(
M+$/,Y<4@P=59<\$54#8^6T0"D42D$&E$!I%EB/M7"*[3*5V@J`JHF*5I$\1O
MC26K/J6()"*%2",RB"Q#W.5!HFJ!HBJ@?)8B$H@D(H5((S*(+$/<OT&B:H&B
M*J!BEJ9=E)#27GJEE`*2J:UHI1!I1`:198B[/$A4+5!4!<1F*8HJM)*(%"*-
MR""R#''_G'[)+KS9QL'`+Z&XY\;%YG9`Q0Q.6S0AW2"A1*H8<RL1*40:D4%D
M&>+A&*2J%JBJ`F+I!@DET$HB4H@T(H/(,L3]<VHE2_<[%V6O;?)U=M'+G6SG
M89'V>$)*>ZN8/Y$J1B01*40:D4%D&>(N#Y)."Y1.`;&4>JL,";22B!0BC<@@
ML@QQ_PKIY&;PX&,<"U14`='W(6+"6D0B('=H*CVM7*0]IFX\R&05VU*(-"*#
MR`;D^\4BL2P4U8<BT37"A59`>200B8#H>)4[BC$>-<7]A$P&?1!B,]T[IKI0
MZ605FBEN0DTRB,W8V$R7*AZ202)LB2(L(.:[M\J0B%;)#XE(191&E(XH532(
M;$05_P8IKB4JKH#<5T2R\5ONW"6K&',1T;R?'C(B/P(FS6PY*6Y`5#1)9Z-T
M1*DA$Q%=9;).%7M/-EIU%7G6!^FT)>JTB.BJD'6@&(EMLDI1\6W1>?V(9+"B
M\^QN0$^:Z6Q>'KQ2V)(.*&O)0$NC<=F29=5X4`HE][&K`PJ\I4?%""HF?YNL
M8F!$0'00/B(9T=C':CP=38O['84-Z5@K-60BHG1D"801%+I>&4$563AX45FB
M(HPH'U@+&%>A7AI$(M2CX]8I5MZ*3BAWXVJQG,TFA8,J?5RLIK$E$U%HJ9G6
MQI7_-#\<^;@J)&,YKG[9O=%R\MYSGR5*R8#RFT%$`I%$I!!I1`:198C[/4A*
M+E%*!L1O!A?%%;--5C&%`I%$I!!I1`:198B[/$A*+E%*!I3IQA:10"01*40:
MD4%D&>+^5:3DQ[X[MT0]&1#YGE^2BLM;FZQ2NGU;6=`D6BE$&I%!9!EBX5@5
M>O+TS5)GS85C0%G/6T0"D42D$&E$!I%EB/M7B$-WY?K0%OL*=6-`1;;+G9YD
MU6<;D42D$&E$!I%EB$=CD)1<H90,B&7;6V5(H)5$I!!I1`:198C[5XA"E^T/
MO&MDA6HQH"+7Y39/LDJY]FUEX9%HI1!I1`:198C'HM""[\QL%'TKC_*U&9%`
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MOFIDY#PP<AX8.0^,G`=&SN>L<'Z0]'(_OU`^58RLVPORC?M?6/"OS'_9[+]M
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M8DTG#FLE%!TZJU<KH>C0N;5:"<6:3GQ52F;4`_IV2:V$/H>^Y5`KH=;HM'VE
M9$ZQIG/?M1**-1V!KI50K.GP<*5D2CV@;W?62LA3^A)DK83Z1E\?K)70"*&O
MTE5*9M1K^A):K83Z1M^&JI1,J&_TI+560GVC)X^U$NH;O>.@5D)]\XM]>3V8
M4G[H^\R5.E,:(?3=WDK)A/RA9SRU$LJ"?\A1?LZ$/*67XM3JT.BEU\G42JAO
M_C$`M$9]HZ<!E3ICJD,ON:N54!UZ<E,KH5C36]1J)11K>O]8K81B3:_BJI50
MK/VS@[+7#=6AEZ)6ZC14AUXG6BD94ZS]U^S+UL84:_JV?:T.Q=I_A03J4*S]
MP]RRI*$Z_O`'E%`=>B]UY7,:BC6]H[E60K&FMQO72BC6]!+@6@G%FEZ?6RFA
M*M4:5*%J3V&N1IF"7(UQ0S&FE\57/KFA&--KUK&$#D/<N!,+E9+EZ,8]_\<2
M>MY_XQ[I8PG]^M27ZMQP'U^QOW,)KG$WE2K\R_3F2_AUJS*[;OI7:MQ1`KO\
M7?<5Z->HWM;?-O]<[[]M7P\7SYM'TENC[ATB>_][5OX?Q_`0[.ON2+]#U3T/
M>Z(?'MO0#\^,W`G^Q]WN&/]!H;CN?\KL\_\%````__\#`%!+`P04``8`"```
M`"$`X=CV)@H#``!@"0``&````'AL+W=O<FMS:&5E=',O<VAE970X+GAM;)16
M76^;,!1]G[3_@/S>@,G7@D*J=%6W2JLT3?MX=L"`5<#(=IKVW^_:)@2'I$U>
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M]U0F4%&@&84FC827D`!\>A73K0$5(:\Q"D&8I:J(T7@VFLZ#,0:XMZ%2/3!-
MB;QD*Q6O_ED0-DE9+I/:/5%DM11\Y\%^`UHV1'</CH#X="Z0A,:N-3A&T(\@
M(Z&`+RN,%TO_!4PG+>;.8N#S@.D0/HAVRJ!VN;(&:V6HKTGES@;Z,N%IF;$K
MHXL^.5OTO5&]",K;-Q$&';_-P&(FIKI]7Q-7\/V*:C"4'MP<RA7B(Z46Y*9S
MQBY8N[RJ&FS4N[*VD=G`U>P:7@UV>=L(?/5\CCN?3F/,KY'28%>JC9@3Y/#J
M>[37ZN;XS>`$?=3U>ITKT49@9<_-Y+2;A:OZ?CMHL"O51H9N,-P_`SMX^K$=
ML]`5V8=<0]/3AK`^X;TZON_(H(_4VBMBV&3Z'%Q!W=X!X>%6,`2@YO;9[(P1
M?8(O-V+/.RATAP6WH1.;<W0)Z%X+\?R"S>DNA(-*&W(W9W[&$Z"N\*311YMC
M0[UKS<XS.S0J*G+ZE9:E]!*^U;,JA#'01;LYNC95.HY/HK6=KW[W#\RWAN3T
MB8B<U=(K:0:<P6@.60@[(>V#X@WD"5..*YALYF<!;S(4IE*@JYIQKO8/4#F_
M>S=:_0<``/__`P!02P,$%``&``@````A`!LT58OV`@``1P@``!@```!X;"]W
M;W)K<VAE971S+W-H965T-RYX;6R4EEUOFS`4AN\G[3\@WQ=CR+="JB:H6Z55
MFJ9]7#M@@E7`R'::]M_OV$X0'UF5W23!O'YYSNO30]?W;U7IO3*IN*AC1/P`
M>:Q.1<;K0XQ^_7R\6R!/:5IGM!0UB]$[4^A^\_G3^B3DBRH8TQXXU"I&A=;-
M"F.5%JRBRA<-J^%.+F1%-5S*`U:-9#2SFZH2AT$PPQ7E-7(.*WF+A\ASGK)$
MI,>*U=J92%92#?RJX(VZN%7I+785E2_'YBX550,6>UYR_6Y-D5>EJZ=#+23=
MEU#W&YG0].)M+T;V%4^E4"+7/MAA!SJN>8F7&)PVZXQ#!29V3[(\1@]DE<P1
MWJQM/K\Y.ZG.;T\5XO1%\NP;KQF$#<=D#F`OQ(N1/F5F"3;CT>Y'>P#?I9>Q
MG!Y+_4.<OC)^*#2<]A0*,G6MLO>$J10"!1L_G!JG5)0``)]>Q4UG0"#TS7Z?
M>*:+&$4S?SH/(@)R;\^4?N3&$GGI46E1_7$B<K9R)N'99`+TY_OAK2;8`=GZ
M$JKI9BW%R8.>@4>JAIH.)"LPOA3F,-I2_U4IE&A,'HQ+C*#9H0@%I_.Z(21<
MXU>(-#UKME<T?<7NHC#Y&=NDLX"!MX6&)+K0UT_APF;$ANWBNG4+X-W"#E!W
M5Q3+/FLREA`2M9H>;=2G-1%'T($?4YM-,8*GM)"$3%I_&\_6:6;GO,D\"(*^
M8M=3+$,R&TD2)YG8]N]F#,UP>\9&/*2=]EFV3C.WM.$4YM<0MBN(R'(Z4B1.
M,6:%OZ$NZVT)FTU#YMF`V6D<\V(Y`MIU[X>+\$J\3C%&GO61/VX&(QZBS@>H
M3N-0R2P:LW8%87`%M2N83+H&O7:>_P^Y$0_)%P-RI[$1V;[>N85S7U\I!2:]
M<>V$Z@:W&VP5DP>V8V6IO%0<S5`.H>?:U?9]\1":GA^L;^$]8J<N;F_`'&_H
M@3U3>>"U\DJ6@V7@S^%DI7L3N`LM&CM.]T+#!+<_"WAA,QAD@0_B7`A]N8`'
MX_9?@,U?````__\#`%!+`P04``8`"````"$`1Z>,@K,%``#1%@``&````'AL
M+W=O<FMS:&5E=',O<VAE970V+GAM;*Q8VXZC1A!]CY1_0+R/H0%C8]E>C8%)
M5MI(493+,X/;-AKCMH`9S_Q]JJD&^L)ZF2@OR[@X59Q375W5V^LO[^79>J-5
M7;#+QB8SU[;H)6?[XG+<V'_]^?2PM*VZR2[[[,PN=&-_T-K^LOWYI_6-52_U
MB=+&@@B7>F.?FN:Z<IPZ/]$RJV?L2B_PYL"J,FO@9W5TZFM%LWWK5)X=SW5#
MI\R*BXT15M64&.QP*'*:L/RUI)<&@U3TG#7`OSX5U[J+5N93PI59]?)Z?<A9
M>840S\6Y:#[:H+95YJNOQPNKLN<SZ'XG099WL=L?1OBRR"M6LT,S@W`.$C4U
M1T[D0*3M>E^``IYVJZ*'C?U(5JDWMYWMNDW0WP6]U=+?5GUBMU^J8O^MN%#(
M-JP37X%GQEXX].N>F\#9,;R?VA7XO;+V])"]GIL_V.U76AQ/#2SW'!1Q8:O]
M1T+K'#(*869((V=G(`#_6F7!2P,RDKVWSUNQ;TX;VP]G\X7K$X!;S[1NG@H>
MTK;RU[IAY3\((IQ4'\030>`Y$N2.HR\<X2D<B3M;$#?R%_#U.XZ!<(3GY[X(
M85N]\)ST10?SU:8_R9ILNZ[8S8*:AHS4UXSO$+*"8%W>D7._$M];"$@>#_+(
MHVQLV(R0XQJJYVT;D;7S!@N>"\C.A&B(N$/P)>%1$]V02@8'^/<B8,'^!Q$\
M"A?1?7_7&095GBHJ[A"=2](9))=(]4D["/@H(J!X9!'CE=\EG(.AQN6$:]QV
M"`EZ.;%N2'1#*AD4:E">TZEQ\,8&E7TM+'TU!3N$A&VA/(1A1%S752$Q0@;V
MB>+C$[(T?%+)1Z$/=2W3YS7N0X>ZGV'NI&58EX&0@6.L&Q+=D$H&A6*H4KQ/
MC8/5#$>!FKX=0A9MAD>RBZ\'YHF,A]&GK48JX17:B\_0YF"5]G*IT49(1WL1
M&4QB1$C,.P-O.CKM[IV^U?BI06MZ/RX([J05Q%RCCY"!7*P;$MV02@8ELY%*
M\7Y!<+":V2C4J"$$,_M`0M_,+"(&\HGL8M90*N$5Y@2VUN>SVWJI&OR%ID%@
M4(2_-#M`+!"2",6'!*&A.Y5]5"%\W$AE<G\-"`XGN>]%A@#$B%68^TN33BSB
MR!(4+R\*S6V1REZJ"#YNIHO`X01SH&_>D;Y'"6(&@K%A20Q+*EM4@GSH3">(
M(TK)LC9@=P0Q7:W/QY*,D$%#(IR"MF/J?:1_J3<2PD?.=/(XH&3RL*_T(D?0
M7?;2H!,GI<XRU@5;DAN[%:NFGD^CZ>QQ=D'F^MH@KG:&V_$S.[2B(;&Q84D,
M2RI;5(9\\$QGB&-*S:]^+"+=+!M)5=R_[`]TPH++08*YV3A3V4EES^?/=/8X
MK53V^I&#(*CO(`NCG\4",BQ!HCI%Q-P0J>RD:N`#2M(P[?!$<*RI6O0SB@"A
MEF4X'Y&"87B'EFI.F[J)$H>$GF<.AE1@OAM)U<Q'FZ3Y!XT?!Z&J51^_I)N6
MHU77O1RJ#BVBZL*1@U#:1]1[DO>?YF_KI<Y?XNKS2X"0EC^2YU@@I.)3?,@R
M"`)CG5/92UD)[U,CN$7K&O3Q)4#=#O*(R2<6&%F%/(/)/%B8U9K*7JH*J(WI
M]>1QM*Y"GW$")`ID/H?+!GV2Q`(CJ\#0Z!6-M`'9197`!^;D+>'A>%6V!-$'
MG0#A_P*)Z\-MC2G!F-.JUZCP5&!:X:H*/B:GJ\"A"D>K;E_N/,,4FZ;$-*6*
M2>6D#6'>8"/8PI^\@>'77$;5:)UR)T#\+#;T4Z+-\'A`=;H3T\1O`_D'(5;?
M@/!V#Z^72EH=:4S/Y]K*V2N_N>,+W5O[6\7'UE^S[^"VL<VZ;O=6<.4"W]/L
MB0>WDR/V1R^`%VT=:!Z0BNY"T^E?P87B-3O2W[+J6%QJZTP/0!LN\D!IA5>2
M^*-AU_;B[)DU<)78_GF"JV,*=U;N#,`'QIKN!T].?QF]_1<``/__`P!02P,$
M%``&``@````A`-E[69)8!````!```!@```!X;"]W;W)K<VAE971S+W-H965T
M-2YX;6R45UV/FSH0?:]T_P/B/0'SF41)JA+8>RNU4G5U/YX).`G:@"/,;G;_
M?<<>DM@.S=(\!+#/'.9X9CQX^?FM/EJOM.45:U8VF;JV19N"E56S7]G__O,T
MF=D6[_*FS(^LH2O[G7+[\_J/3\LS:Y_Y@=+.`H:&K^Q#UYT6CL.+`ZUS/F4G
MVL#,CK5UWL%CNW?XJ:5Y*8WJH^.Y;N34>=78R+!HQW"PW:XJ:,J*EYHV'9*T
M])AWX#\_5"=^8:N+,71UWCZ_G"8%JT]`L:V.5?<N26VK+A9?]PUK\^T1=+^1
M("\NW/+ACKZNBI9QMNNF0.>@H_>:Y\[<`:;ULJQ`@5AVJZ6[E?V%+#(2VLYZ
M*1?HOXJ>N7)O\0,[_]E6Y;>JH;#:$"<1@2UCSP+ZM11#8.S<63_)"/QHK9+N
M\I=C]S<[_T6K_:&#<(>@2`A;E.\IY06L*-!,/>E&P8[@`/Q;=252`U8D?Y/7
M<U5VAY7M1],P=GT"<&M+>?=4"4K;*EYXQ^K_$42$4U<2KR>!:T]"R&^3^#T)
M7'L2+YB2P(U^PY&@YX#K10W<CE0!>N52P/7BP/PC8P>74T8GS;M\O6S9V8*4
MAP7CIUP4$%D`H0A+`-?AL,!2"ILOPDB:`II#+KVN8W_IO$+XBQZ2#$`"';(9
M@(0Z)!V`1#HD&X#$5X@#*J]2(>JJU,<2!7AEP_]-XNQ**U<A04@D]0>QZ[KZ
M_$:=A]U&GTW5V7`>STQ`I@(F84C4%VBZ(!''ZQ)@0]=<]RQ!2"`K1X1[@P.Q
M%`I"Q$\W24V33!G0?(4L'^^K`.N^SHP7)PA!UT@4S^]<VR`BD,X;UNF'UMFP
MM28)JD65)"K(A^WQ<7H)(T,:T=<T0<A%FNMI"2`S<(,0U.9%9O&8!&[L&Y!,
M);@MCB8ONI?W\08AC`QYGB$/(4J6X4"?95$XD&6F2:8,:#['NL^/0R'`AJ_F
M9H80=&WB$P+%>ELM#`5"AM/LP5SVD%H3);Z$E)WZL2@!-D09VV^"D#Z_@L@;
MJ!V$H*C@+K\T@IDWC\.[_%(A$S^*M'=HZJ"#C5<GP(8Z([,3A"CIA0,H%[0,
MI)=IDBD#FJ\$REMU=F33%%:&UT8S2R3SRNZ#XGH#B=9#,"C$D)V:!/%\9D`R
MC>"6QKI"T5659!NI$'LQ-*YKTYS=>C$V38(8)3#]2*\Y#"`1]:TBO;/)U!'=
M<=$U%<<?5PG!'JLY;';Y'G,)R5"+Z2'#Q?^Q??8+>UV8Z*CCA6'_U829FQI!
M#`J;0&T.-)@>\PMEER8O/@"-F&6/V75IHLF.EX8M69-F?L$0Q."G&<@*1+GK
M2;71,('Y89%JTYX;`(=G4&0:9D)</])V%5VD:+7C16)C5D6:59&(TQ/L)VHE
MX0A&%"0-E9)I)`Y]5QKT&,]P>$HXY7OZ/6_W5<.M(]U!7;O3&"Q:/,'A0\=.
M\C2P91V<O.3M`4[:%+X=W2F`=XQUEP=Q1KR>W=<_`0``__\#`%!+`P04``8`
M"````"$`?Z<)<X(.``"620``&0```'AL+W=O<FMS:&5E=',O<VAE970Q-2YX
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MP/W+>KG=[#8/^PMR-W`WBGV^&EP-R-/M]?V:>F!E/]NN'F[./XWFS>3R?'![
MW0KTW_7J^R[X_[/=T^9[M5W?_V/]NB*U:9SL"'S>;+Y8T_K>(FH\@-9E.P+_
MVI[=KQX67Y_W_]Y\-ZOUX].>AGM"/;(=F]__E:]V2U*4W%PD$^MIN7FF&Z#_
MGKVL;6J0(HL_V\_OZ_O]T\UYFER,QL,I69]]7NWVY=IZ/#];?MWM-R__<S8C
M]N1\).R#/L7']&(R&Z:C$YRD[(0^V4DR\TX.1!]S0_KDAI,/M:/^M3VG3PDX
MN1@GD]EE>]L'(DZY)7URRZN/-9QQ0_J4D!_K(\W6]E[I\Z0^7G$[^I2`'^SC
MB#+1)89-23?JAWLY<)G5)FJ^V"]NK[>;[V<T^REY=F\+NY:,YM:MI*A3N$O:
M]W*6DM5Z^63=W)R3`I2/.YIHWVY'L^GUX!M-CB7;W/78:(M,+.Q,L&[S&!0Q
M*&-0Q<#$H(Y!$X`!R=)I0U/F5VACW5AMI%=W`KQ8222$6$B3/`9%#,H85#$P
M,:ACT`1`"4'37@G1OWY)+EAK6JF"7$C'$]W!.V<S<DN5'>H,2`ZD`%("J8`8
M(#60)B2JZ[1PG=!U:TTSB73LYD$ZCN>!,TK#R9*.9UJ@K#/J4@!(`:0$4@$Q
M0&H@34B4'+0>GR"'M6[ED$[<.3)NM\UVBF=`<B`%D!)(!<0`J8$T(5$=I>U#
M==2NBPGM7;+7?GAEM(ZT!HZ0!F&27$;CWQF)=#F0`D@)I`)B@-1`FI`H66AS
M5+(<7@FLM>Z[(^'X`\F!%$!*(!40`Z0&TH1$=91FYPD=M=:ZHXY$@WP5#7)G
MU`TRD`)(":0"8H#40)J0J+Y307)"WZVU[KLCX2`#R8$40$H@%1`#I`;2A$1U
MU!8\)_2T-===%33N=O=,T*Q#.:,932N_+TR&.AL*;R7I4"*J$!E$-:*&T:B]
M+RV#+8"P"+R8T6JW?UHOO]QMZ+;)J&>VIU3L<0GHRBC:_.3V[VA_;W,C5(=1
MJ(Y#,YJ+@3JC6)W.2MR7[)X:"JH0&40UHH91GSJV*OIY=5QMI=1A%*K#R/<H
MM\4$S:_995M5)\-15$H5WD!4*!FYSK2C4R$ROJ&MU\GS6$M>>P/QW"@W.HEL
M"17*U),L=.+LLH4KKC!;')K10`=Y$)?&H\Y*;BIG1-X%%8)\U5T*\E85^C)H
M50OROAI!K2\M@RV=3I#!55HDJ]SZW<BA&8U[($.JQR9CJ\174CFC$2UW7</1
M%<PCYWZLK&:1^]+[DONJ,*+Q5@<BUFQU.&+C?5%$+:DMTDZ0U-5T2E*'9I0Z
MG3+I)$KWS#Z9L3/-'TIR1BJSG%5"NV?@*YJ4I6\86D4G@0HC&M]0A*\%Z8C1
M@:$1*[J]X+Y\1"VI+?!.D-35@TI2AX+\RT:`<D:4DM*;@A%E@Z`2K2KT9="J
M1E^-LM)]MK7>"7UVI:'JLT.4#:'$<>5.JRZD4==0^ERP%:61H%)0N$"!+X-6
MM2#OJQ'4LT#9LN\$&5R5J&1PZ-@"Y:R"!,E'[,L/?<'H\-I08L.*4>#>H%7]
M(?>-:JASQI:.H5CN\=BIE9$K0)6&#AU;D=@J7)$<FOAUO[`+/JU;J5[=HK-&
MR591\OKU@<L$B&BX81"Q[HTXC>K9YEA$I30-I%;Z</G0FNM2G%&0$1FB7!H&
M.<A(Y6`ZC?;-TC<,)W^L'T8TOJ',]+H_8E3I-+YA?T2MGRV/?SI3$U=DAYG*
M2.?--*H7,K8*]TY&0=X4C-*$:]EI.AQ&65/Z>")7A<X-.J^U\U$R0N>-<J[U
MLV7VS^O']7M0SB6,:&+Y?7D:UQYL14,NO<X9S:A>ZQIB.2=6X9XT@G+.WX2X
MKS"B$5\'(]9B=3!BHR)JI6T!?TCI/S9O[YTV*0OE`)&X<X!*58?"!P]L%:`<
M48&H1%0A,HAJ1(U"6@M;C(=:'%GU7.VN^NR0?M`TC<K1+.FL9/QS1`6B$E&%
MR""J$34*:1DHETZ1P9I'B[]#P3AG=L4BJP#EB`I$):(*D4%4(VH4TGV.2_`?
M*BT2K,P%!8\5!`6/%1@=>>CBK21O2D05(H.H1M0PHF*5W&MU;.$;3HP?4\>5
MSVJ^,`K5812JX]#[#UV2SL`+`VXJMG+]:PLLXQN^\]#%&XCG1KG1,MF*.I3I
MR/K!!7BX/3D4;-R9/=I&YV!&E,UR4X4@?^@H!7FK"GT9M*H%>5^-(#S`)+9$
M/:'/KJ)5.<!(;\E1*9>U<>B//N&6W-.P9TMV5NFPK7+2)!GW5#F=)Q&TPGB&
MD2VDWR\!:K;B>*-Q,H-XC?=$\50*4;-3Y&S-]=K+2#VWNXQ/Q=Y(.IPS"I-*
MT,P5B%-Z7RFN#\4D2#+T;="J%D39[<6,*Z5&K##OTE]28;=>(OVXZ`Y'.9U&
MSW<R;ABF(Z.QG\Z%(/M8_MMM3^))?'_^J="S$3?><RV(*HE#\G5]@3R+"^S#
M2Q6=$>(]GI$^,T\AT5S#8$'+N:%*-&=%*ZO5*1U?4:)!IK%-F&G@W*#S6I!S
MWC\AQ:8GSX[5QQ_Z:XQ]&A#52()TGD7/"3*V4GG&=;7/AH*MQF$VI#-0D&]"
M19Q$"VV%$8VX]Q%K03IB=$IOV$JMF&D042]]MBK^^$Z26O-HZCH4)%O&5@'*
M&:G\<PUIEY/EL$2K"GT9M*H%>5^-H)[LBDOM'RJL4JS`!:FQGD7/-#*V4MGE
M?!TYYW+#]D^2_A6SZ#%$Z6]"9*TPHA%?-`9^*8O_4%*+%=V>M\+]@I5HUU.=
M7<<*_(^=<U.L\!D%)YL,48ZH0%0BJA`91#6B1B&MA:V-3YAI7$K[Z7^7.J3/
MN?%H9-Y*QC]'5"`J$56(#*(:4:.0EL%6UB?(X`KQL'2U;XWI0VV&*$=4("H1
M58@,HAI1HY#N,RT(I_39FD>++*/@R)8R"HYLC(Z\8^&M)$%*1!4B@ZA&U##J
M.=#:Q%4R_-"ZVWK1Z@@*U!$4J,/HR''?6W7J(*H0&40UHH91GSJ_I+8><_$9
M+!N"0G78*E3'H?>/^^R&#+PPX*:28-ZS\0W?.>Y[`_'<*#=J+E&EKY/H<`W=
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MET^4@JTX*8<746J7O;%01.<XB&5\0R^BL^)8HXOHCAO?I'_`M(RVE#]AF;3F
MT=QV*,K%*(NRL;,*\B-GI'*1?;G\H,FAWS<L?9/^KKG71S"6\0V]C"H6S.V^
M7@4#ID6T!X%0Q!\KJ_DX$1:.C%2*PFL/=J.F00G2)F=$18CTMQ`T=@\;AQ>P
MH?<%"[K,XD(P(YY]L%H0!XLVS88OZP=D02BE+KV[H=4]7!RUYCI%&07)ER'*
M&87Y*"BHN`7Y%;1"7P:M:D'>5R,('Y!-;%W_TQG5>HFDX`.#SJAXMG+#,*,8
MT0.R+J,$V:WJVVTT@TH)KB(%8^S2"2,9<>LCU8)Z(S7'(NELBD\O\5S]V`.Q
MB3O"A$]%&-'Y4A3*$.6("D0EH@J1050C:A326L3'#JO%#WV_;((G$D;VN.WK
MALNH6LN\E8B6(RH0E8@J1`91C:A12"MTVBEB@J<(1BHKG%6`<K0J$)6(*D0&
M48VH44CWV9:U\=J37K:5ZHE?R)Y85]$"Y%"4%O[DT2X+&3=4$G4-)5,*M"H1
M58@,HAI1HY"6*"[FCVQ)6,%/'`HZF"'*$16(2D05(H.H1M0HI/MLR\Y?E!9<
M0/N"X6["1:U>+>+G%]Y*<B!'5"`J$56(#*(:4:.0EL@6C:%$1]+"U9AJ#W&H
MW?J<:_>S'N[7$EY6V\=5MGI^WITM-U_M3W;0G]ANKSOL?D_D;C*A'Q1I:PJX
M,J4K4[L_P94976D?&<974FI#?U/I:9-2&_HS0]^52[K2%CJQMTE"<=IQARLI
M74G[O$W&=*65!-K0A;X6=,N]=TPWW'N_=+N]=WLUIZ]M]O0OH7NE]RGQ2IY>
MS>TC^9XKX^'</H[NNS*:%_2X%:_0@UMJTW>%?C/F4Z^*]%LR??9W)'NO/76D
MKQ^?QO-/[C=I8LEI+/J&@KY=.K??]\1.Y"/J!'VQL>]*,K=?',0K]*U`:M-W
M)4^F<_L2'[;)D]F\H%<I\`J][D9M^J[<)=0=>B,4V]PE-(G<46#024"_BO.V
M>%S]<[%]7+_NSIY7#S0%A^WW,+;N=W7</_;\[O#GS9Y^$(?V/_I%$_K]HQ7]
MPL30?GG_8;/9RS\H]*#[1:7;_P,``/__`P!02P,$%``&``@````A`)&QJ!#.
M)P``/>D``!D```!X;"]W;W)K<VAE971S+W-H965T,30N>&ULK)W;DAPWDJ;O
MUVS?@<;[)BLSZVR2QL3,.)_6UF9FK]E42:*)9,E8I5;WV\^/!!`X?.BJ2J[Z
MHHOZX/!`_NY`AB,B([[[CW]^_O3J'W=?'S[>?_G^]>;-V>M7=U\^W/_T\<LO
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MRM,/W_WT49_`R/[JZ]W/W[_^<7.[;"[.7K_]X;NC0O_]\>[/A^C?KQY^O?^S
M^?KQI_'CESO)K4"9$/S]_OXW8]K]9)`ZOT7O^AB"__/UU4]W/[__X]/C_[W_
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MZAPT.6AST.6@S\&0@S$'4P[F'"P1>"NM5\&58'^%X,:-$=Q+]<Z#*`*9NM["
M=SGDH,I!G8,F!VT.NAST.1AR,.9@RL&<@R4"B;J:@XFZY:\"G[7&6HM^DK77
MJ6KOK(T6""_;'N0`4H'4(`U("]*!]"`#R`@R@<P@2TP24;4^G2"JL=9JH@A%
M:\%-IJHUVB4+QM59:K1?C;ST!Y`*I`9I0%J0#J0'&4!&D`ED!EEBD@BM]?<$
MH8WU46@OSSM+=C<A5T$.(!5(#=*`M"`=2`\R@(P@$\@,LL0DD5`G-R=(:*Q3
M"2V1A%'V7N7?4ZN15_X`4H'4(`U("]*!]"`#R`@R@<P@2TP2577F=X*JQCI5
MU9+SX^G\\9M]#W(`J4!JD`:D!>E`>I`!9`290&:0)2:)A%KJ$@G-B=;VXHT2
M^<13+>,H5=<2J1OG[#9;3%>C-6=!*I`:I`%I03J0'F0`&4$FD!EDB4DBN*9P
M(OC3IP+&.E75DCAG00X@%4@-TH"T(!U(#S*`C"`3R`RRQ"21T-13)VAX-$]%
M="C+S5V6F\%J34ZBBJ@F:HA:HHZH)QJ(1J*):"9:$I2J;$J%N`9[.E--K9JE
MJD/Q%S_1@:@BJHD:HI:H(^J)!J*1:"*:B98$I9*:^N`$26TYH7-6GW_OS/FK
M5,Y.!,[SQ%VM?,=#Z.A11503-40M44?4$PU$(]%$-!,M"4I5-A7#"2J[`B-6
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M98N2<UR@PP:H(JJ)&J*6J"/JB0:BD6@BFHF6!"62;D\KSH[F:7'F4':.FVV`
M[X/5FKA$%5%-U!"U1!U13S00C403T4RT)"A5^;3B;,OBS*'HA'9/=""JB&JB
MAJ@EZHAZHH%H))J(9J(E0:FD>7'VS5MA6]9M#F4;#MGEAWVP"CEM?45AJFA5
M$S5$+5%'U!,-1"/11#03+0E*`W!:W;9EW>90)-:>Z$!4$=5$#5%+U!'U1`/1
M2#01S41+@E))\[KMVW.:)=UV+=:B$XSK_&I9L`HYO7;TJ*)53=00M40=44\T
M$(U$$]%,M"0H#8"I3%Y^@F'NL5&Q%I]@.)3DM+6*T(%6%5%-U!"U1!U13S00
MC403T4RT)"B5U!11)TAJ:ZY$TK4,BQ,WOYJV7:U\EAZ(*J*:J"%JB3JBGF@@
M&HDFHIEH25"JLBFU3E#95F:)RBC6]EN@`U%%5!,U1"U11]03#40CT40T$RT)
M2B4U=54LJ5F,=]?F)L!3+[9M;8F6R+U6;7%2YY?;7,=DZ5@[^CRO:%43-40M
M44?4$PU$(]%$-!,M"4HC8,JP.`)/7]+8VJHM41F%W-Y9117@@:@BJHD:HI:H
M(^J)!J*1:"*:B98$)9+N3BOWCN;I%YQ#:;EWG5^+"U8^2P]$%5%-U!"U1!U1
M3S00C403T4RT)"A5^;1R;\=RSZ%HXN^)#D0544W4$+5$'5%/-!"-1!/13+0D
M*)7T+ROW=BSW')+:\6*<7Z8+5B&G6>[1JB9JB%JBCJ@G&HA&HHEH)EH2E`;@
MM')OQW+/H22GK56$#K2JB&JBAJ@EZHAZHH%H))J(9J(E0:FD?UFYMV.YYU"6
MT_D5O&`5<IKE'JUJHH:H)>J(>J*!:"2:B&:B)4%I`$XK]W8L]QR*$GA/=""J
MB&JBAJ@EZHAZHH%H))J(9J(E0:FD>;EGSIHO=V_";Q%>_&N`'4M!A[*DSJ_N
M!:N0U-97%*>*5C510]02=40]T4`T$DU$,]&2H#0"IY6".Y:"#D5B[8D.1!51
M3=00M40=44\T$(U$$]%,M"0HE;14"G[3;9?F7O5LQ\BA+*?S"W_!*N0T*T%:
MU40-44O4$?5$`]%(-!'-1$N"T@"<5@F:XB17V:(DIX$.KF-D51'51`U12]01
M]40#T4@T$<U$2X(224V^)<7U-^\U'SVE1:)#YD_X^<9U?DTP6*TY3501U40-
M44O4$?5$`]%(-!'-1$N"T@"<5B2>LTAT2#'V^NV)#D0544W4$+5$'5%/-!"-
M1!/13+0D*)4T+Q*?WC`Z9R7HD)DV4>+F%_Z"E1?^0%01U40-44O4$?5$`]%(
M-!'-1$N"4I5/JP3/60DZI+GA]=L3'8@JHIJH(6J).J*>:"`:B2:BF6A)4"II
MJ1+\MKWF<Y:"#IFE*"3U37[E+UCYH!R(*J*:J"%JB3JBGF@@&HDFHIEH25`:
M@=-*P7.6@@XEJ[&UBM"!5A513=00M40=44\T$(U$$]%,M"0HE30O!9]9C5GN
MG5N4K,:;L[S<"U8A<=>.'E6TJHD:HI:H(^J)!J*1:"*:B98$I2J?5NZ=L]QS
M*%F-K56$#K2JB&JBAJ@EZHAZHH%H))J(9J(E0:FD>;GW3.*RICM?2[-XQ<TO
M60<KGZ4'HHJH)FJ(6J*.J"<:B$:BB6@F6A*4JFS*KY=?W3NWU5I\=<^A:'G=
M$QV(*J*:J"%JB3JBGF@@&HDFHIEH25`BJ1Z3<XJD1_.T<',H67&W-_EEZ6"U
M)BY11503-40M44?4$PU$(]%$-!,M"4I5/JUPNV#AYE"TO.Z)#D0544W4$+5$
M'5%/-!"-1!/13+0D*)7TM,+M@H6;0]DY;GY9.EB%Q+6^HEA4M*J)&J*6J"/J
MB0:BD6@BFHF6!*4JGU:X7;!P<R@2:T]T(*J(:J*&J"7JB'JB@6@DFHAFHB5!
MJ:1YX?;TJ<(%BS.'=%.H3\D]T8&H(JJ)&J*6J"/J';K0F4Q4-&;7Q(=@Y4<_
MTM=$-!,M"4I5/JTXNV!QYE"BLK6*T(%6%5%-U#CTM%AML/)B=?35!ZM8^.S"
M[1"LO*^1OB:BF6A)4"K\:27<!4LXAR*5]T0'HHJH)FH<RH3/Q&J#E1>KHZ\^
M6,7"9]7F$*R\KY&^)J*9:$E0*OQI5=T%JSJ'$N&M580.SBK3+[OX5`4K_YEK
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M=!QC'SS[,0X..3>;-YNSY'^9TY%.I^#TB>'.X3B15;ZB+(G[-."F^HYW__.`
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M#T0544W4$+5$'5%/-!"-1!/13+0D*%79E-CQ=\4S*MN*/+Y2?&E1DKA`!UI5
M1#510]02=40]T4`T$DU$,]&2H$32J[QNS]>(%WTG'+VDW[X.)5M3NTUVVK$/
M5FL^$U5$-5'C4+0!TP:KL(+J=2SI0^"Z8.4'T1,-1"/1Y)`=1*KT::7X%4MQ
MA_34"C_./=&!J"*JB1J/PNE%ZY"I;M=OH.U-MB?3!2L_KM[["D,=B$:BR:/C
M(%+]3BNDKUA(.Q0ER)[H0%0Y9#845QEVF[QJ#E9>AH:^VF`5?&UOLOV4+EAY
M7SU]#<$J^%(UDJ;W&*R\KRGQE:J<E\A/+[%7K(4=2L3:WN2%5K#R@SHX%(6G
M"E;A`VYOLKJZ#E;>5T-?;;`*OG8;"&\_D$;O??7T-91\85QCL/*^IL17*KPI
M^^+OMF];B&WQ&'_E75F4+L3YOOX^6/FQ'AQ*XE'PA>L--7TU]-4&JR@>9UB;
MUR/Z<?7T-91\85QCL/*^IL17&H^\+GUF(K#^-->`5)(FRS70P5N%5;?R*"R>
M-5'C4>C8>A0Z=D2]1Z'CX%'H.!)-'A769E/BQ,G[C%BV(DJRU!5)$FA=8K'U
MOK]R5G[K?9M-WX,W")5AY5&H,6N/W.6!L_.KBWPKNO$VP5/K4?#4>60'E)W=
M]+XU=!@\"FY'CYX8S>1MCMW2/'VNR'O9"1QKO"N'='K\5$1<)1CVXAD3:Q)M
MNE3.=[3M67MDKHIJ4_]:K_I+O\<:9Q'Y:<,8_8SNO!\[H.R[L&>'P2%=VO(^
M1N_#C66K]$C',CD+.Y8T'GDE^&WK.`O$*XNTR>+'N?<H?%D=/`KY53D4;6#6
M'JV;+-S`;.BI]2@,H?/(38!GMAE[;QX\#`[I&I;_7*-#87^5>T"3]U28$::@
MBQ>C/`(OV_:XLG5ALDBA5-P[JZB@/!!51#510]02=40]T4`T$DU$,]&2H"39
MK_/J\>EU_VB>EHD.)?<9[S;YQ:U@Y7/D0%01U40-44O4$?5$`]%(-!'-1$N"
M4I5/JQRO63DZ%&7IGNA`5!'51`U12]01]40#T4@T$<U$2X)22?-BTJP1YK;D
M4]^>Q"KSVJ)L(R^K6?;!*F3TVM&CBE8U44/4$G5$/=%`-!)-1#/1DJ!4_M.J
MS&M6F0X=3UA3UZ9@B%?_9Y8D6U_$J_RU1<ED`3K0JB*JB1JBEJ@CZHD&HI%H
M(IJ)E@2EDIJJY01);9&32&I1-B?R/8'KU<I/@`-11503-40M44?4$PU$(]%$
M-!,M"4I5/JV&NF8-Y5"2N-8J0@=:540U44/4$G5$/=%`-!)-1#/1DJ!44E-Y
MG)"XKN()]RZ\NW:U2ZB5]T0'AY(MK]TFN_Y9!2N?WC510]02=0X5MIFO_Y+Z
MX^@E.U-S]4<L!=#!=4QVFS;Y&R^K8!6DL+[4T:.&5BU1YU!)BN<*@1>5QM>L
M`QR*=L;V1`>']#0A4]%NS_*]QBH8^(]<>S=A(Z8)5LY-5M.VP<"[Z;P;[M3<
MG';&?C1/\\"A]&+_-BN0]]XJA//@D'YNZ\=9.:0[MLQGV[S)7_)=>S?Z9E@W
M(7;;;)^EH>?6>]:90]0QWUWT[EE$WIQVSGTTSW1RI^%*GV@$V46#O>L8;6H<
MO*^P(5$YY.YXO'ASF2E0LT]#U#IDWJ40#0FBV($7]C9N\K/FI\^MCN:9*/8<
M-TN>+*/WKF-T?\?!H[!Q4'EDMQ[R2RBU;WXF==8!^:1L74=SR])3*KF.A=0Y
M[>3VAB>W'J6ID^UU[IU5DCK.5YPZ%KG4R:9I73Y2EEU-L`HB6;?/I9*S.HXG
M^6J^,6?4+_]J/IIGJ81S\KVSBL]VB"JBFJ@A:HDZHIYH(!J))J*9:$E0*JDY
M?3Y!4GNV'9^FWUB4GJ9O\\V88.6SX4!4$=5$#5%+U!'U1`/12#01S41+@E*5
M3SM-O^%IND/QTPJ(#D0544W4$+5$'5%/-!"-1!/13+0D*)7TM-/T&YZF.Y0E
M;K[G$JQ"XEI?T8I1T:HF:HA:HHZH)QJ(1J*):"9:$I2JG!<&SWQYV_/Q9'FP
M*!)K?P-T(*J(:J*&J"7JB'JB@6@DFHAFHB5!J:1Y@?&,I*PD;BS*$C??&`E6
M(7'7CAY5M*J)&J*6J"/JB0:BD6@BFHF6!"4JZ\[UD[[8K'UZLN!9G+L%=B@P
MO2C<'#]YA[#>%`ZF5X6#Z5WA8'I9.)C>%@ZFUX6#Z7WA8'IA.)C>&`ZF5X;'
M+)/XM')G<^:*FVBKQ+,LE[-=D'UDYC-7JEMW472D.IA4!Y/J8%(=3*J#274P
MJ0XFU<&D.IA4!Y/J,<M4/ZV>VIS9FB->DSV+I)/$UBYBDAA,$H-)8C!)#":)
MP20QF"0&D\1@DAA,$H-)8C!)'+-,8E.!O/RD>'-F*Y948E?%1#M?WB[:`I+$
ML)/$8)(83!*#26(P20PFB2U+MA]QEZ947\W\Q)/J<"?5P:0ZF%2/6:;Z:=7=
MYLS6<JGJED4**['!I#J85`>3ZF!2W;*GE5,@5C.OG`(!=PK$:A=V#G!OIP*Q
MFGEW"@3<*1!@"@28`A&S+!"GU82;,Q:%GJ6!L'814R#`%`@P!0),@;`L"T2V
MXZ%`K&9>.04"[A2(U2X.1%;(*A"KF7>G0,"=`@&F0(`I$#'+`G%:V:B'6Q[/
M.=(985DDNF8$F`)A629F5@TI-JN9__2*#=PI-JM=+&9VCJK8K&;>G6(#=XK-
M:A>[RTX3%)O5S+M3;.!.L5GM@CL^U",R\^X4KMA=%JZ\),WO(7K1I8/-&4M5
MS](H6KN(*8J695=2LLU:17$U\Q],480[17&UBW7*=OH4Q=7,NU,4X4Y17.UB
M=]GH%,75S+M3%.%.45SM8G?99KDFW6KFW2F*L;LLBJ>5O)LSUKR>1:'1I+-V
M$5.X'`M7;A0;,,4&?14;V"D08`H$^BH0L)/J8%(=?:4Z["0QF"2.^V82GU8"
M;\Y8`WN67A3895O54MUVC:\*>*;?O/J$D.K6SOPN<MV_YP_HO5GD3H%P7?6%
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MU^FP.\O.@!4J9Y;,+LNBF^\5*L?\W?<7U[NL-%&HX$NA6GV%8>`W,HJ>-7-/
M_BA&#\X5O=6Y_]R*7N(I.T77G(,;!7)U\\08%=O5<V2&IX9XL\*S#38;4_0^
M%>Z7W>5O_>3?<+:@CA9U!=<5V>$+0?/0LOC9(2L+YX$*)OHJF.BKR#D6^FI1
M1%_%"GT5*_15@-!7`4)?10-]-=/BOME,,V7N4]*_K#C:V&HYG6FN@DYG6I9Y
M"H8S2V::9?&S1+R=>YB(?E.TS2H4Q0:N%)O5592=/`WT9O8&K^)$@W,%;W4>
M333'K*?K-Y<WR?^R.DB!A5\%=O7[Q*`5Z_50D5EAYL5'R,)ORN:GPO_2F6?+
M[S3^ED4[UPHVF&8>F)95,$473-$%T\P#T\P#4_#`-//`%"`P!0A,T0#3S(M9
M)KVI=6/IG[[@N-G8VCB5V#))'!)@ES]D2JJO9CY-I3J85`>3ZF!2'4RJ@TEU
M,*D.)M7!I#J85`>3ZF!2/6:9ZJ;\/45U6RZGJEN6)C:8)`:3Q&"2&$P2@TEB
M,$D,)HG!)#&8)`:3Q&"2&$P2QRR3V)2LL<3?>)YM*]]4><N2?315F>D/.I7O
MJUF4[V`*!IB"`:9@6!;M$2D8ENDQ0OX8"L;:-YZ.V8JO^*QFOJOB`Z;X@"D^
MEMFAI+IO3]P/.-IG9TN.Q;]SWY`="JPJL+K`FI6%2W"M9^;9-NM9.2Y[=9&9
M5Z[W+!KR4&!C@4TKX[W5&W,W9)+%SRS/1_M<35>,AD^ZMW[U)('`I";LI*9E
MR<8_GU,2F7E%)##<26#+,H&SC1X)O)IY=Q(8[B2P9=GHLB)5FJ]FWITTC]UE
M&6PJPGCE>$YS6T$F2\36LF1D?&3))ICYD2D,KB`-H5$8BNZRREYYOIIY=PH#
MW"D,EB5AX(-+(C/O3F&`.X5A/6P\;;+1*0RKF7>G,,3NLC"8@BX.P[<MX$IQ
M;)0XEB[@>(#))ICY`2LZUIW^>*;H6):XVUQEWP>*SFKFNRHZ<*?H6&:>^[2N
M0CL\QB0R\^X4';A3=-;#!G<8G:*SFGEWBD[L+HN.*>;BZ#PW26SQETX25Q"&
MXE0+$Y@T=RS1''82&$P"HZ\$MDQ/A?,?54L.^DI-])6:L)-T8)(N[IM)9PJA
M6+IO3&Q;3Z6*NAI+?];4P7Z.1'9F]G<.+#,EN;,(Y;#2W#*]O<K+)LDMV]F?
MVV@-P<:30@!?"@&80N"8'=5S):O"`Q\*CV71&!4>R]P8"R6[HA6[RJ)E:J>_
M(%JV!$NCY5C8`%)H7*D6F()A6;1AJV!8IA^81\&P;&>>86L>(EP,!GPI&&`*
MAF7NNL<+@@$?"H9ET1@5#,O<&,O!B%UEP3`EU5/!>.%&P=:69FDT+(MOHM\X
MNX@I&K!3-,`T-<`T%<"D/IC4!U.Z@TEA,"D,IOP&FPML25DFO2FU8NF?6_!M
M:99*;%GZ:(Y==KZF.;":^=R6ZF!2'4RJ@TEU,*D.)M7!I#J85`>3ZF!2'4RJ
M@TGUF&6JFT+K%-5M89:J;EFR4:"U)+L!61*#26(P20PFB<$D,9@D!I/$8)(8
M3!*#26(P20PFB6.62JS+Q*G$YNMX>_%&7PDG/KIC<W2555^.99MC6<FS]UVC
M(!T*K"JPNL":`FL+K"NPOL"&`AL+;"JPN<"6E&4!,:79"3F_LZ5<DO..17)*
M8FL7,4D,)HG!)#&8)`:3Q&"2&$P2@TEB,$D,)HG!)#&8)(Y9)K$INV*)_S]R
MWE9PJ?J693F?79%40%:SL,Z3*2"P4T#`%!`P!01,`0%30,`4$#`%!$P!`5-`
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MROQPI1R8E`.3<F!2#DS*698IEYU#2KG5S`]%RL&=E%OMPBY1_HI':;E:>6_2
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MG#,+6]-2;NWJ@RKE'-.46MT5[CCV9L&=Q%S=15UYMY8W>_((DAP#EN3K$?R`
M)?E+!JPHQ.ZR*)@"XY0HV((DC8)CFA*K;(5[\76GL%E'M*_B/X"BL';U3%&P
M3/O(P5TI"G"G*,"=4OHE[B0YW$ERN)/D+W$GR6-WF>2FX#A%<EN@I));EB5^
M=OU0B>_,0J9*\K5K)+EC3Z:E5A&XD^1P)\E?XDZ2PYTDASM)_A)WDCQVETEN
MJHU8\F_[)C2OP\R_"3V+LW5WEIU8*!*V:YK\K@8*=WDK^1W3GW4NE9(?[A0)
MN%,D7N).D8`[10+N%(F7N%,D8G=9)$Q1LD9"D^2Y5=\6,6GR6Y8E?W:WDB1W
M9DGR6Q8__L_;F3>V/BDYW$GRU5W4M;#J6[.GCZ`HX`B*PDN.H,"\Y`@*3'R$
M+#"FYCDE,+9&2@/C6#H7LJ)#@;%FZ5Q8NT:KDF7N1UGG9S>[B\R7EB3X4E3@
M2Q/!,G=Q4M>OTUOO)#X<27PXDM*6N4%M+ZYN]$K3U)ETCIUE.IMZZ!2=;?V4
MZNQJ*D5SS=C=.5=_9Y9,@+5KI+-C]L;OOUU?X&<ETAF^I#-\26?'UOL$4FFD
M,QQ)9SB2SHZY05WLKDHZQ\XRG4U=%.O\C4N^<9.?G#N6ICF7?&N6IKEE.CN(
MY'=,B^8:S=*2#W>*`-PI`B]QISC`G>(`=XK#2]PIXV-W622DTU\1">,FCX1E
MV3=!MC^D!<>9)1/!,JV(420<<[^)VI[KI3QI_FHBP)?"L/J*(ECX&K!FX3=1
MJ6_%!+X5DY?X5IB<F1WZ]NQ\6YHNL?\T2+K]Y>D@O?`VB:.?+$J.'6M%>]2W
M#[_>W3T>WC^^_^&[SW=??[G;WWWZ]/#JP_T?7S0%-OHM4\1??;W[^?O7[[11
M?WO<K5>\UCYKV[EI.QZ!;1>F[1AGM&VOU*9;'4H^M]>F[7C'%_O=F+9C)8.V
MW9DYWO&6)[9M3-OQ#ARV;4W;<65`VYGQJ4=GE<9Y9GSJ`4_%-N-33R8JM6TN
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MVDOFHLH2N:CQ1AKK412ET4IC/2*`+6:/_?:X@\XVLV%^>]P.9YO9_;X][FVS
M[<?-[8_%J)E!%,;PSH2YQ,V$*O`?SV]_U*OU"BWOS*)6X@IC*8KZA)?F$Y:B
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M6_-28?:IU&)>$<P6O1+XMBNVZ`6_M^;UO>RC=^](V]*H]2H:M11'?:51ZZ6&
M]/;N6M\">A%?J44+L-XG5VK1$JQ7G;%%KT_7YRGUT1O%I4&YCQ:=8HO>]BT-
M2GW>76G!T9NE.0*]0%O'*;7H==@Z3JE%+[?6<4HMTX62_Z*H]866;5W@YP@:
MM;3%EEXM0[%E4LM<;'EW=:;/4XI/JY:QV/+N4GEM?W*;G]5<*J_M[XK0H@S1
M#^[X>?H+3;R+4B8V%YIV]ND3F;=>+4.QI;G0LJ>G4Y2.HT6OV')0%*IB%!JU
MM,667BV#;7F[#N[AA^]^?__+W?3^ZR\?OSR\^G3WLS8`SMZ8MSQ__?B+V;.S
M__%X_[LV!EZ_^OO]X^/]Y^,_?[U[_]/=5V,@XY_O[Q_]?^B#O/WS_NMOQTV&
M'_Y'`````/__`P!02P,$%``&``@````A`*]`9'6O`@``*@<``!D```!X;"]W
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M^'X.9Y0=N+N7$WHIF%9&%38`.N(3/?6<D(0`TWJ5"W#@RHXT+S*\"=.;!)/U
MJJO/'\'WYN@9F4KMOVJ1?Q<-AV+#-KD-V"KUZ*#WN0O!8G*R^J[;@!\:Y;R@
MN]K^5/MO7)25A=V>@R'G*\U?;KEA4%"@":*Y8V*JA@3@BJ1PG0$%H<_=?2]R
M6V4X2H)H.0_G,>#1EAM[)QPG1FQGK))_/2KLN3Q+U+/`O6>9QL%\,9F&_R<A
M/J/.X"VU=+W2:H^@:4#2M-2U8)@"\?N.P(K#;APXP]#4D*N!77A:A\OIBCQ!
MZ5B/N?$8N+YB!@0!T4$9U,Y7=F"G[&KK4KGQ@6.9Z'V9Z24R#IQAN`[)3Y-X
MX/7*'C/K&N;8S^P2(0>&DH.+(Z7%&Z4>-$YG.8!&U80V.K^:#MRI#^7L(_&)
MJ_@27@<>\_81N`T^P_BU9486%I=(.?!8JH]TYV_$ZX;P48N[PQO/`G#\<;.[
M96.%/@(K!S/3)'E_/Y*QZ,=2#CR6\I&C)O.SR1]=R77)O_"Z-HBIG9L[$1S&
M(3J,Q$WDMO-M?)9NNE%)A@\PJEI:\@>J2]$85/,"*"?!`HQJ/^S\BU4M9`GS
M2EF84=UC!?\D#N=QXNI9*&4/+R!,AK_<^A\```#__P,`4$L#!!0`!@`(````
M(0",]5P?W@(``'X(```9````>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;)16
M76^;,!1]G[3_8/F]&!*2-%%(U:[J5FF3IFD?SXXQ8!5C9#M-^^]WC1,O0->F
M+R&0<\^YY]A<9WWU)&OTR+41JLEP$L48\8:I7#1EAG_]O+NXQ,A8VN2T5@W/
M\#,W^&KS\<-ZK_2#J3BW"!@:D^'*VG9%B&$5E]1$JN4-_%(H+:F%6UT2TVI.
M\ZY(UF02QW,BJ6BP9UCI<SA440C&;Q7;2=Y83Z)Y32WT;RK1FB.;9.?02:H?
M=NT%4[(%BJVHA7WN2#&2;'5?-DK3;0V^GY*4LB-W=S.BEX)I951A(Z`COM&Q
MYR59$F#:K',!#ESL2/,BP]?)ZB9),-FLNX!^"[XW)]^1J=3^LQ;Y5]%P2!O6
MR:W`5JD'![W/W2,H)J/JNVX%OFN4\X+N:OM#[;]P4586EGL&CIRQ5?Y\RPV#
M1($FFLP<$U,U-`"?2`JW-2`1^M1=]R*W58:G\VBVB*<)P-&6&WLG'"5&;&>L
MDG\\J',42"8'$K@>2))YE$YFB\LS6(COJ#-X2RW=K+7:(]@UH&E:ZO9@L@+F
MHS/?1_#Z/ZO@T9%<.Y8,PW8'%P;6YW&3II,U>81,V0%SXS'P&3!)0!#H)K0$
M;9RV]'+(1V4'=LHN=-?*C7]P*O.OD9[,]#TR#IQAX`[-I^DTM.^5/2;M=M*I
MG[0OY"*>PA9\W9<K`EQ/,!T(>LQ8$/;4:8#G";JBH</90-!C0/8DA7G`]-*=
M]WMXW:P##[47@=>GZS%CLXN^T'EF7=%;Z7K,6-`-]<$;\_9RNJ*APV&Z'M-/
M]S*DT$MWV>_A]70=>*B]#+P^78\9FTU@H[[?;5?U5KX'T`N:;E*\.V&8_V.;
MPX@/H%[&LSADX3/VQX"?DI+KDG_B=6T04SLWXA,8;^%I.'ZN)]UK'WZ`Z=_2
MDG^CNA2-034OH#2.%O`&:7]^^!NKVFX&;Y6%N=]]K>"<YS#)X@C`A5+V>.-.
MJ/#/8?,7``#__P,`4$L#!!0`!@`(````(0`U>5+(B0(``%D&```9````>&PO
M=V]R:W-H965T<R]S:&5E=#(U+GAM;)15V8[:,!1]K]1_L/P^<1*V`1%&`R/:
MD5JIJKH\&\=)K(GCR#;;W_?:AH@PM*(\0&R?G'O.7<S\Z2!KM./:"-5D.(EB
MC'C#5"Z:,L,_?ZP?'C$REC8YK57#,WSD!C\M/GZ8[Y5^,Q7G%@%#8S)<6=O.
M"#&LXI*:2+6\@9-":4DM+'5)3*LYS?U+LB9I'(^)I*+!@6&F[^%012$8?U%L
M*WEC`XGF-;6@WU2B-6<VR>ZADU2_;=L'IF0+%!M1"WOTI!A)-GLM&Z7II@;?
MAV1(V9G;+][12\&T,JJP$="1(/2]YRF9$F!:S',!#ES:D>9%AI^3V6J$R6+N
M\_-+\+VY>$:F4OM/6N1?1,,AV5`F5X"-4F\.^IJ[+7B9O'M[[0OP3:.<%W1;
MV^]J_YF+LK)0[1$8<KYF^?&%&P8)!9HH]3*8JD$`?",I7&=`0NC!_^Y%;JL,
M#\;1:!(/$H"C#3=V+1PE1FQKK)*_`RAQHCJ2]$0R`/6G\_1>$A($>7\OU-+%
M7*L]@IZ!D*:EK@.3&1"?C049G=6_.05UCN39L608FAU,&*C.;C$<C.9D!REE
M)\SR%F;<QZS.&%<+$-BI!.N7*F^G_2S&@9T8ESNG;ADV@/M"W>0J\BW,8X?I
MB8$TW2_&@3,,[!>QIQUOT!<PPT[PZF*C%WGX/Y$=^"KR,+Z*'#`37[%T/(KA
MTT>L_H7H:8,^OC\K#GRM+>E'7@;,U&N;P%CUCV':'<6-XZ`JC')H=<EUR5>\
MK@UB:NO&-`76;K>[09Y35X*K_27<+'X.27<`D]W2DG^ENA2-034O@#*.)B!)
MA[LA+*QJ_8!ME(69]H\57.$<>C*.`%PH9<\+U_'=G\+B#P```/__`P!02P,$
M%``&``@````A`,::YL&6#```=SP``!D```!X;"]W;W)K<VAE971S+W-H965T
M,C0N>&ULK%M;;^.Z$7XOT/]@^/WX(LF7-9(<Q+H++5`4I^VSUU$28^,HL+V7
M\^\[%&?$&8YBQVE?UIM/PQG.QX_DD+9N?O^U?QG\J`_'7?-Z.YR.)L-!_;IM
M'G:O3[?#?_V1_;8<#HZGS>O#YJ5YK6^'?];'X>]W?_W+S<_F\.WX7->G`7AX
M/=X.GT^GM]5X?-P^U_O-<=2\U:_PY+$Y[#<G^//P-#Z^'>K-0]MH_S(.)I/Y
M>+_9O0ZMA]7A(SZ:Q\?=MDZ:[?=]_7JR3@[UR^8$_3\^[]Z.Y&V__8B[_>;P
M[?O;;]MF_P8NONY>=J<_6Z?#P7Z[*I]>F\/FZPOD_6L:;;;DN_U#N=_OMH?F
MV#R>1N!N;#NJ<_XR_C(&3W<W#SO(P-`^.-2/M\/[Z:J*EL/QW4U+T+]W]<\C
M^__@^-S\S`^[A[_M7FM@&\;)C,#7IOEF3,L'`T'CL6J=M2/PC\/@H7[<?'\Y
M_;/Y6=2[I^<3#/<,,C*)K1[^3.KC%A@%-Z-@9CQMFQ?H`/P[V.^,-("1S:_;
M80"!=P^GY]MA.!_-%I-P"N:#K_7QE.V,R^%@^_UX:O;_L493=&6=1.@$/M')
M=+2<S:+Y<@%.SC2$IVUT^,2&RU$4S!;+-OJ9AG-L")_4[=$TFLQ-I\\T`]6W
M\>#SNHY^P8;P>5U'IS"B;4CSGP]T=6S'IQWN9'/:W-T<FI\#F$,P`L>WC9F1
MTY7Q10-ML^V&_KV1AR$W7NZ-F]LAY`^#>@2Y_KB+PNG-^`=(;(LV:VWC6<1D
M8?1DW"8^D/I`Y@.Y#Q0^4/I`Q8`QT-)Q`^+]?W!CW!AN**LU`8ZL0%(5DP4U
M27P@]8',!W(?*'R@](&*`8*(T".B?Q4@+1AKF.],"V$TDPFNK<W4SG<SU+%"
M$H6D"LD4DBND4$BID(HC(G58>X0&SJ=NK&$F`8]L'GB#N[9&$4RVSBB,ODB"
MXLZHDX!"4H5D"LD54BBD5$C%$4$'K(-7T&&L6SHHB;5%('="8H4D"DD5DBDD
M5TBAD%(A%4=$HK`#7)&HL9:)(A*Y1!%9=$ABD05\."',)E((:6=$C&4*R152
M**142&61:=LAD?O"R]WN"2.SZ9Z>=]MOZP;Z"XMFSUP(8>VW.X)Q(BE!A%&"
M"*/$(@OX8)1XVT3:&764*"172*&04B&517HH,76MWB:OI,0XD90@PBA!A%%B
MD<6RW56#R=1;2M/N><>&\I$KI.A:F;T:O$92=F7WG+Q6W(>0"Q0O@IL>64#]
M1+HPUI($BRQ`4&S,O44S[HRH/XE%P#,A*2)NI\V43:[\%,JF5'XJ;B-R-R73
M%<FWYC)[A!9\SPAGH1R.&*T"MW`FY`OZUO$V_>+/%;2*A-7"<Y\Y7T1FKB,6
MSNI,Q/)#$2OG"R)*2DTYQN?:>3U!#>$+"J$%;.H=,^',4WA,5JX&21#BFB((
MU,]\>7,P(RNS0E(!',[F<A!S';%P#8GXDB`9<2%]563U7D1)J2GLKJ#4UH%0
MQE"GUJ:D@6G+]!=K*$%H^J5KF"($^B-?F;;*M:]"6Y7:5R6L9,ZFI+LB9ZP`
M><X6`C7P05W*@8BGU@J6+THP04C("'VQM4E;Y=I7H:U*@IROBJ!V,90TF%+N
M"AILY0>T4C;KJ84N+5#6B@DDP89"#=;JTFJ$G7":R=$7<U]H]R5"Y]U7HJ$D
M"X9:D/6IRL?<DWA;'$*75B3;4$C)0C.W[J?H*P1%L;7&.S]D:.6)5ZU(*F*!
M#5G$LC?BW"M4JTL1)=.F^+Q"EEBK<EE:B"DBGBHH04AHT%H)D81S;]_,7$/.
MLN)/12Q<0YI!)4)>1*_"J5S#_HB2/U.I<OX^IU2L=SFM%I*ZF7OU0@P5LI&X
M4*J%F&Y2M`H#+%WGX63BJ29#&[96YMIY@1!S7DKGTV"JG5?"N>3/5+/_.W]8
M$W/^$.+U5CA7M8>U8N)-IA9:P-K73>N><@ZM8-XZ*UW.=9T@#>;HGD4L/A2Q
M)*NS$2NTLO-,,FUJYW-,_]&\047<>YH$5="Q`3RK1=5"[>%)A(0D9<CS%61K
MWA;ECM,H]"2_1BMY;3/W"L'861'SB892#64:RC54:*C44"4@R<QUM76@:VN$
M^`V.AA(-I1K*-)1KJ-!0J:%*0#)GO_C]U%(9Z)J8('9Z)X@=WQ&Z<*7AK$@W
MF89R#14:*C54(03K(;B7[)C"]-ST_-!E3V#+6UXV$L3902O.CH7>O]U`-V#@
MB%%N<@KF/!>NX3LW',Z`/%?"C:3)E*2<I@M+"E:P;&,(+,2VS%A#"4)L.TP)
MX@Q87\PJU[X*:NAN2$J"G*^*('UT`/=7Y6QK2:$!A.1FZ!51<1M'G"T3A,RB
M[[8Y=;>!5N&DK2_"((AT?>$\T2CG.E[AK,[$*V6\:10L5+S*>5(SS=2*5TC(
MEI:"3@N!A%POE_YY-.B,*.$$(>@:02E!"UN:S>'K=;\R(Q/7*M>^"VU5$@1%
MB!L\OT:IR*I'=Z:2Y$1];L&V]:C@#R&NJG#NW:S$@;6"39382A"*W'1."3(7
MWO!E9P]]73!RDVO/!;EQGDN"8(Z?HX^[ETN5*?XX?1>6*JP570_6@87D:76N
MA(96[.(#&PJA62M(RO`$WW,!4TII:,.5IIP7VGE)D'7^SH3DSB51IG[D1'U.
M9\:+O-(-$)(Z\T[H,5H)G=F&0F<(<36$"\5@7T1U_Z@C%@BQB"5!,J)W/J[0
M2JS0_,93,`TKM&3ZO"1;<TDI0GSWU%""$-<?06['RPAB<M.^"FU5$N1\503I
M52ST2^U/J:OUXE&!1;E0U\*[38BQ(5<70A=.F&1U]KR74;_8%9V.6)`O+B5U
MIBW)ZFS$2D24ZKI4X'_LA`G7%/Y$1DB?,,WEFU@Z+@@:*U:(T"WI4>A="JQ;
MI[=#><+T]\W86=&^DF@HU5"FH5Q#A89*#54"DH,!8WT-,\;<T[>%^`DS5%"B
MH51#F89R#14:*C54"4CF;,I<OI%<4`-6Q6S'#1%BAR6"W)$F0>C"#P:<%0DD
MTU"NH4)#I88JA'J.DJ%?X'YNQ=-U;^L81,+902O.#A:^4!AUDRR<>?M6BK[@
M..[8Z1H2E&NK0D.EABJ$^M@Q!1L7R>?8P;*/:P<AS@Y"+LDDM-#[!VUG0"QD
M"-EDVE]UY!HJ7,-W#MK.@#Q7PHV<2Z9<XS1=F$NVNN-5?M@5?$P'"V^QC=&*
M%12):TC]3`D"ETY3"^_2+R,KOH&%"^^8F^N(A6M($4N"SD:LR.J]B))24QQ>
M02G6DEQB?>7EPC\XA=9*E!Q=0THP12OY9<C".UQD:"7+2TVIBEBXAA2Q_%#$
MRC7D0^T&45!J]N@K*&W-Y2Z'D+DN8,KRSPAHQ57J&E*"*4'V)T+^V8">BDB!
MMR[F.E+A&E*DDB"ASJ47L2(K$9$-GJ32KY//3_@(JU^F3H)`#([*I9=@C%9<
MG:XA)9@B!.IL%[.1/]5=$Q9+DVD[R6(5KB'%*F4L16)?F<\B21+[2N!@;GZ;
MW_<K/8#I>Q4X^?D%&$)2FDO_@(%60IK6%S2D'%/RA=(<><MP1L^%5%B6=M?1
ML0K7D&*5!/5.@XJ>OA=)\GE=?1]U]3UU9DV0%*7WI5*,5DPHB6M(OE*$4)23
MD2?MS#4Y*TK;21:K<`TI5BEC34=>CRO7I#^6I/&ZPT"D#P,(>5KT5!2CE="B
M]26TB)#5!TP.^4N>K#>6UJ+UPF(5KJ&C4<12<[OKW$=(!,6*O>93A6-DO'A;
M$$)"HNJK?FS(9),@!#.*\DT)BNPUWV3D;^@47P33Y-HNL6`%>7;!2H(PF+=I
M5I="28F:XO_CQ5&$YP[7FS5"3!"QAA*$A!ZM+[C$)!HS;95K7X6V*@EROBJ"
M]-549,X"/.?/*0H/&9P*A,0@JQ\_M.'E]ST(P=4449$29+:J'W?>#,KPJ:P/
MM9QL?X2<+,0BE6<C59<B2369L\<Y9C]V%05O]JG):J&6(!O2OKMG7^;:UX>G
M.JY?7HZ#;?/=O)<'7^O=W72P?6EP/5O!"P_`L(??!Y/5/=QUZ2?PJX>5^3E!
MWQ-X`Q&^=-=/[L-P=6_?3?3BP`W7REP=Z3;K,((G;7)>&[CT6)EK"-TF">?P
M9-[[9+%*X8BIV\!A%=KT/8$7*N][&8`T^[)<!Y!^3X2U2;$'OX]6]Z!6W:4U
M9-Z;.&37FQQDT)=`LES!JP#:?[%<P8_Y-9X$P<K\5*#O2;A*X:MP_02^5(<V
M[9-Q-T[PVN?;YJG^^^;PM'L]#E[J1Y#?I'TUXF!?'+5_G/!W/E^;$[SP"5L1
MO&P(+_C6\/+79`3K_F/3G.@/"#WN7AF^^R\```#__P,`4$L#!!0`!@`(````
M(0#3JBT<\`(``)L(```9````>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;)16
MVVZC,!!]7VG_`?F]7$)NH)`JW:J[E7:EU6HOSPX8L`H8V4[3_OW.V`1!DJ;I
M"X+)\3ES9NQQ5K<O=>4\,ZFX:!(2N#YQ6).*C#=%0O[\?KA9$D=IVF2T$@U+
MR"M3Y';]^=-J+^23*AG3#C`T*B&EUFWL>2HM64V5*UK6P"^YD#75\"D+3[62
MT<PLJBMOXOMSKZ:\(98AEM=PB#SG*;L7Z:YFC;8DDE540_ZJY*TZL-7I-70U
ME4^[]B85=0L46UYQ_6I(B5.G\6/1"$FW%?A^":8T/7";CQ/ZFJ=2*)%K%^@\
MF^BIY\B+/&!:KS(.#K#LCF1Y0C9!?!>$Q%NO3('^<K97@W='E6+_5?+L.V\8
M5!OZA!W8"O&$T,<,0[#8.UG]8#KP4SH9R^FNTK_$_AOC1:FAW3-PA,;B[/6>
MJ10J"C3N9(9,J:@@`7@Z-<>M`16A+PF9@##/=)F0<.[.%GX8`-S9,J4?.%(2
M)]TI+>I_%A28I"R72>V>:KI>2;%WH-^`5BW%W1/$0'P^%T@"L1L$)P3V(\@H
M*.#S.EPN5]XSF$X[S)W%P+/'!#W"`]%>&=2N5T8P*F-5,)4[&QC*3,[+A!^1
M03"4=9!\N(QZ7JML,5-3U:&?Z4>$$`PE!Q=]F<+(/U+J0*-THC>J"3O@^FHB
MV*CWY>PB9MN-NC0?\^*>G4]=@%_>*;ALK-!%8.7`\1L]6XQ%+TLA>"S514[-
MX"0=;'8T,PO<Q;MN<-U8HHN,W81]_T8EC,:JE]T@>"S514[=!#"!CNT$BPB'
MQSO=,2O'*H?0V-'TO*,`#_F@D)<M&?216C<ESI@Z&@O8H\EL=D63\#`=E>X0
M&IN:O6$*#_;UINP8`(7^#,'=@0D,)H.]"NR\K9DLV!=65<I)Q0['_`0F:!_M
MKZ"-83R.3^.-O9J\_A>X&EI:L!]4%KQ13L5RX/1-H:2]7.R'%BT4'RX(H>%2
M,*\E_`E@,$5]/,BY$/KP`5Z\_F_%^C\```#__P,`4$L#!!0`!@`(````(0!E
MI"@0#QD```F"```9````>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;*R=R7(;
M29*&[V,V[T#CO4@`B86$E=0FYKX!8V,],V<6!4FT$@49R2IUO_UX(-S3P^//
M`@%U]Z%9^M+]STB/U2,7_/JW?SQ]O?AS]_SRN/_V[G)Z-;F\V'U[V']\_/;Y
MW>7__+WXY>;RXN7U_MO'^Z_[;[MWE__<O5S^[?U__L>O/_;/O[]\V>U>+TCA
MV\N[RR^OK]_7U]<O#U]V3_<O5_OONV]TY-/^^>G^E?[Y_/GZY?OS[O[CP>GI
MZ_5L,EE>/]T_?KOT"NOG4S3VGSX]/NRR_<,?3[MOKU[D>??U_I7*__+E\?N+
MJ#T]G"+W=/_\^Q_??WG8/WTGB=\>OSZ^_O,@>GGQ]+"N/W_;/]__]I6N^Q_3
M^?V#:!_^`?)/CP_/^Y?]I]<KDKOV!<5KOKV^O2:E][]^?*0K<&&_>-Y]>G?Y
M8;K>WBPNK]__>@C0_S[N?KP$_WWQ\F7_HWQ^_-@]?MM1M*F>7`W\MM__[DSK
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M[/[U_OVOS_L?%S0TT16_?+]W`]UT[>2D__C3#SWJKSH4=0*G\L')O+ND&J:^
M\D*CP)_OY[/YK]=_4L]]8)L[M)E:BU0L7-]RLED,\A@4,2AC4,6@CD$3@S8&
M70SZ&&QBL`W`-<5Z"#BUK']'P)V,"[B$ZDZ`UL`LBJY8B$L6@SP&10S*&%0Q
MJ&/0Q*"-01>#/@:;&&P#8*)+G<]$=WP:D%;KK&G`#UKM;'ECHW;G;6ADD+"E
M0#(@.9`"2`FD`E(#:8"T0#H@/9`-D&U(3%!I?#HCJ,Z:1A.JH6`L6$11]49S
M&I\'H]EM8HW2P4A"GP')@11`2B`5D!I(`Z0%T@'I@6R`;$-B`DWC[QF!=M:'
M0$MX[CRAJ`I)@61`<B`%D!)(!:0&T@!I@71`>B`;(-N0F!#2LN:,$#IK&T)/
M9HF&$$@&)`=2`"F!5$!J((TGBW!FG=U&,VL[&$F]=R#4`]D`V8;$1)76?&=$
MU5G;J'H21A5(!B0'4@`I/3D>GVHPDOC4(-0,-N&(%`U;[6`D0AT(]4`V0+8A
M,8&F>CXCT,[:!MJ3,-!`,B`YD`)(Z4D4Z"@^U6`D\:E!J!ELPD`O[=#?#D8B
MU(%0#V0#9!L2$VA**LX(M+.V@?8D##20S),H9"M[I?E@)%=:@%`YV(0ABQ8J
MU6`D0C4(-8--*'1K2]0.1B+4@5`_V*A0,IE8H<U@)$+;4,A4ATO93'WX/.3*
M);.O7QX??K_;^RQ\9$&74+[!68A3L?5T$'YW&584HHQ10@/@L!Z9KJ)A-E<K
MN:`"M4JU4JUD$J4ZE5J)5HU:C5J%6M'"OE4KT>I0JU>K4"M:<VW42K2V1LO6
MFDMRPNQQI'9H(V.H'I\3T=)0M.]<QDTU9JH'4"96\\$Q1U0(TKF[%*2.%:):
MD#HV@M2Q1=0)4L=>D#IN$&T%'1QM2%UF<T9(?2)D0NJ1VT`:VG(RB=IRZM;G
M+O#+(:29(+]-YO+O7-#JD-(GM(4R6T2]O!`;52H%A468WD(7X"+<',175U%3
MK$5%A1M!6L16D*;"G2!U[`6IXT:0.FX%'1QMM;CDZ(QJX5PJ;.F,:`@,JB6:
M0%.W>^2JY3:HEL%1>DW.5LGD$+G%/!YY"Y0I&4U5N6(TOSW(W%Y-HEFX1ID&
M95J5D0)VZ-BCXP8=M\;1UH#+FLZH`9]D48U*H>[</IN+;=@JD_B:4['2QI,)
MTL:3"Z+UQ5";TU74@@NQ4JU2D&I5@HYJU6*E6HT@U6H%::/N!*EC+T@=-X+4
M<2OHX&CK@D)HZN+G9FNG$LW6C&PGB99,J=NGC#N)1W.M[IRMYE3KQZH(M$IQ
M5*U*T%&M&LO5B*-JM8)TANC0L1<K==P(4L>M<;15Y'*YL+O\7!7YC-#T(DX2
M*6Y#6)-)M!A-IVREC2YC--=&EPM:RO2R6.+T`DJEN(5%&)E>O.-B)M-+-/_4
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MX'VR&M;IS*-P%QY1ABA'5"`J$56(:D0-HA91AZA'M$&T-<B&U.5Y84A_:BDR
M\]FBB;1'9M<FF48S<LJ.9*7M>7`4E*-5@:AD%&Q75&JE78\>'K%;8;5:R1D;
M1"VB#E'/R!?"1MJEBF&DWVB\G%GJ&O..1`]+:YT'4T09HAQ1@:@4I#-OQ6A)
MO688G.$.1ZU6&C\H:BOR6OH.42_H4`@;/Y<AGA$_GU":)ND1G4+*F<X`98AR
M1F:S.)G&":5:B7R)6I5:A2&-MAIJM1*M!K5:M5(MV@>RS;M3*]'JC9:-LDNY
MSHBR,[=IHEL@$3+!FMW&.8A:2:$R1D'UY&JE%SB[C5+.0JU$JT2M2JU4*YE"
MX(?2BU:#6NV8%I2K4RO1ZHV6#;S+B,+`_]Q`[/,JT^H]L@-QO.6=TLK*U9H9
MB#TR]3%8:0QA*[Y`K9)1H%6IE6HE$QB;AS-*#!O4:L>TH%R=6HE6;[1L?;@L
M*JR/-X9KSL/"X9KS,!WPTAF@3)`.2KD@=2P0E8+4L1*DCC6B1I`ZMH+4L4/4
M"SHXVF"YU?\9P?+)@FFEG#]0]QMF&LC#TQE;R:[T+.J^F1CH>B(7I.E7(8AW
MSB?SU2+>I2W%1I4J0:I4"_(%BE8WC1Q5AU:0RG:"CI2F%YN#FPW]6_G/2?DN
M[6G#.,Z(_ARK$6\5;%-CG7B38-L\Y],%.X*%('?#\,_WMS?3>+.I9(M`IV(4
M[)O7HN/WS:.YL$&'EM%"MTLZT>"RS*AYV#FU9POZ0T.)J0_:][==X:?&\8.*
MG5<9T0PBHU<J2/>%,T':OG)&P=Y>(6C8?\"]O1*5*D%:A%H0=X`W=N`:,5>%
MEM%2'XSJ&,V'XN'V2"]*V".2.$N,:^"T'8&#3%0%G#UBI<=9U/')(AG2)>U:
M\UFTK+ECJVA'(%Y(J94TBPQ1CJA`5"*J$-6(&D0MH@Y1CVB#:&N0[6WG)54)
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M02GCE$SD1V;>\]*`!-,`0>&B,YE%.RTI6_G5EW\911VE/G-&O#1=7"VC"!3H
M4R*J&+DMU&-!X<QD9$'HEK]AAWIC;>!7RZ;G\`+:UF?4HM.$K<+&,SAJ4!CY
M]=IME#\5(F)/%06N5"O1K1@M:38X%J6PC&8$=JN<,Z)T,+>+,T%TBJ`$T06F
M;!4V'764J\D9<=.)NFFA#N&9XB"IE<A6C-YH2F*%36D>KVR/-Z6#>12DOUK!
M4BIV5OQ'5[#1VO3N(/KNTEU04"71%)^JE00J0Y0C*A"5B"I$-:(&48NH0]0C
MVB#:&F0;_GDKV#FN8!E1E"5^*:(,48ZH0%0BJA#5B!I$+:(.48]H@VAKD`WI
M>2M8]Q!2M(?-*%B8I(@R1#FB`E&)J$)4(VH8F34SW(]IU4H:1(=:/:(-HJU!
M-LHT1YPS8COS:##RR$094$;[%M$B,4=4("H9'0]6I582K!JU&K72D6P6SYZM
M6HE6AUH]H@VBK4$V\&ZY>_J"@G91(/"P[D[9*JB+#%&.J$!4,HH"'\W$E5I)
ML&K4:M0J#'ST\$2K5J+5H5:/:(-H:Y`-_'EI`*W9(?`>!5%.V2I`&:,H?M$J
M/U<KN>8"M4JU"N,73=256HE6C5J-6H5:T73>JI5H=:C5JY5JX4LJ:B5:6Z-E
MJR?./GXJB9]C4L(HJ*(44<;(99'#8F>ZBI*G7*WDB@K4*M5*M?`U%;42K1JU
M&K4*M:)RM6HE6AUJ]6H5:D7IV4:M1&MKM&RMN93@C-',9Q!A>D2K]&B"2!%E
M@G23($=4"-(=B5*0.E:(:D'JV`A2QQ91)T@=>T'JN$&T%71P-"%=G)=+'<SM
MS,S(;E<D41Z4BE60<3):ZOY^+LCVBZC-%*A5BF.84L(MP4JLCLK7*-^(HQ:U
M1=2A8X]6&T1;XVBKY[PL;N%3MK#%"S*I[B2:8%.V"E-==92>F3.BVRENIRQ)
MZ!VBJ)X+%"I1J&)$S=()+:^2:,*J4:9!F59EI(@=.O;HN$''K7&T=7!>NDL/
MF,=3.2/;1>"%%;$*NXC7"N[CY6)%4T\P=4`784?5*L51VW`EZ*A6+5:JU0A2
MK5:0WE_L!*EC+T@=-X+4<2OHX&CK(LZ`?VK>IF?;H8H8V6X2-<N4'4TW\8Z4
MM$L;S-F*DD[7NG^9+I?+:`.N0*%2O%2H$C3_RV[B3QZ4IQ$?E6D%Z1S1,0H<
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M`5^'=H)&E:6$K2`O<W.UO#7_BZ;,#HO;BP*U69UKX^)NQ(KR=;7"GA66V59W
MO%7PDST+MQ`6'AT:G3UEG/X>OSG@=A=\4](KG,^B=G/'5G8'/XEN=:1J)165
M(<H1%8A*1!6B&E&#J$74(>H1;1!M#;*!=_EGV+7?"+Q/5\UZWJ-P!Y\>1W/5
M$Z`,48ZH0%0BJA#5B!I$+:(.48]H@VAKD`DI/0QF0QIWGY-&RX.*'2T9F4T:
MRGGLTWVI6@WM&5&.J$!4,@HVCRI&2[VG7ZNC]L8DB8:S1JVD7"VB#E'/R!?"
M1OJ\9-2]"1)-0(SHE0(I5(HH0Y0C*A"5@G3BK1@MJ8L,@S/<!:G52LK5B)86
MM474(>H%'0IAXW=>(DD/;4#\.*W3"TS9*F@S&:*<D1N8AC#@6REJ)6$H4:MB
M%(4TVE&HU4JT&M1J&47EBK*E3JU$JS=:-LHN)SI]B%URXJ=ISQTC4RA\*T6M
MI%`9HZ`N<K72P,/;'X5:B5:)6A4C$WA\*T6M1*M!K991=(U1OMNIE6CU1LL&
MWJ4W8>!_;B#V25(XY;D'16@@L0,QO)6B5E+6C)&ICQ$MV'DO4*M$K8K1RCRR
M`&^EJ)64JT&MEI&Y1BA7IU:BU1LM6Q]QQG9\K4'[L##<>&2&:T`9.YHH@U4A
M5CJ>EH)T-*L8+74SJ!8K=6P$J6,K2*TZ1+V@D;'9+<__]<;K%_FF\?*ZGR(R
MC+RP,YTNV<H_:H4I3R8&FO+DC&CS6!I#P8B>@?ZK[8T2A2I$M2!?GK=RIT;,
MM70MHZ!T'2,NW4C*V!L=VYC?2I).6^5ACD0KJT.S#W8?&-'NM`0V8Q1L2.2,
M:-]8K`I&],#L7X??GRX0JE"[9L3[XV^''T1;+%UG2S<:_E#'AC].&..Q_;3=
M'^K7,,9X=.BW]I0NJPE[Y!O#ET^"J.MI/YO'MZ'NW-SI4R6U2N*[#ZE:2=5F
MB')$!:(2486H1M0@:A%UB'I$&T1;@TS@W7QV1N`/YC9S8A0DI"FB#%&.J$!4
M(JH0U8@:1"VB#E&/:(-H:Y`-Z7F9TPHS)T;!))LBRA#EB`I$):-H.1BMPRNU
MDGY1HU:#J$74&62#=5Z:M,(TB9$)%F1.&5KEB`I$):,H6%$"5*F5!@L*T:B5
M#DCQ]TI;-1*ICI&_1!N^\_*?%>8_C$SXO%6`,K:*HA!E$+E:2=$+E"_52J.0
M)-$MGDJM1*M&K4:MCFBU:B5:G=&R(?VW9#8KS&P8!6%-$66,3&Z0)-'V:ZY6
M<D4%:I5J%41G'MW%K]1*M&K4:M3JB%:K5J+5&2T;:9<XG#[INZ\*1UM,C$Q(
M.1O1="$3*TT7<D2%('4L!:ECA:@6I(Z-('5L$76",$%9Q0G*\>70P3R:E4<R
MD60>[\^S8WCW1U!P]T=0N)\$7^(JQ$K3@E+0T72H$JNC\K58J7PC2(O:"CJJ
MU8G50<LV2;<H/J-)^C5TF`*N&(5[D`D\@L-606:0J:-TG9R1>Z!+T\GX9E.!
M6B5J52=IU:C5H%9[DE9GM&R471IP1I2=>=2\/;(W-^?Q=OV*K;3-9(*TS>2"
MR/A8E$&K%$?5J@0=U:K%2LO5"%*M5M!1K4ZL1MJR2W_"*,=IW$E9],HG4::)
M,PJ;93*)%@,I.YHF[AW#QV?8RKU-<"SXWC'0*L51MW(K04>U:BQ7(XZJU0HZ
MJM49+=/$;\[+JP[FMHDSBIIX=.<G%2MM2ADC>AYZ&$@8N7WT(U%&K5*U`L?X
MIGAUDGR-\LU)\NU)\IV1MW5A$C**P?'9]`83,D&VQ4=)0,I602O-U%'KPLOS
M<Y5S^KG!1214H%")0A4C?:[2WJRL4:5!E981%X=^&?"6OI1KE3JC9$/KDIQA
MC'D[M,X\:N8>1<T\'LEOV"ILYH.CAI:1?PCDEYL%?.*X0*%2D`Z]E:!AA]8&
MI);C6IQ&D*JT@K@XBV0U$MKPPFQH36I'9C\U?-]@QB?(-N9X^&8KTYB]5CA\
ML]4;PS=JE>*H0VXEZ.B06Z-6(XZJU0HZJM49+1M\<C3M^N>"[U2BYNY1U-RC
MO9?TAJVT?66,PN<;!?'SC;,Y?:_*-M0"A4KQ.KXH9RM]OM$*URC<G"3<BI4O
M]&PRIY_>A?$FO'Q;+RZ["\>;N%Y.VYJFW[:%BO$HV)KVOU[K?W?S:??\>9?N
MOGY]N7C8_^%^F?;&/<X^8/[9W.7M^H/_W=SH".U%K]TN+`U5\9'59.TV$_'(
MA_EL_8&>ZL(C]/[TVKTY/'8DH2.'A#(ZSX?%S?J#O]46':%GN=;N*:81M065
MFA[&P2,?9I/U!_H0$AZA[Q6OW9=ZQX[0KPK3*^YXY$-"5THOI>,1^M;1VGWE
M9^P(72E]K`:/T!;*VFV0X!':$%F[[0X\0ML;:[=Y@4?HIY`_C)Z?+F:TQ%3@
M47M7W#']^?J#_TQ97"USJLD1A[L%U<D(IVU=NKBQ(M$>)AT9*Q3M2-)ECQVA
M'3\*XEB!:?^.U,:.T&X<J8T=H:<LUBD]3(#AI6<FUNZ)"#Q"3T"LZ]$C]#S#
MVCVM@#YWRSF=9RQJ.1UQ=_K1A^[LTWG&CM!]>CK/V)&[Y834QAHY/;!%/F-'
MZ.DD.L]8_=`#.Z0V5@OT^`WYC!VAAVGH/&-'Z"W1M7L'%*^4WOE<NS<Z\0B]
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M.\&/_?/OAY\Z?___`@```/__`P!02P,$%``&``@````A`)YR=5$C!0``YQ(`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,C$N>&ULK)C;CJ-&$(;O(^4=$/=C
MS,D'9'LU&'.0$BF*-LDU@]LV&D-;P)S>/M5T-Z:[G%GO*#?K]3?5O[O^JC[`
MZMM[=39>2=.6M%Z;]F1J&J0NZ+ZLCVOSK^_QP\(TVBZO]_F9UF1M?I#6_+;Y
M]9?5&VV>VQ,AG0$*=;LV3UUW"2RK+4ZDRML)O9`:_G*@395W\+4Y6NVE(?F^
M'U2=+6<ZG5E57M8F5PB:>S3HX5`6)*+%2T7JCHLTY)QW,/_V5%Y:J585]\A5
M>?/\<GDH:'4!B:?R7'8?O:AI5$60'6O:Y$]GR/O=]O)":O=?D'Q5%@UMZ:&;
M@)S%)XIS7EI+"Y0VJWT)&3#;C88<UN:C'62V9UJ;56_0WR5Y:T?_-]H3?4N:
M<O];61-P&^K$*O!$Z3,+S?8,P6`+C8[["OS1&'MRR%_.W9_T+27E\=1!N7W(
MB"46[#\BTA;@*,A,')\I%?0,$X!_C:IDK0&.Y.]KTX$?+O?=:6VZLXD_G[HV
MA!M/I.WBDDF:1O'2=K3ZAP?90HJ+>$($/H6(/5GXOC=;S.\7@<A^)O`I1'Y^
M(G.A`9]?GP@LC7XB\"E$_(GG^//%'998W-Z^6E'>Y9M50]\,6`)@8'O)V8*R
M@Z5IR#)Q4X?"_5?=H&!,Y)&IK$V8&)2DA69[W7C.=&6]0H,4(B;$,;8:L941
MK!N8;*2#G0YB'20Z2'60C8`%)@Q.0*?]#TXP%>:$S"&4X&J-HZ4M(^202`<[
M'<0Z2'20ZB`;`25M%Z?MPFJ_O4YEO=D@6)&C>MM+7TTKY#$V7Y&LG%M$(D1V
MB,2()(BDB&1CHN0+>\&XS)_GR8)A98!WH\;6VC;D01Z8-@39RX7JQG8(&JJ,
MR`Z1&)$$D121;$R4W&$+NS]W%MSG+F<<<@*)2K)%)$)DATB,2()(BD@V)DI6
M,S4KOH5-V`[?G<KB.:3\G+A1:1>V*KZ!,0TU64X<]YHL(A$G+GQ<*S_7VF,W
M!$G78D021%)$,D[XA)3\X5`95_5+^3,--7].QODC$G'BSOL=WYG:VA:P&_X^
MI"XT^HM'[WPRQ+!3`S0\=>&DP]^E1B8T^LHH1K"[X^@LNU%PN#O(BK-@-6-.
MQADC$@ERG?\.D1B-2E!,BD@V'J5D!:?R_5FQ8#4K3MBEZ=JCOG8V;T70;&CV
MZ-:PI=[:(HC7WYM.-=D8R2;WR*8_D,W&LHI5-NS!8Z^^M!1Z$=5#B>"'1R9J
M;FQ%E+.\NBB0YPQH)Q';>UXWMC_#MF&A1(ZZ"J42P6Y_G=3<59=/IFBI9K&+
MT-W+!<YQO;,$@M:22W,KT:B1!/+F0]1.H@6W@#F@=PX62N2HJU`J$1?"#9@I
M,FKV[#XTRIZUB@,[R_U'!KL5:&M-(J5/EDNU)%L1I?0)UU+Z1"#>)P_N#8]X
MQ$@G$=(CG50BH0./P9K7F3(?U21VB]),LOV?/%IM<16[MFXHD+(IN=K&OY5!
MXU[B4IZRF:%=20ST9F*%S5'*,=9.Y*A/M5,9Q;5OF<FGZ/2S5LUDU[)/S/Q.
M+[#K_.CF#<_LJ.O$?8\M,/Z+_*F</^=5I#F2+3F?6Z.@+^R)&[:$S6K`_'5`
M-`O@R@$".I\'<(ICGLP#.)DQA]<*CWVA-9V0O6ZX$1\Z`3R98)W0#>`*C_FC
M%SSRUQ;Z#W@!W'OQ@-`/X.8(W!H&P&N&2WXDO^?-L:Q;XTP.8,JT[^J&OZC@
M7SI1D"?:P0N&OC8G>*%$X%%F.H$V.5#:R2_L!X975)M_`0``__\#`%!+`P04
M``8`"````"$`9<'1/L@1``"490``&0```'AL+W=O<FMS:&5E=',O<VAE970Q
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M4!)H"8P$5@)7@&L*PA`)&J7_ADCX5GPDD@^[!')HIL+M9)&J=!(H";0$1@(K
M@2L`<YOF6.EV?8%(>?;&M!04>6ZF&^[.+M@T82GP:6R!=$`4$`W$`+%`7$F8
MG[0VO-]/;TPS@F)6#&@Q7'?!:$:S9C!J9C*Y@]&072`*B`9B@%@@KB3,=UJ^
MWN^[-^Y]3SW>!3+O=YQ^8K9`.B`*B`9B@%@@KB3,*UIV2Z_\TC5;^^TLKM7O
M7KU\0]SC0,CC,K4S/M#;P2@%J@.B@&@@!H@%XDK"@D![3AF$\]/7&W-'`RE3
M"Z0#HH!H(`:(!>)*PKSR.E3L2LO9558-[TZM;XA['(A([5RD=C`:4@M$`=%`
M#!`+Q)6$!8$6EC((YU/KC;FC@<Q[F5CN<PV-ZO>WVUOW#>>I,)^(56X7K<1:
MN!!1S59#6!$I1!J10601D<;NPT+]HF]DP:7]:4P4@FB@#2'U?-<W\/FRG#J(
M.D0*D49D$%E$CB'NG]_OQ12:+J[&+XY^$Q0C*R(QAY8RVZ%B$:`N5TQA5(@T
M(H/((G(,\6AX65!$X_Q<:J*(*+,=4&4V^4WW_2V'+=IW=-`,\XG86';-L)%G
MJV:VDO$=K%(PNUPQ(85((S*(+"+'$(^OWZ3?'X6PI5,44C=W_MJ41EDQ6%I$
M'2*%2",RB"PBQQ#WS^^_A7]>:RQH31A[F12V<>;XL+.7N5[+7`]6*6)=`T@A
MTH@,(HO(,<1CX7?M(A9OS*6PQS.7X[:/:[+?"M_?<M@XQ5P2._FN"59B9Q+7
M+&VVRO$=*B:DT$HC,H@L(L<0C^^H?;_!C3\B-I>B&,@2OD,KA4@C,H@L(L<0
M\V\J](>?2Q_:F?J&N.:)B.],<W$GHLU6*;4=(H5((S*(+"+'$(_&*!TR11T2
M$>Y,4Z$`SL_3WAITGE!PNVC%9]-<7!BWV2K'-XB!(,3Z:TB%5AJ10601.89X
M?$?M_%/<^2,J9Q.B#I%"I!$91!:18XC[-TI_3`?]D3*SBTA,&2'PVVR5*G:(
M%"*-R""RB!Q#W.518L/?#Q#Z-2*64M`?'5HI1!J10601.8:X?WYG+[;!C]_8
MF`:-4&Z^$8ET"P7:9JN<;M0;:*41&406D6.(AV.4WIBBWHB(I3M*D&(_1"N%
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M8R(2TTG>-\E6.=VH8]!*(S*(+"+'$`_'*!TS0QT3$4LWZABT4H@T(H/((G(,
M<?^$CO&RE4Y0^(<VIX?'N]]V!P^J)PEF=&0@'"28H;Q)*!Q3"0^4H]5LN('8
M)2LJH:\)9Q":>;[/P[LZ2G_X)45<021$)?G;%O(^0[2BB_\\^D);=-'N#TED
MV<VZYP=U>0%P7C[TUEP^),2[)R_3HU79O81"][+>X-T;M=7/<:M/B'=/7G)&
M*]:]T%:,7E[;>?=&[=1SW*DCHEBDM+6(.D0*D49D$%E$CB'NG]B6/WS_;(X[
M=D1^&!3C.@_3\/0_6Z4`=8@4(HW((+*('$,\&J.DQ!SO?T2$(F4^:GONK4&D
MY"':1VX7K;A(6<A+M6R5XQMV?ZJ8D$(KC<@@LH@<0SR^8A-_8RW"C7H.^VV+
MJ$.D$&E$!I%%Y!CB_HE=^>.S"3?L^;`[E[,IKZIQ-@U6*;5=KIB00J01&406
MD6.(1T/LX6]D&S?K>4"T=J>>MX@Z1`J11F00642.(>Z?WW[%K;7P[.$-3\.V
M75[/S0.B.\_9TP&5^187*EVN6%KEE8)U>#%*"O367`I$5"8$48=((=*(#"*+
MR#'$_1-:HKC7>3XC_NFK$&41E1G)J(RUS$C=*E]+\!Z/DA<+E!<1L8P$JP)U
M:*40:40&D47D&.+^5>1%/%;W1D903BP"8AD9T-F,5*W^0LTO1DF`WEK,D:`*
MBO"WT:I`'2*%2",RB"PBQQ#/B!`B[Y\C0324J]8B():1`9W-2,UJF:]X>(]'
MB88%BH:(BO"WB#I$"I%&9!!91(XA[E]%-/B?<_S%SRO2Q>T")4)$+!_!BM#9
M?-2LEOD2C_=WU+:^P&T]HO*2"%&'2"'2B`PBB\@QQ/VK;.L?.R^ZP(T^(GY-
MM)17J]DJR8$.D4*D$1E$%I%CB(5C.4HT]-9\08P(KXF68KL^OR/TUG!-E/?5
M<$T4K?@UT5)><V:K(;Z(%"*-R""RB!Q#/+Y^NRY4Y!M1")M[N0HO`RJG$Z(.
MD4*D$1E$%I%CB/OG=]_"/[_AK.@'5://NRW#-LY<#TC,)GD%'"L6`>H0*40:
MD4%D$3F&>#1&R8LEWF&(J'"F1=0A4H@T(H/((G(,<?_\SBZR_:'S6,L@$5BV
M`Q+9EE?`L6(1H`Z10J01&406D6.(1V.4=%FB=(FHLG8*T?#&JC%HA:P"YI.L
M@./:&:S$VBFN;]KE8)773D`*K30B@\@B<@SQ^(Z2(DN4(A$5@Z5%U"%2B#0B
M@\@B<@QQ_X04>2/+*#>6`8DIDV\/A)M&V2JG=*B8D$(KC<@@LH@<0\SEU2BY
MT5MSN1$13IG5*+G16TNYT>1+E#!EHI68,D*4M-DJ!;-#I!!I1`:11>08XO$=
M)3=6*#<B*J<,H@Z10J01&406D6.(^U>1&Q_[(=\*]49$8CJ)=;3-5CG=@U!)
M2*&51F00642.(1Z.47ICA7HC(I;N8%6@#JT4(HW((+*('$/</Z$WSJ^0_O&Q
MN,\7$4_I2LSS-ENE_'6(%"*-R""RB!Q#W.51HF*%HB*B(G\MH@Z10J01&406
MD6.(^^?5A)"0HQ_]KX(D*>5C1'3Z.>6P1=1%Y$]>Y(>6JWPKI%_W5;9*;6E$
M!I%%Y"(*_>*1$/+&7SJ-CP2JGE5`+!*`NFA%9S3\Z8+II!%*6V6#'(383+_[
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M1`:11>08XOY5=-W'KLS6*.XB$C)>K#5MMLKI#FT505-HI1$91!:18XB'PTNE
M0N:>OW)9!V%5ZMF(BIZWB#I$"I%&9!!91(XA[I]7585_?AGYT)W@=9!GS/6`
M1+;E;9=8L0A0AT@ATH@,(HO(,<2BL1FEZWIKKNLB*IQI$76(%"*-R""RB!Q#
MW#^AT'RV_4F8D>\TV`2Y5>8Z(I%K><\E6PTS&Y%"I!$91!:18XC'0@BS\S-[
M@PHL(MPH-W[3+N;4&RU'V4%?,&BF>2,N!79]F_2RJU+!-&MY`R1;Y?A&O9)5
MC4(KC<@@LH@<0SR^0J"\$044(IN`V%P"U*&50J01&406D6.(^R?D4"_`_(&0
ML9-I$$HI9[M-0'PRK85V:K-5JM@A4H@T(H/((G(,\6",4D4;5$41L60'JP)U
M:*40:40&D47D&.+^55311Q9.E$2;0=GDZ=^LQ?1OLU7.]5`Q(856&I%!9!$Y
MAG@L1DFB#4JBB"H+IQ`C;RP9@^+(D9LWXEILMPE68N$45FVV2L'L$"E$&I%!
M9!$YAEA\F\DH%1+,N0Q)K)@[;85U%4;O8O-?S][+1"]C`T9O8P-&KV,#1N]C
M*YGP5.B1\PEO)J@[$A-KI;RV+\R&!%<8.1^^H@@<.0^,G`=&S@,CYTLFG!\E
M0/JSAN*I2&+%3`IOAPZO^WW>OW[?M_NGI^/%W>&G?_,S*<,OGP8<WTN]V=QL
MXXNI11%-GAL_4"EDLH2RZE]GW?]>"LOZ5UWW]X5$V78SN]G2_*^T2"5>3=1*
MYE32^RA:HXV22OJ;FE"RI)+^!A.4K*AD5?N>%=6A!Q[8@^UZ0;WN3_W+UJC$
MWRS`.KLUM4:7V;42Z@%=<=9*UE12C<Z:,D'7+94Z&TH$Y;560FD@_8LEV^7J
M9DM/X+%D1R7^)$>MA/I&9R!J)=0W.BJ`)=M5<[.E^TE8LJ,2__B[5C*EDFJL
M5S1"Z!EJK0Z-$'KZ6"NA_-!#NDK)@GI-YRFQ9+ND7M.1'BS948D_(U@KH5[3
MZ;I:"?6:3IK52JC7=$:K5D*]IO-*6+*=TTBDHYI80K\SN_&_Z:J5T$BD7T/5
M2BC;],N@6@EEFWY34RE9T'BC'W?42B@&]".#6@EY2H?=:R74-SIT72NA'M#Q
MWTK)C+(0;E_+V3BC'M#+#;#.=C:_V=+/_K"$7B)`=>HE%%&ZSUNK0[VF9X^U
M$HHH/8NKE,RI;_0+SUH)C1#ZM2.6;*?3FRV]40%+Z*U<-_X-6+42:BT\))/1
MF9*G](JE6AWRE)XDU$K(TW"C'EHC3^D--[4ZE#EZ$4RMA.9<N)<M6YO1J*)G
M-5AGVU#FFNKW4(E_/R76H5=+4DG5GX;\H?<<8IUML[[9TJ^,L83>)TAUJOXT
MY`^]]:Y29TK^A)\Q2T^I`[7OWU$XJU[2E]>^F[9LBDMU;%")?PMNI5<-S1QZ
M?VRMA,93N)\C^DN/VF_\\W"L0X^>;_S392RAI\E4IU9"?P1C6QVUOF.5EG9^
MF-<X#?*:[UL:+-5\T%"ICA0:*/TXN1[<IC^)\>/V^_Z_;U^_/[X<+Y[VWT@X
M3?IW&KR&/ZH1_G&*#UB^'D[TQS#Z9RT/]-=/]O3V^XD_-_WM<#BE?U"(KH>_
MI_+E_P4```#__P,`4$L#!!0`!@`(````(0!F%6>K_P4``#<7```9````>&PO
M=V]R:W-H965T<R]S:&5E=#$Y+GAM;*R868_B1A"`WR/E/UA^7^RV#0P6L`)\
M2HD419ODV6,,6(,QLCW'_OM47^Z+L.QN7L;#Y^KJJNKJJG8O/W\T9^NMZOJZ
MO:QL-'%MJ[J4[;Z^'%?V7U^23T^VU0_%95^<VTNULK]6O?UY_>LOR_>V>^E/
M5358H.'2K^S3,%Q#Q^G+4]44_:2]5A=X<VB[IAC@9W=T^FM7%7LRJ#D[GNO.
MG*:H+S;5$':/Z&@/A[JLHK9\;:K+0)5TU;D8P/[^5%][KJTI'U'7%-W+Z_53
MV3974/%<G^OA*U%J6TT9YL=+VQ7/9_#[`P5%R763'X;ZIBZ[MF\/PP34.=10
MT^>%LW!`TWJYK\$#'':KJPXK>X/"W'-M9[TD`?J[KMY[Z7^K/[7O:5?O?ZLO
M%40;U@FOP'/;OF#1?(\1#':,T0E9@3\Z:U\=BM?S\&?[GE7U\33`<D_!(^Q8
MN/\:57T)$04U$V^*-97M&0R`OU93X]2`B!0?Y/E>[X?3RO9GD^G<]1&(6\]5
M/R0U5FE;Y6L_M,T_5`@Q552)QY3`DRGQ%A,4N#.LX\XXGXV#)QN'@LG3=!K,
MGN;W1P9L)#S9R,7=F4`;<1.>?";OL9EF;.1<C'S01MAB9$YX?N><X`L9"4\^
M\OZ<#EU5DB11,13K9=>^6[#S8-WZ:X'W,0I!&\\.NB9COOQ7ND">8"4;K&5E
M@Q^0"3WD^-LZ0,'2>8.\+)G,UI1!JL2.2^`DQ&HC'<0Z2'20ZB#302X!!X(P
M1@)R\W^(!-:"(\%]V'(@0N-I;G,)/B320:R#1`>I#C(=Y!)0W(:M);M]NRSP
M=<;"4`"D=4;>0G5G2V40+0!X&7<&B0P2&R0Q2&J0S""Y3!0_H1`\[B<6AAT!
M,9,2>JHY2H4"J,B2T$P5VHU"X^H:)#9(8I#4()E!<IDHOD-1>]QW+$Q\YQ9O
M*0%'.=D9)#)(;)#$(*E!,H/D,E&\@L(K>T5+UP3WA>%4ER_;EK:E&QGM0XFB
MA0OK4)UEA+9"DKZ,^*/[$2-RO4.!V`>*E=`69"MO6`,]D)N#A55S&('2/"89
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M1O+3QJCX3I'BNX$B_/4'N\83?L0F2C@2&95R)`9F)LHYNN$?[IN/^\>ZK+RV
M%.&/1BE_]<J.1BD>\XBCV9@G,4<T`WPT??*ULUO"1<19(.5(*,HX@L8F&25Z
M+LF4G$N1@>JJXU[]>%38@4"."D-*OYMKF;A#HY2("D7>0HH*1;Y+#PXHF,[T
MTT9B:DH9DC1E#`E-KJ=KRI5A:E#P,4$*RH_527K64'8(.WZH&:1M_AT:I42L
M*/+%9TW,I'R/QLH+W$!KP(FI*.6CA**,(RCK]S*(&74C@_#)Y:>#18\_2K`8
MDA/+S*M12,2*(E_4B1@QA(^Z;VM_#G<XOK9%$B8##ZXIY<.$IHPCI@DND6[D
M%9V-IJ.25W#>NQNJ+^T5SFO?NNX@6M1S'4/$4#HCO9&CERU-U1VK774^]U;9
MON+;-FB,Z^6(^54@"C?T1*J]@9-<B$]-$!CCC0=O2#70WD"W#W%+-L=`]PMQ
M@S/?0$.#,;?>P#7EYM8L6VS8#4U;,.NFO!_"-[HY\R8(-W`V-E]L@Q`^;&_P
M:0B?AL"=T6^XMKP6Q^KWHCO6E]XZ5P<(M$N^"#MZ\4E_#&R1G]L!+BS)>I_@
M@KJ"NPIW`I7AT+8#_X$G&*^\U_\"``#__P,`4$L#!!0`!@`(````(0!<[`0S
MR@4``%T6```9````>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;*Q878^K-A!]
MK]3_@'B_`0/Y0DFN-N%3:J6JNFV?64(2M"&.@-WL_?<=8QNP)[W-;ONR;$[&
M)SYGQO;@U=?WZFR\%753TLO:)!/;-(I+3O?EY;@V__@6?5F81M-FEWUVII=B
M;7XO&O/KYN>?5C=:OS2GHF@-8+@T:_/4ME??LIK\5%19,Z'7X@+?'&A=92U\
MK(]6<ZV+;-\-JLZ68]LSJ\K*B\D9_/H1#GHXE'D1T/RU*BXM)ZF+<];"_)M3
M>6TD6Y4_0E=E]<OK]4M.JRM0/)?GLOW>D9I&E?OI\4+K[/D,NM^)E^62N_N`
MZ*LRKVE##^T$Z"P^4:QY:2TM8-JL]B4H8+8;=7%8FT_$3\G<M#:KSJ`_R^+6
MC/XWFA.]Q76Y_Z6\%.`VY(EEX)G2%Q::[AD$@RTT.NHR\%MM[(M#]GIN?Z>W
MI"B/IQ;2/05%3)B__QX430Z.`LW$F3*FG)YA`O#7J$I6&N!(]MX];^6^/:U-
M=S:9SFV70+CQ7#1M5#)*T\A?FY96?_$@(J@XB2-(X"E)G(FSF)+I[`,LGF"!
MIV`AD\5TZLT6\\>G`I&='G@*DH_+F0L.>'Y^(K#`NHG`\Z,3L7B.NI0'69MM
M5C6]&;".(`O--6.KDOA+TY"YYIGIL_]/R8>L,Y(GQK(V85Z0UP8J]FWC.<[*
M>H,JRT7,%L<0-6(G(UA),=I`!T(=B'0@UH%$!](18($)O1-0:?^#$XR%.2$U
M;"4P6*,9LY,1<DB@`Z$.1#H0ZT"B`^D(4&2[JNS[BUSFF07#<A[EV;$U.5L>
M0_AR9FG<(21`2(B0""$Q0A*$I&-$T0E;P#B]/];)@F%%@&>C@G;5<MWR(`_V
MUS[(L:=JT*X/ZK.+D!`A$4)BA"0(2<>(HAUVKL>UL^!.NYSQEB,@5"([A`0(
M"1$2(21&2(*0=(PHJF:J*KYU3=C&WI[*_&5+^2%S)],N;%%\XV(<JEB...X@
M%B$!1UQX])DG<VTW"_L@Z5J$D!@A"4)2CO`)*?KA+!EG]5/Z&8>JGR-C_0@)
M..+.NYW>L8E6]&'_?2]=<'B]JW$?PTX+X/#4A9/TWTN.5'!TF5&,8(WGZ`R[
MDW!H&63&6;"JF"-CQ0@)!#+,/T1(A$;%*"9!2#H>I:B"T_AQ52Q85<41UBOU
M->K8,]7DG0B:]6D)[@PC2[VT11#/_Q+:<UOEC1!O_`AOHO`2>XF(TS&QXA:!
M;?AQN[IHU2\)P2^,#)NKPG8BRED.C@T#9:6&`G)MW@JY2$>$>6+,DZ@\4Z#1
MC$X5'M40UN<\O"K@N-8+2$!:!2UT0_A`9U1"P\#!$!'%*X9X'E(2R5$#42PA
M_I+!6HE$0H)H@:U-94A'I%K">J#'+>$=$S0!4L:6-01LF:DULM0MX5%*C?0#
M)5<HN$2-W,EM)")&//$P`<F3J#P>(U+GDRH\JB&L6WK<$-%;C0WAD%HC1)O`
MCHBH(;6!A(;4AA(2J7462$DD0P:B6$(#42(AL3TAFE0&W*D0UD(];@AON,!?
MF8TM$9!2(43;/W<B:I398!@HN4(!B0HAW@PIB3!1C(D2`7GC29&YULZF"I=:
M)JP%&[GRJ4Z#W2!H1Y2`M.K1WB=V,FI(>B"@Z="1A@)RG6[+=>^<29@GQCR)
MRD/P1I4J/*I/K%7[SS[Q?D\I*@&-\S?7^J4=$7WB^&3BT!0VW_Y(PX>Y&.BR
M%NEM,W/Q#A)A[EA`/^9.5&Z/0`5KFT.J<*MVLH9/V@D;J%YVW^@5]N)_O9K@
M;:/B)X>Z9H[_(K\+XQ<C55$?BUUQ/C=&3E_9/1<<LIM5#_-+N&#F0Z\.:U7'
MYSZTOQB/YSZTM!B'R[RG;O_0>+;LDN]._-;QX54>\VQ=']Y],?[D^4_\LE#_
M`<^'%T8\8#OUX94+<*L?`)=[U^Q8_)K5Q_+2&.?B`*;8W9M6S:\'^8=6).29
MMG"MU^7F!->X!1S<]@26_X'25GY@/]!?#&_^!@``__\#`%!+`P04``8`"```
M`"$`"#$OIA\%```M$P``&0```'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6RL
M6%N/HS84?J_4_X!XWQ`"N:$DJR2$B[25JFK;/C/$2=``CH"9S/S['F,;L$]V
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MS1_T%I'L?&D@W%.PB!GF'=]]4J?@49`93:9,*:4Y+`#^&D7&4@,\DKRUXRT[
M-I>UZ<Q&T_G8L8%N/)&Z"3(F:1KI2]W0XF].LH44%YD($1BEB#NRW?'L)S1<
MH0&CT+!'B^G4G2WFCR\$F*TU,`J1GS=F+C1@_/Q"8'NU"X%1B+@/6V/Q$+41
M]Y,FV:PJ>C-@&T$0ZFO"-J7M+4U#AIH'I@O^CV(/06<B6Z:R-F%A$-8:$O9U
MX]J+E?4*298*S@YS;)6QEPR644S6UX&##@0Z$.I`I`/Q`+#`"9TG(-'^!T\P
M%>8):<-.`KUK)IK9DB&G^#IPT(%`!T(=B'0@'@"*V0XVVX&*<7^ORWBS2;"K
M!_&V%S/5K!WGV'Q7LW#N$>(CY("0`"$A0B*$Q$-$L1=JP3#,']O)R+`SP'>#
MQ%YJAG*2"T[K2/9"(^T[4A=EA!P0$B`D1$B$D'B(*+9#"7O<=D9N;9<KWG$$
M#)7('B$^0@X("1`2(B1"2#Q$%*MFJE6\A(U8A6\N6?J\H_RLN1-I!TH5+V!,
M0S66(Q.G-Q8A/D<<&/K(S[6J=NA(TFL!0D*$1`B).<(7I-@/A\HPJI^RGVFH
M]G-D:#]"?(XX\[;B3\;V5-T9A^[WSG2AT38OK>?#CL-.#=!P58VH^UUJQ$*C
MC8SB"-9_#LZR.P&'WD%&G)%5BSDRM!@AOD#Z]1\0$J!9(>)$"(F'LQ2KX%1^
MW"I&5JWB"&N:^AQ=CE4G[P5IUB6[?W>:GMJ"Q.-O0Y>NZ09(-WQ$-Q(D<$F_
MYKFCKCD>:BL.LZ$2/^ZQEJVZ3$+PAO[]2_W8%JS)LG=:/U$FZT%`<*2R_+:A
M@45.PD(A%HHT(203*S*J0UC+\_#&@!-;SR$!:4FD!60O68,LDA#_2F!-P$%"
MLFA@=_#W3WJ94,[I92()_4@FEH161G4':X4&[OA4P60]@;;3)*2FC5;/]H*E
MI`W7<B==)AT$RV4GU.O&6:!P!U@GE)-ZG4A"T!+TJ8RVDJ*E^HKU4?_95Z(9
MZ]>ULSFD9-0<N4J0^DSPQ3Q7+6=Z79*L&=]TL]D=]R'M4,[Z4#N2+*[M(.58
M$'C^JLYDC=D'SOQ.KU"(_JWWAB]_E'FBXV/YP]_(O^WYEUY!JC/9DSROC92^
ML.]V*!6;50?S2P5_YD'3`0(Z/O?@',=X./?@;,8X7$YLVT!K.CMV:7&'OYMX
M\&V"=7:.!TT\QK>NM^67'_H+7`\Z7SQA-_6@=P3<ZB;`9<4U.9/?DNJ<E;61
MDQ,X9=RVC!6_[N`/C0C($VW@FJ*-S06NI0C4L?$(TN1$:2,?V`NZBZ[-/P``
M`/__`P!02P,$%``&``@````A`"L%CR,V`P``K0L``!``"`%D;V-0<F]P<R]A
M<'`N>&UL(*($`2B@``$`````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
MG%91;YLP$'Z?M/\0\=Z2MEDU582)$:I6:IMHL.W1<N&26`6;VB9*]NMWAB8E
MG?'6O8%]G^_S?7?G"[YLJW*T`:F8X%/O['3LC8#GHF!\-?6^9]<GG[V1TI07
MM!0<IMX.E/<E_/@A6$A1@]0,U`B/X&KJK;6NKWQ?Y6NHJ#K%;8X[2R$KJO%7
MKGRQ7+(<9B)O*N#:/Q^/+WW8:N`%%"?UX4"O._%JH__WT$+DAI_ZD>UJ)!P&
M45V7+*<:;QG>LUP*)99ZE&QS*`._OQD@NQ3R1C*]"\>!W_\-TIR6$./!X9*6
M"@+_=2&X`6J"MJ!,JC#8Z*L-Y%K(D6*_,&SGWNB1*C!TIMZ&2D:Y1EK&K/MI
MO\M::1G^%/))K0&T"GPTZ!;;S[YM_YM-PLEE:X%?QY;FA(X);AQSS)@N0<V7
M"RJUA?+DLL^Y9=$Q[@CM5201+TC"-<:+W/).;2;ZS`]WB.</Z?SN=A9ER8Q\
MC>ZBAS@AZ4V29.E[[<F"_AV29NCI/GG(4C*_)O-%\EY(?!.]&Q+]PUV.B<51
M>F9U,Y<KRMFO-FL)EB!9E)03L23W(%>8?8?`FCSJ5$F;JJ)R9XQ2MN(,ZPTS
MC41Y+AJNK9"%A)HRU'"+!:M`M9[F>@V2Q(T<@+2UOVM-D^>&U::>K:8OGA4*
MMJ./);007)0-H$LK)!95Q;0YL>,2"\PNOL*VA,W&BDBUR)_6HBRPCQ'#1^^L
M=K?8V2H@&=T.'/0-2JJ1F"F)'<DDY8KFIFD,^&T>%3PWR)0D&\/7ZM6MB5UZ
M-^;<ZL<MI-W/2Q=_HR1&"*6RW\8MJ-V+11^7B[Y,+CMW?0Q0<1;(A36P;C$F
M_X'Y9,6X!1P2W5:*9`::LM*NX(#F+Q![V-RJVZDYZYA8(V!+%-=5'/;$?A$7
MPGX-%V(@7_YL1WM!R$"V.!#V7'&QRNQOPU%9N:)J,QP(I]74'D>K:8;C7T-Q
M!CN\8*]OV7`S-M&T0M*W#?D0=^.H#SF:B]Y,0G>,/ZGO=29F^!CL1[WCQ2!=
M4PD%#D'[_=>%X`:G/%F:0^(UQ8>KV-O\N6$&TQ_=]!V>34['%V.<.7MK@?]2
MK?CTA;\!``#__P,`4$L#!!0`!@`(````(0!#5A'%E@```*H````0````>&PO
M8V%L8T-H86EN+GAM;#R.00H",1`$[X)_"'-W9]>#B"194/`%^H"0'4T@F2R9
M(/I[X\5+0]%0W7I^YZ1>5"46-C`-(RAB7Y;(3P/WVW5W!"7-\>)283+P(8'9
M;C?:N^0OP456W<!B(+2VGA#%!\I.AK(2]^91:G:M8WVBK)7<(H&HY83[<3Q@
M[@*PVJMJX#Q-H&(_`2K]$JW&_XK]`@``__\#`%!+`P04``8`"````"$`:)"3
MXC$!``!``@``$0`(`61O8U!R;W!S+V-O<F4N>&UL(*($`2B@``$`````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````G)%!3\,@&(;O)OZ'AGL+M'$QI&6)
MFIU<8N*,QAO"MXU8*`&TV[^7=5V=T9-'\KX\/-]'/=^9-OL$'W1G&T0+@C*P
MLE/:;AKTM%KDUR@+45@EVLY"@_80T)Q?7M32,=EY>/"=`Q\UA"R1;&#2-6@;
MHV,8![D%(T*1&C:%Z\X;$=/1;[`3\EUL`)>$S+"!*)2(`A^`N9N(:$0J.2'=
MAV\'@)(86C!@8\"TH/B[&\&;\.>%(3EK&AWW+LTTZIZSE3R&4WL7]%3L^[[H
MJT$C^5/\LKQ_'$;-M3WL2@+BA_VT(L1E6N5:@[K9\]V;;[,0MC7^G=5*#G9,
M>A`15);>8T>[4_)<W=ZM%HB7A%[E9)93LJ*$D8J1\K7&I]9XGT]`,PK\FW@"
M\,'[YY_S+P```/__`P!02P$"+0`4``8`"````"$`2-^G]1$"```='0``$P``
M````````````````````6T-O;G1E;G1?5'EP97-=+GAM;%!+`0(M`!0`!@`(
M````(0"U53`C]0```$P"```+`````````````````$H$``!?<F5L<R\N<F5L
M<U!+`0(M`!0`!@`(````(0!NW^V?/0(``%8<```:`````````````````'`'
M``!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+`0(M`!0`!@`(````(0#`
MTQ,T]0,``&8.```/`````````````````.T*``!X;"]W;W)K8F]O:RYX;6Q0
M2P$"+0`4``8`"````"$`&-!4#;D#``"B#```&``````````````````/#P``
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L!`BT`%``&``@````A`):6I?O6
M`@``Q0<``!D`````````````````_A(``'AL+W=O<FMS:&5E=',O<VAE970S
M-BYX;6Q02P$"+0`4``8`"````"$`DDF6<(@#``"B#```&0``````````````
M```+%@``>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+`0(M`!0`!@`(````
M(0`FGSU%40,``-D*```9`````````````````,H9``!X;"]W;W)K<VAE971S
M+W-H965T,S@N>&UL4$L!`BT`%``&``@````A`-3J2VON`P``C`X``!D`````
M````````````4AT``'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"+0`4
M``8`"````"$`OY<#D8L#```'#```&0````````````````!W(0``>&PO=V]R
M:W-H965T<R]S:&5E=#,U+GAM;%!+`0(M`!0`!@`(````(0``;6C$[P,``!H/
M```9`````````````````#DE``!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL
M4$L!`BT`%``&``@````A`)J"C8O1%@``XZ```!D`````````````````7RD`
M`'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"+0`4``8`"````"$`B>\M
MZ?X"```<"0``&0````````````````!G0```>&PO=V]R:W-H965T<R]S:&5E
M=#,R+GAM;%!+`0(M`!0`!@`(````(0`"15>@6P(``#T%```9````````````
M`````)Q#``!X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L!`BT`%``&``@`
M```A`-/B;Q[X`@``20D``!D`````````````````+D8``'AL+W=O<FMS:&5E
M=',O<VAE970S,"YX;6Q02P$"+0`4``8`"````"$`&`$;^!`0``#K7@``&0``
M``````````````!=20``>&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+`0(M
M`!0`!@`(````(0"2"$\G+P,``-D)```9`````````````````*19``!X;"]W
M;W)K<VAE971S+W-H965T-#$N>&UL4$L!`BT`%``&``@````A`$]^L.&Z`@``
MTP<``!D`````````````````"ET``'AL+W=O<FMS:&5E=',O<VAE970T,BYX
M;6Q02P$"+0`4``8`"````"$`^$B$Q_(#``"&#@``&`````````````````#[
M7P``>&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L!`BT`%``&``@````A`*T>
MVS"_`@``D0@``!@`````````````````(V0``'AL+W=O<FMS:&5E=',O<VAE
M970S+GAM;%!+`0(M`!0`!@`(````(0#YS7E9%7(``/^%`0`4````````````
M`````!AG``!X;"]S:&%R9613=')I;F=S+GAM;%!+`0(M`!0`!@`(````(0#/
M/N/220P``"9X```-`````````````````%_9``!X;"]S='EL97,N>&UL4$L!
M`BT`%``&``@````A`/MBI6V4!@``IQL``!,`````````````````T^4``'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"+0`4``8`"````"$`;7O;(0`#``"<"```
M&0````````````````"8[```>&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+
M`0(M`!0`!@`(````(0!^RTWTEP0``.P0```9`````````````````,_O``!X
M;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L!`BT`%``&``@````A`,0<PED8
M`P``/`D``!D`````````````````G?0``'AL+W=O<FMS:&5E=',O<VAE970T
M-"YX;6Q02P$"+0`4``8`"````"$`'27/^&8#``#A"@``&0``````````````
M``#L]P``>&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+`0(M`!0`!@`(````
M(0!S8&2V6@0``%0/```8`````````````````(G[``!X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"+0`4``8`"````"$`HA%'M)H"``!#!P``&0``````
M```````````9``$`>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+`0(M`!0`
M!@`(````(0`(:75N70,``+$*```9`````````````````.H"`0!X;"]W;W)K
M<VAE971S+W-H965T,C<N>&UL4$L!`BT`%``&``@````A`#]W7I85!@``CA<`
M`!D`````````````````?@8!`'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q0
M2P$"+0`4``8`"````"$`Z1DG%B4&``!@&```&0````````````````#*#`$`
M>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+`0(M`!0`!@`(````(0!J!&5M
M8`@``-LP```9`````````````````"83`0!X;"]W;W)K<VAE971S+W-H965T
M,3,N>&UL4$L!`BT`%``&``@````A`%"@JW/$`@```@<``!D`````````````
M````O1L!`'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"+0`4``8`"```
M`"$`].&6AH`%```P%0``&0````````````````"X'@$`>&PO=V]R:W-H965T
M<R]S:&5E=#$P+GAM;%!+`0(M`!0`!@`(````(0`26:9Y<A(```]M```8````
M`````````````&\D`0!X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"+0`4
M``8`"````"$`X=CV)@H#``!@"0``&``````````````````7-P$`>&PO=V]R
M:W-H965T<R]S:&5E=#@N>&UL4$L!`BT`%``&``@````A`!LT58OV`@``1P@`
M`!@`````````````````5SH!`'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+
M`0(M`!0`!@`(````(0!'IXR"LP4``-$6```8`````````````````(,]`0!X
M;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"+0`4``8`"````"$`V7M9DE@$
M````$```&`````````````````!L0P$`>&PO=V]R:W-H965T<R]S:&5E=#4N
M>&UL4$L!`BT`%``&``@````A`'^G"7."#@``EDD``!D`````````````````
M^D<!`'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"+0`4``8`"````"$`
MD;&H$,XG```]Z0``&0````````````````"S5@$`>&PO=V]R:W-H965T<R]S
M:&5E=#$T+GAM;%!+`0(M`!0`!@`(````(0"O0&1UKP(``"H'```9````````
M`````````+A^`0!X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L!`BT`%``&
M``@````A`(SU7!_>`@``?@@``!D`````````````````GH$!`'AL+W=O<FMS
M:&5E=',O<VAE970R-BYX;6Q02P$"+0`4``8`"````"$`-7E2R(D"``!9!@``
M&0````````````````"SA`$`>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+
M`0(M`!0`!@`(````(0#&FN;!E@P``'<\```9`````````````````'.'`0!X
M;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L!`BT`%``&``@````A`-.J+1SP
M`@``FP@``!D`````````````````0)0!`'AL+W=O<FMS:&5E=',O<VAE970Q
M-BYX;6Q02P$"+0`4``8`"````"$`9:0H$`\9```)@@``&0``````````````
M``!GEP$`>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+`0(M`!0`!@`(````
M(0"><G51(P4``.<2```9`````````````````*VP`0!X;"]W;W)K<VAE971S
M+W-H965T,C$N>&UL4$L!`BT`%``&``@````A`&7!T3[($0``E&4``!D`````
M````````````![8!`'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"+0`4
M``8`"````"$`9A5GJ_\%```W%P``&0`````````````````&R`$`>&PO=V]R
M:W-H965T<R]S:&5E=#$Y+GAM;%!+`0(M`!0`!@`(````(0!<[`0SR@4``%T6
M```9`````````````````#S.`0!X;"]W;W)K<VAE971S+W-H965T,C(N>&UL
M4$L!`BT`%``&``@````A``@Q+Z8?!0``+1,``!D`````````````````/=0!
M`'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"+0`4``8`"````"$`*P6/
M(S8#``"M"P``$`````````````````"3V0$`9&]C4')O<',O87!P+GAM;%!+
M`0(M`!0`!@`(````(0!#5A'%E@```*H````0`````````````````/_=`0!X
M;"]C86QC0VAA:6XN>&UL4$L!`BT`%``&``@````A`&B0D^(Q`0``0`(``!$`
M````````````````P]X!`&1O8U!R;W!S+V-O<F4N>&UL4$L%!@`````X`#@`
*,0\``"OA`0``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EUAAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" onclick="toggleNextSibling(this);">332,500</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 6.37</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross[us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">15,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice[us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">$ 3.35</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E6YPM">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="3">0 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="2">0 Months Ended</th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Feb. 11, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015

</div>
          <div>sqft</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 03, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 10, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 13, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 26, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 12, 2015</div>
        </th>
        <th class="th">
          <div>Aug. 12, 2013</div>
        </th>
        <th class="th">
          <div>Nov. 28, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 24, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2015</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2015</div>
        </th>
        <th class="th">
          <div>Aug. 13, 2015</div>
        </th>
        <th class="th">
          <div>Apr. 02, 2014</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_EquityMethodInvestmentOwnershipPercentage" onclick="toggleNextSibling(this);">17.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EquityMethodInvestmentOwnershipPercentage</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_Cash" onclick="toggleNextSibling(this);">$ 10,357,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Cash</span><span></span></td>
        <td class="nump"><a title="us-gaap_Cash" onclick="toggleNextSibling(this);">$ 15,571,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Cash</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_Cash" onclick="toggleNextSibling(this);">$ 96,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Cash</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_ProceedsFromTransferAtleastForNotConsummated', window );">Proceeds From Transfer Atleast For Not Consummated</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="rtgn_ProceedsFromTransferAtleastForNotConsummated" onclick="toggleNextSibling(this);">3,800,000</a><span style="display:none;white-space:normal;text-align:left;">rtgn_ProceedsFromTransferAtleastForNotConsummated</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Land Subject to Ground Leases</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_LandSubjectToGroundLeases" onclick="toggleNextSibling(this);">995</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LandSubjectToGroundLeases</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Operating Leases, Rent Expense</a></td>
        <td class="nump"><a title="us-gaap_LeaseAndRentalExpense" onclick="toggleNextSibling(this);">1,700</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LeaseAndRentalExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_LeaseAndRentalExpense" onclick="toggleNextSibling(this);">20,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LeaseAndRentalExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_LeaseAndRentalExpense" onclick="toggleNextSibling(this);">20,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LeaseAndRentalExpense</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Operating Leases, Future Minimum Payments Due</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDue[us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">5,075</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_AgreementTypeAxis=rtgn_NewConsultingAgreementsMember', window );">New Consulting Agreements [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices[rtgn_AgreementTypeAxis=rtgn_NewConsultingAgreementsMember]" onclick="toggleNextSibling(this);">340,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices<br>/ rtgn_AgreementTypeAxis<br>= rtgn_NewConsultingAgreementsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices[rtgn_AgreementTypeAxis=rtgn_NewConsultingAgreementsMember]" onclick="toggleNextSibling(this);">250,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices<br>/ rtgn_AgreementTypeAxis<br>= rtgn_NewConsultingAgreementsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_AgreementTypeAxis=rtgn_OculusSideLetterAgreementMember', window );">Oculus Side Letter Agreement [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Liabilities Assumed</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesAssumed1[rtgn_AgreementTypeAxis=rtgn_OculusSideLetterAgreementMember]" onclick="toggleNextSibling(this);">5,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesAssumed1<br>/ rtgn_AgreementTypeAxis<br>= rtgn_OculusSideLetterAgreementMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_DateOfMergerAxis=rtgn_MergerClosingDateIsNoLaterThanJuly312015Member', window );">Merger Closing Date Is No Later Than July 31, 2015 [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_Cash[rtgn_DateOfMergerAxis=rtgn_MergerClosingDateIsNoLaterThanJuly312015Member]" onclick="toggleNextSibling(this);">9,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Cash<br>/ rtgn_DateOfMergerAxis<br>= rtgn_MergerClosingDateIsNoLaterThanJuly312015Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_DateOfMergerAxis=rtgn_MergerClosingDateIsAfterJuly312015ButNoLaterThanAugust132015Member', window );">Merger Closing Date Is After July 31, 2015 But No Later Than August 13, 2015 [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_Cash[rtgn_DateOfMergerAxis=rtgn_MergerClosingDateIsAfterJuly312015ButNoLaterThanAugust132015Member]" onclick="toggleNextSibling(this);">8,850,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Cash<br>/ rtgn_DateOfMergerAxis<br>= rtgn_MergerClosingDateIsAfterJuly312015ButNoLaterThanAugust132015Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=rtgn_PulmatrixIncMember', window );">Pulmatrix Inc [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_EquityMethodInvestmentOwnershipPercentage[dei_LegalEntityAxis=rtgn_PulmatrixIncMember]" onclick="toggleNextSibling(this);">83.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EquityMethodInvestmentOwnershipPercentage<br>/ dei_LegalEntityAxis<br>= rtgn_PulmatrixIncMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rtgn_OculusMember', window );">Oculus [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_DescriptionOfSeparationAgreement', window );">Description Of Separation Agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">separation agreement became effective upon the completion of the IPO and terminates on the earlier of 8.5 years following the closing of the IPO or when the parties mutually agree to terminate it.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rtgn_OculusMember]" onclick="toggleNextSibling(this);">2,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= rtgn_OculusMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_PercentageOfGrossProceedsPayable', window );">Percentage Of Gross proceeds Payable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="rtgn_PercentageOfGrossProceedsPayable[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rtgn_OculusMember]" onclick="toggleNextSibling(this);">10.00%</a><span style="display:none;white-space:normal;text-align:left;">rtgn_PercentageOfGrossProceedsPayable<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= rtgn_OculusMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets', window );">Proceeds from Sales of Business, Affiliate and Productive Assets</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rtgn_OculusMember]" onclick="toggleNextSibling(this);">10,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= rtgn_OculusMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_FundToPayCertainAccountPayablesOutstanding', window );">Fund To Pay Certain Account Payables Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="rtgn_FundToPayCertainAccountPayablesOutstanding[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rtgn_OculusMember]" onclick="toggleNextSibling(this);">534,000</a><span style="display:none;white-space:normal;text-align:left;">rtgn_FundToPayCertainAccountPayablesOutstanding<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= rtgn_OculusMember</span><span></span></td>
        <td class="nump"><a title="rtgn_FundToPayCertainAccountPayablesOutstanding[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rtgn_OculusMember]" onclick="toggleNextSibling(this);">760,000</a><span style="display:none;white-space:normal;text-align:left;">rtgn_FundToPayCertainAccountPayablesOutstanding<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= rtgn_OculusMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_MinimumDurationForSharesTransfer', window );">Minimum Duration For Shares Transfer</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">41 months 15 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_ShareTransferAgreementTerms', window );">Share Transfer Agreement Terms</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Transfers conducted using this one-time right must be conducted with the consent of the Companys board of directors or within the prescribed requirements for such transfers set forth in the separation agreement, including, for example, that the purchase price discount may not exceed certain percentages, the amount of shares transferred may not exceed $3,800,000 in net proceeds to Oculus, as well as certain other requirements set forth in the separation agreement. The separation agreement provides Oculus with certain piggy back registration rights of up to 30%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_PercentageOfOutstandingSharesForLapsOfTransfer', window );">Percentage Of Outstanding Shares For Laps Of Transfer</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="rtgn_PercentageOfOutstandingSharesForLapsOfTransfer[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rtgn_OculusMember]" onclick="toggleNextSibling(this);">19.90%</a><span style="display:none;white-space:normal;text-align:left;">rtgn_PercentageOfOutstandingSharesForLapsOfTransfer<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= rtgn_OculusMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_ReimbursementOfExpensesRelatedToTransfer', window );">Reimbursement Of Expenses Related To Transfer</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="rtgn_ReimbursementOfExpensesRelatedToTransfer[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rtgn_OculusMember]" onclick="toggleNextSibling(this);">1,450,000</a><span style="display:none;white-space:normal;text-align:left;">rtgn_ReimbursementOfExpensesRelatedToTransfer<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= rtgn_OculusMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rtgn_OculusMember', window );">Oculus [Member] | Minimum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets', window );">Proceeds from Sales of Business, Affiliate and Productive Assets</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets[us-gaap_RangeAxis=us-gaap_MinimumMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rtgn_OculusMember]" onclick="toggleNextSibling(this);">1,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= rtgn_OculusMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rtgn_OculusMember', window );">Oculus [Member] | Maximum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_ConsiderationForSharesTransferByParent', window );">Consideration For Shares Transfer By Parent</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="rtgn_ConsiderationForSharesTransferByParent[us-gaap_RangeAxis=us-gaap_MaximumMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rtgn_OculusMember]" onclick="toggleNextSibling(this);">1,500,000</a><span style="display:none;white-space:normal;text-align:left;">rtgn_ConsiderationForSharesTransferByParent<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= rtgn_OculusMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_PercentageOfSharesTransferByFormerParent', window );">Percentage Of Shares Transfer By Former Parent</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="rtgn_PercentageOfSharesTransferByFormerParent[us-gaap_RangeAxis=us-gaap_MaximumMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rtgn_OculusMember]" onclick="toggleNextSibling(this);">5.00%</a><span style="display:none;white-space:normal;text-align:left;">rtgn_PercentageOfSharesTransferByFormerParent<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= rtgn_OculusMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_OutstandingStockOptionsAndRestrictedStockUnitsTerminationDescription', window );">Outstanding Stock Options And Restricted Stock Units Termination Description</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">a lump-sum payment in the amount of $547,600, less taxes and other withholdings and (ii) a lump-sum equivalent to the CEO&#8217;s premiums under COBRA for one year, in the same amounts for the same medical coverage as in effect as of the effective time of the merger.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_CashBonus', window );">Cash Bonus</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="rtgn_CashBonus[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ChiefExecutiveOfficerMember]" onclick="toggleNextSibling(this);">158,000</a><span style="display:none;white-space:normal;text-align:left;">rtgn_CashBonus<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= us-gaap_ChiefExecutiveOfficerMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member] | 2013 Employee, Director And Consultant Equity Incentive Plan [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_RestrictedStockUnitsGrantsDescription', window );">Restricted Stock units Grants Description</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">equal to the lesser of (i) 930,000 and (ii) the quotient of $3,125,000 divided by the fair market value of the common stock of the combined company as of the effective time of the merger, with such restricted stock units vesting as follows: (i) a number of restricted stock units equal to the lesser of (a) 930,000 and (b) such number of restricted stock units with an aggregate value equal to $1,400,000 shall be fully vested at the effective time of the merger and (ii) an amount equal to 25% of the restricted stock units unvested as of the effective time of the merger will vest on a quarterly basis over the following twelve months.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ChiefFinancialOfficerMember', window );">Chief Financial Officer [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_OutstandingStockOptionsAndRestrictedStockUnitsTerminationDescription', window );">Outstanding Stock Options And Restricted Stock Units Termination Description</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">a lump-sum payment in the amount of $337,500, less taxes and other withholdings and (ii) a lump-sum equivalent to the CFO&#8217;s premiums under COBRA for one year, in the same amounts for the same medical coverage as in effect as of the effective time of the merger.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_RestrictedStockUnitsGrantsDescription', window );">Restricted Stock units Grants Description</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">equal to the lesser of (i) 355,000 and (ii) the quotient of $1,037,500 divided by the fair market value of the common stock of the combined company as of the effective time, with such restricted stock units vesting as follows: (i) a number of restricted stock units equal to the lesser of (a) 355,000 and (b) such number of restricted stock units with an aggregate value equal to $250,000 shall be fully vested at the effective time of the merger and (ii) an amount equal to 25% of the restricted stock units unvested as of the effective time of the merger will vest on a quarterly basis over the following twelve months.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=rtgn_TwoExecutivesMember', window );">Two Executives [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SeveranceCosts1[us-gaap_TitleOfIndividualAxis=rtgn_TwoExecutivesMember]" onclick="toggleNextSibling(this);">1,144,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SeveranceCosts1<br>/ us-gaap_TitleOfIndividualAxis<br>= rtgn_TwoExecutivesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=rtgn_EmployeeAndDirectorMember', window );">Employee And Director [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_TitleOfIndividualAxis=rtgn_EmployeeAndDirectorMember]" onclick="toggleNextSibling(this);">90,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_TitleOfIndividualAxis<br>= rtgn_EmployeeAndDirectorMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_LicenseAgreementAxis=rtgn_EmployeeAgreementMember', window );">Employee Agreement [Member] | Chief Executive Officer [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Officers' Compensation</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_OfficersCompensation[rtgn_LicenseAgreementAxis=rtgn_EmployeeAgreementMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ChiefExecutiveOfficerMember]" onclick="toggleNextSibling(this);">375,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OfficersCompensation<br>/ rtgn_LicenseAgreementAxis<br>= rtgn_EmployeeAgreementMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= us-gaap_ChiefExecutiveOfficerMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualDescription', window );">Deferred Compensation Arrangement with Individual, Description</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">(i) a lump severance payment equal to 24 times the average monthly base salary paid to the CEO over the preceding 12 months; (ii) up to one year (the lesser of one year following the date of termination or until the CEO becomes eligible for medical insurance coverage provided by another employer) reimbursement for health care premiums under COBRA; and (iii) automatic vesting of all unvested options and other equity awards<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_LicenseAgreementAxis=rtgn_EmployeeAgreementMember', window );">Employee Agreement [Member] | Chief Financial Officer [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Officers' Compensation</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_OfficersCompensation[rtgn_LicenseAgreementAxis=rtgn_EmployeeAgreementMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ChiefFinancialOfficerMember]" onclick="toggleNextSibling(this);">225,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OfficersCompensation<br>/ rtgn_LicenseAgreementAxis<br>= rtgn_EmployeeAgreementMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= us-gaap_ChiefFinancialOfficerMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualDescription', window );">Deferred Compensation Arrangement with Individual, Description</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">(i) a lump severance payment equal to 18 times the average monthly base salary paid to the CFO over the preceding 12 months; (ii) up to one year (the lesser of one year following the date of termination or until the CFO becomes eligible for medical insurance coverage provided by another employer) reimbursement for health care premiums under COBRA; and (iii) automatic vesting of all unvested options and other equity awards; provided that in the event the CFO resigns for good reason prior to a change of control, only the vesting of the restricted stock units granted by the Company on May 12, 2014 shall be accelerated.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_LicenseAgreementAxis=rtgn_LicenseAndSupplyAgreementMember', window );">License And Supply Agreement [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantPurchaseCommitmentDescription', window );">Purchase Commitment, Description</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Oculus shall manufacture and supply, at a purchase price equal to 20% over the cost of goods to Oculus<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_LicenseAgreementAxis=rtgn_LicenseAndSupplyAgreementMember', window );">License And Supply Agreement [Member] | First Phase [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfServicesLicensesAndServices', window );">Cost of Services, Licenses and Services</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CostOfServicesLicensesAndServices[rtgn_LicenseAgreementAxis=rtgn_LicenseAndSupplyAgreementMember;us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=rtgn_FirstPhaseMember]" onclick="toggleNextSibling(this);">1,500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CostOfServicesLicensesAndServices<br>/ rtgn_LicenseAgreementAxis<br>= rtgn_LicenseAndSupplyAgreementMember<br>/ us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis<br>= rtgn_FirstPhaseMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_LicenseAgreementAxis=rtgn_LicenseAndSupplyAgreementMember', window );">License And Supply Agreement [Member] | Second Phase [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfServicesLicensesAndServices', window );">Cost of Services, Licenses and Services</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CostOfServicesLicensesAndServices[rtgn_LicenseAgreementAxis=rtgn_LicenseAndSupplyAgreementMember;us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=rtgn_SecondPhaseMember]" onclick="toggleNextSibling(this);">1,500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CostOfServicesLicensesAndServices<br>/ rtgn_LicenseAgreementAxis<br>= rtgn_LicenseAndSupplyAgreementMember<br>/ us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis<br>= rtgn_SecondPhaseMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_LicenseAgreementAxis=rtgn_LicenseAndSupplyAgreementMember', window );">License And Supply Agreement [Member] | Third Phase [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfServicesLicensesAndServices', window );">Cost of Services, Licenses and Services</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CostOfServicesLicensesAndServices[rtgn_LicenseAgreementAxis=rtgn_LicenseAndSupplyAgreementMember;us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=rtgn_ThirdPhaseMember]" onclick="toggleNextSibling(this);">3,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CostOfServicesLicensesAndServices<br>/ rtgn_LicenseAgreementAxis<br>= rtgn_LicenseAndSupplyAgreementMember<br>/ us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis<br>= rtgn_ThirdPhaseMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_LicenseAgreementAxis=rtgn_LicenseAndSupplyAgreementMember', window );">License And Supply Agreement [Member] | Fourth Phase [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfServicesLicensesAndServices', window );">Cost of Services, Licenses and Services</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CostOfServicesLicensesAndServices[rtgn_LicenseAgreementAxis=rtgn_LicenseAndSupplyAgreementMember;us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=rtgn_FourthPhaseMember]" onclick="toggleNextSibling(this);">2,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CostOfServicesLicensesAndServices<br>/ rtgn_LicenseAgreementAxis<br>= rtgn_LicenseAndSupplyAgreementMember<br>/ us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis<br>= rtgn_FourthPhaseMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_LicenseAgreementAxis=rtgn_LicenseAndSupplyAgreementMember', window );">License And Supply Agreement [Member] | Minimum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_RoyaltyGuaranteesCommitmentsPercentage', window );">Royalty Guarantees Commitments Percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="rtgn_RoyaltyGuaranteesCommitmentsPercentage[rtgn_LicenseAgreementAxis=rtgn_LicenseAndSupplyAgreementMember;us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);">3.00%</a><span style="display:none;white-space:normal;text-align:left;">rtgn_RoyaltyGuaranteesCommitmentsPercentage<br>/ rtgn_LicenseAgreementAxis<br>= rtgn_LicenseAndSupplyAgreementMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_LicenseAgreementAxis=rtgn_LicenseAndSupplyAgreementMember', window );">License And Supply Agreement [Member] | Maximum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_RoyaltyGuaranteesCommitmentsPercentage', window );">Royalty Guarantees Commitments Percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="rtgn_RoyaltyGuaranteesCommitmentsPercentage[rtgn_LicenseAgreementAxis=rtgn_LicenseAndSupplyAgreementMember;us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">20.00%</a><span style="display:none;white-space:normal;text-align:left;">rtgn_RoyaltyGuaranteesCommitmentsPercentage<br>/ rtgn_LicenseAgreementAxis<br>= rtgn_LicenseAndSupplyAgreementMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_LicenseAgreementAxis=rtgn_LicenseAndSupplyAgreementMember', window );">License And Supply Agreement [Member] | Oculus [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted', window );">Supply Commitment, Remaining Minimum Amount Committed</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted[rtgn_LicenseAgreementAxis=rtgn_LicenseAndSupplyAgreementMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rtgn_OculusMember]" onclick="toggleNextSibling(this);">$ 8,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted<br>/ rtgn_LicenseAgreementAxis<br>= rtgn_LicenseAndSupplyAgreementMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= rtgn_OculusMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_CashBonus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of bonus price which is settled in cash.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_CashBonus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_CommitmentsAndContingenciesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_CommitmentsAndContingenciesLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_ConsiderationForSharesTransferByParent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum amount of net proceeds for shares transfer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_ConsiderationForSharesTransferByParent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_DescriptionOfSeparationAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This description about separation agreement</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_DescriptionOfSeparationAgreement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_FundToPayCertainAccountPayablesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount related to fund agreement to pay certain account payables outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_FundToPayCertainAccountPayablesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_MinimumDurationForSharesTransfer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The fact represents minimum duration for shares transfer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_MinimumDurationForSharesTransfer</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_OutstandingStockOptionsAndRestrictedStockUnitsTerminationDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>It represents the outstanding stock options and restricted stock units termination description during the period</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_OutstandingStockOptionsAndRestrictedStockUnitsTerminationDescription</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_PercentageOfGrossProceedsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>It represents Percentage Of Gross proceeds Payable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_PercentageOfGrossProceedsPayable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_PercentageOfOutstandingSharesForLapsOfTransfer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents percentage of outstanding shares for laps of transfer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_PercentageOfOutstandingSharesForLapsOfTransfer</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_PercentageOfSharesTransferByFormerParent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum percentage of shares transfer by former parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_PercentageOfSharesTransferByFormerParent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_ProceedsFromTransferAtleastForNotConsummated">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount proceeds atleast for non consummated transfers.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_ProceedsFromTransferAtleastForNotConsummated</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_ReimbursementOfExpensesRelatedToTransfer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount reimbursement of expenses related to transfer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_ReimbursementOfExpensesRelatedToTransfer</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_RestrictedStockUnitsGrantsDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>It represents the number of restricted stock units grants description during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_RestrictedStockUnitsGrantsDescription</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_RoyaltyGuaranteesCommitmentsPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The percentage the entity has committed to make for future royalty guarantees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_RoyaltyGuaranteesCommitmentsPercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_ShareTransferAgreementTerms">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents terms related to share transfers.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_ShareTransferAgreementTerms</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Cash</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfServicesLicensesAndServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cost of generating revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2(d))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CostOfServicesLicensesAndServices</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of the deferred compensation arrangement, including fixed amounts and determinable awards, or the method for determining payments and awards, the timing of such payments and awards, and any requisite service or performance criteria, as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 710<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6409961&amp;loc=d3e20487-108367<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualDescription</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6382943&amp;loc=d3e33918-111571<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandSubjectToGroundLeases">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Area of land subject to a ground lease.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LandSubjectToGroundLeases</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:areaItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAssumed1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The fair value of liabilities assumed in noncash investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesAssumed1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expenditures for salaries of officers. Does not include allocated share-based compensation, pension and post-retirement benefit expense or other labor-related non-salary expense. For commercial and industrial companies, excludes any direct and overhead labor that is included in cost of goods sold.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.P.4(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 5.P.3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section P<br><br> -Subsection 3, 4<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)(10)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35743120&amp;loc=d3e1928-114920<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantPurchaseCommitmentDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excluding long-term commitments, description of arrangements in which the entity has agreed to expend funds to procure goods or services from one or more suppliers, which may include identification of the goods or services to be purchased, identity of the seller, pricing, effects on pricing (such as penalties) of failing to reach minimum quantities required to be purchased, cancellation rights, and termination provisions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 25<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 7<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 17<br><br> -Article 9<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.17)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.(a)(19))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SignificantPurchaseCommitmentDescription</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The floor amount as of the balance sheet date that the entity must expend to satisfy the terms of disclosed arrangements (excluding long-term commitments) in which the entity must commit resources to supply goods or services to one or more customers.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 25<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 7<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 17<br><br> -Article 9<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.17)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.(a)(19))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rtgn_PulmatrixIncMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_LegalEntityAxis=rtgn_PulmatrixIncMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_AgreementTypeAxis=rtgn_NewConsultingAgreementsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_AgreementTypeAxis=rtgn_NewConsultingAgreementsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_AgreementTypeAxis=rtgn_OculusSideLetterAgreementMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_AgreementTypeAxis=rtgn_OculusSideLetterAgreementMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_DateOfMergerAxis=rtgn_MergerClosingDateIsAfterJuly312015ButNoLaterThanAugust132015Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_DateOfMergerAxis=rtgn_MergerClosingDateIsAfterJuly312015ButNoLaterThanAugust132015Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_DateOfMergerAxis=rtgn_MergerClosingDateIsNoLaterThanJuly312015Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_DateOfMergerAxis=rtgn_MergerClosingDateIsNoLaterThanJuly312015Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_LicenseAgreementAxis=rtgn_EmployeeAgreementMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_LicenseAgreementAxis=rtgn_EmployeeAgreementMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_LicenseAgreementAxis=rtgn_LicenseAndSupplyAgreementMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_LicenseAgreementAxis=rtgn_LicenseAndSupplyAgreementMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rtgn_OculusMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rtgn_OculusMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ChiefExecutiveOfficerMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ChiefExecutiveOfficerMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ChiefFinancialOfficerMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ChiefFinancialOfficerMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=rtgn_EmployeeAndDirectorMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=rtgn_EmployeeAndDirectorMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=rtgn_TwoExecutivesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=rtgn_TwoExecutivesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ETIAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization and Plan of Merger (Details Textual) (IPO [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 21, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 26, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">IPO [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_InitialPublicOfferingUnits', window );">Initial Public Offering Units</a></td>
        <td class="nump"><a title="rtgn_InitialPublicOfferingUnits[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember]" onclick="toggleNextSibling(this);">2,650,000</a><span style="display:none;white-space:normal;text-align:left;">rtgn_InitialPublicOfferingUnits<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_IPOMember</span><span></span></td>
        <td class="nump"><a title="rtgn_InitialPublicOfferingUnits[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember]" onclick="toggleNextSibling(this);">2,650,000</a><span style="display:none;white-space:normal;text-align:left;">rtgn_InitialPublicOfferingUnits<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_IPOMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_InitialPublicOfferingPricePerUnit', window );">Initial Public Offering Price Per Unit</a></td>
        <td class="nump"><a title="rtgn_InitialPublicOfferingPricePerUnit[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember]" onclick="toggleNextSibling(this);">$ 7.25</a><span style="display:none;white-space:normal;text-align:left;">rtgn_InitialPublicOfferingPricePerUnit<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_IPOMember</span><span></span></td>
        <td class="nump"><a title="rtgn_InitialPublicOfferingPricePerUnit[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember]" onclick="toggleNextSibling(this);">$ 7.25</a><span style="display:none;white-space:normal;text-align:left;">rtgn_InitialPublicOfferingPricePerUnit<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_IPOMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_InitialPublicOfferingPricePerUnit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price per share or per unit of public offering outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_InitialPublicOfferingPricePerUnit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_InitialPublicOfferingUnits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represent initial public offering units</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_InitialPublicOfferingUnits</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EAJAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Income Taxes (Details 1) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_ReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateLineItems', window );"><strong>Reconciliation Of The Statutory Federal Income Tax Rate To The Company&#x2019;s effective Tax Rate [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
        <td class="nump"><a title="us-gaap_OperatingLossCarryforwards" onclick="toggleNextSibling(this);">$ 3,224,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLossCarryforwards</span><span></span></td>
        <td class="nump"><a title="us-gaap_OperatingLossCarryforwards" onclick="toggleNextSibling(this);">$ 1,427,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLossCarryforwards</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation', window );">Stock-based compensation</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" onclick="toggleNextSibling(this);">262,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards', window );">Charitable donation carryforwards</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" onclick="toggleNextSibling(this);">4,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsGross" onclick="toggleNextSibling(this);">3,490,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsGross</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsGross" onclick="toggleNextSibling(this);">1,427,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsGross</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">Valuation allowance</a></td>
        <td class="num"><a title="us-gaap_OperatingLossCarryforwardsValuationAllowance" onclick="toggleNextSibling(this);">(3,490,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLossCarryforwardsValuationAllowance</span><span></span></td>
        <td class="num"><a title="us-gaap_OperatingLossCarryforwardsValuationAllowance" onclick="toggleNextSibling(this);">(1,427,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLossCarryforwardsValuationAllowance</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsLiabilitiesNet" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsLiabilitiesNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsLiabilitiesNet" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsLiabilitiesNet</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_ReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_ReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible charitable contribution carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Asset<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsValuationAllowance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 30<br><br> -Paragraph 5<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907311&amp;loc=d3e30536-109315<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsValuationAllowance</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EUDAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity (Details 3) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, March 31, 2014</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options Granted</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" onclick="toggleNextSibling(this);">332,500</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options Exercised</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options Forfeited</a></td>
        <td class="num"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" onclick="toggleNextSibling(this);">(16,664)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, March 31, 2015</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" onclick="toggleNextSibling(this);">315,836</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options Exercisable, March 31, 2015</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" onclick="toggleNextSibling(this);">81,522</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, March 31, 2015</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Granted</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 6.37</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercised</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Forfeited</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 6.37</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, March 31, 2015</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 6.37</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercisable, March 31, 2015</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 6.37</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Life Outstanding, March 31, 2015</a></td>
        <td class="text">9 years<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Life Exercisable, March 31, 2015</a></td>
        <td class="text">8 years 8 months 12 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic Value Outstanding, March 31, 2015</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic Value Exercisable, March 31, 2015</a></td>
        <td class="nump"><a title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> Note 2. Summary of Significant Accounting Policies</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>&#160;</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px 0pt -0.5in; FONT: 10pt Times New Roman, Times, Serif"> <strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Liquidity and Financial Condition</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company incurred net losses of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6,691,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,118,000</font> for the years ended March 31, 2015 and 2014, respectively. At March 31, 2015, the Company&#8217;s working capital and accumulated deficit were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9,888,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10,360,000</font>, respectively. The Company has not yet achieved profitability and it is expected that its research and development and general and administrative expenses will continue to increase and, as a result, the Company will eventually need to generate significant product revenues to achieve profitability.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company believes that its existing cash, which includes the proceeds from its IPO, will be sufficient to fund its stand-alone operations through the quarter ending June 30, 2016. However, in order for the Company to execute its research and development strategy and to obtain the necessary regulatory approvals to commercialize RUT58-60 as a drug in the United States, the Company will need to raise additional funds through public or private equity offerings, debt financings, corporate collaborations or other means. The Company has not secured any commitment for new financing at this time, nor can it provide any assurance that new financing will be available on commercially acceptable terms, if at all. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash. See Note 6 &#150; Commitments and Contingencies &#150; Agreement and Plan of Merger.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>&#160;</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Principles of Consolidation</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The consolidated financial statements of the Company include the accounts of its wholly-owned subsidiary, Ruthigen Merger Corp., which was incorporated in the state of Delaware on March 2, 2015. All significant intercompany transactions have been eliminated in the consolidation. See Note 6 &#150; Commitments and Contingencies &#150; Agreement and Plan of Merger.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>&#160;</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Use of Estimates</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (&#8220;U. S. GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include stock-based compensation, the valuation allowance related to the Company&#8217;s deferred tax assets and the expense allocations relating to the Company&#8217;s operations prior to its deconsolidation from its Former Parent on March 26, 2014.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Concentration of Credit Risk</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Financial instruments that potentially subject the Company to concentrations of credit risk include amounts held as cash. Cash is maintained in financial institutions located in the United States. The Company is exposed to credit risk in the event of default by these financial institutions for amounts in excess of the Federal Deposit Insurance Corporation insured limits.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>&#160;</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Fair Value of Financial Assets and Liabilities</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Financial instruments, including cash, accounts payable and accrued expenses are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company measures the fair value of financial assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. The Company uses three levels of inputs that may be used to measure fair value:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Level 1&#160;&#151;&#160;quoted prices in active markets for identical assets or liabilities.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Level 2&#160;&#151;&#160;quoted prices for similar assets and liabilities in active markets or inputs that are observable.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Level 3&#160;&#151;&#160;inputs that are unobservable (for example cash flow modeling inputs based on assumptions).</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>&#160;</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Property and Equipment</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Property and equipment are stated at cost, net of accumulated depreciation and amortization which is recorded commencing at the in-service date. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Depreciation of leasehold improvements is computed using the straight-line method over the lesser of the estimated useful life of the improvement or the remaining term of the lease. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Estimated useful asset life by classification is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="WIDTH: 50%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold"> <div style="CLEAR:both;CLEAR: both">Years</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 80%"> <div style="CLEAR:both;CLEAR: both">Office equipment</div> </td> <td style="WIDTH: 1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; WIDTH: 19%"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3</font></div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">Medical equipment</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5</font></div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">Furniture and fixtures</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 7</font></div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>&#160;</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Impairment of Long-Lived Assets</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.2pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.2pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company periodically reviews the carrying values of its long-lived assets when events or changes in circumstances would indicate that it is more likely than not that their carrying values may exceed their realizable values, and records impairment charges when considered necessary. Specific potential indicators of impairment include, but are not necessarily limited to:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both">&#8226;</div> </td> <td> <div style="CLEAR:both;CLEAR: both">a significant decrease in the fair value of an asset;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both">&#8226;</div> </td> <td> <div style="CLEAR:both;CLEAR: both">a significant change in the extent or manner in which an asset is used or a significant physical change in an asset;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both">&#8226;</div> </td> <td> <div style="CLEAR:both;CLEAR: both">a significant adverse change in legal factors or in the business climate that affects the value of an asset;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both">&#8226;</div> </td> <td> <div style="CLEAR:both;CLEAR: both">an adverse action or assessment by the U.S. Food and Drug Administration or another regulator;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both">&#8226;</div> </td> <td> <div style="CLEAR:both;CLEAR: both">an accumulation of costs significantly in excess of the amount originally expected to acquire or construct an asset; and operating or cash flow losses combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with an income-producing asset.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> When circumstances indicate that an impairment may have occurred, the Company tests such assets for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of such assets and their eventual disposition to their carrying amounts. In estimating these future cash flows, assets and liabilities are grouped at the lowest level for which there are identifiable cash flows that are largely independent of the cash flows generated by other such groups. If the undiscounted future cash flows are less than the carrying amount of the asset, an impairment loss, measured as the excess of the carrying value of the asset over its estimated fair value, will be recognized. The cash flow estimates used in such calculations are based on estimates and assumptions, using all available information that management believes is reasonable.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>&#160;</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Stock-Based Compensation</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company accounts for share-based awards exchanged for employee and director services at the estimated grant date fair value of the award. The Company estimates the fair value of stock options using the Black-Scholes option pricing model. The Company estimates the fair value of restricted stock and restricted stock units (&#8220;RSUs&#8221;) based upon the closing market price of the Company&#8217;s common stock on the date the award is granted. The Company amortizes the fair value of employee awards on&#160;the straight-line basis over the requisite service period of the awards. Stock-based compensation expense includes the impact of an estimate for forfeitures for all stock awards. The Company recognizes stock-based compensation expense for awards with performance conditions if and when the Company concludes that it is probable that the performance condition will be achieved. The Company reassesses the probability of vesting at each reporting period for awards with performance conditions and adjusts stock-based compensation expense based on its probability assessment.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company accounts for equity instruments issued to non-employees at their fair value on the measurement date. The measurement of stock-based compensation is subject to periodic adjustment as the underlying equity instrument vests or becomes non-forfeitable. Non-employee stock-based compensation charges are amortized over the requisite service period.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>&#160;</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Research and Development</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Research and development expense is charged to operations as incurred and consists primarily of personnel expenses, clinical and regulatory services and supplies.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>&#160;</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Net Loss per Share</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company computes basic net loss per share by dividing net loss per share available to common stockholders by the weighted average number of common shares outstanding for the period and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the &#8220;treasury stock&#8221; and/or &#8220;if converted&#8221; methods, as applicable.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div style="CLEAR:both;CLEAR: both">March&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div style="CLEAR:both;CLEAR: both">Options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">315,836</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div style="CLEAR:both;CLEAR: both">Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,145,650</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,140,250</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div style="CLEAR:both;CLEAR: both">Restricted stock units</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">324,047</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div style="CLEAR:both;CLEAR: both">Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,785,533</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,140,250</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>&#160;</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Income Taxes</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company accounts for income taxes under Accounting Standards Codification (&#8220;ASC&#8221;) 740 Income Taxes (&#8220;ASC 740&#8221;). Under ASC 740, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Tax benefits claimed or expected to be claimed on a tax return are recorded in the Company&#8217;s consolidated financial statements. A tax benefit from an uncertain tax position is only recognized if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. Uncertain tax positions have had no impact on the Company&#8217;s consolidated financial condition, results of operations or cash flows.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>&#160;</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Recent Accounting Pronouncements</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In June 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-12, "Compensation - Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could be Achieved after the Requisite Service Period," ("ASU 2014-12"). The amendments in ASU 2014-12 require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Accounting Standards Codification Topic No. 718, "Compensation - Stock Compensation" as it relates to awards with performance conditions that affect vesting to account for such awards. The amendments in ASU 2014-12 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in ASU 2014-12 either: (a) prospectively to all awards granted or modified after the effective date; or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The Company does not anticipate that the adoption of this standard will have a material impact on its consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In August 2014, the FASB issued ASU No. 2014-15, &#8220;Presentation of Financial Statements &#150; Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern.&#8221; The guidance, which is effective for annual reporting periods ending after December 15, 2016, extends the responsibility for performing the going-concern assessment to management and contains guidance on how to perform a going-concern assessment and when going-concern disclosures would be required under U.S. GAAP. The Company does not believe adoption of this ASU will have a material effect on its consolidated financial statements.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Subsequent Events</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Management has evaluated subsequent events or transactions occurring through the date these consolidated financial statements were issued. See Note 10 &#150; Subsequent Events.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>27
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?06YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].4T],241!5$5$
M7T)!3$%.0T5?4TA%1513/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^0T].4T],241!5$5$7T)!3$%.0T5?4TA%15137U!A/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].4T],241!5$5$
M7U-4051%345.5%-?3T9?3U!%/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0T].4T],241!5$5$7U-4051%345.5%-?3T9?0TA!/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].4T],241!
M5$5$7U-4051%345.5%-?3T9?0T%3/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`V+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^0T].4T],241!5$5$7U-4051%345.5%-?3T9?0T%3
M,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970P-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D]R9V%N
M:7IA=&EO;E]A;F1?4&QA;E]O9E]-97)G93PO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P."YH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/E-U;6UA<GE?;V9?4VEG;FEF:6-A;G1?06-C
M;W5N=#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970P.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E!R
M97!A:61?17AP96YS97-?86YD7T]T:&5R7T-U<CPO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,"YH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/E!R;W!E<G1Y7V%N9%]%<75I<&UE;G0\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T,3$N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y!8V-O=6YT
M<U]087EA8FQE7V%N9%]!8V-R=65D7T4\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3(N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y#;VUM:71M96YT<U]A;F1?0V]N=&EN9V5N8VEE
M<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970Q,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T;V-K
M:&]L9&5R<U]%<75I='D\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,30N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y);F-O;65?5&%X97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,34N:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^
M#0H@("`@/'@Z3F%M93Y296QA=&5D7U!A<G1Y7U1R86YS86-T:6]N<SPO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970Q-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-U8G-E<75E;G1?
M179E;G1S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#$W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M4W5M;6%R>5]O9E]3:6=N:69I8V%N=%]!8V-O=6YT,3PO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q
M."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-U;6UA<GE?;V9?4VEG;FEF:6-A
M;G1?06-C;W5N=#(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T,3DN:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z
M3F%M93Y0<F5P86ED7T5X<&5N<V5S7V%N9%]/=&AE<E]#=7(Q/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#(P+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4')O<&5R='E?86YD7T5Q
M=6EP;65N=%]486)L97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C$N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y!8V-O=6YT<U]087EA8FQE7V%N9%]!8V-R=65D7T4Q/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#(R+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W1O8VMH;VQD97)S
M7T5Q=6ET>5]486)L97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C,N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y);F-O;65?5&%X97-?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(T+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^3W)G86YI>F%T:6]N7V%N9%]0;&%N7V]F
M7TUE<F=E,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970R-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/E-U;6UA<GE?;V9?4VEG;FEF:6-A;G1?06-C;W5N=#,\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,C8N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=6UM87)Y7V]F7U-I9VYI9FEC
M86YT7T%C8V]U;G0T/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#(W+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^4W5M;6%R>5]O9E]3:6=N:69I8V%N=%]!8V-O=6YT-3PO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970R."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E!R97!A:61?17AP96YS
M97-?86YD7T]T:&5R7T-U<C(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713
M;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,CDN:'1M;"(O/@T*("`@
M/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@
M("`@/'@Z3F%M93Y0<F]P97)T>5]A;F1?17%U:7!M96YT7T1E=&%I;',\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T,S`N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y0<F]P97)T>5]A
M;F1?17%U:7!M96YT7T1E=&%I;',Q/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#,Q+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^06-C;W5N='-?4&%Y86)L95]A;F1?06-C<G5E9%]%
M,CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970S,BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;6UI
M=&UE;G1S7V%N9%]#;VYT:6YG96YC:65S7SPO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S,RYH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/E-T;V-K:&]L9&5R<U]%<75I='E?1&5T86EL
M<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970S-"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T;V-K
M:&]L9&5R<U]%<75I='E?1&5T86EL<U\Q/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#,U+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^4W1O8VMH;VQD97)S7T5Q=6ET>5]$971A:6QS
M7S(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,S8N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=&]C
M:VAO;&1E<G-?17%U:71Y7T1E=&%I;'-?,SPO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S-RYH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/E-T;V-K:&]L9&5R<U]%<75I='E?1&5T86EL
M<U\T/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#,X+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W1O
M8VMH;VQD97)S7T5Q=6ET>5]$971A:6QS7S4\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,SDN:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y3=&]C:VAO;&1E<G-?17%U:71Y7T1E=&%I
M;'-?5&4\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T-#`N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y)
M;F-O;65?5&%X97-?1&5T86EL<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T,2YH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@("`\>#I.86UE/DEN8V]M95]487AE<U]$971A:6QS7S$\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T-#(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y);F-O;65?5&%X97-?1&5T
M86EL<U\R/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#0S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M26YC;VUE7U1A>&5S7T1E=&%I;'-?5&5X='5A;#PO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T-"YH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/E)E;&%T961?4&%R='E?5')A;G-A8W1I
M;VYS7T1E=#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970T-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/E-U8G-E<75E;G1?179E;G1S7T1E=&%I;'-?5&5X=#PO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T
M-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@(#PO>#I%>&-E
M;%=O<FMS:&5E=',^#0H@(#QX.E-T>6QE<VAE970@2%)E9CTS1")7;W)K<VAE
M971S+W)E<&]R="YC<W,B+SX-"B`@/'@Z06-T:79E4VAE970^,#PO>#I!8W1I
M=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T<G5C='5R93Y&86QS93PO>#I0<F]T
M96-T4W1R=6-T=7)E/@T*("`\>#I0<F]T96-T5VEN9&]W<SY&86QS93PO>#I0
M<F]T96-T5VEN9&]W<SX-"B`\+W@Z17AC96Q7;W)K8F]O:SX-"CPO>&UL/CPA
M6V5N9&EF72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP/E1H:7,@<&%G
M92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@36EC<F]S;V9T($5X8V5L(%A0(&]R
M(&YE=V5R+CPO<#X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
M>'1087)T7SDR-3$W.#5B7S=E8F-?-#<S,5\Y8C$W7S<S-C8Y.39A.#9A9`T*
M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\Y,C4Q-S@U8E\W96)C7S0W
M,S%?.6(Q-U\W,S8V.3DV83@V860O5V]R:W-H965T<R]3:&5E=#`Q+FAT;6P-
M"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-
M"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-
M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%5E5!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY$;V-U;65N
M="!!;F0@16YT:71Y($EN9F]R;6%T:6]N("A54T0@)"D\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^2G5N+B`P-2P@,C`Q-3QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$T/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1O8W5M96YT($EN
M9F]R;6%T:6]N(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!4>7!E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XQ,"U+/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;65N9&UE;G0@1FQA9SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^9F%L<V4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT(%!E
M<FEO9"!%;F0@1&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M36%R(#,Q+`T*"0DR,#$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!&:7-C86P@665A<B!&;V-U<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,C`Q-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@
M1FES8V%L(%!E<FEO9"!&;V-U<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^1ED\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5N=&ET>2!296=I<W1R86YT($YA;64\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/E)U=&AI9V5N+"!);F,N/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@0V5N
M=')A;"!);F1E>"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/C`P,#$U-S0R,S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-U<G)E;G0@1FES8V%L(%EE87(@16YD($1A=&4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/BTM,#,M,S$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!7
M96QL+6MN;W=N(%-E87-O;F5D($ES<W5E<CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^3F\\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!6;VQU;G1A<GD@1FEL97)S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y.;SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y($-U<G)E;G0@
M4F5P;W)T:6YG(%-T871U<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^665S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y%;G1I='D@1FEL97(@0V%T96=O<GD\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/E-M86QL97(@4F5P;W)T:6YG($-O;7!A;GD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N
M=&ET>2!0=6)L:6,@1FQO870\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,3,L-3<R+#<V-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5')A9&EN9R!3>6UB;VP\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/E)41TX\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!#;VUM;VX@4W1O8VLL
M(%-H87)E<R!/=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-"PX,#0L,CDP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
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M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P15!1044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^0T].
M4T],241!5$5$($)!3$%.0T4@4TA%1513("A54T0@)"D\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/D-U<G)E;G0@07-S971S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#87-H/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#$P+#,U-RPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#$U+#4W,2PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R97!A:60@97AP96YS
M97,@86YD(&]T:&5R(&-U<G)E;G0@87-S971S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ-C8L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,RPP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!#=7)R96YT($%S
M<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L-3(S+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$U+#4W-"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0L(&YE=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34W+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T
M86P@07-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PV
M.#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,34L-3<V+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#=7)R96YT($QI86)I;&ET:65S
M.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M8V-O=6YT<R!P87EA8FQE(&%N9"!A8V-R=65D(&5X<&5N<V5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,S4L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#$P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&%Y86)L
M92!T;R!&;W)M97(@4&%R96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-3,W+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E1O=&%L($-U<G)E;G0@3&EA8FEL:71I97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8S-2PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY-#<L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VUM:71M96YT<R!A;F0@8V]N=&EN9V5N8VEE<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/E-T;V-K:&]L9&5R<R<@17%U:71Y.CPO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VLL("0P+C`P
M,#$@<&%R('9A;'5E.R`U,#`L,#`P('-H87)E<R!A=71H;W)I>F5D.R!N;R!S
M:&%R97,@:7-S=65D(&%N9"!O=71S=&%N9&EN9R!A="!-87)C:"`S,2P@,C`Q
M-2!A;F0@,C`Q-"P@<F5S<&5C=&EV96QY/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"`D,"XP,#`Q('!A<B!V86QU
M93L@,3`P+#`P,"PP,#`@<VAA<F5S(&%U=&AO<FEZ960[(#0L.#`T+#(Y,"!A
M;F0@-"PV-3`L,#`P('-H87)E<R!I<W-U960@86YD(&]U='-T86YD:6YG(&%T
M($UA<F-H(#,Q+"`R,#$U(&%N9"`R,#$T+"!R97-P96-T:79E;'D\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0X,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0V-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^061D:71I;VYA;"!P
M86ED+6EN(&-A<&ET86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(P+#0P-"PU,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ."PR.3<L-3,U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-U;75L871E9"!D969I8VET/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,"PS-C`L,#`P*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,L-C8Y
M+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y4;W1A;"!3=&]C:VAO;&1E<G,G($5Q=6ET>3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L,#0U+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T+#8R.2PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4
M;W1A;"!,:6%B:6QI=&EE<R!A;F0@4W1O8VMH;VQD97)S)R!%<75I='D\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3`L-C@P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,34L
M-3<V+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?.3(U,3<X-6)?-V5B8U\T-S,Q7SEB,3=?-S,V-CDY-F$X-F%D#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+SDR-3$W.#5B7S=E8F-?-#<S,5\Y
M8C$W7S<S-C8Y.39A.#9A9"]7;W)K<VAE971S+U-H965T,#,N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$4Q3T%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-/3E-/3$E$051%
M1"!"04Q!3D-%(%-(14544R!;4&%R96YT:&5T:6-A;%T@*%531"`D*3QB<CX\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q
M+"`R,#$U/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@
M,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!R969E<G)E9"!S=&]C:RP@<&%R('9A;'5E("AI;B!D;VQL87)S('!E<B!S
M:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#`Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`P+C`P,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!R969E<G)E9"!3=&]C:RP@4VAA<F5S($%U=&AO<FEZ960\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P,"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,#`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y0<F5F97)R960@4W1O8VLL(%-H87)E<R!)<W-U960\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@4W1O8VLL(%-H87)E
M<R!/=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-O;6UO;B!S=&]C:RP@<&%R('9A;'5E("AI;B!D;VQL87)S('!E<B!S
M:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#`Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`P+C`P,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-O;6UO;B!3=&]C:RP@4VAA<F5S($%U=&AO<FEZ960\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,"PP,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`P+#`P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-O;6UO;B!3=&]C:RP@4VAA<F5S+"!)<W-U960\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0L.#`T+#(Y,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L.#`T+#(Y,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M
M;6]N(%-T;V-K+"!3:&%R97,L($]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XT+#8U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#8U,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7SDR-3$W.#5B7S=E8F-?
M-#<S,5\Y8C$W7S<S-C8Y.39A.#9A9`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B\Y,C4Q-S@U8E\W96)C7S0W,S%?.6(Q-U\W,S8V.3DV83@V860O
M5V]R:W-H965T<R]3:&5E=#`T+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%6$E!13X-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY#3TY33TQ)1$%4140@4U1!5$5-14Y44R!/1B!/
M4$52051)3TY3("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,3(@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4F5V96YU97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/<&5R871I;F<@17AP96YS97,\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S
M96%R8V@@86YD(&1E=F5L;W!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR+#$W."PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#,X,BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E;&QI;F<L(&=E;F5R86P@
M86YD(&%D;6EN:7-T<F%T:79E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT+#4S,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#<S-BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!/<&5R871I;F<@17AP
M96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L-S`X+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,L,3$X+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DQO<W,@1G)O;2!/<&5R871I;VYS/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@V+#<P."PP,#`I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,RPQ,3@L,#`P*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY/=&AE<B!);F-O;64\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^26YT97)E<W0@:6YC;VUE/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ-RPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@3W1H97(@26YC;VUE
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-RPP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T
M($QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-BPV.3$L
M,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^)"`H,RPQ,3@L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY.970@3&]S<R!097(@4VAA<F4\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%S
M:6,@86YD($1I;'5T960@*&EN(&1O;&QA<G,@<&5R('-H87)E*3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q+C,Y*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,2XU,RD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^5V5I9VAT960@079E<F%G92!.=6UB97(@;V8@0V]M;6]N(%-H87)E<R!/
M=71S=&%N9&EN9SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y"87-I8R!A;F0@1&EL=71E9"`H:6X@<VAA<F5S*3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PX,C,L.3`W/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPP,S8L,S`Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
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M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P159504<^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0Q/CQS=')O;F<^0T].4T],241!5$5$(%-4051%345.
M5%,@3T8@0TA!3D=%4R!)3B!35$]#2TA/3$1%4E,G($5154E462`H55-$("0I
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E1O
M=&%L/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D-O;6UO;B!3
M=&]C:R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y!9&1I=&EO;F%L(%!A:60M:6X@0V%P:71A;"!;365M8F5R73QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y!8V-U;75L871E9"!$969I8VET
M(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y"86QA;F-E(&%T($UA<BX@,S$L(#(P,3,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@-#<L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4Y-RPX,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#4U,2PP,#`I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y"86QA;F-E("AI;B!S:&%R97,I(&%T($UA<BX@,S$L(#(P,3,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,#`P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YV97-T;65N
M="!&<F]M($9O<FUE<B!087)E;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$L-C<Y+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#8W.2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R97,@86YD('=A<G)A
M;G1S(&ES<W5E9"!F;W(@8V%S:"!I;B!C;VYN96-T:6]N('=I=&@@:6YI=&EA
M;"!P=6)L:6,@;V9F97)I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$V+#`R,2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR-C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ-BPP,C`L-S,U/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F5S(&%N9"!W87)R
M86YT<R!I<W-U960@9F]R(&-A<V@@:6X@8V]N;F5C=&EO;B!W:71H(&EN:71I
M86P@<'5B;&EC(&]F9F5R:6YG("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR+#8U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@S+#$Q."PP,#`I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S+#$Q."PP,#`I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y"86QA;F-E(&%T($UA<BX@,S$L(#(P,30\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$T+#8R.2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-C4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ."PR.3<L-3,U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,RPV-CDL,#`P
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0F%L86YC92`H:6X@<VAA<F5S*2!A="!-87(N(#,Q+"`R,#$T/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#8U,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E<R!I
M<W-U960@9F]R(&-A<V@@:6X@8V]N;F5C=&EO;B!W:71H('5N9&5R=W)I=&5R
M)W,@97AE<F-I<V4@;V8@;W9E<F%L;&]T;65N="P@;F5T/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`R."PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#(W+#DX-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H
M87)E<R!I<W-U960@9F]R(&-A<V@@:6X@8V]N;F5C=&EO;B!W:71H('5N9&5R
M=W)I=&5R)W,@97AE<F-I<V4@;V8@;W9E<F%L;&]T;65N="P@;F5T("AI;B!S
M:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-30L,CDP
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y3=&]C:RUB87-E9"!C;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L,#<Y+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`W.2PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-BPV.3$L,#`P*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-BPV
M.3$L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0F%L86YC92!A="!-87(N(#,Q+"`R,#$U/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#$P+#`T-2PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0X,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C`L-#`T
M+#4R,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^)"`H,3`L,S8P+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D)A;&%N8V4@*&EN('-H87)E<RD@870@36%R
M+B`S,2P@,C`Q-3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PX
M,#0L,CDP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
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M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P1456044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0T].4T],241!5$5$
M(%-4051%345.5%,@3T8@0T%32"!&3$]74R`H55-$("0I/&)R/CPO<W1R;VYG
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0T/C$R
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CY-87(N(#,Q+"`R
M,#$U/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0R/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^0V%S:"!&;&]W<R!&<F]M($]P97)A=&EN9R!!
M8W1I=FET:65S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B0@*#8L-CDQ+#`P,"D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B0@*#,L,3$X+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^061J=7-T;65N=',@=&\@<F5C;VYC:6QE
M(&YE="!L;W-S('1O(&YE="!C87-H('5S960@:6X@;W!E<F%T:6YG(&%C=&EV
M:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D1E<')E8VEA=&EO;CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4W1O8VLM8F%S960@8V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+#`W.2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/D-H86YG97,@:6X@;W!E<F%T:6YG(&%S<V5T<R!A;F0@;&EA8FEL:71I97,Z
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!R97!A:60@97AP96YS97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#$V,RPP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D%C8V]U;G1S('!A>6%B;&4@86YD(&%C8W)U960@97AP96YS97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,X."PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ-#8L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3F5T($-A<V@@57-E9"!I;B!/<&5R871I;F<@06-T:79I
M=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-2PS.#8L,#`P
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(L.38Y+#`P,"D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V%S:"!&;&]W
M<R!&<F]M($EN=F5S=&EN9R!!8W1I=FET:65S/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!U<F-H
M87-E<R!O9B!P<F]P97)T>2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@Q-38L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M970@0V%S:"!5<V5D(&EN($EN=F5S=&EN9R!!8W1I=FET:65S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-38L,#`P*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^0V%S:"!&;&]W<R!&<F]M($9I;F%N8VEN9R!!8W1I=FET
M:65S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D%D=F%N8V5S(&9R;VT@1F]R;65R(%!A<F5N=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L-#4S+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4F5P87EM96YT(&]F($9O<FUE<B!087)E;G0@861V86YC
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4S-RPP,#`I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.3$V+#`P,"D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@:7-S=6%N8V4@
M;V8@8V]M;6]N('-T;V-K(&%N9"!W87)R86YT<R!L97-S(&ES<W5A;F-E(&-O
M<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-C4L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CQS=7`^
M6S%=/"]S=7`^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-BPR
M,C@L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&9N/CQS=7`^6S%=/"]S=7`^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DEN=F5S=&UE;G0@9G)O;2!&;W)M97(@4&%R96YT/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PV-SDL,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3F5T($-A<V@@4')O=FED960@8GD@1FEN86YC:6YG($%C=&EV:71I
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,R."PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ."PT-#0L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T("A$96-R96%S92D@26YC<F5A
M<V4@26X@0V%S:#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-2PR
M,30L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U+#0W-2PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@+2!"96=I
M;FYI;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U+#4W,2PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY-BPP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@+2!%;F1I;F<\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3`L,S4W+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,34L-3<Q+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1D(&-O;'-P86X],T0U/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$:6YN97)&;V]T
M;F]T93X-"B`@("`@("`@/'1D('9A;&EG;CTS1'1O<#Y;,5T\+W1D/@T*("`@
M("`@("`\=&0@8V]L<W!A;CTS1#0@=F%L:6=N/3-$=&]P/D1U<FEN9R!T:&4@
M>65A<B!E;F1E9"!-87)C:"`S,2P@,C`Q-2P@9W)O<W,@<')O8V5E9',@9G)O
M;2!T:&4@:6YI=&EA;"!P=6)L:6,@;V9F97)I;F<@;V8@)#$L,3$W+#`P,"!L
M97-S("0R-3(L,#`P(&]F(&]F9F5R:6YG(&-O<W1S+"!O9B!W:&EC:"`D.#DL
M,#`P('=A<R!W:71H:&5L9"!F<F]M('1H92!P<F]C965D<R!A;F0@)#$V,RPP
M,#`@=V%S('!A:60@:6X@8V%S:"!T:&%T('=A<R!P<F5V:6]U<VQY(&%C8W)U
M960@870@36%R8V@@,S$L(#(P,30N($1U<FEN9R!T:&4@>65A<B!E;F1E9"!-
M87)C:"`S,2P@,C`Q-"P@9W)O<W,@<')O8V5E9',@9G)O;2!T:&4@:6YI=&EA
M;"!P=6)L:6,@;V9F97)I;F<@;V8@)#$Y+#(Q-BPP,#`@;&5S<R`D,RPQ.34L
M,#`P(&]F(&]F9F5R:6YG(&-O<W1S+"!O9B!W:&EC:"`D,BPX,C8L,#`P('=A
M<R!W:71H:&5L9"!F<F]M('1H92!P<F]C965D<RP@)#(P-BPP,#`@=V%S('!A
M:60@:6X@8V%S:"`H:6YC;'5D:6YG("0T-"PP,#`@<&%I9"!D=7)I;F<@=&AE
M(&9I<V-A;"!Y96%R(&5N9&5D($UA<F-H(#,Q+"`R,#$S*2!A;F0@)#$V,RPP
M,#`@=V%S(&%C8W)U960@87,@;V8@36%R8V@@,S$L(#(P,30N/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7SDR-3$W.#5B7S=E8F-?-#<S,5\Y8C$W7S<S
M-C8Y.39A.#9A9`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\Y,C4Q
M-S@U8E\W96)C7S0W,S%?.6(Q-U\W,S8V.3DV83@V860O5V]R:W-H965T<R]3
M:&5E=#`W+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%3DI!0SX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY#3TY33TQ)1$%4140@4U1!5$5-14Y44R!/1B!#05-(($9,3U=3(%M0
M87)E;G1H971I8V%L72`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0S/C$R($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1W)O<W,@4')O8V5E9',@1G)O;2!)<W-U
M86YC92!/9B!#;VUM;VX@4W1O8VL@06YD(%=A<G)A;G1S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L,3$W+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3DL,C$V+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3V9F97)I;F<@0V]S=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C4R+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,L,3DU+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3V9F97)I;F<@0V]S="!7:71H:&5L9"!&<F]M
M(%1H92!0<F]C965D<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M.#DL,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,BPX,C8L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y087EM96YT<R!O9B!3=&]C:R!)<W-U86YC92!#
M;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38S+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P
M-BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT-"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%C8W)U960@3V9F97)I;F<@0V]S=',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,38S+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.3(U,3<X-6)?-V5B8U\T-S,Q
M7SEB,3=?-S,V-CDY-F$X-F%D#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+SDR-3$W.#5B7S=E8F-?-#<S,5\Y8C$W7S<S-C8Y.39A.#9A9"]7;W)K
M<VAE971S+U-H965T,#@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY/<F=A;FEZ871I;VX@86YD(%!L86X@;V8@365R9V5R/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$U
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/D]R9V%N:7IA=&EO;BP@0V]N<V]L:61A=&EO;B!A;F0@4')E<V5N=&%T:6]N
M(&]F($9I;F%N8VEA;"!3=&%T96UE;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W)G86YI>F%T:6]N
M+"!#;VYS;VQI9&%T:6]N(&%N9"!0<F5S96YT871I;VX@;V8@1FEN86YC:6%L
M(%-T871E;65N=',@1&ES8VQO<W5R92!;5&5X="!";&]C:UT\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y;&4],T0G34%21TE..B`P
M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF("<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ
M5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ(#!P="`P
M<'@[($9/3E0Z(&)O;&0@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^3F]T92`Q+B!/<F=A;FEZ871I;VX@86YD(%!L86X@;V8@365R9V5R
M/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ
M5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ(#!P="`P
M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B`\8CX\:3XF(S$V,#L\+VD^/"]B/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)
M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@/&(^/&D^3W)G86YI>F%T:6]N/"]I
M/CPO8CX\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!
M34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$
M14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V1I=CX@/&1I=B!S
M='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M
M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE.
M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SY2=71H:6=E;BP@26YC+B`H=&AE("8C.#(R,#M#;VUP86YY)B,X
M,C(Q.R!O<B`F(S@R,C`[4G5T:&EG96XF(S@R,C$[*2!W87,@:6YC;W)P;W)A
M=&5D('5N9&5R('1H92!L87=S(&]F('1H92!3=&%T92!O9B!.979A9&$@;VX@
M2F%N=6%R>2`Q."P@,C`Q,RX@5&AE($-O;7!A;GD@=V%S(')E:6YC;W)P;W)A
M=&5D(&9R;VT@3F5V861A('1O($1E;&%W87)E(&]N(%-E<'1E;6)E<B`R-2P@
M,C`Q,RX@5&AE($-O;7!A;GDF(S@R,3<[<R!P<FEN8VEP86P@;V9F:6-E(&ES
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M92!P<F]C961U<F5S+CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[
M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[
M5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9&EV
M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S
M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN
M.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/E1H92!#;VUP86YY(&-L;W-E9"!I=',@:6YI=&EA
M;"!P=6)L:6,@;V9F97)I;F<@*"8C.#(R,#M)4$\F(S@R,C$[*2!O;B!-87)C
M:"`R-BP@,C`Q-"P@<'5R<W5A;G0@=&\@=VAI8V@@86X@86=G<F5G871E(&]F
M(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N
M)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/C(L-C4P+#`P,#PO9F]N=#X@
M=6YI=',@=V5R92!S;VQD(&%T(&$@<')I8V4@;V8@)#QF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4
M+5-)6D4Z(#$P<'0G/C<N,C4\+V9O;G0^('!E<B!U;FET+B!0<FEO<B!T;R!T
M:&4@25!/+"!T:&4@0V]M<&%N>2!W87,@82!W:&]L;'DM;W=N960@<W5B<VED
M:6%R>2!O9B!/8W5L=7,@26YN;W9A=&EV92!38VEE;F-E<RP@26YC+B`H)B,X
M,C(P.T]C=6QU<R8C.#(R,3L@;W(@)B,X,C(P.T9O<FUE<B!087)E;G0F(S@R
M,C$[*2X@4V5E($YO=&4@-R`F(S$U,#L@4W1O8VMH;VQD97)S)B,X,C$W.R!%
M<75I='D@)B,Q-3`[($EN:71I86P@4'5B;&EC($]F9F5R:6YG(&9O<B!A9&1I
M=&EO;F%L(&1E=&%I;',N/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T
M:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P
M=#M-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/CQB/CQI/B8C,38P.SPO:3X\+V(^/"]D:78^(#QD
M:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W
M(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ(#!P="`P<'@[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQB/CQI/D%G
M<F5E;65N="!A;F0@4&QA;B!O9B!-97)G97(\+VD^/"]B/CPO9&EV/B`\9&EV
M('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2
M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'
M24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O
M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P
M<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D]N($UA<F-H
M(#$S+"`R,#$U+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@86X@06=R965M
M96YT(&%N9"!0;&%N(&]F($UE<F=E<B`H=&AE("8C.#(R,#M-97)G97(@06=R
M965M96YT)B,X,C(Q.RD@=VET:"!0=6QM871R:7@@26YC+B`H)B,X,C(P.U!U
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M;&QY(&]W;F5D('-U8G-I9&EA<GD@;V8@4G5T:&EG96X@*'1H92`F(S@R,C`[
M365R9V5R)B,X,C(Q.RDN(%-E92!.;W1E(#8@)B,Q-3`[($-O;6UI=&UE;G1S
M(&%N9"!#;VYT:6YG96YC:65S("8C,34P.R!!9W)E96UE;G0@86YD(%!L86X@
M;V8@365R9V5R(&9O<B!A9&1I=&EO;F%L(&1E=&%I;',N/"]D:78^(#PO9&EV
M/CQT86)L92!B;W)D97(],T0P('-T>6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE
M+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS
M1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7SDR-3$W.#5B7S=E8F-?-#<S,5\Y
M8C$W7S<S-C8Y.39A.#9A9`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B\Y,C4Q-S@U8E\W96)C7S0W,S%?.6(Q-U\W,S8V.3DV83@V860O5V]R:W-H
M965T<R]3:&5E=#`Y+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O
M;&EC:65S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N
M(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D%C8V]U;G1I;F<@4&]L:6-I97,@6T%B<W1R86-T73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:6=N:69I
M8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S(%M497AT($)L;V-K73PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=-05)'24XZ
M(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68@)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,
M63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,'!T
M(#!P>#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX@3F]T92`R+B!3=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U
M;G1I;F<@4&]L:6-I97,\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H
M.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T
M.TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^(#QS=')O;F<^/&D^)B,Q-C`[/"]I/CPO<W1R;VYG
M/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9
M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z
M(#`N-6EN.R!-05)'24XZ(#!P="`P<'@@,'!T("TP+C5I;CL@1D].5#H@,3!P
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M;65S+"!397)I9B<^("8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2
M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z
M(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B!4:&4@
M0V]M<&%N>2!I;F-U<G)E9"!N970@;&]S<V5S(&]F("0\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].
M5"U325I%.B`Q,'!T)SXV+#8Y,2PP,#`\+V9O;G0^(&%N9"`D/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[
M($9/3E0M4TE:13H@,3!P="<^,RPQ,3@L,#`P/"]F;VYT/B!F;W(@=&AE('EE
M87)S(&5N9&5D($UA<F-H(#,Q+"`R,#$U(&%N9"`R,#$T+"!R97-P96-T:79E
M;'DN($%T($UA<F-H(#,Q+"`R,#$U+"!T:&4@0V]M<&%N>28C.#(Q-SMS('=O
M<FMI;F<@8V%P:71A;"!A;F0@86-C=6UU;&%T960@9&5F:6-I="!W97)E("0\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L
M)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SXY+#@X."PP,#`\+V9O;G0^(&%N
M9"`D/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M
M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^,3`L,S8P+#`P,#PO9F]N
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M96YU97,@=&\@86-H:65V92!P<F]F:71A8FEL:71Y+CPO9&EV/B`\9&EV('-T
M>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA
M;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ
M(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B`F(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H
M.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T
M.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@5&AE($-O;7!A
M;GD@8F5L:65V97,@=&AA="!I=',@97AI<W1I;F<@8V%S:"P@=VAI8V@@:6YC
M;'5D97,@=&AE('!R;V-E961S(&9R;VT@:71S($E03RP@=VEL;"!B92!S=69F
M:6-I96YT('1O(&9U;F0@:71S('-T86YD+6%L;VYE(&]P97)A=&EO;G,@=&AR
M;W5G:"!T:&4@<75A<G1E<B!E;F1I;F<@2G5N92`S,"P@,C`Q-BX@2&]W979E
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M8V%S:"X@4V5E($YO=&4@-B`F(S$U,#L@0V]M;6ET;65N=',@86YD($-O;G1I
M;F=E;F-I97,@)B,Q-3`[($%G<F5E;65N="!A;F0@4&QA;B!O9B!-97)G97(N
M/"]D:78^(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W
M(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#X@/&1I
M=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@
M4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^(#QS=')O;F<^
M/&D^)B,Q-C`[/"]I/CPO<W1R;VYG/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)
M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@/'-T<F]N9SX\:3X\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@
M1D].5"U325I%.B`Q,'!T)SX@/"]F;VYT/E!R:6YC:7!L97,@;V8@0V]N<V]L
M:61A=&EO;CPO:3X\+W-T<F]N9SX\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!
M4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%
M.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)B,Q
M-C`[/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)
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M;B!E;&EM:6YA=&5D(&EN('1H92!C;VYS;VQI9&%T:6]N+B!3964@3F]T92`V
M("8C,34P.R!#;VUM:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE<R`F(S$U,#L@
M06=R965M96YT(&%N9"!0;&%N(&]F($UE<F=E<BX\+V1I=CX@/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[
M($9/3E0M4TE:13H@,3!P="<^/"]F;VYT/B`\9&EV('-T>6QE/3-$)T-,14%2
M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z
M(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX@/'-T<F]N9SX\:3XF(S$V,#L\+VD^/"]S
M=')O;F<^/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&
M04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ
M(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B`\<W1R;VYG/CQI/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G
M/B`\+V9O;G0^57-E(&]F($5S=&EM871E<SPO:3X\+W-T<F]N9SX\+V1I=CX@
M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.
M97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@
M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX@)B,Q-C`[/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%
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M,C`[52X@4RX@1T%!4"8C.#(R,3LI(')E<75I<F5S(&UA;F%G96UE;G0@=&\@
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M(&]N($UA<F-H(#(V+"`R,#$T+CPO9&EV/B`\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%
M.B`Q,'!T)SX\+V9O;G0^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].
M5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'
M24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B`\<W1R;VYG/B8C,38P.SPO<W1R;VYG/CPO9&EV/B`\9&EV
M('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2
M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@/'-T<F]N9SX\
M:3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA
M;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX@/"]F;VYT/D-O;F-E;G1R
M871I;VX@;V8@0W)E9&ET(%)I<VL\+VD^/"]S=')O;F<^/"]D:78^(#QD:78@
M<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O
M;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)
M3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^("8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O
M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P
M<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z
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M:6UI=',N/"]D:78^(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM
M97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N
M=#X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE
M<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,'!T(#!P>#L@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^(#QS
M=')O;F<^/&D^)B,Q-C`[/"]I/CPO<W1R;VYG/CPO9&EV/B`\9&EV('-T>6QE
M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&
M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@/'-T<F]N9SX\:3X\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E
M<FEF)SL@1D].5"U325I%.B`Q,'!T)SX@/"]F;VYT/D9A:7(@5F%L=64@;V8@
M1FEN86YC:6%L($%S<V5T<R!A;F0@3&EA8FEL:71I97,\+VD^/"]S=')O;F<^
M/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ
M5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@
M,"XU:6X[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^("8C,38P.SPO9&EV/B`\9&EV('-T>6QE
M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&
M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P
M="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
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M25I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@
M)B,Q-C`[/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&
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M960@=&\@;65A<W5R92!F86ER('9A;'5E.CPO9&EV/B`\9&EV('-T>6QE/3-$
M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4
M+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P
M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B`F(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4
M+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M
M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I
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M+"!397)I9B<^("8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O
M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P
M<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B!,979E;"`R
M)B,Q-C`[)B,Q-3$[)B,Q-C`[<75O=&5D('!R:6-E<R!F;W(@<VEM:6QA<B!A
M<W-E=',@86YD(&QI86)I;&ET:65S(&EN(&%C=&EV92!M87)K971S(&]R(&EN
M<'5T<R!T:&%T(&%R92!O8G-E<G9A8FQE+CPO9&EV/B`\9&EV('-T>6QE/3-$
M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4
M+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P
M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B`F(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4
M+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M
M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@3&5V96P@,R8C,38P.R8C
M,34Q.R8C,38P.VEN<'5T<R!T:&%T(&%R92!U;F]B<V5R=F%B;&4@*&9O<B!E
M>&%M<&QE(&-A<V@@9FQO=R!M;V1E;&EN9R!I;G!U=',@8F%S960@;VX@87-S
M=6UP=&EO;G,I+CPO9&EV/B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX\
M+V9O;G0^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ
M5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ(#!P="`P
M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B`\<W1R;VYG/CQI/B8C,38P.SPO:3X\+W-T<F]N9SX\+V1I=CX@/&1I=B!S
M='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M
M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^(#QS=')O;F<^/&D^
M/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG
M+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^(#PO9F]N=#Y0<F]P97)T>2!A
M;F0@17%U:7!M96YT/"]I/CPO<W1R;VYG/CPO9&EV/B`\9&EV('-T>6QE/3-$
M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4
M+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P
M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B`F(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4
M+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M
M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I
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M+B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA
M;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX@/"]F;VYT/D5S=&EM871E
M9"!U<V5F=6P@87-S970@;&EF92!B>2!C;&%S<VEF:6-A=&EO;B!I<R!A<R!F
M;VQL;W=S.CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M
M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)
M3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F(S$V,#L\+V1I=CX@/'1A
M8FQE('-T>6QE/3-$)U=)1%1(.B`U,"4[($)/4D1%4BU#3TQ,05!313H@8V]L
M;&%P<V4[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^(#QT<B!S='EL
M93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D/B`\9&EV('-T>6QE
M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'
M2%0Z(&)O;&0G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O
M=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/
M3E0M5T5)1TA4.B!B;VQD)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,
M14%2.B!B;W1H)SY996%R<SPO9&EV/B`\+W1D/B`\+W1R/B`\='(@<W1Y;&4]
M,T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VTG/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z
M(#@P)2<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^
M3V9F:6-E(&5Q=6EP;65N=#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5TE$
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M/B`\+W1D/B`\=&0^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@
M8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97(G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z
M(&)O=&@G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W
M(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/B`U/"]F;VYT/CPO
M9&EV/B`\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/
M4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T
M:#M#3$5!4CH@8F]T:"<^1G5R;FET=7)E(&%N9"!F:7AT=7)E<SPO9&EV/B`\
M+W1D/B`\=&0^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T
M:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97(G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O
M=&@G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O
M;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/B`W/"]F;VYT/CPO9&EV
M/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q
M,'!T)SX\+V9O;G0^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&
M04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ
M(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B`F(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H
M.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T
M.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q
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M+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^/"]F;VYT/B`\9&EV('-T>6QE
M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&
M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@/'-T<F]N9SX\:3XF(S$V
M,#L\+VD^/"]S=')O;F<^/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T
M:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P
M=#M-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B`\<W1R;VYG/CQI/CQF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)
M6D4Z(#$P<'0G/B`\+V9O;G0^26UP86ER;65N="!O9B!,;VYG+4QI=F5D($%S
M<V5T<SPO:3X\+W-T<F]N9SX\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB
M;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q
M,'!T.U1%6%0M24Y$14Y4.B`S,"XR<'0[($U!4D=)3CH@,'!T(#!P>#L@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("8C,38P
M.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9
M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z
M(#,P+C)P=#L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE
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M97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`M,"XR-6EN
M.R!-05)'24XZ(#!P="`P<'@@,'!T(#`N-6EN.R!&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)B,Q-C`[/"]D:78^(#QT86)L
M92!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P="<@
M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^
M(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX@/'1D('-T>6QE
M/3-$)U=)1%1(.B`P+C(U:6XG/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[
M0TQ%05(Z(&)O=&@G/CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z
M(#`N,C5I;B<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T
M:"<^)B,X,C(V.SPO9&EV/B`\+W1D/B`\=&0^(#QD:78@<W1Y;&4],T0G0TQ%
M05(Z8F]T:#M#3$5!4CH@8F]T:"<^82!S:6=N:69I8V%N="!D96-R96%S92!I
M;B!T:&4@9F%I<B!V86QU92!O9B!A;B!A<W-E=#L\+V1I=CX@/"]T9#X@/"]T
M<CX@/"]T86)L93X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!
M34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$
M14Y4.B`M,"XR-6EN.R!-05)'24XZ(#!P="`P<'@@,'!T(#`N-6EN.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)B,Q-C`[
M/"]D:78^(#QT86)L92!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"
M3U143TTZ(#!P="<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W
M:61T:#TS1#$P,"4^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P
M)SX@/'1D('-T>6QE/3-$)U=)1%1(.B`P+C(U:6XG/B`\9&EV('-T>6QE/3-$
M)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/CPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5TE$5$@Z(#`N,C5I;B<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T
M:#M#3$5!4CH@8F]T:"<^)B,X,C(V.SPO9&EV/B`\+W1D/B`\=&0^(#QD:78@
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M4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`M,"XR-6EN.R!-
M05)'24XZ(#!P="`P<'@@,'!T(#`N-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)B,Q-C`[/"]D:78^(#QT86)L92!S
M='EL93TS1"=-05)'24XM5$]0.B`P<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P="<@8V5L
M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^(#QT
M<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX@/'1D('-T>6QE/3-$
M)U=)1%1(.B`P+C(U:6XG/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%
M05(Z(&)O=&@G/CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N
M,C5I;B<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^
M)B,X,C(V.SPO9&EV/B`\+W1D/B`\=&0^(#QD:78@<W1Y;&4],T0G0TQ%05(Z
M8F]T:#M#3$5!4CH@8F]T:"<^82!S:6=N:69I8V%N="!A9'9E<G-E(&-H86YG
M92!I;B!L96=A;"!F86-T;W)S(&]R(&EN('1H92!B=7-I;F5S<R!C;&EM871E
M('1H870@869F96-T<R!T:&4@=F%L=64@;V8@86X@87-S970[/"]D:78^(#PO
M=&0^(#PO='(^(#PO=&%B;&4^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@
M1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M4
M15A4+4E.1$5.5#H@+3`N,C5I;CL@34%21TE..B`P<'0@,'!X(#!P="`P+C5I
M;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M("8C,38P.SPO9&EV/B`\=&%B;&4@<W1Y;&4],T0G34%21TE.+51/4#H@,'!T
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-
M05)'24XM0D]45$]-.B`P<'0G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`@=VED=&@],T0Q,#`E/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)
M1TXZ('1O<"<^(#QT9"!S='EL93TS1"=724142#H@,"XR-6EN)SX@/&1I=B!S
M='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SX\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U=)1%1(.B`P+C(U:6XG/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C.#(R-CL\+V1I=CX@/"]T9#X@/'1D
M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/F%N(&%D
M=F5R<V4@86-T:6]N(&]R(&%S<V5S<VUE;G0@8GD@=&AE(%4N4RX@1F]O9"!A
M;F0@1')U9R!!9&UI;FES=')A=&EO;B!O<B!A;F]T:&5R(')E9W5L871O<CL\
M+V1I=CX@/"]T9#X@/"]T<CX@/"]T86)L93X@/&1I=B!S='EL93TS1"=#3$5!
M4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%
M.B`Q,'!T.U1%6%0M24Y$14Y4.B`M,"XR-6EN.R!-05)'24XZ(#!P="`P<'@@
M,'!T(#`N-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX@)B,Q-C`[/"]D:78^(#QT86)L92!S='EL93TS1"=-05)'24XM
M5$]0.B`P<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[($U!4D=)3BU"3U143TTZ(#!P="<@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^(#QT<B!S='EL93TS1"=615)4
M24-!3"U!3$E'3CH@=&]P)SX@/'1D('-T>6QE/3-$)U=)1%1(.B`P+C(U:6XG
M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/CPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N,C5I;B<^(#QD:78@<W1Y
M;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,X,C(V.SPO9&EV/B`\
M+W1D/B`\=&0^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T
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M25I%.B`Q,'!T.TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^("8C,38P.SPO9&EV/B`\9&EV('-T
M>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA
M;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ
M(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
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M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4
M+5-)6D4Z(#$P<'0G/CPO9F]N=#X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H
M.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T
M.TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^(#QS=')O;F<^/&D^)B,Q-C`[/"]I/CPO<W1R;VYG
M/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9
M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@
M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX@/'-T<F]N9SX\:3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I
M;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX@/"]F
M;VYT/E-T;V-K+4)A<V5D($-O;7!E;G-A=&EO;CPO:3X\+W-T<F]N9SX\+V1I
M=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE
M<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I
M;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX@)B,Q-C`[/"]D:78^(#QD:78@<W1Y;&4],T0G
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M<W-E<W-M96YT+CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58
M5"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F(S$V,#L\+V1I=CX@
M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.
M97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@
M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
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M8V4@<&5R:6]D+CPO9&EV/B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@
M)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX\
M+V9O;G0^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ
M5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ(#!P="`P
M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B`\<W1R;VYG/CQI/B8C,38P.SPO:3X\+W-T<F]N9SX\+V1I=CX@/&1I=B!S
M='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M
M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P
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M9B<^("8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58
M5"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@
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M="<^/"]F;VYT/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-
M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P
M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX@/'-T<F]N9SX\:3XF(S$V,#L\+VD^/"]S=')O;F<^/"]D:78^(#QD
M:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W
M(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ(#!P="`P<'@[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`\<W1R;VYG
M/CQI/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O
M;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/B`\+V9O;G0^3F5T($QO
M<W,@<&5R(%-H87)E/"]I/CPO<W1R;VYG/CPO9&EV/B`\9&EV('-T>6QE/3-$
M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4
M+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P
M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B`F(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4
M+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M
M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I
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M3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%
M6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)B,Q-C`[/"]D:78^
M(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@
M3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,"XU:6X[
M($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G
M5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/B`\
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M9B<^("8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58
M5"U!3$E'3CI,969T.R!415A4+4E.1$5.5#H@,&EN.R!724142#H@,3`P)2<^
M(#QT86)L92!S='EL93TS1"=-05)'24XZ(#!I;CL@5TE$5$@Z(#<P)3L@0D]2
M1$52+4-/3$Q!4%-%.B!C;VQL87!S93L@3U9%4D9,3U<Z('9I<VEB;&4G(&-E
M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@86QI9VX],T1L969T/B`\
M='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#0U)3X@
M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H
M/3-$,24^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
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M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78@<W1Y;&4],T0G
M0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#PO
M='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$
M-#4E/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
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M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q,24@8V]L<W!A
M;CTS1#(^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^
M,C`Q-3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD
M:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M
M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV('-T
M>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/C(P,30\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD
M:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D
M:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W
M,#`G('=I9'1H/3-$-#4E/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%
M05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
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M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@
M-S`P)R!W:61T:#TS1#$E/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%
M05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I
M9'1H/3-$,3`E/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O
M=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
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M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W
M:61T:#TS1#$E/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O
M=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$
M,3`E/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@
M=VED=&@],T0Q)3X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B
M;W1H)SXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-#4E/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/D]P=&EO;G,\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV('-T>6QE
M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78@
M<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T
M:#M#3$5!4CH@8F]T:"<^,S$U+#@S-CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78@<W1Y;&4],T0G0TQ%
M05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L
M93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=B!S='EL93TS
M1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N
M;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
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M.B!B;W1H)SXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-#4E/B`\9&EV('-T>6QE/3-$
M)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/E=A<G)A;G1S/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=B!S
M='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV('-T>6QE/3-$)T-,14%2
M.F)O=&@[0TQ%05(Z(&)O=&@G/C,L,30U+#8U,#PO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78@<W1Y;&4]
M,T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^
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M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H
M.T-,14%2.B!B;W1H)SXS+#$T,"PR-3`\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R
M/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0T-24^
M(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^4F5S=')I
M8W1E9"!S=&]C:R!U;FET<SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T
M:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!
M4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG
M:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV('-T>6QE/3-$
M)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/C,R-"PP-#<\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV('-T
M>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@
M<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV('-T>6QE/3-$
M)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[
M(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)
M3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P
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M,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$-#4E/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[
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M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,3`E/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G
M/C,L-S@U+#4S,SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!
M4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I
M=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,W!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@
M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXS+#$T,"PR
M-3`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G
M/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@
M1D].5"U325I%.B`Q,'!T)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@
M,3!P="<^/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[
M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[
M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX@/'-T<F]N9SX\:3XF(S$V,#L\+VD^/"]S=')O;F<^
M/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ
M5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ(#!P="`P
M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B`\<W1R;VYG/CQI/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM
M97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/B`\+V9O
M;G0^/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M
M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^/"]F;VYT/DEN8V]M92!4
M87AE<SPO:3X\+W-T<F]N9SX\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB
M;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q
M,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)B,Q-C`[
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M:69I8V%T:6]N("@F(S@R,C`[05-#)B,X,C(Q.RD@-S0P($EN8V]M92!487AE
M<R`H)B,X,C(P.T%30R`W-#`F(S@R,C$[*2X@56YD97(@05-#(#<T,"P@9&5F
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M.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)B,Q
M-C`[/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)
M3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.
M5#H@,"XU:6X[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^($%30R`W-#`@86QS;R!C;&%R:69I
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M:6X@82!T87@@<F5T=7)N+CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O
M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P
M<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F(S$V,#L\
M+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4
M:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P
M+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
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M.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G
M/CPO9F]N=#X\+V1I=CX@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4
M:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^/"]F
M;VYT/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I
M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@
M/'-T<F]N9SX\:3XF(S$V,#L\+VD^/"]S=')O;F<^/"]D:78^(#QD:78@<W1Y
M;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N
M.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`\<W1R;VYG/CQI/CQF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG
M<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/B`\+V9O;G0^4F5C96YT($%C8V]U
M;G1I;F<@4')O;F]U;F-E;65N=',\+VD^/"]S=')O;F<^/"]D:78^(#QD:78@
M<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O
M;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)
M3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^("8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O
M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P
M<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B!);B!*=6YE
M(#(P,30L('1H92!&:6YA;F-I86P@06-C;W5N=&EN9R!3=&%N9&%R9',@0F]A
M<F0@*"8C.#(R,#M&05-")B,X,C(Q.RD@:7-S=65D($%C8V]U;G1I;F<@4W1A
M;F1A<F1S(%5P9&%T92`H)B,X,C(P.T%3528C.#(R,3LI($YO+B`R,#$T+3$R
M+"`B0V]M<&5N<V%T:6]N("T@4W1O8VL@0V]M<&5N<V%T:6]N("A4;W!I8R`W
M,3@I.B!!8V-O=6YT:6YG(&9O<B!3:&%R92U"87-E9"!087EM96YT<R!7:&5N
M('1H92!497)M<R!O9B!A;B!!=V%R9"!0<F]V:61E('1H870@82!097)F;W)M
M86YC92!487)G970@0V]U;&0@8F4@06-H:65V960@869T97(@=&AE(%)E<75I
M<VET92!397)V:6-E(%!E<FEO9"PB("@B05-5(#(P,30M,3(B*2X@5&AE(&%M
M96YD;65N=',@:6X@05-5(#(P,30M,3(@<F5Q=6ER92!T:&%T(&$@<&5R9F]R
M;6%N8V4@=&%R9V5T('1H870@869F96-T<R!V97-T:6YG(&%N9"!T:&%T(&-O
M=6QD(&)E(&%C:&EE=F5D(&%F=&5R('1H92!R97%U:7-I=&4@<V5R=FEC92!P
M97)I;V0@8F4@=')E871E9"!A<R!A('!E<F9O<FUA;F-E(&-O;F1I=&EO;BX@
M02!R97!O<G1I;F<@96YT:71Y('-H;W5L9"!A<'!L>2!E>&ES=&EN9R!G=6ED
M86YC92!I;B!!8V-O=6YT:6YG(%-T86YD87)D<R!#;V1I9FEC871I;VX@5&]P
M:6,@3F\N(#<Q."P@(D-O;7!E;G-A=&EO;B`M(%-T;V-K($-O;7!E;G-A=&EO
M;B(@87,@:70@<F5L871E<R!T;R!A=V%R9',@=VET:"!P97)F;W)M86YC92!C
M;VYD:71I;VYS('1H870@869F96-T('9E<W1I;F<@=&\@86-C;W5N="!F;W(@
M<W5C:"!A=V%R9',N(%1H92!A;65N9&UE;G1S(&EN($%352`R,#$T+3$R(&%R
M92!E9F9E8W1I=F4@9F]R(&%N;G5A;"!P97)I;V1S(&%N9"!I;G1E<FEM('!E
M<FEO9',@=VET:&EN('1H;W-E(&%N;G5A;"!P97)I;V1S(&)E9VEN;FEN9R!A
M9G1E<B!$96-E;6)E<B`Q-2P@,C`Q-2X@16%R;'D@861O<'1I;VX@:7,@<&5R
M;6ET=&5D+B!%;G1I=&EE<R!M87D@87!P;'D@=&AE(&%M96YD;65N=',@:6X@
M05-5(#(P,30M,3(@96ET:&5R.B`H82D@<')O<W!E8W1I=F5L>2!T;R!A;&P@
M87=A<F1S(&=R86YT960@;W(@;6]D:69I960@869T97(@=&AE(&5F9F5C=&EV
M92!D871E.R!O<B`H8BD@<F5T<F]S<&5C=&EV96QY('1O(&%L;"!A=V%R9',@
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M+CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9
M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z
M(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F(S$V,#L\+V1I=CX@/&1I=B!S='EL
M93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[
M1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P
M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX@26X@075G=7-T(#(P,30L('1H92!&05-"(&ES<W5E9"!!4U4@3F\N
M(#(P,30M,34L("8C.#(R,#M0<F5S96YT871I;VX@;V8@1FEN86YC:6%L(%-T
M871E;65N=',@)B,Q-3`[($=O:6YG($-O;F-E<FX@*%-U8G1O<&EC(#(P-2TT
M,"DZ($1I<V-L;W-U<F4@;V8@56YC97)T86EN=&EE<R!A8F]U="!A;B!%;G1I
M='DF(S@R,3<[<R!!8FEL:71Y('1O($-O;G1I;G5E(&%S(&$@1V]I;F<@0V]N
M8V5R;BXF(S@R,C$[(%1H92!G=6ED86YC92P@=VAI8V@@:7,@969F96-T:79E
M(&9O<B!A;FYU86P@<F5P;W)T:6YG('!E<FEO9',@96YD:6YG(&%F=&5R($1E
M8V5M8F5R(#$U+"`R,#$V+"!E>'1E;F1S('1H92!R97-P;VYS:6)I;&ET>2!F
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M9&EV/B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2
M;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX\+V9O;G0^(#QD:78@
M<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O
M;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F(S$V,#L\+V1I
M=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE
M<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,'!T(#!P>#L@
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M1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P
M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX@)B,Q-C`[/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@
M1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M4
M15A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^($UA;F%G96UE;G0@
M:&%S(&5V86QU871E9"!S=6)S97%U96YT(&5V96YT<R!O<B!T<F%N<V%C=&EO
M;G,@;V-C=7)R:6YG('1H<F]U9V@@=&AE(&1A=&4@=&AE<V4@8V]N<V]L:61A
M=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S('=E<F4@:7-S=65D+B!3964@3F]T
M92`Q,"`F(S$U,#L@4W5B<V5Q=65N="!%=F5N=',N/"]D:78^(#PO9&EV/CQT
M86)L92!B;W)D97(],T0P('-T>6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA
M>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^
M/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7SDR-3$W.#5B7S=E8F-?-#<S,5\Y8C$W
M7S<S-C8Y.39A.#9A9`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\Y
M,C4Q-S@U8E\W96)C7S0W,S%?.6(Q-U\W,S8V.3DV83@V860O5V]R:W-H965T
M<R]3:&5E=#$P+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^4')E<&%I9"!%>'!E;G-E<R!A;F0@3W1H97(@0W5R<F5N="!!<W-E
M=',\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L
M(#(P,34\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^4')E<&%I9"!%>'!E;G-E(&%N9"!/=&AE<B!!<W-E=',L($-U<G)E
M;G0@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y$:7-C;&]S=7)E($]F(%!R97!A:60@17AP96YS97,@06YD
M($]T:&5R($-U<G)E;G0@07-S971S(%M497AT($)L;V-K73PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P
M="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68@)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4
M:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,'!T(#!P
M>#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SY.;W1E(#,N(%!R97!A:60@17AP96YS97,@86YD($]T:&5R($-U<G)E
M;G0@07-S971S/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].
M5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4
M+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]D:78^(#QD
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M4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%2
M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB
M;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q
M,'!T.U1%6%0M04Q)1TXZ3&5F=#L@5$585"U)3D1%3E0Z(#!I;CL@5TE$5$@Z
M(#$P,"4G/B`\=&%B;&4@<W1Y;&4],T0G34%21TE..B`P:6X[(%=)1%1(.B`W
M,"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($]615)&3$]7.B!V:7-I
M8FQE)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P(&%L:6=N/3-$
M;&5F=#X@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@]
M,T0T-24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@
M<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,C,E(&-O;'-P86X],T0U
M/B`\9&EV/DUA<F-H)B,Q-C`[,S$L/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P
M)R!W:61T:#TS1#0U)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P
M,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/
M3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV
M/C(P,34\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$Q)2!C;VQS<&%N
M/3-$,CX@/&1I=CXR,#$T/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T
M:#TS1#0U)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI
M9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$P)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z
M(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%
M24=(5#H@-S`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#0U)3X@/&1I=CY0<F5P86ED(&EN<W5R
M86YC93PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
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M;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q,"4^(#QD:78^,3(L,#`P/"]D:78^(#PO=&0^(#QT9"!S
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M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z
M(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXM
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-#4E/B`\9&EV/D-L:6YI
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M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.
M1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E
M/B`\9&EV/C$Q-"PP,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,2PP,#`\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL
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M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C(L,#`P/"]D:78^(#PO=&0^(#QT
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M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.
M1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E
M/B`\9&EV/C(L,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T
M<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-#4E
M/B`\9&EV/D]T:&5R('!R97!A:60@97AP96YS97,@86YD(&-U<G)E;G0@87-S
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M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4
M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))
M1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD
M:78^,S@L,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4
M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED
M.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$
M24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^
M(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#0U)3X@
M/&1I=CY4;W1A;#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I
M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,38V+#`P,#PO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M
M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D
M;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[
M(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^
M,RPP,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A
M8FQE/B`\+V1I=CX@/"]D:78^/'1A8FQE(&)O<F1E<CTS1#`@<W1Y;&4],T0G
M=VED=&@Z,3`P)3L@=&%B;&4M;&%Y;W5T.F9I>&5D.R<@8V5L;'-P86-I;F<]
M,T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T<CX\+W1A8FQE
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.3(U
M,3<X-6)?-V5B8U\T-S,Q7SEB,3=?-S,V-CDY-F$X-F%D#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+SDR-3$W.#5B7S=E8F-?-#<S,5\Y8C$W7S<S
M-C8Y.39A.#9A9"]7;W)K<VAE971S+U-H965T,3$N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-
M13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY0<F]P97)T>2!A;F0@17%U:7!M
M96YT/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q
M+"`R,#$U/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/E!R;W!E<G1Y+"!0;&%N="!A;F0@17%U:7!M96YT(%M!8G-T<F%C
M=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4')O<&5R='DL(%!L86YT(&%N9"!%<75I<&UE;G0@1&ES8VQO<W5R92!;5&5X
M="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@
M<W1Y;&4],T0G34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF("<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z
M8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@
M,3!P=#M-05)'24XZ(#!P="`P<'@[($9/3E0Z(&)O;&0@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^($YO=&4@-"X@4')O<&5R='D@86YD
M($5Q=6EP;65N=#PO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58
M5"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F(S$V,#L\+V1I=CX@
M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.
M97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@
M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
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M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("8C,38P.SPO9&EV/B`\
M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE
M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T.R!415A4
M+4E.1$5.5#H@,&EN.R!724142#H@,3`P)2<^(#QT86)L92!S='EL93TS1"=-
M05)'24XZ(#!I;CL@5TE$5$@Z(#<U)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL
M87!S93L@3U9%4D9,3U<Z('9I<VEB;&4G(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`@86QI9VX],T1L969T/B`\='(^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-S`P)R!W:61T:#TS1#4P)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R
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M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$-3`E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED
M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=.
M.B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q
M,24@8V]L<W!A;CTS1#(^(#QD:78^,C`Q-3PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4
M.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@
M5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G
M('=I9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV/C(P,30\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$-3`E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
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M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G
M('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
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M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3`E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T
M<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-3`E
M/B`\9&EV/D]F9FEC92!E<75I<&UE;G0\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C0L,#`P
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M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M
M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$P)3X@/&1I=CXT+#`P,#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#4P)3X@/&1I=CY-961I8V%L(&5Q=6EP;65N=#PO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C$U-BPP,#`\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ
M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P
M>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXM/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-3`E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'
M+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C$V,"PP,#`\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.
M1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXT+#`P,#PO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#4P)3X@/&1I=CY,97-S.B!A
M8V-U;75L871E9"!D97!R96-I871I;VX@86YD(&%M;W)T:7IA=&EO;CPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@
M<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$P)3X@/&1I=CXH,RPP,#`I/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L
M93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E
M/B`\9&EV/B@R+#`P,"D\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4
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M3TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,W!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@
M/&1I=CXQ-3<L,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@
M<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXR+#`P,#PO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M
M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#PO='(^(#PO=&%B;&4^(#QF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4
M+5-)6D4Z(#$P<'0G/CPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!
M4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%
M.B`Q,'!T.TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^(#QS=')O;F<^)B,Q-C`[/"]S=')O;F<^
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M($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SXQ+#`P,#PO
M9F]N=#X@86YD("0\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S
M($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SXR+#`P,#PO
M9F]N=#X@9F]R('1H92!Y96%R<R!E;F1E9"!-87)C:"`S,2P@,C`Q-2!A;F0@
M,C`Q-"P@<F5S<&5C=&EV96QY+B!$97!R96-I871I;VX@97AP96YS92!I<R!R
M969L96-T960@:6X@<V5L;&EN9RP@9V5N97)A;"!A;F0@861M:6YI<W1R871I
M=F4@97AP96YS97,@:6X@=&AE(&-O;G-O;&ED871E9"!S=&%T96UE;G1S(&]F
M(&]P97)A=&EO;G,N($%S(&]F($UA<F-H(#,Q+"`R,#$U+"!T:&4@0V]M<&%N
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M9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7SDR-3$W.#5B7S=E8F-?
M-#<S,5\Y8C$W7S<S-C8Y.39A.#9A9`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B\Y,C4Q-S@U8E\W96)C7S0W,S%?.6(Q-U\W,S8V.3DV83@V860O
M5V]R:W-H965T<R]3:&5E=#$R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^06-C;W5N=',@4&%Y86)L92!A;F0@06-C<G5E9"!%
M>'!E;G-E<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R
M+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY087EA8FQE<R!A;F0@06-C<G5A;',@6T%B<W1R86-T73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O
M=6YT<R!087EA8FQE(&%N9"!!8V-R=65D($QI86)I;&ET:65S($1I<V-L;W-U
M<F4@6U1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\9&EV('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B`G/B`\9&EV('-T>6QE/3-$
M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4
M+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B!B;VQD(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B!.;W1E(#4N($%C8V]U
M;G1S(%!A>6%B;&4@86YD($%C8W)U960@17AP96YS97,\+V1I=CX@/&1I=B!S
M='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M
M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE.
M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX@)B,Q-C`[/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T
M:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P
M=#M415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^(#QF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G
M.R!&3TY4+5-)6D4Z(#$P<'0G/B`\+V9O;G0^06-C;W5N=',@<&%Y86)L92!A
M;F0@86-C<G5E9"!E>'!E;G-E<R!C;VYS:7-T(&]F('1H92!F;VQL;W=I;F<Z
M/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ
M5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@
M,"XU:6X[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^("8C,38P.SPO9&EV/B`\9&EV('-T>6QE
M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&
M3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T.R!415A4+4E.1$5.5#H@
M,&EN.R!724142#H@,3`P)2<^(#QT86)L92!S='EL93TS1"=-05)'24XZ(#!I
M;CL@5TE$5$@Z(#<U)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@3U9%
M4D9,3U<Z('9I<VEB;&4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS
M1#`@86QI9VX],T1L969T/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-S`P)R!W:61T:#TS1#4P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-4
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M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`W,#`G('=I9'1H/3-$-3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q,24@8V]L<W!A
M;CTS1#(^(#QD:78^,C`Q-3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'
M3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$
M,3$E(&-O;'-P86X],T0R/B`\9&EV/C(P,30\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`W,#`G('=I9'1H/3-$-3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
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M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$
M,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
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M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&
M3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L
M:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED
M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-3`E/B`\9&EV/D%C
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M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z
M(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXY
M,BPP,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,3`E/B`\9&EV/C$P.2PP,#`\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,
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M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^-#,L,#`P/"]D:78^(#PO
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M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,3`E/B`\9&EV/C4P+#`P,#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#4P)3X@/&1I=CY!8V-R=65D(&QE9V%L(&9E97,\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$
M24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M,"4^(#QD:78^,30T+#`P,#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
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M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXQ.#,L,#`P
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-3`E/B`\9&EV/D%C8W)U
M960@;W1H97(@<')O9F5S<VEO;F%L(&9E97,\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))
M1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD
M:78^-3`L,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C0U+#`P,#PO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#4P)3X@/&1I=CY!8V-R=65D(')E<V5A
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M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(
M5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV
M/C$R."PP,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^.2PP,#`\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=4
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M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,30V+#`P,#PO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
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M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
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M/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M-3`E/B`\9&EV/D]T:&5R(&%C8W)U960@97AP96YS97,\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&
M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXS,BPP,#`\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I
M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXQ-"PP,#`\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S
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M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!L
M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,3`E/B`\9&EV/C8S-2PP,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@
M9&]U8FQE.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4
M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))
M1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C0Q,"PP,#`\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E
M<FEF)SL@1D].5"U325I%.B`Q,'!T)SX\+V9O;G0^/"]D:78^(#PO9&EV/CQT
M86)L92!B;W)D97(],T0P('-T>6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA
M>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^
M/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7SDR-3$W.#5B7S=E8F-?-#<S,5\Y8C$W
M7S<S-C8Y.39A.#9A9`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\Y
M,C4Q-S@U8E\W96)C7S0W,S%?.6(Q-U\W,S8V.3DV83@V860O5V]R:W-H965T
M<R]3:&5E=#$S+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^0V]M;6ET;65N=',@86YD($-O;G1I;F=E;F-I97,\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]M;6ET
M;65N=',@86YD($-O;G1I;F=E;F-I97,@1&ES8VQO<W5R92!;06)S=')A8W1=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O
M;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S($1I<V-L;W-U<F4@6U1E>'0@
M0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T
M>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B`G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O
M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P
M<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX@/&(^3F]T92`V+B!#;VUM:71M96YT<R!A;F0@
M0V]N=&EN9V5N8VEE<SPO8CX\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB
M;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q
M,'!T.TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^(#QB/CQI/B8C,38P.SPO:3X\+V(^/"]D:78^
M(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@
M3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ(#!P="`P<'@[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`\8CX\
M:3Y!9W)E96UE;G0@86YD(%!L86X@;V8@365R9V5R/"]I/CPO8CX\+V1I=CX@
M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.
M97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@
M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!
M4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%
M.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY/;B!-
M87)C:"`Q,RP@,C`Q-2P@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O('1H92!-
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M;&QY(&]W;F5D('-U8G-I9&EA<GD@;V8@4G5T:&EG96X@*'1H92`F(S@R,C`[
M365R9V5R)B,X,C(Q.RDN/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T
M:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P
M=#M415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]D
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M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4
M+5-)6D4Z(#$P<'0G/C$W/"]F;VYT/B4@;V8@=&AE(&-O;6)I;F5D(&-O;7!A
M;GDN/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)
M3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.
M5#H@,"XU:6X[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]D:78^(#QD:78@<W1Y
M;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N
M.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@
M,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^5&AE($-O;7!A;GDF(S@R,3<[<R!A;F0@4'5L;6%T<FEX)B,X,C$W
M.W,@;V)L:6=A=&EO;G,@=&\@8V]N<W5M;6%T92!T:&4@365R9V5R(&%R92!S
M=6)J96-T('1O('1H92!S871I<V9A8W1I;VX@;W(@=V%I=F5R(&]F(&-U<W1O
M;6%R>2!C;&]S:6YG(&-O;F1I=&EO;G,L(&EN8VQU9&EN9RP@86UO;F<@;W1H
M97)S+"!O8G1A:6YI;F<@=&AE(')E<75I<VET92!A<'!R;W9A;',@;V8@=&AE
M('-T;V-K:&]L9&5R<R!O9B!2=71H:6=E;B!A;F0@4'5L;6%T<FEX+"!I;F-L
M=61I;F<@=&AE(&%P<')O=F%L(&]F('1H92!I<W-U86YC92!O9B!T:&4@<VAA
M<F5S(&]F(&-O;6UO;B!S=&]C:R!O9B!2=71H:6=E;B!T;R!B92!I<W-U960@
M:6X@8V]N;F5C=&EO;B!W:71H('1H92!-97)G97(@86YD('1H92!C:&%R=&5R
M(&%M96YD;65N=',@8GD@=&AE('-T;V-K:&]L9&5R<R!O9B!2=71H:6=E;BP@
M86YD('1H92!E9F9E8W1I=F5N97-S(&]F(&$@<F5G:7-T<F%T:6]N('-T871E
M;65N="!O;B!&;W)M(%,M-"!R96QA=&EN9R!T;R!T:&4@<VAA<F5S(&]F(%)U
M=&AI9V5N(&-O;6UO;B!S=&]C:R!T;R!B92!I<W-U960@=&\@4'5L;6%T<FEX
M('-T;V-K:&]L9&5R<R!P=7)S=6%N="!T;R!T:&4@365R9V5R($%G<F5E;65N
M="X@4G5T:&EG96X@:7,@<F5Q=6ER960@=&\@:&%V92!U;G)E<W1R:6-T960@
M8V%S:"!O;B!H86YD+"!N970@;V8@;W5T<W1A;F1I;F<@;&EA8FEL:71I97,L
M(&%T(&-L;W-I;F<@;V8@870@;&5A<W0@*&$I("0\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U3
M25I%.B`Q,'!T)SXY+#`P,"PP,#`\+V9O;G0^+"!I9B!T:&4@365R9V5R(&-L
M;W-I;F<@9&%T92!I<R!N;R!L871E<B!T:&%N($IU;'D@,S$L(#(P,34@;W(@
M*&(I("0\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2
M;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SXX+#@U,"PP,#`\+V9O
M;G0^+"!I9B!T:&4@365R9V5R(&-L;W-I;F<@9&%T92!I<R!A9G1E<B!*=6QY
M(#,Q+"`R,#$U(&)U="!N;R!L871E<B!T:&%N($%U9W5S="`Q,RP@,C`Q-2X@
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M+B!3964@3F]T92`V("8C,34P.R!#;VUM:71M96YT<R!A;F0@0V]N=&EN9V5N
M8VEE<R`F(S$U,#L@3F5W($-O;G-U;'1I;F<@06=R965M96YT<RX@3VX@36%Y
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M-C`[/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)
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M=6YT960@9F]R(&%S)B,Q-C`[82!R979E<G-E)B,Q-C`[86-Q=6ES:71I;VX@
M;V8@4G5T:&EG96X@8GD@4'5L;6%T<FEX('5N9&5R($=!05`N(%5N9&5R('1H
M92`F(S@R,C`[86-Q=6ES:71I;VXF(S@R,C$[(&UE=&AO9"!O9B!A8V-O=6YT
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M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S
M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN
M.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)
M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[
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M<W5E(&%N(&%G9W)E9V%T92!O9B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T
M)SXY,"PP,#`\+V9O;G0^('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@=&\@86X@
M96UP;&]Y964@86YD(&$@9&ER96-T;W(@;V8@=&AE($-O;7!A;GDN/"]D:78^
M(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@
M3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,"XU:6X[
M($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%
M05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:
M13H@,3!P=#M415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,'!T(#!P>#L@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^5&AE
M(&9O;&QO=VEN9R!O=&AE<B!M97)G97(M<F5L871E9"!A9W)E96UE;G1S(&AA
M=F4@8F5E;B!D:7-C;&]S960@:6XZ("AI*2!.;W1E(#8@)B,Q-3`[($-O;6UI
M=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S("8C,34P.R!.97<@16UP;&]Y;65N
M="!!9W)E96UE;G1S+"`H:6DI($YO=&4@-B`F(S$U,#L@0V]M;6ET;65N=',@
M86YD($-O;G1I;F=E;F-I97,@)B,Q-3`[($YE=R!#;VYS=6QT:6YG($%G<F5E
M;65N=',L("AI:6DI($YO=&4@-B`F(S$U,#L@0V]M;6ET;65N=',@86YD($-O
M;G1I;F=E;F-I97,@)B,Q-3`[($]C=6QU<R!3:61E($QE='1E<B!!9W)E96UE
M;G0L("AI=BD@3F]T92`W("8C,34P.R!3=&]C:VAO;&1E<G,F(S@R,3<[($5Q
M=6ET>2`F(S$U,#L@3F5W(#(P,3,@4&QA;BX\+V1I=CX@/&1I=B!S='EL93TS
M1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].
M5"U325I%.B`Q,'!T.TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&(^/&D^)B,Q-C`[/"]I/CPO
M8CX\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,
M63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,'!T
M(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^/&(^/&D^16UP;&]Y;65N="!!9W)E96UE;G1S/"]I/CPO8CX\+V1I=CX@
M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.
M97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@
M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!
M4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%
M.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY/;B!!
M=6=U<W0@,3(L(#(P,3,L('1H92!C;VUP96YS871I;VX@8V]M;6ET=&5E(&]F
M($]C=6QU<R!A<'!R;W9E9"!T:&4@9W)A;G0@;V8@82!O;F4M=&EM92!C87-H
M(&)O;G5S(&]F("0\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S
M($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SXQ-3@L,#`P
M/"]F;VYT/B!T;R!T:&4@0V]M<&%N>28C.#(Q-SMS($-H:65F($5X96-U=&EV
M92!/9F9I8V5R("@F(S@R,C`[0T5/)B,X,C(Q.RD@:6X@;W)D97(@=&\@<F5C
M;V=N:7IE('1H92!#14\F(S@R,3<[<R!E9F9O<G1S(')E;&%T960@=&\@=&AE
M('!R97!A<F%T:6]N(&%N9"!F:6QI;F<@;V8@=&AE($-O;7!A;GDF(S@R,3<[
M<R!R96=I<W1R871I;VX@<W1A=&5M96YT(&]N($9O<FT@4RTQ(&9O<B!I=',@
M25!/+CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-
M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P
M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&
M3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%
M6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY/;B!*=6YE(#(T+"`R
M,#$T+"!T:&4@8V]M<&5N<V%T:6]N(&-O;6UI='1E92!O9B!T:&4@0V]M<&%N
M>28C.#(Q-SMS(&)O87)D(&]F(&1I<F5C=&]R<R!A<'!R;W9E9"!A;B!E;7!L
M;WEM96YT(&%G<F5E;65N="!F;W(@:71S($-H:65F($9I;F%N8VEA;"!/9F9I
M8V5R("@F(S@R,C`[0T9/)B,X,C(Q.RDL('=H:6-H(')E<&QA8V5D('1H92!O
M9F9E<B!L971T97(@<')E=FEO=7-L>2!I;B!E9F9E8W0@8F5T=V5E;B!T:&4@
M0V]M<&%N>2!A;F0@=&AE($-&3RX@5&AE(&5M<&QO>6UE;G0@86=R965M96YT
M(&-O;G1I;G5E<R!T;R!P<F]V:61E(&9O<B!A;B!A;FYU86P@8F%S92!S86QA
M<GD@;V8@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W
M(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/C(R-2PP,#`\+V9O
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M;V0@<F5A<V]N+"!T:&4@0T9/(&ES(&5N=&ET;&5D('1O.B`\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@
M1D].5"U325I%.B`Q,'!T)SXH:2D@82!L=6UP('-E=F5R86YC92!P87EM96YT
M(&5Q=6%L('1O(#$X('1I;65S('1H92!A=F5R86=E(&UO;G1H;'D@8F%S92!S
M86QA<GD@<&%I9"!T;R!T:&4@0T9/(&]V97(@=&AE('!R96-E9&EN9R`Q,B!M
M;VYT:',[("AI:2D@=7`@=&\@;VYE('EE87(@*'1H92!L97-S97(@;V8@;VYE
M('EE87(@9F]L;&]W:6YG('1H92!D871E(&]F('1E<FUI;F%T:6]N(&]R('5N
M=&EL('1H92!#1D\@8F5C;VUE<R!E;&EG:6)L92!F;W(@;65D:6-A;"!I;G-U
M<F%N8V4@8V]V97)A9V4@<')O=FED960@8GD@86YO=&AE<B!E;7!L;WEE<BD@
M<F5I;6)U<G-E;65N="!F;W(@:&5A;'1H(&-A<F4@<')E;6EU;7,@=6YD97(@
M0T]"4D$[(&%N9"`H:6EI*2!A=71O;6%T:6,@=F5S=&EN9R!O9B!A;&P@=6YV
M97-T960@;W!T:6]N<R!A;F0@;W1H97(@97%U:71Y(&%W87)D<SL@<')O=FED
M960@=&AA="!I;B!T:&4@979E;G0@=&AE($-&3R!R97-I9VYS(&9O<B!G;V]D
M(')E87-O;B!P<FEO<B!T;R!A(&-H86YG92!O9B!C;VYT<F]L+"!O;FQY('1H
M92!V97-T:6YG(&]F('1H92!R97-T<FEC=&5D('-T;V-K('5N:71S(&=R86YT
M960@8GD@=&AE($-O;7!A;GD@;VX@36%Y(#$R+"`R,#$T('-H86QL(&)E(&%C
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M97)A=&EO;B!O9B!T:&4@97%U:71Y(&%W87)D<R`H:6YC;'5D:6YG(&$@9W)O
M<W,@=7`@;V8@86YY(&%D9&ET:6]N86P@9F5D97)A;"P@<W1A=&4@86YD(&QO
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M9B<^)B,Q-C`[/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].
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M9&EA<GD@;V8@3V-U;'5S+CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O
M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P
M<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I
M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N
M-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/E1H92!E;7!L;WEM96YT(&%G<F5E;65N="!C
M;VYT:6YU97,@=&\@<')O=FED92!F;W(@86X@86YN=6%L(&)A<V4@<V%L87)Y
M(&]F("0\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2
M;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SXS-S4L,#`P/"]F;VYT
M/B!T;R!T:&4@0T5/+"!S=6)J96-T('1O(&EN8W)E87-E+"!A<R!D971E<FUI
M;F5D(&)Y('1H92!#;VUP86YY)B,X,C$W.W,@8F]A<F0@;V8@9&ER96-T;W)S
M+B!4:&4@96UP;&]Y;65N="!A9W)E96UE;G0@9G5R=&AE<B!P<F]V:61E<R!F
M;W(@<&%Y;65N=',@=&\@=&AE($-%3R!I;B!T:&4@979E;G0@;V8@=&5R;6EN
M871I;VX@=VET:&]U="!C875S92!O<B!R97-I9VYA=&EO;B!B>2!T:&4@0T5/
M(&9O<B!G;V]D(')E87-O;BP@87,@<W5C:"!T97)M<R!A<F4@9&5F:6YE9"!I
M;B!T:&4@96UP;&]Y;65N="!A9W)E96UE;G0N($EN('1H92!E=F5N="!T:&%T
M('1H92!#14\@:7,@=&5R;6EN871E9"!W:71H;W5T(&-A=7-E(&]R(')E<VEG
M;G,@9F]R(&=O;V0@<F5A<V]N+"!T:&4@0T5/(&ES(&5N=&ET;&5D('1O.B`\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L
M)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SXH:2D@82!L=6UP('-E=F5R86YC
M92!P87EM96YT(&5Q=6%L('1O(#(T('1I;65S('1H92!A=F5R86=E(&UO;G1H
M;'D@8F%S92!S86QA<GD@<&%I9"!T;R!T:&4@0T5/(&]V97(@=&AE('!R96-E
M9&EN9R`Q,B!M;VYT:',[("AI:2D@=7`@=&\@;VYE('EE87(@*'1H92!L97-S
M97(@;V8@;VYE('EE87(@9F]L;&]W:6YG('1H92!D871E(&]F('1E<FUI;F%T
M:6]N(&]R('5N=&EL('1H92!#14\@8F5C;VUE<R!E;&EG:6)L92!F;W(@;65D
M:6-A;"!I;G-U<F%N8V4@8V]V97)A9V4@<')O=FED960@8GD@86YO=&AE<B!E
M;7!L;WEE<BD@<F5I;6)U<G-E;65N="!F;W(@:&5A;'1H(&-A<F4@<')E;6EU
M;7,@=6YD97(@0T]"4D$[(&%N9"`H:6EI*2!A=71O;6%T:6,@=F5S=&EN9R!O
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M97(@4V5C=&EO;B`R.#!'(&%N9"!396-T:6]N(#0Y.3D@;V8@=&AE($EN=&5R
M;F%L(%)E=F5N=64@0V]D92!B96-A=7-E(&]F(&%N>2!A8V-E;&5R871I;VX@
M;V8@=&AE(&5Q=6ET>2!A=V%R9',@*&EN8VQU9&EN9R!A(&=R;W-S('5P(&]F
M(&%N>2!A9&1I=&EO;F%L(&9E9&5R86PL('-T871E(&%N9"!L;V-A;"!T87AE
M<R!P87EA8FQE(&%S(&$@<F5S=6QT(&]F('1H92!R96EM8G5R<V5M96YT(&]F
M('1H92!T87@@<&%Y;65N=',I+B!&=7)T:&5R;6]R92P@=&AE($-O;7!A;GD@
M=VEL;"!R96EM8G5R<V4@=&AE($-%3R!F;W(@<F5L;V-A=&EO;B!E>'!E;G-E
M<R!I9B!T:&4@0V]M<&%N>28C.#(Q-SMS('!R:6YC:7!A;"!E>&5C=71I=F4@
M;V9F:6-E<R!A<F4@;6]V960@;W(@=&AE($-%3R!I<R!R97%U:7)E9"!T;R!R
M96QO8V%T92P@<W5B:F5C="!T;R!C97)T86EN(&-O;F1I=&EO;G,N/"]D:78^
M(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@
M3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,"XU:6X[
M($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%
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M<F]U<"`H87,@<W5C:"!T97)M(&ES(&1E9FEN960@:6X@=&AE(&5M<&QO>6UE
M;G0@86=R965M96YT*2P@;V8@86QL('!R;W!E<G1Y(&)E;&]N9VEN9R!T;R!T
M:&4@0V]M<&%N>2!'<F]U<"P@<F5C96EV960@9G)O;2!O<B!O;B!A8V-O=6YT
M(&]F('1H92!#;VUP86YY($=R;W5P+"!O<B!A;GD@;W1H97(@96YT:71Y(&]F
M('1H92!#;VUP86YY($=R;W5P+"!O<B!A;GD@;V8@=&AE($-O;7!A;GD@1W)O
M=7`F(S@R,3<[<R!R97-P96-T:79E(&%F9FEL:6%T97,@8GD@=&AE($-%3RX@
M26X@861D:71I;VXL('1H92!#14\@:7,@;F]T(&5N=&ET;&5D('1O('-U8V@@
M8F5N969I=',@:68@=&AE($-%3R!D;V5S(&YO="!C;VUP;'D@=VET:"!T:&4@
M;F]N+6-O;7!E=&ET:6]N+"!I;G9E;G1I;VX@87-S:6=N;65N="P@8V]N9FED
M96YT:6%L:71Y+"!N;VXM<V]L:6-I=&%T:6]N('!R;W9I<VEO;G,@;V8@=&AE
M(&5M<&QO>6UE;G0@86=R965M96YT+CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)
M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-
M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%
M3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D%S(&]F($UA<F-H(#,Q+"`R,#$U
M+"!T:&4@<&]T96YT:6%L(&-A<V@@<V5V97)A;F-E('!A>6UE;G0@<F5L871E
M9"!T;R!T:&4@0V]M<&%N>28C.#(Q-SMS(&5M<&QO>6UE;G0@86=R965M96YT
M<R!C=7)R96YT;'D@:6X@969F96-T('=I=&@@:71S($-%3R!A;F0@0T9/(&%M
M;W5N=&5D('1O("0\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S
M($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SXQ+#$T-"PP
M,#`\+V9O;G0^+CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2
M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX\8CX\:3XF(S$V,#L\+VD^/"]B/CPO9&EV/B`\9&EV('-T
M>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA
M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\8CX\:3Y.97<@16UP
M;&]Y;65N="!!9W)E96UE;G1S/"]I/CPO8CX\+V1I=CX@/&1I=B!S='EL93TS
M1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].
M5"U325I%.B`Q,'!T.TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]D:78^(#QD:78@
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M;F5W(&5M<&QO>6UE;G0@86=R965M96YT+CPO9&EV/B`\9&EV('-T>6QE/3-$
M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4
M+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P
M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M
M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)
M3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/DEF('1H92!-97)G97(@:7,@
M87!P<F]V960@8GD@=&AE(')E<W!E8W1I=F4@<W1O8VMH;VQD97)S+"!T:&4@
M0T5/(&%N9"!#1D\@=VEL;"!T97)M:6YA=&4@=&AE:7(@8W5R<F5N="!E;7!L
M;WEM96YT(&%G<F5E;65N=',@=VET:"!2=71H:6=E;B!D871E9"!.;W9E;6)E
M<B`R."P@,C`Q-"!A;F0@2G5N92`R-"P@,C`Q-"P@<F5S<&5C=&EV96QY+B!!
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M('=I;&P@<F5M86EN(&EN(&5F9F5C="!A;F0@=&AE(&QO8VLM=7`@86=R965M
M96YT<R!A;F0@8V%N8V5L;&%T:6]N(&%G<F5E;65N=',@=VEL;"!N;W0@8F5C
M;VUE(&5F9F5C=&EV92X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H
M.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T
M.TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%
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M92!T97)M:6YA=&5D(&EN(&5X8VAA;F=E(&9O<B`H:2D@82!L=6UP+7-U;2!P
M87EM96YT(&EN('1H92!A;6]U;G0@;V8@)#4T-RPV,#`L(&QE<W,@=&%X97,@
M86YD(&]T:&5R('=I=&AH;VQD:6YG<R!A;F0@*&EI*2!A(&QU;7`M<W5M(&5Q
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M.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9&EV/B`\
M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE
M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-
M05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/E1H92!#14\@<VAA;&P@86QS;R!R96-E:79E(&$@9W)A
M;G0@;V8@<F5S=')I8W1E9"!S=&]C:R!U;FET<RP@<'5R<W5A;G0@=&\@4G5T
M:&EG96XF(S@R,3<[<R`R,#$S($5M<&QO>65E+"!$:7)E8W1O<B!A;F0@0V]N
M<W5L=&%N="!%<75I='D@26YC96YT:79E(%!L86XL(#QF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4
M+5-)6D4Z(#$P<'0G/F5Q=6%L('1O('1H92!L97-S97(@;V8@*&DI(#DS,"PP
M,#`@86YD("AI:2D@=&AE('%U;W1I96YT(&]F("0S+#$R-2PP,#`@9&EV:61E
M9"!B>2!T:&4@9F%I<B!M87)K970@=F%L=64@;V8@=&AE(&-O;6UO;B!S=&]C
M:R!O9B!T:&4@8V]M8FEN960@8V]M<&%N>2!A<R!O9B!T:&4@969F96-T:79E
M('1I;64@;V8@=&AE(&UE<F=E<BP@=VET:"!S=6-H(')E<W1R:6-T960@<W1O
M8VL@=6YI=',@=F5S=&EN9R!A<R!F;VQL;W=S.B`H:2D@82!N=6UB97(@;V8@
M<F5S=')I8W1E9"!S=&]C:R!U;FET<R!E<75A;"!T;R!T:&4@;&5S<V5R(&]F
M("AA*2`Y,S`L,#`P(&%N9"`H8BD@<W5C:"!N=6UB97(@;V8@<F5S=')I8W1E
M9"!S=&]C:R!U;FET<R!W:71H(&%N(&%G9W)E9V%T92!V86QU92!E<75A;"!T
M;R`D,2PT,#`L,#`P('-H86QL(&)E(&9U;&QY('9E<W1E9"!A="!T:&4@969F
M96-T:79E('1I;64@;V8@=&AE(&UE<F=E<B!A;F0@*&EI*2!A;B!A;6]U;G0@
M97%U86P@=&\@,C4E(&]F('1H92!R97-T<FEC=&5D('-T;V-K('5N:71S('5N
M=F5S=&5D(&%S(&]F('1H92!E9F9E8W1I=F4@=&EM92!O9B!T:&4@;65R9V5R
M('=I;&P@=F5S="!O;B!A('%U87)T97)L>2!B87-I<R!O=F5R('1H92!F;VQL
M;W=I;F<@='=E;'9E(&UO;G1H<RX\+V9O;G0^(%1H92!S:&%R97,@;V8@4G5T
M:&EG96X@8V]M;6]N('-T;V-K('5N9&5R;'EI;F<@=&AE('9E<W1E9"!R97-T
M<FEC=&5D('-T;V-K('5N:71S(&%T('1H92!E9F9E8W1I=F4@=&EM92!O9B!T
M:&4@;65R9V5R('=I;&P@8F4@9&5L:79E<F5D('1O('1H92!#14\@;VX@=&AE
M(&9I<G-T('1R861I;F<@9&%Y(&9O;&QO=VEN9R!T:&4@9FER<W0@86YN:79E
M<G-A<GD@;V8@=&AE(&5F9F5C=&EV92!T:6UE(&]F('1H92!M97)G97(L(&%N
M9"!T:&4@<VAA<F5S(&]F(%)U=&AI9V5N(&-O;6UO;B!S=&]C:R!U;F1E<FQY
M:6YG('1H92!R97-T<FEC=&5D('-T;V-K('5N:71S('1H870@=VEL;"!V97-T
M(&]N(&$@<75A<G1E<FQY(&)A<VES('1H97)E869T97(@=VEL;"!B92!D96QI
M=F5R960@;VX@=&AE(&9I<G-T('1R861I;F<@9&%Y(&9O;&QO=VEN9R!T:&4@
M,34L(#$X+"`R,2!A;F0@,C0@;6]N=&@@86YN:79E<G-A<GD@;V8@=&AE(&5F
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M5"U325I%.B`Q,'!T.TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]D:78^(#QD:78@
M<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O
M;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)
M3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^070@=&AE(&5F9F5C=&EV92!T:6UE(&]F('1H92!M97)G97(L
M(&%N>2!A;F0@86QL(&]U='-T86YD:6YG('-T;V-K(&]P=&EO;G,@86YD(')E
M<W1R:6-T960@<W1O8VL@=6YI=',@<')E=FEO=7-L>2!G<F%N=&5D('1O('1H
M92!#1D\@=VEL;"!B92!T97)M:6YA=&5D(&EN(&5X8VAA;F=E(&9O<B`H:2D@
M82!L=6UP+7-U;2!P87EM96YT(&EN('1H92!A;6]U;G0@;V8@)#,S-RPU,#`L
M(&QE<W,@=&%X97,@86YD(&]T:&5R('=I=&AH;VQD:6YG<R!A;F0@*&EI*2!A
M(&QU;7`M<W5M(&5Q=6EV86QE;G0@=&\@=&AE($-&3R8C.#(Q-SMS('!R96UI
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M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]D:78^(#QD:78@<W1Y;&4],T0G
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M97%U86P@=&\@=&AE(&QE<W-E<B!O9B`H:2D@,S4U+#`P,"!A;F0@*&EI*2!T
M:&4@<75O=&EE;G0@;V8@)#$L,#,W+#4P,"!D:79I9&5D(&)Y('1H92!F86ER
M(&UA<FME="!V86QU92!O9B!T:&4@8V]M;6]N('-T;V-K(&]F('1H92!C;VUB
M:6YE9"!C;VUP86YY(&%S(&]F('1H92!E9F9E8W1I=F4@=&EM92P@=VET:"!S
M=6-H(')E<W1R:6-T960@<W1O8VL@=6YI=',@=F5S=&EN9R!A<R!F;VQL;W=S
M.B`H:2D@82!N=6UB97(@;V8@<F5S=')I8W1E9"!S=&]C:R!U;FET<R!E<75A
M;"!T;R!T:&4@;&5S<V5R(&]F("AA*2`S-34L,#`P(&%N9"`H8BD@<W5C:"!N
M=6UB97(@;V8@<F5S=')I8W1E9"!S=&]C:R!U;FET<R!W:71H(&%N(&%G9W)E
M9V%T92!V86QU92!E<75A;"!T;R`D,C4P+#`P,"!S:&%L;"!B92!F=6QL>2!V
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M>2!F;VQL;W=I;F<@=&AE(#$U+"`Q."P@,C$@86YD(#(T(&UO;G1H(&%N;FEV
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M97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ(#!P="`P<'@[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQB
M/CQI/B8C,38P.SPO:3X\+V(^/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z
M8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@
M,3!P=#M-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/CQB/CQI/DYE=R!#;VYS=6QT:6YG($%G<F5E
M;65N=',\+VD^/"]B/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[
M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[
M5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9&EV
M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S
M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN
M.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
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M9B<[($9/3E0M4TE:13H@,3!P="<^,S0P+#`P,#PO9F]N=#X@<VAA<F5S(&]F
M(&-O;6UO;B!S=&]C:R!U<&]N(&5F9F5C=&EV96YE<W,@;V8@=&AE(&UE<F=E
M<BP@87,@82!S=6-C97-S(&9E92X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!
M4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%
M.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,
M63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4
M.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY/;B!-87)C:"`Q,"P@,C`Q-2P@=&AE
M($-O;7!A;GD@97AE8W5T960@86X@86=R965M96YT('=I=&@@86X@:6YD:79I
M9'5A;"!T;R!P<F]V:61E('!O<W0M;65R9V5R(&EN=F5S=&]R(')E;&%T:6]N
M<R!S97)V:6-E<R!F;W(@;VYE('EE87(L(&EN(&5X8VAA;F=E(&9O<B!T:&4@
M:7-S=6%N8V4@;V8@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE
M<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^,C4P+#`P
M,#PO9F]N=#X@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!U<&]N(&5F9F5C=&EV
M96YE<W,@;V8@=&AE($UE<F=E<BX\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!
M4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%
M.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,
M63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4
M.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY4:&4@0V]M<&%N>2!W:6QL(&%C8V]U
M;G0@9F]R('1H92!C;VUM;VX@<W1O8VL@=7!O;B!I<W-U86YC92!O9B!T:&4@
M<VAA<F5S+CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M
M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE.
M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX\8CX\:3XF(S$V,#L\+VD^/"]B/CPO9&EV/B`\9&EV('-T>6QE
M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&
M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\8CX\:3Y,:6-E;G-E(&%N
M9"!3=7!P;'D@06=R965M96YT/"]I/CPO8CX\+V1I=CX@/&1I=B!S='EL93TS
M1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].
M5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@
M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4
M+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M
M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I
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M8V]V97)E9"!2550U."TV,"!A;F0@86YY(&EM<')O=F5M96YT<R!T;R!I="`H
M=&AE("8C.#(R,#M0<F]D=6-T)B,X,C(Q.RD@:6X@=&AE(%5N:71E9"!3=&%T
M97,L($-A;F%D82P@=&AE($5U<F]P96%N(%5N:6]N(&%N9"!*87!A;B`H8V]L
M;&5C=&EV96QY+"!T:&4@)B,X,C(P.U1E<G)I=&]R>28C.#(R,3LI(&EN(&-E
M<G1A:6X@:6YV87-I=F4@=7-E<R!I;B!H=6UA;G,@*'1H92`F(S@R,C`[1FEE
M;&0F(S@R,C$[*2!W:&EC:"!D;R!N;W0@:6YC;'5D92!D97)M871O;&]G:6,@
M=7-E<R!O<B!U<V5S(&9O<B!O<&AT:&%L;6EC+"!S:6YU<VET:7,@;W(@;W1I
M8R!I;F1I8V%T:6]N<RX\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H
M.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T
M.TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%
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M:7-C<F5T:6]N*2P@86YD(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G
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M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]D:78^(#QD:78@<W1Y;&4],T0G
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M)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SXX/"]F;VYT/B!M:6QL:6]N(&]F
M(&UI;&5S=&]N92!P87EM96YT<R!T;R!/8W5L=7,@;W9E<B!T:&4@;F5X="!S
M979E<F%L('EE87)S(&9O<B!T:&4@9FER<W0@4')O9'5C="!O;FQY+"!A<R!F
M;VQL;W=S.B`D/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.
M97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^,2XU/"]F;VYT
M/B!M:6QL:6]N('5P;VX@=&AE(&-O;7!L971I;VX@;V8@;&%S="!P871I96YT
M(&5N<F]L;&UE;G0@:6X@=&AE(%!H87-E(#$O,B!C;&EN:6-A;"!T<FEA;"P@
M)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N
M)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/C$N-3PO9F]N=#X@;6EL;&EO
M;B!U<&]N('1H92!C;VUP;&5T:6]N(&]F(&QA<W0@<&%T:65N="!E;G)O;&QM
M96YT(&]F('1H92!#;VUP86YY)B,X,C$W.W,@9FER<W0@<&EV;W1A;"!T<FEA
M;"P@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O
M;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/C,\+V9O;G0^(&UI;&QI
M;VX@=7!O;B!C;VUP;&5T:6]N(&]F('1H92!F:7)S="!M965T:6YG('=I=&@@
M=&AE($9$02!F;VQL;W=I;F<@8V]M<&QE=&EO;B!O9B!T:&4@0V]M<&%N>28C
M.#(Q-SMS(&9I<G-T('!I=F]T86P@8VQI;FEC86P@=')I86PL(&%N9"`D/&9O
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M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z
M(#$P<'0G/C,\+V9O;G0^)2!A;F0@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P
M="<^,C`\+V9O;G0^)2!A;F0@=VEL;"!I;F-R96%S92!B87-E9"!O;B!V87)I
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M.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,
M63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4
M.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE
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M.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,
M63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4
M.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY3964@3F]T92`V("8C,34P.R!#;VUM
M:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE<R`F(S$U,#L@3V-U;'5S(%-I9&4@
M3&5T=&5R($%G<F5E;65N="!F;W(@861D:71I;VYA;"!D971A:6QS+CPO9&EV
M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S
M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\8CX\
M:3XF(S$V,#L\+VD^/"]B/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O
M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P
M<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX\8CX\:3Y3:&%R960@4V5R=FEC97,@06=R965M
M96YT/"]I/CPO8CX\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&
M3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%
M6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V1I=CX@
M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.
M97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@
M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SY4:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!S:&%R
M960@<V5R=FEC97,@86=R965M96YT('=I=&@@3V-U;'5S('=H:6-H('=A<R!E
M9F9E8W1I=F4@=7!O;B!T:&4@8V]M<&QE=&EO;B!O9B!T:&4@25!/+"!P=7)S
M=6%N="!T;R!W:&EC:"!/8W5L=7,@=VEL;"!P<F]V:61E(%)U=&AI9V5N('=I
M=&@@9V5N97)A;"!S97)V:6-E<RP@:6YC;'5D:6YG(&=E;F5R86P@86-C;W5N
M=&EN9R!A;F0@:'5M86X@<F5S;W5R8V5S+"!U;G1I;"!T:&4@=&5R;6EN871I
M;VX@;V8@86=R965M96YT+B!!9&1I=&EO;F%L;'DL($]C=6QU<R!W:6QL('!E
M<FUI="!T:&4@0V]M<&%N>2!T;R!A8V-E<W,@:71S(%!E=&%L=6UA+"!#86QI
M9F]R;FEA(&%N9"!396%T=&QE+"!787-H:6YG=&]N(&9A8VEL:71I97,@9'5R
M:6YG(&YO<FUA;"!B=7-I;F5S<R!H;W5R<R`H<W5B:F5C="!T;R!C97)T86EN
M(&5X8V5P=&EO;G,I(&%N9"!F;W(@=&AE('!U<G!O<V5S(&1E<V-R:6)E9"!I
M;B!T:&4@<VAA<F5D('-E<G9I8V5S(&%G<F5E;65N="X\+V1I=CX@/&1I=B!S
M='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M
M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE.
M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H
M.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T
M.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q
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M+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M
M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V1I=CX@/&1I
M=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@
M4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%2
M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SY/;B!-87)C:"`U+"`R,#$U+"!T:&4@0V]M<&%N>2!R96-E
M:79E9"!A('=R:71T96X@;F]T:6-E(&9R;VT@3V-U;'5S(&]F('1E<FUI;F%T
M:6]N(&]F('1H92!S:&%R960@<V5R=FEC97,@86=R965M96YT+"!E9F9E8W1I
M=F4@;VX@07!R:6P@-BP@,C`Q-2X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!
M4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%
M.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,
M63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4
M.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY3964@3F]T92`V("8C,34P.R!#;VUM
M:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE<R`F(S$U,#L@3V-U;'5S(%-I9&4@
M3&5T=&5R($%G<F5E;65N="!F;W(@861D:71I;VYA;"!D971A:6QS+CPO9&EV
M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S
M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\8CX\
M:3XF(S$V,#L\+VD^/"]B/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O
M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P
M<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX\8CX\:3Y397!A<F%T:6]N($%G<F5E;65N=#PO
M:3X\+V(^/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&
M04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.
M1$5.5#H@,"XU:6X[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]D:78^(#QD:78@
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M57`@4&5R:6]D)B,X,C(Q.RD@:6UM961I871E;'D@9F]L;&]W:6YG('1H92!)
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M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]D:78^(#QD:78@<W1Y;&4]
M,T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/
M3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,'!T
M(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^1F]L;&]W:6YG('1H92!,;V-K+55P(%!E<FEO9"P@=')A;G-F97)S(&)Y
M($]C=6QU<R!O9B!T:&4@4G5T:&EG96X@<VAA<F5S(&ET(&]W;G,@;75S="!B
M92!C;VYD=6-T960@=VET:"!T:&4@8V]N<V5N="!O9B!T:&4@8F]A<F0@;V8@
M9&ER96-T;W)S(&]R('=I=&AI;B!T:&4@<')E<V-R:6)E9"!R97%U:7)E;65N
M=',@9F]R('-U8V@@=')A;G-F97)S('-E="!F;W)T:"!I;B!T:&4@<V5P87)A
M=&EO;B!A9W)E96UE;G0N(%1H97-E('!R97-C<FEB960@<F5Q=6ER96UE;G1S
M(&EN8VQU9&4@=&AA="!T:&4@=')A;G-F97)S(&UU<W0@8F4@:6X@<')I=F%T
M92!P;&%C96UE;G0@=')A;G-A8W1I;VYS+"!T:&4@<'5R8VAA<V4@<')I8V4@
M9&ES8V]U;G0@;6%Y(&YO="!E>&-E960@8V5R=&%I;B!P97)C96YT86=E<R!D
M97!E;F1I;F<@;VX@=&AE('1R86YS9F5R964L('1H92!A;6]U;G0@;V8@<VAA
M<F5S('1R86YS9F5R<F5D(&EN(&$@9VEV96X@=')A;G-F97(@*&]R('-E<FEE
M<R!O9B!T<F%N<V9E<G,@8V]M<')I<VEN9R!A('-I;F=L92!T<F%N<V%C=&EO
M;BD@;6%Y(&YO="!E>&-E960@=&AE(&=R96%T97(@;V8@/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/
M3E0M4TE:13H@,3!P="<^-3PO9F]N=#XE(&]F('1H92!#;VUP86YY)B,X,C$W
M.W,@;W5T<W1A;F1I;F<@<VAA<F5S(&]R("0\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%
M.B`Q,'!T)SXQ+#4P,"PP,#`\+V9O;G0^(&EN(&YE="!P<F]C965D<R!T;R!/
M8W5L=7,L(&%S('=E;&P@87,@8V5R=&%I;B!O=&AE<B!R97%U:7)E;65N=',@
M<V5T(&9O<G1H(&EN('1H92!S97!A<F%T:6]N(&%G<F5E;65N="X@26X@861D
M:71I;VX@=&\@=&AE(&UA;FYE<B!D97-C<FEB960@86)O=F4L(&EF+"!F;VQL
M;W=I;F<@82!M:6YI;75M(&]F(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G
M/C0Q+C4\+V9O;G0^(&UO;G1H<R!F;VQL;W=I;F<@=&AE(&-L;W-I;F<@;V8@
M=&AE($E03R!H879E(&QA<'-E9"!A;F0@3V-U;'5S(&AA<R!N;W0@8V]N<W5M
M;6%T960@=')A;G-F97)S(&]F('1H92!2=71H:6=E;B!S:&%R97,@:70@;W=N
M<R!R97-U;'1I;F<@:6X@870@;&5A<W0@)#QF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z
M(#$P<'0G/C,N.#PO9F]N=#X@;6EL;&EO;B!I;B!N970@<')O8V5E9',@=&\@
M3V-U;'5S+"!T:&5N($]C=6QU<R!H87,@82!O;F4M=&EM92!T<F%N<V9E<B!A
M;F0@<F5G:7-T<F%T:6]N(')I9VAT('1O('1R86YS9F5R('1H92!2=71H:6=E
M;B!S:&%R97,@:70@;W=N<R!I;B!A;B!A;6]U;G0@97%U86P@=&\@=&AE(&1I
M9F9E<F5N8V4@8F5T=V5E;B`D,RXX(&UI;&QI;VX@86YD('1H92!P<F]C965D
M<R!R96-E:79E9"!B>2!/8W5L=7,@9G)O;2!P<FEO<B!T<F%N<V9E<G,@87,@
M;V8@=&AE('1I;64@3V-U;'5S(&5L96-T<R!T;R!E>&5R8VES92!I=',@;VYE
M+71I;64@<FEG:'0N(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM
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M,"PP,#`@:6X@;F5T('!R;V-E961S('1O($]C=6QU<RP@87,@=V5L;"!A<R!C
M97)T86EN(&]T:&5R(')E<75I<F5M96YT<R!S970@9F]R=&@@:6X@=&AE('-E
M<&%R871I;VX@86=R965M96YT+B!4:&4@<V5P87)A=&EO;B!A9W)E96UE;G0@
M<')O=FED97,@3V-U;'5S('=I=&@@8V5R=&%I;B`F(S@R,C`[<&EG9WD@8F%C
M:R8C.#(R,3L@<F5G:7-T<F%T:6]N(')I9VAT<R!O9B!U<"!T;R`S,"4\+V9O
M;G0^(&]F('1H92!V86QU92!O9B!T:&4@<V5C=7)I=&EE<R!T:&4@0V]M<&%N
M>2!R96=I<W1E<G,@869T97(@=&AE(&QO8VLM=7`@<&5R:6]D+"!I9B!T:&4@
M0V]M<&%N>2!P<F]P;W-E<R!T;R!R96=I<W1E<B!A;GD@;V8@:71S(&-O;6UO
M;B!S=&]C:R!F;VQL;W=I;F<@=&AE(&-O;7!L971I;VX@;V8@=&AE($E03RP@
M<W5B:F5C="!T;R!C97)T86EN(&-O;F1I=&EO;G,@86YD(&QI;6ET871I;VYS
M+CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9
M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z
M(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9&EV/B`\9&EV('-T>6QE
M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&
M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P
M="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
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M=VX@;&5S<R!T:&%N(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM
M97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/B`Q.2XY
M/"]F;VYT/B4@;V8@=&AE(&]U='-T86YD:6YG('-H87)E<R!O9B!T:&4@0V]M
M<&%N>28C.#(Q-SMS(&-O;6UO;B!S=&]C:RX\+V1I=CX@/&1I=B!S='EL93TS
M1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].
M5"U325I%.B`Q,'!T.TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]D:78^(#QD:78@
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M($E03RX@1'5R:6YG('1H92!Y96%R(&5N9&5D($UA<F-H(#,Q+"`R,#$T+"!T
M:&4@0V]M<&%N>2!I;F-U<G)E9"`D/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P
M="<^,2PT-3`L,#`P/"]F;VYT/B!O9B!)4$\@86YD(&]T:&5R(&-O<W1S('=H
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M+"!397)I9B<^)B,Q-C`[/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T
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M.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,
M63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4
M.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY3964@3F]T92`V("8C,34P.R!#;VUM
M:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE<R`F(S$U,#L@3V-U;'5S(%-I9&4@
M3&5T=&5R($%G<F5E;65N="!F;W(@861D:71I;VYA;"!D971A:6QS+CPO9&EV
M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S
M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\8CX\
M:3XF(S$V,#L\+VD^/"]B/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O
M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P
M<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX\8CX\:3Y&=6YD:6YG($%G<F5E;65N=#PO:3X\
M+V(^/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)
M3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.
M5#H@,"XU:6X[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]D:78^(#QD:78@<W1Y
M;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N
M.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@
M,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^3VX@2F%N=6%R>2`S,2P@,C`Q-"P@=&AE($-O;7!A;GD@96YT97)E
M9"!I;G1O(&$@9G5N9&EN9R!A9W)E96UE;G0@=VET:"!/8W5L=7,L('!U<G-U
M86YT('1O('=H:6-H($]C=6QU<R!A9W)E960@=&\@9G5N9"!T:&4@0V]M<&%N
M>2!I;B!T:&4@861D:71I;VYA;"!A;6]U;G0@;V8@=7`@=&\@)#QF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G
M.R!&3TY4+5-)6D4Z(#$P<'0G/C<V,"PP,#`\+V9O;G0^('1O('!A>2!C97)T
M86EN(&%C8V]U;G1S('!A>6%B;&5S(&]U='-T86YD:6YG(&%T($1E8V5M8F5R
M(#,Q+"`R,#$S(&%N9"!T;R!F=6YD(&-E<G1A:6X@9G5T=7)E(&5X<&5N9&ET
M=7)E<R!T:')O=6=H('1H92!C;&]S:6YG(&]F('1H92!)4$\N(%1H<F]U9V@@
M=&AE(&-L;W-I;F<@;V8@=&AE($E03RP@3V-U;'5S(&9U;F1E9"!T:&4@0V]M
M<&%N>2!I;B!T:&4@861D:71I;VYA;"!A;6]U;G0@;V8@)#QF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&
M3TY4+5-)6D4Z(#$P<'0G/C4S-"PP,#`\+V9O;G0^+"!W:&EC:"!W87,@<F5P
M86ED('1O($]C=6QU<R!O;B!!<')I;"`Q+"`R,#$T+CPO9&EV/B`\9&EV('-T
M>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA
M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\8CX\:3XF(S$V,#L\
M+VD^/"]B/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M
M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE.
M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX\8CX\:3Y/8W5L=7,@4VED92!,971T97(@06=R965M96YT/"]I
M/CPO8CX\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!
M34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$
M14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V1I=CX@/&1I=B!S
M='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M
M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE.
M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
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M>2!O9B!T:&4@<')O<&]S960@<'5R8VAA<V5R+CPO9&EV/B`\9&EV('-T>6QE
M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&
M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P
M="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58
M5"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@
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M34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q
M,'!T)SXU+#`P,#PO9F]N=#X@9'5E(&%N9"!P87EA8FQE(&]N('1H92!E9F9E
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M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]D:78^(#QD:78@<W1Y
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M>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G
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M25I%.B`Q,'!T)SXQ,"XP/"]F;VYT/B!M:6QL:6]N+"!2=71H:6=E;B!W:6QL
M(&)E(&]B;&EG871E9"!T;R!P87D@=&5N('!E<F-E;G0@*#QF;VYT('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&
M3TY4+5-)6D4Z(#$P<'0G/C$P/"]F;VYT/B4I(&]F('1H92!A9V=R96=A=&4@
M9W)O<W,@<')O8V5E9',@=&\@3V-U;'5S('=I=&AI;B!T96X@*#$P*2!C86QE
M;F1A<B!D87ES+CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58
M5"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9&EV/B`\
M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE
M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-
M05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/DEN(&%D9&ET:6]N+"!T:&4@3V-U;'5S(%-I9&4@3&5T
M=&5R($%G<F5E;65N="!P<F]V:61E<R!T:&%T+"!A<R!O9B!T:&4@969F96-T
M:79E(&1A=&4@;V8@=&AE(&UE<F=E<BP@8V5R=&%I;B!P<F]V:7-I;VYS(&EN
M('1H92!S97!A<F%T:6]N(&%G<F5E;65N="!R96=A<F1I;F<@;6%R:V5T:6YG
M(&%N9"!S=&]C:R!T<F%N<V9E<B!R97-T<FEC=&EO;G,L(&QO8VLM=7`L(')E
M9VES=')A=&EO;B!R:6=H=',L('9O=&EN9RP@;6%N86=E;65N="P@8V]M<&5N
M<V%T:6]N(&%N9"!E<75I='D@:6YC96YT:79E('!L86XL('=I;&P@8F4@=&5R
M;6EN871E9"X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4
M+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M
M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V1I=CX@/&1I
M=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@
M4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%2
M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SY4:&4@3V-U;'5S(%-I9&4@3&5T=&5R($%G<F5E;65N="!I
M<R!C;VYD:71I;VYE9"!U<&]N('1H92!R96-E:7!T(&]F('!A>6UE;G0@8GD@
M3V-U;'5S(&9O<B!/8W5L=7,F(S@R,3<[<R!S:&%R97,@;V8@4G5T:&EG96X@
M8V]M;6]N('-T;V-K('-O;&0@:6X@8V5R=&%I;B!S<&5C:69I960@=')A;G-A
M8W1I;VYS+CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M
M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE.
M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX\8CXF(S$V,#L\+V(^/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%
M05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:
M13H@,3!P=#M-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQB/CQI/D]P97)A=&EN9R!,96%S93PO
M:3X\+V(^/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&
M04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.
M1$5.5#H@,"XU:6X[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]D:78^(#QD:78@
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M97)A=&EN9R!L96%S92!F;W(@87!P<F]X:6UA=&5L>2`\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].
M5"U325I%.B`Q,'!T)SX@.3DU/"]F;VYT/B!S<75A<F4@9F5E="!O9B!E>&5C
M=71I=F4@;V9F:6-E('-P86-E+B!/;B!&96)R=6%R>2`Q,2P@,C`Q-2P@=&AE
M($-O;7!A;GD@86YD('1H92!L86YD;&]R9"!A9W)E960@=&\@86UE;F0@=&AE
M(&QE87-E('-U8V@@=&AA="!T:&4@;&5A<V4@;F]W(&5X<&ER97,@;VX@2G5N
M92`S,"P@,C`Q-2!A;F0@=&AE(&UO;G1H;'D@8F%S92!R96YT(&ES(&%P<')O
M>&EM871E;'D@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@
M3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/C$L-S`P/"]F
M;VYT/BX@5&AE(&%G9W)E9V%T92!B87-E(')E;G0@<&%Y86)L92!O=F5R('1H
M92!L96%S92!T97)M(&ES(&)E:6YG(')E8V]G;FEZ960@;VX@82!S=')A:6=H
M="UL:6YE(&)A<VES+B!296YT(&5X<&5N<V4@<F5L871E9"!T;R!T:&4@;&5A
M<V4@86UO=6YT960@=&\@87!P<F]X:6UA=&5L>2`D/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M
M4TE:13H@,3!P="<^,C`L,#`P/"]F;VYT/B!A;F0@)#QF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4
M+5-)6D4Z(#$P<'0G/C(P+#`P,#PO9F]N=#X@9F]R('1H92!Y96%R<R!E;F1E
M9"!-87)C:"`S,2P@,C`Q-2!A;F0@,C`Q-"P@<F5S<&5C=&EV96QY+B!296YT
M(&5X<&5N<V4@:7,@<F5F;&5C=&5D(&EN('-E;&QI;F<L(&=E;F5R86P@86YD
M(&%D;6EN:7-T<F%T:79E(&5X<&5N<V5S(&EN('1H92!C;VYS;VQI9&%T960@
M<W1A=&5M96YT<R!O9B!O<&5R871I;VYS+B!&=71U<F4@;6EN:6UU;2!R96YT
M86QS('1H<F]U9V@@=&AE(&QE87-E(&5X<&ER871I;VX@9&%T92!O9B!*=6YE
M(#,P+"`R,#$U(&%R92`D/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4
M:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^-2PP
M-S4\+V9O;G0^+CPO9&EV/B`\+V1I=CX\=&%B;&4@8F]R9&5R/3-$,"!S='EL
M93TS1"=W:61T:#HQ,#`E.R!T86)L92UL87EO=70Z9FEX960[)R!C96QL<W!A
M8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<CX\=&0^/"]T9#X\+W1R/CPO
M=&%B;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
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M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-T;V-K:&]L9&5R<R<@
M17%U:71Y/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N
M(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/E-T;V-K:&]L9&5R<R<@17%U:71Y($YO=&4@6T%B<W1R86-T
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M=&]C:VAO;&1E<G,G($5Q=6ET>2!.;W1E($1I<V-L;W-U<F4@6U1E>'0@0FQO
M8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE
M/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B`G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[
M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[
M34%21TE..B`P<'0@,'!X.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B!.;W1E(#<N(%-T;V-K:&]L9&5R<R8C.#(Q
M-SL@17%U:71Y/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].
M5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'
M24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B`\<W1R;VYG/CQI/B8C,38P.SPO:3X\+W-T<F]N9SX\+V1I
M=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE
M<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,'!T(#!P>#L@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^(#QS
M=')O;F<^/&D^4F5V97)S92!3=&]C:R!3<&QI=#PO:3X\+W-T<F]N9SX\+V1I
M=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE
M<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I
M;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX@)B,Q-C`[/"]D:78^(#QD:78@<W1Y;&4],T0G
M0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M
M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,'!T(#!P
M>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M($]N(%-E<'1E;6)E<B`R-2P@,C`Q,RP@=&AE(&)O87)D(&]F(&1I<F5C=&]R
M<R!A;F0@=&AE('-T;V-K:&]L9&5R<R!O9B!T:&4@0V]M<&%N>2!A<'!R;W9E
M9"!A(#$M9F]R+3(N-2!R979E<G-E('-T;V-K('-P;&ET(&]F('1H92!#;VUP
M86YY)B,X,C$W.W,@;W5T<W1A;F1I;F<@8V]M;6]N('-T;V-K+"`D/&9O;G0@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I
M9B<[($9/3E0M4TE:13H@,3!P="<^,"XP,#`Q/"]F;VYT/B!P87(@=F%L=64L
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M(&]F('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@;W5T<W1A;F1I;F<@9G)O;2`\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L
M)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX@-2PP,#`L,#`P/"]F;VYT/B!T
M;R`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA
M;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX@,BPP,#`L,#`P/"]F;VYT
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M;65S+"!397)I9B<^("8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2
M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z
M(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B!!;&P@
M8V]M;6]N('-H87)E<R!A;F0@<&5R('-H87)E(&%M;W5N=',@8V]N=&%I;F5D
M(&EN('1H92!#;VUP86YY)B,X,C$W.W,@86-C;VUP86YY:6YG(&9I;F%N8VEA
M;"!S=&%T96UE;G1S(&AA=F4@8F5E;B!R971R;V%C=&EV96QY(&%D:G5S=&5D
M('1O(')E9FQE8W0@82`Q+69O<BTR+C4@<F5V97)S92!S=&]C:R!S<&QI="P@
M969F96-T:79E(&%S(&]F(%-E<'1E;6)E<B`R-2P@,C`Q,RX\+V1I=CX@/&1I
M=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@
M4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^(#QS=')O;F<^
M/&D^)B,Q-C`[/"]I/CPO<W1R;VYG/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)
M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE
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M,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-
M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%
M3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B!4:&4@0V]M<&%N>2!I<R!A=71H
M;W)I>F5D('1O(&ES<W5E('5P('1O(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P
M<'0G/B`Q,#`L,#`P+#`P,#PO9F]N=#X@<VAA<F5S(&]F(&-O;6UO;B!S=&]C
M:R!W:71H(&$@<&%R('9A;'5E(&]F("0\9F]N="!S='EL93TS1"=&3TY4+49!
M34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q
M,'!T)SXP+C`P,#$\+V9O;G0^('!E<B!S:&%R92!A;F0@/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/
M3E0M4TE:13H@,3!P="<^(#4P,"PP,#`\+V9O;G0^('-H87)E<R!O9B!P<F5F
M97)R960@<W1O8VL@=VET:"!A('!A<B!V86QU92!O9B`D/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/
M3E0M4TE:13H@,3!P="<^,"XP,#`Q/"]F;VYT/B!P97(@<VAA<F4N/"]D:78^
M(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@
M3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ(#!P="`P<'@[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`\<W1R
M;VYG/CQI/B8C,38P.SPO:3X\+W-T<F]N9SX\+V1I=CX@/&1I=B!S='EL93TS
M1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].
M5"U325I%.B`Q,'!T.TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^(#QS=')O;F<^/&D^1&5S8W)I
M<'1I;VX@;V8@0V]M;6]N(%-T;V-K/"]I/CPO<W1R;VYG/CPO9&EV/B`\9&EV
M('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2
M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'
M24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B`F(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB
M;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q
M,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@16%C:"!S
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M:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,'!T(#!P
M>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M(#QS=')O;F<^/&D^)B,Q-C`[/"]I/CPO<W1R;VYG/CPO9&EV/B`\9&EV('-T
M>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA
M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T
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M,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-
M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%
M3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B!);B!397!T96UB97(@86YD($]C
M=&]B97(@,C`Q,RP@<F5S<&5C=&EV96QY+"!T:&4@0V]M<&%N>28C.#(Q-SMS
M(&)O87)D(&]F(&1I<F5C=&]R<R!A;F0@<W1O8VMH;VQD97)S(&%P<')O=F5D
M('1H92`R,#$S($5M<&QO>65E+"!$:7)E8W1O<B!A;F0@0V]N<W5L=&%N="!%
M<75I='D@26YC96YT:79E(%!L86X@*'1H92`F(S@R,C`[,C`Q,R!0;&%N)B,X
M,C(Q.RDL('=H:6-H(&)E8V%M92!E9F9E8W1I=F4@=7!O;B!T:&4@8VQO<VEN
M9R!O9B!T:&4@25!/+B!4:&4@,C`Q,R!0;&%N('=I;&P@97AP:7)E(&]N(%-E
M<'1E;6)E<B`S,"P@,C`R,RX@56YD97(@=&AE(#(P,3,@4&QA;BP@=&AE($-O
M;7!A;GD@;6%Y(&=R86YT(&EN8V5N=&EV92!S=&]C:R!O<'1I;VYS+"!N;VXM
M<75A;&EF:65D('-T;V-K(&]P=&EO;G,L(')E<W1R:6-T960@86YD('5N<F5S
M=')I8W1E9"!S=&]C:R!A=V%R9',@86YD(&]T:&5R('-T;V-K+6)A<V5D(&%W
M87)D<RX@5&AE<F4@87)E(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G
M5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/B`Y
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M3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%
M6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)B,Q-C`[/"]D:78^
M(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@
M3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,"XU:6X[
M($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^($EN(&%D9&ET:6]N+"!T:&4@,C`Q,R!0;&%N(&-O
M;G1A:6YS(&%N("8C.#(R,#ME=F5R9W)E96XF(S@R,C$[('!R;W9I<VEO;BP@
M=VAI8V@@86QL;W=S(&9O<B!A;B!A;FYU86P@:6YC<F5A<V4@:6X@=&AE(&YU
M;6)E<B!O9B!S:&%R97,@;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!C;VUM;VX@
M<W1O8VL@879A:6QA8FQE(&9O<B!I<W-U86YC92!U;F1E<B!T:&4@,C`Q,R!0
M;&%N(&]N('1H92!F:7)S="!D87D@;V8@96%C:"!C86QE;F1A<B!Y96%R(&)E
M9VEN;FEN9R!W:71H(&-A;&5N9&%R('EE87(@,C`Q-2X@5&AE(&%N;G5A;"!I
M;F-R96%S92!I;B!T:&4@;G5M8F5R(&]F('-H87)E<R!S:&%L;"!B92!E<75A
M;"!T;R!T:&4@;&]W97-T(&]F.B`H82D@,C,R+#4P,"!S:&%R97,@;V8@=&AE
M($-O;7!A;GDF(S@R,3<[<R!C;VUM;VX@<W1O8VL[("AB*2`U)2!O9B!T:&4@
M;G5M8F5R(&]F('-H87)E<R!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&-O;6UO
M;B!S=&]C:R!O=71S=&%N9&EN9R!A<R!O9B!S=6-H(&1A=&4[(&%N9"`H8RD@
M86X@86UO=6YT(&1E=&5R;6EN960@8GD@=&AE($-O;7!A;GDF(S@R,3<[<R!B
M;V%R9"!O9B!D:7)E8W1O<G,@;W(@8V]M<&5N<V%T:6]N(&-O;6UI='1E92X\
M+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4
M:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P
M+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX@)B,Q-C`[/"]D:78^(#QD:78@<W1Y;&4]
M,T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/
M3E0M4TE:13H@,3!P=#M-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`\<W1R;VYG/CQI/DYE=R`R
M,#$S(%!L86X\+VD^/"]S=')O;F<^/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%
M05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:
M13H@,3!P=#M415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,'!T(#!P>#L@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("8C
M,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-
M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%
M3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B!/;B!-87)C:"`Q,BP@,C`Q-2P@
M:6X@8V]N;F5C=&EO;B!W:71H('1H92!-97)G97(@06=R965M96YT+"!2=71H
M:6=E;B8C.#(Q-SMS(&-O;7!E;G-A=&EO;B!C;VUM:71T964@86YD(%)U=&AI
M9V5N)B,X,C$W.W,@8F]A<F0@;V8@9&ER96-T;W)S('5N86YI;6]U<VQY(&%P
M<')O=F5D('1H92!2=71H:6=E;BP@26YC+B!!;65N9&5D(&%N9"!297-T871E
M9"`R,#$S($5M<&QO>65E+"!$:7)E8W1O<B!A;F0@0V]N<W5L=&%N="!%<75I
M='D@26YC96YT:79E(%!L86X@*'1H92`F(S@R,C`[3F5W(#(P,3,@4&QA;B8C
M.#(R,3LI+"!S=6)J96-T('1O('1H92!A<'!R;W9A;"!O9B!2=71H:6=E;B8C
M.#(Q-SMS('-T;V-K:&]L9&5R<RX@5&AE($YE=R`R,#$S(%!L86X@=VEL;"!A
M;&QO=R!F;W(@=&AE(&ES<W5A;F-E(&]F('5P('1O(#QF;VYT('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4
M+5-)6D4Z(#$P<'0G/B`V+#@U,RPS,3D\+V9O;G0^('-H87)E<R!O9B!2=71H
M:6=E;B8C.#(Q-SMS(&-O;6UO;B!S=&]C:RP@=7`@9G)O;2`\9F]N="!S='EL
M93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@
M1D].5"U325I%.B`Q,'!T)SX@,2PR,S`L.#4U/"]F;VYT/B!S:&%R97,L('!U
M<G-U86YT('1O(&%W87)D<R!T;R!B92!G<F%N=&5D('5N9&5R('1H92!.97<@
M,C`Q,R!0;&%N+B!);B!A9&1I=&EO;BP@=&AE($YE=R`R,#$S(%!L86X@8V]N
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M8V%L96YD87(@>65A<B`R,#$V+B!4:&4@86YN=6%L(&EN8W)E87-E(&EN('1H
M92!N=6UB97(@;V8@<VAA<F5S('-H86QL(&)E(&5Q=6%L('1O('1H92!L;W=E
M<W0@;V8Z("AI*2`R+#4U,2PU,#`@<VAA<F5S(&]F(%)U=&AI9V5N)B,X,C$W
M.W,@8V]M;6]N('-T;V-K.R`H:6DI(&9I=F4@<&5R8V5N="`H-24I(&]F('1H
M92!N=6UB97(@;V8@<VAA<F5S(&]F(%)U=&AI9V5N)B,X,C$W.W,@8V]M;6]N
M('-T;V-K(&]U='-T86YD:6YG(&%S(&]F('-U8V@@9&%T93L@86YD("AI:6DI
M(&%N(&%M;W5N="!D971E<FUI;F5D(&)Y(%)U=&AI9V5N)B,X,C$W.W,@8F]A
M<F0@;V8@9&ER96-T;W)S+CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O
M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P
M<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX@/'-T<F]N9SX\:3XF(S$V,#L\+VD^/"]S=')O
M;F<^/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)
M3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ(#!P
M="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B`\<W1R;VYG/CQI/DEN:71I86P@4'5B;&EC($]F9F5R:6YG/"]I/CPO
M<W1R;VYG/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M
M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)
M3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F(S$V,#L\+V1I=CX@/&1I
M=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@
M4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%2
M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX@3VX@36%R8V@@,C$L(#(P,30L('1H92!#;VUP86YY(&%N
M;F]U;F-E9"!T:&%T(&ET(&AA9"!P<FEC960@:71S($E03R!O9B`\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF
M)SL@1D].5"U325I%.B`Q,'!T)SX@,BPV-3`L,#`P/"]F;VYT/B!U;FET<R`H
M=&AE("8C.#(R,#M)4$\F(S@R,C$[*2P@=VET:"!E86-H('5N:70@8V]N<VES
M=&EN9R!O9B`H:2D@;VYE('-H87)E(&]F(&-O;6UO;B!S=&]C:R!A;F0@*&EI
M*2!O;F4@4V5R:65S($$@=V%R<F%N="`H=&AE("8C.#(R,#M397)I97,@02!7
M87)R86YT)B,X,C(Q.RDL(&%T(&%N($E03R!P<FEC92!O9B`D/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[
M($9/3E0M4TE:13H@,3!P="<^-RXR-3PO9F]N=#X@<&5R('5N:70@*&5A8V@@
M82`F(S@R,C`[56YI="8C.#(R,3LI+"!L97-S('5N9&5R=W)I=&EN9R!D:7-C
M;W5N=',@86YD(&-O;6UI<W-I;VYS(&%N9"!)4$\@97AP96YS97,N($EN(&%D
M9&ET:6]N+"!T:&4@0V]M<&%N>2!G<F%N=&5D('1O('1H92!U;F1E<G=R:71E
M<G,@82`T-2UD87D@;W!T:6]N("AT:&4@)B,X,C(P.T]V97(M06QL;W1M96YT
M($]P=&EO;B8C.#(R,3LI('1O('!U<F-H87-E('5P('1O("AI*2`\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF
M)SL@1D].5"U325I%.B`Q,'!T)SX@,SDW+#4P,#PO9F]N=#X@861D:71I;VYA
M;"!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&%T('!R:6-E(&]F("0\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF
M)SL@1D].5"U325I%.B`Q,'!T)SXV+C8V,#@\+V9O;G0^('!E<B!S:&%R92P@
M=VAI8V@@<')I8V4@<F5F;&5C=',@=6YD97)W<FET:6YG(&1I<V-O=6YT<R!A
M;F0@8V]M;6ES<VEO;G,L(&%N9"]O<B`H:6DI(#QF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)
M6D4Z(#$P<'0G/B`S.3<L-3`P/"]F;VYT/B!A9&1I=&EO;F%L(%-E<FEE<R!!
M(%=A<G)A;G1S(&%T(&$@<')I8V4@;V8@)#QF;VYT('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z
M(#$P<'0G/C`N,#`Y,CPO9F]N=#X@<&5R(%-E<FEE<R!!(%=A<G)A;G0L('=H
M:6-H('!R:6-E(')E9FQE8W1S('5N9&5R=W)I=&EN9R!D:7-C;W5N=',@86YD
M(&-O;6UI<W-I;VYS+CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[
M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[
M5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F(S$V,#L\+V1I
M=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE
M<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I
M;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX@3VX@36%R8V@@,C8L(#(P,30L('1H92!#;VUP
M86YY(&-L;W-E9"!O;B!T:&4@<V%L92!O9B`\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%
M.B`Q,'!T)SX@,BPV-3`L,#`P/"]F;VYT/B!5;FET<R!A;F0@=&AE('5N9&5R
M=W)I=&5R<R!E>&5R8VES960@82!P;W)T:6]N(&]F('1H92!/=F5R+4%L;&]T
M;65N="!/<'1I;VX@8GD@<'5R8VAA<VEN9R!397)I97,@02!787)R86YT<R!F
M<F]M('1H92!#;VUP86YY('1O('!U<F-H87-E(#QF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)
M6D4Z(#$P<'0G/B`S.3<L-3`P/"]F;VYT/B!S:&%R97,@;V8@8V]M;6]N('-T
M;V-K(&9O<B!N;VUI;F%L('9A;'5E+"!A;&P@;V8@=VAI8V@@<F5S=6QT960@
M:6X@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O
M;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/C$V+#`R,2PP,#`\+V9O
M;G0^(&]F(&%G9W)E9V%T92!N970@<')O8V5E9',@=&\@=&AE($-O;7!A;GD@
M*"0\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA
M;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SXQ.2PR,38L,#`P/"]F;VYT
M/B!O9B!G<F]S<R!P<F]C965D<R!L97-S("0\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%
M.B`Q,'!T)SXS+#$Y-2PP,#`\+V9O;G0^(&]F(&ES<W5A;F-E(&-O<W1S*2X@
M07,@82!R97-U;'0L(&%N(&%G9W)E9V%T92!O9B`\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U3
M25I%.B`Q,'!T)SX@,BPV-3`L,#`P/"]F;VYT/B!S:&%R97,@;V8@8V]M;6]N
M('-T;V-K(&%N9"!397)I97,@02!787)R86YT<R!T;R!P=7)C:&%S92!A;B!A
M9V=R96=A=&4@;V8@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE
M<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^(#,L,#0W
M+#4P,#PO9F]N=#X@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!W97)E(&ES<W5E
M9"!I;B!T:&4@25!/+CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[
M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[
M5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F(S$V,#L\+V1I
M=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE
M<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I
M;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX@5&AE(%-E<FEE<R!!(%=A<G)A;G0@:7,@97AE
M<F-I<V%B;&4@870@82!P<FEC92!O9B`D/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@
M,3!P="<^-RXR-3PO9F]N=#X@<&5R('=A<G)A;G0@9F]R("AX*2!O;F4@<VAA
M<F4@;V8@8V]M;6]N('-T;V-K(&%N9"`H>2D@;VYE(%-E<FEE<R!"('=A<G)A
M;G0@*'1H92`F(S@R,C`[4V5R:65S($(@5V%R<F%N="8C.#(R,3LI('1O('!U
M<F-H87-E(&]N92!S:&%R92!O9B!C;VUM;VX@<W1O8VL@870@86X@97AE<F-I
M<V4@<')I8V4@;V8@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM
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M(&%T(&$@<')I8V4@8F5L;W<@8F]T:"`H82D@=&AE(&-U<G)E;G0@97AE<F-I
M<V4@<')I8V4@;V8@=&AE(%-E<FEE<R!!(%=A<G)A;G0[(&%N9"`H8BD@=&AE
M(&-U<G)E;G0@;6%R:V5T('!R:6-E(&]F('1H92!#;VUP86YY)B,X,C$W.W,@
M8V]M;6]N('-T;V-K+B!4:&4@4V5R:65S($$@5V%R<F%N=',@;6%Y(&)E(&-A
M;&QE9"!B>2!T:&4@0V]M<&%N>2P@9F]R(&-O;G-I9&5R871I;VX@97%U86P@
M=&\@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O
M;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/C`N,#`P,3PO9F]N=#X@
M<&5R(%-E<FEE<R!!(%=A<G)A;G0L(&]N(&YO="!L97-S('1H86X@,3`@8G5S
M:6YE<W,@9&%Y<R8C.#(Q-SL@;F]T:6-E(&EF('1H92!C;&]S:6YG('!R:6-E
M(&]F('1H92!C;VUM;VX@<W1O8VL@:7,@86)O=F4@/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M
M4TE:13H@,3!P="<^(#$U,#PO9F]N=#XE(&]F('1H92`D/&9O;G0@<W1Y;&4]
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M;F1I;F<@9FEN86YC:6%L(&EN<W1R=6UE;G1S.R`H8BD@:6YD97AE9"!T;R!T
M:&4@0V]M<&%N>28C.#(Q-SMS(&]W;B!S=&]C:SL@*&,I(&YO="!P97)M:71T
M960@=&\@8F4@<V5T=&QE9"!F;W(@8V%S:#L@86YD("AD*2!E>&5R8VES86)L
M92!I;G1O(&-O;6UO;B!S=&]C:R!F;W(@=VAI8V@@=&AE($-O;7!A;GD@:&%S
M('-U9F9I8VEE;G0@875T:&]R:7IE9"!A;F0@=6YI<W-U960@<VAA<F5S+CPO
M9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I
M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N
M-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B`F(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS
M1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].
M5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@
M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX@5&AE($-O;7!A;GD@:7-S=65D('1O('1H92!R97!R97-E;G1A=&EV92!O
M9B!T:&4@=6YD97)W<FET97)S('=A<G)A;G1S('1O('!U<F-H87-E(#QF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R
M:68G.R!&3TY4+5-)6D4Z(#$P<'0G/B`Y,BPW-3`\+V9O;G0^('-H87)E<R!O
M9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!A="!A;B!E>&5R
M8VES92!P<FEC92!O9B`D/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4
M:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^.2XP
M-C(U/"]F;VYT/B!P97(@<VAA<F4@*'1H92`F(S@R,C`[4F5P<F5S96YT871I
M=F4F(S@R,3<[<R!787)R86YT<R8C.#(R,3LI+B!4:&4@4F5P<F5S96YT871I
M=F4F(S@R,3<[<R!787)R86YT<R!A<F4@97AE<F-I<V%B;&4@8V]M;65N8VEN
M9R!O;B!-87)C:"`R,2P@,C`Q-2!A;F0@97AP:7)I;F<@;VX@36%R8V@@,C$L
M(#(P,3DN(%1H92!297!R97-E;G1A=&EV928C.#(Q-SMS(%=A<G)A;G1S(&%N
M9"!T:&4@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!U;F1E<FQY:6YG('1H92!W
M87)R86YT<R!H879E(&)E96X@9&5E;65D(&-O;7!E;G-A=&EO;B!B>2!&:6YA
M;F-I86P@26YD=7-T<GD@4F5G=6QA=&]R>2!!=71H;W)I='DL($EN8RX@*"8C
M.#(R,#M&24Y2028C.#(R,3LI(&%N9"!A<F4L('1H97)E9F]R92P@<W5B:F5C
M="!T;R!A(#$X,"UD87D@;&]C:RUU<"!P=7)S=6%N="!T;R!2=6QE(#4Q,3`H
M9RDH,2D@;V8@1DE.4D$N/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T
M:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P
M=#M-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B`F(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#
M3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U3
M25I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@
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M.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`\<W1R;VYG/CQI/B8C
M,38P.SPO:3X\+W-T<F]N9SX\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB
M;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q
M,'!T.TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^(#QS=')O;F<^/&D^56YD97)W<FET97(F(S@R
M,3<[<R!%>&5R8VES92!O9B!)4$\@3W9E<BU!;&QO=&UE;G0@3W!T:6]N/"]I
M/CPO<W1R;VYG/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58
M5"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F(S$V,#L\+V1I=CX@
M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.
M97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@
M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX@1F]L;&]W:6YG('1H92!C;&]S:6YG(&]F('1H92!)
M4$\L(&1U<FEN9R!T:&4@>65A<B!E;F1E9"!-87)C:"`S,2P@,C`Q-2!A;F0@
M:6X@8V]N;F5C=&EO;B!W:71H(&ET<R!)4$\L('1H92!U;F1E<G=R:71E<G,@
M97AE<F-I<V5D(&$@<&]R=&EO;B!O9B!T:&4@;W9E<BUA;&QO=&UE;G0@;W!T
M:6]N('!U<G-U86YT('1O('=H:6-H('1H92!#;VUP86YY('-O;&0@86X@861D
M:71I;VYA;"`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE
M=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX@,34T+#(Y,#PO
M9F]N=#X@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!A="`D/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/
M3E0M4TE:13H@,3!P="<^-BXV-C`X/"]F;VYT/B!P97(@<VAA<F4L('=H:6-H
M(')E<W5L=&5D(&EN(&%P<')O>&EM871E;'D@)#QF;VYT('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)
M6D4Z(#$P<'0G/C$L,#(X+#`P,#PO9F]N=#X@;V8@86=G<F5G871E(&YE="!P
M<F]C965D<R!T;R!T:&4@0V]M<&%N>2X@26X@8V]N;F5C=&EO;B!W:71H('1H
M92!U;F1E<G=R:71E<G,F(S@R,3<[('!A<G1I86P@97AE<F-I<V4@;V8@=&AE
M(&]V97(M86QL;W1M96YT(&]P=&EO;BP@=&AE($-O;7!A;GD@:7-S=65D('1O
M('1H92!R97!R97-E;G1A=&EV92!O9B!T:&4@=6YD97)W<FET97)S(&$@9FEV
M92UY96%R('=A<G)A;G0@=&\@<'5R8VAA<V4@86X@861D:71I;VYA;"`\9F]N
M="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E
M<FEF)SL@1D].5"U325I%.B`Q,'!T)SX@-2PT,#`\+V9O;G0^('-H87)E<R!O
M9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!A="!A;B!E>&5R
M8VES92!P<FEC92!O9B`D/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4
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M;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q
M,'!T.TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^(#QS=')O;F<^/&D^)B,Q-C`[/"]I/CPO<W1R
M;VYG/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-
M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P
M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX@/'-T<F]N9SX\:3Y);G9E<W1M96YT(&9R;VT@1F]R;65R(%!A<F5N
M=#PO:3X\+W-T<F]N9SX\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H
M.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T
M.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)B,Q-C`[/"]D
M:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM
M97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,"XU
M:6X[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^($1U<FEN9R!T:&4@>65A<B!E;F1E9"!-87)C
M:"`S,2P@,C`Q-"P@=&AE($-O;7!A;GDF(S@R,3<[<R!&;W)M97(@4&%R96YT
M(&UA9&4@8V%P:71A;"!C;VYT<FEB=71I;VYS('1O('1H92!#;VUP86YY(&EN
M('1H92!A;6]U;G0@;V8@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G
M5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/C$L
M-C<Y+#`P,#PO9F]N=#XL('=H:6-H('=E<F4@<F5C;W)D960@87,@861D:71I
M;VYA;"!P86ED+6EN(&-A<&ET86P@:6X@=&AE(&-O;G-O;&ED871E9"!S=&%T
M96UE;G0@;V8@8VAA;F=E<R!I;B!S=&]C:VAO;&1E<G,F(S@R,3<[(&5Q=6ET
M>2X@4V5E($YO=&4@.2`F(S$U,#L@4F5L871E9"!087)T>2!4<F%N<V%C=&EO
M;G,@9F]R(&1E=&%I;',@87-S;V-I871E9"!W:71H('1H92!&;W)M97(@4&%R
M96YT)B,X,C$W.W,@;W=N97)S:&EP(&EN=&5R97-T(&EN('1H92!#;VUP86YY
M+CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9
M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@
M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX@/'-T<F]N9SX\:3XF(S$V,#L\+VD^/"]S=')O;F<^/"]D:78^(#QD:78@
M<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O
M;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`\<W1R;VYG/CQI
M/E-T;V-K(%=A<G)A;G1S/"]I/CPO<W1R;VYG/CPO9&EV/B`\9&EV('-T>6QE
M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&
M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P
M="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B`F(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&
M3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%
M6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@/&9O;G0@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/
M3E0M4TE:13H@,3!P="<^/"]F;VYT/D$@<W5M;6%R>2!O9B!T:&4@=V%R<F%N
M="!A8W1I=FET>2!D=7)I;F<@=&AE('EE87)S(&5N9&5D($UA<F-H(#,Q+"`R
M,#$U(&ES('!R97-E;G1E9"!B96QO=SH\+V1I=CX@/&1I=B!S='EL93TS1"=#
M3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U3
M25I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@
M)B,Q-C`[/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&
M04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4%,
M24=..DQE9G0[(%1%6%0M24Y$14Y4.B`P:6X[(%=)1%1(.B`Q,#`E)SX@/'1A
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M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,S8E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
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M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T
M:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#<P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
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M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q,"4^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R
M/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#,V
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P
M,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
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M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-S`P)R!W:61T:#TS1#$Q)2!C;VQS<&%N/3-$,CX@/&1I=CY!=F5R86=E/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
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M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3`E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T
M<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0S
M-B4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%
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M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W
M,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
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M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I
M9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV/D%V97)A9V4\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-S`P)R!W:61T:#TS1#$Q)2!C;VQS<&%N/3-$,CX@/&1I=CY296UA:6YI;F<\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q,"4^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS
M1#,V)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$Q)2!C
M;VQS<&%N/3-$,CX@/&1I=CY.=6UB97(F(S$V,#MO9CPO9&EV/B`\+W1D/B`\
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M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G
M('=I9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV/D5X97)C:7-E/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#<P,"<@=VED=&@],T0Q,24@8V]L<W!A;CTS1#(^(#QD:78^3&EF93PO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&
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M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV/DEN
M=')I;G-I8SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P
M,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@
M/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0S-B4^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[
M(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV
M/E=A<G)A;G1S/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%
M6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV/E!R
M:6-E/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)
M1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`W,#`G('=I9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV/DEN)B,Q-C`[
M665A<G,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!
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M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,S8E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
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M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@
M-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)
M1TA4.B`W,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%
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M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H
M/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
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M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
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M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@
M-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)
M1TA4.B`W,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,S8E/B`\9&EV/D]U='-T86YD:6YG+"!-
M87)C:"`S,2P@,C`Q-#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
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M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXS+#$T,"PR-3`\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,3`E/B`\9&EV/C<N,S`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D
M;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
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M14E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,S8E/B`\9&EV/D=R86YT960\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q,"4^(#QD:78^-2PT,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U
M<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^.2XP
M-CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
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M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
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M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&
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M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@
M-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/BT\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
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M(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
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M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS
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M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=.
M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U
M<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'
M3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@
M-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/BT\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)
M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
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M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#,V)3X@/&1I=CY/=71S=&%N9&EN9RP@36%R8V@@,S$L(#(P,34\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4
M64Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
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M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X
M(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$58
M5"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU2
M24=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXW+C,Q/"]D:78^
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M3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,3`E/B`\9&EV/C$N,3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B
M;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)
M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z
M(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M
M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#,V)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@
M,W!X(&1O=6)L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P
M,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z
M(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52
M+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L
M93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`S<'@@
M9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0S-B4^(#QD:78^
M17AE<F-I<V%B;&4L($UA<F-H(#,Q+"`R,#$U/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L
M93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4
M+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXS+#$T,"PR-3`\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT
M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXW+C,P/"]D:78^
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M3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ
M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P
M>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXQ+C$\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!L
M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ
M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P
M>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXM/"]D
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M97)I9B<[($9/3E0M4TE:13H@,3!P="<^/"]F;VYT/CPO9&EV/B`\9&EV('-T
M>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA
M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)B,Q-C`[/"]D:78^
M(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@
M3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,"XU:6X[
M($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G
M5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/B`\
M+V9O;G0^5&AE(&9O;&QO=VEN9R!T86)L92!P<F5S96YT<R!I;F9O<FUA=&EO
M;B!R96QA=&5D('1O('-T;V-K('=A<G)A;G1S(&%T($UA<F-H(#,Q+"`R,#$U
M.CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9
M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z
M(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F(S$V,#L\+V1I=CX@/&1I=B!S='EL
M93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[
M1D].5"U325I%.B`Q,'!T.U1%6%0M04Q)1TXZ3&5F=#L@5$585"U)3D1%3E0Z
M(#!I;CL@5TE$5$@Z(#$P,"4G/B`\=&%B;&4@<W1Y;&4],T0G34%21TE..B`P
M:6X[(%=)1%1(.B`W,"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($]6
M15)&3$]7.B!V:7-I8FQE)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P(&%L:6=N/3-$;&5F=#X@/'1R/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H
M/3-$,S4E(&-O;'-P86X],T0U/B`\9&EV/E=A<G)A;G1S)B,Q-C`[3W5T<W1A
M;F1I;F<\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!
M3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#<P,"<@=VED=&@],T0S,R4@8V]L<W!A;CTS1#4^(#QD:78^5V%R<F%N
M=',F(S$V,#M%>&5R8VES86)L93PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].
M5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q
M-R4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED
M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4
M.B`W,#`G('=I9'1H/3-$,34E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
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M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$V)2!C
M;VQS<&%N/3-$,CX@/&1I=CY796EG:'1E9#PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4
M.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U7
M14E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&
M3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$U)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T
M:#TS1#$W)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$V
M)2!C;VQS<&%N/3-$,CX@/&1I=CY/=71S=&%N9&EN9SPO9&EV/B`\+W1D/B`\
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M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G
M('=I9'1H/3-$,38E(&-O;'-P86X],T0R/B`\9&EV/D%V97)A9V4\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-S`P)R!W:61T:#TS1#$V)2!C;VQS<&%N/3-$,CX@/&1I=CY%>&5R8VES
M86)L93PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@
M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%
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M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS
M1#$V)2!C;VQS<&%N/3-$,CX@/&1I=CY.=6UB97(F(S$V,#MO9CPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-4
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M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`W,#`G('=I9'1H/3-$,38E(&-O;'-P86X],T0R/B`\9&EV/E)E;6%I;FEN
M9R8C,38P.TQI9F4\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$V)2!C;VQS<&%N
M/3-$,CX@/&1I=CY.=6UB97(F(S$V,#MO9CPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H
M/3-$,3@E(&-O;'-P86X],T0R/B`\9&EV/E!R:6-E/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,38E
M(&-O;'-P86X],T0R/B`\9&EV/E=A<G)A;G1S/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,38E(&-O
M;'-P86X],T0R/B`\9&EV/DEN)B,Q-C`[665A<G,\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-4
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M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I
M9'1H/3-$,3<E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
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M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,34E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P
M,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(
M5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M
M5T5)1TA4.B`W,#`G('=I9'1H/3-$,34E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-4
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M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I
M9'1H/3-$,34E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.
M1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3<E
M/B`\9&EV/C<N,C4P,#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
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M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$U)3X@/&1I=CXS+#`T-RPU,#`\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q-24^(#QD:78^,2XP/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(
M5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,34E/B`\9&EV
M/C,L,#0W+#4P,#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^
M(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$W)3X@/&1I=CXY+C`V,C4\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)
M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z
M(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$U)3X@/&1I=CXY
M."PQ-3`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9
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M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-
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M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3<E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'
M3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@
M-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$U)3X@/&1I=CXS+#$T-2PV-3`\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
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M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O
M=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!4
M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'
M+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,34E/B`\9&EV/C,L,30P+#(U
M,#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#PO=&%B;&4^
M(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N
M)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#X\+V1I=CX@/&1I
M=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@
M4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("8C,38P.SPO
M9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I
M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@
M/'-T<F]N9SX\:3Y3=&]C:R!/<'1I;VYS/"]I/CPO<W1R;VYG/CPO9&EV/B`\
M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE
M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-
M05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3XF(S$V,#L\+V1I=CX@/&1I
M=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@
M4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%2
M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)R!A;&EG;CTS1&IU<W1I9GD^5&AE($-O;7!A;GD@:&%S(&-O
M;7!U=&5D('1H92!F86ER('9A;'5E(&]F(&]P=&EO;G,@9W)A;G1E9"!U<VEN
M9R!T:&4@0FQA8VLM4V-H;VQE<R!O<'1I;VX@<')I8VEN9R!M;V1E;"X@3W!T
M:6]N(&9O<F9E:71U<F5S(&%R92!E<W1I;6%T960@870@=&AE('1I;64@;V8@
M=F%L=6%T:6]N(&%N9"!R961U8V4@97AP96YS92!R871A8FQY(&]V97(@=&AE
M('9E<W1I;F<@<&5R:6]D+B!4:&ES(&5S=&EM871E('=I;&P@8F4@861J=7-T
M960@<&5R:6]D:6-A;&QY(&)A<V5D(&]N('1H92!E>'1E;G0@=&\@=VAI8V@@
M86-T=6%L(&]P=&EO;B!F;W)F96ET=7)E<R!D:69F97(L(&]R(&%R92!E>'!E
M8W1E9"!T;R!D:69F97(L(&9R;VT@=&AE('!R979I;W5S(&5S=&EM871E+"!W
M:&5N(&ET(&ES(&UA=&5R:6%L+B!4:&4@0V]M<&%N>2!E<W1I;6%T960@9F]R
M9F5I='5R97,@<F5L871E9"!T;R!O<'1I;VX@9W)A;G1S(&%T(&%N(&%N;G5A
M;"!R871E(&]F(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@
M3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/C`\+V9O;G0^
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M(&)E:6YG('9A;'5E9"X\+V1I=CX@/"]D:78^/'1A8FQE(&)O<F1E<CTS1#`@
M<W1Y;&4],T0G=VED=&@Z,3`P)3L@=&%B;&4M;&%Y;W5T.F9I>&5D.R<@8V5L
M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T
M<CX\+W1A8FQE/CQD:78@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF("<^)B,Q-C`[
M/"]D:78^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68@)SX@/&1I=B!S='EL
M93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[
M1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P
M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
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M:69Y/B8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58
M5"U!3$E'3CI,969T.R!415A4+4E.1$5.5#H@,&EN.R!724142#H@,3`P)2<^
M(#QT86)L92!S='EL93TS1"=-05)'24XZ(#!I;CL@5TE$5$@Z(#4P)3L@0D]2
M1$52+4-/3$Q!4%-%.B!C;VQL87!S93L@3U9%4D9,3U<Z('9I<VEB;&4G(&-E
M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@86QI9VX],T1L969T/B`\
M='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#(U)3X@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#(S)2!C;VQS<&%N
M/3-$-3X@/&1I=CY&;W(F(S$V,#MT:&4F(S$V,#M996%R)B,Q-C`[16YD960\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,C4E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@
M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,
M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-S`P)R!W:61T:#TS1#(S)2!C;VQS<&%N/3-$-3X@/&1I=CY-87)C:"8C
M,38P.S,Q+#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P
M,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@
M/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0R-24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[
M(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P
M)R!W:61T:#TS1#$Q)2!C;VQS<&%N/3-$,CX@/&1I=CXR,#$U/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@
M1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U7
M14E'2%0Z(#<P,"<@=VED=&@],T0Q,24@8V]L<W!A;CTS1#(^(#QD:78^,C`Q
M-#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED
M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,C4E/B`\9&EV/E)I
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M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4
M+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q,"4^(#QD:78^,2XV-SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)3PO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/FXO83PO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#(U)3X@/&1I=CY%>'!E8W1E9"!T97)M
M("AY96%R<RD\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^-2XV,3PO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
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M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/FXO83PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#(U)3X@/&1I=CY%>'!E8W1E9"!V
M;VQA=&EL:71Y/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/CDU/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXE
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/FXO83PO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#(U)3X@/&1I=CY%>'!E8W1E9"!D:79I9&5N
M9',\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,"XP,#PO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)3PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CYN+V$\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U3
M25I%.B`Q,'!T)SX\+V9O;G0^/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z
M8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@
M,3!P=#M-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3XF(S$V,#L\+V1I
M=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE
M<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I
M;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)R!A;&EG;CTS1&IU<W1I9GD^5&AE('=E:6=H=&5D
M(&%V97)A9V4@97-T:6UA=&5D(&9A:7(@=F%L=64@;V8@=&AE(&]P=&EO;G,@
M9W)A;G1E9"!D=7)I;F<@=&AE('EE87(@96YD960@36%R8V@@,S$L(#(P,34@
M=V%S("0\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2
M;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SXT+C<Y/"]F;VYT/B!P
M97(@<VAA<F4N(%1H97)E('=E<F4@;F\@;W!T:6]N<R!G<F%N=&5D(&1U<FEN
M9R!T:&4@>65A<B!E;F1E9"!-87)C:"`S,2P@,C`Q-"X\+V1I=CX@/&1I=B!S
M='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M
M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<@86QI9VX],T1J=7-T
M:69Y/CQS=')O;F<^/&D^)B,Q-C`[/"]I/CPO<W1R;VYG/CPO9&EV/B`\9&EV
M('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2
M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'
M24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G(&%L:6=N/3-$:G5S=&EF>3Y/;B!-87D@,3(L(#(P,30L('1H
M92!#;VUP86YY(&=R86YT960@;W!T:6]N<R!T;R!E;7!L;WEE97,@86YD(&1I
M<F5C=&]R<R!T;R!P=7)C:&%S92!A;B!A9V=R96=A=&4@;V8@/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[
M($9/3E0M4TE:13H@,3!P="<^(#,S,BPU,#`\+V9O;G0^('-H87)E<R!O9B!C
M;VUM;VX@<W1O8VL@870@86X@97AE<F-I<V4@<')I8V4@;V8@)#QF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G
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M5"U325I%.B`Q,'!T)SXQ+#4Y,RPP,#`\+V9O;G0^('=I;&P@8F4@<F5C;V=N
M:7IE9"!P<F]P;W)T:6]N871E('1O('1H92!V97-T:6YG('!E<FEO9"X\+V1I
M=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE
M<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I
M;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX@)B,Q-C`[/"]D:78^(#QD:78@<W1Y;&4],T0G
M0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M
M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,'!T(#!P
M>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M(%1H92!#;VUP86YY(')E8V]R9&5D('-T;V-K)B,Q-3`[8F%S960@8V]M<&5N
M<V%T:6]N(&5X<&5N<V4@<F5L871E9"!T;R!S=&]C:R!O<'1I;VYS(&]F("0\
M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L
M)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SXT-3(L,#`P/"]F;VYT/B!A;F0@
M)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N
M)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/C`\+V9O;G0^(&1U<FEN9R!T
M:&4@>65A<G,@96YD960@36%R8V@@,S$L(#(P,34@86YD(#(P,30L(')E<W!E
M8W1I=F5L>2X@07,@;V8@36%R8V@@,S$L(#(P,34L('1H97)E('=A<R`D/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S
M97)I9B<[($9/3E0M4TE:13H@,3!P="<^,2PP-C`L,#`P/"]F;VYT/B!O9B!U
M;G)E8V]G;FEZ960@<W1O8VLM8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4@
M<F5L871E9"!T;R!S=&]C:R!O<'1I;VYS('1H870@=VEL;"!B92!A;6]R=&EZ
M960@;W9E<B!A('=E:6=H=&5D(&%V97)A9V4@<&5R:6]D(&]F(#QF;VYT('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G
M.R!&3TY4+5-)6D4Z(#$P<'0G/B`R+C$\+V9O;G0^('EE87)S+CPO9&EV/B`\
M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE
M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-
M05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B`F(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!
M4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%
M.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@/&9O
M;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S
M97)I9B<[($9/3E0M4TE:13H@,3!P="<^/"]F;VYT/D$@<W5M;6%R>2!O9B!T
M:&4@<W1O8VL@;W!T:6]N(&%C=&EV:71Y(&1U<FEN9R!T:&4@>65A<B!E;F1E
M9"!-87)C:"`S,2P@,C`Q-2!I<R!P<F5S96YT960@8F5L;W<Z/"]D:78^(#QD
M:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W
M(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,"XU:6X[($U!
M4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^("8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2
M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z
M(#$P<'0[5$585"U!3$E'3CI,969T.R!415A4+4E.1$5.5#H@,&EN.R!72414
M2#H@,3`P)2<^(#QT86)L92!S='EL93TS1"=-05)'24XZ(#!I;CL@5TE$5$@Z
M(#@U)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@3U9%4D9,3U<Z('9I
M<VEB;&4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@86QI9VX]
M,T1L969T/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T
M:#TS1#,V)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#<P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
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M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
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M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV
M/E=E:6=H=&5D/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
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M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I
M9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P
M,"<@=VED=&@],T0S-B4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
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M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
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M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`W,#`G('=I9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV/E=E:6=H
M=&5D/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q,24@8V]L<W!A;CTS1#(^(#QD
M:78^079E<F%G93PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
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M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W
M:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W
M,#`G('=I9'1H/3-$,S8E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
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M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-S`P)R!W:61T:#TS1#$Q)2!C;VQS<&%N/3-$,CX@/&1I=CY!=F5R
M86=E/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
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M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
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M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G
M('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#<P,"<@=VED=&@],T0S-B4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@
M=VED=&@],T0Q,24@8V]L<W!A;CTS1#(^(#QD:78^3G5M8F5R)B,Q-C`[;V8\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-S`P)R!W:61T:#TS1#$Q)2!C;VQS<&%N/3-$,CX@/&1I=CY%
M>&5R8VES93PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
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M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3$E(&-O;'-P86X],T0R
M/B`\9&EV/DQI9F4\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$Q)2!C;VQS<&%N
M/3-$,CX@/&1I=CY);G1R:6YS:6,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G
M('=I9'1H/3-$,S8E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$Q)2!C;VQS
M<&%N/3-$,CX@/&1I=CY/<'1I;VYS/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q
M<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3$E(&-O;'-P86X]
M,T0R/B`\9&EV/E!R:6-E/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L
M:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\
M9&EV/DEN)B,Q-C`[665A<G,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S
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M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO
M='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$
M,S8E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
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M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&
M3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L
M:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
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M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4
M.B`W,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
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M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$
M,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
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M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&
M3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L
M:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED
M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,S8E/B`\9&EV/D]U
M='-T86YD:6YG+"8C,38P.TUA<F-H)B,Q-C`[,S$L)B,Q-C`[,C`Q-#PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G
M('=I9'1H/3-$,3`E/B`\9&EV/BT\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@
M/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q,"4^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
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M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS
M1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0S-B4^(#QD:78^1W)A;G1E9#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
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M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXS,S(L
M-3`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
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M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C8N,S<\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
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M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,S8E/B`\9&EV/D5X97)C
M:7-E9#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
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M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S
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M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU2
M24=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\
M9&EV/BT\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
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M=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,S8E/B`\9&EV/D9O<F9E:71E9#PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@
M/&1I=CXH,38L-C8T*3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S
M;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,3`E/B`\9&EV/C8N,S<\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L
M:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q
M<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4
M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#,V)3X@/&1I=CY/=71S=&%N9&EN9RP@36%R
M8V@@,S$L(#(P,34\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!4
M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)
M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z
M(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,S$U+#@S-CPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N
M;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^
M(#QD:78^-BXS-SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'
M3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@
M-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXY+C`\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@
M9&]U8FQE.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV
M/BT\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0S-B4^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
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M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$
M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI
M9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#-P
M>"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P
M,#`@,W!X(&1O=6)L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
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M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^
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M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C
M,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU4
M3U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,S8E/B`\9&EV/D5X97)C:7-A8FQE+"!-87)C:"`S,2P@,C`Q-3PO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,
M24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4
M.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
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M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4
M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))
M1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD
M:78^-BXS-SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE
M.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$
M24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
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M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE
M.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$
M24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^
M(#PO=&%B;&4^(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@
M3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#X\
M+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4
M:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,'!T(#!P
M>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M("8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M
M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)
M3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U3
M25I%.B`Q,'!T)SX@/"]F;VYT/E1H92!F;VQL;W=I;F<@=&%B;&4@<')E<V5N
M=',@:6YF;W)M871I;VX@<F5L871E9"!T;R!S=&]C:R!O<'1I;VYS(&%T($UA
M<F-H(#,Q+"`R,#$U.CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[
M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[
M5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F(S$V,#L\+V1I
M=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE
M<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M04Q)1TXZ3&5F=#L@
M5$585"U)3D1%3E0Z(#!I;CL@5TE$5$@Z(#$P,"4G/B`\=&%B;&4@<W1Y;&4]
M,T0G34%21TE..B`P:6X[(%=)1%1(.B`W,"4[($)/4D1%4BU#3TQ,05!313H@
M8V]L;&%P<V4[($]615)&3$]7.B!V:7-I8FQE)R!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P(&%L:6=N/3-$;&5F=#X@/'1R/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)
M1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`W,#`G('=I9'1H/3-$,S4E(&-O;'-P86X],T0U/B`\9&EV/D]P=&EO;G,F
M(S$V,#M/=71S=&%N9&EN9SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
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M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$
M,S(E(&-O;'-P86X],T0T/B`\9&EV/D]P=&EO;G,F(S$V,#M%>&5R8VES86)L
M93PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED
M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M
M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@
M1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q-R4^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E
M<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,34E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,38E(&-O;'-P
M86X],T0R/B`\9&EV/E=E:6=H=&5D/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P
M,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(
M5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M
M5T5)1TA4.B`W,#`G('=I9'1H/3-$,34E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4]
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M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$
M,3<E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
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M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,38E(&-O
M;'-P86X],T0R/B`\9&EV/D]U='-T86YD:6YG/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#<P,"<@=VED
M=&@],T0Q-B4@8V]L<W!A;CTS1#(^(#QD:78^079E<F%G93PO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%
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M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W
M,#`G('=I9'1H/3-$,38E(&-O;'-P86X],T0R/B`\9&EV/D5X97)C:7-A8FQE
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$X)2!C;VQS<&%N
M/3-$,CX@/&1I=CY%>&5R8VES93PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
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M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,38E
M(&-O;'-P86X],T0R/B`\9&EV/DYU;6)E<B8C,38P.V]F/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#<P
M,"<@=VED=&@],T0Q-B4@8V]L<W!A;CTS1#(^(#QD:78^4F5M86EN:6YG)B,Q
M-C`[3&EF93PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
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M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,38E(&-O;'-P86X],T0R
M/B`\9&EV/DYU;6)E<B8C,38P.V]F/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
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M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P
M,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q-B4@8V]L
M<W!A;CTS1#(^(#QD:78^3W!T:6]N<SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$V)2!C;VQS<&%N
M/3-$,CX@/&1I=CY);B8C,38P.UEE87)S/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,38E(&-O;'-P
M86X],T0R/B`\9&EV/D]P=&EO;G,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$
M,3<E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&
M3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L
M:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,34E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
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M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@
M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@
M-S`P)R!W:61T:#TS1#$U)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$U
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z
M(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$W)3X@/&1I=CXV
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M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4
M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))
M1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q-24^(#QD
M:78^,S$U+#@S-CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
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M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$U)3X@/&1I=CXX+C<\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT
M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$U)3X@/&1I=CXX,2PU,C(\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL
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M-R4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L
M93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4
M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))
M1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,34E/B`\9&EV/C,Q-2PX,S8\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N
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M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X
M(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE
M.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$
M24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L
M:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,34E/B`\9&EV/C@Q+#4R
M,CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#PO=&%B;&4^
M(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N
M)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#X\+V1I=CX@/&1I
M=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@
M4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^(#QS=')O;F<^
M/&D^)B,Q-C`[/"]I/CPO<W1R;VYG/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)
M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@/'-T<F]N9SX\:3Y297-T<FEC=&5D
M(%-T;V-K(%5N:71S/"]I/CPO<W1R;VYG/CPO9&EV/B`\9&EV('-T>6QE/3-$
M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4
M+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P
M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B`\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@;F]R;6%L)SXF(S$V,#L\
M+V9O;G0^/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&
M04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.
M1$5.5#H@,"XU:6X[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^($]N($UA>2`Q,2P@,C`Q-"P@
M=&AE($-O;7!A;GD@9W)A;G1E9"!24U5S(&ES<W5A8FQE(&9O<B!A;B!A9V=R
M96=A=&4@;V8@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.
M97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^(#0P.2PS-34\
M+V9O;G0^('-H87)E<R!T;R!E;7!L;WEE97,@86YD(&1I<F5C=&]R<RP@<'5R
M<W5A;G0@=&\@=&AE(#(P,3,@4&QA;BX@4E-5<R!F;W(@,S0Q+#`P,"!S:&%R
M97,@;V8@8V]M;6]N('-T;V-K('9E<W0@<F%T86)L>2!O=F5R('1H<F5E('EE
M87)S(&]N(&$@<75A<G1E<FQY(&)A<VES(&%N9"!H860@86X@86=G<F5G871E
M(&=R86YT(&1A=&4@=F%L=64@;V8@)#(L,30X+#`P,"X@4E-5<R!F;W(@-C@L
M,S4U('-H87)E<R!H860@86X@86=G<F5G871E(&=R86YT(&1A=&4@=F%L=64@
M;V8@)#0S,2PP,#`@86YD('9E<W0@:6X@97%U86P@:6YS=&%L;&UE;G1S(&)A
M<V5D(&]N(&%C:&EE=F5M96YT(&]F('1H92!F;VQL;W=I;F<Z("@Q*2!E;G)O
M;&QM96YT(&]F('1H92!F:7)S="!P871I96YT(&EN('1H92!F:7)S="!P:79O
M=&%L(&-L:6YI8V%L('1R:6%L(&9O<B!2550U."TV,"!O;B!O<B!P<FEO<B!T
M;R!-87D@,3$L(#(P,3<[("@R*2!E;G)O;&QM96YT(&]F('1H92!F:7)S="!P
M871I96YT(&EN('1H92!S96-O;F0@<&EV;W1A;"!C;&EN:6-A;"!T<FEA;"!F
M;W(@4E54-3@M-C`@;VX@;W(@<')I;W(@=&\@36%Y(#$Q+"`R,#$X.R!A;F0@
M*#,I(&-O;7!L971I;VX@;V8@=&AE(&-L:6YI8V%L('-T=61Y(')E<&]R="!C
M;VYT86EN:6YG('1H92!R97-U;'1S(&]F('1H92!S96-O;F0@<&EV;W1A;"!C
M;&EN:6-A;"!T<FEA;"!F;W(@4E54-3@M-C`@;VX@;W(@<')I;W(@=&\@36%Y
M(#$Q+"`R,#$Y+CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58
M5"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F(S$V,#L\+V1I=CX@
M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.
M97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@
M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX@5&AE($-O;7!A;GD@<F5C;W)D960@<W1O8VLF(S$U
M,#MB87-E9"!C;VUP96YS871I;VX@97AP96YS92!R96QA=&5D('1O(%)357,@
M;V8@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O
M;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/C8R-RPP,#`\+V9O;G0^
M(&%N9"`D/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@
M4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^,#PO9F]N=#X@9'5R
M:6YG('1H92!Y96%R<R!E;F1E9"!-87)C:"`S,2P@,C`Q-2!A;F0@,C`Q-"P@
M<F5S<&5C=&EV96QY+B!!<R!O9B!-87)C:"`S,2P@,C`Q-2P@=&AE<F4@=V%S
M("0\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA
M;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SXQ+#4R,BPP,#`\+V9O;G0^
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M=F5D+B!!<R!O9B!-87)C:"`S,2P@,C`Q-2P@=&AE($-O;7!A;GD@:&%S(&YO
M="!R96-O9VYI>F5D(&%N>2!E>'!E;G-E(')E;&%T960@=&\@4E-5<R!W:71H
M('!E<F9O<FUA;F-E(&-O;F1I=&EO;G,N($%S(&]F($UA<F-H(#,Q+"`R,#$U
M+"!T:&5R92!W87,@)#0S,2PP,#`@;V8@=6YR96-O9VYI>F5D('-T;V-K+6)A
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M("8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M
M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)
M3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U3
M25I%.B`Q,'!T)SX\+V9O;G0^02!S=6UM87)Y(&]F(%)352!A8W1I=FET>2!F
M;W(@=&AE('EE87)S(&5N9&5D($UA<F-H(#,Q+"`R,#$U(&%N9"`R,#$T(&ES
M('!R97-E;G1E9"!B96QO=SH\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB
M;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q
M,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)B,Q-C`[
M/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ
M5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4%,24=..DQE
M9G0[(%1%6%0M24Y$14Y4.B`P:6X[(%=)1%1(.B`Q,#`E)SX@/'1A8FQE('-T
M>6QE/3-$)TU!4D=)3CH@,&EN.R!724142#H@-S`E.R!"3U)$15(M0T],3$%0
M4T4Z(&-O;&QA<'-E.R!/5D521DQ/5SH@=FES:6)L92<@8V5L;'-P86-I;F<]
M,T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&QE9G0^(#QT<CX@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,S,E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
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M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$P
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$Q)2!C;VQS
M<&%N/3-$,CX@/&1I=CY796EG:'1E9#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
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M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-S`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,S,E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
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M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$P)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$Q)2!C;VQS<&%N/3-$
M,CX@/&1I=CY!=F5R86=E/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%
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M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G
M('=I9'1H/3-$,S,E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
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M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H
M/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV/DYU;6)E<B8C,38P.V]F/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
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M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
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M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-S`P)R!W:61T:#TS1#,S)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-4
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M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
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M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3$E(&-O
M;'-P86X],T0R/B`\9&EV/D9A:7(F(S$V,#M686QU93PO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#<P,"<@=VED=&@],T0S,R4^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED
M=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L
M:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q,"4^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4
M.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U7
M14E'2%0Z(#<P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS
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M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
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M24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&
M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXM/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,S,E/B`\9&EV/D=R86YT960\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0
M041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
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M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXM/"]D:78^(#PO
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M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,3`E/B`\9&EV/BT\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4
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M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/BT\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
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M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXM/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,S,E/B`\9&EV/D9O<F9E:71E9#PO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'
M3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@
M-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/BT\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)
M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z
M(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXM
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L
M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,
M24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4
M.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^
M+3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#,S)3X@/&1I=CY.;VXM
M=F5S=&5D+"!-87)C:"`S,2P@,C`Q-#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,3`E/B`\9&EV/BT\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N
M;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^
M(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$
M1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXM/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,S,E/B`\9&EV/D=R86YT960\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q,"4^(#QD:78^-#`Y+#,U-3PO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D
M;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
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M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@
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M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C(L-3<Y+#`P,#PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#,S)3X@/&1I=CY697-T960\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B@X
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M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C8N,S`\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B@U,S<L,#`P*3PO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#,S)3X@/&1I=CY&;W)F96ET
M960\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M
M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'
M2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I
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M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=.
M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4
M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))
M1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD
M:78^+3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$58
M5"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU2
M24=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\
M9&EV/BT\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^
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M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D
M;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[
M(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^
M,S(T+#`T-SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT
M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q,"4^(#QD:78^-BXS,#PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[
M(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)
M3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI
M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,BPP-#(L
M,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
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M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^/"]F;VYT/CPO9&EV/B`\
M+V1I=CX\=&%B;&4@8F]R9&5R/3-$,"!S='EL93TS1"=W:61T:#HQ,#`E.R!T
M86)L92UL87EO=70Z9FEX960[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P/CQT<CX\=&0^/"]T9#X\+W1R/CPO=&%B;&4^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
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M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/DEN8V]M92!487AE<SQB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY);F-O;64@5&%X($1I<V-L
M;W-U<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y);F-O;64@5&%X($1I<V-L;W-U<F4@6U1E>'0@0FQO
M8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE
M/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B`G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[
M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[
M34%21TE..B`P<'0@,'!X.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B!.;W1E(#@N($EN8V]M92!487AE<SPO9&EV
M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S
M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN
M.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B`F(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#
M3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U3
M25I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@
M5&AE($-O;7!A;GD@:7,@:6YC;'5D960@:6X@=&AE(%4N4RX@9F5D97)A;"!A
M;F0@<W1A=&4@*$-A;&EF;W)N:6$I('1A>"!R971U<FYS('=I=&@@:71S($9O
M<FUE<B!087)E;G0@=&AR;W5G:"!T:&4@36%R8V@@,C8L(#(P,30@8VQO<VEN
M9R!D871E(&]F('1H92!)4$\N(%!O<W0M25!/+"!T:&4@0V]M<&%N>2!F:6QE
M9"!S97!A<F%T92P@<W1A;F0M86QO;F4@=&%X(')E='5R;G,N($1U<FEN9R!T
M:&4@>65A<B!E;F1E9"!-87)C:"`S,2P@,C`Q-2P@9F]L;&]W:6YG('1H92!D
M96-O;G-O;&ED871I;VXL('1H92!#;VUP86YY(&%D:G5S=&5D(&ET<R!N970@
M;W!E<F%T:6YG(&QO<W,@*"8C.#(R,#M.3TPF(S@R,C$[*2!C87)R>2!F;W)W
M87)D('1O(')E9FQE8W0@=&AE('9A;'5E(&]F('1H92!.3TP@879A:6QA8FQE
M('1O('1H92!#;VUP86YY(&EN(&9U='5R92!P97)I;V1S+CPO9&EV/B`\9&EV
M('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2
M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)B,Q-C`[/"]D
M:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM
M97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,"XU
M:6X[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^(%1H92!F;VQL;W=I;F<@<W5M;6%R:7IE<R!T
M:&4@:6YC;VUE('1A>"!P<F]V:7-I;VX@*&)E;F5F:70I.CPO9&EV/B`\9&EV
M('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2
M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)B,Q-C`[/"]D
M:78^(#QT86)L92!S='EL93TS1"=724142#H@.#`E.R!"3U)$15(M0T],3$%0
M4T4Z(&-O;&QA<'-E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/B`\
M='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL
M93TS1'=H:71E+7-P86-E.FYO=W)A<#L^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=W:&ET92US<&%C93IN;W=R87`[($9/3E0M5T5)
M1TA4.B!B;VQD)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)W=H:71E+7-P86-E.FYO=W)A<#L@5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#8^(#QD:78^1F]R(%1H92!9
M96%R<R!%;F1E9#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G=VAI=&4M<W!A
M8V4Z;F]W<F%P.R!&3TY4+5=%24=(5#H@8F]L9"<^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@
M8F]T=&]M)SX@/'1D('-T>6QE/3-$=VAI=&4M<W!A8V4Z;F]W<F%P.SX@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)W=H:71E+7-P86-E
M.FYO=W)A<#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O
M;&0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G=VAI
M=&4M<W!A8V4Z;F]W<F%P.R!"3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L
M:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O
M;'-P86X],T0V/B`\9&EV/DUA<F-H(#,Q+#PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G=VAI=&4M<W!A8V4Z;F]W<F%P.R!0041$24Y'+4)/5%1/33H@,7!T
M.R!&3TY4+5=%24=(5#H@8F]L9"<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#PO='(^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M)SX@
M/'1D('-T>6QE/3-$=VAI=&4M<W!A8V4Z;F]W<F%P.SX@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)W=H:71E+7-P86-E.FYO=W)A<#L@
M4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G=VAI=&4M<W!A8V4Z
M;F]W<F%P.R!"3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M
M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X],T0R
M/B`\9&EV/C(P,34\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)W=H:71E+7-P
M86-E.FYO=W)A<#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z
M(&)O;&0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M=VAI=&4M<W!A8V4Z;F]W<F%P.R!0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4
M+5=%24=(5#H@8F]L9"<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=W:&ET92US<&%C93IN;W=R87`[($)/4D1%4BU"3U143TTZ(&)L
M86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(
M5#H@8F]L9"<@8V]L<W!A;CTS1#(^(#QD:78^,C`Q-#PO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G=VAI=&4M<W!A8V4Z;F]W<F%P.R!0041$24Y'+4)/5%1/
M33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#PO='(^(#QT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!R
M9V(H,C`T+#(S."PR-34I.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D
M/B`\9&EV/D9E9&5R86P\+V1I=CX@/"]T9#X@/'1D/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H="<^(#QD:78^)B,Q-C`[/"]D:78^
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M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B`\9&EV/B0\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX@/&1I=CXM/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SX@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^(#QD:78^)#PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/B`\9&EV
M/BT\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G
M0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR,S@L,C4U*3L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1"=0041$24Y'+4Q%1E0Z(#EP
M=#L@5TE$5$@Z(#<T)2<^(#QD:78^1&5F97)R960\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U=)1%1(.B`Q)2<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[(%=)1%1(.B`Q,"4G/B`\9&EV/B@Q+#<U-"PP,#`\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q
M)2<^(#QD:78^*3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#$E
M)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@5TE$5$@Z(#$P
M)2<^(#QD:78^*#$L,#,Q+#`P,#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@/&1I=CXI/"]D:78^(#PO
M=&0^(#PO='(^(#QT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!W:&ET
M93L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9#X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/"]T<CX@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R
M,#0L,C,X+#(U-2D[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<^(#QD:78^4W1A=&4@86YD(&QO8V%L
M/"]D:78^(#PO=&0^(#QT9#X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9#X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#PO='(^(#QT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!W:&ET
M93L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1"=0041$
M24Y'+4Q%1E0Z(#EP="<^(#QD:78^0W5R<F5N=#PO9&EV/B`\+W1D/B`\=&0^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX@/&1I=CXM/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SX@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^(#QD:78^+3PO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<B!S='EL93TS1"="04-+
M1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(S."PR-34I.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[
M(%!!1$1)3D<M3$5&5#H@.7!T)SX@/&1I=CY$969E<G)E9#PO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^(#QD:78^*#,P.2PP
M,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B`\9&EV/BD\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,7!T('-O;&ED.R!415A4+4%,24=..B!L969T)SX@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P
M="!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G/B`\9&EV/B@Q.#(L,#`P/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$
M24Y'+4)/5%1/33H@,7!T)SX@/&1I=CXI/"]D:78^(#PO=&0^(#PO='(^(#QT
M<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!W:&ET93L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;2<^(#QT9#X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H="<^(#QD:78^*#(L,#8S+#`P,#PO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^(#QD
M:78^*3PO9&EV/B`\+W1D/B`\=&0^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SX@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX@
M/&1I=CXH,2PR,3,L,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)SX@/&1I=CXI/"]D:78^(#PO=&0^(#PO='(^(#QT<B!S
M='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(S."PR-34I.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B`\9&EV/D-H86YG92!I
M;B!V86QU871I;VX@86QL;W=A;F-E/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,7!T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI
M9#L@5$585"U!3$E'3CH@;&5F="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[
M(%1%6%0M04Q)1TXZ(')I9VAT)SX@/&1I=CXR+#`V,RPP,#`\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]4
M5$]-.B`Q<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#%P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L
M:60[(%1%6%0M04Q)1TXZ(&QE9G0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED
M.R!415A4+4%,24=..B!R:6=H="<^(#QD:78^,2PR,3,L,#`P/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/
M5%1/33H@,7!T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R
M('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z('=H:71E.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^(#QD:78^26YC;VUE('1A>"!P<F]V
M:7-I;VX@*&)E;F5F:70I/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,BXU<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE
M.R!415A4+4%,24=..B!L969T)SX@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%
M6%0M04Q)1TXZ(')I9VAT)SX@/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,BXU<'0G
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#(N-7!T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@
M5$585"U!3$E'3CH@;&5F="<^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4
M+4%,24=..B!R:6=H="<^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SX@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/"]T86)L93X@/&1I=B!S
M='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M
M86X[1D].5"U325I%.B`Q,'!T.T-,14%2.B!B;W1H)SX@)B,Q-C`[/"]D:78^
M(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@
M3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,"XU:6X[
M($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^(%1H92!#;VUP86YY(&AA<R!T:&4@9F]L;&]W:6YG
M(&YE="!D969E<G)E9"!T87@@87-S971S.CPO9&EV/B`\9&EV('-T>6QE/3-$
M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4
M+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)B,Q-C`[/"]D:78^(#QT86)L
M92!S='EL93TS1"=724142#H@.#`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA
M<'-E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/B`\='(@<W1Y;&4]
M,T0G5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1'=H:71E
M+7-P86-E.FYO=W)A<#L^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=W:&ET92US<&%C93IN;W=R87`[(%!!1$1)3D<M0D]45$]-.B`Q
M<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)W=H:71E+7-P86-E.FYO=W)A<#L@0D]21$52+4)/
M5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/
M3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$-CX@/&1I=CY-87)C:"`S,2P\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)W=H:71E+7-P86-E.FYO=W)A<#L@
M4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G5D525$E#
M04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1'=H:71E+7-P86-E.FYO
M=W)A<#L^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=W
M:&ET92US<&%C93IN;W=R87`[(%!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M
M5T5)1TA4.B!B;VQD)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)W=H:71E+7-P86-E.FYO=W)A<#L@0D]21$52+4)/5%1/33H@8FQA
M8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M5T5)1TA4
M.B!B;VQD)R!C;VQS<&%N/3-$,CX@/&1I=CXR,#$U/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=W:&ET92US<&%C93IN;W=R87`[(%!!1$1)3D<M0D]45$]-
M.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)W=H:71E+7-P86-E.FYO=W)A<#L@4$%$1$E.
M1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G=VAI=&4M<W!A8V4Z;F]W<F%P
M.R!"3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ
M(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X],T0R/B`\9&EV
M/C(P,30\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)W=H:71E+7-P86-E.FYO
M=W)A<#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G
M0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR,S@L,C4U*3L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;2<^(#QT9#X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H="<^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SX@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R
M('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z('=H:71E.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M(%=)1%1(.B`W-"4G/B`\9&EV/DYE="!O<&5R871I;F<@;&]S<R!C87)R>69O
M<G=A<F1S/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=724142#H@,24G/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@5TE$5$@Z(#$E)SX@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@5TE$5$@Z(#$P)2<^(#QD:78^
M,RPR,C0L,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!724142#H@,24G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5TE$5$@Z(#$E)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^
M(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[(%=)1%1(.B`Q,"4G/B`\9&EV/C$L-#(W+#`P,#PO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)T)!
M0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C,X+#(U-2D[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VTG/B`\=&0^(#QD:78^4W1O8VLM8F%S960@8V]M<&5N<V%T
M:6]N/"]D:78^(#PO=&0^(#QT9#X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/B`\
M9&EV/C(V,BPP,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
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M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B`\9&EV/D-H87)I
M=&%B;&4@9&]N871I;VX@8V%R<GEF;W)W87)D<SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q
M<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T
M('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^(#QD:78^-"PP,#`\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M
M0D]45$]-.B`Q<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@
M<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O
M;&ED.R!415A4+4%,24=..B!R:6=H="<^(#QD:78^+3PO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ
M(#%P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<B!S='EL
M93TS1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(S."PR-34I.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[(%!!1$1)3D<M3$5&5#H@.7!T)SX@/&1I=CY'<F]S<R!D969E<G)E
M9"!T87@@87-S971S/"]D:78^(#PO=&0^(#QT9#X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0G/B`\9&EV/C,L-#DP+#`P,#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9#X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/B`\9&EV/C$L-#(W+#`P,#PO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<B!S='EL93TS1"="04-+
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M86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX@/&1I=CXH,RPT.3`L
M,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!0041$24Y'+4)/5%1/33H@,7!T)SX@/&1I=CXI/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SX@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q
M<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX@/&1I=CXH,2PT,C<L,#`P
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0
M041$24Y'+4)/5%1/33H@,7!T)SX@/&1I=CXI/"]D:78^(#PO=&0^(#PO='(^
M(#QT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(S."PR
M-34I.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SX@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI
M=&4[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SX@/&1I=CXF
M(S$V,#M.970@9&5F97)R960@=&%X(&%S<V5T<SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T)SX@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^(#QD:78^)#PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU
M<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^(#QD:78^+3PO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"
M3U143TTZ(#(N-7!T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R
M+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/B`\9&EV/B0\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T
M(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/B`\9&EV/BT\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]4
M5$]-.B`R+C5P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#PO
M=&%B;&4^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ
M5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ(#!P="`P
M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B`F(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4
M+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M
M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I
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M24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B`F(S$V,#L\+V1I=CX@/'1A8FQE('-T>6QE/3-$)U=)1%1(
M.B`X,"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&-E;&QS<&%C:6YG/3-$
M,"!C96QL<&%D9&EN9STS1#`^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'
M3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$=VAI=&4M<W!A8V4Z;F]W<F%P.SX@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)W=H:71E+7-P
M86-E.FYO=W)A<#L@1D].5"U714E'2%0Z(&)O;&0G/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G=VAI=&4M<W!A8V4Z;F]W<F%P.R!4
M15A4+4%,24=..B!C96YT97([($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N
M/3-$-CX@/&1I=CY&;W(@5&AE(%EE87)S($5N9&5D/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=W:&ET92US<&%C93IN;W=R87`[($9/3E0M5T5)1TA4.B!B
M;VQD)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R('-T>6QE
M/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T1W:&ET
M92US<&%C93IN;W=R87`[/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G=VAI=&4M<W!A8V4Z;F]W<F%P.R!0041$24Y'+4)/5%1/33H@
M,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=W:&ET92US<&%C93IN;W=R87`[($)/4D1%4BU"
M3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#8^(#QD:78^36%R8V@@,S$L
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=W:&ET92US<&%C93IN;W=R87`[
M(%!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)
M0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T1W:&ET92US<&%C93IN
M;W=R87`[/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M=VAI=&4M<W!A8V4Z;F]W<F%P.R!0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4
M+5=%24=(5#H@8F]L9"<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=W:&ET92US<&%C93IN;W=R87`[($)/4D1%4BU"3U143TTZ(&)L
M86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(
M5#H@8F]L9"<@8V]L<W!A;CTS1#(^(#QD:78^,C`Q-3PO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G=VAI=&4M<W!A8V4Z;F]W<F%P.R!0041$24Y'+4)/5%1/
M33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=W:&ET92US<&%C93IN;W=R87`[(%!!1$1)
M3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)W=H:71E+7-P86-E.FYO=W)A
M<#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=.
M.B!C96YT97([($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,CX@/&1I
M=CXR,#$T/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=W:&ET92US<&%C93IN
M;W=R87`[(%!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD
M)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$
M)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C,X+#(U-2D[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@5TE$5$@Z(#<T)2<^(#QD:78^17AP96-T960@9F5D97)A;"!S=&%T=71O
M<GD@<F%T93PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#$E)SX@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@5TE$5$@Z(#$P)2<^
M(#QD:78^*#,T+C`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^(#QD:78^*24\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U=)1%1(.B`Q)2<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[(%=)1%1(.B`Q,"4G/B`\9&EV/B@S-"XP/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B`\
M9&EV/BDE/"]D:78^(#PO=&0^(#PO='(^(#QT<B!S='EL93TS1"="04-+1U)/
M54Y$+4-/3$]2.B!W:&ET93L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SX@/&1I=CY3=&%T92!T87@@
M<F%T92P@;F5T(&]F(&9E9&5R86P@8F5N969I=#PO9&EV/B`\+W1D/B`\=&0^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX@/&1I=CXH-BXP/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SX@/&1I=CXI)3PO9&EV
M/B`\+W1D/B`\=&0^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX@/&1I=CXH-BXP
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SX@
M/&1I=CXI)3PO9&EV/B`\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=2
M3U5.1"U#3TQ/4CH@<F=B*#(P-"PR,S@L,C4U*3L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;2<^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SX@/&1I
M=CY#:&%N9V4@:6X@969F96-T:79E('-T871E('1A>"!R871E/"]D:78^(#PO
M=&0^(#QT9#X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/B`\9&EV/C`N,#PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^(#QD:78^
M)3PO9&EV/B`\+W1D/B`\=&0^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SX@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX@/&1I
M=CXH,"XS/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)SX@/&1I=CXI)3PO9&EV/B`\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G
M0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VTG/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^(#QD:78^4&5R
M;6%N96YT(&ET96US("T@<W1O8VLM8F%S960@8V]M<&5N<V%T:6]N/"]D:78^
M(#PO=&0^(#QT9#X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/B`\9&EV/C(N-3PO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^(#QD
M:78^)3PO9&EV/B`\+W1D/B`\=&0^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SX@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX@
M/&1I=CXP+C`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0G/B`\9&EV/B4\+V1I=CX@/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$
M)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C,X+#(U-2D[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<^(#QD:78^4&5R;6%N96YT(&ET96US("T@;F]N+61E9'5C=&EB;&4@;65R
M9V5R(&5X<&5N<V5S/"]D:78^(#PO=&0^(#QT9#X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0G/B`\9&EV/C`N-#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<^(#QD:78^)3PO9&EV/B`\+W1D/B`\=&0^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT)SX@/&1I=CXP+C`\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B`\9&EV/B4\+V1I=CX@/"]T9#X@
M/"]T<CX@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z('=H:71E.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0G/B`\9&EV/E!E<FUA;F5N="!I=&5M<R`M(&]T:&5R/"]D:78^
M(#PO=&0^(#QT9#X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/B`\9&EV/C`N,3PO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^(#QD
M:78^)3PO9&EV/B`\+W1D/B`\=&0^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SX@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX@
M/&1I=CXQ+C,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0G/B`\9&EV/B4\+V1I=CX@/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$
M)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C,X+#(U-2D[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<^(#QD:78^061J=7-T;65N="!O9B!.3TP@9'5E('1O(&1E8V]N<V]L:61A
M=&EO;CPO9&EV/B`\+W1D/B`\=&0^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SX@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX@
M/&1I=CXV+C(\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0G/B`\9&EV/B4\+V1I=CX@/"]T9#X@/'1D/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H="<^(#QD:78^,"XP/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)SX@/&1I=CXE/"]D:78^(#PO=&0^(#PO='(^(#QT
M<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!W:&ET93L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!0041$24Y'+4)/5%1/33H@,7!T)SX@/&1I=CY#:&%N9V4@:6X@=F%L=6%T
M:6]N(&%L;&]W86YC93PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#%P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M
M04Q)1TXZ(&QE9G0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,
M24=..B!R:6=H="<^(#QD:78^,S`N.#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^(#QD
M:78^)3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#%P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&QE
M9G0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R:6=H
M="<^(#QD:78^,SDN,#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^(#QD:78^)3PO9&EV
M/B`\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@
M<F=B*#(P-"PR,S@L,C4U*3L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT
M9#X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H="<^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SX@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)T)!0TM'4D]5
M3D0M0T],3U(Z('=H:71E.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R
M+C5P="<^(#QD:78^26YC;VUE('1A>"!P<F]V:7-I;VX@*&)E;F5F:70I/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU<'0G
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T
M)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@<FEG
M:'0G/B`\9&EV/C`N,#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SX@/&1I=CXE/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU<'0G
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T
M)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@<FEG
M:'0G/B`\9&EV/C`N,#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SX@/&1I=CXE/"]D
M:78^(#PO=&0^(#PO='(^(#PO=&%B;&4^(#QD:78@<W1Y;&4],T0G0TQ%05(Z
M8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@
M,3!P=#M-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B`F(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS
M1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].
M5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@
M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX@1F]R('1H92!Y96%R<R!E;F1E9"!-87)C:"`S,2P@,C`Q-2!A;F0@,C`Q
M-"P@=&AE($-O;7!A;GD@:&%D(&%P<')O>&EM871E;'D@)#@L,#4Y+#`P,"!A
M;F0@)#(L-3,Y+#`P,"!O9B!F961E<F%L(&%N9"!S=&%T92!N970@;W!E<F%T
M:6YG(&QO<W,@8V%R<GEO=F5R<R`H)B,X,C(P.TY/3',F(S@R,C$[*2P@<F5S
M<&5C=&EV96QY+"!W:&EC:"!B96=I;B!T;R!E>'!I<F4@:6X@,C`S,RX@5&AE
M<V4@;F5T(&]P97)A=&EN9R!L;W-S(&-A<G)Y;W9E<G,@87)E('-U8FIE8W0@
M=&\@86YN=6%L(&QI;6ET871I;VYS('5N9&5R($EN=&5R;F%L(%)E=F5N=64@
M0V]D92!396-T:6]N(#,X,B!B96-A=7-E('1H97)E(&AA<R!B965N(&$@9W)E
M871E<B!T:&%N(#4P)2!O=VYE<G-H:7`@8VAA;F=E(&9O;&QO=VEN9R!T:&4@
M36%R8V@@,C8L(#(P,30@8VQO<VEN9R!O9B!T:&4@25!/+CPO9&EV/B`\9&EV
M('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2
M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'
M24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B`F(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB
M;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q
M,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@5&AE($-O
M;7!A;GDL(&%F=&5R(&-O;G-I9&5R:6YG(&%L;"!A=F%I;&%B;&4@979I9&5N
M8V4L(&9U;&QY(')E<V5R=F5D(&ET<R!D969E<G)E9"!T87@@87-S971S('-I
M;F-E(&ET(&ES(&UO<F4@;&EK96QY('1H86X@;F]T('1H870@<W5C:"!B96YE
M9FET<R!W:6QL(&YO="!B92!R96%L:7IE9"!I;B!F=71U<F4@<&5R:6]D<RX@
M5&AE($-O;7!A;GD@:&%S(&EN8W5R<F5D(&QO<W-E<R!F;W(@8F]T:"!F:6YA
M;F-I86P@<F5P;W)T:6YG(&%N9"!I;F-O;64@=&%X('!U<G!O<V5S(&9O<B!T
M:&4@>65A<G,@96YD960@36%R8V@@,S$L(#(P,34@86YD(#(P,30N(%1H92!#
M;VUP86YY('=I;&P@8V]N=&EN=64@=&\@979A;'5A=&4@:71S(&1E9F5R<F5D
M('1A>"!A<W-E=',@=&\@9&5T97)M:6YE('=H971H97(@86YY(&-H86YG97,@
M:6X@8VER8W5M<W1A;F-E<R!C;W5L9"!A9F9E8W0@=&AE(')E86QI>F%T:6]N
M(&]F('1H96ER(&9U='5R92!B96YE9FET+B!)9B!I="!I<R!D971E<FUI;F5D
M(&EN(&9U='5R92!P97)I;V1S('1H870@<&]R=&EO;G,@;V8@=&AE($-O;7!A
M;GDF(S@R,3<[<R!D969E<G)E9"!T87@@87-S971S('-A=&ES9GD@=&AE(')E
M86QI>F%T:6]N('-T86YD87)D<RP@=&AE('9A;'5A=&EO;B!A;&QO=V%N8V4@
M=VEL;"!B92!R961U8V5D(&%C8V]R9&EN9VQY+CPO9&EV/B`\9&EV('-T>6QE
M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&
M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P
M="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B`F(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&
M3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%
M6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@5&AE($-O;7!A;GD@
M9&]E<R!N;W0@:&%V92!A;GD@=&%X('!O<VET:6]N<R!F;W(@=VAI8V@@:70@
M:7,@<F5A<V]N86)L>2!P;W-S:6)L92!T:&%T('1H92!T;W1A;"!A;6]U;G0@
M;V8@9W)O<W,@=6YR96-O9VYI>F5D('1A>"!B96YE9FET<R!W:6QL(&EN8W)E
M87-E(&]R(&1E8W)E87-E('=I=&AI;B`Q,B!M;VYT:',@;V8@36%R8V@@,S$L
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M:71S(&EN8V]M92!T87@@<')O=FES:6]N(&]R(&)E;F5F:70N)B,Q-C`[/"]D
M:78^(#PO9&EV/CQT86)L92!B;W)D97(],T0P('-T>6QE/3-$)W=I9'1H.C$P
M,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7SDR-3$W.#5B7S=E
M8F-?-#<S,5\Y8C$W7S<S-C8Y.39A.#9A9`T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B\Y,C4Q-S@U8E\W96)C7S0W,S%?.6(Q-U\W,S8V.3DV83@V
M860O5V]R:W-H965T<R]3:&5E=#$V+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^4F5L871E9"!087)T>2!4<F%N<V%C=&EO;G,\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P
M,34\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^4F5L871E9"!087)T>2!4<F%N<V%C=&EO;G,@6T%B<W1R86-T73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296QA=&5D
M(%!A<G1Y(%1R86YS86-T:6]N<R!$:7-C;&]S=7)E(%M497AT($)L;V-K73PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=-
M05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68@)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4
M+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)
M3CH@,'!T(#!P>#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX@3F]T92`Y+B!296QA=&5D(%!A<G1Y(%1R86YS86-T
M:6]N<SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-
M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%
M3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F(S$V,#L\+V1I=CX@/&1I=B!S
M='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M
M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE.
M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
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M)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SXS-BPP,#`\+V9O;G0^+CPO9&EV
M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S
M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN
M.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B`F(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#
M3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U3
M25I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@
M57!O;B!C;VUP;&5T:6]N(&]F('1H92!)4$\L(&]N($UA<F-H(#(V+"`R,#$T
M+"!/8W5L=7,@;W=N960@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ("=4
M:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@,3!P="<^(#(L
M,#`P+#`P,#PO9F]N=#X@<VAA<F5S(&]F('1H92!#;VUP86YY)B,X,C$W.W,@
M8V]M;6]N('-T;V-K(&]R(&%P<')O>&EM871E;'D@/&9O;G0@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M
M4TE:13H@,3!P="<^(#0S/"]F;VYT/B4@;V8@=&AE('1H96X@;W5T<W1A;F1I
M;F<@8V]M;6]N('-T;V-K+CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O
M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P
M<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F(S$V,#L\
M+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4
M:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P
M+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX@3VX@36%R8V@@,3,L(#(P,34L($]C=6QU
M<R!E;G1E<F5D(&EN=&\@82!S96-U<FET:65S('!U<F-H87-E(&%G<F5E;65N
M="!W:71H('-E=F5R86P@:6YV97-T;W)S+"!P=7)S=6%N="!T;R!W:&EC:"!T
M:&4@:6YV97-T;W)S(&%G<F5E9"!T;R!P=7)C:&%S92`\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].
M5"U325I%.B`Q,'!T)SX@,S4P+#`P,#PO9F]N=#X@<VAA<F5S(&]F('1H92!#
M;VUP86YY)B,X,C$W.W,@8V]M;6]N('-T;V-K(&%T(&$@<')I8V4@;V8@)#QF
M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG
M<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/C(N-S4\+V9O;G0^('!E<B!S:&%R
M92X@3VX@36%R8V@@,C,L(#(P,34L('1H:7,@<V%L92!C;&]S960N($]C=6QU
M<R!R971A:6YE9"!T:&4@=F]T:6YG(')I9VAT<R!T;R!T:&4@,S4P+#`P,"!S
M:&%R97,@=6YT:6P@86YD('1H<F]U9V@@=&AE(&1A=&4@;V8@8VQO<VEN9R!O
M9B!T:&4@365R9V5R+B!);B!T:&4@979E;G0@=&AA="!T:&4@8VQO<VEN9R!O
M9B!T:&4@365R9V5R(&1O97,@;F]T(&]C8W5R(&]N(&]R('!R:6]R('1O(%-E
M<'1E;6)E<B`S,"P@,C`Q-2P@=&AE(#,U,"PP,#`@<VAA<F5S(&]F('1H92!#
M;VUP86YY)B,X,C$W.W,@8V]M;6]N('-T;V-K('=I;&P@8F5C;VUE(&9U;&QY
M('1R861A8FQE(&%N9"!F=6QL('9O=&EN9R!R:6=H=',@=VEL;"!T<F%N<V9E
M<B!T;R!T:&4@<'5R8VAA<V5R<R!O9B!S=6-H('-H87)E<RX\+V1I=CX@/&1I
M=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@
M4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%2
M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX@/&9O;G0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&YO<FUA
M;"<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O
M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P
M<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!N;W)M86PG
M/D]N($UA<F-H(#$S+"`R,#$U+"!/8W5L=7,@96YT97)E9"!I;G1O(&$@<V5C
M=7)I=&EE<R!P=7)C:&%S92!F;VQL;W<M=7`@86=R965M96YT('=I=&@\+V9O
M;G0^(#QF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!N;W)M86PG/G-E=F5R
M86P@:6YV97-T;W)S(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^
M<'5R<W5A;G0@=&\@=VAI8V@@3V-U;'5S(&%G<F5E9"!T;R!S96QL(#QF;VYT
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R
M:68G.R!&3TY4+5-)6D4Z(#$P<'0G/B`Q+#8U,"PP,#`\+V9O;G0^('-H87)E
M<R!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!A="!A('!R
M:6-E(&]F("0\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE
M=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SXR+C<U/"]F;VYT
M/B!P97(@<VAA<F4@=&\@=&AE(&EN=F5S=&]R<R!U<&]N(&-O;7!L971I;VX@
M;V8@=&AE($UE<F=E<BP@<')O=FED960@=&AA="`\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U3
M25I%.B`Q,'!T)SX@-3`L,#`P/"]F;VYT/B!S:&%R97,@;6%Y(&)E('-O;&0@
M=&\@;VYE(&]R(&UO<F4@:6YV97-T;W)S('!R:6]R('1O(&-L;W-I;F<N($EF
M('1H92!-97)G97(@9&]E<R!N;W0@8VQO<V4@8GD@075G=7-T(#$S+"`R,#$U
M(&]R(&%S(&UA>2!B92!E>'1E;F1E9"!U<"!T;R`V,"!C86QE;F1A<B!D87ES
M(&%T($]C=6QU<R8C.#(Q-SMS(&1I<V-R971I;VXL('1H97)E('=I;&P@8F4@
M;F\@;V)L:6=A=&EO;B!O9B!T:&4@:6YV97-T;W)S('1O('!U<F-H87-E('1H
M92!S:&%R97,N($]C=6QU<R!W:6QL(')E=&%I;B!T:&4@=F]T:6YG(')I9VAT
M<R!T;R!T:&4@-3`L,#`P('-H87)E<R!U;G1I;"!A;F0@=&AR;W5G:"!T:&4@
M9&%T92!O9B!C;&]S:6YG(&]F('1H92!-97)G97(N($EN('1H92!E=F5N="!T
M:&%T('1H92!C;&]S:6YG(&]F('1H92!-97)G97(@9&]E<R!N;W0@;V-C=7(@
M;VX@;W(@<')I;W(@=&\@4V5P=&5M8F5R(#,P+"`R,#$U+"!T:&4@-3`L,#`P
M('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@=VEL;"!B96-O;64@9G5L;'D@=')A
M9&%B;&4@86YD(&9U;&P@=F]T:6YG(')I9VAT<R!W:6QL('1R86YS9F5R('1O
M('1H92!I;G9E<W1O<G,N/"]F;VYT/CPO9F]N=#X\+V1I=CX@/"]D:78^/'1A
M8FQE(&)O<F1E<CTS1#`@<W1Y;&4],T0G=VED=&@Z,3`P)3L@=&%B;&4M;&%Y
M;W5T.F9I>&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\
M='(^/'1D/CPO=&0^/"]T<CX\+W1A8FQE/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?.3(U,3<X-6)?-V5B8U\T-S,Q7SEB,3=?
M-S,V-CDY-F$X-F%D#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+SDR
M-3$W.#5B7S=E8F-?-#<S,5\Y8C$W7S<S-C8Y.39A.#9A9"]7;W)K<VAE971S
M+U-H965T,3<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY3=6)S97%U96YT($5V96YT<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=6)S97%U96YT($5V96YT<R!;
M06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-U8G-E<75E;G0@179E;G1S(%M497AT($)L;V-K73PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=-05)'24XZ
M(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68@)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,
M63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,'!T
M(#!P>#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX@3F]T92`Q,"X@4W5B<V5Q=65N="!%=F5N=',\+V1I=CX@/&1I
M=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@
M4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^(#QB/CQI/B8C
M,38P.SPO:3X\+V(^/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@
M1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-
M05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B`\8CX\:3Y3=&]C:RU"87-E9"!#;VUP96YS871I;VX\
M+VD^/"]B/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M
M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)
M3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F(S$V,#L\+V1I=CX@/&1I
M=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@
M4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%2
M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX@3VX@07!R:6P@,S`L(#(P,34L('1H92!#;VUP86YY(&=R
M86YT960@=&\@:71S(&1I<F5C=&]R<R!F=6QL>2UV97-T960L('1E;BUY96%R
M(&]P=&EO;G,@=&\@<'5R8VAA<V4@86X@86=G<F5G871E(&]F(#$U+#`P,"!S
M:&%R97,@;V8@8V]M;6]N('-T;V-K(&%T(&%N(&5X97)C:7-E('!R:6-E(&]F
M("0S+C,U('!E<B!S:&%R92P@<'5R<W5A;G0@=&\@=&AE(#(P,3,@4&QA;BX\
M+V1I=CX@/"]D:78^/'1A8FQE(&)O<F1E<CTS1#`@<W1Y;&4],T0G=VED=&@Z
M,3`P)3L@=&%B;&4M;&%Y;W5T.F9I>&5D.R<@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T<CX\+W1A8FQE/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.3(U,3<X-6)?
M-V5B8U\T-S,Q7SEB,3=?-S,V-CDY-F$X-F%D#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+SDR-3$W.#5B7S=E8F-?-#<S,5\Y8C$W7S<S-C8Y.39A
M.#9A9"]7;W)K<VAE971S+U-H965T,3@N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5"3T%#/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@
M06-C;W5N=&EN9R!0;VQI8VEE<R`H4&]L:6-I97,I/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%C8V]U;G1I;F<@
M4&]L:6-I97,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y,:7%U:61I='D@1&ES8VQO<W5R92!;4&]L:6-Y
M(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M9&EV('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B`G/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)
M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@/"]D:78^(#QD:78@<W1Y;&4],T0G
M0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M
M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,'!T(#!P
M>"`P<'0@+3`N-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
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M("8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M
M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)
M3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B!4:&4@0V]M<&%N>2!I;F-U
M<G)E9"!N970@;&]S<V5S(&]F("0\9F]N="!S='EL93TS1"=&3TY4+49!34E,
M63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T
M)SXV+#8Y,2PP,#`\+V9O;G0^(&%N9"`D/&9O;G0@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[($9/3E0M4TE:13H@
M,3!P="<^,RPQ,3@L,#`P/"]F;VYT/B!F;W(@=&AE('EE87)S(&5N9&5D($UA
M<F-H(#,Q+"`R,#$U(&%N9"`R,#$T+"!R97-P96-T:79E;'DN($%T($UA<F-H
M(#,Q+"`R,#$U+"!T:&4@0V]M<&%N>28C.#(Q-SMS('=O<FMI;F<@8V%P:71A
M;"!A;F0@86-C=6UU;&%T960@9&5F:6-I="!W97)E("0\9F]N="!S='EL93TS
M1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].
M5"U325I%.B`Q,'!T)SXY+#@X."PP,#`\+V9O;G0^(&%N9"`D/&9O;G0@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ("=4:6UE<R!.97<@4F]M86XG+"=S97)I9B<[
M($9/3E0M4TE:13H@,3!P="<^,3`L,S8P+#`P,#PO9F]N=#XL(')E<W!E8W1I
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M:65V92!P<F]F:71A8FEL:71Y+CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2
M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z
M(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F(S$V
M,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,
M63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4
M.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@5&AE($-O;7!A;GD@8F5L:65V97,@
M=&AA="!I=',@97AI<W1I;F<@8V%S:"P@=VAI8V@@:6YC;'5D97,@=&AE('!R
M;V-E961S(&9R;VT@:71S($E03RP@=VEL;"!B92!S=69F:6-I96YT('1O(&9U
M;F0@:71S('-T86YD+6%L;VYE(&]P97)A=&EO;G,@=&AR;W5G:"!T:&4@<75A
M<G1E<B!E;F1I;F<@2G5N92`S,"P@,C`Q-BX@2&]W979E<BP@:6X@;W)D97(@
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M=&4@-B`F(S$U,#L@0V]M;6ET;65N=',@86YD($-O;G1I;F=E;F-I97,@)B,Q
M-3`[($%G<F5E;65N="!A;F0@4&QA;B!O9B!-97)G97(N/"]D:78^(#PO9&EV
M/CQT86)L92!B;W)D97(],T0P('-T>6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE
M+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS
M1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G-O;&ED871I;VXL
M(%!O;&EC>2!;4&]L:6-Y(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B`G/B`\
M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE
M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@/"]D:78^
M(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@
M3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ(#!P="`P<'@[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`\<W1R
M;VYG/CQI/E!R:6YC:7!L97,@;V8@0V]N<V]L:61A=&EO;CPO:3X\+W-T<F]N
M9SX\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,
M63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4
M.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)B,Q-C`[/"]D:78^(#QD:78@<W1Y
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M92!C;VYS;VQI9&%T:6]N+B!3964@3F]T92`V("8C,34P.R!#;VUM:71M96YT
M<R!A;F0@0V]N=&EN9V5N8VEE<R`F(S$U,#L@06=R965M96YT(&%N9"!0;&%N
M(&]F($UE<F=E<BX\+V1I=CX@/"]D:78^/'1A8FQE(&)O<F1E<CTS1#`@<W1Y
M;&4],T0G=VED=&@Z,3`P)3L@=&%B;&4M;&%Y;W5T.F9I>&5D.R<@8V5L;'-P
M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T<CX\
M+W1A8FQE/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^57-E(&]F($5S=&EM871E<RP@4&]L:6-Y(%M0;VQI8WD@5&5X
M="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@
M<W1Y;&4],T0G34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF("<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z
M8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@
M,3!P=#M-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B`\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!
M4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%
M.B`Q,'!T.TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^(#QS=')O;F<^/&D^57-E(&]F($5S=&EM
M871E<SPO:3X\+W-T<F]N9SX\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB
M;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q
M,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)B,Q-C`[
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M(%-T871E<R!O9B!!;65R:6-A("@F(S@R,C`[52X@4RX@1T%!4"8C.#(R,3LI
M(')E<75I<F5S(&UA;F%G96UE;G0@=&\@;6%K92!E<W1I;6%T97,@86YD(&%S
M<W5M<'1I;VYS('1H870@869F96-T('1H92!R97!O<G1E9"!A;6]U;G1S(&]F
M(&%S<V5T<R!A;F0@;&EA8FEL:71I97,@86YD(&1I<V-L;W-U<F5S(&]F(&-O
M;G1I;F=E;G0@;&EA8FEL:71I97,@870@=&AE(&1A=&5S(&]F('1H92!C;VYS
M;VQI9&%T960@9FEN86YC:6%L('-T871E;65N=',@86YD('1H92!R97!O<G1E
M9"!A;6]U;G1S(&]F(')E=F5N=65S(&%N9"!E>'!E;G-E<R!D=7)I;F<@=&AE
M(')E<&]R=&EN9R!P97)I;V1S+B!!8W1U86P@<F5S=6QT<R!C;W5L9"!D:69F
M97(@9G)O;2!T:&5S92!E<W1I;6%T97,N(%-I9VYI9FEC86YT(&5S=&EM871E
M<R!A;F0@87-S=6UP=&EO;G,@:6YC;'5D92!S=&]C:RUB87-E9"!C;VUP96YS
M871I;VXL('1H92!V86QU871I;VX@86QL;W=A;F-E(')E;&%T960@=&\@=&AE
M($-O;7!A;GDF(S@R,3<[<R!D969E<G)E9"!T87@@87-S971S(&%N9"!T:&4@
M97AP96YS92!A;&QO8V%T:6]N<R!R96QA=&EN9R!T;R!T:&4@0V]M<&%N>28C
M.#(Q-SMS(&]P97)A=&EO;G,@<')I;W(@=&\@:71S(&1E8V]N<V]L:61A=&EO
M;B!F<F]M(&ET<R!&;W)M97(@4&%R96YT(&]N($UA<F-H(#(V+"`R,#$T+CPO
M9&EV/B`\+V1I=CX\=&%B;&4@8F]R9&5R/3-$,"!S='EL93TS1"=W:61T:#HQ
M,#`E.R!T86)L92UL87EO=70Z9FEX960[)R!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P/CQT<CX\=&0^/"]T9#X\+W1R/CPO=&%B;&4^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYC
M96YT<F%T:6]N(%)I<VLL($-R961I="!2:7-K+"!0;VQI8WD@6U!O;&EC>2!4
M97AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I
M=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68@)SX@/&1I=B!S='EL93TS1"=#3$5!
M4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%
M.B`Q,'!T.TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^(#PO9&EV/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)
M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@/'-T<F]N9SX\:3Y#;VYC96YT<F%T
M:6]N(&]F($-R961I="!2:7-K/"]I/CPO<W1R;VYG/CPO9&EV/B`\9&EV('-T
M>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA
M;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ
M(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B`F(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H
M.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T
M.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q
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M:71S+CPO9&EV/B`\+V1I=CX\=&%B;&4@8F]R9&5R/3-$,"!S='EL93TS1"=W
M:61T:#HQ,#`E.R!T86)L92UL87EO=70Z9FEX960[)R!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P/CQT<CX\=&0^/"]T9#X\+W1R/CPO=&%B;&4^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y&86ER(%9A;'5E($UE87-U<F5M96YT+"!0;VQI8WD@6U!O;&EC>2!497AT
M($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S
M='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68@)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB
M;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q
M,'!T.TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^(#PO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2
M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z
M(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX@/'-T<F]N9SX\:3Y&86ER(%9A;'5E(&]F
M($9I;F%N8VEA;"!!<W-E=',@86YD($QI86)I;&ET:65S/"]I/CPO<W1R;VYG
M/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9
M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z
M(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F(S$V,#L\+V1I=CX@/&1I=B!S='EL
M93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[
M1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P
M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
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M("8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M
M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)
M3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B!4:&4@0V]M<&%N>2!M96%S
M=7)E<R!T:&4@9F%I<B!V86QU92!O9B!F:6YA;F-I86P@87-S971S(&%N9"!L
M:6%B:6QI=&EE<R!B87-E9"!O;B!T:&4@97AC:&%N9V4@<')I8V4@=&AA="!W
M;W5L9"!B92!R96-E:79E9"!F;W(@86X@87-S970@;W(@<&%I9"!T;R!T<F%N
M<V9E<B!A(&QI86)I;&ET>2`H86X@97AI="!P<FEC92D@:6X@=&AE('!R:6YC
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M5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@
M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX@)B,Q-C`[/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].
M5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4
M+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^($QE=F5L(#$F(S$V,#LF
M(S$U,3LF(S$V,#MQ=6]T960@<')I8V5S(&EN(&%C=&EV92!M87)K971S(&9O
M<B!I9&5N=&EC86P@87-S971S(&]R(&QI86)I;&ET:65S+CPO9&EV/B`\9&EV
M('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2
M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'
M24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B`F(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB
M;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q
M,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@3&5V96P@
M,B8C,38P.R8C,34Q.R8C,38P.W%U;W1E9"!P<FEC97,@9F]R('-I;6EL87(@
M87-S971S(&%N9"!L:6%B:6QI=&EE<R!I;B!A8W1I=F4@;6%R:V5T<R!O<B!I
M;G!U=',@=&AA="!A<F4@;V)S97)V86)L92X\+V1I=CX@/&1I=B!S='EL93TS
M1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].
M5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@
M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX@)B,Q-C`[/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].
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M<W5M<'1I;VYS*2X\+V1I=CX@/"]D:78^/'1A8FQE(&)O<F1E<CTS1#`@<W1Y
M;&4],T0G=VED=&@Z,3`P)3L@=&%B;&4M;&%Y;W5T.F9I>&5D.R<@8V5L;'-P
M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T<CX\
M+W1A8FQE/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4')O<&5R='DL(%!L86YT(&%N9"!%<75I<&UE;G0L(%!O;&EC
M>2!;4&]L:6-Y(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\9&EV('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B`G/B`\9&EV('-T
M>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA
M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@/"]D:78^(#QD:78@
M<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O
M;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`\<W1R;VYG/CQI
M/E!R;W!E<G1Y(&%N9"!%<75I<&UE;G0\+VD^/"]S=')O;F<^/"]D:78^(#QD
M:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W
M(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,"XU:6X[($U!
M4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^("8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2
M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z
M(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/
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M9B!T:&4@;&5A<V4N(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM
M97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/B`\+V9O
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M.SPO9&EV/B`\=&%B;&4@<W1Y;&4],T0G5TE$5$@Z(#4P)3L@0D]21$52+4-/
M3$Q!4%-%.B!C;VQL87!S93L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
M,#X@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0^
M(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T
M.R!&3TY4+5=%24=(5#H@8F]L9"<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T
M:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ
M(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/EEE87)S/"]D:78^(#PO=&0^(#PO='(^
M(#QT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!W:&ET93L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!724142#H@.#`E)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,
M14%2.B!B;W1H)SY/9F9I8V4@97%U:7!M96YT/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=724142#H@,24G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[
M0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!724142#H@,3DE)SX@/&1I=B!S='EL93TS
M1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SX\9F]N="!S='EL93TS1"=&3TY4
M+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U325I%
M.B`Q,'!T)SX@,SPO9F]N=#X\+V1I=CX@/"]T9#X@/"]T<CX@/'1R('-T>6QE
M/3-$)T)!0TM'4D]53D0M0T],3U(Z('=H:71E.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B`\9&EV
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M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG<V5R:68G.R!&
M3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#X@/&1I=B!S='EL93TS1"=#3$5!4CIB
M;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q
M,'!T.TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^("8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$
M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4
M+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P
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M<F5D+CPO9&EV/B`\+V1I=CX\=&%B;&4@8F]R9&5R/3-$,"!S='EL93TS1"=W
M:61T:#HQ,#`E.R!T86)L92UL87EO=70Z9FEX960[)R!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P/CQT<CX\=&0^/"]T9#X\+W1R/CPO=&%B;&4^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y);7!A:7)M96YT(&]R($1I<W!O<V%L(&]F($QO;F<M3&EV960@07-S971S
M+"!0;VQI8WD@6U!O;&EC>2!497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68@)SX@
M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.
M97<@4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@,'!T(#!P>#L@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^(#PO9&EV
M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S
M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@/'-T
M<F]N9SX\:3Y);7!A:7)M96YT(&]F($QO;F<M3&EV960@07-S971S/"]I/CPO
M<W1R;VYG/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M
M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)
M3D1%3E0Z(#,P+C)P=#L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)B,Q-C`[/"]D:78^(#QD
M:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W
M(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,S`N,G!T.R!-
M05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
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M(&YO="!N96-E<W-A<FEL>2!L:6UI=&5D('1O.CPO9&EV/B`\9&EV('-T>6QE
M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&
M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z("TP+C(U:6X[($U!4D=)3CH@
M,'!T(#!P>"`P<'0@,"XU:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B`F(S$V,#L\+V1I=CX@/'1A8FQE('-T>6QE/3-$
M)TU!4D=)3BU43U`Z(#!P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@34%21TE.+4)/5%1/33H@,'!T)R!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X@/'1R('-T>6QE
M/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@<W1Y;&4],T0G5TE$5$@Z
M(#`N,C5I;B<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T
M:"<^/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=724142#H@,"XR-6EN)SX@
M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXF(S@R,C8[
M/"]D:78^(#PO=&0^(#QT9#X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,
M14%2.B!B;W1H)SYA('-I9VYI9FEC86YT(&1E8W)E87-E(&EN('1H92!F86ER
M('9A;'5E(&]F(&%N(&%S<V5T.SPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE
M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S
M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z("TP+C(U
M:6X[($U!4D=)3CH@,'!T(#!P>"`P<'0@,"XU:6X[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F(S$V,#L\+V1I=CX@/'1A
M8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+4)/5%1/33H@,'!T
M)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P
M)3X@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@<W1Y
M;&4],T0G5TE$5$@Z(#`N,C5I;B<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T
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M<V5T.SPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\9&EV('-T>6QE/3-$
M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4
M+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z("TP+C(U:6X[($U!4D=)3CH@,'!T
M(#!P>"`P<'0@,"XU:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B`F(S$V,#L\+V1I=CX@/'1A8FQE('-T>6QE/3-$)TU!
M4D=)3BU43U`Z(#!P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@34%21TE.+4)/5%1/33H@,'!T)R!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X@/'1R('-T>6QE/3-$
M)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N
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M63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4
M.B`M,"XR-6EN.R!-05)'24XZ(#!P="`P<'@@,'!T(#`N-6EN.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)B,Q-C`[/"]D
M:78^(#QT86)L92!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"3U14
M3TTZ(#!P="<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T
M:#TS1#$P,"4^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX@
M/'1D('-T>6QE/3-$)U=)1%1(.B`P+C(U:6XG/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5TE$5$@Z(#`N,C5I;B<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#
M3$5!4CH@8F]T:"<^)B,X,C(V.SPO9&EV/B`\+W1D/B`\=&0^(#QD:78@<W1Y
M;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^86X@861V97)S92!A8W1I
M;VX@;W(@87-S97-S;65N="!B>2!T:&4@52Y3+B!&;V]D(&%N9"!$<G5G($%D
M;6EN:7-T<F%T:6]N(&]R(&%N;W1H97(@<F5G=6QA=&]R.SPO9&EV/B`\+W1D
M/B`\+W1R/B`\+W1A8FQE/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58
M5"U)3D1%3E0Z("TP+C(U:6X[($U!4D=)3CH@,'!T(#!P>"`P<'0@,"XU:6X[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F
M(S$V,#L\+V1I=CX@/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%2
M1TE.+4)/5%1/33H@,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P('=I9'1H/3-$,3`P)3X@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=.
M.B!T;W`G/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N,C5I;B<^(#QD:78@<W1Y
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M:6%T960@=VET:"!A;B!I;F-O;64M<')O9'5C:6YG(&%S<V5T+CPO9&EV/B`\
M+W1D/B`\+W1R/B`\+W1A8FQE/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[
M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[
M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX@)B,Q-C`[/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%
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M:7,@<F5A<V]N86)L92X\+V1I=CX@/"]D:78^/'1A8FQE(&)O<F1E<CTS1#`@
M<W1Y;&4],T0G=VED=&@Z,3`P)3L@=&%B;&4M;&%Y;W5T.F9I>&5D.R<@8V5L
M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T
M<CX\+W1A8FQE/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N+"!/<'1I;VX@
M86YD($EN8V5N=&EV92!0;&%N<R!0;VQI8WD@6U!O;&EC>2!497AT($)L;V-K
M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS
M1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68@)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&
M3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.TU!
M4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^(#PO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[
M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[
M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
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M.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9
M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z
M(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W
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M('-T;V-K(&%N9"!R97-T<FEC=&5D('-T;V-K('5N:71S("@F(S@R,C`[4E-5
M<R8C.#(R,3LI(&)A<V5D('5P;VX@=&AE(&-L;W-I;F<@;6%R:V5T('!R:6-E
M(&]F('1H92!#;VUP86YY)B,X,C$W.W,@8V]M;6]N('-T;V-K(&]N('1H92!D
M871E('1H92!A=V%R9"!I<R!G<F%N=&5D+B!4:&4@0V]M<&%N>2!A;6]R=&EZ
M97,@=&AE(&9A:7(@=F%L=64@;V8@96UP;&]Y964@87=A<F1S(&]N)B,Q-C`[
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M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE.
M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX@)B,Q-C`[/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T
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M/'1A8FQE(&)O<F1E<CTS1#`@<W1Y;&4],T0G=VED=&@Z,3`P)3L@=&%B;&4M
M;&%Y;W5T.F9I>&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
M,#X\='(^/'1D/CPO=&0^/"]T<CX\+W1A8FQE/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S96%R8V@@86YD($1E
M=F5L;W!M96YT($5X<&5N<V4L(%!O;&EC>2!;4&]L:6-Y(%1E>'0@0FQO8VM=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$
M)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B`G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2
M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX@/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@
M1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-
M05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B`\<W1R;VYG/CQI/E)E<V5A<F-H(&%N9"!$979E;&]P
M;65N=#PO:3X\+W-T<F]N9SX\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB
M;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q
M,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)B,Q-C`[
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M:65S+CPO9&EV/B`\+V1I=CX\=&%B;&4@8F]R9&5R/3-$,"!S='EL93TS1"=W
M:61T:#HQ,#`E.R!T86)L92UL87EO=70Z9FEX960[)R!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P/CQT<CX\=&0^/"]T9#X\+W1R/CPO=&%B;&4^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%87)N:6YG<R!097(@4VAA<F4L(%!O;&EC>2!;4&]L:6-Y(%1E>'0@0FQO
M8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE
M/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B`G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[
M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[
M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX@/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T
M:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P
M=#M-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B`\<W1R;VYG/CQI/DYE="!,;W-S('!E<B!3:&%R
M93PO:3X\+W-T<F]N9SX\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H
M.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T
M.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)B,Q-C`[/"]D
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M4F]M86XL(%1I;65S+"!397)I9B<^("8C,38P.SPO9&EV/B`\9&EV('-T>6QE
M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&
M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P
M="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2
M;VUA;B<L)W-E<FEF)SL@1D].5"U325I%.B`Q,'!T)SX@/"]F;VYT/E1H92!F
M;VQL;W=I;F<@<V5C=7)I=&EE<R!A<F4@97AC;'5D960@9G)O;2!T:&4@8V%L
M8W5L871I;VX@;V8@=V5I9VAT960@879E<F%G92!D:6QU=&EV92!C;VUM;VX@
M<VAA<F5S(&)E8V%U<V4@=&AE:7(@:6YC;'5S:6]N('=O=6QD(&AA=F4@8F5E
M;B!A;G1I+61I;'5T:79E.CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O
M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P
M<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F(S$V,#L\
M+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4
M:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M04Q)1TXZ3&5F
M=#L@5$585"U)3D1%3E0Z(#!I;CL@5TE$5$@Z(#$P,"4G/B`\=&%B;&4@<W1Y
M;&4],T0G34%21TE..B`P:6X[(%=)1%1(.B`W,"4[($)/4D1%4BU#3TQ,05!3
M13H@8V]L;&%P<V4[($]615)&3$]7.B!V:7-I8FQE)R!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P(&%L:6=N/3-$;&5F=#X@/'1R/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0T-24^(#QD:78@<W1Y;&4]
M,T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV
M('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q
M<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,C,E(&-O;'-P86X]
M,T0U/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/DUA
M<F-H)B,Q-C`[,S$L/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[
M0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#0U)3X@/&1I=B!S
M='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^
M(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P
M,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/
M3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV
M('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/C(P,34\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV('-T>6QE/3-$
M)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[
M(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P
M)R!W:61T:#TS1#$Q)2!C;VQS<&%N/3-$,CX@/&1I=B!S='EL93TS1"=#3$5!
M4CIB;W1H.T-,14%2.B!B;W1H)SXR,#$T/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV('-T>6QE/3-$
M)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\
M+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS
M1#0U)3X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G
M('=I9'1H/3-$,24^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@
M8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@]
M,T0Q)3X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$P)3X@
M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H
M/3-$,24^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@
M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$P)3X@/&1I=B!S
M='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^
M(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[
M/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#0U)3X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,
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M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,3`E/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O
M=&@G/C,Q-2PX,S8\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%
M05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T
M:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$
M24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M,"4^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^+3PO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q
M-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#0U)3X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H
M.T-,14%2.B!B;W1H)SY787)R86YT<SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78@<W1Y;&4],T0G0TQ%
M05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
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M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$P)3X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2
M.B!B;W1H)SXS+#$T-2PV-3`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O
M=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78@<W1Y;&4],T0G0TQ%
M05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q,"4^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T
M:"<^,RPQ-#`L,C4P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q)3X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,
M14%2.B!B;W1H)SXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-#4E/B`\9&EV('-T>6QE
M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/E)E<W1R:6-T960@<W1O8VL@
M=6YI=',\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O
M=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4
M64Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H
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M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4
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M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=.
M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U
M<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78@<W1Y
M;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^+3PO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M
M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78@<W1Y
M;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO
M=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#0U)3X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H
M)SY4;W1A;#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@
M8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=B!S
M='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X
M(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I
M=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXS+#<X-2PU,S,\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&UI9&1L93L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78@<W1Y;&4],T0G
M0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[
M(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)
M3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI
M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78@<W1Y;&4]
M,T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^,RPQ-#`L,C4P/"]D:78^(#PO
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M,3!P="<^/"]F;VYT/CPO9&EV/B`\+V1I=CX\=&%B;&4@8F]R9&5R/3-$,"!S
M='EL93TS1"=W:61T:#HQ,#`E.R!T86)L92UL87EO=70Z9FEX960[)R!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<CX\=&0^/"]T9#X\+W1R
M/CPO=&%B;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y);F-O;64@5&%X+"!0;VQI8WD@6U!O;&EC>2!497AT($)L
M;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL
M93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68@)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H
M.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T
M.TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^(#PO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O
M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P
M<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX@/'-T<F]N9SX\:3X\9F]N="!S='EL93TS1"=&
M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF)SL@1D].5"U3
M25I%.B`Q,'!T)SX@/"]F;VYT/DEN8V]M92!487AE<SPO:3X\+W-T<F]N9SX\
M+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4
M:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P
M+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX@)B,Q-C`[/"]D:78^(#QD:78@<W1Y;&4]
M,T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/
M3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,'!T
M(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^(%1H92!#;VUP86YY(&%C8V]U;G1S(&9O<B!I;F-O;64@=&%X97,@=6YD
M97(@06-C;W5N=&EN9R!3=&%N9&%R9',@0V]D:69I8V%T:6]N("@F(S@R,C`[
M05-#)B,X,C(Q.RD@-S0P($EN8V]M92!487AE<R`H)B,X,C(P.T%30R`W-#`F
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M63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4
M.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)B,Q-C`[/"]D:78^(#QD:78@<W1Y
M;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N
M.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@
M,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^($%30R`W-#`@86QS;R!C;&%R:69I97,@=&AE(&%C8V]U;G1I;F<@
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M9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I
M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N
M-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B`F(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS
M1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].
M5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@
M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
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M+CPO9&EV/B`\+V1I=CX\=&%B;&4@8F]R9&5R/3-$,"!S='EL93TS1"=W:61T
M:#HQ,#`E.R!T86)L92UL87EO=70Z9FEX960[)R!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P/CQT<CX\=&0^/"]T9#X\+W1R/CPO=&%B;&4^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M97<@06-C;W5N=&EN9R!0<F]N;W5N8V5M96YT<RP@4&]L:6-Y(%M0;VQI8WD@
M5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD
M:78@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF("<^(#QD:78@<W1Y;&4],T0G0TQ%
M05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:
M13H@,3!P=#M-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`\+V1I=CX@/&1I=B!S='EL93TS1"=#
M3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U3
M25I%.B`Q,'!T.TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.
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M;65S+"!397)I9B<^("8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2
M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z
M(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B!);B!*
M=6YE(#(P,30L('1H92!&:6YA;F-I86P@06-C;W5N=&EN9R!3=&%N9&%R9',@
M0F]A<F0@*"8C.#(R,#M&05-")B,X,C(Q.RD@:7-S=65D($%C8V]U;G1I;F<@
M4W1A;F1A<F1S(%5P9&%T92`H)B,X,C(P.T%3528C.#(R,3LI($YO+B`R,#$T
M+3$R+"`B0V]M<&5N<V%T:6]N("T@4W1O8VL@0V]M<&5N<V%T:6]N("A4;W!I
M8R`W,3@I.B!!8V-O=6YT:6YG(&9O<B!3:&%R92U"87-E9"!087EM96YT<R!7
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M5&]P:6,@3F\N(#<Q."P@(D-O;7!E;G-A=&EO;B`M(%-T;V-K($-O;7!E;G-A
M=&EO;B(@87,@:70@<F5L871E<R!T;R!A=V%R9',@=VET:"!P97)F;W)M86YC
M92!C;VYD:71I;VYS('1H870@869F96-T('9E<W1I;F<@=&\@86-C;W5N="!F
M;W(@<W5C:"!A=V%R9',N(%1H92!A;65N9&UE;G1S(&EN($%352`R,#$T+3$R
M(&%R92!E9F9E8W1I=F4@9F]R(&%N;G5A;"!P97)I;V1S(&%N9"!I;G1E<FEM
M('!E<FEO9',@=VET:&EN('1H;W-E(&%N;G5A;"!P97)I;V1S(&)E9VEN;FEN
M9R!A9G1E<B!$96-E;6)E<B`Q-2P@,C`Q-2X@16%R;'D@861O<'1I;VX@:7,@
M<&5R;6ET=&5D+B!%;G1I=&EE<R!M87D@87!P;'D@=&AE(&%M96YD;65N=',@
M:6X@05-5(#(P,30M,3(@96ET:&5R.B`H82D@<')O<W!E8W1I=F5L>2!T;R!A
M;&P@87=A<F1S(&=R86YT960@;W(@;6]D:69I960@869T97(@=&AE(&5F9F5C
M=&EV92!D871E.R!O<B`H8BD@<F5T<F]S<&5C=&EV96QY('1O(&%L;"!A=V%R
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M;G1S+CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-
M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%
M3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F(S$V,#L\+V1I=CX@/&1I=B!S
M='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M
M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE.
M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX@26X@075G=7-T(#(P,30L('1H92!&05-"(&ES<W5E9"!!4U4@
M3F\N(#(P,30M,34L("8C.#(R,#M0<F5S96YT871I;VX@;V8@1FEN86YC:6%L
M(%-T871E;65N=',@)B,Q-3`[($=O:6YG($-O;F-E<FX@*%-U8G1O<&EC(#(P
M-2TT,"DZ($1I<V-L;W-U<F4@;V8@56YC97)T86EN=&EE<R!A8F]U="!A;B!%
M;G1I='DF(S@R,3<[<R!!8FEL:71Y('1O($-O;G1I;G5E(&%S(&$@1V]I;F<@
M0V]N8V5R;BXF(S@R,C$[(%1H92!G=6ED86YC92P@=VAI8V@@:7,@969F96-T
M:79E(&9O<B!A;FYU86P@<F5P;W)T:6YG('!E<FEO9',@96YD:6YG(&%F=&5R
M($1E8V5M8F5R(#$U+"`R,#$V+"!E>'1E;F1S('1H92!R97-P;VYS:6)I;&ET
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M+CPO9&EV/B`\+V1I=CX\=&%B;&4@8F]R9&5R/3-$,"!S='EL93TS1"=W:61T
M:#HQ,#`E.R!T86)L92UL87EO=70Z9FEX960[)R!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P/CQT<CX\=&0^/"]T9#X\+W1R/CPO=&%B;&4^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M=6)S97%U96YT($5V96YT<RP@4&]L:6-Y(%M0;VQI8WD@5&5X="!";&]C:UT\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y;&4],T0G
M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF("<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].
M5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M-05)'
M24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B`\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&
M3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.TU!
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M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("8C,38P.SPO9&EV/B`\
M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE
M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-
M05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B!-86YA9V5M96YT(&AA<R!E=F%L=6%T960@<W5B<V5Q
M=65N="!E=F5N=',@;W(@=')A;G-A8W1I;VYS(&]C8W5R<FEN9R!T:')O=6=H
M('1H92!D871E('1H97-E(&-O;G-O;&ED871E9"!F:6YA;F-I86P@<W1A=&5M
M96YT<R!W97)E(&ES<W5E9"X@4V5E($YO=&4@,3`@)B,Q-3`[(%-U8G-E<75E
M;G0@179E;G1S+CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@
M3F5W(%)O;6%N)RPG<V5R:68G.R!&3TY4+5-)6D4Z(#$P<'0G/CPO9F]N=#X\
M+V1I=CX@/"]D:78^/'1A8FQE(&)O<F1E<CTS1#`@<W1Y;&4],T0G=VED=&@Z
M,3`P)3L@=&%B;&4M;&%Y;W5T.F9I>&5D.R<@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T<CX\+W1A8FQE/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.3(U,3<X-6)?
M-V5B8U\T-S,Q7SEB,3=?-S,V-CDY-F$X-F%D#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+SDR-3$W.#5B7S=E8F-?-#<S,5\Y8C$W7S<S-C8Y.39A
M.#9A9"]7;W)K<VAE971S+U-H965T,3DN:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4R1CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY3=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C
M8V]U;G1I;F<@4&]L:6-I97,@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06-C;W5N=&EN9R!0;VQI
M8VEE<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!R;W!E<G1Y(%!L86YT($%N9"!%<75I<&UE;G0@57-E
M9G5L($QI9F4Q(%M486)L92!497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68@)SX@
M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.
M97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@
M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
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M97)I9B<^("8C,38P.SPO9&EV/B`\=&%B;&4@<W1Y;&4],T0G5TE$5$@Z(#4P
M)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,#X@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B
M;W1T;VTG/B`\=&0^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@
M8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^(#QD:78@<W1Y;&4]
M,T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[
M(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G/B`\9&EV
M('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/EEE87)S/"]D:78^
M(#PO=&0^(#PO='(^(#QT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!W
M:&ET93L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!724142#H@.#`E)SX@/&1I=B!S='EL93TS1"=#
M3$5!4CIB;W1H.T-,14%2.B!B;W1H)SY/9F9I8V4@97%U:7!M96YT/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=724142#H@,24G/B`\9&EV('-T>6QE/3-$
M)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!724142#H@,3DE)SX@
M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SX\9F]N="!S
M='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<L)W-E<FEF
M)SL@1D].5"U325I%.B`Q,'!T)SX@,SPO9F]N=#X\+V1I=CX@/"]T9#X@/"]T
M<CX@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z('=H:71E.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G
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M9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE
M(&]F($%N=&ED:6QU=&EV92!396-U<FET:65S($5X8VQU9&5D(&9R;VT@0V]M
M<'5T871I;VX@;V8@16%R;FEN9W,@4&5R(%-H87)E(%M486)L92!497AT($)L
M;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL
M93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68@)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H
M.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T
M.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q
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M:6]N('=O=6QD(&AA=F4@8F5E;B!A;G1I+61I;'5T:79E.CPO9&EV/B`\9&EV
M('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2
M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'
M24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B`F(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB
M;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q
M,'!T.U1%6%0M04Q)1TXZ3&5F=#L@5$585"U)3D1%3E0Z(#!I;CL@5TE$5$@Z
M(#$P,"4G/B`\=&%B;&4@<W1Y;&4],T0G34%21TE..B`P:6X[(%=)1%1(.B`W
M,"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($]615)&3$]7.B!V:7-I
M8FQE)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P(&%L:6=N/3-$
M;&5F=#X@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@]
M,T0T-24^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P
M)R!W:61T:#TS1#$E/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z
M(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E
M<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I
M9'1H/3-$,C,E(&-O;'-P86X],T0U/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O
M=&@[0TQ%05(Z(&)O=&@G/DUA<F-H)B,Q-C`[,S$L/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV('-T
M>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\
M+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W
M:61T:#TS1#0U)3X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B
M;W1H)SXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`W,#`G('=I9'1H/3-$,24^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#
M3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@
M8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3$E
M(&-O;'-P86X],T0R/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z
M(&)O=&@G/C(P,34\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS
M1#$E/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$Q)2!C;VQS<&%N/3-$,CX@
M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXR,#$T/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS
M1#$E/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C
M,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-S`P)R!W:61T:#TS1#0U)3X@/&1I=B!S='EL93TS1"=#3$5!4CIB
M;W1H.T-,14%2.B!B;W1H)SXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78@<W1Y;&4],T0G
M0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U7
M14E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I=B!S='EL93TS1"=#3$5!4CIB
M;W1H.T-,14%2.B!B;W1H)SXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@
M-S`P)R!W:61T:#TS1#$P)3X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,
M14%2.B!B;W1H)SXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78@<W1Y;&4],T0G0TQ%05(Z
M8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z
M(#<P,"<@=VED=&@],T0Q)3X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,
M14%2.B!B;W1H)SXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W
M:61T:#TS1#$P)3X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B
M;W1H)SXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`W,#`G('=I9'1H/3-$,24^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#
M3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#0U)3X@/&1I=B!S='EL
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M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/C,Q-2PX,S8\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV('-T>6QE
M/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78@
M<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T
M:#M#3$5!4CH@8F]T:"<^+3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T
M:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#0U)3X@/&1I=B!S
M='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SY787)R86YT<SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[
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M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=B!S='EL93TS
M1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXS+#$T-2PV-3`\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78@<W1Y;&4],T0G0TQ%
M05(Z8F]T:#M#3$5!4CH@8F]T:"<^,RPQ-#`L,C4P/"]D:78^(#PO=&0^(#QT
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M9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$-#4E/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G
M/E)E<W1R:6-T960@<W1O8VL@=6YI=',\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O
M=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)
M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z
M(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=B!S
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M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=B!S
M='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B;W1H)SXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X
M('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q,"4^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T
M:"<^+3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T
M:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#0U)3X@/&1I=B!S='EL93TS1"=#3$5!
M4CIB;W1H.T-,14%2.B!B;W1H)SY4;W1A;#PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78@<W1Y;&4],T0G
M0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[
M(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q)3X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2.B!B
M;W1H)SXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$P)3X@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.T-,14%2
M.B!B;W1H)SXS+#<X-2PU,S,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O
M=&@[0TQ%05(Z(&)O=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,
M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4
M64Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q,"4^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#M#3$5!4CH@8F]T:"<^
M,RPQ-#`L,C4P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
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M<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7SDR-3$W.#5B7S=E
M8F-?-#<S,5\Y8C$W7S<S-C8Y.39A.#9A9`T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B\Y,C4Q-S@U8E\W96)C7S0W,S%?.6(Q-U\W,S8V.3DV83@V
M860O5V]R:W-H965T<R]3:&5E=#(P+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^4')E<&%I9"!%>'!E;G-E<R!A;F0@3W1H97(@
M0W5R<F5N="!!<W-E=',@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4')E<&%I9"!%>'!E;G-E(&%N
M9"!/=&AE<B!!<W-E=',L($-U<G)E;G0@6T%B<W1R86-T73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y38VAE9'5L92!/9B!0
M<F5P86ED($5X<&5N<V5S($%N9"!/=&AE<B!#=7)R96YT($%S<V5T<R!;5&%B
M;&4@5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQD:78@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF("<^(#QD:78@<W1Y;&4],T0G
M0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M
M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,'!T(#!P
M>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M(#PO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9
M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z
M(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B!0<F5P86ED(&5X<&5N<V5S(&%N9"!O
M=&AE<B!C=7)R96YT(&%S<V5T<R!C;VYS:7-T<R!O9B!T:&4@9F]L;&]W:6YG
M.CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9
M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z
M(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F(S$V,#L\+V1I=CX@/&1I=B!S='EL
M93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[
M1D].5"U325I%.B`Q,'!T.U1%6%0M04Q)1TXZ3&5F=#L@5$585"U)3D1%3E0Z
M(#!I;CL@5TE$5$@Z(#$P,"4G/B`\=&%B;&4@<W1Y;&4],T0G34%21TE..B`P
M:6X[(%=)1%1(.B`W,"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($]6
M15)&3$]7.B!V:7-I8FQE)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P(&%L:6=N/3-$;&5F=#X@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#<P,"<@=VED=&@],T0T-24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,C,E
M(&-O;'-P86X],T0U/B`\9&EV/DUA<F-H)B,Q-C`[,S$L/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-S`P)R!W:61T:#TS1#0U)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3$E(&-O;'-P
M86X],T0R/B`\9&EV/C(P,34\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)
M1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS
M1#$Q)2!C;VQS<&%N/3-$,CX@/&1I=CXR,#$T/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-S`P)R!W:61T:#TS1#0U)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS
M1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@
M1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E
M<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#0U)3X@/&1I=CY0
M<F5P86ED(&EN<W5R86YC93PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
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M1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,3(L,#`P/"]D:78^
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M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!
M1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
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M<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-#4E
M/B`\9&EV/D-L:6YI8V%L('1E<W1I;F<@86YD(&]T:&5R(&1E<&]S:71S/"]D
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M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,3`E/B`\9&EV/C$Q-"PP,#`\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))
M1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD
M:78^,2PP,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\
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M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C(L,#`P/"]D
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M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,3`E/B`\9&EV/C(L,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$-#4E/B`\9&EV/D]T:&5R('!R97!A:60@97AP96YS97,@86YD
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M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED
M.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X
M('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q,"4^(#QD:78^,S@L,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X
M('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#0U)3X@/&1I=CY4;W1A;#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P
M>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%
M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M
M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,38V+#`P,#PO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I
M=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4
M64Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q,"4^(#QD:78^,RPP,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\+W1R/B`\+W1A8FQE/B`\+V1I=CX@/"]D:78^/'1A8FQE(&)O<F1E<CTS
M1#`@<W1Y;&4],T0G=VED=&@Z,3`P)3L@=&%B;&4M;&%Y;W5T.F9I>&5D.R<@
M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^
M/"]T<CX\+W1A8FQE/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?.3(U,3<X-6)?-V5B8U\T-S,Q7SEB,3=?-S,V-CDY-F$X-F%D
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+SDR-3$W.#5B7S=E8F-?
M-#<S,5\Y8C$W7S<S-C8Y.39A.#9A9"]7;W)K<VAE971S+U-H965T,C$N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY0<F]P97)T
M>2!A;F0@17%U:7!M96YT("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E!R;W!E<G1Y+"!0;&%N="!A
M;F0@17%U:7!M96YT(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4')O<&5R='DL(%!L86YT(&%N9"!%<75I
M<&UE;G0@6U1A8FQE(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B`G/B`\9&EV
M('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2
M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'
M24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B`\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&
M3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%
M6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@4')O<&5R='D@86YD
M(&5Q=6EP;65N="!C;VYS:7-T<R!O9B!T:&4@9F]L;&]W:6YG.CPO9&EV/B`\
M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE
M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-
M05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B`F(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!
M4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%
M.B`Q,'!T.U1%6%0M04Q)1TXZ3&5F=#L@5$585"U)3D1%3E0Z(#!I;CL@5TE$
M5$@Z(#$P,"4G/B`\=&%B;&4@<W1Y;&4],T0G34%21TE..B`P:6X[(%=)1%1(
M.B`W-24[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($]615)&3$]7.B!V
M:7-I8FQE)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P(&%L:6=N
M/3-$;&5F=#X@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED
M=&@],T0U,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q
M<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,C,E(&-O;'-P86X]
M,T0U/B`\9&EV/DUA<F-H)B,Q-C`[,S$L/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-S`P)R!W:61T:#TS1#4P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[
M($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\
M9&EV/C(P,34\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E
M<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$Q)2!C;VQS
M<&%N/3-$,CX@/&1I=CXR,#$T/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W
M:61T:#TS1#4P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E
M<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$P)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'
M2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4
M+5=%24=(5#H@-S`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#4P)3X@/&1I=CY/9F9I8V4@97%U
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M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%
M.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXT+#`P,#PO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D
M;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
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M.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^
M-"PP,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^
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M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L
M:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q
M<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M
M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$P)3X@/&1I=CXQ-38L,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
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M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#4P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$P)3X@/&1I=CXQ-C`L,#`P/"]D:78^(#PO=&0^(#QT9"!S
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M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q,"4^(#QD:78^-"PP,#`\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=.
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M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q
M<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD
M:78^*#,L,#`P*3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI
M9#L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXH,BPP,#`I/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-3`E/B`\9&EV/E!R;W!E<G1Y
M(&%N9"!E<75I<&UE;G0L(&YE=#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D
M;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M
M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'
M2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,34W+#`P,#PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P
M,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%
M.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M,"4^(#QD:78^,BPP,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M+W1R/B`\+W1A8FQE/B`\+V1I=CX@/"]D:78^/'1A8FQE(&)O<F1E<CTS1#`@
M<W1Y;&4],T0G=VED=&@Z,3`P)3L@=&%B;&4M;&%Y;W5T.F9I>&5D.R<@8V5L
M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T
M<CX\+W1A8FQE/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?.3(U,3<X-6)?-V5B8U\T-S,Q7SEB,3=?-S,V-CDY-F$X-F%D#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+SDR-3$W.#5B7S=E8F-?-#<S
M,5\Y8C$W7S<S-C8Y.39A.#9A9"]7;W)K<VAE971S+U-H965T,C(N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY!8V-O=6YT<R!0
M87EA8FQE(&%N9"!!8V-R=65D($5X<&5N<V5S("A486)L97,I/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E!A>6%B
M;&5S(&%N9"!!8V-R=6%L<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F($%C8V]U;G1S
M(%!A>6%B;&4@86YD($%C8W)U960@3&EA8FEL:71I97,@6U1A8FQE(%1E>'0@
M0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T
M>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B`G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O
M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P
M<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`\+V1I=CX@
M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.
M97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@
M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
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M+"!397)I9B<^("8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O
M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P
M<'0[5$585"U!3$E'3CI,969T.R!415A4+4E.1$5.5#H@,&EN.R!724142#H@
M,3`P)2<^(#QT86)L92!S='EL93TS1"=-05)'24XZ(#!I;CL@5TE$5$@Z(#<U
M)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@3U9%4D9,3U<Z('9I<VEB
M;&4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@86QI9VX],T1L
M969T/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS
M1#4P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S
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M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G
M('=I9'1H/3-$-3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].
M5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q,24@8V]L<W!A;CTS1#(^(#QD:78^
M,C`Q-3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3$E(&-O;'-P86X]
M,T0R/B`\9&EV/C(P,30\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H
M/3-$-3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
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M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@
M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@
M-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)
M1TA4.B`W,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$-3`E/B`\9&EV/D%C8W)U960@96UP;&]Y
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M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&
M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXY,BPP,#`\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$
M1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,3`E/B`\9&EV/C$P.2PP,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&
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M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q,"4^(#QD:78^-#,L,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL
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M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(
M5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV
M/C4P+#`P,#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT
M<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#4P)3X@/&1I
M=CY!8V-R=65D(&QE9V%L(&9E97,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U
M<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,30T
M+#`P,#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
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M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXQ.#,L,#`P/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$-3`E/B`\9&EV/D%C8W)U960@;W1H97(@<')O
M9F5S<VEO;F%L(&9E97,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^-3`L,#`P/"]D
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M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,3`E/B`\9&EV/C0U+#`P,#PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
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M(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C$R."PP,#`\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q,"4^(#QD:78^.2PP,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
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M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q,"4^(#QD:78^,30V+#`P,#PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
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M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I
M=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$-3`E/B`\9&EV/D]T
M:&5R(&%C8W)U960@97AP96YS97,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@
M<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N
M;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$P)3X@/&1I=CXS,BPP,#`\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4
M64Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXQ-"PP,#`\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4
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M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@
M9&]U8FQE.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV
M/C8S-2PP,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4
M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,3`E/B`\9&EV/C0Q,"PP,#`\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\+V1I=CX@/"]D:78^/'1A
M8FQE(&)O<F1E<CTS1#`@<W1Y;&4],T0G=VED=&@Z,3`P)3L@=&%B;&4M;&%Y
M;W5T.F9I>&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\
M='(^/'1D/CPO=&0^/"]T<CX\+W1A8FQE/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?.3(U,3<X-6)?-V5B8U\T-S,Q7SEB,3=?
M-S,V-CDY-F$X-F%D#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+SDR
M-3$W.#5B7S=E8F-?-#<S,5\Y8C$W7S<S-C8Y.39A.#9A9"]7;W)K<VAE971S
M+U-H965T,C,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$591$%#/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/E-T;V-K:&]L9&5R<R<@17%U:71Y("A486)L97,I/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T;V-K
M:&]L9&5R<R<@17%U:71Y($YO=&4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y38VAE9'5L92!/9B!3:&%R
M92U"87-E9"!#;VUP96YS871I;VXL(%=A<G)A;G0L($%C=&EV:71Y(%M486)L
M92!497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68@)SX@/&1I=B!S='EL93TS1"=#
M3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U3
M25I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@
M/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ
M5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@
M,"XU:6X[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^($$@<W5M;6%R>2!O9B!T:&4@=V%R<F%N
M="!A8W1I=FET>2!D=7)I;F<@=&AE('EE87)S(&5N9&5D($UA<F-H(#,Q+"`R
M,#$U(&ES('!R97-E;G1E9"!B96QO=SH\+V1I=CX@/&1I=B!S='EL93TS1"=#
M3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U3
M25I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@
M)B,Q-C`[/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&
M04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4%,
M24=..DQE9G0[(%1%6%0M24Y$14Y4.B`P:6X[(%=)1%1(.B`Q,#`E)SX@/'1A
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M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,S8E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
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M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T
M:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#<P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
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M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q,"4^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R
M/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#,V
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P
M,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
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M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-S`P)R!W:61T:#TS1#$Q)2!C;VQS<&%N/3-$,CX@/&1I=CY!=F5R86=E/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
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M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3`E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T
M<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0S
M-B4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%
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M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W
M,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
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M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I
M9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV/D%V97)A9V4\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-S`P)R!W:61T:#TS1#$Q)2!C;VQS<&%N/3-$,CX@/&1I=CY296UA:6YI;F<\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q,"4^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS
M1#,V)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$Q)2!C
M;VQS<&%N/3-$,CX@/&1I=CY.=6UB97(F(S$V,#MO9CPO9&EV/B`\+W1D/B`\
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M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G
M('=I9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV/D5X97)C:7-E/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#<P,"<@=VED=&@],T0Q,24@8V]L<W!A;CTS1#(^(#QD:78^3&EF93PO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@]
M,T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV/DEN
M=')I;G-I8SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P
M,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@
M/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0S-B4^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[
M(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV
M/E=A<G)A;G1S/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%
M6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV/E!R
M:6-E/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)
M1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`W,#`G('=I9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV/DEN)B,Q-C`[
M665A<G,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!
M3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#<P,"<@=VED=&@],T0Q,24@8V]L<W!A;CTS1#(^(#QD:78^5F%L=64\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,S8E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
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M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@
M-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)
M1TA4.B`W,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%
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M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H
M/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
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M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
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M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@
M-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)
M1TA4.B`W,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,S8E/B`\9&EV/D]U='-T86YD:6YG+"!-
M87)C:"`S,2P@,C`Q-#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
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M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXS+#$T,"PR-3`\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,3`E/B`\9&EV/C<N,S`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D
M;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
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M14E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,S8E/B`\9&EV/D=R86YT960\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q,"4^(#QD:78^-2PT,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U
M<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^.2XP
M-CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
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M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
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M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&
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M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@
M-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/BT\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
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M(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
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M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS
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M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=.
M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U
M<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'
M3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@
M-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/BT\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)
M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
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M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#,V)3X@/&1I=CY/=71S=&%N9&EN9RP@36%R8V@@,S$L(#(P,34\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4
M64Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
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M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X
M(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$58
M5"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU2
M24=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXW+C,Q/"]D:78^
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M3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,3`E/B`\9&EV/C$N,3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B
M;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)
M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z
M(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M
M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#,V)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@
M,W!X(&1O=6)L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P
M,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z
M(",P,#`P,#`@,W!X(&1O=6)L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52
M+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L
M93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`S<'@@
M9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0S-B4^(#QD:78^
M17AE<F-I<V%B;&4L($UA<F-H(#,Q+"`R,#$U/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L
M93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4
M+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXS+#$T,"PR-3`\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@]
M,T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT
M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXW+C,P/"]D:78^
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M3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ
M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P
M>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXQ+C$\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!L
M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@
M=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ
M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P
M>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXM/"]D
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M<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D
M=6QE($]F(%-H87)E($)A<V5D($-O;7!E;G-A=&EO;BP@5V%R<F%N=',L($)Y
M($5X97)C:7-E(%!R:6-E(%)A;F=E(%M486)L92!497AT($)L;V-K73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=-05)'
M24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68@)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!
M34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.TU!4D=)3CH@
M,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^(#PO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M
M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)
M3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM
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M("8C,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M
M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!
M3$E'3CI,969T.R!415A4+4E.1$5.5#H@,&EN.R!724142#H@,3`P)2<^(#QT
M86)L92!S='EL93TS1"=-05)'24XZ(#!I;CL@5TE$5$@Z(#<P)3L@0D]21$52
M+4-/3$Q!4%-%.B!C;VQL87!S93L@3U9%4D9,3U<Z('9I<VEB;&4G(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@86QI9VX],T1L969T/B`\='(^
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI
M9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0S-24@8V]L<W!A;CTS1#4^(#QD
M:78^5V%R<F%N=',F(S$V,#M/=71S=&%N9&EN9SPO9&EV/B`\+W1D/B`\=&0@
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M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#,S)2!C
M;VQS<&%N/3-$-3X@/&1I=CY787)R86YT<R8C,38P.T5X97)C:7-A8FQE/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'
M2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4
M+5=%24=(5#H@-S`P)R!W:61T:#TS1#$W)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q-24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)
M1TA4.B`W,#`G('=I9'1H/3-$,38E(&-O;'-P86X],T0R/B`\9&EV/E=E:6=H
M=&5D/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H
M/3-$,34E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].
M5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
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M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3<E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@]
M,T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`W,#`G('=I9'1H/3-$,38E(&-O;'-P86X],T0R/B`\9&EV/D]U
M='-T86YD:6YG/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q-B4@8V]L<W!A;CTS
M1#(^(#QD:78^079E<F%G93PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
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M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,38E(&-O
M;'-P86X],T0R/B`\9&EV/D5X97)C:7-A8FQE/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-S`P)R!W:61T:#TS1#$X)2!C;VQS<&%N/3-$,CX@/&1I=CY%>&5R8VES
M93PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
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M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,38E(&-O;'-P86X],T0R/B`\9&EV
M/DYU;6)E<B8C,38P.V]F/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q-B4@8V]L
M<W!A;CTS1#(^(#QD:78^4F5M86EN:6YG)B,Q-C`[3&EF93PO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%
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M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W
M,#`G('=I9'1H/3-$,38E(&-O;'-P86X],T0R/B`\9&EV/DYU;6)E<B8C,38P
M.V]F/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI
M9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q."4@8V]L<W!A;CTS1#(^(#QD
M:78^4')I8V4\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$58
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M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!
M3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#<P,"<@=VED=&@],T0Q-B4@8V]L<W!A;CTS1#(^(#QD:78^26XF(S$V
M,#M996%R<SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P
M,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4
M+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-S`P)R!W:61T:#TS1#$V)2!C;VQS<&%N/3-$,CX@/&1I=CY787)R
M86YT<SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@
M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/
M3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI
M9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q-R4^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z
M(#<P,"<@=VED=&@],T0Q-24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q
M-24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/
M3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI
M9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q-24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q-R4^(#QD:78^-RXR-3`P/"]D:78^(#PO
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M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,34E/B`\9&EV/C,L,#0W+#4P,#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
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M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$U)3X@/&1I=CXQ
M+C`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q-24^(#QD:78^,RPP-#<L-3`P/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,3<E/B`\9&EV/CDN,#8R-3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P
M>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P
M,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,34E/B`\9&EV/CDX+#$U,#PO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D
M;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
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M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$U)3X@
M/&1I=CXT+C`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[
M(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)
M3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$U
M)3X@/&1I=CXY,BPW-3`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4
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M2%0Z(#0P,"<@=VED=&@],T0Q-R4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
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M(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,34E
M/B`\9&EV/C,L,30U+#8U,#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
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M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$U)3X@/&1I=CXQ+C$\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&UI9&1L93L@0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4
M+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q-24^(#QD:78^,RPQ-#`L,C4P/"]D:78^(#PO=&0^(#QT9"!S='EL
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M:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT
M9#X\+W1D/CPO='(^/"]T86)L93X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F(%-H87)E+6)A<V5D
M(%!A>6UE;G0@07=A<F0L(%-T;V-K($]P=&EO;G,L(%9A;'5A=&EO;B!!<W-U
M;7!T:6]N<R!;5&%B;&4@5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQD:78@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF("<^(#QD
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M97)I9B<@86QI9VX],T1J=7-T:69Y/B8C,38P.SPO9&EV/B`\9&EV('-T>6QE
M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&
M3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T.R!415A4+4E.1$5.5#H@
M,&EN.R!724142#H@,3`P)2<^(#QT86)L92!S='EL93TS1"=-05)'24XZ(#!I
M;CL@5TE$5$@Z(#4P)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@3U9%
M4D9,3U<Z('9I<VEB;&4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS
M1#`@86QI9VX],T1L969T/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-S`P)R!W:61T:#TS1#(U)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W
M:61T:#TS1#(S)2!C;VQS<&%N/3-$-3X@/&1I=CY&;W(F(S$V,#MT:&4F(S$V
M,#M996%R)B,Q-C`[16YD960\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E
M<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I
M9'1H/3-$,C4E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#(S)2!C;VQS<&%N
M/3-$-3X@/&1I=CY-87)C:"8C,38P.S,Q+#PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#<P,"<@=VED=&@],T0R-24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$Q)2!C;VQS<&%N/3-$,CX@
M/&1I=CXR,#$U/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT
M97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q,24@8V]L
M<W!A;CTS1#(^(#QD:78^,C`Q-#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].
M5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,C4E/B`\9&EV/E)I<VL@9G)E92!I;G1E<F5S="!R871E/"]D:78^
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M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'
M2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,2XV-SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E
M/B`\9&EV/FXO83PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^
M(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#(U)3X@
M/&1I=CY%>'!E8W1E9"!T97)M("AY96%R<RD\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))
M1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD
M:78^-2XV,3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
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M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,3`E/B`\9&EV/FXO83PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO
M='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#(U
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M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU2
M24=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\
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M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\
M9&EV/FXO83PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT
M<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#(U)3X@/&1I
M=CY%>'!E8W1E9"!D:79I9&5N9',\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U
M<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,"XP
M,#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CYN
M+V$\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE
M/B`\+V1I=CX@/"]D:78^/'1A8FQE(&)O<F1E<CTS1#`@<W1Y;&4],T0G=VED
M=&@Z,3`P)3L@=&%B;&4M;&%Y;W5T.F9I>&5D.R<@8V5L;'-P86-I;F<],T0P
M(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T<CX\+W1A8FQE/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4V-H961U;&4@;V8@4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N+"!3=&]C:R!/
M<'1I;VYS+"!!8W1I=FET>2!;5&%B;&4@5&5X="!";&]C:UT\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y;&4],T0G34%21TE..B`P
M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF("<^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&04U)3%DZ
M5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.1$5.5#H@
M,"XU:6X[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^(#PO9&EV/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)
M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B!!
M('-U;6UA<GD@;V8@=&AE('-T;V-K(&]P=&EO;B!A8W1I=FET>2!D=7)I;F<@
M=&AE('EE87(@96YD960@36%R8V@@,S$L(#(P,34@:7,@<')E<V5N=&5D(&)E
M;&]W.CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-
M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%
M3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F(S$V,#L\+V1I=CX@/&1I=B!S
M='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M
M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M04Q)1TXZ3&5F=#L@5$585"U)3D1%
M3E0Z(#!I;CL@5TE$5$@Z(#$P,"4G/B`\=&%B;&4@<W1Y;&4],T0G34%21TE.
M.B`P:6X[(%=)1%1(.B`X-24[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[
M($]615)&3$]7.B!V:7-I8FQE)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P(&%L:6=N/3-$;&5F=#X@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#<P,"<@=VED=&@],T0S-B4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
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M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
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M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$P
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$Q)2!C;VQS
M<&%N/3-$,CX@/&1I=CY796EG:'1E9#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
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M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-S`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,S8E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
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M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$P)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$Q)2!C;VQS<&%N/3-$
M,CX@/&1I=CY796EG:'1E9#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
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M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3$E(&-O
M;'-P86X],T0R/B`\9&EV/D%V97)A9V4\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#<P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#,V)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q,"4^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q,24@8V]L<W!A;CTS
M1#(^(#QD:78^079E<F%G93PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
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M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3$E(&-O
M;'-P86X],T0R/B`\9&EV/E)E;6%I;FEN9SPO9&EV/B`\+W1D/B`\=&0@<W1Y
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M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-S`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,S8E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&
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M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV/DYU
M;6)E<B8C,38P.V]F/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
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M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$Q
M)2!C;VQS<&%N/3-$,CX@/&1I=CY,:69E/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&
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M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-S`P)R!W:61T:#TS1#,V)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED
M=&@],T0Q,24@8V]L<W!A;CTS1#(^(#QD:78^3W!T:6]N<SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS
M1#$Q)2!C;VQS<&%N/3-$,CX@/&1I=CY0<FEC93PO9&EV/B`\+W1D/B`\=&0@
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M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$Q)2!C
M;VQS<&%N/3-$,CX@/&1I=CY);B8C,38P.UEE87)S/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3$E
M(&-O;'-P86X],T0R/B`\9&EV/E9A;'5E/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-S`P)R!W:61T:#TS1#,V)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$P
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].
M5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@
M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@
M-S`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$P
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#,V)3X@/&1I=CY/=71S=&%N9&EN9RPF(S$V,#M-87)C:"8C,38P.S,Q+"8C
M,38P.S(P,30\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
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M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-S`P)R!W:61T:#TS1#$P)3X@/&1I=CXM/"]D:78^(#PO=&0^
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M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.
M1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3`E
M/B`\9&EV/BT\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
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M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H
M/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#<P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI
M9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,S8E/B`\9&EV/D=R86YT960\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$
M24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M,"4^(#QD:78^,S,R+#4P,#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXV+C,W/"]D
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M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO
M='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#,V
M)3X@/&1I=CY%>&5R8VES960\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
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M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
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M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#,V)3X@/&1I=CY&;W)F96ET960\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I
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M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4
M64Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXV+C,W/"]D:78^(#PO=&0^(#QT
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M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI
M9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P
M>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0S-B4^(#QD:78^3W5T
M<W1A;F1I;F<L($UA<F-H(#,Q+"`R,#$U/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U
M8FQE.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0
M041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C,Q
M-2PX,S8\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,
M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,3`E/B`\9&EV/C8N,S<\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S
M<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B
M;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!
M1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
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M4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
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M/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,S8E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N
M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]5
M3D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/
M4#H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$
M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U
M8FQE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#-P
M>"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#,V)3X@/&1I=CY%>&5R8VES86)L92P@36%R
M8V@@,S$L(#(P,34\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!4
M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O
M=6)L93L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,3`E/B`\9&EV/C@Q+#4R,CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D
M;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X
M(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,3`E/B`\9&EV/C8N,S<\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@
M9&]U8FQE.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,3`E/B`\9&EV/C@N-SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,3`E/B`\9&EV/BT\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&
M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\+V1I=CX@/"]D:78^/'1A8FQE(&)O
M<F1E<CTS1#`@<W1Y;&4],T0G=VED=&@Z,3`P)3L@=&%B;&4M;&%Y;W5T.F9I
M>&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D
M/CPO=&0^/"]T<CX\+W1A8FQE/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4V-H961U;&4@;V8@4VAA<F4M8F%S960@
M0V]M<&5N<V%T:6]N+"!3:&%R97,@075T:&]R:7IE9"!U;F1E<B!3=&]C:R!/
M<'1I;VX@4&QA;G,L(&)Y($5X97)C:7-E(%!R:6-E(%)A;F=E(%M486)L92!4
M97AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I
M=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68@)SX@/&1I=B!S='EL93TS1"=#3$5!
M4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%
M.B`Q,'!T.TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^(#PO9&EV/B`\9&EV('-T>6QE/3-$)T-,
M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)
M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B!4
M:&4@9F]L;&]W:6YG('1A8FQE('!R97-E;G1S(&EN9F]R;6%T:6]N(')E;&%T
M960@=&\@<W1O8VL@;W!T:6]N<R!A="!-87)C:"`S,2P@,C`Q-3H\+V1I=CX@
M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE<R!.
M97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M24Y$14Y4.B`P+C5I;CL@
M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX@)B,Q-C`[/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%
M05(Z8F]T:#L@1D].5"U&04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:
M13H@,3!P=#M415A4+4%,24=..DQE9G0[(%1%6%0M24Y$14Y4.B`P:6X[(%=)
M1%1(.B`Q,#`E)SX@/'1A8FQE('-T>6QE/3-$)TU!4D=)3CH@,&EN.R!72414
M2#H@-S`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!/5D521DQ/5SH@
M=FES:6)L92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG
M;CTS1&QE9G0^(#QT<CX@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P
M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#,U)2!C
M;VQS<&%N/3-$-3X@/&1I=CY/<'1I;VYS)B,Q-C`[3W5T<W1A;F1I;F<\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'
M2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED
M.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#,R)2!C;VQS<&%N/3-$-#X@/&1I
M=CY/<'1I;VYS)B,Q-C`[17AE<F-I<V%B;&4\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I
M9'1H/3-$,3<E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W
M,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'
M2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4
M+5=%24=(5#H@-S`P)R!W:61T:#TS1#$U)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-S`P)R!W:61T:#TS1#$V)2!C;VQS<&%N/3-$,CX@/&1I=CY796EG:'1E
M9#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS
M1#$U)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E
M<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F
M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&
M3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$W)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-S`P)R!W:61T:#TS1#$V)2!C;VQS<&%N/3-$,CX@/&1I=CY/=71S
M=&%N9&EN9SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
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M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D
M;&4[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,38E(&-O;'-P86X],T0R
M/B`\9&EV/D%V97)A9V4\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$V)2!C;VQS
M<&%N/3-$,CX@/&1I=CY%>&5R8VES86)L93PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
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M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-S`P)R!W:61T:#TS1#$V)2!C;VQS<&%N/3-$,CX@/&1I=CY.
M=6UB97(F(S$V,#MO9CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
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M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,38E(&-O;'-P
M86X],T0R/B`\9&EV/E)E;6%I;FEN9R8C,38P.TQI9F4\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P
M)R!W:61T:#TS1#$V)2!C;VQS<&%N/3-$,CX@/&1I=CY.=6UB97(F(S$V,#MO
M9CPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED
M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[
M(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3@E(&-O;'-P86X],T0R/B`\9&EV
M/E!R:6-E/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M
M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`W,#`G('=I9'1H/3-$,38E(&-O;'-P86X],T0R/B`\9&EV/D]P=&EO
M;G,\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E
M<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'
M3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z
M(#<P,"<@=VED=&@],T0Q-B4@8V]L<W!A;CTS1#(^(#QD:78^26XF(S$V,#M9
M96%R<SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@
M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,
M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-S`P)R!W:61T:#TS1#$V)2!C;VQS<&%N/3-$,CX@/&1I=CY/<'1I;VYS
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U7
M14E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&
M3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$W)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED
M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P
M)R!W:61T:#TS1#$U)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&UI9&1L93L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q-24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)
M1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].
M5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q-24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL
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M13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q-R4^(#QD:78^-BXS-SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D
M;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P
M,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,34E/B`\9&EV/C,Q-2PX,S8\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0
M041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
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M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED
M.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X
M('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
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M/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3<E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
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M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@
M-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,34E/B`\9&EV/C@N
M-SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H
M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$U)3X@/&1I=CXX,2PU,C(\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\+W1R/B`\+W1A8FQE/B`\+V1I=CX@/"]D:78^/'1A8FQE
M(&)O<F1E<CTS1#`@<W1Y;&4],T0G=VED=&@Z,3`P)3L@=&%B;&4M;&%Y;W5T
M.F9I>&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^
M/'1D/CPO=&0^/"]T<CX\+W1A8FQE/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V-H961U;&4@;V8@4VAA<F4M8F%S
M960@0V]M<&5N<V%T:6]N+"!297-T<FEC=&5D(%-T;V-K(&%N9"!297-T<FEC
M=&5D(%-T;V-K(%5N:71S($%C=&EV:71Y(%M486)L92!497AT($)L;V-K73PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=-
M05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68@)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4
M+49!34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.U1%6%0M
M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I
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M<R!E;F1E9"!-87)C:"`S,2P@,C`Q-2!A;F0@,C`Q-"!I<R!P<F5S96YT960@
M8F5L;W<Z/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&
M04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.
M1$5.5#H@,"XU:6X[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("8C,38P.SPO9&EV/B`\9&EV
M('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2
M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T.R!415A4+4E.
M1$5.5#H@,&EN.R!724142#H@,3`P)2<^(#QT86)L92!S='EL93TS1"=-05)'
M24XZ(#!I;CL@5TE$5$@Z(#<P)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S
M93L@3U9%4D9,3U<Z('9I<VEB;&4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D
M9&EN9STS1#`@86QI9VX],T1L969T/B`\='(^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%
M24=(5#H@-S`P)R!W:61T:#TS1#,S)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
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M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@
M=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-S`P)R!W:61T:#TS1#,S)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#<P,"<@=VED=&@],T0Q,24@8V]L<W!A;CTS1#(^(#QD:78^079E
M<F%G93PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
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M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\
M9&EV/E1O=&%L/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R
M/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#,S
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$Q)2!C;VQS
M<&%N/3-$,CX@/&1I=CY.=6UB97(F(S$V,#MO9CPO9&EV/B`\+W1D/B`\=&0@
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M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I
M9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV/D=R86YT)B,Q-C`[1&%T93PO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&
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M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV/D=R
M86YT)B,Q-C`[1&%T93PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@]
M,T0S,R4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@
M<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3$E(&-O;'-P86X],T0R
M/B`\9&EV/E5N:71S/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[
M(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3$E(&-O;'-P86X],T0R/B`\9&EV
M/D9A:7(F(S$V,#M686QU93PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/
M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U7
M14E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O
M;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$Q)2!C;VQS<&%N/3-$,CX@
M/&1I=CY&86ER)B,Q-C`[5F%L=64\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`W,#`G
M('=I9'1H/3-$,S,E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
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M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P
M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3`E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
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M.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%
M24=(5#H@-S`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%
M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/
M3E0M5T5)1TA4.B`W,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
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M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-S`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`W,#`G
M('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#<P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z
M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T
M,#`G('=I9'1H/3-$,S,E/B`\9&EV/DYO;BUV97-T960L($UA<F-H(#,Q+"`R
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M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4
M.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/BT\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@
M-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/BT\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4
M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@
M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#,S)3X@/&1I=CY'<F%N=&5D/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(
M5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV
M/BT\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&
M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M
M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D
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M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I
M=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED
M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,S,E/B`\9&EV/E9E
M<W1E9#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[
M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I
M9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
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M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S
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M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU2
M24=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\
M9&EV/BT\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D
M;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#,S)3X@/&1I=CY&;W)F96ET960\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&
M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXM/"]D:78^(#PO=&0^
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M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@
M1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F9F8[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].
M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/BT\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z
M(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2
M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'
M3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=4
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M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P
M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@
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M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P
M,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$
M24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L
M:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/BT\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)
M6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z
M(#5P>#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U7
M14E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R
M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M
M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#,S)3X@/&1I=CY'<F%N=&5D/"]D:78^(#PO=&0^
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M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
M:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$
M1$E.1RU224=(5#H@-7!X.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,3`E/B`\9&EV/C0P.2PS-34\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].
M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%
M24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@
M;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/
M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F
M9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^-BXS,#PO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
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M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q
M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$P)3X@/&1I=CXR+#4W.2PP,#`\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@
M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED
M9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z
M(#0P,"<@=VED=&@],T0S,R4^(#QD:78^5F5S=&5D/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M
M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI
M9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T
M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4
M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXH.#4L,S`X*3PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U3
M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,
M+4%,24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
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M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W
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M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%
M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@
M-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXH-3,W+#`P,"D\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO
M<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@
M;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL93TS1"=415A4
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M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4
M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($)!0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q
M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H
M=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-F9F9F
M9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].
M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG
M:'0[($9/3E0M4U193$4Z(&YO<FUA;#L@4$%$1$E.1RU224=(5#H@-7!X.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F
M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/BT\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#
M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!
M3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS
M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I
M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D<M4DE'2%0Z(#5P>#L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F
M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXM/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4
M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!
M0TM'4D]53D0Z("-F9F9F9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM
M04Q)1TXZ(&UI9&1L93L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,S,E/B`\9&EV/DYO;BUV97-T960L
M($UA<F-H(#,Q+"`R,#$U/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M
M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&UI9&1L93L@1D].5"U714E'
M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L
M93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P
M)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4
M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))
M1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/
M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C,R-"PP-#<\+V1I
M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!
M3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T
M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^
M)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[($9/3E0M4TE:
M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$
M,3`E/B`\9&EV/C8N,S`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3
M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(
M5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE
M.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)1TA4.B`T,#`G
M('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=.
M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U
M<'@[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60[($9/3E0M5T5)
M1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C(L,#0R+#`P,#PO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,
M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,
M24=..B!M:61D;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#PO=&%B;&4^(#PO9&EV/B`\
M+V1I=CX\=&%B;&4@8F]R9&5R/3-$,"!S='EL93TS1"=W:61T:#HQ,#`E.R!T
M86)L92UL87EO=70Z9FEX960[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P/CQT<CX\=&0^/"]T9#X\+W1R/CPO=&%B;&4^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
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M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14M(/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/DEN8V]M92!487AE<R`H5&%B;&5S*3QB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ
M,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY);F-O;64@
M5&%X($1I<V-L;W-U<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y38VAE9'5L92!O9B!#;VUP;VYE;G1S
M(&]F($EN8V]M92!487@@17AP96YS92`H0F5N969I="D@6U1A8FQE(%1E>'0@
M0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T
M>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B`G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O
M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P
M<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
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M*&)E;F5F:70I.CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/
M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2
M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX@)B,Q-C`[/"]D:78^(#QT86)L92!S='EL93TS1"=72414
M2#H@.#`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)
M1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1'=H:71E+7-P86-E.FYO=W)A<#L^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=W:&ET92US
M<&%C93IN;W=R87`[($9/3E0M5T5)1TA4.B!B;VQD)SX@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)W=H:71E+7-P86-E.FYO=W)A<#L@
M5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A
M;CTS1#8^(#QD:78^1F]R(%1H92!996%R<R!%;F1E9#PO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G=VAI=&4M<W!A8V4Z;F]W<F%P.R!&3TY4+5=%24=(5#H@
M8F]L9"<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<B!S='EL
M93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$=VAI
M=&4M<W!A8V4Z;F]W<F%P.SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)W=H:71E+7-P86-E.FYO=W)A<#L@4$%$1$E.1RU"3U143TTZ
M(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G=VAI=&4M<W!A8V4Z;F]W<F%P.R!"3U)$15(M
M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@
M1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X],T0V/B`\9&EV/DUA<F-H(#,Q
M+#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G=VAI=&4M<W!A8V4Z;F]W<F%P
M.R!0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)4
M24-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$=VAI=&4M<W!A8V4Z
M;F]W<F%P.SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)W=H:71E+7-P86-E.FYO=W)A<#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].
M5"U714E'2%0Z(&)O;&0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G=VAI=&4M<W!A8V4Z;F]W<F%P.R!"3U)$15(M0D]45$]-.B!B
M;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'
M2%0Z(&)O;&0G(&-O;'-P86X],T0R/B`\9&EV/C(P,34\+V1I=CX@/"]T9#X@
M/'1D('-T>6QE/3-$)W=H:71E+7-P86-E.FYO=W)A<#L@4$%$1$E.1RU"3U14
M3TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G=VAI=&4M<W!A8V4Z;F]W<F%P.R!0041$
M24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=W:&ET92US<&%C93IN;W=R
M87`[($)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'
M3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#(^(#QD
M:78^,C`Q-#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G=VAI=&4M<W!A8V4Z
M;F]W<F%P.R!0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L
M9"<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<B!S='EL93TS
M1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(S."PR-34I.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M)SX@/'1D/B`\9&EV/D9E9&5R86P\+V1I=CX@/"]T
M9#X@/'1D/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SX@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
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M/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT)SX@/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0G/B`\9&EV/BT\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P
M-"PR,S@L,C4U*3L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL
M93TS1"=0041$24Y'+4Q%1E0Z(#EP=#L@5TE$5$@Z(#<T)2<^(#QD:78^1&5F
M97)R960\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!724142#H@,24G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q,"4G/B`\
M9&EV/B@Q+#<U-"PP,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^(#QD:78^*3PO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G5TE$5$@Z(#$E)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@5TE$5$@Z(#$P)2<^(#QD:78^*#$L,#,Q+#`P,#PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z
M(#$E)SX@/&1I=CXI/"]D:78^(#PO=&0^(#PO='(^(#QT<B!S='EL93TS1"="
M04-+1U)/54Y$+4-/3$]2.B!W:&ET93L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;2<^(#QT9#X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T)SX@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SX@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)T)!
M0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C,X+#(U-2D[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^
M(#QD:78^4W1A=&4@86YD(&QO8V%L/"]D:78^(#PO=&0^(#QT9#X@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9#X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<B!S='EL93TS1"="
M04-+1U)/54Y$+4-/3$]2.B!W:&ET93L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;2<^(#QT9"!S='EL93TS1"=0041$24Y'+4Q%1E0Z(#EP="<^(#QD:78^0W5R
M<F5N=#PO9&EV/B`\+W1D/B`\=&0^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SX@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX@
M/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H="<^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO
M='(^(#QT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(S
M."PR-34I.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`Q<'0[(%!!1$1)3D<M3$5&5#H@.7!T)SX@/&1I
M=CY$969E<G)E9#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#%P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)
M1TXZ(&QE9G0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=.
M.B!R:6=H="<^(#QD:78^*#,P.2PP,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B`\
M9&EV/BD\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`Q<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L
M969T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@<FEG
M:'0G/B`\9&EV/B@Q.#(L,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,7!T)SX@/&1I=CXI
M/"]D:78^(#PO=&0^(#PO='(^(#QT<B!S='EL93TS1"="04-+1U)/54Y$+4-/
M3$]2.B!W:&ET93L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9#X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M="<^(#QD:78^*#(L,#8S+#`P,#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<^(#QD:78^*3PO9&EV/B`\+W1D/B`\=&0^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT)SX@/&1I=CXH,2PR,3,L,#`P/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SX@/&1I=CXI/"]D
M:78^(#PO=&0^(#PO='(^(#QT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2
M.B!R9V(H,C`T+#(S."PR-34I.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-
M.B`Q<'0G/B`\9&EV/D-H86YG92!I;B!V86QU871I;VX@86QL;W=A;F-E/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SX@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX@/&1I
M=CXR+#`V,RPP,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^(#QD
M:78^,2PR,3,L,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,7!T)SX@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],
M3U(Z('=H:71E.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^
M(#QD:78^26YC;VUE('1A>"!P<F]V:7-I;VX@*&)E;F5F:70I/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU<'0G/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX@/&1I
M=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX@/&1I=CXM
M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0
M041$24Y'+4)/5%1/33H@,BXU<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T)SX@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^(#QD:78^
M)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^(#QD:78^+3PO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$
M1$E.1RU"3U143TTZ(#(N-7!T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@
M/"]T<CX@/"]T86)L93X@/"]D:78^/'1A8FQE(&)O<F1E<CTS1#`@<W1Y;&4]
M,T0G=VED=&@Z,3`P)3L@=&%B;&4M;&%Y;W5T.F9I>&5D.R<@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T<CX\+W1A
M8FQE/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4V-H961U;&4@3V8@4F5C;VYC:6QI871I;VX@3V8@5&AE(%-T871U
M=&]R>2!&961E<F%L($EN8V]M92!487@@4F%T92!4;R!4:&4@0V]M<&%N>>*`
MF7,@969F96-T:79E(%1A>"!2871E(%M486)L92!497AT($)L;V-K73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=-05)'
M24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68@)SX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!
M34E,63I4:6UE<R!.97<@4F]M86X[1D].5"U325I%.B`Q,'!T.T-,14%2.B!B
M;W1H)SX@/"]D:78^(#QD:78@<W1Y;&4],T0G0TQ%05(Z8F]T:#L@1D].5"U&
M04U)3%DZ5&EM97,@3F5W(%)O;6%N.T9/3E0M4TE:13H@,3!P=#M415A4+4E.
M1$5.5#H@,"XU:6X[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^(%1H92!#;VUP86YY(&AA<R!T
M:&4@9F]L;&]W:6YG(&YE="!D969E<G)E9"!T87@@87-S971S.CPO9&EV/B`\
M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE
M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)B,Q-C`[
M/"]D:78^(#QT86)L92!S='EL93TS1"=724142#H@.#`E.R!"3U)$15(M0T],
M3$%04T4Z(&-O;&QA<'-E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P
M/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S
M='EL93TS1'=H:71E+7-P86-E.FYO=W)A<#L^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=W:&ET92US<&%C93IN;W=R87`[(%!!1$1)
M3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)W=H:71E+7-P86-E.FYO=W)A
M<#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=.
M.B!C96YT97([($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$-CX@/&1I
M=CY-87)C:"`S,2P\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)W=H:71E+7-P
M86-E.FYO=W)A<#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z
M(&)O;&0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(@<W1Y
M;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1'=H
M:71E+7-P86-E.FYO=W)A<#L^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=W:&ET92US<&%C93IN;W=R87`[(%!!1$1)3D<M0D]45$]-
M.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)W=H:71E+7-P86-E.FYO=W)A<#L@0D]21$52
M+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT97([
M($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,CX@/&1I=CXR,#$U/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=W:&ET92US<&%C93IN;W=R87`[(%!!
M1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)SX@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)W=H:71E+7-P86-E.FYO
M=W)A<#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G=VAI=&4M
M<W!A8V4Z;F]W<F%P.R!"3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[
M(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P
M86X],T0R/B`\9&EV/C(P,30\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)W=H
M:71E+7-P86-E.FYO=W)A<#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U7
M14E'2%0Z(&)O;&0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\
M='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR,S@L,C4U
M*3L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9#X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T
M9#X@/"]T<CX@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z('=H:71E
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[(%=)1%1(.B`W-"4G/B`\9&EV/DYE="!O<&5R871I;F<@
M;&]S<R!C87)R>69O<G=A<F1S/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=7
M24142#H@,24G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@/&1I=CXD/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@5TE$5$@Z
M(#$P)2<^(#QD:78^,RPR,C0L,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B`\9&EV/B8C,38P.SPO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#$E)SX@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M(%=)1%1(.B`Q)2<^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q,"4G/B`\9&EV/C$L-#(W+#`P
M,#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M5TE$5$@Z(#$E)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R
M('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C,X+#(U-2D[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0^(#QD:78^4W1O8VLM8F%S
M960@8V]M<&5N<V%T:6]N/"]D:78^(#PO=&0^(#QT9#X@/&1I=CXF(S$V,#L\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B`\
M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0G/B`\9&EV/C(V,BPP,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX@/&1I=CXM/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SX@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M
M0T],3U(Z('=H:71E.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G
M/B`\9&EV/D-H87)I=&%B;&4@9&]N871I;VX@8V%R<GEF;W)W87)D<SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^(#QD:78^
M-"PP,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^(#QD:78^+3PO
M9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$
M1$E.1RU"3U143TTZ(#%P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO
M='(^(#QT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(S
M."PR-34I.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M3$5&5#H@.7!T)SX@/&1I=CY'
M<F]S<R!D969E<G)E9"!T87@@87-S971S/"]D:78^(#PO=&0^(#QT9#X@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0G/B`\9&EV/C,L-#DP+#`P,#PO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#QT9#X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B`\9&EV/B8C,38P.SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/B`\9&EV
M/C$L-#(W+#`P,#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<B!S
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M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX@
M/&1I=CXH,RPT.3`L,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,7!T)SX@/&1I=CXI/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SX@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX@/&1I
M=CXH,2PT,C<L,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,7!T)SX@/&1I=CXI/"]D:78^
M(#PO=&0^(#PO='(^(#QT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!R
M9V(H,C`T+#(S."PR-34I.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SX@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.
M1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N
M-7!T)SX@/&1I=CXF(S$V,#M.970@9&5F97)R960@=&%X(&%S<V5T<SPO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T)SX@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^
M(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^(#QD
M:78^+3PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SX@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/B`\
M9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/B`\9&EV
M/BT\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#PO='(^(#PO=&%B;&4^(#PO9&EV/CQT86)L92!B;W)D97(],T0P('-T
M>6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^
M/"]T86)L93X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-C:&5D=6QE(&]F($5F9F5C=&EV92!);F-O;64@5&%X(%)A
M=&4@4F5C;VYC:6QI871I;VX@6U1A8FQE(%1E>'0@0FQO8VM=/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)TU!4D=)3CH@
M,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B`G/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9
M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@
M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
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M;W=S.CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-
M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P
M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX@)B,Q-C`[/"]D:78^(#QT86)L92!S='EL93TS1"=724142#H@.#`E
M.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O
M='1O;2<^(#QT9"!S='EL93TS1'=H:71E+7-P86-E.FYO=W)A<#L^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=W:&ET92US<&%C93IN
M;W=R87`[($9/3E0M5T5)1TA4.B!B;VQD)SX@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)W=H:71E+7-P86-E.FYO=W)A<#L@5$585"U!
M3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#8^
M(#QD:78^1F]R(%1H92!996%R<R!%;F1E9#PO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G=VAI=&4M<W!A8V4Z;F]W<F%P.R!&3TY4+5=%24=(5#H@8F]L9"<^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<B!S='EL93TS1"=6
M15)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$=VAI=&4M<W!A
M8V4Z;F]W<F%P.SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE
M/3-$)W=H:71E+7-P86-E.FYO=W)A<#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@
M1D].5"U714E'2%0Z(&)O;&0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\
M=&0@<W1Y;&4],T0G=VAI=&4M<W!A8V4Z;F]W<F%P.R!"3U)$15(M0D]45$]-
M.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U7
M14E'2%0Z(&)O;&0G(&-O;'-P86X],T0V/B`\9&EV/DUA<F-H(#,Q+#PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G=VAI=&4M<W!A8V4Z;F]W<F%P.R!0041$
M24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^(#QD:78^)B,Q
M-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)424-!3"U!
M3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$=VAI=&4M<W!A8V4Z;F]W<F%P
M.SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)W=H:71E
M+7-P86-E.FYO=W)A<#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'
M2%0Z(&)O;&0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G=VAI=&4M<W!A8V4Z;F]W<F%P.R!"3U)$15(M0D]45$]-.B!B;&%C:R`Q
M<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O
M;&0G(&-O;'-P86X],T0R/B`\9&EV/C(P,34\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)W=H:71E+7-P86-E.FYO=W)A<#L@4$%$1$E.1RU"3U143TTZ(#%P
M=#L@1D].5"U714E'2%0Z(&)O;&0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G=VAI=&4M<W!A8V4Z;F]W<F%P.R!0041$24Y'+4)/
M5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^(#QD:78^)B,Q-C`[/"]D
M:78^(#PO=&0^(#QT9"!S='EL93TS1"=W:&ET92US<&%C93IN;W=R87`[($)/
M4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#(^(#QD:78^,C`Q
M-#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G=VAI=&4M<W!A8V4Z;F]W<F%P
M.R!0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT<B!S='EL93TS1"="04-+
M1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(S."PR-34I.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)
M1%1(.B`W-"4G/B`\9&EV/D5X<&5C=&5D(&9E9&5R86P@<W1A='5T;W)Y(')A
M=&4\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^(#QD:78^
M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!724142#H@,24G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q,"4G/B`\9&EV
M/B@S-"XP/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!724142#H@,24G/B`\9&EV/BDE/"]D:78^(#PO=&0^(#QT9"!S='EL
M93TS1"=724142#H@,24G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@/&1I=CXF
M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!724142#H@,3`E)SX@/&1I=CXH,S0N,#PO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@/&1I=CXI
M)3PO9&EV/B`\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#
M3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<^(#QD:78^4W1A=&4@=&%X(')A=&4L
M(&YE="!O9B!F961E<F%L(&)E;F5F:70\+V1I=CX@/"]T9#X@/'1D/B`\9&EV
M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H="<^(#QD:78^*#8N,#PO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^(#QD:78^*24\+V1I=CX@/"]T
M9#X@/'1D/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^(#QD:78^*#8N,#PO9&EV
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^(#QD:78^
M*24\+V1I=CX@/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M
M0T],3U(Z(')G8B@R,#0L,C,X+#(U-2D[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VTG/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^(#QD:78^0VAA
M;F=E(&EN(&5F9F5C=&EV92!S=&%T92!T87@@<F%T93PO9&EV/B`\+W1D/B`\
M=&0^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX@/&1I=CXP+C`\+V1I=CX@/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B`\9&EV/B4\+V1I
M=CX@/"]T9#X@/'1D/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^(#QD:78^*#`N
M,SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^
M(#QD:78^*24\+V1I=CX@/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)T)!0TM'
M4D]53D0M0T],3U(Z('=H:71E.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B`\9&EV/E!E<FUA;F5N
M="!I=&5M<R`M('-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;CPO9&EV/B`\+W1D
M/B`\=&0^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX@/&1I=CXR+C4\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B`\9&EV/B4\
M+V1I=CX@/"]T9#X@/'1D/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^(#QD:78^
M,"XP/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)SX@/&1I=CXE/"]D:78^(#PO=&0^(#PO='(^(#QT<B!S='EL93TS1"="04-+
M1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(S."PR-34I.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B`\
M9&EV/E!E<FUA;F5N="!I=&5M<R`M(&YO;BUD961U8W1I8FQE(&UE<F=E<B!E
M>'!E;G-E<SPO9&EV/B`\+W1D/B`\=&0^(#QD:78^)B,Q-C`[/"]D:78^(#PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SX@/&1I=CXF(S$V
M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M)SX@/&1I=CXP+C0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0G/B`\9&EV/B4\+V1I=CX@/"]T9#X@/'1D/B`\9&EV/B8C,38P
M.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^
M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H="<^(#QD:78^,"XP/"]D:78^(#PO=&0^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)SX@/&1I=CXE/"]D:78^(#PO=&0^(#PO='(^
M(#QT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!W:&ET93L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)SX@/&1I=CY097)M86YE;G0@:71E;7,@+2!O=&AE<CPO9&EV/B`\+W1D
M/B`\=&0^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX@/&1I=CXP+C$\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B`\9&EV/B4\
M+V1I=CX@/"]T9#X@/'1D/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^(#QD:78^
M,2XS/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)SX@/&1I=CXE/"]D:78^(#PO=&0^(#PO='(^(#QT<B!S='EL93TS1"="04-+
M1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(S."PR-34I.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B`\
M9&EV/D%D:G5S=&UE;G0@;V8@3D],(&1U92!T;R!D96-O;G-O;&ED871I;VX\
M+V1I=CX@/"]T9#X@/'1D/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^(#QD:78^)B,Q-C`[/"]D:78^
M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^(#QD:78^
M-BXR/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)SX@/&1I=CXE/"]D:78^(#PO=&0^(#QT9#X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0G/B`\9&EV/C`N,#PO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<^(#QD:78^)3PO9&EV/B`\+W1D/B`\+W1R/B`\='(@<W1Y
M;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$
M1$E.1RU"3U143TTZ(#%P="<^(#QD:78^0VAA;F=E(&EN('9A;'5A=&EO;B!A
M;&QO=V%N8V4\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`Q<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=.
M.B!L969T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@
M<FEG:'0G/B`\9&EV/C,P+C@\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B`\9&EV/B4\
M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G
M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L969T)SX@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G/B`\
M9&EV/C,Y+C`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B`\9&EV/B4\+V1I=CX@/"]T
M9#X@/"]T<CX@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R
M,#0L,C,X+#(U-2D[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9#X@/&1I=CXF(S$V,#L\+V1I=CX@
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B`\9&EV/B8C
M,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9#X@
M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^(#QD:78^)B,Q-C`[
M/"]D:78^(#PO=&0^(#PO='(^(#QT<B!S='EL93TS1"="04-+1U)/54Y$+4-/
M3$]2.B!W:&ET93L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,BXU<'0G
M/B`\9&EV/DEN8V]M92!T87@@<')O=FES:6]N("AB96YE9FET*3PO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T)SX@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX@
M/&1I=CXP+C`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^(#QD:78^)3PO9&EV/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T)SX@/&1I
M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^(#QD
M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX@
M/&1I=CXP+C`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^(#QD:78^)3PO9&EV/B`\
M+W1D/B`\+W1R/B`\+W1A8FQE/B`\+V1I=CX\=&%B;&4@8F]R9&5R/3-$,"!S
M='EL93TS1"=W:61T:#HQ,#`E.R!T86)L92UL87EO=70Z9FEX960[)R!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<CX\=&0^/"]T9#X\+W1R
M/CPO=&%B;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%\Y,C4Q-S@U8E\W96)C7S0W,S%?.6(Q-U\W,S8V.3DV83@V860-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.3(U,3<X-6)?-V5B8U\T-S,Q
M7SEB,3=?-S,V-CDY-F$X-F%D+U=O<FMS:&5E=',O4VAE970R-2YH=&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P151)04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3W)G86YI>F%T
M:6]N(&%N9"!0;&%N(&]F($UE<F=E<B`H1&5T86EL<R!497AT=6%L*2`H25!/
M(%M-96UB97)=+"!54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,2!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^36%R+B`R,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y-87(N(#(V+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y)4$\@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^26YI=&EA;"!0=6)L:6,@3V9F97)I;F<@56YI=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-C4P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-C4P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^26YI=&EA;"!0=6)L:6,@3V9F97)I;F<@4')I8V4@4&5R(%5N:70\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-RXR-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-RXR-3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.3(U,3<X
M-6)?-V5B8U\T-S,Q7SEB,3=?-S,V-CDY-F$X-F%D#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+SDR-3$W.#5B7S=E8F-?-#<S,5\Y8C$W7S<S-C8Y
M.39A.#9A9"]7;W)K<VAE971S+U-H965T,C8N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5!3$%#
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-U;6UA<GD@;V8@4VEG;FEF:6-A
M;G0@06-C;W5N=&EN9R!0;VQI8VEE<R`H1&5T86EL<RD\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]F9FEC92!E<75I<&UE;G0@
M6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY0<F]P97)T>2P@4&QA;G0@86YD($5Q=6EP;65N="!;3&EN92!)=&5M
M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4')O<&5R='DL(%!L86YT(&%N9"!%<75I<&UE;G0L(%5S969U;"!,:69E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XS('EE87)S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-961I8V%L
M(&5Q=6EP;65N="!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/E!R;W!E<G1Y+"!0;&%N="!A;F0@17%U:7!M96YT
M(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0<F]P97)T>2P@4&QA;G0@86YD($5Q=6EP;65N="P@57-E
M9G5L($QI9F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C4@>65A
M<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D9U<FYI='5R92!A;F0@9FEX='5R97,@6TUE;6)E<ET\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY0<F]P97)T>2P@4&QA
M;G0@86YD($5Q=6EP;65N="!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O<&5R='DL(%!L86YT(&%N
M9"!%<75I<&UE;G0L(%5S969U;"!,:69E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XW('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%\Y,C4Q-S@U8E\W96)C7S0W,S%?.6(Q-U\W,S8V.3DV
M83@V860-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.3(U,3<X-6)?
M-V5B8U\T-S,Q7SEB,3=?-S,V-CDY-F$X-F%D+U=O<FMS:&5E=',O4VAE970R
M-RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I
M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M
M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P14Q+044^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S("A$
M971A:6QS(#$I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0R/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-
M87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^4W5M;6%R>2!/9B!3:6=N:69I8V%N="!!8V-O=6YT
M:6YG(%!O;&EC:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;G1I9&EL=71I=F4@4V5C=7)I=&EE
M<R!%>&-L=61E9"!F<F]M($-O;7!U=&%T:6]N(&]F($5A<FYI;F=S(%!E<B!3
M:&%R92P@06UO=6YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M+#<X-2PU,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS+#$T,"PR-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D5M<&QO>65E(%-T;V-K($]P=&EO;B!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/E-U;6UA<GD@3V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^06YT:61I;'5T:79E(%-E8W5R:71I97,@17AC;'5D960@9G)O
M;2!#;VUP=71A=&EO;B!O9B!%87)N:6YG<R!097(@4VAA<F4L($%M;W5N=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S$U+#@S-CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A
M;G1S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^4W5M;6%R>2!/9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O
M;&EC:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!;G1I9&EL=71I=F4@4V5C=7)I=&EE<R!%>&-L
M=61E9"!F<F]M($-O;7!U=&%T:6]N(&]F($5A<FYI;F=S(%!E<B!3:&%R92P@
M06UO=6YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#$T-2PV
M-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS+#$T,"PR-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E)E<W1R:6-T960@4W1O8VL@56YI=',@*%)357,I(%M-
M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^4W5M;6%R>2!/9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S
M(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y!;G1I9&EL=71I=F4@4V5C=7)I=&EE<R!%>&-L=61E9"!F
M<F]M($-O;7!U=&%T:6]N(&]F($5A<FYI;F=S(%!E<B!3:&%R92P@06UO=6YT
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,C0L,#0W/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.3(U,3<X-6)?
M-V5B8U\T-S,Q7SEB,3=?-S,V-CDY-F$X-F%D#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+SDR-3$W.#5B7S=E8F-?-#<S,5\Y8C$W7S<S-C8Y.39A
M.#9A9"]7;W)K<VAE971S+U-H965T,C@N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5)1$%#/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@
M06-C;W5N=&EN9R!0;VQI8VEE<R`H1&5T86EL<R!497AT=6%L*2`H55-$("0I
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0R/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R
M,#$U/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L
M(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^4W5M;6%R>2!/9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC
M:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y.970@26YC;VUE("A,;W-S*2!!='1R:6)U=&%B;&4@
M=&\@4&%R96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#8L
M-CDQ+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B0@*#,L,3$X+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=O<FMI;F<@0V%P:71A;#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PX.#@L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2971A:6YE9"!%
M87)N:6YG<R`H06-C=6UU;&%T960@1&5F:6-I="D\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^)"`H,3`L,S8P+#`P,"D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#,L-C8Y+#`P,"D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7SDR-3$W.#5B
M7S=E8F-?-#<S,5\Y8C$W7S<S-C8Y.39A.#9A9`T*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B\Y,C4Q-S@U8E\W96)C7S0W,S%?.6(Q-U\W,S8V.3DV
M83@V860O5V]R:W-H965T<R]3:&5E=#(Y+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%04A!0SX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY0<F5P86ED($5X<&5N<V5S(&%N9"!/
M=&AE<B!#=7)R96YT($%S<V5T<R`H1&5T86EL<RD@*%531"`D*3QB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R
M,#$U/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L
M(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^4')E<&%I9"!%>'!E;G-E<R!!;F0@3W1H97(@0W5R<F5N="!!<W-E
M=',@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!R97!A:60@:6YS=7)A;F-E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#$R+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0VQI;FEC86P@=&5S=&EN
M9R!A;F0@;W1H97(@9&5P;W-I=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$Q-"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4')E<&%I9"!R96YT/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<B!P<F5P86ED
M(&5X<&5N<V5S(&%N9"!C=7)R96YT(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,S@L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#$V-BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
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M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P151&044^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0Q/CQS=')O;F<^4')O<&5R='D@86YD($5Q=6EP;65N="`H1&5T86EL
M<RD@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4')O<&5R='DL(%!L86YT(&%N9"!%
M<75I<&UE;G0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W!E<G1Y(%!L86YT($%N9"!%<75I<&UE
M;G0@1W)O<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,38P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@-"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DQE<W,Z(&%C8W5M=6QA=&5D(&1E<')E8VEA=&EO;B!A
M;F0@86UO<G1I>F%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@S+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@R+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T>2!A;F0@97%U:7!M96YT+"!N970\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U-RPP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3V9F:6-E($5Q=6EP;65N="!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E!R;W!E<G1Y+"!0;&%N="!A;F0@17%U
M:7!M96YT(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T>2!0;&%N="!!;F0@17%U:7!M96YT
M($=R;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y-961I8V%L($5Q=6EP;65N="!;365M8F5R73PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E!R;W!E<G1Y+"!0;&%N="!A
M;F0@17%U:7!M96YT(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T>2!0;&%N="!!;F0@17%U
M:7!M96YT($=R;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#$U-BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
M>'1087)T7SDR-3$W.#5B7S=E8F-?-#<S,5\Y8C$W7S<S-C8Y.39A.#9A9`T*
M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\Y,C4Q-S@U8E\W96)C7S0W
M,S%?.6(Q-U\W,S8V.3DV83@V860O5V]R:W-H965T<R]3:&5E=#,Q+FAT;6P-
M"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-
M"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-
M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%2D8^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4')O<&5R='D@
M86YD($5Q=6EP;65N="`H1&5T86EL<R!497AT=6%L*2`H55-$("0I/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0R/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E<')E8VEA
M=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
M7SDR-3$W.#5B7S=E8F-?-#<S,5\Y8C$W7S<S-C8Y.39A.#9A9`T*0V]N=&5N
M="U,;V-A=&EO;CH@9FEL93HO+R]#.B\Y,C4Q-S@U8E\W96)C7S0W,S%?.6(Q
M-U\W,S8V.3DV83@V860O5V]R:W-H965T<R]3:&5E=#,R+FAT;6P-"D-O;G1E
M;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E
M;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT
M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%04Y!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY!8V-O=6YT<R!087EA
M8FQE(&%N9"!!8V-R=65D($5X<&5N<V5S("A$971A:6QS*2`H55-$("0I/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@
M,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R
M+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY!8V-O=6YT<R!087EA8FQE($%N9"!!8V-R=65D($5X<&5N
M<V5S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!8V-R=65D(&5M<&QO>65E(&-O;7!E;G-A=&EO;CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Y,BPP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$P.2PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D%C8W)U960@9&ER96-T;W(@8V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT,RPP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@;&5G
M86P@9F5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30T+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$X,RPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%C8W)U960@;W1H97(@<')O9F5S<VEO;F%L(&9E97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0U+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C
M<G5E9"!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0@9F5E<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3(X+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDL,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D(&9R
M86YC:&ES92!T87AE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,30V+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D]T:&5R(&%C8W)U960@97AP96YS97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,R+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8S-2PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0Q,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7SDR-3$W
M.#5B7S=E8F-?-#<S,5\Y8C$W7S<S-C8Y.39A.#9A9`T*0V]N=&5N="U,;V-A
M=&EO;CH@9FEL93HO+R]#.B\Y,C4Q-S@U8E\W96)C7S0W,S%?.6(Q-U\W,S8V
M.3DV83@V860O5V]R:W-H965T<R]3:&5E=#,S+FAT;6P-"D-O;G1E;G0M5')A
M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP
M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@
M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%-EE0
M33X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VUM:71M96YT<R!A;F0@0V]N
M=&EN9V5N8VEE<R`H1&5T86EL<R!497AT=6%L*2`H55-$("0I/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C`@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#(^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^,"!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R
M/C`@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#(^,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3X\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1F5B+B`Q,2P@,C`Q-3QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/G-Q9G0\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#`S+"`R,#$U
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,3`L(#(P
M,34\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`Q,RP@
M,C`Q-3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#(V
M+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@
M,3(L(#(P,34\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^075G
M+B`Q,BP@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y.
M;W8N(#(X+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DIU;BX@,C0L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^36%R+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y*=6XN(#,P+"`R,#$U/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DIU;"X@,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^075G+B`Q,RP@,C`Q-3QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y!<'(N(#`R+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DIA;BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]M;6ET;65N=',@06YD($-O
M;G1I;F=E;F-I97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5Q=6ET>2!-971H;V0@26YV97-T;65N
M="P@3W=N97)S:&EP(%!E<F-E;G1A9V4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$W+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V%S:#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`Q,"PS-3<L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q-2PU-S$L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Y-BPP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R
M;V-E961S($9R;VT@5')A;G-F97(@071L96%S="!&;W(@3F]T($-O;G-U;6UA
M=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#@P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DQA;F0@4W5B:F5C="!T;R!'<F]U;F0@3&5A<V5S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XY.34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P97)A=&EN9R!,96%S97,L(%)E;G0@
M17AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PW,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-U8G-E<75E;G0@179E;G0@6TUE;6)E<ET\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM:71M96YT
M<R!!;F0@0V]N=&EN9V5N8VEE<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!E<F%T:6YG($QE87-E
M<RP@1G5T=7)E($UI;FEM=6T@4&%Y;65N=',@1'5E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XU+#`W-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5W($-O;G-U;'1I;F<@06=R965M
M96YT<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D-O;6UI=&UE;G1S($%N9"!#;VYT:6YG96YC:65S(%M,:6YE
M($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y3=&]C:R!)<W-U960@1'5R:6YG(%!E<FEO9"P@4VAA<F5S+"!)<W-U
M960@9F]R(%-E<G9I8V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS-#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3V-U;'5S(%-I9&4@3&5T=&5R($%G<F5E;65N
M="!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D-O;6UI=&UE;G1S($%N9"!#;VYT:6YG96YC:65S(%M,:6YE($ET
M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y,:6%B:6QI=&EE<R!!<W-U;65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XU+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^365R9V5R($-L;W-I;F<@1&%T92!)<R!.;R!,871E
M<B!4:&%N($IU;'D@,S$L(#(P,34@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM:71M96YT<R!!;F0@0V]N
M=&EN9V5N8VEE<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-97)G97(@0VQO<VEN9R!$871E($ES
M($%F=&5R($IU;'D@,S$L(#(P,34@0G5T($YO($QA=&5R(%1H86X@075G=7-T
M(#$S+"`R,#$U(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^0V]M;6ET;65N=',@06YD($-O;G1I;F=E;F-I97,@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-A<V@\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C@L.#4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4'5L;6%T<FEX($EN8R!;365M8F5R73PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O;6UI=&UE;G1S($%N
M9"!#;VYT:6YG96YC:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%<75I='D@365T:&]D($EN=F5S
M=&UE;G0L($]W;F5R<VAI<"!097)C96YT86=E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XX,RXP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]C=6QU<R!;365M8F5R73PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O;6UI=&UE;G1S
M($%N9"!#;VYT:6YG96YC:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97-C<FEP=&EO;B!/9B!3
M97!A<F%T:6]N($%G<F5E;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^<V5P87)A=&EO;B!A9W)E96UE;G0@8F5C86UE(&5F9F5C=&EV92!U
M<&]N('1H92!C;VUP;&5T:6]N(&]F('1H92!)4$\@86YD('1E<FUI;F%T97,@
M;VX@=&AE(&5A<FQI97(@;V8@."XU('EE87)S(&9O;&QO=VEN9R!T:&4@8VQO
M<VEN9R!O9B!T:&4@25!/(&]R('=H96X@=&AE('!A<G1I97,@;75T=6%L;'D@
M86=R964@=&\@=&5R;6EN871E(&ET+CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@27-S=65D($1U<FEN9R!0
M97)I;V0L(%-H87)E<RP@3F5W($ES<W5E<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,BPP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y097)C96YT86=E($]F($=R;W-S('!R
M;V-E961S(%!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$P+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4')O8V5E9',@9G)O;2!386QE<R!O9B!"=7-I;F5S<RP@069F
M:6QI871E(&%N9"!0<F]D=6-T:79E($%S<V5T<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1G5N9"!4;R!087D@0V5R=&%I
M;B!!8V-O=6YT(%!A>6%B;&5S($]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XU,S0L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S8P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36EN:6UU;2!$=7)A
M=&EO;B!&;W(@4VAA<F5S(%1R86YS9F5R/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XT,2!M;VYT:',@,34@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4@5')A;G-F97(@
M06=R965M96YT(%1E<FUS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
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M,"PP,#`@:6X@;F5T('!R;V-E961S('1O($]C=6QU<RP@87,@=V5L;"!A<R!C
M97)T86EN(&]T:&5R(')E<75I<F5M96YT<R!S970@9F]R=&@@:6X@=&AE('-E
M<&%R871I;VX@86=R965M96YT+B!4:&4@<V5P87)A=&EO;B!A9W)E96UE;G0@
M<')O=FED97,@3V-U;'5S('=I=&@@8V5R=&%I;B!P:6=G>2!B86-K(')E9VES
M=')A=&EO;B!R:6=H=',@;V8@=7`@=&\@,S`E/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y097)C96YT86=E($]F($]U
M='-T86YD:6YG(%-H87)E<R!&;W(@3&%P<R!/9B!4<F%N<V9E<CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DN.3`E/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296EM8G5R<V5M96YT
M($]F($5X<&5N<V5S(%)E;&%T960@5&\@5')A;G-F97(\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L-#4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3V-U;'5S(%M-96UB97)=
M('P@36EN:6UU;2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D-O;6UI=&UE;G1S($%N9"!#;VYT:6YG96YC:65S
M(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M(%-A;&5S(&]F($)U<VEN97-S+"!!
M9F9I;&EA=&4@86YD(%!R;V1U8W1I=F4@07-S971S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]C=6QU<R!;365M8F5R72!\
M($UA>&EM=6T@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY#;VUM:71M96YT<R!!;F0@0V]N=&EN9V5N8VEE<R!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V]N<VED97)A=&EO;B!&;W(@4VAA<F5S(%1R86YS9F5R($)Y
M(%!A<F5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PU,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y097)C96YT86=E($]F(%-H87)E<R!4<F%N<V9E<B!">2!&;W)M97(@
M4&%R96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+C`P)3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0VAI968@17AE8W5T:79E($]F9FEC97(@6TUE;6)E<ET\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM:71M96YT<R!!;F0@
M0V]N=&EN9V5N8VEE<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W5T<W1A;F1I;F<@4W1O8VL@3W!T
M:6]N<R!!;F0@4F5S=')I8W1E9"!3=&]C:R!5;FET<R!497)M:6YA=&EO;B!$
M97-C<FEP=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^82!L
M=6UP+7-U;2!P87EM96YT(&EN('1H92!A;6]U;G0@;V8@)#4T-RPV,#`L(&QE
M<W,@=&%X97,@86YD(&]T:&5R('=I=&AH;VQD:6YG<R!A;F0@*&EI*2!A(&QU
M;7`M<W5M(&5Q=6EV86QE;G0@=&\@=&AE($-%3R8C.#(Q-SMS('!R96UI=6US
M('5N9&5R($-/0E)!(&9O<B!O;F4@>65A<BP@:6X@=&AE('-A;64@86UO=6YT
M<R!F;W(@=&AE('-A;64@;65D:6-A;"!C;W9E<F%G92!A<R!I;B!E9F9E8W0@
M87,@;V8@=&AE(&5F9F5C=&EV92!T:6UE(&]F('1H92!M97)G97(N/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H
M($)O;G5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3@L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#:&EE9B!%>&5C=71I=F4@3V9F:6-E<B!;365M8F5R72!\(#(P,3,@16UP
M;&]Y964L($1I<F5C=&]R($%N9"!#;VYS=6QT86YT($5Q=6ET>2!);F-E;G1I
M=F4@4&QA;B!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D-O;6UI=&UE;G1S($%N9"!#;VYT:6YG96YC:65S(%M,
M:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y297-T<FEC=&5D(%-T;V-K('5N:71S($=R86YT<R!$97-C<FEP
M=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^97%U86P@=&\@
M=&AE(&QE<W-E<B!O9B`H:2D@.3,P+#`P,"!A;F0@*&EI*2!T:&4@<75O=&EE
M;G0@;V8@)#,L,3(U+#`P,"!D:79I9&5D(&)Y('1H92!F86ER(&UA<FME="!V
M86QU92!O9B!T:&4@8V]M;6]N('-T;V-K(&]F('1H92!C;VUB:6YE9"!C;VUP
M86YY(&%S(&]F('1H92!E9F9E8W1I=F4@=&EM92!O9B!T:&4@;65R9V5R+"!W
M:71H('-U8V@@<F5S=')I8W1E9"!S=&]C:R!U;FET<R!V97-T:6YG(&%S(&9O
M;&QO=W,Z("AI*2!A(&YU;6)E<B!O9B!R97-T<FEC=&5D('-T;V-K('5N:71S
M(&5Q=6%L('1O('1H92!L97-S97(@;V8@*&$I(#DS,"PP,#`@86YD("AB*2!S
M=6-H(&YU;6)E<B!O9B!R97-T<FEC=&5D('-T;V-K('5N:71S('=I=&@@86X@
M86=G<F5G871E('9A;'5E(&5Q=6%L('1O("0Q+#0P,"PP,#`@<VAA;&P@8F4@
M9G5L;'D@=F5S=&5D(&%T('1H92!E9F9E8W1I=F4@=&EM92!O9B!T:&4@;65R
M9V5R(&%N9"`H:6DI(&%N(&%M;W5N="!E<75A;"!T;R`R-24@;V8@=&AE(')E
M<W1R:6-T960@<W1O8VL@=6YI=',@=6YV97-T960@87,@;V8@=&AE(&5F9F5C
M=&EV92!T:6UE(&]F('1H92!M97)G97(@=VEL;"!V97-T(&]N(&$@<75A<G1E
M<FQY(&)A<VES(&]V97(@=&AE(&9O;&QO=VEN9R!T=V5L=F4@;6]N=&AS+CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0VAI968@1FEN86YC:6%L($]F9FEC97(@6TUE;6)E<ET\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM:71M96YT<R!!;F0@
M0V]N=&EN9V5N8VEE<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W5T<W1A;F1I;F<@4W1O8VL@3W!T
M:6]N<R!!;F0@4F5S=')I8W1E9"!3=&]C:R!5;FET<R!497)M:6YA=&EO;B!$
M97-C<FEP=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^82!L
M=6UP+7-U;2!P87EM96YT(&EN('1H92!A;6]U;G0@;V8@)#,S-RPU,#`L(&QE
M<W,@=&%X97,@86YD(&]T:&5R('=I=&AH;VQD:6YG<R!A;F0@*&EI*2!A(&QU
M;7`M<W5M(&5Q=6EV86QE;G0@=&\@=&AE($-&3R8C.#(Q-SMS('!R96UI=6US
M('5N9&5R($-/0E)!(&9O<B!O;F4@>65A<BP@:6X@=&AE('-A;64@86UO=6YT
M<R!F;W(@=&AE('-A;64@;65D:6-A;"!C;W9E<F%G92!A<R!I;B!E9F9E8W0@
M87,@;V8@=&AE(&5F9F5C=&EV92!T:6UE(&]F('1H92!M97)G97(N/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-T
M<FEC=&5D(%-T;V-K('5N:71S($=R86YT<R!$97-C<FEP=&EO;CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^97%U86P@=&\@=&AE(&QE<W-E<B!O
M9B`H:2D@,S4U+#`P,"!A;F0@*&EI*2!T:&4@<75O=&EE;G0@;V8@)#$L,#,W
M+#4P,"!D:79I9&5D(&)Y('1H92!F86ER(&UA<FME="!V86QU92!O9B!T:&4@
M8V]M;6]N('-T;V-K(&]F('1H92!C;VUB:6YE9"!C;VUP86YY(&%S(&]F('1H
M92!E9F9E8W1I=F4@=&EM92P@=VET:"!S=6-H(')E<W1R:6-T960@<W1O8VL@
M=6YI=',@=F5S=&EN9R!A<R!F;VQL;W=S.B`H:2D@82!N=6UB97(@;V8@<F5S
M=')I8W1E9"!S=&]C:R!U;FET<R!E<75A;"!T;R!T:&4@;&5S<V5R(&]F("AA
M*2`S-34L,#`P(&%N9"`H8BD@<W5C:"!N=6UB97(@;V8@<F5S=')I8W1E9"!S
M=&]C:R!U;FET<R!W:71H(&%N(&%G9W)E9V%T92!V86QU92!E<75A;"!T;R`D
M,C4P+#`P,"!S:&%L;"!B92!F=6QL>2!V97-T960@870@=&AE(&5F9F5C=&EV
M92!T:6UE(&]F('1H92!M97)G97(@86YD("AI:2D@86X@86UO=6YT(&5Q=6%L
M('1O(#(U)2!O9B!T:&4@<F5S=')I8W1E9"!S=&]C:R!U;FET<R!U;G9E<W1E
M9"!A<R!O9B!T:&4@969F96-T:79E('1I;64@;V8@=&AE(&UE<F=E<B!W:6QL
M('9E<W0@;VX@82!Q=6%R=&5R;'D@8F%S:7,@;W9E<B!T:&4@9F]L;&]W:6YG
M('1W96QV92!M;VYT:',N/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y4=V\@17AE8W5T:79E<R!;365M8F5R73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O;6UI=&UE
M;G1S($%N9"!#;VYT:6YG96YC:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3979E<F%N8V4@0V]S
M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,30T+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M16UP;&]Y964@06YD($1I<F5C=&]R(%M-96UB97)=/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]M;6ET;65N=',@06YD($-O
M;G1I;F=E;F-I97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K($ES<W5E9"!$=7)I;F<@4&5R
M:6]D+"!3:&%R97,L($YE=R!)<W-U97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/CDP+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^16UP;&]Y964@06=R965M96YT(%M-96UB97)=
M('P@0VAI968@17AE8W5T:79E($]F9FEC97(@6TUE;6)E<ET\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM:71M96YT<R!!
M;F0@0V]N=&EN9V5N8VEE<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3V9F:6-E<G,G($-O;7!E;G-A
M=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S<U+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1&5F97)R960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT('=I=&@@26YD:79I
M9'5A;"P@1&5S8W)I<'1I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/BAI*2!A(&QU;7`@<V5V97)A;F-E('!A>6UE;G0@97%U86P@=&\@,C0@
M=&EM97,@=&AE(&%V97)A9V4@;6]N=&AL>2!B87-E('-A;&%R>2!P86ED('1O
M('1H92!#14\@;W9E<B!T:&4@<')E8V5D:6YG(#$R(&UO;G1H<SL@*&EI*2!U
M<"!T;R!O;F4@>65A<B`H=&AE(&QE<W-E<B!O9B!O;F4@>65A<B!F;VQL;W=I
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M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;7!L;WEE92!!9W)E96UE;G0@
M6TUE;6)E<ET@?"!#:&EE9B!&:6YA;F-I86P@3V9F:6-E<B!;365M8F5R73PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O;6UI
M=&UE;G1S($%N9"!#;VYT:6YG96YC:65S(%M,:6YE($ET96US73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/9F9I8V5R<R<@
M0V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M,C4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y$969E<G)E9"!#;VUP96YS871I;VX@07)R86YG96UE;G0@=VET
M:"!);F1I=FED=6%L+"!$97-C<FEP=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^*&DI(&$@;'5M<"!S979E<F%N8V4@<&%Y;65N="!E<75A
M;"!T;R`Q."!T:6UE<R!T:&4@879E<F%G92!M;VYT:&QY(&)A<V4@<V%L87)Y
M('!A:60@=&\@=&AE($-&3R!O=F5R('1H92!P<F5C961I;F<@,3(@;6]N=&AS
M.R`H:6DI('5P('1O(&]N92!Y96%R("AT:&4@;&5S<V5R(&]F(&]N92!Y96%R
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M('1H92!#;VUP86YY(&]N($UA>2`Q,BP@,C`Q-"!S:&%L;"!B92!A8V-E;&5R
M871E9"X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DQI8V5N<V4@06YD(%-U<'!L>2!!9W)E96UE;G0@6TUE;6)E<ET\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM
M:71M96YT<R!!;F0@0V]N=&EN9V5N8VEE<R!;3&EN92!)=&5M<UT\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4'5R8VAA<V4@
M0V]M;6ET;65N="P@1&5S8W)I<'1I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/D]C=6QU<R!S:&%L;"!M86YU9F%C='5R92!A;F0@<W5P<&QY
M+"!A="!A('!U<F-H87-E('!R:6-E(&5Q=6%L('1O(#(P)2!O=F5R('1H92!C
M;W-T(&]F(&=O;V1S('1O($]C=6QU<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&EC96YS92!!;F0@4W5P<&QY($%G
M<F5E;65N="!;365M8F5R72!\($9I<G-T(%!H87-E(%M-96UB97)=/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]M;6ET;65N
M=',@06YD($-O;G1I;F=E;F-I97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O<W0@;V8@4V5R=FEC
M97,L($QI8V5N<V5S(&%N9"!397)V:6-E<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,2PU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,:6-E;G-E($%N9"!3=7!P;'D@06=R
M965M96YT(%M-96UB97)=('P@4V5C;VYD(%!H87-E(%M-96UB97)=/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]M;6ET;65N
M=',@06YD($-O;G1I;F=E;F-I97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O<W0@;V8@4V5R=FEC
M97,L($QI8V5N<V5S(&%N9"!397)V:6-E<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,2PU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,:6-E;G-E($%N9"!3=7!P;'D@06=R
M965M96YT(%M-96UB97)=('P@5&AI<F0@4&AA<V4@6TUE;6)E<ET\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM:71M96YT
M<R!!;F0@0V]N=&EN9V5N8VEE<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]S="!O9B!397)V:6-E
M<RP@3&EC96YS97,@86YD(%-E<G9I8V5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQI8V5N<V4@06YD(%-U<'!L>2!!9W)E
M96UE;G0@6TUE;6)E<ET@?"!&;W5R=&@@4&AA<V4@6TUE;6)E<ET\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM:71M96YT
M<R!!;F0@0V]N=&EN9V5N8VEE<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]S="!O9B!397)V:6-E
M<RP@3&EC96YS97,@86YD(%-E<G9I8V5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQI8V5N<V4@06YD(%-U<'!L>2!!9W)E
M96UE;G0@6TUE;6)E<ET@?"!-:6YI;75M(%M-96UB97)=/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]M;6ET;65N=',@06YD
M($-O;G1I;F=E;F-I97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)O>6%L='D@1W5A<F%N=&5E<R!#
M;VUM:71M96YT<R!097)C96YT86=E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3&EC96YS92!!;F0@4W5P<&QY($%G<F5E;65N="!;
M365M8F5R72!\($UA>&EM=6T@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM:71M96YT<R!!;F0@0V]N=&EN
M9V5N8VEE<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4F]Y86QT>2!'=6%R86YT965S($-O;6UI=&UE
M;G1S(%!E<F-E;G1A9V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(P+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3&EC96YS92!!;F0@4W5P<&QY($%G<F5E;65N="!;365M8F5R
M72!\($]C=6QU<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D-O;6UI=&UE;G1S($%N9"!#;VYT:6YG96YC:65S
M(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y3=7!P;'D@0V]M;6ET;65N="P@4F5M86EN:6YG($UI;FEM
M=6T@06UO=6YT($-O;6UI='1E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`X+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7SDR-3$W.#5B7S=E8F-?-#<S,5\Y8C$W7S<S-C8Y.39A
M.#9A9`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\Y,C4Q-S@U8E\W
M96)C7S0W,S%?.6(Q-U\W,S8V.3DV83@V860O5V]R:W-H965T<R]3:&5E=#,T
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%55!!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3
M=&]C:VAO;&1E<G,G($5Q=6ET>2`H1&5T86EL<RD@*%531"`D*3QB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3:&%R
M92UB87-E9"!#;VUP96YS871I;VX@07)R86YG96UE;G0@8GD@4VAA<F4M8F%S
M960@4&%Y;65N="!!=V%R9"!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F(%=A<G)A;G1S
M($]U='-T86YD:6YG+"!-87)C:"`S,2P@,C`Q-3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,RPQ-#4L-C4P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@5V%R<F%N=',@
M17AE<F-I<V%B;&4L($UA<F-H(#,Q+"`R,#$U/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS+#$T,"PR-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S($5X97)C:7-A8FQE
M(%=E:6=H=&5D($%V97)A9V4@4F5M86EN:6YG($QI9F4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/C$@>65A<B`Q(&UO;G1H(#8@9&%Y<SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R
M<F%N="!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N
M="!B>2!3:&%R92UB87-E9"!087EM96YT($%W87)D(%M,:6YE($ET96US73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB
M97(@;V8@5V%R<F%N=',@3W5T<W1A;F1I;F<L($UA<F-H(#,Q+"`R,#$T/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#$T,"PR-3`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E
M<B!O9B!787)R86YT<R!'<F%N=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XU+#0P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F(%=A<G)A;G1S($5X97)C:7-E9#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F(%=A
M<G)A;G1S($9O<F9E:71E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3G5M8F5R(&]F(%=A<G)A;G1S($]U='-T86YD:6YG+"!-87)C:"`S
M,2P@,C`Q-3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPQ-#4L
M-C4P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.=6UB97(@;V8@5V%R<F%N=',@17AE<F-I<V%B;&4L($UA<F-H(#,Q
M+"`R,#$U/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#$T,"PR
M-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E=E:6=H=&5D($%V97)A9V4@17AE<F-I<V4@4')I8V4@3W5T<W1A;F1I
M;F<L($UA<F-H(#,Q+"`R,#$T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#X@-RXS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E($5X97)C:7-E(%!R:6-E($=R
M86YT960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B`Y+C`V/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y7
M96EG:'1E9"!!=F5R86=E($5X97)C:7-E(%!R:6-E+"!%>&5R8VES960\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!=F5R
M86=E($5X97)C:7-E(%!R:6-E($9O<F9E:71E9#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@17AE<F-I<V4@
M4')I8V4@3W5T<W1A;F1I;F<L($UA<F-H(#,Q+"`R,#$U/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#X@-RXS,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@079E<F%G92!%
M>&5R8VES92!0<FEC92!%>&5R8VES86)L92P@36%R8V@@,S$L(#(P,34\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B`W+C,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V
M97)A9V4@4F5M86EN:6YG($QI9F4@3W5T<W1A;F1I;F<L($UA<F-H(#,Q+"`R
M,#$U/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XQ('EE87(@,2!M
M;VYT:"`V(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E=A<G)A;G1S($5X97)C:7-A8FQE(%=E:6=H=&5D($%V
M97)A9V4@4F5M86EN:6YG($QI9F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/C$@>65A<B`Q(&UO;G1H(#8@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YT<FEN<VEC(%9A;'5E
M($]U='-T86YD:6YG+"!-87)C:"`S,2P@,C`Q-3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DEN=')I;G-I8R!686QU92!%>&5R8VES86)L
M92P@36%R8V@@,S$L(#(P,34\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
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M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P14M*044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W1O8VMH;VQD97)S
M)R!%<75I='D@*$1E=&%I;',@,2D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#
M;VUP96YS871I;VX@07)R86YG96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N
M="!!=V%R9"!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@3W5T<W1A;F1I;F<@3G5M8F5R
M(&]F(%=A<G)A;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M+#$T-2PV-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E=A<G)A;G1S($5X97)C:7-A8FQE(%=E:6=H=&5D($%V97)A
M9V4@4F5M86EN:6YG($QI9F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/C$@>65A<B`Q(&UO;G1H(#8@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@17AE<F-I<V%B
M;&4@3G5M8F5R(&]F(%=A<G)A;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS+#$T,"PR-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E(%!R:6-E(%)A;F=E($]N92!;
M365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!B>2!3
M:&%R92UB87-E9"!087EM96YT($%W87)D(%M,:6YE($ET96US73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!/
M=71S=&%N9&EN9R!%>&5R8VES92!0<FEC93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^(#<N,C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S($]U='-T86YD:6YG($YU;6)E
M<B!O9B!787)R86YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,RPP-#<L-3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y787)R86YT<R!%>&5R8VES86)L92!796EG:'1E9"!!=F5R
M86=E(%)E;6%I;FEN9R!,:69E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XQ('EE87(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E=A<G)A;G1S($5X97)C:7-A8FQE($YU;6)E<B!O9B!7
M87)R86YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPP-#<L
M-3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y%>&5R8VES92!0<FEC92!286YG92!4=V\@6TUE;6)E<ET\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3:&%R92UB87-E
M9"!#;VUP96YS871I;VX@07)R86YG96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y
M;65N="!!=V%R9"!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@3W5T<W1A;F1I;F<@17AE
M<F-I<V4@4')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B`Y
M+C`V,C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E=A<G)A;G1S($]U='-T86YD:6YG($YU;6)E<B!O9B!787)R86YT
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3@L,34P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R
M86YT<R!%>&5R8VES86)L92!796EG:'1E9"!!=F5R86=E(%)E;6%I;FEN9R!,
M:69E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XT('EE87)S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y7
M87)R86YT<R!%>&5R8VES86)L92!.=6UB97(@;V8@5V%R<F%N=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDR+#<U,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.3(U,3<X-6)?-V5B8U\T-S,Q
M7SEB,3=?-S,V-CDY-F$X-F%D#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+SDR-3$W.#5B7S=E8F-?-#<S,5\Y8C$W7S<S-C8Y.39A.#9A9"]7;W)K
M<VAE971S+U-H965T,S8N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5)1D%#/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/E-T;V-K:&]L9&5R<R<@17%U:71Y("A$971A:6QS(#(I
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0R/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R
M,#$U/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L
M(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y
M(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0@6TQI;F4@271E;7-=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)I<VL@9G)E
M92!I;G1E<F5S="!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ+C8W)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T960@=&5R;2`H>65A<G,I/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XU('EE87)S(#<@;6]N=&AS
M(#$P(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5X<&5C=&5D('9O;&%T:6QI='D\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/CDU+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T960@
M9&EV:61E;F1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P
M)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?.3(U,3<X-6)?-V5B8U\T-S,Q7SEB,3=?-S,V-CDY-F$X-F%D
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+SDR-3$W.#5B7S=E8F-?
M-#<S,5\Y8C$W7S<S-C8Y.39A.#9A9"]7;W)K<VAE971S+U-H965T,S<N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$551$%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-T;V-K
M:&]L9&5R<R<@17%U:71Y("A$971A:6QS(#,I("A54T0@)"D\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4M
M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D
M(%!A>6UE;G0@07=A<F0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!/<'1I;VYS($]U
M='-T86YD:6YG+"!-87)C:"`S,2P@,C`Q-#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F($]P=&EO;G,@1W)A;G1E9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S,R+#4P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F
M($]P=&EO;G,@17AE<F-I<V5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.=6UB97(@;V8@3W!T:6]N<R!&;W)F96ET960\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#$V+#8V-"D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!/<'1I
M;VYS($]U='-T86YD:6YG+"!-87)C:"`S,2P@,C`Q-3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,S$U+#@S-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F($]P=&EO;G,@
M17AE<F-I<V%B;&4L($UA<F-H(#,Q+"`R,#$U/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XX,2PU,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@17AE<F-I
M<V4@4')I8V4@3W5T<W1A;F1I;F<L($UA<F-H(#,Q+"`R,#$U/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@
M17AE<F-I<V4@4')I8V4@1W)A;G1E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`V+C,W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E($5X97)C:7-E(%!R
M:6-E($5X97)C:7-E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y796EG:'1E9"!!=F5R86=E($5X97)C:7-E(%!R:6-E($9O<F9E:71E
M9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V+C,W/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG
M:'1E9"!!=F5R86=E($5X97)C:7-E(%!R:6-E($]U='-T86YD:6YG+"!-87)C
M:"`S,2P@,C`Q-3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V
M+C,W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y796EG:'1E9"!!=F5R86=E($5X97)C:7-E(%!R:6-E($5X97)C:7-A
M8FQE+"!-87)C:"`S,2P@,C`Q-3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`V+C,W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E(%)E;6%I;FEN9R!,:69E
M($]U='-T86YD:6YG+"!-87)C:"`S,2P@,C`Q-3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^.2!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@079E<F%G92!296UA
M:6YI;F<@3&EF92!%>&5R8VES86)L92P@36%R8V@@,S$L(#(P,34\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/C@@>65A<G,@."!M;VYT:',@,3(@
M9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^26YT<FEN<VEC(%9A;'5E($]U='-T86YD:6YG+"!-87)C:"`S,2P@
M,C`Q-3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1R
M:6YS:6,@5F%L=64@17AE<F-I<V%B;&4L($UA<F-H(#,Q+"`R,#$U/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7SDR-3$W.#5B7S=E8F-?-#<S,5\Y
M8C$W7S<S-C8Y.39A.#9A9`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B\Y,C4Q-S@U8E\W96)C7S0W,S%?.6(Q-U\W,S8V.3DV83@V860O5V]R:W-H
M965T<R]3:&5E=#,X+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%44E!13X-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY3=&]C:VAO;&1E<G,G($5Q=6ET>2`H1&5T86EL<R`T*2`H
M55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q
M+"`R,#$U/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@
M,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT
M(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0@6TQI;F4@271E;7-=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO
M;G,@3W5T<W1A;F1I;F<@17AE<F-I<V4@4')I8V4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@-BXS-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N<R!/=71S=&%N9&EN
M9R!.=6UB97(@;V8@3W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,S$U+#@S-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@17AE<F-I<V%B;&4@5V5I9VAT960@
M079E<F%G92!296UA:6YI;F<@3&EF93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^."!Y96%R<R`X(&UO;G1H<R`Q,B!D87ES/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS($5X
M97)C:7-A8FQE($YU;6)E<B!O9B!/<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XX,2PU,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E(%!R:6-E(%M-96UB97)=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA
M<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A
M<V5D(%!A>6UE;G0@07=A<F0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@3W5T<W1A;F1I
M;F<@17AE<F-I<V4@4')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@-BXS-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3W!T:6]N<R!/=71S=&%N9&EN9R!.=6UB97(@;V8@3W!T
M:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S$U+#@S-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3W!T:6]N<R!%>&5R8VES86)L92!796EG:'1E9"!!=F5R86=E(%)E;6%I;FEN
M9R!,:69E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XX('EE87)S
M(#@@;6]N=&AS(#$R(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@17AE<F-I<V%B;&4@3G5M8F5R
M(&]F($]P=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@Q
M+#4R,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M.3(U,3<X-6)?-V5B8U\T-S,Q7SEB,3=?-S,V-CDY-F$X-F%D#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+SDR-3$W.#5B7S=E8F-?-#<S,5\Y8C$W
M7S<S-C8Y.39A.#9A9"]7;W)K<VAE971S+U-H965T,SDN:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$4R6$%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-T;V-K:&]L9&5R<R<@
M17%U:71Y("A$971A:6QS(#4I("A297-T<FEC=&5D(%-T;V-K(%M-96UB97)=
M+"!54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#(^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA
M<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4F5S=')I8W1E9"!3=&]C:R!;365M8F5R73PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D($-O;7!E
M;G-A=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R92UB87-E9"!087EM96YT($%W
M87)D(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@56YI=',@3F]N+79E<W1E9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!5;FET
M<R!'<F%N=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,#DL
M,S4U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3G5M8F5R(&]F(%5N:71S(%9E<W1E9#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH.#4L,S`X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!5;FET<R!&;W)F
M96ET960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB
M97(@;V8@56YI=',@3F]N+79E<W1E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,S(T+#`T-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@1W)A;G0@1&%T
M92!&86ER(%9A;'5E($YO;BUV97-T960\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@079E<F%G92!'<F%N="!$871E
M($9A:7(@5F%L=64@1W)A;G1E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`V+C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@1W)A;G0@1&%T92!&
M86ER(%9A;'5E(%9E<W1E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`V+C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@1W)A;G0@1&%T92!&86ER
M(%9A;'5E($9O<F9E:71E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E($=R86YT($1A=&4@1F%I<B!6
M86QU92!.;VXM=F5S=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#8N,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5&]T86P@1W)A;G0@1&%T92!&86ER(%9A;'5E($YO;BUV
M97-T960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5&]T86P@1W)A;G0@1&%T92!&86ER(%9A;'5E($=R86YT960\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-3<Y+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L($=R86YT
M($1A=&4@1F%I<B!686QU92!697-T960\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#4S-RPP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@1W)A;G0@1&%T92!&86ER(%9A
M;'5E($9O<F9E:71E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E1O=&%L($=R86YT($1A=&4@1F%I<B!686QU92!.;VXM=F5S=&5D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(L,#0R+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.3(U,3<X
M-6)?-V5B8U\T-S,Q7SEB,3=?-S,V-CDY-F$X-F%D#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+SDR-3$W.#5B7S=E8F-?-#<S,5\Y8C$W7S<S-C8Y
M.39A.#9A9"]7;W)K<VAE971S+U-H965T-#`N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5"5$%-
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-T;V-K:&]L9&5R<R<@17%U:71Y
M("A$971A:6QS(%1E>'1U86PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,2!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,CXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XP($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,"!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3X\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^36%R+B`R-BP@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#(U+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#$R+"`R,#$U/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,C$L(#(P,30\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%Y(#$Q+"`R,#$T/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA>2`Q,BP@,C`Q-#QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y/8W0N(#,Q+"`R,#$S/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E
M+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R92UB87-E
M9"!087EM96YT($%W87)D(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!#;VUP96YS
M871I;VX@07)R86YG96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R
M9"P@3W!T:6]N<RP@17AE<F-I<V5S(&EN(%!E<FEO9#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N
M($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0L($]P
M=&EO;G,L($=R86YT<R!I;B!097)I;V0L(%=E:6=H=&5D($%V97)A9V4@1W)A
M;G0@1&%T92!&86ER(%9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#0N-SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A
M;F=E;65N="!B>2!3:&%R92UB87-E9"!087EM96YT($%W87)D+"!/<'1I;VYS
M+"!697-T960@:6X@4&5R:6]D+"!&86ER(%9A;'5E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#$L-3DS+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06QL;V-A=&5D(%-H87)E
M+6)A<V5D($-O;7!E;G-A=&EO;B!%>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XT-3(L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16UP;&]Y964@4V5R=FEC92!3:&%R
M92UB87-E9"!#;VUP96YS871I;VXL($YO;G9E<W1E9"!!=V%R9',L($-O;7!E
M;G-A=&EO;B!#;W-T($YO="!Y970@4F5C;V=N:7IE9#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2PP-C`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;7!L;WEE92!397)V:6-E
M(%-H87)E+6)A<V5D($-O;7!E;G-A=&EO;BP@3F]N=F5S=&5D($%W87)D<RP@
M0V]M<&5N<V%T:6]N($-O<W0@3F]T('EE="!296-O9VYI>F5D+"!097)I;V0@
M9F]R(%)E8V]G;FET:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XR('EE87)S(#$@;6]N=&@@-B!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!#;VUP96YS
M871I;VX@07)R86YG96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R
M9"P@3W!T:6]N<RP@1W)A;G1S(&EN(%!E<FEO9"P@1W)O<W,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,S,BPU,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D($-O
M;7!E;G-A=&EO;B!!<G)A;F=E;65N=',@8GD@4VAA<F4M8F%S960@4&%Y;65N
M="!!=V%R9"P@3W!T:6]N<RP@1W)A;G1S(&EN(%!E<FEO9"P@5V5I9VAT960@
M079E<F%G92!%>&5R8VES92!0<FEC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`V+C,W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y3=&]C:VAO;&1E<G,G($5Q=6ET>2P@4F5V97)S
M92!3=&]C:R!3<&QI=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M,2UF;W(M,BXU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#;VUM;VX@4W1O8VLL(%!A<B!O<B!3=&%T960@5F%L=64@
M4&5R(%-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N
M,#`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,"XP,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`P+C`P,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!3=&]C:RP@4VAA<F5S+"!/
M=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PP
M,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-"PV-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-"PV-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!)<W-U960@1'5R:6YG
M(%!E<FEO9"P@4VAA<F5S+"!2979E<G-E(%-T;V-K(%-P;&ET<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPP,#`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@4W1O
M8VLL(%-H87)E<R!!=71H;W)I>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,#`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$P,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@4W1O
M8VLL(%-H87)E<R!!=71H;W)I>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D(%-T;V-K+"!087(@
M;W(@4W1A=&5D(%9A;'5E(%!E<B!3:&%R93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`P+C`P,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`P,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1W)O<W,@4')O8V5E9',@
M1G)O;2!)<W-U86YC92!/9B!#;VUM;VX@4W1O8VL@06YD(%=A<G)A;G1S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#$Q-RPP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.2PR,38L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y/9F9E<FEN9R!#;W-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR-3(L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,RPQ.34L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@4W1O8VLL(%-H87)E<RP@
M27-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#@P-"PR
M.3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT+#@P-"PR.3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-H87)E($)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E
M;65N="!">2!3:&%R92!"87-E9"!087EM96YT($%W87)D($5Q=6ET>2!);G-T
M<G5M96YT($]T:&5R(%1H86X@3W!T:6]N<R!%<75I='D@26YS=')U;65N=',@
M17AE<F-I<V%B;&4@3G5M8F5R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS+#$T,"PR-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DEN=F5S=&UE;G0@5V%R<F%N=',L($5X97)C:7-E
M(%!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`P
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0VQO<VEN9R!0<FEC92!/9B!#;VUM;VX@4W1O8VL@4&5R8V5N=&%G93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34P+C`P)3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M
M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D
M(%!A>6UE;G0@07=A<F0L($YO;BU/<'1I;VX@17%U:71Y($EN<W1R=6UE;G1S
M+"!/=71S=&%N9&EN9RP@3G5M8F5R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS+#$T-2PV-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-L87-S($]F(%=A<G)A;G0@3W(@4FEG:'0@
M1'5R871I;VX@1G)O;2!7:&EC:"!787)R86YT<R!/<B!2:6=H=',@17AE<F-I
M<V%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C$@>65A<CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M26YV97-T;65N="!&<F]M($9O<FUE<B!087)E;G0\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L-C<Y+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&5R8V5N=&%G92!/9B!/<'1I
M;VYS(%5N=F5S=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4F5P<F5S96YT871I=F4@3V8@56YD97)W<FET97)S(%M-96UB97)=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA
M<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A
M<V5D(%!A>6UE;G0@07=A<F0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1E<FT@3V8@5V%R<F%N=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^-2!Y96%R<SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@
M27-S=65D($1U<FEN9R!097)I;V0L(%-H87)E<RP@3W1H97(\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4L-#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R97,@27-S=65D+"!0
M<FEC92!097(@4VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@.2XP-C(U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y.97<@,C`Q,R!0;&%N(%M-96UB97)=/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4M8F%S960@0V]M
M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@
M07=A<F0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A
M;F=E;65N="!B>2!3:&%R92UB87-E9"!087EM96YT($%W87)D+"!$97-C<FEP
M=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^5&AE(&%N;G5A
M;"!I;F-R96%S92!I;B!T:&4@;G5M8F5R(&]F('-H87)E<R!S:&%L;"!B92!E
M<75A;"!T;R!T:&4@;&]W97-T(&]F.B`H:2D@,BPU-3$L-3`P('-H87)E<R!O
M9B!2=71H:6=E;B8C.#(Q-SMS(&-O;6UO;B!S=&]C:SL@*&EI*2!F:79E('!E
M<F-E;G0@*#4E*2!O9B!T:&4@;G5M8F5R(&]F('-H87)E<R!O9B!2=71H:6=E
M;B8C.#(Q-SMS(&-O;6UO;B!S=&]C:R!O=71S=&%N9&EN9R!A<R!O9B!S=6-H
M(&1A=&4[(&%N9"`H:6EI*2!A;B!A;6]U;G0@9&5T97)M:6YE9"!B>2!2=71H
M:6=E;B8C.#(Q-SMS(&)O87)D(&]F(&1I<F5C=&]R<RX\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K($ES<W5E
M9"!$=7)I;F<@4&5R:6]D+"!3:&%R97,L($YE=R!)<W-U97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C8L.#4S+#,Q.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@27-S=65D
M($1U<FEN9R!097)I;V0L(%-H87)E<RP@4&5R:6]D($EN8W)E87-E("A$96-R
M96%S92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,C,P+#@U
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^25!/(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M
M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0@6TQI;F4@271E;7-=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H
M87)E(%!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8N
M-C8P.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5V%R<F%N=',@=&\@4'5R8VAA<V4@;V8@0V]M;6]N(%-T;V-K/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS.3<L-3`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,SDW+#4P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M26YI=&EA;"!0=6)L:6,@3V9F97)I;F<@4')I8V4@4&5R(%5N:70\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-RXR-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-RXR-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0VQA<W,@
M;V8@5V%R<F%N="!O<B!2:6=H="P@17AE<F-I<V4@4')I8V4@;V8@5V%R<F%N
M=',@;W(@4FEG:'1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#DN,#8R-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^26YI=&EA;"!0=6)L:6,@3V9F97)I;F<@56YI=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-C4P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-C4P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4')O8V5E9',@9G)O;2!)<W-U86YC92!O9B!#;VUM;VX@4W1O8VL\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$V+#`R,2PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=R;W-S(%!R
M;V-E961S($9R;VT@27-S=6%N8V4@3V8@0V]M;6]N(%-T;V-K($%N9"!787)R
M86YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DL,C$V+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3V9F97)I;F<@0V]S=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,RPQ.34L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#;VUM;VX@4W1O8VLL(%-H87)E<RP@27-S=65D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#8U,"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E
M($)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!">2!3:&%R92!"87-E
M9"!087EM96YT($%W87)D($5Q=6ET>2!);G-T<G5M96YT($]T:&5R(%1H86X@
M3W!T:6]N<R!%<75I='D@26YS=')U;65N=',@17AE<F-I<V%B;&4@3G5M8F5R
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#`T-RPU,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H
M87)E($)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!">2!3:&%R92!"
M87-E9"!087EM96YT($%W87)D($5Q=6ET>2!);G-T<G5M96YT($]T:&5R(%1H
M86X@3W!T:6]N<R!%<75I='D@26YS=')U;65N=',@17AE<F-I<V%B;&4@5V5I
M9VAT960@079E<F%G92!%>&5R8VES92!0<FEC93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`W+C(U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=F5R+4%L;&]T;65N="!/<'1I;VX@
M6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R86YG96UE;G0@8GD@
M4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"!;3&EN92!)=&5M<UT\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V%L92!O9B!3
M=&]C:RP@3G5M8F5R(&]F(%-H87)E<R!)<W-U960@:6X@5')A;G-A8W1I;VX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U-"PR.3`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-A;&4@
M;V8@4W1O8VLL(%!R:6-E(%!E<B!3:&%R93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`V+C8V,#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-A;&4@;V8@4W1O8VLL($-O;G-I9&5R
M871I;VX@4F5C96EV960@;VX@5')A;G-A8W1I;VX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L,#(X+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S=')I8W1E9"!3=&]C:R!5
M;FET<R`H4E-5<RD@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R
M86YG96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"!;3&EN92!)
M=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^06QL;V-A=&5D(%-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!%>'!E;G-E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,C<L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16UP
M;&]Y964@4V5R=FEC92!3:&%R92UB87-E9"!#;VUP96YS871I;VXL($YO;G9E
M<W1E9"!!=V%R9',L($-O;7!E;G-A=&EO;B!#;W-T($YO="!Y970@4F5C;V=N
M:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PU,C(L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%;7!L;WEE92!397)V:6-E(%-H87)E+6)A<V5D($-O;7!E;G-A=&EO;BP@
M3F]N=F5S=&5D($%W87)D<RP@0V]M<&5N<V%T:6]N($-O<W0@3F]T('EE="!2
M96-O9VYI>F5D+"!097)I;V0@9F]R(%)E8V]G;FET:6]N/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XR('EE87)S(#$@;6]N=&@@-B!D87ES/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R86YG96UE;G0@8GD@4VAA<F4M
M8F%S960@4&%Y;65N="!!=V%R9"P@07=A<F0@5F5S=&EN9R!2:6=H=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/E)357,@9F]R(#,T,2PP,#`@
M<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!V97-T(')A=&%B;'D@;W9E<B!T:')E
M92!Y96%R<R!O;B!A('%U87)T97)L>2!B87-I<R!A;F0@:&%D(&%N(&%G9W)E
M9V%T92!G<F%N="!D871E('9A;'5E(&]F("0R+#$T."PP,#`N(%)357,@9F]R
M(#8X+#,U-2!S:&%R97,@:&%D(&%N(&%G9W)E9V%T92!G<F%N="!D871E('9A
M;'5E(&]F("0T,S$L,#`P(&%N9"!V97-T(&EN(&5Q=6%L(&EN<W1A;&QM96YT
M<R!B87-E9"!O;B!A8VAI979E;65N="!O9B!T:&4@9F]L;&]W:6YG.B`H,2D@
M96YR;VQL;65N="!O9B!T:&4@9FER<W0@<&%T:65N="!I;B!T:&4@9FER<W0@
M<&EV;W1A;"!C;&EN:6-A;"!T<FEA;"!F;W(@4E54-3@M-C`@;VX@;W(@<')I
M;W(@=&\@36%Y(#$Q+"`R,#$W.R`H,BD@96YR;VQL;65N="!O9B!T:&4@9FER
M<W0@<&%T:65N="!I;B!T:&4@<V5C;VYD('!I=F]T86P@8VQI;FEC86P@=')I
M86P@9F]R(%)55#4X+38P(&]N(&]R('!R:6]R('1O($UA>2`Q,2P@,C`Q.#L@
M86YD("@S*2!C;VUP;&5T:6]N(&]F('1H92!C;&EN:6-A;"!S='5D>2!R97!O
M<G0@8V]N=&%I;FEN9R!T:&4@<F5S=6QT<R!O9B!T:&4@<V5C;VYD('!I=F]T
M86P@8VQI;FEC86P@=')I86P@9F]R(%)55#4X+38P(&]N(&]R('!R:6]R('1O
M($UA>2`Q,2P@,C`Q.2X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A
M;F=E;65N="!B>2!3:&%R92UB87-E9"!087EM96YT($%W87)D+"!%<75I='D@
M26YS=')U;65N=',@3W1H97(@=&AA;B!/<'1I;VYS+"!'<F%N=',@:6X@4&5R
M:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,#DL,S4U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2
M97-T<FEC=&5D(%-T;V-K(%5N:71S("A24U5S*2!;365M8F5R72!\(%!E<F9O
M<FUA;F-E(%-H87)E<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!
M<G)A;F=E;65N="!B>2!3:&%R92UB87-E9"!087EM96YT($%W87)D(%M,:6YE
M($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y!;&QO8V%T960@4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($5X<&5N
M<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0S,2PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P
M,3,@4&QA;B!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E
M;65N="!B>2!3:&%R92UB87-E9"!087EM96YT($%W87)D(%M,:6YE($ET96US
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R86YG96UE;G0@8GD@4VAA<F4M
M8F%S960@4&%Y;65N="!!=V%R9"P@3W!T:6]N<RP@1W)A;G1S(&EN(%!E<FEO
M9"P@1W)O<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,S,BPU
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N=',@8GD@
M4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"P@3W!T:6]N<RP@1W)A;G1S(&EN
M(%!E<FEO9"P@5V5I9VAT960@079E<F%G92!%>&5R8VES92!0<FEC93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V+C,W/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;&%S<R!O9B!7
M87)R86YT(&]R(%)I9VAT+"!%>&5R8VES92!0<FEC92!O9B!787)R86YT<R!O
M<B!2:6=H=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP
M,#DR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#;VUM;VX@4W1O8VLL(%-H87)E<R!!=71H;W)I>F5D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XY.3@L,S4U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!#
M;VUP96YS871I;VX@07)R86YG96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N
M="!!=V%R9"P@1&5S8W)I<'1I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/E1H92!A;FYU86P@:6YC<F5A<V4@:6X@=&AE(&YU;6)E<B!O9B!S
M:&%R97,@<VAA;&P@8F4@97%U86P@=&\@=&AE(&QO=V5S="!O9CH@*&$I(#(S
M,BPU,#`@<VAA<F5S(&]F('1H92!#;VUP86YY)B,X,C$W.W,@8V]M;6]N('-T
M;V-K.R`H8BD@-24@;V8@=&AE(&YU;6)E<B!O9B!S:&%R97,@;V8@=&AE($-O
M;7!A;GDF(S@R,3<[<R!C;VUM;VX@<W1O8VL@;W5T<W1A;F1I;F<@87,@;V8@
M<W5C:"!D871E.R!A;F0@*&,I(&%N(&%M;W5N="!D971E<FUI;F5D(&)Y('1H
M92!#;VUP86YY)B,X,C$W.W,@8F]A<F0@;V8@9&ER96-T;W)S(&]R(&-O;7!E
M;G-A=&EO;B!C;VUM:71T964N/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y5;F1E<G=R:71E<G,@6TUE;6)E<ET\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3:&%R92UB
M87-E9"!#;VUP96YS871I;VX@07)R86YG96UE;G0@8GD@4VAA<F4M8F%S960@
M4&%Y;65N="!!=V%R9"!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0VQA<W,@;V8@5V%R<F%N="!O<B!2
M:6=H="P@17AE<F-I<V4@4')I8V4@;V8@5V%R<F%N=',@;W(@4FEG:'1S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#DN,#8R-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M
M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D
M(%!A>6UE;G0@07=A<F0L($YO;BU/<'1I;VX@17%U:71Y($EN<W1R=6UE;G1S
M+"!/=71S=&%N9&EN9RP@3G5M8F5R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XY,BPW-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-L87-S(&]F(%=A<G)A;G0@;W(@4FEG:'0L($1A
M=&4@9G)O;2!W:&EC:"!787)R86YT<R!O<B!2:6=H=',@17AE<F-I<V%B;&4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/DUA<B`R,2P-"@D),C`Q
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0VQA<W,@3V8@5V%R<F%N="!/<B!2:6=H=',@17AP:7)I;F<@1&%T92!7
M87)R86YT<R!/<B!2:6=H=',@17AE<F-I<V%B;&4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/DUA<B`R,2P-"@D),C`Q.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N(%-T;V-K
M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y
M(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0@6TQI;F4@271E;7-=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E+6)A
M<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R92UB87-E9"!0
M87EM96YT($%W87)D+"!/<'1I;VYS+"!%>&5R8VES97,@:6X@4&5R:6]D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS.3<L-3`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G9E<W1M
M96YT($9R;VT@1F]R;65R(%!A<F5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
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M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P14=.04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^26YC;VUE
M(%1A>&5S("A$971A:6QS*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$R($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1F5D97)A;"!);F-O;64@
M5&%X($5X<&5N<V4@*$)E;F5F:70I+"!#;VYT:6YU:6YG($]P97)A=&EO;G,@
M6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#=7)R96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D1E9F5R<F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@Q+#<U-"PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,2PP,S$L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=&%T92!A;F0@
M3&]C86P@26YC;VUE(%1A>"!%>'!E;G-E("A"96YE9FET*2P@0V]N=&EN=6EN
M9R!/<&5R871I;VYS(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0W5R<F5N=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@S,#DL,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#$X,BPP,#`I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#=7)R96YT($EN8V]M
M92!487@@17AP96YS92`H0F5N969I="D\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#(L,#8S+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@Q+#(Q,RPP,#`I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#:&%N9V4@:6X@=F%L
M=6%T:6]N(&%L;&]W86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,BPP-C,L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,2PR,3,L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F-O;64@=&%X('!R;W9I<VEO;B`H
M8F5N969I="D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.3(U
M,3<X-6)?-V5B8U\T-S,Q7SEB,3=?-S,V-CDY-F$X-F%D#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+SDR-3$W.#5B7S=E8F-?-#<S,5\Y8C$W7S<S
M-C8Y.39A.#9A9"]7;W)K<VAE971S+U-H965T-#(N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5!
M2D%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/DEN8V]M92!487AE<R`H1&5T
M86EL<R`Q*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY296-O;F-I;&EA=&EO;B!/
M9B!4:&4@4W1A='5T;W)Y($9E9&5R86P@26YC;VUE(%1A>"!2871E(%1O(%1H
M92!#;VUP86YYXH"9<R!E9F9E8W1I=F4@5&%X(%)A=&4@6TQI;F4@271E;7-=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE
M="!O<&5R871I;F<@;&]S<R!C87)R>69O<G=A<F1S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#,L,C(T+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PT,C<L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C
M:RUB87-E9"!C;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(V,BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#:&%R:71A8FQE(&1O;F%T:6]N(&-A<G)Y9F]R
M=V%R9',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D=R;W-S(&1E9F5R<F5D('1A>"!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,L-#DP+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-#(W+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5F%L=6%T:6]N(&%L
M;&]W86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,RPT.3`L
M,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#$L-#(W+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y.970@9&5F97)R960@=&%X(&%S<V5T<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
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M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14E004,^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^26YC;VUE(%1A>&5S("A$971A:6QS(#(I/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0R/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M169F96-T:79E($EN8V]M92!487@@4F%T92!296-O;F-I;&EA=&EO;B!;3&EN
M92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^17AP96-T960@9F5D97)A;"!S=&%T=71O<GD@<F%T93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S0N,#`E*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,T+C`P)2D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T871E
M('1A>"!R871E+"!N970@;V8@9F5D97)A;"!B96YE9FET/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@V+C`P)2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V+C`P)2D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-H86YG92!I;B!E
M9F9E8W1I=F4@<W1A=&4@=&%X(')A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,"XS,"4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y097)M86YE;G0@:71E;7,@+2!S=&]C
M:RUB87-E9"!C;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(N-3`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!E<FUA;F5N="!I=&5M<R`M(&YO;BUD961U
M8W1I8FQE(&UE<F=E<B!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,"XT,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4&5R;6%N96YT(&ET96US("T@;W1H97(\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,3`E/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2XS,"4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%D
M:G5S=&UE;G0@;V8@3D],(&1U92!T;R!D96-O;G-O;&ED871I;VX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8N,C`E/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XP,"4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-H86YG92!I
M;B!V86QU871I;VX@86QL;W=A;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS,"XX,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS.2XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F-O;64@=&%X('!R;W9I<VEO;B`H
M8F5N969I="D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,#`E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
M7SDR-3$W.#5B7S=E8F-?-#<S,5\Y8C$W7S<S-C8Y.39A.#9A9`T*0V]N=&5N
M="U,;V-A=&EO;CH@9FEL93HO+R]#.B\Y,C4Q-S@U8E\W96)C7S0W,S%?.6(Q
M-U\W,S8V.3DV83@V860O5V]R:W-H965T<R]3:&5E=#0T+FAT;6P-"D-O;G1E
M;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E
M;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT
M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%0D1!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY);F-O;64@5&%X97,@
M*$1E=&%I;',@5&5X='5A;"D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y-87(N(#$S+"`R,#$U/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3W!E<F%T:6YG($QO<W,@0V%R
M<GEF;W)W87)D<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R960@5&%X($%S<V5T<RP@3W!E
M<F%T:6YG($QO<W,@0V%R<GEF;W)W87)D<RP@4W5B:F5C="!T;R!%>'!I<F%T
M:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#@L,#4Y+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,BPU,SDL,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y/<&5R871I;F<@3&]S<R!#87)R>69O<G=A<F1S+"!%
M>'!I<F%T:6]N(%!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^,C`S,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^17%U:71Y($UE=&AO9"!);G9E<W1M96YT+"!/=VYE<G-H:7`@
M4&5R8V5N=&%G93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<N
M,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y)4$\@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY/<&5R871I;F<@3&]S<R!#87)R>69O<G=A<F1S(%M,
M:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y%<75I='D@365T:&]D($EN=F5S=&UE;G0L($]W;F5R<VAI<"!0
M97)C96YT86=E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,"XP
M,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7SDR
M-3$W.#5B7S=E8F-?-#<S,5\Y8C$W7S<S-C8Y.39A.#9A9`T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B\Y,C4Q-S@U8E\W96)C7S0W,S%?.6(Q-U\W
M,S8V.3DV83@V860O5V]R:W-H965T<R]3:&5E=#0U+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M5TY!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY296QA=&5D(%!A<G1Y(%1R
M86YS86-T:6]N<R`H1&5T86EL<R!497AT=6%L*2`H55-$("0I/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C`@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,2!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^36%R+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y-87(N(#$S+"`R,#$U/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^36%R+B`R-BP@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^26UM961I871E($9A;6EL>2!-96UB97(@;V8@36%N
M86=E;65N="!O<B!0<FEN8VEP86P@3W=N97(@6TUE;6)E<ET\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY296QA=&5D(%!A<G1Y
M(%1R86YS86-T:6]N(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y386QA<FEE<RP@5V%G97,@86YD($]F
M9FEC97)S)R!#;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,S8L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y/8W5L=7,@6TUE;6)E<ET\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY296QA=&5D(%!A<G1Y(%1R
M86YS86-T:6]N(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!)<W-U960@1'5R:6YG(%!E<FEO
M9"P@4VAA<F5S+"!.97<@27-S=65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DYO;F-O;G1R;VQL:6YG($EN=&5R97-T+"!/
M=VYE<G-H:7`@4&5R8V5N=&%G92!B>2!.;VYC;VYT<F]L;&EN9R!/=VYE<G,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0S+C`P)3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V%L92!O
M9B!3=&]C:RP@3G5M8F5R(&]F(%-H87)E<R!)<W-U960@:6X@5')A;G-A8W1I
M;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,U,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-A
M;&4@;V8@4W1O8VLL(%!R:6-E(%!E<B!3:&%R93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`R+C<U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y386QE(&]F(%-T;V-K+"!$97-C<FEP
M=&EO;B!O9B!4<F%N<V%C=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^26X@=&AE(&5V96YT('1H870@=&AE(&-L;W-I;F<@;V8@=&AE($UE
M<F=E<B!D;V5S(&YO="!O8V-U<B!O;B!O<B!P<FEO<B!T;R!397!T96UB97(@
M,S`L(#(P,34L('1H92`S-3`L,#`P('-H87)E<R!O9B!T:&4@0V]M<&%N>28C
M.#(Q-SMS(&-O;6UO;B!S=&]C:R!W:6QL(&)E8V]M92!F=6QL>2!T<F%D86)L
M92!A;F0@9G5L;"!V;W1I;F<@<FEG:'1S('=I;&P@=')A;G-F97(@=&\@=&AE
M('!U<F-H87-E<G,@;V8@<W5C:"!S:&%R97,N/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/8W5L=7,@6TUE;6)E<ET@
M?"!-97)G97(@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY296QA=&5D(%!A<G1Y(%1R86YS86-T:6]N(%M,:6YE
M($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y386QE(&]F(%-T;V-K+"!.=6UB97(@;V8@4VAA<F5S($ES<W5E9"!I
M;B!4<F%N<V%C=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PV-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y386QE(&]F(%-T;V-K+"!0<FEC92!097(@4VAA<F4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BXW-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V%L92!/9B!3
M=&]C:R!.=6UB97(@3V8@4VAA<F5S($ES<W5E9"!);B!4<F%N<V%C=&EO;B!/
M;F4@3W(@36]R92!);G9E<W1O<G,@4')I;W(@5&\@0VQO<VEN9SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y386QE(&]F(%-T;V-K
M+"!$97-C<FEP=&EO;B!O9B!4<F%N<V%C=&EO;CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
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M('1H92!V;W1I;F<@<FEG:'1S('1O('1H92`U,"PP,#`@<VAA<F5S('5N=&EL
M(&%N9"!T:')O=6=H('1H92!D871E(&]F(&-L;W-I;F<@;V8@=&AE($UE<F=E
M<BX@26X@=&AE(&5V96YT('1H870@=&AE(&-L;W-I;F<@;V8@=&AE($UE<F=E
M<B!D;V5S(&YO="!O8V-U<B!O;B!O<B!P<FEO<B!T;R!397!T96UB97(@,S`L
M(#(P,34L('1H92`U,"PP,#`@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!W:6QL
M(&)E8V]M92!F=6QL>2!T<F%D86)L92!A;F0@9G5L;"!V;W1I;F<@<FEG:'1S
M('=I;&P@=')A;G-F97(@=&\@=&AE(&EN=F5S=&]R<RX\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7SDR-3$W.#5B7S=E8F-?-#<S
M,5\Y8C$W7S<S-C8Y.39A.#9A9`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B\Y,C4Q-S@U8E\W96)C7S0W,S%?.6(Q-U\W,S8V.3DV83@V860O5V]R
M:W-H965T<R]3:&5E=#0V+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%54%!13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY3=6)S97%U96YT($5V96YT<R`H1&5T86EL<R!497AT
M=6%L*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^07!R+B`S,"P@,C`Q-3QB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=6)S97%U96YT($5V96YT
M(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R86YG96UE
M;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"P@3W!T:6]N<RP@1W)A
M;G1S(&EN(%!E<FEO9"P@1W)O<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,S,BPU,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A
M;F=E;65N=',@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"P@3W!T:6]N
M<RP@1W)A;G1S(&EN(%!E<FEO9"P@5V5I9VAT960@079E<F%G92!%>&5R8VES
M92!0<FEC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V+C,W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y3=6)S97%U96YT($5V96YT(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5B<V5Q=65N="!%=F5N="!;3&EN
M92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y
M(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0L($]P=&EO;G,L($=R86YT<R!I
M;B!097)I;V0L($=R;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N
M=',@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"P@3W!T:6]N<RP@1W)A
M;G1S(&EN(%!E<FEO9"P@5V5I9VAT960@079E<F%G92!%>&5R8VES92!0<FEC
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+C,U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
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M.D9I;&4@2%)E9CTS1")3:&5E=#`Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970P,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#,N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`T+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970P-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,#8N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`W
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P."YH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,#DN:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#$P+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q
M,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3(N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$S+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970Q-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,34N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$V+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970Q-RYH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,3@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#$Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R,"YH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C$N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#(R+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970R,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C0N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(U+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970R-BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,C<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(X+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R.2YH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,S`N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#,Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S,BYH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S,N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#,T+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970S-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S8N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,W+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970S."YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,SDN:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#0P+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970T,2YH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T-#(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#0S+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970T-"YH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-#4N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#0V+FAT;6PB+SX-"CPO>&UL/@T*+2TM+2TM
M/5].97AT4&%R=%\Y,C4Q-S@U8E\W96)C7S0W,S%?.6(Q-U\W,S8V.3DV83@V
&860M+0T*
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EIPAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes (Details 2)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Expected federal statutory rate</a></td>
        <td class="num"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" onclick="toggleNextSibling(this);">(34.00%)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</span><span></span></td>
        <td class="num"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" onclick="toggleNextSibling(this);">(34.00%)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax rate, net of federal benefit</a></td>
        <td class="num"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" onclick="toggleNextSibling(this);">(6.00%)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</span><span></span></td>
        <td class="num"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" onclick="toggleNextSibling(this);">(6.00%)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Change in effective state tax rate</a></td>
        <td class="nump"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</span><span></span></td>
        <td class="num"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" onclick="toggleNextSibling(this);">(0.30%)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Permanent items - stock-based compensation</a></td>
        <td class="nump"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" onclick="toggleNextSibling(this);">2.50%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</span><span></span></td>
        <td class="nump"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensesPercent', window );">Permanent items - non-deductible merger expenses</a></td>
        <td class="nump"><a title="rtgn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensesPercent" onclick="toggleNextSibling(this);">0.40%</a><span style="display:none;white-space:normal;text-align:left;">rtgn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensesPercent</span><span></span></td>
        <td class="nump"><a title="rtgn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensesPercent" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">rtgn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensesPercent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther', window );">Permanent items - other</a></td>
        <td class="nump"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" onclick="toggleNextSibling(this);">0.10%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther</span><span></span></td>
        <td class="nump"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" onclick="toggleNextSibling(this);">1.30%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_ChangeInAvailableNolDueToDeconsolidation', window );">Adjustment of NOL due to deconsolidation</a></td>
        <td class="nump"><a title="rtgn_ChangeInAvailableNolDueToDeconsolidation" onclick="toggleNextSibling(this);">6.20%</a><span style="display:none;white-space:normal;text-align:left;">rtgn_ChangeInAvailableNolDueToDeconsolidation</span><span></span></td>
        <td class="nump"><a title="rtgn_ChangeInAvailableNolDueToDeconsolidation" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">rtgn_ChangeInAvailableNolDueToDeconsolidation</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
        <td class="nump"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" onclick="toggleNextSibling(this);">30.80%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</span><span></span></td>
        <td class="nump"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" onclick="toggleNextSibling(this);">39.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax provision (benefit)</a></td>
        <td class="nump"><a title="us-gaap_EffectiveIncomeTaxRateContinuingOperations" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</span><span></span></td>
        <td class="nump"><a title="us-gaap_EffectiveIncomeTaxRateContinuingOperations" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_ChangeInAvailableNolDueToDeconsolidation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>It represents percentage of change in available NOL due to deconsolidation during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_ChangeInAvailableNolDueToDeconsolidation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_EffectiveIncomeTaxRateReconciliationLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_EffectiveIncomeTaxRateReconciliationLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensesPercent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to merger expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensesPercent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity-based compensation costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EAHAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_PrepaidExpensesAndOtherCurrentAssetsLineItems', window );"><strong>Prepaid Expenses And Other Current Assets [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
        <td class="nump"><a title="us-gaap_PrepaidInsurance" onclick="toggleNextSibling(this);">$ 12,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidInsurance</span><span></span></td>
        <td class="nump"><a title="us-gaap_PrepaidInsurance" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidInsurance</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Clinical testing and other deposits</a></td>
        <td class="nump"><a title="us-gaap_OtherAssetsCurrent" onclick="toggleNextSibling(this);">114,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAssetsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherAssetsCurrent" onclick="toggleNextSibling(this);">1,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAssetsCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidRent', window );">Prepaid rent</a></td>
        <td class="nump"><a title="us-gaap_PrepaidRent" onclick="toggleNextSibling(this);">2,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidRent</span><span></span></td>
        <td class="nump"><a title="us-gaap_PrepaidRent" onclick="toggleNextSibling(this);">2,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidRent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_OtherPrepaidExpensesAndCurrentAssets', window );">Other prepaid expenses and current assets</a></td>
        <td class="nump"><a title="rtgn_OtherPrepaidExpensesAndCurrentAssets" onclick="toggleNextSibling(this);">38,000</a><span style="display:none;white-space:normal;text-align:left;">rtgn_OtherPrepaidExpensesAndCurrentAssets</span><span></span></td>
        <td class="nump"><a title="rtgn_OtherPrepaidExpensesAndCurrentAssets" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">rtgn_OtherPrepaidExpensesAndCurrentAssets</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total</a></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" onclick="toggleNextSibling(this);">$ 166,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" onclick="toggleNextSibling(this);">$ 3,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_OtherPrepaidExpensesAndCurrentAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of other prepaid expenses and current assets as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_OtherPrepaidExpensesAndCurrentAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_PrepaidExpensesAndOtherCurrentAssetsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_PrepaidExpensesAndOtherCurrentAssetsLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Assets<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (g)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 340<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=47804770&amp;loc=d3e5865-108316<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 340<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=47804770&amp;loc=d3e5879-108316<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidRent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Assets<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 340<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=47804770&amp;loc=d3e5865-108316<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 340<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=47804770&amp;loc=d3e5879-108316<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (g)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PrepaidRent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EIDAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (6,691,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (3,118,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_WorkingCapital', window );">Working Capital</a></td>
        <td class="nump"><a title="rtgn_WorkingCapital" onclick="toggleNextSibling(this);">9,888,000</a><span style="display:none;white-space:normal;text-align:left;">rtgn_WorkingCapital</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit)</a></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">$ (10,360,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">$ (3,669,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_SummaryOfSignificantAccountingPoliciesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_SummaryOfSignificantAccountingPoliciesLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_WorkingCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of working capital as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_WorkingCapital</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 31<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EBDAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 13, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" onclick="toggleNextSibling(this);">$ 8,059,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" onclick="toggleNextSibling(this);">$ 2,539,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_OperatingLossCarryforwardsExpirationPeriod', window );">Operating Loss Carryforwards, Expiration Period</a></td>
        <td class="text">2033<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_EquityMethodInvestmentOwnershipPercentage" onclick="toggleNextSibling(this);">17.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EquityMethodInvestmentOwnershipPercentage</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_EquityMethodInvestmentOwnershipPercentage[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember]" onclick="toggleNextSibling(this);">50.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EquityMethodInvestmentOwnershipPercentage<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_IPOMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_OperatingLossCarryforwardsExpirationPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expiration period of each operating loss carryforward included in operating loss carryforward.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_OperatingLossCarryforwardsExpirationPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6382943&amp;loc=d3e33918-111571<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ETFAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Property and Equipment (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property Plant And Equipment Gross</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross" onclick="toggleNextSibling(this);">$ 160,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross" onclick="toggleNextSibling(this);">$ 4,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
        <td class="num"><a title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(3,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</span><span></span></td>
        <td class="num"><a title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(2,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">157,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">2,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property Plant And Equipment Gross</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember]" onclick="toggleNextSibling(this);">4,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_OfficeEquipmentMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember]" onclick="toggleNextSibling(this);">4,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_OfficeEquipmentMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rtgn_MedicalEquipmentMember', window );">Medical Equipment [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property Plant And Equipment Gross</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=rtgn_MedicalEquipmentMember]" onclick="toggleNextSibling(this);">$ 156,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= rtgn_MedicalEquipmentMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=rtgn_MedicalEquipmentMember]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= rtgn_MedicalEquipmentMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 14<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rtgn_MedicalEquipmentMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=rtgn_MedicalEquipmentMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EJF">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
        <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">$ 1,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td>
        <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">$ 2,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Depreciation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization and Plan of Merger<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif">Note 1. Organization and Plan of Merger</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><i>&#160;</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><i>Organization</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">Ruthigen, Inc. (the &#8220;Company&#8221; or &#8220;Ruthigen&#8221;) was incorporated under the laws of the State of Nevada on January 18, 2013. The Company was reincorporated from Nevada to Delaware on September 25, 2013. The Company&#8217;s principal office is located in Santa Rosa, California. Ruthigen is a biopharmaceutical company focused on pioneering new hypochlorus acid, or HOCl, based therapies designed to improve patient outcomes and reduce healthcare costs associated with infections related to post-operative invasive procedures.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The Company closed its initial public offering (&#8220;IPO&#8221;) on March 26, 2014, pursuant to which an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,650,000</font> units were sold at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7.25</font> per unit. Prior to the IPO, the Company was a wholly-owned subsidiary of Oculus Innovative Sciences, Inc. (&#8220;Oculus&#8221; or &#8220;Former Parent&#8221;). See Note 7 &#150; Stockholders&#8217; Equity &#150; Initial Public Offering for additional details.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"><b><i>Agreement and Plan of Merger</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">On March 13, 2015, the Company entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) with Pulmatrix Inc. (&#8220;Pulmatrix&#8221;), a privately held biopharmaceutical company focused on the discovery, development, and commercialization of inhalable therapeutics and enabling technologies that treat and control respiratory infectious diseases. The Merger Agreement provides for the merger of Pulmatrix with and into Ruthigen Merger Corp., with Pulmatrix continuing after the merger as the surviving corporation and a wholly owned subsidiary of Ruthigen (the &#8220;Merger&#8221;). See Note 6 &#150; Commitments and Contingencies &#150; Agreement and Plan of Merger for additional details.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35735333&amp;loc=d3e288-107754<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 235<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472506&amp;loc=d3e38932-110933<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 272<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EANAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_AccountsPayableAndAccruedExpensesLineItems', window );"><strong>Accounts Payable And Accrued Expenses [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued employee compensation</a></td>
        <td class="nump"><a title="us-gaap_AccruedEmployeeBenefitsCurrent" onclick="toggleNextSibling(this);">$ 92,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedEmployeeBenefitsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccruedEmployeeBenefitsCurrent" onclick="toggleNextSibling(this);">$ 109,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedEmployeeBenefitsCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_AccruedDirectorCompensation', window );">Accrued director compensation</a></td>
        <td class="nump"><a title="rtgn_AccruedDirectorCompensation" onclick="toggleNextSibling(this);">43,000</a><span style="display:none;white-space:normal;text-align:left;">rtgn_AccruedDirectorCompensation</span><span></span></td>
        <td class="nump"><a title="rtgn_AccruedDirectorCompensation" onclick="toggleNextSibling(this);">50,000</a><span style="display:none;white-space:normal;text-align:left;">rtgn_AccruedDirectorCompensation</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_AccruedLegalFees', window );">Accrued legal fees</a></td>
        <td class="nump"><a title="rtgn_AccruedLegalFees" onclick="toggleNextSibling(this);">144,000</a><span style="display:none;white-space:normal;text-align:left;">rtgn_AccruedLegalFees</span><span></span></td>
        <td class="nump"><a title="rtgn_AccruedLegalFees" onclick="toggleNextSibling(this);">183,000</a><span style="display:none;white-space:normal;text-align:left;">rtgn_AccruedLegalFees</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued other professional fees</a></td>
        <td class="nump"><a title="us-gaap_AccruedProfessionalFeesCurrent" onclick="toggleNextSibling(this);">50,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedProfessionalFeesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccruedProfessionalFeesCurrent" onclick="toggleNextSibling(this);">45,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedProfessionalFeesCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_AccruedResearchAndDevelopmentCurrent', window );">Accrued research and development fees</a></td>
        <td class="nump"><a title="rtgn_AccruedResearchAndDevelopmentCurrent" onclick="toggleNextSibling(this);">128,000</a><span style="display:none;white-space:normal;text-align:left;">rtgn_AccruedResearchAndDevelopmentCurrent</span><span></span></td>
        <td class="nump"><a title="rtgn_AccruedResearchAndDevelopmentCurrent" onclick="toggleNextSibling(this);">9,000</a><span style="display:none;white-space:normal;text-align:left;">rtgn_AccruedResearchAndDevelopmentCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_AccruedFranchisesTaxes', window );">Accrued franchise taxes</a></td>
        <td class="nump"><a title="rtgn_AccruedFranchisesTaxes" onclick="toggleNextSibling(this);">146,000</a><span style="display:none;white-space:normal;text-align:left;">rtgn_AccruedFranchisesTaxes</span><span></span></td>
        <td class="nump"><a title="rtgn_AccruedFranchisesTaxes" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">rtgn_AccruedFranchisesTaxes</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
        <td class="nump"><a title="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">32,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">14,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total</a></td>
        <td class="nump"><a title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">$ 635,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">$ 410,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_AccountsPayableAndAccruedExpensesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_AccountsPayableAndAccruedExpensesLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_AccruedDirectorCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to directors pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_AccruedDirectorCompensation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_AccruedFranchisesTaxes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Its represents accrued franchise taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_AccruedFranchisesTaxes</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_AccruedLegalFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value balance sheet date provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_AccruedLegalFees</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_AccruedResearchAndDevelopmentCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_AccruedResearchAndDevelopmentCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, and other costs not separately disclosed in the balance sheet that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EBTAM">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="2">0 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 26, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 25, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 12, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 21, 2014</div>
        </th>
        <th class="th">
          <div>May 11, 2014</div>
        </th>
        <th class="th">
          <div>May 12, 2014</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" onclick="toggleNextSibling(this);">$ 4.79</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" onclick="toggleNextSibling(this);">$ 1,593,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense" onclick="toggleNextSibling(this);">452,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" onclick="toggleNextSibling(this);">1,060,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">2 years 1 month 6 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" onclick="toggleNextSibling(this);">332,500</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 6.37</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders' Equity, Reverse Stock Split</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">1-for-2.5<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.0001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.0001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.0001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">5,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">4,650,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">4,650,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Stock Issued During Period, Shares, Reverse Stock Splits</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" onclick="toggleNextSibling(this);">2,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">100,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">100,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesAuthorized" onclick="toggleNextSibling(this);">500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesAuthorized</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesAuthorized" onclick="toggleNextSibling(this);">500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesAuthorized</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.0001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockParOrStatedValuePerShare</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.0001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockParOrStatedValuePerShare</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_GrossProceedsFromIssuanceOfCommonStockAndWarrants', window );">Gross Proceeds From Issuance Of Common Stock And Warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="rtgn_GrossProceedsFromIssuanceOfCommonStockAndWarrants" onclick="toggleNextSibling(this);">1,117,000</a><span style="display:none;white-space:normal;text-align:left;">rtgn_GrossProceedsFromIssuanceOfCommonStockAndWarrants</span><span></span></td>
        <td class="nump"><a title="rtgn_GrossProceedsFromIssuanceOfCommonStockAndWarrants" onclick="toggleNextSibling(this);">19,216,000</a><span style="display:none;white-space:normal;text-align:left;">rtgn_GrossProceedsFromIssuanceOfCommonStockAndWarrants</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_OfferingCost', window );">Offering Cost</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="rtgn_OfferingCost" onclick="toggleNextSibling(this);">252,000</a><span style="display:none;white-space:normal;text-align:left;">rtgn_OfferingCost</span><span></span></td>
        <td class="nump"><a title="rtgn_OfferingCost" onclick="toggleNextSibling(this);">3,195,000</a><span style="display:none;white-space:normal;text-align:left;">rtgn_OfferingCost</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">4,804,290</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">4,804,290</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber', window );">Share Based Compensation Arrangement By Share Based Payment Award Equity Instrument Other Than Options Equity Instruments Exercisable Number</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber" onclick="toggleNextSibling(this);">3,140,250</a><span style="display:none;white-space:normal;text-align:left;">rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentWarrantsExercisePrice', window );">Investment Warrants, Exercise Price</a></td>
        <td class="nump"><a title="invest_InvestmentWarrantsExercisePrice" onclick="toggleNextSibling(this);">$ 0.0001</a><span style="display:none;white-space:normal;text-align:left;">invest_InvestmentWarrantsExercisePrice</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_ClosingPriceOfCommonStockPercentage', window );">Closing Price Of Common Stock Percentage</a></td>
        <td class="nump"><a title="rtgn_ClosingPriceOfCommonStockPercentage" onclick="toggleNextSibling(this);">150.00%</a><span style="display:none;white-space:normal;text-align:left;">rtgn_ClosingPriceOfCommonStockPercentage</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" onclick="toggleNextSibling(this);">3,145,650</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_ClassOfWarrantOrRightDurationFromWhichWarrantsOrRightsExercisable', window );">Class Of Warrant Or Right Duration From Which Warrants Or Rights Exercisable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">1 year<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_InvestmentFromFormerParent', window );">Investment From Former Parent</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="rtgn_InvestmentFromFormerParent" onclick="toggleNextSibling(this);">1,679,000</a><span style="display:none;white-space:normal;text-align:left;">rtgn_InvestmentFromFormerParent</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_PercentageOfOptionsUnvested', window );">Percentage Of Options Unvested</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="rtgn_PercentageOfOptionsUnvested" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">rtgn_PercentageOfOptionsUnvested</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=rtgn_RepresentativeOfUnderwritersMember', window );">Representative Of Underwriters [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_TermOfWarrant', window );">Term Of Warrant</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Stock Issued During Period, Shares, Other</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesOther[us-gaap_TitleOfIndividualAxis=rtgn_RepresentativeOfUnderwritersMember]" onclick="toggleNextSibling(this);">5,400</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesOther<br>/ us-gaap_TitleOfIndividualAxis<br>= rtgn_RepresentativeOfUnderwritersMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharesIssuedPricePerShare[us-gaap_TitleOfIndividualAxis=rtgn_RepresentativeOfUnderwritersMember]" onclick="toggleNextSibling(this);">$ 9.0625</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesIssuedPricePerShare<br>/ us-gaap_TitleOfIndividualAxis<br>= rtgn_RepresentativeOfUnderwritersMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rtgn_NewTwoThousandThirteenPlanMember', window );">New 2013 Plan [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Share-based Compensation Arrangement by Share-based Payment Award, Description</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">The annual increase in the number of shares shall be equal to the lowest of: (i) 2,551,500 shares of Ruthigen&#8217;s common stock; (ii) five percent (5%) of the number of shares of Ruthigen&#8217;s common stock outstanding as of such date; and (iii) an amount determined by Ruthigen&#8217;s board of directors.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_PlanNameAxis=rtgn_NewTwoThousandThirteenPlanMember]" onclick="toggleNextSibling(this);">6,853,319</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_PlanNameAxis<br>= rtgn_NewTwoThousandThirteenPlanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease', window );">Stock Issued During Period, Shares, Period Increase (Decrease)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease[us-gaap_PlanNameAxis=rtgn_NewTwoThousandThirteenPlanMember]" onclick="toggleNextSibling(this);">1,230,855</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease<br>/ us-gaap_PlanNameAxis<br>= rtgn_NewTwoThousandThirteenPlanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharePrice[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember]" onclick="toggleNextSibling(this);">$ 6.6608</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharePrice<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_IPOMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_WarrantsToPurchaseOfCommonStock', window );">Warrants to Purchase of Common Stock</a></td>
        <td class="nump"><a title="rtgn_WarrantsToPurchaseOfCommonStock[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember]" onclick="toggleNextSibling(this);">397,500</a><span style="display:none;white-space:normal;text-align:left;">rtgn_WarrantsToPurchaseOfCommonStock<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_IPOMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="rtgn_WarrantsToPurchaseOfCommonStock[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember]" onclick="toggleNextSibling(this);">397,500</a><span style="display:none;white-space:normal;text-align:left;">rtgn_WarrantsToPurchaseOfCommonStock<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_IPOMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_InitialPublicOfferingPricePerUnit', window );">Initial Public Offering Price Per Unit</a></td>
        <td class="nump"><a title="rtgn_InitialPublicOfferingPricePerUnit[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember]" onclick="toggleNextSibling(this);">$ 7.25</a><span style="display:none;white-space:normal;text-align:left;">rtgn_InitialPublicOfferingPricePerUnit<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_IPOMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="rtgn_InitialPublicOfferingPricePerUnit[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember]" onclick="toggleNextSibling(this);">$ 7.25</a><span style="display:none;white-space:normal;text-align:left;">rtgn_InitialPublicOfferingPricePerUnit<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_IPOMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember]" onclick="toggleNextSibling(this);">$ 9.0625</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_IPOMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_InitialPublicOfferingUnits', window );">Initial Public Offering Units</a></td>
        <td class="nump"><a title="rtgn_InitialPublicOfferingUnits[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember]" onclick="toggleNextSibling(this);">2,650,000</a><span style="display:none;white-space:normal;text-align:left;">rtgn_InitialPublicOfferingUnits<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_IPOMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="rtgn_InitialPublicOfferingUnits[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember]" onclick="toggleNextSibling(this);">2,650,000</a><span style="display:none;white-space:normal;text-align:left;">rtgn_InitialPublicOfferingUnits<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_IPOMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfCommonStock[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember]" onclick="toggleNextSibling(this);">16,021,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfCommonStock<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_IPOMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_GrossProceedsFromIssuanceOfCommonStockAndWarrants', window );">Gross Proceeds From Issuance Of Common Stock And Warrants</a></td>
        <td class="nump"><a title="rtgn_GrossProceedsFromIssuanceOfCommonStockAndWarrants[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember]" onclick="toggleNextSibling(this);">19,216,000</a><span style="display:none;white-space:normal;text-align:left;">rtgn_GrossProceedsFromIssuanceOfCommonStockAndWarrants<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_IPOMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_OfferingCost', window );">Offering Cost</a></td>
        <td class="nump"><a title="rtgn_OfferingCost[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember]" onclick="toggleNextSibling(this);">3,195,000</a><span style="display:none;white-space:normal;text-align:left;">rtgn_OfferingCost<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_IPOMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember]" onclick="toggleNextSibling(this);">2,650,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_IPOMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber', window );">Share Based Compensation Arrangement By Share Based Payment Award Equity Instrument Other Than Options Equity Instruments Exercisable Number</a></td>
        <td class="nump"><a title="rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember]" onclick="toggleNextSibling(this);">3,047,500</a><span style="display:none;white-space:normal;text-align:left;">rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_IPOMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice', window );">Share Based Compensation Arrangement By Share Based Payment Award Equity Instrument Other Than Options Equity Instruments Exercisable Weighted Average Exercise Price</a></td>
        <td class="nump"><a title="rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember]" onclick="toggleNextSibling(this);">$ 7.25</a><span style="display:none;white-space:normal;text-align:left;">rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_IPOMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Stock, Number of Shares Issued in Transaction</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember]" onclick="toggleNextSibling(this);">154,290</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_OverAllotmentOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SaleOfStockPricePerShare[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember]" onclick="toggleNextSibling(this);">$ 6.6608</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SaleOfStockPricePerShare<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_OverAllotmentOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of Stock, Consideration Received on Transaction</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SaleOfStockConsiderationReceivedOnTransaction[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember]" onclick="toggleNextSibling(this);">1,028,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_OverAllotmentOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">627,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">1,522,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">2 years 1 month 6 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">RSUs for 341,000 shares of common stock vest ratably over three years on a quarterly basis and had an aggregate grant date value of $2,148,000. RSUs for 68,355 shares had an aggregate grant date value of $431,000 and vest in equal installments based on achievement of the following: (1) enrollment of the first patient in the first pivotal clinical trial for RUT58-60 on or prior to May 11, 2017; (2) enrollment of the first patient in the second pivotal clinical trial for RUT58-60 on or prior to May 11, 2018; and (3) completion of the clinical study report containing the results of the second pivotal clinical trial for RUT58-60 on or prior to May 11, 2019.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">409,355</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Performance Shares [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember;us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">431,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_PerformanceSharesMember<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rtgn_TwoThousandThirteenPlanMember', window );">2013 Plan [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross[us-gaap_AwardTypeAxis=rtgn_TwoThousandThirteenPlanMember]" onclick="toggleNextSibling(this);">332,500</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross<br>/ us-gaap_AwardTypeAxis<br>= rtgn_TwoThousandThirteenPlanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=rtgn_TwoThousandThirteenPlanMember]" onclick="toggleNextSibling(this);">$ 6.37</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= rtgn_TwoThousandThirteenPlanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_AwardTypeAxis=rtgn_TwoThousandThirteenPlanMember]" onclick="toggleNextSibling(this);">$ 0.0092</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_AwardTypeAxis<br>= rtgn_TwoThousandThirteenPlanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized[us-gaap_AwardTypeAxis=rtgn_TwoThousandThirteenPlanMember]" onclick="toggleNextSibling(this);">998,355</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized<br>/ us-gaap_AwardTypeAxis<br>= rtgn_TwoThousandThirteenPlanMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Share-based Compensation Arrangement by Share-based Payment Award, Description</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">The annual increase in the number of shares shall be equal to the lowest of: (a) 232,500 shares of the Company&#8217;s common stock; (b) 5% of the number of shares of the Company&#8217;s common stock outstanding as of such date; and (c) an amount determined by the Company&#8217;s board of directors or compensation committee.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rtgn_UnderwritersMember', window );">Underwriters [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_AwardTypeAxis=rtgn_UnderwritersMember]" onclick="toggleNextSibling(this);">$ 9.0625</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_AwardTypeAxis<br>= rtgn_UnderwritersMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber[us-gaap_AwardTypeAxis=rtgn_UnderwritersMember]" onclick="toggleNextSibling(this);">92,750</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber<br>/ us-gaap_AwardTypeAxis<br>= rtgn_UnderwritersMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Class of Warrant or Right, Date from which Warrants or Rights Exercisable</a></td>
        <td class="text">Mar. 21,  2015<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_ClassOfWarrantOrRightsExpiringDateWarrantsOrRightsExercisable', window );">Class Of Warrant Or Rights Expiring Date Warrants Or Rights Exercisable</a></td>
        <td class="text">Mar. 21,  2019<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">397,500</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_InvestmentFromFormerParent', window );">Investment From Former Parent</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="rtgn_InvestmentFromFormerParent[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">rtgn_InvestmentFromFormerParent<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentWarrantsExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price of the warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 12<br><br> -Section 13<br><br> -Sentence Column A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">invest_InvestmentWarrantsExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>invest_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_ClassOfWarrantOrRightDurationFromWhichWarrantsOrRightsExercisable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>It represents the period from which the warrants are exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_ClassOfWarrantOrRightDurationFromWhichWarrantsOrRightsExercisable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_ClassOfWarrantOrRightsExpiringDateWarrantsOrRightsExercisable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date the warrants or rights are expiration , in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_ClassOfWarrantOrRightsExpiringDateWarrantsOrRightsExercisable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_ClosingPriceOfCommonStockPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the percentage of Closing Price of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_ClosingPriceOfCommonStockPercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_GrossProceedsFromIssuanceOfCommonStockAndWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross proceeds from the issuance of common stock and warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_GrossProceedsFromIssuanceOfCommonStockAndWarrants</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_InitialPublicOfferingPricePerUnit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price per share or per unit of public offering outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_InitialPublicOfferingPricePerUnit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_InitialPublicOfferingUnits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represent initial public offering units</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_InitialPublicOfferingUnits</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_InvestmentFromFormerParent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value due to investment from the former parent during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_InvestmentFromFormerParent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_OfferingCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total Offering cost for issuance of common stock and warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_OfferingCost</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_PercentageOfOptionsUnvested">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>It represents the percentage of options unvested during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_PercentageOfOptionsUnvested</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represented the value of Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average exercise price of other than options exercisable, including both vested and non-vested instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_TermOfWarrant">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period of time between issuance and maturity of Warrant.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_TermOfWarrant</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_WarrantsToPurchaseOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represent warrants to purchase of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_WarrantsToPurchaseOfCommonStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date the warrants or rights are exercisable, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(3))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 3<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price per share or per unit of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrecognized cost of unvested share-based compensation awards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash received on stock transaction after deduction of issuance costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of award terms as to how many shares or portion of an award are no longer contingent on satisfaction of either a service condition, market condition or a performance condition, thereby giving the employee the legal right to convert the award to shares, to sell the shares, and be entitled to the cash proceeds of such sale. For example, vesting may be expressed as being 25 percent of the shares under option on each anniversary of the grant date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>General descriptive information regarding an arrangement under which employees and directors receive: (a) awards of equity shares, equity share options, or other equity instruments; or (b) the entity incurs liabilities to them: (1) in amounts based, at least in part, on the price of the entity's shares or other equity instruments; or (2) that require or may require settlement by issuance of the entity's shares. Such an arrangement is usually provided to employees and directors to compensate them, provide performance incentives to them, and to attract or retain their services. May also include pertinent information particular to a plan that is not elsewhere specified in the taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Price of a single share of a number of saleable stocks of a company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount per share or per unit of equity securities issued by non-development stage entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the period in the number of shares issued.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Reduction in the number of shares during the period as a result of a reverse stock split.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rtgn_TwoThousandThirteenPlanMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rtgn_TwoThousandThirteenPlanMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rtgn_UnderwritersMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rtgn_UnderwritersMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rtgn_NewTwoThousandThirteenPlanMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PlanNameAxis=rtgn_NewTwoThousandThirteenPlanMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=rtgn_RepresentativeOfUnderwritersMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=rtgn_RepresentativeOfUnderwritersMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EPQAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
        <td class="nump"><a title="us-gaap_Cash" onclick="toggleNextSibling(this);">$ 10,357,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Cash</span><span></span></td>
        <td class="nump"><a title="us-gaap_Cash" onclick="toggleNextSibling(this);">$ 15,571,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Cash</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" onclick="toggleNextSibling(this);">166,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" onclick="toggleNextSibling(this);">3,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
        <td class="nump"><a title="us-gaap_AssetsCurrent" onclick="toggleNextSibling(this);">10,523,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AssetsCurrent" onclick="toggleNextSibling(this);">15,574,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">157,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">2,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
        <td class="nump"><a title="us-gaap_Assets" onclick="toggleNextSibling(this);">10,680,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Assets</span><span></span></td>
        <td class="nump"><a title="us-gaap_Assets" onclick="toggleNextSibling(this);">15,576,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Assets</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
        <td class="nump"><a title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">635,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">410,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Payable to Former Parent</a></td>
        <td class="nump"><a title="us-gaap_DueToRelatedPartiesCurrent" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DueToRelatedPartiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DueToRelatedPartiesCurrent" onclick="toggleNextSibling(this);">537,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DueToRelatedPartiesCurrent</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
        <td class="nump"><a title="us-gaap_LiabilitiesCurrent" onclick="toggleNextSibling(this);">635,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesCurrent" onclick="toggleNextSibling(this);">947,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 500,000 shares authorized; no shares issued and outstanding at March 31, 2015 and 2014, respectively</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockValue" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockValue" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockValue</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 100,000,000 shares authorized; 4,804,290 and 4,650,000 shares issued and outstanding at March 31, 2015 and 2014, respectively</a></td>
        <td class="nump"><a title="us-gaap_CommonStockValue" onclick="toggleNextSibling(this);">480</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockValue" onclick="toggleNextSibling(this);">465</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
        <td class="nump"><a title="us-gaap_AdditionalPaidInCapitalCommonStock" onclick="toggleNextSibling(this);">20,404,520</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdditionalPaidInCapitalCommonStock</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdditionalPaidInCapitalCommonStock" onclick="toggleNextSibling(this);">18,297,535</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdditionalPaidInCapitalCommonStock</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">(10,360,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">(3,669,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">10,045,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">14,629,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
        <td class="nump"><a title="us-gaap_LiabilitiesAndStockholdersEquity" onclick="toggleNextSibling(this);">$ 10,680,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesAndStockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesAndStockholdersEquity" onclick="toggleNextSibling(this);">$ 15,576,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesAndStockholdersEquity</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Assets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Cash</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(k)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (d)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 08<br><br><br><br> -Paragraph k<br><br><br><br> -Subparagraph 1<br><br><br><br> -Article 4<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EWNAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Related Party Transactions (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="2">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 13, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 26, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember', window );">Immediate Family Member of Management or Principal Owner [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalariesWagesAndOfficersCompensation', window );">Salaries, Wages and Officers' Compensation</a></td>
        <td class="nump"><a title="us-gaap_SalariesWagesAndOfficersCompensation[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember]" onclick="toggleNextSibling(this);">$ 36,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalariesWagesAndOfficersCompensation<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rtgn_OculusMember', window );">Oculus [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rtgn_OculusMember]" onclick="toggleNextSibling(this);">2,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= rtgn_OculusMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rtgn_OculusMember]" onclick="toggleNextSibling(this);">43.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= rtgn_OculusMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Stock, Number of Shares Issued in Transaction</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rtgn_OculusMember]" onclick="toggleNextSibling(this);">350,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= rtgn_OculusMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SaleOfStockPricePerShare[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rtgn_OculusMember]" onclick="toggleNextSibling(this);">$ 2.75</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SaleOfStockPricePerShare<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= rtgn_OculusMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockDescriptionOfTransaction', window );">Sale of Stock, Description of Transaction</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">In the event that the closing of the Merger does not occur on or prior to September 30, 2015, the 350,000 shares of the Company&#8217;s common stock will become fully tradable and full voting rights will transfer to the purchasers of such shares.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rtgn_OculusMember', window );">Oculus [Member] | Merger [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Stock, Number of Shares Issued in Transaction</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rtgn_OculusMember;us-gaap_RestructuringPlanAxis=rtgn_MergerMember]" onclick="toggleNextSibling(this);">1,650,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= rtgn_OculusMember<br>/ us-gaap_RestructuringPlanAxis<br>= rtgn_MergerMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SaleOfStockPricePerShare[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rtgn_OculusMember;us-gaap_RestructuringPlanAxis=rtgn_MergerMember]" onclick="toggleNextSibling(this);">$ 2.75</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SaleOfStockPricePerShare<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= rtgn_OculusMember<br>/ us-gaap_RestructuringPlanAxis<br>= rtgn_MergerMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_SaleOfStockNumberOfSharesIssuedInTransactionOmneOrMoreInvestorsPriorToClosing', window );">Sale Of Stock Number Of Shares Issued In Transaction One Or More Investors Prior To Closing</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="rtgn_SaleOfStockNumberOfSharesIssuedInTransactionOmneOrMoreInvestorsPriorToClosing[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rtgn_OculusMember;us-gaap_RestructuringPlanAxis=rtgn_MergerMember]" onclick="toggleNextSibling(this);">50,000</a><span style="display:none;white-space:normal;text-align:left;">rtgn_SaleOfStockNumberOfSharesIssuedInTransactionOmneOrMoreInvestorsPriorToClosing<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= rtgn_OculusMember<br>/ us-gaap_RestructuringPlanAxis<br>= rtgn_MergerMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockDescriptionOfTransaction', window );">Sale of Stock, Description of Transaction</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">If the Merger does not close by August 13, 2015 or as may be extended up to 60 calendar days at Oculus&#8217;s discretion, there will be no obligation of the investors to purchase the shares. Oculus will retain the voting rights to the 50,000 shares until and through the date of closing of the Merger. In the event that the closing of the Merger does not occur on or prior to September 30, 2015, the 50,000 shares of common stock will become fully tradable and full voting rights will transfer to the investors.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_SaleOfStockNumberOfSharesIssuedInTransactionOmneOrMoreInvestorsPriorToClosing">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Its represents the number of shares sold to one or more investors prior to closing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_SaleOfStockNumberOfSharesIssuedInTransactionOmneOrMoreInvestorsPriorToClosing</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesWagesAndOfficersCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expenditures for salaries for officers and non-officers. Does not include allocated share-based compensation, pension and post-retirement benefit expense or other labor-related non-salary expense. For commercial and industrial companies, excludes any direct and overhead labor that is included in cost of goods sold.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SalariesWagesAndOfficersCompensation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockDescriptionOfTransaction">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 23<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569655-111683<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1B<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4582445-111684<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SaleOfStockDescriptionOfTransaction</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rtgn_OculusMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rtgn_OculusMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>39
<FILENAME>0001144204-15-036361-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001144204-15-036361-xbrl.zip
M4$L#!!0````(`"`PRD:<M3+_'^@``.$"#@`1`!P`<G1G;BTR,#$U,#,S,2YX
M;6Q55`D``]P*>%7<"GA5=7@+``$$)0X```0Y`0``[%W]<^(XFO[]JNY_T&9W
M9G:K0H+Y2.>C>[;H=-*;W22D$OIF]JZN4L(6H!MC>R0Y@;VZ__U>R1_8Q)"$
MQF!C=<UT`Y)EO<_[O!^2)?GC7R=C&ST1QJGK?-HS#NI[B#BF:U%G^&GO6^^R
M=KR'_OKSO__;QS_4:N@K<0C#@EBH/T5?L,`]ALW?>'0],@Z,@V,$'^HGM;_[
M3JU1-]KHO^J-TT;CM/7AO]'_WMW\'[IXZ*$:>GY^/K"@!:%:.##=,:K5HOM\
MQASN`>W\^OG^&C4.C+!LTF<V/95_(^BVPT^9&$*O1T)XIX>'LDGFBQ$=$D<V
M>"AO7V\VC;VPMDV=WU*U94L'+AM"S7KS4!;WX<Y1=5EJT?B"9.6CPZ`PKOJB
MZ>>FJFN<G)P<JM*X*J=9%:%1X_#7F^L'<T3&N$8=+K!CIOI"E_1]OC[E;JMA
M?%AV15`CNL`B'B.FU.W":TX.,3.9:Y/#`39%C4P\&SM8N&QZ"=^CADS7=P2;
MIF'CQ#P8ND^'8:'43+-6-VHSW9@^8T"\1=>%I?+"5OI"B]#L:Z`@HSJ9F*/L
M^K(DXP+J/!$NLB\)RC*D<3`U>?8UJDA>8J0OX=3,O@`*LJH+CRVH#R49%_B\
M-L38BZ\98-Y7F@T+,D2?V$OX\^MU@M2^8$MH`Z5[8+X(?92&<,H5Q>_)`"G#
M.!53CWS:XW3LV9*_ZK<1(X-/>]*\:Y$5'TRXM8<.H:'`2YR[CB`3@1Z(*<#Y
M*`\!MPA\A!D64J#S7;WQ6#<>93L]%SX;P>>@2_$5Q!%43,/?XE^I)7\?4,*0
MZC9)B1E!?G[UC[V?ZV#![0^M1K/]\7#^XNA6AW/W2O7`(XRZUGP/P*Z9`%]+
M?I:=KM4;H*.HG5E9U%1"'"MUD6',;FZ%ER2[E+AY]%.(8=AV)K#-$-@6`-M\
M;!RISV4$%IC??#>PZJ+&40[`=GC7`4"-9IF8&L0@$5*N63.:<?-AR?J0:1IE
MHEH"&<69II$W,F7E3"[(U%NAFVHH-Q4@U"P)0BDW!<Z_]6XWU4P#NT[_'P';
M3`!;%J-,`=M<!=A6_L"V$L"6Q:;G`^O[@6WG!JQRDD>/]7:9`$T[R:-:O9V'
MDSQ)V/+)8Z-=6B<)MGRRBI,\J37:>5&N;(`F*#>'S+HSEI/'9KU,82.=RYW4
MFO6\<[ER<N:[<SDYQO]"Q\114XMO&.5G)B./%V//=J>$/`C7_*WKR49NR+A/
MF,_EM$?PRY5CD0FQ>NX5YSYA_.)W'\0._NY,*-^P!N:]&QD"#"*^7UA@04<F
MGDU-*@*)D!7!]6DOG-4Y?:M\4?V%<'T\S+SG#(3#K,[N;&*6)MDOF#$@>))8
M#P)N*9$(4#YWQY[KP%=>;CZ](E94+06(ILX2ZMP3+A@U!;&4R7USJ.#W#]^2
M5.H\8V;UIAXI-W7FQ(A^7@J`IL[BX:`.;>4.;04;&B\@F0YM!0QMY:".#FT%
M#&U%H\Y1@CI'CXU6D!6=CR@97%('.R;%=G<PH"9A2>+<$ULN5KB#WD][8(\<
MJ_$A_SQ-EDAUQ&&R,V1$V7?0CGRX?`W-.GQ64DX62DE.LT5110L`6$S`54S@
M[0J9V<<2+6_/.HY62?R.:HU6#M9A&#/KD,L6CA/6<3$AIB_H$]'6L</6D:WE
MK5F'6E7T7NN`BQK'FTL[>L]NC!I/6D6/"AMPA!$#?:*6C^UR$CKBQP)Q%*DS
M,-#YQA+.:(^J/:JVCJ76H;/Q*EA'T;+Q(EE'>H7=8Z1CQWKP/<^>OI'1CUW3
MMWV^FOGLGCF\@N+VS$+U+JFKS1G!1E9%IE?2ZGG>@LSS;F&ML-9]\72_(;MO
M/T(ZS$S*R1T#1WR/G2'I.B05G.1OY=9Z0H0@!5LL<]64W7MV*Z?L6.8=4_:B
M90+:PK=CX44>R[R9*]I!5)XKRX)(*F<<84;4WGV95P'L6`ZNU*^\XXN1R^B_
MB/7-L0A+K,&YL[$<@+W40KE9E@L8+_E:V4"FB5<MXI7&03;GUSU5=KW3%GW3
M.C:@O.*;EB[CUCK?AELHQ[)M394"4*7($41[DP)$D(U-OFM=;UW7.8YDYDY(
M"NT;,O,QY.3S^J[V0Y<7H&PO-*QZ%E2.H2&BSM5=-T49O\^I13&;/F"Y&E#!
M5W*Z+!8IJA*#L+W0T-C@Q,<=80.7C>4!C\$X/A4D0`B+VFI)VP,Q?48%)?QB
M8MJ^1:Q+YHZEP?E"30-T!Q>8.=09<F@SF"F89C>@EJKH'3RK[>!9J0?YZ7$F
MSP(FZ23\]<1,DW]+V]<VDZBU$YZW_6@T@FC;>W9[(]?GV+%Z(\H$(6JF=/<Y
M$.TB6"S]]GQ&>Y7LK%TS&GG,\<SQ1I_J4"C?L2[J;.+T7)W@;S7!+_(8,/N@
M94V5DE,EQZ.C(V^B$Y@")#`;F3N(%*]]0['FB8[RU[5:S/$,XWW">$4L^Z7(
MNZGB:$V)?F)0K"<&&UEK,L>!CF51.?F'[3M,K2OG''M48%OS(784RP#:;6[<
M$X&I0ZQH6EB38C83D87,CK%AT<9]'34*%36*_/1C`85TT"E'T"DAM73,*FK,
M*@69T@NP=:@K<*@KZL+L-(5TJ"MAJ"L'M72H*T6H*QB9YG8%Z!!7K!"W^=T"
M.D:5)49M@QLZR!0UR&QC7Y&.%H6-%AL[[TE'B])%BXUQ0T>+$D2+C9^Q$AS[
M*_'QI!1)4MPQ%^XDIG(%E>@X5ESI\[3\:TS>)%S\YK$LD/3L[!):W6#''V!3
M^`P,ZA*;U`9I-;FRR+4$*DVQ)12[],%;`VKR*.E+.I&?N&98%L,6(Z4)EC&L
MUB&Q^"%Q&],M-\2B)K8U,3*%4ZMTLR':95KH#+ID[F)CXVWM+LKD+C8_\*[4
M6V%*]D*6(F>K"_BTXMN)RD>EW%XP5$D2-1(D:CY>C<?@DN$>EWA,[7`6HCNX
MP0X>*@R[[(Y1QZ0>MKO/SJHOA2L?Z;[G/6LK@KHEHC96(6HS/Z)F[X37T;-$
MT;.(V^4UCXK/HXWLNXT=3%LY&`B".CTO.C%2#J:]BH-1%QG-/`-6FD\WA`WG
MTR4NF!\^]Y%CY0J^+#1GWJW6E0RUQ/,5,R5JMB?"J?::)?":\[-=,T*L?Q)4
MNSWM]LI`U[EHK2=G2^#'UA0/\YVN2/-)NT'M!G>1[:T$VUN/S7K`=GE0&_G=
M!RDOGN8>?,X5E?]AYT*!%E38-GU6>@C1JC7K^:^[TB<8%N,$P]P61QCU^$&3
M/J:T6,>40GI=S_F-2.%\6".($;?D^0T<D-]O\;CD%$A+H1CPFOBERR_R.6P_
M>ZF#=AY%XTW15C=D/S36Q^;JQ\"O+,I[(JQCVZY0RS+4B[)U2KH0%.ULLI:#
M:PH5DD+;7.M[3SQ&./06RW>U=0>+`E&/"@G@E6/1)VKYV"XW,1:(HP+3ZY!H
M[Y*YB5\SJ<!,VN0^D^@1ZYUOC[%@='+EF(%@%J'79(CM"]7S<FH>9#A](832
M]TMY=^R9I-+OA[EG1^>VRZDSE&[EBM^ZU_`OZXVP\W??GC8-67&VSE]6Z@Z"
MZ\JI?:7HEV(D'L.\%8]M<>-#CK9_/+>\(H5%9P!(S%#X[(L$.AU_Z'-A-"O.
MEW=BM"T.'6]DS4/$I8NQ9[M3(C?.?*&,F,)E%<TH%B)1OEG93:QP#6?TST>4
M#"XFQ/2#/$QN^-7[@]ZP/V@)<.4C7"Z/`980[I(ZV#$IMC7AWD>X;.`TX3;C
MX>)H&P48B#7G4-.W990/CJN#\8T$](E4YJGH:J`LYJSVX,4TJ'HS7@00ZA=2
M\WB?-I^-3.+?ROMT3A$[0XYH&<!B`$I'G?HFLLVZILX.4L?(8WWATJV=#Z"M
M:R)@T)]Q4L:ND^<5",I'GTWNY*0.'?OC5-Z'G2&I\@+^2/[$J:9)E+:7H95_
MFTH^U%YT:N]$4[NX>U,RK"RI,/W`?/W'8RWU]N5C=6YG9VTV:F@^K\[G)2Y>
M\UG[YVWQ^9(R+NY&F)/43*?/3/F;?(T/58L'+R:F[5LPY+UVG2&,7,:S(L7O
MRAR#&$^COA>BT#3F`5^/+>C#&8OG\A\(M&Y]OVU5ST9>(*>-9%>-1&ZEJJ2-
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M$Y*_`4/^^T`L4)`OV*DL7E$[GO]"*6EA984WM?WQ#[7:A:T&S.B!*(=?JP55
M@XU]E)NV*Z_O#NX8\3"U+B:>''%S&')WQ8BP<Y\Q.=SEG`C>`W/X;+OF;RBT
MC7LR6#@=LJ>$N91QQGHT]G[^T19G`#'B8FJ#"[OIW'^]NCU%=4_`_Y,S=-F]
M[9TB0W[O@;_AZ)8\HWMWC)W]X(=]D('1`=K[<2C.T%QSY]<7G?O3OBM&04NU
MR\[-U?4_3^>:.E-E#U?_>1'<ZFQ!-_JN;;VA+ZHKMZX@J'F`0@11!"'"CH44
MB"A$$04PRJX?0M_7*4?OXM=>[>KVRX7L??V@39TSM#+$2JP?\=@[^Z-Q5#\K
M1W\C^$D2?E?!;X;P8P6_)"^G'#ZX`P3E:.#:MOM,G>%I.23=@&8ZUU=?;T^O
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MFR#NVM0*Z5M4"!K-'_:D"0#)@<?M%WC<8&:.9J`TC?UJ*_Y0,&WG99.P.G8>
M]K+7O<OLXF*$C*0;:+R`2^;3)6+"RC!HHGP_45HE(HJ.$#I"K,OPBR#@-AU?
MJ>6O[P@`6L-:?LWPC8=L6TU4?2<4IDG(ZE"T7@G8T?0D=;C/L&.2%72^63''
MU+)LLD3,==MTP;28(=Z?5I"*T>%H@5AWG2]?KFZ_UNZ#F[>CF>#-BYKAG8S&
M/CBWPJM1L[32+*T57H,Y$K0@@?/[<HC7`N>Y31UJ8AL)PN61/(GG>A;Q7$XS
M'JANB`-O%KR<3FI]>EVW>/EYJS7*G!53C=8V@ZKFJ^;K^_A:=;86),)N9F@J
MU\A4.9TJ@G@[Y)KR3?SUZ+0`XFFV:K:6*I#F.U0-%OMZ60M1TTM0JYQ2K;I4
MHV#ZWSP`91U$-(^K/HK0E*\8Y;<V*UT$MA<DU.<[9NZY`MM53NA>->DFF+3E
M^GUY_^TK]SWK-M;T>.V=N!1H:+,R6%E3B$='51_[:%/1IO*F1+GJAI+,'`[5
M?L+9U]0U4;-VM.VP[S*+,+4G,`1(=>94;E$\0ZI.S<93UQ>G`SHAUMFK>POC
M]EG\R8H^'28_LMG'J,<?#[]O>W6T,3PZ2Z%CFJ[O"'Z'I_(6<#'\PGQB75/<
MIS85E/#9S5;?I=W8X5W:Z%9NTVX?H`A,%**IIF="/..]VR\H5\B-P*AL>[15
MSP;`RJAK*0?UTUP#/^W_Q.6E/[WP2K/&#F5K\ENL5B^A5ARJ-9Z*"[=^EW7G
M]R84WLECZW=;;_U^QU+JMEXLOC,[_19"H+=^5WYCG[;SW;%SO?5[Z_O#*D\4
MO?5;1XBR25CYC:%5EU\SO"0":H9KAA<O9!=LK4!6P(XFE\G8L]TI(9#%C>5\
M))8'LE;Y>4\1Q-,;;)=[JI/*+UTN@GB:I:^L,JF?5)VF!0FEZUM8N2R46I01
M4[BL$*&T"(LNBR#>#NT&RG=Y<&NK*WTT735=WT77=KWJ="U(;-W,,-4F0VRC
M`<E8!56A=*H(XNV0A\HY_6]M]5P5S5?-U_?Q]5BO]2Y&2-W,<-4--X:[`\+E
M>_2V'%^+D%(50;P=\E=Z!*#IJND:S:^TJT[7@D37S0Q8&>%$+I966SXL\D1L
MUU/OO-1CV.V+MT-.*^_SMK=Z3HKFJ^;KN_BJ'[@6(\9N9@0[D.^L&%%.D,`3
M/7+=MG@[Y*7R'0H8K:T>/Z+YJOGZ+K[JD\.V'U'S';4&AX3.GTQ0Y41JJ\<C
M%FM@4)3C$?,=.C3UFF)-^6I1?KLO?BD"Y0L2W/,=+F_U6-`BI'#;/>LPUSU]
MNW;6X>;`RC"4HV;EG]%I4]&F\J:GV4;E5U\L.1AT7:<)JJ:CPP1?=B;JKUW4
M$T>_\ZS0^2-'S]WQF`KY%%V>57H.N$`OB6.NZ:319LE.&GW/^99]^>E6GC9Z
M=(`2.*KE"2DDE0[[F80KD"CR`\TP5AIWO#PB=(:,$+4V1"KCSL:./`KTAK`A
M89L2:OW'@I;M&-BN@]3IALAH[B/I&_;5::Q@*QYVID@=;T$L1!WAJH)`/VBF
MO&<J1NC.M\=8,#K91QAYC#YA0>PI&A';0GWJ>B,,L<XDOE!O#S;#Q@>NZ7.Y
M)-=135O@S-PGPJ;[R95#^\$[F\!V"3,IMNF_U`93R17JC+"M(H"<Q\6>:C^P
M;>+`[_(-Q8*8(\>UW2'8.%3#`@E&L`@;=01S;;EHR:,,"Y=-H<T!`;?H^ESV
MAV`NX7H>44#(8^X3M:"9@<M4A\<!%M"36/X`#MFX0NS>%R,*'B:"[=QEWL'^
M'&:J']3QU0N5!X!WLG',U3=P\4_T2=8PH0F7!1BH<W6A=ZX-8+O/#F#)_3ZG
M%L4@"O0KOO^?92,!-X\;C?I9:&;1#\;97P[*P=>RV=>#W_\?(!0*S0>T.^81
M^2PJM<BC$Y#G36M?&H8T)U<R;HQ1'W,*C<,_H&C?"\W&\<?]@(4<S(SPE-ZE
MW4`]+F1F`'WH$T0Y]Y5%)VZZ/SM^6?TJDPKY.=6S_?C-:3/JJH:!?Y!_!6)!
M=2K?!L[IT"'0F6=JVY*:"'L@R(2.`\^PSG3QN)E*&'^(>@VR]ZFTB<C?)%_^
M%B-4!`F,#V^30-MH+OWMS0)>Y!&-#V<!&V*JITI<""Y#'%@O6)4\RMP?2V(D
M#1F,4;KCI/G+PQ'X0.;=,H(Q](SI4V"[$`EAM"K==F1[,P>Q#\9JVKX<G$`T
M!'L>!KM8H,#M"TR=R&P9^=VGG$(W%%>?L!T[EQ3-DQXB)63B3NJJJ)FH%>D[
ML&.2N-78XZ0<3;+]>:<#8CDD`$"%P21@@?4A$UJ581"#%[2"?+T_72K%?GPM
M&:CX_40<PE45#*@,*1=AR.0"M*02%_AR"6X5/=1:4,7&0@GMSLGU!D\*7Q8X
M1,]G$J]8_?,>_F#6/.6!]EC0X`@_$>0[T`EHU132!6`^DGT>@:3[R"'JX'P8
MTH)`CM*7/1M4`APBZ</AFPVIC$!_QG]!?UJGYU(K#^,ID<B!`8U2(2WJBB4M
M!"1U7`1XJT0'LOZ_^^!.FT:0?DJK^'-_S;T\WC]NO[^702Z6[EW?%W.][_A#
M,-TX?3Y`5]*R+5GL0A('>E*4EMH;@Z6._7&D:,7L^71[B(=$)G6>#?ER,#H:
MRK^IM%1(;ZD7I[]JP#0`L:'/D'.[+*+9@NB-;3%R_>%("H"!NDQ9L@G-`)?#
MY-8*<N1DTRK^]8.3TFP"5#P`UTF"=W@<16]!:-?/EH^ODQ6EVLZER[25S<7F
MP`^0&HY,42LY%GF#_?:)"<YB9OPZ4.;2WT[$H*3;DBH*SBG`IN)UX,@5;92'
M3'A3*O@+1QHH+3GFF1]2RJ*^#Y26+CW(B7`80`)JXF"B3:Z-=>60:8:K]/X0
M83E)_&0&03*THE@4"#$S-^X[TH*_=CIW!^B;^CPW@$JTDAA%@02`D*6L,^B3
MBMDJE*KW"BEH$IXZU8-('$9,Z4'`S6.>2`6E]86=GH&E7'V0LLIA;$!_-,#P
M'>*V#W<($_T!@.;(`?3,A'AJZ'J`>F^I%D6]V4AU4=<">1@9V*%^.0G[M*_\
MJ"IV7!&(K&XG-Q#!D!PK*<#O`CT2UZ,1^`&7J3F$63\]-U*F@@"<BNJPZQ&&
MX_%5A+%V#/DX!J[R+`G^BS$C83)%1?</WP+VARFB%^@FY#QP"+CGV_:T]O_M
M_6USXDBR``I_WXC]#WI\9NYV1V`/[[:[=R:"=K=G?8ZG[;#=VW?OEPX9%:`=
M(;%ZL<W^^B<SJR25A``!`B2HC9T9#%)5OE569E9FU@N(`LI7<DBP"6$KX98F
MC]K0CN71($+$032&)A9TZZ^Z"R-(^PILRAC=QSEK2\VRY)XL*3+8%O4A/#5$
M"P%`*=22FC50YIG7`#9`$K4PY5&@J`V;H/^5<AFW[#+&(1/>4X!KO5/R)9@L
M?MR:?V:@X@U^8$.NT`?MG?E^4SOJ"TD!&42Q'56#D3<?.M-$HZ$W&_NN'UB!
MISV"N:G=,M]/+KUWYHL8_5Q^Z5'RJR177/L"V[`_38,.QF.+CA2V(OX;BGKE
M#W-F,<B40G6(L\-#G-`-;9+GU*I%EEG8D9.V$!-6&^U<8@WR^`[CH9.ABWLB
MA4P<FYUB*@+W6Y\=.Z!=J%"GO-&YF-WQQ(Z<%8V[&IELH'UY8_V`;-R[P<`$
MXT)[)UGE5U_NY#,--`PB7QRMZJ%M_I?'Z*0G:73P0AS7][10>PM`)GA7J'3:
M,C`MR;/.`G.IM]H@)P4]H9O[NS+JI^H)__\&-M.:/&C07B;Z\QCW[*#1"`^$
MEI2T/")S2T1DPL//D)-<-J\CGR13-J\3LAF>*H*`8:B'+T$*NH`W39LBR-X+
M'D1:>"H9NLG/S']%0T*V4,/8)\S`G;A,6,4I(Z.(M0CW<'\91=L.`&P\6=(\
MW1*GAX4N]V:SDQ&!D^+CIMUW\;R5O%Z#X4D9G7V(T&\^EBW`?Q"X8>NG^!AW
MHD^YQ1(JGNN[T)M@+XRK0PZ)'H6L'?!=^WK@,>%QFD/Q8P@IC(%C#QT'_5G=
M0Y\#</("8+<X`'09H#@@_,+I,F`FOR6&A1]?AU!Z$6#,F`>7-PN(]#Z,:?H6
M*;L/A?HR:-?JFA6,)YJ'X1<*-`I2:^P_*&I`[\:%2'>C\`@^!@X>>#G^""1>
M%D6\K5EF$"8)A-H95@XJY$:3O^E]Y*9O,,$78!O3IDQW^?&WQ3R/'[9$WR=/
M/0WAULD,!_)A%,>*)N>^*A#/`F<3<P^0PF.``J,2IAV%51V!4!18?<:%RCT%
MX;JY[X$KYO@9W-%8G8P8QFF!D2[A-S8#D!<>CKJZ^_30^TC+G1OA>H!G1K[9
MU]!I#H/]X*X&MO"B0S<;WQ%S<X.97&2@5C+N:R;%C6,\1Y3BF+,^ZYWCV;7%
MEX,$&H_F1D<:W)L-;-2@9'S,K';<-C$>+,R:-GK$4<B/61CA8<99TH1(N/IF
M0M]+!W5>-M0X>H)"\P#C87*7C`G[5#Z'05)']`_AC>,;6AC?P"R5-\QI\2B%
MQ1RC$/&SY9BRMI$^0HQ0D.)M,XBD`AXSX8Q([!(*BTX@WOI19P'->940AX>X
M&#Z*X[OF1?UW@C#\HGUY>1F"=(.)0QB+>4!A"G!^@U&<GA34@":+F"CADJ3^
MN_@\4@=6.)Z'2SM\72!(+?P`,AT82!87C[(ZN"(Y(M%%U+-QJN0*%%_"6]'6
MH#)CMF:W?04E2<DKS8NMVFYTD"S67!1I7FS0?;D+#30OF.`!@B$VJLS75C?5
MO@A3C2_US$%?^;E??$3R.DJ-]DKRS/._3K/RO[B;5Y.GI9?H\T@WW;$>+;P,
M&D8C+#"K`(&Q[IJ`.6Q60'"/=*C+P)!EL!&2915ZF]$FA.=%_:G\E.1WQ2<R
MC*_[+)S4HMQ:7+.,WD/K?-9[B$Q"7*NE<R2^%.!(?-FZ(_%E0T?B2QD<B69[
M'4?BRSX=B2\'YD@D%N:9LL%7M\&_Y+'!OQRM#:Y=<ZT[=ER6FYA@5```A%G8
MW"4EC8E=`%AN8X*5A4(AHLP.1?*XHAV3/2F2_X7JDY/VQ'0LL1N%Y]]Q.J<R
M7;8"[P.H<',2BX^D>Y^9#7NDC]:`UW?-9USZS\!,9&`_/*;TPSJ4F:,!+@PB
MZ4Z#1U',D=MH9="*MW03-^,A,-KS9?FJD3<1&;!X$DK%(7A&.L##!%2#'S.G
ME0V"@>N,M=!_0&T6V2DC<R(J7K!R)NQN'Z;$\`*<6'E$&;>R/\)T,"=$<I8,
MZ4?9;4B!Y@>NG3JLR4`L6BOBB=]=!S3'.]F$01;D,&#>U\(=";9!\,=`.SW#
M:K.'4M)N8I8:GO<P\X7Z)0+Q,#'"#I.R4JYD^(90OV)[0YMFNN3)C!_3/`Q3
MLB2JQ`S)VB.X7L&\*,FLX@2+Y#A48O"LX3#^-*5A36,6VXY]2IZT'^[#-AI_
M=)+EH6CQ\W:0_P&8%?"#;@'"-7H/:Z/[IL^%3TJT"?>'+!.S&EJB:EJM1T3G
M)7IA%C(7E(GC<Z[Q0]I9^SAUE)FUXV4QT@MK9!+!#!(K$1GAZ1W7=UB+P-,N
M88IBSX9K\C5"D5U9PL/2`TSFF)M65!&$*K;"XPK<9KB\%Y?)I/(4XW#9@B`H
MNDIR.G&4*4^><SJE.+0(PCU&.F`.S6W:6[GF":.JLZ<ZM2A6@GEO@8=Y;[AM
MO];XIAP7(9$=!I9'Z(B$);8)#SI9[Y+,(YT/A&P$C7D2!Q_<=*.HEA%O<E1(
MR=P7;O7/E./&KU.2##G_J9UV-C,59L*6'FK;W!F\-XG*'E-:"<+XDBPSN62K
MEI#Y2-ZC`%DH-Z**-'O_I`4;R;9!F_#,40=-D$I<B8&RIF=:SQ=F,B#'X9JG
MF26[7EJM.9X.\:,%+R(D<1&-UHN<>PL,0^PN<@KVNX0I5=2BT6%9(D<J_BT\
M_DA4&LY2UQ^%:$?1%7G`=1=]9BA'6LARWKF$\8S<H&6]DNSD$(TL]2JIUC&&
M"V++*R3;BN27JBM22*HM>V.CW,^QB<KN^EHB+!TJA@%0*78=%@M)L7N4F3<1
MA\1-*HZ>GWK!./(+A)O-C7<ZJ>FTSVO=>KU&D6T1KHL#O2BS*.(`O!?&C!,#
M8PCL1;=87%&1#AADQ9\)Q#"`7@NA\K".CX,6-]J@+\/0>!00USUYE>0R;93L
M%U,L#_+'H^JZY3F1-:C'*<3S[$&Y]";<&!*20IG[7T1I2TW['%:UB(H"C!KC
MZR+M_P9TGTV\QF3_6J%G3]'Q4O+(!Q?598N*=>+%@(_\)W!\4\2O?VK5&CS?
M$2S?Z-0&GZ+*O+'N_LE\7@PG%?@E"NC%=ZD.%CD->-IFR'B8HUO"8Q[=$T=7
MW@>A+N)V(G->G4<7/467Y_<<@J4#BI8Y4FD5)TPTT4^-6IM7F<?Y7\ESG.7Z
M6%)<=JCZX@/$3M1R8PZ,T6%2/@YP[8RO\!XN,!%V-.#'D6!51`>/TKGA*[->
MQ+&EETIIPS6WK"4!:59K&AY!"G#GH).'8.$&8S`+FU0D=Q\G+"IU,=[MZ@8O
MG)^F#D+Y[[IMXPB>2`S(LW5RDV=%G.<@2\>$2QB"&QWCWMXLWCF11<^]@=9]
M@Q!HMCDS5T<_Z09(S$]U%(DL0CQI8_J?:&;(SB<A;IECT\<#<!9*KA>-9P1N
M"+QGO@EP)Z`3'2-]HLV),0V/_4*`/,_IFU'BP&*IJZ%UPB:1D<#>,(`)GC%X
MVD0<ZJ1"*T-_2Q1)IZ=Q$T<]$3YJ=Z^^97M=K&7;:IW7.H5:MM='9-FJ.-*3
MD,ECMG9;G<X2:[=1J_-UMAMK=V_V;8(2!=JWS8ZR;DMCW5XKZU99M\JZ/>;3
M[\S.%ZJ=P<Y/Q+-;4E,ZGBCL29YIZ38E.7G4A01TG_TGLA`TVUBN6@"3_53L
M`E2HSX9F/SKRK<WX&CBWW/>RT+*&=OZN/]3P=Z:]96)C\:A8IH\:1QLPU05O
MVPD;]77DDTQD89I%(NEX?BB37()Y]K)H8!;E(\PXECN3U&9&`\W5)?4/Y:ON
MI(TQ-_/";-=0-F:9E-W/5UD:.\'@%I:T[?%"B<=@@LF[D;6AC(U]K)K$;1<Z
M&.DQ@SS.H)1"%X6MO%`8"VMCUR?JSS_3'C-#EC.X?7-_EPP@\4G$C"/<ZQ$6
M\EMA%X`O><O,$.BP[D0D]F/:O&LRGSR1\$Z,:3IU'L>RPQLUYK0W\AAN?HD[
M.N9?T6&S5X`IO-D#H'WX]M2Y..WR&`I.:8XIN28JG@1W+GU9Q;WK&$'?3W=V
MPJ>^@>L%HSYBQ1&P]4JW=4/G^_&7`"L%8,N%9T3WIO_5`1_M71^<O]`#Y<]*
MDSTQUS7Q*I#T="%!87_6/>(PE1/9VB@`R?)FH+XVF64D!N$<-!Q*R^%%5>A[
MNF/=IQM*^GQ(K!3TPLU^,@(_UQJ;_1HXL7:`=1WTA(/%>FA,\/JF4NKLBFD"
MN7'WA.(?X;;I\9:RLL2+#5.(9BT.X?"._%AVPKM!H0."N:YBX<8UH+#`265(
M?;7C3L-Z,L<W<R7B%7L\JA`O/"9#%2X2DL3PCTB^J7`W5!Q<QX7AQPES\<81
M?O""5H1KD)40)0XN7_L3O,_)8V1\8.6`G41+>\<7PUC'0AYM[!CFP%Q<HXU*
MQ"4]^I['T(HT;P5W.`7@\0`O:0A<6?=3IV4=53*8W!YU;NA+0=QF_><X\(DB
M@R*"!=-2!X14\RN953H_@)II\8#UA>`.I%O8RH^,1$.'2"`B$$.5%2.$XHB'
M6IQULF`N1$[7Z.(\%`P\@L`SJAE<*>@5#1WA#'K+T>*"<P$S\ETF<U)J#3;!
MAAU8@J)\A:W`&VN:149.1J'M,TN4O([U/_$DS,>[E@MO^G"1]#;',+\P*^`C
M^L@V2_1=$)(<2:;-WGQ1%V61RQR?N_)H=RAQV*NJEC@K*K::Z:R3C<D<&]'"
MJSKPG@?*([9=`$H^WKZG%=KXI:GU+=.FDV/?-;'PNI10+VC;P[DP,5](?+:!
M1&L!"K-]ZSD\>&D'O_A"[';7GWO2@<'L:\M12S,*%UNQW147X"E`F2M/'L/:
M]#FPIO8=7".BI"=9L!,L,5WF:P_7F>J6/\U:R?RF,XQ34+([=9G!FV_D\YYH
M$=-F1L:)Z+[!\8Y-$WHM]'@,7LR1VI;Z=.'?0J,JN@TPW@I###"6+([BT,T*
M"R"V)\\_%VX'->L9$_`.^**K3LP40)+N28PYXH_`/<2$&B]^#PP[[&G*MW3J
M+!(J#S"%Z<)%05">#F.%O19T@_'3P71(RPWB:.?,/A`=K$VQ1CK3HHHZ`GDQ
M__7^R&0O4?L).M>7+N@SR7]^1L?X3)M?D2L;9%0WPF_[C?IZ3,`4EF_)F-G$
ME+&SM1!/LI,5]FG`SKL8S;!]/4Y8>]5=3.HQ8_4RT5WZ$U,W7!)@2A*Q@:F@
M+;BL8=$\%=*#,16&^N-*G"AV(P^',OX,2\#@FP&\_V(Z8;R?=M/7FDBA2T(9
M=4#CTFOZD;B%J71Q#X/0MLNJLHK4)@\W+/85DRLQ&7Q"<WULFX-I%`V;F<UT
M#4)\&G7*<$TO\HSG.GSR);`9T24WX4&D=H/%KB^!&'I'_-R>7[07U:A)/2VB
MD!NXR52ZE84[OA0G%:Z(?O+R'M,&Q1&XV"`/IO\%\'QVPY*Q93*+A:9#"P,1
M?>K>A4IS$(!+BQ$X&RESIGTQ"4X.$3IBB>K&5#-$';=V@`;PQ99-:!((</@E
M/M3FE:>6D`DP='B?(/#6)X%/62N.%81EL7@RF;(H6%YH1,\+1WH\WJX-)[HA
MJD9FA4?';U&?BVC'$"TTZ,P*D#)YGT-7>P$H@:K4R'"`BKF&R6M6>+VCSRC3
M!X-_XL%IU`N>UY<:_PXH&(=!#-W^TPTP@P-/\P!_:KK&+:3PMSZVAA&_X6>1
M54@-7?`]SX3M07=1#ZA=83LW\VYVB=VB6TSXRHD[8X')@;)4QACM`9ZK/>(A
M)G9$$X?FZE"M3(=J'N=.W&*A@!,U;?%A&7D.8:J%=-L>3!<V\Y+3?\)F=^%O
M\4U^I!'HN(?VM<"E-^*0?JI;A=1^,UE)GX`+WTEZH4@GGL2#IN8]*`\+YL33
M+<L$S6*;NFCYI_N^Q6K:=QUV#7OHHZ^O]\.T0I'^:./5X59\?^((P/:T=QD=
MZF([Z'VBSP70=>+@/AMW3PLC!_-XJ;:L[60>R:<45(P02G4RTN*/>(M**Q):
M.O*EJ$[(K#/M$;W<B'?1X0^X-!9OU"@N702!`:,(A(&?`82-52G:@:W<TH<\
M<Z4B#)V87J)!(D]@DFZU'P<^1GI>7>S[+2=1A1$5J9]T=+&CUEMP(27IAX1=
M'YGP>-*'5AV!RI>\:#4JN3.$F8DFIZ%//6Z(\R1=2JUV!MQ!XB>%IDT](&;:
ME<[IZK-`(<+0Y-F%EK=:5MM-Z.MD17.B/H)Z))$VGKZSQ/%9NMOO8-E2B/<U
M>+PW`<=#ZXHKI*M!M:IQ6=G[AVKOQU>T*5-_KZ8^!@;3YKYT?UZFI4]1S"@F
M^R>;RC4^/`4Z;O'JV#R^%*5&8[1$'BU9UY-I"/"MNLA#DTP<TU?2+W%?A)4F
M0E]>>$K"=-<R>77AQ5DG.L1.(&DYGG2_$HZ%@;_PV",,.'.C*CS=)X)&@3;3
MSRK)R\**C,Z(6\A>5\3*PZHH'J0.;33YJM;P8`:G=G7;&PAS+?+(1#HY242X
MK;[:8*F*/ZC==E1[Q8.G8B"7&[I1"5IZ3(SXP5!R31@_'HR[^DNI>[=8>O9M
M`JX7%HLE$P&EOF))/B#A`]OB;EMH-?"^AB(AQG`P%V9AS/M3V,/Q<]S#,>S_
MQ72#!Q'1#*%"@;G#;.MF2:7NKA,\3PI*+1)'3_(?EDCD&*]M?:8[!3`\'Q8!
M<D7!1<>9?T&/&[LG5-@4.NCBE)W;-6B=\$Z"$7BS3EO&:B=-Z<T?-TQAC8Y1
MX_%#K$RZ)NX%E0Q=<\ESP_`QO2^.7$2(0<X[HWQAK%S`\P!T@#`T@87A(E(1
MG[U[LP?+(1!,-$V,NT&$^B74&2*_41MBE4JLD]XAN2*]%N.$>EL<W.B8C#NT
MF(S*^S2T.#F0$GVWHJMQDIDY/R]*1$DTZ!#U.F[1W9H[]8SJ(*`MI@;0L0^3
MTR`IC>2580S#B_/4Z5PG(5\YA50Z3HJ:/.K@9[OI=O]X%4E-TMJZ!ON?.0[&
M1;.G/9L[187ORW=N.F2T](DG;B>1TOUMZO$>WIUB2(*Y1,/PNS;HY-K&H`Y>
M6^`7G&9U-B=7;X$,^*,XDD,GRO&MT]%2Y`?@TH7*48[K0@LBQ!SQG>V'0.D_
ME)5"IZ1A4.DG0"*".]QT(\"C*$"LV&DC%[U%(U[$'10($_$HPWH#CY=JT'4S
MC$*[$<*$UEFA,O@DZ:UP9PD\+GIF>NH5=J&<U^]M=V>2PO0U&H2]Z6A4U^*]
M:/TM)<>VD1KDIU;M0C2HVY72FVNA1[>2R=D8X7R2C3LQAT/L#]'_4[)O,Q8;
MR3._!:M5_SFYRH5()#J[>*P/-C:Y',DH&@Y,*R2*TX8='B;">DI=%(4E2XXX
MWP]?#VU\7#V)<L8<CM^2:WEXHPGL)['%BAIE0"]V+1-WZL4\<GBFQ6`@9"7N
M+BV:"^F^S\83'L/[A2L5/$##U)=(M=2$&V4/?<JEX8<1_`8]46_`G73PG6E=
MAIO`?_!44;H,9I'#&LW&E^A8_[?C2J]&.30)=YDZDCU;YE!D]0@'6SIHRR(8
MF0F)-,?8:1;]SD9ZL>FG6N/R[#+;]LRR,^?O&/+:+6.8]*`657B_$@D@B+9C
M\.+/\(!7MZ)KTD)F3D1>-QY_@W2A:1I>)Q/?I!:><R6NRIMSRH4C#"@N%69"
MRI?8)F]1"Z]RD^^>368!\SYLR>>$'2"`(ZL"3R?QYL?PVJWH_B3=>,&"-KK,
MC2Z%=.;'4I[92+<&=/Z9O,XJ]13/*Q,!)ITK`G$?1%;/H5GC_TS['$>G*"[%
M;RU.I!JWDX=3$0\*=NC:6>T>`-0P4LD-%W[>*7(U\+`RXHDA7_OK+XA3>B.P
M=?A-\:)%E=IW=ZLBHBV7MC%*-.79E2+M7V2X8L'W@-G<+<4<?W#:W+'89I)I
MF1D7P?&E,YL(B]WU*&=9NCI/&FJ!G9LT%_C]-AYV#>-=_X3LX5T*8:PZ<DX2
M06D49KKC,?E]?`$KS#%T]3%OWA4NSXGN\<I7D8X;C4%?9MR@70O=21HK2K:@
M+1.=)S,K8@[$![_,3:0A\U>%\T'A-]0#5*[KAL^$\\?W!DKHX-5NTZC7J%IM
MZK!9'3;GQ^`ZX":N.FG>1YK._^IV@*GWV<90ZNAY(%B5>>Z\(%TTS@W#$=(I
M7&0PQZLO#A/Q&$FA=MAY-\,*$SEKH7,LLE.C^Y63$7_8T3^S/K]Y2A"MQ?U:
M@5TXS""@*AJRGP&Y@/NUKA,,1W/-U:>%OT=IKC@/RT_'0BG8:<U>(UF3LHM=
M%MX)'_K.83*6D#"E5G>"P:(-3VG8'7;`F7_O9`W7AFA\&#7FO`^LL>Z[YEM*
M^<J6>CJ[8B&OI5R+#!5=0SV!6H9<!#Q>&'JUI-ZNQ0D6<>Y-6!+.(R`<&Q@3
M.X*_ZOA`9G=V.20'3V.59%R&B!G03/<<WBX+I@(_EI>B\;+%F;XX9/WCX8H7
MUF4:J<Y`806]K,`7-8E;E`_-CT7T,/:`S1EPN+A60<HL"CM*QI1+:7/1F1(&
M[`5#/"D26TGW(V\Z'F:ASUZ.3B.&SA[%UZ6^Q^(P/49\$;*U^8'01$/M.=FV
M_(+#!>3"/5!_<5RY'_?'L*\Z-KUW-#?`;`'J(B!J&>,:B;BG;'P?:U20&->4
MB'.-^6)0"W=G7KN(-#>`EM0VGN[;&&3+*KAW+^8+Y<;Q4YM=4%4Z3YEQ7N/,
MIZSJ8W[C>!P7%V<]1G1LI\)`VX$WDDXS%!';D10=KSVB9@@DJW&/`D9%K%+^
M'"E.-SJ\$U7L41</N5T#EC#S6RB-@,NA,%;Q-#V"*#;"=B&[X1:B<U-45DSQ
MR2[B6JP].FO/ITD29GXNV+SD8A>PV$TW$;Q/,2:B+QY:![:)47R7]J]DI?4B
M4JO%N!5X[R7[!EG`<S&BUC4N&P0>YJS0%0_@K4B7)45>;'3VPC>F2)]&^U%4
M^2=?-,%[5$3Y3_'5)*FTB:+]L<992OI%PHTLIFA@<`)@G<T@G4@9IOM)J7=R
M?)3T#J51#7#QO.N\CRE`Q5L\_T"Z9('?XL)+>GPGG#0FE3@--K&IA`^3>UQ)
MTHE5+F)C-^PW@)0?<_`[GW#M)2P#*><$L?G3I,!TLLM2+4PPEI(LTANH`"R^
MZ<.A3"=CYH[U6MQZIZ_'IV@BZN_YF&Y,@0:\XSV1/)5YJX_'JPE#N.@JY3`<
M[41*54I^RA;VE+Z*$][BW$[!\TEJ\8BP#4^S1^JFJVY-`:2>&,;T$EEUX<XA
M/Q)6!7KR.@D3?$3A+&=YL6NEOGRQ1$SF.WA<THAE:B*G27M7+%3)\__WH03&
MM!FZCN=EI$!%&6$`V[M&_3V(EL7P^(,6IMICMN73)]N&+CQ;2!VH9=T'E>5+
M1UET<>G.HLR5N)<2UR)AE3)/Y8I2.^4<F>CZ^5I6CEI->W%\2@8$(NA#%O4,
MPFP`/=HB&+]'S8SN49O0/6JS%PXJ6=S:&?1"\>/*F$MKI,O1,(IWZ[#1FY2'
MZ[A9[N>RZ[4\AW>&"F47_5/>A%BN3RAU_#?)_NH$>WEV$4:W,$BDXKO[J-6T
M>.\L/6P90H<RCV!/Z?"ZE^PVPOUQ'6PX^[2/602\0803\5$$^S#B.($]X,T<
M\PJY0G,/+R]3114>WG/'\*8CT@S\XAVJJ*=D#%C1>I^=:7>V=LV>73HX;&0V
M;(Q*[."#Y;B&=`0(MGI<?X=WL5&V>IADSK^SG5?NAO.ZS?\-;*:UQ-U`T=AA
MVPSL<P'ZC"N[)+4*SN$Z3T4:>#)-;*;%D$2AA[!S,L<+]T.$\IGQFMN^,[3-
M__+FGSK=G86;[ZD%'@^_:/!,>Z`6LSP)+\H8C.[2Q$&YCR.(NSWTFQDGI\5W
MW<V8)(P(\U+=C`P^+A+\]#IY%V*">%3L.L"Z$9X&[#'+(@LG:DN$N5@&>O#<
M&'IA<FIF5+KA6*:A\[L*X3\\-H<Q_S##$YAVS<]^PV``BH1N)8]_.>^D6%-H
M!::$'88I.EYVGESULQMR^`=^]GE4D>YQ^/6D?A+"\&H:_NA#HU[_^:-&SYQ:
M^M0)_`_4T^;C"5@!EH7Z`DA,[^'?$S2<^=_1^&[TR8CV*?FC&W_$:?"OO_\2
M>*=#79]\D/)_>K:1R/[Y;'IXZ`)\>&)O_B<T=G_[ZU_^^A=-^WOX]B.:+9AY
MQUR/WPB,&489+_*&A6_^`QO\>G)?;_^H-WZ@O#TY]=:/%GWNG&BF`:Q!*\?X
MT3[Y+;5GK;W/:"<[L#R>T73+N>?Q-*SS,TTFGYQDQTE9/KN)H("E[=C#?(?]
MR6>K@<P#=N<'S4+,T1XG8(CL%*OB;2RM:D8AVD>/;.+S)*$F[X'4X@921F%?
M=+0B+:=4I0??UWG+I,8I;(BGS;,.;"N<U<+[0E;GK5N6_;:"+PBHG\$.WDAN
MX1/=Y7'-VDP?0F[\S)*+JI"S<B<RL*[A61K8HDB4.3<HBF3ZOH6GP.23BFR"
M9U$5!,83'LK1Z^FWN9V716Z7&4%?I&+%UY;/@4%F`!U0%VK,TT%89G);H=,T
M,Z?A%.*7EL1TT`-_Y+ADX"8(,7-+`$_!IC,&"GSR]WAG$[Q1,;LM7I:0/S"R
MR@SMBKD^,+HOK*H;N^^X$R<,U&-U])A,R1K)(L;2*>#OAM%MS6"\/?_<`IP,
M>:A(E*MZ&K4'XA&*D+A*W*;+D\2"Y3Y01IU?EHQ@@B=]R^\RIDO%L(]C;,Z3
M)#YC9HO+8+?4A4-!/:D]/ZRJ(E]BF4:6^]+QX&^&KJN.>7%0ME(OUD]7^L0$
MY:5,I1T#+`?0,'P3<R12_3P-O-!-K,&WL-SW+XO#_<B,*?QD,M-HBK5;P7?2
M:)G=96+<)Z#;>%N&,J"OM.-^D/E,'48F82+4%5\0Y%<J-;EC@+]@MFVF;S)[
M626Z,2^.+RY[DAS*Q&LX%&6,6ES7`MZ80FIXO/$!EICP.W4P59:Z'+[HIFAC
M'79',-"?DOHRSSJW:NWN!QFJ2KJW=%NMU!T#?",',W@6G>^0L4\Q(/E\8OY-
MQ'.B1(D(4102PD&(WU_&$\N98I>^L-=E6!.+[<HPL8M'9M$9%ND:*"(SY22Q
M\"1J1WCD9D$7ULR"-@$;341I(?Q<+QGTX<<=S99\87/T6O)D$7/8*&M32CH1
MX97PRBD\5,7L.A[G2?TH]3M%X@2V](70C*]`?$]JRD!?G_)V^OQ'0@P-,[?8
MOK?:Y>5%K=5)G\JNU/Q%MJ$'=)42)O7UF90#'I$VV0E$2L;DEK<-8,^QB.$9
M3`/R!E.)OU)YCXJ$;$^_)+//8O+'7803?<DP)H&G[_)RCO/*PG6MTSV]X0UE
MXFK0Z(I*$4W)"G'FD\G(>%@FDF&V/L]A-70J:*%BHRBWD2JKGMG0M.WH5MGD
MC]3TGQ_.YT0DZA^1R,L%DC"ZB_N#]DY_KS5;36S,N2+R'[5WS^^U3M37:6TB
M)LJ0O2A%&`^.15U5_[W4GC&ZEG/A)?#9G083B7Y].F3U655:6VQY46_'8L-W
ME-6VQQ,[48C;#-.9YD3]>>FN7#.563V8O8`2%9++EF%@Z[8)2]FSIDEC+RZQ
M!$/N3.OQ@PP^=GC\4:A!F)3-A%$H%2S2R0W!J2^HJI1,6*ZA$X.'W<A`\49Y
M/]%N$;6$*-3DZM8N.JU:JW$YS^B:QU_I`!7`*OY`KU%K@EU\D6T-)DNYA<D*
MGYY95-,4;ZX)$I_-FA!)%NS'C%A*Y>4VQ&2A^3`P/;RM*V4\X"I/FP[=HDT'
M$TR'6J?32!D/2U$6Q>!4=A65GG3B`I'UZ+C<C*#R['F&1$[UI2(_^T'FQH:%
M#6)X'X`SUM?NL%8-.*TLBGU9%,W,SDJ@7&!M\=21\-)Q@Y>(\E9_U,VQV";Z
MH(2Z65TH`QLG3&_Z`$`J_H,F$*E2?(&7/O(>&``GZKBY^3.A5N&///*;('KA
M-=LS,T</?.</),'0Z=IH),]V"FK/SYJI'7="5W$#RN_X9>4RK-_@^R1\5$X:
MW2J#Y`D[I7M1!Q/8O*(VQ8A)F&:<L3>'`B-5*N/7TK4U6'+0[IS27L=/:V;Z
MP\#6?=J#G9DR9;4[>BIQ"0_6.(9URMS&0H86*GRMRW/<_Y*DE?I5S0DTZ?Z6
M^-P]ZW;K%[.<)CA"<X9/+5(]\K*U%O;,)I'?*1'32X=ZQ>I;HB">VEXV9RF8
M!F(C8JJ8P]8WJ&[6!H71?!:U<0X[(>QB._I&VU&8%9M0=&&Y.^;!BER]T!;.
MU'%HKPJ]AD(VNSK25X<E%.'V5^X<G8?^C>U@Y:P5ILV*3D5\(?'[9WB26[$E
M3MU:'>R5K#[5<953^C8.F7SOB@7GLM9$D#+`257$TZ9;[`4\M<9E1F\9O"DC
M]#RI6??[,ZV'.S#G28TW:@M)M:,5,V_KI"O-TR(O2_A6@6W5ZNW\,D\)VG3L
M%.5N5N?.O>II?PQPI&4#$_"$A@VO*]^6Z9!M9(<.`>J_=V]+'8IIPI_XM,R?
M^)3E3R26PX+YR.F(NJULARB79_5N%EEX%EPFRWB*CLPTL6&'U821LDK<AAIM
MZPR;`Z`SB@VN/*SG%=MI^GT^?8H`X1X]$X>*[Z4@CVE&T/`0_YE)VWGR`GN>
M9LW[%XC>72_BPBS.CBA9J2:G6M/ION,.==O\KV@RB?<AF&/3PJL?7GB7<)ZX
M(/H#+;U))>F095QWA*UJPMP"?Y9$@IR<`K&6D!B80AT4(29RH8G#^\GS&A/>
M62=9%$3:TING4/FEBU%7(V#T"Y9$H(Q0M8O\\/N0SJ)IL;3RGQG&XE%GT1$H
M)7K@!1FVOQ#5F-DBIOB<?%<T.TJ\N9P9V4M`2%,?;*29LT[>M3/1IBF.T^XD
MAW76&W+HOGOI0J%&/=E12RZFM'D;+<'Z,,<F0;<$VS&)&J]F+/@LHI-J4A3.
MO>5=(0[S1$$8?K0P#?NP`AS-.N^,*7H5))N3B=YF2/"Q0^W%J#\AWMB<?##J
M^T8D%5="T$5WNI_4OI]BT0L;W<S3P%&ETZNLKX690WF4.,",7AZ8`\RXGJ.6
M9\;CAQT2#,F\'NJ]$#8@DOI-"@IF+5H^KG124,,0)0$;7@"2;&(4MFCCA5%2
M.Z&HJB;5Z(&?`=+:C?1(-B14:T-W14:7UF&NUGR;5WIJEF/O$ITL9P<@?].:
MAC2:&>!]DK;2V4B$6H2"9(!_2NW88=\DH%/`:XXPL2[P,KB+:G>`'(QJ!Z.2
M)>E]GF6"E\N\Q5'"S#+0U_ATJ?^>5[XA"KZ(+N(=*LRGM&!2G;HW$BK<>)^0
M\YE=9,YU5)B@[`780,2D3J)Q>AI/P!.K@?-#&?P[*;0ABH<],IFX<D<7K5YF
MXRZO6<YCL8F/S=IY9ZZGF"_';.\V^HSG\9`@;0+T4!W(S@A7+3E>FK'ZJ2VZ
MW1>7=B<.GGAW%,JZS?KY<H5)5]*<D<S$Q90&ILP8R=P8,->N(WUV$U[/],"&
M@:7[#GSLA<7`(MWEG43?ZYNO#[V$.T<]7%Q^4;G+0"&Q6M*\;ES4Z:@DNBI5
M2J-X"("4G4:C_F[X_EV#CMEIAE*>95=8`=7X7<W9%WR%=YU=\PNX[G7R%TB(
M$C<BA`R,FB!Z<9*6K+RDG'*/24]G-ZR*KTK#79MF#6]!D,0H[FPGNW^XE>*/
M>"6Q=(4U6:O)#(R%GEE-HVL70<G:0\8M2C>QV$&J:ZD$I.B21&'3":L7A%UN
MT9MP['T*GU(U0@!F47QE@4B[FM?$X'5)0FF";^+8&`Q)8:0ZSV@[1CK"1;/#
MEF_$7KX;<85%;7FBJX[3-TDNE+"DQ\W>``(\:J(Q^.&G;LN':HT+3L2HTL'I
M<S>6[R^S[0YYJ*&46N,(,F"^Q;*2$,POH67@\%LWLT_%59[,;@&^7G*':\)C
MG7>':V?>1;DBDZ:VTE$B-NT[U2/!$$D5L[>;R?L']3Y-JHV"`S#M6O,RY[F/
MOX=,"?E,<JM-&.O-B_4/*.=V%9)E0PZ_D26@6[%;L4A&4C<)K^IEZ93I>4I"
M'IYEI$_KMB1>G5I[_CE=1;PO;A>\9I]E)1RD].5,V8<=X4AKN3TYO![T+([(
M7SD"R^,&#'EQ;D6RE3"%E66Q8X!7OOM]OANCC74##P6H1Q`52+CF<Q#=8Y?0
M^N(BSNW<OMFH=<\OY]^_*9K<8;-6NIY$VB[P5LY3JG;@2"QL:$M*COQ/ZGPK
M%^W(FR./8I]IT=W,E_*5RP^B6?$]W4_^)+6`)T]+W+*,U[(Y?9.>C';CY,))
M1:\!B)$YH6IEK-U.=?I2NF\_R/!^HU%44RF['0-<H)))Z):>1C?YQ$>0D5F$
MYWYXB)7RS^:TZ#8QW$0&,(:/,*G@0U5(NWU9Z-W>_/[UPRT;8)PT@0'"__WF
M\],_\/'ZSS&S>5_N='-IZ?&+SL\?M4]W#Y^_/)Q>W=W>]NX?8<X^N-OZQ&,?
MM;M_?GFXOKW[_D'#"CX8;&G+;DVWS*']ZXD%<$J`N"$4__AR\_L_D+#-R9OT
MNQ'^+J&J]2F6&\K?T[]N`38;M+YN)<FG^40_[$3A$OVT3[VK__O]X>[;U\\?
MM/\9T/]FQ/BC!L@]W5SU;L/Y@#&^,Q8/?A>`GM<!*6ID_NM)JRL1-^Q_/I_S
MHD5YE3!L*`2KCF#]X#%4"%8=026CE4<0,$1#`4P!V.V;,]A^%QFJ!X'KP3/S
MX!%4"F<N@N+V'&6G5PG#PU^Q!X^@4DF51U#90,?#S!ZOM#H(5`^>EP>/H-H\
ME#VKV*T0+!&"2B55'D%E`AT-+Q_8F-=8'`2R!\_-@T=0[1[*H%7LKA*"2S:8
MK]3O)\;9&1P$UL?.UK!`[B!P/79FWIH#Q<A*(+B$D3=8;&![9O\@D%66DK*4
M5D-0I#!_NGMZNOL#H*O3_[3&Y$VCRA61,5U:$BP[2)0K)A2[#YW=]U@7JWA]
M%+R^L6.*_`LK8Q3?CX+O_\26[<?-:V6M'16[RX6@4"]/=_>9ND7AKP+U%4=0
M2;B2<,5AA;^2\.HBJ"1<27CYW"Z+>E!L2(I^G['U2=%>XG3=R;<2)-LYK<']
MW2(\-@W#8@L0+GIUEXR?1:/G8A5.-G[WO<^?;[[^?OK`H>B$C5]VCW.&PFK5
M&NUZK2DZWI>9I4IB9]#[Z8@$]?RLI62T@C*Z+:U:&L&L$/^4>"KQ+#'_MBB>
M)?%'-G/-EODCOV/^QEJ5X+M%KIIJJ#C>5<?W*!#G#-44]WHO,SN5M"IIQ<_8
M\K_TW%3"6D8+;[N"62'^*?%4XEEB_AV^`[+=`Y&P;FMO+D@97,TRH%<F153J
MJ/)IZ5FI)%5)JI+4$J!7)DDMC516B']*/)5XEIA_A^][;/?PX]IQ!\Q4QQ]K
M5;:5C+^[)T!5@])[LPJ5M"MI5]*NI+W:TEX:R=Z_H:I$7(FX$O%C\<7V51C3
M.68_?.GJ;L'J-IS@&>??/\M7J8O;,X%*%-1?FVISBG,ZM:XJSCG.59.WO$<M
M%OQ\?M9JJ'5RC.M$[2YK+9C&F5HO1[E>U+Y2B:!C&19)2=S5[1X=JLA$6=!;
MM'YEM;,S]/<46%L??Q5X*S%Z2KR5>"OQ5N*MQ+N*Z"GQ5N)]V&[63JK#=!`2
M=2I8V3A4F2A0HHC3RN=ZJNG>X<K]X0=85SV94Y)^F)*N-+PZ6SLNB5>Z79V.
M9;EMO_CHV$1_#AS;#W%/8/6W)T+K*Z#U@&C]K?8WC[GFX&\SJ!!4-#0.%OTA
M`P.?PTFN;K_T'CX`#T=),J:F^YBFUQ^]A]]O@$SP&?X1HL5_TU+OUO@7->T1
M`19$FT^I`H`CJ;GY^OD+@E0_ZY@@!9L"7"!SM`1WGD9,&SB6Y;R:]E`C<=`F
M+O.8[7N::0]0QGW3L3676;K/#,UW``BG_Z?V*J[>U'0_Y1A_J`I5MR\&?#G?
MDNY(8H#P?[_Y_/0/?%S649P'8O((0^GQ\_K/43SKZN[VMG?_"'/V@8GZQ`.=
M<0?*Y/KV[OL'[<7T3!CL1.LS"^_;ZP./?SVI\[\GNF&$?^N6.;1_/4$=)P&2
M.Z93\1L)6QWY1L+.C&*-+IF-Y$7*%5]C*RD=`=2ME">MUJHR($4&CUL&JGM;
MI;I$:$W\SX^=``K_X\:_<R`$4!R>AW]W\2W5WQG&/M9JW%(Y4AR[*!P[_DK9
M':#M>_#B?OC6ZQ&S<,GNK.(S%4-P"3][+\S5AT<>9ZD*@DMXJ>)F!VP[7.3B
M_9$SOBH(+EG(7X/Q,W-CG)W!06!][&Q]8&/=M-%RBM"^-0=JR58"0;5D=[`%
M5_RH<]DF?>^:?;7<#X37R\+8X;&V8O<QL/O&CBGR+Z:[BN_'P7>US*OM<*NC
MJR-/5%$<5OBKP]E*(Z@D7$FXXK#"7TGX;FWVPZG.K%SI98;U?7[6[-1587T%
MI?3P+S#.4,.M6KU]7E,2NW?TE,3FE-C&6?EE=>?,//"E6%595=JU/!;N9L9^
MI2S<`E'-L'`OS^K=YMZ:`^;&3=V(6*D;$<LC\AEZ_/*BUMA?7\!RB?R!"_0A
MB&M[?R9RN9A99O5<POVIJO)^V:R='[=Z+HF-75X'N9BN[-L-'>]_*RZ#NUBQ
M+I7JQL2=4BTSR*+NXRT%>F52ZJ4."U:A#W$9^T[O9[4J#5\&#7_T-S.HML9;
M[F=;0`MCSW<=>QA2S\0/C]1+^&Z"/89Y>8(943?Y>+D;"H<M=/\=>+XYF)XL
MD=Q*P(^]H:^<\42WI]I(][0^?`ZH!S0VC=9-5WO1K8!ISD!S.`.U(9:9P!.!
M1^VDX;E/EM[_\_2Q/W(LF)X_ITU<$WL1:V/'8-:98+\V<-P!,_W`A0=UEVD,
M0!E3TVG=I[%0"^%L."WO2JW;AN8R(^C#TV\39GM,<W5<_5/->6$NO?6"X\!D
M$T#4,<ZTIY'I16.#XK$L[9EINH&HPUS\,;.O6S#(L^[!5S`1#L3>?`::Q'>T
MUY'9'VEZWP]T*\1)AMXP!P/FUC3'Y8@`:'W1/#O\:0"*E$:=N.S%=((8I!H,
MSVS-]#6`$[]P3=U"L&-NQ)219Y5:=`N8AE&';AUI92.X+F(-1"Q2,]83JO%G
MA"H2B<!&!@!81N"&0C%ENJLQVX!ODZW#.9HQO9@[!EGB>$8CFIX7<#1MQSYE
MXXGE3!G#[VGP/H#A"MY8YH"1D/BK#!L/B:\:I@NO.6XT04Q]+BM(31)-?P24
M3B^%M`"`K#EQ>Z(D7P/?M,S_,CX-5Q\7S6;]HV<"1.;`9$;T9>.C-F;^R.%"
MQ5Z8Y4R0RY%@(U`S2"/?XV$GEF[:L)IL6`.Z/')(@*0<G6F/IMUG-*R`.'RI
M<?[1$WWA45/8C@]X@A!/P`@S^["0@".&H+>N><%@``H`%A/\8CG1V@P)69.G
M0*ISNJ#T((8A1B\.R#O\X$^U@3F$)1`O5UW#5072*Z@`2QXXB(LZ?LM$[4=:
M0I^9G_TG,$'+B.6>H".)E!C6M&&/"L;XV#-#\$@A&C7\'7AF6KH+&$X<ST0R
MHL`0/4B3`M6!T:^F/S)QL6.W?0,TD#OE(N&:WI^G`Y?A),`Z8"M?N:]`7H,A
M,TT<,%(C)"'PQ=1DEN'Q[[^=/<)@+M.]P)UJ_V6N<]IW@@G0Y]FQ#3XYD4IT
M?.`R`NO'`W(A4O1`IA0MP/YLUDX+33DK;&__[+@&<ZGWO%`_9`!^P%;X'_DU
M!*>6/H6%\F%@OC'CX](>]M'X;O3)B$P'^:,;?PRMQ-2.O/8NJBW8]HN=HSI&
MQ-8,\!M8Y9.)-<UO:,1W5Z1T=%+?T,;@)^[%>!7=7C6=-R+3=-@KQGR0"MQV
ML2?CE#M]Q5Y^T2G=Y1>E+KQHJM*2JB/87'(SQ;4C-?0!M97L\"#=5X'F]B$0
MY!@;`*@%OL,\C]*18)D*(!\Z)@HXT\?->+7.CXK=55OG:]<)-Q9W^5GS4OK*
MD4$)RN:"TJZ0H)1RARA9ND'6_O!@>G]JLR'$8SXE+@-Z94B-.[2LB,S;S+OG
ME9&%59C]<V6P*HN$%[1Q[56<[5_TTO/]\#/XBRO4R-JPOR1.V=[A*;GW?E]<
M+T/=1AG0.Z"TW0)QSM!0G;/NWO)VR\O-`T>O%#YAB??.,FC1DNR=VW5VO\QF
M!1VSO50&]`YHYRP0YPS]=+FW=B'*4:WD=KE=<52N9AFVRQVYFO"W:3#;6.=N
MB(.QD,J`W@'MEMNUYNMG^VL8MU5N[FV_+*^,*O>R_,KSN"LO#[7P;R;E7:HY
M2Y3^8:9\NN8I3ZD75;+\5*24M,_.+Q.2@F4]FC?2748U-2YB!?^RG74`;L_6
MM91/\*S,(MN4/!Y.A>V=#3R:@DW..92LXPAY&_)Z06$?_#0)@->ZQZA2<CAT
MV7`+=9):J]6,^MU&4DH2ZN%<?6<\=FQ1I,*K-IFX,IM*60B@0M=,]ZQU/F?-
MU)`F7J#'-7!`XY9V;^DV+U$3<+^(Q!*YZA:33NCXBA?C_2?07=C'>4&MZ?'7
M8RH3IS0#/T9JI5`L&[7.9:M63Q,^K/T%,7"&MOE?+-!SG8GCHL`@-`+O5`5Q
M^=<*AZQ"NQ!!)E?"(DM<U,&T%@0JG?I'7N&)]9/,]G@->%3X'9<_)ZN\BI:F
M=J<Y*TNH4`J=)35^:H?RLO=4A()K0EB9Z.&;+\R:GFD]HD+R8=*6+BM^'V[4
MZMWZ+(4`@,"6EAHQZ70=AE*==52X/\;UB@.*6MX9RR4N[BU4ES=%FZ((0>*+
MT@[;`GA;_D1/\X+Q6'>GH34K"QLV>3!?L,0\ETUK>MC/P6-D>#PSRWFM0'GH
MKN1A&_6@%QU5#[I"QG2K>X@!FJ.J!SU\!#-";`>&H4*PZ@@J&:T\@DN*I+X+
M-^(@<#UX9AX\@DKA'%.YM[+3%8*E1U"II,HCJ&R@XV%FCX?##P+5@^?EP2.H
M-@]ESRIV*P1+A*!2295'4)E`1\/+A[!K^4$@>_#</'@$U>ZA#%K%[BHAN&2#
M^1J,GYG40-L9'`36Q\[6+R*A_B!P/79FWIH#Q<A*(+B$D3>V[YJV9_8/`EEE
M*2E+Z1`;4J^]O.4+/A6W#YW;]UBJJ'A]%+R^L9,7#JDU?AQ\_R<6ZAXWKY6Q
M=E3L+A>"^[P]I=+XJSA]11!4$JXD7'%8X:\DO+H(*@E7$EX^MZMD3::SG*Z[
MP/=\W<:F%+68+AD7O49_K'FIW\&T;2YQP^UM:K:R]KQ?ILU.E:R64E:7(/B3
M$E$EH@>L3LN'8-&6H))0):%*0M5-(D5Y*K_S-LO[XG-NY-3U(55Q/`K$.4,U
MR2VXR\Q0):]*7O%SU*&]S-Q4PKHS82V-8%:(?TH\E7B6F'^'[X)L][`D+.G:
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M6G^K_<UCKCGXVPPJ!!4-C8-%?\C`P.=PDJO;+[V'#\##49*,J>D^INGU1^_A
M]QL@$WR&?X1H\=^TU+LU_D5->T2`!='F4ZH`X$AJ;KY^_H(@U<\Z)DC!I@`7
MR!PMP9VG$=,&CF4YKZ8]U$@<M(G+/&;[GF;:`Y1QO&Y3<YFE^\S0?`>`</I_
M:@Z_AE/3_913_*$J1-V^%/#5?$NJ(XD!PO_]YO/3/_!Q645Q%HC)(PREQ\_K
M/T>QK*N[V]O>_2/,V0<>ZA,/5,8=Z)+KV[OO'[07TS-AL!.MSRR\>Z\/+/[U
MI,[_GNB&$?ZM6^;0_O4$59P$2.YX3L5O)VQUY-L).[,YX>*^V4A<I"3Q-3:2
MTN%?[>AVYDZI[M],2GA3EO#V<@F70I['+>'5O993W9:T)O[GQTX`A?]QX]\Y
M$`(<+(>7FSS=Q?=M?V<8N%FKS4SEI+GBO%;X*VVFC-NC4>W+$3P4\_2(6;AD
M=U;AI5(AN+&UU7MAKCX\\D!*51!<PDL5&#M@V^$B%^^/G/%507#)0OX:C)^9
M&^/L#`X"ZXJS=>.]]H&-==-&RRE"^]8<J"5;"035DMW!%ESQH\QEF_2]:_;5
M<C\07B]SE,6QM>)V!;B]\=9^8\<4^1?37<7W2O!=K?+C=K?5P=61YZ$H#BO\
MU=%LA3-KE7PK^58<5O@K"=^MQ7XX9:65JQG-L+U5/X`]WG!3B78`.[^UK$"J
M9"AR=87#<:)757E5W2N4?CXF_:R:<97$Q-[,VSC`1ILKV=7[WXHW.\(\A-Y#
M6PT8'&PSKMU1K7S6>;G6S!&A5R)QKHIU7BYF*OVN]'OIK?LR+!G5IXZ@\'S7
ML8<A@&8&`<T(^N2SU4#F@<&79A];RSU27[EOMNE[.T5L5PW[PO7!%^1)!BNW
M*8M;P/+.UO[0IUJ#-_YKUS1_Q+0K9SS1[:DV='4;N?KP^,W33,\+J+'=P'$U
MW=;TX=!E0]UGFC,H=$F#\KFLM3J=!#DU;Z2[,(CO:&P\L9PI@S]TV]`,TV5]
MWW$!K4G@`H@`!#R$:`!"+>W>TNTSC@$"WFHW:JC4Q7``>M\9CQU;=$1\`5'6
M7!UUU51S7I@+`[F,:5/,5M7@,5W[3Z"[/G/A]V?=,SD0(]U(DH0HIQGX\46W
M`J+13\U:HWV!LTOP="\0U1"<?..T6QP'G)D`-FV-`5@6?/!\W;+&U/H1P`/>
M(<S]D<E>&'Z+[_MRO\@/VKO&>XW9KL-?BQXP71AXHOLF?@D32%^:+P[,HO4M
MTS;[\`$6/_P;L7GX]M2Y..W6<5;X<^*:\&_@AB1BYQ^U=\W<,WJL[P"6FTUY
M\9%(]:[U'ID]L1AUPQ331D-Z?F!,-9=-'->'YVR?5R'10\";P/*]\)U"H+H\
MJXB*J%RKU2=)A8%R<%R#&7Q]"U0Z]8]\<:`X,-OC[5'9&WYF<IM46J:XY(K4
M;]WF.2[?I'I#`2UTEM3X1N"&PLQU&;.1*LFVKP0%WP9`XB>@5\T79DW/M!Y1
M(?DP;14NTUYUKUC(R6R>I1``$-C(SJ%M_C=DZ.D*?/1'N@\VK65ISTS3Q[#,
M:1S2\KKV*AHJ:3JO]=<F`*)C%+ZY-<\:2;R('6<S0DM8>LNQ)&V#Z+V:_@B!
MIGZ_=I^A#C-,WN#7'!!K7T?,3FSP\$C?"@PFB&/"_SU05LXS;?3T'3Z>.6I,
M2KZ]&`O$))IP!,)B.[XF\1&_GL>R!3CE$,IPG]Q8<A:!41&=6#DEOC4GL:=Y
MP7BLNU.4"V`OR"^H.=.?TE+*J2#Y.J$>V_#0,P-C2O7,/K*>V:7.>FRU5%ZG
M0K#D"!9]*6/Y,#QX!!L'UZ;TB)EY\`@JA7.`Y<G*!E((5A=!I9(JC^`2&T@U
M#ZT0@DMX^80'/@>!J#(4E*%P2`@N6;BJ\V`U$5S"UM\Q/R)&^;/NJWVV$@@J
MOJI=5^VZ1]`:<,E"CU-%%:\/G=?7NBE98/_$?$;%><7Y8^2\VLZ/BMWE0E#U
M2EL3?Q6KKPB"2L*5A"L.*_R5A%>P&4]Q/9>R3-*OCGV*17/,J"63NUMK,/]@
M^C"5`;TR]58J3]NP#'UU6GI6*DD]GD:[2D#+AYY2I4I2*V/O;6;Z+K/W?N<]
M+/;%Y]S(55,C%<>[ZFBD`G$NDT92DJHD54FJDE0EJ8<EJ26Q\K8;U?LG1?2.
MV9@O`WH'I)"4VZDD54FJDM2]HZ<D54EJ98R\[8;RKAUWP$P5S-O?)5'E<DW+
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M7)%`)0HO%9FBTVJV:_7VN5HSQ[AF\J:JJ:6B`K5JG:AUDC<-H-YN[C,-H`R+
M1;;!?_%UX'WTY\"Q_1#W!%9_>R*TO@):#XC6WVI_\YAK#OXV@PI!14/C8-$?
M"6!">)'6.#_PVC68^^L)H"=F)RP_-.KUGS]J],RII4^=P/\P,-^8\?%$ZS,+
M;V7JF_:0WL._)[IAB+^C\=WHDQ$!(W]TXX\A*?[^2^"=#G5]\N'1=_I_CAP+
M@/.^_"<P_>E7QV>?3:]O.5[@LB?VYG^RX)G?_OJ7O_Y%T_X>OGAKPM,&/)_Q
MK-8'PL`?#VSPZ\E]O?VCWOB!=5-/3KWUHT6?.R>::0`+]+YO&C\Z)[\)+H?4
M^:/W\/L-2`G0&_X1"Y#37TMQJL:_J&F/R"\M(33A<%>W7WH/'V#!C9+"G!KJ
M8UIJUP;C9$86B@*)5NS-U\]?$)#Z6<>$%9@"D_Y[*GY;'6+/=QU[&$J-B1\B
M;FNZ;6C7IJW;?5.WM"O'AF]-QR9,S4C2DD/L@00KXSU?LY03X*<1`^J/)[H]
MU4R['[@N,T`I^QJL10]>=@;:3T4JO&ZM>]F(-I90\Y$X%#I/J]9H7,S.,W!<
MS0>4ITQW/8W9!F";C#P0**AE:IK+O`D#Q?+"K.F9UO-33]9H)$$\SOB+9N/\
MHZ>].NZ?H%ZUOCXQ?1!O'%+O]X-Q8.D^S&BP@=DW?>V5N:Q8M"]K%Q<9:!=.
MWD:]UNK69R9*TTR6KI$.N[WC`^E](,;(9"]`B8GK#(!$SZ85*@4@BPF<><-1
MX`%_I,,7OH<#,R(_/F3`RY8S&3/`!O\>,INY(:&-L6F;H#ETA()&LE&27TW+
MHAW%M`.F^0Z*N\MTC^%;-0V@TW&2P/(3C.7OP7RV'^B6-87%@6`Y8DZ?:9XY
MM$U@J`[``#Y&T/=A('@A@%GA08%L$M>SBNB'2BNT9V8AY;U8BM@;2`9?FMZH
MIKV.3)`H$`0K,.@QXA*8GH:G#<`LI7=N[N]J7`J>@=G!`-<N"AZP=A"0Q'I`
M!Q"B4]UR;*8Y$Y0+V,QP0-<)AB,:^#^![OK,1:6#`/QO`(^VZJ1*NF?:/YQ7
M@-2M`3`:V7B1J@J1@>G8&^L'('$+UP-)/AORU00O.<^^#H/B4#;K,\_3W2F\
M/41=Y,!'?0(HO^@6R6K?&8^9BWNR^5^F/7Q[ZER<=NM\<1AN,-3$2'AI+RR#
M1Q^F\C+62[A(7-W$!6;PW1U6*%(LILL$'"JS#P@#V<T77$R,C$?8=@;`4GL(
M8QOLV=<&W%2@+_J..W%HY?4=R]*?G9#:,`Q(()!NS'3;R]8^'E`0MSC\#I$U
M?2(:$AM=D6@>#03&'X$F0C>EAAX,B(R-V@FI91J,1M`],%CA!<8E+#E"*#+Z
MBVY:9+T[MD1@4"6P)[`)-^Q!,L:`&QB>,`[\>*;=#!)D!5`"FS_J""QDNHJM
MIH80CG44?>`QT-+E?(#'00JLQ9(#:M,W26MZ7'CT/Q-S`%G1/B=!@7&#/G+`
M@Q$CF24)`FWKOG`AQ55V!JN3:>@.:-U0G73J'Q$Q07T^VQ6I9M"JL+H\^<'>
MT&4L4O7W%K`!K)(_F#MD[JP:K8[/M,CU2;M)WSQV-_@"JFN,"VYEQZBK'*-=
M@I3A^0`#46HC%BI'9P]VP<1E$YWO%LB,0>1_>KB/<55DHHZV83\8XS[T:OHC
M5--.0,H)MREX8V+!;,+FC-0X*-JLS1$GZH'*!_M0>Q=Z"<WZQV^@%\^TWWN]
M^^C+QL?WH=+V0(G;^I"K/="J8U3%+%K_9.?"WC.>A'8&[AJP9_9]@@#P=%R$
M01\CY`0$/,^$JK5,;H6:8B@C4D#T9#_4Q'[R23ZV$6*%?Z"VQ_`BN369]*2-
M9`Y(D96,#T6&NA'@SB^]1(0'"CH&;.J]/MKAPE)'31A8B`#:"]QD@_<\B59`
M9LD^GT]"800"Z*!^3Y_!+S!PLT:82&"XD0-V4L#E!SCOO-+6[S+NU0&;YCF$
MX/`Q\JQ]_4UF!#XO\*8!^\*2H2&)"//'E,Q,D$J'-E_<<PT6,P4!C>S8:Y!I
M(-*][B)GX1?NSC:[O!M1E;?2Y/:8WCP?1X#R)^3HE<30.V)\SS9N;+S!$ZP>
M-"V\>Z!<?[KR#GNN=M@][[`4@CXE-FLRG]5.NT</7&R='CE8'JY#H5KU5]TU
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ML89D;<#K)<CFP;]A^PV9(F:2T091=,"*0+SG&0@1`#0:IP"9CX`'FI-D*_3#
M@PZ/7'U@_^N(V0E''QZ)$*"H%?)BXCK/W/D?B560.6H<<Q`!UC06:'M07%^$
MNI[#T"M0"#/Q1.2#P?LSQE=>Q'@0]M^!Y^<@%O_)L<E"D0'BD*(-J4*ENU;4
M(@AGVK!B`^$6@:G,;5S;L4_#E1[J9-`"LBK@`BW"1>3"H';ALBA_&ZK=+`$!
MH?>"YW^31^,("33[0K!X-(A+<6"#26I-44YGX":9IL#@,RQ@RC<`Z,72Q_5T
MIGV5T)D/#>Q2[A#1Q:B;4('&<N5599MZ#:LY;7A_T5T;8[;WS*71^%/KG^]?
M*"-[ST;V5S`O;AW/0_G6B*?*O-ZCUD8=%:"MB<94/SJW)^Z0M:T]3\&0?C'I
MR"GCY_AL0AS^A&:AR.7!]U'!O3(TW-!N!Y6G#YEF!^-G&(6B1?PM'`]4;>#3
M61C.%YY@"?.!!WDDXXQ1P(H'IP"9B>.C1J&0FF%:`1W?TDD'Q9_.M,_X)<#`
MA%J)\:"#DPD>;-A43/!*4:$PI$/F+0U(.Q-L6?QWIP]CQU8T>\.#&8S3NJB9
M`%%/!`K1-EP"'4R6HJ#D0TBFO._2_C?ESTA&/9+G%YA9>M8<"#BPJE=Z<LS\
MD6-X_,QZ,@&=2EM91>2W<@NNR+P)+9$N@4MYX&`@$25%$B9<FF*I&%%44^OK
M5A]/;854SJS)2"R32Q),'SWPF+#3:%&08/-%,(*WX1%P0L#;,T_#,3Y4A3G;
MER:>:'I+6:U)#!#^[S>?G_Z!C\M9M-RR2]LHTN/G:-N)A-VKN]O;WOTCS$GG
MV1./?=3N_OGEX?KV[OL'[07L2AALJ=$'2LH<VK^>8/:M!,A:I6-HV3%WST63
MYU(.;[OS\S)[C7_$H48G:R7$EYH`C>WCOUI1:>DHU&S]?((+")8(K(+.JN2B
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M/_3\HE/KM%IJ2:HE63;Z'>N25*$A=7="88T6EG1)2#=5`/+THH:$]ZYCP\<^
M;[;'W]RTR\*EZK*PYRX+#PQ3V+28S5J2SX2)ZKFP.X!O;-ZOF]\+@+78\=T5
M$I<>L?,!]4?ZY&`3+;F'UW7O\5.BAY?HJ)/Y^K<)M>.2W^\]?DN\_M4Y(W!.
M&\V:=B*W:-%.>9.L1!<\[=V3,S'[VGGCXOT'>5)LTD!J1[3.N]>GO.//][`Q
MU1.VIA8MM'K4'.Q>M,#F;4>U>ZD/U!/VR?%A:JPM?V8PD^CTKP]\T2SG(6J6
M\RB:Y=Q3@XC:B?;N!-`,T3IYSSL&Z0"/$35GE1X(FZ6&<,C]J'P.A]08U8L;
M7-GB7H%^"*4^"^7<?F3P.#9QH,)[+S5KU`7K3.M)_;.P<80_U;P1S8<M&Z9Q
M)_IA8!KT,B*7)0Q7CD'M2XF-G(O(?.!D'L:?()2F+[J4\@L)EO?PDAO*AF2C
MJPP(/M[-+\`6XE*OM/E\HG8&-!AV)Z`V8K:-75Q%5U=^\0,F[9KCZ#L$CQKJ
M.G1%0^+Y9S8T;9MX20S[#`J3^I'@K1RXH9UIL*MB:UY#=.PSJ5O(V/2IH]T7
M9(A)77:G@A_^0@R8B8WE/VCO]/?8I2R^XX*H8EDA347//&PA,B:V)60JI@$N
M[X_XU+MG[/GK+QARADU<M$,>`6GEGBMZU)HWII'X@@%%`&<_2<RX;4K8OGA^
M&U\.%UJE"?PXG$@@1K@FF\X9#N.M][&_1-^<\#Z#HHM=Q!^"T107*:".H4YV
MU)Q"U[!IGXL`A>W\>+NXI<V'54N4[>V'O6`8@"Q).R)L<-&F!DLGWJ!@34H;
MV3V7MZB-2;R3/L;B)K7__]U!&;YR0/1=V,8>@V>?=&"SWCEMUV$SB]OGXW#?
M\#F\\8(W4GF&Q8$;%ZWX9!?,GN@T"&)]%5X+0QH],>.9W'D'Y3K4U]'M(5ZV
M;IOI71W>_)&MLKHUV!)\QF_'8'2/#HBW*6#$<84.")L*#1'*T[Z@2]PND;<+
MCYJ'X\)%#P`HXL5[#9!^Y+R*SGHX*J`]=\"H367R";EK^&NXDT:73E!;/NW;
MF6AR/D<GB!M:9O4`2E"F"N"TWD`%5,<Q7-73F^E['3Q[P`YX_LM+<>YAHZ[\
MPWVWNHX8JW'.*H=PQP#_$2M8O%F(\7L!,`<H9@W=&4;-1WVP"CU</71+$7:=
M$S<<Q+=#A>V7O3QW*M"]<7RKE6[7:=3E;7-&1LY4["VCR6D>%3FC5_LC9@06
MNQOT0#6''=,>H_9M7T3GMFO7&5]1AT;>.G60CO1MH(0;957"6VK`5P&=H+KY
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M_9[G,=][0O@V*`9NJF+@LH$IV*XQP7=JHN(@Y[4^9SUU6!$M3$S/C_HV127$
MJFA7%>WNU]Q;5'2P\4E3Z3!L%(!@-6J5YI)@4=DM?CZ*NMJ=1IA*1PRUS@]G
MG6^C)A$_'V=MJQ*4=03E$*M3U0ZA=H@J(+A/Q5=I_.L'0@#%886_DO"=;]DE
MRU7*VK##^*1I>X&++:'W=?JQM3R2C46Z9%S,0.^G-;"J8AX4?FXT:Z#<2L]&
M):5'+:6'EXY7O8US>_EV^/G*,FVSKUN:+]TFQ`_V##9QO#V6"VPMD:`<2FIK
MJ4L;HU>BQ)G5]M1&>Y^;JI)7):^KR>NQ2VM)=MC=N*:8)'/,YE09T#L@U;1=
MPU]YIR5`3TFKDM9*;:3;=54IT1CO]YS-1$WFH!ZS2;77>MMRN0AE*:C=KA/1
MNCAV+T*)_)&)_-ZBTF60]I)L]=OUF?=:YET&@VZ_1:,K,[>@HM%5CM=*4PRZ
M.V)EA1"[W6/W?=1244LEEZ%\[`OE<*J>-ZY)7G`%,K^AWKO7I_@&C`7?N`$S
M;DW]V;2HF'K3^N:6JF\N&Y@AV[4)YSM%E73.^3C4)&J;56GSCDN;.ZJT>854
MX8Y*ACZ82K:Y)%"ES4=?N*;6^>&L<U7:O/?ZIZ,7%%7:K':(JF%X](6/QXZ_
MDO"*(*@D7$EX^;;LDIV%9VW8O3`*.9Y8SI0QL.+&&(^D!I['?)Y1!O14`>EB
M375Y]*FY94!/2>F2+(KZY;&+:4FVTN(2!Q=MI8;ILK[ON*782LN05%@&]`ZH
MVF6[Z:_MO6:R*'%5XKJ2N';JQRZN)=E;=^.F6FRH6]J`L?)?,UI-#:7*1PLW
M_]M[[1NBY%7)ZVKR>J%RF<NQI>[&775$X;,S8)X'GNJ>]]<RF%1E0.^`])7R
M`)2X*G$-XRN=8Q?7DNRNNW%87>8Q3):FD@^#O3#+F8RQF8CR8?>/W@$IK6WW
MD]YK'Q`EKTI>5Y)7=>!:CCUV-Q[L`.]D&)D>TWS]37FN^T;O@+34=EV!1GNO
M[364O"IY74E>56>L_>^HV_5:>1/,=&>"8S:D]MK^KUR.05G:_VW7=6BIG&(E
M\L<E\ON]V*0,(E^2S7V[[O)>VUZ6P83;;R^_K=;T'5HOO]T1*V.A=%M'?T:G
MEHI:*KE.LQM'GWUQ.(TOB^A7&?:^3#71?!SI+GO6/69<2451WW77U6V_U_?-
M%].?;MKYLJTZ7Y8-S)[F!>.Q[D[#KI:OG.6:+GBN&8&+%X/B;U.FNY[&;(,9
M&G68TUJ-FH9\UDP/KV;QL+F`H3TSRWE573&WVA7S0G7%7*7+1*NK^F@H!$N.
MH.KUHA`L.X)*1BN/X))>D-\9NL+,.`A<#YZ9!X^@4CC'U+-4V>D*P=(CJ%12
MY1%4-M#Q,+/WPEQ]R`X"U8/GY<$CJ#8/9<\J=BL$2X2@4DF51U"90$?#RP<V
MUDW;M(<'@>S!<_/@$52[AS)H%;NKA."2#>9K,'YF;HRS,S@(K(^=K5_>F-LW
M/64$5@+!)<R\-0>*D95`<`DC;VS?-6W/[!\$LLI24I;2(=Z[N_Y!(D^G7Z=%
M0_EP5>Q>QNY[U^RK??DX>'UCQQ3Y%U;&*+X?!=__J5O!D:]Q9:T=%;O+A:"Z
M2EI=):TXK/!7$EY=!)6$*PE7'%;X*PG?K=M5LA:064[77>![OFYC5XI:LLM(
M>PWN'TP'Q#*@=T"-N+?<H[;6:-=KS<Y1]^PL`WKK2&S>!G.'(*CG9RTEHQ64
MT6UIU=((9H7XI\13B6>)^:>Z<F_FC_R.^1MK58(?3`?5,J!7)C54ZDN`.K7V
M<??[+0-Z2EKS7@1Y5N^6GIM*6,MHX6U7,"O$/R6>2CQ+S+_#=T"V>R`2UFWM
MS04I@ZM9!O3*I(A*'57>VSVD2E*5I"I)59*JHLM*/)5X*O$\`M]CNX<?UXX[
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MG8YEN6V_^.C8Q'\FW@F'19+@8T!KUV#NKR<`A2`0`?.A4:___%&C9TXM?>H$
M_H>!^<:,CR=:GUEXT5??M(?T'OX]T0U#_!V-[T:?C/#3+_)'-_X80OSW7UQ_
M:']X[(^8$5CL;O`XTEWVK'O,N'+&$V9[NF\ZMK@ALM?WS1?3GS[AZT_LS?]D
M.?T_?_OK7_[Z%TW[>]9(G^:,Y'V:ABU#Z#K"!]T>LN2P6M^Q??CC@0U^/;FO
MMW_4&S^PP?J34V_]:-'GSHEF&K^>7.L`E_$#_OQ-<#(D[1^]A]]O0!)`/.`?
ML7JXN&A/)&1?0<@>4,AJ_(N:]LA<<Z`E!",<[NKV2^_A`ZR645)@4T-]3$OF
MVF"<9$M5`2#1JKSY^OD+`E(_ZYBPRC8$\VG$M(%C6<XK"":79&WB,H\!NS73
M'N!*1Q'07&;I/C,TWP$LD-.O0B@TW4^%!SY4!/<%:J,H@+E2NR4-FL0`X?]^
M\_GI'_BXK*DY#])K07K\''6.V*^N[FYO>_>/,&<?F*A//-"<=Z!2KV_OOG_0
M7DS/A,&6*B--M\RA_>L):GH)D-R1K8K?R]CJR/<R=F:VE^BJW4A>I(SY-3;4
MTA%`W<UYTFJM*@-2?/2X9:"Z=W:JJY36Q/_\V`F@\#]N_#L'0@#%X7GX=Q??
MU?V=801HK?8UE2/%L8O"L>.OE-T!VKX'+^Z';[T>,0N7[,XJ/E,Q!)?PL_?"
M7'UXY'&6JB"XA)<J;G;`ML-%+MX?.>.K@N"2A?PU&#\S-\;9&1P$UL?.U@<V
MUDT;+:<([5MSH)9L)1!42W8'6W#%CSJ7;=*4VW/<<G$XO%X6Q@Z/M16[CX'=
M-W9,D7\QW55\/PZ^JV5>;8=;'5T=>:**XK#"7QW.5AI!)>%*PA6'%?Y*PG=K
MLQ].C6KE"E`SK._SLV:GKMH+5%!*#_\:YPPUW*K5V^<U);%[1T]);$Z);9R5
M7U9WSLP#7XI5E56E7<MCX6YF[%?*PBT0U0P+]_*LWFWNK45B;MS4O9"5NA>R
M/"*?H<<O+VJ-_75'+)?('[A`'X*XMO=G(I>+F656SR7<GZHJ[Y?-VOEQJ^>2
MV-CE=9"+Z4V_W=#Q_K?B,KB+%>O5J>Z-W"G5,H,LZE;B4J!7)J5>ZK!@%;HQ
ME['[]GY6J]+P9=#P1W\_Q6$W=]Z@)7/8Z3GP3H>Z/LD<^5Z?CIGM]UYUUWC$
M[KYW$YS$^Z=N!31=S_.",?]NTX;/W;(V?"ZVPW#84_??@>>;@RE!>F-K^F1B
M3:G5\HAIGRR]_^<I,,2Q8"2'Z*M-@(_XP-@QF!6W6^:_>MH0V<Z,&@V`$J';
M4RWPL#-SHI7SJVA0INF\=X:FQRRL0(/F+/)5M%]SIW3]FDN=*]A4V9!51["Y
MI)GRM2/5H(/:2A8E2BV6;:-2'1:WP/'JUJRI!;[#HXG2D6"9"J`;(V*BM!JU
MXV:\6N='Q>ZJK?.U2UL:BPO3U[Q-MG)D4(*RN:"T*R0HI=PA2A8AS]H?'DSO
M3VW@,J:9R#CF^9JK^^MT(SJ8P&89T"O#:>ZA!?(SKR'MGE=&%E9A]L^5P:HL
M$E[0QK57<;9_T4O/]\-/.BLNMS!KP_[R-F%]NA>2N6/MW12;BKW?%]?+D&I8
M!O0.*-.D0)PS-%3GK+NW5)/R<O/`T2N%3UCBO;,,6K0D>^=VG=UH[WQQ+-TW
M+=.?'K.]5`;T#FCG+!#G#/UTN;<*5^6H5G*[W*XX*E>S#-OECEQ-^-LTF&VL
MT\[X8"RD,J!W0+OE=JWY^MG^>IQLE9M[VR_+*Z/*O2R_\CR<8H'M9/7GJ1F0
MJQ'DT7M]'_9G?[IIG<#Y<=0)9`M>.<'L:2`O8]V=:LZ`R@WDT@1-%XS7C,`-
M*QSP/$!CF,:K4<:?UFK4-.2U9GK:Q&4>*DM#>V:6\UJ!J@0.637+$"XZJ@QA
MA42=5O<0[8*C*D,X?`0S++L#PU`A6'4$E8Q6'L$EN;G?1:GI0>!Z\,P\>`25
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MJGHK&7]W3X`J!%+>-;JU;K?]7@FX$O`B!5R=NBB!/RJ!+XUP[]\\52*N1%R)
M^+%X8+LKE4G=QWO,WO?2U=V"U6TXP3/.OW^6KU(IMV<"E2B4OS;5LA+C&IW:
M1:NKULPQKIF\=3UJJ>S;.U3K1.TME5LPEV=[2[A6ZT7M*Z4DEDJV**6SNMWC
M0A67*`MZB]:OK'9VAOZ>PFKKXZ_";B5&3XFW$F\EWDJ\E7A7$3TEWDJ\#]O-
MVDE%F`Y"HLX$*QN'*A,%2A1Q6DGI731JG693"?U!"OWA1U?5L9R2=*7>%ZCW
M,R7QARGQ2K>KH[$LG^T7'[V:^,_$.^&P2!)\#&CM&LS]]02@$`0B8#XTZO6?
M/VKTS*FE3YW`_S`PWYCQ\43K,PMO_>J;]I#>P[\GNF&(OZ/QW>B3$7[Z1?[H
MQA]#B/_^2^"=#G5]\N&Q/V)&8+&[P>-(=]DGW6/&E3.>,-O3\:K(1]_I_REN
MC>SU??/%]*=/.,P3>_,_6?#C;W_]RU__HFE_SSTB?NOU`G_DN.9_F?'-!L)(
MT]Q;NNU]FH:]1.@.PP?='L8S:GW']N&/!S;X]>2^WOY1;_S`KNM/3KWUHT6?
M.R>::?QZ<JT#R,:/QL7);X+9(?7_Z#W\?@/"`A($_X@%QB5*>R(Y_`IR^(!R
M6.-?U+1'YIH#+2$[X7!7MU]Z#Q]@08V2,IT:ZF-:>-<&XR1;\`H`B1;NS=?/
M7Q"0^EG'A(6X(9A/(Z8-',MR7D%VN;!K$Q`"9ON>9MH#5`;(>LUEENXS0_,=
MP`(Y[7#)TW0_%3WX4!'4%RB6H@#F:N^6=&P2`X3_^\WGIW_@X[(NYRQ(+P7I
M\7/42F)'N[J[O>W=/\*<?>"A/O%`M]Z!TKV^O?O^07LQ/1,&6ZJN--TRA_:O
M)[@72(#D#GQ5_!K'5D>^QK$SFSPO+N:-Q$7*IE]CQRT=_M4^!L@T*=1%I4D)
M;\H2WEXNX5)L^+@EO+KWEZIKI=;$__S8":#P/V[\.P="@(/E\'*3I[OX8O+O
M#"-<:_7CJ9PT5YS7"G^ES91Q>S2J?3F"AV*>'C$+E^S.*KQ4*@0WMK9Z+\S5
MAT<>2*D*@DMXJ0)C!VP[7.3B_9$SOBH(+EG(7X/Q,W-CG)W!06!=<;9NO-<^
ML+%NVF@Y16C?F@.U9"N!H%JR.]B"*WZ4N6R3IIRDXY:+P^'U,D=9'%LK;E>`
MVQMO[3=V3)%_,=U5?*\$W]4J/VYW6QU<'7D>BN*PPE\=S58XLU;)MY)OQ6&%
MOY+PW5KLAU-_6[GBV@S;6S5.V.-50)7HF[#SZ]T*I$J&(E=W71PG>E655]7F
M0^GG8]+/JFM924SLS;R-`^Q(NI)=O?^M>+,CS$-HTK35@,'!=BW;'=7*9YV7
M:\T<$7HE$N>J6.?E8J;2[TJ_E]ZZ+\.2.<*&?ANWWUO2\.\Y/>,#\WP8Q6<&
M3=.SC=0WWVS3G]-<</56?Y=E;?6WC>9R:3$M)Y@]S0O&8]V=:LY`>WC\INF"
MU]K`<35_Q+0IIEIJ#$312/7YTW3;P`]MS?3"GH'PT#.SG%?5`_#(>@"6^A2W
MU5+GU`K!DB-8]&T\Y</PX!%L'%S;I2-FYL$CJ!3.`99;*!M((5A=!)5*JCR"
M2VP@U0RI0@@NX>63X^O602"J#`5E*!P2@DL6KNJD4DT$E[#U=U>W_1CES[JO
M]ME*(*CXJG9=M>L>0:N3)0N=3ML5KX^"U]>Z*5E@_]2MX,B5NN+\L7)>;>='
MQ>YR(:AZ/ZR)OXK55P1!)>%*PA6'%?Y*PBM87%Q<#7F62?K5L4]?F.<SHY9,
M[FZMP?R#J2LO`WIEJA4O3QN$#'UU6GI6*DD]GL9A2D#+AYY2I4I2*V/O;6;Z
M+K/WZ"1YK0*$@RDK+@-Z!Z21"L2Y3!I)2:J25"6I2E*5I!Z6I);$RMMN5.^?
M%-$[9F.^#.@=D$)2;J>25"6I2E+WCIZ25"6IE3'RMAO*NW;<`3-5,&]_3>_+
MY9J6I>F]<EZ5M"MI5]*NI%U)NY+VJMFL>THW;!^SNU(&],K0^+VD?O?:)"F3
MBE-ROC4YKW@NHQ)O)=Y*O)5X5\1`5?F1U55CY7*J#\%E;M<O:ZU.I_0,5?*J
MY!4_=\]:]=)S4PFK$E;\W*QUSB]K8#"6GJ6';_:IA,G**J9*)O?L![\,)?3N
MHE-KU2_>EYY[2CBKLFMN5V#W:>(I82V?L)9&,-]U6N=HS1VU*BV).:=2(U7Z
MC$J?4>DS>V>VDG8E[4K:E;0K:2^OM)?$9MU3:N3>#O?*X*XL7><M6.>&$SSC
M_/OG^#ZS)U<D4(G"2T6FZ+2:[5J]?:[6S#&NF;RI:FJIJ$"M6B=JG>1-`ZBW
MF_M,`RC#8I%M\%]\'7@?_YEX)QP628*/`4M<@[F_G@`4@D`$S(=&O?[S1XV>
M.;7TJ1/X'P;F&S,^GFA]9N'E27W3'M)[^/=$-PSQ=S2^&WTRPD^_R!_=^&,(
M\=]_";S3H:Y//CSV1\P(+'8W>!SI+GO6/69<.>,)LSW=-QW[`8QQU^R#0?[H
M._T_>[:1^H8N:^OU??/%]*=/.,$3>_,_6?#3;W_]RU__HFE_#^?JV;YIF%8`
MS[)'U@]<TS>9]^6M;P4&,ZZ!Z3ASX-/$=X,ONFL#KMX]<PFVWM@);%_K.[8/
M,SRPP:\G]_7VCWKC!W9J?W+JK1\M^MP^T4SCUY-K':`RX(L3+0`@Z04/!_).
M-(/U31!`[]>3FZ_7)[^U&NUZLU./R5((J'O#_\>7\<1RIHP1A^XF.-X?#"^[
M#3R$A']S8QL,).W)N?&\@+G>E_\$P$+^[]Z;Z26IV%A.Q<.AWW?=Q11HF6:/
M,"P;,]OG!,*9'!O^]&9)U3P^@<M2"@^/WV0"]EYUUWB:3M@LP5J'+5MMB52=
M).;M'*)R?M'IM%J'@O\V=%,GSX+K7+2Z!T/$S114-Y>"ZG0KK:"2!-M,09WG
M(%BS76^?;YE>5[HW2J+;\^[L>8;/A03UM\?/,LCUD]\:G<XY6)\2BW'T%6=,
MJ;/+Q3/66YWSI3/>NVRBF\:7-[1!&1B<=_Z(N3W/8[YW%;@N2W-\`0E:]84`
MM1+`Y)BX6%B3Q&LU%A.OV]T4VC5IV%PJ1NT$9(7`D*)-:XE@=9JM_##<N\Z$
MN?[TW@(5"I1#A3E!S?F5K4"6]D*0FBEFS9^Q(.A2!.LL8=KYVO!QTN:G4W>I
M^'0S6+?RK"G\SY<(3/>BGF?6?A_5L'>O3]&S!<K`-V[`C%M3?S8M4NDKKZ?%
M:KG=2`&6'X3M0)\B[&(5WVUUBH+^<\">G`=F@55CW.ON.J1N+U;_G59R%<R?
ML1#8DH1L+U;W:X&U@52V%VOYRW:25,O9MX&,M1=K^[2,+8<%+*VQZ8_)&+:-
M*P`#3"UF]^&-_`2:T?=OGOG!-JU?3WP0Z!/MEV)F39%B1H\OFQ7L@@$#*G`[
MEZY5SX_C8EV=M#[2LVP&2`KMQ>I[-4"0#XZ]#CF6:.IN1[)D4Y-L`$2*%(L5
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M'O.)V;#YKK'.EBGCRW1$8,&LA<&8HN02W=Q<`T2BNWCTL^FRON^X<N9$?@(N
M5MJ=>LSF!=,5`%:29N>+%7F[M398MVRH6]=L!>?[?(DNOY@%)IID70A2U%BB
MP]OMY1"DY.O>=0;,\\C+P,=677CGBS5Z>R82MV#2PD!,46VQXN_,A#IS@"B3
M^(%Y#*L$0-5]9B_,<BAHO3(A%V\&ES.<73AMD7"FJ+G$0&]>K`?I_&`M-T4V
M#GF?+]DBVDMBQHO!V"(:*?HOWD5:,[O(1FC<#<`5!@]EOO*N=Z6C[NZ/9IOG
MXER-3#:X-FVPITW=$L/(!]U2+'GZ!&:WA^@YMO=I*O^"I^!1LD9OZ#)*+N#C
MH(C=PK!X\AC^,G-J?KYX7VLVDPHJ"]_5:=)HQ#2!S\T+B29?WEB?SN/W1Y.+
M)0?2YZO3Y!'6-?E.5X[G>XU<V1!/KTY$#$\FPY/I8R[HC6V8+Z81Z-8L!DNV
MXG`GG`/>S$F*"-_*&/8PMV5(!/QN^J,8F,_,Z[OF)&,E9*-9&JXW3WY[9[[7
M=,T*QA/-"TFB3?0IOJ"Q_P!VFN]HS;;(@@95H>GXV)!I8T!U9$TU3,[5/-W2
MW:F&ACZ^@,]=?;G3''B6_IB`#<8P1UAK-/F;WD?MG0FS!Q-\P;&9-H4]07N'
M3UNPT<*+SB#^?N!8EO.*`^`#!E`!?_:9.P:50J1W7)``W[2BR9]9WT&@F64.
M3<QV'L`C8X"B#UB94@A!(#1Q'6`H,[3GJ:;;#JI%C7'ZNN\UEYGCY\#UB)8T
MU(CIEC_2^KI+^(W-8.P!"`:\=G7WZ:'W$48Q$$FD<>`[8X"SKV$=(:(!T.N6
M!<_SPD+-(0'RZ!TQ-P\_Z9@`Y$D';VO*YNYEO`3:_J*55\8;%^O(^/4^9?SZ
MP&3\8PR>/])]@)_P!)X!-"'&+O/,(8R!T`T=QX`O=`](,W%-^`;(K&O]$0HQ
MSHZBZCI6#6@,7,0A)-#P3S=*P-,\.KO!3<33AKS5-%*)YH4EHMM3&$7[0Y\"
M>_F]*)HW0O2>05[Z?68!A>&=L^)7ZB,@;,(*`I@>@\G$FL9GN`]LK)MX7/$'
M_'L<C'F"'O\=$5A@1/X(%X]M\%%SKJ\?=_W`"KSU%G-R<2[PPTZ[)[]=\.(@
M:==>FQ`S),5LQD_ILA*).9^F\2/W7%=0)N97Q^:YP#Q$?V.#_`1TFGX7^)X/
MD@TP?`V0-HL<D<U292]RI1:G<OEW@?(.R"RZP&\_'_DB1SYRIUW?+H4%MCN@
M*QBD;M_T=D+9'(G+VR5KA.P.""L:G@5N.JZW%=)>[)NT$KHE4[J;DO8RE])-
MUB?L4NE2A&WM"=/S4%CH"2PI#H8W;PUA%&G;I+]<I5ARWV38$SLDL?C.L-B;
M&3UN](?*[AX,W86']ALR*16"^3%A[@]"3N95\^2W\[/6[MF4DSQ[8I[8YO,S
M;AM[QV4S)P,OS^K=G3,P!XGVJPCWSKY6'O9):00EH]">N!?UH]TS]]JEY5XN
M"E5VU]N4;YW\NUY#[7KS3*<],:];9I,E)WD*\[)FI2<%X7QIBJ)O6$_B`G$#
MW7IB[G@''N_E^<EO]XU_-?[H?B[`[=H&#;:SNF8@FR\N^^3.A<2=\A$@<^W,
M=!N:!>YY9>!ZPZ'+AD"V&X#`M#VS3[4PDCAM4<WESK_>)_X[6B9S`)&$9WN,
M:-07)UH4OL>L@?U,B9BE>][=0.!]YS[@RDIL0-&/GO@UG>Z1(F'BY0=$Z<YF
MB>,D_"Z#>+D"#&W<K3&)1RI`6P>%?=#AZ=7)0X=<?GJ;^^G-3L%TV'<0-T6+
M'$V:]AJ4+0O9UE]U>9I!U=OGG2V?A%61PCG7<X[3W,N+QF$<*^S*;$V1N%L)
M,[1\D.7KG;:N:N&NF^+(#CB24Q6AN]8^(HX4>\J9(F:^`^.C/K5<[1!Y7473
MR'-^'-HP^Z9`13F13\$T<C3LO6R>EVE%;&QS7>NF2UYVS_.",9_^P?3^O'89
MNN$,<U`?,-EWU1[2C8;L"4X"=`"7->+9%Q8+C+-&:P:+A!M;/ZLWNN<%&+]Y
M42@L*I@U(=9!8[XQ;FJYRF)2Q`*"W'?^=?Y'HYZ.=V\%PJW*3SC3/QT+AK%@
M0:ZY#CK[70<KX;&(N=T%*Z&)*^&RLZ5UD(W"3JCV&3/@F6VLR?OS<O`^!Q:+
M.'^QC/.%A%?R(E`8Q69/S9;GQJ<HD\.*+H(T\R`MFA24Q^3=V/?,-1WC=]?Q
MUHAGY+H]HM4L)B8W'_#,%E34&]WX'+A`0OXL#>M)G=572S9/H;[:E0^K@U0T
MPZ6$Z)!X:V"=X_:&1K?;;1?'[PRX]ZD6T@3)%?A/=M<OO6[8(-B0Y\Z&BT:G
MV2R.'-OSF);F6N1.:4X1*5>R5L:1^/:16)EVWDKJ>M/DQA0=\^9-=<]:JSAN
MQ>%4.#G#T;=%T?,M2&:A.!5.T8S]I6":7NQ'2E=$K'Q:,TW'R^W0<4^*,_^N
M5@SYTK=][(A\FV2/KA-)6CL_LKGZRFXU3GZ[O_Q7`?&O]:$NFG"K'XFM$3UL
M@9C=7_SKXH]&LXCHX?J@;U'I)3/;5EBGBQO7;<<D3`*[19E*3K0P,2U%EL7-
M\HI('ET*;0FWR.0)6"(=-!,X'G#H!?[(<<W_,N,;]E"1X@]XQPT8%K/G:K-G
M:.E;=`Y[/]X@!VNW7,EU?=T^`A+EVY3VR:;S`]T!-SB_WRT#<G2HJ$R@:FFB
MTU=']+Y:RI-6^C+(?)=`-EH[.A]9%=7=T3@9%5KG8N"<I&[G.'79":F3&)>,
MT@MO.,U+Z1R'/.WZ9:M3Q'%X:<G]3UI.NQ#L'*=+.Q'L),8EHW0A@IWCV.JB
MTZI?'#*UHX8"NQ#M'.=B.Q'M&:3+1^]"!#Q',<NATSN_T;>V5.=P-@_;Z,M/
MX[4E>8WKU0^9T"G'EHRBS[K/HIRR+3@WZ;LNMWI@7R`I]F62K\BC8G?:7,>$
MN^+5BG2I&L.*V*K3EZ4NBB,?-\^2AO(^%UGZRMC]+K(5Z5(UAA6RR/(V5=S5
M(BLMSZ2TF;VNL!7:*):+*)5B52%K:X6>B>4B2L7,][77TB[S;2MIOA?"GK77
MSPIIO"7ET);[%$0`[<3;77*!^/:[@RU`=T<$3Q<9[7+C7WR/XO:IOPSW<K.@
MD`U]R=V,G7/IUM.#9T324M_I6NCNNT_A,MS+S8(BUD)W\8V6G=;Y+I9"2?@P
M<YBSV]6P^);M[7,A!_JE9T0A:V)IBO;^T2^U9;KV"EB:!'[PENEZ!%];TA=?
M_MZLMYN[4/\YR!YZA?>NN.V2T+S7W3N7&B,;]#2L%@(A?ZUN-Y=SRML#U>N-
MV#W-!TCAX*?*)KJY"CJW!#X](J7KKD#U'-FYG=2MG(OG+@S2-(%SY+T6#RGO
M))&?GN>KI8S.G[(0X%(D/%^ME<9FP.7K=)\FWVJ)B4OF+0[,-"%S9/6M#R8H
M];%C%Z16SW/%S#/T4@XHB@4\3>-<L>3"`5]?E9[GR-%JU.OI.XX7S%T,F&FZ
MYDAS*AC,E95HCDVI?0$FT>4B`+-5U>K`I>F78Q\J#+BUE.A%CCVHW>TLX6\^
M!;6!$KW(D_._"9@;=Z=J)5S9IO"H)!#6O!7D(L<NU[I,==@OIJ_5_#K7$+V;
M^[L$6L&S9QJF[DX?=8O=#6BJ#)1RG:*W\6BIVYW)=M]*(>D6,N52.._R.'K/
M*5/;2V9+T31OK7/[[/RR7&3=H)PT&76-IEFCX<-%=V$<H=&Y;-5GF@1N`?(T
MA7J6Y?31#LOF%/:DM+UUUN#2(]35(-@>W.G`T#>`VGMX_)8S0'2Q]+1RCX@N
M$LC%1WSM3C,AC_L&?D,N72X^1^LVS\N%+2S;@>..=;O/N"61P-,&G$PK\,T7
M]LCZ8'7X)@/[HF\%!C.N76>,TP8^S7HW^**[6/?NA4[6IVGV`$BU3<F\^*RL
MW6H40.8OXXGE3!E`[KZ8@CXS[T8!4X+6>W)\W9)_OW(\_ZOC_XL!K'UG:*_F
MJZ5OZ$YK\WHW:1UO#>12T&93H5E\F(0M"`Z,F&)3=ESQ%3ZWADUQB2WHFZD;
M5W<+=/E)MJEP=DI'X[5M:OH7&H:P&_!+!7=!P.[);_"TI\%^IK7:C1JL98W[
MUIHS``#0:=<\'%E#>FFN[NO/UE1SP,C7_)'+F#9EN@M/VYJN_2?079^Y\#M8
MOJ:GZ;:AC70#_JOIX96:VA`=`\W`CR_D[L!$/S5KC?8%SGZF1?!T+VJM3B<$
M)]\XL(D1#C@S`6S:&@.P+/C@`8\M.L#3R#`GF/LCD[T08_!]?\1@:MCX7H$+
M'[1WC?<:LUV'OQ8]8+HP\`08BU_"!-*7Y@M*DM:W3-OLPP?@#?P;L7GX]M2Y
M..W6<5;X<P*R!!1TM#_TJ=9HU#3@YOE'[5TS]XP>2"%@N=F4%Q^)5.]:[Y'9
M$XNAM(;31D-Z?F!,-9=-'-<GJ>3->N@AX$U@^5[X3B%079X5X*3.+JC=-ZGO
M2&NV\Z/1Y#[-TZOS-'("#RC_-#)AQ3!J#91WS>:IN-U#5_L=)1HNIG`A7N-E
MGDAZ5?JJ;*T#]E9D>TM-=(MOF4TI)=]UEUY\<NX#MS^"P>\&4J`[5V!\K<AQ
MLY[G:HM+Z:JV):`6AU9W([1RG&ZLC=8-FFRZ=1\\6V;_;C!@=""`3`6VHXHH
M/L+?S'<+=9/?QBUP6@KG]B[=#I'=:!4WZWF/-?`0^E)J85>R*\@WE.6\.01;
MN8"\>"I0-\-7UP0#W\LK"'FS$0HEP?Q%1';`-K5RCF2&9G@XNP3,0K#93(!S
M&)JK8A,R^`&<+CM@\WS<^6<7S7KND'XXQXISSX_I-.N+P_*YYO;`7>Z/>K;Q
M&1ZQG`D=?J]YD--L+(Z<-UH7R>C<PNF+@'4!\1J+P\_-QOG%^K`^,@L\S>'O
MS`:3S8)7>L88/$\PJG6,HZ]/X"6QY/-6-WDRF`N.0J%?1/+%P=MVIU4O`/H[
MT.HZ>MGB]S46=6-QYGRKT4C*QLR4Z\*TB'B+D\N[Y_5U8;JQ^\Z8W<Z_TVX1
MI18?59_.)U4\Z_J`+2+7XC/ET_GTF@_8#05I<=GS9[XZMA.^M0;I<N\<B^8M
M`,9%5%R\PS22)Z&KP"G_QI]>6RDVE]8]+IUT4^@6D+"Y>)])D3`_A,S?9-TV
M%V\DL^LV,=\ZP"PBT>)]X;3;O6SD!V;F"%OWS#[NVGB(/??RRD6TRN4Y@=-\
MVCCKM*23G\6`%`/W(K+F3<,"N%N7:\.="D_Q5H=@Q>.K4F+GYFS(X\W46]V6
MG$>^'G!;17$1QW*X..V+9NNR?EXTBN1TC1P+G&J/QX`7]<I(@;UX)VLG5=SL
M3)O!LGDN;S-]6=I,X=XVP>\9!IW=@J.JF\:-?:5/3%^WUD0E?7%9N@+]$MV:
M+6+SP/`TCAFA$ED7C<6[YFFGTUA5J%9(<B]"IEHY\L.;Z0*-==/A*5^3?WWM
MN%>Z-UI=^2RY2JM1;U[,DCP/*%O%H0A.+?;V&IW2X5RPRECL60+CSR\ORD>$
MHC3-8@]VBP(O%Q'M6.+SE(]UDM5/^9&8274U_AUPM]![<N:(;G8*^P,#5#S3
M#Y.G^)12OM-Z!0K-UF*#I5$7+8MVA4$9*5:$F.6.3Q\E@8O5XNTEL7<ET\7M
M&>W%UND>J;QR6*B`9=Y>VFFIL"!2$O2"%U#NJV0+1J,HH5QLQFX[I%>$("TV
M1+<'>L&"E-NB+!B-H@1IV=')2N'8E>('A:BC)=&H;MJ5*2[\4;A*6G+\<M&\
M/.^TMHE/02*5OK5B1C>!3&TS2%B$=DK?XI"6JXMM@E^L7*7O-YAM5%;'FLXM
MXE.47"TY.6K46ZGJNF(#A47HJTZ.R^YF6F@L#Q2NTM.C""QR7"$WTU%E*1:?
MV<2%,<@@7OW$*-TJ?3:L+\$B3[4&&`NB#4LZA#=R@Y&=5[X&77)G'F3/N!%<
MBPBU9+M+N[#YH`/3Q&7PT&?&_WMCW[ML`EIT[82#)8V63QNIK(C%\Q<$[P*Z
M+NE*W.BV"@:XU^\[`:B)>WV*]W=CYE:_[P;,N#7U9].B"O(UR+XD^:W=78)&
M'K"VBMPB'BW>R5H7%UM`#@QW#-C>N\Z+:3#CT_2;AWU`HE2H'L#V0F]>`3ZF
M'<!WXD?'7H>#2US4YF7*#-P,P)V@NXBGB_W9TT[KHKM%=$5A$0:>^K!_8X<F
MS"WRIU@[X8.`X*Y.6:QK<#*WCYL?BL+A7\2:)7MR)\F8]9&8PU*>*K>-)99[
M;]\,LIW@N8B!BVV%TS0'B\46ANDS9GC8/^6!6=B6Y%X'<?C,GM=83.=+0O<\
M,5IN13I_]@(@74#U\]R![U5@?`#K@J^ONT$!U%QL)EPVDH*Q:/("`%U$S,5;
M?GA9Q#J`RM3'LUGL#73G\O*:+.\\%UV7I$ETFZD$D>5`%`;V(BHOWH0OR+->
M!VA18A2F/*<%?0T"+VG[UI4OTID_\6;P+:)DOINNED.V1"=?FS90?0M[X_F2
M8_^+=KN=9]/(">!.T%W$K\5;9*LY<QQ4(+(T%!U9IEV5U?EVL61_[+3/DXMX
M_N0;@[F`WA?+<A:;C?8&8.;/Q[U8L@-V9Z!(Z`SJIY&I!^5:=C!ZPY+7-3BZ
M)-?PLBEVZ?4`V@HZBSB_9&ML-,Z+PB8L8\6.4&O0??%FV&I<=F)`Y:E6A6$1
ML99$93O-%4'X;OJC$;.HF6%(US5(LWAW@T75S88K:_HB8%U$PL4;V<7EZI"F
M/5U1AAW*)KX^#]"F!&A:$RUI'-K.]+*SYBX`S@7,7]+RLUG/#@=L"=`%G%_2
M-#,=RET%T#MWJ-OF?T6_.=MS+-/@C6MLX]YE'HPCFH0*DT"WHO,A[[/I]2W'
M"USV!/A\LF;[LN1!KGGRV_]C^1\-\T7S_*G%?CWYH_?P^\W7#UI]XL,_;Q^U
MZ[NO3Q^T!O[]9(Z9IWUEK]J#,];M&O^BICV"P`^TD_]GZ'_44L-=W7[I/7QX
M=OP1'^GTNO?'S>V_/J2&^DB_/=[\?U_X5!_G@/'L6$8.6`B4KX[/M,:9)I.9
MFIUA"`G;E?W!W"%S$>!?`.(=0)\3<(+B&3_A!Y,^Z./)Q_^!+9J^^L4,?_PE
M>JST*,ALV!423U_^WZ?3FZ^?OR#H];..:7_4-D,LQ8C2P_L0^"-SR.`GL'C/
MM'?8HH_C<-%LUC_B,9YN3Z-O&A^Q)9_T0/B^],1[[57W--/N.^[$<='7!`5I
M4#M(IEGZ:]0*D)05_O&5O>B&COW^_E>W`]V=:HT+ZO/7.M.>X$$!!8WKLL3(
M`]@YP_=]1_L,SNTK7H@#8SVRB4]'YUJSDS%:"''C_*.'309!?TYT"\`98"LS
MT]-$=V-LI_@(5I\.-/3TFG:E6^;`<6U3/]-"[/%Q77LVG<E(=\=ZGP4^-37L
M"\`'3C\0#24G(-Z,#`#-!KZ,IA.G/[(<-X`1^J910_K^X^[*JHD>E-CL39_@
M"9;!/'-HXU>.9HXGX!6RJ.6C$_B8[L4[:KK,"`"%$=,M?]3GUP/AWJ9[GH,'
MV3#$*Q@>@-B`];DKZ_*@``X]@6=/1<DSS&#:+[J''R9HGQBPGWAGU1#MJBU%
M6=)QZT;1\W$A4<\<;4)-<U`^N?2\DU;AS?U=8@&"G/V!K5&T9I<DOUV#UUTT
M-7QD\>O(A-\2S5)A%2)A!F`AA)21J:']+07_WVI_\Q#ROPFJQ90A7)JU;J>.
MC5:)]#@JT3Z@CD2O#$32PYU:]V'93*AW(#9G+1("[)>6G!Q$F@`XT^[#EJ*H
MA8!V-?H@:QD=:.18UO34><45YT4-D1#.NWY@P7*]L6WGA2^2QSZLPCZRDVM1
MB37\X?D*]-IQQP#8/2Q3@%-BXAF(!M/(2#D7+S0Z]8^:G"\EZ3!-A&.E)T6W
M)8VW6])"QX.:K.I1^AKH%5\WK>VLZ@U7<.7MG%D,>K#B>#OA.::F,GMV`.]=
MJ"`;+5*0G:0*`/:`CL*M'Y0$<&@1TV9L)O%U]$[2-,*-]SZPQKKOFF^SZB+Z
M27ZKQK4D*!MF334,&.2S-1`P`_Q`;,8]K<%"C[IDU0@1;-^-+?/`HA'N#V!E
MVB/=PH0587K0^-RP8#9\3WV=67]D.Y8S1+O$'X$:]UVF^V)0VW<="_L^3TPP
M(AQ0FJ&E`5H3X,%XJL=ML32MT,K`8#=O\(WPC_D3`%A,-2(BSD7\B8PP,=@5
M6(=GM32E^U&(7-,'/DL,KGN\-77@OI@O/#.3&YBA1QAN!UK6=A#-GRT(<W1Z
M5];4&&8T>5$2S<?C^3!F'PDL/;A0$//J]?`/_.P3IY\=%[83#%B$2_75-/S1
MAT:]_O-'C9XYM?0I6)D?!N8;,SZ>:'UF6=Y$QW,(>@__GN#L_.]H?#?Z9$3J
M3/[HQA]Q&OQ+:@%5<`1D)D\2#&H3['U,&>'96EA&"[,@W3>)F[0..&["Y;<)
MLAR,QV(-2(348DIJ(2G+MS$3%!XH*GN8S\!(/KN''8[^>RI^*P;7`LUM+6%K
MWYI@C!IHCJ*:BM8FZC6NGLI&W)4I6C%[)Q%&,>U^@/<F:S;S-="0'K_,HU#W
MJUOK7C9F'4`4AT+G:=4:C8O9>4+K@=\]PFP#L.4&7XO?(-$A4+AKC)8*FB=@
M'4W/M)Z?>C)A&B:B1J^.^R>9"[SVAYL*_7XP#G@TQ6"@$DV?.[R%HGU9N[C(
M0+MP\C;JM59WUI%/TTR6KA%84[;C`^G]\/84`\VZ`9"(TIZY4@"RF,"9-QR%
MPEQ@/F)PP!5=7>DAR6*EOX>\\2@G=*+U*(U$?3Q?3<L*K3U&L3)QE(]OU31R
M[OF=)"FW']_#KKQ^H*.I9S,>#^-SPH[G27L<X&,$?1\&$JV"T4_@R"9QK4BL
MK-H*[9E92'DOEB+V9GJ\P:;NC6HBX`6"@'?L<6-_$I[U4@09WZ%`$$G!,_H"
M&`>FV"JP=A#8/!A'95&GNN783'/B3"!_Y#K!<$0#BSN.4.D@`/\;P*.M.JF2
M[IGV#^<5('5K&%4FHSM252$R,!U[8_T`)&[A>B#)9T.^FN`EYQD+^&@HF_69
MYZ%IYK(AZB+TP?0)^E:Z1;(J>WXLOG&'%H?A!L/P#B'LS0W+@(QJ+V.]A(O$
MU4U<8+'S@12+Z1+&+MW0C<4[EU`3A-%,#[W39U\;A+E-\$44Y8=/%GBD3DAM
M&,9!WQ3<-]WVLK6/AQ<C,KP1:DK(<N^*B(UA]V@>#$&"^P:@@H35X%471,9&
M[20\41I!]\"-P'-:+F')$4*1T5_`W2)WBDJM0@*#*H$]@4VXIP62,0;<P*Q'
M=]FRSK2;08*L`$I@\T<=@85,5['5U!#"L8ZB#SRF!'CB`SR.3M]BR>$19=2:
MW-OT]3\3<P!9T6LB01%G"?P`(9)9DB#0MNX+%U)<95OU;6?5:%$[7'(#5;[)
MSI#9FO-QS\_R+&[5)L(&RNW8PR[=CSB`Y[61+^A%@9KP/%CR3W"?IN]T441'
MD4D\.\H^EJG-C0+2SC]S(!U>D1>>0,OGQN+DC!O_X`^`=I=-/Q-CPV&P%?9@
MV]/%(>I(!W7XS``&L$?`.)5GZLMBJ%2E4I6E4)7?/)+^+V`KC]'"4_IQ#_IQ
M@K7<;G3^DJDA32K>QTO%T6KFYQ]QF'42[WC"0XZ,SE@#)4QYG*@'!BJHM,3Q
MTS=036?:[[W>?>+42IB8'IB<MLYOS$,;<(R&(PN%AWOE8"F/)Z%7A#;N`(]^
MQ$V@>#\H&N7C2*?#\TQH.TNJUB:3-8K?B[MFA3+TDT_RL8T0*S_7CD-F[QR0
M(I^>CKS"L()!+3:EEXCP5"L`+DBOCU&#Z*Y3X(R%"*!WPQU,>,^3:'66B)C/
M)V&X%=(-NZ<\(Z@OM5;@+AE>;RL.J_!J6G)4I(R>>>$K@P%XY#CH;S(C\'F!
M-PW8UZ4D(2+"_#$EISBZN!7W;8,E=L#8ZT[D/\PFKASU;I;49FKKDCD&ME$?
M)";6FU<@R>`4/YC>GVH;VS'`\0F/&=]3R_7_!*Q<V^=Q$+#7_QUN!E*XJR^S
MDNMZSDL7>!FIP%!#4_J#'L8<J`[+Q(W)M'D#*]SO!@EX3#_@(TL9G3,[8C*,
MQ$/3E(.'`";`X?KQA?'KMT&)ZJ#SM>>IT/%SYJ;#>8$"WCG^AB&Z<,.Z9@;%
MM3_#SN+!3#=V&&^ZDC(13/R6X48)5D#&N?X1:49EYZ^D+*]UT]5X4UZ0N'BU
M]N)-7VI*H]1G&=1G36B^^!0CBH5,>$>A\+P1>PK%ABKE>^NN:S+*K\7(;1@&
MD:SWZ,B$C@7>A/DY0#EY(3DQ^.$914E&8.Z>8N1:LW4?`])<;7E,AE>==.W@
MI"L.S<.7$K<2?N,<GXI[#R(M$/:?$5Y^+K*O::M^):^%3A3ZS,1C6]JT;#X@
MG=[H)O<H,.R%OHT>S3#5WNFXK=')"0SY/MPII=(*5QMC@:INO&`]Q9!A/N!8
M=_]D?G0*%DT5CVMB#AX_>+`2$3<`U7_%<)L8`[QHW\2IR)&S188?$8QD'OW!
MY#8_UD'RS?\*>@8\&N(\X\$&+3#3G@2"DGC8//-H8,\^_#I"B&A:2K:.F)2<
M.O!H*)<QS<*S&1[AY$,0-\3I3B!L$(&(--Z'BLAOY1;<+?)#:TAPB\AK0[(W
M_A,X/B4V@*R31:=3-H2016[OF0::OOUX24IR;5:FCJ:J#&RNPD!DEP<+W-+=
M>?ISEL?(8FG%TOE!I`\4=[?*W=9B[J;YDM#4[Y#;[`T>MAC95MK`<EYA<S(8
MI;>+EZ,-4XK(O5=NEW*[\I]$\YZ$I$JBAH3*O=HQP`DVL*A%):H%.A*0_"3,
MB,53B402I]1JFCRN,4;_1<&,R"S#X'@?35115"/E%J%A>.KQ*V.$"9KH7@W3
M3;(!-#V*]=/-I8$7GCY@WA?>+WH*J@KM6W_D@))Z$14MX5$"OL$&@04[V$M\
M,!)G;8I-;A86"U,EL;PPK#$6!U!KP&(QF,,-Y\Z`;!!ZDO)<FO`$P&C739M7
M&X'G*1XD\,X*U;O)-?LE#2;W2`C89RS,A;_IW(:'Y+"J&HP'/';Q#L`@YTEJ
M`N3O-Y^?_O%!ZV`-T*>[A\]?'DZO[FYO>_>/`!SEY$T\ML+D>6J&.!1N",(_
MOSP\W5SU;D][MS>_?\4Z%=]WQM*3QA):\X_XWFA9H>(OTF"^$8YUW_O\^>;K
M[Z>?[IZ>[OX`/">^8.#W+S>__T/4SBRKT=D8#$'_$(IG2^__B;!H=*;V42,Q
M$43J4_EB`5#^"[/G%P(HZK=27/O4N_J_WQ_NOGW]C`)S!T."FO1!5):S,QQ"
MQL=B`_A=2.-%_>=5T;CC+1U88@->3G(Q86/E^59F;A;SPMDO5Y^^2-W82BC'
M<LC"J@3Y@QGDA.<5@-VS>Z\L[AP`BZ\#US8I-(TFU,!\P\^+5=?1\?E\/3['
M=;F'[^U6S;/Y-@$;U&6^Z4:FLZ=;K":RH#Q?]`/BGLQ\K\8E<]MY"1LJX>O/
MND4GT-Z(,5]*F,(,)[3*ASJ5`U`!(7>`!A:OY<+OHS2@,^T//)IG-@W&P9GH
MIBL.JD:Z.^0!;BESB&?K4HVB"K>H<$M>U^UFC((U%HD9MS#QZ2T=8_%C[OW%
M75KULR:Z#=513P5!+!]X\5Q)-,0LK$M[,=DK/TO#P^HI:A0ZU8HR_2WDGT7\
M$P%Y.EFCQ!L*O?,#3)X;:[J@VK`X#V/Y_!S3M'$RGX5%@90EY(#.L<P_L8T*
M?&U3J1CO7S)BICL#"I[!8:8.[\,&#[B,>J6@D\P?J0F5AL$?#\,8H01RS2:`
MQMQ'TV"\YEK4YIUICQ/0P.":Q#E2(=".R\D0#R>RH&K:<\`C5PAY.)8)Z%!2
M$&G2[8<A3D$ZYK8H6*]#0<Z0!)_P].GNGB;-/TT(:^1!HPI9%I#0J`O*KR?8
M!B5/=,)W)EG&K7#E.-'6,0'S.ZMKSA'F>G>73;?BP'JB<L8(&[F+S(!D_D*8
M9["V9:JD7$EY":1<Y-6$>:)OOC#,@5DVPP-CJ?TBA9:QXI<.&C&=)M%D8#3U
M>&NO:$BU2-0B.81%HALOS/68)-D6&V+;`+W/C1\W7$#/>-J$J=)]B\YEY*HB
M+ZI^43N(6AQ57AQVM")$:J/#TY`\CV?K3GG!PMGCF7;M.`8Y'9^Q3T=/ZH(C
M7K-Y<XRH]8=:#FHY5&\YA+%*D9;`&Y!(6X@UG2VCX?4UL`C,H6E3G"'N+X7]
MF:B(E4('#N6M]_UXSZ`EY83WNM)#46*8Z)'6=\;/5&'$ZV^U$:P[A_<_7/PB
M6783U_DWBQ;WP'$9/">B#P8;$T24A"]U*A7OIQNW8X,:&_N]G_(^5)1K@EAD
M]/K<V5*O3G"KF-C[=PKL)`)/R9`3<BD.X&`HB1I$.'T>V4YV4P+&HWP'Z!CP
M:!?F*&)<";:%,!/^><J[_$:5R%).C4V-?D'\,88?T%%8)(=>8AWP$'X<Z!>Y
M[/+<(MH/[GG8$`VKL:DV#>67UX7(\3)1V7:FW=@A4`)&K(A+@U.;6_8-CPU=
M)YCPG"Q*^'%>84">(T\TX=X3;G&,GN=)U@.3]+V$<I3Z:6$@CM2%P2;8"I#'
MAWGH,7H\;/-F()7Y#DH4(7"\J$W3$CK3?*B1*+J8B&Z&RFD0USG44C*"R[T6
M9OH;85OBI(Y+AB@3P_',*VI_%LE%'&.)>YNA5($>_2\S>$E"K*_B0G3R2$'!
M$@W`!^T+7<Q1C#)CYU:NUT26&&AAJ3&622T,N%(710ZS%4ETEJ1[CIV=1:W.
M?]3Y3_;Y#]V,</J)9/-*:I*POX.?(TVXE8]]HJ)%JK`8@?80;2RPWY+A185H
MO-B,C2>6,V5,-``!3>7C:SQ[-FKV$:NWH:N+PJY4-)F4(LZ0K+J*]=5L`)IZ
M;(`EQ]5<G.3Z"7/M3A_[(X=:BM'O5#:"#U#-0/XY8._UX4T$G4_'3X]27_)K
M4N2^+`^/W^0[1-X+#1Q,1)D;-DHA<$0E7'BERKPV'7VZUS)$V8Y:J,1T0S5,
MU&4I$HKTYTST8O9QYCIV++NS^<*``TP2I0M3DQFP,%C(;W%DF&`G=DZ9TPLE
MZEF2Z/.)VVO?%^&AD#4D:_#/@%'2D*C.QT9?G"EB)AGM:-/TYC9CB0"@T3@%
MR%X'/&C?LZF3HFB![5$32&`_G1#*MB#V0P@1B(XNP=)_%K<RB%60.6K<C5*T
MWDUCP:,*+&J"^AP:ET`AO"9:Y*TS>'^FT4U>Q'A[WG\'9-(N(U9D2Z#,RP#%
M\0]52K5K12W:L\K=/$PP[K@#83OV:;C20YT,6D!6!8N*;^5O0[6;)2"F%S<,
M<:+T`2%8O(+#"VUR+`U&.9V!FV2://!GQF](0^C%TB<#4_LJH3,?FO`\'\W?
M4`4:RY67LE^5_9K7?GV0&_9^CAOV*OMUQP`_S.N<'%D8WO+,Q?`R)+!Q:&,#
MPX,2=;#>B[G@WMK,BKIVU/!XR^:EXF011FV[8]O7QH:GDXF563FNM(K2*ME:
MY2OX`[>8HXOW'SZB`Z;TR1[-+%%%2=7E8,V$5[`0=\@]QO@CH&$:_(K8F9_C
M:)KHXQ_Z<>).R/"P\)6AIX5Z""/(0Z;9`5V&2X<I_"T<S\.[8^E:@_!J2.%;
MF.*8$1STV)MBXMR=W*EIHKF;85H!5992TWK>X$+[C%]B=R+=Q5)."0_J@3_A
M=WAA,#Q,VHQ;/_,!PT@A_YV"Y[';R]ZPQ[X7GNG@":HX+T)G;@ET_/:XA"<<
M._V2[XU7VX'!.N7/R#=Y`GE^2=[F:0X$'("3_"0OC?7X]2.HP_NJ1<0V`=Z:
M-L6ES,M]45(D8<*E*9:*5$0A1<Y1*F?69"26R24)OHJ.QS+<L:)%08+-%T'<
M9UP'\3X-QSB`\N.B`.8'Z[=4-YK$`.$/2RN3Q_.S^0+)Q\^7E$'?_?/+P_7M
MW?</V@LX@C#8\CP!W3*']J\GR8*W.$_@'Z)TM]&<O"TKFDO4_#X^_>L68+,Q
M-&,ER4?WG'AT@XE+]-/BZKT/VO\,Z'\S"V%>*5^JQOB\'B<_M#O[J9LM#0%V
M4#><*@K_GSK]3VM,WI:6A9>!0LW6SR>X@&")P"KHK%S6BRY:3+-6HZ;$9N7:
M7:5CE+`<@(X14%*"7P:(\PG8D%50<U5JX@TQ%9*CM:FDQ&S?8M:ND)BIO4WM
M;246EG+A7V*=7&GRK-XFJI+T4?*AEH]:/A5:/IN;*KP=WH:4ZO<96Y]2[<T,
ME3N>8[F&G)0,]QUKD=UB/S8-PV+EP=[%LY-L],,FG0\<R$YX*+%[@5A=;[8:
MG=I%JUMZ<5"+02V&K2^&4R4(9;<<-K.Q-K0<ONLNUB3LS70H#ODJ:LO<V!^/
MMBQ0(-8P'6J-=J?6[=1++Q!J.:CEL)/E4*\U*[`<CMZ(V&OXX2&SWK+TEF<9
M=.AJQ[3'8IFO2Y\#=>):S7:MWCY7"THM*+6@5%3D*`R:O49%GAQ?MTIO])98
MW;9`G1A.\(PBO'^O8)5#VW+3KT2.YMI$7<<//;_HU#JMEEJ2:DF6C7['NB15
M:&@52VH7EWYM=>"*5/VK%@;9_-1V(RDWU$57>]+?V!ZOAZI,6>V.FD_QWL::
MCUSAS9VT'O\=:ZX?L5<!M2"[<HSX)F:Y6U[O\2K1+.^\7==D5J<?Q@?D%\ZT
M;WQ6_E--,]B`44\7@&E1[UJ#X5W5U",Z:FO&6QD,8`!&38*?F?_*1,>W@8G7
MXN'%3W&K->J]"]/@`+S1PISY;(-?5QZUGJ9&$=1U!D`U?=XJ%@C*&[;QW@;,
MUGD?8)B!MYO&+MK4U2%J_C!ENG1/21I^7N@>MQ,6#?9@0-'B%>E\IOU3MP)Q
MNR!6R^OQNQ[N+:8W8J+U770C%F].;`1X3WH&P7G7X;#5<`(&:FJ+-W-E71A8
M3NFOW'(5BP'8Z3EX#3K\8(JN('J\.E&&`N"UZ^.MC]2C/;&<X][#XCH;2OR=
MN*;'$@TJXY4!XN*+2^A1MK%E2-\UGU&:PM%$EQ#XA2ZNQ\?D)G,3UZ$.RM3T
M<7;<Q"CI=W']D1#&S:_U/QFU<$\)(/\>D>*+B_F!:RMIW-;F@1J2V6R`72-!
M&N$!(X,IT2])MH@;3_'2/BZ(\_NDVN2-\%[:&3)YIO6XMN:P\,X?(-;1&D@*
M#_8[M:UI8AD,\EQ.F!PF;/+I!1[.(7IQO^FP]7"=*WH`P4NTI03^R.%]2FK)
MC<EG_1%O.S8&VOI1E_%P)MZQT9>)G5S!_*+9)43B5.$-YF,DD`=1K_,$5-2Q
MW?,CHA(11M@Z1QN"GO>IYR(0:&`.?+I8LD_=TY%TYLCA'6.?&6(>[@J\91#>
M7$OM7T%3.+RY$&[U69SR>)>5D0Z;;+3'.2L+2M04M2;:[GO2;1$XBWQ=!&_K
MMAN72/6+4\[6O"Z4M)HDB_L>9G=0H=%B5G[2C@&^L;7_#6RF814XOS3D.M(O
MF7[1)P?[=\L^SG7O\5/"(Q+-?#-?_S:A3N!)'^E;XO6OSAF!<]IHUK03N=>^
M=LK[<R<:\&OOGIR)V=?.&Q?O/\B3HD5&+0E%U_Y[?<HWC.]A3^PG\*=$NSFM
M1WW)01I?3".\8T6[EUI0/^&^X</4V"4+ML>>Z(&MZ0-?].E]B/KT/HH^O??4
MZJYVHKT[`31#M$[>\ZU/!W@,T0`9((@?X!U_W0@.N16VS^%(W%07]=:FJU7@
MAWX(I3X+Y=Q6Z&AGT@Y(MX/HV0VXT2:)_4EL@0>[))C&.!\VG\-KD4P.S3"`
M+0M?1N26^MB<B\A\X&0>QI]00U1?W$!/+ER.]N$2W2*RT?U-!!^_2(!L":E-
M^WP^D<])@V&?->I@;MMXHPTG*?<J\(9ZUQQ'WR%X9-TX>"5;\OEG-C1MFWA)
M#/L,"I,Z*S8Z-9RU<Z9]T5V@LFZ(RP),ZGLX-GUJIO\%&8*N$UX)Q/GA+\2`
MF7@=S0?MG?X>?1EOPG&QR&&F"U8X346[?KILE-B6D*F8!KB\/^)3[Y[?HT&\
M8,@9-G'1EF[7D;M'ZI']&--(?,&`(B;:=`EBQ@T@HSN!Y_E]`BZ,KR?PXW#2
M=4"$:[+?O>%@3-[QJ5->WYQ$ES,1Q4/^$(S8;ER(/;>OR0#4-3087;J;.S("
MR>=8ZAE49'NIXG[8"X;@^<@[(FQPT:8&2R?>H&!-2AO9/9>WJ"%CO),^QN(F
M*-*I?]1^=U"&KQST$6`;>PR>?=*!S7KGM%V'S>RSZ>'=&W@-%`P7^1(\0O?L
M!'0-&*WXI+_0$Y<<@%A?\?O>&-?HB1G/Y!ZB*->AOJZ)X!P(;:9N2]_<`(^)
M)9JILKHU?E$Q7TGHJDRP<;6`$<<5.B!LCSI$*$_[@B[2396`SSB^TTFTP$:*
M>/%>`Z0?.:^BJ3^.BG[=O`&C&S*23Q@1W3W1%?.9A5NR(8+&=%WF[[W>_1R=
M(&Z<FM4#*$&9*D`$2M=7`0?M=FU5D53-C0)5X8$XH@A_>5%^TQX`_B/60Q@[
M8B]T(H%)_S%KZ'I#BL+X8#QY_/)=3]S1R)6=ZP3#4>*")"]/R.L5[R?D.](9
M0,5@2X*W&W5Y=YF1D8S[.\4?E)Y`!RS/&+1TJ7^LH#DE!GS`=K8?-7KFU-*G
ML/5\&)AOS/BXM`]M-+X;?3(BP90_NO'',#W@[[\$WNE0UR<?'N.[66-/XAZ(
MU(>]\`FVET\6N`>__?4O?_V+IOW=8.:'STZ?[FAYFDZ(HCX\],`&OY[<U]L_
MZHT?N($_.?76CQ9][IQHI@%+%)ED_&A>MD]^:]1/_^_OOZ3'DN?HA5;UM:4/
MUYBD<_+;0+<\QF=)C):%"G<FO]C&9Y25U:?KGOR&WY[66Z>M1A*SQ-!9<U_#
MEJA;_P)+^QJ^\=:8_9S/GIPW->S\F3F`Z\Y]<?+;];^R9I:&E>?F-M4#^!EX
MJ9CM?P7_:8UI+T]^>PA@TQ\RT"$W=O^,@Y`U^NSL5P"DJULW8&V\_1^;KCQ]
MJUX_^:U>AZ_/V\U61YXZ-;0\]Q5>+R+S95UQ:]4;)[^=RK(V;^A9U+^#"OD_
MVWFU'^FJ3F;<H*ISUX"A>?+;5T=&?<[0LS#\T[%`R^CN]-JT\.*#U>=NI>=.
M#9G!<DZAA]"^1K=A#7EOU4%[_8MY"99G#CT+`H%V!5P9XOTPJ\\,*NUQ#+XT
M<"N:*S2.97@2\\R"<1\\@VZ_MAR*94E`]+P[NWX)$Q$@J<F[)U1M1T]^>_Q\
MHAFL;P(T'FY$OS5:G?/F>;<M@R'-(P/QY.JX?SU.Q\^.M0850-<]//W^E<^4
M&"R#Z=2<G\);%*WT[J2@QRSNW1_U3M:4%Q+NO-&_C/[-U^N3W]H7]7;SLIX0
MBP63AZ"Z_M#^<&-CL(P4I^N,K\&O8NZ]CB(UASPMB3QI/ETNYE/W_!+TUM]_
M63)Q@?#]D.CP!SFO@8=V1^2W?Z&KWU".06>`+=5[,[TD4HWZ0J1VBT[/X.%.
MV.!TT[BQK_2)Z>O6NJ@U2L>O!\:/IK^(JU_6Q:Q9)-/`,G7!(K_#="8`ZLKQ
M_'G*>\'J:+264+L5$SMKQA293;RCAJNY\+%[O,`5+)]OMIFE75L_FEU.Y9O[
MNP1AP:,P#1,VL$?=8G<#6BX91&TG$?@Q8>X/TBXR*K`SGY\U.Q&%E\`98A4Z
M!%>1CP1B3H[`-'(#5E?8\/=O*5]S;?]06Y9!O>O(1#6")<!L<',G%D]+3+!7
M!3?VD#R[/`B1O`$Z<;M6E''K#"B8^3IR+&MZ"F:WB)!P-5+30O=(^X.Y0[`9
MKQQW<A;&GU_YA8?PE>/JTC$.P8!#?V86'M%0T)<N[-":X2%9#^];CH,&_`RN
M+T!-A&/B"X^895*.4U;R$9U\1I&6KAQH0=O!]./#)!YR!Z0P-B$_V!NZ+`Y=
MWULZ!84YYE4.SBS2Q1EZNT_>)S[[8'I_7E$Z,7Y:0VUWE=K>L]I.\),T-T\/
M1X8JO;UC@.,#1_EN;3J2EJ\KC"Z^EK0W758HL9)4MTCU=W%QANH]S)`?,8O2
M1##!\$R[PC1#3#/%XTF>-&K:TK:!\)A^P$<&O2`K633OX"\RV[WD:9I)F?B.
MQU-ND^#PD_\7D4=ML($>6+[(3?78O+GI&%.@@,4);Y2\+;:R:P;Z%=[XS"A3
M4[NQO<"E4\4KL0E1PH7-LTIQMZAV5'V!,D[K[6O==+'J@OT1YZ]S5;^Y\7VN
MM/B>M3AREXIJ6#)OH1=7!]W&U4%*KY=!K]>$2J8P(:C?6FQU3_0IZ1WDF\Y#
M!-%EX)17A<5;E."$_K_GAP:WE%PATA?H0EG7>:/,=M">*"<O)"=&P,*B*6_D
MN/XI%J=I8#V+;!6NA25X5<K2#DH=1<D#S[21N`4,B3?$.35_B2H)V!A'.C@Q
M>+=\G\FW)%,J3)^9F%3*DX+X@'C./=%-VJG)P1J`/Z=',TRU=UB0]6;Z?,CW
MX18^X8X_P$6I=YC%9[R`RP:2Z`1H4;A_LKA\,)HJ'I>7>M$6:R5\NZ@:4HPQ
MT5V>IT>>*9]=+L="7S=I?XQUD'SSOX*>>&DN%E@\8]ZLJ$><!(*2X#G./AK8
MLP]3OA&?EK*4(R8EIPX\&@H\1LV"A6AQ7YH/0=S`!,]GFHE(+A"1QE-7]FX)
MX%ODA]:0X!8^?D,J`_E/X*!52[).IJ;.\^BX+(I:9`-M\GZ\)"6YQAO.*T*/
MBC*PN0H#*2\<%KBEN_/TYRR/J=P\7K$4J8KT@>+N5KG;6LS=-%\2FOK=@(H]
MX6&+Q15TF!<.5A'H;/%RM&&"0`1C?NW,^RK[@[F=O+1W>.]BU:$_Q9BFW[,-
M/'F;Q&]OXAQ>*.=P[R<SG+FD\"+.*B=PQP`GV,!"-I#RH@,1R9NCSAT#=/V"
M<6#1;P:;@-5NZE$?`GV,R3G_Y5]$^?Y1V7K?&8_Q!`.S^GFDT+1/PWHQ;BA_
MEH>$Z2;9`)IX!CX&A8FI\UZ8XX^9;]@L[!04*EKA_@@KJU_"<B*/UU+C&VP0
M6+#/OK`H3(<5!*(J@6_%L[!8H,`8]6LPQP#7BSBR6@<6B\$<;E1J-`O9(/1W
MY;DT)RRVPY`HS83^L7B0P#LK-&D_F2#^)0TF]YL(V.<I=B[PO+CT#LBBHXF#
MO52\`W`;^"XK0/Y^\_GI'Q^T#FZMHBG<U=WM;>_^$8#K`\[ZQ&,K3)YG*TXU
MC,WN42>WCEU"ZXW[^(7=]\)&?HU)V'4N[`+W#(MEU^T$GRT=;`*`9>DUW)M`
MB:FFBQOP9[?YC5OLH<#<P9"@)K&X<3D[YW?Z$])XL7J7P;O!`'4O2VS`RTDN
M)MS3E:3A[)>K3U^D;FPEE&,Y9&%5@OS!#`H5Y!6`W;-[KRSN'`"+KP/7-BF`
MCB84N'[X>=G=(4?&Y_/U^+R+GJ-E<>.JYME\P_9)+O---S*=/=UB-9&"Y?%\
M*=[FP5C@U5#;K;%#!Q/8$XIZ!>@6'>![(\9\T1^#B79)U*,">S-AV!7;&Y(#
M-+!XCR_\/FJE=*;]@9D-S*;!.#@3W73%<=H(&Q=0&%[JOL2SU[#N(J-O8'6"
M0GEC.^F8T,T8"80/WKF?36_B`$_O!K>./;S%LR-^M+QY?.A2Q8?V'!^*&8WN
M+3+XE#@LL@?V%RAJU<^:Z.=41Y\6!+%\CLA;-*#E2)T!7TSVRH\HJ8$KJD`Z
M+(Q2=2WDGT7\$^<<=&`9US+S<V$Z[NB;+NABK!?J1YT23!LG"SNAY&@^:+HS
MH.#1)F9F,4,\P#OMD9KDC]2$#L9HE4?-4X0$<E4L@,;T71.4*C/B/K!GVN,$
MM@SPI>*<N!!HQ^5DB(<366\U[3G@H3:$/!S+!'0H"8Q4__;C)J<@'5G[+?\O
MWXJW$T/A$_)F^O4P=)!GFA#6R.5'PVG9OA6WXI>]Y/GA%-^99%GCPO?D1%O'
M9LWO7:\Y1]A_I;MLNA4'UA.I[P;KNQAOC+H@)=)"PO2-M4UI)>5*RDL@Y2)=
M*<P+QH9#Y$D`LVPF=1R/TI5,C^?.8`I38J3):.I1I"4>4BT2M4@.89'HQ@MS
M/29)ML6&(.D#\*;(^''#!?2,QV.8&M^W>%?C1+])?$+M(&IQ5'UQV-&*$!FC
MCBNWAQ.-SJG5VS6V_D:GX[,;#+6>@?F>7E3WA&FP#O:)!)]DB,$IQU7+02V'
MZBV',+@J\BCZU,-`VD*LZ6S9%*^G@D5@#DV;X@SR10EZG[<R=JA_#Y8#]/UX
MSZ`E%=\R(W>LIY@LHXR-9ZHHHWZQNC:"=8?-:>)>]W->),MNXCI8["96Z<!Q
M&3PGH@\&&Q-$5-O0YYTRP[MNL/3!\QP,+D=3A]>-G,*@1L"38Q"+C/#NSI9Z
M=8);Q1P64//N9.`I&7)"+L4!'`PE484W[[K'C%JR[)&1?%/#9Q[MPM1/C"O!
MMA`6&&#"##[OA@E#4A*0C;U"4?SQT"&@L[OXRH7$.N!G#O')A"@1D.<6QQ/@
MGE.X#7NM&A0Y%Y?#..EXF:AD/,.VM0(H`2-60*;!J2VZ76KH.L&$)Y%1AI+S
MB@V5J?2`:!+=UX2GD]A]D'+7!R;I>PGE**.6[MD@=6&P";,-$1_FH<?H\2&S
M&2_N!RKS'90H0N`@8OR-)72F^5`C470Q$=T,E=,@+A^II60$EWLMOBU$]\(*
M&$G')4.4B>%XJAC&3F.YB&,LM>@^E?AN$U[I$>NK\#WAD8*")1J`#]H7NIBC
M&"4<QR]0*E^<?EP3:6W49?M%-RU1>4(MML5-1E0[,EOH18=?V!,M.SF].@=6
MZQP\I0^O'F`!84.)GFU\QB7@T(G7%UY#Q]]=_:RJ65=G57L^JPKYRBWYF+/[
M.Z0ZTFSF!".,F!%AG2JEZBX[5@];@'LF[N(3%W0B'<I@,C)X=8YMP^85%K[6
M,)3!KZ/B9T?"3YN&UV!P9>H%DXF567Q5'0V80WO-G-:38?NDOVU\(M]L*"UW
ML(W'U9VV)2GT5G?:JCMMU9VVI098W6FK[K0M#\#J3EMUI^UAWFE;42=MGL>5
MZ-\L)U\_Z5+R]3<JZ[PU!ZSQA&-OXK`UR^JP;4$-JL)851BK"F-58:PJC*5I
M56'LP1=,JL+8X^!S,86QY;>?U[2+<[>LBD?(8TK_X+M/]+9\7\K<*3Y-\2;!
MV9M3FJV3W^Y;_\I1>QD#N2V\_M#M`-."J4LE`$BI,)MAUP;L.N7`+E(H,,:U
M4">;(=<!Y,ZWA%Q\#_0F;E[5+DM`DS:WT_,5K^5HGVD+FI55VG,K*<!;.VB<
MT^TL.NP783?NFH.&.@#GO"B`N4ER2UY5$@.$/W0\DDG2LUG;R<?/.XN#!'=@
M"U[?WGW_H+V8G@F#+<_6UBUS:/]ZDC0'8ZOS'\*Q;30G;\M,RH1'_/CTKUN`
MS<:,-RM)/LTG^ME`/Y?HI\6V[0?M?P;TOQGIG&?HICSP\WJ<@MY)>;&%N8VE
MP;!1`(*IH,?_U.E_6F/RMC3L4082-%L_G^`2`"$'.>[,T(-NI(J)TFK4CIOQ
MV=ZE6N>EQO!XUKF`DHJ5,D"<3Z&&K`::,^1"2[Q"DK`V&92@;"XH[0H)BMHA
MU`Y1U,(O`X+[5'R5QE])>$405!*N)+Q\6S8__M^0%/T^8^N3HKUDPUXSPV!_
M6(Y-P[#8`BR+7M(E8V(&>C^M@96+MT)DHQ7F#3WPR3MA)'CWJ&;(:[L&JJWT
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M:G^8:/EWIO7HFR2PM;F=!<?IE!/1E!#;(S);FUAZGR`&OHK.[P@J7HY"#5*Q
MZ6#RDICX]6%@2V$R<1L,[[9;Y5:$JS2>R-VT8I-6%>=E;56QI1X*%="1JB&#
M:LB@RO#*B^'QU-_.)8%JR*#*;=4Z/YAUKAHR[+UJ\^@%135D4#M$U3`\^G+M
M8\=?27A%$%02KB2\?%MV!9)=5$.&<J&G:MU52GWIT5-"JH2T"EOG=NL^5$,&
ME?E^O,7IJB&#DOECDWG5D&'_>[IJR'!</H8J45<-&92T*VE7#1D.:!/?KF.N
M&C(H%T85K*N&#$J^#UR^54.&DNSGJB%#&76;JC)75>9#U9!!+16U5%1#AHT;
M,AQ:1?;J==B_NX[G)6NP>]Z='=5>MU.UUQ<G6F";_,EOCY]/-(/U39`*#['[
M#1A6SP$F35H<B#]XPE_TPA]L_,S<P,-AYX[Z:?HTG;#>F^FE,+PL(X8B+Z,8
M%%OUA2CN'K]4@7^KL1`^6/#[8$*G4#%K-<LG9IV"Q:RUF(V=[@9(]N)(J-Q_
M!#Y;##_``#TI'CIW\/RJK]5>B$XS@4Q1X.T![?1B["Q$N[55M%U_:..@;L",
M:U>W^R/38]Z3_L96V+-:W67J;L$TFT&2IN7YXA71YBLB!S@AP1^#9X_])P"2
M?7G!WC@;M%5I792UK<H<,)X=R\C=R..KXS-X^$R+*:9QDLW8@=N#>)6F+\^A
M`6AFF+IF9!U&CY4>A4<?Q/+TD^XQ@WHG,=N+CZIV@%`UN\,4"_"=K?4FKFEI
MK7I&GRQM",I&]#0S?4\S3-#@ON-ZVB"PK.GI"_/@5WB%V:?8)TQS)M2""Y^?
M!&Y_I&-C-%O3AT.7#6$3P+8_,`=ZK]Y(=QGU`>H[X[%C`W%02^D^OL#>F-L'
M':<!;'UZZZ?66:NCP>;`7ZSA^%X`T.%<"#(`W])PWZAR9ZVYVCNQZWQF7M\U
MB=1W@T<VT7GGLQX0F<WNY=FJ_L==/[`"3[;G'ACMT_<Z;,!/P'@/]P'@YJ>I
M_$N&67=Y\IL700',#L%X9GU]S#3P]WEO."V8.&$CM[$P`,)&4#?W=Q3Y]ID[
M-FV8#42#/PMR99G`=WCPXJPC^M%%?:/X<);CX6=I+,?57D>,CP"@^28,.`[\
M0`>YY2"2X(2S@7B?B7UV&75G=EQS:)O@!X`LW@N9A^4S-GWJB!8/EHLKMR#N
MML?`]'D,)A-K&LW*&84`AH^$O\PRI`VF`V<O+A;+TF#Q!P/X,7"I=YWFT=@U
M6FSQ0N5K#<1/MY`VS?K/FO/"7,$PST?R#AW'H.7-QY<D-R<5TM2;)W09K>16
MMV#:C8.W8"[/-$%"C6BHR42LR"94N5WS$QN:MHT:Q[1%GTG<?I)[)P,5YTR!
M+["?F6/L,HEZ9J"/3=!`8UK.H<*Z&IELH'UY8_V`]"2/*[C48M*66EN"ONJ/
M;!.<*%MLE+IMXW+U=$MWISB</IFXSANX$#Z#:0IM$MKJSG0)G=UKR\FPRDG8
MMPEM&!F[9`WW12%SW9KHORJTO?-J@[P5R7.-#@MFN\/&UMN\MJH)JPYVXZ1@
M%@ICNY4`[N<0+!\-`+#A/!\V/5RM,DQ*=+?G4G#Q1(7(70HAGM0U(>REJVL>
MJ#O7),LL=A8BX_'5]$?PR`OU!C9M=#7`\4C:_:\C$^9!5D</\!&,A`=2J+"U
M.ILO!VYW1:Y-D?`US\X[2=@BG^DL9DVS%7M[IH?;!S>BF7$6,LMEOFZB.D&,
M7AQJ7TP'HE[H<0E*A,@'MF_R+L[^R'6"(6>,(;R^E(G^!W.'S#W3;H2-C]X.
M?-+]+'N>/ZP9#IXK.F"']D%P4`V"6@$J8J-J!R1PXO--->G*IJ#,RZ)7$^QF
M<&`<<&#(V=5\5S?(>404\:L45>@-'ZVO`7-#&H4RZ-+,7@"TYX!41OUDR69X
M',O/?T\RXE';[$6_*RSET^EY:&^D[+@3>QI,4FHON7[S<F!&5R[#BMZ:5:<"
M_EB/8J?V8G5HH]:MK!8-5W9,YB#;5N-:"S8LUWDQ#5*D`'&A=%Q`Q+$^!?6%
M^2'$0\=FJ"W'CBM#'BE/H7!!'V=K7-H;M.>IU@N&@>='TDZ&7309^.;\G@"0
M:!BT6]?ZL+'8A@XCZ5,/&<:%*\%3`SQ]ERA'"AL`%+H79M:<9\L<ZC)98^CE
M+1Y_$8HU%&`:A>]B\_>P2FQA,SO8-G:JB*YGLPI\KC:O3F1UA3C33(`/G6M0
MW-_U(?-ZMB&\<T\^LY@3FVI*L:G6CYLP"G!-00`>TKL;_*';,#)J_SOWWC7M
MOCG1K3MPY=PBHK/MQ7D%K>29>QY<9^B#8GCC>0$S/L,>9P_O06<YQB.)*^@R
M^BEU*`I4D:-WS:[(VRDL*-V6<PWXRI$QO_EZS4_HD]CGPB2-_Q\F[,*F/[VA
M'=_SB77>R)S`V]@I#DCY:?K5L9$`KD.WGO!',L^)MT`*.4\!-":3"=$\^:U^
MUF[%-%@;FXQEP^X&1-*O`9=T3DA.X!M;PF&.<'1(.&#E%'QBT>XL%P[P&](K
M(S<Z6R<%WTZ2I/!\-\`0/XJMI=N(=9$DZRXG6:.['9K=HXT'XD?O9BZ:+8A(
M*C/C!QB`/PB`U.I!4S$3XP34A6"W!ZY?;(4*=,ZVBG#<C6UVY_X!UNM-:*;<
MH]7TY%P).ZNDJ^9R^:H1:Z9XFBR0N<099U[E4_S)<0<,D..-`&6NEWF<V18S
M=[\F.@U@NG(SC][-W$S\$4A*'9,]DYX+;W!7ZM,T?N1>GU*BQ*ON&G<\0^EW
M3&SR;FQNX&?D04<N'"Z7]H]6G2^75(*.O!Y2/V6G0'>:.<RH3M*(*A[5E:GI
MK33'=X8"P(P>!B2'[(M(YB)38#=4;N4T6S"I;`5*%T>&-`=N;%Q83_I;(7DO
MG?;!Y[U<H$8D941IT%4Y9ZC:8>Z3E-!BXCVL?2LP^`6NJ,V_G3V>:0-F1!>X
MTJ6LVKLKW3('CFN;^GO-U]]P?PQ<V^.'NIA)>NVX8]@4P$3@VUF\#293&Z(-
M+MP=11;$F7;O>/XIY4/(23<#T\*K87G6'JMI=/1_JEL8_Y8`.=-X?">ZX3;S
M@MM:*LT05$=T`6UH1T0SZ\:_`X_NMO6Q^M$/TW;@70MWEW>A-=*L?_QZ=QO]
MU?CX'NP7UYWBC;NH2W"G%#?E<H-"MX((=7A3TU]TTZ*-5^RI$8-LV(8IR6]"
M"F@[AXS'N`1B.?""\5AWS?_"6]R<(1V$HD7G/!Z:D.^>F<T&IO]^*Y>:;H_^
MB5M$Q<6A%_7%%X?FGCQ/F#_5X2.[&#JKU\?KR/39*8[./MC.JZM//FY>19\Q
M:/(<&'>M[4PS][*1Q-3Q963=&3!`P9+D_HO2I;^@=BL#VMFM7$K(Z+#`/^P5
MT)C)`M@>]U-M"IXM'8Q``&#I)7JYI2/:YTI+(24H>Q"4C2Z_+!MQ#IXQ>2^;
M+,OBC?N`H"5Q]_!!<X?/[YKU=JW9NJ@U.YWW\_J?R`M\9J/CWL<26FS,Y70C
ME"UTHBV^M>_Z(Y8(E`K0*Z^\TTK,(^3A$.$RO?UR#4OR<C(+X57@NLMO9=D^
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MW9@<N]QI^"U`SW0+4#]]"]"!Z=%F=Y/SN"/;=,J:EK"%`.Z<DQS7Y"$%P[%%
MD\DU=AUU6B`&WVRW4B<YV^1-<5'<'9S@;.=4=WY2$N].E!$?/42MWZJU+^MJ
MD\Q+KDV-Q0/9+/^IDATV3^';<.6I)+[M\&5S?W!W:7PJ]%C:4)JB5V5VN&69
M"%^SC\O7U*PJ<V13?:I2>@Z1,=M-Z3FV+GH]S<7NB7W3,A-]EK%A9.`[V/Y0
MM)&46NIA#\=4DT..N.CI'-\L'3UM>M@IFJ<6J02B@TL@4OWW5`)0Y?),5*:8
M$A25*79PC#G.3+&U,FB^O$W`4`-O-33R8K,/K;:<A#S0?D.M]ME66@W]K,BZ
M>[+N+&PT`QCO9Q,Z0C7>@WX0K3A1^+6$(H5+P"YBA.^Z:W-Z]56C*%3,`MAJ
M;Z>X##H.$7B)]7&(7*X7Q^3#7`7ULU;)5D'QV\`]<\>ZC;>JP,AC3SO5O&/*
ML#S+ZRX=YQ+8F8HHQ38PNQ9LQSXUF!'`EH"QUC&_+X^]X:+(N$7J(#B>UT]5
M*Z(4*V(76X*#-V`>)C<;2MH7Y0L69P%50/_WZ$XVO*41/6&\.\T(Z$`Q=9/;
M(7*Z>]94*^&H]+[J$+;SY,Q6_>QB32G*QZV\,5S%D9`CEQM$?3?GB$J4+4H_
MJT39BM"K=(FRA][X;MN3%FTOY>7;NGN=8LV>6:,R98O,E,7,P?!:<B_S7G*Z
MM`034)(WD(]T0],GH/+>S+'N,VNJ_711JW>H,3N]\E.SUFGQ/Z6#X?C:]HQ;
MRZGBW'EA[LP%YE[T9^/C^YKF,F_"#]JL:0UU/<#[S(9X3[R#\573)9^C66^U
MSC`QTELVG0XO>,'SO^D:=`>@M`,`UC+'ID].BZ<%0!I7N\'L'1M^>F`OS`Z0
M'`8#>O;)LVE=-`&,OA[`?!CS8M1]\)DQ<'JTH<L`;:2V;FN=^L^:\VK#U"-S
MHO6YEY2\_WW.U?32K?05$;'*K0FI?61-TP?(-`S@F"``R`'P7S7]13<M2J!F
M+_`].+,U;1!8L`I`-)G[`JO(]#/+J#7@8A^DT\?D\;$#,F*9?^+R(;FP'1\_
M@`L2D$B3%>%IKR;,B;\],YA`M\S_X@0V3.D',`*(M>D8WME,XTN8*J#Y4=X9
M9JJ[U-=3&Y@V>.`F"+++)HY+:P*7IGS#?.!.G/"EG"HB"0%!#92#T7D@C/$@
M`)M+&PJ6`;W'ILU@63-<1!H.Q5<((J3U3;<?C$&'`!EA#3N!!8J(SMT)2DX>
M.>O?=$,Z"7J>:3<#P8!HM@QR<D80=5`!B(6751F0R68`P1M,9V!"P`WLJ,'5
M:498A-.-.&T$?1A5[_<=%S/GK:E:\SMH&6LX\#2NMI'^PDC\:#V`_N62@`N"
M[SE<B("]GF.#-ICB0QZ=]9'L((-]Q\=M;^P$/"X\I/X*@8T%*D.;%C*.GESJ
ML`QQ4*;!3`83GU]-?P1"VFB"VK#]$4ED<AWRY3=_[+$^30PM]ATC<,--QV9O
M/BUT0I(?X!`JNFMZM*?B4R2-NCO%U>?B4`/M.0"]QKP,'<0LGHP):]ME`_P#
MAH%5QSR?],:$P7[JFT!RW?==\SG@A2GP>*R,D%FB,@<`Q`@[?)QRH&I8@J-3
MKH%CB^`[(FMF.6:H_X026&0]AP:V%9;)/`/*S*5*EC#/UC3\T8=&'2MFZ)E3
M2Y\Z@?]A8+XQXV.N"ACNQ$:?C/#3+_)'-_X8&KM__R7P3H>Z/OG`O<\G_>VS
MZ:&%`.KK"2CTR7+Z?_[VU[_\]2^:]O?PV<?^"!2*Q>X&5R&MO+M!-,(7?BS]
MB9/G">>*AB(M#G\\L`%X1/7VCWKC!^K[)Z?>^M&BSYT3S31^/;G6P10R?K0Z
MG9/?4JM][16JG93)PJ^./HOM22\8CV&Q_)?Q7MB92R.*6:@Z-E7'MM8TJHYM
MWXP^I"H85<>F!$75L1T<8XZSCFUFH^/AT"6TV)C+1W4TJ.A5DJ/4ZEP#O79/
M[9F1#O'VY^I29Y>7/D=2OK`F><6[G@^T2K91.^]LJX]_WER+@R5M'3RC?9!6
MW;I<S?U?T:M\FTK.NGL\-[&<OG(@U(*HP((X8`=B"^P\1$_B`,BT2Y<B$=]:
MOAA6]"U4]49H,[?JEZH%?>FXTKC8Y-ZJ73:@5QY--@>!?]U6D?>$+%M$U213
MH]9L[)!,^[UQ2%6)[DA_;KKXU.UCV^7/IJM^+[>0J7*Z@FJVCO%N`\68DC)F
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MW++,DJ_9Q^5K:E:5";2I/E4I6H?(F$JG:.TBKVI^E\OHO<2X22`VSM$Z+VN.
MUG&TN>QI;H*?89=F+Q2MJ/&\U//2I:N9G;GMG.-;G*.G30^[S/)<,941=G`9
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M`7ZKQV@LF;H82!?E65]N"=+P[HQT"OJFI.W6%P)\VJBW0#0EN/,!4BCX"^C=
M;2P!_[S3+@!\P2S*,>C9QBU>:54$\9LK2LMB`(J$>A'-6UN%.N10XJWBY+V]
M1&`NFIGRD@>:+6"RB`V=Q9BTZI>%81)5C/?"4$DX&KS:PWHZ'E>YL7MC)[#7
MX4MW(3:-9J.5P&95B+:$T2+^G"_$J%GO%HM1<4LD]VZ;4WJ*$_G<NVM.R.["
M/G6WCN==R?V"DL#UO#M['KG.%^^@C7;S/,'G^7,6`EV*9.>+-\A6L]E>$[JT
M='KP(?Q.4/U*2K<`C2.8X'T93RQGRA(_KT#OW)MFL1#N#?\T1Q=OO\UN]@:V
M(R+$C;BN`"'7?`[PM767UN+->A&6.>#8,BYIMBW>KK.MU$+1X9V1\A-_R8Z<
MUFO9\VT,59J,BW?55AN-GI6AFJ_U9G?E%2BX>"-=86>8A6)+&*2IO7C#G:'V
M)AC,<.K6U)]-R_1-YF$/A]QDOUB\(2\2CN24Q4&8(NO%XDUY?0CSQ&YZ8<PA
M*FM//+RZO7@A;\B3P&4R.BWP1.IGK;:$4P%`[@[O!=;H1:L2>&?[>\Q;@]'M
MI0C7NRLB/`^Z'6"ZB+6=<F,:>H)?;!WKRM9?NMWE>-9;J^&9#=O6L5S$S?,%
M6#9`WYZMR,KB4(0OKT"]@[5]ASF):W#P8C$'`;?&B@Q,P;0]M!:Q['(I6O7&
MSM'ZZMAQ]K1PGA[!,F>?L+I`]I.N'&^-R,MEO6!!70W@O9%D@2!<-I8*0K.S
M"Z)0CZ!UA_^#$NW%']X]<['J>@WY6&1IA?)1/*`[)\$B>5AB=*%B:&^3".OL
M$S-6_#*?+)<P++'&P/J\7'-?RP'O?LBQ2#"6F&Q`COK%GLF!L1O3#L`_%HZR
M8Z]AAE\N,MKR[1)9@!2.PB)F;6Z1Y4%!G#\6=C)RN3B@<SIS2K48@$+`743E
MQ=&;TYDCJ-7`G5D6\Z,_C\'SOX&'3PZ,:+JK!?S;]<7QG&:GE7W0N1Y<.\.R
MD\)R<4SHHM[9!I:T3\Y_,WX!=D'3,5:6P7:]B4>=K9;8DO-/-:.._A.8_O0/
MYH\<X\9^8;RPY>[59JXW,B=BE]:'"^.S/V[N[_Y@XV?F!AZ."I3Q3,/4W>FC
MCKE/=+U.[\WT4D@L,CI(7<DF:%Y`9SI"XN0CQS+@03[(`WN!SXQ^>)Q8,SK@
M4E)9ES^:'?J<`KU]\EOC%(A\VI2!S#'7C'9RQF.,8L#O][I[YU(\P\"MD`%.
M9$!GD'X>6*G3D!\@%S]H#)FT;6[/R9Y>#B@6`$Z_>W>![_FZC0ET*T`L[[H>
MC2.#>O/U^N2W3KV>C(<OFCJ3_3>>%S#C<^#"`WP=\/=FN)/>=/.(POER#)II
M#%:$:BGM>P&L"]?\+S-F2=^HBW7:^O'TZCR-G,`#4CV-3-=GS+ZW=%M>NSU4
M&T_3"<M8KQ?+,;V\O&AU.@M8%4,ZPZE,9['GNF@NXF+_-(T?N=>G^!5!^YEY
M?=><S&X,H*$X^SJD21M-^OSC*WO-00C\^ZL^SJ+#Y<EOV(51M^V`MQ9U&<"$
MU4_84]0.<!"L#>0TPO]8V"I'8__!YT7K43!Q08G!8Q^T=^9[K5GK=!HU$/7P
M+7C_`6AE#IF=:$_:)XKR_@L?X55X=X"=2";"]WO7^?E]V`=U!I0\@VJ.M)!U
M>L<+^B/-T#'3'K['26%6W=9TGL1C,)^Y8],&Z7N>9D_P[`"C<"C#=&'3=%SO
M3%H-!7!^!]*4N2]ON*8:]:)E20=9:C53DC2OUVU*F)[?:YV?%PE/GG%RR$]_
MOO3,FV%6@#3'370>(2!,'QBP;=%:I+Q!N=!/Z9UD.ZJHT5BNDKL7G5:K<9ES
M\XG@7PEK_OE&2.]G)J1X)R1H+B=!H]FJ7W32AMIJR*3I<>\Z?<8,[]IUQC@2
MQBON!M)^-P=[KCV:W4TLY\;B9*5&M]Y,II<O!3;AN5`RQ])7>K;Q7<>%-&,U
M%8KJXF2EQF43L*V'`=J5(4]Z;`-P_D`8,F+JA:*T.&<)UFHGQDB&::D9R"4Z
MTU7;$.0<9GJSVUEBIG/P$B1?6S]S]^K&]GPW($\03Y^>1KI]1SK;2_\.GC`8
M2*:'R5Y?^<ZV!3+E\`5:]?9Y)V+O'O$/^6"2-_TA=JK#M2'>8/>N.1,ZSEP/
M*6)<K.B,Y@,D(3Y7EN.A]L8?$DM\7N`B%^"+3DD;H'/0Y<\[_?ZE_3O#^CYF
M],"K!(`6<+60-="LYV%[\^2W\[-F9Y^K8!%="O,FOCH"E!E(I)A%#GWTS3:8
M^^J:8"I[.5V+9@[;\+()NJ@`:WD%-&<V,4OWO+N!6.MW[@-PQ?,_@[.`^_?W
MD=D?A7J`_YA@8JYM>AWB48"UT3FMMTZ;<J!L(VA3NFMV*)\';(%8..0^\&X1
MWI<AWIM#.K.48N7!!0+^D*R#&_L)1O(0G)P.^!VL7SPQY`%ADL)UU%8[AQO1
M:3?EP]]54%E`!M(X"X*]A:.:-TK</>MVY=/=>3`OP.T*E+!IB)/$!]9GY@LS
M[O;%XR6Y]_7F13)*NPH>B;7]Q-QQM&!R8?C`)B`X:#/@F>S=8-[:?3)]!.H&
M-.J+:02ZE8'F^<EO]YU_B<6;`&4EISYWDEFAP.<(,F/Q<4Y?/C,I35ZD^1=?
MD4A>YER!EV?UKIR(-1?RY3L+T(:$=XU=-<>!9`O6SWWC7XLVC%4`2*`3&]-W
M`V'7?2,?(>WJY@)T4>8;KQ)8-FFQ9ZB-5A:4BU+2FN@R-<X+.!LM!/(?]X$U
MUGW7?+NQ^WPA&,R\94/=^F+[,/ZL_+<6G?P2>A>M`M"[TKU1!N3GT9+F*6G"
MBT,[YL;[ZMS"?\F'^-_`FK8:^"#'"N4"'[H;\/<R\%H<K+J<.<@$`',"?1&1
M.P/HW@!`CL']%/@2&KU@&'A^H[42(HM#5!<7Z5!/!B)%A,D%RF'-9,\V/HOP
M_XH:MY4C@'6YPAGM3)B<!^MB9X?>%HH#P'X`J05][6.C`/CA&X#B/=&Q!^G$
M58\PKT8F&X"^[`=\+QK`5I`@R0.S\`3_7G?]J62D>)^F\B\9=`+;0=>L8#PY
M]8*Q-N$^7G@<)4YLG('V4Z=]7NO6ZS7-8IZ';;&`E7BV0TV`M5?3'V$>!!#"
M"X\,WVO2P`S6]`N85S!:>!7CE[O$@0]LMF,S&'O`-MAGM:N[3P\];>"XFF,S
M;<ITMQ9"Y>GC$#2/GHB^'#/#[.L6D)3[^'@<%5W?(,ZF\&'IRD<37A/?\C[>
M9V$@M@#>[E%8KN%ENV_J5I'"<I%36%JM<SR0+%!8KH],6+)>^YVLISVJCD@O
MATH9\$-'*;``=S\,!>'F##/E/]%K79[\ECS>!JGA)]&8*7'9JM=`4<>2@H_\
M)W!\DX7B5FLT._0,;0CQP?)`-UUMK+M_,I\:U4;<2YY?1]\]TZETGQ]'YQ2!
M&LDS/_)V(ZZ)H7$+\C0T8<3A>'BG+&&F2V?N<UZ=1Q<]19?G]QR"I0,2L'@8
M/QRZ8++Y3!`FFNBG1@W<+1HY2CX8!)8UU80)KOM+:2*MZNC8/YJ@&:<<S($Q
M"*W]?!P`G`#,%\J(@.E`-D!@F0L0/^N>"4/`^N;B0,1'3OBOS(*Q0`;\D1<N
MXEQK;INK=!LZNUU?N+A:G<Z2Q=6HU;DVW\WBVMMR2E"BP.74[*C%M&PQY3+!
M^??7COO(W!=8'HM=B7HK2C<16Q0,UP,FT;F&%SM&T7?9`?)VCE.55GL%3V(&
MC2T2H5$OB`@Y<FZ:G2*(,!.+261XW.O3!8<A21_RKA]8@5>("EV:M][("")E
M`9YFM=2&H@<4`8NTL0)NCZ"-;YD/JS-B7WZ.+HY<=!*LS`!S4784AM&]N\&G
MP`.-[WD]V,RP%`R]>7B,J@1?&*^VR(7M'Z9MCH-Q@I5X0$DF:8%L7A`#.>W@
M<4$JFK,FSKLD78'467"6(E&G./+PP+)\#(/J@K0'P3U@[J<I`)NS_O7''_K;
M3J1H<6>E1D=0:07TDB:G,]4M?_H[;,NPF3+F75$6+.GSN4DPV12Y!<5K>\B#
MQV`RL:896B1\)/R%B+5H/::(L:BM`L5]ZV%)4SZ\2D>*!4*5(L62)*/Z67,M
M2L3)=YY_-PBW4P$L!B#F&`K9=+@V7<^_'^E8O2VY[H';Q^]B0+Z\]:W`H`(T
M>XCIW/%/1)<UZ9DD66=!Q2*IG$XZO+Z,!MLAVKK"\XAETL;FU$Y1;4$%Y"%0
M#3/&BR?:@FZ8IUU,XBP'T:Z=P/5'I5F@"]+2D6HS97"YJ4:*\#JPC2<'3.<K
MYOJZ:??Z?71^A2V]I/ZP$16K%K>W=Q8;S>==:6O/#WQQ.(/,-`O'>?')8*?5
MWAAGV6M*6T!@%(V96SXSK[.H>P2W;#H93N$B]!(T$396E$.1M@WS95$5ARZF
M&+4;?S0ZGP56RP!,<EAR!<('>K[%=,^'%[\Z/D4GQF-]K12/1?=:X([7NI!M
M[E5@F4WFCMZ(W&O0K?ET=X'<P()4`0C-C0X44`Z]JZ'FCS!,9[-3"N[192_:
M./!\C#W&SU+@DD=F;4_$>J5:O'D%>/B:.%G#[*B^:S[#8"Z>V+D\J$2';!0\
M]2,0P:_#KV'&\%2.3731VD$/*8E'=F+3JM$@[$T?3RQ6@S=$F'0B]CF8&Y/9
M#=,C!:.-]:EF.SZ\@:S5^ES]A"6RL/*\6NJ(4I0XAB"Z\%9JD)]:M0MQ#@)#
MV8#!1$@.QETY,VL85'UEEH7_#6?EAYP)DN3"_TQ[FO,+OX'*`'CYM)QY$9;F
M<(C1V?Z?,.G0]'SQ.G&>8K[!!$%NU7^6T^^S)7E^(I9TPDFT@\5RJT_`J=^3
M2NHNZO)&G8H:EY=9R5U+$4D=\9CCY\#UB$1W@["=E8#MR5F"?:(-3I'8+^YS
MTFAW))67%X=DZ$7W1I\<.T@KMPL)LPMQ?M7:7H+*DLM=&IT+*9P2@CP39]71
MSA7M6WYW00D8MUCCF;]C=CMQ78OWGX&?SO6ZE-(VY\XW`QA^2UD"()V68$R*
MX$TILM?\T<@$;DG1Y'DBFILUYSJ`+6_UU%YRNTHSZ1X4#MD"HV')32GK0!9W
MY2%>7P<^:"5A)XGB&>]SD)5;V?W1$B<UF-D..P=Z<"^1-Q8GO4L_9<?UEUR7
MTJF?2V*:$^"$6KB!P4W=N@^>+;,OBE4'0^H<@RG2LRU5\DC)D@[O47ES3@BV
M`/`/J=@OP11LG$,.-V6_H/4$IA?0+8,UB_N(-;N=O2+8,PP3-3*,I)O&C7VE
M3TR0]36177:="["T?M[:+\8/#.TG9GS171MST=9%=6D;^J)P'-)CZ2/";<GK
M>9Y#WZYL9RR`.6E:A#<PO>BF107*C@5ZYLGYC!%1NJ4YH^U;'DUROO2H-K(5
M<L)0).`+MJ/SI6U(Z]WF.J#__?]W>GKM.#XXMDQ[9+P$"V8Y/0TQLTS[SP\#
M>`2<'W8+?VAO])7KX+V:(]^??/CEE]?7U[.W9]<Z<]SA+[`YMG[!GW_!!T_$
M\SYL2+^>`-8,>\&>_(:#A\-;3E\\-7(1P_\1>#<1;_EU>%`'7S/\$M!C%GW[
M`U;9+P+D--`K`!R^`A.,+1@>+_]D]NFWQR08(.L.^)HL!<?U5P#C-Y[.0'X<
MIIIJA*_VAPZ^J=9JU#3D;DT;THTLD<\X<)TQO6+R10*^+*X2<,_X,A&Y5HW&
M.;F<E#C[4[/3I+_@M^BYON/YX'C"5Z]85*/]='%)S[SJW"\<,<N(9XOFQR2B
MGQK=5O3L!+0\NJ-]K#\@#YN^==F+Z02>-=7T?M\->(I2`K?VF9:#`NTU*7!9
M:S:Z$@E:M<9E9SD1FK6+9C<''6KP:+V;381W4?Q!^ZG=IF?H=R/&=F!ZF#(\
M#^G6^UDZ1V0D5SQ%R;__DA#D.?+=<_L)Z80Q3C1Q`VXC$EQ'R*?X&U&/5@[_
M"MY;LD;$$[\,8'F>QFLEO?#F+^=.WN7<FK^<-T2W50BZ`-0O,YH1OO_[+SB$
M^0'_3?#__P%02P,$%`````@`(##*1F0_E4Q#"0``"H(``!4`'`!R=&=N+3(P
M,34P,S,Q7V-A;"YX;6Q55`D``]P*>%7<"GA5=7@+``$$)0X```0Y`0``Y5UM
M;^,V$OY>H/]!YWY6'#O;ZVZPZ<)K)T4.V21PLH<##L6"EL8VL3+IDE(2M^A_
M+ZF7Q+(DBK+EB'(^U=5R1O/,,QP.WY2/GYX6GO4`C&-*SCJ]H^..!<2A+B:S
ML\[7^PO[?<?Z].N//WS\EVU;OP$!AGQPK<G*&B$?W3/D?.>)O-4[ZAV]M\2/
MXP_V?P)B]X][/UO_/^Z?]ONG[W[YW?KK]LO?UOG=O65;CX^/1Z[0X(<:CARZ
ML&Q;OL?#Y/L$<;"$882?=>:^OSSM=F7[IPGSCBB;=?O'QR?=I&$G:GGZQ'&J
M]>-)TK;7_=^7JSMG#@MD8\)]1)P7*:DF3Z[WX<.';OBOHBG'ISR4OZ(.\D-7
ME=IE%;:0_V<GS6SYR.[U[9/>T1-W.\('EO6140_&,+5"`T[]U1+..APOEIXT
M/'PV9S`]ZS!_%KGY^"22_^F6P1)A]_QI"80#'Q#WQI\#&P:,`?$'G(//.Y;4
M_W5\F8+!`G^.9T`D&5W9H*NGJRM,WM'H@>/0@/C\%JW0Q`/Q(O&$!?#\:EV+
M-1358.Z=3YWO<^JY(N[/_PBPO]*U+T^R!H.&E'#J85?VS<_(DP%^-X<*3"L4
MU&">3AR-P$?8JS4TGU6^1H16M%]?7\WA<2=R+BR$C_C-]&8IT[E(9UO%29&F
M/1H\1'Q^X=''G>U=4U1+?%.!WU\)%F6G7LJ7Z`=RGNR>C*K<R10J:C#Q4E0:
M"[A'3_H)/B52KPD5G9,GN1>#>MM;U-N32?WM3>JOF>0@SPF\,&]<"0-2IL&3
M#\0%-S%.JMMZ$`N+*O%"CSJIEWBRG*,L[8#X'6'--D5\$A9N`;=G""U%`==[
MUP7/Y\D3Z:IW]G$OKM]^BA]_2ZJC2+.')N"%[_NVV2#Q1A/FQ<-EJ97/[=:,
M72-OP-)V(^8D*L7/#'/I:CANT>7!8A%JL[%(TXG\E-%%OM_B%U*EO0$7KZ9+
MJ19Y'8LR47B):8Z8Y3P"GLU]\;LI!N00I'!\],_&^'LC4C;='EEKL+?3]6)2
M+NKV`BWIMG"E!2:?RKX95$95R:W(\/YZ:7(-:@Y58L:05\R:RGQMN@2^[L:P
M^Q9&XRN,)MC#/@ZGBGFS\,*X*1=MIANLV56>P/(:&Q#RNK1L=H8\.`8//H63
M_4H<5M)B%KDE(U(E9`;S/`K@GH[!DRGO%C$]6E5"K6)1!<3@<J+28%"2_@T@
MJ5(>S6MI,%6B<IV"B*@(X7^1%X"RX,MI;0!9^O3D(C`X_PWI8D&)%CG9IJUB
M)FN^P=UFX+HXLNM6S/LNR1`ML8^\-0RJJD-#N%74Z0#*)_/$!#+'<AF5@'N.
M&,%DQD6E%"R"<-`=P10[6%5KZ`BWBDP=0/EDOFMR;EQE][*!V?+K+I:]/K!+
MP@,6GP(I0;'6U(".48&8@E6_-3P&%Q*5XLW0M=@=N&K=@FR(=*R5%L8'P$\*
MREYJA>PFK'P2!49V\-@XD)6AH()L.XFI`-#`:D#C4$T#1<`U^-'N_17EJGWL
MC78-#1B1J\A,R^3<U@9$?J[+,X-#GO$FC^6)O2]',,N)R1[7;)`617`5DO,"
MH)P:N\')Y`.00$G)2Q.3F-B,I>R\,+':;/=S$"Z8BU%J)`SV:+BA&V-3<J*4
M:Q=12B@&5[UWX`F=L^A.A"?WK-P%)IC[$O@#E+.HJZ!-=.IB,GB![9H2FD[X
MY50J9`Q@3ZNL4$`PN!->D@?@ODP9D<WK*!1\J<5,H*PL"#?I4R/2+@^;G_2\
MG,QO8,XC7WX+#%-7>)$!XC""Z+\E)S6+A!I*8>"'1C'Z@`4KGU=?.0CCGK/X
MP!').-K2IT0\",2S]1L<JKG>3HH-Z%GE%&<RXXZ@#9Z;[3[';W!,JR'$<ZAN
MR:QZ!$L&#@[AJ`X7I9H=+&]IF`;7*W=SQ."S2#;ND"[D@%Y&8)'`P5)9!-C@
M&</F0'))TJO0RD*T3/1@B2Z'7KY4W]S23=9ZG4.LE2)!3^$;B@\]A^1'S<\F
M)(H"1T5SMSW4Y=J*#0BBVNIR;=`&EPDBPL/I\#T=.'\$F$'A[1_5AGL%)08$
M0#V=([-57\$))F\5%'CG`A-$G#VD#FW%!D1.;:E#&[3!Q:C`Y`"X_$*X:>TR
MQFH$DY+;D0HQ`TBNIP/DW*I4P#9X_C\6I?(J7C*M0+-:[&!I5L,N+P2:R_OK
M`7K)>2"/;MZP.^3!S;3TMI*.\,%RK@/^-<_NO>S0;":;HA-[*HF#HZT4L8$'
M]U3?1VKDV/Y^/XQ@`I3?F'JGHDS0@'ZC0Y/VUQ]B6`97*JDK.2_+].*W!Z'O
MB3M84.;C/\/GV\QTZWM%2\.C/@?HUT*OEV:UOY78Q&>^&OVTP^L"#5V^6'IT
M!?`9"$RQUA?$2@0-Z');D)C3`Y4H]Y*@"RK-V)81%HE`R)3L-):+M)NA<GQ[
M60A6<W,%,^1=0.Z.4$&[PV%A#93!"VFQL6*LG`+GH8'29NV$5RC8;B)U46I/
MU^KK5/EGR8L)JR#;;LXJ`-W+[JF:M@MY'WF.11T7?]97252F]>%0DX&63\:_
M#<F.&Y"C6YJU%+]EJMI-^?:X\^/AER:7P/*^.=W`-&P4?RA)&!)=]%USGWKU
MJU2RJ?.=&V:5+7P5"1C05S3)R1[JS$=D\%K7\Y$G>7YXB!A;32E[1,S5NO2:
M(V0B>ZE(++P`FP/&8.(R(,6/Y%F\RK0^9Q2Y.IGA)S-^S?.\=;^H=0%2MP,,
M/L65@3J<(X9].=C+'3&&)X$T6S=/;*>N_0&B!=/@A83BE"@_'1C1X7GTL>2#
M5-74F$B[WK!?#:>)^Q5Y?_2D@9KX?#H%N04/S_:,D0\5CP=64=),]\JW<`P.
M)8Z(MBA@_`MPY8UT>=,T$(:L4HTKXZ^HW8#.6#T8-OME+9XPN`34P1=>5!8E
MR94PPTO]*:J=`JA8[9N)G&(7&%S@Z0`3U0N9B0;G!#E^.!C6D'&*E+Z9<"ER
M@,%EH`ZL:RI+C4`T$]5N/!O*OQ`YI%RUJK6/E[V9X*KJF-?<ZMK6_B_`9L"2
M`S.WP!S%GEC-+VEUX.S#(09?4=1!*AX.Q;P.^SS<L-@Q#66TM3I<=D*^E_V^
M@D22C*"#!S%!E8LKU]0+_X++2-H8?YI'<6)(7[[5?%;$JKU#9V;/3H!FEFXJ
MK535_J961]#>O)(?:^]U=X,_=J69$U'2A-[]!U!+`P04````"``@,,I&D5L/
M14H]``!Y(P0`%0`<`')T9VXM,C`Q-3`S,S%?9&5F+GAM;%54"0`#W`IX5=P*
M>%5U>`L``00E#@``!#D!``#M?5ESXTB2YON:[7_(S7G.0Q<EE77-F%)'F68R
M19FDZMJQM3481`9%3(&`&H>.'MO_OAX@*8%$>!Q`!,.)RI>N;#$BX)][G%^X
M>_SMWUYF\8<GEN51FOSZ<>?SUX\?6#)*QU'R\.O'W^\N/AU]_/!O__H__\??
M_M>G3Q]^8PG+PH*-/]R_?C@+B_`N"T=_YLOZ'W8^[WP^^@#_^'K\Z=_+Y-/N
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M]2^WY6P69J_#R6WTD$23:!0FQ<EHE)9)`>:_3N-H%+'\C!5A%.<['S_P+_U^
M<[F"/2N+:?3`$F[!+[S`%]-6OP",CD!.TR2'=L>\:WX+8V[?VREC1:XKLZ0!
M"^(9:>2.O11E&#O1]EO;%D!=9^PQC,;G+X\LR5E^DHR'Q91EIV66,1`AST%[
MB\_J8C%JT@*$A9[RZ_`UO(\9?`_^DI7L30)#^?7;L]+G9[.HF(%BN**@`W-[
MP]3=NB<9-&AC3!3IZ,]I&H]AZ3C_1QD5KX;*EC3@4CS]:5#2@DL!=SL+N.M6
MP+W.`NZY%7"_LX#[;@4\Z"S@@=ME]SKD$_:4%;`<&<P_>JVYU*SIXJMLQ[*6
M;V'#S*HI>C@9/O*]..Q%6^URL)8<"GPZ#6%!R2^3IMJZ(I`V[1)2F$\OXO2Y
MLPEJ#6U"W,X#5*=5"T#.TE')OP(;DG/8CQ2OE\DDS6959]456]Z&!2&'V4.8
M1/^L&H2/7,/4-9S\8-D#R]I-*P8-;OITXN188ND\DL(T5KQR,\/`?^0F-SY_
M2)IP*Z)A#]%IR4K7N,_9/TIH_/R)C_6V1U1Y*Q8$O6$QGY5@`BI>[[(PR<-1
MM9ZU$UBW-0N"7R;P5787OAB/,%%-)P)IGWB$59V(I'W&$59U(I)A%Y,T\"9>
MF(V6$B[^66_WC1&,DN++.)I]693Y$L;Q1R4DA)M<4HN<E#RHD%:M=14)_LT2
MSA!_&K-)6,:%10$%;5L4-YV%4>)&VD73G86MVODT8[-[EMF4=+7=KF).0:)L
M5-ZS3V\JL"BLL/6N(B=I<6)U+"T;?!,,>FR41'QM^0[-K7P(9@.6C-EX^2DN
MD5WBO;H]`"'B=+3RY9A?<:29:@KD?PGT/@G@V"4<%_)EFW%XS^+J2T&;9H+!
MX;L2NR(83=FXC!E\6TN(.\[LHCC:-!8<K*)Y[Q0GV2HNZ)C++R_ZJ-%J,,G2
M64>E+Z1)K6`N<Y`_?>1(^;J79G!H__4C[!GFX^:749H4,`S.X^J@"6.//?!_
MO/\>ISD;__JQR$IFWA_JBIN$^7VEO3+_]!"&CS!\=_:_L+C(EW_A/6?_T]>=
MQ2W=ORS^')P\A]GX#KYR\A*)NK>P7'!PY-#BDIEVO0>T-MUJ/\!!BDV\Z\M:
MM],P8]]"Z#6GZ8Q?R<R/V%G&V:.*S?CV^E[F.GRM>`..ZAW:_#Q^%<[8V<KF
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M[^4Z9X`>H5R^4K0\W\PI)U6]!H+!`8DUT<!2YJ9>@XN8>J?_IJ:UH&[.YJJE
M=L<;[W8^>XS35\:J4]8<CW+=1>L$@X'_-=A@("+[)2D\Q(#>V*T36)#&45P6
MT1.[9:,R`WVS_/QE%)=C-KX`]?#M2%E4Q_7AY#S,$EC`\FN65:?UDQE?TF3T
MN(WV@X%+6EW1,2Q=J=A7"-*5%ELA4-.7U5M(-W>3>("-T36D919%=C&)%PX.
MO3%_;\)@UY#B@L&A2X9'>,6H4)^"L7F7N@^7A&^P3N,PSV%VX'.^+F.W7B<X
M=,GO:)UB).92V%4(AM@E85U&Y::T63@X=$H1F/-O0IV+[82@(7;5UMU`M$X(
MUBQ%]L)J'KIY<I_S:&_I/G"E8'#H]-BN>25ELH`)Y"=V@S27<!E2JVN1M?+!
M(8$CF$#7,J.((!"[_^&!-+*I#'X.#ETZBQEI7J109+):"D[L!F<UWGP9;KZ"
M3F(.C=K!H<<3:5MKZ>(B=I^C:[8U($Z]J=P8J(F`V'W.,CJ)^V$4]1"E*R8?
M4'BUX(B`=XKY2%(`HG8=,P>H'#S!D4LZP>FHJ42G=C7R/0KOH[AB^*"7-$.8
M-;9INDT$1TZ]0QQLJ8V04;OXJ`FOO^7&*P5'!-P/C`RBM*D((;G;#RRO3Q.'
M;.[4;R4X<NFI8&YGD9&06=80I/QV8O.F/BO975J+_]6R+%XI."+`8+0RI`(3
M8C=OM(;12!3U10*$1BL[(5@0^_BC-O#D8C+&`Z\5'!$@0EI93`4*,9TWEJ35
M?E2V+2#`B5C8PR@0(E;T1H]<0UL,NN@<[-_#N)1='PM*!T<$J!*%TE%"2P@&
M,9$WVH1/#&FB99_UHL$Q`7JDE7&$2)`;87^\R'@<S86Y#J/Q97(:/D9%&-=D
ME^W[E96#8P)\2BOK:6)#[.F-<+GA.1`2-EZZ3<$9I9R5U5[W#'0_BF1+F[IR
M<$R"9&EA3TULB#W]Q74+LOX9;$V"8P*T2BM[(5@0^W@C4%3;K0[$9G!,@"II
M93LM9(@E-^R]V2K)^!;GE]GYVF*K03?!S/%V))BIM+XZ5CJ"[I7SJ-60[^-M
MSD!SW#+D^YA>1AH[0<3'-'+"J+4OMAH.BICGJ2UK$?4_M60VLFZH5ZR8Y]W\
MGN:RJ7.E'"Q+'D_GMA92"31K#JK(!NB/-/L3Q%Q0`]C.9K442.;Q"&UU]R("
M1LSOU#4=LO/5X_G:]@C2Q2OU==W4P<WD124;YS6=[RE/:T:-@+);$/;*LYJ.
M#)HG->VF`(K+6VC\H-9"X=)CFB'B7IW2K(3X[7QU>6)O<SPS-*GB="8&3.QH
MUC7,;.>KTXMN"X&`E=:1:SD$#[$#F04;$3V+=3<6V6/88BZY3/(R6SS%BIEL
MO6BPL^/QHMO.8BG'1BQ<T"@B2A`HM+/C^_!LS5X8.F*'N07>&ZW@M9LY"M]G
M;=MCZAV6M8A#Y,10R=D4?T5R[(B@4Q=0^#X[VSD=Z(,E%E?H/DAT9\?C%;:3
M\:>&*XU8W!0[HOU>LPUJ1/DQ)2^BWT*PT\973DF*"`4HLW<!-!D1O7:@H_BY
MMS;5LY0+,<%*APC)V>CS0_H$HS":SY3PC_4)$OX4?&</87Q>O:J)D!V"4@"6
MVNVSB956S8WB<\)FZ-IE+@QZ(EXO`A+[O4%&M=A4=E-N)YR$0TW38!PZJ)PL
ML["<IQ>Y-;^Q!+2JE11"6A&F>=^GV&YKD@E,U]?!"QG.HHR-H$[]G0_)Q@>K
M`C+[/KQ:V"XH`5KC&.1&J>:#"R:,R1.6`^E\'T_MJ7\-%;%D10LAK[-TPO*\
M$HK+JCVW(14!J^_3I]6Y30K3&K4@'T8W+&>@@"D@.6-/+$ZKI"^XI;3K`@J/
M\>26AYL&4FMYC>3VNN#\^S2JMODORLEOK72P[S,?N66;"+&1RU+4@#MGF:SD
MY)`W!?K;;F-W`TXM<=+F$[/L['I,.^#4_@K,\LQ*FTLCC^9.<!!])/F:DJS5
MJ1L,#NV=J][)+,FG-0E:50O!SI[+:WB<FM77JI24U</GEXY%S/P]&E57*P\9
MJSZ+T*YH68!&[;5'/6L(#(KCLT:^:EH!Y?\DI4%2I]2%DG15Z%!#X74@UEA8
MQRJGP;[:U+T#.A:QP9(X?!,"?<5)5AQD]DT:R3JR0/=2(*X)TZ6LR?BV?'R,
M7S65KZ@&LOOF?0R-H`6(F#/6753P%>XR&4=/T1CVI0J7<&%Y0.:2]=G4DJV!
MD1CEVI#TCZB85CD10<!\&CW>I8KKOY8M@3:<T@S:ON,26VD:5P<H,8\OKV:G
ML3W9I/U5VQ=[=._=<WK^PD;5HWJY?/44%`59":2<;#7`!*LI"M`>VZO:1"9O
M%YZ:V\CU"L'`[32Y68LH8%+C7FNY@5_OLC#)PU$%^-MK_1?%?D>_$5`;-:>Q
M+IL@4^#4$MO7I50N@\W"`(I&RA)3.ZBM60=(+9&]!:O1VI^X-)_R.6U[O,IP
M5,:E8D=2+Q/L[!/(]XKU>L':UA2>6@+YTVG$)F\[HN%D$HT8OB_1J`4P"61U
MU;.1-AQR:>6YP!=1$L*J&\9&5A/7`I@$<K>VL)H,CKV,\M+YZS))TJ>P>K$<
M]D#)B,%?1CJ3FJ1B,-@G<.@RGNF4B*BEA[\)8>NJVJPORT"O<DG@;WPOOHJ+
M6EKX2CSEG%8K!3"<4OOZF^M5Q4JT7Q><6O+W5OHGMDUN80C5]M=?]O8?H,19
M.5.:9*4<0"+P%%.CLXM-(9"<6LKU'^&+GA'JY0`*`<).UPA-R=WD57<<;.ET
M`[6IM1I%)D^03BWZ;[!+,,YR7QC4VI0;477'([M#5=-8A#OH7+D&VXL`NR[C
M65ADT8ORS-8L&0R<NH,JIG5Q9Q4<S3#!$=W:.QZ?P>%Q./G!L@>6R?PUU\L!
MDC[<>4BP(:JW%Y%5_ZS<8[!9$GJ'4S\U/0=-L>(4&JX#0'1L[UJ]JXYI3-,V
ME*V:K_?LW:+//WT:ISD,0"[-97Z5?H?_9G?3,/GW,G[=V^&UY'.Y62L`T;?/
M(-;)!29J@PTQ6XNCKK[93B8@TKLXW\JB)N9)^5#FQ<Y>*U,:M@PJ\!U=VLV\
MK?`B)O=VL+Z.P^0JG*G(V'HQ`.+RTF+3?&P3&F(C;_?H2PF5=^BK!8.!VRM!
M;6*VJ6&Y)>KB([;PETVVO2UH;#RZ&T6Y[;`7C+!T4EMZJ,T'=PX?#Y?OQ\#I
M"H9]],2XH'J>?6:M`60"=[2BL2%8IKI`1*QI,>W+,H3B#JK*3J:-@B"@RR/_
M1H^F"#A$^_9H@97OR@].@J(@I-];/IGN5%JN0T#T;#$K2V<]TU@H["A<N5C8
M(P:NV/-BKH.1^":.PL]-6@D`^#ZBH/U88`(-+$C(ICVB8.Z0<AN-V7=6P%E(
M,WQ040V$]YX(Q<`06F@04WB[Y[XNL]$TS-G[PG;^,HK+,?2E[VGR`#!F[S^I
MCHNF;8%*^N3CTQ(_TB7\D0,F,-0G(O/6@L&!TPE8_PC;SJ`6>D==$4C_\$=,
M4.@?-'9+E#J*,D.#O5""BRC+BVLNHWQ]7R\'8A)PS6D]$`5KOA@A8@"+>9C8
M*$W&&A9H%`0!"?@ZVS0!`A&Q@3U>XVX:93HF6"\'XCE]LVWS%A`C1`Q@C]JX
M2,NLF.I,0^L%04"G+E(>YB$Q1,0&WB(`;LO[G/VCY%"?Y(R@H@;`<TE,;?KD
M($6)&-%;K(!`6.4N#ZT3#`YI9"&1FD#;:G502,XF;S$&UNU&:P]NVX"J_?2!
M-\YF36RE>[RP/$`DL!%4#"$ML]7Q(*;RQJ4L`B5SQ0L4LN+!SK['_6*GC*AJ
M6(B]O'$;M^R)50^EGJ9YD>_(!M5J28#C<4MIQ4I"1(B!O'EBG+$)RS(VKG>E
MDRSCT38<.4^+\YXDYXSEHRQZ5`RZMDT&.P<>/=*MF+P;=*1O>$NO<!L])!',
M-&%2S+,WOJOGAG%E@G(646\G,YZ9?/Y[\9X=7#3.6S<*2O+]HE/G*:$C>*2'
MV"-A:GUR.+EECV$V[\/+JS>,$E#5"_8/MW71-<"'F,=;+LQ:=VN2(WJ3N6X3
MH("M7Z^-H"*V]D8%S=W2?K!BFHXODR>65V(/GQ/8)TZCQVN6<8>U\$'TDH!Q
M&\'`:4+Z35C;$"MB;F^DT6F83R66Y#^#X+[?/>EJI'<82(YH?^1/D8[^O,QS
M_@)@F0$JZ#!1.KZ=AAG+K]AS]9.4B-5J`,!OZ[K9!BAB97NA/,.RR(LPX7<"
ME5S#ZEL<V`W,`%DT@JU6]</OH.3\CF6S**E6>OEJ::UM4,.V+J.6=8!TA1;,
M$](51`+]!D>U(M>PM5;E8+"U3),I2,1:_G@GV:0S__M%FMVR["D:M9^F&PV!
M,K9U^'8!C%C?GH/,^VYL./DM2_/\.DM'C(V73Z%APU15+QAL+>5D@`\QCS=>
MJ?9<W0ETJ!D;RXAA06F`M>W'#Q058BQOV3J7/>H"\-^&,<N'DV]E#A#S_&0R
M`0AAP;.?0[%Q.>(!40"'%5*WYG8M@GH\1I!9,7HGY$C'L.?_PZ,>(FBTVH_Q
M.;Z:\JL,S1.6?7N]#F5/(>O5!BB^GY'J-.&:H$0,9B]&ZB9]#>/B];<RY)LR
M_F[V.S0IWV-0.Q@,MGJ%-$&)&,P?QY/F!6>;YUNMQ5-:7`<:^U9E78"\[6NH
M)D;D@2I[T5H793*^2V'+=<JR`E`OWNE=[,'RVID8]:C4;@$@;>LJV`HI8CQ[
MC%!]"[T^F\,$/V.9?-W3K0]PMGKE,\.)F,T>>[.X)84CJG@IQLREJ@?B^TZ7
MU,E,>O@0\]A[^+6^TUU^^J2(69@7(-)56E0AMK-9*'86,&X#8/F.,>XVNHRQ
M(B:TQ[E4_>9-EK>X79;A[Z=+JH#0OF./N[U#KH*&V,->C%)]`J[3[-7PAD[R
M/7R$\Z1J_C-K!:!MZQ5B:[2((>WYV-RP:'9?9GG5@X:3\Y?':M^Z>*_B+E69
M4+<^P-GRZP<3G(C9+-(C83[]EB8E.ON]%0"!MO460`0$T:PW3Y?O(7]-^OZ_
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M,O@Z8!\7OXQ@"H)!?1Y7+?[Z,6</"T_\Q>]Q"HW_^K'(^`SLR]T&MN15Q'TU
M?7!MI$DUA2JBT67U0#TN.1VMF'1'-D<ZEEH;R+L`?IW.WP15AC\+RP,R(B'K
M:OV+#2>!A>1KW'J#$8M5MVXY9?8G7Q;\(^13C3I(?:4<("(0G"X9)F+K"#`@
M<1C>%KZV.XVK-)G[1B_32>>P?E?+1XVGO"I5F0@V\'G0.X'D/HZW=!O3(^)C
MTJ/^6WF(RT.`G7TTV/'IK;2U?75%>PA?V*,>>OX"&_\HWW0???LLZ-DC>;FU
MO71-?PAWUJ-^>I%F$Q9Q_M`)IZ7U8=`U@7<[MJZO-C0H[JWVTO:WQK`N^K"8
MSM_>6H3N8<.0DQGH_M2W2*!SCUY<;GLM#=TBK*4]I]K-(:SMU/]@T<,4=D(G
M/'/3`UNN.-=9-$+]Z,D)"@;RZ`O7J\YOI'%D2-AS5=X<[L6!@/9PT!`2#$,@
M07HOAH*VMI%A8,_U>^-K'_6!H"4F&(<`!=R+H6"@;V0PV'.TWQSJQ9&&^F#0
M$A.,0^#-@%X,!@-](X/!<LC"ID]%M(>#IJ#!CD\WV%X-"".-(T-B^^XSFT>G
M-3WA1ZFWS*?<V3(+1T49QEB8$4DYP90_^?S-*QP9._8"==QAQN<(D\%`3T@P
M3&]O"ZAJ&QD&?B]L[]4JNC=6T<G#0\8>PH)=@AZB)(]&?P_CDLGS*U`0"PSE
M,?9_@PN$5_TB`\%>OAUW@Q^!6)L3-C_]JV4"M?^\97.K7*1/'Q,)$-KY&2$D
MZ$U'WOSQMRQ"R.F+6<XCA+B9D;70KHKZ$"%TPP$KHH'>R@!LE_2LK\@?;DMQ
MAUE#3BS*IY).&7!0*P4HG+J,:T?TK.E5HORZX,1B=EJIGU9\3AL[.(C`0?;U
M*[QL)<4P43R!+*D""P,!*KW1J07;6R4(:\$VVHJ_>TY-%?]6!60F0,.V4_P:
M"&)1(J=QF.?#R2(<:YC=<'YJ!<3;C_GB5^E;CZW:`\WTA$3!-XX=%-/_L`UZ
M@7%'/:$_)">9C>G16CC'S\L<:]<+1SWQ(V[V;ZK:_ADFLME0AJ.>N`>[[N%M
M=2L/$_'.7^_^Y*\%G>GX)W^M1^@=N62YG//7QYO@KX]0/FV[^.NW##.+(UHU
MI>AFMUJO`[IW21'YXK>/&FR'IB:(\=UU(949DIJ%`9-3'LH\GY58ZU(*HH&'
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M`LWV@WZ3+:9NE$:1;NN`LLI4EE\FURR+TO%O69H[V>7B7P.M]H-@<]@54;51
M8];X>>\2CJ=P(BTS&#AS@2ML>?7CJLN7/*FX<6.@DW[P7K*NU%(K?:&Q%NAJ
M*:.7P\+AM"7X&FBU'U25PVD+55M?LM$W'5B=;^6:KH.[7_N1G<]A1T249LU_
MF$8W;)^:>\,2@/;[\4C29DX?:E7:RR^_H9Z,<E_"#:^KWFQ/BF!WAT`8J^<>
M;5N=]E+$$^G52XS>.[:1(&`,`I'"Q/MV"XW:2_U.I'L+MON^.KBA*&"0?F1B
M=-G%6^G47DIW&GOL]JFL-RP!J/\GK6I3E?;RL7OVLVV=27A7U:LW*PV8I?]L
MKR^UDDRUWD$1YC'F3MS-VTL#9OEK\,T^U&HO.3J-74IMV*^F3-T,][?Z35!Q
M/]Y2V@S;)U)>;[*6-P?J*MP-3;IK'P4E_S6N4!QJ3YY/W+O#^?Y/AW-!=]GU
MMY_;*H?SW5V7#*ASAW-N9F16L*LB.@[GM@?MW+_F!":<-(O^R<:_P\24U=QM
MKN,P`0TU<U6JLE[8_QJ8PB69Z<D=ONI?)ILO"SHDEFFC`\XF2F4:"`=?`ZTZ
M]3K6S_7AJL=8[Z!R51)+,]*+#DHC8J)?/=53=G*#Y-B+?-*[NV0O32Q,%ZLV
MERNA9V$.6^0;M]L3GE=RZMBD*JF%2-C#[B-L;+<G5.Y&.F==:13C+_[:]VF[
M/>%\%5W9AUI_QG?8#%78[8FSO+LY%U&:-+[#^Y7$P<\K"4$GV?.W,]NN*XD]
MER2O\RL);F;G5Q)[N`/J5EU)S#'!5Q27"2OE`+Y+LM77-<`>RET)T&\%@:\#
M_AU;,N9$SU4X:TN0=OL<Z-4I0Z9-X0NLW7)OT5H+6\&^;UWOHL6_>^]F9/,?
MW;"\R"*>?++:X:J?7!65!X3;X,/=>HH0]Q6)*OI"NRL?_;I*DR=0`QN[.U&;
MR@`6Z`F[*=E=;U:9?2'?E>A78YN]].95$4#_/>$W?71FD2XI,OA.P/^]&L9>
M^_*J"*#_GE"@/OJR2)=](>B5X!=!RYZ[<T.*8'>_)_E"?/1H1)U]2>>DO]5:
MNY6K5JVSL&!O3P7XW58KQ0.[]23O@M<=MZ:>MRY+E*7M&\U18B@CF+`G&9O]
M[^<UE;UU^:<L;1%ICA=#&<&$9%UYZ8^75LK>NH1673>@/!42S<%B(B`8;QLX
M>*(CQ5S3]E)B(3$0&]AQ:G5S?\*`HGO+Y/O6JKT\6!OOONO/*/COPRJ)0.6]
M9?%)J-9>GJN-]^;5/1J%WJR2"%3>6QZ?A&KMY;':>&]N<+H4.K2&4,'N06^9
M?"K:E:>_VI0C_RF(G,;1&.0;?POC,!FQVREC17X-Z!/`5D0C$,^'4W\!,G$5
M?]=QTF\4!B7[N\5>2J/TG%\I""*[9'?D[N^(`I&3IT#N/OBDO^$ZC<,\'TXJ
M3S95LANL#JC%)05AYJLN,)C"M&(XQ)S/ZT(JG7N;A0&3T[AT_=PM<JV+387A
M(>;";<%&M-RG+1J+K"/T-;3%LFSAS`N;@6%6P1Y7.QC8V53;(XDA]1H`'5"@
M`HP6/Q-DQ#R?5T6OY*PE7]&VYGI%P$KA"-S!BF)$Q!Q]12+/'\TTM-R\4K`[
MH'#(ZVRU.AIB[JPB<6NI-`S-5JL):"D\7]39=@U(Q'PX3]/9+$W:KH$:M0$U
M!6<Q(T-JPR+FNUB3VV#ID]0"E!3<E]H:3PR'FD-=0V#EDH?4`'@4G&>Z6:L.
MA9HK5T-8O:5.5@V`4G#CZ&:S!AZY3Y'W'"YWT%CIB?3M3/F[\$QZ-_M@UU\D
M_'9E<AFX/->[SN0R:"86=:2B7K'F\UF$:R--.'Y=YEQ4#]3CDE/PE>F%VUQ!
MO./:($:^KPFJY':%Y8/=0Z<LA#D%C^M?;#@)+&),O#6#$>7CK5F.+"U?VULJ
M<Y,TR@(R`J219+@H]]-U',2H]9;IS`[[^*H)OL@)T!,CV=N#)Y1PZI#&BR0"
M:R-['V=:('8AT)/>16O]]][-5-L%;]<7:SFY?@?SY#>WOYNF-5NM!X@I\*C.
MI@QQW]%0B;7K#L1/^>XYO9NF91XFX[MIE!6,5>^CR!^$D58"N2G0JQLRI:X^
M[-V`((:L7KEYSJ*"9;G<>LV2P6#'Y9:1HLDP)5"[_[@M[_-H'(79ZVU8[:-U
MO$>Q.J`-EZZ)](X&"DV0B\-^%Y)WX>'D#G20AR,NH'I?IJP,H)T&>^K38G*S
M(+;4Q&<O:GAKC$IKZ^S0NJI-<9O@6CM6OKP>*G?`;V4`"@4/5<T!)3;8&AA[
MX:%V[#%\8ME)'*<%7RSF851*^Z!U@H'3AX(W8B\%.'L!D9:HSZ2`.20NB^B)
MW;)1"3NUB.7G+Z.X'+/Q!2B';Q;*HMHK#"?G8<8?6<J7OF+?7L4-J(A4=U\%
MV_RU[AZ=ZU(>[$BERVIQ:JJJP>X1C0M-YT8UZ4OK^D$ZA#>FS'&'H+7K(]PS
ME+M&;][#@'Z29K-YA#1WZU/N49`:`)/`-:S>,!4;4@H,<5+QYC^\))D4VXEZ
M,0#RU[J6;8)'K.B-6].^\EKC%`^.G4:F:2_&30W++5$7'[&%-^JK@RUHK8/M
MC:):IMJX"2.7!5?LN=7%CZI>,/A*(/Q/U-\%5P!Z8!!;>".:[J*"3]R7R3AZ
MBL9E&"O6(&%YT(E+`HK>8B31`F)@;\Q50]0_HF)ZP^)*&?DT>KQ+SV&?5;PJ
MITK#EH+!KM,[>.UU36(L3>OJ`$7L[HWQ\FIW6FOH)CJ`<K5MP2,AJ^T->X3S
M#,Q5(3\8#2?Z5_7JF@"%@+=%JP$H6))U\2(F\_<L#R?EYV&49W#J31[F:=KF
M!]GJQ]7WUZ6AIN:-P3Z30LRPVQBIEEI!NHK?QVZNLVBDS'=>%0(0V^`8U\VT
M:VB1")?M>WZ%SB,K;5_W..I'=G!5Y]NT2I$>[O?!E'NU$NX1):PFW7T#NZ/J
MR@X^"0JFX%OAOL\ZTQW2.;U1@]QK8<2SP8B5>O["_RF;-?4:`/`4$HXY[3@F
MFD"Z@;]`T]ECG+XR=LNRIVAQ2=1`\/8H0Z63_"XMPKC^^VF:%U=I\9^LN&&C
M]"%1Y.EQ]LU@]Y@`4>JVLSE6'M(_O1&SSN`N9NDT6_R)EY.MK)L5!(Q!X.9Y
M2WNR1*-(]_9&2[?6</4_?,<!9_8;OCMVDDZG^150(P6G39J'%TQ=2*^C&SEM
M=#K[+4MS)[T/_QJHM?_4G"NU(;V1;J2UI3>87'110Q'``'\-WG%CND0ZL[\[
MB]:W[3K,UY*%UV*Z-R,%F('`59GG+FU;G4BOMA>@_D>852+=I==E-IJ"V,-)
M+7L/=G.JJ`;".WVDPV=?T,>/)**R%Y1^R54:QM?E?1R-AI,)JR[N>.^!_L73
M'6#F4U8$`+V]FC#1`&)"?_EZYT^2++K?,*L.%ROSQMN/^>+77$9FM&H/5-/[
M.X`.BD'Z3`N"WV385]E-C,9[50-$[BTMKP4=L9:_>/9&BN<;!MN#G,VS4S_&
MPEG=H'9PT']N7%L-B/4I)(MT]'C%0?_Y9&TU(-;W1@*[R,9_T'^:5HT?,;0_
MWE7F;=>8JN0)N8U:`G7TGR]MHQ*DAWCC0NT_?'/0?\91"1^QLC>2T-7C?@?]
MI^)T-("8VU\\^H9>Z#SH+_O61A-(VO'M<W@^8_DHBRH@+NZP:LV#XGK+_]G7
M$]+!_/D;RW9`5^RY^JGUKO*M@6#PM?=G21--(-W`7[Y+F>SS?U\FHXR!8L[8
M_+]M^X2X-5!+[P^?K=6"]!9OQ.-UEHX8&^<\EQ#'PU/%J.X"M>L"Y-Z?.S65
M@-B]!>6(7`]4'CY*84Z2\?+^`KLU,&X(`/;VC-E%(XC)6_",B,F7]QK<"1:S
M9KT,B-7;`R("%K&!-PH0>2;6A-Q9/"P[^-K[TYX4.F)9>PD&K#FRK?NQ-1S=
M%A?,/-W*52G+7.!1)%!Z;X^&-'2+=.B.+&7.1I\?TB=0.(^CX!/5WN+?O,OO
MU::H^5^#R^H_7-#E:J;R.M2K""![ZSYBH@'$S/9\^T[C-%]Z-:UL4.!8,N)9
M0!Y$1M2M"B#Z[3FBK0/D.3Q[?GY>9B1#CV.:@@:#G=XZNU#6.#(D_&9@:*.F
MJW2AD&90PKN3`;I7V^3G0?']9V,WID>D`WOC<D7^J/D\]PG8X(]I-)JNNZ/6
M!JRA![!^PZ"LWO-Z-C2$="=[*6>%_LH@QV/$:1`NK%GWZ-XH`.\W&6A!.TBW
M\.9^6G\#IYH,%UEC%WS+95)[$T>VW!DT`XKH+1797A](Q_"7GN`=P3)(1N6K
M@E4!@+WG*^78$>/Z\T9]E_84=OX1B%-IXX:-6/3$QD/S8:]N!U316QJQ@T*0
MOF&/S+YCV>QMT<(6_I5"(%AO^3H,+6(&FAEPJZ-[6\^-JC*`[BV79ZH%Q/1^
M,]HN=@K::R]6!Q346SY,$[S8OH?VV%KAN0"Z7`6RY6G=3L.@@-Y21#8UA'21
M%NPE&L&[O!_B0EVDV8QEUP`97Y'Q&B!R;_?36M`1:]F+MWZ_[QE.%NSX[XMD
M=)BY)%5`Z-YN?/6P(P9;D&&@D2_O*H'/_;E0U=]6_[JB*?92L&3\;H\573T_
M/W_.RF(:/;#D\RB=?:D4Q7?D:1R-JWRM/'1@3@>#R(M=>O[Q7WUL]!:2O.E9
MNK%;+QSL??7'$2REN5-0SJL%06273L)A'$M&`:)`;`?9E!MY\A*:`('&Q2^C
M-"F@<Y['5<5?/^;L83:?YA>_QRD,L%\_%AG/3&_#OV/,HKG-X!_KIH(_!=_9
M0QB?5\^%(&];"4H!6)<\O]F+5@(SK!H,!8"\5K$9Q9_+GQ=:+P(2^WTO"M5B
M4]E-N9'$560U3>.%I@XJ5SVXY.U.@4=<)_)PHV41P$%A*VNT**S*COAT^=+]
M8B^3/"Q2S^<G]WF1A2-9"AFT#B"DL'$ULHX"#,+U^!LJ.0-U3$^2\1ETJSA]
MY$#5+S!(ZP%2`O2MPA#8V%+B0LX2WO;`+(8V'WYC"<"-0>Z3\0R4S:'R)]?4
MIM1K`+`3X&M;V=0$H-BXWDCX!EZ36338H^")V,ID"!:Q=;SQY&]27B9PQF??
MY;G(!:4!%0%VM)N%UM$@QU-OJ0^NTB1=E74!4V-CHJP+D"F$&QMM4#1!(7;T
MYD_[SLG.A:[#D)A05@V`$G`EU+2'V)AJ>(@=O;F5HG#;C$.`2,#CKY,%%=@0
M\WF+V;]BA=9JMU(.H!#PN.MFIB8>Q#3^WJL*LP2@Y<O+YV]A'HWX02:*2QXZ
MH5[O-%L`^%M'FAA!0RSKC511"-_>H@"7`,%B9)M6YIWC1,SJC7Q9"VI:==2M
M18EHC%S3ID`A!"@:LR'<#B-B=&]\C0Q%#83^$&_7("B'`)_3SJ3FW4.E!Z23
M'-'P#SB=<A>)_#)I)AG?2H>!78].K2T=!G9).0SLHH-`)#<=AP$+AIMW>^Y!
ME"9\="`.!5KU0#UD70QVT9.(!B0G3@<=MJ^K@J*WY-+R@,RO<X*!_I$]*@[+
MB>\"`8/1\'%P9SFR+A"UW"$_5O9@\BQ?\[*`C`!=(QDN8BLA.(@Y2)R,Q]%<
MENLP&E\FI^%C5(2QTDK2>H"4`"-C;#$-3.3\)0K`Q,9+OD%I-G$%P$:!=S&U
MEPP,-;>(YE%)MDM<+PR8"!R/3??^8A3$?!H:AWN98=;+!GM[!'P:#.TB!F'-
MF6$3$3_[)-)J:ZE="XH]+P6#%Q,G#]53$<.)\<N)JS6#P2&!>VLC:^A!LN=S
M8/R.I>C)4E45$)K`[7-'.ZQ@H>8L@$105SUG_F<8VJ=A/E4M[CIMP+1,P!NK
MQ9JO#XZ:-X$T0KZC@06-@!*V9AEKBXZ:5\+)^+_*^4J<WZ7(@:\"<[\>&GK#
M8!.;1P6[9=G3/*@>@-^P4?HPMUG5RZ5'9K>?!H5OS3J\69U0<Z!HZ;6TMS7+
MNP2`W.O!^]TF3%P7<?J\G:'/;9Y8]WR3N>>2US"^R=Q77W/5Y*9SD^DX]'G?
M)<G1Z5Z2FV'58"B`[0I]WG>Z]V\7^LRUV%1V4^[M"GW>WZ%Q+=A!Y63O_6#]
MYROJ=98^1;!`?WO]/>?9/M^B=4Y&1?0$2F8Y+,CPAQ+^]IY^1"<DQLH'0(=$
M=\[X@F03.;$[R9;;XWT"VV.;5M':4N_C291)'+'Y@2P913%;D?LNU=22QA3@
MXG.@5P(N!^X[DSO=$;M_/6./&1M%E68D?:E>#'`0<&)P9R%QCVAJ@.)];2-O
MF^K2ME$!L!%P>=BT=66Z(!;-OOYF<`WS@A?46!OT&P$=$(A`V71_,-4/M6CZ
MIOS7&7L,H[$ZB%=5%0`3<+DQ-9"NF458Z878KTM],AJE)8R-Z_"5TS\\=\IH
ME)5L_#T*[Z.XZO9&)M=I,-@[(.#CXZHCZ&N`VF5\M]VQ,TX!E$7@VGXCY]#.
M6J)V_X]@FGMO.:2K##\`RB/J-V!,5[5"3LVG8)$=FM]@C_Y11AD#E"!Z\7H=
MATD!4RIW?WV<B5T=S1L!)1!@*VT:5-QE3#5"\):_@X:<S2*@++I$J<7N8T-+
MU%(T()@NHB2$DZ*[!<KP`Z`\`O2IE06J%7)J21X`U(BQ<<Z=SV]8S)U>KD.8
M2,_8O71)DE0#H`3849M&0Q8AI0[DR1I\Q(0]+A;.X<3`V+)J`)0`6>K>V&H=
M(,;VQI+6NR?WO@5-L&$V?W9/&6>FK@R@"9!@FQWE,DT@/D0VXW3J@4+U/BBP
MHZ)&L#<@0%RY,YX6?,1BWDC-;NIPMG,#9=%EK2P.=!M:0KJ4-R*T`E1YOZ_3
MNY+N@E<"D%O'+JG0(";S1C0J0HCFX3,#`BR/N1GF<B,*WR?FY3^/P9VR(AJ!
MF-OH\M_FV4[/+O\#EV<)8Y?_PX:'K4SNOXS+_\"E-T0GE_]!XQ$`%,!VN?P/
MG!ZUVKG\#QI7R6*YM\OE?W!,V.5?3^4.7/Z1(^EO69KGP@/RI);BZB09+U\5
MQDZJQ@W!Y$S@4**W:'1!:,W]'K'@,K7":9JCR5;J94`JHB<`1.]-X:VYQ&NH
M](^HF$Y9/.8&7QI?1\VB>B`]T5V_ANIQ0,2\P:_?6-ZW=`9\E'(,LOVWK!K@
M)'"K:K;!5>.QYON-#*.%KUF]$Z%#1U0VV'?Z*J_]X8*#D+I?;^K`?):.2@Z$
M.U=4&X[+9))FL[F+?>OCL>X^;OGUVD=EQV)5E6#OJ*-+4`?!L4.QK#@([+(W
M"X_&>DIL[D?E&.@<DRWP&Z=QF"_G2-W\WNMU8(Q[CZ%7FTW!@XA!$<ON71=2
MF2FZ61@P^8V\U]0Z0L`B>(@E]+9@(QH'>`?&<AS+;[JDW4&SBF6,%X'YPZ/'
M5]=%[!V!DTAX79V?@"SCZBH[#D5I:!ME0&:/3EAMM2Z`X"2"W;2KSR\0SY/Q
M&0QF19]?*0L8/+I'=>W\`BA.CNNFYKB(\E$8_R<+LPOXB^H`L%8:<'@,Y^QJ
M$B$8)W'8[8PR[S+Z9JF5!RP>/<KL&*8!QTGHM-GMQPU[J)Z03XJK<(;-7J*B
MP=ZQ1R^QM@;!D;@)438SQBF@R<+X,AFSE_]@(M<]M"R`\'CGT<T<0BANHHIU
M[7%:9MG*A"I?WK'B`,7CC4A;J\C1N(GG-1LH?[`X_H\D?4YN69BG"1M7&80S
MZ8!!Z@`HCU1PMX$CA>0F2-;,3G]/XS(IPNSU(HI9ABWZPK(`PN/%2#>["*&X
MB3XU7&#F(_N&/:89CV7C_`.Z%Y-5`4A;>&Y7(W(3"VIFI*K3G,)\^Y!F\CW`
M2DD`L(6'>A2(FQ!*,TO,7YBXB--0Y/\@+`?";^&9'H'A)AY1UP9W6<B?&;I]
MG=VG,:+_E3(@]!8>W@40W(0&&BX5[XY'.D]=Z54$>%MXBM?%)0_RV]1=_#![
M")/HGQ6TDV3,DQX,)S]8]L"R,_[P79S?0:OE=OJM[_M\Q*>=W_K^5Y?+LJG?
M>J5`\;V22.Z?%_+-BSF7ZWL7#_?*8`K3BN'T[BK>Z3;`RE5\(QA!A:=W5_%'
MVW,5;V@LLFGU;\O[/!I'8?8Z#U'7F@FQ.H#4Y5[.U4PHAT,LHWU-1GY3,9S`
M82')PQ&73SGJU)5A-^"4^]2?*>5604RIB8]8FOL-V)38S.K.N*J9UENDP.7U
M4/FF^EL90$(A!D!S.(GMM0;&=0``_@2L0.&*&B`Q@7PG>F<U+2CNG^06?/\Z
MFS^FR.4PLD&](LA/,W+/R!1-1'+G@DTQ0[?E;`:S,`SRZ"&))M&(I\.<YW'F
M4J<`(6+Y@B3RP0ZAB3IUV")UY6!_SUO^GMO1E(U+/L.B<BIY)<TF@OU=EW=S
M4L9)UPC(HF^$\"<WU3BI[KJD&LU.9$:F-&:M=E%N<GM9JUVG%X<V6*M=]%B-
MX>D;:[5[2.QL9<]89%DK=`+Y]LH#,!2SI49M0$\G:XV%>5,;,C&V"T<,7U8.
M5XW:L/=PZHZI/<=J6\C0P.M0B5%?&S$PK0EZ,Y8FRX/!D1C.PF]2*SDQ87E`
M2(`?TQYT8DM*D!%[*?%'F)23<%24G,NX"$?\-:=7I>4DM0`E@;3^'>VGQ$?L
M'<2+,@,5EQE_FNLB>N'_RI5&Q"L!1@)Y^SO:4`6/VC.%*-S?<S8IX^_11,87
M:=0&V`3RX'0CC;1ARB.*-D7"+L6M2]IGRO7`G[?#)BE7I^]^=Z9<#QI^K>T0
M_J1<&S2+T\>^'5$'DH>>Y4#[1KFZ?<O;!N6Z;\3BX>]Q;R_ENK\]E*NIL?[*
ME*O39],W/F]J0_[K4:YNG_2S2[GB+V!K0_WK4:X'![0FZ,U8NN^4*X67^[0'
MG1'EBK_'9\\_\0<;\Z=AU%:0E`[V?:9TZ6@#)2YB="D*L\K-WV:*K"J":BC;
M4(LBT$%(C3D]&8W*65D]ZG?&'C,VBJIX6/AWS!:!L2<SGOYA'B?;YN%U6Y\`
M!1)X-:%;%[&K"S>IGQS,#5=,\0PR6@V`;@GQWF)>>,,G3Q5%@''?YDCX@3=*
MIW4DO--W98TCX0?JS.4UN7]2WPVZR^G3KYWB/P?JQ_G$</I&<+M]DM4&P3U`
M+W8Q/'TCN`?$7-8L&HLLP5W?I4K,52\&>`AXH9DM9$WYI?SSY@+1[G/VCQ)0
MG#_!_^0$=F.K$FGMR9`JP?ZAOWP!JS(I]V>"XB"^RS5#ODN3JA19T%$,O=BQ
MK:%37[XA-4`E+@^<9KLUU&1Z)EZ!1&S')I!5G=0!JP,(G2XY1ODY4`MH&ZT.
MBM@FSKK9B&WI+-N/[+YN36KEY9>P?'#PE8"_NF(`:5FMCH>8YT&50_-;""OL
M:3I[A(X\3UC)WS=^8//;VO<BBQ='3Y[#;#RL(.2_50\A7R;S1S54MS0.O@9:
M)4#AMMHRN5(&,=\')<[<".@?+'J8%FQ\\L2R\(&=O\".)\I9E>VC2]>S)P58
M@<(1U467M*TDJ=/&IL[!-ZRZ,KL.L^*UEFV)P'D8D4SG7*RJ&NP?>PMM>W?U
MPU3_[77E%^WX`(/V@OW-/]=K9AQDC+8'VX>C.`):<1R7U`+5N)RM6_K`&MM6
MW%F4N(F=VQ%YE8=`:3U`2L/Y56D-(R/6P1$[QSLS(ZWSO"M[DCW7Z\U*[>9B
M02.@"X)A76ZG9E0-Q(B#NI!&X_JMFSM]@J3KG(R:06W,.D!B1W$+1MN*&=B*
M]<B&%ES.9FP<@<07X2R*%]DOAI,?81+.3^G##([8R2AZ#./A<\(R=0[D=BW"
M,85`REYL[(EMW0FJZWB%X:B,2SP_2*,,2$6`:=(S`"(\L0"$&Y;#Z7:17X:[
MU"HW,X+R`)]@6*6U?0N*F%KX04-4C35/6`.Z*I7="JI\36O5`5'S\+=J+VH;
M%7N&4VU,VCS.A@;0\0?K5&%S[V6"@Z\D=@223B]8E9H(W+S:W.FUDC"+6/X'
M;%+RDV0\CZG,\OHUC8P@UZ@.G9%`K&DG9EP;I9M'H+M$!*2C/ZM7P\=G\TY;
MW9_-'[B\8L_53_+P`)T&0'D$8MPZF=@`IYM'I#LD=(R2-(N*U\ND8"!M49TN
M\FGT"!A&</"`7OOM]2I-^"T,Z!.^_S`O(K%[ZS9!102<:[ITA8[0W3QL;><]
MJG)^)IWWZGEOOTQJ^I'/]-K-@"(())/L..,;HG7SEK85LR_?JZD0Z)EXI0H`
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M53QG?G*?%QGLGB3&;=]H<+#GD>:WLOK:4@(QMZS3,LM`*0M4#3RRH2ZO"6@)
M'#6[6@N9#'2@$W/E.F,3!E*/Y1J1V%NO`<!.X'CIQNPF&B#F`E:M>2?)^#M\
MPO*JT+5IT)?'@$RK:X,=51![5VPQV:U@:[%.R.L#<@*.:7;L)UTS=-1`S,5M
M.>WI:$=C_=!I!O1`X+;197<PUP8U9[E%AS;O"/**P8'3C#>;7`YT@%)SJ?M[
M&)?S(.XX3I_#9,26/14`G.0Y*TZG/+C[,CF9I:4TT[)I4]#-/=Y'6K5\.^CV
MO/,LQ0T8#VU\`G/IW[Q)RTH1RKT`_5TX[5BY<;IAHS3A#ZB&\_LVOG254/EU
M_3QT`TO:7<HU'B:O^?EDPD9%]+3\17DK9?L[P<&^BYLK2V)JWF[9_!HHQ,\-
MF!O+2F_)[.OMYTU:@S;?IW:39M_JQK=M^SV\;=LG?]NV;W2!L]_#V[;][;EM
M,S46V=NVQ=$_>?B>YOEIF&6ODS3C6:YD\RE>";`ZC1[3V"YO8J76502Q&[/U
MDUP._UC^;7$H6$F&EHP79X3\?/88IZ]LY6<-PLS.AX*#`]]7L)OL5"Z41_1&
M[PWBZ33,HH+O63@KF47W)1=5=SYJTQSHQ>,EK_].I:TB8M>!#2"J1*SB"H#-
MXV6O?_/7E$#LT@Y?4YO49*L]2K,9T(-OXI[&K@53#=%KO;?>_#T*[T%W1<0C
M(W5N\I":@-;C7:[_64&D#?GEG3]F>-<*,_RFMQ6]KAI!2?L:-1(<#%I<D2DY
M71T9-`E;[::@@[B\','9V!8*EU*MAHA_\J@-0N3`Y;&_#8]J:%)CDO0`/=YO
M+TGJ]+5,*R3I`9KL#,/3-Y)T\'5K2%)38Y$E277FDI.E3_7;AFVEL,3*%EH'
M[7ET.K.S)%M7!S'R50>7V*5.F@ZG2[.@)X]9,3;?;>1Z(,:1Z@!:NF*=)^&H
MJ,YQ%N8:<:.@(]\N;AOM*S(M$*-$=>!<I?S`74(QV/(N;A'$3^"<IKF,0;'_
M,="I[SO#C?:L-MIQG8VWK=SS=(*+_Y,OTE%UH4FT/Q(<'/J^%+3#0CC0"C&Z
M5N\H_G*:L7%4Y,-B*DW@W:(UT+UO)]Z-SC!"^/:",+"T+DN_\*<PBCFS<I7&
M9R6[2\^X<'D:1V/,;\"H?C`XW'IKM@!,+=S"9!/5N&@PNLJS_"68(WW?_'O9
MR6JKAEHPAQBD*'S-N!.)&@$E^'8-<-P_<-14PT`\/DR)WY;+[@4-:@<'1]Z.
MCKAXJH<H%36A.[ED)*5/3FKKW-0]HH;LYQ5@@^X_)/.`F98%C6_\#E&.<'MO
M_`Z=<GHV;OP.T:>L,#Q]N_$[/-R:&S]38Y&]\>,OBD?C*,Q>:RE;55,C5@>0
MDGDCJ<O4*,='[+JMGG`YG+&5'+O*8:BN#!L(&@_M*JR"F%(3'[$KL0W8E-A4
MZ\ZX=)]\O!ZJ'W%<E@$D!-YUT!U.8GNM@2'FCK_I=Y`/Z#Q1WV&M-`5,[,:F
MZ^.Y!TX?A73RXO&!WB/F=8#4TEI9L!JMY<^E^90O"]ISTK](LQG+X/L\I9;\
M@4%!41#6HWN$:@P(KK50#-3N%1H7(OB$#QNQ_V*CXBX]?WF,,N/P9Z.&05D$
MT@]W)%%MJ,#>RY38&]2H3.^BS%_=P\:K?@L`B4!VX996;865VLN3Y_\HH^+U
M!RNFZ7C^L%+U!GKS+3W9+:)N&Z`"CR&EE@:Q(5KY*Y3"R\._?>$?O@]S5FGJ
M_P-02P,$%`````@`(##*1ED0C'",6```LBP%`!4`'`!R=&=N+3(P,34P,S,Q
M7VQA8BYX;6Q55`D``]P*>%7<"GA5=7@+``$$)0X```0Y`0``[7WK<R0WDM]W
M1_A_@+6.#2FB*6DTN_9)>W<.#CDCT^8,&1Q*\H;B8J/8A2;K5%W56P\^SN'_
MW4B@WBB\Z@&@J?UPMQHV$I69^.4#K\0__X_G?8P><99':?(O7[SY^MLO$$ZV
M:1@E]__RQ4^W'T[^Z0OT/_[U/_^G?_XO)R?H1YS@+"APB.Y>T'E0!+=9L/TM
MK^G1FZ_??/U/B/S'M]^?_*\R.?GNVS=_1K]^^]T/WWWWPY_^^[^A_WO]\?^A
M]Y]OT0EZ>GKZ.B0]%+2'K[?I'IV<P'?B*/GM+L@Q(HPE^;]\\5`4AQ^^^0;:
M/]]E\==I=O_-=]]^^_:;NN$7K.4/SWG4:_WTMF[[YIO_\_'R\_8![X.3*,F+
M(-FV5-#-&-V;[[___AOZ*VF:1S_DE/XRW08%5962+R1L`?\ZJ9N=P)].WGQW
M\O;-U\]Y^`71`4+_G*4QOL$[1!GXH7@YX'_Y(H_VAQ@8IW][R/!NG(LXR[X!
M^F\2?`^#!5_X'K[PYK_!%_Y0_?DRN,/Q%PA:_G1S(13H^UY?%=$WA$M;?%[C
M+$K#]\DTAH?4]CG_7`19,8/W+KU-[F_3(H@G\=VEM,GQ)SQ-SRV=5?T2IXFG
MZ;=#N33'!<^ML5(Y;<;P[TO"0X\[_%S@),1AS1]02_PJ[9SZ8^HBH=MTV^LP
M!N><9J/RTKYV07Y'.RSSD_L@.)".W_SI&QP7>?T7"%E_.OGV3>6-_U#]^6_7
M&3X$4?C^^8"3')\FX57Q@+/3/,=%?E9F&4Z*T[L<@EE1?YX*39GZVZ1>:NW5
M^NN)FN$\+;,M-M(=&Y4^=\'=-.Y(]"1]0)*`DY.?/G_QKQ4UJLA1D(2(=H!8
M#QM4]8%^K7OYMW]F/`T$/<WZPQIDVYIK\I\*2:L6WVQ3$N0/Q4E/Z%V6[F>,
M2,54.D-MW4'506]6W+,TZMNW%2+A+W\[C_)MG.9EAJ]V_>_G-0/UIRD?M\36
MWI$/_#8"SKD=6L/I;,F'D&W[0E<[-`!PCDX;!-?(95VB7Z%31'L50'BV#L)T
M6^[))VFR:4,7[Y,B(GH(6Y6D.X2AMS`JR#]SM`]"C*($!>$C)-#P^],#3A#Y
M#,+$W-)]M$5W9(:PBPKX$?Z^3?,"/45Q3'Y`&0[BZ#]PN*&^X>DAVCXTOV'&
M=P@?V)7P072@V4_NSD<L8VFUNUC2S"S&O>`EN(LI=Z?;;58&<:X3YV14]N.:
M5`8NCE6M*4CK]G[%+/68<#%*=T#L(8OPD99)D5>LU9R1*684W$5Q5$0X;\U%
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MYFPER8EZ0[JXSA2M-S>1D3F8B4BEX.<=G>8;5.'+2YSIC`\_L]`=''LX^RG'
M5[OW>1'M@P+G$F0-&UK'$L?I$#VD`>SI-$W\!M"XXH>0D6G=JC/:DOEP1H%[
M$^6_G668^$OX+[DO$E.Y<$42&48\4=L:0:,-8@35/WR&EL9PC;@FO;&R![H/
M093]',0E_H@#",FP(L.TK1\.#?JP#D@3^8;P!%I$B5&'VF]4&H_G$*,3!]/F
M`:ST@+/BY9J,57&:A#`E/K1<Z@!6OPL'1Z^TI>//73%2`E`@IFO*#;G?J#4=
M4_[DU90!G7'LJOO!VZ#S09)*[,KX,MKA-[>P[:@\;S6E)[L'K2;)*@(GQ2:"
M,6JQB5A'B/:$?J5]J?$Y6^BB<WC6EN0%\D%RK3-EBPA/&I1QD'5/D^W2#!UJ
MG1P:3X4;G91,)S'YP->.SWQ--_/>8:^Y-C[#4<%EE[",=4^9:;FL>7W:=5XS
MY>?V(*KN3(^)^F38"ZMDQ,0].3#JVGLL87L]/[*<X5G<T6QXUCF0I71`RW1K
M?]]SGA:$;H@8B_;!/UTO9'5S=`%T</NEBT%CD;C[^2'(,-SO#,_2/9@K=<Z_
M!%D&<Y5M$3U&Q8MIX)W4J:O(.TT#LM!+>SQY!UVB;I\;5/6Z076_W@;?9;0R
M'GTA@";E_HZD(C1@XNC^`>X?!H\X"^XA9N)L&^4D4F;1EKB&+TE.3BRVOKU-
M%RCSKVBJG@.;Z(FQE9.>`Q*6,7RF+.`"-=P/1^1O\,D[?!\E"?T#9/3D_RI>
M7G"0;=`CSN'&./V-!*XM_*-(Z9\W-4MTK!INBH@Z--8[UQ]TU)&4_"9D]A[^
M`/E#+7G8^0C\G8BZPU%1IQB$OR@CC<(R`W'J;_J34<SP*H*48K9+6<Y;OA-P
MD;][>5^-WS4`]X98`I[D.F=]P:D?G:<;I5-%$J>:;]"[%U1_!='/(/H=OYWL
MLBH;][B5SQEZU@W4Q[C/TO)`E)I!_^1/4;*-R[#V*^7A4+GI."6^"L71/B*^
MJ_)TM!M&N1ES=CDJDY#\^ZD9HMK9HW%G3[^4X7T044=-O`X]Z%,&<2-#@;.]
M1Y.GI5R"S.\MY@]<3*Q:"4BB"\9Q2D8RI,<&KPX@3`X;.E0L,C,L]^QO$Z9:
MRWS(X>1K(4W)IF,L-:5Q%%4?0?0K&T2_@ZH/;5#S*=3YEN>SM"6A)IZW+8\S
MMV;9=2Q=*;1G?TMV[H7Y&6M$U^3ZB<O`XHSGA*Z-;!IP=`QK#FH\,B::`IV6
MQ4.:P?KP3Y`+=<2!#9?Q$+Z$L2WP<?^,<0F-3C16EL^VWZY2VZX1TTU4EE7/
MFH=X9=B+@=C8\!=&L#/'P"U;W."\(-R2:1`5YS0)!W_Y*2&3K+GQ=^'/NG8&
M2VMQFAMH/U%9/DQ8N3_2+Q]50%\%HPJ+7Q&@RZSVE?M]D+V0_XCNDV@7;>E2
MX_`R$F5#8V'/I#-G:WA&$DN7ZUA/]#_;OM#H[33:GT.3F#_LHL6;J6-N\78D
MS%UOR5=.GR/9U8]!._MW(`=\<M<>X7<$#="OT,0##SNJ6NYRHUBO%O.5T?SK
M-*,+N[0*PKN7\56/EOTDA'SL4[#'YRDLW\KRE%4^9S\_64=K7,4[=HV<`?Q7
MULP#=*^)&2YO6!TP]FQM+*.Y^?S31PP;)Q*C4=!91[]*CB&,!3GREX0F_PK]
MRN@\P+76^`P!:C`X-JMU!`6U#N9!P'32A):TD8=Z!9V#JAQR.00.LVWG34:@
M-2)\@0WMX;"'K0$ORI`O:&\=2R*^51CR*/!*53\$CX;>[8&FVK56AKI!.^L@
M&?(Y!$?UNR)HS6;S$6=WJ?@.D"&WN4<Q=A0(0^A*4&`/LFRE^2()\3.\%W&1
MYV53YXC]?T4PU>W`.LBU)1OBJ=KJJ"CAB"2CI46O\KKJE2\AUVP`AQB<,GI^
M@!/F/,JHK-N!5^#L238)G)MJG<B;D&XVD"8@%8VBQ4QQ?XC3%XP[&W?*!$!"
M8S]CE/#/98U5V_ZFL#]Q5SD67/JH-Q!S=ENTEL@OHP1?D%G06*2=UHWE'19C
M*;F]%8/]%.@'T8Z<;ZI,&]W^=LJ<H;6XD4+8":.X+*)'_!EORXS>WWK_#(>I
M<?B!Z`5F824[&GZU>Q]D<,(YO\897;D\W8-`L@V89?JWOW&SD%ZX#9].OZCM
M&-4](X`BZO1-ZX)5O:-K.+D#_6\0^X+;.=Q1*\GJGMJ25L;MQ2UO8@Y6>Z]V
M'Z(D2+91$%^G>41W2G1*@NN0NUO[E4O%%V.NR`#/#2&J*;TJB&LR<,*U8>U1
M<P!(T0$944-W(!,>;&G@Y/RLBER[0GPX/6/2<'$6!WE.$CEZN$MS$XJG<8>/
M$?ZYHI'0A!XAI%-`7Y;!E$,@1(Y<_Q;KCW;X4"YLC36V7VUTC&,57KQ9DQ+K
MFZL;JE"V`T<C6R^0-7;G6J1S_S;\>#&U5ZM;Z$W<3]-I\2&=%R`&#>U/G(><
M<I.[JGR7(I>U-H?5X]<];,<AP$T&)>-O&Z[Z+W?[\D:W[FO<IF]NVP6SFO]^
M*;T??`&WYI/@"SW^O5""%^0/LI2._FP_B6-<<>-._NP6H?898W4+22C/BAG,
MH1/TKB[$M"JC[Y-P'IOO:?4H]R;=-0PN]^:LPF:I\VZ5Q[K(8\^G2.Q9B]I!
M@7,=F?@BRKU:J_1.("NU.HAO;EW&/.%P74@6I$NI=-LJ^@62S&ZV<$5:!/$Z
MHMU"U^X-W,"0^-+RAE;D*'7535E=IZKJ%-4ERK7P/"CO[![>6D#V`K+"AQH^
M87DHDY'Y\T@'D\+P80Y"Y#IJ31*G7[9_@Y+5Y-`,4.M*X<5[*!TST7X#A;,1
MVQ%*&9J<Q23#-32;,4@8?/P*.O)HX^[YV*:^-[$$_@%EC74^_2X</"NK+1W_
MQ&Q;#[X.0_0N@1^+@@M*)GHMW+WAF(*3?TAW"C*=&)_^LKJ,R*6!J1>H.XW]
M6V4WDJ1FOD/DP7J[&DX2`_%DY5WG(0J->;Q)+_8S*B,9N;1+\Q433Q;Z%A+V
MT!$VJ(2M5P&=IJ"SQ/-DT6^"T7%9[%2+L^=:SDM\F][@."B@+DNFYTED1-8=
MAU2"(;9(8[AS6#5'57M/O(*1)+6C(])\2+,]SD`8H0@V#4<-J:&=Z.+)91)J
ME'QZD71J)ILN`X5^/$`CV:5[J.N'`G\\_EFZWT<%+<I%`M)92F_IX03NZ,E.
M=\BH[!_ZD,K`34S:UC15ZK5W?$ADEB!;M2!6ST&HD<4=C]"%E<TSRA.6^[Q:
MX#-:^!(M=*'3HLBBN[*HLPR67GBS-+&(D!ZL3Y@OX/FW9'=-^L(DJ+'51'A<
M17:=;+2UBX-$(SR/G*UAK=B",'MU!V]8T9+0];ZKF00YD^"_?OOUM]]^^P8=
M@@P]`M%?T)^__79#_E8_"18T%?W_@I*T_FM$16:'B_IO-WXDD']`;]]L$)2/
MH"T`*!M$R."=QN@1QQXLG$M0.G)J1PY1N^E:]<:*RK#XIDX2LP&W8TE,FGAH
M3_J\BRWI#;,DD37]:?-/W_YI\]WWWU(C^=/FO_VYU_3H34P$UK&T3XQ4BPOK
M84BO8@?Q=1"%%\E9<(C(9+/#GFP]78/8_C*ZCD3<@G)#A(`*10FJZ#:H:ZZ.
M%\UGB@;G,$^(:%M&Y]Y:]-''+2P;0L]F]>PBB!(<UK4W3K?;<E_2E;USO(NV
MD6P6I4/LH(ZVAD1\,6U&U-9J^;)#ARK"K]P:U"3)NF*$K)5[2])''5\8W`QR
M+M<AC-8?O%AWF+_>X')U6DL>MCIM=EQH-OL&-[VTA'@7D']NL>OK7O-Y=;MR
MH[]BX\&^UNCA+[U=+@&I=R<9Y3M@G1.,GNR!Z0K!?,[K.;*HL6FF`3E[5O0)
M%Q?)-MWCRS27;9H-VEFWCR&?0QR1WQ%K@+Z$)E]Y&(1U9("?W*;2.ES&0BYM
MVN(H=H>&)P'NC%+"OZ39;R3'KB:K(W8SVLIN(6".1^ZU!M:@7B!9"79A2J8A
MQ/)H)<O)O+*"EU"\ZJGBNEK[0`$M:54\8'3'TBF4/V""T9!,?+YV7)-X'":]
MDL,RC"SRLFC_VFY>W]NMSP/3VRF:[XH:=.7J55$3:65OB@ZNV>?HM+EGW[_S
MZKY,X]SQ%CPH.G&P9V!6YXN7JNKLAIW8Q:FIA(KB#S)47OI0O6WZL/9`.6-,
MK9<HN4CR,H,P)#\V,&CJJOA(EUL1V)HVSL\(Z'(<R3EV4&^#0X6@N(8`$A;?
M^3&IJ^-%&1VMZBLV*^049%*O1+,6UV>$.MJ2'+?`.7UWHRV'$^(#U-[V8!:F
M7T#&GWHQE;7=:)6-NG%:'NI&7BGIQOE5#ST^_;C/,3+N`D?,#_J,Q)8"GT]B
M>OF+*)_5H[6;QFK*,^Z$1W-8G3I"ZSKF^8(=QHJ762E;IK7$,E&V=N$EU972
MZR49$UOL34+,#7&1Y9O1BY=EAAL>--=N=/MQM7"C+:=LU8:[.WW*[DY#/ZW#
M\6W%QFR(!<LU4\;7-.'*\?;K^_3QFQ!'+-<B_S%,L<B?_G:)[X/X?5*(GZP=
M;64->N,\<ONKT`*Q)LX?UY"HM0:$4J=K#3?[GO"A#+Z)U8$><,>]HUF-K_/'
M,$2:[`ZO6(TS8HWP:G_M.91KKB8]V(TO1K(I*W&<=BIQM-'$GY56\Y'L!9.I
MPVBU>@SEIWHJ]AU.\"[2*ORJ('11(T8NR0@8&>[J=W]K$D\J/DP6"-<";=,]
MP(Q.8MPO%>A!;:1,BC;.YKEL^,QYE.$MH3GK:$[BH\4DUIVRA'L13NKFZ$R)
MD[4Q/T.*L)9"C78[RP)F8IP%6?8"*]'TDIATHD^7#.[BZ)[V1=P4IH^;`C%\
M`9[&;)>S#VE>9+@@3-"WI^X:WQ8E=&TA)!_)TO+^@?QO4/4/U'79J!W1Z`%G
M?R^C/"I(4#YDZ6,$C\X6::/R'%K`$7E@@?P]Q]ECM"6-R<\X>JQ?J"7\[+]&
M/^6,F%AA3*BIC/4JQR'-ZO=KX<]QY_#BER'1RE-4/$3D9Y(6O.`@0X2WZD_0
M/$FS/9E70(G:@"[J;U^V1()HA^(TN<?95ZY72#2<RS!MT/,L\QT>G=Y\P*/E
M/03MG+BV+I\B3\"FE]#(O1/3X3>F_.[6X]?$7<D8'OBH$<_4>(?*)-FI?NI$
MF)1;XH[RUO>`K6?$*9$&6.3M^KX%Y(^)2]F`KZ,^CW1`7!@F3>$N%;@+YABI
MBZO\8I#=147&'L<&[[;'8<3^13C>8@R-<D_<`V>*8SY!8(?6)PS76;K#>4ZO
M&0([VA,&(:&K"8-8$I'==BFHN_%KPF`N4+T/T1%+[)4<3!D48!-,&;20-C^"
MWN`<PP5\,KD_QX\X3FEA?+$]&-`ZB;0J>40@JNGHFDZ'TK%Q+"%:5HL&(21L
M*7V)W:9R39]SF,P>1%KS)-QJV>U8"#8PVOG>Y0.<77N(Z&[3LS)+YUH[\2`\
MSR+#:ELBVM2]B]#G?5>W1,6*K)NX`37O%P7,S0]@F;1,X+@HGABH`/IC)BG%
MO<M2[.R`WB+UV%5=>5"472FM5F7VZF3I$=5G-Y:;B:A7E=UM67,]`*MKFYN@
M=Y%3/I+BH9KG>]0]N#K9HR&;\$P/R>>ZE6)/AR5OY6=Y[,2S69*>1_DV3O,R
MH[)&R0Y6A^F2SU96(==UT#-'KN#8DAEL9]C:9;2ESY;>9YCN,0@.)DG:VK4?
M`;]\$0C:##7MG)]44FJ[AP2UJA<<<^$1)6EKM^,N/+@T,O+.SS!I:%TZ^@N?
M;*JWX9O^/^+]'<Y$`!`VMXL`,=?<V;7ZZ$0'`ZRQ:PPH--\#@9;:%_`"2?BY
M/!SB%TTT*,G<^`6Q%$('`05U*(U_.-$<FU&GH34P]J;3MU$!"<U%$D:/45@&
ML2##4+2W/C$6\<U5:H)VD*2V+9WG&EJZ'T[W-!3O$#6_1,4#?3\(%K`?HL-M
MJCA>/;DG]TA3RLK7(FT;PS:[-X>W9PZG$J(F8SDC5-X^I>^?\;:$(MRY/#R.
M-K4;$L>YY?S6$\%)T\R7P"?1="_8*=5LLQYR\ZK9RVT6)'FPI7!\]]+]11'U
M3#IQ4!_90,)1WU0]Q.?^OM#T0>/+"D\;,3?`5(;)L<9.@28/=BV@O(EQ8G7+
MH+-PI+K:EG&I"%']-I:OR/?YX[94Z,^^!*,Q9?;O/@LU:?'UF(<([YI8>+7;
MD6E@)@2`%I7]-V6D,G`'7Z!UF[N@JKT'J#$8$^Z]%-T!L8RL#U$2)-LHB(V0
M):)R@RRA#./(:IK[BBSYF(PB2V=`+&8F1.E8E1&W;>SG(1W^N/0#?O,GCQUJ
MDLLUQM5H>:R57J/7RLUX"[U"->+^))J\1D='W:V-?XR2:%_NE2,_:&=][(=\
M#D>_^MVC&#"JV2$")&JUB('@60\#_7;V,3#@D\,`^]TG#(QIEL.`6*T6*V>R
MA"-77,:6-[=?/7.<:VZ^6C5CCW&H;V#;A(A,\5P)2J76+;Z*A1\QK?5Z!K<-
MWTBPPK6T_QX6QRMW9*]N@6@3][`0J)=[T$BF6WM@.*]>Z>T"\S3+(+V!K6W8
M_VEW@\YQOLVB@\+#3._2.KQF2,\=J*S?B.[VA3J=T;OXG4WL#>ITZ!ZV<X$P
MQ/<R*+#H%:/[)")..D@*=KRC/2%Z@_?LAG65\['2E.SW`H<R!SJC4_N^=HX&
M.+?,#OZT76Q0TPFJ4_ZJQF?3CWLKF(\"SL\O!`&+EM`<DOX,;VJ_"W*A%>?O
M7MHVU\$+/4G[%&2AZ/+`"M^P;R<+ZD=V`8%2GMP!J3"HY.CNI=>P^@BB7W%?
M<70U3'%FM@Z@+%J=BFT1UY>2*HE+=F[?SI;0"&=@&D:EL*E+'^HN+@\;SJ(6
MQLP1F-*G-+FB22A[&_,BR8N,WL/*K\HB+P):4>=3J5ALL_/YXS%',ZTN;K`;
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MD6=T]@!^P=']`P'T*9PUOL?U]/$ZB[9CI[-\9?2UYB3Z(^5/IM+=T*N91A77
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M$@\7N]KZD1VF$>7Z2*L*6!I`B28OH]V$@W!'<7EM32^VV%VW]5V8#S-*3BIQ
MY#0)(#XR>:0SR85&R,(L,A^=1LKFC/;CAL6[8BL-W.CM,44<>14SQK7T.9PM
M9HWJMAU0$N#L8>;8F2:.S")AYHCHBQC7R5^3C\GY;?(_R?]\9H]D[-)L'Q0;
M^%_23[`_P%23M7[SUS]_?//VG+7+ZOMN.;WN1OZ99L#ACO!"9Z\)1B\XR$A/
M\`C@GK#Y0#X-T]/B(2)-<8+"X.7US$J7C%+KS$B7#U&69Z-W:B7<&2OA]/X^
MHW4A+HBD49)'VY_AZF8G<U)-/IVQY6:NZ6X4W$TM&_90PQ^B#/9FG5X4-/5G
M>`:J.H*)HF,',SHO],*[>#D-%`C1B6KV9WTZ/+V629Z6_L?G=`J?O<"<3NBQ
MNW.2U[$#N,S`2-3T*C?WEM%:]081F?"$T6Z',PQ/R=WAX@GF-[L@RMI"(#!-
M*I,09_$+3-QRX#)',(G*'F'B1"9<49Z7]#$ZF";Q.X+5GA[,M"C&E?=D:3_;
M,B-L%?%+=U[X>J==^E'!TBS+-"3,B+6]C<,;X/PJ$3_NK":Q&ZGDW`\M;W`6
M@;9'A,"#5V!UQZ('0.V!6!0?MT^I*3XZ)*[QT>5>"Q^$P%]\<&.AP(=@(.PM
MRIS%09Y?[:K5WJOL!M:0>GPV/^;5K]('8R?V9WT99*K<0XC2?CKEU!!)`6CK
MS?"D5;=X7=W(\;;U4DH8?>M#YZ">S=6!64@?3NL7@/D1'`/Z0))?FNB<DJ1V
MSU*AFRC_[4.&(1,BJ7)>W)"L:(VC/?K?/I[C.@;Z7&&=%+Y>30P[W]\@X``!
M"ZCF`0$31WJB9H:.J2)VH(BH5D0F5,11G(`Q->#%3K5,L]XCV(L:$^S]\P%O
MR:P>=M=DN=&:'SV>?20=#5KT?O6GZ7$0#WR>+94V<M,3!U_"/G_^E2>N;E7#
M7&R'QM`JCS3?JR7Z.8U)-W%4O-C,^$1?/^Z<3ZA3%WZO9>*UI7W::FYT\=BT
M],03VK'B5=,^'1,^<M]X'CU&(4Y"%YZQ_^W7X1<'^G3A%6L67JM/5*BXT4-8
MM3OFAWI-3=>*.Q3;[1$X0_YJBO`]HQ6_=3S.3J*O%9S;^&VZHW_7WD")[2LW
M]5DB#\OH^ZJ08WVOWD`=(TI`G(J...*I_/-B$4[/.1]/1*-U<O.+Y)H:[X]9
MFJ]R;UWVM:.+:N,Z6S.NL2_"'2CV3?@+^>IQ^RT]-?*._/A?E%?;WM+^2FEX
M%CU6D6Y_NR#S`S(E*#/B0!E/E/V<_MB_Z25_&7Y"9_;]S12)UW0G]7<Z'L7%
MM>!%]</["46U9:N>8C+F.4<P$_#'DYET7CZN_=:*F<GHUXXN,QG7V9JNI//%
M]9R)I:?0C93(^YO7\/RYVO:6SDR4AG<\'DOXLNL*_DKQ:NM1>"N=)XI72'O8
M[3"W3X[;5*$P,[)X3<[2E%)''6,%=%[A4IC0&2WMP!6>Z'C<]_1'I*US<'2N
M?N:SSVML#WG[DK-[G?OWC+"+O:6C5YK]_2=#E8WM2OEVB\IR5%EQH^HH"S;G
M1@O;:\7M);GP+W8OJN,I\3N?O@_FY9-'?FA^U@/"7KG8Y9V`L9M=RP,<D:MM
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M/"M`G:#>?RC!SB'1X3>/;I5'IC]K$XK!(S+'OHYCHM/C>^UL36-=\>R=S%*/
M,K'O"V0I?^<^>LQI.J]!:]FXCQ[/EE)G/QEVI%FAP&!73/ZDUNHZQZ-_S4_+
MXB'-HO_`X4_PR%GG_OPU`4W^[H5_P.;T.3*OD#/S:Y[D=7-UIO7:T:_0V.$[
M1Q9@HY=G+(B9HS`V7I#S%*:+ZQB;^&O'9&P2G>DF$QN6/N2H_11[\1'1CU49
M!**?XYYXJDR6??2XC58%OP6-5@][2SV99_!4G@=/Y.D^C>?C@WBZ#^&Y?0#O
M!N<D+X.*O!270G@HVEMWDR*^N4>-FG:5!W,/%2W5#QV,AMY=QW6-I1#E2[.?
MTH0]$;Q>R11S'CS)`=;1[PK+#,+GS8O.\^8;U/#R"HHS+Z#XMNK(3TE$5$8H
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M?/S9P'`<2?3+#W@Z<IIQY/>V/>)A&)GEH5Y#&.F4G_0SAI@Q^(H"B.'(.-^Q
M`49_[U.0F6.F&3=^3WM`1H[)^O;0!*\TXZJ2A24Y+:?ODAF[UZU<:7S4F:-W
M<F?^KG+F5;N>,]?SY>VNCF][.%Z-QFU:!+&WVS3_4%6MJC#=4AFH[+YKBNDD
MW:&D40O"]!-5<G:H[#EJO[A!^'D;E_0MP)S>W_LRS5"91,57**W3,V+@!7H,
MXBB,7TC[*"]0D(0('$7:>4LPR.'C1`1T%Q#&MACE#Q@7*"1\?^WXYJC3P->[
MF^I!U/,R@>@OQ_J01:@Y>BVIA(;N+>83M]U\HMJBNJ@7%GV:#?HW*K)@*=US
M.O9(.4%73;B\9Q#;!R%&89E!*(,@QM(D1""=MFGN>(Q$!R@T\7ICG*YOMA3H
MS!RSE]&NOVKL0[13<_1:HIV&[EW-GJMM-,O13N\TNW^C(HMVLIVQ8P]V$U35
M!+L%)X0,JYV(F>%#FA7P+Q8[7V]`U'7?E@*BF>_V,B!RMR5\B(E:3+V6L*@W
M`JXB8WNIZ_<X%9PV-K+XJ-@!//80.4UA*T3))TQ@OVO`^[N,E@:^W5+`-';L
M]@[J7).^<)95=>BN@^PJ^UQ`7DZY(MQ2D24':70[L'[015NRH5DVA*S$X(8$
MD`RE4#(5J"N'=@TU5*$#MR=#%A`R9T(>B)"/5+0OHP2%:1P'60Z^`N70Q5?N
MCVZ8075XM&(*3EV9(66E4VA6V_QX0L=F-R*)TMP83:=DL6_0$PV/''+RL7$+
MM8L\+XUA5A-Y`;%&`EUX,0(_H=4?#AU8C8V%6TAUWL<QQ%6/T@MP]67115B'
MRD^8C0R1#M:$XV,/<"1!WZ?)U)15B]HZ\/1D&H*/41U!ICI+O*/)40V`.30U
M8U0Z,3>#U%1*Y=*\-)+2OEEYF)%J#(D$8+[DHAQ+RD142.$>4,(4=`Q,&V\2
M4,48*%'D-O7DV-'+.^5D[K$DSSC'`>55OJDS+DIH^95I*A]3&6GK$DG"1U2Z
M\/'H`16AJB4XF?IPBF##^?8IO7U(RYQ@[O8AR@J,Z:-.\E>6%$1V-VQ5$G";
M=D\IJ@E034$?!%,@P\H6IZDT9$3?ZC!O;9=+"U"]72@#-%F\SEW>Y5$8!=G+
MYR#&5SMJ>ZK',L4T]B\]2_CGCAB0%K`I6[E'7UZL5(T`=Y543_T6,=2R\2G8
MD_^\S8(D#[:P0ZI^#%*#V#ZJ="12P,N?UQ6UAX=#FN'8V(/<Q?65,FGKM+$.
MH"Y_W%/6UU<>!#&A)H<@$*C1WEB?)@5Q=W%91(_X,]Z6651$.']/S\W@\`.1
M"$YUE.R$T-7N?9`E9%J1UTMK[U[&.U`$N56_:AV/Z^IPB/!N8]2V]B;D6D#4
MT(JLP<FU74*@4`9]-:DG%M*31A/F&P14'B4`N@.EAUG1*%G<E,;9+LWV<#.<
MK28I4P$AA?U-:"'OW.9SV[+>IO`G:U`,`;?9K*-_BP`BB@88*U*`?C/[4.ES
MR>$#%D.8I_$DK(ZIE4."4*>62]C1)[UE\]).(S>EW&H.QV]*T%_=CSFOR]'*
M5R.*/(*2A?Y42G_]]=!]JGJ^4EWSHZB&YTG5[2.LK7VG%O-.(&;_WF4CSAN5
M*UGEDVY\QCK:6],Y\*6JO7,`*T)RU-)7QZ/%U8V8=H[#<1?V_AG^4Q;K=3NP
MO]*A*QFWWE$3(J$95<3NX6\V?-S*QX2QLP?-]_M#G+Y@_!EGCU$UH^9X;(JX
M42/+Z17>[N]G:5Y\2HN_XN(&;]/[1''D<\5O6C>`-?4WM)GZ6ZCZF-!T.N_8
ML4A#(DS/M."#I$V!7G"!VF^Z-[75X3BT3DM8?`4&7073-*O^!.UD2:5M1EZ/
MZ8LT;=T?;.JB%KLT0QUF7K&?D*+<FO/0@/@1+'G1_P>Y>)3<W\!L6WH0;,FO
M',]2U:B.5IAILK(VU8<0^Y)[,UX!6HNM&JEP->,`\2]!1M>B;M-K`L0'\N6K
M7>>XLN@(L9+,[B%BM13<0R`5!2I25-/`*;?N47.7I7_,);I]B'*$8V:!&3X0
MUN"_GCJ"'CJ";CL7%5V7UM$$8>_8L1$"9QC(!82\(+XN[^)H>[7;82A01/=]
M2&3\B?PH,A$-0KM&HB,)=ZB/T2!&A&HJMDU';^H"H4M#F2+5^V><;2-B!P<J
M1G,?%ZXBPS^@4!78R(%)G=92=ZKYNS89;5CVC,80DTN;#7QA+/%24GA@*#7O
MNA9"VWMG&"(I!,$CJH0;&D(I%LZM!?00IH;^"+PL'O9.2`S&]-8\S?3N\B(+
MMF/Q1$EA_R"XD'?>/J`E:IJB7^O&'ASM40P!=V9<1__V`'2#'W%28ME4MFUB
M'2(=[H:8J']R6^!C,H,V$3H<XR$DQP?8'@:O2+X4P+RTVCS*-=R8A,8Z2F7\
M#U'1M*WW`W.E,[.%Y7EBN(>Y$D9#W&MBR*8SSC$1^N$T"<^)3<;I`4*$>C]=
M0>?`;<OEX%TE:T^?/.M0R/?,[?GX&=*$+85["]'"%Q\=M,%E<1$?QZ3/^Q]Q
M0DPX)JR=AGLRT0#SA2L9:I/1[<#^TKNN9-RJ.B/<H(J4PJ]/[(<]S9?POB-A
MT"-V;V-FR.26]R?`TF&B9I*@^9"8S<AD9C-;P$ZI<0XVMLY"GQPXB@Q,._-R
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M:(+/T*1<F=*@6L"G$DH.7>VX`N0:$<R\*^O&-D%:[JCWL+8%ZX36-.4>/MK8
M"W*:EKFN!NKS[AZ^`#45Z$,[GH=R/PR[PZ9^Z)S:H5=&+I5\IJG;BL%:Z>QB
M2A@/S#08B_80?#%K-<Q-C%L7XQ://M1'1ZORTP]I'!)LL/>8-0*V)KW]@P^:
M<G&G`II3P76!\8KRCW]X^_U?$*/WZL2PT0AR)P3,A\]B99@PI)=[@_@ZB,*+
MY"PX1$40*XN0*NCLUX%1R,&5?VG:(R`X(;ZR(O&H,*G6X'#E7O1'QN8YR2*(
M$AS6LRLEOD0$#DY&"CCG#Q&RAJB9][M]F<98@-/MMMR7,:V)=(YWT38J/+(%
M.8+X(Y!J^%@N8*#YY)L/[[SI/.ZF_9S;;&X/M!8%B:)9H<*Z#N/O@IB6H5:F
MQPLQ_CX)K;)MO7R"SIMY"SR4)[QR6F^VP@FD#VFVQ]DU^5@BN:(MIK!]Y53"
MNV2;GYZU8LT1:^_P\3/OA="\-VL@135#B?8'DKG#)*9XP-6+SR'YOR)%42LG
M6`UML&.R'FBOI"&]4PL_,#_A_FZYRI`&-VOUK&CAV^2[>UI)\VIG?*M\2.G^
M=CDGB]XM\]U]]63ZU6[5^^9ZQC]!K&I1#M:JFCHE$7V>E];YV@;Y`Q2B):!-
M,'V>"SU%Q8/H6KIOM^V5XM_4%^US:OWTY$CE/8@KN9!=OO?1:^C:J/)>OLQ`
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MHG4J'ZM>PEK_TP[V4U?7)K\EVWP2EM`&.[2HW:'=2.J,-U]O:I)7%<25U<-M
M.2P'FJ7&6ZEKV^G0O6.R9;3\)KE-BW5RU`A\\8<X?=*IS24G<WFP:$P*Z7DB
M($"4PM<31,*!D1P<4HR*Q7N$N`!>KK/T,0IQ^.[EIQP>NFINT)^2G.F19H]G
M*4DCDY+\K:T*H'.)?:$/V+^AN)1FQNXM453774.E_2^A=Q(3O^J4%6F_`*]K
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M;6K77*CQ)*^;)>W9`[S7E@]2L#S'!3NH$D?!713[DHZ90W?DU8M)N'5IGM<9
M/@11J*YLI2;UP!0Y:30-L*);JW3T]TR>!-_#32%SFU.*5?./O:F2JXLTM0W)
M8.;2<DZWV[0D\ZGKX"6XBS&4L=YNLY*,;^O6C.Q)KT,/K$Q3<DW;JWM#57>L
MI#OK$'5Z]"T03M1"(^ZA(VY0B>NS_9K@76W5YF`_E@V;U39JCFZ#9M6-&:=%
M*5=32Z6)5[D)L\[FBV=.@MWQ6G%7U_@#OC@-<\T8.H_F`\>_JSM?5\-=W3'E
M>.M0)AJ1IF.994'V'$SUKCT<MMK^O8PR3.0@S!4OUV2@"Y(PP95:>@99XD1,
M.K'N*(PDY*:\%3$]]\C(44V_0;2'#<VMFT[<SNKG"5N]W)[3Q[8K0BH=EDMG
MTYC-`3LTV*EH/9:HOUJT/[HHOVIT]W!JL(!:ZJG!:XSDZT1PSYS$AR@)DNV*
M4P/C#_CB-,PU8^@\F@\<_]1@OJZ&4X,QY7CK4"8:D:9CF65!%J<&6;K%.,QA
M^&XP+3]W'9`TZ1S?22<#4C+[Z;]<"GZ/BS5GU8$J`D0I$)"XM59#84[#1RA-
M5@FC4=+):B*O`2\N==?&ELT*FH=J0G&U,S`3.9F#:II2*49*Y=0S8S)77-],
MS&;!4X4!67I6@H+*@MR;BP[,^&*;NAAS$U7@>C*H]RK[',3X:L?*MVG&%A&Q
MTP@CE$@>9VHRE&8("`&(C-2?>#-1M*@1;0<G(.%UBYP6+^@5$8IQGK=-MVGN
MLF:..51E<4H'IXN5V>Q:^8@=*2E<EMD<\*ZJ4-D+.MZ4V=070C<GFRW$A#*;
M"BENFZJ:6;]D7EM=L[+^K!JD`^D);A)]V1/X*_=%\E3&(RFM*;:<8UD$6FWQ
MY^@6?59=[/%PI7AAM;S&Q9UU%G5<.0K*,JV(,3PE)W$",B+K!BZ58&SU<5-7
MF!DY$NK2)(T$`7/KG&1M1+E()"6^;!J9&EA#`])%U8RD^,<LS?/1)'S'7MBC
M][).D_"7:@(BRI4G=&0WA9XBZ1!CM`_43-L^]&:D5^VCA'3:1KI"=5\N$];E
M!#_TYJLTC=69L[K.72=CO)?2S@3X#!NMZ\J>D<F^R/SZ;>Q:UH"_(7::$L[P
MNTM#4/!9/5=?<PM+*[2>XE%@?`PC/?B*`;(0,G^)BH<''(=@&K69Z*!UG,X=
M@@5R2%&-:B(6$F#67Y/Z`GA-L7ZNB_BG/3MXJN5K/'\="WP"O@R"0F-0X\_^
M&=/JF<4ZP@";LB4(.9FS<Z0"*80G1^NG--N4ZLR3Y6V-81&=G52/B3UX767W
M01+]!_499,J=IW$4TG^0K.6:K4[2?U[MJCEZ$#<%_'3.02W4OW7`+J47+D9T
M^J4K7FW/-'GH]DUW5.O>4=N]5R4@%P70T&)60,^1F-9YE&_C-"\S?(N?BW>$
MS=_6LK+13QV7P8UK:Q7;:S^%?H6/(?JU8S=$"=P6M4DEUBS6?XKNDV@7;>':
M`KOI#/7?B33;".<Z1J?;@?WZ4+J2<0676D+44J*:U#/`FPT@5Y1IPNC-F!:?
M5Y,SN"$##U&\7"3P<B(S''$:94!K=WJL*0]7JJXBHRNAC!!U*+W(;(S'JS>/
M-!\L4Y>7X^W7]^GC-R&.F+<C_S%T<N1/#2<=!FZAD,,(S.3-K2%+P;403#T$
MT=8.X:.C^AHQ^GI?&R2WI%L%,%@3)V"HN!,"`'[W8\2[>AP;95Z):XWL*?E<
M2(_;Q,'8T^PC;:R.[9`_[OQ]_3N"!FY'=U27W>&5*')MR[VNWV,_)TFVPH0'
M;9W8\I!?H5%7!Q!(2P1-_;#O46V/&;I$U6LCX@.99`7Q7W&0?2!_&5LEEK9V
M@@J>9R$N6%,$;1%M[`<R!%H?PX94Y7;0P>"ICX]>>X<(Z?.MPDCE0KQ#R8CV
MQ3@1JGXMI+!YRPV^CV"ZDA2?@KTHL(PWM8H/`;=#:%23S;8=@H9N02%3=!</
M:BVO"X4S@L4LB"^2$#__;SQV-T+2U@$8>'X%:*@:(MH2D:8^X$&@;1X04E6O
MA8BS,LMZ(4R>>8J;6\6%A&ON]"MKVDLS_,A!5:KO(D1/[^NZC5]P'/_O)'U*
M/N,@3Q,<TA=5,ZG[$-(X<"-B_@7N!`A.?@,*5).P9X4S'_R*8CAX_Z(U%NM"
MZ.<T+I,BR%X^1#'.1*FJH*T#R/#\"J#2-$2LI0\`$2B;!X94TRNG(LROW>!#
MFL&.#6PM"J<P<A(7B8F(>U%^4L6BA@`Q"A_0(A^)D6Q%8QC6Q0Y%ZQD)@O=I
M)D]B!RT=(&7(JP`@M!FJV_D`BU$E\VB0:'A=$%R7=W&T_1"GP=A^JZ"=`P#T
M^10,/VN$:"L?!G]$N?S0"S6[UL#?9D$(#N=E?Y=R2J_X'[2Q.N!#_KA;".QW
MQ!JX'>=177;'6*+(E3.#]L8-?7`KORJ+O`@2X$:>'T@)760)<DE$N4+GHMD&
M,4+4H?3!/^B,T4CFH#U`%H]27$8)OBCP7K5\/D[B^DA%EWN]8Q5`@2B)?V<K
MN+%0G*\0#,2,XUW5RRC=2R3"FT[C;>T>WQ+P._(2#GWTIG>SR>G])4W&X;I5
ML(=3?7"0MWZ[IW>!*4=A2?]!KR[1/1;7%Y=D*.H=,E-#R.*S6_M#$&4P<%?9
M>90?TCR(KW:7:7)_&3WB\)0^)D@/5K[HG*J=UIW])[>F2<V5-&JZ@>IE=4>`
M6>CJA/:%6&<;=@[W!?U:_:]7AW'GH(![BFHV!%R_(GQUJ`[$7Q#ED1SF$4-Y
M_(IG"?@G]>;)^\,JF74?)]X@UA.]DM'T19^+R+TV@1E0T'LQV``'-BNXYI@H
MZH&P=8X?<9S2QQ^JIR"5@->B=E#/54<FOA(JHZ+`[=#53Y;Z[<`-QI&OE&HX
MB/;0^3[($I(@Y=<XHS:EGX<H*:VC4BT+MS)04<`Y*+8BX#<&-4=KB#^CH;+Z
M'FVZQ[?!LT'R*R1Q\::LB/N15V-)4T3:^@TOU8",/(FJ,1HVZU4^=:ZJ96E"
M_G/+[E4R#O6!9MZ5@YJ4QM+R]=^>>O<8>YWXC=6I8\T77)PST!;G4>5=CO]>
M0M[P.`70FO3VYTJ:<G&SHX8.,4*_X6HT?-QLQWSL+`)S^X##$FJ/GQ(;"J.X
MA(G79[PM,UJG]/WS-BY#3&L%P62MK&^_#[,2+12O\#'[D%]#8YQ]5!^!I;+N
M9U#['51_B%6HZGR*OA#`Y<;5U5'/#&LU^'%6N#+V7)BL\'%*T45H\RX<FI=2
MNI'');J/K_;?7G5_<WKJ^(F1;#)X5E]Q&>?JW0M<#SY]CJ25W72H7;SCHB&3
M$2`W]%HW^A5H/4"EP:B-O&AB-F0>8)';4S>!HF"#W2T2+R5G'A2>\=*'PP_F
M0Z:-0\%X>0!#L(_S=!]$W(D`'8UTJ?T!8D^F22Z14?N,17[<M,$H&C0/T/A3
MCG=E?!GM9+FC%K4_:.S)9(A&1HN`V&,L\J.FC471D%FL(KG;15O<,/01[^]&
MK]`IVMNOYRC@>Z1H-FG7#;:LJ>.GG0W9QYKLV[0'*7*XJHYJV-C#_,<@*7?!
MMJ#G\SX$VRB.BA<E\J54UO$OEV$(HUYK5#?WQ!8,1<%A!!>G?30)#6`-#4,;
M5?;,XT.9)1%A")-(]2%ZAO_*E=8A([)N'%()AH!J&M/LHV[NB6W,D&2G)XE-
M^U`C:V@>NK#R('G7J%:O0>M/XBXILZI8SO"@R*KQ:&FG[*[+O@L9,ROI;M:-
M/ZC4*\4N!ZBW-=:GC*TV<#VJC2Y>FYF#7"_Q.AVE/FX7ZP^<_G*<MV"DS^]-
M`6)%Z`\(:TD,E]\HF=O\=[)(E42G/9.2".2%%?40IVU!(W"S9SVGVVVY+^EC
MZ^?PWOPVHL<VR'_'N+I.<KJ'BBSL10^A$!([6^X3UBUR0>V,W)VMNT;=OC>H
MZ9W:<[?_#1I8_*9O\DO;^O=,2PF^!S95MKZBLBYQGO\`]W0;E86=+U`E!)VN
MW;N(I<UJZ$S6L2EWYWDU)M]B$N>G=B53;>Z@KE?3:]4PJ([BNIY,#_F9<A3<
MI^/?1D>^/9O\*L="!2;G,XD!0\I#H*/-76-(=+AS"!^/SG-*U*[`C--SFD->
MU&<SA13.02,^@\GAQJM3EXHQ4,''\>G*$7:4A]DD-#Z@2'AP38`C;XZJ*<="
M`TMNCZ4-&+K4.*$K)G&-I4O):5P^E%WZ=`!7-0X*(`D&P6;)#CJOO`[(A/$V
M"Y*<)/AD#JDS1U.3.BC6H92&K]3!UA@H#>H2>35YTQTGOAZ'R2#->=04Y]LL
M.K!K8)_Q(<C8,Y?W&<:"-4--.LN/F:KEX(HDMB3H:H=:(M10N2R3-T&BVX<H
M1V%'K.`N+0N4MY(%<LFLE<G3A5W_758CS#EYAOJ:0.$AR#'4.XT*NB7<,BT+
M\MI=N'R*6B4=MU%4M4<M`2R=-R3N_;/IT$F>H#88-_=Y@ME!%J->O,D>](ZQ
M2!();\^P3!A5W03#HQ,L[1U@$;/O7GJ_:%\(-^K/X>UP,[EE]17$*-^@NY?!
MS_ZL.LY!@/A*^>3A=^ZW%6N74BI?_+)@#5.(4&_6,37&1-/+NES/%+"D7--4
MT/F"+N':I@1?WJQO:HV-)L8<KW,&<9!%./\EN,?Y:1*RNVE9WJV%*PO56N3V
M([.>5%P@KL@VB!+2HS`UZ1__\/;[O_2*)[N'H<G@<5'6>.2LUCDNLK*Z!P;'
M;)3A=+2]BUK&HWR/5"]NV]'#9Q[%3HGJ1XH1J_1N\VV$/0XCXF$_!/LHKJX-
M7NT^!@E!."MP?TWXW$:'(+YZ2G"FO,8WN4<'+R1,E9U_)*'J";&N$&L)4Y.V
M-W@_H>D/T0X]NE@W$PC\"PD+H&#&PG]UQU==E4#:VNXBOY!GT05FW9($UM:]
MY5KOK7;KJ-QB0@=/=]''@\-SYI?I<SOL,:]/^(G^)-W&UNS`?E*G*QF7U@$A
M>QPZ1.=5T*6T]=MM&P3EBUD'[AV8V1!RB=V$\;-8;B)*TBPJ7BZ2`A-^"NHQ
M\X?H0+B$AS:(3WWW\HGH*4T*HC/R_7O61(+8&7W:+U4Q0WZNY':O&:J[W*"F
M4]3V"JN'`P+6S#W>9V."JR.Q#""LSL+QU8Y:[J>2Y1?,7ID=7R2=]0+Y;-R@
M&Q>S<A,I1V;G=(F\>G63=4'_P-[?K!Q\E'07C=RC>\K8CDS6)PZL$PR3?'B+
MZQ+%>G@=D+C$YI![!0YI\[:RM5>`&QT(";@DH^!\X?M2XPBFFM27Y>]+R9%,
MR0KXI4]G,W4'2G,A7#!*#I<=-?9:!!3NEQXE^RO\XJ-'&RO2(5`N0$[=3!&N
MO63WDH7"D3:VUUEZ_/&K*_"S/TLJO#('"RDB3<X80I/4Z6J?X*OL8YKAB^21
M0"O-<A(1T^PV/8O3?/QM^S4^8A=$2VMH-%^ZJO*E.FV_&J;M%[VT'<&'T%6&
MX%.H^1:B'T.W*:H^M]*Y7S)M%)?C\%AI+G6F=59Z;;5=%#G*X`Y_3B_UPG/C
M23-/S)GN\C0.49&BE&B+*&8/VHH:;1VHMLC/6_81U^^4K^*_>FYW1>?E9/;9
M.WUNO'`BIG8Y)Y7(I)B>=B]/D+_ZNC2B&C3)I%5OQ)Q='51N,PO:N[XT*,PJ
M^1N#SO-++=4KK@JZW;9KWC]MSW5K7!&44KE[QG94!O%+MKWS^Q[="=08$^$S
MMJH!<8HLH^>1_;@[HI!"$UQ>70[1&1@-?'ET_0/.#I*LFF3>5[N&T^IM^G<X
MP;N(%1DQ>YYS0J\.KX),T8'L0DC;'_RK@^NJ3_1EU>M77A9)70`<XOLA,Y$Q
M9U6I<T<%-!'%4?5"YV<R`2Y)-R\?<(BS(&[XN@D*3*9)A.4@><G?[W9X"X]^
MUK^H[,+.9RVO/*VN1:%E7<%5J^XWX2^W#Q@U7T;5I[LV!]^`E11H6/'PQS_\
MTW=O_OM?<H1K7MJ6N@9I:>W%NK9)@S(.LFX()C[,ANJ=K]K8\0_]=1R;SL%%
M>M'PU^._+^R$_&)*MPX3C$E:D&4838><N0W,U._\8CHZQ`G&7&@LDF'H9CGJ
MI$&_)U=Y@(&LLM#>29JO1I/FJB_W-ZAGCK4@`$P;Z!EHU?@@=RQDB%.S/NPB
MU%"^(3;U\7CIPP&?R4/:@^/T\;3XO-L@(>JS=Y8F1924<#SX@%D-(YW";7,Z
MM?\\W!P-<(^N\7D[MTRQ06VGJ.W5JY7?^;#@WFY;"!/V3..LS#)BO!7C',L2
M_"LIK8-<+0OGL1E%,Q,=A;+;YV`F"^7>OC2Q-30B(V#9LY1SO,.$L5!NXQ*#
MT>W`NMUH2\:7;&2$8RLYGIG1;!G=FY,9`(=6-05]-N^SDAGW:1)>DD\LG*?-
M[]K!'=C9VN!OQ\)2#Y0ZH9T>?>ZV%&#X>[5+HL5Z'M=C?T(VIZ)WE=,IY1)E
M=D/<>QB:9HKHWA:-L"?(]DR`9S_GT_$*&IF?7C?.\C]-*859H$F,\2,;G"FQ
M>].;`E!19FB.3NOAS=ST5(2N`IH^V.I(YJ\U613)05@SM"83P-FSGY^#N&35
M^>,X?0J(_+75$Q9/\QP79P]DA/!%<KI/2^G;M.9=6;>Q"=(.(=IT@9H^X)9%
M%>D`L;2?#6`XPU!4_\MSS/Z+S)]8MVZM<@$EL`90:^.Q44=0]^;>0*>">FBR
M\Q#MW?E"N\<*7\=I0D\.$;K>#5X7D!;.L2UFF@LQI3P.L?QW[)KC"GKB2UFL
M;GS^G,=8"W<]VUL7=/:RVFKY-;F_3//\+,BREUV:/059**L>)".RGJE*)1@:
M0M,806O4:^XVUS02XQ,N4-J($H,H6[4H-A-+-:Z&*:0NJ.PO7=8I;`[7R:J_
M57/2LTX1^-,DK*:H^?O](4Y?<.]GC<7-I3[D;/ES,4T)%TB;:6.^89<6ZQ^J
MSVQZ+P_0E=3Z4QM4?TSC=0+;RZBK:8[>_#^Y(Y/J$&V]>I1A'?,2+<VN85L.
M71&93F=1`?DZ;*5FT5T)[.D&\&G=N7<K>E)K.8^V*]3MRZ>48"'Q.Y*&:<+\
MHF?9PAQX*PW>&-L.S?K'C"0_)H9;$;@WS9IS+>.CC=<J298606QL6B+VZ=]1
M6`M1$"$"2N"AT?3`HS2+$>3X,.WD5Y(G343'NO%H:CHJI<ED=8-&ME>6MJCO
MF9@)OH<RM--GL%K2_NSC_L@4G.I/;%4@=1B(+J/@+HJC(H*G,'0.Y@@IW8<F
M3A:M&$6:>A6AE%+`HM!Q!*IQ<"DCE@Q9BVPA:M]B5N\/&G3E:O//1%K9SI[A
MM7C7VP,SAENP^S9QK&=`5N>+RGTSPT[LPM14PB%`]4'IS\;5I%'M87+&D-K+
M-728/*WOKC7[:KW&DGQDD=ZMYRS+Z&2J$6Q0T%[@;'>%!T2;^I$LMZMB*ZGJ
M^4!Z)8G3KE)#WJB!).\>S$06M)IAHK6XR?CE2\8/94N?=IS7K9?>0Z*%Z6Y#
M?%T!GHH\&G=AH!LF,<RN,NH2$]B)WS5>XX[M'1V'NU`9QA0_H6<5?CF(^FCJ
M^R2`$+!,CB'JU$OG(-3`=-?0'GRN.CW&/$);+ZVT[=FXO.<JCL,ER$UABD/0
ML0._W,&G-`G)S)XT(U/VZH@`?>?C'1RBZ)X&.$MSV=+H&A_STGT8:VRZ6^E]
MJCWT0[]6G7+I'0""#QZ1PYFM22+I/H!:8BB".3XZ(6[(UP-`ZQGC%$<UQQ)7
M7LH;8XV]`5?](Z\`/F>IS^`C_BT%FFAH<>=3O1Y8?\FQN[&B,][-)&ERTE'.
MGND$5SVY+.=M01?UT_%D)@@OJ841^62&B1,D$\+B">,$WEI+LX*^NDTQ!FDA
MKB_LWM4/$\!,&M<K4=*6X,E+:'7W@H+#(7Z!8P+TVX0F+Z+MR$)6IT/(2'-X
MO.V08?AW]=.7<)3\*P2NFGRA*6"3M@5L@H*=H*+'R0C]8)Q=EQ-?Q9L:+[%/
M=*5^I<'DCV<9#J,BOR*XDKW+-:DW+Q-97N;IP0)^8)UM$.WMB-)0M1[X`)!"
MR^-(*@70GI(U2G$]ITYT?5WZ,8AB<+:?TOB\Q+?I.7P^3^,H%-TJ,:2W7!]:
M7R[!&LM%@AIB].GJ$A%RN*@XZ,!A\C5#QM/PW\N\@)0&<@F0+BQIG`VM2*>5
M3\T0[Z+H/CI[Z"5.VV8)+>@-[[@"R)^S.N4A_41IZ#KU,+78?@GP2>;J5\)0
MR\"=VS(ZTKOXE[Q,-,QTM<0J_,@9Q[$CQ$>4I,S3H>>%658RN#DK^,;6YN#I
M3NVB9OY4,].O^>5O^3)C&6#-X9"ECU$.=M<L:[BW.\-299[5*!-?-1`=6]:F
M].CRC.A0LNR^C/O#QX9CI'^+9.+1XI4NCHCY_%S>_3L)-K<IL94H,ZZ)8-BQ
M^VLGIIK0NI4BOQ-6=0SSI;9K]Y!?!B3*^R$S$#)CI4;\U?9CUW2&*EJK,>G!
M[FJ-D6QFUQ?;#A#KP>62QBPY.Y*PE0A8S<#!]D%6H@=V7.(RI-L\LG:N5S7,
MT=U;UY@*;8LK&W\OH^+E(RX>TO`B><1L]>WJ*<%9_A`=VLT]V9J%?A_V5R,,
MY..036D1(T8M-0E#-3UJ.W`?9XS'DIL.3QM('Q+\2\EU+R-JCQ+]2\D%+WFR
M?^G#I:X)@Z:?]0M&;$8B\R'-]CB[#FCQ[8]X?S>ZZ2MN:C<U&>>6>V>1MD)5
M,_0K:^CZHI]$T[WHJ52SS=>ETNUO#VD<$D_(O.0-?B3_C>D/GP^Q=+5-B]K!
M&U$Z,HT65*NH_OB'M]__!3':#:JH$6V!*+U[YV,P</Q#3H:C9AF.%WE>XO"<
M;@2R))*>U\PY+F4QT;@G-S`UDG44LHAU@5@?U:2K.CF=CX+7@](1$\=Y%,E3
M!]DBJD>/&Y]F&6S`0";Z[J5M<AV\P)].(1LXQ_DVBPZ*);5ENK>/_V6TPAF%
MZ,I`IV<X7=EM5_6.:/?PF$7S`0],94'P</:S.'+L&=4U&?5/P1Z?I_L@DIG'
ML*%UH'.<<H?NR+\0M$"_LC8>3&[&U3L$D$RW,Z8LG_#3[5-Z^Y"6>9"$MP]1
M5F"<P,?D\Q<UG=W)C(8<?+6G)T1H4$V$:BI$42*?Z:R]+SQ'*#+*;W5DL#9;
MTP59;^IFAC!/$F?VW_5S3/5C3%.39U%O?B700IFG)-'LWV,/6KEWU#-&WBB=
MUAEVB]$_2[<8A_D'H@_@&$XI7>U(%K.'6@5$#%E"H*:UGR-HR,.E#14-N]=3
M4\$N%:-C<S[W"-4>*RZ[,!LH4_3E>/OU??KX341W!`![;ZO_!M2][:"._?5O
M[=;!+P'DR$7^_AEGVRC'UUDT>OI5E]`:WK0EX0]XU12H)H'-7D:$*)4[I)F-
M3PVS*8,SY^I'G.;@4Z'3'HJE>Y'ZI)8O?&A)PYW.950,+U!DLNNIE'N.=@X-
M3)/LIKW_4-U=Z-R!Z(L-ER*8V/0.O^NC``:X[-]M,`7E#-OY*0EQ]I1%!<YR
M^11PK*5=RQCE=0B7;B-?)D1B)??&7:5ABT]?QT&>7^TJMWV5W43W#WEQ'A08
M,H9?'J+M0^W2V8^-:U><FIW;L?VGL^=J@G?4I$/P5!492C-$Z38(>F4IYQ/T
MVZ0#39,<=?IVGWXN@Q+N,>L%(3(KJ>#9*-@A+.*;@1TS"UBB4]N)R#P-C"/_
MJD7^50?6K%-F`@WNK_1Q;RN#658E5%S(:IXZIIXQD8,,0Y6(^J3D!LX]GIW]
M]:\G'S^>G)^C79KM@\)]BK.`E0R2G\5,Q.(B80!ES6F.=I8F>116Y3]N\!9'
MCSB\2FX)RWFP56TXFO5C?V'04$YN29#00^RC/<#+@YT^4-T)(O_=Z<9]G)LT
MNMP2X/2AG1'%;G&V;XQ)%)4&C>Q&F2&'0\C`[YV@X=+[JUB];@ZS%]&^K604
MU>N'L.E$?':9P1GA-@-T[<-',=+SR1*`>+(1HZJXHT/LUS:+J(Z,SJ[*E1^5
M9?1'S&B_9&+=F`5/'.6,-;I`0SBC?U,=(QJG<7,V2,#_Z(&?O,+:IEIC(^T9
MSCS`EVHL1D_EJ`=BZ5DC@3"-*Q/73I;JV(/9HZ$FM&>0J.X80<_HE_[RR7%,
M(V?JIE\IJ*WRTUU0ZLTTV?RRZ=)U%K*8Y:AGD]/-QN*]I4><0940=I^*G@<4
M+L]KT-B_HR3AG[N91-J>-(T1:^W!VKWV6'"7D/0&8D:<:3;%`JA%<[73W\;1
MH;0;*;1D$>X*4B*("3YN_.@/4\]KF8[1#""U6XI7.X;4_">Z;8^%M^^E)':A
M(^=>4G>8X*5JCVH"EPF!F1RCH;ZS*9Y6DI55%_Z5_M-`7<\@M"$WPQ)@:?EJ
MQZH.GSY'PE<@^79V,3_"Y^BV`H%X56?]5VCFVA6*U-L;9[ENY[BY,MX'118]
M7R1;>7P<:VG9J8WQROFRNA&<G?4EW(FUW+=FA8H7,F+A_15A2W>&++S!,C1E
MY]=8%&H6FO/"%UE8I]5)*?C.1?XIO23_F]T^!,G_*N.7MV^`2F[LIKW8!8BQ
MC$/P5*"I#\E1+%WDZ%.*:"\(ND'0#WK[9@/W2/[LBR>9-KP]\,T9VV6!>;HC
M'VT_^*XL.HR<EO=E7KQY.PFLQCT[!["Y+C1!33L>@)GT/@`[^P)Z\]9[N$\$
MC<H$9B%FSJM-^T.<OF!XZ?(\RO"6T,G1+B&P_)J2A'.N_E/5%I'&J&[M"\B4
M0]!_MD5/_W/J`)9%7@1)2+!)]_NJB1WYX`V9V641O.E#?_@IB8H<]J"CA,ZB
MY9?W%^S;<NW`9?3!K:ZVW5:W`>J5#P!IVW7U(^T<=7I77]JWLT:RDGKXQ92T
MHS!ZCZ!94($#'%FK,/9C2156=!06MA_DEUY<ER=<T.CZA0L7M[@9KN7T/L.T
MS,(M(94MYHPTM&OT8YQR;YS4;1`T\F,Y1ZCA'B@4ZET@GZAC$\$9'*LK8X+!
M@M5>NDA@S3!ZQ.KR!E-[<Y.)&,LL2E,V;8X"L:#MK*K0A9KNO*F1L)@.:-6$
M=11A/:.;9@2CZ=X<"[!X29U`ZR'(,=R-B^@NZ_MGJ`Y,ZSXF]Q",VY\$_G]&
M7_8OL4^0EU\Q9GV@MB7<,ZZZ0=#/"734^=UYJ)D]WMS%]WF#O51*(E^:'FWJ
M,"T1+DX/$Q,_%J<EFA8G)\O76:K<)T%6\R'%T0P%D?4*2U()QBH1M02HI?`E
M6&H-R;`DD>YXS%D&V99QF7^.0GR)"^*`F@_)P:(DL[QXH92"6Y>@%`A($*-I
M0>,+9C3'IC\1-AF8V;BY2)+TD1X3^KR-X`'M7+G#K4'H`CMR203H:8E03;7Q
M:4=<>Y!&(*0]0K/.$?)K,S_2L[`:BZR:Q+9/$^I)Q!\H'"R$LG4]1NK+&NA4
MX?A%SJ0$',%I,<&"YCT37+J6Z?H8F1%Z!R<LC:'KR4TW]O</:?899X\1<0J2
MJ:UI1W[=@!N3=,IMN.K779JANB?W,]II8VQT3TXQP`L=&OXQ2_.\KB=W';S(
M+C&IZ=P='Q;((3]#3(G@74Y6+K`B\^4DL:9(_>"@(Z!KOZ^+/^$98C7X['G[
MRRBXB^*HB'!^2BQVC\,W$I<^VMJZWQ[G>0BL3BM4-7/O>"7J'GI7I:[=5&6%
M2A+YU>Y=F4<)SO/3W8X^/`TG-4BSL*3/4[,''F7+WE-[=%K!U4QV>5U7VA=D
MP'5O&]3T1[?ZVQZKUT3=HW<F#F1U8">#8,YUZ6XE%,A4:.)""Z'L</;NY3J`
MAYQ$Z80NM>6+S[HR<;>;>]5P/J35/?L<U;3HW0MBU$XO+T^5[Y;,&_?!<[0O
M]RC8IR74OMNA!!=M?@$Y>LZ$+JH.7><:9A#M7SZ>@$]/]U#5;X%,Z<WO?53Q
MJR)3=E*=[XTM,.ZS=E,7WF'[$&5Y<0U?5[R\R+6S_.PBSR?WYB(T0;2-+^O6
M(NWV7UN4JG;&V'[&A,=08W!'&MH=W3%.N34JVL:O\15JN#?`"O7.J4OW$&4Z
M`\RWLUR=CN>33VM($[]&5Z3=?E$WJ6IG/8M;9L6#CFOF&]I^$I?GE'\0%]KX
M-;Y"#0\>PY6J=\ZN8?H2Q,7+CV4`6R88YVV4S]5O+NA26]XWU)6)VSADA*BE
M[.1]N2=/+TR6[K9?70+V_N`0*)&7X(J^MA`5L'58I&1N]QNF,[A=69091EFE
MF/OFHZ[G<F:X[6\83@"MQ7K]:5Y<[>I]GDOR_Y(<P]T+C4U"#5K[5?<UY.&7
M3W*ZH%`WV:":CB[F^;/UISU87&5\LY&:$\++)+Q-KX.7,YP59-9VNMW">DVU
M4Y)W[OH(8[M!#Y:#OHEL7#90PL.1*6R$H8H>51W4FV,YZG3ATN?/$A3\?K5(
ME^$XJ%S\#L0/FE-ZY"\'HHAMI8B@4L2A5D3G)IUKUV^.Z'XN-1'."VVR#U<.
M/Z39'F?RU7%]>G>;[@JYY)OO(ZOCC-Z#1?(90G:7R?MUO08KX_#6]HX)?*"=
MN;8Q4\0*M^?UX3JG4$>4@(Z;8J##]7F17:GI+!?94,O!E=!@))VJN?QFDTOK
MF2`26,TNV/:.LNPK,<-:3`^WEW11V*_K803!.3&HLS]<=WY:Q#C("_+13VE!
M[T?L]X&L7*11'Y9CD9E\PO,$M.IT$XBJ'JA5D3Y0IQ.G,6F>L)V,L-FO#2I)
MP;`28F#;MH?&PIS/^J>`N!^:)B-XSAX(6'3SM>:J&L[VPF(&4A++^R)2[D<?
M&NC83WNM$`A<VHR9'-VG2J%)=^I$XXX_1J$!K_Y6D"ZVEJI%W"DG0F,;L;3+
MX)!?[53YF6DO#BL6Z\BH*&+<+>[#,AN(.M`+_.Q#,C=;XHY5#>H<=POU,.$A
M$,4@/#S"Y$F*-PW6XOK'AIB>=3LLVM^564YM_6KW_OE`5QQOF%>[356FJ$]O
M^XZ8MEP\&#ND8&(U,:JH8770![.;(6-O[:\K+C$J7(O;"6V^&)HI7`<WPJ9@
M=<[9UR!_>)<FI3"=ZS2P?(*UPQFWRT)^0_1'IV=0)1QVT$OP>@>MR(0%GJYB
MC^!$.<IQ0=+W$%Y4W9*>7..60T+_%.DX#"Q>4"'!YG-Y]^]X6]RF/V9$L^$E
MF?M(-Q4E-/8OJTCXYZZLT*U"UAA<&VN.6'OW6X?*H>"NL.B-@T4PP==I44!B
MXG'E965`&F]O'T0"OKFZ!`=ZWAN.`5,];Q!0U%F"!PB2Z9]#CUKY%E_$JC7+
M%/N!'C*I5D*O@Q=Z$N.\E&%)NP?[KV5IRZ;&&R-&]1I_38X(O7OX&0XB][#6
ME!&<=3^I.>3#"N+!MW&RC>#X18(O"BQ>C=.CM7TW24L>_FA->YZMJH_8$J)?
M@111VK4J0VI>3)HD'.4^@A_;O2.TBY*`4`8QJH"=DV01KC:PK#%`!;T'C4BR
MF>.V#2SQE3F;%851OHU3\BOI-<UH>T(*&[9L,RK(\W0;T3G44U0\H)#>CT![
M>E03"F\0'MC74L)@FJ%]D+R@X!DVKU)Z$*_PX2ZVB8D,;D>9VH>]6/-^M\/T
MON-%LDWW^#9XOB$#Q7@L"9N5'TH360YLTHGUB&,D(5<_MB9&C!H1<@3T)-D!
MS-"+HX1V4Y]^7<DM%"E)2R[7E+22KR#R';+T,<K!<K^\PPFQSN(K]_'4'*C#
MD&J*4B(EDYH8Z6_DW^1?Y#_N2#BF:OC_4$L#!!0````(`"`PRD;/.@*T.$4`
M`&KO!``5`!P`<G1G;BTR,#$U,#,S,5]P<F4N>&UL550)``/<"GA5W`IX575X
M"P`!!"4.```$.0$``.U]6W/C.I+F^T;L?Z@]\UP7R[)=[NB>"9<O)SSC*CEL
M5Y^=V-A@T!(D<PY%NGEQV3VQ_WT3I"13$A(7$A22M%_Z5,L`B._+Q"TSD?CK
MOSW/PP]/+$F#./K;;WN?OOSV@47C>!)$L[_]]O/NXN/7WS[\V[_^S__QU__U
M\>.'WUG$$C]CDP_W+Q_._,R_2_SQG^FR_H>]3WN?OGZ`?WPY_OCO>?1Q\&7O
MX,/_^3+XRV#PE^'1__WPW]??_]^'\]N[#Q\__/KUZ],$6LB*%CZ-X_F'CQ_Y
M=\(@^O/>3]D'Z%B4_NVWARQ[_,OGS[S\\WT2?HJ3V>?!ER_[GY<%?RM+_N4Y
M#=9*_]I?EMW[_+^_7]V.']C<_QA$:>9'X]=:O!E1O;WCX^//Q5^A:!K\)2WJ
M7\5C/RNH4O;K`UJ"_[^/RV(?^4\?]P8?]_<^/:>3WX"##Q_^FL0ANV'3#T4'
M_I*]/+*__98&\\>0=[SX[2%AT[_]EF2SDN8O^V7]?SF+Q_F<1=E)-#F/LB![
MN8RF<3(O>OW;!][NSYO+M>XG>?80S%C$A?"9%_@L;^,S=+%A)Z\3]N@'D_/G
M1Q:E+(7OC+('EISF2<(_FZ8L2W4[J]>6E4['CRS)7C@K_\B#1\Z0?B=%=2UT
MZF0\CO,H2Z_]%_\^9-`^_)+D;,6';@\U&K+0W=-X/@\RCIX+ZC0&[8J@&^-`
MOZ/2)BQT\3:+QW\^Q.$$)C4NJ^Q%MV>BFA8Z=`GS\9S=^<_Z'*U5L="%&Q;R
M:?_:!Q6&.3]*_3&?"[3[@]>W(;#\/F7_R$$ASI^X5FB+:ZN>E<[,YW[R,IK>
M!K,HF`9C'^:@<FB!FE['8<`5=?E?_:Z:M6IEI$8IM#?A<OOFAWS-O'U@!O.R
MI(&=\7S'IS+++"_;W-$R:`;!I,66ED33#N,M[&)Y-.NM=G.MK$.&VHS6M[LF
MF?5*4-%"=T;)S(^"?Q8;5!#*-<PVH^EWELQ8<L8R/PC3._:<Y7ZHVTV#!G<V
MF2T^;'<V6S6Z:QA[K>#8VST00\VJUW:;"SKLRF#2?6`9]$4;AFYK.UHE#<>&
M49,MK9/&798TT6X7#35<IZ5=+.V&!.NWU^XYN![I!@VVLC<Q79SP!MKLGOZB
M(VFAS0X.&G=PT&X']QMW<+_=#@X;=W!H?;F]S>!_B[$YFHX>N0G=Q'BBTU*;
MC!XT9O2@W0Z:[L"4[=@](!E.C:*:K71(>S(45FVE2]K3G[!J*UTR5"Y)`RW:
M8>OU5;>U%FRT=<].\E9:G+9/'WS83Z6747WW0*VFVX3DIP\78?RK\4)4:6@7
MW6U\7M5IM5VCE`4SU`X-'79-&Y6./R8L!=(+>%?0SS4$,*A9-&&3)0;^B29^
MZ\*Q#A\-X_':=T+NTH\3%57\%T_V@9/[E`<S9,N&0O^>A47SGG9=;_]K91W3
M[>R"DR+((&7C3[/XZ?.$!9^A_T/^#PYD^/'+WB+$X%_@IU5O*ITH[+&"WLN*
M0X?WUSI<%>E)LMYY/QDOFX=_;LES/4AB4>+S8S$N/XX?@G"E"M,DGM=B=M&;
M6!=8GD(7XT?^*Y\4X@2FYK_]!KL?@#EE2<(F5R5/*(P"0T%F,[E._?2^:#5/
M/\Y\_[$4+@NS=/G+II07/WNKV>XT]%.8\8I5YN0Y2`6B5M;QAE^^N)2W6F3K
M(M8$));SH%-RKB([B^=^$$D$O%T8B-AS*5E-28G%B\$1RW7?@5P;S,NP,K)+
MX$0T8%558$P,NS1>]?"(Q3KL@%COH%F%&'D1@'E`4&P;8L!%]XI!+*H#PJ(Z
M`0`3#N(B]&>(K-;*`-##+@I+`$(LK4/"TEH"OV9)$,/V;W(&RX=BA*V5!>!'
M792>!(Q8BD<=D.)%D,+I^S^9GUS`+ZH%;Z,T@/_:94D*X8AE^;4SLBS54U^:
ME?)`P''WY;D%2"S18\(2+0_5-VP6\+-TE/WPY]@4*RKJ[1]3/#,JY8AC0<P"
M7\C+\!0H2/SP,IJPY_]@+U(A;I0%Y$[/A\VD*`2#B-&%>4=7C(L(I=>E0K[C
MP8H#_D$7A2G'@\C3A1G';%C^P<+P/Z+X5W3+_#2.V.0R37.62(<G4@>8<&J0
M;39,I:`0\5*VYI2H_AZ'.4@@>;D(0I9@^R!A64!.T7ZC*4XA&$2,E*TWBS6D
MG'QNV&.<<(<6MU2BNUI9%>"AD]8=-29$MI3-/26H0D%/8269Q8E\6[16$E!W
MTO2#0D$$2-D"5&*YSN_#8'P1QK[(`2LL!X@[:?E!@""BHVSVN4M\GFC@]F5^
M'X>(V-;*`-).FG@$(!!Q4;;L+.;_>#Z/RUBEVP=@*QWE&<^IP`'*%T-)1>"D
MD[8>762(M)M8?8"DSYL!-&T%UFCE6#`*L+'C\U[OU[);97^6G</#<FJTXNT=
MFX\U+)@(3K%AG.8)&TVU[NV"X+[!!_Y$(XSJ-N@-G!KHZLIA?3A:H,!^N,]N
M!ZD@QXB305GV@T<K9M7.:`U%15UON/^UV6K7`K!7K9.-T3K-`%RGZZ*A7-9'
M9'W`W1Z(ZE0Z+D9EV9ETV1L_3'7&(U[+&S0,5:V/!27X*O#O@S#(^*U'HS%9
MLT5OX-38JBLE\;!L@KG;`U260LK!T)3=W5WQKS%8C=KQ!@>NAJ]6/W5&K5E#
MWL"IK:Z^E,3#MP;X;H]:P?4H!X-UNQ<_XDQG=,HK>@-GVUIQQ\Q&HG8;WH#$
M?E9#&.)19P:TVP.NFD70P4A;?=YH$934\@Z^.!MD@F[IC"M9-8!#8BPI&1>/
M)#6T;H\>-.>E@Z&$]45C/*FJ>L.C(U>#"KW`;C3&#%KQAE])6$KUA"(>=\9P
MNST,M[*\NM@S;O1!9[>(5/&&A^XVBAM]TMH88G4`"(G52TXTL@F4@^KZ@#'*
M->Q@.&WW1F-`X96\_3U7(^HJ@"/$A&<@,EJQ9-6\?:>1O9ITB\>5$E<?[N._
M9B(!%`4Y+WJV+KR:-]QS&E#82.AJ8'VXG?\S9:/I>9H%<]A\R5(OK!?T]DDX
M&&H)5H"$SGW\1N-W7-PFX2AN@O3/4^AVD/%_R8<O5@N4G(1ANN[HE>.B<U>_
MOL@O_"#YNQ_F[#OS^:)4W+LM9BK]^5N[#:#-:5AJ(W4P1$DG.T`+42'ZNJ';
M!)#F-/RUD6J8@:23B:"!S7?^",.!0QPEL*-]C%,_'$VOXFAV%3RQ21F!IJ\E
M=9H#,DF<LFMI3'W`=#(@-+"V\$CB;W[*)J?QG,<-%3(;%:!@^%P6ZR[PP,?3
M@@69'<:\-6_?Z=6S1JI3%RZ==`M-K.(I`XH?`.<9>V)A7,RRB]@SI:)HU/:&
M-.*%:VF&-CXZ>1KJJ\*YGT1`3WK-DF)$Z"\VBIK>?G<-#CK0"&5XL.!S-MAC
M(%5@2)#(#EAO'R$%12@+1'U1_V"_*M0D<03_')<YCDT/JJ9->?O=M5[4PDHH
MS80]7YZIEFC5]_:[:\G0!]A"7HK=!D-C[W0ZB:Y<9'\=32^""/H2^.%UG`:%
MQNC$6*JK>T=?G`VZ9?>P5-OB@MX1B;57FUQD0&UCZH,[SVYZ[2,2SEN!J!0R
M%0+I@]^N:5;M(Q+^.[F<$,^.&$P?7'@K.JXDJ;7QPMX1"<.8^2A=1]`'SUQI
M`]8)_UDKZ!V1,%\@@A%+48#`DOOLB27W<<JNW`M2/V>#."O`$8VCZ+:D9"(5
M@;#D_J(@6?["DFS-A#][1S3.B:@XD!5RV75+[B8*TM+(P2%U9"MK>T<T7-B&
MLM9%9LF!1$$5=(6^00(-?[.A>+<Q6'+_9''FAXY'-!)W\8/5RL0"U3P:MV#,
MQ[`"DBVO#YW1JQRVWE<2MJ5ZX[7HO"W_C?N16LF[`=JY?=-88UNLVX3WE9:A
M2><`9(3-EI.&PE"N`-<_(.&5/+=/-M82IU(C1!AM.68HZ(!.LAZ-K9I^*Y[;
MA^,T18RL#H8P;:4DIZ`H9SF[BRMW?+7T`J_DN7V(KI$:*%#92E9.0>I&LX!H
M%)`PG-62,H+&5B9S]]M"6;8RB5T-K^6Y??&ND;15L&QE0:<PJ&N=`&0;*1*6
M-PO[/@5&6ZG5*>C`];+'!>;B:I7<_KI9VG/[B)ZFR%"CJQ".K6SJ%`1<R1VO
MDNYF4<_MNWJ-1"O$@@2,=-/^-ID$)9!K/YA<1J?^8P`[B0INV3E-6=ES^QI?
M(]EKHD.TP=BP1T$;;ECF!Q&;+.\>P'DTG^?%R>2,38-Q($_!I:KLN7W.KY$V
M:*)#M*&3!CU!)E.3#9WG]HF_1M)&T"#2-3;5N3^MJ;:W#8SWGMNW`!O)70L;
MH@7&=KA-+:"7/JL(V>M'\BQ[#^)4_;-W?L4_^S-ETSR\"J9LKR!.^1*.>4O>
M<$!B"54PO3ZX&F&U%'R?P1!VO)J.']@D#]EH>@+$38(PYS>[;]DX3XKYYOQY
M'.8PB"^`;'X;/"^%.IIN7@35NO=D_6/>D,0ISDCQ6F;#_L4!:H^EN9O_#1[9
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M70T&^I`W0DD%_S4]@0UPG`3_9).?L%%.*OP4>6.%ZX0-36S\<>^`A%VR/4VU
MPU`?TL^K-L4W#-@.QMDBB!+.J1N__(R"K/%L:O6SW@'1.(=ZVFN?&_O)\7=I
M1*@\*^O.>M#"X[)[SLSJKPK'U2R.^.V(T735V85)]1N+V#3(:@QQXU:!#!);
M):6\5`.X)G+B=H8;-HZC<1`&"V\\OX:=0S,O%PPZZH<KI#=^QNYB3H(?O:3G
MTRGCD]+J+X;&AU8^"X23V.L8JMKNJ.F7F6*%>(V1=?IJS'#FS0*Y)'8IC:>X
MNM#M&QQVN0D9)3,_"OY92BN:\`/#:/J=)3.6G/&`]+!XU#4'9`XV)]7.K3V/
MR'M:(:*2B'>524/'5VFE?6_XQ9U;LV8BY>$7$KY'B_PCHUL`^SW9\F;NV^$7
M$O>@1<)2B%4,I0\K?=-\R\,O)"XY*R0E%B\&IQ>F_?P^#2:!G[S<^H5E1&?D
M8G6`%B)N;.V1*X?2"Y/Z*[`?_AS^>9?X40H+%8!2CF1U96](XYRGD"0B?DUX
M?3!(7UZ/OK/Y/4LDXEZ5`=@D3E&Z`A*+=P-.']XN;9HB?TC#`%AC;[6!P>U3
MHH@I[S(*,O[Z2GX?!N,1'."3()H57@/,"H?7`)A$8GK$`A#8S51@W+[B:2*S
MPC-YS1+>>2/152L":"+A,,TDN(W)_AN<]*X"+\Q-?;@+/!P,W5N(\?L3*EN1
M9A,`DT1.1)4@5(9?'93O1J.M\_N`A`G13(S&YJ0!:C!\8^:D`2T3H5A2^N:D
M`6HF[)8Y"57Z;R]W\&W%Z-:H#531,"1:&.?:</M@AL)I@B\KIP"-VMYPG\31
M5ENJADJQB;0/-BDX8<#18@51:9\2E@<Z2-BJM"4G%KP$6X]>'?ON1_D4ML(Y
M/UA>^#R2(7M1REU2"Q@BL>MO*'TEPAZ]97:1)U&0\8"8:'(1//-_I4H5P"L!
M/R2V_@TU0`6P1R^8H4SI&+75E8$O&G:W-O>(&VCM6^0(J<5KQK0Z>O%:&Z@B
MX:O4%:JA2FP"M?5L6A?,M'M]L-,>'%KS:E3NNN@GOE2'BALTYAV0,-$HZ!;X
M0.JC[8-5MKCGK&&K62OG'3@URC04FWB:W0;8!\.K^-[F"4^P,"OC6+^]B.^^
MO_)1AF7S>`QU_%`+G_,.2`29;>L'8LUOBX(^V(M%%RQO;G\J3X/2>MXAC<")
MM@0OUC,U)7TP(Z\\+N7-W]=[@+J.0U$][]#I>;&5Y4L-N`\&Y`UPRO5(6-X[
M).$X4$M,+&D<4Q\"'A?)GY0KPEHY[Y#$.1^7C%B2VQAZ9/4M,X!<1A/VS"9W
M\66:YJL$#HOG*N13N%X#WJ%39U`K<[D!<K<AENUKBI:W6*\![Y"$X\A`N.;:
ML8&V#U;B\_EC&+\P5DDKI%P<T#K>(0G7D8$(D3V`%&`+AF`;)DJMN5'F$JK3
MC'?HU"QI=7VHC1]1B(Y9*IL];7(RYQ3)+)PVVO<."5A&:V@(8A.U1@FB@1:>
M#23KHG*8N,*VH^JX5XZJ8^J.JF.;CJKCGCBJVK$$'A.8KFN+M8XE\+@GCBT[
MEL!C$JXEM<1,+(''SGU%M`X`>U^<NH>LCO'Z!/3!&?2#965RM*LXE4WY:^4`
M/@%O3QV1B0>]`)Q;SPXRVO^(DS\!V^)1>6PPKY<".$Y=,[9DA4+K@X=&_5"\
MU)&O?&5^[XM39X[M\:J+V'Z"BUV>C%_3Y[')-S_THS&[?6",O\O%R7Y@&7#H
MY"R\VEQ5LOA=QVE0J)/.*U7JZMY@(\^_"WB&*1@'5)*[Z]*K..Q44/7JM&OE
MLOS@@(3K2R0LA5C%4/IP@&UZ)7YP0,*5I9"46+P8G#Z$.#;-V#6@$4=?8ZQN
M8.C#B?-ZV=5"56$O,TH*N!/^&AA;^CDD`M9K``BCD>4`$:58\";8+!U1*00V
MK</>?`))6Q<V*P)/M(R1-71`C*D/AUX1SB)LPU3@925O0"1FO;&PJWC<YFAL
M3]"C/$LS/YK`\=U0VI6:0!&-6\J-1;X%J@]!B*?Q?+YX>K'&,J]1&ZBB%7:N
M)7]M8)9"#2DL\!7,!JN[I!8P1"(^O;;HQ8`<AQFV)&SEJH[4`$YH6=3J";D*
MIA=A@UL(]59S635@AY8]K9ZHMQ#9"M)SY(.`O<JC'TP6SP*F)]%DE#VPY#1/
M.)DG:<HREUE^U[NW[%W9K64?U?X(@U:\O3HO0RGC]G1HUHS:TVX*H)"P=AJS
M+PK?J`O_W:^Q:6+><_MR5#-QFGH^]M[?EBI=!7O4WY;:,WI;:L_]VU+(G*^C
MT#(OAWDC0(93(ZC-$5T7?4_\)ASV993F"8\%46]H5D6]/;?OH-05&VH_$Z#K
MD3=D>P,DD?5V8>##?72F-6EC^"QY0#*6N/=]<:9NY&*NE`+\[B,Z;8_F5V`D
M\C4@JW>!<1OZ&FILT=:I"PRX#]1L+%I#N)9<'61&LNPDV\P*`7RYS\QA>^2K
M`5OR@V1QYH>.;KDN$\Y6<\TZM9LA^6^UK&6*NMYP^#;>RAJ2L%AKR@,QC1B!
M?;>6;;U1-"1A0S43HZF5K`#Y;B6+@`A:<:1B26E;R0HX?8@/WL&364,:]E$+
MXUP;;C^,9JT_F47C'HBV5`V58A-I'S*>6GHRB\:E`FW)(>8U')O;&&/$`O.=
M3?BM1[7P)*6]X3&)L-&:HE,BZT?,<,OO&Q&YJ]GF@KZ!M@\AQ2C6WQ-Y_@IY
M12"(]HRP(4I#1:A@[%%,\=JM?^C^."C$!?\.62&W:'(RCY,L^&?Q.\J.1&ML
M?0*X)Q&HWDR_[++1.-3YN%3%B,UXCQQ;_A&H/U@M4RI4`Y)(!+BW-"6M$-H*
MB"9JW7>8L;)E(__&U4H7)ES#_!Q#&A<$-;E56&DKD-[-\EMV4&+W`BO",C:^
MX[<!WYCQG=A=/[&D](WO^`V_;AG?FR;G&!*[R*<_5C<P],%>7MW72\18+0;@
M:9A2$+&(A;B-P+YE>Y=;T$4FO?3:?^'ZRX]BXW&2LU6<CLMHD[)/Z;)3?JB3
M.UU2R]O;:R-[NI##/'GE4/,*EEX[`(*&`T'%L\#Z7`\KG7UJRL:?9O'3YPD+
M2C6&?VQJ+_SD7;&9'YY'&?ZREJ`4@*64`=U$0NNB1K'1V8[J"K)$@&X[-XL`
M3*=W9E#FMP6TW6V2]YZ4ZY-L]VC8@K<W<'_=Q<8`K(6[#]O0)<+%DUS?6,2F
M@4X0M;PB$.3^9HRI/%%;O!(HB2M1^'S`^W\6P"X<ZE2?=Y9,`%@5P.O^2DPS
MP>I!M!23T:9(BW7K@C'91+Y6#I"YO_1B3W@;N$A<9[(Z*U\G\92E:0&(X]2>
ME9&*P)/[6RU69V4I4$MA&&T.X1O@'[A[`!;.V!,+X\(]@<M9NRXPX#1:TO)0
MU\!*(MY"+NT+?HOZ(2@VHL_*:7NCM#=T^_RK98D*T=E*RD9D#M^@JKQUMUB[
M`O\^"(L7*;5F=:.F@/NNJTHSZ+9"'6CJD1T5DE'H/C%16]JC0&TKB9S+&!F>
M*B_(^/I87`./BU=_6$3C<5=9YX)T',9IGC`-GX51.R#;&B$T2B^&I`^:_@M5
M"][>/HE`FAIL2WT9>KC=>C$0\5\%X^(2_2QAA0\4\5:@90&:>\N8J20$PL2Q
MN?59:(H-=5!(2@,\][8OG'<-(55QD'1>+*VLJQ[+;QTAQ0&@>SN7C'N!J*10
MW'H:%$,JFMSFCX_ABZ;,%-4`L'L;E:'LM"#UX3[G79#Q1>,RF@1/P02VD(JX
M46%YH,.]::K9"JB!KP_OQFS!^R/('FY86$@J?0@>[V*%N[]F2T`AB6P?$OEJ
M*H0.3K>W2)'9_>Y7?/[,QGD6/+%4/J,+B@(P$B%7M>0AF.%1B&ZO>JIV4='*
MP:FYC]JLX!T2'8@UY:@`:LF'X'32+EAADVL_R5[N$C]*X4C.2?KV4OV+8N'6
M;P2HIA2#UV0U-P7=BR=DJM"4R_AV86""Q,-_IK)3:T`5G^.W9+`<J>,\S!5K
M<[6,MS<D84W$6!;,U]O=;^&9%P=6\(>`35<;BC(S#+Y$:]0";DC<P],3K38@
M1-C=NK95H%R]#V\D;'$MX(;$!;T:PI8!0H3MV,I5SD"7410_^5Q+;V$K$8T9
M_#+6F7DE%;U#&DD.C:=C)29$DMVR==WXL'%4;9.794"#W5N<+>V"US$ALNR6
M(:O`I)QR*Z4`.XFKEAO"D$BLVF]$9MW*2_8]B()Y/E=*;:T<X">1)')+)&+)
M"?J.R*Y;R<.^^\]ZLJN6`_PD;$VZLMON.R([%_:CEN]=NMVY6%CM4%1(]((+
MHTY;5RX/!_2N7`Z%=V*WNXV(Q[$EYCH/YWZ6!,_*4\%V2>_0;8R7F&?!YA_K
M.B(2QP$_9W"F&4V_LV3&$EF,UF8Y@-]U>[8$%R(KQU$_U;[*`[.V2X(.NC]Y
MB<E62*7:?T0NCFT?93]/PS@%I>-=OTQ_Q%?PW^3NP8_^/0]?]O=X+55J:)-6
M@`_W\3^8F`02K8,.D?:N["/ZTCZ9`HY7#-_RK(+M))_E:;:W7TL##%L&WMS'
M##73BEJ($4WIEO6%IU_\X<^5KX-4B@%Z]Z&V=NQIV[`0H7;+/+.$I7[:8ZV@
M=TC#4;4M%;GTJKU'Y$<DZ&<9UU(J:IJ'F1]E//-I]@(;=Z`F>&(<E5Y$D%EK
MP`\)SY1(:H)9N@E(1`F(W#=>!B!+'F42%P1PE#+ZU#[^(,"02P^[LN[HB$M^
M`!(4!63N=\P(WRK)5!$@LG%LVOG!?BWF!-"\5=\543?22H#6_5X6E8)`8AIH
M$-DYM@&5[NK;8,*N6`8[;<T;*HIJ@)C`[7H#^6GA0238K5";ZSP9/_@I>UTV
MSI_'83X!O;V*HQE@G[_^274<,6T+>'1OB;)T9JF''=&A;F7$,\*N/OV8M^8=
M$GGHL)X26-"H*@^(3CFVE5T$29I=<T#RI62S'&`BX>.N+0[!\B+&B,C-\:.&
MMVP<1Q,-P6T5!%0DHO5L2@X!B8C.]86TAR#1D=QF.<!$XD5AFX(38T3DYM@N
M=1'G2?:@,U=N%@14).Z66)TLQ2`1T77KYMEM?I^R?^2<GR>Y[4E1`SAQ;]&P
MLY.6(D32.G3K`ID`H7)7C-;Q#H]([(^D8M.6=!43(NN.O1VVCE$9WRDL#WR0
MV$DI!*8EY2HB1,*.;6"2R>M*]1"`3EW`[MZ::<%AH(\5D7.W+&6+^U>I(AV\
MK+BW-W0?*:<O-O%XQH$A8NZ6,>N6/3&>:!?VKFF6[LFFZO62P('3O;<5X0HQ
M(7+MUN6TLT5/JVI[DB3\Y@*GBV?'>,V5<<;2<1(\*H9XW28]6'$ZKRG-P",J
MU:THK=M@%@4P&?I15F8Q>^7TAO%M$3"ZN*]T,N=9=<N_9Z^Y:46S2NU&@5GW
M>3(;3T`-X2.*Y=@25]'_T?26`8^E4)9N131X6U'/&QYU=T-A@!"1:K>N^%54
M>]L^IK?BZ#8!K/5@+V($%E&1;MD#RPBZ[RQ[B">7T1-+"ZRC7Q'LMQ^"QVN6
M\-@Z?R9[6%Z[#>^00%[EIDIBB!9)*=HM^^&IGSY(%(#_&="ZOV_:5+:O0!"Q
M=<P4R%]8OTQ3_HA:G@`5H)Q!/+E]`";3'^Q7\2?Y`^4Z#0!CW=T3U(&**(?K
M2+H\2S,_XBZO`LRHZ"!GXP8FJ208PY:U^,//*,C2.Y;,@Z@0D7PG8*UMX*Z[
M6P3++"`:Y/B.IPC%[W#`SE(-%=&J[!UVV!YI"A,1<L>LD[)YL?S](DYN6?(4
MC.NO)5L-`8/=G2R:0$:4QG$LW>NN=C3]/8G3]#J)QXQ-EJ\V89."JIYWV&'#
MI`%"1*K=LCY6'N0Z`>6=LXG,62$H#5QT__R'XD)DW+$KHPOMO0#2;OV0I:/I
MMSP%7M+T9#H%W'[&$W-#L4D^YG?N@`.626/TZ[4(G+J_7=Q45QIA1_3)<:@@
MOV440$\*.?#5JUC,BG3.T*=O+]>^[%E<O=J`W_TMC4:K@@E.1,Z[LB-B9X'X
MQ0^SE]]SGV]N^;/-KWQ(K8(&M;W#PXZO_B8XD==F.F8)C-.,NTW*+>OB425.
MG,8)0%D7>.K^_D`3):(-CF_27N31Y"Z&K>LI2S(_B!:/LR[VLFG%`()&B&NW
M`#QT=X6OA161N6.[8?4$L[E.P=(U9XE\3=>M#QQT?%4W0XI(V[&-;Q'*<)8C
M>Q-,RJIZ@-G]?8!&TM5#B$C5<1:XZD%CV=^3+&1^F@&.'W%6)`>8SWUQ*)!Q
M&\"%^XCB9F/9&"TB><>6N4)'5P!6&0=8@H>,2ZH`4O=Y$QK)50D.$:/C2Z_5
MI:7J9BIF(%#(*_\Q'4U5D[19*\!'=UWVM?$B\G<<KW?#@OE]GJ2%MHZFY\^/
MQ;%A\>['7:R2O&Y]X*#S#C@3I(BT71O1_/3A6QSE^*V>90%`T5T_F`@*(I!N
M1<U=^?P9Z?O_8N/L+OX]@4/?Y`IV#E+K!UH'F.NN%4P3'?)\;K=L7P6@(M@#
MA!,N)AZ9Q$7E@8_NV[@DR!!)=RMP;O18F.ZC6:G#%WF6)VQQ/KSV7PKBSG*9
M[#5;`,ZZ:P.KA171CR8V,*#M<Y4WZ/2?"T;_NOG[&J'L.6/1Y/5$O$5IDF</
M`5#Q:1S/R\\6(1T/<0B]3LM(X#.6^4&8_O:OCF)SUCH#YU9V<I]FB3\6V>OT
M*GI[&^ZW74):W1(N-O'?0*&P"U_IMY?7,@L]._GE)Y,[)"+%^C>`*!(OD.F(
M4SQT+5.!/*[4J;G_%L17`"Z9Y&S$43$W*O*DR.H!/23RQ5F6-Z)4:B:0S,R=
M4I0-=,J$*L+R0`>-9"IJF8F%+4&%)$SJE)#_\/F(4&=162L'\$ED3Y'(1BQ,
M`0KDEENGA*B<Z["I;K7]E<W[C1L'HDEDO]O-XF")+B1JZFWHY8\X*N^>+!]`
M@)U>7LBE8@7_D:LR/^W@\R`L$OD!;:F=9:4V9A(QGYJJ_6-Y$2'SD^RJ9R.@
MN(PC3WC1VD>]/;<!C9W5]C7^$!/1;E]M(:O?Y\\L&0?IKC5\]5F0$8G7H3JG
MXQL,BK7<V#$9L9G/;P[T3<TOXF3*`FY);F7SK?5A$!2)I[(ZI^I;'(J57=_I
M>UQ1]D79'NDZO4V[VTC=SNH]PB1B%C?V?I>[]O.H[@"0A1#6(6(3_RA[*)]*
M721&P)9`;B-`%=UUET!D-)PZK2@_#7:1`6'L*.K\@*A,&'^P8/8`B]L)SX<Z
M8\O=XG42C-%K=N0Z"N*EX>?JP^`QXAP94L8NM>:6(>>#:F%,H#V@-#H)@J7A
M&^S#8-+F&QE(QF[+5AX-WOG*37T8:743!$O"']N+@63`.#*4C)W''1]*"VL(
M]:&DU4T0+`U?=1^&D@'CR%`R]G=W?"CU\+S48_<X9<Z1`573D]YA$T3%1$-[
M2&EVU-MS>YVJ5T/*B'-D2!D[[IL.*<=^GNUY:8-E?)Y:/3C"+^'PV/W<#[&K
M_"3["8KP'AS@@G)D[!F'$]#>'V[QA<]/)D.)7B=!J#V./*#*-S*(C.^F9RRA
M$'=VKR;WWIC<D]DL*:(P+H'!($J#\=_],&?RS'`4N@4B?BM!#4X91JYV]2[8
M09>@RFRT^Z5'W2<0VGNX0]OT(F/"2KP#B=OO>[VZ_K[QOOW[]7?Q-X`H&FXU
M#7$BJZ5=*OIP_?V&`U9<=5^5`=@TO$%VY2A6E@W4?;C"7D!2WFVNE`+H)/P5
M&[*0"*S:;[<7TI$-Z9HAM>CR*,)EHJKB[7TE8?W>XEZP+U/"<'OW7%M>=[]B
M4WFMJ@!0$@;3>O+:@/&F[V1?[2A7P%<:AL%=K+BVZ+)T:=KMPQNAGZ:CZ2)#
MQRBYX8;-M1&Y^F.Z^&LJ>YZK5GM`9V]L:%PQQ&K7@)KWJ\O=NN?VM3>V+UR=
M=\>DI2O-[SY($IT$F?;F+L_VZ*#*=].;TA9<D)1"T@A?$_W:F\LY;8^.NNS:
MNC>].1A(N$P&O7*9?/WZ[C+1.NU^)6$_U1%GZRZ3KW@8=J>.YJO<J8N#8T&N
M;K;@S3K>WC$)`ZYE.2/*)&>A#RZ6*C)EBN#MPD`$"?NP0E)20\H6G#XD!B9O
M)S[NFYU8,HU8HNM-YSJ^\(.DB%XZ2=-\7F[4;X+TSXN$\?`F!OJ3W<`DT(;:
MZGX;Q-0;^_.Q?8.=&8V6O'5D;-5UHEY%C/'GC,;\*3F6S&4>E/8^"O+IC5U:
MH>8M\F?)ZT=&OVW-"$NJ_AZ'T$P(9[]=3NOBKX/$>F-KWM'$+B/RW0TIY^PL
M>`HF+)JX4/SJMT%:O3$B[UCMMVELS?M(PER\WRMS\?&[N5COT'O<"7/Q\2[,
MQ<>DS,4I&W^:Q4^?)RPHE0_^L:ES\)-WQ69^>!YEP!EB$A:4\J"K).1N5WKK
M*H+BIF/VU15RB0`U[VX6`9A.C;HH\]L"VN[VN_&V?>/MX$O?C+?;P]\V76_:
M>+N=/J2]`$OL6R"&OAAG"X6RK*YRVBP98SO_KM>"I2);;WH971=X?D_BM)49
M%_\:2*4O)M@6E1DEKD^V5W[VN4S3G$W.\@2&;0FVX"4M_K@>\BE_F,NX,>"S
M+Y91F2+6Y,62H9-(PIX&(['RXM)R.+8X80J^!O+HBRFSQ0D3):ZI\;(/#V01
MV<32R&E!6HT1VBS=7>AX_L_M&R"MJ_%V_/S@"XW$'*35&*&-RG-M-/2X?LKU
M'?<`A$?#64):YXW(M/M.6P?,$J@94WC@;6L\V.N%-]BCX4AR.R9L$VKKL342
M]HVFY"WY<3XLC#H"@J1QL8+VR*C!*8T'U(@,#L&!W]7P,.P*").&$Y+V`*G%
M*HV'T=[/%X9;XKUW_Z9=,FV]:M:/DW;]EYAVW`,0WKMSU"Z95)XC<WP?J_8S
M.`/5J-AM;T"H;\%KZXI86R^-D=D_-2#1/--4*Y<:Z_<&1/I6/,<NB+7U,ECW
M8R0JT\WZ>QV[.5NL?Q.$\^YH;DJ?K0>[^K%KJDP1ZV3M:,+?^"B(Z*WXH%OD
MK\WGM$A<;!SVZ6+C8/#%V>S1J8N-@P$-[XN&.)%Q;Y<*.A<;;>_/RAC>$Y@0
MXB3X)YO\A(DCJ83T7H=^!`QM/RZARJ!G_VL@"AHN#[NZ9;(UL\`?G>N;3E1Y
MFQIEVK\6O@:B(.RLL*!EUI5:SB3]IZ,,GB!:O-DS&!"VXEN0V;J*R&EXT[='
MKW9TJWE`PR;N;G4UI^M-/ZG5O0B!06\LV5SY'$<(#%#K=3<ODMKCS<6]J$%O
MS-4[4>TJ;7U+Q_>VO96#WEBU%0/!!;$DGA"C,=\[OD`XZ,UEJO;F>X0V2_=@
MW6:BA/&9QF$PX??)5Z\_I*/IZ!'&<8'>A>/F,H(.LE5_-#PV2`UO?R,'VTZ]
M3XO.*/TM:P6ARR3,TU)&D8$F`$+'Y=%N+L=](FFQ!")8%Q;:>3H6_;82,NZ[
MS?:$,K\MH.UN]R(AXU(YM4R16X6!"!JF1>484V'H@QWZACVQ*&<R$2Z+`&@:
M%C-$'&+AK?>^1^^H+/9VT8QG68]2EFKLK]`ZP`X-DY&1;!5P>F2/O`%I`),/
M)]'D#!0ZC!\Y20O8TK$KJ0<LD3"/*,2(C6LELCZ9\E@(;<Y^9Q%0%0+FD\D\
MB`).4Q8\,;4BZ#4`O)&P)-32"!.(/3)=;7%E,O][^S1RCM02.(+&UJOL<>:'
M-"1;'N*OY(EU!:6!#Q*1F\VDNXG'VDOCS@7\(X[B=90+@C2V<LJZ0!8)"Y39
MEDX3EJUD5Q0F\,OHB:499Z@$7*5`:BO%JP%)).Q8FM(4JX(:8)]2.Z%4U9D#
M@!X2X8*-Y*]`9RMU$8%E@&5:*_Q:.2"!A!FMF8BW$=E*M^->K.=^PGWGZ35+
MEH[)8,R/JT&8<Q^[>HW7;`&(ZZ!AS@B<K>0S[B]&*V#7UP8@BH0)STBNM52C
M1&HK"PN%Q7\C[J:,3UC$/%<#U33F#-.F@$P21D"SR:,>RCZE(I$Q4"%`?WJI
MUR`02\)B6$\AS)5+Q41;&3Q(7/\^Z-7U[WUW,47=NOZ]3\2.I!8GXABP2P6=
M6*CZ&EAB@J\H+FZOE0/X)*Q*EN4I5AH!<CJA52Z2)+\2$DWXA<X?_KSN;>EF
MGP-AD#!N"30$F7]:(Z$/X60W#&;P8%Q$+L,,CUZ-EI8'.DA8P]H3-1H%@9'1
MA^@T\K>D]VD8WG:Q(-JBZTW?DBXWKI<1C-J\O*.1/;#D[L&/%K=4?L2%UXM-
MVKM&9-H'$!L)PZ(M!;2LWO7HM!2;V)G'FFJSM_[<CY/QL-X%D!\-@VE'AX.(
MS3Y%:K9&W-^+2<3I2%CO`LB.A.VWJR-!Q.;[V\(:Q"W>\7$\&+9ZX0V&)()I
MNSH>$$*;QO.^B2%!\MPP)!%]W-7A(*3S_;UC0_(VG+G%[O,,)H(+/TA:>U#`
M8O=`[#3<;UT?19I,O[EGE"T=Y&B.,\,^@@K0\'!V=+#5HKM/4?R[.BS2'&V&
M?03QDW#D=G6TU:+;VK4)YY'4K1]$^3O!-`>:20=![-UPC1,=9>9<O[\8_=9.
M:#2B`#HZP$R9IO(0-?+0PPZ(TAHB[CH#8NIQP(!K7NV^/MW$0+'S`;!^O*0P
M"E0]`I'U.%B`!+DT+G7M?"RL'_XHC`55CT!</0X7($%NX]MG5GRE.Q\+6XYC
M"L-!HU/>X*#'`0-4^+7U\'3'%HCNG!8.>APFX)K7WC])?0>-Y0"M3S>3#X^<
MF?NZ=3/YD,;A2D.<B%'-+A5]N)F\R@-2,LG9B"..7_7$M*P>T$/CZ&%7WHA2
MJ9GHPTWF#73*J\C"\M[@B,8.7"TSL;`EJ/IP.1B`S>-([V+P5EF@@<3.4B(C
ML5`1)'VXT5LS\<01C1C(74S?`N1OXLIL%Q)/')&(#A1H2$V?;6T2+%U?I91X
MXF<49.G-[4_3!!3K]8">;L2TU1:]6-4T2+%TR;.FSB#VM[M?\=U#G*=^-+E[
M")*,L8B#1I5`70G`=B/>RI(&Z#)"XLD-1`M^1M"97TG`@QKEHM\NZ1T2R;._
M2WEC-%AZ>\/M3B6_3X-)X"<OMWZQU^,3FLKZ@-4!!FD$A^W$\B!GP=;=-;?:
M\8J,CY/1]`Z(2_TQ1Z7>E2HK`U,T8J?DHD3DKPG/UATKIXIP>3U2;A5790`W
M#5.UIH3$\MV`8^OBCE,QCF!#<1*&<?'02.E54XH5K>,=#FCL!1J)60'/U@T2
MMW:H*(/I+<SYRW"W;)S#5B9@Z?GS.,PG;'(!C/+5,2\E-YIN9:1_$3>@LFJU
M]U40Z-MQ<;3.HZTK'`1U7,M\IJKJ#;Z2\)NTK@@F^K=)CZV+"DZ5"*B:QLG<
MC\:LH`P_'RMJ`"<DO#%ZLA/+70K-5F"^6W$OSO^*A:Q:#-#3V/3L8N79!FXK
M_IR$V)4+PX9]Z."8Q*9C6RIRZ55[;^O%#KMVZ1_L5RW3M*J>=_B%Q,(MDH3`
MSJ@'AT:$KYV1>!=D?`J[C";!4S#)_5`Q$PO+`Y\TS`V[F)(E#-B*?G4Z-V_A
M^R/('FY86#"8/@2/=_$Y[&FR%^7D;=@2'/=)^#(E`M;4"!V<B*[LRBB)K`,W
M[)7T)\"D[ZE2UP3<)#R5M<0E6"QT$2.2[I;=LOEUA2;1,^J[$(<#$K$RN_%[
M6:(+4<QN658+J_-EFN9L<@:'ZVA6WLXJS\O%'Q=W5\Z?63(.4NFCA.:-P?:?
MAN)9T@E$XVKR@FA8M^R:!<KK)!@K,\,4A0`YB6U,RQJQ@1>1=+>,C[4IHY.B
MLFYFQ*\TP@#:U]E=DXH,C&Z9:0M:[M7,W2/,K:<36#&TIQH!+7P2I$+#5M&^
MJK?&'J+3W;)!\Y"#,4\[(9;$^3/_IVR.UFL`&"-ALVY7WTRX0+1G5Q9P2]<!
MYX]A_,+8+4N>@H5[;@OVZKI\061Z%V=^6/W[:9QF/^+L/UEVP\;Q+`K^*3V=
MM/9-;W!,PDK?KHZV3!^BUMT*1FZ-H\5"$B>+GW@YV?*_VXZ`!$D$"W1T`$@X
M16X%=\LE4ELLQ?_PO500S6[X<:$5*^CV5X![&C$2-,]S&&&(LG8K4-SN*??W
M)$Y;45K\:R"+MV!2;8LX1(G?B+NIBP^\'K\5>_'.V$3&0,<\6[4]B#KVRJ6G
M1LNQL9M>@.Q(!`@X'@FV"44&PZZ<<$BDR1]^4N"XBZ_S9/P`6$?32B(:+,Q$
M40T0T[C_VHH*Z3.`R'Q7[CA$YI?\:.B'U_E]&(Q'4^@'=R5S305=YCD<,*DK
M*P+J'CNP3#A`)-\M?]-IZ*?I:+I0]5%2'-+6IK;5']/%7U.9-:E6>\#G&_`4
M-:`&437'*5:$XZ1($&,TNQ0U`&>/G3=:X!$A=\M;LYTR]88]\1?EBC_</H;"
MI<>@MG?P%CPHVD0@2M,M7TAE4W7M)Z.D2)HY*?S@RPN=LB5'71NX>@->!VTB
MD'R3W7(55-"6T9&C/$LS/YK`K*JG+5O5@)TW8,Q7,X#H1\>L\[)(VJW95)Z!
MVJ@EX/`M6-7KD((H5K<LYEOCYR3/'N)$$5(BJ07<O`&[M)(`1#FZ94J^7G;5
M5#_D%8&A-V"PU>$`T9)N7718!UICSZO7`##68QMM'2X0[7DCER?.6#I.@@)]
M&^[82O/`=H^MQ/:90O2R6[9DZ9;P!_M5_*GV1GO5@'?XY0T<YDVX0+2G6[<$
MI(#+?U]&XX0!FV>L_&]=51*W!ER^@=-_;6(0)>N6>?HZB<>,35*>0(Z3P!-^
MJ;SAVG6!IS=P\->D`5&771FF$9=5$;VG1'`239:..,R39=P0L-+C0WX33I!'
M<'9EC48T9>F@XU'XF!)4RP"6'I_0$;B(Z+IE*-XR3)6KHXDMKZP!G+R!X[84
M/*(0NS+PMOT6\V9$[%;(["*<@^>5^9'+DC@Y[!)(JL=G<QKL(N/`A2T[9>-/
ML_CI<U#<-N/3XO[BWWRD[%<FQ/)7[[+X#T>W7*=5$<QZ%8&9'D=YF7"`:(?C
M..'3,$Z7@8YK.S8X%8ZYG&;H^_(:50%YWP.\M%E`Y.\X9MC)I&EX5X)F1[W#
MO1['I%'F'!E)';.;U^7V1[Q@<?OJUFM(#[H/W>7G05IOP6:_,R81O>^6Q5\4
M$)^6F;U`<'\\!..'S7CXRN1@>`E!OV%@^`V8<6UPA&BAXPS[PGL6T/G'@!NO
M.$(SK6K>*+#5=]NO!7X0;>I6*'OU@;9BOE[D)UY8R2ZCRH-MLC79H!E@K\>6
MY_J,($^9=RO*O0)[>0-1%1N&50%6WH!Y6HX>T8EN.2PJ$$_A!!4`AH+"&S9F
MP1.;C,PG&74[P%^/K<8-*$%4RK'+XXXE\]5RC&UJU@H!FAZ;9S&\B/2Z%70N
MC>DI#"YU(Z6*RL!4CTVWICP@&M.M`/3JUDE[7X'5`59[;/[4A(^HA6.;OO!8
M!NI=,%/3RF*G86"MQQ9!FQPAFK4K&S>:_&'IZ.1(+N)DSI+K@G%,9?`:@+/'
M)Q,M\(B0'6?X>'5<CJ8+?\W/1=):3,J2*H"TQT<(/?2(G)N83('(SU4FH9=_
M+CC^Z^;O:Q2SYXQ%DU=1;I&<Y-E#,&/1IW$\+S][&<$_V9W_S-(SEOE!F/[V
MK[O?O:QZ<1:DXS!.\X2=W*=9`L<RR?Y%4LL[V-CA-O*CKUXFX^H51X4;9[KZ
M^B)#_S<6L6F0W<D66?.6O`,:6S$EUR(7<TVTR".QW=J/\PN+?)Y9[!G*2&GY
M`[%H':#%Z=:JD32QPYD4*_(B0*=4H(I,^>#K=F$@@L;M);FDI,[(+3A(=B/'
M9RJU/J\V"NCQR:`-H,*I/]KB<*Z)';E+U*GA?<&X+3E$`)_&419$>1#-1H\+
MDW.JL:6IWZAWL.]THU!3$\331U,:$,]SI_3K-$\XWPLJMDB0K27RFD`1"4--
M4R$C*X\.>.309JH?3RRYCU-VY5)-SA8=EK,IT1:]!H`W$KN1=I3&A`.Q[AC;
M=2CH3K&U.XDF5_`)RPM9TZ:!:_=[)%O+F1TRQ(K7K>OZB]EYC9`:2YN\/M!%
M(SK/BMBERYP.$6*],8["HS!A+>=I'68UECR=9H!#&L%X+2J3.1^(B<XX%(^"
M4BV&DKD:R2MZ!T?]6<%TH"(Z86RWI:`3/--<*:@PC'_QE!?+,0+@3]*49:</
MW+ET&9W,XUSH(JW;%`PPITXUJWI3#SRB2<;F7PJ:9#ZMX!.OTW`^JWHAQ8B(
MW]A*O"U^MY[5O9ZX5O?;<*WR]V^C<1`&A0"XZ\#/<FCF9?-,?@-[E+N8*Z(?
MO:3GTRD;9\'3ZB]Z[E>;7_,.AO1=M/LJ%ZU]1M[=N%L.LR$E-ZY]B1N[>H?O
MKM[2-SHD85Q52$K?U3NDZNJUI/-*=[#M[P"E[@^3NYLZ6N2P#Z[GA74GFEW%
M:7KJ)\G+-$YX/*-L6<(K`3%.KX.T*&WQE*6BPI+[F,+Q<_.XG?+]X>*WQ=EK
M+68VFBR.8NGY_#&,7]C:GS5LJG8^Y!T<N(]FV*5*MD%?#[W<*WI.'_PDR/CZ
MP8W>27"?<YBZ<V&=YH!3][MWIRJI35*/7.1;)!0YD4U4JZ@`O#C=X;M7G@H-
MEAS969SYH5/EP/<1VW;O6CNS[6:`0?<'`1I[-8R<IO[NXU*](C;C;P[1FGVN
M`O\>>,\"_F2(CHL;J0E,.0V1<#\?B?BPY=7>G)G<NAT&/7$['!RUX'98*=.:
MLJUKIJ9/0;LI@$(B,8>2;:G#P!#NNS=@RZ9ZX-[J4EN<QJ;^`]2N\L9,_8<D
MG(4*2>F;^@_Q-^O=FOIU%%IIQS=J!,AP;R&P-*+KHN^#>5T']LGRALEJT[I6
M6#(G6&@=J'8:DUI7.<2SBC5">F2VU^%$'*TK?8^S2;/`L=.<+KM7.CD3/;*N
MZY"QC-,\C^!X4)RC+<QSXD:!7_<1L#O5-!D//3*FZU#Q(^8&CQR*P<YDX?D2
MY_=!'O)K[V,@#_<GMIWJ91U^+%GWF^EK@S.!"/-WELQ8LO@_Z2(G5),S@_9'
MO(,C]X[PQCK7%B\]NMJF=UI[/@5,0:;,`5NC-9";^_L%.YW=A`30N-F&9:I9
M7I9Y\H.P>*(P#L]R=A>?<6!I'`83+$['J+YW>-0#7:@!N4]WV$PVGEON,2,'
MMN4OP=SNWH[F9/^O34Z?;LB)"1+=939605$C0*#[4)R6M0O';>MN'2T7]QVT
MD@.>?CBZCX;T`IHP'[AF30!%(HN"DG?3(*0*NG</]Y8K\8A$%G`MZ1D[M(]0
M&_`;<V@?T<@!+I>4OD/["+6Y=NP-F?P^#2:!G[Q4WD!2#66L#M!"(F2IR5"6
M8^N#X[KZI)X_AW]6WK92#FUU9>_@*XE%7"%)1/R:\/J0.O3R>O2=*1Z)7I4!
MV"16:5T!B<6[`<>2<]:I%&]8R`/0K_TD>ZEPD7Y[J?Y%,:/K-P+$D<B:UV"*
M-P5KR;5*1DN4<_QV82""Q,)N*CJU`E3QN4V=B1CS5V\&<7[0^1HK"L!(O.&'
M42XPQ:,H++GQB-[)OY($F1K4!JI('+0:S,_:*&TYX9QJQ)8Q'X</.]K_8N/L
M+B[>5S>^:F_4,#!,(OV[MC*(=<D&";:\?7;7!1S(:__+ITRQY4*_!>"!1.:A
MFLI0"ZTMWYG;&/5_Y$'V\IUE#_'D]2G"T:^()>E#\/CZ;)W,9Z;;!O#F]-*Q
MI2G#$*\M5UE%3W;I)<-VU.Y=9EC/-/QFJJK><&,^VZ7UK9(>2^<PHW*IU6H/
M""`Q5/4$A9CJZ@/O@P\.`5W/T%.<F(<T+#L-Y&ID[WG%W`?_'`+2R-:S;4H=
MTC#E*R5H)/@JMCZX\'9M`1X2\03L:)Y`*>B#+["I77A(S[RH(SIMN_`0-SQV
MS-DWG[-)`/`N_'D0OI1VU='TNQ_YY>/GH^0Z":)Q\.B'Q5E'[1JLUZ(W/":1
MV@`3-N(X;`+6K9L1LQ^-\S!/Y0Z%:AF`0F)[J"<WI/O]<.7!V2@?9SGHV^PZ
M]-5;?D%YX(R$0Z^%11Q%VX>7\;;@:2S:PAHP'HBLW*B\-`5<Q>/618C,M.7-
M1/E,6RWC'7PALD)*F!9,M]L8>N&@0R8F'7^MJBI0V==96`>X8\>:M6A*/PE8
M^@=L!-.3:#*:3H,Q2U+-A.@ZU8%I$CY]/:DBUEIMG+UPO!4!BI=IFK/)63E_
M%J[%(BM"^H/]*OXDORZATP`P3L(QVT@S#)"VX&S;O6Y\#Z(X";*7RRAC`%'D
M6OSV\B..QCQ]>AR&_'Y>442B+K7;!%XIFWBU-*@A>$2INF7(J\9%YZ5QHAQ!
MY<BZC"JD:H;WJYH!]D@8@ALN2X9X$6WIEC6P`OLZ@748!DH!6T\SUJH`*WW8
MG$BP(1)W;+\ST=S1/&*CY'N<L#*@)4Y2P!DG=_%I&*<P'6+'4JL?@3,AB9#"
M.IK2%AN(;AE;)&'A<YR?H4+.&4O'25"`6KN?HS>[8+6!L.[O=75A(GK1Q%BY
MRZ@R?O>._2.')L^?X'\(1)-M]D@CB@RKX@TW$L^X@Z$,#A,4A^Z3&$=R>I'Q
M@^+I0TC7)CKXGL9-;$$-H(1$>!\N+CWQKL'I0Y26`*#ZQC56!V@AX9&52DU;
MT%5,?8C*VH"H#*<0EH?-``GKC$)>6D*N(NI#Z-0&/!U_$%8%6"0I9L/Y>@-/
M'\*FQ&F,3Y*$9^+C<3_?7EZ+7/LO_*<3?M=D5.!.?X>"67JYN%FD>A6RA:_!
M>*.X%=A0%42]VJ*C#WD?E.2D1NS\P8+9`QQK3YY8XL_8^3-+QD'*"G-8$XVU
MUPL0'<7MCAU-MDV3_4"W79H/3E<I=]EDE;$K'4W+!*A`0V%!>8A#0)66]_6<
MV!2675N8=-8ZI&-@T*GO[0_<61N6'53:&=8*0I=I6!CT^<5<T]NP>F%H6.(J
MJ>!S4AP5-AC-'(ZB>D`/C9V&0&@*\>)P^F!TV$"G-#@(RP,=-%9?M<S$PI:@
MZH.Y`8#-XW)=5)H:MLH"#23.GQ(9B86*(.F#>>%D,@E*`-=^,+F,3OW'(/-#
MI7"E]8`>$B$;QH+60-4'<\,-]Y-%;'+N)U$0S?#K.?(*0`B)F`QC,<O@].@E
MO=4BIF4TW"H,?-`(&S??:6U@Z,-]+,%95";,S<)`!(F+.)B(,(&*<5BZ8_58
MA@!G?I*Y':A%>,\HS]+,CR;B0"FTK+>_3^(>CZ%DQ3`LW:QJ+E@D'.XU4],%
M$+#*(<GP!_CP&MZ01J21GN"TP)!^K^PR@KT=[.SR^S`8CZ;0G2":SOBC1FPT
M_0E_1!]>5]?T#HF$0IC(4@\4C5?(#&0Z*SJ_9R+,114`3,OZ4$^*:VCZ]#@7
M<H>GT-GR9YB23OWT0;4UTFD#%B02<<0U=DSZ\&S=="*L'=78Z=KJ(6@$".S0
M\ET7GZU;2Q04Y&3R7WFY>TGO8L344Q!QO^E"O6%P^$B#C-VRY*F\N0&D\1?R
M9E'12C&^I.:R=C\-PNK0_F.WK-BZ2D5!A7^PK'PU[DH>XK-6#FCHT+9&`L'6
M%2D*DFQLS]DGX4MI;L_9Q^_&&EOHRG/_>33IM#F'A.^DN3D'O\5:TU"W+E<2
MD4*P3[H(XU^IX[B@53_,PH&VJH'4OCKW5IA&`>W3,FRCM"I\%A4T=()_4C;^
M-(N?/D]84$H2_K$I0/C)NV(S/SR/L@#-`"LHY>T/:5FN*R)8%Q;:>3J!.[J2
M*A&@T3F;10"F4RL(RORV@+:[W8>(F\9.W"$M*P4ZQE08^A!M`V<:OCA<)_%3
M`#N0;R\_4WZA?_64R,DX"Y[@_,I2V''`#SG/(5/^4>])"CL?`,+)6A.&J/??
M)G9+43X4#IHU309#$B8#FS+5,C,,43-#)ZT,:Q8V;AZ+QD'(UC#?Q9H,:TP_
M;7P.9$+"TM&^*K;'GJ4`*`H:?<:@S^-`_2SA:S'@@(1)I3WYBO5IFP-+<5,4
M]$!\UTUE:=NJ`+R0B&'=M6[(V+`4A$5!2X"]A`'*,U;^M\+7PK^DL:KI-P+\
MD0B9W;4VF3)$(TZL+16[3MBC'TS.G_FXDEDR556!+!*V35/QZBJ)"&WC<+/C
M4C4B-N/6>F*J<3(>QSF,RFO_A=M!3J()_)+DT,_`OP_"8L`9*8Q.@][^`0D[
M:UMJI,]!GX+AFIU'6K,A`=$DPN9V8CEHS).M^+LLAM%#41W+B/$639N&'P#:
M:=G#FY@V:V'O4T3?(H4)CQX;_R,/$@8,`>SLA;\CD\%"P(-,'N?BZQGFC0"!
M).SB-M5!K'"FG#2.L2.T:VO&;FLS&!!-V21O4?EL\&0K5)#LPGH11#Z<ZMM;
M6`T_`+23,--;65AK8;<5Q$AB84WB,6.3E%_S6WL*D]U+EU))-2")A!7>ILB1
MQ5/)@JVX2`JJ<L,>%YN%]7?=%*HBJP8DD3#*MZ\J:A805=&WQA/:654'!K]K
M!"RR45*^5J",@5=7!L)(F$MW.\/(N$#"$ZG<QZY>)J]JOT`+%#6\_4,2)L[V
M1*]%`"+O'=_5IK#O;6V_"T13MF]:G&1L\(0HI+'!W?TQK*"BN(:RZ8"0J!I>
M">CIH!U2A0<1=P?-V8IKXN4%Z4,2UD!S$98]1X1E;`BFDD5)3V0D;&BU1(9:
MM0;&<<GD[].5284>6!:,'3WDU<;ENL-#5V.C]N6Z0Q('<36M2)2;`,V;N5QW
M2"(4322"=6&AG7\#E^L.G1HL4.:W!;3=[??+=4#6$0FK@WJ,J3"XO5R'&(B*
MIW2$IJYI)2/W233YPT^*ATLPNY%Q0T`*B4,^)BZ!::@F1K?IK!'!+_/8G<8I
MFE>S6@:@D#U,(^+:[K[;UZ(T)/%'D#T\L'#"E6NI:#K2$=4#R&3/SAH2PR'U
M(=7T]<HEM<H6QR<2#ERV/LJJ`3ED#][;\M9'9.E"E=U!NXA^KBHL.E!%9;TA
MD<?\]`<G#L/29:;0C:%DE,S\*/AGR7PTX=%WH^EWELQ8XL(J4NW.JPUGT;<*
M]-%TX27PPU?SCH;YQ$K[H"3.["R-`)P%Z3B,TSQA_`7[;]#-/]OB2O`IH(V$
MK<>B#HAG]7:(LV]6VN4\<YO/YW[R`@M=,(N":3#F4;[EM1J>(Q8H&O.;20ZF
MG.U>Z.0A0"N!L(Z=61MDW.H,>;T&O/VO)*P2*B$@%@H#C#L;<W_]S/O*L]`6
MK/Y_4$L#!!0````(`"`PRD92>4Z+_1```,[)```1`!P`<G1G;BTR,#$U,#,S
M,2YX<V155`D``]P*>%7<"GA5=7@+``$$)0X```0Y`0``[5UM;^,V$OY>H/]!
MYP,.O0^.XSAIF]RFA9,XN^YEXUSL[;8HBH*1:)M8F7))*8GO</_]AI1DRY9(
M4;8W8:_ZLNM8G.$S\_!M1B3]YOOGF>\\8L9)0,\;[8/#AH.I&WB$3LX;'T;7
MS6\;SO????G%F[\TF\Y;3#%#(?:<AX5SA4(T8LC]Q%-YIWW0/OC6@0^'I\T?
M(MH\.FR?.+\<'IT='9T=?_.K\Y^[]_]U>L.1TW2>GIX./-`02@T';C!SFDU1
M#W>G>(:<$+$)#F_1#/,Y<O%Y8QJ&\[-62\BQ*)R2":9"JB7J..QTVH#;QS-,
MP^N`S:[P&$5^>-[X/4(^&1/L-1PPE/(S%DZHB3)9>JW@4^<@8!,H<MAN_?3^
M9BAQIFI]0C^ME7Y^8'Y:OM,2CQ\0QVEQ\=0+EP+9PB>M^.&RJ*_1^],-*,XJ
M)9K"A/(047<%(@<Z,;%]>GK:DD_3HA%O3A":+PN/$7^019,'PG''S<-V<^FZ
M,S>(:,@6ZS9R[!Y,@L=6\E"(=3;$(L:@`:KDDJ<%]7F8%,O`@X+B^-F=%I<7
M3PH$"'W$/"P6B9\56$,1<7FQC'PD1-KK(IRXQ0+PH*`X$!`NYI@74B.?%-C"
MPSE35`)/"FKQ\)QA5_1\9?LZ;2'FLL#'@,`-F_AY[B.*PH`MKN'OI4,"2J-9
ML1(O9"V!N`6%FE`*,^(NY<J%$@$80QSG#:(T@,$%!B7YM_AF/B=T'"1_PA>B
M?9\)P",0=\2'#_=]]=`@3;L*W$B,,5WJ]6A(PD4?5+*9K*CA$/".ML2R\K1Z
M#X\))1)F^[`-PV(JGOT(JIQ8EY-1]J:UJ>'++S;51QQ[`_J=_`P$<M`F9<6H
MD<@G1?2RJTJJ2KK(=R-?66DBUEKC(J-R*Y(N`\H#GWBBN5X@7PQYPRG&(8\9
M4C_6TW,$G`S!?SCAYW)P.QS<]*^ZH]Z5<]&]Z=Y>]ISANUYO-*RYJ<S-'8*!
M/9SBD`"L$J+6R^I9ZYBSYORRIOC7FD43%I?.Y8/Q8"Z6AX"DH*LIRNG9.]:Q
M-QS!?^][M\#<X-H9W/7NNZ,^%*AYJ\K;Y131">9].@P#]],T\#U8T/=^CV#*
MT1.I$]0S>V+.[.6[[NW;WM#IW\*#P>4_WPUNKGKWP[_]M7/Z#Z?WKP_]T<\U
MY94I1WQZ[0=/)3UU54Q/Y]<5Z.P.WSG7-X./=4?=GK62Z=)`1L_G-]OP64^@
MIOP.V`11\F]9*2SO[V!Q,QB_QVR"64RFKH">N6]%Z$"XZP<\8AC^R*IR$,02
M0ID3C)U874V2BJ1A-)LAMAB,AV1"R1B:-(1UKDQ=$#JY@[[F$IR,GX9E]=2=
M;E*7:!5D9?0Z*\5.JKEF4<7B'<-S1+S>\QQ3CCETI@$,4.Q29I+"+N?+P-"H
MI);!]N$F@XE.)U4J.Z!4ZR1ZG5AQ3:":P`#"A7`A,BJPLIR+&2DEK.")GJ!V
MGJ!8AR1FJ:5F0\5&,O;`8F*!'GP,KH=O6(27W2:FIKR8GJ>C39Y2A4ZB4?*5
MZ%SVKIHV]8)R-B.A7!$"%[!4%+,'IJL)3%=`3U5GDZJ,*LG2FK*:(N5R0Q%[
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MQ^Q]QOQK(W85`3W#N61.A:B_'JZW"?LWB%07T!+7*4C7%`?^-4L[L+0VP!J4
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M00>H:M%&G]FO77%_RU[E"']EKWJ47X%9`0L=6GAYK.I.U/C>V9O`E:HT(N*O
M9BK7%%\UVT?-3OO@F7LK[U<!L;*Q&HA4;@L0Q3?.&E:?"HAZ3TQKU%X9JZA8
M5EHHV,)^R--OFBM5E>S77-^J`U0@EGQNKE1L!:3H6EP3)%FY](^=L11=M6L$
M)BNX_&M7CG*W\II`60K)3[M"R-_8:X)A)15_;*X4;(5B\QI@$PRIC/BP<_V;
M-P0;`4B%Y*<M(.1O&Y:3#<43$2&8C5P^8VM28O@Z%<-F^^N=81@.GAD(X5ZJ
MU]^Y;`HIJZ6W4K(%0NW-VR8M)941'[;HL/J[H8T<LBFU*T_%UUI70Q+0VZW!
MZ"\$WW[FE;K4%"6W\4M`YXU5?#@8&YUQA3CQP@_<3PTG7JO&%X>?A>GW_1#/
M1+C5<-`#%S\B$)XWQLB75^R+>_#/8`%)`F\DA;V()5=T4^+[8DO7>2-DD5AP
M0:@:DC`23]^R()J?-V)Q`OKCV%BLB'_;`;_"(^EF07$V9H0R>Q`_<#R.("88
MX[8\\62;*[8!KO"!^`T%+_)-?6JC-W8SH=0OPREB6*SQO<M@)A1+N!\18_(X
M0$@>T_..]CIF*QO,/'.AT,HO%KUGS%S"\1V,FOA>7%/\1W#33@:5^\S\VHC4
M/3%H<`04*')-;.T>/..%9U.09&[T@/M*'U4Q0.4.(QTWA$H8_,4=D6\B50$K
M#/\8L$\@<(GF)!2)WZQ=LP!6I%!)I=8?)T'"O&5QT8?XSGYP`7X@H;F]FSCW
M-WG8V:@KP%>N)<HU6-2@*\)5&"UE\JHV+G:UM9&;H2]M^H5'(&"5NGYSA9WM
MWA2[P@FEIS\L:O%5L*K-%0)7A&$7@O/L&N$%6[D+]%1IYEK4>DMO\`3YUQB_
M9"?>TKP,5+U-]YACQ-PI-(`K_(C]0`9.2:>WW\X2^'K;KV$=ZTZ)[-?/?P16
M<X!+1V/-`2:+Q^%RU`K#;R`0@<&K.V%8?MU])B\_UH*)'H':Q0]0;IA8C,_0
MF*M@A@C=B!(]^>7+SATJ8`H[>K.Y'RSPJOQ[/'L0/ROQZH8HD94P0KUA-)_[
M"_LL*D6HL&ST%$`T[X+^1\RML:80E6KQ[49^9`_T=3BJ<;HPP=(5^96)+'>Q
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M0^IV;"M%Y4YY<9Y^E$VFYJFB4UZ<IV4H5%-5W2_JUP&C:1!Q1+W1E+`08RHV
MUUHSS9;@4VTW2W8NCH*[B+E3\&C\JC&@\HZ7G5/BN]M5BE!A65\<1$7^7?3@
M$W<P'F/QDE.N08#Z#Y2$KQ]@&T"L8IR0V'RU^QJ,Z<`I[1&K$?'%-0MFT$UG
MF-VA/>VW,!ZGJFY!T*&N0-QX(D>>P;B`0-L,+D=?N<6VK6ZR;<,VF[U<P^*Y
M50=:82>HX_R.!2[&'A=2?<XC4?G:.-RE7CI26VS^%K:HWJTGC>0RX%:/4>LX
M#8SY2,+I%/N>\$[JJ3^*@<785:?=`E>N$L75\C24"\<Q#.'Q8C,QZ/4WI9JA
MU&_JR[K(YMY9#%=%'^8N(W)=/Q@/\1S%F):[>TRI^YSG$4LA*FQ[#UW`1?[R
MT)XU088*F-(.\5-B%J'/PE%%Y4B>81+S0+PS)CGTQ<54(2+'S!57@QG%`_8^
M@,!!SJL!@\F%!&P47/H!AP9GP=)FS_:4;J^]QVY`7>(3E+3[$`%(<=H=>Y@A
M?WEEW#TL/4`QA/B(+G@/.KTX9;A\8O<YP,]DI<GFY3D,V2*W,5[6D9Q/N,`4
MCTEH]R9F0_0*1Q@HL.A`236T+]JS[&P?^[50X=`]56)1.]N_1:5M<2F[IGL=
MB,4-K0)\U;M6`PT6-9&*<'<P^C:@'G@9B@',9+"+%U[I,;H[(">S0$_RK^*K
M%Y[.]VR.:LZ:BO<6?=I]1$3"O`W\JPCZX96HB`<^\=8."+Z>/\R1JO((@`>)
M@TDW`>>7B+$%Q*KBS0P'9Y$87OSB9;U'3'[&B+VPL56P*LQ=9GR933%:(2J%
M!;?XR?;W6N405?TN#EGD^Y2U]%[28=$$6]#E3$`J#/P`(Q-[8J"1V7/(IPB4
MDB#$866<I%H'[%[L)HQ['[A$O)5-L["K9XKM>Y[8T_;2S.V$7O66&;/94JD5
M.TDW$%7A\BJI7*1C/TZ).S7G\W5LW8,5RJ!C=>GSHWQ99F'?-0&INMQD.5P-
MQLEFBP_)#K/7'V2UX%3I9>C`@W&\TK/MR'0>FXJ5R)\A@/H,"UQK6ED1*`,2
MK#GJ701*F_].YG@AU^>WP0W\+S<E_1#YBTY;7.-M#3=5`9O;W1V#DI6"BRC,
M*.Y&DXB'[8[MOJAL1-GQ?[J\=,4:LS785%'?ZI"J7+JFAPVHN(H$.KH+XZQ\
M(#=4B/4$H1)DYOV8!6_K]F.&ZDUL^LY/H+5M/BD`5])PTY817T7"(U]LA$NW
M7XJY%M8/5D61VP(WH=.:F:D0E3KR3QP`#6\I:,]:M`2?]L:+(?'P#0YA7+;O
M-I)2A%K+^I0&CW)U/G0)A@;+;5K9&6!4AD?Y$38^_V#7'&&(TR!(6MN)EMPX
M9U>D5(Q0^6(6)A8/)Y%R$.^FYG)KP1BSBX7]FWE-+5#E@@GCX9W8GFY-=\Q#
M4KW6$^E]SR[P!9A4*;,I89:!ST-2OD&(6#BU"WP!)M6H'2R0'R[>1DA>=H)Y
MYI(ZFY+LICA5)$74&P4P`EYB%@(=R3VAR9"8O:/'XNL2JQAA,'UMCHY%1S;L
MF,;T2%4)#$+)+)HM4[^;TX$5V>IRD.I?M5AN@$\+=T,?(QZ"DML@E"OOV0QE
MLK<V3MG5[-"=PEQ*+R.H_$T>K[+@U*(SR<5GDAJR<8!C;M"<#\:;3=F.WFJ"
M5QE#D-E#Q+C\;C!.MV<D9UQ&07'?M:M%F]N@6H<C/KT(:&3S-O\,1O4V3]5E
MMQ;MJ3)#*4Q\TXI_P4E:^S]02P$"'@,4````"``@,,I&G+4R_Q_H``#A`@X`
M$0`8```````!````I($`````<G1G;BTR,#$U,#,S,2YX;6Q55`4``]P*>%5U
M>`L``00E#@``!#D!``!02P$"'@,4````"``@,,I&9#^53$,)```*@@``%0`8
M```````!````I(%JZ```<G1G;BTR,#$U,#,S,5]C86PN>&UL550%``/<"GA5
M=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`(##*1I%;#T5*/0``>2,$`!4`
M&````````0```*2!_/$``')T9VXM,C`Q-3`S,S%?9&5F+GAM;%54!0`#W`IX
M575X"P`!!"4.```$.0$``%!+`0(>`Q0````(`"`PRD99$(QPC%@``+(L!0`5
M`!@```````$```"D@94O`0!R=&=N+3(P,34P,S,Q7VQA8BYX;6Q55`4``]P*
M>%5U>`L``00E#@``!#D!``!02P$"'@,4````"``@,,I&SSH"M#A%``!J[P0`
M%0`8```````!````I(%PB`$`<G1G;BTR,#$U,#,S,5]P<F4N>&UL550%``/<
M"GA5=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`(##*1E)Y3HO]$```SLD`
M`!$`&````````0```*2!]\T!`')T9VXM,C`Q-3`S,S$N>'-D550%``/<"GA5
E=7@+``$$)0X```0Y`0``4$L%!@`````&``8`&@(``#_?`0``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EEVAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="4">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th" colspan="2">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th" colspan="2">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows From Operating Activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (6,691,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (3,118,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
        <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">1,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">2,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">1,079,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInPrepaidExpense" onclick="toggleNextSibling(this);">(163,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInPrepaidExpense</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInPrepaidExpense" onclick="toggleNextSibling(this);">1,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInPrepaidExpense</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" onclick="toggleNextSibling(this);">388,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" onclick="toggleNextSibling(this);">146,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net Cash Used in Operating Activities</a></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(5,386,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(2,969,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows From Investing Activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(156,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net Cash Used in Investing Activities</a></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(156,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows From Financing Activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Advances from Former Parent</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromRelatedPartyDebt" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromRelatedPartyDebt</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_ProceedsFromRelatedPartyDebt" onclick="toggleNextSibling(this);">1,453,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromRelatedPartyDebt</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayment of Former Parent advances</a></td>
        <td class="num"><a title="us-gaap_RepaymentsOfRelatedPartyDebt" onclick="toggleNextSibling(this);">(537,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfRelatedPartyDebt</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num"><a title="us-gaap_RepaymentsOfRelatedPartyDebt" onclick="toggleNextSibling(this);">(916,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfRelatedPartyDebt</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance of common stock and warrants less issuance costs</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" onclick="toggleNextSibling(this);">865,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" onclick="toggleNextSibling(this);">16,228,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_InvestmentFromRelatedParty', window );">Investment from Former Parent</a></td>
        <td class="nump"><a title="rtgn_InvestmentFromRelatedParty" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">rtgn_InvestmentFromRelatedParty</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="rtgn_InvestmentFromRelatedParty" onclick="toggleNextSibling(this);">1,679,000</a><span style="display:none;white-space:normal;text-align:left;">rtgn_InvestmentFromRelatedParty</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net Cash Provided by Financing Activities</a></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">328,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">18,444,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashPeriodIncreaseDecrease', window );">Net (Decrease) Increase In Cash</a></td>
        <td class="num"><a title="us-gaap_CashPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">(5,214,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashPeriodIncreaseDecrease</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_CashPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">15,475,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashPeriodIncreaseDecrease</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash - Beginning</a></td>
        <td class="nump"><a title="us-gaap_Cash" onclick="toggleNextSibling(this);">15,571,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Cash</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_Cash" onclick="toggleNextSibling(this);">96,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Cash</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash - Ending</a></td>
        <td class="nump"><a title="us-gaap_Cash" onclick="toggleNextSibling(this);">$ 10,357,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Cash</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_Cash" onclick="toggleNextSibling(this);">$ 15,571,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Cash</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr>
        <td colspan="5"></td>
      </tr>
      <tr>
        <td colspan="5">
          <table class="outerFootnotes" width="100%">
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[1]</td>
              <td style="vertical-align: top;" valign="top">During the year ended March 31, 2015, gross proceeds from the initial public offering of $1,117,000 less $252,000 of offering costs, of which $89,000 was withheld from the proceeds and $163,000 was paid in cash that was previously accrued at March 31, 2014. During the year ended March 31, 2014, gross proceeds from the initial public offering of $19,216,000 less $3,195,000 of offering costs, of which $2,826,000 was withheld from the proceeds, $206,000 was paid in cash (including $44,000 paid during the fiscal year ended March 31, 2013) and $163,000 was accrued as of March 31, 2014.</td>
            </tr>
          </table>
        </td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_InvestmentFromRelatedParty">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The value represents the investments from related parties (Former Parent).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_InvestmentFromRelatedParty</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Cash</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash. Cash is the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashPeriodIncreaseDecrease</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Depreciation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EKJAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity (Details 1) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding Number of Warrants</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" onclick="toggleNextSibling(this);">3,145,650</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms', window );">Warrants Exercisable Weighted Average Remaining Life</a></td>
        <td class="text">1 year 1 month 6 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber', window );">Warrants Exercisable Number of Warrants</a></td>
        <td class="nump"><a title="rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber" onclick="toggleNextSibling(this);">3,140,250</a><span style="display:none;white-space:normal;text-align:left;">rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=rtgn_ExercisePriceRangeOneMember', window );">Exercise Price Range One [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants Outstanding Exercise Price</a></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_RangeAxis=rtgn_ExercisePriceRangeOneMember]" onclick="toggleNextSibling(this);"> 7.2500</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_RangeAxis<br>= rtgn_ExercisePriceRangeOneMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding Number of Warrants</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber[us-gaap_RangeAxis=rtgn_ExercisePriceRangeOneMember]" onclick="toggleNextSibling(this);">3,047,500</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber<br>/ us-gaap_RangeAxis<br>= rtgn_ExercisePriceRangeOneMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms', window );">Warrants Exercisable Weighted Average Remaining Life</a></td>
        <td class="text">1 year<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber', window );">Warrants Exercisable Number of Warrants</a></td>
        <td class="nump"><a title="rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber[us-gaap_RangeAxis=rtgn_ExercisePriceRangeOneMember]" onclick="toggleNextSibling(this);">3,047,500</a><span style="display:none;white-space:normal;text-align:left;">rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber<br>/ us-gaap_RangeAxis<br>= rtgn_ExercisePriceRangeOneMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=rtgn_ExercisePriceRangeTwoMember', window );">Exercise Price Range Two [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants Outstanding Exercise Price</a></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_RangeAxis=rtgn_ExercisePriceRangeTwoMember]" onclick="toggleNextSibling(this);"> 9.0625</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_RangeAxis<br>= rtgn_ExercisePriceRangeTwoMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding Number of Warrants</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber[us-gaap_RangeAxis=rtgn_ExercisePriceRangeTwoMember]" onclick="toggleNextSibling(this);">98,150</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber<br>/ us-gaap_RangeAxis<br>= rtgn_ExercisePriceRangeTwoMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms', window );">Warrants Exercisable Weighted Average Remaining Life</a></td>
        <td class="text">4 years<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber', window );">Warrants Exercisable Number of Warrants</a></td>
        <td class="nump"><a title="rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber[us-gaap_RangeAxis=rtgn_ExercisePriceRangeTwoMember]" onclick="toggleNextSibling(this);">92,750</a><span style="display:none;white-space:normal;text-align:left;">rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber<br>/ us-gaap_RangeAxis<br>= rtgn_ExercisePriceRangeTwoMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represented the value of Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term of exercisable other than options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price per share or per unit of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=rtgn_ExercisePriceRangeOneMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=rtgn_ExercisePriceRangeOneMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=rtgn_ExercisePriceRangeTwoMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=rtgn_ExercisePriceRangeTwoMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Accounts payable and accrued expenses consist of the following:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>March&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Accrued employee compensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>92,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>109,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Accrued director compensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>43,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>50,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Accrued legal fees</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>144,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>183,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Accrued other professional fees</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>50,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>45,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Accrued research and development fees</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>128,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Accrued franchise taxes</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>146,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Other accrued expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>32,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>14,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>635,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>410,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EIFAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity (Details 2)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" onclick="toggleNextSibling(this);">1.67%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
        <td class="text">5 years 7 months 10 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" onclick="toggleNextSibling(this);">95.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iv)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EKH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The following summarizes the income tax provision (benefit):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="white-space:nowrap;"> <div>&#160;</div> </td> <td style="white-space:nowrap; FONT-WEIGHT: bold"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"> <div>For The Years Ended</div> </td> <td style="white-space:nowrap; FONT-WEIGHT: bold"> <div>&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="white-space:nowrap;"> <div>&#160;</div> </td> <td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"> <div>March 31,</div> </td> <td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div>&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="white-space:nowrap;"> <div>&#160;</div> </td> <td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> <div>2015</div> </td> <td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div>&#160;</div> </td> <td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> <div>2014</div> </td> <td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div>&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td> <div>Federal</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="PADDING-LEFT: 9pt"> <div>Current</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>$</div> </td> <td style="TEXT-ALIGN: right"> <div>-</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>$</div> </td> <td style="TEXT-ALIGN: right"> <div>-</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="PADDING-LEFT: 9pt; WIDTH: 74%"> <div>Deferred</div> </td> <td style="WIDTH: 1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%"> <div>(1,754,000</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> <div>)</div> </td> <td style="WIDTH: 1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%"> <div>(1,031,000</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> <div>)</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left"> <div>State and local</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="PADDING-LEFT: 9pt"> <div>Current</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>-</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>-</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt; PADDING-LEFT: 9pt"> <div>Deferred</div> </td> <td style="PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> <div>(309,000</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> <div>)</div> </td> <td style="PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> <div>(182,000</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> <div>)</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>(2,063,000</div> </td> <td style="TEXT-ALIGN: left"> <div>)</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>(1,213,000</div> </td> <td style="TEXT-ALIGN: left"> <div>)</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> <div>Change in valuation allowance</div> </td> <td style="PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> <div>2,063,000</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> <div>1,213,000</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> <div>Income tax provision (benefit)</div> </td> <td style="PADDING-BOTTOM: 2.5pt"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> <div>$</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> <div>-</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> <div>&#160;</div> </td> <td style="PADDING-BOTTOM: 2.5pt"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> <div>$</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> <div>-</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> <div>&#160;</div> </td> </tr> </table> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_ScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateTableTextBlock', window );">Schedule Of Reconciliation Of The Statutory Federal Income Tax Rate To The Company&#x2019;s effective Tax Rate [Table Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company has the following net deferred tax assets:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="white-space:nowrap;"> <div>&#160;</div> </td> <td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"> <div>March 31,</div> </td> <td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div>&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="white-space:nowrap;"> <div>&#160;</div> </td> <td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> <div>2015</div> </td> <td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div>&#160;</div> </td> <td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> <div>2014</div> </td> <td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div>&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 74%"> <div>Net operating loss carryforwards</div> </td> <td style="WIDTH: 1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%"> <div>3,224,000</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> <div>&#160;</div> </td> <td style="WIDTH: 1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%"> <div>1,427,000</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> <div>&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td> <div>Stock-based compensation</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>262,000</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>-</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> <div>Charitable donation carryforwards</div> </td> <td style="PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> <div>4,000</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> <div>-</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt"> <div>Gross deferred tax assets</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>3,490,000</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>1,427,000</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> <div>Valuation allowance</div> </td> <td style="PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> <div>(3,490,000</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> <div>)</div> </td> <td style="PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> <div>(1,427,000</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> <div>)</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> <div>&#160;Net deferred tax assets</div> </td> <td style="PADDING-BOTTOM: 2.5pt"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> <div>$</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> <div>-</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> <div>&#160;</div> </td> <td style="PADDING-BOTTOM: 2.5pt"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> <div>$</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> <div>-</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> <div>&#160;</div> </td> </tr> </table> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> A reconciliation of the statutory federal income tax rate to the Company&#8217;s effective tax rate is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="white-space:nowrap;"> <div>&#160;</div> </td> <td style="white-space:nowrap; FONT-WEIGHT: bold"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"> <div>For The Years Ended</div> </td> <td style="white-space:nowrap; FONT-WEIGHT: bold"> <div>&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="white-space:nowrap;"> <div>&#160;</div> </td> <td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"> <div>March 31,</div> </td> <td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div>&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="white-space:nowrap;"> <div>&#160;</div> </td> <td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> <div>2015</div> </td> <td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div>&#160;</div> </td> <td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> <div>2014</div> </td> <td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div>&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 74%"> <div>Expected federal statutory rate</div> </td> <td style="WIDTH: 1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%"> <div>(34.0</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> <div>)%</div> </td> <td style="WIDTH: 1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%"> <div>(34.0</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> <div>)%</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left"> <div>State tax rate, net of federal benefit</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>(6.0</div> </td> <td style="TEXT-ALIGN: left"> <div>)%</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>(6.0</div> </td> <td style="TEXT-ALIGN: left"> <div>)%</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left"> <div>Change in effective state tax rate</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>0.0</div> </td> <td style="TEXT-ALIGN: left"> <div>%</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>(0.3</div> </td> <td style="TEXT-ALIGN: left"> <div>)%</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left"> <div>Permanent items - stock-based compensation</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>2.5</div> </td> <td style="TEXT-ALIGN: left"> <div>%</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>0.0</div> </td> <td style="TEXT-ALIGN: left"> <div>%</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left"> <div>Permanent items - non-deductible merger expenses</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>0.4</div> </td> <td style="TEXT-ALIGN: left"> <div>%</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>0.0</div> </td> <td style="TEXT-ALIGN: left"> <div>%</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left"> <div>Permanent items - other</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>0.1</div> </td> <td style="TEXT-ALIGN: left"> <div>%</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>1.3</div> </td> <td style="TEXT-ALIGN: left"> <div>%</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left"> <div>Adjustment of NOL due to deconsolidation</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>6.2</div> </td> <td style="TEXT-ALIGN: left"> <div>%</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>0.0</div> </td> <td style="TEXT-ALIGN: left"> <div>%</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> <div>Change in valuation allowance</div> </td> <td style="PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> <div>30.8</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> <div>%</div> </td> <td style="PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> <div>39.0</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> <div>%</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> <div>Income tax provision (benefit)</div> </td> <td style="PADDING-BOTTOM: 2.5pt"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> <div>0.0</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> <div>%</div> </td> <td style="PADDING-BOTTOM: 2.5pt"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> <div>0.0</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> <div>%</div> </td> </tr> </table> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_ScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular Disclosure of Of Reconciliation Of The Statutory Federal Income Tax Rate To The Company&#x2019;s effective Tax Rate.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_ScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanysEffectiveTaxRateTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ENJAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS [Parenthetical] (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_GrossProceedsFromIssuanceOfCommonStockAndWarrants', window );">Gross Proceeds From Issuance Of Common Stock And Warrants</a></td>
        <td class="nump"><a title="rtgn_GrossProceedsFromIssuanceOfCommonStockAndWarrants" onclick="toggleNextSibling(this);">$ 1,117,000</a><span style="display:none;white-space:normal;text-align:left;">rtgn_GrossProceedsFromIssuanceOfCommonStockAndWarrants</span><span></span></td>
        <td class="nump"><a title="rtgn_GrossProceedsFromIssuanceOfCommonStockAndWarrants" onclick="toggleNextSibling(this);">$ 19,216,000</a><span style="display:none;white-space:normal;text-align:left;">rtgn_GrossProceedsFromIssuanceOfCommonStockAndWarrants</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_OfferingCost', window );">Offering Cost</a></td>
        <td class="nump"><a title="rtgn_OfferingCost" onclick="toggleNextSibling(this);">252,000</a><span style="display:none;white-space:normal;text-align:left;">rtgn_OfferingCost</span><span></span></td>
        <td class="nump"><a title="rtgn_OfferingCost" onclick="toggleNextSibling(this);">3,195,000</a><span style="display:none;white-space:normal;text-align:left;">rtgn_OfferingCost</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_OfferingCostWithheldFromProceeds', window );">Offering Cost Withheld From The Proceeds</a></td>
        <td class="nump"><a title="rtgn_OfferingCostWithheldFromProceeds" onclick="toggleNextSibling(this);">89,000</a><span style="display:none;white-space:normal;text-align:left;">rtgn_OfferingCostWithheldFromProceeds</span><span></span></td>
        <td class="nump"><a title="rtgn_OfferingCostWithheldFromProceeds" onclick="toggleNextSibling(this);">2,826,000</a><span style="display:none;white-space:normal;text-align:left;">rtgn_OfferingCostWithheldFromProceeds</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs</a></td>
        <td class="nump"><a title="us-gaap_PaymentsOfStockIssuanceCosts" onclick="toggleNextSibling(this);">163,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsOfStockIssuanceCosts</span><span></span></td>
        <td class="nump"><a title="us-gaap_PaymentsOfStockIssuanceCosts" onclick="toggleNextSibling(this);">206,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsOfStockIssuanceCosts</span><span></span></td>
        <td class="nump"><a title="us-gaap_PaymentsOfStockIssuanceCosts" onclick="toggleNextSibling(this);">44,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsOfStockIssuanceCosts</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_AccruedOfferingCosts', window );">Accrued Offering Costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="rtgn_AccruedOfferingCosts" onclick="toggleNextSibling(this);">$ 163,000</a><span style="display:none;white-space:normal;text-align:left;">rtgn_AccruedOfferingCosts</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_AccruedOfferingCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of accrued offering costs during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_AccruedOfferingCosts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_GrossProceedsFromIssuanceOfCommonStockAndWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross proceeds from the issuance of common stock and warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_GrossProceedsFromIssuanceOfCommonStockAndWarrants</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_OfferingCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total Offering cost for issuance of common stock and warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_OfferingCost</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_OfferingCostWithheldFromProceeds">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of offering cost withheld from the proceeds.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_OfferingCostWithheldFromProceeds</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for cost incurred directly with the issuance of an equity security.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E1OAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS [Parenthetical] (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.0001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockParOrStatedValuePerShare</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.0001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockParOrStatedValuePerShare</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesAuthorized" onclick="toggleNextSibling(this);">500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesAuthorized</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesAuthorized" onclick="toggleNextSibling(this);">500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesAuthorized</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesIssued" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesIssued</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesIssued" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesIssued</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesOutstanding" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesOutstanding</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesOutstanding" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesOutstanding</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.0001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.0001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">100,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">100,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">4,804,290</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">4,804,290</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">4,650,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">4,650,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> Note 10. Subsequent Events</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><i>&#160;</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><i>Stock-Based Compensation</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> On April 30, 2015, the Company granted to its directors fully-vested, ten-year options to purchase an aggregate of 15,000 shares of common stock at an exercise price of $3.35 per share, pursuant to the 2013 Plan.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EVUAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document And Entity Information (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Jun. 05, 2015</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-K<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Mar. 31,  2015<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2015<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">FY<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">Ruthigen, Inc.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001574235<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--03-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Smaller Reporting Company<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="dei_EntityPublicFloat" onclick="toggleNextSibling(this);">$ 13,572,764</a><span style="display:none;white-space:normal;text-align:left;">dei_EntityPublicFloat</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
        <td class="text">RTGN<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="dei_EntityCommonStockSharesOutstanding" onclick="toggleNextSibling(this);">4,804,290</a><span style="display:none;white-space:normal;text-align:left;">dei_EntityCommonStockSharesOutstanding</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_AmendmentFlag</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentType</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityFilerCategory</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityPublicFloat</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityRegistrantName</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Trading symbol of an instrument as listed on an exchange.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_TradingSymbol</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EBOAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiquidityDisclosureTextBlock', window );">Liquidity Disclosure [Policy Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px 0pt -0.5in; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>Liquidity and Financial Condition</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company incurred net losses of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6,691,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,118,000</font> for the years ended March 31, 2015 and 2014, respectively. At March 31, 2015, the Company&#8217;s working capital and accumulated deficit were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9,888,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10,360,000</font>, respectively. The Company has not yet achieved profitability and it is expected that its research and development and general and administrative expenses will continue to increase and, as a result, the Company will eventually need to generate significant product revenues to achieve profitability.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company believes that its existing cash, which includes the proceeds from its IPO, will be sufficient to fund its stand-alone operations through the quarter ending June 30, 2016. However, in order for the Company to execute its research and development strategy and to obtain the necessary regulatory approvals to commercialize RUT58-60 as a drug in the United States, the Company will need to raise additional funds through public or private equity offerings, debt financings, corporate collaborations or other means. The Company has not secured any commitment for new financing at this time, nor can it provide any assurance that new financing will be available on commercially acceptable terms, if at all. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash. See Note 6 &#150; Commitments and Contingencies &#150; Agreement and Plan of Merger.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation, Policy [Policy Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>Principles of Consolidation</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The consolidated financial statements of the Company include the accounts of its wholly-owned subsidiary, Ruthigen Merger Corp., which was incorporated in the state of Delaware on March 2, 2015. All significant intercompany transactions have been eliminated in the consolidation. See Note 6 &#150; Commitments and Contingencies &#150; Agreement and Plan of Merger.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>Use of Estimates</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (&#8220;U. S. GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include stock-based compensation, the valuation allowance related to the Company&#8217;s deferred tax assets and the expense allocations relating to the Company&#8217;s operations prior to its deconsolidation from its Former Parent on March 26, 2014.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration Risk, Credit Risk, Policy [Policy Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>Concentration of Credit Risk</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Financial instruments that potentially subject the Company to concentrations of credit risk include amounts held as cash. Cash is maintained in financial institutions located in the United States. The Company is exposed to credit risk in the event of default by these financial institutions for amounts in excess of the Federal Deposit Insurance Corporation insured limits.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement, Policy [Policy Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>Fair Value of Financial Assets and Liabilities</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Financial instruments, including cash, accounts payable and accrued expenses are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company measures the fair value of financial assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. The Company uses three levels of inputs that may be used to measure fair value:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Level 1&#160;&#151;&#160;quoted prices in active markets for identical assets or liabilities.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Level 2&#160;&#151;&#160;quoted prices for similar assets and liabilities in active markets or inputs that are observable.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Level 3&#160;&#151;&#160;inputs that are unobservable (for example cash flow modeling inputs based on assumptions).</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>Property and Equipment</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Property and equipment are stated at cost, net of accumulated depreciation and amortization which is recorded commencing at the in-service date. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Depreciation of leasehold improvements is computed using the straight-line method over the lesser of the estimated useful life of the improvement or the remaining term of the lease. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Estimated useful asset life by classification is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="WIDTH: 50%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold"> <div style="CLEAR:both;CLEAR: both">Years</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 80%"> <div style="CLEAR:both;CLEAR: both">Office equipment</div> </td> <td style="WIDTH: 1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; WIDTH: 19%"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3</font></div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">Medical equipment</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5</font></div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">Furniture and fixtures</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 7</font></div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>Impairment of Long-Lived Assets</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.2pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.2pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company periodically reviews the carrying values of its long-lived assets when events or changes in circumstances would indicate that it is more likely than not that their carrying values may exceed their realizable values, and records impairment charges when considered necessary. Specific potential indicators of impairment include, but are not necessarily limited to:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both">&#8226;</div> </td> <td> <div style="CLEAR:both;CLEAR: both">a significant decrease in the fair value of an asset;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both">&#8226;</div> </td> <td> <div style="CLEAR:both;CLEAR: both">a significant change in the extent or manner in which an asset is used or a significant physical change in an asset;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both">&#8226;</div> </td> <td> <div style="CLEAR:both;CLEAR: both">a significant adverse change in legal factors or in the business climate that affects the value of an asset;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both">&#8226;</div> </td> <td> <div style="CLEAR:both;CLEAR: both">an adverse action or assessment by the U.S. Food and Drug Administration or another regulator;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both">&#8226;</div> </td> <td> <div style="CLEAR:both;CLEAR: both">an accumulation of costs significantly in excess of the amount originally expected to acquire or construct an asset; and operating or cash flow losses combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with an income-producing asset.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> When circumstances indicate that an impairment may have occurred, the Company tests such assets for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of such assets and their eventual disposition to their carrying amounts. In estimating these future cash flows, assets and liabilities are grouped at the lowest level for which there are identifiable cash flows that are largely independent of the cash flows generated by other such groups. If the undiscounted future cash flows are less than the carrying amount of the asset, an impairment loss, measured as the excess of the carrying value of the asset over its estimated fair value, will be recognized. The cash flow estimates used in such calculations are based on estimates and assumptions, using all available information that management believes is reasonable.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>Stock-Based Compensation</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company accounts for share-based awards exchanged for employee and director services at the estimated grant date fair value of the award. The Company estimates the fair value of stock options using the Black-Scholes option pricing model. The Company estimates the fair value of restricted stock and restricted stock units (&#8220;RSUs&#8221;) based upon the closing market price of the Company&#8217;s common stock on the date the award is granted. The Company amortizes the fair value of employee awards on&#160;the straight-line basis over the requisite service period of the awards. Stock-based compensation expense includes the impact of an estimate for forfeitures for all stock awards. The Company recognizes stock-based compensation expense for awards with performance conditions if and when the Company concludes that it is probable that the performance condition will be achieved. The Company reassesses the probability of vesting at each reporting period for awards with performance conditions and adjusts stock-based compensation expense based on its probability assessment.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company accounts for equity instruments issued to non-employees at their fair value on the measurement date. The measurement of stock-based compensation is subject to periodic adjustment as the underlying equity instrument vests or becomes non-forfeitable. Non-employee stock-based compensation charges are amortized over the requisite service period.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>Research and Development</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Research and development expense is charged to operations as incurred and consists primarily of personnel expenses, clinical and regulatory services and supplies.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>Net Loss per Share</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company computes basic net loss per share by dividing net loss per share available to common stockholders by the weighted average number of common shares outstanding for the period and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the &#8220;treasury stock&#8221; and/or &#8220;if converted&#8221; methods, as applicable.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div style="CLEAR:both;CLEAR: both">March&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div style="CLEAR:both;CLEAR: both">Options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">315,836</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div style="CLEAR:both;CLEAR: both">Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,145,650</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,140,250</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div style="CLEAR:both;CLEAR: both">Restricted stock units</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">324,047</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div style="CLEAR:both;CLEAR: both">Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,785,533</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,140,250</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Income Taxes</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company accounts for income taxes under Accounting Standards Codification (&#8220;ASC&#8221;) 740 Income Taxes (&#8220;ASC 740&#8221;). Under ASC 740, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Tax benefits claimed or expected to be claimed on a tax return are recorded in the Company&#8217;s consolidated financial statements. A tax benefit from an uncertain tax position is only recognized if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. Uncertain tax positions have had no impact on the Company&#8217;s consolidated financial condition, results of operations or cash flows.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>Recent Accounting Pronouncements</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In June 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-12, "Compensation - Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could be Achieved after the Requisite Service Period," ("ASU 2014-12"). The amendments in ASU 2014-12 require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Accounting Standards Codification Topic No. 718, "Compensation - Stock Compensation" as it relates to awards with performance conditions that affect vesting to account for such awards. The amendments in ASU 2014-12 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in ASU 2014-12 either: (a) prospectively to all awards granted or modified after the effective date; or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The Company does not anticipate that the adoption of this standard will have a material impact on its consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In August 2014, the FASB issued ASU No. 2014-15, &#8220;Presentation of Financial Statements &#150; Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern.&#8221; The guidance, which is effective for annual reporting periods ending after December 15, 2016, extends the responsibility for performing the going-concern assessment to management and contains guidance on how to perform a going-concern assessment and when going-concern disclosures would be required under U.S. GAAP. The Company does not believe adoption of this ASU will have a material effect on its consolidated financial statements.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Events, Policy [Policy Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>Subsequent Events</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Management has evaluated subsequent events or transactions occurring through the date these consolidated financial statements were issued. See Note 10 &#150; Subsequent Events.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for credit risk.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13531-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13537-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61082-112788<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61044-112788<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.3A-02)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph k<br><br> -Article 1<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02, 03<br><br> -Article 3A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section CC<br><br> -Subsection 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6390181&amp;loc=d3e202-110218<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 30<br><br> -Section 05<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6423966&amp;loc=d3e40913-109327<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 954<br><br> -SubTopic 740<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 17<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32247-109318<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32280-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiquidityDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for reporting when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). Disclose: (a) pertinent conditions and events giving rise to the assessment of substantial doubt about the entity's ability to continue as a going concern for a reasonable period of time, (b) the possible effects of such conditions and events, (c) management's evaluation of the significance of those conditions and events and any mitigating factors, (d) possible discontinuance of operations, (e) management's plans (including relevant prospective financial information), and (f) information about the recoverability or classification of recorded asset amounts or the amounts or classification of liabilities. If management's plans alleviate the substantial doubt about the entity's ability to continue as a going concern, disclosure of the principal conditions and events that initially raised the substantial doubt about the entity's ability to continue as a going concern would be expected to be considered. Disclose whether operations for the current or prior years generated sufficient cash to cover current obligations, whether waivers were obtained from creditors relating to the company's default under the provisions of debt agreements and possible effects of such conditions and events, such as: whether there is a possible need to obtain additional financing (debt or equity) or to liquidate certain holdings to offset future cash flow deficiencies. Disclose appropriate parent company information when parent is dependent upon remittances from subsidiaries to satisfy its obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiquidityDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Research and Development<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for reporting subsequent events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsequentEventsPolicyPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EXIAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
        <td class="nump"><a title="us-gaap_Revenues" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Revenues</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">2,178,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">1,382,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
        <td class="nump"><a title="us-gaap_SellingGeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">4,530,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SellingGeneralAndAdministrativeExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_SellingGeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">1,736,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SellingGeneralAndAdministrativeExpense</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total Operating Expenses</a></td>
        <td class="nump"><a title="us-gaap_OperatingExpenses" onclick="toggleNextSibling(this);">6,708,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingExpenses</span><span></span></td>
        <td class="nump"><a title="us-gaap_OperatingExpenses" onclick="toggleNextSibling(this);">3,118,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingExpenses</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss From Operations</a></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(6,708,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(3,118,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Income</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNonoperating', window );">Interest income</a></td>
        <td class="nump"><a title="us-gaap_InvestmentIncomeNonoperating" onclick="toggleNextSibling(this);">17,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InvestmentIncomeNonoperating</span><span></span></td>
        <td class="nump"><a title="us-gaap_InvestmentIncomeNonoperating" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InvestmentIncomeNonoperating</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total Other Income</a></td>
        <td class="nump"><a title="us-gaap_NonoperatingIncomeExpense" onclick="toggleNextSibling(this);">17,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NonoperatingIncomeExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_NonoperatingIncomeExpense" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NonoperatingIncomeExpense</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (6,691,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (3,118,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net Loss Per Share</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and Diluted (in dollars per share)</a></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (1.39)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (1.53)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted Average Number of Common Shares Outstanding</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and Diluted (in shares)</a></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">4,823,907</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">2,036,301</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNonoperating">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InvestmentIncomeNonoperating</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Revenues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 4<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 30<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34747878&amp;loc=d3e3636-108311<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> Note 5. Accounts Payable and Accrued Expenses</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Accounts payable and accrued expenses consist of the following:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>March&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Accrued employee compensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>92,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>109,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Accrued director compensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>43,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>50,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Accrued legal fees</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>144,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>183,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Accrued other professional fees</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>50,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>45,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Accrued research and development fees</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>128,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Accrued franchise taxes</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>146,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Other accrued expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>32,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>14,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>635,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>410,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19(a),20,24)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20, 24<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment Disclosure [Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> Note 4. Property and Equipment</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Property and equipment consists of the following:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>March&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Office equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Medical equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>156,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>160,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>4,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Less: accumulated depreciation and amortization</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(3,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(2,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Property and equipment, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>157,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Depreciation expense amounted to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,000</font> for the years ended March 31, 2015 and 2014, respectively. Depreciation expense is reflected in selling, general and administrative expenses in the consolidated statements of operations. As of March 31, 2015, the Company&#8217;s medical equipment had not been placed into service and, as a result, the Company had not begun depreciating the assets.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13-14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EYDAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_ScheduleOfSharebasedCompensationWarrantActivityTableTextBlock', window );">Schedule Of Share-Based Compensation, Warrant, Activity [Table Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> A summary of the warrant activity during the years ended March 31, 2015 is presented below:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Number&#160;of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Intrinsic</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>In&#160;Years</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Outstanding, March 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,140,250</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7.30</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5,400</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9.06</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Outstanding, March 31, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,145,650</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>7.31</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1.1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Exercisable, March 31, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,140,250</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7.30</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_ScheduleOfShareBasedCompensationWarrantsByExercisePriceRangeTableTextBlock', window );">Schedule Of Share Based Compensation, Warrants, By Exercise Price Range [Table Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The following table presents information related to stock warrants at March 31, 2015:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%" colspan="5"> <div>Warrants&#160;Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="33%" colspan="5"> <div>Warrants&#160;Exercisable</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="17%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="17%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Exercisable</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="18%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Number&#160;of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Remaining&#160;Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Number&#160;of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="18%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>In&#160;Years</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="17%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div>7.2500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>3,047,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>1.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>3,047,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div>9.0625</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>98,150</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>4.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>92,750</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>3,145,650</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>1.1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>3,140,250</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In applying the Black-Scholes option pricing model to stock options granted, the Company used the following weighted average assumptions:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 50%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="25%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>For&#160;the&#160;Year&#160;Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="25%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>March&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="25%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="25%"> <div>Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1.67</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>n/a</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="25%"> <div>Expected term (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5.61</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>n/a</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="25%"> <div>Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>95</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>n/a</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="25%"> <div>Expected dividends</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>n/a</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> A summary of the stock option activity during the year ended March 31, 2015 is presented below:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Number&#160;of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Intrinsic</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>In&#160;Years</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Outstanding,&#160;March&#160;31,&#160;2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>332,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.37</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(16,664)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.37</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Outstanding, March 31, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>315,836</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6.37</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>9.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Exercisable, March 31, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>81,522</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.37</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>8.7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The following table presents information related to stock options at March 31, 2015:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%" colspan="5"> <div>Options&#160;Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="32%" colspan="4"> <div>Options&#160;Exercisable</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="17%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="17%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Exercisable</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="18%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Number&#160;of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Remaining&#160;Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Number&#160;of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="18%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>In&#160;Years</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="17%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div>6.37</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>315,836</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>8.7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>81,522</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>315,836</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>8.7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>81,522</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> A summary of RSU activity for the years ended March 31, 2015 and 2014 is presented below:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="33%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="33%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="33%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Number&#160;of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Grant&#160;Date</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Grant&#160;Date</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="33%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Units</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Fair&#160;Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Fair&#160;Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="33%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div>Non-vested, March 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div>Vested</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div>Non-vested, March 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>409,355</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.30</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,579,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div>Vested</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(85,308)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.30</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(537,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div>Non-vested, March 31, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>324,047</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6.30</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,042,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_ScheduleOfSharebasedCompensationWarrantActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share warrants that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share warrants that were granted, exercised or converted, forfeited, and expired during the year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_ScheduleOfSharebasedCompensationWarrantActivityTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_ScheduleOfShareBasedCompensationWarrantsByExercisePriceRangeTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of warrant exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under warrants, weighted average exercise price and remaining contractual warrant terms.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_ScheduleOfShareBasedCompensationWarrantsByExercisePriceRangeTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_PropertyPlanTandEquipmentUsefulLife1TableTextBlock', window );">Property Plant And Equipment Useful Life1 [Table Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Estimated useful asset life by classification is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="WIDTH: 50%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold"> <div style="CLEAR:both;CLEAR: both">Years</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 80%"> <div style="CLEAR:both;CLEAR: both">Office equipment</div> </td> <td style="WIDTH: 1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; WIDTH: 19%"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3</font></div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">Medical equipment</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5</font></div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">Furniture and fixtures</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 7</font></div> </td> </tr> </table> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div style="CLEAR:both;CLEAR: both">March&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div style="CLEAR:both;CLEAR: both">Options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">315,836</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div style="CLEAR:both;CLEAR: both">Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,145,650</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,140,250</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div style="CLEAR:both;CLEAR: both">Restricted stock units</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">324,047</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div style="CLEAR:both;CLEAR: both">Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,785,533</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,140,250</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_PropertyPlanTandEquipmentUsefulLife1TableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure for property plant and equipment useful life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_PropertyPlanTandEquipmentUsefulLife1TableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> Note 8. Income Taxes</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company is included in the U.S. federal and state (California) tax returns with its Former Parent through the March 26, 2014 closing date of the IPO. Post-IPO, the Company filed separate, stand-alone tax returns. During the year ended March 31, 2015, following the deconsolidation, the Company adjusted its net operating loss (&#8220;NOL&#8221;) carry forward to reflect the value of the NOL available to the Company in future periods.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The following summarizes the income tax provision (benefit):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="white-space:nowrap;"> <div>&#160;</div> </td> <td style="white-space:nowrap; FONT-WEIGHT: bold"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"> <div>For The Years Ended</div> </td> <td style="white-space:nowrap; FONT-WEIGHT: bold"> <div>&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="white-space:nowrap;"> <div>&#160;</div> </td> <td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"> <div>March 31,</div> </td> <td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div>&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="white-space:nowrap;"> <div>&#160;</div> </td> <td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> <div>2015</div> </td> <td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div>&#160;</div> </td> <td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> <div>2014</div> </td> <td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div>&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td> <div>Federal</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="PADDING-LEFT: 9pt"> <div>Current</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>$</div> </td> <td style="TEXT-ALIGN: right"> <div>-</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>$</div> </td> <td style="TEXT-ALIGN: right"> <div>-</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="PADDING-LEFT: 9pt; WIDTH: 74%"> <div>Deferred</div> </td> <td style="WIDTH: 1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%"> <div>(1,754,000</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> <div>)</div> </td> <td style="WIDTH: 1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%"> <div>(1,031,000</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> <div>)</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left"> <div>State and local</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="PADDING-LEFT: 9pt"> <div>Current</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>-</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>-</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt; PADDING-LEFT: 9pt"> <div>Deferred</div> </td> <td style="PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> <div>(309,000</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> <div>)</div> </td> <td style="PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> <div>(182,000</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> <div>)</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>(2,063,000</div> </td> <td style="TEXT-ALIGN: left"> <div>)</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>(1,213,000</div> </td> <td style="TEXT-ALIGN: left"> <div>)</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> <div>Change in valuation allowance</div> </td> <td style="PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> <div>2,063,000</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> <div>1,213,000</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> <div>Income tax provision (benefit)</div> </td> <td style="PADDING-BOTTOM: 2.5pt"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> <div>$</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> <div>-</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> <div>&#160;</div> </td> <td style="PADDING-BOTTOM: 2.5pt"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> <div>$</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> <div>-</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company has the following net deferred tax assets:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="white-space:nowrap;"> <div>&#160;</div> </td> <td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"> <div>March 31,</div> </td> <td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div>&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="white-space:nowrap;"> <div>&#160;</div> </td> <td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> <div>2015</div> </td> <td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div>&#160;</div> </td> <td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> <div>2014</div> </td> <td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div>&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 74%"> <div>Net operating loss carryforwards</div> </td> <td style="WIDTH: 1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%"> <div>3,224,000</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> <div>&#160;</div> </td> <td style="WIDTH: 1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%"> <div>1,427,000</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> <div>&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td> <div>Stock-based compensation</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>262,000</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>-</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> <div>Charitable donation carryforwards</div> </td> <td style="PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> <div>4,000</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> <div>-</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt"> <div>Gross deferred tax assets</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>3,490,000</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>1,427,000</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> <div>Valuation allowance</div> </td> <td style="PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> <div>(3,490,000</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> <div>)</div> </td> <td style="PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> <div>(1,427,000</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> <div>)</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> <div>&#160;Net deferred tax assets</div> </td> <td style="PADDING-BOTTOM: 2.5pt"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> <div>$</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> <div>-</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> <div>&#160;</div> </td> <td style="PADDING-BOTTOM: 2.5pt"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> <div>$</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> <div>-</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> A reconciliation of the statutory federal income tax rate to the Company&#8217;s effective tax rate is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="white-space:nowrap;"> <div>&#160;</div> </td> <td style="white-space:nowrap; FONT-WEIGHT: bold"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"> <div>For The Years Ended</div> </td> <td style="white-space:nowrap; FONT-WEIGHT: bold"> <div>&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="white-space:nowrap;"> <div>&#160;</div> </td> <td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"> <div>March 31,</div> </td> <td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div>&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="white-space:nowrap;"> <div>&#160;</div> </td> <td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> <div>2015</div> </td> <td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div>&#160;</div> </td> <td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> <div>2014</div> </td> <td style="white-space:nowrap; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div>&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 74%"> <div>Expected federal statutory rate</div> </td> <td style="WIDTH: 1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%"> <div>(34.0</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> <div>)%</div> </td> <td style="WIDTH: 1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%"> <div>(34.0</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> <div>)%</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left"> <div>State tax rate, net of federal benefit</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>(6.0</div> </td> <td style="TEXT-ALIGN: left"> <div>)%</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>(6.0</div> </td> <td style="TEXT-ALIGN: left"> <div>)%</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left"> <div>Change in effective state tax rate</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>0.0</div> </td> <td style="TEXT-ALIGN: left"> <div>%</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>(0.3</div> </td> <td style="TEXT-ALIGN: left"> <div>)%</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left"> <div>Permanent items - stock-based compensation</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>2.5</div> </td> <td style="TEXT-ALIGN: left"> <div>%</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>0.0</div> </td> <td style="TEXT-ALIGN: left"> <div>%</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left"> <div>Permanent items - non-deductible merger expenses</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>0.4</div> </td> <td style="TEXT-ALIGN: left"> <div>%</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>0.0</div> </td> <td style="TEXT-ALIGN: left"> <div>%</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left"> <div>Permanent items - other</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>0.1</div> </td> <td style="TEXT-ALIGN: left"> <div>%</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>1.3</div> </td> <td style="TEXT-ALIGN: left"> <div>%</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left"> <div>Adjustment of NOL due to deconsolidation</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>6.2</div> </td> <td style="TEXT-ALIGN: left"> <div>%</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>0.0</div> </td> <td style="TEXT-ALIGN: left"> <div>%</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> <div>Change in valuation allowance</div> </td> <td style="PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> <div>30.8</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> <div>%</div> </td> <td style="PADDING-BOTTOM: 1pt"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> <div>39.0</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> <div>%</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> <div>Income tax provision (benefit)</div> </td> <td style="PADDING-BOTTOM: 2.5pt"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> <div>0.0</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> <div>%</div> </td> <td style="PADDING-BOTTOM: 2.5pt"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> <div>0.0</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> <div>%</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> For the years ended March 31, 2015 and 2014, the Company had approximately $8,059,000 and $2,539,000 of federal and state net operating loss carryovers (&#8220;NOLs&#8221;), respectively, which begin to expire in 2033. These net operating loss carryovers are subject to annual limitations under Internal Revenue Code Section 382 because there has been a greater than 50% ownership change following the March 26, 2014 closing of the IPO.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company, after considering all available evidence, fully reserved its deferred tax assets since it is more likely than not that such benefits will not be realized in future periods. The Company has incurred losses for both financial reporting and income tax purposes for the years ended March 31, 2015 and 2014. The Company will continue to evaluate its deferred tax assets to determine whether any changes in circumstances could affect the realization of their future benefit. If it is determined in future periods that portions of the Company&#8217;s deferred tax assets satisfy the realization standards, the valuation allowance will be reduced accordingly.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company does not have any tax positions for which it is reasonably possible that the total amount of gross unrecognized tax benefits will increase or decrease within 12 months of March 31, 2015. The unrecognized tax benefits may increase or change during the next year for items that arise in the ordinary course of business. The Company has elected to reflect interest and penalties attributable to income taxes, to the extent they arise, as a component of its income tax provision or benefit.&#160;</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>Note 6. Commitments and Contingencies</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><i>&#160;</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><i>Agreement and Plan of Merger</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">On March 13, 2015, the Company entered into the Merger Agreement with Pulmatrix, a privately held biopharmaceutical company focused on the discovery, development, and commercialization of inhalable therapeutics and enabling technologies that treat and control respiratory infectious diseases, which provides for the merger of Pulmatrix with and into Ruthigen Merger Corp., with Pulmatrix continuing after the merger as the surviving corporation and a wholly owned subsidiary of Ruthigen (the &#8220;Merger&#8221;).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">Subject to the terms and conditions of the Merger Agreement, on a pro forma basis, based upon the number of shares of Ruthigen common stock to be issued in the Merger, following the closing of the Merger, current Pulmatrix stockholders and their designees will own approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">83</font>% of the combined company and current Ruthigen stockholders and their designees will own approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">17</font>% of the combined company.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The Company&#8217;s and Pulmatrix&#8217;s obligations to consummate the Merger are subject to the satisfaction or waiver of customary closing conditions, including, among others, obtaining the requisite approvals of the stockholders of Ruthigen and Pulmatrix, including the approval of the issuance of the shares of common stock of Ruthigen to be issued in connection with the Merger and the charter amendments by the stockholders of Ruthigen, and the effectiveness of a registration statement on Form S-4 relating to the shares of Ruthigen common stock to be issued to Pulmatrix stockholders pursuant to the Merger Agreement. Ruthigen is required to have unrestricted cash on hand, net of outstanding liabilities, at closing of at least (a) $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9,000,000</font>, if the Merger closing date is no later than July 31, 2015 or (b) $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8,850,000</font>, if the Merger closing date is after July 31, 2015 but no later than August 13, 2015. In order to meet the cash minimum requirements, the Company engaged a placement agent in anticipation of an offering prior to the closing of the Merger, although no assurance can be provided that an offering will be completed. See Note 6 &#150; Commitments and Contingencies &#150; New Consulting Agreements. On May 4, 2015, the registration statement on Form S-4 became effective.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">Although Ruthigen is the legal acquirer and will issue shares of its common stock to effect the merger with Pulmatrix, the business combination will be accounted for as&#160;a reverse&#160;acquisition of Ruthigen by Pulmatrix under GAAP. Under the &#8220;acquisition&#8221; method of accounting, the assets and liabilities of Ruthigen will be recorded, as of the completion of the merger, at their respective fair values in the financial statements of Pulmatrix. The financial statements of Pulmatrix issued after the completion of the merger will reflect these values, but will not be restated retroactively to reflect the historical financial position or results of operations of Ruthigen.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">As a result of the Merger, certain RSUs and stock options will become fully-vested as a result of change of control provisions in the original award agreements. In addition, pursuant to the Merger Agreement, the Company will issue an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">90,000</font> shares of common stock to an employee and a director of the Company.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The following other merger-related agreements have been disclosed in: (i) Note 6 &#150; Commitments and Contingencies &#150; New Employment Agreements, (ii) Note 6 &#150; Commitments and Contingencies &#150; New Consulting Agreements, (iii) Note 6 &#150; Commitments and Contingencies &#150; Oculus Side Letter Agreement, (iv) Note 7 &#150; Stockholders&#8217; Equity &#150; New 2013 Plan.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"><b><i>Employment Agreements</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">On August 12, 2013, the compensation committee of Oculus approved the grant of a one-time cash bonus of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">158,000</font> to the Company&#8217;s Chief Executive Officer (&#8220;CEO&#8221;) in order to recognize the CEO&#8217;s efforts related to the preparation and filing of the Company&#8217;s registration statement on Form S-1 for its IPO.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">On June 24, 2014, the compensation committee of the Company&#8217;s board of directors approved an employment agreement for its Chief Financial Officer (&#8220;CFO&#8221;), which replaced the offer letter previously in effect between the Company and the CFO. The employment agreement continues to provide for an annual base salary of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">225,000</font>, subject to increase, as determined by the Company&#8217;s board of directors. The employment agreement further provides for payments to the CFO in the event of termination without cause or resignation by the CFO for good reason, as such terms are defined in the employment agreement. In the event that the CFO is terminated without cause or resigns for good reason, the CFO is entitled to: <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">(i) a lump severance payment equal to 18 times the average monthly base salary paid to the CFO over the preceding 12 months; (ii) up to one year (the lesser of one year following the date of termination or until the CFO becomes eligible for medical insurance coverage provided by another employer) reimbursement for health care premiums under COBRA; and (iii) automatic vesting of all unvested options and other equity awards; provided that in the event the CFO resigns for good reason prior to a change of control, only the vesting of the restricted stock units granted by the Company on May 12, 2014 shall be accelerated.</font> In addition, if the Company consummates a change of control, all equity awards granted by the Company that are then-outstanding and unvested shall become fully vested and exercisable immediately prior to and subject to the consummation of the change of control. In addition, the Company will reimburse the CFO for any excise taxes owed by the CFO under Section 280G and Section 4999 of the Internal Revenue Code because of any acceleration of the equity awards (including a gross up of any additional federal, state and local taxes payable as a result of the reimbursement of the tax payments).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">On November 28, 2014, the compensation committee of the Company&#8217;s board of directors approved an amended and restated employment agreement for its CEO, which supersedes the employment agreement previously in effect between the Company and the CEO. The prior employment agreement went into effect when the Company was a wholly-owned subsidiary of Oculus, and the CEO was the Chairman of the board of directors of Oculus. The employment agreement primarily removes all references to Oculus and other legacy references related to Ruthigen being a subsidiary of Oculus.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The employment agreement continues to provide for an annual base salary of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">375,000</font> to the CEO, subject to increase, as determined by the Company&#8217;s board of directors. The employment agreement further provides for payments to the CEO in the event of termination without cause or resignation by the CEO for good reason, as such terms are defined in the employment agreement. In the event that the CEO is terminated without cause or resigns for good reason, the CEO is entitled to: <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">(i) a lump severance payment equal to 24 times the average monthly base salary paid to the CEO over the preceding 12 months; (ii) up to one year (the lesser of one year following the date of termination or until the CEO becomes eligible for medical insurance coverage provided by another employer) reimbursement for health care premiums under COBRA; and (iii) automatic vesting of all unvested options and other equity awards</font>. In addition, if the Company consummates a change of control, all equity awards granted by the Company that are then-outstanding and unvested shall become fully vested and exercisable immediately prior to and subject to the consummation of the change of control. In addition, the Company will reimburse the CEO for any excise taxes owed by the CEO under Section 280G and Section 4999 of the Internal Revenue Code because of any acceleration of the equity awards (including a gross up of any additional federal, state and local taxes payable as a result of the reimbursement of the tax payments). Furthermore, the Company will reimburse the CEO for relocation expenses if the Company&#8217;s principal executive offices are moved or the CEO is required to relocate, subject to certain conditions.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">Receipt of the termination benefits described above is contingent on the CEO&#8217;s execution of a general release of claims against the Company, its subsidiaries and its affiliates; the CEO&#8217;s resignation from any and all directorships and every other position held by the CEO with the Company and each of its subsidiaries; and the CEO&#8217;s return to the Company and its affiliates or the Company Group (as such term is defined in the employment agreement), of all property belonging to the Company Group, received from or on account of the Company Group, or any other entity of the Company Group, or any of the Company Group&#8217;s respective affiliates by the CEO. In addition, the CEO is not entitled to such benefits if the CEO does not comply with the non-competition, invention assignment, confidentiality, non-solicitation provisions of the employment agreement.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">As of March 31, 2015, the potential cash severance payment related to the Company&#8217;s employment agreements currently in effect with its CEO and CFO amounted to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,144,000</font>.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"><b><i>New Employment Agreements</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">On March 12, 2015, in connection with the Merger Agreement, the Ruthigen board of directors approved that, as of the effective time of the merger, each of the CEO and the CFO will receive cash and restricted stock units, further discussed below, from Ruthigen as consideration for the termination of outstanding stock options and restricted stock units held by them and for their continued provision of services after the merger and for the one-year non-competition provisions in their new employment agreement.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">If the Merger is approved by the respective stockholders, the CEO and CFO will terminate their current employment agreements with Ruthigen dated November 28, 2014 and June 24, 2014, respectively. At such time, the New Employment Agreement with the CEO and the New Employment Agreement with the CFO will each become effective. Additionally, lock-up agreements and cancellation agreements between Ruthigen and the CEO and CFO with respect to the cancellation of outstanding stock options and restricted stock units immediately prior to the merger will become effective. If the Merger is not approved by the respective stockholders, the current employment agreements with each of the CEO and CFO will remain in effect and the lock-up agreements and cancellation agreements will not become effective.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">At the effective time of the merger, any and all outstanding stock options and restricted stock units previously granted to the CEO will be terminated in exchange for (i) a lump-sum payment in the amount of $547,600, less taxes and other withholdings and (ii) a lump-sum equivalent to the CEO&#8217;s premiums under COBRA for one year, in the same amounts for the same medical coverage as in effect as of the effective time of the merger.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The CEO shall also receive a grant of restricted stock units, pursuant to Ruthigen&#8217;s 2013 Employee, Director and Consultant Equity Incentive Plan, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">equal to the lesser of (i) 930,000 and (ii) the quotient of $3,125,000 divided by the fair market value of the common stock of the combined company as of the effective time of the merger, with such restricted stock units vesting as follows: (i) a number of restricted stock units equal to the lesser of (a) 930,000 and (b) such number of restricted stock units with an aggregate value equal to $1,400,000 shall be fully vested at the effective time of the merger and (ii) an amount equal to 25% of the restricted stock units unvested as of the effective time of the merger will vest on a quarterly basis over the following twelve months.</font> The shares of Ruthigen common stock underlying the vested restricted stock units at the effective time of the merger will be delivered to the CEO on the first trading day following the first anniversary of the effective time of the merger, and the shares of Ruthigen common stock underlying the restricted stock units that will vest on a quarterly basis thereafter will be delivered on the first trading day following the 15, 18, 21 and 24 month anniversary of the effective time of the merger, respectively. The shares are subject to lock-up and leak out provisions that limit sales of these shares during the six month period following the delivery of any shares associated with vested restricted stock units, except to the extent necessary to cover tax liabilities associated with receipt of these shares.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">At the effective time of the merger, any and all outstanding stock options and restricted stock units previously granted to the CFO will be terminated in exchange for (i) a lump-sum payment in the amount of $337,500, less taxes and other withholdings and (ii) a lump-sum equivalent to the CFO&#8217;s premiums under COBRA for one year, in the same amounts for the same medical coverage as in effect as of the effective time of the merger.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The CFO shall also receive a grant of restricted stock units, pursuant to Ruthigen&#8217;s 2013 Employee, Director and Consultant Equity Incentive Plan, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">equal to the lesser of (i) 355,000 and (ii) the quotient of $1,037,500 divided by the fair market value of the common stock of the combined company as of the effective time, with such restricted stock units vesting as follows: (i) a number of restricted stock units equal to the lesser of (a) 355,000 and (b) such number of restricted stock units with an aggregate value equal to $250,000 shall be fully vested at the effective time of the merger and (ii) an amount equal to 25% of the restricted stock units unvested as of the effective time of the merger will vest on a quarterly basis over the following twelve months.</font> The shares of Ruthigen common stock underlying the vested restricted stock units at the effective time of the merger will be delivered to the CFO on the first trading day following the first anniversary of the effective time of the merger, and the shares of Ruthigen common stock underlying the restricted stock units that will vest on a quarterly basis thereafter will be delivered on the first trading day following the 15, 18, 21 and 24 month anniversary of the effective time of the merger, respectively. The shares are subject to lock-up and leak out provisions that limit sales of these shares during the six month period following the delivery of any shares associated with vested restricted stock units, except to the extent necessary to cover tax liabilities associated with receipt of these shares.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"><b><i>New Consulting Agreements</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">On March 3, 2015, the Company executed an agreement with an investment banking firm to provide pre-merger strategic services, in exchange for the issuance of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">340,000</font> shares of common stock upon effectiveness of the merger, as a success fee.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">On March 10, 2015, the Company executed an agreement with an individual to provide post-merger investor relations services for one year, in exchange for the issuance of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">250,000</font> shares of common stock upon effectiveness of the Merger.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The Company will account for the common stock upon issuance of the shares.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"><b><i>License and Supply Agreement</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The Company entered into a license and supply agreement with Oculus which was effective upon the completion of the<b><i></i></b>IPO, pursuant to which Oculus has agreed to exclusively license certain of its proprietary technology to the Company to enable the Company&#8217;s research, development and commercialization of newly discovered RUT58-60 and any improvements to it (the &#8220;Product&#8221;) in the United States, Canada, the European Union and Japan (collectively, the &#8220;Territory&#8221;) in certain invasive uses in humans (the &#8220;Field&#8221;) which do not include dermatologic uses or uses for ophthalmic, sinusitis or otic indications.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">In order to pay for the costs of development of the Product, Ruthigen obtained financing from Oculus until the IPO was completed. Under the agreement, the Company&#8217;s right to commercialize the Product in the Field in the Territory is exclusive and shall be performed in accordance with the development and commercialization plan set forth in the agreement (which may be modified by the Company&#8217;s discretion), and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Oculus shall manufacture and supply, at a purchase price equal to 20% over the cost of goods to Oculus</font>, the Product as and when the Company requests. In addition, the Company has the right to purchase certain manufacturing equipment from Oculus at a purchase price equal to a fixed percentage over the cost of the equipment to Oculus, so that the Company may manufacture the Product independently.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">Under the license and supply agreement, the Company will be required to make a total of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8</font> million of milestone payments to Oculus over the next several years for the first Product only, as follows: $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.5</font> million upon the completion of last patient enrollment in the Phase 1/2 clinical trial, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.5</font> million upon the completion of last patient enrollment of the Company&#8217;s first pivotal trial, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3</font> million upon completion of the first meeting with the FDA following completion of the Company&#8217;s first pivotal clinical trial, and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2</font> million upon first patient enrollment in the second pivotal clinical trial. In addition, as further consideration under the agreement, the Company will be required to make royalty payments to Oculus based on its annual net sales of the Product from the date of first commercial sale to the date that the Company ceases to commercialize the Product, which percentage royalty rate will vary between <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">20</font>% and will increase based on various net sales thresholds and will differ depending on the country in which the sales are made. The Company will accrue for the milestone payment liability if and when the Company determines that the achievement of such conditions is probable. As of March 31, 2015, the Company has not accrued for any portion of the milestone payments.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The agreement contains representations and warranties of the parties regarding its enforceability, no conflict with agreements to which the parties are bound, and no violations of law, and representations of Oculus that it has not granted any other license with respect to the Product for use in the Field in the Territory. The Company has agreed to indemnify Oculus with respect to third party claims arising from the Company&#8217;s development, commercialization or manufacture of the Product in the Field in the Territory with certain exceptions, and the Company and Oculus have each agreed to indemnify the other with respect to third party claims arising from their respective inaccuracy and/or breach of representations and warranties or negligence or willful misconduct. Either party may terminate the agreement for an uncured material breach, but only after undergoing a dispute resolution process. In addition, either party may terminate the agreement if the other party ceases to do business, makes an assignment for the benefit of creditors or voluntarily files, fails to contest an involuntary filing or is adjudicated bankrupt or insolvent under bankruptcy, insolvency, receivership or similar law.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">See Note 6 &#150; Commitments and Contingencies &#150; Oculus Side Letter Agreement for additional details.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"><b><i>Shared Services Agreement</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The Company entered into a shared services agreement with Oculus which was effective upon the completion of the IPO, pursuant to which Oculus will provide Ruthigen with general services, including general accounting and human resources, until the termination of agreement. Additionally, Oculus will permit the Company to access its Petaluma, California and Seattle, Washington facilities during normal business hours (subject to certain exceptions) and for the purposes described in the shared services agreement.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">Oculus shall also provide the Company with consulting and technical services. Such services shall be billable at the hourly or fixed monthly rate as set forth in the shared services agreement, which is subject to change based upon mutual written agreement between Oculus and Ruthigen. After the completion of the IPO, the Company agreed to pay invoices generated by Oculus within thirty days of receipt thereof. The costs incurred by the Company in connection with the shared services agreement were not material.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">On March 5, 2015, the Company received a written notice from Oculus of termination of the shared services agreement, effective on April 6, 2015.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">See Note 6 &#150; Commitments and Contingencies &#150; Oculus Side Letter Agreement for additional details.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"><b><i>Separation Agreement</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The Company has entered into a separation agreement with Oculus that contains key provisions relating to the ongoing relationship with Oculus following the completion of the IPO. The <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">separation agreement became effective upon the completion of the IPO and terminates on the earlier of 8.5 years following the closing of the IPO or when the parties mutually agree to terminate it.</font> The separation agreement also contains a series of restrictions on Oculus&#8217; ability to transfer the Ruthigen shares that Oculus owns. Oculus is restricted from transferring any of the Ruthigen shares it owns during the first year (the &#8220;Lock-Up Period&#8221;) immediately following the IPO unless it receives consent to do so from the Company&#8217;s Board of Directors and the lead underwriter in the Company&#8217;s IPO.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">Following the Lock-Up Period, transfers by Oculus of the Ruthigen shares it owns must be conducted with the consent of the board of directors or within the prescribed requirements for such transfers set forth in the separation agreement. These prescribed requirements include that the transfers must be in private placement transactions, the purchase price discount may not exceed certain percentages depending on the transferee, the amount of shares transferred in a given transfer (or series of transfers comprising a single transaction) may not exceed the greater of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5</font>% of the Company&#8217;s outstanding shares or $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,500,000</font> in net proceeds to Oculus, as well as certain other requirements set forth in the separation agreement. In addition to the manner described above, if, following a minimum of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">41.5</font> months following the closing of the IPO have lapsed and Oculus has not consummated transfers of the Ruthigen shares it owns resulting in at least $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.8</font> million in net proceeds to Oculus, then Oculus has a one-time transfer and registration right to transfer the Ruthigen shares it owns in an amount equal to the difference between $3.8 million and the proceeds received by Oculus from prior transfers as of the time Oculus elects to exercise its one-time right. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Transfers conducted using this one-time right must be conducted with the consent of the Company&#8217;s board of directors or within the prescribed requirements for such transfers set forth in the separation agreement, including, for example, that the purchase price discount may not exceed certain percentages, the amount of shares transferred may not exceed $3,800,000 in net proceeds to Oculus, as well as certain other requirements set forth in the separation agreement. The separation agreement provides Oculus with certain &#8220;piggy back&#8221; registration rights of up to 30%</font> of the value of the securities the Company registers after the lock-up period, if the Company proposes to register any of its common stock following the completion of the IPO, subject to certain conditions and limitations.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The separation agreement also provides for certain cooling off periods between market attempts and/or successful transfers, the length of which are dependent upon whether and the quantity of the Ruthigen shares that Oculus transfers. The majority of the material restrictions and obligations contained in the separation agreement lapse if and when Oculus own less than <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 19.9</font>% of the outstanding shares of the Company&#8217;s common stock.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The separation agreement also defined the methodology for the allocation of the operational and IPO related expenses incurred prior to and in connection with the IPO for which the Company was required to reimburse Oculus. The Company will also reimburse Oculus for expenses such as salaries and benefits advanced or paid on the Company&#8217;s behalf or for the Company&#8217;s benefit during a transition period following the closing of the IPO. During the year ended March 31, 2014, the Company incurred $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,450,000</font> of IPO and other costs which were reimbursed to Oculus at the closing of the IPO or shortly thereafter.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The separation agreement provides that each party will indemnify, defend and hold harmless the other party and its affiliates for third party claims asserted against the other party. The separation agreement also provides that, so long as Oculus maintains a directors&#8217; and officers&#8217; insurance program covering the past and present officers and directors of Oculus, the program shall be standard in Oculus&#8217; industry and Oculus shall not exclude any former Oculus director from any insurance policy coverage.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">See Note 6 &#150; Commitments and Contingencies &#150; Oculus Side Letter Agreement for additional details.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"><b><i>Funding Agreement</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">On January 31, 2014, the Company entered into a funding agreement with Oculus, pursuant to which Oculus agreed to fund the Company in the additional amount of up to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">760,000</font> to pay certain accounts payables outstanding at December 31, 2013 and to fund certain future expenditures through the closing of the IPO. Through the closing of the IPO, Oculus funded the Company in the additional amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">534,000</font>, which was repaid to Oculus on April 1, 2014.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"><b><i>Oculus Side Letter Agreement</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">In connection with the Merger, on March 13, 2015, Pulmatrix entered into an agreement (the &#8220;Oculus Side Letter Agreement&#8221;), pursuant to which, among other things, Oculus agreed, from the effective date of the merger, to (i) waive Ruthigen&#8217;s obligations to use commercially reasonable efforts to develop and commercialize products licensed from Oculus under the outstanding License and Supply Agreement between Oculus and Ruthigen, for a period lasting until the earlier of one year from the closing of the merger or August 31, 2016; (ii) provide a general release from claims and liabilities arising under the License and Supply Agreement, the separation agreement and the shared services agreement, each between Oculus and Ruthigen, in favor of Ruthigen; and (iii) to run a sale process for the pre-merger Ruthigen business, including any products licensed from Oculus, and to assign or delegate all of Ruthigen&#8217;s surviving rights under the License and Supply Agreement, the separation agreement and the shared services agreement, subject to Oculus&#8217;s consent with respect to the identity of the proposed purchaser.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">Ruthigen is under no obligation to achieve any milestone event during the waiver period, and no payments will accrue or become due and payable by Ruthigen to Oculus under the License and Supply Agreement, the separation agreement and the shared services agreement, other than the liabilities not exceeding $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,000</font> due and payable on the effective date of the merger. After the expiration of the waiver period, Ruthigen may unilaterally terminate the License and Supply Agreement.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">Pursuant to the right of first refusal that was granted to Oculus, prior to a sale of the pre-merger business of Ruthigen with a minimum aggregate purchase price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.0</font> million, Ruthigen must first notify Oculus of the pending transaction and Oculus will have five (5) business days after receipt of such notice to notify Ruthigen whether it intends to acquire the pre-merger business of Ruthigen on exactly the same terms, including the amount and kind of consideration, unless securities of the proposed acquirer will be offered as consideration, in which case Oculus will instead pay cash equal to the fair market value of such securities. If Oculus does not exercise its right of first refusal, Ruthigen may consummate the transaction pursuant to the agreed upon terms. Additionally, if such a transaction is consummated and the transaction generates aggregate proceeds in excess of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10.0</font> million, Ruthigen will be obligated to pay ten percent (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10</font>%) of the aggregate gross proceeds to Oculus within ten (10) calendar days.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">In addition, the Oculus Side Letter Agreement provides that, as of the effective date of the merger, certain provisions in the separation agreement regarding marketing and stock transfer restrictions, lock-up, registration rights, voting, management, compensation and equity incentive plan, will be terminated.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The Oculus Side Letter Agreement is conditioned upon the receipt of payment by Oculus for Oculus&#8217;s shares of Ruthigen common stock sold in certain specified transactions.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"><b>&#160;</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"><b><i>Operating Lease</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The Company leases a facility in Santa Rosa, California under a non-cancelable operating lease for approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 995</font> square feet of executive office space. On February 11, 2015, the Company and the landlord agreed to amend the lease such that the lease now expires on June 30, 2015 and the monthly base rent is approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,700</font>. The aggregate base rent payable over the lease term is being recognized on a straight-line basis. Rent expense related to the lease amounted to approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">20,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">20,000</font> for the years ended March 31, 2015 and 2014, respectively. Rent expense is reflected in selling, general and administrative expenses in the consolidated statements of operations. Future minimum rentals through the lease expiration date of June 30, 2015 are $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,075</font>.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> Note 7. Stockholders&#8217; Equity</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>&#160;</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>Reverse Stock Split</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> On September 25, 2013, the board of directors and the stockholders of the Company approved a 1-for-2.5 reverse stock split of the Company&#8217;s outstanding common stock, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.0001</font> par value, which was effected on September 25, 2013. In connection with the reverse stock split, every 2.5 shares of common stock were reclassified and combined into one share of common stock. The reverse stock split reduced the number of shares of common stock outstanding from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5,000,000</font> to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,000,000</font>. The total number of authorized common stock that the Company shall have the authority to issue as set forth in the Company&#8217;s Restated Certificate of Incorporation, as amended, was not proportionally decreased in connection with the reverse stock split.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> All common shares and per share amounts contained in the Company&#8217;s accompanying financial statements have been retroactively adjusted to reflect a 1-for-2.5 reverse stock split, effective as of September 25, 2013.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>&#160;</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>Authorized Capital</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company is authorized to issue up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100,000,000</font> shares of common stock with a par value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.0001</font> per share and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 500,000</font> shares of preferred stock with a par value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.0001</font> per share.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>&#160;</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>Description of Common Stock</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Each share of common stock has the right to one vote. The holders of common stock are entitled to dividends when funds are legally available and when declared by the board of directors.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>&#160;</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>2013 Plan</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In September and October 2013, respectively, the Company&#8217;s board of directors and stockholders approved the 2013 Employee, Director and Consultant Equity Incentive Plan (the &#8220;2013 Plan&#8221;), which became effective upon the closing of the IPO. The 2013 Plan will expire on September 30, 2023. Under the 2013 Plan, the Company may grant incentive stock options, non-qualified stock options, restricted and unrestricted stock awards and other stock-based awards. There are <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 998,355</font> shares of the Company&#8217;s common stock authorized for issuance under the 2013 Plan. The Company intends to issue new shares of common stock to satisfy 2013 Plan obligations.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In addition, the 2013 Plan contains an &#8220;evergreen&#8221; provision, which allows for an annual increase in the number of shares of the Company&#8217;s common stock available for issuance under the 2013 Plan on the first day of each calendar year beginning with calendar year 2015. The annual increase in the number of shares shall be equal to the lowest of: (a) 232,500 shares of the Company&#8217;s common stock; (b) 5% of the number of shares of the Company&#8217;s common stock outstanding as of such date; and (c) an amount determined by the Company&#8217;s board of directors or compensation committee.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>New 2013 Plan</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> On March 12, 2015, in connection with the Merger Agreement, Ruthigen&#8217;s compensation committee and Ruthigen&#8217;s board of directors unanimously approved the Ruthigen, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan (the &#8220;New 2013 Plan&#8221;), subject to the approval of Ruthigen&#8217;s stockholders. The New 2013 Plan will allow for the issuance of up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6,853,319</font> shares of Ruthigen&#8217;s common stock, up from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,230,855</font> shares, pursuant to awards to be granted under the New 2013 Plan. In addition, the New 2013 Plan contains an &#8220;evergreen&#8221; provision, which allows for an annual increase in the number of shares of Ruthigen&#8217;s common stock available for issuance under the plan on the first day of each fiscal year beginning in calendar year 2016. The annual increase in the number of shares shall be equal to the lowest of: (i) 2,551,500 shares of Ruthigen&#8217;s common stock; (ii) five percent (5%) of the number of shares of Ruthigen&#8217;s common stock outstanding as of such date; and (iii) an amount determined by Ruthigen&#8217;s board of directors.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>&#160;</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>Initial Public Offering</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> On March 21, 2014, the Company announced that it had priced its IPO of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,650,000</font> units (the &#8220;IPO&#8221;), with each unit consisting of (i) one share of common stock and (ii) one Series A warrant (the &#8220;Series A Warrant&#8221;), at an IPO price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7.25</font> per unit (each a &#8220;Unit&#8221;), less underwriting discounts and commissions and IPO expenses. In addition, the Company granted to the underwriters a 45-day option (the &#8220;Over-Allotment Option&#8221;) to purchase up to (i) <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 397,500</font> additional shares of common stock at price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6.6608</font> per share, which price reflects underwriting discounts and commissions, and/or (ii) <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 397,500</font> additional Series A Warrants at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.0092</font> per Series A Warrant, which price reflects underwriting discounts and commissions.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> On March 26, 2014, the Company closed on the sale of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,650,000</font> Units and the underwriters exercised a portion of the Over-Allotment Option by purchasing Series A Warrants from the Company to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 397,500</font> shares of common stock for nominal value, all of which resulted in $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">16,021,000</font> of aggregate net proceeds to the Company ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">19,216,000</font> of gross proceeds less $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,195,000</font> of issuance costs). As a result, an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,650,000</font> shares of common stock and Series A Warrants to purchase an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,047,500</font> shares of common stock were issued in the IPO.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Series A Warrant is exercisable at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7.25</font> per warrant for (x) one share of common stock and (y) one Series B warrant (the &#8220;Series B Warrant&#8221;) to purchase one share of common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9.0625</font> per share. The Series A Warrants are exercisable on the date of issuance and terminate on the second anniversary of the date of issuance. The exercise price and the number of shares for which each Series A Warrant may be exercised is subject to adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting the Company&#8217;s common stock. In addition, subject to certain exceptions, the exercise price of the Series&#160;A Warrants is subject to a weighted average reduction if the Company issues shares of common stock (or securities convertible into common stock) in the future at a price below both (a) the current exercise price of the Series A Warrant; and (b) the current market price of the Company&#8217;s common stock. The Series A Warrants may be called by the Company, for consideration equal to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.0001</font> per Series A Warrant, on not less than 10 business days&#8217; notice if the closing price of the common stock is above <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 150</font>% of the $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7.25</font> IPO price per unit for any period of 20 consecutive business days ending not more than three business days prior to the call notice date. The Series B Warrants will be exercisable on the date that the warrants are issued and will terminate on the fifth anniversary of the date the warrants are first exercisable. The Company agrees that, during the period the Series A Warrants are outstanding, it will maintain the effectiveness of the registration statement such that the holder may exercise the Series A Warrants to receive registered shares of common stock and registered Series B Warrants (and the shares of common stock underlying the Series B Warrants). The Company determined that the Series A and Series B Warrants are equity instruments because the warrants are (a) freestanding financial instruments; (b) indexed to the Company&#8217;s own stock; (c) not permitted to be settled for cash; and (d) exercisable into common stock for which the Company has sufficient authorized and unissued shares.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company issued to the representative of the underwriters warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 92,750</font> shares of the Company&#8217;s common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9.0625</font> per share (the &#8220;Representative&#8217;s Warrants&#8221;). The Representative&#8217;s Warrants are exercisable commencing on March 21, 2015 and expiring on March 21, 2019. The Representative&#8217;s Warrants and the shares of common stock underlying the warrants have been deemed compensation by Financial Industry Regulatory Authority, Inc. (&#8220;FINRA&#8221;) and are, therefore, subject to a 180-day lock-up pursuant to Rule 5110(g)(1) of FINRA.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company, its officers and directors and its Former Parent have entered into lock-up agreements with the underwriters. Under these agreements, the Company and the other parties have agreed, subject to specified exceptions, not to sell or transfer any common stock or securities convertible into, or exchangeable or exercisable for, common stock, during a period ending 180 days after the date of its prospectus (one year for the shares of common stock owned by the Company&#8217;s Former Parent), without first obtaining the written consent of representative of the underwriters. The lock up period for the Company, its officers and directors is subject to extension for up to an additional 18 days upon the occurrence of certain specified events.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>&#160;</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>Underwriter&#8217;s Exercise of IPO Over-Allotment Option</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Following the closing of the IPO, during the year ended March 31, 2015 and in connection with its IPO, the underwriters exercised a portion of the over-allotment option pursuant to which the Company sold an additional <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 154,290</font> shares of common stock at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6.6608</font> per share, which resulted in approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,028,000</font> of aggregate net proceeds to the Company. In connection with the underwriters&#8217; partial exercise of the over-allotment option, the Company issued to the representative of the underwriters a five-year warrant to purchase an additional <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5,400</font> shares of the Company&#8217;s common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9.0625</font> per share. The warrant is exercisable commencing one year from the date of issuance. The warrant and the shares of common stock underlying the warrant have been deemed compensation by FINRA and are, therefore, subject to a 180-day lock-up pursuant to Rule 5110(g)(1) of FINRA.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>&#160;</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>Investment from Former Parent</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> During the year ended March 31, 2014, the Company&#8217;s Former Parent made capital contributions to the Company in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,679,000</font>, which were recorded as additional paid-in capital in the consolidated statement of changes in stockholders&#8217; equity. See Note 9 &#150; Related Party Transactions for details associated with the Former Parent&#8217;s ownership interest in the Company.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>&#160;</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>Stock Warrants</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of the warrant activity during the years ended March 31, 2015 is presented below:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Number&#160;of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Intrinsic</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>In&#160;Years</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Outstanding, March 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,140,250</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7.30</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5,400</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9.06</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Outstanding, March 31, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,145,650</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>7.31</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1.1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Exercisable, March 31, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,140,250</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7.30</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table presents information related to stock warrants at March 31, 2015:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%" colspan="5"> <div>Warrants&#160;Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="33%" colspan="5"> <div>Warrants&#160;Exercisable</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="17%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="17%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Exercisable</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="18%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Number&#160;of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Remaining&#160;Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Number&#160;of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="18%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>In&#160;Years</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="17%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div>7.2500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>3,047,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>1.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>3,047,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div>9.0625</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>98,150</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>4.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>92,750</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>3,145,650</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>1.1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>3,140,250</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>Stock Options</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company has computed the fair value of options granted using the Black-Scholes option pricing model. Option forfeitures are estimated at the time of valuation and reduce expense ratably over the vesting period. This estimate will be adjusted periodically based on the extent to which actual option forfeitures differ, or are expected to differ, from the previous estimate, when it is material. The Company estimated forfeitures related to option grants at an annual rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font>% for options unvested during the year ended March 31, 2015. The expected term used for options issued to non-employees is the contractual life and the expected term used for options issued to employees and directors is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the &#8220;simplified&#8221; method to develop an estimate of the expected term of &#8220;plain vanilla&#8221; employee option grants. Since the Company&#8217;s stock has not been publicly traded for a sufficiently long period of time, the Company is utilizing an expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected life of the instrument being valued, of similarly positioned public companies within its industry. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif ">&#160;</div><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>In applying the Black-Scholes option pricing model to stock options granted, the Company used the following weighted average assumptions:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 50%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="25%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>For&#160;the&#160;Year&#160;Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="25%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>March&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="25%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="25%"> <div>Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1.67</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>n/a</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="25%"> <div>Expected term (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5.61</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>n/a</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="25%"> <div>Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>95</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>n/a</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="25%"> <div>Expected dividends</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>n/a</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The weighted average estimated fair value of the options granted during the year ended March 31, 2015 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.79</font> per share. There were no options granted during the year ended March 31, 2014.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><i>&#160;</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On May 12, 2014, the Company granted options to employees and directors to purchase an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 332,500</font> shares of common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6.37</font> per share, pursuant to the 2013 Plan. The shares vest ratably over three years on a quarterly basis. The aggregate grant date value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,593,000</font> will be recognized proportionate to the vesting period.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company recorded stock&#150;based compensation expense related to stock options of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">452,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font> during the years ended March 31, 2015 and 2014, respectively. As of March 31, 2015, there was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,060,000</font> of unrecognized stock-based compensation expense related to stock options that will be amortized over a weighted average period of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2.1</font> years.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of the stock option activity during the year ended March 31, 2015 is presented below:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Number&#160;of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Intrinsic</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>In&#160;Years</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Outstanding,&#160;March&#160;31,&#160;2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>332,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.37</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(16,664)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.37</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Outstanding, March 31, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>315,836</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6.37</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>9.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Exercisable, March 31, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>81,522</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.37</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>8.7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table presents information related to stock options at March 31, 2015:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="35%" colspan="5"> <div>Options&#160;Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="32%" colspan="4"> <div>Options&#160;Exercisable</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="17%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="17%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Exercisable</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="18%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Number&#160;of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Remaining&#160;Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Number&#160;of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="18%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>In&#160;Years</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="17%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div>6.37</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>315,836</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>8.7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>81,522</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="17%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>315,836</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>8.7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>81,522</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>&#160;</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>Restricted Stock Units</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-WEIGHT: normal">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> On May 11, 2014, the Company granted RSUs issuable for an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 409,355</font> shares to employees and directors, pursuant to the 2013 Plan. RSUs for 341,000 shares of common stock vest ratably over three years on a quarterly basis and had an aggregate grant date value of $2,148,000. RSUs for 68,355 shares had an aggregate grant date value of $431,000 and vest in equal installments based on achievement of the following: (1) enrollment of the first patient in the first pivotal clinical trial for RUT58-60 on or prior to May 11, 2017; (2) enrollment of the first patient in the second pivotal clinical trial for RUT58-60 on or prior to May 11, 2018; and (3) completion of the clinical study report containing the results of the second pivotal clinical trial for RUT58-60 on or prior to May 11, 2019.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company recorded stock&#150;based compensation expense related to RSUs of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">627,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font> during the years ended March 31, 2015 and 2014, respectively. As of March 31, 2015, there was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,522,000</font> of unrecognized stock-based compensation expense related to RSUs that will be amortized over a weighted average period of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2.1</font> years. The Company recognizes stock-based compensation expense for RSUs with performance conditions if and when the Company concludes that it is probable that the performance condition will be achieved. As of March 31, 2015, the Company has not recognized any expense related to RSUs with performance conditions. As of March 31, 2015, there was $431,000 of unrecognized stock-based compensation expense related to RSUs with performance conditions.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of RSU activity for the years ended March 31, 2015 and 2014 is presented below:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="33%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="33%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="33%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Number&#160;of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Grant&#160;Date</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Grant&#160;Date</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="33%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Units</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Fair&#160;Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Fair&#160;Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="33%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div>Non-vested, March 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div>Vested</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div>Non-vested, March 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>409,355</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.30</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,579,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div>Vested</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(85,308)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.30</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(537,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div>Non-vested, March 31, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>324,047</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6.30</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,042,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Related Party Transactions<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions Disclosure [Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> Note 9. Related Party Transactions</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Beginning in March 2013, the Company employed an immediate family member of the Chief Executive Officer as an operations technician at an annual salary of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">36,000</font>.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Upon completion of the IPO, on March 26, 2014, Oculus owned <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,000,000</font> shares of the Company&#8217;s common stock or approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 43</font>% of the then outstanding common stock.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> On March 13, 2015, Oculus entered into a securities purchase agreement with several investors, pursuant to which the investors agreed to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 350,000</font> shares of the Company&#8217;s common stock at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.75</font> per share. On March 23, 2015, this sale closed. Oculus retained the voting rights to the 350,000 shares until and through the date of closing of the Merger. In the event that the closing of the Merger does not occur on or prior to September 30, 2015, the 350,000 shares of the Company&#8217;s common stock will become fully tradable and full voting rights will transfer to the purchasers of such shares.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-WEIGHT: normal">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-SIZE: 10pt; FONT-WEIGHT: normal">On March 13, 2015, Oculus entered into a securities purchase follow-up agreement with</font> <font style="FONT-WEIGHT: normal">several investors <font style="FONT-SIZE: 10pt">pursuant to which Oculus agreed to sell <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,650,000</font> shares of the Company&#8217;s common stock at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.75</font> per share to the investors upon completion of the Merger, provided that <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 50,000</font> shares may be sold to one or more investors prior to closing. If the Merger does not close by August 13, 2015 or as may be extended up to 60 calendar days at Oculus&#8217;s discretion, there will be no obligation of the investors to purchase the shares. Oculus will retain the voting rights to the 50,000 shares until and through the date of closing of the Merger. In the event that the closing of the Merger does not occur on or prior to September 30, 2015, the 50,000 shares of common stock will become fully tradable and full voting rights will transfer to the investors.</font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph b<br><br> -Article 3A<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph k<br><br> -Article 4<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EUPAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Warrants Outstanding, March 31, 2015</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" onclick="toggleNextSibling(this);">3,145,650</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber', window );">Number of Warrants Exercisable, March 31, 2015</a></td>
        <td class="nump"><a title="rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber" onclick="toggleNextSibling(this);">3,140,250</a><span style="display:none;white-space:normal;text-align:left;">rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms', window );">Warrants Exercisable Weighted Average Remaining Life</a></td>
        <td class="text">1 year 1 month 6 days<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Warrants Outstanding, March 31, 2014</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber[us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">3,140,250</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Warrants Granted</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted[us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">5,400</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Warrants Exercised</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised[us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Number of Warrants Forfeited</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures[us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Warrants Outstanding, March 31, 2015</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber[us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">3,145,650</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber', window );">Number of Warrants Exercisable, March 31, 2015</a></td>
        <td class="nump"><a title="rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber[us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">3,140,250</a><span style="display:none;white-space:normal;text-align:left;">rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, March 31, 2014</a></td>
        <td class="nump"><a title="rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice[us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);"> 7.30</a><span style="display:none;white-space:normal;text-align:left;">rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsGrantedWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Granted</a></td>
        <td class="nump"><a title="rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsGrantedWeightedAverageExercisePrice[us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);"> 9.06</a><span style="display:none;white-space:normal;text-align:left;">rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsGrantedWeightedAverageExercisePrice<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisedWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
        <td class="nump"><a title="rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisedWeightedAverageExercisePrice[us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);"> 0</a><span style="display:none;white-space:normal;text-align:left;">rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisedWeightedAverageExercisePrice<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Forfeited</a></td>
        <td class="nump"><a title="rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice[us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);"> 0</a><span style="display:none;white-space:normal;text-align:left;">rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, March 31, 2015</a></td>
        <td class="nump"><a title="rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice[us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);"> 7.31</a><span style="display:none;white-space:normal;text-align:left;">rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercisable, March 31, 2015</a></td>
        <td class="nump"><a title="rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice[us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);"> 7.30</a><span style="display:none;white-space:normal;text-align:left;">rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Life Outstanding, March 31, 2015</a></td>
        <td class="text">1 year 1 month 6 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms', window );">Warrants Exercisable Weighted Average Remaining Life</a></td>
        <td class="text">1 year 1 month 6 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Intrinsic Value Outstanding, March 31, 2015</a></td>
        <td class="nump"><a title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding[us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);"> 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable', window );">Intrinsic Value Exercisable, March 31, 2015</a></td>
        <td class="nump"><a title="rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable[us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);"> 0</a><span style="display:none;white-space:normal;text-align:left;">rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represented the value of Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average exercise price of other than options exercisable, including both vested and non-vested instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisedWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average exercise price of other than options exercised, including both vested and non-vested instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsExercisedWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average exercise price of other than options forfeited, including both vested and non-vested instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsGrantedWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average exercise price of other than options granted, including both vested and non-vested instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsGrantedWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average exercise price of other than options outstanding, including both vested and non-vested instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of other than options outstanding and currently exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term of exercisable other than options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Intrinsic value of equity-based compensation awards outstanding. Excludes stock and unit options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of non-option equity instruments exercised by participants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net number of non-option equity instruments granted to participants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment [Table Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Property and equipment consists of the following:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>March&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Office equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Medical equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>156,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>160,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>4,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Less: accumulated depreciation and amortization</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(3,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(2,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Property and equipment, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>157,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph b<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EALAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
        <td class="text">3 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember', window );">Medical equipment [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
        <td class="text">5 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
        <td class="text">7 years<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EGNAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Federal Income Tax Expense (Benefit), Continuing Operations [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Current</a></td>
        <td class="nump"><a title="us-gaap_CurrentFederalTaxExpenseBenefit" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CurrentFederalTaxExpenseBenefit</span><span></span></td>
        <td class="nump"><a title="us-gaap_CurrentFederalTaxExpenseBenefit" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CurrentFederalTaxExpenseBenefit</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Deferred</a></td>
        <td class="num"><a title="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">(1,754,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</span><span></span></td>
        <td class="num"><a title="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">(1,031,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>State and Local Income Tax Expense (Benefit), Continuing Operations [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Current</a></td>
        <td class="nump"><a title="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</span><span></span></td>
        <td class="nump"><a title="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">Deferred</a></td>
        <td class="num"><a title="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">(309,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</span><span></span></td>
        <td class="num"><a title="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">(182,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current Income Tax Expense (Benefit)</a></td>
        <td class="num"><a title="us-gaap_CurrentIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">(2,063,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CurrentIncomeTaxExpenseBenefit</span><span></span></td>
        <td class="num"><a title="us-gaap_CurrentIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">(1,213,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CurrentIncomeTaxExpenseBenefit</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
        <td class="nump"><a title="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" onclick="toggleNextSibling(this);">2,063,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</span><span></span></td>
        <td class="nump"><a title="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" onclick="toggleNextSibling(this);">1,213,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision (benefit)</a></td>
        <td class="nump"><a title="us-gaap_IncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxExpenseBenefit</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxExpenseBenefit</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Paragraph Question 1-7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510177<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510177<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Income Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32123-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EVUAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Total</div>
        </th>
        <th class="th">
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Additional Paid-in Capital [Member]</div>
        </th>
        <th class="th">
          <div>Accumulated Deficit [Member]</div>
        </th>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2013</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">$ 47,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">$ 200</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">$ 597,800</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">$ (551,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2013</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharesOutstanding[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">2,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesOutstanding<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_InvestmentFromFormerParent', window );">Investment From Former Parent</a></td>
        <td class="nump"><a title="rtgn_InvestmentFromFormerParent" onclick="toggleNextSibling(this);">1,679,000</a><span style="display:none;white-space:normal;text-align:left;">rtgn_InvestmentFromFormerParent</span><span></span></td>
        <td class="nump"><a title="rtgn_InvestmentFromFormerParent[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">rtgn_InvestmentFromFormerParent<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="rtgn_InvestmentFromFormerParent[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">1,679,000</a><span style="display:none;white-space:normal;text-align:left;">rtgn_InvestmentFromFormerParent<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="nump"><a title="rtgn_InvestmentFromFormerParent[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">rtgn_InvestmentFromFormerParent<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_InitialPublicOfferinfgValueOfUnits', window );">Shares and warrants issued for cash in connection with initial public offering</a></td>
        <td class="nump"><a title="rtgn_InitialPublicOfferinfgValueOfUnits" onclick="toggleNextSibling(this);">16,021,000</a><span style="display:none;white-space:normal;text-align:left;">rtgn_InitialPublicOfferinfgValueOfUnits</span><span></span></td>
        <td class="nump"><a title="rtgn_InitialPublicOfferinfgValueOfUnits[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">265</a><span style="display:none;white-space:normal;text-align:left;">rtgn_InitialPublicOfferinfgValueOfUnits<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="rtgn_InitialPublicOfferinfgValueOfUnits[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">16,020,735</a><span style="display:none;white-space:normal;text-align:left;">rtgn_InitialPublicOfferinfgValueOfUnits<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="nump"><a title="rtgn_InitialPublicOfferinfgValueOfUnits[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">rtgn_InitialPublicOfferinfgValueOfUnits<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_InitialPublicOfferingUnits1', window );">Shares and warrants issued for cash in connection with initial public offering (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="rtgn_InitialPublicOfferingUnits1[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">2,650,000</a><span style="display:none;white-space:normal;text-align:left;">rtgn_InitialPublicOfferingUnits1<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(3,118,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">(3,118,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2014</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">14,629,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">465</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">18,297,535</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">(3,669,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2014</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharesOutstanding[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">4,650,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesOutstanding<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForCash', window );">Shares issued for cash in connection with underwriter's exercise of overallotment, net</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueIssuedForCash" onclick="toggleNextSibling(this);">1,028,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueIssuedForCash</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueIssuedForCash[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">15</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueIssuedForCash<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueIssuedForCash[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">1,027,985</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueIssuedForCash<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueIssuedForCash[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueIssuedForCash<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForCash', window );">Shares issued for cash in connection with underwriter's exercise of overallotment, net (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesIssuedForCash[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">154,290</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesIssuedForCash<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" onclick="toggleNextSibling(this);">1,079,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">1,079,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(6,691,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">(6,691,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2015</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">$ 10,045,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">$ 480</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">$ 20,404,520</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">$ (10,360,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2015</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharesOutstanding[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">4,804,290</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesOutstanding<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_InitialPublicOfferinfgValueOfUnits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the total value of Initial public offering units during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_InitialPublicOfferinfgValueOfUnits</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_InitialPublicOfferingUnits1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represent initial public offering units</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_InitialPublicOfferingUnits1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_InvestmentFromFormerParent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value due to investment from the former parent during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_InvestmentFromFormerParent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415241&amp;loc=d3e4534-113899<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11149-113907<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11178-113907<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued which are neither cancelled nor held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForCash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued as consideration for cash for development stage entities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 215<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472370&amp;loc=d3e38297-110927<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForCash</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForCash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of shares issued as consideration for cash for development stage entities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 215<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472370&amp;loc=d3e38297-110927<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForCash</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsTextBlock', window );">Disclosure Of Prepaid Expenses And Other Current Assets [Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif">Note 3. Prepaid Expenses and Other Current Assets</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">Prepaid expenses and other current assets consists of the following:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>March&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Prepaid insurance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>12,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Clinical testing and other deposits</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>114,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Prepaid rent</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Other prepaid expenses and current assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>38,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>166,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Entire disclosure of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELKAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details 1)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" onclick="toggleNextSibling(this);">3,785,533</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</span><span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" onclick="toggleNextSibling(this);">3,140,250</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">315,836</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_OptionIndexedToIssuersEquityEquityAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_OptionIndexedToIssuersEquityEquityAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">3,145,650</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">3,140,250</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">324,047</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_SummaryOfSignificantAccountingPoliciesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_SummaryOfSignificantAccountingPoliciesLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.1.9</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>115</ContextCount>
  <ElementCount>254</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>43</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>101 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>102 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>103 - Statement - CONSOLIDATED BALANCE SHEETS [Parenthetical]</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS [Parenthetical]</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>104 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>105 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>106 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>107 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS [Parenthetical]</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/ConsolidatedStatementsOfCashFlowsParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS [Parenthetical]</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>108 - Disclosure - Organization and Plan of Merger</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/OrganizationAndPlanOfMerger</Role>
      <ShortName>Organization and Plan of Merger</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>109 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>110 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/PrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>111 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>112 - Disclosure - Accounts Payable and Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/AccountsPayableAndAccruedExpenses</Role>
      <ShortName>Accounts Payable and Accrued Expenses</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>113 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>114 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>115 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>116 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>117 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>118 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>119 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>120 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/PrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>121 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>122 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/AccountsPayableAndAccruedExpensesTables</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>123 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>124 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>125 - Disclosure - Organization and Plan of Merger (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/OrganizationAndPlanOfMergerDetailsTextual</Role>
      <ShortName>Organization and Plan of Merger (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>126 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>127 - Disclosure - Summary of Significant Accounting Policies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/SummaryOfSignificantAccountingPoliciesDetails1</Role>
      <ShortName>Summary of Significant Accounting Policies (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>128 - Disclosure - Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>129 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>130 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/PropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>131 - Disclosure - Property and Equipment (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/PropertyAndEquipmentDetailsTextual</Role>
      <ShortName>Property and Equipment (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>132 - Disclosure - Accounts Payable and Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/AccountsPayableAndAccruedExpensesDetails</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>133 - Disclosure - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/CommitmentsAndContingenciesDetailsTextual</Role>
      <ShortName>Commitments and Contingencies (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>134 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>135 - Disclosure - Stockholders' Equity (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/StockholdersEquityDetails1</Role>
      <ShortName>Stockholders' Equity (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>136 - Disclosure - Stockholders' Equity (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/StockholdersEquityDetails2</Role>
      <ShortName>Stockholders' Equity (Details 2)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>137 - Disclosure - Stockholders' Equity (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/StockholdersEquityDetails3</Role>
      <ShortName>Stockholders' Equity (Details 3)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>138 - Disclosure - Stockholders' Equity (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/StockholdersEquityDetails4</Role>
      <ShortName>Stockholders' Equity (Details 4)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>139 - Disclosure - Stockholders' Equity (Details 5)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/StockholdersEquityDetails5</Role>
      <ShortName>Stockholders' Equity (Details 5)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>140 - Disclosure - Stockholders' Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/StockholdersEquityDetailsTextual</Role>
      <ShortName>Stockholders' Equity (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>141 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>142 - Disclosure - Income Taxes (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/IncomeTaxesDetails1</Role>
      <ShortName>Income Taxes (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>143 - Disclosure - Income Taxes (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/IncomeTaxesDetails2</Role>
      <ShortName>Income Taxes (Details 2)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>144 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>145 - Disclosure - Related Party Transactions (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/RelatedPartyTransactionsDetailsTextual</Role>
      <ShortName>Related Party Transactions (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>146 - Disclosure - Subsequent Events (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ruthigen.com/role/SubsequentEventsDetailsTextual</Role>
      <ShortName>Subsequent Events (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element rtgn_ChangeInAvailableNolDueToDeconsolidation had a mix of decimals attribute values: 1 3.</Log>
    <Log type="Info">Element rtgn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMergerExpensesPercent had a mix of decimals attribute values: 1 3.</Log>
    <Log type="Info">Element rtgn_RoyaltyGuaranteesCommitmentsPercentage had a mix of decimals attribute values: 1 2.</Log>
    <Log type="Info">Element us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost had a mix of decimals attribute values: 1 3.</Log>
    <Log type="Info">Element us-gaap_EquityMethodInvestmentOwnershipPercentage had a mix of decimals attribute values: 1 2.</Log>
    <Log type="Info">Element us-gaap_SaleOfStockPricePerShare had a mix of decimals attribute values: 2 4.</Log>
    <Log type="Info">Element us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue had a mix of decimals attribute values: 0 2.</Log>
    <Log type="Info">Element us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue had a mix of decimals attribute values: 0 2.</Log>
    <Log type="Info">Element us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue had a mix of decimals attribute values: 0 2.</Log>
    <Log type="Info">Element us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue had a mix of decimals attribute values: 0 2.</Log>
    <Log type="Info">Element us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice had a mix of decimals attribute values: 0 2.</Log>
    <Log type="Info">Process Flow-Through: 102 - Statement - CONSOLIDATED BALANCE SHEETS</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Mar. 31, 2013'</Log>
    <Log type="Info">Process Flow-Through: 103 - Statement - CONSOLIDATED BALANCE SHEETS [Parenthetical]</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Sep. 25, 2013'</Log>
    <Log type="Info">Process Flow-Through: 104 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</Log>
    <Log type="Info">Process Flow-Through: 106 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</Log>
    <Log type="Info">Process Flow-Through: 107 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS [Parenthetical]</Log>
  </Logs>
  <InputFiles>
    <File>rtgn-20150331.xml</File>
    <File>rtgn-20150331.xsd</File>
    <File>rtgn-20150331_cal.xml</File>
    <File>rtgn-20150331_def.xml</File>
    <File>rtgn-20150331_lab.xml</File>
    <File>rtgn-20150331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EQIAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity (Details 4) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding Exercise Price</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 6.37</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding Number of Options</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" onclick="toggleNextSibling(this);">315,836</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options Exercisable Weighted Average Remaining Life</a></td>
        <td class="text">8 years 8 months 12 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable Number of Options</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" onclick="toggleNextSibling(this);">81,522</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=rtgn_ExercisePriceMember', window );">Exercise Price [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding Exercise Price</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=rtgn_ExercisePriceMember]" onclick="toggleNextSibling(this);">$ 6.37</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= rtgn_ExercisePriceMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding Number of Options</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=rtgn_ExercisePriceMember]" onclick="toggleNextSibling(this);">315,836</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= rtgn_ExercisePriceMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options Exercisable Weighted Average Remaining Life</a></td>
        <td class="text">8 years 8 months 12 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable Number of Options</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=rtgn_ExercisePriceMember]" onclick="toggleNextSibling(this);">81,522</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= rtgn_ExercisePriceMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=rtgn_ExercisePriceMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=rtgn_ExercisePriceMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rtgn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock', window );">Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block]</a></td>
        <td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Prepaid expenses and other current assets consists of the following:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>March&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="45%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Prepaid insurance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>12,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Clinical testing and other deposits</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>114,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Prepaid rent</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Other prepaid expenses and current assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>38,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="45%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>166,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rtgn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">rtgn_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>rtgn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
